2007 ACR/ARHP Scientific Meeting Program Book - American ...
2007 ACR/ARHP Scientific Meeting Program Book - American ...
2007 ACR/ARHP Scientific Meeting Program Book - American ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
program<br />
BOOK<br />
<strong>American</strong> College of Rheumatology<br />
71st Annual <strong>Scientific</strong> <strong>Meeting</strong><br />
Association of Rheumatology Health Professionals<br />
42nd Annual <strong>Scientific</strong> <strong>Meeting</strong><br />
Printing of this publication was supported by a grant from Amgen, Inc. and Wyeth Pharmaceuticals.
ABOUT <strong>ACR</strong>/<strong>ARHP</strong> EDUCATION<br />
The <strong>American</strong> College of Rheumatology and the<br />
Association of Rheumatology Health Professionals, a<br />
division of the <strong>ACR</strong>, are organizations of physicians,<br />
health professionals and scientists serving members<br />
through programs, including education and research.<br />
Through these programs, the <strong>ACR</strong> and the <strong>ARHP</strong> foster<br />
excellence in the care of people with rheumatic and<br />
musculoskeletal diseases.<br />
The <strong>2007</strong> <strong>ACR</strong>/<strong>ARHP</strong> Annual <strong>Scientific</strong> <strong>Meeting</strong><br />
programs have been independently planned by the<br />
<strong>ACR</strong> Committee on Education, <strong>ACR</strong> Annual <strong>Meeting</strong><br />
Planning Committee, <strong>ARHP</strong> <strong>Program</strong> Committee and<br />
<strong>ARHP</strong> Clinical Focus Course Task Force. This program<br />
is sponsored by the <strong>American</strong> College of Rheumatology<br />
for educational purposes only. The material presented is<br />
not intended to represent the only or the best methods<br />
appropriate for the medical situations discussed, but<br />
rather is intended to present the opinions of the authors<br />
or presenters, which may be helpful to other healthcare<br />
professionals. Attendees participating in this medical<br />
education program do so with full knowledge that they<br />
waive any claim they may have against the <strong>ACR</strong> for<br />
reliance on any information presented during these<br />
educational activities. The <strong>ACR</strong> does not guarantee,<br />
warrant or endorse any commercial products or services.<br />
PROGRAM OBJECTIVES<br />
∙ To provide an in-depth presentation of the recent<br />
advances in the diagnosis, management and treatment of<br />
rheumatic diseases<br />
∙ To provide a forum for exchange of new research data by<br />
scientists/investigators working in the area of rheumatic<br />
diseases<br />
∙ To provide an opportunity to interact with experts in<br />
small group sessions<br />
∙ To provide an opportunity to update knowledge<br />
concerning available pharmaceutical products, as well as<br />
medical and assistive devices for use in the management<br />
of patients with rheumatic diseases<br />
The information and materials displayed and/or<br />
presented during this meeting are the property of the<br />
<strong>American</strong> College of Rheumatology and the presenter<br />
and cannot be photographed, copied, photocopied,<br />
transformed to electronic format, reproduced or<br />
distributed without the written permission of the<br />
<strong>American</strong> College of Rheumatology and the presenter.<br />
The names, insignias, logos and acronyms of the <strong>ACR</strong>,<br />
the <strong>ARHP</strong> and the REF are proprietary marks. Use of the<br />
names in any fashion, by any entity, for any purpose, is<br />
prohibited without the written permission of the <strong>ACR</strong>.<br />
2
table of contents<br />
Accreditation<br />
<strong>Meeting</strong> Evaluations, CME Credit, <strong>ARHP</strong> Certificates<br />
of Participation and Certificates of Attendance........... 8<br />
Conflict of Interest/Disclosure Statements...................... 8<br />
<strong>ACR</strong> Abstract Embargo Policy ............................ 9<br />
<strong>Meeting</strong> Information<br />
Ask Me Staff.................................................................... 10<br />
Cell Phones, Pagers, PDAs, Other Electronic Devices... 10<br />
Children.......................................................................... 10<br />
Emergency Contact Information.................................... 10<br />
Exhibit Hall..................................................................... 10<br />
Food Service ................................................................... 10<br />
Location/Parking............................................................ 10<br />
<strong>Meeting</strong> Disclaimer......................................................... 10<br />
Name Badges................................................................... 11<br />
No Smoking Policy.......................................................... 11<br />
Opening Dessert Reception............................................ 11<br />
Photography and Videotaping........................................ 11<br />
Shuttle Service................................................................. 11<br />
Special Needs................................................................... 11<br />
Important Locations........................................................ 12<br />
Definition of Session Types............................................ 13<br />
Educational Track Information, Pain Management,<br />
Encore Theater, Interactive Audience<br />
Response Sessions....................................................... 14<br />
<strong>Meeting</strong> Services<br />
<strong>ACR</strong> Central................................................................... 16<br />
<strong>ACR</strong>/<strong>ARHP</strong> Membership Booth................................... 16<br />
<strong>ACR</strong> Practice Advocacy Coding Center......................... 16<br />
Advocacy Booth............................................................... 16<br />
Conference Recording Sales Desk.................................. 16<br />
Encore Theater................................................................ 16<br />
Interactive Audience Response Sessions........................ 16<br />
Lost and Found............................................................... 16<br />
Message Center............................................................... 16<br />
Newsroom....................................................................... 17<br />
Opportunities and Announcements............................... 17<br />
Registration..................................................................... 17<br />
REF Booth....................................................................... 17<br />
REF Donors’ Lounge...................................................... 17<br />
Speaker Ready Room...................................................... 17<br />
Electronic Syllabus.......................................................... 17<br />
Wireless Access................................................................ 17<br />
<strong>ACR</strong>/<strong>ARHP</strong> <strong>Meeting</strong> Hotels + Map .............18–19<br />
Special Offers at the <strong>2007</strong> <strong>ACR</strong>/<strong>ARHP</strong><br />
Annual <strong>Scientific</strong> <strong>Meeting</strong> ............................. 22<br />
Poster Sessions<br />
Poster Presenter Instructions.......................................... 25<br />
Poster Session Hours....................................................... 25<br />
Industry-Supported Educational Symposia<br />
Industry Roundtable-Supported Symposia..................... 26<br />
Industry-Supported Post-Conference Symposia.............. 27<br />
REF Sponsored Events ......................................... 29<br />
Pre-Conference <strong>Program</strong><br />
Tuesday, November 6, <strong>2007</strong><br />
<strong>ACR</strong>/<strong>ARHP</strong> Registration............................................... 31<br />
<strong>ACR</strong> Clinical Research Conference............................... 31<br />
<strong>ACR</strong>/ABIM Maintenance of Certification Learning<br />
Session for Recertification Module 30-R.................... 35<br />
<strong>ACR</strong> Basic Research Conference - Day One.................. 36<br />
Wednesday, November 7, <strong>2007</strong><br />
<strong>ACR</strong>/<strong>ARHP</strong> Registration............................................... 37<br />
<strong>ACR</strong> Basic Research Conference - Day Two.................. 37<br />
<strong>ACR</strong> Review Course....................................................... 38<br />
<strong>ARHP</strong> Clinical Focus Course......................................... 39<br />
Opening Lecture<br />
<strong>ACR</strong>/<strong>ARHP</strong> Opening Lecture and Awards .................. 40<br />
Opening Dessert Reception............................................ 41<br />
<strong>ACR</strong>/<strong>ARHP</strong> Annual <strong>Scientific</strong> <strong>Meeting</strong><br />
Thursday, November 8, <strong>2007</strong><br />
<strong>ACR</strong>/<strong>ARHP</strong> Registration............................................... 43<br />
<strong>ARHP</strong> Special Session: Moderator Orientation............. 43<br />
<strong>ARHP</strong> Special Session: Attendee Orientation............... 43<br />
<strong>ACR</strong> State-of-the-Art....................................................... 43<br />
<strong>ACR</strong> REF Special Session: Gluck Lecture...................... 43<br />
<strong>ACR</strong> Year in Review....................................................... 44<br />
<strong>ACR</strong> Meet the Professor Sessions................................... 44<br />
<strong>ARHP</strong> Special Session: Networking Forum................... 46<br />
<strong>ACR</strong> Workshops............................................................. 46<br />
<strong>ACR</strong>/<strong>ARHP</strong> Coffee and Tea Break............................... 47<br />
<strong>ACR</strong> Poster Session A..................................................... 47<br />
Exhibits............................................................................ 47<br />
<strong>ACR</strong> Medical Aspects of Rheumatic Diseases - <strong>ACR</strong><br />
. Hench Lecture............................................................. 47<br />
<strong>ACR</strong> State-of-the-Art....................................................... 47<br />
<strong>ARHP</strong> General Session I................................................. 48<br />
<strong>ACR</strong> Workshops............................................................. 48<br />
3
table of contents<br />
<strong>ACR</strong> Plenary Session I.................................................... 49<br />
<strong>ARHP</strong> Concurrent Sessions............................................ 49<br />
<strong>ARHP</strong> Fitness Session: Tai Chi...................................... 50<br />
Encore Theater................................................................ 50<br />
<strong>ACR</strong> Meet the Professor Sessions................................... 50<br />
<strong>ACR</strong> Special Session: Career Choices in<br />
. Rheumatology............................................................. 52<br />
<strong>ACR</strong> Practice Issues......................................................... 52<br />
<strong>ACR</strong> Workshops............................................................. 52<br />
<strong>ACR</strong> Basic Science Symposium...................................... 53<br />
<strong>ACR</strong> Clinical Symposium............................................... 53<br />
<strong>ACR</strong> Concurrent Abstract Sessions............................... 54<br />
<strong>ACR</strong> Mini-Symposiums................................................... 57<br />
<strong>ACR</strong> REF Special Session: Schiff Lecture...................... 59<br />
<strong>ARHP</strong> Concurrent Sessions............................................ 59<br />
<strong>ARHP</strong> Concurrent Abstract Sessions............................. 60<br />
<strong>ACR</strong> Workshops............................................................. 60<br />
<strong>ARHP</strong> Concurrent Session............................................. 61<br />
<strong>ACR</strong> Basic Science Symposium...................................... 61<br />
<strong>ACR</strong> Clinical Symposium............................................... 62<br />
<strong>ACR</strong> Concurrent Abstract Sessions .............................. 62<br />
<strong>ACR</strong> Meet the Professor Sessions................................... 66<br />
<strong>ACR</strong> REF Special Session: Dubois Lecture.................... 67<br />
<strong>ACR</strong>/<strong>ARHP</strong> Concurrent Abstract Session.................... 68<br />
<strong>ARHP</strong> Concurrent Sessions............................................ 68<br />
Industry Roundtable-Supported Symposia..................... 69<br />
<strong>ACR</strong>/<strong>ARHP</strong> Poster Session A (Abstracts #1–664)<br />
Systemic Sclerosis, Fibrosing Syndromes and<br />
Raynaud’s: Clinical Aspects and Therapeutics I<br />
(Abstracts #1–32)........................................................ 70<br />
Systemic Sclerosis, Fibrosing Syndromes and<br />
Raynaud’s: Pathogenesis, Animal Models and<br />
Genetics (Abstracts #33–69)....................................... 72<br />
Epidemiology and Health Services Research I<br />
(Abstracts #70– 102)................................................... 75<br />
Fibromyalgia: Etiology and Treatment I<br />
. (Abstracts #103–127).................................................. 77<br />
Cytokines, Mediators and Gene Regulation I<br />
. (Abstracts #128–156).................................................. 79<br />
Education (Abstracts #157–161)..................................... 81<br />
Improving Quality of Care by Design, Redesign,<br />
. and Innovation (Abstracts #162–183)........................ 82<br />
Osteoarthritis: Clinical Aspects I<br />
(Abstracts #184–218).................................................. 83<br />
Pediatric Rheumatology: Clinical and Therapeutic<br />
Aspects I (Abstracts #219–255)................................... 85<br />
RA New and Established Therapies: Efficacy and<br />
Safety I (Abstracts #256–291)..................................... 88<br />
RA: Clinical Aspects I (Abstracts #292–356)................. 91<br />
RA: Human Etiology and Pathogenesis I<br />
. (Abstracts #357–393).................................................. 97<br />
SLE: Animal Models I (Abstracts #394–425)................. 99<br />
SLE: Clinical Aspects and Treatment I<br />
. (Abstracts #426–509)................................................ 101<br />
SLE: Human Etiology and Pathogenesis I<br />
(Abstracts #510–535)................................................... 105<br />
Genetics, Genomics and Proteomics I<br />
. (Abstracts #536–555)................................................ 107<br />
Spondylarthropathies and Psoriatic Arthritis:<br />
Pathogenesis, Etiology (Abstracts #556–577)........... 109<br />
Spondylarthropathies and Psoriatic Arthritis:<br />
. Treatment I (Abstracts #578–616)............................ 110<br />
Clinical Osteoporosis and Metabolic Bone Disease I<br />
. (Abstracts #617–640)................................................ 113<br />
Imaging of Rheumatic Diseases<br />
(Abstracts #641–664)................................................ 115<br />
Industry Roundtable-Supported Symposia................... 118<br />
Friday, November 9, <strong>2007</strong><br />
REF 5K Run/Walk....................................................... 123<br />
<strong>ACR</strong>/<strong>ARHP</strong> Registration............................................. 123<br />
<strong>ACR</strong> Immunology Updates for Clinicians................... 123<br />
<strong>ACR</strong> State of the Art..................................................... 124<br />
<strong>ARHP</strong> Concurrent Sessions.......................................... 124<br />
<strong>ACR</strong> Meet the Professor Sessions................................. 125<br />
<strong>ACR</strong> Workshops........................................................... 126<br />
<strong>ACR</strong>/<strong>ARHP</strong> Coffee and Tea Break............................. 127<br />
<strong>ACR</strong>/<strong>ARHP</strong> Poster Session B...................................... 127<br />
Exhibits..........................................................................127<br />
<strong>ACR</strong> Medical Aspects of Rheumatic Diseases.............. 127<br />
<strong>ACR</strong> State-of-the-Art..................................................... 127<br />
<strong>ARHP</strong> Special Session: How to Decipher a Poster....... 128<br />
<strong>ARHP</strong> Concurrent Sessions.......................................... 128<br />
<strong>ARHP</strong> Concurrent Abstract Session............................ 128<br />
<strong>ACR</strong> Workshops........................................................... 129<br />
<strong>ARHP</strong> General Session II............................................. 129<br />
<strong>ACR</strong> Practice Issues....................................................... 130<br />
<strong>ACR</strong> Plenary Session II................................................. 130<br />
<strong>ACR</strong> Special Session: Curbside Consults..................... 130<br />
<strong>ACR</strong> Special Session: Workforce Issues....................... 131<br />
<strong>ARHP</strong> Special Session: Networking at Noon............... 131<br />
Encore Theater.............................................................. 132<br />
<strong>ACR</strong> Meet the Professor Sessions................................. 132<br />
<strong>ACR</strong> Special Session: Young Investigators................... 133<br />
<strong>ACR</strong> Workshops........................................................... 134<br />
<strong>ACR</strong> Basic Science Symposium.................................... 134<br />
<strong>ACR</strong> Clinical Symposia................................................ 135<br />
4
table of contents<br />
<strong>ACR</strong> Concurrent Abstract Sessions............................. 135<br />
<strong>ACR</strong> CORC Forum...................................................... 139<br />
<strong>ACR</strong>/<strong>ARHP</strong> Combined Clinical Symposium............. 139<br />
<strong>ACR</strong> Special Session: Clinician Scholar<br />
Educator Awards....................................................... 140<br />
<strong>ARHP</strong> Concurrent Sessions.......................................... 140<br />
<strong>ARHP</strong> Concurrent Abstract Session............................ 141<br />
<strong>ACR</strong> Mini-Symposium.................................................. 141<br />
<strong>ACR</strong> Workshops........................................................... 142<br />
<strong>ACR</strong> Basic Science Symposia........................................ 142<br />
<strong>ACR</strong> Clinical Symposium............................................. 143<br />
<strong>ACR</strong> Concurrent Abstract Sessions............................. 143<br />
<strong>ACR</strong>/<strong>ARHP</strong> Combined Concurrent Abstract Session... 148<br />
<strong>ACR</strong> Meet the Professor Sessions................................. 149<br />
<strong>ARHP</strong> Concurrent Sessions.......................................... 151<br />
<strong>ACR</strong> Study Groups: Session I....................................... 152<br />
Encore Theater.............................................................. 158<br />
<strong>ACR</strong> Study Group Reception....................................... 158<br />
<strong>ACR</strong> Study Groups: Session II..................................... 158<br />
<strong>ACR</strong> Poster Session B (Abstracts #769–1275)<br />
Cytokines, Mediators and Gene Regulation II<br />
(Abstracts #769–797).................................................... 164<br />
Epidemiology and Health Services Research II<br />
. (Abstracts #798–810)................................................ 166<br />
. (Abstracts #815-821) & (Abstracts #825-832).......... 167<br />
. (Absstracts #833-837)................................................ 168<br />
Genetics, Genomics and Proteomics II<br />
. (Abstracts #811–814)................................................ 168<br />
. (Abstracts #822–824) & (Abstracts #838–850)........ 169<br />
Miscellaneous Rheumatic and Inflammatory Diseases I<br />
(Abstracts #851–875).................................................... 170<br />
Pediatric Rheumatology: Clinical and Therapeutic<br />
Aspects II (Abstracts #876–913)................................... 171<br />
RA Animal Models: Novel Experimental Therapies<br />
(Abstracts #914–939).................................................... 174<br />
RA New and Established Therapies: Efficacy and<br />
Safety II (Abstracts #940–975).................................. 176<br />
RA: Clinical Aspects II (Abstracts #976–1039)............ 179<br />
RA: Human Etiology and Pathogenesis II<br />
(Abstracts #1040–1076)................................................ 183<br />
Sjögren’s Syndrome (Abstracts #1077–1103)............... 186<br />
SLE: Clinical Aspects and Treatment II<br />
(Abstracts #1104–1152)................................................ 188<br />
Spondylarthropathies and Psoriatic Arthritis:<br />
Treatment II (Abstracts #1153–1192).......................... 192<br />
Systemic Sclerosis, Fibrosing Syndromes, and<br />
Raynaud’s: Clinical Aspects and Therapeutics II<br />
(Abstracts #1193–1225)................................................ 195<br />
Vasculitis I (Abstracts #1226–1250)............................. 197<br />
<strong>ARHP</strong> (Abstracts #1251–1275).................................... 199<br />
Saturday, November 10, <strong>2007</strong><br />
<strong>ACR</strong>/<strong>ARHP</strong> Registration............................................. 203<br />
<strong>ACR</strong> Special Session: Quality Town Hall <strong>Meeting</strong>...... 203<br />
<strong>ARHP</strong> Special Session: <strong>Meeting</strong> Success...................... 203<br />
<strong>ACR</strong> Medical Aspects of Rheumatic Diseases.............. 204<br />
<strong>ACR</strong> State-of-the-Art..................................................... 204<br />
<strong>ARHP</strong> Concurrent Sessions.......................................... 204<br />
<strong>ACR</strong> Meet the Professor Sessions................................. 205<br />
<strong>ACR</strong> Special Session: A&R at 50.................................. 206<br />
REF Estate Planning Session........................................ 207<br />
<strong>ACR</strong> Workshops........................................................... 207<br />
<strong>ARHP</strong> Concurrent Session........................................... 207<br />
<strong>ACR</strong>/<strong>ARHP</strong> Coffee and Tea Break............................. 207<br />
<strong>ACR</strong>/<strong>ARHP</strong> Poster Session C...................................... 208<br />
Exhibits..........................................................................208<br />
<strong>ACR</strong> Immunology Updates for Clinicians................... 208<br />
<strong>ACR</strong> REF Special Session: Klemperer Lecture............. 208<br />
<strong>ARHP</strong> Concurrent Sessions.......................................... 208<br />
<strong>ARHP</strong> Concurrent Abstract Session............................ 209<br />
<strong>ARHP</strong> Special Session: How to Decipher a Poster....... 209<br />
<strong>ACR</strong> Workshops........................................................... 209<br />
<strong>ARHP</strong> Concurrent Sessions.......................................... 209<br />
<strong>ACR</strong> Practice Issues....................................................... 210<br />
<strong>ACR</strong> Clinical Symposium............................................. 210<br />
<strong>ACR</strong> Plenary Session III................................................ 211<br />
<strong>ARHP</strong> Fitness Session: Tai Chi.................................... 211<br />
<strong>ACR</strong> Special Session: Recertification Information...... 211<br />
Encore Theater.............................................................. 212<br />
<strong>ACR</strong> Meet the Professor Sessions................................. 212<br />
<strong>ACR</strong> Workshops........................................................... 213<br />
<strong>ACR</strong> Business <strong>Meeting</strong> and Late-Breaking Abstracts... 214<br />
<strong>ACR</strong> Advocacy Issues.................................................... 214<br />
<strong>ACR</strong> Basic Science Symposium.................................... 214<br />
<strong>ACR</strong> Concurrent Abstract Sessions............................. 215<br />
<strong>ACR</strong> Special Session: The Great Debate...................... 219<br />
<strong>ARHP</strong> Concurrent Sessions.......................................... 220<br />
<strong>ARHP</strong> Concurrent AbstractSession.............................. 220<br />
<strong>ACR</strong> Workshops........................................................... 221<br />
<strong>ARHP</strong> Concurrent Session........................................... 222<br />
<strong>ACR</strong> Basic Science Symposium.................................... 222<br />
<strong>ACR</strong> Clinical Symposium............................................. 222<br />
<strong>ACR</strong> Concurrent Abstract Sessions............................. 222<br />
<strong>ACR</strong> Meet the Professor Sessions................................. 228<br />
<strong>ACR</strong>/<strong>ARHP</strong> Combined Clinical Symposium............. 230<br />
<strong>ARHP</strong> Concurrent Sessions.......................................... 230<br />
Industry Roundtable-Supported Symposia................... 231<br />
5
table of contents<br />
<strong>ACR</strong>/<strong>ARHP</strong> Poster Session C (Abstracts #1387-2050)<br />
Antiphospholipid Syndrome I (Abstracts #1387–1412).... 232<br />
B-Cell Biology and Targets in Autoimmune<br />
Disease II (Abstracts #1413-1438)................................. 234<br />
Biology and Pathology of Bone and Joint<br />
(Abstracts #1439-1471)................................................. 235<br />
Cell, Cell Adhesion, Cell Trafficking and Angiogenesis<br />
(Abstracts #1472-1483)............................................. 238<br />
Epidemiology and Health Services Research III<br />
(Abstracts #1484-1517)............................................. 239<br />
Fibromyalgia: Etiology and Treatment II<br />
(Abstracts #1518-1543)............................................. 241<br />
Clinical Osteoporosis and Metabolic Bone Disease II<br />
(Abstracts #1544-1568)............................................. 243<br />
Infection Related Rheumatic Disease<br />
(Abstracts #1569-1582)............................................. 245<br />
Innate Immunity and Rheumatic Disease<br />
(Abstracts #1583-1613)............................................. 246<br />
Metabolic and Crystal Arthropathies<br />
(Abstracts #1614-1627)............................................. 248<br />
Miscellaneous Rheumatic and Inflammatory Diseases II<br />
(Abstracts #1628-1653)............................................. 249<br />
Muscle Biology, Myositis and Myopathies<br />
(Abstracts #1654-1671)............................................. 251<br />
Osteoarthritis: Clinical Aspects II<br />
(Abstracts #1672-1706)............................................. 252<br />
Pediatric Rheumatology: From Genes to Cells<br />
(Abstracts #1707-1733)............................................. 255<br />
Post-Surgical Rehabilitation and Low Back Pain<br />
(Abstracts #1734-1741)............................................. 257<br />
RA Animal Models: Clues to Pathogenesis<br />
(Abstracts #1742-1768)............................................. 258<br />
RA Treatment: Novel Targets, Mechanisms of Action and<br />
Predictors of Response (Abstracts #1769-1805)....... 260<br />
RA: Clinical Aspects III (Abstracts #1806-1901).......... 263<br />
SLE: Clinical Aspects and Treatment III<br />
(Abstracts #1902-1951)............................................. 268<br />
SLE: Human Etiology and Pathogenesis II<br />
(Abstracts #1952-1978)............................................. 272<br />
T-Cells in Autoimmunity (Abstracts #1979-1999)....... 274<br />
Vasculitis II (Abstracts #2000-2025)............................. 275<br />
<strong>ARHP</strong> (Abstracts #2026-2050)...................................... 277<br />
Industry Roundtable-Supported Symposia................... 280<br />
Sunday, November 11, <strong>2007</strong><br />
<strong>ACR</strong>/<strong>ARHP</strong> Registration............................................. 285<br />
<strong>ACR</strong>/<strong>ARHP</strong> Coffee and Tea Break……………………..….285<br />
<strong>ACR</strong> Immunology Updates for Clinicians................... 285<br />
<strong>ACR</strong> Practice Issues....................................................... 285<br />
<strong>ACR</strong> Special Session: Rheumatology Roundup........... 285<br />
<strong>ARHP</strong> Concurrent Sessions.......................................... 285<br />
<strong>ACR</strong> Basic Science Symposium.................................... 286<br />
<strong>ACR</strong> Clinical Symposia................................................ 287<br />
<strong>ACR</strong> Concurrent Abstract Sessions............................. 287<br />
<strong>ARHP</strong> Concurrent Session........................................... 289<br />
<strong>ARHP</strong> Concurrent Abstract Session............................ 289<br />
<strong>ARHP</strong> Concurrent Sessions.......................................... 290<br />
<strong>ACR</strong> Basic Science Symposium.................................... 291<br />
<strong>ACR</strong> Clinical Symposia................................................ 292<br />
<strong>ACR</strong> Concurrent Abstract Sessions............................. 292<br />
Industry-Supported Post-Conference Symposia............ 294<br />
Floor Plans .............................................................. 302<br />
Exhibitor Information......................................... 307<br />
Recognition<br />
Acknowledgements....................................................... 316<br />
<strong>2007</strong> <strong>ACR</strong> Annual <strong>Meeting</strong> Leadership....................... 317<br />
<strong>2007</strong> <strong>ARHP</strong> Annual <strong>Meeting</strong> Leadership..................... 320<br />
<strong>ACR</strong>/<strong>ARHP</strong> Award Recipients.................................... 321<br />
<strong>ACR</strong>, <strong>ARHP</strong> and REF Staff Members.......................... 324<br />
<strong>ACR</strong> Research and Education Foundation<br />
REF Leadership & Councils......................................... 326<br />
REF Award <strong>Program</strong>s & Recipients............................. 327<br />
REF Honor Roll Of Donors......................................... 332<br />
REF Within Our Reach .................................................. 336<br />
Calls for Proposals<br />
2008 <strong>ACR</strong> Call for Suggestions.................................... 338<br />
2008 <strong>ARHP</strong> Call for Proposals..................................... 339<br />
Indices<br />
Speaker Index................................................................ 340<br />
Moderator Index........................................................... 355<br />
<strong>ACR</strong> Clinical Research Conference<br />
Abstract Author Index.............................................. 360<br />
<strong>ACR</strong>/<strong>ARHP</strong> Abstract Author Index............................ 362<br />
<strong>ACR</strong>/<strong>ARHP</strong> Abstract Moderator Index....................... 413<br />
<strong>ACR</strong>/<strong>ARHP</strong> Abstract Keyword Index.......................... 418<br />
Conference Recording Order Information<br />
. ...................................................................................425<br />
6
the<br />
<strong>ACR</strong>/<strong>ARHP</strong><br />
ANNUAL SCIENTIFIC MEETING<br />
The premier event for specialists in the field of rheumatology and<br />
we are continuing to enhance our meeting to bring you the best...<br />
INNOVATIVE SESSION FORMATS<br />
<strong>ACR</strong> Curbside Consults - Ask the Professors Speakers<br />
will respond to specific case-based clinical questions;<br />
answers are based on a combination of published data<br />
and clinical experience.<br />
Rheumatology Roundup: Highlights from the<br />
<strong>2007</strong> <strong>ACR</strong> Annual <strong>Scientific</strong> <strong>Meeting</strong> Leaders in the field<br />
will offer their personalized commentary on abstracts<br />
presented during the annual meeting.<br />
new this year<br />
Arthritis & Rheumatism 50 Year Anniversary Session<br />
Former editors and current scientists will provide their perspective on the evolution of current<br />
clinical concepts, the role of Arthritis & Rheumatism in that evolution, and the future of<br />
rheumatology publications.<br />
MORE OPTIONS FOR CLINICIANS<br />
· Disease specific and case-based clinical symposia scheduled opposite the plenary sessions.<br />
· Translational content incorporated throughout the meeting.<br />
ENCORE THEATER<br />
· Selected <strong>ACR</strong> sessions will be recorded and replayed during the annual meeting.<br />
ENHANCED ELECTRONIC SYLLABI<br />
View, download and print speaker syllabi during and after the annual meeting. Printed copies of<br />
syllabi will not be available this year; printed syllabi for the pre-conference courses, Meet the<br />
Professor sessions and Workshops will be distributed on site. You may print limited copies of speaker<br />
syllabi in the message center located in the North Lobby. Following the meeting, a complete<br />
scientific syllabus on CD will be mailed to each scientific registrant.<br />
INTERNET ACCESS AND RECHARGE AREAS<br />
· Recharge areas will include work stations with power outlets designed for you to connect your<br />
laptop, recharge your mobile or check e-mail via the complimentary Wi-Fi-enabled Internet access.
CME Credits/Certificates of Participation<br />
Physicians<br />
The <strong>American</strong> College of Rheumatology is accredited by the<br />
Accreditation Council for Continuing Medical Education<br />
(ACCME) to sponsor continuing medical education<br />
for physicians. The <strong>ACR</strong> designates the Basic Research<br />
Conference, the Clinical Research Conference, Review<br />
Course, <strong>ARHP</strong> Clinical Focus Course, <strong>ACR</strong> <strong>Scientific</strong><br />
Sessions, Special Lectures, <strong>ACR</strong> Workshops and the <strong>ACR</strong><br />
Meet the Professor Sessions for AMA PRA Category 1<br />
Credits TM . Physicians should only claim credit commensurate<br />
with the extent of their participation in the activity.<br />
Health Professionals<br />
As a division of the College, the Association of Rheumatology<br />
Health Professionals offers a Certificate of Participation.<br />
The <strong>ARHP</strong> designates the Clinical Focus Course, <strong>Scientific</strong><br />
Sessions, <strong>ACR</strong> pre-conference courses and the <strong>ACR</strong> Meet the<br />
Professor/Workshop sessions for hours of participation.<br />
International Physicians<br />
As an accredited provider, the <strong>American</strong> College of<br />
Rheumatology may issue credits to both U.S. and<br />
international physicians for any program, including the<br />
<strong>ACR</strong>/<strong>ARHP</strong> Annual <strong>Scientific</strong> <strong>Meeting</strong>, that has been<br />
designated for AMA PRA Category 1 Credits TM in accordance<br />
with PRA requirements.<br />
<strong>Meeting</strong> Evaluations, CME Credit, <strong>ARHP</strong><br />
Certificates of Participation and Certificates<br />
of Attendance<br />
You will have the opportunity to complete your CME/Certificate<br />
of Participation application and <strong>Meeting</strong> Evaluation form online<br />
during the meeting. Computers and printers will be available for<br />
you to update the sessions you have attended daily and you can<br />
print your credit/participation certificate. In addition, you can<br />
complete the process online from your hotel room during the<br />
meeting or after you return home.<br />
If you are an international physician and require a Certificate of<br />
Attendance, this is enclosed in your meeting briefcase. If your<br />
country recognizes AMA PRA Category 1 Credits in accordance<br />
with PRA requirements, please complete a meeting evaluation<br />
and CME application.<br />
Your evaluation of the meeting is very important, and we<br />
encourage you to complete your evaluation and CME/Certificate<br />
application online. If you must use the printed form, please<br />
complete and return it at the conclusion of the meeting to the<br />
message center. CME and certificates of participation will be<br />
e-mailed within 12 weeks of the meeting.<br />
If necessary, you may mail the completed form to the <strong>ACR</strong>/<br />
<strong>ARHP</strong> office within two weeks of the close of this meeting, and<br />
a CME Credit Certificate/Certificate of Participation will be<br />
e-mailed to you.<br />
The <strong>ACR</strong> is not responsible for forms that are incomplete,<br />
incorrect or submitted after the deadline of November 21,<br />
<strong>2007</strong>. CME credit is provided only to registered <strong>ACR</strong> attendees.<br />
Certificates of participation are provided to registered <strong>ARHP</strong><br />
attendees. Guest registrants and exhibitors are not eligible for<br />
credit. Please do not submit more than one form.<br />
Conflict of Interest/Disclosure Statements<br />
As an educational provider accredited by the Accreditation<br />
Council for Continuing Medical Education (ACCME), the<br />
<strong>American</strong> College of Rheumatology must ensure balance,<br />
independence, objectivity and scientific rigor in all its<br />
educational activities. Therefore, all speakers and moderators<br />
participating in an <strong>ACR</strong>-sponsored activity are required<br />
to disclose to the planning committee and audience any<br />
financial or other relationships including, but not limited to:<br />
None: Nothing to disclose<br />
1. Stock, stock options or bond holdings in a for-profit<br />
corporation or self-directed pension plan<br />
2. Research grants<br />
3. Employment (full or part-time)<br />
4. Ownership or partnership<br />
5. Consulting fees or other remuneration (payment)<br />
6. Non-remunerative positions of influence such as<br />
officer, board member, trustee or public spokesperson<br />
7. Receipt of royalties<br />
8. Speakers’ bureau<br />
9. Other<br />
Speakers, moderators and abstract authors were required<br />
to submit their disclosure online prior to publication.<br />
Disclosures for invited speakers are listed in the program<br />
book indices and online. These disclosures are listed by<br />
speaker or moderator last name in numeric format according<br />
to the list above.<br />
Abstract author disclosures are published in supplement to<br />
the September issue of Arthritis & Rheumatism and online.<br />
Disclosures for the Late-Breaking and Fellows-in-Training<br />
Abstracts are published in the <strong>Program</strong> <strong>Book</strong> Supplement and in<br />
the December issue of Arthritis & Rheumatism. An individual<br />
who refuses to disclose relevant financial relationships will<br />
be disqualified from being a planning committee member,<br />
a presenter, or an author of CME, and cannot have control<br />
of, or responsibility for, the development, management,<br />
presentation or evaluation of the CME activity.<br />
8 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
acr abstract embargo policy<br />
Accepted abstracts are made available to the public on the<br />
<strong>ACR</strong> Web site and are published in a special supplement<br />
of Arthritis & Rheumatism in advance of the meeting.<br />
Information contained in those abstracts may not be<br />
released until the abstracts appear on the <strong>ACR</strong> Web site.<br />
Academic institutions, private organizations, and<br />
companies with products whose value may be influenced<br />
by information contained in an abstract may issue a press<br />
release to coincide with the availability of an <strong>ACR</strong> abstract<br />
on the <strong>ACR</strong> Web site.<br />
However, the <strong>ACR</strong> continues to require that information<br />
that goes beyond that contained in the abstract, e.g.,<br />
discussion of the abstract done as part of a scientific<br />
presentation or presentation of additional new<br />
information that will be available at the time of the<br />
meeting, is under embargo until 5:30 p m Eastern Time<br />
on Wednesday, November 7. Violation of this policy may<br />
result in the abstract being withdrawn from the meeting<br />
and other measures deemed appropriate.<br />
It is not considered a violation of this policy if the<br />
abstract is published in a peer reviewed journal after the<br />
abstract submission deadline. Authors are responsible<br />
for notifying financial and other sponsors about this<br />
policy. The one exception to this embargo policy is that<br />
the abstracts presented at the <strong>ACR</strong> Clinical Research<br />
Conference are under embargo until 8:00 a m Eastern<br />
Time on Tuesday, November 6.<br />
Visit <strong>ACR</strong> Central<br />
in the North Lobby<br />
Education<br />
New Annual <strong>Meeting</strong> products<br />
Slide Collections<br />
2008 <strong>ACR</strong>/<strong>ARHP</strong> Educational Events<br />
Recertification<br />
Information<br />
Advocacy<br />
Coding Help<br />
Continuous Professional Development<br />
Quality Movement<br />
the spot for…<br />
www.rheumatology.org—Rheumatology’s Home on the Web 9
meeting information<br />
Ask Me Staff<br />
If you have a question about the meeting or need directions<br />
to a room, look for one of the Ask Me staff who will be<br />
available throughout the convention center.<br />
Cell Phones, Pagers, PDAs, Other Electronic Devices<br />
Electronic devices must be operated in silent/vibrate<br />
mode within educational sessions. No cellular phone<br />
conversations will be permitted within meeting rooms.<br />
Children<br />
Registrants may not take children into educational sessions.<br />
Individuals 18 years and over are required to pay the guest<br />
fee to be admitted to the exhibit hall and attend the opening<br />
reception. An adult must accompany children at all times.<br />
Individuals under 18 years of age are not permitted into<br />
the exhibit hall during move-in or move-out times. Strollers<br />
and children’s scooters are not permitted in the exhibit<br />
hall. You may make arrangements for childcare through<br />
the front desk or concierge of your hotel.<br />
Emergency Contact Information<br />
Space is provided on the back of your badge to list name<br />
and telephone numbers of your emergency contacts. Please<br />
complete this information before inserting your badge in<br />
your badge holder.<br />
Exhibit Hall<br />
Exhibitors will provide the latest information on products<br />
and services available to rheumatologists, researchers and<br />
other health professionals. The <strong>2007</strong> exposition will be<br />
open 8:00 a m–4:30 pm, Thursday - Saturday.<br />
Food Service<br />
Pre-conference courses include a continental breakfast and<br />
box lunch. Beverages are provided for Meet the Professor<br />
sessions and Workshops.<br />
Complimentary coffee will be available in the poster area of<br />
the exhibit hall from 8:00–9:30 a m on Thursday - Saturday.<br />
On Sunday, complimentary coffee will be served from 7:30–<br />
9:00 a m in the shuttle bus lobby of the convention center.<br />
Breakfast, lunch and snacks will be available for purchase<br />
in the exhibit hall on Thursday - Saturday. In addition,<br />
food outlets will be open in several locations throughout<br />
the convention center during the conference.<br />
Attendees can also have lunch in approximately 18<br />
neighborhood restaurants by using the complimentary<br />
trolley service, which departs from the North Lobby. Pickup<br />
and drop-off occurs every 7-10 minutes between noon<br />
and 3:00 pm either at the convention center or from a<br />
participating restaurant. For more information, visit one<br />
of the Dining in the Neighborhood Trolley Booths located<br />
throughout the convention center.<br />
Location, Parking and Metro<br />
The conference will be held at the Boston Convention and<br />
Exhibition Center, 415 Summer Street, Boston, MA 02110<br />
in the South Boston Seaport District, which is just east of<br />
downtown.<br />
Public parking is available at the convention center for<br />
conference attendees. Valet is $15 ($20 after 4:00 pm); selfparking<br />
is $10. The convention center is serviced by the<br />
Silver Line which is accessed at South Station (Red Line).<br />
<strong>Meeting</strong> Disclaimer<br />
Unless otherwise stated, attendance at any scientific session<br />
is open to all registrants of the Annual <strong>Scientific</strong> <strong>Meeting</strong>.<br />
Attendance at sessions is on a first-come, first-served basis.<br />
Although the <strong>ACR</strong> makes every attempt to accommodate<br />
everyone, due to room size limitations, the <strong>ACR</strong> cannot<br />
guarantee a seat at any of the scientific sessions. In the<br />
event that room capacity is achieved, the session will<br />
be closed and you will not be permitted to enter until<br />
someone has left. We regret that the <strong>ACR</strong> cannot issue<br />
refunds for sessions that are closed.<br />
Important Fire Safety Information<br />
Seating capacity has been maximized in all session rooms<br />
according to local fire regulations. Standing in the aisle<br />
or against the walls is not permitted. If overcrowding<br />
occurs, staff/security personnel will close the session.<br />
Additional individuals will be allowed to enter as<br />
participants exit the room.<br />
If space does not permit you to attend a session, a<br />
CD or MP3 of the session may be available for purchase<br />
at the Conference Recording Sales desk located next to<br />
<strong>ACR</strong> Central. Alternatively, the session may be replayed in<br />
the Encore Theater. See page 69 for more information.<br />
10 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
meeting information<br />
Name Badges<br />
For security reasons, your badge will be required for<br />
admittance to all sessions, exhibits, social events and shuttle<br />
buses. Please wear your badge so it can be easily seen at<br />
all times. Lost badges should be reported to Registration<br />
immediately.<br />
No Smoking<br />
All meeting facilities at the convention center, hotel<br />
meeting rooms and other venues have been designated as<br />
non-smoking areas.<br />
Opening Dessert Reception<br />
Join us on Wednesday evening, November 7, from 8:30–<br />
10:30 pm for a dessert reception at Sheraton Boston Hotel<br />
in the Back Bay. Shuttle bus transportation to/from the<br />
Sheraton Boston Hotel will be provided from official <strong>ACR</strong><br />
hotels that are not within walking distance.<br />
Photography and Videotaping<br />
Photographers will be present at the meeting. Your picture<br />
may be used in future promotional material. Visual<br />
reproduction of sessions is prohibited without prior<br />
written permission of the <strong>ACR</strong>. <strong>ACR</strong> reserves the rights<br />
to audio or video reproduction at the <strong>2007</strong> <strong>ACR</strong>/<strong>ARHP</strong><br />
Annual <strong>Scientific</strong> <strong>Meeting</strong>.<br />
Shuttle Bus Service<br />
The following hotels are within walking distance and will<br />
not have bus service: Westin Waterfront and Seaport hotels.<br />
All other <strong>ACR</strong> hotels will have complimentary bus<br />
transportation to/from the convention center. Service<br />
begins at approximately 6:30 am on Tuesday, November 6 and<br />
concludes at approximately 4:00 pm on Sunday, November 11.<br />
Detailed schedule information will be posted in the<br />
bus lobby of the convention center and the lobbies of<br />
participating hotels.<br />
The <strong>ACR</strong> thanks Abbott Laboratories, Bristol-Myers Squibb Company<br />
and UCB, Inc. for their support of the <strong>2007</strong> Conference Shuttle Buses.<br />
Special Needs<br />
If you require special arrangements in order to participate<br />
in the meeting, please contact Ron Olejko, Senior Director<br />
– <strong>Meeting</strong> Services, in the <strong>ACR</strong> Office at (617) 954-3680.<br />
<strong>ACR</strong> CODING<br />
IF YOU HAVE QUESTIONS... WE HAVE ANSWERS.<br />
HCPCS? CPT? ICD-9?<br />
Come visit the <strong>ACR</strong> certified coders at the “Coding Center” located in the<br />
North Lobby next to <strong>ACR</strong> Central for a chance to win a special prize!<br />
www.rheumatology.org—Rheumatology’s Home on the Web 11
Important Locations<br />
<strong>ACR</strong>, <strong>ARHP</strong> and REF Awards Exhibit...............................North Lobby<br />
<strong>ACR</strong> Central............................................................North Lobby<br />
<strong>ACR</strong> Office..............................................................Room 204<br />
tel: (617) 954-3680 f a x: (617) 954-3684<br />
<strong>ACR</strong> Practice Advocacy Coding Center........................North Lobby<br />
Advocacy Booth......................................................North Lobby<br />
Business Center.......................................................Between North Lobby and Room 101<br />
Coat/Baggage........................................................Shuttle Bus Lobby<br />
Conference Recording Sales Desk...............................North Lobby<br />
First Aid.................................................................Between North Lobby and Room 150<br />
Hotel Reservations .................................................<strong>ACR</strong> Registration (Exhibit Level)<br />
Industry Symposia Information..................................North Lobby<br />
Job Opportunities ..................................................North Lobby<br />
and Announcements<br />
Journals................................................................North Lobby<br />
Lost and Found.......................................................<strong>ACR</strong> Office (Room 204)<br />
Membership Booth....................................................<strong>ACR</strong> Registration (Exhibit Level)<br />
Message Center and CME Information..........................North Lobby<br />
w e b : acr<strong>2007</strong>.globalmessenger.net (no www or http required)<br />
tel: (617) 954-3690<br />
See “<strong>Meeting</strong> Services” on page 16-17 for a detailed description of how to use the global messenger service.<br />
Newsroom..............................................................Room 252<br />
tel: (617) 954-3685 f a x: (617) 954-3687<br />
REF Booth..............................................................North Lobby<br />
REF Donors’ Lounge.................................................Boardroom Suite 201-202<br />
Registration...........................................................<strong>ACR</strong> Registration (Exhibit Level)<br />
Restaurant Reservations..........................................North Lobby<br />
Speaker Ready Room.................................................Room 206<br />
Visitor Information.................................................North Lobby<br />
12 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
definition of Session Types<br />
Pre-Conference Courses<br />
Pre-conference courses are designed to offer<br />
attendees with a specific interest a unique<br />
learning opportunity. A separate registration<br />
fee is required.<br />
<strong>ARHP</strong> General Sessions<br />
Interdisciplinary sessions scheduled without<br />
competing programs. The topics are of broad<br />
general interest or the speaker is of such<br />
status as to appeal to the membership at large.<br />
<strong>ACR</strong> Year in Review<br />
This session highlights publications of<br />
major interest to the membership that have<br />
appeared in rheumatology literature since<br />
the last meeting. Both the basic science and<br />
clinical perspectives are represented.<br />
<strong>ACR</strong> Practice Issues<br />
This series will address the major changes<br />
in the practice of rheumatology with the<br />
advent of new medications, devices, and<br />
diagnostic and ancillary services for patients.<br />
An update of regulatory tools required in the<br />
new practice environment will be provided.<br />
<strong>ACR</strong> and <strong>ARHP</strong> Clinical Symposia<br />
These symposia provide instruction to<br />
improve patient care. Developments from<br />
other specialties and practical patient<br />
management skills will be emphasized.<br />
<strong>ACR</strong> Basic Science Symposia<br />
These symposia provide an update of the<br />
most recent scientific developments in the<br />
field of rheumatology.<br />
<strong>ACR</strong> Immunology Updates for Clinicians<br />
Sessions designed for clinicians and nonclinicians<br />
who are not involved in<br />
immunological research who desire a<br />
“refresher” in immunology, including new<br />
developments and their implications.<br />
<strong>ACR</strong> Medical Aspects of<br />
Rheumatic Diseases<br />
These sessions cover topics in other<br />
subspecialty areas in internal medicine<br />
that are of importance to the practice of<br />
rheumatology, presented by experts from<br />
other medical subspecialties.<br />
<strong>ACR</strong> State-of-the-Art<br />
These sessions present current information<br />
about topics related to rheumatology, and<br />
are presented by leading experts in their<br />
respective fields.<br />
<strong>ACR</strong> Study Groups<br />
These sessions are designed to bring<br />
together attendees with a common interest<br />
in one disease, a group of related disorders<br />
or a specialized field of study for discussion<br />
and dissemination of information.<br />
<strong>ACR</strong>/<strong>ARHP</strong> Poster Sessions<br />
Sessions featuring the poster presentation of<br />
abstracts, facilitating one-on-one interaction<br />
between the presenter and the audience.<br />
<strong>ACR</strong> Workshops<br />
Workshops are designed to bring attendees<br />
together to foster hands-on learning and<br />
provide an opportunity for interaction and<br />
consultation with highly respected professionals<br />
who have expertise in a particular area. A<br />
separate registration fee is required.<br />
<strong>ACR</strong> Workshops for Trainees<br />
To create an opportunity for fellows to<br />
interact with respected professionals, several<br />
sessions are designated for trainees only. A<br />
separate registration fee is required.<br />
<strong>ACR</strong> and <strong>ARHP</strong> Concurrent<br />
Abstract Sessions<br />
Abstract sessions are the main forums for<br />
didactic presentation of original research,<br />
special interest or case report abstracts<br />
related to rheumatic diseases.<br />
<strong>ARHP</strong> Concurrent Sessions<br />
These sessions offer educational programs<br />
of interest to various health professionals.<br />
Concurrent sessions include invited speakers;<br />
peer-reviewed programs and lectures.<br />
<strong>ACR</strong> Mini-Symposia<br />
Mini-symposia are designed to integrate<br />
oral abstract presentations with review talks<br />
to enhance and broaden understanding<br />
of the research area and to permit a more<br />
balanced view.<br />
<strong>ACR</strong> Plenary Sessions: Discovery <strong>2007</strong><br />
Three plenary sessions will be offered. Each<br />
thematic session will highlight abstracts<br />
of significant novelty and importance.<br />
Translational commentaries will be<br />
provided by experts in the field.<br />
<strong>ACR</strong> Poster Discussions<br />
Abstracts are presented on poster boards,<br />
with time allotted for attendees to view the<br />
various posters. Each presenter makes a<br />
short oral presentation from the podium.<br />
<strong>ACR</strong> Meet the Professor Sessions<br />
These sessions provide an opportunity for<br />
interaction and consultation with highly<br />
respected professionals who have expertise<br />
in a particular area. A separate registration fee<br />
is required.<br />
<strong>ACR</strong> Meet the Professor Sessions for Trainees<br />
To create an opportunity for fellows to<br />
interact with respected professionals, several<br />
sessions are designated for trainees only. A<br />
separate registration fee is required.<br />
<strong>2007</strong> Special Sessions<br />
Rheumatology Roundup: Highlights from<br />
the <strong>2007</strong> <strong>ACR</strong> Annual <strong>Scientific</strong> <strong>Meeting</strong><br />
Leaders in the field will offer their<br />
personalized commentary on abstracts<br />
presented during the annual meeting.<br />
The <strong>2007</strong> Rheumatology Roundup is supported<br />
through an educational grant from Novartis.<br />
Arthritis & Rheumatism at 50: The Best<br />
of the Past, the Best of the Future<br />
Former editors and current scientists will<br />
provide their perspective on the evolution<br />
of current clinical concepts, the role of<br />
Arthritis & Rheumatism in that evolution, and<br />
the future of rheumatology publications.<br />
Clinicopathologic Conference Format<br />
A clinical teaching exercise in which the<br />
history and progression of a specific patient’s<br />
illness is discussed by invited consultants.<br />
<strong>ACR</strong> Curbside Consults - Ask the Professors<br />
Speakers will respond to specific case-based<br />
clinical questions; answers are based on a<br />
combination of published data and<br />
clinical experience.<br />
<strong>ACR</strong> Great Debate<br />
A controversial topic is defined, and two or<br />
more speakers address their specific viewpoints.<br />
REF Memorial Lectureships<br />
These sessions are awarded to experts in the<br />
fields of lupus, bone metabolism, pathology,<br />
and musculoskeletal medicine.<br />
www.rheumatology.org—Rheumatology’s Home on the Web 13
educational track information<br />
<strong>ACR</strong><br />
Clinical Practice Basic and<br />
Translational Research<br />
Dual interest to clinicians<br />
and Researchers<br />
Pediatrics<br />
Fellows-in-Training<br />
<strong>ARHP</strong><br />
Clinical Practice<br />
Pediatrics<br />
Fellows-in-Training<br />
The <strong>ACR</strong> and <strong>ARHP</strong> have designed educational tracks to help you maximize the<br />
scheduling of your time and meeting experience by emphasizing primary areas of interest.<br />
There are five tracks for <strong>ACR</strong> and three tracks for <strong>ARHP</strong>. Designated sessions include<br />
the main symposia, lectures and select <strong>ACR</strong> Meet the Professor sessions and Workshops.<br />
However, the concurrent abstract sessions and poster discussions are not included.<br />
Those sessions that are predominantly translational in content are designed to be of<br />
interest to both clinicians and researchers. These are indicated as “C/R”. Sessions with<br />
mainly pediatric content are indicated as “P”, and may be of interest to both pediatric<br />
and adult rheumatologists.<br />
As the annual meeting has a variety of session types scheduled concurrently, use these<br />
suggested tracks as a tool to assist you in developing your own individualized schedule<br />
for the meeting.<br />
track indicator example<br />
Please use the following as an example to identify the available tracks.<br />
C R C/R P F<br />
Clinical<br />
Practice<br />
Basic and<br />
Translational<br />
Research<br />
Dual Interest<br />
to Clinicians<br />
and Researchers<br />
Pediatrics<br />
Fellowsin-Training<br />
PM - Pain Management<br />
The <strong>ACR</strong> designates certain sessions for pain management credit as required by the Medical Board of California (AB487).<br />
This designation is identified by the icon shown and will be placed next to the session title.<br />
¹<br />
Encore Theater - NEW THIS YEAR!<br />
Selected <strong>ACR</strong> sessions will be recorded and replayed during the annual meeting. Therefore, if you missed a session<br />
you can watch the session later that day or the next day in the Encore Theater located in Room 255 of the<br />
convention center. See page 69 for more information.<br />
>>> In addition, over 90 sessions on CD and MP3 will be available for purchase during the annual meeting. Visit the<br />
Conference Recording Sales Desk in the North Lobby next to <strong>ACR</strong> Central.<br />
ARS - Interactive Audience Response Sessions - NEW THIS YEAR!<br />
This year, audience response systems will be introduced into selected sessions to allow a portion of the participants to<br />
participate in the session. In turn, this will provide the <strong>ACR</strong> with valuable learning assessment to continue to enhance<br />
future programs.<br />
14 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
Bone<br />
andJoint<br />
2002 - USA - 2011<br />
MEMBER<br />
The <strong>ACR</strong>, <strong>ARHP</strong> and REF support the<br />
Bone and Joint Decade<br />
The <strong>American</strong> College of Rheumatology, the<br />
Association of Rheumatology Health Professionals,<br />
and the <strong>ACR</strong> Research and Education Foundation<br />
are official supporters of the Bone and Joint Decade.<br />
www.boneandjointdecade.org<br />
www.usbjd.org
meeting services<br />
<strong>ACR</strong> Central<br />
Located in the North Lobby. Need information on<br />
upcoming events in 2008? Would you like to purchase<br />
popular <strong>ACR</strong> and <strong>ARHP</strong> products and get a sneak<br />
preview of upcoming new ones? Or do you just need<br />
directions to your next session? You’re in luck: we have it<br />
all and more at <strong>ACR</strong> Central.<br />
The editorial office staff of Arthritis & Rheumatism and<br />
Arthritis Care & Research is also available to answer<br />
questions concerning online article submission and article<br />
review processes for the journals.<br />
<strong>ACR</strong> Central is open on Wednesday from Noon–6:00 pm,<br />
Thursday–Saturday from 7:30 a m–6:00 pm, and on<br />
Sunday from 7:30 a m–1:30 pm.<br />
<strong>ACR</strong>/<strong>ARHP</strong> Membership Booth<br />
Located at <strong>ACR</strong> Registration on the Exhibit Level. This is<br />
the place to go if you want to become a member, pay dues,<br />
reinstate your membership, learn more about member<br />
benefits and awards, or volunteer to serve on a committee.<br />
<strong>ACR</strong> Practice Advocacy Coding Center<br />
Located in the North Lobby near <strong>ACR</strong> Central. Visit the<br />
<strong>ACR</strong> certified coders for any coding and billing questions.<br />
The coders will be available on Wednesday from Noon–<br />
6:00 pm, Thursday–Saturday from 7:30 a m–6:00 pm, and<br />
on Sunday from 7:30 a m–1:30 pm.<br />
Advocacy Booth<br />
Located in the North Lobby. <strong>ACR</strong> members will be able to:<br />
∙ Learn who their representatives are in Congress<br />
∙ E-mail their legislators about important advocacy issues<br />
∙ Learn how they can become more involved in the<br />
<strong>ACR</strong>’s advocacy efforts<br />
∙ Get copies of the <strong>ACR</strong>’s monthly Public Policy Monitor<br />
Conference Recording Sales Desk<br />
Selected annual meeting sessions are available for<br />
purchase and are marked in the program book.<br />
To purchase, visit the Conference Recording Sales<br />
desk near <strong>ACR</strong> Central in the North Lobby during the<br />
meeting or to pick up the order form for post-conference<br />
ordering instructions.<br />
Encore Theater - Room 255<br />
Selected <strong>ACR</strong> sessions will be recorded and<br />
replayed during the annual meeting. Therefore, if<br />
you missed one of the designated sessions you can watch<br />
the session later that day or the next day in the Encore<br />
Theater located in Room 255 of the convention center.<br />
A complete list of sessions will be available in the <strong>ACR</strong>/<br />
<strong>ARHP</strong> Daily News and on site. However, some sessions<br />
have already been designated for replay and are marked in<br />
the program book. Please see page 69 for hours of operation<br />
and a tentative list of sessions.<br />
Interactive Audience Response Sessions ARS<br />
This year, audience response systems (ARS) will be<br />
introduced into selected sessions to allow some attendees<br />
to participate in the session by answering questions.<br />
Tabulated results are instantly displayed on screen. In<br />
turn, this will provide the <strong>ACR</strong> with valuable learning<br />
assessment to continue to enhance future programs.<br />
Sessions during which audience response systems will be<br />
used are marked in the program book.<br />
Lost and Found<br />
Found items should be returned to the <strong>ACR</strong> Office,<br />
Room 204. If you are looking for a lost item, go to the<br />
<strong>ACR</strong> Office or call (617) 954-3680.<br />
¹<br />
Message Center<br />
Located in the North Lobby. Leave this important information<br />
with your office, family and colleagues to receive messages:<br />
t e l: (617) 954-3690<br />
w e b : acr<strong>2007</strong>.globalmessenger.net (no http or www required)<br />
When you get a message, your name will instantly appear<br />
on one of the scrolling monitors at a message kiosk. If the<br />
wireless delivery option is selected, your message will also<br />
be sent to your personal e-mail account, cell phone, pager<br />
or Palm OS Device.<br />
When utilizing this service, attendees will have the<br />
ability to customize their conference profile by creating<br />
their own password for their mailbox. With the wireless<br />
delivery option, when an attendee sends a message to<br />
another attendee, the message will be delivered to all<br />
of the following: the scrolling monitors on site; the<br />
globalmessenger.net Web site; to their e-mail address and<br />
wirelessly to their cell phone or wireless PDA.<br />
The <strong>ACR</strong> thanks Genentech, Inc. and Biogen Idec for their support<br />
of the <strong>2007</strong> Message/Internet Center.<br />
16 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
meeting services<br />
A simple menu allows you to read, print and reply to messages.<br />
To leave messages for another attendee at the meeting simply<br />
search the names database, select the recipient, and type<br />
your message. The message will be processed immediately.<br />
The Global Messenger System is operational 24 hours a day.<br />
You may also use your laptop PC and the Internet address<br />
above at anytime to post and/or receive messages.<br />
Hours of operation are:<br />
Tuesday, Nov. 6<br />
1:00–6:00 pm<br />
Wednesday, Nov. 7<br />
7:00 a m–7:30 pm<br />
Thursday, Nov. 8<br />
7:00 a m–6:00 pm<br />
Friday, Nov. 9<br />
7:00 a m–6:00 pm<br />
Saturday, Nov. 10<br />
7:00 a m–6:00 pm<br />
Sunday, Nov. 11<br />
7:00 a m–1:30 pm<br />
Newsroom<br />
Located in Room 252. Use of the Newsroom is limited to<br />
media representatives with press passes.<br />
Opportunities and Announcements<br />
Located in the North Lobby. Display boards will be<br />
available in the lobby of the convention center for posting<br />
announcements of employment positions and events of<br />
interest. Posted materials are limited to 8.5” x 11” in size.<br />
Registration<br />
Registration counters are located in on the Exhibit Level<br />
near the Entrance to Hall B.<br />
Hours of operation are:<br />
Tuesday, Nov. 6<br />
7:00 a m–5:00 pm<br />
Wednesday, Nov. 7<br />
7:00 a m–6:30 pm<br />
Thursday, Nov. 8<br />
7:00 a m–5:00 pm<br />
Friday, Nov. 9<br />
7:00 a m–5:00 pm<br />
Saturday, Nov. 10<br />
7:00 a m–5:00 pm<br />
Sunday, Nov. 11<br />
7:00 a m–1:00 pm<br />
REF Booth<br />
Located in the North Lobby. Find out what the REF is<br />
doing to ensure the future of rheumatology by visiting<br />
the REF Booth during the annual meeting. At the booth,<br />
you can view and order the latest print in the Rodnan<br />
Commemorative Gout Print Series, learn more about<br />
current REF initiatives and even receive a gift just for<br />
stopping by!<br />
The REF booth is open on Wednesday from Noon–6:00 pm,<br />
Thursday–Saturday from 7:30 a m–6:00 pm, and on Sunday<br />
from 7:30 a m–1:30 pm.<br />
REF Donors’ Lounge<br />
Located in Boardroom Suite 201-202. At the REF Donors’<br />
Lounge, donors have quick access to e-mail, as well as a<br />
place to network, relax and enjoy refreshments. The lounge<br />
is available to REF lifetime donors, annual donors who<br />
contributed at least $500 to the REF from July 1, 2006<br />
through June 30, <strong>2007</strong> and donors who contribute $500 or<br />
more during the annual meeting. Donors must be wearing<br />
the REF donor ribbon to be admitted. Donor ribbons can<br />
be picked up at the Donors’ Booth, located just outside the<br />
lounge. The lounge is open on Saturday from Noon–6:00 pm,<br />
Sunday–Tuesday from 7:00 a m–6:00 pm, and on<br />
Wednesday from 7:00 a m–12:30 pm.<br />
Speaker Ready Room<br />
Located in Room 206. Check-in is expected of all speakers.<br />
Plan to check in 24 hours prior to your presentation<br />
time. In the Speaker Ready Room, you can review your<br />
presentation and approve the file to be uploaded to the<br />
central server. Professional audiovisual technicians will be<br />
available for assistance. Computers in the Speaker Ready<br />
Room will be configured with hardware and software<br />
exactly like the ones in the meetings rooms and will allow<br />
you to preview your presentation, identify problems and<br />
make corrections as necessary before your presentation.<br />
Hours of operation are:<br />
Tuesday, Nov. 6<br />
7:00 a m–5:30 pm<br />
Wednesday, Nov. 7<br />
7:00 a m–7:30 pm<br />
Thursday, Nov. 8<br />
7:00 a m–6:00 pm<br />
Friday, Nov. 9<br />
7:00 a m–9:15 pm<br />
Saturday, Nov. 10<br />
7:00 a m–6:00 pm<br />
Sunday, Nov. 11<br />
7:00 a m–12:30 pm<br />
The <strong>ACR</strong> thanks UCB, Inc. for their support of the <strong>2007</strong><br />
Speaker Ready Room.<br />
Electronic Syllabus<br />
View, download and print speaker syllabi during and after<br />
the annual meeting. Pre-printed copies of syllabi will not<br />
be available this year.You may print a copy of speaker<br />
syllabi from online up to two weeks prior to the meeting<br />
or you may print a copy in the message center located in<br />
the North Lobby. Following the meeting, a complete scientific<br />
syllabus on CD will be mailed to each scientific registrant.<br />
Wireless Access<br />
The convention center provides free wireless access for<br />
meeting attendees.<br />
www.rheumatology.org—Rheumatology’s Home on the Web 17
acr meeting hotels + Map<br />
∙ Complimentary shuttle buses will operatate to/from the Boston Convention and Exhibition Center and official <strong>ACR</strong><br />
hotels beginning at approximately 6:30 a m on Tuesday, November 6 and concludes at approximately 4:00 pm on<br />
Sunday, November 11.<br />
∙ The following hotels are within walking distance of the convention center and will not have bus service: Westin<br />
Waterfront and Seaport hotels. However, bus service to the Opening Dessert Reception on Wednesday night will be<br />
provided from these hotels.<br />
∙ Detailed schedule information will be posted in the shuttle bus lobby of the convention center and the lobbies of<br />
participating hotels. Pick-up a copy of the schedule at the Transportation Desk located at the shuttle bus entrance of the<br />
convention center.<br />
1 Boston Marriott Copley Place<br />
110 Huntington Avenue, 02113<br />
t e l: (617) 236-5800<br />
2 Boston Marriott Long Wharf<br />
296 State Street, 02109<br />
t e l: (617) 227-0800<br />
3 Boston Park Plaza Hotel & Towers<br />
64 Arlington Street, 02116<br />
t e l: (617) 426-2000<br />
4 Colonnade Hotel<br />
120 Huntington Avenue, 02116<br />
t e l: (617) 424-7000<br />
5 Copley Square Hotel<br />
47 Huntington Avenue, 02116<br />
t e l: (617) 536-9000<br />
6 Courtyard by Marriott Boston Tremont<br />
275 Tremont Street, 02116<br />
t e l: (617) 426-1400<br />
7 Doubletree Hotel Boston Downtown<br />
821 Washington Street, 02111<br />
t e l: (617) 956-7900<br />
8 Embassy Suites Boston at Logan Airport<br />
207 Porter Street, 02128<br />
t e l: (617) 567-5000<br />
9 Fairmont Copley Plaza<br />
138 St. James Avenue, 02116<br />
t e l: (617) 267-5300<br />
10 Hampton Inn & Suites Boston<br />
Crosstown Center<br />
811 Massachusetts Avenue, 02118<br />
t e l: (617) 445-6400<br />
11 Hilton Boston Back Bay<br />
40 Dalton Street, 02116<br />
t e l: (617) 236-1100<br />
12 Hilton Boston Financial District<br />
89 Broad Street, 02110<br />
t e l: (617) 556-0006<br />
13 Hilton Boston Logan Airport<br />
1 Hotel Drive, 02128<br />
t e l: (617) 568-6700<br />
14 Hotel 140<br />
140 Clarendon Street, 02116<br />
t e l: (617) 585-5600<br />
15 Hyatt Harborside at Boston’s<br />
Logan International Airport<br />
101 Harborside Drive, 02128<br />
t e l: (617) 568-1234<br />
16 Hyatt Regency Boston<br />
1 Avenue de Lafayette, 02111<br />
t e l: (617) 912-1234<br />
17 InterContinental Boston<br />
500 Atlantic Avenue, 02110<br />
t e l: (617) 747-1000<br />
18 Jurys Boston Hotel<br />
350 Stuart Street, 02116<br />
t e l: (617) 266-7200<br />
19 Lenox<br />
61 Exeter Street, 02116<br />
t e l: (617) 536-5300<br />
20 Midtown Hotel<br />
220 Huntington Avenue, 02115<br />
t e l: (617) 262-1000<br />
18 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
21 Omni Parker House<br />
60 School Street, 02108<br />
t e l: (617) 227-8600<br />
22 Radisson Hotel Boston<br />
200 Stuart Street, 02116<br />
t e l: (617) 482-1800<br />
23 Seaport Hotel<br />
1 Seaport Lane, 02210<br />
t e l: (617) 385-4000<br />
24 Sheraton Boston Hotel<br />
(co-headquarters)<br />
39 Dalton Street, 02199<br />
t e l: (617) 236-2000<br />
25 Westin Copley Place Boston<br />
(co-headquarters)<br />
10 Huntington Avenue, 02116<br />
t e l: (617) 262-9600<br />
26 Westin Boston Waterfront (headquarters)<br />
425 Summer Street, 02110<br />
t e l: (617) 532-4600<br />
www.rheumatology.org—Rheumatology’s Home on the Web 19
<strong>ACR</strong> TOOLS: YOUR FOUNDATION FOR<br />
RECERTIFICATION AND SELF-ASSESSMENT<br />
<strong>ACR</strong> CARE PROGRAM: 2006 and <strong>2007</strong> programs are available now!<br />
CARE (Continuing Assessment, Review and<br />
Evaluation), the Web-based self-assessment<br />
program from the <strong>American</strong> College of Rheumatology:<br />
07<br />
Continuing<br />
Assessment<br />
Review<br />
Evaluation<br />
<strong>ACR</strong> CONTINUOUS PROFESSIONAL DEVELOPMENT<br />
self-assessment program<br />
· 60 clinically relevant case-based questions with answer rationales and educational objectives<br />
· Images and over 100 educational links to UpToDate® topic reviews, scientific articles from such journals<br />
as the New England Journal of Medicine and Arthritis & Rheumatism articles, and <strong>ACR</strong> Guidelines<br />
· This activity has been approved for up to 18 AMA PRA Category 1 Credits TM and/or 20 points in the<br />
self-evaluation of medical knowledge category of the Maintenance of Certification program for<br />
physicians enrolled with the ABIM*<br />
· Member registration fees start at $120<br />
>>> Begin CARE Today at www.rheumatology.org/CARE.<br />
<strong>ACR</strong> AIM PRACTICE IMPROVEMENT MODULE<br />
Practice Improvement Modules (PIMs) are required by an<br />
increasing number of physicians enrolled in the ABIM’s<br />
Maintenance of Certification program. A PIM is a selfevaluation<br />
tool designed to guide an abstractor through<br />
medical chart review and abstraction.<br />
AIM (Assess, Improve, Measure), is a Web-based practice improvement tool specifically designed for<br />
rheumatologists engaged in the ABIM Maintenance of Certification program or those interested in<br />
completing a quality improvement program. The AIM questions, based on rheumatology measures and<br />
guidelines, will generate a report that will enable the physicians to:<br />
· Reflect on practice performance data<br />
· Identify practice strengths and areas for improvement<br />
· Develop and implement an improvement plan<br />
· Assess impact of practice changes through chart re-measurement<br />
· Report changes<br />
· Solo practice member enrollment fees start at $99<br />
Currently, AIM: Rheumatoid Arthritis is available and offers year-round enrollment with two<br />
abstraction phases a year and AIM: Gout opens for enrollment in November <strong>2007</strong> with the first<br />
abstraction phase beginning in March 2008.<br />
>>> Begin AIM Today at www.rheumatology.org/AIM.<br />
10% off:<br />
Enroll for both CARE and AIM at <strong>ACR</strong> Central during<br />
the annual meeting and recieve a 10% discount.
<strong>ACR</strong> Annual <strong>Meeting</strong><br />
Fellows Scholarship<br />
Nearly 20% of rheumatologists are expected<br />
to retire in the next three to five years,<br />
making it essential that the next generation of<br />
rheumatologists has access to the resources<br />
needed to provide quality rheumatic care. The<br />
<strong>ACR</strong> is pleased to offer programs designed<br />
to provide those resources to hundreds of<br />
rheumatology fellows through access to mentors<br />
and superior education.<br />
The <strong>ACR</strong> Fellows Education Fund is supported by<br />
educational grants from Abbott Laboratories, Amgen,<br />
Inc. and Wyeth Pharmaceuticals,Bristol-Myers Squibb<br />
and Genentech, Inc. and Biogen Idec.<br />
Through the <strong>ACR</strong> Fellows Education Fund, the<br />
<strong>ACR</strong> is able to present the <strong>ACR</strong> Annual <strong>Meeting</strong><br />
Fellows Scholarship. In addition to travel<br />
assistance, all fellow attendees at the annual<br />
meeting are invited to special educational<br />
sessions and networking events.<br />
Through programs like the <strong>ACR</strong> Annual <strong>Meeting</strong><br />
Fellows Scholarship, the <strong>ACR</strong> is committed to<br />
meeting the challenge of ensuring high-quality<br />
rheumatic care for years to come.
special offers at the annual scientific meeting<br />
<strong>ACR</strong> Commemorative Annual <strong>Meeting</strong> T-Shirt<br />
Through the generous support of Abbott Laboratories, the<br />
<strong>ACR</strong> is pleased to announce that complimentary<br />
commemorative annual meeting t-shirts will be available<br />
from the Abbott Inc. exhibit, Booth 301. Redeem the<br />
voucher in your briefcase for your commemorative t-shirt.<br />
Recertification Kiosk<br />
The Recertification Kiosk near <strong>ACR</strong> Central has answers<br />
to your questions about the rheumatology recertification<br />
policies. While there take the opportunity to participate in<br />
demonstrations of the <strong>ACR</strong>’s web-based recertification tools<br />
–CARE and AIM. You will receive a 10% discount off the<br />
total cost for both web-based recertification tools CARE and<br />
AIM when you purchase them at <strong>ACR</strong> Central.<br />
Annual <strong>Meeting</strong> Products <strong>2007</strong><br />
∙ Selected annual meeting content will be offered via<br />
streaming CME Web casts and Vodcasts<br />
∙ Audio CDs, MP3s, and Video CD-ROMs of select<br />
sessions will be available through the Conference<br />
Recording Sales Desk<br />
<strong>ACR</strong> Educational Products—Sale!<br />
<strong>ACR</strong> products, including the expanded <strong>ACR</strong> Slide Collection<br />
on the Rheumatic Diseases CD-ROM, the Core Curriculum<br />
CollectionTwo, and the Radiology Collection will be offered at<br />
exceptional sale prices, available to both members and nonmembers,<br />
during the annual meeting only. To preview and<br />
purchase any of these CD-ROM collections or to gather<br />
information about other educational products, visit <strong>ACR</strong><br />
Central in the North Lobby.<br />
Recharge Areas<br />
Recharge areas will include work stations with power<br />
outlets designed for you to connect your laptop, recharge<br />
your mobile or check e-mail via the complimentary<br />
Wi-Fi-enabled Internet access.<br />
The <strong>ACR</strong> thanks TAP Pharmaceutical Products, Inc. for its<br />
support of the <strong>2007</strong> Recharge Areas.<br />
<strong>ARHP</strong> Products<br />
<strong>ARHP</strong> Clinical Care Text, 3rd Edition<br />
The <strong>ARHP</strong> Clinical Care Text, 3rd Edition is an authoritative<br />
reference text on the clinical management of rheumatic<br />
diseases, with topics ranging from clinical foundations and<br />
assessment to clinical interventions and medications, is<br />
designed for use by physicians, health professionals, and<br />
rheumatology training programs: Member $30,<br />
Non-member $40.<br />
<strong>ARHP</strong> Teaching Slide Collection on CD-ROM, 3rd Edition<br />
A collection of 328 slides, topics include society and<br />
rheumatic diseases, anatomy and pathophysiology,<br />
clinical manifestations of common rheumatic diseases,<br />
assessment, and management. Appropriate for both health<br />
professionals and patient audiences. Member $25,<br />
Non-member $35.<br />
Complimentary Patient Information<br />
Stop by <strong>ACR</strong> Central to learn about the <strong>ACR</strong>’s<br />
complimentary patient education resources.<br />
<strong>Meeting</strong> Abstracts on <strong>ACR</strong> Web site and CD<br />
Annual <strong>Meeting</strong> abstracts will be available online at<br />
www.rheumatology.org, as well as on CD (included in the<br />
meeting briefcases). The Abstracts on <strong>ACR</strong> Web site and CD<br />
is supported by an educational grant from Bristol-Myers<br />
Squibb Company.<br />
Medical Bag<br />
Don’t forget to pick up a Medical Bag prior to visiting the<br />
exhibits. Each bag contains special offers and invitations<br />
from our exhibitors and will be distributed from the<br />
exhibition entrance while supplies last.<br />
Gifts for you at <strong>ACR</strong> Central<br />
Pick up gifts by visiting <strong>ACR</strong> Central. While supplies last!<br />
22 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
<strong>ACR</strong>/<strong>ARHP</strong><br />
Product<br />
Highlights<br />
The <strong>ACR</strong> and <strong>ARHP</strong> are pleased to showcase new<br />
and current educational products during the annual<br />
meeting. Head to <strong>ACR</strong> Central for demonstrations<br />
and annual meeting-only product discounts!<br />
Skill Training Workshop Series DVD<br />
This innovative product consists of two workshops<br />
– Musculoskeletal Ultrasonography: Basic and<br />
Osteoporosis: Focus on DXA Interpretation. These<br />
workshops are presented as instructional tools<br />
to assist in trainee education or for physicians<br />
wanting to brush up on their ultrasound and DXA<br />
interpretation skills.<br />
<strong>ACR</strong> Slide Collection, 3rd Edition<br />
With over 1,200 slides, this edition should be a staple<br />
in the library of all rheumatologists. The collection,<br />
which includes clinical, pathological, radiological<br />
and disease-specific text slides, is provided on CD-<br />
ROM with a full-color printed syllabus. The Radiology<br />
Collection images are included. Images are provided<br />
in a flexible PowerPoint format.<br />
<strong>ACR</strong> Core Curriculum, Collection Two<br />
This new compact disc contains 13 pediatric cases,<br />
each with a series of multiple-choice questions directing<br />
the user to the diagnosis of a patient-management<br />
situation. The cases are presented in self-study and<br />
tutorial formats. Case topics include JRA, scleroderma and<br />
Kawasaki disease.<br />
<strong>ARHP</strong> Teaching Slide Collection, 3rd Edition<br />
This compact disc consists of 328 slides covering the<br />
major topics of society and rheumatic diseases,<br />
anatomy and pathophysiology, clinical manifestations<br />
of common rheumatic diseases, assessment, and<br />
management.<br />
<strong>ACR</strong> Radiology Collection<br />
With over 350 images, this is a comprehensive<br />
collection of radiographs, MRI scans, CT scans, and<br />
bone scans illustrating various rheumatic diseases.<br />
Images are provided in a flexible PowerPoint format,<br />
and would be an excellent supplement to previous<br />
editions of the <strong>ACR</strong> slide collection.<br />
Video CD-ROMs, Vodcasts & Web Casts<br />
Video CD-ROMs of select sessions will be available for<br />
purchase at the Conference Recording Sales Desk in the<br />
North Lobby. The selected sessions will also be available<br />
as Web casts and Vodcasts following the meeting.<br />
Audio Recordings<br />
Missed your favorite annual meeting session? Over 90<br />
sessions on CD, MP3 and Podcasts are available at the<br />
Conference Recording Sales Desk in the North Lobby.<br />
<strong>ARHP</strong> Clinical Care in the Rheumatic Diseases,<br />
3rd Edition<br />
An authoritative reference text on the clinical<br />
management of rheumatic diseases, this 312-page<br />
text was written by more than 60 experts in the<br />
fields of rheumatology, nursing, physical therapy,<br />
occupational therapy and the behavioral sciences.<br />
For more information visit <strong>ACR</strong> Central or www.rheumatology.org/products.
Own a unique<br />
piece of history<br />
and help the REF<br />
ensure the future<br />
of rheumatology.<br />
<strong>2007</strong><br />
To celebrate the introduction of the <strong>2007</strong> Rodnan<br />
Commemorative Gout Print – A King-Fisher – the <strong>ACR</strong><br />
Research and Education Foundation is offering attendees a<br />
unique opportunity.<br />
Attendees who purchase any of the Rodnan Commemorative Gout Prints at the REF booth will be<br />
entered into a drawing to personally select the 2008 Rodnan Commemorative Gout Print.<br />
Not only will you receive a chance to choose the next print, but this popular series of 17th and 18th century<br />
gout prints is a great idea for your office or exam room, a keepsake of the <strong>ACR</strong>/<strong>ARHP</strong> Annual <strong>Scientific</strong><br />
<strong>Meeting</strong> or a presentation piece to honor a colleague, employee or friend.<br />
Proceeds from the sale of these prints support REF research, training and education programs.<br />
>>> To purchase your Rodnan Commemorative Gout Print, simply visit the REF Booth located in the<br />
North Lobby.<br />
A special thanks to our 2006 winner, Kenneth I. Austin, MD, who selected this year’s commemorative print.
Poster sessions<br />
The presentation of posters facilitates one-on-one<br />
interaction between the presenter and the audience.<br />
There will be one poster session on Thursday,<br />
Friday and Saturday. Posters will remain in the Boston<br />
Convention and Exhibition Center Exhibit Hall A–B from<br />
8:00 a m–4:30 pm, with presenters in attendance to answer<br />
questions about their abstracts from 9:00–11:00 a m each<br />
day. There is no poster session on Sunday.<br />
The numbering system for the poster sessions includes<br />
two sets of numbers. The first number (in parentheses)<br />
is the permanent poster board number and will remain<br />
the same during each poster session. The second number<br />
refers to the abstract number being presented, and this<br />
will change for each poster session.<br />
Poster Session Presenter Instructions<br />
If you are presenting a poster, please set up and remove<br />
your poster during the times listed below. You must wear<br />
your green Poster Presenter ribbon to enter Convention<br />
Center Exhibit Hall A–B when the exhibits are closed.<br />
See schedule below.<br />
Poster presenter ribbons were mailed to all presenting<br />
authors prior to the meeting. If you need a replacement<br />
ribbon, please go to the Speaker Ribbon booth located in<br />
the East registration area. Thursday presenters may pick<br />
up board pushpins at the entrance of the Exhibit Hall<br />
and are asked to leave them at their board for Friday and<br />
Saturday posters.<br />
Posters must be removed by 6:30 pm. Only those with a<br />
poster presenter ribbon are permitted to enter the hall<br />
after it is closed. Posters not removed by 6:30 pm will be<br />
removed and discarded. <strong>ACR</strong> is not responsible for lost,<br />
damaged or discarded posters.<br />
Poster Session A (<strong>ACR</strong>)<br />
Thursday, November 8<br />
Set Up<br />
Presentation<br />
Posters to remain up until<br />
Removal<br />
8:00 a m–4:30 pm<br />
7:00–8:00 a m<br />
9:00–11:00 a m<br />
4:30 pm<br />
4:30–6:30 pm<br />
Poster Session C (<strong>ACR</strong>/<strong>ARHP</strong>)<br />
Saturday, November 10<br />
8:00 a m–4:30 pm<br />
Set Up<br />
7:00–8:00 a m<br />
Presentation<br />
9:00–11:00 a m<br />
Posters to remain up until 4:30 pm<br />
Removal<br />
4:30–6:30 pm<br />
Poster Session B (<strong>ACR</strong>/<strong>ARHP</strong>)<br />
Friday, November 9<br />
8:00 a m–4:30 pm<br />
Set Up<br />
7:00–8:00 a m<br />
Presentation<br />
9:00–11:00 a m<br />
Posters to remain up until 4:30 pm<br />
Removal<br />
4:30–6:30 pm<br />
www.rheumatology.org—Rheumatology’s Home on the Web 25
Industry Roundtable-supported symposia<br />
The REF would like to thank the following industry leaders that have made a significant multi-year commitment to<br />
the REF for participation in the Industry Roundtable. In appreciation for their commitment, these industry leaders<br />
have been invited to host a symposium during the annual meeting. Please visit the organization’s exhibit booth or<br />
the industry-supported symposia booth for more information. The sponsoring organization is responsible for planning and<br />
providing CME credit for their respective symposium.<br />
Thursday, November 8, <strong>2007</strong><br />
6:30–9:30 p m<br />
Tackling the Controversies of Biologic Therapy in<br />
Rheumatoid Arthritis and Spondyloarthropathy:<br />
Application of Emerging Clinical Data into Daily<br />
Treatment Decisions<br />
Westin Boston Waterfront, Grand Ballroom A-E<br />
Sponsored by The Chicago Medical School at the Rosalind<br />
Franklin University of Medicine and Science<br />
Supported by an educational grant from Abbott Laboratories<br />
Challenging Current RA Treatment: Do Disparities Exist?<br />
Westin Copley Place Boston, <strong>American</strong> Ballroom, North-<br />
Center-South<br />
Sponsored by the Academy for Healthcare Education Inc.<br />
Supported by an educational grant from Amgen, Inc. and Wyeth<br />
Pharmaceuticals<br />
Biological Therapies in RA and SLE - Applying Lessons<br />
from Clinical Trials to the Clinic<br />
Sheraton Boston Hotel, Grand Ballroom, Independence<br />
Ballroom and Liberty A-B-C<br />
Sponsored by Discovery Institute of Medical Education<br />
Supported by an educational grant from Genentech, Inc.<br />
Balancing Pain Relief Risks & Benefits in Arthritis &<br />
Fibromyalgia: An Interactive Patient Case Symposium<br />
Boston Convention & Exhibition Center, Room 52 A & B<br />
Jointly sponsored by Beth Israel Medical Center-St. Luke’s<br />
Roosevelt Hospital Center and Health Education Alliance, Inc.<br />
Supported by an educational grant from Pfizer Inc<br />
Saturday, November 10, <strong>2007</strong><br />
6:30–9:30 p m<br />
Strategies to Improve Outcomes in Rheumatoid Arthritis:<br />
Understanding the Role of Newer Biologic Agents<br />
Westin Boston Waterfront, Grand Ballroom A-E<br />
Sponsored by education/outcomes/science<br />
Supported by an educational grant from Bristol-Myers Squibb<br />
Company<br />
Pathology and Treatment of Rheumatoid Arthritis:<br />
Focus on IL-6<br />
Sheraton Boston Hotel, Grand Ballroom, Independence<br />
Ballroom and Liberty A-B-C<br />
Sponsored by University of Kentucky College of Medicine<br />
Supported by an educational grant from Roche<br />
Rheumatoid Arthritis: The Next Generation of<br />
Biologic Agents<br />
Westin Copley Place Boston, <strong>American</strong> Ballroom North-<br />
Center-South<br />
Sponsored by the Center for Bio-Medical Communication<br />
Supported by an educational grant from UCB, Inc.<br />
26 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
industry-supported post-CONFERENCE symposia<br />
The <strong>ACR</strong> is pleased to present the following schedule for the Industry-Supported Post-Conference Symposia. The<br />
sponsoring organization is responsible for planning and providing CME credit for their respective symposium. We invite you<br />
to visit the supporting organization’s exhibit booth or the industry-supported symposia booth for more information.<br />
Sunday, November 11, <strong>2007</strong><br />
1:00–4:00 pm<br />
The Prevention and Management of Infections in<br />
Patients Receiving TNF Inhibitors<br />
Boston Convention & Exhibition Center, Room 107 A-B-C<br />
Sponsored by the University of Texas Southwestern Medical<br />
Center at Dallas<br />
Supported by an educational grant from Abbott Laboratories,<br />
Centocor Inc. and Wyeth Pharmaceuticals<br />
Practical Approaches to Vascular Complications in<br />
Systemic Sclerosis<br />
Westin Boston Waterfront, Grand Ballroom B<br />
Sponsored by Medical Education Resources<br />
Supported by an educational grant from Actelion Pharmaceuticals<br />
US, Inc.<br />
Osteoarthritis and Synovitis: The Link Between<br />
Pathogenesis, Detection and Treatment<br />
Westin Boston Waterfront, Commonwealth A-C<br />
Sponsored by Vindico Medical Education<br />
Supported by an educational grant from Bioiberica<br />
New Approaches to Understanding, Diagnosing, and<br />
Treating Fibromyalgia<br />
Boston Convention & Exhibition Center, Room 52 B<br />
Sponsored by the University of Kentucky<br />
Supported by an educational grant from Forest Research Institute<br />
Pulmonary Arterial Hypertension in Connective Tissue<br />
Disease: Current Concepts in Pathophysiology,<br />
Recognition and Treatment Stratagems<br />
Westin Boston Waterfront, Grand Ballroom A<br />
Sponsored by education/outcomes/science<br />
Supported by an educational grant from Gilead Sciences<br />
Medical Affairs<br />
Opioid Analgesia in Patients With Rheumatologic<br />
Disorders: Strategies for Optimizing Analgesia and<br />
Minimizing Risk<br />
Boston Convention & Exhibition Center, Room 160 A-B-C<br />
Sponsored by The Johns Hopkins University School of Medicine<br />
Supported by an educational grant from King Pharmaceuticals, Inc.<br />
www.rheumatology.org—Rheumatology’s Home on the Web 27
REF sponsored events<br />
The <strong>ACR</strong> Research and Education Foundation is pleased to present the following events at the <strong>ACR</strong>/<strong>ARHP</strong><br />
Annual <strong>Scientific</strong> <strong>Meeting</strong>. For more information on these and other REF events, please stop by the REF Booth<br />
located in the North Lobby.<br />
HOW YOU CAN PROTECT YOUR ASSETS<br />
AND MINIMIZE ESTATE TAXES<br />
Estate Planning Session<br />
Saturday, November 10 • 7:45–9:15 a m<br />
Want to protect your assets and save as much as $500,000<br />
in estate taxes? Be sure to attend the popular estate planning<br />
session during this year’s <strong>ACR</strong>/<strong>ARHP</strong> Annual <strong>Scientific</strong><br />
<strong>Meeting</strong> to learn about the most effective financial strategies<br />
you can utilize to increase tax savings, provide for your heirs<br />
and benefit your favorite nonprofit causes. This session is open<br />
to all meeting attendees and features Joel M. Blau, CFP, President<br />
MEDIQUS Asset Advisors (formerly AMA Investment Advisors, an<br />
affiliate of the <strong>American</strong> Medical Association).<br />
Some of the financial strategies discussed include:<br />
∙ Protecting assets from lawsuits<br />
∙ Reducing or completely eliminating estate tax exposure<br />
∙ Avoiding accidental disinheritance of heirs<br />
∙ Eliminating capital gains tax on the sale of<br />
appreciated property<br />
∙ Planning bequests for favorite charities while maximizing<br />
income on assets during life<br />
<strong>2007</strong> REF 5K Run/Walk<br />
Friday, November 9<br />
6:00–8:00 a m<br />
The rheumatologists are coming! It’s not quite the midnight<br />
ride of Paul Revere, but we’ll definitely let Boston know that<br />
the <strong>ACR</strong> and <strong>ARHP</strong> have arrived. Start the day with an<br />
early morning run/walk along the city’s beautiful waterfront<br />
and make a stand for the future of rheumatology This year’s<br />
REF 5K Run/Walk has plenty to offer the competitive<br />
runner or casual walker. Complimentary shuttle service will<br />
be provided from convention hotels to the run course. A prerun<br />
warm up and refreshments will be offered at an indoor<br />
pavilion at Carson Beach. All participants will receive an<br />
official race t-shirt.<br />
Participants may register onsite in the <strong>ACR</strong>/<strong>ARHP</strong><br />
Registration area until 5:00 pm, Thursday, November 8.<br />
A minimum donation of $30 is required. Proceeds raised<br />
from this event support activities of the <strong>ACR</strong> Research and<br />
Education Foundation.<br />
Memorial Lectureships<br />
Thursday, November 8 • 7:45–8:45 a m<br />
Oscar S. Gluck, MD, Memorial Lectureship<br />
Osteoclasts: What Do They Do and How Do They Do It?<br />
Speaker: Steven L. Teitelbaum, MD<br />
Thursday, November 8 • 2:30–4:00 pm<br />
Marshall J. Schiff, MD, Memorial Lectureship<br />
Signaling Pathways Controlling Chondrocyte Maturation:<br />
Implications for the Development and Treatment of Osteoarthritis<br />
Speaker: Regis O’Keefe, MD, PhD<br />
Thursday, November 8 • 4:30–6:00 pm<br />
Edmund L. Dubois, MD, Memorial Lectureship<br />
Early Events in Lupus Autoimmunity: Lessons to be Learned<br />
Speaker: Judith A. James, MD, PhD<br />
Saturday, November 10 • 9:15–10:15 a m<br />
Paul Klemperer, MD, Memorial Lectureship<br />
The Vocation of Medicine: Lessons from Real and<br />
Imagined Doctors<br />
Speaker: Paul H. Plotz, MD<br />
Relax in the REF Donors’ Lounge<br />
REF donors should plan to spend time in the Donors’<br />
Lounge and take advantage of special perks! Enjoy breakfast<br />
each morning and special treats each day; catch up on<br />
work and check e-mail at one of our computer stations;<br />
retrieve conference messages without waiting in line; grab a<br />
refreshment or take a breather just steps away from the hustle<br />
and bustle of the annual meeting. Donors need only their<br />
donor ribbon on their badge for entry. A minimum annual<br />
donation of $500 is required to gain admittance into the<br />
Donors’ Lounge.<br />
Visit the REF Booth<br />
Located in the North Lobby. Find out what the REF is doing<br />
to ensure the future of rheumatology by visiting the REF<br />
booth during the annual meeting. View and order the latest<br />
poster in the Rodnan Commemorative Gout Print poster<br />
series, learn more about REF programs and initiatives and<br />
even receive a free gift just for stopping by!<br />
The REF thanks UCB, Inc., for their support of the <strong>2007</strong> REF<br />
5K Run/Walk.<br />
www.rheumatology.org—Rheumatology’s Home on the Web 29
time locatioN EVENT<br />
pre-conference: Tuesday + Wednesday · agenda at-a-glance<br />
7:00 a m—5:00 pm East Registration <strong>ACR</strong>/<strong>ARHP</strong> Registration<br />
8:00 a m—5:15 pm Grand Ballroom East <strong>ACR</strong> Clinical Research Conference<br />
5:15—6:15 pm Clinical Research Conference<br />
Reception with Poster Viewing<br />
8:30 a m—4:30 pm Room 102 <strong>ACR</strong>/ABIM Maintenance of Certification Learning Session for<br />
Recertification Module 30-R<br />
1:00—5:30 pm Room 210 <strong>ACR</strong> Basic Research Conference (Day One)<br />
5:30—6:30 pm Basic Research Conference Reception<br />
tuESDAY<br />
7:00 a m—6:30 pm East Registration <strong>ACR</strong>/<strong>ARHP</strong> Registration<br />
8:30 a m—5:00 pm Room 210 <strong>ACR</strong> Basic Research Conference (Day Two)<br />
8:00 a m—5:00 pm Hall C <strong>ACR</strong> Review Course<br />
8:30 a m—4:30 pm Room 259 <strong>ARHP</strong> Clinical Focus Course<br />
5:30—7:30 pm Hall C <strong>ACR</strong>/<strong>ARHP</strong> Opening Lecture and Awards<br />
8:30—10:30 pm Sheraton Boston Hotel <strong>ACR</strong>/<strong>ARHP</strong> Opening Dessert Reception at the<br />
sheraton Boston Hotel<br />
<strong>ACR</strong><br />
CLINICAL PRACTICE<br />
BASIC AND<br />
TRANSLATIONAL<br />
RESEARCH<br />
DUAL INTEREST TO<br />
CLINICIANS AND<br />
RESEARCHERS<br />
PEDIATRICS<br />
FELLOWS-IN-TRAINING<br />
<strong>ARHP</strong><br />
CLINICAL PRACTICE<br />
PEDIATRICS<br />
FELLOWS-IN-TRAINING<br />
WEDNESDAY<br />
PLAN YOUR SCHEDULE USING EDUCATIONAL TRACKS TO ENHANCE<br />
YOUR MEETING EXPERIENCE<br />
The <strong>ACR</strong> and <strong>ARHP</strong> have designed educational tracks to help you maximize the scheduling of your time and<br />
meeting experience by emphasizing primary areas of interest. There are five tracks for <strong>ACR</strong> and three tracks for<br />
<strong>ARHP</strong>. Designated sessions include the main symposia, lectures and select <strong>ACR</strong> Meet the Professor Sessions and<br />
Workshops. However, the concurrent abstract sessions and poster discussions are not included.<br />
Those sessions that are predominantly translational in content are designed to be of interest to both clinicians and<br />
researchers. These are indicated as “C/R”. Sessions with mainly pediatric content are indicated as “P”, and may be<br />
of interest to both pediatric and adult rheumatologists.<br />
As the annual meeting has a variety of session types scheduled concurrently, use these suggested tracks as a tool to<br />
assist you in developing your own individualized schedule for the meeting.<br />
Track Indicator Example<br />
Please use the following as an example to identify the available tracks.<br />
C R C/R P F<br />
CLINICAL<br />
PRACTICE<br />
BASIC AND<br />
TRANSLATIONAL<br />
RESEARCH<br />
DUAL INTEREST TO<br />
CLINICIANS AND<br />
RESEARCHERS<br />
PEDIATRICS<br />
FELLOWS-IN-<br />
TRAINING<br />
PM - PAIN MANAGEMENT<br />
The <strong>ACR</strong> designates certain sessions for pain management credit as required by the Medical Board of California<br />
(AB487). This designation is identified by the icon shown and will be placed next to the session title.<br />
30
Tuesday, November 6, <strong>2007</strong><br />
<strong>ACR</strong>/<strong>ARHP</strong> Registration<br />
7:00 a m—5:00 p m<br />
East Registration<br />
<strong>ACR</strong> Clinical Research Conference<br />
8:00 a m—5:15 p m<br />
Grand Ballroom East<br />
Admission to the <strong>ACR</strong> Clinical Research Conference is by ticket only.<br />
Pharmacotherapy in Rheumatic Disease: Assessing the<br />
Safety, Effectiveness and Value<br />
7:00—8:00 a m Continental Breakfast<br />
10:15—10:30 a m Break<br />
Noon—1:30 p m<br />
Boxed Lunch with Poster Presentations<br />
Poster presenters will be available from Noon-1:30 pm.<br />
Grand Ballroom Foyer<br />
3:30—3:45 p m Break<br />
5:15—6:15 p m Reception with Poster Viewing<br />
Grand Ballroom Foyer<br />
Upon completion of this session, participants should be able to:<br />
∙ Examine the safety of pharmacotherapy for rheumatic diseases<br />
∙ Discuss the regulatory initiatives for improving the<br />
safety of drug treatments<br />
∙ Assess the economic implications of new treatments for<br />
rheumatic diseases<br />
∙ Identify the key methodological issues in studying drug safety<br />
8:00 a m<br />
Welcome and Introduction<br />
Daniel H. Solomon, MD, MPH; Brigham and Women’s<br />
Hospital; Boston, MA<br />
9:10 a m<br />
Evaluation of Drug Safety: Clinical Trials versus Clinical Practice<br />
John J. Cush, MD; Arthritis Care and Research Center;<br />
Dallas, TX<br />
9:35 a m<br />
Combining Efficacy and Safety: Is a Single Score Possible?<br />
Peter Tugwell, MD; Institute of Population Health;<br />
Ottawa, Ontario<br />
10:00 a m<br />
Panel Discussion<br />
10:15—10:30 a m<br />
Break<br />
Session II: Economics of Rheumatic Pharmacotherapy<br />
Moderator:<br />
Arthur Kavanaugh, MD; Center for Innovative Therapy;<br />
La Jolla, CA<br />
10:30 a m<br />
Pharmacoeconomics 301: A Graduate Level Review<br />
John B. Wong, MD; Tufts-New England Medical Center;<br />
Boston, MA<br />
10:55 a m<br />
Pharmacoeconomics in Other Rheumatic Conditions; Current Data,<br />
Unmet Needs, Future Directions<br />
Nick Bansback; Centre for Health Evaluation and Outcome<br />
Sciences; Vancouver, British Columbia<br />
11:20 a m<br />
Pharmacoeconomics: Where the Expensive Rubber Meets the Thrifty Road<br />
Andreas Maetzel, MD; University Health Network;<br />
Toronto, Ontario<br />
11:45 a m<br />
Panel Discussion<br />
pre-conference Tuesday<br />
8:15 a m<br />
Morning Keynote: Drug Safety in Rheumatic Diseases<br />
The Turbulent 2000’s: The Two Faces of Molecular Medicine<br />
Steven B. Abramson, MD; New York University Hospital for<br />
Joint Diseases; New York, NY<br />
Session I: Drug Safety and Effectiveness<br />
Moderator:<br />
Alan J. Silman, MD; University of Manchester; Manchester,<br />
England<br />
8:45 a m<br />
Evaluation of Drug Effectiveness: Clinical Trials versus Clinical Practice<br />
Kimme L. Hyrich, MD, PhD; University of Manchester;<br />
Manchester, England<br />
Noon—1:30 p m<br />
Boxed Lunch with Poster Presentations<br />
Poster presenters will be available from Noon-1:30 pm.<br />
Poster Session (Abstracts CRC1-CRC50)<br />
Grand Ballroom East<br />
Drug Effectiveness in Rheumatology<br />
CRC01. Unsuccessful Treatment with Extracorporeal Photopheresis<br />
(ECP) of a patient with Systemic onset Juvenile Idiopathic Arthritis<br />
(SoJIA). Claudia Bracaglia, Paola Sabrina Buonuomo, Rita<br />
Carsetti, Elisabetta Cortis, Antonella Insalaco, Alberto G Ugazio.<br />
Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy.<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 31
Tuesday pre-conference<br />
CRC02. Anakinra in Systemic-Onset Juvenile Idiopathic Arthritis<br />
(ANAJIS trial): Preliminary Results. Pierre Quartier 1 , Rolando<br />
Cimaz 2 , Pascal Pillet 3 , Isabelle Kone-Paut 4 , Irene Lemelle 5 ,<br />
Behrouz Kassai 2 , Marine Desjonqueres 2 , Olivier Richer 6 ,<br />
Agnes Duquesne 7 , Florence Allantaz 8 , Xavier Bossuyt 9 ,<br />
Agnes Mogenet 1 , Jean-Marc Treluyer 1 , Jean-Louis Bresson 1 ,<br />
Jacques Bienvenu 10 , Paul Landais 1 , Claude Messiaen 1 .<br />
1<br />
Hopital Necker-Enfants Malades, Paris, France; 2 Hopital<br />
Edouard Herriot, Lyon, France; 3 Hopital Pellegrin-Enfants,<br />
Bordeaux, France; 4 Hopital Bicetre, Kremlin-Bicetre,<br />
France; 5 Hopital Brabois, Nancy, France; 6 Hopital Pellegrin,<br />
Bordeaux, France; 7 Hopital Edouard Herriot, Paris, France;<br />
8<br />
Baylor Institute, Dallas, TX; 9 Laboratory Medicine, Immunology,<br />
Leuwen, Belgium; 10 Universite Lyon, Lyon, France.<br />
CRC03. Efficacy and Safety of Tacrolimus in Patients with<br />
Rheumatic Disease: Appropriate Clinical Application for Various<br />
Rheumatic Conditions. Katsuya Suzuki, Hideto Kameda,<br />
Kouichi Amano, Hayato Nagasawa, Naoya Sekiguchi,<br />
Hirofumi Takei, Eiko Nishi, Ayumi Okuyama, Hiroe<br />
Ogawa, Kensei Tsuzaka, Tsutomu Takeuchi. Saitama<br />
Medical Center, Kawagoe, Saitama, Japan.<br />
CRC04. Efficacy of Vardenafil in a Patient with Digital<br />
Gangrene due to Severe Raynaud’s. Anand Lal 1 , Christine E.<br />
Fernando 2 . 1 The Permanente Medical Group, Roseville,<br />
CA; 2 The Permanente Medical Group, Sacramento, CA.<br />
CRC05. Takayasu’s Arteritis in Mexican Mestizos Patients: Clinical,<br />
Laboratory and Angiographic Findings and the Cause of Death. Olga<br />
L. Vera-Lastra, Pilar Cruz Dominguez, Gabriela Medina.<br />
Instituto Mexicano del Seguro Social, Mexico, City, Mexico.<br />
CRC06. Early Treatment With and Time on First Disease<br />
Modifying Anti-Rheumatic Drug Predicts Long Term Functional<br />
Outcome in Patients with Inflammatory Polyarthritis. Tracey<br />
M. Farragher 1 , Mark Lunt 1 , Stephanie C. Manning 1 ,<br />
Diane Bunn 2 , Deborah P.M Symmons 1 . 1 arc Epidemiology<br />
Unit, The University of Manchester, Manchester, United<br />
Kingdom; 2 Norfolk Arthritis Register, Norfolk and Norwich<br />
University Hospital, Norwich, United Kingdom.<br />
CRC07. Intravenous Immunoglobulins in Childhood-Onset<br />
Polyarteritis Nodosa. Richard Mouy, Pierre Quartier,<br />
Christine Bodemer, Anne-Marie Prieur. Hopital Necker-<br />
Enfants Malades, Paris, France.<br />
CRC08. Two Regimens of Prospidium Chloride Treatment for<br />
Active Ankylosing Spondylitis: a Pilot Study. Denis Poddubnyy,<br />
Andrey Rebrov. Saratov State Medical University, Saratov,<br />
Russian Federation.<br />
CRC09. Polyarteritis Nodosa Associated with Hepatitis B<br />
Virus - Improvement Profile with Antiviral Therapy and Plasma<br />
Exchange. Lakshman K. Dinavahi 1 , Margaret Tsai 2 , Nora<br />
Singer 2 , Bashar Katirji 3 . 1 Huron Hospital, Cleveland Clinic<br />
Health System, East Cleveland, OH; 2 University Hospitals<br />
of Cleveland, Cleveland, OH; 3 University Hospitals of<br />
Cleveland, Cleveland, OH.<br />
CRC10. A Novel Treatment of Burning Mouth Syndrome in<br />
a Patient with Sjögrens Syndrome. Lakshman K. Dinavahi,<br />
Howard R. Smith. Huron Hospital, Cleveland Clinic<br />
Health System, East Cleveland, OH.<br />
CRC11. Drug Discontinuation Due to Inefficacy in Ankylosing<br />
Spondylitis Patients Treated with Anti-TNF Drugs: Results<br />
from the British Society for Rheumatology Biologics Register<br />
(BSRBR). Paul Lord, Mark Lunt, Kath Watson, Deborah<br />
P M Symmons, Kimme L. Hyrich, on behalf of the BSR<br />
Biologics Register. University of Manchester, Manchester,<br />
United Kingdom.<br />
CRC12. A Pilot Study on Tacrolimus Treatment in Patients with<br />
Systemic Lupus Erythematosus without Renal Involvement. Yoshie<br />
Kusunoki, Kenji Takagi, Kimiko Akimoto, Shinichiro<br />
Nishio, Nahoko Matsumoto, Shinichi Kawai. Toho<br />
University School of Medicine, Tokyo, Japan.<br />
Drug Safety in Rheumatology<br />
CRC13. Tuberculosis in Japanese Patients with Rheumatoid<br />
Arthritis Treated with Infliximab: Findings from the Post<br />
Marketing Surveillance Trial. O. Dabbous 1 , K. Gilmer 1 , Y.<br />
Tatsuki 2 , P. Shane 1 , M. Togo 2 , Y. Nogami 2 , B. Tang 1 , H.<br />
Thompson 1 , M. Rahman 1 . 1 Centocor, Inc., Horsham, PA;<br />
2<br />
Tanabe Seiyaku Co., Ltd., Osaka, Japan.<br />
CRC14. Serious Infusion Reactions in Japanese Patients<br />
with Rheumatoid Arthritis: Findings from the Post Marketing<br />
Surveillance Trial. O. Dabbous 1 , K. Gilmer 1 , Y. Tatsuki 2 , P.<br />
Shane 1 , M. Togo 2 , Y. Nogami 2 , B. Tang 1 , H. Thompson 1 , M.<br />
Rahman 1 . 1 Centocor, Inc., Horsham, PA; 2 Tanabe Seiyaku<br />
Co., Ltd., Osaka, Japan.<br />
CRC15. Double Blind Randomized Comparison of A Split- and a<br />
Virosomal Influenza Vaccine in Immunosuppressed Rheumatologic<br />
Patients. Michael Seitz. Inselspital, Bern, Switzerland.<br />
CRC16. Pregnancy Outcome in Women Affected by Juvenile<br />
Idiopathic Arthritis Exposed to Biological Agents. Irene<br />
Pontikaki, Valeria Gerloni, Maurizio Gattinara, Flavio<br />
Fantini. Gaetano Pini Institute, Milan, Italy.<br />
CRC17. A Review of Lymphoma Occurring in Rheumatoid<br />
Arthritis Patients in the Consortium of Rheumatology Researchers<br />
of North America (CORRONA) Database. P. Callegari 1 , O.<br />
Dabbous 1 , J. Kremer 2 , G. Reed 3 . 1 Centocor, Inc., Horsham,<br />
PA; 2 Albany Medical College/The Center for Rheumatology,<br />
Albany, NY; 3 University of Massachusetts Medical School,<br />
Epidemiology and Biostatistics Unit, Worcester, MA.<br />
CRC18. Influence of Low-Dose Prednisolone Therapy on Dmard<br />
Survival in Patients with Rheumatoid Arthritis. Olga Malysheva,<br />
Matthias Wahle, Ulf Wagner, Matthias Pierer, Sybille<br />
Arnold, Wolfram Seidel, Christoph Baerwald. University<br />
Hospital, Leipzig, Germany.<br />
32 = Recorded Sessions (order form on page 430)
CRC19. Comparative Efficacy, Safety and Tolerability of<br />
Lornoxicam and Diclofenac in Patients with Osteoarthritis.<br />
Akhilesh Sharma 1 , Arvind Goregaonkar 2 , K. J. Mathiazhagan 3 ,<br />
Ravindra R. Shah 4 , Praveen Taneja 5 , Vidyagauri P. Baliga 1 .<br />
1<br />
Glenmark Pharmaceuticals Ltd, Mumbai, India; 2 LTMMC<br />
and General Hospital, Mumbai, India; 3 Kilpauk Medical<br />
College, Chennai, India; 4 Khaja Banda Nawaz Institute of<br />
Medical Sciences, Gulbarga, India; 5 RGS Healthcare Pvt.<br />
Ltd., Mohali, India.<br />
CRC20. A Safety Assessment of TNF Antagonists During<br />
Pregnancy: A Review of the FDA Database. John D. Carter,<br />
Anil Ladhani, Louis Ricca, Joanne Valeriano, Frank B.<br />
Vasey. University of South Florida, Tampa, FL.<br />
CRC21. Angiotensin Converting Enzyme (ACE) Inhibition<br />
Protects the Jejunal Mucosa in Non Steroidal Anti Inflammatory<br />
Drugs-Related Injury of the Small Imtestine. Jaroslaw Biernat,<br />
Ryszard Sendur, Rafal Obuchowicz, Tomasz Brzozowski,<br />
Wieslaw W. Pawlik. Jagiellonian University Medical<br />
College, Cracow, Poland.<br />
New Methods for the Study of Drug Safety and<br />
Effectiveness in Rheumatology<br />
CRC22. Empirical Examination of the Best Method in Haplotype<br />
Inference of HLA Gene. Taro Yabuki 1 , Tomoya Saito 1 , Hiroshi<br />
Sakuta 1 , Fujio Takeuchi 2 , Shoji Kuwata 3 , Yeong-Wook Song 4 .<br />
1<br />
Aoyama Gakuin University, Sagamihara, Japan; 2 the University<br />
of Tokyo, Tokyo, Japan; 3 Teikyo University, Chiba, Japan;<br />
4<br />
Seoul National University, Seoul, Republic of Korea.<br />
CRC23. The Impact of Gout; A Qualitative Study to Generate<br />
Strategies to Improve Patient Outcomes. Karen Lindsay, Dr 1 ,<br />
Philip Logo, Mr 1 , Peter Gow, Dr 1 , Jane Vanderpyl, Dr 1 ,<br />
Nicola Dalbeth, Dr 2 . 1 Middlemore Hospital, Auckland, New<br />
Zealand; 2 Department of Medicine, University of Auckland,<br />
New Zealand.<br />
CRC24. Are TS (Thymidylate synthase) and MTHFR (Methylene<br />
tetrahydrofolate) Genes Linked with Methotrexate (MTX)<br />
Response (Efficacy, Toxicity) in Indian (Asian) Rheumatoid<br />
Arthritis (RA) Patients? Yogita Ghodke 1 , Arvind Chopra 2 ,<br />
Kalpana Joshi 1 , K. Satyamoorthy 3 , Bhushan Patwardhan 1 .<br />
1<br />
Interdisciplinary School of Health Sciences., Pune, India;<br />
2<br />
Center for Rheumatic Diseases, Pune, India; 3 MAHE,<br />
Manipal, Manipal, India.<br />
CRC25. Circulating CD22+CD20-CD19+ Cells at Baseline<br />
May Predict the Clinical Response to Rituximab in Patients with<br />
Active RA. Kasia M. Owczarczyk 1 , Gunter Valet 2 , Doro<br />
Passon 1 , Tobias Roehrs 1 , Norma Jung 1 , Dirk Taubert 1 ,<br />
Andrea Rubbert 1 . 1 University Hospital Cologne, Cologne,<br />
Germany; 2 Max-Planck Institute of Biochemistry, Munich-<br />
Martinsried, Germany.<br />
Pharmaco-Economics of Treatments for Rheumatic Diseases<br />
CRC26. Cost-Utility Analysis of a Rheumatologist’s Treatment of<br />
Osteoarthritis of the Knee Supports the Usage of Hyaluronic Acid<br />
(Euflexxa). Hind T. Hatoum 1 , Swu-Jane Lin 1 , Kathleen<br />
Kolsun 2 , Erol Onel 2 . 1 University of Illinois at Chicago,<br />
Chicago, IL; 2 Ferring Pharmaceuticals, Suffern, NY.<br />
CRC27. Impact of Co-Morbidity Burden on Real World Health<br />
Care Costs of Rheumatoid Arthritis Patients Initiating Anti-<br />
Tumor Necrosis Factor Therapy. B. Tang 1 , M. Rahman 1 , J. J.<br />
Stephenson 2 , R. Quimbo 2 , A. Naim 1 , H. Thompson 1 , O.<br />
Dabbous 1 . 1 Centocor, Inc., Horsham, PA; 2 HealthCore Inc.,<br />
Wilmington, DE.<br />
CRC28. Impact of Anti-Tumor Necrosis Factors on Healthcare<br />
Costs in Patients with Rheumatoid Arthritis. B. Tang 1 , M.<br />
Rahman 1 , J. J. Stephenson 2 , R. Quimbo 2 , H. Thompson 1 ,<br />
O. Dabbous 1 . 1 Centocor, Inc., Horsham, PA; 2 HealthCore,<br />
Inc., Wilmington, DE.<br />
CRC29. Comparison of Therapeutic Persistence Among Anti-<br />
Tumor Necrosis Factors in the Treatment of Rheumatoid Arthritis.<br />
B. Tang 1 , O. Dabbous 1 , B. Meissner 2 , H. Thompson 1 , M.<br />
Rahman 1 . 1 Centocor, Inc., Horsham, PA; 2 Xcenda, Palm<br />
Harbor, FL.<br />
CRC30. Assessing the Relationship between the Number of<br />
Biological Agents Ever Used and Clinical Outcomes and Work<br />
Productivity in Patients with Rheumatoid Arthritis. B. Tang 1 , M.<br />
Rahman 1 , O. Dabbous 1 , A. Naim 1 , H. Thompson 1 , C. Han 2 .<br />
1<br />
Centocor, Inc., Horsham, PA; 2 Centocor Research and<br />
Development, Inc., Malvern, PA.<br />
CRC31. Infliximab and Adalimumab in the Treatment of<br />
Patients with Rheumatoid Arthritis: Physicians and Patients Survey.<br />
O. Dabbous, M. Lee, B. Tang, H. Thompson, R. Hilliard, A.<br />
Naim, M. Rahman. Centocor, Inc., Horsham, PA.<br />
CRC32. A Five-Year Longitudinal Analysis Comparing Dose<br />
Changes for Patients with Rheumatoid Arthritis Taking Infliximab<br />
in a Medicare and in a Commercially Insured Population. K. V.<br />
Nair 1 , B. Tang 2 , J. Van Den Bos 3 , V. Zhang 3 , J. Saseen 1 , M.<br />
Rahman 2 . 1 School of Pharmacy, University of Colorado<br />
at Denver and Health Sciences Center, Denver, CO;<br />
2<br />
Centocor, Inc., Horsham, PA; 3 Milliman, Denver Health,<br />
Denver, CO.<br />
CRC33. Cost of Illness: Systemic Lupus Erythematosus Versus<br />
Lupus Nephritis. D. F. Eisenberg, N. Zhao, B. Hsu, Y. Wu,<br />
K. Renahan, C. Han, M. Bala. Centocor Research &<br />
Development, Inc., Malvern, PA.<br />
CRC34. The Association between Co-Existing Immune Mediated<br />
Inflammatory Diseases and the Healthcare Costs in Patients with<br />
Rheumatoid Arthritis who Received Anti-Tumor Necrosis Factors.<br />
B. Tang 1 , M. Rahman 1 , J. J. Stephenson 2 , R. Quimbo 2 , O.<br />
Dabbous 1 , H. Thompson 1 . 1 Centocor, Inc., Horsham, PA;<br />
2<br />
HealthCore, Inc., Wilmington, DE.<br />
pre-conference Tuesday<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 33
Tuesday pre-conference<br />
CRC35. Infliximab Treated Rheumatoid Arthritis Patients:<br />
Physicians and Patients Survey. O. Dabbous, M. Lee, B. Tang,<br />
H. Thompson, R. Hilliard, A. Naim, M. Rahman. Centocor,<br />
Inc., Horsham, PA.<br />
CRC36. Factors Predicting Work Loss and Productivity Impairment<br />
Using Worker Productivity and Impairment Questionnaire in<br />
Patients with Rheumatoid Arthritis. B. Tang 1 , M. Rahman 1 , H.<br />
Thompson 1 , O. Dabbous 1 , A. Naim 1 , C. Han 2 . 1 Centocor,<br />
Inc., Horsham, PA; 2 Centocor Research and Development,<br />
Inc., Malvern, PA.<br />
CRC37. Prediction Models of Rheumatoid Arthritis (RA) Disease<br />
Activity Using Macro Economic Variables, Based on Gross<br />
Domestic Product (GDP) and Total National Health Expenditure<br />
Per Capita (TNEH) in Different Countries. T. Sokka 1 , Theodore<br />
Pincus 2 , Bernard Combe Combe 3 , Kai Immonen 4 , Troels<br />
Mork Hansen 5 , Sergio Toloza 6 , Gianfranco Ferraccioli 7 ,<br />
Susan MM Verstappen 8 , Witold Tlustochowicz 9 , Wojciech<br />
Romanowski 10 , Jaime Calvo-Alen 11 , Patricia Minnock 12 , Selda<br />
Celik 13 , Martin Bergman 14 , Pál Géher 15 , Ilona Ujfalussy 16 ,<br />
Jolanta Dadoniene 17 , Marika Tammaru 18 , Rolf Kuuse 18 ,<br />
Riina Kallikorm 18 , Rolf Oding 19 , Margareth Liveborn 19 ,<br />
Ann-Carin Holmqvist 20 , On Behalf of the QUEST-RA<br />
Group. 1 Jyväskylä Central Hospital, Jyväskylä, Finland; 2 New<br />
York University Hospital for Joint Diseases, New York, NY;<br />
3<br />
Hôpital Lapeyronie, Montpellier, France; 4 North Karelia<br />
Central Hospital, Joensuu, Finland; 5 Copenhagen University<br />
Hospital at Herlev, Herlev, Denmark; 6 Hospital San Juan<br />
Bautista, Catamarca, Argentina; 7 Catholic University of<br />
Sacred Heart, Rome, Italy; 8 University Medical Center<br />
Utrecht, Utrecht, The Netherlands; 9 Military Institute<br />
of Medicine, Warshaw, Poland; 10 Poznan Rheumatology<br />
Center in Srem, Srem, Poland; 11 Hospital Sierrallana Ganzo,<br />
Torrelavega, Spain; 12 Our Lady’s Hospice, Dublin, Ireland;<br />
13<br />
Cerrahpasa Medic Faculty, Istanbul, Turkey; 14 Taylor<br />
Hospital, Ridley Park, PA; 15 Semmelweis University of<br />
Medical Sciences, Budapest, Hungary; 16 Polyclinic of the<br />
Hospitaller Brothers of St. John of God, Budapest, Hungary;<br />
17<br />
Institute of Experimental and Clinical Medicine at Vilnius,<br />
Vilnius, Lithuania; 18 Tartu University Hospital, Tartu,<br />
Estonia; 19 Centrallasarettet, Västerås, Sweden; 20 Hudiksvall<br />
Medical Clinic, Hudiksvall, Sweden<br />
CRC38. The Value of Convenience: Are Patients Willing to<br />
Trade-Off Other Attributes of Treatment for Better Convenience?.<br />
F. R. Johnson 1 , A. B. Hauber 2 , S. Ozdemir 1 , M. Bala 3 .<br />
1<br />
RTI International, Research Triangle Park, NC; 2 Health<br />
Preference Assessment, Doylestown, PA; 3 Centocor<br />
Research & Development, Inc., Malvern, PA.<br />
CRC39. The Association between Therapeutic Persistence and<br />
Non-Pharmacy Cost Among Anti-Tumor Necrosis Factors in the<br />
Treatment of Rheumatoid Arthritis. B. Tang 1 , H. Thompson 1 ,<br />
B. Meissner 2 , O. Dabbous 1 , M. Rahman 1 . 1 Centocor, Inc.,<br />
Horsham, PA; 2 Xcenda, Palm Harbor, FL.<br />
CRC40. Stability of Dosing in Long-Term Rheumatoid Arthritis<br />
Patients Receiving Infliximab. G. Watson 1 , M. Rahman 2 , H.<br />
Thompson 2 , M. Ziskind 2 , B. Tang 2 , R. Hilliard 2 , A. Naim 2 ,<br />
M. Kugel 1 , O. Dabbous 2 . 1 The Moran Company, Arlington,<br />
VA; 2 Centocor, Inc., Horsham, PA.<br />
CRC41. Switching Patterns Among Anti-Tumor Necrosis Factors in<br />
the Treatment of Rheumatoid Arthritis. B. Tang 1 , M. Rahman 1 ,<br />
B. Meissner 2 , A. Naim 1 , H. Thompson 1 , O. Dabbous 1 .<br />
1<br />
Centocor, Inc., Horsham, PA; 2 Xcenda, Palm Harbor, FL.<br />
CRC42. Time to Anti-Tumor Necrosis Factor Initiation from<br />
Rheumatoid Arthritis Diagnosis. B. Tang 1 , M. Rahman 1 , B.<br />
Meissner 2 , H. Thompson 1 , O. Dabbous 1 . 1 Centocor, Inc.,<br />
Horsham, PA; 2 Xcenda, Palm Harbor, FL.<br />
CRC43. The Impact of Anti-Tumor Necrosis Factors on Healthcare<br />
Costs in Patients with Immune Mediated Inflammatory Diseases.<br />
B. Tang 1 , M. Rahman 1 , J. J. Stephenson 2 , R. Quimbo 2 , H.<br />
Thompson 1 , O. Dabbous 1 . 1 Centocor, Inc., Horsham, PA;<br />
2<br />
HealthCore, Inc., Wilmington, DE.<br />
CRC44. Cutaneous Lupus Erythematosus Patients Have<br />
Significantly Worse Quality of Life Than Healthy Normal<br />
Volunteers. D. F. Eisenberg, C. Calderon, A. Piantone, M.<br />
Pupek, K. Renahan, C. Han, M. Bala. Centocor Research &<br />
Development, Inc., Malvern, PA.<br />
CRC45. Household Income and Quality of Life in Patients<br />
with Rheumatoid Arthritis: Results from a Mestizo Population<br />
with Full Health-Care Coverage. Augusto Garcia-Poma 1 ,<br />
Maria I. Segami 1 , Henry N. Terrazas 1 , Cecilia P. Chung 2 .<br />
1<br />
Universidad Nacional Mayor de San Marcos, Lima, Peru;<br />
2<br />
Vanderbilt University, Nashville, TN.<br />
CRC46. Comparing Medical Utilization and Expenditures<br />
Between Switchers and Non Switchers for Tumor Necrosis Factor<br />
Inhibitors (anti-TNFs) in the Treatment of Rheumatoid Arthritis.<br />
K. V. Nair 1 , B. Tang 2 , J. Van Den Bos 3 , V. Zhang 3 , A.<br />
Naim 2 , M. Rahman 2 . 1 School of Pharmacy, University of<br />
Colorado at Denver and Health Sciences Center, Denver,<br />
CO; 2 Centocor, Inc., Horsham, PA; 3 Milliman, Denver<br />
Health, Denver, CO.<br />
CRC47. Persistency among Anti-Tumor Necrosis Factors in the<br />
Treatment of Rheumatoid Arthritis from a Payor Perspective.<br />
O. Dabbous 1 , M. Lee 1 , J. Rambharose 1 , B. Tang 1 , H.<br />
Thompson 1 , R. Hilliard 1 , A. Naim 1 , R. Delise 2 , M.<br />
Rahman 1 . 1 Centocor, Inc., Horsham, PA; 2 Trinity Partners,<br />
Waltham, MA.<br />
CRC48. Impact of Anti-Tumor Necrosis Factors on Health<br />
Care Resource Utilization in Patients with Immune-Mediated<br />
Inflammatory Diseases. B. Tang 1 , M. Rahman 1 , A. Naim 1 ,<br />
J. J. Stephenson 2 , R. Quimbo 2 , H. Thompson 1 , O.<br />
Dabbous 1 . 1 Centocor, Inc., Horsham, PA; 2 HealthCore Inc.,<br />
Wilmington, DE.<br />
34 = Recorded Sessions (order form on page 430)
CRC49. Infliximab Dosing Patterns and Cost are Stable in the<br />
Treatment of Rheumatoid Arthritis Disease. O. Dabbous, T.<br />
Young, M. Ziskind, B. Tang, H. Thompson, M. Rahman.<br />
Centocor, Inc., Horsham, PA.<br />
CRC50. Comparison of Switching Patterns among Anti-Tumor<br />
Necrosis Factors in the Treatment of Rheumatoid Arthritis.<br />
B. Tang 1 , M. Rahman 1 , B. Meissner 2 , O. Dabbous 1 , H.<br />
Thompson 1 . 1 Centocor, Inc., Horsham, PA; 2 Xcenda, Palm<br />
Harbor, FL.<br />
1:30 p m<br />
Afternoon Keynote: The Coxib Experience: What Has<br />
(and Hasn’t) It Taught Us about Drug Risks?<br />
Jerry Avorn, MD; Harvard Medical School; Boston, MA<br />
Session III: Drug Policy and Regulation<br />
Moderator:<br />
Jeffrey N. Siegel, MD; FDA; Silver Spring, MD<br />
2:00 p m<br />
FDA Approach to Drug Safety Pre-and Post-Approval<br />
Paul Seligman, MD, MPH; Food and Drug Administration;<br />
Rockville, MD<br />
2:25 p m<br />
Drug Development in the 21st Century: The Role of Targeted Therapy<br />
Hal Barron; Genentech, Inc.; South San Francisco, CA<br />
2:50 p m<br />
Assuring Safety and Effectiveness for Anti-Rheumatic Drugs<br />
Claire Bombardier, MD; University of Toronto; Toronto,<br />
Ontario<br />
3:15 p m<br />
Panel Discussion<br />
3:30—3:45 p m<br />
Break<br />
Session IV: Methods in Drug Evaluation<br />
Moderator:<br />
Kenneth G. Saag, MD, MSc; University of Alabama at<br />
Birmingham; Birmingham, AL<br />
3:45 p m<br />
Post-Marketing Surveillance of Anti-Rheumatic Agents:<br />
Methodologic Challenges and Opportunities<br />
Samy Suissa, PhD; Royal Victoria Hospital, McGill<br />
University Health Centre; Montreal, PQ<br />
4:10 p m<br />
Methodologic Challenges for Drug Registries<br />
Angela Zink, PhD; German Arthritis Research Centre;<br />
Berlin, Germany<br />
4:35 p m<br />
Evaluating Drug Safety: Propensity Scores, Instrumental Variables<br />
and Other New Methods<br />
Sebastian Schneeweiss, MD, ScD; Brigham and Women’s<br />
Hospital, Harvard Med School; Boston, MA<br />
5:00 p m<br />
Panel Discussion<br />
5:15—6:15 p m<br />
Reception with Poster Viewing<br />
Grand Ballroom East<br />
<strong>ACR</strong>/ABIM Maintenance of Certification<br />
Learning Session for Recertification<br />
Module 30-R ARS<br />
8:30 a m—4:30 p m<br />
Room 102<br />
Admission to the <strong>ACR</strong>/ABIM Maintenance of Certification Learning<br />
Session is by ticket only. Learn in an interactive environment as the clinical<br />
experts lead you through 60 case—based questions from ABIM’s Module<br />
30-R (Rheumatology Recent Advances). At the end of the program, submit<br />
your answers to ABIM and receive MOC credit for the SEP module.<br />
7:30—8:30 a m Continental Breakfast<br />
9:45—10:00 a m Break<br />
Noon—1:00 p m Boxed Lunch<br />
3:00—3:15 p m Break<br />
Moderator:<br />
Carol Langford, MD, MHS; Cleveland Clinic Foundation;<br />
Cleveland, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Satisfy a self-evaluation (SEP) requirement for<br />
ABIM recertification<br />
∙ Assess your strengths and weaknesses in clinical<br />
decision making<br />
∙ Acquire knowledge in an interactive environment<br />
8:30 a m<br />
<strong>Program</strong> Overview<br />
8:45 a m<br />
Session I<br />
Carol Langford, MD, MHS; Cleveland Clinic Foundation;<br />
Cleveland, OH<br />
9:45—10:00 a m<br />
Break<br />
pre-conference Tuesday<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 35
Tuesday pre-conference<br />
10:00 a m<br />
Session II<br />
Elena M. Massarotti, MD; New England Medical Center;<br />
Boston, MA<br />
11:00 a m<br />
Session III<br />
Kenneth G. Saag, MD, MSc; University of Alabama at<br />
Birmingham; Birmingham, AL<br />
Noon—1:00 p m<br />
Boxed Lunch<br />
1:00 p m<br />
Session IV<br />
John J. Cush, MD; Arthritis Care & Research Center;<br />
Dallas, TX<br />
2:00 p m<br />
Session V<br />
W. Winn Chatham, MD; University of Alabama at<br />
Birmingham; Birmingham, AL<br />
3:00—3:15 p m<br />
Break<br />
3:15 p m<br />
Session VI<br />
Maureen D. Mayes, MD, MPH; University of Texas-<br />
Houston; Houston, TX<br />
4:15 p m<br />
Wrap-Up<br />
<strong>ACR</strong> Basic Research Conference (Day One)<br />
1:00—5:30 p m<br />
Room 210<br />
Admission to the <strong>ACR</strong> Basic Research Conference is by ticket only.<br />
Musculoskeletal Engineering and Regeneration<br />
3:00—3:20 p m Break<br />
5:30—6:30 p m Reception<br />
Upon completion of this session, participants should be able to:<br />
∙ Define and describe knowledge of various stem cell<br />
populations and their potential for tissue regeneration<br />
and repair<br />
∙ Identify biomaterials applicable as three-dimensional<br />
scaffolds for tissue engineering<br />
∙ Discuss the various ex vivo and in vivo approaches to<br />
gene therapy<br />
∙ Evaluate some of the current clinical applications of<br />
cell-and gene-based approaches in tissue regeneration<br />
and repair<br />
Session I: Stem Cells<br />
Moderator:<br />
Rocky S. Tuan, PhD; NIAMS, National Institutes of<br />
Health; Bethesda, MD<br />
1:00 p m<br />
The Use of Embryonic Stem Cells in Regenerative Medicine<br />
Robert Lanza, MD; Worcester, MA<br />
1:35 p m<br />
Cardiac Repair with Human Embryonic Stem Cells<br />
Michael A. Laflamme, MD, PhD; University of Washington;<br />
Seattle, WA<br />
2:10 p m<br />
Adult Skeletal Stem Cells<br />
Pamela G. Robey, PhD; National Institutes of Health;<br />
Bethesda, MD<br />
3:00—3:20 p m<br />
Break<br />
Session II: Biomaterial Scaffolds<br />
Moderator:<br />
Rocky S. Tuan, PhD; NIAMS, National Institutes of<br />
Health; Bethesda, MD<br />
3:20 p m<br />
Novel Biomaterials for Gene and Cell Therapy<br />
Jeffrey M. Karp, BEng, PhD; Harvard-MIT Division of<br />
Health Sciences and Technology, HMS; Cambridge, MA<br />
4:00 p m<br />
Nanofibrous Scaffolds for Skeletal Tissue Engineering<br />
Rocky S. Tuan, PhD; NIAMS, National Institutes of<br />
Health; Bethesda, MD<br />
4:40 p m<br />
Versatile Hyaluronan-Based Synthetic ECMs for Reparative Medicine<br />
Glenn D. Prestwich, PhD; University of Utah; Salt Lake<br />
City, UT<br />
5:30—6:30 p m<br />
Reception<br />
Foyer<br />
36 = Recorded Sessions (order form on page 430)
Wednesday, November 7, <strong>2007</strong><br />
<strong>ACR</strong>/<strong>ARHP</strong> Registration<br />
7:00 a m—6:30 p m<br />
East Registration<br />
<strong>ACR</strong> Basic Research Conference (Day Two)<br />
8:30 a m—5:00 p m<br />
Room 210<br />
Admission to the <strong>ACR</strong> Basic Research Conference is by ticket only.<br />
Musculoskeletal Engineering and Regeneration<br />
7:30—8:30 a m Continental Breakfast<br />
9:55—10:10 a m Break<br />
11:00 a m—12:45 pm Boxed Lunch<br />
2:45—3:00 p m Break<br />
Upon completion of this session, participants should be able to:<br />
∙ Define and describe various stem cell populations and<br />
their potential for tissue regeneration and repair<br />
∙ Identify biomaterials applicable as three-dimensional<br />
scaffolds for tissue engineering<br />
∙ Discuss ex vivo and in vivo approaches to gene therapy<br />
∙ Evaluate some of the current clinical applications of cell<br />
and gene-based approaches in tissue regeneration and repair<br />
Session III: Gene-Based Therapies<br />
Moderator:<br />
Christopher H. Evans, PhD, DSc; Harvard Medical School;<br />
Boston, MA<br />
8:30 a m<br />
Adult Mesenchymal Stem Cells as Vehicle for Gene Therapy:<br />
Applications to Bone Metastasis<br />
Christian Jorgensen, MD, PhD; Hospital Lapeyronie;<br />
Montpellier, France<br />
9:13 a m<br />
Expedited, Gene-Based Approaches to the Repair and Regeneration<br />
of Connective Tissues<br />
Christopher H. Evans, PhD, DSc; Harvard Medical School;<br />
Boston, MA<br />
9:55—10:10 a m<br />
Break<br />
Session IV: Engineering Technologies<br />
Moderator:<br />
Farshid Guilak, PhD; Department of Surgery; Durham, NC<br />
10:10 a m<br />
Stem Cells and Genes as Key Players in Skeletal Tissue Engineering<br />
Dan Gazit, DMD, PhD; Hebrew University/Cedars Sinai<br />
Medical Center; Los Angeles, CA<br />
11:00 a m—12:45 p m<br />
Boxed Lunch<br />
Session IV: Engineering Technologies (continued)<br />
Moderator:<br />
Farshid Guilak, PhD; Department of Surgery; Durham, NC<br />
12:45 p m<br />
Stem Cells, Scaffolds, and Cartilage Regeneration: Can We<br />
Engineer a Living Joint Replacement?<br />
Farshid Guilak, PhD; Department of Surgery; Durham, NC<br />
1:25 p m<br />
Bioreactor—Based Strategies in Musculoskeletal Tissue Engineering<br />
Ivan Martin, PhD; University Hospital Basel; Basel,<br />
Switzerland<br />
2:05 p m<br />
Advanced Technologies for Cartilage and Bone Tissue Engineering<br />
Gordana Vunjak Novakovic, PhD; Columbia University;<br />
New York, NY<br />
2:45—3:00 p m<br />
Break<br />
Session V: Clinical Applications<br />
Moderator:<br />
Frank P. Luyten, MD, PhD; University Hospitals Katholieke<br />
Universiteit Leuven; Leuven, Belgium<br />
3:05 p m<br />
Clinical Application of Cell-Based Skeletal Tissue Engineering<br />
Frank P. Luyten, MD, PhD; University Hospitals Katholieke<br />
Universiteit Leuven; Leuven, Belgium<br />
3:45 p m<br />
Technology Musculoskeletal Regeneration: Strategies and<br />
Mechanism of Action<br />
Frank P. Barry, PhD; National University of Ireland;<br />
Galway, Ireland<br />
4:25 p m<br />
Regenerative Medicine Based on Muscle Stem Cells: Potential<br />
Applications for Musculoskeletal Tissue Regeneration<br />
Johnny Huard, PhD; Children’s Hospital of Pittsburgh;<br />
Pittsburgh, PA<br />
pre-conference wednesday<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 37
wednesday pre-conference<br />
<strong>ACR</strong> Review Course<br />
8:45 a m—5:00 p m<br />
Hall C<br />
Admission to the <strong>ACR</strong> Review Course is by ticket only.<br />
7:30—8:45 a m Continental Breakfast<br />
10:15—10:45 a m Break<br />
12:15—1:30 p m Boxed Lunch<br />
3:00—3:30 p m Break<br />
Moderators:<br />
Mary Anne Dooley, MD, MPH; University of North<br />
Carolina at Chapel Hill; Chapel Hill, NC<br />
John H. Stone, MD, MPH; Massachusetts General<br />
Hospital/UpToDate; Sudbury, MA<br />
8:45 a m<br />
Vasculitis: New Therapies and Pitfalls in Treatment of<br />
ANCA-Associated Vasculitis<br />
Ulrich Specks, MD; Mayo Clinic; Rochester, MN<br />
Upon completion of this session, participants should be able to:<br />
∙ Compare and contrast the clinical features of Wegener’s<br />
granulomatosis, microscopic polyangiitis, and the Churg-<br />
Strauss Syndrome<br />
∙ Discuss the role of ANCA in the diagnosis and<br />
management of patients with these disorders<br />
∙ Discuss approaches for the induction and maintenance of<br />
remission in patients with ANCA-associated vasculitis<br />
9:30 a m<br />
Fibromyalgia: New Treatments PM<br />
Daniel J. Clauw, MD; University of Michigan;<br />
Ann Arbor, MI<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the scope of clinical findings in patients with fibromyalgia<br />
∙ Discuss the current knowledge about the etiopathogenesis<br />
of this disorder<br />
∙ Discribe the issues related to formulating a patient-specific<br />
treatment approach to fibromyalgia<br />
10:15—10:45 a m<br />
Break<br />
10:45 a m<br />
Osteoarthritis: Hormones Diet and Genetics Influence the<br />
Risk of Acquiring OA<br />
Joanne M. Jordan, MD, MPH; University of North Carolina<br />
Thurston Arthritis Research Center; Chapel Hill, NC<br />
Upon completion of this session, participants should be able to:<br />
∙ Review new insights into the epidemiology of osteoarthritis<br />
∙ Examine the broad concepts of the role of genetics in<br />
defining the phenotype of generalized osteoarthritis<br />
∙ Describe the contributions of anthropometric measures<br />
and diet to the expression of osteoarthritis<br />
11:30 a m<br />
SLE: Therapeutics<br />
David A. Isenberg, MD; University College; London, England<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the status of biologic approaches to the therapy of<br />
systemic lupus erythematosus<br />
∙ Develop an approach to the management of lupus nephritis<br />
∙ Describe the evaluation and initial therapeutic approach<br />
to patients with neuropsychiatric lupus<br />
12:15—1:30 p m<br />
Boxed Lunch<br />
1:30 p m<br />
Transitions in the Care of Adolescents with Rheumatic Diseases<br />
Patience H. White, MD, MA; George Washington<br />
University; Washington, DC<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss issues unique to the care of the adolescent with a<br />
connective tissue disorder in a case-based approach<br />
∙ List aspects of medical therapy that differ between the<br />
adolescent and adult patient<br />
∙ Review the essential steps in the effective transfer of the<br />
adolescent patient from pediatric to adult rheumatologist<br />
2:15 p m<br />
Ophthalmologic Manifestations of Rheumatic Disease<br />
James T. Rosenbaum, MD; Oregon Health and Science<br />
University; Portland, OR<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the common ocular presentations of patients<br />
with systemic inflammatory illnesses<br />
∙ Discuss the vocabulary necessary to collaborate effectively<br />
with the ophthalmologist<br />
∙ Review the eye-specific and systemic approaches to the<br />
treatment of ocular inflammatory disease<br />
3:00—3:30 p m<br />
Break<br />
38 = Recorded Sessions (order form on page 430)
3:30 p m<br />
Challenges in the Treatment of Early RA<br />
Ferdinand C. Breedveld, MD; Leiden University Medical<br />
Center; Leiden, Netherlands<br />
Upon completion of this session, participants should be able to:<br />
∙ Debate the pros and cons of initial biologic therapy for<br />
the treatment of RA<br />
∙ Analyze the factors that dictate the decision to change<br />
therapy in a patient with RA<br />
∙ Describe the features that determine the prognosis of a<br />
patient with newly diagnosed RA<br />
4:15 p m<br />
Inflammatory Muscle Disease<br />
Chester V. Oddis, MD; University of Pittsburgh; Pittsburgh, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the distinguishing clinical and pathological<br />
features of the inflammatory myopathies<br />
∙ Describe the role of autoantibodies in predicting disease<br />
phenotype and prognosis<br />
∙ Discuss the formulation of an effective treatment regimen<br />
for the patient with inflammatory muscle disease<br />
8:30 a m<br />
Introduction<br />
Benjamin J. Smith, PA-C; McIntosh Clinic; Thomasville, GA<br />
8:45 a m<br />
Hematology/Oncology<br />
Thomas DeLoughery, MD; Oregon Health and Science<br />
University; Portland, OR<br />
9:45 a m<br />
Psychological<br />
Sheryl S. Russell, PhD, APRN, BC; William Jennings Bryan<br />
Dorn Veterans Affairs Medical Center; Irmo, SC<br />
10:45—11:00 a m<br />
Break<br />
11:00 a m<br />
Gastrointestinal<br />
Peter H. Schur, MD; Brigham and Women’s Hospital;<br />
Boston, MA<br />
Noon—1:00 p m<br />
Boxed Lunch<br />
pre-conference wednesday<br />
<strong>ARHP</strong> Clinical Focus Course<br />
8:30 a m—4:30 p m<br />
Room 259<br />
The <strong>ARHP</strong> thanks Roche and Novartis for providing educational grants in<br />
support of this course.<br />
Admission to the <strong>ARHP</strong> Clinical Focus Course is by ticket only. The <strong>ACR</strong><br />
Committee on Education has approved this course for CME credit.<br />
7:30—8:30 a m Continental Breakfast<br />
10:45—11:00 a m Break<br />
Noon—1:00 p m Boxed Lunch<br />
3:00—3:15 p m Break<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize clinical manifestations and complications of<br />
rheumatic diseases<br />
∙ Select appropriate laboratory and radiographic studies and<br />
analyze data obtained from these tests when evaluating<br />
rheumatic diseases<br />
∙ Propose, apply, and manage pharmacologic and<br />
non-pharmacologic treatment for rheumatic diseases<br />
Completing the Puzzle: Other Aspects of Rheumatic Diseases<br />
Moderators:<br />
Kori A. Dewing, MN, ARNP; Seattle Rheumatology<br />
Associates; Seattle, WA<br />
Benjamin J. Smith, PA-C; McIntosh Clinic; Thomasville, GA<br />
1:00 p m<br />
Metabolic Bone Disease<br />
Joseph M. Grisanti, MD; Buffalo Rheumatology; Orchard<br />
Park, NY<br />
2:00 p m<br />
Ear, Nose and Throat<br />
Andrew J. White, MD; St. Louis Children’s Hospital;<br />
St Louis, MO<br />
3:00—3:15 p m<br />
Break<br />
3:15 p m<br />
Genitourinary/Reproductive<br />
Vaidehi R. Chowdhary, MD; Mayo Clinic; Rochester, MN<br />
4:15 p m<br />
Wrap-Up<br />
Benjamin J. Smith, PA-C; McIntosh Clinic; Thomasville, GA<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 39
wednesday Opening Lecture + Awards<br />
<strong>ACR</strong>/<strong>ARHP</strong> Opening Lecture and Awards<br />
5:30—7:30 p m<br />
Hall C<br />
Medicine In silico: The Information Age<br />
Comes to Medicine<br />
Moderators:<br />
Neal S. Birnbaum, MD; Pacific Rheumatology<br />
Associates Medical Group; San Francisco, CA<br />
Karen L. Kerr, MSN, NP, CPNP; Children’s Hospital of<br />
Michigan; Detroit, MI<br />
Speaker:<br />
David Blumenthal, MD, MPP; Massachusetts General<br />
Hospital/Partners Health System; Boston, MA<br />
David Blumenthal, MD, MPP, is Director of the Institute<br />
for Health Policy and a Physician at The Massachusetts<br />
General Hospital/Partners HealthCare System in Boston.<br />
He is also Samuel O. Thier Professor of Medicine and<br />
Professor of Health Care Policy at Harvard Medical School.<br />
From 1981 to 1987, he was Senior Vice President at<br />
Boston’s Brigham and Women’s Hospital. From 1981 to<br />
1987 he was Executive Director of the Center for Health<br />
Policy and Management and Lecturer on Public Policy at<br />
the John F. Kennedy School of Government at Harvard.<br />
During the late 1970s, Dr. Blumenthal was a professional<br />
staff member on Senator Edward Kennedy’s Senate<br />
Subcommittee on Health and <strong>Scientific</strong> Research.<br />
Dr. Blumenthal is a member of the Institute of Medicine, a<br />
National Associate of the National Academy of Sciences,<br />
and serves on several editorial boards. He is also a National<br />
Correspondent for The New England Journal of Medicine.<br />
He currently serves as a trustee of the University of<br />
Pennsylvania Health System (Penn Medicine).<br />
5:30<br />
Recognition of <strong>2007</strong> <strong>ACR</strong> Masters<br />
Frank C. Arnett, Jr., MD Kate R. Lorig, DrPH<br />
Robert M. Bennett, MD, FRCP Anne-Marie Prieur, MD<br />
Lynn Bonfiglio<br />
Kenneth E. Sack, MD<br />
Jean-Michel Dayer, MD William E. Seaman, MD<br />
Raphael J. DeHoratius, MD John S. Sergent, MD<br />
C. Garrison Fathman, MD Levinus B. Van de Putte, MD, PhD<br />
Shu Man Fu, MD, PhD Alan S. Wiik, MD, PhD<br />
David N. Glass, MD John B. Winfield, MD<br />
Recognition of <strong>2007</strong> <strong>ACR</strong> Awards of Distinction Recipients<br />
<strong>ACR</strong> Presidential Gold Medal Award<br />
Edward D. Harris, Jr., MD<br />
<strong>ACR</strong> Distinguished Basic Investigator Award<br />
Peter K. Gregersen, MD<br />
<strong>ACR</strong> Distinguished Clinician Scholar Award<br />
W. Joseph McCune, MD<br />
<strong>ACR</strong> Henry Kunkel Young Investigator Award<br />
Daniel H. Solomon, MD, MPH<br />
<strong>ACR</strong> Distinguished Clinical Investigator Award<br />
Daniel J. Lovell, MD, MPH<br />
<strong>ACR</strong> Paulding Phelps Award<br />
Luis R. Espinoza, MD<br />
<strong>ACR</strong> Distinguished Service Award<br />
Maren L. Mahowald, MD<br />
REF Excellence in Investigative Mentoring Award<br />
Bevra H. Hahn, MD<br />
Recognition of <strong>2007</strong> <strong>ARHP</strong> Merit Awards and<br />
Lifetime Achievement Award Recipients<br />
<strong>ARHP</strong> Addie Thomas Service Award<br />
Janalee Taylor, RN, MSN, CNS<br />
<strong>ARHP</strong> Distinguished Scholar Award<br />
Joan C. Rogers, PhD, OTR/L<br />
<strong>ARHP</strong> Master Clinician Award<br />
Norma L. Liburd, RNC, MN<br />
Gail R. McIlvain-Simpson, MSN, APRN, BC<br />
<strong>ARHP</strong> Ann Kunkel Advocacy Award<br />
Amye L. Leong, MBA<br />
Kathleen A. Arntsen, BA<br />
<strong>ARHP</strong> Lifetime Achievement Award<br />
Marian A. Minor, PhD, PT<br />
<strong>ARHP</strong> President’s Award<br />
Erica B. Stern, PhD, OTR/L<br />
The <strong>ARHP</strong> thanks Merck & Company, Inc., for its support of the<br />
<strong>2007</strong> Merit Awards.<br />
6:15<br />
Presidential Address<br />
Neal S. Birnbaum, MD; <strong>ACR</strong> President<br />
6:45<br />
Medicine In silico: The Information Age Comes to Medicine<br />
Moderators:<br />
Neal S. Birnbaum, MD; Pacific Rheumatology Associates<br />
Medical Group; San Francisco, CA<br />
Karen L. Kerr, MSN, NP, CPNP; Children’s Hospital of<br />
Michigan; Detroit, MI<br />
Speaker:<br />
David Blumenthal, MD, MPP; Massachusetts General<br />
Hospital/Partners Health System; Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the impact of health information technology on<br />
the quality of medical care<br />
∙ Discuss the impact of health information technology on<br />
the efficiency of the health care system<br />
∙ Distinguish between factors that encourage or discourage<br />
the spread of health information technology<br />
40 = Recorded Sessions (order form on page 430)
<strong>ACR</strong>/<strong>ARHP</strong> Opening Dessert Reception<br />
at the Sheraton Boston Hotel<br />
8:30—10:30 p m<br />
Join your colleagues for dessert at the Sheraton Boston<br />
Hotel, a contiguous part of the landmark Prudential<br />
Center/Copley Place Complex. Desserts display artistic<br />
talent as well as culinary expertise, ending on a sweet and<br />
elegant note. You won’t want to miss this evening of fun,<br />
music and wonderful sweets. <strong>ACR</strong> shuttle buses will<br />
leave from official hotels that are not within walking distance.<br />
do<br />
you?<br />
then...<br />
The quality movement is a complex topic, but it will have important<br />
implications for both practicing and academic rheumatologists.<br />
Want to know how quality initiatives will affect your practice?<br />
Want to learn more about what the <strong>ACR</strong> is doing to prepare for the<br />
quality movement?<br />
Come to one of <strong>ACR</strong>’s Educational Sessions on “Quality.”<br />
Opening Lecture + Awards wednesday<br />
Thursday, November 8<br />
8:00 a m–4:30 pm<br />
Thursday, November 8<br />
11:00 a m-12:30 pm<br />
Thursday, November 8<br />
4:30–6:00 pm<br />
Friday, November 9<br />
2:30–4:00 pm<br />
Friday, November 9<br />
4:30–6:00 pm<br />
Saturday, November 10<br />
7:00–8:00 a m<br />
<strong>ACR</strong> Poster Session A: Improving Quality of Care by Design, Redesign and Innovation.<br />
<strong>ACR</strong> Plenary Session I: Discovery <strong>2007</strong>: Advances in the Management of Arthritis and<br />
Osteoporosis.<br />
<strong>ACR</strong> Concurrent Abstract Session: Improving Quality of Care by Design, Redesign<br />
and Innovation.<br />
<strong>ACR</strong> Clinical Symposium: Doing the Right Thing: Evidence and Guidelines for Rheumatoid<br />
Arthritis Treatment. Review the <strong>ACR</strong> process for developing guidelines, learn about the<br />
components in developing a truly evidence based guideline and recognize the important<br />
new aspects of the 2008 <strong>ACR</strong> Guidelines for treating RA.<br />
<strong>ARHP</strong> Concurrent Session: Improving Patient Outcomes: Implications for Rheumatology<br />
Practice. Review the Institute of Medicine Reports, examine implications of medical errors<br />
in rheumatology practice, and learn about improving patient safety with regard to the<br />
roles of the quality movement and technology.<br />
<strong>ACR</strong> Quality Initiatives Town Hall Breakfast <strong>Meeting</strong>: An open forum to discuss the<br />
quality movement and the <strong>ACR</strong>’s quality efforts with the <strong>ACR</strong> leadership.<br />
>><br />
Stop by <strong>ACR</strong> Central for take-home resources, demonstrations of the new initiatives and opportunities<br />
to register for recertification tools at a discounted price.<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 41
time locatioN EVENT<br />
tHURSDAY · agenda at-a-glance<br />
7:00 a m—5:00 pm East Registration <strong>ACR</strong>/<strong>ARHP</strong> Registration<br />
7:15—7:45 a m Room 260 <strong>ARHP</strong> Special Session: Moderator Orientation<br />
7:15—7:45 a m Room 261 <strong>ARHP</strong> Special Session: Attendee Orientation<br />
7:45—8:45 a m Room 205 <strong>ACR</strong> State-of-the-Art<br />
7:45—8:45 a m Room 210 <strong>ACR</strong> REF Special Session: Gluck Lecture<br />
7:45—9:00 a m Hall C <strong>ACR</strong> Year in Review<br />
7:45—9:15 a m Convention Center (various locations) <strong>ACR</strong> Meet the Professor Sessions<br />
7:45—9:30 a m Room 253 <strong>ARHP</strong> Special Session: Networking Forum<br />
7:45—9:45 a m Room 213 <strong>ACR</strong> Workshops<br />
8:00—9:30 a m Exhibit Hall A-B <strong>ACR</strong>/<strong>ARHP</strong> Coffee and Tea Break<br />
8:00 a m—4:30 pm Exhibit Hall A-B <strong>ACR</strong> Poster Session A<br />
8:00 a m—4:30 pm Exhibit Hall A-B exhibits<br />
9:15—10:15 am Hall C <strong>ACR</strong> Medical Aspects of Rheumatic Diseases - <strong>ACR</strong> Hench Lecture<br />
9:15—10:15 a m Convention Center (various locations) <strong>ACR</strong> State-of-the-Art<br />
9:45—11:15 a m Room 258 <strong>ARHP</strong> General Session I<br />
10:30 a m—12:30 pm Convention Center (various locations) <strong>ACR</strong> Workshops<br />
11:00 a m—12:30 pm Hall C <strong>ACR</strong> Plenary Session I<br />
11:30 a m—12:30 pm Convention Center (various locations) <strong>ARHP</strong> Concurrent Sessions<br />
12:45—1:45 pm Room 154 <strong>ARHP</strong> Fitness Session: Tai Chi<br />
12:45—2:15 pm Room 255 encore Theater<br />
12:45—2:15 pm Convention Center (various locations) <strong>ACR</strong> Meet the Professor Sessions<br />
12:45—2:15 pm Room 104 <strong>ACR</strong> Special Session: Career Choices in Rheumatology<br />
1:15—2:15 pm Room 253 <strong>ACR</strong> Practice Issues<br />
1:15—3:15 pm Convention Center (various locations) <strong>ACR</strong> Workshops<br />
2:30—4:00 pm Room 205 <strong>ACR</strong> Basic Science Symposium<br />
2:30—4:00 pm Hall C <strong>ACR</strong> Clinical Symposium<br />
2:30—4:00 pm Convention Center (various locations) <strong>ACR</strong> Concurrent Abstract Sessions<br />
2:30—4:00 pm Room 210 <strong>ACR</strong> REF Special Session: Schiff Lecture<br />
2:30—4:00 pm Convention Center (various locations) <strong>ARHP</strong> Concurrent Sessions<br />
<strong>ACR</strong><br />
CLINICAL PRACTICE<br />
BASIC AND<br />
TRANSLATIONAL<br />
RESEARCH<br />
DUAL INTEREST TO<br />
CLINICIANS AND<br />
RESEARCHERS<br />
PEDIATRICS<br />
FELLOWS-IN-TRAINING<br />
<strong>ARHP</strong><br />
CLINICAL PRACTICE<br />
PEDIATRICS<br />
FELLOWS-IN-TRAINING<br />
PLAN YOUR SCHEDULE USING EDUCATIONAL TRACKS TO ENHANCE<br />
YOUR MEETING EXPERIENCE<br />
The <strong>ACR</strong> and <strong>ARHP</strong> have designed educational tracks to help you maximize the scheduling of your time and<br />
meeting experience by emphasizing primary areas of interest. There are five tracks for <strong>ACR</strong> and three tracks for<br />
<strong>ARHP</strong>. Designated sessions include the main symposia, lectures and select <strong>ACR</strong> Meet the Professor Sessions and<br />
Workshops. However, the concurrent abstract sessions and poster discussions are not included.<br />
Those sessions that are predominantly translational in content are designed to be of interest to both clinicians and<br />
researchers. These are indicated as “C/R”. Sessions with mainly pediatric content are indicated as “P”, and may be<br />
of interest to both pediatric and adult rheumatologists.<br />
As the annual meeting has a variety of session types scheduled concurrently, use these suggested tracks as a tool to<br />
assist you in developing your own individualized schedule for the meeting.<br />
Track Indicator Example<br />
Please use the following as an example to identify the available tracks.<br />
C R C/R P F<br />
CLINICAL<br />
PRACTICE<br />
BASIC AND<br />
TRANSLATIONAL<br />
RESEARCH<br />
DUAL INTEREST TO<br />
CLINICIANS AND<br />
RESEARCHERS<br />
PEDIATRICS<br />
FELLOWS-IN-<br />
TRAINING<br />
PM - PAIN MANAGEMENT<br />
The <strong>ACR</strong> designates certain sessions for pain management credit as required by the Medical Board of California<br />
(AB487). This designation is identified by the icon shown and will be placed next to the session title.<br />
42
2:30—4:00 pm Room 261 <strong>ARHP</strong> Concurrent Abstract Session<br />
2:30—4:15 pm Convention Center (various locations) <strong>ACR</strong> Mini-Symposia<br />
4:00—6:00 pm Convention Center (various locations) <strong>ACR</strong> Workshops<br />
4:00—6:00 pm Room 213 <strong>ARHP</strong> Concurrent Session<br />
4:30—6:00 pm Room 205 <strong>ACR</strong> Basic Science Symposium<br />
4:30—6:00 pm Convention Center (various locations) <strong>ACR</strong> Clinical Symposia<br />
4:30—6:00 pm Convention Center (various locations) <strong>ACR</strong> Concurrent Abstract Sessions<br />
4:30—6:00 pm Convention Center (various locations) <strong>ACR</strong> Meet the Professor Sessions<br />
4:30—6:00 pm Grand Ballroom West <strong>ACR</strong> REF Special Session: Dubois Lecture<br />
4:30—6:00 pm Room 151 <strong>ACR</strong>/<strong>ARHP</strong> Combined Concurrent Abstract Session<br />
4:30—6:00 pm Convention Center (various locations) <strong>ARHP</strong> Concurrent Sessions<br />
6:30—9:30 pm Various Locations industry Roundtable-Supported Symposia<br />
thursday<br />
THURSDAY, November 8, <strong>2007</strong><br />
<strong>ACR</strong>/<strong>ARHP</strong> Registration<br />
7:00 a m—5:00 p m<br />
East Registration<br />
<strong>ARHP</strong> Moderator/Assistant Orientation<br />
7:15—7:45 a m<br />
Room 260<br />
Coffee and tea will be available.<br />
<strong>ARHP</strong> First-Time Attendee Orientation<br />
7:15—7:45 a m<br />
Room 261<br />
Coffee and tea will be available.<br />
First-time <strong>ARHP</strong> annual meeting attendees are invited<br />
to an orientation to learn the “ins and outs” of the<br />
annual meeting. The <strong>ARHP</strong> Committee on Practice and<br />
Membership will be on hand to provide a glossary of terms<br />
and advice to assist you in planning how to get the most out<br />
of your first annual meeting. This orientation is before the<br />
Networking Forum scheduled today at 7:45 a m.<br />
Moderator:<br />
Cindy F. Mendelson, PhD, RN; University of New Mexico;<br />
Albuquerque, NM<br />
<strong>ACR</strong> State-of-the-Art R<br />
7:45—8:45 a m<br />
Room 205<br />
Th17 Cells: The New Kids on the Block<br />
Moderator:<br />
Anne Davidson, MB, BS, FRACP; Feinstein Institute for<br />
Medical Research; Manhasset, NY<br />
Speaker:<br />
Daniel Cua, PhD; Schering-Plough Biopharma; Palo Alto, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the heterogeneity of the T-cell subsets that<br />
contribute to autoimmune diseases<br />
∙ Identify the key pathways that regulate the formation of Th 17 cells<br />
∙ Recognize the effect or pathways whereby Th17 cells<br />
promote inflammation<br />
<strong>ACR</strong> REF Special Session C/R<br />
7:45—8:45 a m<br />
Room 210<br />
Oscar S. Gluck, MD, Memorial Lectureship<br />
Moderator:<br />
James R. O’Dell, MD; University of Nebraska<br />
Medical Center; Omaha, NE<br />
Osteoclasts: What Do They Do and How Do They Do It?<br />
Speaker:<br />
Steven L. Teitelbaum, MD; Washington University; St. Louis, MO<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the means by which osteoclasts degrade bone<br />
∙ Appraise the necessity for new anti-resorptive drugs<br />
∙ Describe the mechanisms of bone loss in osteoporosis and<br />
inflammatory arthritis<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 43
THURSDAY<br />
<strong>ACR</strong> Year in Review C/R<br />
7:45—9:00 a m<br />
Hall C<br />
7:45 a m<br />
Slide Competition Winners<br />
8:00 a m<br />
The Year in Review<br />
Dr. Mary K. Crow and Dr. E. William St. Clair will present<br />
significant contributions to the basic science and clinical<br />
rheumatology medical literature over the past year.<br />
Moderators:<br />
Richard A. Furie, MD; North Shore Long Island Jewish<br />
Health System; Lake Success, NY<br />
Brian F. Mandell, MD, PhD; Cleveland Clinic; Cleveland, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss selected recent publications on the pathophysiological<br />
basis of rheumatic diseases by literature review of<br />
important publications<br />
∙ Describe selected treatment modalities for rheumatic<br />
diseases from the recent published literature<br />
∙ Enumerate how these new advances may impact the<br />
practice of rheumatology<br />
8:00 a m<br />
Research Perspective<br />
Mary K. Crow, MD; Hospital for Special Surgery; New<br />
York, NY<br />
8:30 a m<br />
Clinical Perspective<br />
E. William St. Clair, MD; Duke University Medical Center;<br />
Durham, NC<br />
<strong>ACR</strong> Meet the Professor Sessions<br />
7:45—9:15 a m<br />
Admission to the Meet the Professor Sessions is by ticket only. To verify the<br />
session for which you are registered, refer to the registration codes below in<br />
parentheses. Meet the Professor sessions include beverages only.<br />
Allergy for Rheumatologists (014)<br />
Room 162 B<br />
John S. Sundy, MD, PhD; Duke University Medical Center;<br />
Durham, NC<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize immunologic disorders that are common to<br />
allergy and rheumatology practices<br />
∙ Review the presentations of autoimmune chronic urticaria,<br />
systemic mastocytosis, and common variable immune deficiency<br />
∙ Discuss upper airway and sinus disorders in allergic and<br />
rheumatic diseases<br />
Fibromyalgia (006)<br />
Room 109 A<br />
Lesley M. Arnold, MD; Cincinnati, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the most recent thoughts regarding the pathophysiology<br />
of fibromyalgia and related disorders<br />
∙ Prescribe a treatment program for the typical fibromyalgia<br />
patient and serve as a consultant to that patient and the<br />
primary care provider<br />
∙ Describe the principles of a comprehensive treatment<br />
program for the more challenging fibromyalgia patient<br />
Inflammatory Eye Disease: Focus on Uveitis (012)<br />
Room 161<br />
Sergio Schwartzman, MD; Hospital for Special Surgery;<br />
New York, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the clinical manifestations of inflammatory eye<br />
disease encountered by rheumatologists<br />
∙ Discuss diagnostic pearls for the evaluation of someone<br />
with inflammatory eye disease<br />
∙ Discuss the treatment paradigms used for the inflammatory<br />
eye diseases<br />
∙ Use cases to reinforce objectives 1-3<br />
Opportunistic Infections in Rheumatic Diseases (001)<br />
Room 106<br />
Francisco M. Marty, MD; Brigham and Women’s Hospital;<br />
Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the common opportunistic infections in the<br />
immunosuppressed rheumatic disease patient<br />
∙ Discuss treatment options for patients with rheumatic<br />
disease and opportunistic infections<br />
∙ Discuss indications for prophylactic coverage in the<br />
rheumatic disease patient<br />
Pain: Soft Tissue Rheumatism (004) f PM<br />
Room 107 C<br />
Hans Carlson, MD; Oregon Health and Science University;<br />
Portland, OR<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the commonly encountered soft tissue rheumatic<br />
complaints<br />
∙ Prescribe a treatment program for the commonly<br />
encountered soft tissue rheumatic complaints<br />
∙ Understand which conditions will respond to therapeutic<br />
injections and which should be treated conservatively<br />
44 = Recorded Sessions (order form on page 430)
Pediatric Systemic Lupus (009) P<br />
Room 160 A<br />
Deborah M. Levy, MD, MS; Columbia University Medical<br />
Center; New York, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss differences in presentation, disease course and<br />
treatment options between childhood-onset and adultonset<br />
Lupus<br />
∙ List recent and ongoing research efforts in childhoodonset<br />
Lupus<br />
∙ Describe important developmental issues in the care of<br />
children and adolescents with a chronic disease<br />
Pediatrics: Periodic Fevers in Children (008) P<br />
Room 159<br />
Philip J. Hashkes, MD, MSc; Cleveland Clinic Foundation;<br />
Cleveland, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the differential diagnosis and expanding<br />
spectrum of these syndromes<br />
∙ Determine when to suspect and how to diagnose these<br />
syndromes, including the utility of genetic testing<br />
∙ Relate the pathogenesis of these syndromes to knowledge<br />
of the various gene functions<br />
∙ Discuss the treatment rationale based on the pathogenesis<br />
and to expand on practical issues in the management of<br />
these patients<br />
Pregnancy, Fertility and Medication in Rheumatic<br />
Diseases (002)<br />
Room 107 A<br />
Bonnie L. Bermas, MD; Brigham and Women’s Hospital;<br />
Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the effects of pregnancy on the activity of<br />
rheumatic diseases<br />
∙ Recognize the challenging management issues unique<br />
to pregnancy<br />
Psoriatic Arthritis (010)<br />
Room 160 B<br />
Iain B. McInnes, PhD; University of Glasgow;<br />
Glasgow, Scotland<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the molecular basis for the pathogenesis of<br />
psoriatic arthritis<br />
∙ Discuss the recent advances in the treatment of patients<br />
with psoriatic arthritis<br />
Sarcoidosis (005)<br />
Room 108<br />
W. Winn Chatham, MD; University of Alabama at<br />
Birmingham; Birmingham, AL<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the various musculoskeletal manifestations<br />
of sarcoidosis<br />
∙ Describe the pathophysiology of sarcoidosis<br />
∙ Design treatment strategies for bone and joint sarcoidosis<br />
∙ Recognize neurologic and other organ manifestations<br />
of sarcoidosis<br />
Scleroderma: Systemic Sclerosis (013) F<br />
Room 162 A<br />
Richard M. Silver, MD; Medical University of South<br />
Carolina; Charleston, SC<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the classification of systemic sclerosis and its<br />
impact on treatment and prognosis<br />
∙ Apply cardiopulmonary testing to determine the relative<br />
contributions of alveolitis, fibrosis and vasculopathy<br />
∙ Formulate a therapeutic regimen to improve quality of life<br />
and organ-specific symptomatology<br />
SLE: CNS Lupus (011)<br />
Room 160 C<br />
C. Michael Neuwelt, MD; Univeristy of California, San<br />
Francisco and Stanford; San Leandro, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize manifestations of central nervous system lupus<br />
∙ Select appropriate diagnostic tests in patients with central<br />
nervous system lupus<br />
∙ Formulate a treatment plan<br />
Still’s Disease and Febrile Illnesses (007)<br />
Room 109 B<br />
John Esdaile, MD, MPH; Arthritis Research Center of<br />
Canada; Vancouver, British Columbia<br />
Upon completion of this session, participants should be able to:<br />
∙ List the clinical features of Still’s disease and other febrile<br />
syndromes<br />
∙ Discuss how to make optimal use of diagnostic tests in<br />
diagnosing febrile syndromes<br />
∙ Describe the immunogenetic mechanisms and treatment<br />
for adult Still’s disease and related syndromes<br />
THURSDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 45
THURSDAY<br />
Vasculitis: An Update (003)<br />
Room 107 B<br />
Simon Carette, MD; Toronto Western Hospital; Toronto,<br />
Ontario<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the various forms of vasculitis classified by<br />
affected vessel size<br />
∙ Utilize the various available tests with emphasis on ANCA<br />
∙ Identify current and novel therapeutic modalities<br />
<strong>ARHP</strong> Special Session<br />
7:45—9:30 a m<br />
Room 253<br />
A ticket is required and will be provided with your name badge. Breakfast<br />
will be available.<br />
<strong>ARHP</strong> Networking Forum<br />
All <strong>ARHP</strong> attendees are invited to a kick-off forum for the<br />
annual meeting. A continental breakfast will be served. You<br />
will have an opportunity to meet and network with other<br />
health professionals and the <strong>ARHP</strong> leadership.<br />
Moderator:<br />
Cindy F. Mendelson, PhD, RN, University of New Mexico,<br />
Albuquerque, NM<br />
8:00 a m<br />
<strong>Program</strong> Overview<br />
Linda S. Ehrlich-Jones, PhD, RN, Rehabilitation Institue of<br />
Chicago, Aurora, IL<br />
8:10 a m<br />
Presidential Welcome<br />
Karen L. Kerr, MSN, NP, CPNP; Children’s Hospital of<br />
Michigan; Detroit, MI<br />
Membership Recruitment Award<br />
The <strong>ARHP</strong> Membership Recruitment<br />
Award is presented to the member who has recruited the<br />
most members in the current year.<br />
To be announced<br />
<strong>ACR</strong> Workshops<br />
7:45—9:45 a m<br />
Admission to the Workshop sessions is by ticket only. To verify the session<br />
for which you are registered, refer to the registration codes below in<br />
parentheses. Workshops include beverages only.<br />
Designing a Web site for Your Practice (017)<br />
Room 213<br />
Peter J. Embi, MD, MS; University of Cincinnati;<br />
Cincinnati, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the basics of creating web sites on the internet<br />
∙ Describe how to secure a web address or domain name for<br />
a practice web site<br />
∙ Develop a basic web site using online or PC-based tools<br />
Musculoskeletal Ultrasonography: Basic (015)<br />
Equipment provided by Biosound Esaote Ultrasound<br />
Room 211<br />
George A.W. Bruyn, MD, PhD; Medisch Centrum<br />
Leeuwarden; Loenga, Netherlands<br />
Wolfgang A. Schmidt, MD; Medical Center for<br />
Rheumatology Berlin-Buch; Berlin, Germany<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the indications for ultrasound in rheumatic diseases<br />
∙ Discuss the techniques of ultrasonography<br />
∙ Recognize normal and abnormal anatomical structures by<br />
ultrasound imaging<br />
Rheumatology Physical Examination: Anatomical<br />
Correlates (016)<br />
Room 209<br />
Juan J. Canoso, MD; <strong>American</strong> British Cowdray Medical<br />
Center; Mexico City, Mexico<br />
Robert A. Kalish, MD; New England Medical Center;<br />
Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Review clinical and surface anatomy important to the<br />
rheumatologist<br />
∙ Relate human anatomy to clinical syndromes seen in the<br />
practice of rheumatology<br />
∙ Integrate these physical examination skills into a<br />
rheumatology practice<br />
Synovial Fluid Analysis and Crystal Identification (018)<br />
(Trainees Only) C f<br />
Room 212<br />
H. Ralph Schumacher, Jr., MD; Veteran’s Affairs Medical<br />
Center; Philadelphia, PA<br />
Lan X. Chen, MD, PhD; University of Pennsylvania;<br />
Philadelphia, PA<br />
Gilda M. Clayburne, MLT; VA Medical Center;<br />
Philadelphia, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Prepare synovial fluid samples for microscopic examination<br />
∙ Identify various components of synovial fluid<br />
∙ Recognize crystals in synovial fluid<br />
46 = Recorded Sessions (order form on page 430)
<strong>ACR</strong>/<strong>ARHP</strong> Coffee and Tea Break<br />
8:00—9:30 a m<br />
Exhibit Hall A-B<br />
<strong>ACR</strong> Poster Session A<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Admission to <strong>ACR</strong> poster sessions is by name badge only.<br />
Poster presenters will be available from 9:00—11:00 a m.<br />
Please note the numbering system for the poster sessions<br />
will include two sets of numbers. The first number is the<br />
permanent poster board number and will remain the same<br />
during all the poster sessions [e.g.:(1), (2)]. The next number<br />
will refer to the abstract number being presented, and this<br />
will change for each of the poster sessions.<br />
Abstracts #1-664<br />
For complete listing of the abstracts presented in this poster session, see<br />
pages 70--117.<br />
Exhibits<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the role of adipokines in the development of<br />
cardiovascular disease<br />
∙ Discuss the effects of obesity on the cardiovascular,<br />
pulmonary and hepatic systems<br />
∙ Evaluate the relative success of medical and surgical<br />
approaches to the treatment of obesity<br />
10:00 a m<br />
Discussion<br />
<strong>ACR</strong> State-of-the-Art R<br />
9:15—10:15 a m<br />
Room 210<br />
¹<br />
Apoptosis: Death by A Thousand Cuts<br />
Moderator:<br />
Keith B. Elkon, MD; University of Washington; Seattle, WA<br />
Speaker:<br />
Douglas R. Green, PhD; St. Jude Children’s Research<br />
Hospital; Memphis, TN<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the main pathways that lead to apoptosis<br />
∙ Discuss how defects in apoptosis can lead to disease<br />
∙ Explain how enhancing apoptosis can potentially be used<br />
to treat certain diseases<br />
THURSDAY<br />
<strong>ACR</strong> Medical Aspects of Rheumatic Diseases<br />
<strong>ACR</strong> Hench Lecture C<br />
9:15—10:15 a m<br />
Hall C<br />
Supported by the Dr. Paul J. and Madge Bilka Mayo Clinic Hench Society<br />
Lecture Endowment.<br />
<strong>ACR</strong> Hench Lecture<br />
Dr. Philip S. Hench joined Mayo Clinic as its first rheumatologist<br />
in 1926. In 1950, Dr. Hench was a co-winner of the Nobel<br />
Prize in Physiology and Medicine for the discovery of cortisone,<br />
and its first clinical use, in rheumatoid arthritis. The Mayo<br />
Clinic Hench Society is made up of rheumatologists trained<br />
at Mayo Clinic, and provides support for the Hench Society<br />
Lecture during the <strong>American</strong> College of Rheumatology<br />
Annual <strong>Scientific</strong> <strong>Meeting</strong>.<br />
Obesity<br />
Moderator:<br />
Eric L. Matteson, MD; Mayo Clinic; Rochester, MN<br />
Speaker:<br />
Frank Svec, MD, PhD; Metairie, LA<br />
10:00 a m<br />
Discussion<br />
<strong>ACR</strong> State-of-the-Art P<br />
9:15—10:15 a m<br />
Room 253<br />
Management of Complications of Systemic Juvenile<br />
Idiopathic Arthritis<br />
Moderator:<br />
Suzanne L. Bowyer, MD; James Whitcomb Riley Hospital;<br />
Indianapolis, IN<br />
Upon completion of this session, participants should be able to:<br />
∙ Distinguish systemic JIA from other forms of juvenile<br />
arthritis and febrile syndromes of childhood<br />
∙ List important complications of systemic JIA<br />
∙ Discuss the use and complications of new therapeutics in<br />
the treatment of systemic JIA<br />
Treatment and Complications of Systemic JIA<br />
Ronald M. Laxer, MD; Hospital for Sick Children;<br />
Toronto, Ontario<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 47
THURSDAY<br />
<strong>ARHP</strong> General Session I<br />
9:45—11:15 a m<br />
Room 258<br />
The <strong>ARHP</strong> thanks Roche for its support of General Session I.<br />
<strong>ARHP</strong> Graduate Student Recognition Award<br />
The <strong>ARHP</strong> Graduate Student Recognition Award recognizes<br />
creative research or clinical project efforts that merge theory<br />
and clinical practice in assessing and/or improving the lives<br />
of patients with rheumatic diseases, broadly defined and<br />
encourages the interest of non-medical graduate students in<br />
the field of rheumatology.<br />
Steffany Haaz, MFA; Johns Hopkins University, Baltimore, MD<br />
<strong>ARHP</strong> Mentor: Susan J. Bartlett, PhD<br />
Allen J. Lehman, MA; University of British Columbia,<br />
Vancouver, BC<br />
<strong>ARHP</strong> Mentor: Catherine L. Backman, PhD, OT(C)<br />
Terri L. White, MS, RN, FNP-C; Texas Woman’s<br />
University, Robinson, TX<br />
<strong>ARHP</strong> Mentor: Gail C. Davis, RN, EdD<br />
Keynote Address<br />
Moderator:<br />
Mary E. Christenson, PT, MS; Regis University;<br />
Denver, CO<br />
Speakers:<br />
The Physician, The Patient, The Disease:<br />
Why Bother with Person-Centered Care?<br />
Amye L. Leong, MBA; Healthy Motivation;<br />
North Wales, PA<br />
Bernie Siegel, MD; Woodbridge, CT<br />
Upon completion of this session, participants should be able to:<br />
∙ Gain insight into (Examine) the person-centered care of<br />
chronic and rheumatic diseases from a patient advocate<br />
and a physician and its outcome benefits<br />
∙ Identify practical skills, tools and environments for<br />
improving doctor-patient communications, personal and<br />
professional satisfaction and treatment adherence<br />
∙ Discuss evidence and initiatives advocating for patientcentered<br />
care and their effects on systems of health care<br />
and patient’s therapeutic response<br />
<strong>ACR</strong> Workshops<br />
10:30 a m—12:30 p m<br />
Admission to the Workshop sessions is by ticket only. To verify the session<br />
for which you are registered, refer to the registration codes below in<br />
parentheses. Workshops include beverages only.<br />
Dermatopathology of Rheumatic Diseases (019)<br />
Room 212<br />
Dirk M. Elston, MD; Geisinger Medical Center; Danville, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Review dermatopathology in rheumatic diseases<br />
∙ Relate the importance of dermatopathology in clinical<br />
decision making in patients with rheumatic diseases<br />
∙ Apply the knowledge gained to clinical practice<br />
Designing a Web site for Your Practice (020)<br />
Room 213<br />
Peter J. Embi, MD, MS; University of Cincinnati;<br />
Cincinnati, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the basics of creating web sites on the internet<br />
∙ Describe how to secure a web address or domain name for<br />
a practice web site<br />
∙ Develop a basic web site using online or PC-based tools<br />
Knee Braces and Foot Orthosis for Knee Osteoarthritis (022)<br />
Room 211<br />
Howard J. Hillstrom, PhD; Hospital for Special Surgery;<br />
New York, NY<br />
Kelly D. Krohn, MD; Eli Lilly & Company; Indianapolis, IN<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the biomechanical rationale for the use of knee<br />
braces and foot orthoses for knee OA<br />
∙ Discuss the clinical data to support these modalities<br />
∙ Apply these modalities to their patients<br />
Redesigning Your Rheumatology Practice: Practical<br />
Approaches (021)<br />
Room 209<br />
J. Timothy Harrington, Jr., MD; University of Wisconsin;<br />
Madison, WI<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the importance and advantages of redesigning<br />
practice processes<br />
∙ Discuss the basics of rapid cycle process improvement (an<br />
essential method for clinical improvement)<br />
∙ Create a practice improvement project<br />
48 = Recorded Sessions (order form on page 430)
<strong>ACR</strong> Plenary Session I C/R<br />
11:00 a m—12:30 p m<br />
Hall C<br />
Discovery <strong>2007</strong>: Advances in the Management of Arthritis<br />
and Osteoporosis (Abstracts #665-670)<br />
Moderators:<br />
Neal S. Birnbaum, MD; Pacific Rheumatology Associates<br />
Medical Group; San Francisco, CA<br />
David A. Fox, MD; University of Michigan Medical Center;<br />
Ann Arbor, MI<br />
11:00 a m<br />
Industry Roundtable Awards<br />
11:10 a m<br />
665. Active-Comparator Trial of Teriparatide Versus Alendronate<br />
in the Treatment of Glucocorticoid-Induced Osteoporosis. Kenneth<br />
G. Saag 1 , Elizabeth Shane 2 , Steven Boonen 3 , David W.<br />
Donley 4 , Fernando Marin 4 , Margaret R. Warner 4 , Kathleen<br />
A. Taylor 4 , Gail P. Dalsky 4 , Robert Marcus 4 . 1 University<br />
of Alabama at Birmingham, Birmingham, AL; 2 Columbia<br />
University, College of Physicians & Surgeons,, New York,<br />
NY; 3 Katholieke Universiteit Leuven, Leuven, Germany; 4 Eli<br />
Lilly and Company, Indianapolis, IN<br />
11:23 a m<br />
666. Efficacy and Safety of Zoledronic Acid 5 mg in Preventing<br />
Fractures in Men and Women With Prevalent Hip Fracture: The<br />
HORIZON-Recurrent Fracture Trial. K. Lyles 1 , C. Colon-<br />
Emeric 1 , J. Magaziner 2 , J. Adachi 3 , C. Pieper 1 , L. Hyldstrup 4 ,<br />
C. Mautalen 5 , C. Recknor 6 , K. Moore 1 , C. Lavecchia 7 , J.<br />
Zhang 7 , P. Mesenbrink 7 , E. Eriksen 8 , S. Boonen 9 . 1 Duke<br />
University Medical Center, Durham, NC; 2 University<br />
of Maryland, Baltimore, MD; 3 McMaster University,<br />
Hamilton, ON, Canada; 4 Hvidovre Hospital, University of<br />
Copenhagen, Denmark; 5 Centro de Osteopatías Médicas,<br />
Buenos Aires, Argentina; 6 United Osteoporosis Centers,<br />
Gainesville, GA; 7 Novartis Pharmaceuticals Corp, East<br />
Hanover, NJ; 8 Novartis Pharma AG, Basel, Switzerland;<br />
9<br />
University of Leuven, Leuven, Belgium<br />
11:36 a m<br />
667. A Safety Assessment of TNF Antagonists During Pregnancy:<br />
A Review of the FDA Database. John D. Carter, Anil<br />
Ladhani, Louis Ricca, Joanne Valeriano, Frank B. Vasey.<br />
Univ of South Florida, Tampa, FL<br />
11:49 a m<br />
668. A New Safety Warning: Decreased Gastroprotection is<br />
Associated with an Increase of Serious Ulcer Complications<br />
in Elderly Users of NSAIDs. Gurkirpal Singh 1 , Shweta<br />
Vadhavkar 2 , Alka Mithal 2 , George Triadafilopoulos 1 .<br />
1<br />
Stanford University School of Medicine, Palo Alto, CA;<br />
2<br />
Institute of Clinical Outcomes Research and Education<br />
(ICORE), Palo Alto, CA<br />
12:02 p m<br />
669. <strong>ACR</strong> Quality Performance Indicators for Rheumatoid<br />
Arthritis - Benchmarking, Variability, and Opportunities to<br />
Improve Quality of Care. Leena G. Adhikesavan 1 , Eric<br />
Newman 1 , Androniki Bili 1 , Mark P. Diehl 1 , G. Craig<br />
Wood 2 . 1 Geisinger Health System, Danville, PA; 2 Geisinger<br />
Center for Health Research, Danville, PA<br />
12:15 p m<br />
670. Prediction Models of Rheumatoid Arthritis (RA) Disease<br />
Activity Using Macro Economic Variables, Based on Gross<br />
Domestic Product (GDP) and Total National Health Expenditure<br />
per Capita (TNEH) in Different Countries. T. Sokka 1 , H.<br />
Kautiainen 1 , T. Pincus 2 , M. Hetland 3 , S. Toloza 4 , E.<br />
Baecklund 5 , B. Bresnihan 6 , V. Skakic 7 , A. Dimic 7 , S.<br />
Sierakowski 8 , S. Stropuviene 9 , R. Muller 10 , D. Andersone 11 ,<br />
B. Rojkovich 12 , F. Gogus 13 , M. Cazzato 14 , L. Gossec 15 , M.<br />
Huisman 16 , A. Woolf 17 , A. Naranjo 18 , C. Pohl 19 , R. Alten 19 ,<br />
R. Luukkainen 1 , Y. Yazici 2 , On Behalf of the QUEST-RA<br />
Group. 1 , Finland; 2 , NY; 3 , Denmark; 4 ,Argentina; 5 , Sweden;<br />
6<br />
, Ireland; 7 , Serbia; 8 , Poland; 9 , Lithuania; 10 , Estonia; 11 ,<br />
Latvia; 12 , Hungary; 13 , Turkey; 14 , Italy; 15 , France; 16 , The<br />
Netherlands; 17 , United Kingdom; 18 , Spain; 19 , Germany<br />
<strong>ARHP</strong> Concurrent Session C<br />
11:30 a m—12:30 p m<br />
Room 257<br />
Arthritis and Manual Therapy: “What Is The Evidence?”<br />
Moderator:<br />
Mary E. Christenson, PT, MS; Regis University; Denver, CO<br />
Speaker:<br />
Joshua A. Cleland, PT, DPT, PhD, OCS; Franklin Pierce<br />
College; Hillsborough, NH<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the level of evidence for implementing manual<br />
therapy as a treatment intervention in rheumatic conditions<br />
∙ Identify subgroups of clients who benefit from manual<br />
therapy interventions<br />
∙ Describe manual therapy techniques used in the treatment<br />
of rheumatic conditions<br />
THURSDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 49
THURSDAY<br />
<strong>ARHP</strong> Concurrent Session C<br />
11:30 a m—12:30 p m<br />
Room 261<br />
Improving Sleep: Non-Pharmalogical Strategies<br />
Moderator:<br />
Susan M. Oliver, MSc; Royal College of Nursing;<br />
Barnstaple, England<br />
Speakers:<br />
Pamela J. Degotardi, PhD; Queens College; Flushing, NY<br />
Diana G. Fox, PsyD; Hamden, CT<br />
Upon completion of this session, participants should be able to:<br />
∙ Assess common sleep and fatigue symptoms in patients<br />
with rheumatic disease or fibromyalgia<br />
∙ Teach patients basic sleep hygiene, relaxation and<br />
cognitive-behavioral strategies for sleep improvement<br />
∙ Monitor and assess patient’s progress<br />
<strong>ARHP</strong> Concurrent Session C<br />
11:30 a m- 12:30 p m<br />
Room 258<br />
Rheumatic Disease Update: Lyme Disease<br />
Moderator:<br />
Elizabeth L. Roth-Wojcicki, RN, MS, CPNP; Children’s<br />
Hospital of Wisconsin; Milwaukee, WI<br />
Speaker:<br />
Allen C. Steere, MD; Massachusetts General Hospital;<br />
Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the clinical manifestations of the infection<br />
∙ Describe diagnostic tests for Lyme disease<br />
∙ Identify appropriate antibiotic treatment regimens for<br />
Lyme disease<br />
<strong>ARHP</strong> Concurrent Session<br />
11:30 a m—12:30 p m<br />
Room 260<br />
The Evolution of CDC-Funded State Arthritis <strong>Program</strong>s<br />
Moderator:<br />
Kam M. Nola, PharmD, MS; Tennessee Pharmacist<br />
Association; Nashville, TN<br />
Speakers:<br />
Teresa J. Brady, PhD, OT; Centers for Disease Control and<br />
Prevention; Atlanta, GA<br />
Lee Ann B. Ramsey, BBA, GCPH; Centers for Disease<br />
Control and Prevention; Atlanta, GA<br />
Joseph E. Sniezek, MD, MPH; Center for Disease Control<br />
& Prevention; Atlanta, GA<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the current status of state arthritis programs<br />
∙ Discuss the results of CDC’s programmatic review on<br />
“doing the right things” and “doing them the best way”<br />
∙ Identify potential future directions for CDC and CDCfunded<br />
state arthritis programs<br />
<strong>ARHP</strong> Fitness Session<br />
12:45—1:45 p m<br />
Room 154<br />
Participants must sign a waiver to participate in this fitness session.<br />
Tai Chi<br />
Moderator:<br />
Nancy E. Maher, MPH; Brigham and Women’s Hospital;<br />
Boston, MA<br />
Instructor:<br />
Jay Van Schelt, Master Trainer; Arthritis Foundation;<br />
Bristol, CT<br />
Encore Theater<br />
12:45—2:15 p m<br />
Room 255<br />
State-of-the-Art - Apoptosis: Death by A<br />
Thousand Cuts<br />
Please see page 69 for hours of operation and a tentative list of sessions.<br />
¹<br />
<strong>ACR</strong> Meet the Professor Sessions<br />
12:45—2:15 p m<br />
Admission to the Meet the Professor Sessions is by ticket only. To verify the<br />
session for which you are registered, refer to the registration codes below in<br />
parentheses. Meet the Professor sessions include beverages only.<br />
Ankylosing Spondylitis: <strong>2007</strong> Update (028)<br />
Room 109 A<br />
Muhammad Asim Khan, MD, MACP; Case Western<br />
Reserve University; Cleveland, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the natural history of ankylosing spondylitis<br />
∙ Describe clinical and radiographic outcome measures used<br />
in ankylosing spondylitis trials<br />
∙ Review the scientific data on biologic agents as possible<br />
disease modifying agents in the treatment of AS<br />
Ankylosing Spondylitis: Disease Modification (023)<br />
Room 106<br />
John C. Davis, Jr., MD, MPH; University of California-San<br />
Francisco; San Francisco, CA<br />
50 = Recorded Sessions (order form on page 430)
Upon completion of this session, participants should be able to:<br />
∙ Discuss the natural history of ankylosing spondylitis<br />
∙ Describe clinical and radiographic outcome measures used<br />
in ankylosing spondylitis trials<br />
∙ Review the scientific data on biologic agents as possible disease<br />
modifying agents in the treatment of ankylosing spondylitis<br />
Antiphospholipid Syndrome (036)(Trainees Only) F<br />
Room 162 B<br />
Daniel J. Wallace, MD; Cedars-Sinai Medical Center; Los<br />
Angeles, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the diverse clinical subsets within the spectrum<br />
of APS<br />
∙ Discuss the laboratory tests used to confirm APS<br />
∙ Analyze the therapeutic alternatives for the different<br />
manifestations of APS, including the benefit/risk, adverse<br />
effects and limitations<br />
Crystal: Management of Gout (033)<br />
Room 160 C<br />
Peter A. Simkin, MD; University of Washington; Seattle, WA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the management of gout in patients with renal<br />
insufficiency or organ transplants<br />
∙ Identify strategies to treat patients who are intolerant of<br />
approved therapies<br />
∙ List agents in development for the treatment of hyperuricemia<br />
and gout<br />
Immune Deficiency Syndromes (035)<br />
Room 162 A<br />
Troy R. Torgerson, MD, PhD; University of Washington;<br />
Seattle, WA<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the immunology and clinical manifestations of the<br />
major immune deficiency syndromes that both adult and<br />
pediatric rheumatologist might encounter<br />
∙ Discuss the diagnostic evaluation for someone suspected of<br />
have an immune deficiency syndrome<br />
∙ Use cases to reinforce objectives 1 & 2 and to illustrate<br />
therapeutic options<br />
Osteoarthritis: Update <strong>2007</strong> (026)<br />
Room 107 C<br />
David J. Hunter, MBBS, PhD; New England Baptist<br />
Hospital; Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the potential causes and exacerbating factors of<br />
the disease<br />
∙ Discuss the appropriate use of laboratory testing and<br />
imaging modalities<br />
∙ Design an efficacious, safe and cost-effective therapeutic strategy<br />
Osteoporosis: Pitfalls in Bone Density Testing (025)<br />
(Trainees Only) F<br />
Room 107 B<br />
Maria W. Greenwald, MD; Annenberg Health Sciences<br />
Center; Palm Desert, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the indications for bone densitometry<br />
∙ List common pitfalls in bone densitometry interpretation<br />
Pediatrics: JIA for Adult Rheumatologists (031) F P<br />
Room 160 A<br />
Marilynn G. Punaro, MD; Texas Scottish Rite Hospital;<br />
Dallas, TX<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the ILAR classification for JIA<br />
∙ Discuss current therapeutic strategies for JIA<br />
∙ Recognize the role of IL-1 in the pathogenesis of systemic<br />
onset JIA<br />
Pediatrics: Pediatric Rheumatology for Adult<br />
Rheumatologists (024)(Trainees Only) F P<br />
Room 107 A<br />
Helen M. Emery, MD; Children’s Hospital; Seattle, WA<br />
Upon completion of this session, participants should be able to:<br />
∙ Diagnose the various forms of arthritis that are unique<br />
to children<br />
∙ Recognize how the evaluation of children with rheumatic<br />
diseases may be different from that of adults<br />
∙ Describe current treatments of arthritis in children<br />
Pediatrics: What to Do with Children with Joint Pain and<br />
Normal PE (030) pm P<br />
Room 159<br />
Michael L. Miller, MD; Childrens Memorial Hospital;<br />
Chicago, IL<br />
Upon completion of this session, participants should be able to:<br />
∙ Learn the differential diagnosis of arthralgia in the absence<br />
of arthritis, including infections, neurologic disorders, and<br />
malignancies<br />
∙ Understand the potential for psychosocial problems to<br />
manifest as arthralgia, and how to evaluate a child<br />
∙ Become acquainted with strategies for monitoring children<br />
with persisting symptoms but normal examinations, to<br />
avoid both misdiagnoses and missing diagnoses<br />
Psoriatic Arthritis (032)<br />
Room 160 B<br />
Christopher T. Ritchlin, MD; University of Rochester<br />
Medical Center; Rochester, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the molecular basis for the pathogenesis of<br />
psoriatic arthritis<br />
∙ Discuss the recent advances in the treatment of patients<br />
with psoriatic arthritis<br />
THURSDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 51
THURSDAY<br />
RA: Early Rheumatoid Arthritis (029)<br />
Room 109 B<br />
Jeffrey R. Lisse, MD; University of Arizona; Tucson, AZ<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify the clinical syndrome of rheumatoid arthritis early<br />
in its course<br />
∙ Determine which modalities are of use in diagnosis and<br />
determining prognosis<br />
∙ Evaluate which therapeutic regimens yield the best longterm<br />
outcomes<br />
Scleroderma: Systemic Sclerosis (034)<br />
Room 161<br />
Robert W. Simms, MD; Boston University Arthritis Center;<br />
Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the classification of systemic sclerosis and its<br />
impact on treatment and prognosis<br />
∙ Apply cardiopulmonary testing to determine the relative<br />
contributions of alveolitis, fibrosis and vasculopathy<br />
∙ Formulate a therapeutic regimen to improve quality of life<br />
and organ-specific symptomatology<br />
SLE: Novel Treatments (027)(Trainees Only) F<br />
Room 108<br />
David A. Isenberg, MD; University College; London,<br />
England<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss current concepts of SLE pathogenesis<br />
∙ Describe the development of targeted therapies<br />
∙ Review recent clinical trial data<br />
<strong>ACR</strong> Special Session F<br />
12:45—2:15 p m<br />
Room 104<br />
Career Choices in Rheumatology: Many Choices,<br />
Great Lifestyles!<br />
Moderator:<br />
William R. Gilliland, MD; UniforMedical Service<br />
University of Health Science; Bethesda, MD<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the diverse career options in the field of<br />
rheumatology<br />
∙ Identify unique aspects of each of the career pathways<br />
presented that may be appealing to their own individual<br />
career goals<br />
12:45 p m<br />
Introduction<br />
12:50 p m<br />
My Life as a Private Practitioner<br />
Yousaf Ali, MD; Rheumatology Associates; Providence, RI<br />
1:05 p m<br />
My Life as an Academician<br />
George V. Lawry, II, MD; University of Iowa Hospital and<br />
Clinics; Iowa City, IA<br />
1:20 p m<br />
My Life as a Researcher<br />
Robert A. Colbert, MD, PhD; Cincinnati Children’s<br />
Hospital; Cincinnati, OH<br />
1:35 p m<br />
My Life in Industry<br />
Barbara White, MD; Medimmune, Inc.; Gaithersburg, MD<br />
1:50 p m<br />
Panel Discussion<br />
<strong>ACR</strong> Practice Issues C<br />
1:15—2:15 p m<br />
Room 253<br />
Physician Fee Schedule: What is an RVU?<br />
Moderator:<br />
Karen S. Kolba, MD; Pacific Arthritis Center; Santa Maria, CA<br />
Speaker:<br />
Barton C. McCann, MD, MPH; Washington, DC<br />
Upon completion of this session, participants should be able to:<br />
∙ Interpret what relative value units are and how to optimize<br />
reimbursement for their practice<br />
∙ Discuss the relationship of RVUs to payment and the<br />
problems with the annual update of the conversion factor<br />
∙ Understand the political difficulties associated with<br />
physician payment reform<br />
∙ Examine the political difficulties associated with physician<br />
payment reform<br />
2:05 p m<br />
Discussion<br />
<strong>ACR</strong> Workshops<br />
1:15—3:15 p m<br />
Admission to the Workshop sessions is by ticket only. To verify the session<br />
for which you are registered, refer to the registration codes below in<br />
parentheses. Workshops include beverages only.<br />
Creating Presentations Using PowerPoint: Basic (037)<br />
Room 213<br />
Steve Blevins, BA, BS, MBA; <strong>American</strong> College of<br />
Rheumatology; Atlanta, GA<br />
Upon completion of this session, participants should be able to:<br />
∙ Create a basic slide<br />
∙ Design slides by changing the style, color and template<br />
∙ Assemble a presentation composed of multiple slides and<br />
display this presentation<br />
52 = Recorded Sessions (order form on page 430)
Peripheral MRI in Clinical Rheumatology (038)<br />
Equipment provided by Esaote S.p.A.<br />
Room 211<br />
Philip G. Conaghan, MD, PhD; Chapel Allerton Hospital;<br />
Leeds, England<br />
Mikkel Ostergaard, MD, PhD, DMSc; Copenhagen<br />
University Hospital at Hvidovre; Hvidovre, Denmark<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the merits of joint assessment by peripheral MRI<br />
∙ Identify the pitfalls of peripheral MRI in musculoskeletal<br />
imaging<br />
Physical Examination Skills for Improved Detection of<br />
Synovitis and Cervical Thoracolumbar Disorders (039)<br />
Room 209<br />
Edward C. Keystone, Dr., MD; Mount Sinai Hospital;<br />
Toronto, Ontario<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss sensitive techniques for the detection of synovitis<br />
in peripheral joints, especially elbows, wrists, hands, feet<br />
and knees<br />
∙ Demonstrate techniques to determine the origin of<br />
referred pain from the neck and thoracolumbar spine<br />
∙ Describe simple techniques to improve the symptoms of<br />
mechanical neck and back pain at the bedside<br />
Synovial Fluid Analysis and Crystal Identification (040)<br />
Room 212<br />
H. Ralph Schumacher, Jr., MD; Veteran’s Affairs Medical<br />
Center; Philadelphia, PA<br />
Lan X. Chen, MD, PhD; University of Pennsylvania;<br />
Philadelphia, PA<br />
Gilda M. Clayburne, MLT; Veterans Affairs Medical<br />
Center; Philadelphia, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Prepare synovial fluid samples for microscopic examination<br />
∙ Identify various components of synovial fluid<br />
∙ Recognize crystals in synovial fluid<br />
<strong>ACR</strong> Basic Science Symposium R<br />
2:30—4:00 p m<br />
Room 205<br />
Signal Transduction Pathways in Scleroderma<br />
Moderators:<br />
William Robinson, MD, PhD; Stanford University;<br />
Stanford, CA<br />
Maria Trojanowska, PhD; Medical University of South<br />
Carolina; Charleston, SC<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the TGFb and PDGF-R signaling pathways,<br />
including their molecular components and downstream<br />
cellular responses<br />
∙ Describe the roles of the TGFb and PDGF-R pathways<br />
in scleroderma, pulmonary fibrosis, and other rheumatic<br />
diseases<br />
∙ Discuss approaches to attenuate pathogenic cellular<br />
responses mediated by the TGFb and PDGF-R pathways<br />
2:30 p m<br />
Imatinib and Matrix Remodeling in Scleroderma<br />
Oliver Distler, MD; University Hospital Zurich; Zurich,<br />
Switzerland<br />
2:55 p m<br />
TGF-b Signaling in Scleroderma<br />
John Varga, MD; Northwestern University Feinberg School<br />
of Medicine; Chicago, IL<br />
3:20 p m<br />
PDGF-Receptor and Pulmonary Fibrosis<br />
Peter Huber, MD, PhD; German Cancer Research Center;<br />
Heidelberg, Baden-Württemberg, Germany<br />
3:45 p m<br />
Discussion<br />
<strong>ACR</strong> Clinical Symposium ARS<br />
2:30—4:00 p m<br />
Hall C<br />
Challenges in the Management of Lupus<br />
Moderator:<br />
Susan Manzi, MD, MPH; University of Pittsburgh;<br />
Pittsburgh, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Develop a strategy for managing pregnancy in a patient<br />
with lupus<br />
∙ Define cognitive dysfunction and identify the possible<br />
mechanisms for it in patients with lupus<br />
∙ Describe alternative management options for patients with<br />
lupus nephritis<br />
2:30 p m<br />
Management of Pregnancy in a Patient with SLE<br />
Caroline P. Gordon, MD; University of Birmingham;<br />
Birmingham, England<br />
3:00 p m<br />
Being “Mindful” of Cognitive Dysfunction in Lupus<br />
Melanie J. Harrison, MD, MSCE; Wyeth Pharmaceuticals;<br />
Collegeville, PA<br />
3:30 p m<br />
Lupus Nephritis: Can We Do Better Than Cyclophosphamide?<br />
Frederic A. Houssiau, MD, PhD; Universite Catholique de<br />
Louvain; Brussels, Belgium<br />
C<br />
¹<br />
THURSDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 53
THURSDAY<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 104<br />
Animal Models of Rheumatoid Arthritis: Pathogenesis<br />
and Novel Therapeutic Targets (Abstracts #671-676)<br />
Moderators:<br />
Wim B. VandenBerg, PhD; Radboud University Nijmegen<br />
Medical Center; Nijmegen, The Netherlands<br />
Ernest Brahn, MD; University of California –Los Angeles;<br />
Los Angeles, CA<br />
2:30 p m<br />
671. Crucial Role of IL-6/IL-17 Axis in the Generation of GPIinduced<br />
Arthritis. Keiichi Iwanami, Isao Matsumoto, Yoko<br />
Watanabe-Tanaka, Asuka Inoue, Daisuke Goto, Satoshi Ito,<br />
Akito Tsutsumi, Takayuki Sumida. University of Tsukuba,<br />
Tsukuba Ibaraki, Japan<br />
2:45 p m<br />
672. Suppression of Collagen-Induced Arthritis by PTEN Gene-<br />
Mediated Inhibition of Angiogenesis. Chrong-Reen Wang 1 ,<br />
Ai-Li Shiau 1 , Shih-Yao Chen 1 , Ling-Ling Lin 1 , Pey-Ru Lin 1 ,<br />
I-Ming Jou 1 , Ming-Hong Tai 2 , Chao-Liang Wu 1 . 1 Medical<br />
College, National Cheng Kung University, Tainan, Taiwan;<br />
2<br />
Veterans General Hospital, Kaohsiung, Taiwan<br />
3:00 p m<br />
673. Decreased Passive K/BxN-Induced Arthritis in MKK6<br />
Deficient Mice: Novel Uncoupling of p38 Activation from<br />
Cytokine Regulation. Toshio Yoshizawa 1 , Sanna Rosengren 1 ,<br />
Deepa Hammaker 1 , Georg Schett 2 , David L. Boyle 1 , Gary<br />
S. Firestein 1 . 1 UCSD School of Medicine, La Jolla, CA;<br />
2<br />
University of Erlangen, Erlangen, Germany<br />
3:15 p m<br />
674. Opposing Roles of TNFR-1 and -2 in the Development of<br />
Experimental Arthritis. Stephan Blüml 1 , Nikolaus Binder 1 ,<br />
Karin Polzer 2 , Birgit Türk 1 , Clemens Scheinecker 1 , George<br />
Kollias 3 , Josef Smolen 1 , Kurt Redlich 1 . 1 Medical University<br />
Vienna, Vienna, Austria; 2 University of Erlangen, Germany,<br />
Erlangen, Germany; 3 Institute of Immunology, Biomedical<br />
Sciences Research Center Alexander Fleming, Vari, Greece<br />
3:30 p m<br />
675. T-Cell Specific Gata-3 Transgenic Mice are Protected Against<br />
Severe Joint Inflammation During Th17 Driven Experimental<br />
Arthritis. Jan Piet van Hamburg, Anne-Marie Mus,<br />
Marjolein de Bruyn, Patrick Asmadidjaja, Lisette de Vogel,<br />
Rudi Hendriks, Erik Lubberts. Erasmus MC, Rotterdam,<br />
The Netherlands<br />
3:45 p m<br />
676. RANKL-Dependent Expression of IP-10 by Osteoclast<br />
Precursors Mediates Bone-Erosive Experimental Arthritis. Yeong<br />
Wook Song 1 , Eun Young Lee 1 , Hee Jung Ryu 1 , Yun Jong<br />
Lee 1 , Eun Bong Lee 1 , Han Bok Kwak 2 , Hong-Hee Kim 2 ,<br />
Zang Hee Lee 2 . 1 Seoul National University College of<br />
Medicine, Seoul, Republic of Korea; 2 Seoul National<br />
University College of Dentistry, Seoul, Republic of Korea<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 253<br />
Biologics in Pediatric Rheumatology: Clinical Trial<br />
Results (Abstracts #677-682)<br />
Moderators:<br />
Carlos D. Rose, MD; Thomas Jefferson University;<br />
Wilmington, DE<br />
Carine Wouters, Sr., MD PhD; University Hospital<br />
Gasthuisberg; Leuven, Belgium<br />
2:30 p m<br />
677. Muckle-Wells-Syndrome - Effective Treatment with<br />
Anakinra. Jasmin B. Kuemmerle-Deschner 1 , Nikolay<br />
Tzaribachev 1 , Anja Bialkowski 1 , Ina Koetter 2 . 1 Division of<br />
Pediatric Rheumatology, Dept. of Pediatrics, University<br />
Hospital Tübingen, Tuebingen, Germany; 2 Division of<br />
Rheumatology, Dept. of Internal Medicine, University<br />
Hospital Tübingen, Tuebingen, Germany<br />
2:45 p m<br />
678. Functional Outcomes of One Year of Treatment of<br />
Neonatal Onset Multisystem Inflammatory Disease (NOMID)<br />
with Anakinra. Scott M. Paul, Hanna Hildenbrand, Minal<br />
S. Jain, Michaele R. Smith, Edith Wiggs, Leora Comis,<br />
Delores Koziol, Raphaela Goldbach-Mansky. National<br />
Institutes of Health, Bethesda, MD<br />
3:00 p m<br />
679. Efficacy of Abatacept in Different Sub-Populations of<br />
Juvenile Idiopathic Arthritis (JIA): Results of a Randomized<br />
Withdrawal Study. E. H. Giannini 1 , N. Ruperto 2 , A. M.<br />
Prieur 2 , E. Paz 2 , N. E. Rubio-Perez 2 , C. A. Silva 2 , C. Abud 2 ,<br />
R. Burgos-Vargas 2 , V. Gerloni 2 , J. Melo-Gomes 2 , C. Saad<br />
Magalhaes 2 , F. Sztajnbok 2 , C. Goldenstein-Schainberg 2 ,<br />
M. Scheinberg 2 , P. Hashkes 1 , C. Hom 1 , L. H. Sigal 3 , A. J.<br />
Block 3 , A. Covucci 3 , D. J. Lovell 1 , A. Martini 2 . 1 Cincinnati<br />
Children’s Hospital Medical Center, PRCSG, Cincinnati,<br />
OH; 2 IRCCS Istituto G Gaslini-PRINTO, University<br />
of Genoa, Genoa, Italy; 3 Global Clinical Research -<br />
Immunology, Bristol-Myers Squibb, Princeton, NJ<br />
54 = Recorded Sessions (order form on page 430)
3:15 p m<br />
680. Abatacept Treatment of Juvenile Idiopathic Arthritis<br />
(JIA): Safety Report. D. J. Lovell 1 , N. Ruperto 2 , A. M.<br />
Prieur 2 , E. Paz 2 , N. Rubio-Perez 2 , C. A. Silva 2 , C. Abud 2 , R.<br />
Burgos-Vargas 2 , V. Gerloni 2 , J. A. Melo-Gomes 2 , C. Saad<br />
Magalhaes 2 , F. Sztajnbok 2 , C. Goldenstein-Schainberg 2 ,<br />
M. Scheinberg 2 , P. Hashkes 1 , C. Hom 1 , L. H. Sigal 3 , A. J.<br />
Block 3 , A. Covucci 3 , P. L. N Cornet 3 , L. Pagliaro 3 , E. H.<br />
Giannini 1 , A. Martini 2 . 1 Cincinnati Children’s Hospital<br />
Medical Center, PRCSG, Cincinnati, OH; 2 IRCCS Istituto<br />
G Gaslini-PRINTO, University of Genoa, Genoa, Italy;<br />
3<br />
Global Clinical Research - Immunology, Bristol-Myers<br />
Squibb, Princeton, NJ<br />
3:30 p m<br />
681. Adalimumab is Safe and Effective During Long-Term<br />
Treatment of Patients with Juvenile Rheumatoid Arthritis: Results<br />
from a 2-Year Study. Daniel J. Lovell 1 , Nicolino Ruperto 2 ,<br />
Steven Goodman 3 , Andreas Reiff 4 , Dana Nêmcová 2 , Anne-<br />
Marie Prieur 1 , R. Joos 2 , Valeria Gerloni 2 , John Bohnsack 1 ,<br />
Linda Wagner-Weiner 1 , Hans-Iko Huppertz 2 , N. Olson 1 ,<br />
Melissa McIlraith 5 , John Medich 6 , Edward Giannini 1 ,<br />
Alberto Martini 2 . 1 PRCSG, Cincinnati, OH; 2 PRINTO-<br />
IRCCS G Gaslini, Genova, Italy; 3 Arthritis Associates of<br />
South Florida, Del Ray Beach, FL; 4 Children’s Hospital of<br />
Los Angeles, Los Angeles, CA; 5 Abbott GmbH & Co KG,<br />
Ludwigshafen, Germany; 6 Abbott Laboratories, Parsippany, NJ<br />
3:45 p m<br />
682. Safety and Efficacy of Over 8 Years of Continuous<br />
Etanercept (Enbrel®) Therapy in Patients with Juvenile<br />
Rheumatoid Arthritis. A. O. Reiff 1 , D. J. Lovell 2 , N.<br />
T. Ilowite 3 , C. A. Wallace 4 , Y. Chon 5 , S-L Lin 5 , S. W.<br />
Baumgartner 5 , E. H. Giannini 2 , Pediatric Rheumatology<br />
Collaborative Study Group. 1 Childrens Hospital of Los<br />
Angeles, Los Angeles, CA; 2 Cincinnati Children’s Hospital<br />
Medical Center, Cincinnati, OH; 3 Schneider Children’s<br />
Hospital, New Hyde Park, NY; 4 Children’s Hospital and<br />
Regional Medical Center, Seattle, WA; 5 Amgen, Thousand<br />
Oaks, CA<br />
2:30 p m<br />
683. Do Autoantibodies Predict Cardiovascular Events and<br />
Mortality in the General Population?. Kimberly P. Liang, Hilal<br />
Maradit Kremers, Cynthia S. Crowson, Terry M. Therneau,<br />
Veronique L. Roger, Sherine E. Gabriel. Mayo Clinic,<br />
Rochester, MN<br />
2:45 p m<br />
684. The Risk of Stroke in Patients with Rheumatoid Arthritis<br />
Compared to the General Population. Alison L. Endean 1 ,<br />
Christopher J. Edwards 1 , David Fisher 2 , Tjeerd van<br />
Staa 2 , Cyrus Cooper 2 , Nigel K. Arden 2 . 1 Department<br />
of Rheumatology, Southampton University Hospitals,<br />
Southampton, United Kingdom; 2 Medical Research<br />
Council Epidemiology Resource Centre, University of<br />
Southampton, Southampton, United Kingdom<br />
3:00 p m<br />
685. Serum Uric Acid (SUA) is Associated with Carotid Intima<br />
Media Thickness but not Coronary Artery Calcification: The<br />
NHLBI Family Heart Study. T. Neogi 1 , RC Ellison 1 , S.<br />
Hunt 2 , R. Terkeltaub 3 , DT Felson 1 , YQ Zhang 1 . 1 BUSM,<br />
Boston, MA; 2 University of Utah, Salt Lake City, UT;<br />
3<br />
UCSD, San Diego, CA<br />
3:15 p m<br />
686. Hyperuricemia and Coronary Heart Disease: A Meta-<br />
Analysis. Seo Young Kim 1 , Hyon K. Choi 2 , Daniel A.<br />
Albert 3 . 1 University of Pennsylvania, Philadelphia, PA;<br />
2<br />
University of British Columbia, Vancouver, BC, Canada;<br />
3<br />
Dartmouth Hitchcock Medical Center, Lebanon, NH<br />
3:30 p m<br />
687. Risk Factors for Cardiovascular Complications<br />
following Total Joint Replacement Surgery. Jeffrey N. Katz 1 ,<br />
Frederick Basilico 2 , Gerald Sweeney 2 , James Gaydos 2 ,<br />
Debra Skoniecki 2 , Elizabeth A. Wright 1 , Elena Losina 1 .<br />
1<br />
Department of Orthopaedic Surgery and Division of<br />
Rheumatology, Brigham and Women’s Hospital, Boston,<br />
MA; 2 Departments of Medicine and Physical Therapy, New<br />
England Baptist Hospital, Boston, MA<br />
THURSDAY<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 156<br />
Epidemiology and Health Services Research:<br />
Comorbidities and Rheumatic Disease (Abstracts #683-688)<br />
Moderators:<br />
Tore K. Kvien, MD PhD; Diakonhjemmet Hospital; Oslo, Norway<br />
Allan C. Gelber, MD; Johns Hopkins University; Baltimore, MD<br />
3:45 p m<br />
688. Comparison of the Rate of Hospitalizations for Upper and<br />
Lower Gastrointestinal Events Between New Users of Cox-2<br />
Inhibitors and traditional NSAIDS with PPI. Myrthe P.P.<br />
Sukel 1 , Ernst Kuipers 2 , Michiel van der Linden 1 , Ron MC<br />
Herings 1 , Sabine Gaugris 3 . 1 PHARMO Institute, Utrecht,<br />
The Netherlands; 2 Dept. of Gastroenterology, Erasmus<br />
MC, Rotterdam, The Netherlands; 3 Merck & Co., Inc.,<br />
Whitehouse Station, NJ<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 55
THURSDAY<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 153<br />
Imaging of Rheumatic Diseases (Abstracts #689-694)<br />
Moderator:<br />
Carl Winalski, MD; Cleveland Clinic; Cleveland, OH<br />
2:30 p m<br />
689. Multimodal Nanoparticle Contrast Agents Can Be Used<br />
to Image Synovial Infiltration of Macrophages in Inflammatory<br />
Arthritis Disease Models. Jason S. Kim, Kathryn M. Taylor,<br />
William J. Reiter, Denise Esserman, Hongyu An, Wenbin<br />
Lin, Teresa K. Tarrant. University of North Carolina,<br />
Chapel Hill, NC<br />
2:45 p m<br />
690. Imaging of Activated Macrophages at Sites of<br />
Inflammation. Philip S. Low, PhD 1 , Wilfredo Ayala-López,<br />
ABD 1 , Bindu Varghese, PhD 1 , Ryan Rothenbuhler, DVM,<br />
MS 1 , Walter A. Henne, PhD 1 , Chrystal Paulos, PhD 1 ,<br />
Gert Breur, DVM, PhD 1 , Richard Messman, MD 2 , Eric L.<br />
Matteson, MD 3 . 1 Purdue University, West Lafayette, IN;<br />
2<br />
Endocyte Inc, West Lafayette, IN; 3 Mayo Clinic College of<br />
Medicine, Rochester, MN<br />
3:00 p m<br />
691. Correlation of Bone Marrow Edema with<br />
Myelopoiesis. Steven T. Proulx 1 , Christopher T. Ritchlin 1 ,<br />
David J. Shealy 2 , Lianping Xing 1 , Edward M. Schwarz 1 .<br />
1<br />
University of Rochester, Rochester, NY; 2 Centocor R&D,<br />
Inc., Radnor, PA<br />
3:15 p m<br />
692. Multi-Photon Imaging of Synovium. Sanjay Chabra 1 ,<br />
Nivedan Tiwari 2 , Paula Sweet 2 , Tatiana Krasieva 2 , Brian<br />
S. Andrews 1 , George M. Peavy 2 . 1 University of California,<br />
Irvine, Division of Rheumatology, Orange, CA; 2 Beckman<br />
Laser Institute, Irvine, CA<br />
3:30 p m<br />
693. [18f]FDG-PET Changes after 2 Weeks of Infliximab<br />
Treatment Correlate with Long-Term Clinical Outcome in<br />
Rheumatoid Arthritis Patients. Ernst H. Elzinga, Conny<br />
J. van der Laken, Emile FI Comans, Otto S. Hoekstra,<br />
Adriaan A. Lammertsma, Ben AC Dijkmans, Alexandre E.<br />
Voskuyl. VU University Medical Center, Amsterdam, The<br />
Netherlands<br />
3:45 p m<br />
694. Same Level of Inflammatory Activity Assessed by Ultrasound<br />
in Ra Patients with or without Remission. Damien Loeuille 1 ,<br />
Ghislaine Gill 2 , Jean Philippe Sommier 2 , Christine<br />
Batot-Michel 2 , Anne Christine Rat 2 , Virginie Hoenen-<br />
Clavert 2 , Virginie Hoenen-Clavert 2 , Norbert Sauliere 2 ,<br />
Jacques Pourel 2 , Alain Blum 3 , Isabelle Chary-Valckenaere 2 .<br />
1<br />
Rheumatology -UMR CNRS 7561, Vandoeuvre les Nancy,<br />
France; 2 Rheumatology, Vandoeuvre les Nancy, France;<br />
3<br />
Radiology, Nancy, France<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Grand Ballroom East<br />
RA New Treatments Clinical Trials I (Abstracts #695-700)<br />
Moderators:<br />
Clifton O. Bingham, MD; Johns Hopkins University;<br />
Baltimore, MD<br />
Mark C. Genovese, MD; Stanford University Medical<br />
Center; Stanford, CA<br />
2:30 p m<br />
695. Ocrelizumab, a Novel Humanized Anti-CD20 Antibody:<br />
Week 72 Results from a Phase I/II Clinical Trial in Patients<br />
with Rheumatoid Arthritis. M. Genovese 1 , J. Kaine 2 ,<br />
M. Lowenstein 3 , J. Del Giudice 4 , A. Baldassare 5 , J.<br />
Schechtman 6 , E. Fudman 7 , M. Kohen 8 , S. Gujrathi 9 , R.<br />
Trapp 10 , N. Sweiss 11 , G. Spaniolo 9 , W. Dummer 9 . 1 Stanford,<br />
Palo Alto, CA; 2 Arth Ctr, Sarasota, FL; 3 Arth Ctr, Palm<br />
Harbor, FL; 4 Arth & Ost Assoc, Lubbock, TX; 5 Arth<br />
Cons, St Louis, MO; 6 Sun Valley, Glendale, AZ; 7 Austin<br />
Rheum Res, Austin, TX; 8 Coastal Med Res, Port Orange,<br />
FL; 9 Genentech, South San Francisco, CA; 10 Arth Ctr,<br />
Springfield, IL; 11 Univ of Chicago, Chicago, IL<br />
2:45 p m<br />
696. Liquid Formulation Certolizumab Pegol with Methotrexate<br />
Decreases Progression of Structural Joint Damage in Rheumatoid<br />
Arthritis Patients: The RAPID 2 Study. Robert B. Landewé 1 ,<br />
Vibeke Strand 2 , Josef Smolen 3 , Desiree van der Heijde 1 .<br />
1<br />
University Hospital of Maastricht, Maastricht, The<br />
Netherlands; 2 Stanford University, Portola Valley, CA;<br />
3<br />
Division of Rheumatology, Medical University of Vienna,<br />
Vienna, Austria<br />
3:00 p m<br />
697. Clinical and Radiological Efficacy of Four Different<br />
Treatment Strategies in Patients with Recent Onset Rheumatoid<br />
Arthritis: 4-year Follow-up of the Best Study. Sjoerd M. Van<br />
Der Kooij 1 , Yvonne P.M. Goekoop-Ruiterman 1 , Jeska<br />
K. de Vries-Bouwstra 2 , Pit J.S.M. Kerstens 3 , Peter B.J. de<br />
Sonnaville 4 , Ferdinand C. Breedveld 1 , Ben A.C. Dijkmans 5 ,<br />
Cornelia F. Allaart 1 . 1 LUMC, Leiden, The Netherlands;<br />
2<br />
VUMC, Amsterdam, The Netherlands; 3 JBI, Amsterdam,<br />
The Netherlands; 4 Oosterschelde Hospital, Goes, The<br />
Netherlands; 5 VUMC, JBI, Amsterdam, The Netherlands<br />
56 = Recorded Sessions (order form on page 430)
3:15 p m<br />
698. Denosumab Inhibits RANKL, Reducing Progression of<br />
the Total Sharp Score and Bone Erosions in Patients With<br />
Rheumatoid Arthritis: 12-month X-Ray Results. Désirée van<br />
der Heijde 1 , Stanley Cohen 2 , John T. Sharp 3 , Peter Ory 3 ,<br />
Lifen Zhou 4 , Wayne Tsuji 4 , Richard Newmark 4 . 1 Leiden<br />
University Medical Center, Leiden, The Netherlands;<br />
2<br />
Metroplex Center for Clinical Research, Dallas, TX;<br />
3<br />
University of Washington, Seattle, WA; 4 Amgen, Inc.,<br />
Thousand Oaks, CA<br />
3:30 p m<br />
699. Long-Term Efficacy and Safety of Abatacept through 3 Years<br />
of Treatment in Rheumatoid Arthritis Patients in the AIM and<br />
ATTAIN Trials. J. Kremer 1 , R. Westhovens 2 , M. Luggen 3 , A.<br />
Russell 4 , R. Aranda 5 , J-C Becker 5 , C. Joshi 6 , M. Gandhi 6 , M.<br />
C. Genovese 7 . 1 Center for Rheumatology, Albany, NY; 2 UZ<br />
Gasthuisberg, Leuven, Belgium; 3 University of Cincinnati<br />
Medical Center, Cincinnati, OH; 4 University of Alberta<br />
Hospital, Edmonton, AB, Canada; 5 Bristol-Myers Squibb,<br />
Princeton, NJ; 6 Bristol-Myers Squibb, Mumbai, India;<br />
7<br />
Stanford University, Palo Alto, CA<br />
3:45 p m<br />
700. The Anti-TNF Certolizumab Pegol in Combination with<br />
Methotrexate is Significantly More Effective than Methotrexate<br />
Alone in the Treatment of Patients with Active Rheumatoid<br />
Arthritis: 1-Year Results from the RAPID 1 Study. Edward<br />
Keystone 1 , David Mason 2 , Bernard Combe 3 . 1 University of<br />
Toronto, Toronto, ON, Canada; 2 UCB Inc, Smyrna, GA;<br />
3<br />
Montpellier University Hospital, Montpellier, France<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 258<br />
Vasculitis (Abstracts #701-706)<br />
Moderators:<br />
Peter Lamprecht, MD; University of Luebeck; Luebeck, Germany<br />
Gene G. Hunder, MD; Mayo Clinic; Rochester, MN<br />
2:30 p m<br />
701. Risk of Wegener’s Granulomatosis among Close Relatives of<br />
Patients with the Disease. Ann Knight 1 , Sven Sandin 2 , Johan<br />
Askling 3 . 1 Inst of Medical Sciences, Dpt of Rheumatology,<br />
Uppsala, Sweden; 2 Dpt of Medical Epidemiology,<br />
Karolinska Institute, Stockholm, Sweden; 3 Unit of Clinical<br />
Epidemiology and Dpt of Rheumatology, Karolinska<br />
Institute, Stockholm, Sweden<br />
2:45 p m<br />
702. Renal Graft Survival and Patient Mortality in Wegener’s<br />
Granulomatosis (WG): A Case/Control Study. Curry L.<br />
Koening 1 , Carol A. Langford 1 , H. Lester Kirchner 2 , Andrew<br />
O’Connor 2 , Emilio Poggio 1 , E. Regis Mcfadden 2 , Gary<br />
S. Hoffman 1 . 1 Cleveland Clinic, Cleveland, OH; 2 Case<br />
Western Reserve University, Cleveland, OH<br />
3:00 p m<br />
703. Circulating Pr3-specific T-helper-17 Cells In Wegener’s<br />
Granulomatosis. Wayel H. Abdulahad, Coen A. Stegeman,<br />
Pieter C. Limburg, Cees G.m Kallenberg. University<br />
Medical Center, Groningen, The Netherlands<br />
3:15 p m<br />
704. Effect of Biopsy Length and Bilateral Sampling on the Rate<br />
of Positive Temporal Artery Biopsies. Gabriel S. Breuer 1 , Ronit<br />
Nesher 2 , Gideon Nesher 1 . 1 Shaare Zedek Medical Center,<br />
Jerusalem, Israel; 2 Meir Medical Center, Kfar Saba, Israel<br />
3:30 p m<br />
705. Diagnostic reproducibility of Giant Cell Arteritis on Temporal<br />
Artery Biopsy Sspecimen: The GRACG Study. Denis Chatelain 1 ,<br />
Pierre Duhaut 1 , Robert Loire 2 , Sylvie Bosshard 2 , Hélène<br />
Pellet 2 , Jean-Charles Piette 3 , Henri Sevestre 1 , Jean-Pierre<br />
Ducroix 1 . 1 Chu Nord, Amiens, France; 2 Recif, Lyon, France;<br />
3<br />
Pitié-Salpêtrière Hospital, Paris, France<br />
3:45 p m<br />
706. Intimal Hyperplasia in Temporal Artery Biopsy a Predictor<br />
for Neuro Opthalmic Complications of Giant Cell Arteritis?<br />
Damodar Makkuni 1 , Konrad Wolfe, Dr 2 , Andrew Hutchings 3 ,<br />
Bhaskar Dasgupta 4 . 1 Rheumatology department;Southend<br />
University Hospital, Westcliff on sea, United Kingdom;<br />
2<br />
Pathology departmenrt;Southend University Hospital,<br />
Southend on sea, United Kingdom; 3 Health Services<br />
Research Unit, London School of Hygiene & Tropical<br />
Medicine, London, United Kingdom; 4 Southend University<br />
Hospital, Westcliff-on-sea, United Kingdom<br />
<strong>ACR</strong> Mini-Symposium<br />
2:30—4:15 p m<br />
Grand Ballroom West<br />
Angiogenesis, Cell-Cell Adhesion, Migration and Vascular<br />
Biology in Arthritis and Inflammation (Abstracts #707-711)<br />
Moderators:<br />
Dorian O. Haskard, DM; Imperial College; London, England<br />
Alisa E. Koch, MD; University of Michigan; Ann Arbor, MI<br />
2:30 p m<br />
Introductory Talk<br />
Arthritis: An Angiogenesis-Dependent Disease?<br />
Judah Folkman, MD; Children’s Hospital; Boston, MA<br />
THURSDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 57
THURSDAY<br />
3:00 p m<br />
707. Fucosyltransferase 1 Plays a Critical Role in Mouse<br />
Inflammatory Arthritis and Rheumatoid Arthritis. Mohammad<br />
A. Amin 1 , Jeffrey H. Ruth 1 , Bradley J. Rabquer 1 , Phillip<br />
L. Campbell 1 , Andrew C. Cosgrove 1 , Jafar Haghshenas 1 ,<br />
Steven E. Domino 2 , Alisa E. Koch 3 . 1 University of Michigan,<br />
Ann Arbor, MI; 2 Veteran’s Administration and University<br />
of Michigan, Ann Arbor, MI; 3 Veteran’s Administration<br />
and University of Michigan, Ann Arbor, MI<br />
3:15 p m<br />
708. Statins and Rapamycin Act Synergistically to Enhance<br />
Vascular Cytoprotection in Inflammation. Shahir Hamdulay,<br />
Faisal Ali, Elaine Lidington, Dorian O. Haskard, Justin C.<br />
Mason. Imperial College London, London, United Kingdom<br />
3:30 p m<br />
709. Statin-Mediated Cytoprotection of Human Vascular<br />
Endothelium Through Induction of Heme Oxygenase-1 by the<br />
Transcription Factor Kruppel-Like Factor 2 (KLF2). Faisal Ali,<br />
Shahir Hamdulay, Anne Kinderlerer, Elaine Lidington,<br />
Nadira Ali, Joseph Boyle, Anna Randi, Dorian Haskard,<br />
Justin C. Mason. Imperial College London, London, England<br />
3:45 p m<br />
710. Histone Deacetylases at the Crossroads of Inflammation and<br />
Lipid Metabolism. Nilamadhab Mishra 1 , John Parks 1 , Eric<br />
Olson 2 , Richard St. Clair 1 . 1 Wake Forest University School<br />
of Medicine, Winston Salem, NC; 2 UT Southwestern<br />
Medical School, Dallas, TX<br />
4:00 p m<br />
711. IL-13 Gene Therapy as an Effective Antagonist of<br />
Angiogenesis in Rat Adjuvant Induced Arthritis. Jeffrey H.<br />
Ruth 1 , Christian S. Haas 1 , Mohammad A. Amin 1 , Brittany<br />
L. Allen 1 , Salahuddin Ahmed 1 , Angela Pakozdi 1 , James<br />
M. Woods 2 , Shiva Shahrara 3 , Alisa E. Koch 4 . 1 University<br />
of Michigan, Ann Arbor, MI; 2 Midwestern University,<br />
Downers Grove, IL; 3 Northwestern University, Chicago, IL;<br />
4<br />
Veterans Administration and University of Michigan, Ann<br />
Arbor, MI<br />
<strong>ACR</strong> Mini-Symposium<br />
2:30—4:15 p m<br />
Room 102<br />
Fibromyalgia: Etiology and Treatment (Abstracts #712-716)<br />
Moderators:<br />
Daniel Wallace, MD; Rheum Arthritic Disorder; Los<br />
Angeles, CA John McBeth, PhD; University of Manchester;<br />
Manchester, England<br />
2:30 p m<br />
Introductory Talk<br />
Fibromyalgia: Translating an Improved Mechanistic<br />
Understanding Into More Efficacious Treatments<br />
Daniel J. Clauw, MD; University of Michigan; Ann Arbor, MI<br />
3:00 p m<br />
712. Physical Adversity and Poor Social Environment in<br />
Childhood Increase the Risk of Chronic Widespread Pain<br />
in Adulthood - Results from the 1958 British Birth Cohort<br />
Study. Gareth T. Jones 1 , Chris Power 2 , Gary J. Macfarlane 1 .<br />
1<br />
Aberdeen Pain Research Collaboration (Epidemiology<br />
Group), University of Aberdeen, United Kingdom;<br />
2<br />
Institute of Child Health, University College, London,<br />
United Kingdom<br />
3:15 p m<br />
713. Differential Sustained Changes in μ-Opioid Receptor (MOR)<br />
Availability Following Acupuncture and Sham Acupuncture<br />
Therapy in Fibromyalgia (FM). Richard E. Harris 1 , Jon-Kar<br />
Zubieta 2 , David J. Scott 2 , Laura Mayo-Bond 1 , Richard H.<br />
Gracely 1 , Daniel J. Clauw 1 . 1 Rheumatology, University of<br />
MI, Ann Arbor, MI; 2 Molecular & Behavioral Neuroscience,<br />
University of MI, Ann Arbor, MI<br />
3:30 p m<br />
714. Variation in Glutamate and Glutamine Levels within<br />
the Insula are Associated with Improvements in Clinical and<br />
Experimental Pain in Fibromyalgia (FM). Richard H. Harris 1 ,<br />
Pia C. Sundgren 2 , Yuxi Pang 2 , Najma Khatri 1 , Richard<br />
H. Gracely 1 , Daniel J. Clauw 1 . 1 Rheumatology, University<br />
of Michigan, Ann Arbor, MI; 2 Radiology, University of<br />
Michigan, Ann Arbor, MI<br />
3:45 p m<br />
715. Efficacy of Pregabalin Monotherapy for Relief of Pain<br />
Associated with Fibromyalgia: Time Course and Durability of<br />
Pain Results of a 14-Week, Double-Blind, Placebo-Controlled<br />
Trial. Rachel Duan 1 , Erdal Diri 2 , James P. Young, Jr 1 , Susan<br />
Martin 1 , George Haig 1 , Jeannette Barrett 3 . 1 Pfizer Global<br />
Research and Development, Ann Arbor, MI; 2 Trinity<br />
Health Center-Medical Arts, Minot, ND; 3 Pfizer Global<br />
Pharmaceuticals, New York, NY<br />
58 = Recorded Sessions (order form on page 430)
4:00 p m<br />
716. The Efficacy and Safety of Milnacipran in the Treatment of<br />
Fibromyalgia. Daniel J. Clauw 1 , Robert H. Palmer 2 , Olivier<br />
Vitton 3 , Philip Mease 4 , R. Michael Gendreau 5 . 1 University<br />
of Michigan, Ann Arbor, MI; 2 Forest Research Institute,<br />
Jersey City, NJ; 3 Pierre Fabre Medicament, Castres, France;<br />
4<br />
Seattle Rheumatology Associates, Seattle, WA; 5 Cypress<br />
Bioscience, Inc., San Diego, CA<br />
<strong>ACR</strong> REF Special Session C/R<br />
2:30—4:00 p m<br />
Room 210<br />
Marshall J. Schiff, MD, Memorial Lectureship<br />
and Abstracts #717-718<br />
Moderator:<br />
James R. O’Dell, MD; University of Nebraska<br />
Medical Center; Omaha, NE<br />
2:30 p m<br />
Signaling Pathways Controlling Chondrocyte Maturation:<br />
Implications for the Development and Treatment of<br />
Osteoarthritis<br />
Speaker:<br />
Regis J. O’Keefe, MD, PhD; University of Rochester<br />
Medical Center; Rochester, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Interpret the manner in which growth factors and signaling<br />
pathways are integrated to control chondrocyte maturation<br />
∙ Recognize the cellular and molecular events that occur in<br />
articular cartilage with arthritis<br />
∙ Describe the manner in which transgenic approaches using<br />
murine models of osteoarthritis provide insight into the<br />
pathogenesis and possible treatment of osteoarthritis<br />
Abstract Presentations<br />
3:30 p m<br />
717. Deletion of Frizzled Related Protein Reduces Running<br />
Exercise Performance in Mice. Rik J.U. Lories, Jenny Peeters,<br />
Frank P. Luyten. KU Leuven, Leuven, Belgium<br />
3:45 p m<br />
718. Effects of Interleukin-1 Beta on the Notch Pathway in<br />
Chondrocytes. Sébastien Ottaviani 1 , Pascal Richette 2 , Khadija<br />
Tahiri 1 , Géri Meduri 3 , Francis Berenbaum 4 , Maité Corvol 1 ,<br />
François Rannou 5 , Jean-François Savouret 1 . 1 INSERM-<br />
UMR-S-747, Paris, France; 2 Hôpital Lariboisière, Paris,<br />
France; 3 Hôpital Kremlin Bicêtre, Paris, France; 4 CNRS<br />
UMR-7079, Paris, France; 5 Hôpital Cochin, Paris, France<br />
<strong>ARHP</strong> Concurrent Session C<br />
2:30—4:00 p m<br />
Room 257<br />
Advances in the Management of Total Hip Arthroplasty<br />
(THA) Patients: <strong>Meeting</strong> the Challenges of Reduced<br />
Length of Stay<br />
Moderator:<br />
Jennifer L. Trizuto, BSPT, MPT; Mills Health Center; San<br />
Mateo, CA<br />
Speakers:<br />
Janet Cahill, PT; Hospital for Special Surgery; New York, NY<br />
Karen Juliano, PT; Hospital for Special Surgery; New York, NY<br />
Lisa Kosman, MS, PT; Hospital for Special Surgery; New<br />
York, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Integrate information from standard care models to rapid<br />
recovery acute care models for THA patients<br />
∙ Recognize the role of functional outcomes in developing<br />
pathways, monitoring progress and participation in research<br />
∙ Describe advances in surgical procedures, epidural/spinal<br />
anesthesia and nerve blocks in THA<br />
∙ Integrate the various administrative considerations in planning<br />
a clinical pathway, both standard and rapid recovery<br />
<strong>ARHP</strong> Concurrent Session<br />
2:30—4:00 p m<br />
Room 260<br />
Developing a Research Career: Finding and Following a<br />
Path to Independence<br />
Moderator:<br />
Janet L. Poole, PhD, OTR; University of New Mexico;<br />
Albuquerque, NM<br />
Speakers:<br />
Nancy A. Baker, ScD, OTR/L; University of Pittsburgh;<br />
Pittsburgh, PA<br />
Susan L. Murphy, ScD, OTR; University of Michigan; Ann<br />
Arbor, MI<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify grant options for career development from predoctoral<br />
opportunities in independent scientist awards<br />
∙ Discuss the importance of a supportive environment<br />
including mentorship and options and strategies that may<br />
advance a research career<br />
∙ Identify the strengths and weaknesses of a participant’s<br />
current situation and create a specific plan for personal<br />
career development<br />
THURSDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 59
THURSDAY<br />
<strong>ARHP</strong> Concurrent Session<br />
2:30—4:00 p m<br />
Room 259<br />
Health Literacy: Foundations for Improving Clinical<br />
Practice and Patient Outcomes<br />
Moderator:<br />
Gail C. Davis, RN, EdD; Texas Woman’s University;<br />
Denton, TX<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize, describe and relate the importance of patient<br />
literacy to health outcomes with a specific focus on<br />
musculoskeletal conditions<br />
∙ Specify the consequences of poor health literacy at both an<br />
individual and population health level including the types<br />
and magnitude of patient health disparities, impact on the<br />
health care system relating to the utilization of services and<br />
associated costs and as a pertinent barrier to providing and<br />
receiving optimal clinical care<br />
∙ Critically appraise the measurement properties of currently<br />
available health literacy assessment within the clinical care<br />
setting<br />
∙ Identify and analyze the strengths and weaknesses of<br />
current health literacy assessment measures<br />
∙ Propose new concepts and approaches within the health<br />
literacy field and describe and translate the potential for<br />
these approaches to reduce health disparities and improve<br />
patient health outcomes within the clinical practice setting<br />
2:30 p m<br />
Health Literacy in the Population: Who is Affected Most and Why<br />
Rachelle Buchbinder, MBBS, PhD, FRACP; Cabrini<br />
Hospital and Monash University; Malvern, Australia<br />
2:50 p m<br />
Why Health Literacy is Important in Musculoskeletal Health<br />
and Disease<br />
Rachelle Buchbinder, MBBS, PhD, FRACP; Cabrini<br />
Hospital and Monash University; Malvern, Australia<br />
3:10 p m<br />
Operationalization of Health Literacy: A New Framework for<br />
Measure, Improving Clinical Practice and Population Health<br />
Joanne E. Jordan, BA, BSc, MPH; Royal Melbourne<br />
Hospital, University of Melbourne; Melbourne, Australia<br />
3:30 p m<br />
The State of the Art of Measurement of Health Literacy<br />
Richard H. Osborne, PhD; University of Melbourne;<br />
Melbourne, Australia<br />
<strong>ARHP</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 261<br />
Considerations in Arthritis Self-Help <strong>Program</strong>s<br />
(Abstracts #719-724)<br />
Moderator:<br />
Erik Taal, PhD; University of Twente; Enschede, Netherlands<br />
2:30 p m<br />
719. The Value of Self Management Education: Making the Case<br />
among People with Arthritis. Teresa J. Brady, Susan Jernick.<br />
Centers for Disease Control and Prevention, Atlanta, GA<br />
2:45 p m<br />
720. A Health Care Provider’s Recommendation is the Most<br />
Influential Factor in Taking an Arthritis Self-Management Course<br />
(SMC): A National Perspective from the Arthritis Conditions<br />
Health Effects Survey (ACHES). Louise Murphy, Kristina<br />
Theis, Teresa Brady, Jennifer Hootman, Charles Helmick,<br />
Julie Bolen, Jeffrey Sacks. Centers for Disease Control and<br />
Prevention, Atlanta, GA<br />
3:00 p m<br />
721. Factors Associated with Utilization of Arthritis Self-Help<br />
<strong>Program</strong>s in Michigan. Peter DeGuire 1 , Emily C. Somers 2 ,<br />
Steven Springer 1 , Judith Lyles 1 . 1 Michigan Dept of<br />
Community Health, Lansing, MI; 2 University of Michigan<br />
Health System, Ann Arbor, MI<br />
3:15 p m<br />
722. Online Self-Management <strong>Program</strong> in Rheumatoid<br />
Arthritis: RAHelp.org 3-Month Analysis. Karen L. Smarr 1 ,<br />
Chokkalingam Siva 2 , Rebecca A. Johnson 2 , Kathleen<br />
Donovan Hanson 2 , Dale R. Musser 3 , John E. Hewett 2 ,<br />
Bin Ge 2 , Jerry C. Parker 2 . 1 Harry S. Truman Memorial<br />
Veterans’ Hospital, Columbia, MO; 2 University of Missouri-<br />
Columbia, Columbia, MO; 3 Eyebits Studios, Tarboro, NC<br />
3:30 p m<br />
723. Is a Mail-Delivered Arthritis Self-Management <strong>Program</strong><br />
Effective? A Randomized 4-Month Study. Kate R. Lorig 1 , Jean<br />
Goeppinger 2 , Christina Lum 1 , P. Ritter 1 , Sonal Mutatkar 2 .<br />
1<br />
Stanford University, Palo Alto, CA; 2 University of North<br />
Carolina, Chapel Hill, NC<br />
3:45 p m<br />
724. Outcomes from the Arthritis Foundation Exercise <strong>Program</strong>:<br />
A Randomized Controlled Trial. Marian A. Minor, Evan<br />
Prost, Margaret Nigh, Bin Ge, John E. Hewett. University of<br />
Missouri, Columbia, MO<br />
60 = Recorded Sessions (order form on page 430)
<strong>ACR</strong> Workshops<br />
4:00—6:00 p m<br />
Admission to the Workshop sessions is by ticket only. To verify the session<br />
for which you are registered, refer to the registration codes below in parentheses.<br />
Workshops include beverages only.<br />
Dermatopathology of Rheumatic Diseases (042)<br />
Room 212<br />
Dirk M. Elston, MD; Geisinger Medical Center; Danville, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Review dermatopathology in rheumatic diseases<br />
∙ Relate the importance of dermatopathology in clinical<br />
decision making in patients with rheumatic diseases<br />
∙ Apply the knowledge gained to clinical practice<br />
Musculoskeletal Ultrasonography: Advanced (041)<br />
Equipment provided by Biosound Esaote Ultrasound<br />
Room 211<br />
George A.W. Bruyn, MD, PhD; Medisch Centrum<br />
Leeuwarden; Loenga, Netherlands<br />
Wolfgang A. Schmidt, MD; Medical Center for<br />
Rheumatology Berlin-Buch; Berlin, Germany<br />
Upon completion of this session, participants should be able to:<br />
∙ Use standard and alternative scanning techniques for joint<br />
evaluation by ultrasound<br />
∙ Recognize abnormal anatomical structures by ultrasound<br />
∙ Identify special indications for sonography in vasculitis,<br />
myositis, Sjögrens Syndrome and carpal tunnel syndrome<br />
Osteoporosis: Focus on DXA Interpretation (043)<br />
Room 209<br />
Edward S. Leib, MD; University of Vermont College of<br />
Medicine; Burlington, VT<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the basic principles of DXA interpretation and the<br />
ISCD guidelines for DXA interpretation<br />
∙ Identify some of the pitfalls of DXA interpretation and the<br />
clinical pearls associated with these unusual situations<br />
∙ Create a report based on the lumbar spine and hip bone<br />
densitometry results<br />
<strong>ARHP</strong> Concurrent Session<br />
4:00—6:00 p m<br />
Room 213<br />
There is no charge to attend this session in the computer workshop room but<br />
participation is limited.<br />
Research beyond Google: Efficient and Effective Research<br />
on the Web for Clinicians and Educators<br />
Moderator:<br />
Carol M. Greco, PhD; University of Pittsburgh; Pittsburgh, PA<br />
Speaker:<br />
Laura E. Ray, MA, MLS; Cleveland State University;<br />
Cleveland, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss how to access, as well as demonstrate efficient and<br />
effective searching methods on, Web-based databases<br />
∙ List key Web directories and search engines, as well as<br />
demonstrate efficient and effective Web searching methods<br />
∙ Discuss guidelines for the critical evaluation of Web sites<br />
<strong>ACR</strong> Basic Science Symposium R<br />
4:30—6:00 p m<br />
Room 205<br />
Regenerating Musculosketal Tissues<br />
Moderators:<br />
Robert A. Colbert, MD, PhD; Cincinnati Childrens<br />
Hospital Medical; Cincinnati, OH<br />
Frank P. Luyten, MD, PhD; University Hospitals Katholieke<br />
Universiteit Leuven; Leuven, Belgium<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the potential applications of stem cell technology<br />
in regeneration of joint tissues<br />
∙ Recognize the role of biomechanical factors in cartilage<br />
matrix remodeling<br />
∙ Identify the potential approaches for soft tissue repair in<br />
joint structures.<br />
4:30 p m<br />
Mesenchymal Stem Cells and Tissue Engineering<br />
Johnny Huard, PhD; Children’s Hospital of Pittsburgh;<br />
Pittsburgh, PA<br />
THURSDAY<br />
4:55 p m<br />
Mechanobiology of Cartilage and Joints for Regeneration<br />
Robert L. Sah, MD, ScD; University of California, San<br />
Diego; La Jolla, CA<br />
5:20 p m<br />
Soft Tissue Engineering<br />
David Kaplan, PhD; Tufts University; Medford, MA<br />
5:45 p m<br />
Discussion<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 61
THURSDAY<br />
<strong>ACR</strong> Clinical Symposium ARS<br />
4:30—6:00 p m<br />
Hall C<br />
Sjögren’s Syndrome: Update on a Systemic Disease<br />
Moderators:<br />
Mary-Carmen Amigo, MD; ABC Medical Center; Mexico<br />
City, Mexico<br />
Steven E. Carsons, MD; Winthrop-University Hospital;<br />
Mineola, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the diversity of organ involvement in Sjögren’s<br />
syndrome<br />
∙ Describe recent advances in understanding the pathogenesis<br />
of Sjögren’s syndrome<br />
∙ Evaluate the therapeutic potential of targeted biological<br />
agents for Sjögren’s syndrome<br />
4:30 p m<br />
Sjögren’s Syndrome: A Systemic Disease<br />
Ann L. Parke, MD; St. Francis Hospital and Medical<br />
Center; Hartford, CT<br />
4:55 p m<br />
Understanding the Pathogenesis of Sjögren’s Syndrome<br />
Haralampos M. Moutsopoulos, MD; National University<br />
Medical School; Athens, Greece<br />
C<br />
4:55 p m<br />
New Approaches to AVN<br />
Julian M. Aldridge, III., MD; Duke University Medical<br />
Center; Durham, NC<br />
5:25 p m<br />
Childhood Osteoporosis: Treatment Controversies<br />
Egla C. Rabinovich, MD, MPH; Duke University Medical<br />
Center; Durham, NC<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Grand Ballroom East<br />
Biologic Therapies in RA: Clinical Aspects<br />
(Abstracts #725-730)<br />
Moderators:<br />
Eric Matteson, MD, MPH; Mayo Clinic; Rochester, MN<br />
John D. Isaacs, PhD, FRCP; University of Newcastle;<br />
Newcastle upon Tyne, England<br />
4:30 p m<br />
725. B-Cell Activity in Synovium Predicts Responsiveness to<br />
Rituximab in Patients with Refractory Rheumatoid Arhtritis. Yoe<br />
Kie Onno Teng, M. Hashemi, N. Levarht, I.M. Bajema,<br />
R.E.M. Toes, T.W.J. Huizinga, J.M. van Laar. Leiden<br />
University Medical Center, Leiden, The Netherlands<br />
5:20 p m<br />
Use of Biologic Therapy for Sjögren’s Syndrome<br />
E. William St. Clair, MD; Duke University Medical Center;<br />
Durham, NC<br />
5:45 p m<br />
Discussion<br />
<strong>ACR</strong> Clinical Symposium P<br />
4:30—6:00 p m<br />
Room 253<br />
Bone Health in Children and Adolescents with<br />
Rheumatic Disease<br />
Moderator:<br />
Emily Von Scheven, MD; University of California–San<br />
Francisco; San Francisco, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the biology of bone metabolism and its relevance<br />
to pediatric rheumatic disease<br />
∙ List the early signs of osteonecrosis and discuss new<br />
surgical interventions to treat it<br />
∙ Describe issues in diagnosing and treating osteoporosis<br />
in childhood<br />
4:30 p m<br />
Biology of Bone in Children<br />
Matthew Warman, MD; Children’s Hospital Boston; Boston, MA<br />
4:45 p m<br />
726. Efficacy and Safety of Etanercept 100 mg in Patients<br />
with Rheumatoid Arthritis Who Are Suboptimal Responders<br />
to Etanercept 50 mg. Michael E. Weinblatt 1 , Michael H.<br />
Schiff 2 , Eric M. Ruderman 3 , Clifton O. Bingham, III 4 , Juan<br />
Li 5 , James Louie 5 , Daniel E. Furst 6 . 1 Brigham and Women’s<br />
Hospital, Boston, MA; 2 Denver Arthritis Clinic, Denver,<br />
CO; 3 Northwestern University, Chicago, IL; 4 Johns Hopkins<br />
University, Baltimore, MD; 5 Amgen Inc., Thousand Oaks,<br />
CA; 6 UCLA, Los Angeles, CA<br />
5:00 p m<br />
727. Response to Second or Third Tnf-inhibitor in Rheumatoid<br />
Arthritis: Results from an Observational Study. Johan Karlsson,<br />
Lars-Erik Kristensen, Meliha C. Kapetanovic, Anders<br />
Gülfe, Tore Saxne, Pierre Geborek, SSATG (South Swedish<br />
Arthritis Treatment Group). Clinical Sciences, Lund, Sweden<br />
5:15 p m<br />
728. Persistence of Clinical Benefit in Rheumatoid Arthritis<br />
After Discontinuation of TNF-Inhibitor Therapy: Analysis from<br />
the CORRONA Database. Susan J. Lee 1 , George Reed 2 ,<br />
Lilian Soto 1 , Joel Kremer 3 , Arthur Kavanaugh 1 . 1 University<br />
of California San Diego, La Jolla, CA; 2 University of<br />
Massachusetts, Worcester, MA; 3 Albany Medical College,<br />
Albany, NY<br />
62 = Recorded Sessions (order form on page 430)
5:30 p m<br />
729. The Prevalence, Incidence, and Effect of Anti-Tumor<br />
Necrosis Factor (TNF) on Work Disability in Rheumatoid<br />
Arthritis. Frederick Wolfe 1 , Saralynn Allaire 2 , Kaleb<br />
Michaud 3 . 1 National Data Bank for Rheumatic Diseases,<br />
Wichita, KS; 2 Boston University, Boston, MA; 3 University<br />
of Nebraska Medical Center, Omaha, NE<br />
5:45 p m<br />
730. Pregnancy Outcome after Exposure to Biologics: Results from<br />
the German Biologics Register RABBIT. Anja Strangfeld 1 ,<br />
Joachim Listing 1 , Rolf Rau 2 , Matthias Schneider 3 , Franka<br />
Hierse 1 , Andreas Krause 4 , Marina Backhaus 5 , Angela Zink 1 .<br />
1<br />
German Rheumatism Research Center, Berlin, Germany;<br />
2<br />
Evangelisches Fachkrankenhaus, Ratingen, Germany;<br />
3<br />
University Duesseldorf, Berlin, Germany; 4 Immanuel<br />
hospital, Berlin, Germany; 5 Charite university hospital,<br />
Berlin, Germany<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 156<br />
Improving Quality of Care by Design, Redesign and<br />
Innovation (Abstracts #731-736)<br />
Moderators:<br />
Eric Newman, MD, FACP; Geisinger Medical Center;<br />
Danville, PA<br />
J. Timothy Harrington, MD; University of Wisconsin;<br />
Madison, WI<br />
4:30 p m<br />
731. Improving DXA Scheduling for Osteoporosis Diagnosis and<br />
Monitoring Using an Electronic Health Record-Based Process<br />
Redesign. Eric D. Newman 1 , Nancy M. Gilhooley 2 , Nancy J.<br />
English 1 . 1 Geisinger Health System, Danville, PA; 2 Geisinger<br />
Medical Group - Kistler Clinic, Wilkes-Barre, PA<br />
4:45 p m<br />
732. Similarity of an Index without Formal Joint Counts, Routine<br />
Assessment of Patient Index Data (RAPID3), ro DAS and<br />
CDAI to Help Guide Tight Control of Rheumatoid Arthritis in<br />
Standard Care. Theodore Pincus 1 , Yusuf Yazici 1 , Martin<br />
Bergman 2 . 1 NYU-Hospital for Joint Diseases, New York,<br />
NY; 2 Rheumatology, Ridley Park, PA<br />
5:00 p m<br />
733. Pre-Appointment Management in an Academic<br />
Rheumatology Practice Improves Access and Patient Mix : A<br />
Follow-up Study. Walter G. Barr, Bethany Chiaramonte,<br />
Janet Barber-Harris, James J. Foody, Eric M. Ruderman.<br />
Northwestern University, Chicago, IL<br />
5:15 p m<br />
734. Measuring Quality of Care Using Electronic<br />
Medical Records: Laboratory Testing in Patients Prescribed<br />
Dmards. Jessica C. Agnew-Blais, Jyotsna Mehta, Jeffrey N.<br />
Katz, Ronald Anderson, Jonathan S. Coblyn, Daniel H.<br />
Solomon. Brigham and Women’s Hospital, Boston, MA<br />
5:30 p m<br />
735. Rheumatology Dashboard - An Efficient Summary that<br />
Alters Physician Treatment Decisions in Rheumatoid Arthritis<br />
Patients. Mark P. Diehl 1 , Eric D. Newman 1 , Androniki<br />
Bili 1 , Leena G. Adhikesavan 1 , G. Craig Wood 2 . 1 Geisinger<br />
Health System, Danville, PA; 2 Geisinger Center for Health<br />
Research, Danville, PA<br />
5:45 p m<br />
736. Does Pain During Physician-Performed Syringe and Needle<br />
Procedures Indicate Trauma to Patient Tissues? Gautam R.<br />
Moorjani, Kye S. Park, Adrian A. Michael, Courtney R.<br />
Johnson, Wilmer L. Sibbitt, Jr., Arthur D. Bankhurst.<br />
University of New Mexico Health Sciences Center,<br />
Albuquerque, NM<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 153<br />
Osteoarthritis: Clinical Aspects I (Abstracts #737-742)<br />
Moderators:<br />
Nigel K. Arden, MRCP; MRC Epidemiology Resource<br />
Centre; Southampton, England<br />
Joanne Jordan, MD, MPH; University of North Carolina<br />
Thurston ARC; Chapel Hill, NC<br />
4:30 p m<br />
737. Comparing Apples with Oranges: Choice of Comparator<br />
Non-Selective NSAIDs Alters the Gastrointestinal Safety<br />
Advantages of Cox-2 Inhibitors in Clinical Trials of Arthritis<br />
Patients. Gurkirpal Singh 1 , Shweta Vadhavkar 2 , Alka<br />
Mithal 2 , George Triadafilopoulos 1 . 1 Stanford University<br />
School of Medicine, Palo Alto, CA; 2 Institute of Clinical<br />
Outcomes Research and Education (ICORE), Palo Alto, CA<br />
4:45 p m<br />
738. Effects of Strontium Ranelate on Radiographic Spinal<br />
Osteoarthritis Progression. Olivier Bruyere 1 , Danielle<br />
Delferriere 1 , Christian Roux 2 , John D. Wark 3 , Tim<br />
Spector 4 , Jean-Pierre Devogelaer 5 , Kim Brixen 6 , Silvio<br />
Adami 7 , Jacques Fechtenbaum 2 , Sami Kolta 2 , Jean-Yves<br />
Reginster 1 . 1 University of Liege, Liege, Belgium; 2 Cochin<br />
Hospital, Paris, France; 3 Royal Melbourne Hospital,<br />
Parkville, Australia; 4 St Thomas Hospital, London, United<br />
Kingdom; 5 Universite Catholique de Louvain, Brussels,<br />
Belgium; 6 Odense University Hospital, Odense, Denmark;<br />
7<br />
Rheumatology Unit, Valeggio, Italy<br />
THURSDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 63
THURSDAY<br />
5:00 p m<br />
739. A Randomized Controlled Trial of Acupuncture for<br />
Osteoarthritis of the Knee: Effects of Provider Communication<br />
Style. Maria Suarez-Almazor 1 , Carol Looney 1 , Richard<br />
Street, Jr. 2 , Yanfang Liu 3 , Vanessa Cox 1 , Kenneth Pietz 4 ,<br />
Donald Marcus 4 . 1 UT MD Anderson Cancer Center,<br />
Houston, TX; 2 Texas A&M University, College Station, TX;<br />
3<br />
<strong>American</strong> College of Acupuncture and Oriental Medicine,<br />
Houston, TX; 4 Baylor College of Medicine, Houston, TX<br />
5:15 p m<br />
740. Racial Differences in Individual Radiographic Features<br />
of Hip Osteoarthritis (OA) in African <strong>American</strong> (AA) and<br />
White Women and Men: The Johnston County Osteoarthritis<br />
Project. A. E. Nelson 1 , L. Braga 2 , J. B. Renner 1 , J. Atashili 1 ,<br />
J. Woodard 1 , M. C. Hochberg 3 , C. G. Helmick 4 , J. M.<br />
Jordan 1 . 1 UNC School of Medicine, Chapel Hill, NC;<br />
2<br />
University of Nebraska Medical Center, Omaha, NE;<br />
3<br />
University of Maryland School of Medicine, Baltimore, MD;<br />
4<br />
Centers for Disease Control and Prevention, Atlanta, GA<br />
5:30 p m<br />
741. Racial/Ethnic Disparities in Unmet Social Support Need<br />
Among Total Knee Replacement Candidates. Megan Huisingh-<br />
Scheetz 1 , Rowland W. Chang 2 , Dorothy Dunlop 2 , Anh<br />
Chung 2 , Huan J. Chang 2 . 1 University of Illinois at Chicago,<br />
Chicago, IL; 2 Northwestern University Feinberg School of<br />
Medicine, Chicago, IL<br />
5:45 p m<br />
742. The Effect of Meniscal Damage on Incident Radiographic<br />
Knee Osteoarthritis. M. Englund 1 , A. Guermazi 1 , F. W.<br />
Roemer 1 , M. Yang 1 , C. E. Lewis 2 , J. Torner 3 , M. Nevitt 4 , D.<br />
T. Felson 1 . 1 BUSM, Boston, MA; 2 UA, Birmingham, AL;<br />
3<br />
UI, Iowa City, IA; 4 UCSF, San Francisco, CA<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 157<br />
RA Pathogenesis: Genetics and the Environment<br />
(Abstracts #743-748)<br />
Moderators:<br />
Eric F. Morand, MD, PhD; Monash University; Clayton,<br />
Australia<br />
Maripat Corr, MD University of California, San Diego<br />
School of Medicine; San Diego, California<br />
4:30 p m<br />
743. Whole Genome Association Study in Rheumatoid Arthritis<br />
Implicates TRAF1-C5 as a New Susceptibility Locus. Robert<br />
Plenge 1 , Elaine F. Remmers 2 , Michael F. Seldin 3 , Leela<br />
Davies 4 , Chao Tian 3 , Wei Chen 5 , Annette T. Lee 6 , Lindsey<br />
A. Criswell 7 , Daniel L. Kastner 2 , John Carulli 8 , Chris<br />
I. Amos 5 , Peter K. Gregersen 6 . 1 Brigham and Women’s<br />
Hospital, Boston, MA; 2 NIAMS, Bethesda, MD; 3 University<br />
of California at Davis, Davis, CA; 4 Broad Institute of MIT<br />
and Harvard, Cambridge, MA; 5 M. D. Anderson Cancer<br />
Center, Houston, TX; 6 The Feinstein Institute for Medical<br />
Research, Manhasset, NY; 7 University of California at San<br />
Francisco, San Francisco, CA; 8 Biogen-Idec, Cambridge, MA<br />
4:45 p m<br />
744. How to Acquire HLA Susceptibility Alleles in Rheumatoid<br />
Arthritis by Microchimerism. Laetitia Maestroni 1 , Justyna<br />
Marta Rak 1 , Nathalie S. Balandraud 2 , Sandrine Guis 2 ,<br />
Hélène Boudinet 2 , Marie Caroline Guzian 2 , Isabelle Auger 1 ,<br />
Chantal Roudier 1 , Marielle Martin 1 , Rémi Didelot 3 , Jean<br />
Roudier 2 , Nathalie Lambert 1 . 1 INSERM U639, Marseille,<br />
France; 2 AP-HM, service de Rhumatologie, Marseille,<br />
France; 3 CESAM13, Marseille, France<br />
5:00 p m<br />
745. Genomic Hypomethylation of Rheumatoid Arthritis Synovial<br />
Fibroblasts. Emmanuel Karouzakis 1 , Caroline Ospelt 1 ,<br />
Gerald G. Schumann 2 , Christoph Kolling 3 , Beat A. Michel 1 ,<br />
Renate E. Gay 1 , Steffen Gay 1 , Michel Neidhart 1 . 1 University<br />
Hospital Zurich and Zurich Center of Integrative Human<br />
Physiology (ZHIP), Zurich, Switzerland; 2 Paul-Ehrlich<br />
Institut,Section PR2/Retroelements, Langen, Germany;<br />
3<br />
Schulthess Clinic, Zurich, Switzerland<br />
5:15 p m<br />
746. Oxidative Damage and Hypoxia in Inflammatory Arthritis:<br />
Evidence from in vivo and ex vivo studies of Inflammatory<br />
Arthritis. A. Kennedy, C. Ng, CAE Walsh, B. Bresnihan, O.<br />
FitzGerald, U. Fearon, D. J. Veale. St. Vincent’s University<br />
Hospital, Dublin, Ireland<br />
5:30 p m<br />
747. Autoimmunity to the Polymorphic Region of a Major<br />
Susceptibility Gene Occurs Frequently in Rheumatoid<br />
Arthritis. Antony Rosen 1 , Michelle L. Harris 1 , Gordon K.<br />
Lam 1 , Susan J. Bartlett 1 , Audrey V. Grant 1 , Peisong Gao 1 ,<br />
Hani El-Gabalawy 2 , Livia Casciola-Rosen 1 , Kathleen C.<br />
Barnes 1 , Joan M. Bathon 1 . 1 Johns Hopkins University,<br />
Baltimore, MD; 2 University of maniitoba, Winnipeg, MB,<br />
Canada<br />
5:45 p m<br />
748. Autoantibodies Precede Cytokine/Chemokine and C-Reactive<br />
Protein Elevations in the Pre-Clinical Period of Rheumatoid<br />
Arthritis (RA) Development. Kevin D. Deane 1 , Wolfgang<br />
Hueber 2 , Ann M. Lazar 1 , Beren H. Tomooka 2 , Lezlie A.<br />
Parrish 1 , Mark C. Parish 1 , Jill M. Norris 1 , Anna E. Baron 1 ,<br />
William H. Robinson 2 , V. Michael Holers 1 . 1 University of<br />
Colorado, Denver, CO; 2 Stanford University, Palo Alto, CA<br />
64 = Recorded Sessions (order form on page 430)
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 210<br />
Spondylarthropathies and Psoriatic Arthritis: Treatment I<br />
(Abstracts #749-754)<br />
Moderators:<br />
Walter P. Maksymowych, MD, FRCPC; University of<br />
Alberta; Edmonton, Alberta<br />
John C. Davis, Jr., MD, MPH; University of California–San<br />
Francisco; San Francisco, CA<br />
4:30 p m<br />
749. Efficacy, Safety, and Tolerability of Infliximab in Juvenileonset<br />
Spondyloarthropathies (JO-SpA): Results of the Three-<br />
Month, Randomized, Double-Blind, Placebo-Controlled Trial<br />
Phase. Ruben Burgos-Vargas, Julio Casasola-Vargas, Raúl<br />
Gutierrez-Suarez, Janitzia Vazquez-Mellado. Hospital<br />
General de Mexico, Mexico city, Mexico<br />
4:45 p m<br />
750. Examination of the Association of Clinical Descriptors with<br />
Radiographic Findings in a Primary Back Pain Cohort. Finbar<br />
D. O’Shea 1 , Carlo Ammendolia 1 , Eleanor Boyle 1 , David<br />
Salonen 1 , Cindy Peterson 2 , William Hsu 2 , Robert D. Inman 1 .<br />
1<br />
Toronto Western Hospital, Toronto, ON, Canada; 2 Canadian<br />
Memorial Chiropractor College, Toronto, ON, Canada<br />
5:00 p m<br />
751. Radiographic Progression in Ankylosing Spondylitis (AS) - The<br />
Natural Course. A Retrospective Cohort Study. Xenofon Baraliakos 1 ,<br />
J. Listing 2 , A.v.d. Recke 1 , J. Braun 1 . 1 Rheumazentrum<br />
Ruhrgebiet, Herne, Germany; 2 DRFZ, Berlin, Germany<br />
5:15 p m<br />
752. Sustained Disease Activity in Ankylosing Spondylitis: A<br />
Prospective Study. J. Martindale 1 , J. Smith 2 , D. Grennan 3 , L.<br />
Goodacre 2 , J. A. Goodacre 2 . 1 Ashton Leigh and Wigan PCT,<br />
Wrightington Hospital, United Kingdom; 2 Interdisciplinary<br />
Research and Teaching Group for Chronic Disease and<br />
Rehabilitation, University of Central Lancashire, United<br />
Kingdom; 3 Wrightington Wigan Leigh NHS Trust,<br />
Wrightington Hospital, United Kingdom<br />
5:30 p m<br />
753. Efficacy of Adalimumab in the Treatment of Preradiographic<br />
Axial Spondyloarthritis: 52-Week Results of a Randomized Controlled<br />
Trial and Open-Label Extension. Hildrun Haibel 1 , Martin<br />
Rudwaleit 1 , Anna Amtenbrink 1 , Frank Heldmann 2 , Joachim<br />
Listing 3 , Robert Wong 4 , Hartmut Kupper 5 , Jürgen Braun 2 ,<br />
Joachim Sieper 1 . 1 Charité University Medicine, Campus<br />
Benjamin Franklin, Berlin, Germany; 2 Centre of Rheumatology,<br />
Herne, Germany; 3 Epidemiology German Rheumatism Research<br />
Centre, Berlin, Germany; 4 Abbott Laboratories, Parsippany, NJ;<br />
5<br />
Abbott GmbH & Co. KG, Ludwigshafen, Germany<br />
5:45 p m<br />
754. Drug Discontinuation Due to Inefficacy in Ankylosing<br />
Spondylitis Patients Treated with Anti-TNF drugs: Results from the<br />
British Society for Rheumatology Biologics Register (BSRBR). Paul<br />
Lord, Mark Lunt, Kath D. Watson, Deborah P.M. Symmons,<br />
Kimme L. Hyrich, on behalf of the BSR Biologics Register.<br />
The University of Manchester, Manchester, United Kingdom<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 258<br />
Uric Acid and Gout (Abstracts #755-760)<br />
Moderators:<br />
Lan X. Chen, MD, PhD; University of Pennsylvania;<br />
Philadelphia, PA<br />
H. Ralph Schumacher, Jr., MD; University of Pennsylvania<br />
&Veteran’s Affairs Medical Center; Philadelphia, PA<br />
4:30 p m<br />
755. Mouse IL-1 Trap Reduces Pain and Inflammation in Animal<br />
Models of Gout. Richard Torres 1 , Lynn Macdonald 1 , Joel<br />
Reinhardt 1 , Susan D. Croll 2 , Donna M. Hylton 1 , John S.<br />
Rudge 1 , George D. Yancopoulos 1 , Andrew J. Murphy 1 .<br />
1<br />
Regeneron Pharmaceuticals, Tarrytown, NY; 2 Dept. of<br />
Psychology, Queens College & Graduate Center of CUNY,<br />
Queens, NY<br />
4:45 p m<br />
756. Disordered Osteoclast Development in Patients with<br />
Tophaceous Gout; Uric Acid Crystals Promote Osteoclastogenesis<br />
Through Interactions with Stromal Cells. Nicola Dalbeth,<br />
Timothy Smith, Kate Gregory, Barnaby Clark, Karen<br />
Callon, Fiona McQueen, Ian Reid, Jillian Cornish.<br />
University of Auckland, Auckland, New Zealand<br />
5:00 p m<br />
757. Urate-Lowering Therapy (Febuxostat [FEB] or<br />
Allopurinol [ALLO]) in Subjects with Gout: Interim Results<br />
from the Febuxostat Comparative Extension Long-Term Study<br />
(EXCEL). M. A. Becker 1 , H. R. Schumacher, Jr 2 , P. A.<br />
MacDonald 3 , E. J. Lloyd 3 , C. Lademacher 3 , N. Joseph-<br />
Ridge 3 . 1 University of Chicago, Chicago, IL; 2 University<br />
of Pennsylvania, Philadelphia, PA; 3 TAP Pharmaceutical<br />
Products Inc, Lake Forest, IL<br />
5:15 p m<br />
758. Gout Flare Incidence in Relation to Average Serum Urate<br />
during the First Year of Urate-Lowering Therapy. M. A.<br />
Becker 1 , P. A. MacDonald 2 , B. J. Hunt 2 , C. Lademacher 2 , N.<br />
Joseph-Ridge 2 . 1 University of Chicago, Chicago, IL; 2 TAP<br />
Pharmaceutical Products Inc, Lake Forest, IL<br />
THURSDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 65
THURSDAY<br />
5:30 p m<br />
759. Is there a Relationship between Uric Acid and<br />
Inflammation?. Paola De Pablo, Timothy McAlindon. Tufts-<br />
New England Medical Center, Boston, MA<br />
5:45 p m<br />
760. Identification of Novel Monosodium Urate Crystal-induced<br />
mRNAs by Transcript Profiling of the Dissected Murine Air Pouch<br />
Membrane. Frank Pessler 1 , Christian T. Mayer 2 , Sung M.<br />
Jung 3 , Ed Behrens 1 , H. Ralph Schumacher 3 . 1 The Children’s<br />
Hospital of Philadelphia, Philadelphia, PA; 2 Technical<br />
University Munich, Munich, Germany; 3 University of<br />
Pennsylvania, Philadelphia, PA<br />
<strong>ACR</strong> Meet the Professor Sessions<br />
4:30—6:00 p m<br />
Admission to the Meet the Professor Sessions is by ticket only. To verify the<br />
session for which you are registered, refer to the registration codes below in<br />
parentheses. Meet the Professor sessions include beverages only.<br />
Antiphospholipid Syndrome (054)<br />
Room 160 C<br />
Silvia S. Pierangeli, PhD; University of Texas Medical<br />
Branch; Galveston, TX<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the diverse clinical subsets within the spectrum<br />
of APS<br />
∙ Discuss the laboratory tests used to confirm APS<br />
∙ Analyze the therapeutic alternatives for the different<br />
manifestations of APS, including the benefit/risk, adverse<br />
effects and limitations<br />
Behçet’s Disease (046)<br />
Room 107 B<br />
Fereydoun Davatchi, MD; Tehran University for Medical<br />
Sciences; Tehran, Iran<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the epidemiology and diagnostic evaluation of<br />
Behçets Syndrome<br />
∙ Describe current approaches to the management of<br />
patients with Behçets Syndrome<br />
Dermatological Manifestations of Rheumatic Diseases (045)<br />
Room 107 A<br />
Jeffrey P. Callen, MD; University Louisville; Louisville, KY<br />
Upon completion of this session, participants should be able to:<br />
∙ List the diagnostic criteria for skin diseases with<br />
rheumatologic implications<br />
∙ Develop a differential diagnosis for these conditions<br />
∙ Construct a strategy for management of skin disease seen<br />
in patients with rheumatologic diseases<br />
Fibromyalgia (053) PM<br />
Room 160 B<br />
Gary E. Myerson, MD; Arthritis and Rheumatology of GA;<br />
Atlanta, GA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the most recent thoughts regarding the<br />
pathophysiology of fibromyalgia and related disorders<br />
∙ Prescribe a treatment program for the typical fibromyalgia<br />
patient and serve as a consultant to that patient and the<br />
primary care provider<br />
∙ Describe the principles of a comprehensive treatment<br />
program for the more challenging fibromyalgia patient<br />
Osteoarthritis: Novel Treatments (051)<br />
Room 159<br />
Timothy E. McAlindon, MD, MPH, MRCP; Tufts-NEMC;<br />
Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe basic pathophysiologic mechanisms in OA<br />
∙ Discuss multiple treatment options for OA<br />
∙ Recognize newer novel treatment strategies for OA<br />
Pain - Depression Interface in the Rheumatic Diseases<br />
(047) PM<br />
Room 107 C<br />
Don L. Goldenberg, MD; Newton-Wellesley Hospital;<br />
Newton, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the spectrum of chronic pain in the rheumatic<br />
diseases<br />
∙ Recognize the associations between pain and depression<br />
∙ Develop treatment strategies that may be effective in<br />
managing this interface<br />
Polymyalgia Rheumatica (055)<br />
Room 161<br />
Robert F. Spiera, MD; Hospital for Special Surgery; New<br />
York, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe modern concepts of pathogenesis of pmR<br />
∙ Discuss evolving strategies in treatment of pmR<br />
Psoriatic Arthritis (052)<br />
Room 160 A<br />
Iain B. McInnes, PhD; University of Glasgow; Glasgow,<br />
Scotland<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the molecular basis for the pathogenesis of<br />
psoriatic arthritis<br />
∙ Discuss the recent advances in the treatment of patients<br />
with psoriatic arthritis<br />
66 = Recorded Sessions (order form on page 430)
RA: Challenging Cases (057)<br />
Room 162 B<br />
Gary W. Williams, MD, PhD; Scripps Clinic and Research<br />
Foundation; La Jolla, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss management of patients with refractory RA<br />
∙ Identify novel treatment options for those failing<br />
conventional therapies<br />
RA: Difficult Cases (044)<br />
Room 106<br />
Clifton O. Bingham, III, MD; Johns Hopkins University;<br />
Baltimore, MD<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the management of patients with refractory<br />
rheumatoid arthritis<br />
∙ Identify novel treatment options for those failing<br />
conventional therapies<br />
∙ Develop effective management plans for complicated<br />
rheumatoid arthritis patients<br />
Vasculitis: Update (049) F<br />
Room 109 A<br />
Carol Langford, MD, MHS; Cleveland Clinic Foundation;<br />
Cleveland, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the classification of vasculitis according to<br />
affected vessel size<br />
∙ Utilize the various available laboratory tests, with emphasis<br />
on ANCA testing<br />
∙ Identify current and novel therapeutic modalities<br />
<strong>ACR</strong> REF Special Session C/R<br />
4:30—6:00 p m<br />
Grand Ballroom West<br />
Edmund L. Dubois, MD, Memorial<br />
Lectureship and Abstracts #761-762<br />
Moderator:<br />
James R. O’Dell, MD; University of Nebraska<br />
Medical Center; Omaha, NE<br />
THURSDAY<br />
RA: Safety of Novel Therapies (048)<br />
Room 108<br />
Arthur Kavanaugh, MD; Center for Innovative Therapy;<br />
La Jolla, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the management of patients with refractory<br />
rheumatoid arthritis<br />
∙ Identify novel treatment options for those failing<br />
conventional therapies<br />
Scleroderma Mimics (056)<br />
Room 162 A<br />
Virginia D. Steen, MD; Georgetown University Medical<br />
Center; Washington, DC<br />
Upon completion of this session, participants should be able to:<br />
∙ Generate a differential diagnosis for conditions simulating<br />
scleroderma<br />
∙ Formulate strategies to distinguish these various conditions<br />
∙ Discuss why these various conditions may have similar<br />
manifestations<br />
SLE: Difficult to Treat SLE (050)<br />
Room 109 B<br />
Susan Manzi, MD, MPH; University of Pittsburgh;<br />
Pittsburgh, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Utilize laboratory testing in the management of patients<br />
with SLE<br />
∙ Determine the most relevant and beneficial therapeutic<br />
approach<br />
∙ Identify appropriate assessment tools for use in<br />
management and prognosis<br />
4:30 p m<br />
Early Events in Lupus Autoimmunity: Lessons to be Learned<br />
Speaker:<br />
Judith A. James, MD, PhD; Oklahoma Medical Research<br />
Foundation; Oklahoma City, OK<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify early events in pre-clinical autoimmunity<br />
∙ Discuss potential environmental triggers for lupus<br />
autoimmunity<br />
∙ Describe autoimmune traits often found in unaffected<br />
family members of SLE patients<br />
∙ Review some of the working hypotheses for initiation and<br />
perpetuation of lupus autoimmunity<br />
Abstract Presentations<br />
5:30 p m<br />
761. Identification of Novel Autoantibodies in Sera from SLE<br />
Patients Using High Density Auto-Antigen Arrays: Relationship<br />
to Type I Interferon Gene Signature and Bioactivity. Jonathan<br />
Zmuda 1 , Christina Strange 1 , Yihong Yao 1 , Christopher A.<br />
Morehouse 1 , Wendy L. Trigona 1 , Colin Wheeler 2 , Rachel<br />
Fallon 2 , Phoebe Bonner 2 , Henry Hepburn-Scott 1 , Peter<br />
Kiener 1 , Bahija Jallal 1 , Wendy I. White 1 . 1 MedImmune<br />
Inc, Gaithersburg, MD; 2 Procognia Limited, Maidenhead<br />
Berkshire, United Kingdom<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 67
THURSDAY<br />
5:45 p m<br />
762. Longitudinal Interferon-Response Gene Expression Signatures<br />
in Patients with Systemic Lupus Erythematosus. Michelle Petri 1 ,<br />
S. Singh 1 , H. Tesfasyone 1 , R. Dedrick 2 , K. Fry 2 , P. Lal 2 ,<br />
G. Williams 2 , P. Gregersen 3 , T. Behrens 4 , E. Baechler 5 .<br />
1<br />
Department of Medicine, Johns Hopkins University,<br />
Baltimore, MD; 2 XDx, Brisbane, CA; 3 The Feinstein<br />
Institute for Medical Research, Manhasset, NY; 4 Genentech,<br />
South San Francisco, CA; 5 The University of Minnesota,<br />
Minneapolis, MN<br />
<strong>ACR</strong>/<strong>ARHP</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 151<br />
Physical Activity in Musculoskeletal Disorders<br />
(Abstracts #763-768)<br />
Moderators:<br />
David Borenstein, MD; Arthritis & Rheumatism Associates;<br />
Washington, DC<br />
Nadine M. Fisher, EdD; State University of New York at<br />
Buffalo; Buffalo, NY<br />
4:30 p m<br />
763. The Effects of Spinning® Group Cycling on Pain, Gait<br />
Velocity and Quality of Life in Persons with Mild to Moderate<br />
Knee Osteoarthritis: A Randomized-Controlled Trial. Scott<br />
Lewis 1 , Greg Marchetti 2 , Amanda Salacinski 3 , M. Holland 2 ,<br />
K. Ireland 2 , Kelly Krohn 1 . 1 Mercy Hospital of Pittsburgh,<br />
Pittsburgh, PA; 2 Duquesne University, Pittsburgh, PA;<br />
3<br />
University of Pittsburgh, Pittsburgh, PA<br />
4:45 p m<br />
764. Does Malalignment Mediate the Effect of Quadriceps<br />
Strengthening on Knee Joint Loading in Patients with Medial<br />
Knee Osteoarthritis?. Boon W. Lim, Rana S. Hinman, Tim<br />
V. Wrigley, Kim L. Bennell. University of Melbourne,<br />
Melbourne, Australia<br />
5:15 p m<br />
766. Effect of Exercise on the Disease Activity of Rheumatoid<br />
Arthritis. Laura D. Bilek, Elizabeth R. Lyden, Geoffrey<br />
M. Thiele, James R. O’Dell, Gilbert M. Willett. UNMC,<br />
Omaha, NE<br />
5:30 p m<br />
767. Long Term Return to Work after a Restauration <strong>Program</strong> for<br />
Low Back Pain Patients, a Prospective Study. Cecile Poulain,<br />
Violaine Foltz, Sylvie Rozenberg, Bruno Fautrel, Pierre<br />
Bourgeois. Department of Rheumatology, University of<br />
Paris VI, Pitie Salpetriere Hospital, Paris, France<br />
5:45 p m<br />
768. The Influence of Postgraduate Education about Back<br />
Pain and Special Interests in Back Pain, Musculoskeletal or<br />
Occupational Medicine on the Back Pain Beliefs of General<br />
Practitioners. Rachelle Buchbinder 1 , Damien Jolley 2 .<br />
1<br />
Cabrini Hospital and Monash University, Victoria,<br />
Australia; 2 Monash University, Melbourne, Australia<br />
<strong>ARHP</strong> Concurrent Session C<br />
4:30—6:00 p m<br />
Room 257<br />
Radiology 101<br />
Moderator:<br />
Leslie D. McDowell, ANP, MSN; Mountain Medical<br />
Associates; Clyde, NC<br />
Speaker:<br />
Walter G. Barr, MD; Northwestern University; Chicago, IL<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify classic findings of osteoarthritis on plain<br />
radiographs<br />
∙ Differentiate between features of osteoarthritis from classic<br />
features of rheumatoid arthritis on plain radiographs<br />
∙ Describe classic radiologic appearance of inflammatory<br />
disorders of the axial skeleton<br />
f<br />
5:00 p m<br />
765. Long-Term Effectiveness of Exercise Therapy in Patients with<br />
Osteoarthritis of Hip or Knee: A Systematic Review. Martijn<br />
F. Pisters 1 , Cindy Veenhof 1 , Nico LU Van Meeteren 2 ,<br />
Raymond W. Ostelo 3 , Dinny H. De Bakker 1 , François G.<br />
Schellevis 1 , Joost Dekker 3 . 1 Netherlands Institute for Health<br />
Services Research (NIVEL), Utrecht, The Netherlands;<br />
2<br />
Department of Physiotherapy Research, Academy of Health<br />
Sciences, Utrecht University, Utrecht, The Netherlands;<br />
3<br />
Department of Rehabilitation Medicine, EMGO Institute,<br />
VU University Medical Centre, Amsterdam, Netherlands<br />
<strong>ARHP</strong> Concurrent Session<br />
4:30—6:00 p m<br />
Room 259<br />
Improving Employment Situations among People<br />
with Arthritis<br />
Moderator:<br />
Janet S. Austin, PhD; National Institutes of Health;<br />
Bethesda, MD<br />
Speakers:<br />
Saralynn H. Allaire, ScD, RN, CRC; Boston University;<br />
Boston, MA<br />
Diane V. Lacaille, MD, MHSc; Arthritis Research Centre<br />
Canada; Vancouver, British Columbia<br />
68 = Recorded Sessions (order form on page 430)
Kristina A. Theis, MPH; Centers for Disease Control;<br />
Atlanta, GA<br />
Thomas R. Waters, PhD; National Institute for<br />
Occupational Safety and Health; Cincinnati, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the impact and implications of arthritis on<br />
employment<br />
∙ Identify at least two areas in which collaboration between<br />
the perspectives represented above should result in<br />
improved employment situations for persons with arthritis<br />
(e.g., health care encounters directing patients to effective<br />
employment accommodation programs)<br />
<strong>ARHP</strong> Concurrent Session<br />
4:30—6:00 p m<br />
Room 260<br />
Speak Out: Using Your Voice to Improve Rheumatology<br />
Practice and Patient Care<br />
Moderators:<br />
Ann Kunkel, BS; University of Kansas Medical Center;<br />
Oregon, MO<br />
Deborah A. McCloskey, RN, BSN; Robert Wood Johnson<br />
Medical School, University of Medicine and Dentistry of<br />
New Jersey; New Brunswick, NJ<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify current legislative issues affecting rheumatology<br />
practice and patient care<br />
∙ Discuss current rheumatology issues in a clear and<br />
concise manner<br />
∙ Recognize the importance of communicating with legislators<br />
∙ List steps toward effective communication with legislators<br />
∙ Review tools and methods available to develop advocacy skills<br />
4:30 p m<br />
Time for Action: Getting Your Message Out<br />
John K. Brennan; Amgen; Washington, DC<br />
5:00 p m<br />
Current Legislative Issues Affecting Rheumatology Practice and<br />
Patient Care<br />
Joseph Flood, MD; Musculosketal Medical Specialists, Inc.;<br />
Columbus, OH<br />
5:30 p m<br />
Speak Out and Be Heard<br />
Amye L. Leong, MBA; Healthy Motivation; North Wales, PA<br />
Industry Roundtable-Supported Symposia<br />
6:30—9:30 p m<br />
Various Locations<br />
The REF would like to thank the supporting industry leaders<br />
that have made a significant multi-year commitment to the<br />
REF for participation in the Industry Roundtable. In<br />
appreciation for their commitment, these industry leaders have<br />
been invited to host a symposium. Please visit the organization’s<br />
exhibit booth or the industry-supported symposia booth<br />
for more information. The sponsoring organization is<br />
responsible for planning and providing CME credit for their<br />
respective symposium.<br />
Refer to pages 118-121 for complete program information.<br />
THURSDAY<br />
Encore Theater - NEW THIS YEAR!<br />
The following <strong>ACR</strong> sessions will be recorded and replayed at the following<br />
times in the Encore Theater, located in Room 255:<br />
¹<br />
Thursday, November 8 ∙ 12:45—2:15 pm<br />
State-of-the-Art - Apoptosis: Death by A<br />
Thousand Cuts<br />
∙ From Thursday, Nov. 8, 9:15-10:15 a m<br />
Friday, November 9 ∙ 6:15—7:45 pm<br />
Medical Aspects of Rheumatic Disease -<br />
Pulmonary Hypertension<br />
∙ From Friday, Nov.. 9, 9:15-10:15 a m<br />
Friday, November 9 ∙ 12:45—2:15 pm<br />
Clinical Symposium - Challenges in the<br />
Management of Lupus<br />
∙ From Thursday, Nov. 8, 2:30-4:00 pm<br />
Saturday, November 10 ∙ 12:45—2:15 pm<br />
Clinical Symposium - Therapeutic Decisions in<br />
Systemic Vasculitis<br />
∙ From Friday, Nov. 8, 2:30-4:00 pm<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 69
Poster Session A<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s:<br />
Clinical Aspects and Therapeutics I<br />
(1)-1. Similar Outcome and Organ Involvement Patter of Patients<br />
with Juvenile and Young Adult Onset Systemic Sclerosis. Data<br />
from the Eustar Database. Ivan Foeldvari 1 , Alan Tyndall 2 ,<br />
Zulian Francesco 3 , Ulf Mueller-Ladner 4 , Laszlo Czirjak 5 ,<br />
Otylia Kowal-Bielecka 6 , Dominique Farge Bancel 7 , Maroc<br />
Matucci-Cerinic 8 , for the EUSTAR Group. 1 Hamburger<br />
Zentrum fur Kinder und Jugendrheumatologie, Hamburg,<br />
Germany; 2 Rheumatologische Universitatsklinik, Basel,<br />
Switzerland; 3 University Childrens Hospital, Padua,<br />
Italy; 4 Rheumatologie- Universitat Justus-Liebig, Giessen,<br />
Germany; 5 Rheumatology—Hungarian Brothers of St.<br />
John of God University, Pecs, Hungary; 6 Department of<br />
Rheumatology, Medical University of Bialystok, Bialystok,<br />
Poland; 7 Department of Internal Medicine, Hopital Saint-<br />
Louis, Paris, France; 8 Department of Internal Medicine,<br />
University of Florence, Florence, Italy.<br />
(2)-2. Skin Thickness Progression Rate in Systemic Sclerosis<br />
with Diffuse Cutaneous Involvement: A Predictor of Outcome.<br />
Robyn T. Domsic, Tatiana S. Rodriguez-Reyna, Noreen<br />
Fertig, Mary Lucas, Molly T. Vogt, Thomas A. Medsger, Jr..<br />
University of Pittsburgh Medical Center, Pittsburgh, PA.<br />
(3)-3. The Prognostic Value of Renal Biopsy in Scleroderma Renal<br />
Crisis. Henry Penn 1 , Alec J. Howie 2 , Richard J. Stratton 1 ,<br />
Chris C. Bunn 1 , Edward J. Kingdon 3 , Carol M. Black 1 ,<br />
Aine Burns 1 , Christopher P. Denton 1 . 1 Royal Free Hospital,<br />
London, United Kingdom; 2 University College, London,<br />
London, United Kingdom; 3 Brighton University Hospital,<br />
Brighton, United Kingdom.<br />
(4)-4. Obstetric Hospitalizations in Women with Systemic Sclerosis<br />
and Primary Pulmonary Hypertension. Eliza F. Chakravarty 1 ,<br />
Dinesh Khanna 2 , Lorinda Chung 1 . 1 Stanford University,<br />
Palo Alto, CA; 2 University of Cincinnati and VAMC,<br />
Cincinnati, OH.<br />
(5)-5. Prevalence and Clinical Correlates of Symptoms of<br />
Depression in Patients with Systemic Sclerosis. Brett D. Thombs,<br />
Marie Hudson, Suzanne S. Taillefer, Canadian Scleroderma<br />
Research Group, Murray Baron. SMBD Jewish General<br />
Hospital and McGill University, Montreal, PQ, Canada.<br />
(6)-6. Risk Factors For Mortality In Patients With Systemic<br />
Sclerosis And Interstitial Lung Disease. Beatriz E. Joven, Raquel<br />
Almodovar, Patricia E. Carreira. 12 Octubre Hospital,<br />
Madrid, Spain.<br />
(7)-7. Chronic Articular Involvement In Systemic Sclerosis. Beatriz<br />
E. Joven, Raquel Almodovar, Eugenia Enriquez, Patricia E.<br />
Carreira. 12 Octubre Hospital, Madrid, Spain.<br />
(8)-8. Intraspinal and Paraspinal Calcinosis Associated with<br />
Systemic Sclerosis. Takehiko Ogawa, Kana Ogawa, Takehisa<br />
Ogura, Yuich Izumi, Norihide Hayashi, Ayako Hirata, Reiko<br />
Miura, Eizo Saito. Department of Rheumatology, Toho<br />
University Ohashi Hospital, Tokyo, Japan.<br />
(9)-9. Hospital-Based Management of Severe Digital Vasculopathy<br />
in Systemic Sclerosis. Svetlana I. Nihtyanova, Geraldine M.<br />
Brough, Carol M. Black, Christopher P. Denton. Royal Free<br />
Hospital, London, United Kingdom.<br />
(10)-10. Predictive Value of Nailfold Capillaroscopic Findings in<br />
Patients with Raynaud Phenomenon. Atusa Movasat, Beatriz<br />
Joven, Patricia E Carreira. Depatment of Rheumatology,<br />
Hospital 12 de Octubre, Madrid, Spain.<br />
(11)-11. Diagnostic Validity in Detecting Different Capillaroscopic<br />
Patterns by Qualitative versus Quantitative Scoring Methods.<br />
Francesca Ingegnoli 1 , Roberta Gualtierotti 1 , Chiara Lubatti 1 ,<br />
Patrizia Boracchi 2 , Lenka Zahalkova 1 , Silvana Zeni 1 , Flavio<br />
Fantini 1 . 1 Department of Rheumatology, University of<br />
Milano, Istituto G. Pini, Milano, Italy; 2 Institute of Medical<br />
Statistics and Biometry, Milano, Italy.<br />
(12)-12. Utility and Reliability of Different Capillaroscopic Measures<br />
for the Identification of Secondary Raynaud’s Phenomenon.<br />
Francesca Ingegnoli 1 , Roberta Gualtierotti 1 , Chiara Lubatti 1 ,<br />
Lenka Zahalkova 1 , Laura Meani 1 , Patrizia Boracchi 2 , Silvana<br />
Zeni 1 , Flavio Fantini 1 . 1 Department of Rheumatology,<br />
University of Milano, Istituto G. Pini, Milano, Italy;<br />
2<br />
Institute of Medical Statistics and Biometry, Milano, Italy.<br />
(13)-13. Cardiac Involvement in Systemic Sclerosis: The Strongest<br />
Predictive Factor of Prognosis in Patients with Scleroderma.<br />
Sumiaki Tanaka 1 , Kazuo Nishi 1 , Nobuko Iizuka 1 , Hirobumi<br />
Kondo 2 , Shunsei Hirohata 1 . 1 Kitasato University School of<br />
Medicine, Sagamihara, Kanagawa, Japan; 2 Kitasato Institute<br />
Medical Center Hospital, Kitamoto, Saitama, Japan.<br />
(14)-14. Sub-Maximal Exercise Testing in the Prospective<br />
Assessment of Interstitial Lung Disease (ILD) Secondary to<br />
Systemic Sclerosis (SSc): Correlations with Objective and Subjective<br />
Measures of Parenchymal Lung Disease. Elena Schiopu 1 , Ann<br />
J. Impens 1 , Kristine Phillips 1 , Christopher P. Denton 2 ,<br />
Daniel E. Furst 3 , Loic Guillevin 4 , Lewis J. Rubin 5 , Athol U.<br />
Wells 6 , Marco Matucci-Cerinic 7 , Gabriela Riemekasten 8 ,<br />
Paul Emery 9 , Harbajan Chadha-Boreham 10 , Pascal Charef 10 ,<br />
Sebastien Roux 10 , Carol M. Black 2 , James R. Seibold 1 .<br />
1<br />
University of Michigan, Ann Arbor, MI; 2 Royal Free<br />
and University College Medical School, London, United<br />
Kingdom; 3 University of California, Los Angeles, CA;<br />
4<br />
Universite Rene Descartes, Paris, France; 5 University of<br />
California, San Diego, CA; 6 Royal Brompton Hospital,<br />
London, United Kingdom; 7 University of Florence,<br />
Florence, Italy; 8 Charite University Hospital, Berlin,<br />
Germany; 9 University of Leeds, Leeds, United Kingdom;<br />
10<br />
Actelion, Allschwil, Switzerland.<br />
70 (Permanent Board Number)-Abstract Number
(15)-15. Gastric Antral Vascular Ectasia in Systemic Sclerosis.<br />
Kristin M. Ingraham 1 , Marie S. O’Brien 2 , Chris T. Derk 2 ,<br />
Virginia D. Steen 1 . 1 Georgetown University Hospital,<br />
Washington, DC; 2 Thomas Jefferson University,<br />
Philadelphia, PA.<br />
(16)-16. Brain Natriuretic Peptide and Uric Acid as Predictors<br />
of Pulmonary Arterial Hypertension in Patients with Systemic<br />
Sclerosis. Angelo Gaffo, Raymond Benza, Barri J. Fessler.<br />
University of Alabama at Birmingham, Birmingham, AL.<br />
(17)-17. Lower Gastrointestinal Symptoms and Quality of Life<br />
in Patients with Systemic Sclerosis. A Population-Based Study.<br />
Karin Franck-Larsson, Wilhelm Graf, Anders Rönnblom.<br />
University of Uppsala, Uppsala, Sweden.<br />
(18)-18. Characteristics of Patients with Early Systemic Sclerosis<br />
and Severe Gastrointestinal Tract Involvement. Yasushi<br />
Kawaguchi 1 , Emi Nishimagi 1 , Akiko Tochimoto 1 , Takashi<br />
Satoh 2 , Masataka Kuwana 2 , Tomoko Sugiura 1 , Makoto<br />
Soejima 1 , Sayumi Baba 1 , Naoyuki Kamatani 1 , Masako Hara 1 .<br />
1<br />
Tokyo Women’s Medical University, Tokyo, Japan; 2 Keio<br />
University School of Medicine, Tokyo, Japan.<br />
(19)-19. Predicting Pulmonary Artery Hypertension in Patients<br />
with Systemic Sclerosis.. Theresa C. Barnes 1 , Caroline Dore 2 ,<br />
Angela Gliddon 3 , Peter Maddison 3 , Robert Moots 1 .<br />
1<br />
University of Liverpool, Liverpool, United Kingdom; 2 ARC<br />
Clinical Trials Unit, London, United Kingdom; 3 Bangor<br />
University, Bangor, United Kingdom.<br />
(20)-20. Fulminant Scleroderma as an Early Cause of Death in<br />
Patients with Systemic Sclerosis. Gonzalo Huaman, Franklin<br />
Otieno, Sergio A. Jimenez, Chris T. Derk. Thomas Jefferson<br />
University, Philadelphia, PA.<br />
(21)-21. Physician and Patient Assessment of Disease Severity in<br />
Systemic Sclerosis (SSc). Ann J. Impens 1 , Elena Schiopu 1 , Maya<br />
H. Buch 2 , Kevin C. Chung 1 , James R. Seibold 1 . 1 University<br />
of Michigan, Ann Arbor, MI; 2 University of Leeds, Leeds,<br />
United Kingdom.<br />
(22)-22. Ambulatory Raynaud’s Monitor: A Novel Measurement<br />
Device to Assess Raynaud’s Phenomenon in an Ambulatory<br />
Setting. Ami A. Shah, Laura K. Hummers, Paul Schwartz,<br />
Binh Le, Wayne Dellinger, David Stott, Robert A. Wise,<br />
Fredrick M. Wigley. Johns Hopkins University, Baltimore, MD.<br />
(23)-23. Radiological and Functional Lung Indices Worsening<br />
in Scleroderma Patients: Relationship with Alveolitis and Low<br />
Respiratory Tract Infections. Maria De Santis, Silvia Bosello,<br />
Giusy Peluso, Barbara Tolusso, Stefano Alivernini, Michela<br />
Pinnelli, Gianfranco Ferraccioli. Catholic University of the<br />
Sacred Heart, Rome, Italy.<br />
(24)-24. Sparing of the Thumb in Raynaud’s Phenomenon. Batsi<br />
G. Chikura 1 , Tonia L. Moore 2 , Joanne B. Manning 2 , Andy<br />
Vail 3 , Ariane L. Herrick 4 . 1 The Royal Liverpool University<br />
Hospital, Liverpool, United Kingdom; 2 Rheumatic<br />
Diseases Centre, Hope Hospital, Salford,Manchester,<br />
United Kingdom; 3 Research and Development Unit, Hope<br />
Hospital, Manchester, United Kingdom; 4 University of<br />
Manchester, Manchester, United Kingdom.<br />
(25)-25. Is Statin Use Protective Against Development of Systemic<br />
Sclerosis? A Retrospective Case Controlled Study. Rachel Gross 1 ,<br />
Mansi Mehta 2 , Margaret Peterson 2 , Harry Spiera 2 , Robert F.<br />
Spiera 2 . 1 Mount Sinai School of Medicine, New York, NY;<br />
2<br />
Hospital for Special Surgery, New York, NY.<br />
(26)-26. Safety and Tolerability of MQX-503, a Novel<br />
Investigational Topical Formulation of Nitroglycerin for the<br />
Treatment of Raynaud’s Phenomenon. Sangeeta D. Sule 1 ,<br />
Laura Hummers 1 , Lee Shapiro 2 , David Fiorentino 3 ,<br />
Lorinda Chung 3 , Murray Baron 4 , Joseph Shanahan 5 ,<br />
Vivien Hsu 6 , Naomi Rothfield 7 , Virginia Steen 8 , Richard<br />
Martin 9 , Carin Dugowson 10 , Edwin Smith 11 , Maureen<br />
Mayes 12 , Robert Simms 13 , Janet Pope 14 , Bashar Kahaleh 15 ,<br />
Mary Ellen Csuka 16 , Barry Gruber 17 , David Collier 18 ,<br />
Nadera Sweiss 19 , Leslie Klaff 20 , Frederick J. Dechow 1 , Jeff<br />
Gregory 21 , Fredrick M. Wigley 1 . 1 Johns Hopkins University,<br />
Baltimore, MD; 2 Center for Rheumatology, Albany, NY;<br />
3<br />
Stanford University, Palo Alto, CA; 4 McGill University,<br />
Quebec City, PQ, Canada; 5 Duke University, Durham, NC;<br />
6<br />
UMDNJ, New Brunswick, NJ; 7 Universtiy of Connecticut,<br />
Farmington, CT; 8 Georgetown University, Washington<br />
D.C., DC; 9 Michigan State University, Grand Rapids,<br />
MI; 10 University of Washington, Seattle, WA; 11 MUSC,<br />
Charleston, SC; 12 University of Texas, Houston, TX;<br />
13<br />
Boston University, Boston, MA; 14 Universtiy of Western<br />
Ontario, London, ON, Canada; 15 Medical College of<br />
Wisconsin, Milwaukee, WI; 16 Medical University of Ohio,<br />
Toledo, OH; 17 SUNY, Stony Brook, NY; 18 University of<br />
Colorado, Denver, CO; 19 University of Chicago, Chicago,<br />
IL; 20 Rainier Clinical Research Center, Renton, WA;<br />
21<br />
MediQuest Therapeutics Inc., Bothell, WA.<br />
(27)-27. Promising Effects of Mycophenolate Mofetil on<br />
Autoimmune Related Pulmonary Fibrosis. Lesley Ann Saketkoo,<br />
Luis R. Espinoza. Louisiana State Health Sciences Center,<br />
New Orleans, LA.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 71
Poster Session A<br />
(28)-28. Phenotypical and Functional Characteristics of in<br />
vitro Expanded Bone Marrow Mesenchymal Stem Cells from<br />
Systemic Sclerosis Patients. JérÒme Larghero 1 , Dominique<br />
Farge 2 , Alessandra Braccini 3 , Séverine Lecourt 1 , Arnaud<br />
Scherberich 3 , Elena Foïs 1 , Franck Verrecchia 4 , Thomas<br />
Daikeler 5 , Eliane Gluckman 1 , Alan Tyndall 5 , Chiara<br />
Bocelli-Tyndall 6 . 1 Cell Therapy Unit, Saint-Louis Hospital,<br />
Paris, France; 2 Department of Internal Medicine, Saint-<br />
Louis Hospital, Paris, France; 3 Department of Surgery<br />
and of Research, University Hospital Basel, Basel,<br />
Switzerland; 4 INSERM U697, Paris, France; 5 Department<br />
of Rheumatology, University of Basel, Basel, Switzerland;<br />
6<br />
Department of Surgery and of Research and Department of<br />
Rheumatology, University of Basel, Basel, Switzerland.<br />
(29)-29. Are Scleroderma Patients Less Microchimeric after<br />
Autologous Stem Cell Transplantation?. Justyna M. RAK 1 ,<br />
Dominique Farge 2 , Franck Verrecchia 3 , Christophe<br />
Deligny 4 , Jerôme Larguero 3 , Nathalie C. Lambert 1 .<br />
1<br />
INSERM U639, Marseille, France; 2 Service de Médecine<br />
Interne et Pathologie Vasculaire, Hôpital St Louis, PARIS,<br />
France; 3 INSERM U697, Hôpital St Louis, PARIS, France;<br />
4<br />
Service de Médecine Interne CHU, Fort de France, France.<br />
(30)-30. EULAR/EUSTAR Recommendations for the Treatment<br />
of Systemic Sclerosis (SSc). Otylia Kowal-Bielecka 1 , Robert<br />
Landewe 2 , Jerome Avouac 3 , Sylwia Chwiesko 1 , Irene<br />
Miniati 4 , Laszlo Czirjak 5 , Philip Clements 6 , Christopher<br />
Denton 7 , Dominique Farge 8 , Kim Fligelstone 9 , Ivan<br />
Földvari 10 , Daniel Furst 6 , Ulf Müller-Ladner 11 , James<br />
Seibold 12 , Richard Silver 13 , Kazuhiko Takehara 14 , Beate<br />
Garay Toth 15 , Alan Tyndall 16 , Gabriele Valentini 17 ,<br />
Frank van den Hoogen 18 , Fredrick Wigley 19 , Francesco<br />
Zulian 20 , Marco Matucci-Cerinic 4 , on behalf of EUSTAR<br />
centers. 1 MUB, Bialystok, Poland; 2 UH, Maastricht, The<br />
Netherlands; 3 RDU, Paris, France; 4 UF, Florence, Italy;<br />
5<br />
UP, Pecs, Hungary; 6 UCLA, Los Angeles, CA; 7 RFH,<br />
London, United Kingdom; 8 HSL, Paris, France; 9 FESCA,<br />
Harlesden, United Kingdom; 10 KE, Hamburg, Germany;<br />
11<br />
JLU, Bad Nauheim, Germany; 12 UMI, Ann Arbor, MI;<br />
13<br />
MUSC, Charleston, SC; 14 USMS, Kanazawa, Japan;<br />
15<br />
FESCA, Budapest, Hungary; 16 UH, Basel, Switzerland;<br />
17<br />
SUN, Naples, Italy; 18 RUMC, Nijmegen, The Netherlands;<br />
19<br />
JHU, Baltimore, MD; 20 UP, Padua, Italy.<br />
(31)-31. Evolution of Fibrosing Alveolitis Associated with Systemic<br />
Sclerosis after Autologous Bone Marrow Transplantation. David<br />
Launay 1 , Zora Marjanovic 2 , Cedric de Bazelaire 3 , Sarah<br />
Zohar 4 , Laura Florea 5 , Homah Keshmand 5 , Christophe<br />
Deligny 6 , Dominique Farge 5 . 1 Service de Médecine Interne,<br />
Centre National de Référence «Atteintes vasculaires de la<br />
sclérodermie», Hôpital Claude-Huriez, Lille, France; 2 Service<br />
d’Hématologie, Hôpital Hotel-Dieu, Paris, France; 3 Service<br />
de Radiologie, Hôpital Saint-Louis, Paris, France; 4 Service<br />
de Biostatistiques, Hôpital Saint-Louis, Paris, France;<br />
5<br />
Service de Médecine Interne, Hôpital Saint-Louis, Paris,<br />
France; 6 Service de Médecine Interne, CHU Fort-de-France,<br />
Fort-de-France, France.<br />
(32)-32. Imatinib Mesylate Treatment Improves Skin Changes of<br />
Nephrogenic Systemic Fibrosis. Jonathan Kay. Massachusetts<br />
General Hospital, Boston, MA.<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s:<br />
Pathogenesis, Animal Models and Genetics<br />
(33)-33. Association between Genetic Polymorphisms in the<br />
Surfactant Protein Genes and Pulmonary Fibrosis in Systemic<br />
Sclerosis. Yoshiko Sumita, Tomoko Sugiura, Yasushi<br />
Kawaguchi, Manabu Kawamoto, Yasuhiro Katsumata,<br />
Makoto Soejima, Tokiko Kanno, Akiko Tochimoto, Ikuko<br />
Masuda, Kae Takagi, Masako Hara, Naoyuki Kamatani.<br />
Institute of Rheumatology, Tokyo Women’s Medical<br />
University, Tokyo, Japan.<br />
(34)-34. The Shared Amino Acid Sequence “FLED” of Some<br />
DRB1 and DRB5 Alleles is Associated with Systemic Sclerosis.<br />
Hilary S. Gammill 1 , Michael A. Tasch 1 , VK Gadi 1 , Laurence<br />
S. Loubiere 1 , Nick D. Boespflug 2 , J Lee Nelson 1 . 1 Fred<br />
Hutchinson and U of WA, Seattle, WA; 2 Fred Hutchinson<br />
Cancer Research Center, Seattle, WA.<br />
(35)-35. Whole Genome Association by DNA Pooling Leads to<br />
Interesting Candidate Genes for Systemic Sclerosis. Isaac TW<br />
Harley, Kenneth M. Kaufman, Joel M. Guthridge, Jeff<br />
Kilpatrick, David Hutchings, John B. Harley, Judith A.<br />
James. OMRF, Oklahoma City, OK.<br />
(36)-36. Gene-Gene Interactions Mediating Susceptibility to<br />
Scleroderma: Investigation of A 3 Gene Network. Pravitt Gourh 1 ,<br />
Frank C. Arnett 1 , Sanjay Shete 2 , Maureen D. Mayes 1 ,<br />
Filemon K. Tan 1 . 1 University of Texas-Houston HSC,<br />
Houston, TX; 2 University of Texas-M.D.Anderson Cancer<br />
Center, Houston, TX.<br />
(37)-37. Comparative Analysis of Dermal Fibroblast Gene<br />
Expression Profiles from Patients with Systemic Sclerosis and<br />
Hypertrophic Burn Scars. Pravitt Gourh, Xiaodong Zhou,<br />
Shervin Assassi, Frank C. Arnett, Filemon K. Tan.<br />
University of Texas-Houston HSC, Houston, TX.<br />
(38)-38. Systemic Sclerosis and Systemic Lupus Erythematosus<br />
have Distinct Gene Expression Profiles in the Peripheral Blood<br />
Cells. Shervin Assassi 1 , Maureen D. Mayes 1 , Pravitt Gourh 1 ,<br />
Frank C. Arnett 1 , John D. Reveille 1 , Cameron Poage 1 ,<br />
Terry McNearney 2 , Michael Fischbach 3 , Filemon K. Tan 1 .<br />
72 (Permanent Board Number)-Abstract Number
1<br />
University of Texas Health Science Center at Houston,<br />
Houston, TX; 2 University of Texas Medical Branch,<br />
Galveston, TX; 3 University of Texas Health Science Center<br />
at San Antonio, San Antonio, TX.<br />
(39)-39. Abstract Withdrawn<br />
(40)-40. Molecular Subtypes of Systemic Sclerosis (SSc) From Gene<br />
Expression Signatures. Ausra Milano 1 , Sarah A. Pendergrass 1 ,<br />
Jennifer L. Sargent 1 , Xiaoquin Dou 2 , M. Kari Connolly 2 ,<br />
Michael L. Whitfield 1 . 1 Dartmouth Medical School,<br />
Hanover, NH; 2 University of California San Francisco, San<br />
Francisco, CA.<br />
(41)-41. Adenosine A2A Receptor Occupancy Regulates<br />
Expression of Multiple Genes Involved in Fibrosis. Hailing Liu,<br />
Xiao Hu, Bruce N. Cronstein. NYU School of Medicine,<br />
New York, NY.<br />
(42)-42. Pharmacological Blockade of Adenosine A2A Receptors<br />
Reduces IL-13 Production and Fibrotic Features in a Novel Model<br />
of Skin Fibrosis. Patricia Fernandez 1 , Sean Trzaska 1 , Tuere<br />
Wilder 1 , Michael R. Blackburn 2 , Bruce N. Cronstein 1 , Edwin<br />
SL Chan 1 . 1 NYU School of Medicine, New York, NY;<br />
2<br />
University of Texas-Houston Medical School, Houston, TX.<br />
(43)-43. Nilotinib and Dasatinib, Two Novel and More Potent<br />
Inhibitors of C-abl and Pdgf Signalling, for the Treatment of<br />
Experimental Dermal Fibrosis. Alfiya Akhmetshina 1 , Clara Dees 1 ,<br />
Catherine Skhirtladse 1 , Margarita Pileckyte 2 , Steffen Gay 3 ,<br />
Georg Schett 1 , Oliver Distler 3 , Jörg H.W. Distler 1 . 1 Department<br />
of Internal Medicine III, Erlangen, Germany; 2 Department of<br />
Rheumatology, Kaunas Medical University Hospital, Lithuania;<br />
3<br />
Center of Experimental Rheumatology and Zurich Center of<br />
Integrative Human Physiology, Zurich, Switzerland.<br />
(44)-44. The Antifibrogenic Effects of Trichostatin A are<br />
Mediated Through the Down-Regulation of Histone Deacetylase<br />
7. Hossein Hemmatazad 1 , Hanna Maciejewska 1 , Margarita<br />
Pileckyte 2 , Joerg HW Distler 3 , Renate E. Gay 1 , Beat Michel 1 ,<br />
Steffen Gay 1 , Oliver Distler 1 , Lars C. Huber 1 , Astrid<br />
Juengel 1 . 1 Center of Experimental Rheumatology, University<br />
Hospital and Zurich center of Integrative Human Physiology<br />
(ZIHP), Zurich, Switzerland; 2 Department of Rheumatology,<br />
Kaunas Medical University Hospital, Kaunas, Lithuania;<br />
3<br />
Department of Rheumatology, University of Erlangen-<br />
Nuremberg, Nuremberg, Germany.<br />
(45)-45. Altered in vivo Dermal and Epidermal TGFβ Signalling<br />
in TβRII Conditional Knockout Mice. Korsa Khan, Patricia<br />
Leoni, Rachel Hoyles, Xu Shiwen, David Abraham,<br />
Christopher P. Denton. Royal Free and University College<br />
London, London, United Kingdom.<br />
(46)-46. Role of Type I Interferons in a Murine Model of<br />
Scleroderma. Tracy A. Delaney, Christopher J. Groves, Jing<br />
Zhang, Ricardo Cibotti, Laurent A. Audoly, Peter Kiener,<br />
Anthony J. Coyle. MedImmune, Inc., Gaithersburg, MD.<br />
(47)-47. Development of Smad7 Conditional-Knockout Mice and<br />
Its Altered Fibrotic Responses in Fibroblast in Vitro. Yoko Wada,<br />
Madhumita Ray, Minglang Zhao, Marilyn Diaz. National<br />
Institute of Environmental Health Sciences (NIEHS),<br />
Research Triangle Park, NC.<br />
(48)-48. Intercellular Adhesion Molecule-1 Deficiency Attenuates<br />
the Development of Skin Fibrosis in Tight-skin Mice. Minoru<br />
Hasegawa 1 , Yukiyo Matshushita 1 , Takashi Matshushita 1 ,<br />
Manabu Fujimoto 1 , Douglas Steeber 2 , Thomas Tedder 3 ,<br />
Kazuhiko Takehara 1 , Shinichi Sato 4 . 1 Kanazawa University,<br />
Kanazawa, Japan; 2 University of Wisconsin-Milwaukee,<br />
Milwaukee, WI; 3 Duke University Medical Center, Durham,<br />
NC; 4 Nagasaki University Graduate School of Biomedical<br />
Science, Nagasaki, Japan.<br />
(49)-49. Chemokine Receptors CCR2 and CX3CR1 Regulate<br />
Skin Fibrosis in a Cytokine-induced Scleroderma Mouse Model.<br />
Minako Arai, Yuka Ikawa, Sonoko Chujo, Fumiaki<br />
Shirasaki, Manabu Fujimoto, Kazuhiko Takehara, Naofumi<br />
Mukaida. Kanazawa University, kanazawa, Japan.<br />
(50)-50. Baff Antagonist Attenuates the Development of Skin<br />
Fibrosis in Tight-Skin Mice. Manabu Fujimoto 1 , Takashi<br />
Matsuishita 1 , Minoru Hasegawa 1 , Kazuhiko Takehara 1 ,<br />
Shinichi Sato 2 . 1 Kanazawa University, Kanazawa, Ishikawa,<br />
Japan; 2 Nagasaki University, Nagasaki, Japan.<br />
(51)-51. An in vitro Study of the Effect of Gadolinium<br />
Compounds on Normal Human Peripheral Blood Mononuclear<br />
Cells.. Peter J. Wermuth, Francesco Del Galdo, Sergio A.<br />
Jimenez. Division of Rheumatology, Thomas Jefferson<br />
University, Philadelphia, PA.<br />
(52)-52. Macrophage Migration Inhibitory Factor (MIF)<br />
Production by T Cells is Strongly Upregulated by Allograft<br />
Inflammatory Factor-1 (AIF-1) Expression and Contributes to<br />
the Profibrotic Effects of AIF-1. Francesco Del Galdo 1 , Megan<br />
Musick 1 , Alexander M. Shaw 2 , Sergio A. Jimenez 1 . 1 Thomas<br />
Jefferson University, Philadelphia, PA; 2 Kimmel Cancer<br />
Center Thomas Jefferson University, Philadelphia, PA.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 73
Poster Session A<br />
(53)-53. IGFBP-5 is a Novel Chemoattractant for Immune Cells<br />
and Fibroblasts and Plays a Role in the Inflammatory and Fibrotic<br />
Phases of Pulmonary Fibrosis. Hidekata Yasuoka, Carol A.<br />
Feghali-Bostwick. University of Pittsburgh, Pittsburgh, PA.<br />
(54)-54. IGFBP-5 Induces Extracellular Matrix Production via<br />
Egr-1 and MAPK-Dependent Pathway. Hidekata Yasuoka,<br />
Ximena Ruiz, Richard Steinman, Augustine MK Choi,<br />
Carol A. Feghali-Bostwick. University of Pittsburgh,<br />
Pittsburgh, PA.<br />
(55)-55. Insulin-Like Growth Factor-ii (IGF-II) is Aberrantly<br />
Expressed in Scleroderma-Associated Pulmonary Fibrosis and<br />
Contributes tt Abnormal Matrix Production. Eileen Hsu, Carol<br />
A. Feghali-Bostwick. University of Pittsburgh, Pittsburgh, PA.<br />
(56)-56. Assembly of Fibrillin-1 and Elastic Fibers is Repressed<br />
by CCN3, a Growth Factor Upregulated in Tsk Mice and<br />
Downregulated in a Marfan Syndrome Model: Novel Molecular<br />
Insights into Extracellular Matrix Remodeling in Connective Tissue<br />
Disorders. Raphaël Lemaire, Julie Bayle, Robert Lafyatis.<br />
Boston University School of Medicine, Boston, MA.<br />
(57)-57. Heparan Sulphate-Dependent ERK Activation<br />
Contributes to the Over-Expression of Fibrotic Proteins and the<br />
Enhanced Contraction by Lesional Dermal Scleroderma Fibroblasts<br />
of Their Extracellular Matrix. Yunliang Chen 1 , Andrew Leask 2 ,<br />
David J. Abraham 3 , Daphne Pala 2 , Xu Shi-wen 3 , Korsa<br />
Khan 3 , Christopher P. Denton 3 , Carol M. Black 3 , Andrew<br />
A. Pitsillides 4 , Mark Eastwood 5 . 1 University of Westminster<br />
and University College London, London, United Kingdom;<br />
2<br />
Schulich School of Dentistry, University of Western<br />
Ontario, London, ON, ON, Canada; 3 University College<br />
London, London, United Kingdom; 4 The Royal Veterinary<br />
Collage, London, United Kingdom; 5 University of<br />
Westminster, London, United Kingdom.<br />
(58)-58. Up-take of Silica and Carbon Nanotubes by Human<br />
Macrophages Induces Activation of T-Cells and Fibroblasts in<br />
vitro—Potential Implication for Pathogenesis of Fibrosing Diseases.<br />
Xiaodong Zhou, filemon K. Tan, Xinjian Guo, Neelam<br />
Tejpal, Barry D. Kahan, Stanislaw M. Stepkowski, Frank<br />
C. Arnett. University of Texas Houston Medical School,<br />
Houston, TX.<br />
(59)-59. Differential Dynamic Properties of the TGFB Pathway<br />
between Normal Fibroblasts and Scleroderma Fibroblasts in<br />
Response to Perturbation by Environmental Stimuli. Momiao<br />
Xiong 1 , Xinjian Guo 2 , Hao Xiong 3 , Frank C. Arnett 2 ,<br />
Xiaodong Zhou 2 . 1 University of Texas School Public Health<br />
at Houston, Houston, TX; 2 University of Texas Houston<br />
Medical School, Houston, TX; 3 Texas A&M University,<br />
College Station, TX.<br />
(60)-60. DNA Methylation Induction by a Circulating Activity in<br />
SSc Sera: Possible Role for Oxidation and Autoantibodies Related<br />
Mechanisms. Yongqing Wang, bashar kahaleh. University of<br />
Toledo, Toledo, OH.<br />
(61)-61. High Levels of Circulating Endothelial Progenitor Cells<br />
and Functional Properties of Their Late Outgrowth in Systemic<br />
Sclerosis. Jérôme Avouac 1 , André Kahan 1 , Gilles Chiocchia 2 ,<br />
Catherine Boileau 3 , Georges Uzan 4 , Yannick Allanore 1 .<br />
1<br />
Department of Rheumatology A, Cochin Hospital, Paris,<br />
France; 2 INSERM U567, Cochin Hospital, Paris, France;<br />
3<br />
INSERM U781, Necker Hospital, Paris, France; 4 INSERM<br />
U602, Paul Brousse Hospital, Villejuif, France.<br />
(62)-62. Disturbed Sera Angiogenic Markers in Systemic Sclerosis.<br />
Jérôme Avouac 1 , Julien Wipff 1 , André Kahan 1 , Catherine<br />
Boileau 2 , Yannick Allanore 1 . 1 Rheumatology A Department,<br />
Cochin Hospital, Paris, France; 2 U.V.S.Q University,<br />
Ambroise Paré Hospital, Boulogne, France.<br />
(63)-63. Reactive Oxygen Species Production in Scleroderma.<br />
patricia leoni, henry penn, carmen fonseca, christopher<br />
denton, carol black, david abraham. University College<br />
London, Royal Free Hospital, London, United Kingdom.<br />
(64)-64. Paradoxical Increase in Monocytic Progenitors for<br />
Endothelial Cells in Patients with Systemic Sclerosis. Yukie<br />
Yamaguchi 1 , Yuka Okazaki 2 , Noriyuki Seta 2 , Takashi<br />
Satoh 2 , Kazuo Takahashi 1 , Zenro Ikezawa 1 , Masataka<br />
Kuwana 2 . 1 Yokohama City University Graduate School of<br />
Medicine, Yokohama, Japan; 2 Keio University School of<br />
Medicine,Tokyo, Japan, Tokyo, Japan.<br />
(65)-65. Anti-Fibroblast Antibodies (AFA) Detected by Cell-Based<br />
Elisa in Systemic Sclerosis (SSc) Sera Preferentially Induce Pro-<br />
Fibrotic Chemokine Production in Human Dermal Fibroblasts.<br />
Serena Fineschi 1 , Franco Cozzi 2 , Danielle Burger 1 , Jean-<br />
Michel Dayer 1 , Pierluigi Meroni 3 , Carlo Chizzolini 1 .<br />
1<br />
Geneva University Hospital, Geneva, Switzerland;<br />
2<br />
University Hospital of Padua, Padua, Italy; 3 Milan<br />
University, Milan, Italy.<br />
(66)-66. Serum COMP in Systemic Sclerosis—A Promising New<br />
Biomarker for Skin Involvement. Roger Hesselstrand 1 , Anja<br />
Kassner 2 , Dick Heinegård 2 , Tore Saxne 1 . 1 Department<br />
of Rheumatology, Lund University Hospital, Sweden;<br />
2<br />
Department of Experimental Medical Science, Section for<br />
Connective Tissue Biology, Lund University, Sweden.<br />
(67)-67. Involvement of IC-IL-1RA in the Transition of Low<br />
Density Seeded Fibroblasts into Myofibroblasts. Sivadasan -.<br />
Kanangat, Karen A. Hasty, Heri -. Park, Sara -. Woods,<br />
Whitney -. Appling, Andrew H. Kang, Arnold E.<br />
Postlethwaite. Ut-Memphis, Memphis, TN.<br />
(68)-68. Collagenase Expression is Inhibited in Fibroblasts from<br />
Fibrotic, but Not Non-fibrotic, Scleroderma Skin: The Role of<br />
Intracellular Interleukin 1 Receptor Antagonist. Karen A. Hasty,<br />
Siva Kanangat, Arnold E. Postlethwaite. University of<br />
Tennessee Health Science Center, Memphis, TN.<br />
74 (Permanent Board Number)-Abstract Number
(69)-69. Anti-Topoisomerase I, but not Anti-Centromere,<br />
Autoantibodies Induce IFN-a through a Toll Like Receptor<br />
Pathway: Correlations with Disease Manifestations. Anders<br />
Peck 1 , Daniel Kim 1 , Prashant Patole 1 , Deanna Santer 1 , Jerry<br />
Molitor 2 , Frank Arnett 3 , Keith B. Elkon 1 . 1 University of<br />
Washington, Seattle, WA; 2 Benaroya Research Institute,<br />
Seattle, WA; 3 University of Texas, Houston, TX.<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Epidemiology and Health Services Research I<br />
(70)-70. Change in Medical Expenditure and Job Loss after<br />
Abatacept Treatment. Jason C. Cole 1 , Tracy Li 2 , Gene V.<br />
Wallenstein 1 , Ross MacLean 2 , Peggy Lin 1 . 1 QualityMetric,<br />
Lincoln, RI; 2 Bristol-Myers Squibb, Princeton, NJ.<br />
(71)-71. Incremental Cost-Effectiveness of Proton Pump Inhibitors<br />
for the Prevention of NSAID Ulcers: A Pharmacoeconomic<br />
Analysis Linked to a Case-Control Study. Harald E. Vonkeman 1 ,<br />
Annemarie MA Braakman-Jansen 2 , Rogier M. Klok 3 ,<br />
Maarten J. Postma 3 , Jacobus RBJ Brouwers 3 , Mart AFJ van<br />
de Laar 1 . 1 Medisch Spectrum Twente Hospital & University<br />
of Twente, Enschede, The Netherlands; 2 University of<br />
Twente, Enschede, The Netherlands; 3 Department of Social<br />
Pharmacy, Pharmacoepidemiology and Pharmacotherapy,<br />
Groningen University, Groningen, The Netherlands.<br />
(72)-72. Under-Utilisation of Gastroprotective Drugs in Patients<br />
with NSAID-Related Ulcers. Harald E. Vonkeman 1 , Robert W.<br />
Fernandes 2 , Mart AFJ van de Laar 1 . 1 Medisch Spectrum Twente<br />
Hospital and University of Twente, Enschede, Netherlands;<br />
2<br />
Stroinkslanden Pharmacy, Enschede, Netherlands.<br />
(73)-73. Access to the Rheumatologist for Early Arthritis Patients:<br />
What are the Determinants of Delayed Specialized Care?<br />
Results from the ESPOIR Cohort. Bruno Fautrel 1 , Mathilde<br />
Benhamou 1 , Violaine Foltz 1 , Nathalie Rincheval 2 , Anne<br />
Christine Rat 3 , Bernard Combe 4 , Francis Berenbaum 5 ,<br />
Francis Guillemin 3 , Pierre Bourgeois 1 , le CRI et la SFR.<br />
1<br />
Department of Rheumatology, Pierre et Marie Curie<br />
University—Paris VI, Pitie Salpetriere Hospital, Paris,<br />
France; 2 Coordination Center, Lapeyronie Hospital,<br />
Montpellier, France; 3 School of Public Health, Nancy<br />
Hospital, Nancy, France; 4 Department of Rheumatology,<br />
Lapeyronie Hospital, Montpellier, France; 5 Department of<br />
Rheumatology, Pierre et Marie Curie University—Paris VI,<br />
St Antoine Hospital, Paris, France.<br />
(74)-74. Who Receives Biologics For Treatment Of RA?. Esi<br />
Morgan DeWitt 1 , Li Lin 1 , Henry Glick 2 , Kevin Schulman 1 ,<br />
Bharathi Lingala 3 , Shelby Reed 1 . 1 Duke University Medical<br />
Center, Durham, NC; 2 University of Pennsylvania,<br />
Philadelphia, PA; 3 Stanford University, Palo Alto, CA.<br />
(75)-75. Comparison between Rheumatologists’ Practice and<br />
Clinical Guidelines. How Far They Are? Results from the ESPOIR<br />
Cohort. Mathilde Benhamou 1 , Nathalie Rincheval 2 , Carine<br />
Roy 3 , Violaine Foltz 1 , Pierre Bourgeois 1 , Philippe Ravaud 3 ,<br />
Bruno Fautrel 1 . 1 Department of Rheumatology, University<br />
of Paris VI, Pitie Salpetriere Hospital, Paris, France;<br />
2<br />
Coordination Center, Lapeyronie Hospital, Montpellier,<br />
France; 3 Department of Epidemiology and Clinical Research,<br />
University of Paris VII, Bichat Hospital, Paris, France.<br />
(76)-76. Work Characteristics Associated with Sick Leave in<br />
Patients with Early Inflammatory Joint Complaints. Goedele A.<br />
Geuskens, Alex Burdorf, Pieternella J. Barendregt, Johanna<br />
M.W. Hazes. Erasmus MC, University Medical Center<br />
Rotterdam, Rotterdam, The Netherlands.<br />
(77)-77. Productivity Losses at Work: Comparisons of Different<br />
Measurement Instruments. Xin Li 1 , Monique Gignac 2 ,<br />
Dorcas Beaton 2 , Elizabeth Badley 3 , Diane Lacaille 4 , Claire<br />
Bombardier 2 , Aslam H. Anis 1 . 1 University of British<br />
Columbia, Vancouver, BC, Canada; 2 University of Toronto,<br />
Toronto, ON, Canada; 3 Arthritis Community Research &<br />
Evaluation Unit, Toronto, ON, Canada; 4 Arthritis Research<br />
Centre of Canada, Vancouver, BC, Canada.<br />
(78)-78. Direct Healthcare Costs of Systemic Lupus Erythematosus<br />
and Predictors of Costs. Pantelis Panopalis 1 , Jinoos Yazdany 1 ,<br />
Joann Gillis 2 , Laura Julian 1 , Aimee Hersh 1 , Laura Trupin 1 ,<br />
Patricia Katz 1 , Ed Yelin 1 . 1 University of California, San<br />
Francisco, San Francisco, CA; 2 National Jewish Medical and<br />
Research Center, Denver, CO.<br />
(79)-79. The Direct Medical Expenditures and Work<br />
Productivity Costs to Employers for Patients with Systemic<br />
Lupus Erythematosus, in Comparison to Other High Cost and<br />
High Prevalence Conditions. Ronald J. Ozminkowski 1 , Tracy<br />
Li 2 , Shaohung Wang 3 , Ron Z. Goetzel 4 , Ross Maclean 2 .<br />
1<br />
Thomson Medstat, Ann Arbor, MI; 2 Bristol-Myers Squibb<br />
Company, Princeton, NJ; 3 Thomson Medstat, Cambridge,<br />
MA; 4 Thomson Medstat, Washington, DC.<br />
(80)-80. Costs and Benefits of Strategies for Treating New<br />
Onset Rheumatoid Arthritis within 12 Weeks. A. Finckh 1 , N.<br />
Bansback 2 , C. Marra 2 , A. H. Anis 2 , K. Michaud 3 , S. Lubin 2 ,<br />
M. White 4 , V. Gall 4 , M. H. Liang 4 . 1 Geneva University,<br />
Geneva, Switzerland; 2 University of British Columbia,<br />
Vancouver, BC, Canada; 3 University of Nebraska Medical<br />
Center, Omaha, NE; 4 Brigham and Women’s Hospital,<br />
Boston, MA.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 75
Poster Session A<br />
(81)-81. Cost-Effectiveness of Abatacept in Patients with<br />
Moderately to Severely Active Rheumatoid Arthritis and<br />
Inadequate Response to Tumor Necrosis Factor α Inhibitors.<br />
Montserrat Vera-Llonch 1 , Elena Massarotti 2 , Nancy<br />
Shadick 3 , Frederick Wolfe 4 , Rene Westhovens 5 , Ross<br />
Maclean 6 , Tracy Li 6 , Gerry Oster 1 . 1 Policy Analysis Inc.<br />
(PAI), Brookline, MA; 2 Tufts-New England Medical Center,<br />
Boston, MA; 3 Brighams & Women’s Hospital, Boston,<br />
MA; 4 National Data Bank for Rheumatic Diseases, Wichita,<br />
KS; 5 University Hospital, Katholieke University, Leiden,<br />
Belgium; 6 Bristol-Myers Squibb, Princeton, NJ.<br />
(82)-82. The Impact of Anti-Tumor Necrosis Factors on Healthcare<br />
Costs in Patients with Immune Mediated Inflammatory Diseases.<br />
B. Tang 1 , M. Rahman 1 , J. J. Stephenson 2 , R. Quimbo 2 , H.<br />
Thompson 1 , O. Dabbous 1 . 1 Centocor, Inc., Horsham, PA;<br />
2<br />
HealthCore, Inc., Wilmington, DE.<br />
(83)-83. Modeling Cost-Effectiveness of Abatacept versus<br />
Infliximab in Patients with Rheumatoid Arthritis (RA) in the<br />
U.S.. Y. Yuan 1 , Z. Wang 2 , M. Kim 2 , R. Maclean 3 . 1 Health<br />
Information Science, Bristol-Myers Squibb, Plainsboro, NJ;<br />
2<br />
US Outcomes Research, Bristol-Myers Squibb, Plainsboro,<br />
NJ; 3 GEOR, Bristol-Myers Squibb, Princeton, NJ.<br />
(84)-84. Cost-Effectiveness of Total Knee Replacement (TKR) in<br />
the U.S.: Impact of Patient Risk and Hospital Volume. Elena<br />
Losina 1 , Courtenay L. Kessler 1 , Rochelle P. Walensky 2 ,<br />
Parastu S. Emrani 1 , William M. Reichmann 1 , Elizabeth A.<br />
Wright 1 , Daniel H. Solomon 1 , A. David Paltiel 3 , Edward<br />
Yelin 4 , Jeffrey N. Katz 1 . 1 Brigham and Women’s Hospital,<br />
Boston, MA; 2 Massachusetts General Hospital and Brigham<br />
and Women’s Hospital, Boston, MA; 3 Yale University<br />
School of Medicine, New Haven, CT; 4 University of<br />
California, San Francisco, San Francisco, CA.<br />
(85)-85. Cost Effectiveness of Traditional Chinese Acupuncture<br />
as Adjunctive Therapy in Osteoarthritis (OA) of the Knee. Sonia<br />
Yousuf 1 , Kevin D. Frick 2 , Marc Hochberg 1 , Lixing Lao 1 ,<br />
Brian Berman 1 , Christine Spencer 2 , Donald Steinwachs 2 .<br />
1<br />
University of Maryland, Baltimore, MD; 2 Bloomberg<br />
School of Public Health, Baltimore, MD.<br />
(86)-86. Time to Disease Modifying Anti-Rheumatic Drug<br />
Treatment in a National, Multi-Centre, Historical Inception<br />
Cohort of Randomly Selected, Early Rheumatoid Arthritis. Ruben<br />
Tavares 1 , George Tomlinson 1 , Gilles Boire 2 , Andreas<br />
Laupacis 1 , Claire Bombardier 1 , UNCOVER Investigators.<br />
1<br />
University of Toronto, Toronto, ON, Canada;<br />
2<br />
Universite� de Sherbrooke, Sherbrooke, PQ, Canada.<br />
(87)-87. Logistic Regression Modeling and Bootstrap Validation<br />
of Predictors of Early Treatment with Disease Modifying<br />
Anti-Rheumatic Drugs (DMARDs) in a National, Multi-<br />
Centre, Historical Inception Cohort of Randomly Selected,<br />
Early Rheumatoid Arthritis (RA). Ruben Tavares 1 , George<br />
Tomlinson 1 , Gilles Boire 2 , Andreas Laupacis 1 , Claire<br />
Bombardier 1 , UNCOVER Investigators. 1 University<br />
of Toronto, Toronto, ON, Canada; 2 Universit�e de<br />
Sherbrooke, Sherbrooke, PQ, Canada.<br />
(88)-88. Rheumatologic Clinical Management in a National,<br />
Multi-Centre, Historical Inception Cohort of Randomly Selected<br />
Early Rheumatoid Arthritis (RA). Ruben Tavares 1 , Gilles<br />
Boire 2 , George Tomlinson 1 , Andreas Laupacis 1 , Claire<br />
Bombardier 1 , UNCOVER Investigators. 1 University<br />
of Toronto, Toronto, ON, Canada; 2 Universit�e de<br />
Sherbrooke, Sherbrooke, PQ, Canada.<br />
(89)-89. Prevalence and Costs of Gout in Patients with Chronic<br />
Kidney Disease in a Privately Insured Population. Lisa A. Rocca<br />
Rey, Leslie J. Hinyard, Mark A. Schnitzler. Saint Louis<br />
University, Saint Louis, MO.<br />
(90)-90. The Agreement with the Dutch Regulation for<br />
Reimbursement of Anti-tnfa for Patients with Rheumatoid Arthritis<br />
in Daily Clinical Practice Discussed. Wietske Kievit 1 , Eddy<br />
M. Adang 1 , Jaap Fransen 1 , Ina H. Kuper 2 , Mart AFJ van de<br />
Laar 2 , Dirk-Jan RAM de Rooij 3 , Carla MA De Gendt 4 , Karel<br />
H. Ronday 5 , Tim L. Jansen 6 , Piet CM van Ooijen 7 , Piet<br />
LCM van Riel 1 . 1 Radboud University Nijmegen Medical<br />
Centre, Nijmegen, The Netherlands; 2 Medisch Spectrum<br />
Twente, Enschede, The Netherlands; 3 Sint Maartenskliniek,<br />
Nijmegen, The Netherlands; 4 Rijnstate Hospital, Arnhem,<br />
The Netherlands; 5 Leyenburg Hospital, Den Haag, The<br />
Netherlands; 6 Medical Centre Leeuwarden, Leeuwarden,<br />
The Netherlands; 7 Jeroen Bosch Hospital, Den Bosch, The<br />
Netherlands.<br />
(91)-91. Arthritis-Related Drug Use in a Population Based<br />
Cohort: Are There Differences by Gender and Age?. Judith E.<br />
Fisher 1 , Peri J. Ballantyne 2 , Gillian A. Hawker 1 . 1 University<br />
of Toronto, Toronto, ON, Canada; 2 Trent University,<br />
Peterborough, ON, Canada.<br />
(92)-92. Why are People with Rheumatoid Arthritis (RA) not<br />
using DMARDs?-Understanding Gaps in Care. Diane Lacaille,<br />
Pamela Rogers. University of British Columbia; Arthritis<br />
Research Centre of Canada, Vancouver, BC, Canada.<br />
(93)-93. Nation-Wide Utilization of DMARDS in Patients with<br />
Rheumatoid Arthritis in the Veterans Health Administration<br />
(VHA). Gail Kerr 1 , John Williams 2 , C. Kent Kwoh 3 .<br />
1<br />
VAMC, Georgetown, Howard University, Washington,<br />
DC; 2 University of Pennsylvannia, Philadelphia, PA;<br />
3<br />
Pittsburgh VAHS, University of Pittsburgh, Pittsburgh, PA.<br />
76 (Permanent Board Number)-Abstract Number
(94)-94. <strong>Scientific</strong> Validity of Clinical Practice Guidelines for<br />
the Use Oo Infliximab and Etanercept in Rheumatoid Arthritis.<br />
Maria A. Lopez-Olivo 1 , Michael A. Kallen 1 , Zulma Ortiz 2 ,<br />
Aimee K. Roundtree 1 , Becky Skidmore 3 , Maria Suarez-<br />
Almazor 1 . 1 UT MD Anderson Cancer Center, Houston,<br />
TX; 2 Academia Nacional de Medicina de Buenos Aires,<br />
Buenos Aires, Argentina; 3 The Society of Obstetricians and<br />
Gynaecologists of Canada, Ottawa, ON, Canada.<br />
(95)-95. Systematic Review of Reviews on the Use of Biologics<br />
for Rheumatoid Arthritis. Maria Suarez-Almazor 1 , Aimee K.<br />
Roundtree 1 , Michael A. Kallen 1 , Maria A. Lopez-Olivo 1 ,<br />
Zulma Ortiz 2 , Becky Skidmore 3 . 1 UT MD Anderson<br />
Cancer Center, Houston, TX; 2 Centro de Investigaciones<br />
Epidemiológicas, Academia Nacional de Medicina de Buenos<br />
Aires, Buenos Aires, Argentina; 3 The Society of Obstetricians<br />
and Gynaecologists of Canada, Ottawa, ON, Canada.<br />
(96)-96. Discontinuing, Switching, or Adding of Nonsteroidal<br />
Anti-Inflammatory Drugs among Osteoarthritis Patients. Clifton<br />
O. Bingham, III 1 , Kristijan H. Kahler 2 , Elizabeth L. Stanley 2 ,<br />
Douglas Gause 2 . 1 Johns Hopkins University, Baltimore, MD;<br />
2<br />
Novartis Pharmaceuticals Corporation, East Hanover, NJ.<br />
(97)-97. Underused Resources? People with Hip and Knee<br />
Pain do not Consult Health Care Professionals. Carina A.<br />
Thorstensson 1 , Rachael Gooberman-Hill 2 , Salma Ayis 2 ,<br />
Susan Williams 2 , Paul Dieppe 2 . 1 Spenshult Hospital for<br />
Rheumatic Diseases, Oskarström, Sweden; 2 MRC Health<br />
Service Research Collaboration, Department of Social<br />
Medicine, Bristol University, Bristol, United Kingdom.<br />
(98)-98. Effect of Adalimumab Combination Therapy on Work<br />
Performance: Results from a Companion Study to PREMIER.<br />
Ronald F. van Vollenhoven 1 , Gianfranco F. Farraccioli 2 ,<br />
Ferdinand C. Breedveld 3 , Saurabh Ray 4 , Mary Cifaldi 4 .<br />
1<br />
Karolinska University Hospital, Stockholm, Sweden;<br />
2<br />
Catholic University of Rome, Rome, Italy; 3 Leiden<br />
University Medical Center, Leiden, The Netherlands;<br />
4<br />
Abbott, Abbott Park, IL.<br />
(99)-99. Determinants of Return to Employment in Rheumatoid<br />
Arthitis (RA) in the United States from the CORRONA Registry.<br />
D. Ridley 1 , M. Cifaldi 2 , J. Greenberg 3 , O. Segurado 2 , S.<br />
Messing 4 , K. Johnson 4 , X. Tu 4 , E. Moreta 1 , J. Kremer 5 , V.<br />
Strand 6 . 1 St Paul Rheumatology, St Paul, MN; 2 Abbott,<br />
Abbott Park, IL; 3 NYU Hosp Jt Diseases, NY, NY; 4 Univ of<br />
Rochester, Rochester, NY; 5 Albany Med College, Albany,<br />
NY; 6 Stanford Univ, Palo Alto, CA.<br />
(100)-100. Short-Term Impact of Adalimumab on Productivity<br />
Outcomes in Patients with Rheumatoid Arthritis. Wei Zhang 1 ,<br />
Nick Bansback 1 , Daphne Guh 1 , Xin Li 2 , Bohdan Nosyk 1 ,<br />
Carlo A. Marra 1 , Aslam H. Anis 1 . 1 Centre for Health<br />
Evaluation and Outcome Sciences, Vancouver, BC, Canada;<br />
2<br />
Department of Health Care and Epidemiology, University<br />
of British Columbia, Vancouver, BC, Canada.<br />
(101)-101. Relationship Between Health-Related Quality of<br />
Life and Employment Outcomes During Adalimumab (ADA)<br />
Plus Methotrexate (MTX) Combination Therapy Versus MTX<br />
Monotherapy in Patients with Early Rheumatoid Arthritis.<br />
Miriam Kimel 1 , Mary Cifaldi 2 , Joseph Chmiel 2 , Naijun<br />
Chen 2 , Dennis Revicki 1 . 1 United Biosource Corporation,<br />
Bethesda, MD; 2 Abbott Laboratories, Abbott Park, IL.<br />
(102)-102. The Effects of Rheumatoid Arthritis on Work<br />
Performance and Retention in an Employed Population. R. C.<br />
Kessler 1 , J. R. Maclean 2 , M. Petukhova 1 , C. A. Sarawate 1 ,<br />
T. T. Li 2 , P. E. Stang 3 . 1 Harvard Medical School, Boston,<br />
MA; 2 Bristol-Myers Squibb, Lawrenceville, NJ; 3 620 Sentry<br />
Parkway, Blue Bell, PA.<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Fibromyalgia: Etiology and Treatment I<br />
(103)-103. Increased Frequency of the Minor Allele for beta-3<br />
Adrenergic Receptors in Individuals with Fibromyalgia and<br />
Related Syndromes. Daniel J. Clauw 1 , Inna Belfer 2 , Mitchell<br />
Max 2 , David A. Williams 1 , Richard H. Gracely 1 , Samuel A.<br />
McLean 3 , Richard E. Harris 1 , Andi Neely 4 , Eric Bair 4 , Luda<br />
Diatchenko 4 , William Maixner 4 . 1 Rheumatology, University<br />
of Michigan, Ann Arbor, MI; 2 NIH, NIDCR, Bethesda,<br />
MD; 3 Emergency Medicine, University of Michigan, Ann<br />
Arbor, MI; 4 Center for Sensory Disorders, UNC-Chapel<br />
Hill, Chapel Hill, NC.<br />
(104)-104. Catechol-O-Methyl Transferase (COMT) Gene<br />
Haplotypes in Mexican and Spaniard Patients with Fibromyalgia..<br />
Gilberto Vargas-Alarcon 1 , Jose-Manuel Fragoso 1 , David<br />
Cruz-Robles 1 , Angelica Vargas 1 , Alfonso Vargas 1 , Jose-<br />
Ignacio Lao-Villadoniga 2 , Ferran Garcia-Fructuoso 3 , Rashidi<br />
Springall 1 , Rafael Bojalil 1 , Manuel Ramos-Kuri 4 , Fernando<br />
Hernandez 4 , Manuel Martinez-Lavin 1 . 1 National Institute<br />
of Cardiology, Mexico, Mexico; 2 Echevarne Laboratory,<br />
Barcelona, Spain; 3 CIMA Clinic, Barcelona, Spain;<br />
4<br />
Panamerican University, Mexico, Mexico.<br />
(105)-105. Genetics Of Fibromyalgia: Results Of A Candidategene<br />
Approach Studies. Jacob N. Ablin 1 , Anat Bar - Shira 2 ,<br />
Michael Yaron 1 , Avi Orr - Urtreger 2 . 1 Institute of<br />
Rheumatology, Tel - Aviv Sourasky Medical Center and<br />
Sackler Faculty of Medicine, Tel - Aviv University, Tel<br />
- Aviv, Israel; 2 Institue of Genetics, Tel - Aviv Sourasky<br />
Medical Center and Sackler Faculty of Medicine, Tel - Aviv<br />
University, Tel - Aviv, Israel.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 77
Poster Session A<br />
(106)-106. Functional MRI (fMRI) Appears to Act as a<br />
Biomarker in Fibromyalgia (FM) by Identifying Neurobiological<br />
Correlates of Changes in Pain Over Time. David A. Williams,<br />
Rupal Patel, Linda Skalski, Samantha J. Chriscinske,<br />
Michael Rubens, Jeremy Lapedis, Richard E. Harris,<br />
Richard H. Gracely, Daniel J. Clauw. Rheumatology,<br />
University of Michigan, Ann Arbor, MI.<br />
(107)-107. Altered Regional Cerebral Blood Flow at Rest in<br />
an Animal Model of Fibromyalgia. S. E. Harte 1 , S. Kim 1 , D.<br />
J. Clauw 1 , T. J. Morrow 2 . 1 Rheumatology, University of<br />
Michigan, Ann Arbor, MI; 2 Neurology, VA Ann Arbor<br />
Healthcare System, Ann Arbor, MI.<br />
(108)-108. Functional MRI (fMRI) of Pain Processing is Stable<br />
over Time in Fibromyalgia (FM) Patients without Changes in<br />
Clinical Status. Rupal Patel, David A. Williams, Richard H.<br />
Gracely, Linda Skalski, Samantha J. Chriscinske, Gina Alesi,<br />
Daniel J. Clauw. Rheumatology, University of Michigan,<br />
Ann Arbor, MI.<br />
(109)-109. Significant Association between Changes in Glutamate<br />
Levels and fMRI BOLD Signal in the Posterior Insula of<br />
Fibromyalgia Patients. Michael C. Hsu 1 , Seong-Ho Kim 1 , Pia<br />
C. Sundgren 2 , Yuxi Pang 2 , Richard H. Gracely 1 , Daniel<br />
J. Clauw 1 , Richard E. Harris 1 . 1 Rheumatology, University<br />
of Michigan, Ann Arbor, MI; 2 Radiology, University of<br />
Michigan, Ann Arbor, MI.<br />
(110)-110. Variation in Glutamate and Glutamine Levels within<br />
the Inslula are associated with Improvements in Working Memory<br />
in Fibromyalgia (FM). Jennifer M. Glass 1 , Richard C. Harris 1 ,<br />
Pia C. Sundgren 2 , Yuxi Pang 2 , Richard H. Gracely 1 , Daniel<br />
J. Clauw 1 . 1 Rheumatology, University of Michigan, Ann Arbor,<br />
MI; 2 Radiology, University of Michigan, Ann Arbor, MI.<br />
(111)-111. Hysterectomy and Abdominal Surgery are More<br />
Frequently Performed in Fibromyalgia Patients than Controls.<br />
Robert S. Katz 1 , Sharon Ferbert 2 , Frank Leavitt 3 .<br />
1<br />
Rheumatology Associates, Rush University Medical Center,<br />
Chicago, IL; 2 Rheumatology Associates, Chicago, IL; 3 Rush<br />
University Medical Center, Chicago, IL.<br />
(112)-112. Effects of Sleep Restriction and Exercise Deprivation<br />
on Mood, Pain, Fatigue, Somatic Symptoms and Cognition in<br />
Healthy Adults. Jennifer M. Glass, Angela K. Lyden, Cathryn<br />
J. Byrne-Dugan, Kim H. Groner, Kirsten R. Ambrose, Peter<br />
J. Grace, Dave A. Williams, Richard H. Gracely, Daniel J. Clauw.<br />
Rheumatology, University of Michigan, Ann Arbor, MI.<br />
(113)-113. Post-Call Residents Manifest a Fibromyalgia-like<br />
Syndrome. Amanda Borham 1 , Rami Taha 2 , Francis Griffin 3 ,<br />
Naomi Schlesinger 1 . 1 UMDNJ/RWJMS, New Brunswick,<br />
NJ; 2 UMDNJ/RWJMSRosalind Franklin University,<br />
Chicago, IL; 3 UMDNJ/RWJMSMuhlenberg Regional<br />
Medical Center, Plainfield, NJ.<br />
(114)-114. Baseline Heart Rate Variability Predicts Changes<br />
in Pain and Cognition, but not Mood or Fatigue after Exercise<br />
and Sleep Restriction. Jennifer M. Glass, Angela K. Lyden,<br />
Cathryn J. Byrne-Dugan, Kim H. Groner, Kirsten R.<br />
Ambrose, Richard H. Gracely, David A. Williams, Daniel J.<br />
Clauw. Rheumatology, University of Michigan, Ann Arbor, MI.<br />
(115)-115. Working Memory in Fibromyalgia Patients: Impaired<br />
Function Caused by Distracting Information, Not Rapid Decay<br />
of Stored Information. Jennifer M. Glass 1 , Denise C. Park 2 ,<br />
Leslie J. Crofford 3 , Daryl Fougnie 4 , Daniel J. Clauw 1 .<br />
1<br />
Rheumatology, University of Michigan, Ann Arbor,<br />
MI; 2 Beckman Institute, University of Illinois, Urbana-<br />
Champaign, IL; 3 Rheumatology, University of Kentucky,<br />
Louisville, KY; 4 Vanderbilt University, Nashville, TN.<br />
(116)-116. Predictors of Persistent Moderate or Severe Neck<br />
and/or Back Pain 1 and 6 Months after Minor Motor Vehicle<br />
Collision. S. Schon 1 , S. A. McLean 1 , Y. Mistry 1 , E. M.<br />
Zaleski 1 , R. Swor 2 , D. Robinson 2 , M. R. Sochor 1 , CRH<br />
Newton 3 , I. Liberzon 4 , D. J. Clauw 5 . 1 Emergency Medicine,<br />
University of Michigan, Ann Arbor, MI; 2 Emergency<br />
Medicine, William Beaumont Hospital, Royal Oak, MI;<br />
3<br />
Emergency Medicine, St. Joseph Mercy Hospital, Ann<br />
Arbor, MI; 4 Pscyhiatry, University of Michigan, Ann Arbor,<br />
MI; 5 Rheumatology, University of Michigan, Ann Arbor, MI.<br />
(117)-117. Characteristics Associated with Neck Pain<br />
Persistence versus Recovery after Minor Motor Vehicle Collision.<br />
D. Robinson 1 , S. A. McLean 2 , R. Swor 1 , E. M. Zaleski 2 ,<br />
Y. Mistry 2 , Schon S 2 , M. R. Sochor 2 , CRH Newton 3 , I.<br />
Liberzon 4 , D. J. Clauw 5 . 1 Emergency Medicine, William<br />
Beaumont Hospital, Royal Oak, MI; 2 Emergency Medicine,<br />
University of Michigan, Ann Arbor, MI; 3 Emergency<br />
Medicine, St. Joseph Mercy Hospital, Ann Arbor, MI;<br />
4<br />
Psychiatry, University of Michigan, Ann Arbor, MI;<br />
5<br />
Rheumatology, University of Michigan, Ann Arbor, MI.<br />
(118)-118. Fibromyalgia: The Straight Spine Flies below the<br />
Radar. Robert S. Katz 1 , Frank Leavitt 2 . 1 Rheumatology<br />
Associates, Rush University Medical Center, Chicago, IL;<br />
2<br />
Rush University Medical Center, Chicago, IL.<br />
(119)-119. Intermittent Cervical Cord Compression and<br />
Fibromyalgia: A Common Co-Morbidity with Important<br />
Diagnostic and Treatment Implications. Andrew J. Holman.<br />
Pacific Rheumatology Research, Inc., Renton, WA.<br />
(120)-120. Ultrasonography and Pressure Algometry in evaluation<br />
of Achilles and Patella Tendons. Intra- and Inter Observer<br />
Variability. Ulrich Fredberg 1 , Mogens Pfeiffer-Jensen 2 , Lars<br />
Bolvig 2 , Niels T. Andersen 3 , Lone Hyldgaard 1 , Kristian<br />
Stengaard-Pedersen 2 . 1 Silkeborg Central Hospital, Silkeborg,<br />
Denmark; 2 Aarhus University Hospital, Aarhus, Denmark;<br />
3<br />
Aarhus University, Aarhus, Denmark.<br />
78 (Permanent Board Number)-Abstract Number
(121)-121. Accuracy of Physical Examination in the Evaluation<br />
of Impingement Syndrome diagnosed by MRI. Lucía Silva 1 ,<br />
Pilar Muñoz 1 , Mónica Fernández-Castro 1 , Javier R. Godo 1 ,<br />
José Campos 1 , Jesús Sanz 1 , Carmen Barbadillo 1 , Miguel<br />
Pastrana 2 , Isabel Millán 3 , José L. Andreu 1 . 1 Rheumatology<br />
Division. Hospital Universitario Puerta de Hierro, Madrid,<br />
Spain; 2 Radiology Division. Hospital Universitario Puerta<br />
de Hierro, Madrid, Spain; 3 Biostatistics Department.<br />
Hospital Universitario Puerta de Hierro, Madrid, Spain.<br />
(122)-122. Accuracy of Clinical Examination versus Magnetic<br />
Resonance Imaging and Arthroscopy for the Detection of Shoulder<br />
Pathology, a Validity Study. Andrew J K Ostor 1 , Graham<br />
Tytherleigh-Strong 1 , Philip W. Bearcroft 1 , Christine C.<br />
Richards 1 , A Toby Prevost 2 , Cathy A. Speed 1 , Brian L.<br />
Hazleman 1 . 1 Addenbrooke’s Hospital, Cambridge, United<br />
Kingdom; 2 General Practice and Primary Care Research<br />
Unit, Department of Public Health and Primary Care,<br />
Institute of Public Health, Forvie Site, Robinson Way,<br />
Cambridge, United Kingdom.<br />
(123)-123. Personal Characteristics Associated with Widespread<br />
Tenderness in the MOST Study. Neil A. Segal 1 , Janelle Regier 1 ,<br />
Jeffery Curtis 2 , Jingbo Niu 3 , James C. Torner 1 . 1 University of<br />
Iowa, Iowa City, IA; 2 University of Alabama at Birmingham,<br />
Birmingham, AL; 3 Boston University School of Medicine,<br />
Boston, MA.<br />
(124)-124. Inflammatory Fibromyalgia : Is It Real ?. Samy K.<br />
Metyas, Daniel Arkfeld, Glenn Ehresmann. LAC/USC, Los<br />
Angeles, CA.<br />
(125)-125. Can Clinicians Predict Neurally Mediated<br />
Hypotension and Postural Orthostatic Tachycardia Syndrome in<br />
Fibromyalgia Patients?. Kim D. Jones, Cinda Hugos, Samidha<br />
S. Bhat, Jessica M. Morea, Atul A. Deodhar, Robert M.<br />
Bennett. Oregon Health & Science University, Portland, OR.<br />
(126)-126. Musculoskeletal Symptoms and Signs Associated with<br />
Aromatase Inhibitor Therapy in Breast Cancer. Monika Mohan 1 ,<br />
Dina Dadabhoy 1 , Daniel J. Clauw 1 , N. Lynn Henry 1 , Daniel<br />
F. Hayes 1 , Vered Stearns 2 , Jon T. Giles 2 , Anna Maria<br />
Storniolo 3 , Dennis Ang 3 . 1 Rheumatology, University of<br />
Michigan, Ann Arbor, MI; 2 Johns Hopkins University,<br />
Baltimore, MD; 3 Indiana University, Indianapolis, IN.<br />
(127)-127. Trained Nurses can Safely and Efficiently Replace<br />
Rheumatologists in the Diagnosis of Fibromyalgia Syndrome: a<br />
Randomised Trial. Mariëlle EAL Kroese 1 , Guy JC Schulpen 1 ,<br />
Monique CM Bessems 1 , Hans L Severens 1 , Frans J Nijhuis 2 ,<br />
Piet P Geusens 1 , Robert BM Landewe 1 . 1 University Hospital<br />
Maastricht, Maastricht, The Netherlands; 2 University of<br />
Maastricht, Maastricht, The Netherlands.<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Cytokines, Mediators and Gene Regulation I<br />
(128)-128. Il-12 P35 Il12/23p40 and Il-23 P19 Subunit<br />
Expression in Temporal Arterial Lesions from Patients with<br />
GianT-Cell Arteritis (GCA). Georgina Espígol, Ester Lozano,<br />
Ana Garcia-Martinez, Marta Segarra, Jose Hernández-<br />
Rodríguez, Sergio Prieto, Josep M Grau, Maria C Cid,<br />
Vasculitis Research Unit. Department of Internal Medicine<br />
Hospital Clínic. University of Barcelona.. Hospital Clínic<br />
Barcelona, Barcelona, Spain.<br />
(129)-129. Different Role of IL-17 and IFNgamma in Fcgamma<br />
Receptor Mediated Cartilage Destruction during Immune Complexmediated<br />
Arthritis. Lilyanne C. Grevers, Peter L.E.M. van<br />
Lent, Marije I. Koenders, Annet W. Sloetjes, Wim B. van<br />
den Berg. Radboud University Nijmegen Medical Centre,<br />
Nijmegen, The Netherlands.<br />
(130)-130. A Potential Role For TNF-Like Weak Inducer of<br />
Apoptosis (TWEAK) in the Pathogenesis of Lupus Nephritis.<br />
Hua-Xin Gao 1 , Linda Burkly 2 , Sean R. Campbell 1 ,<br />
Bernhard Banas 3 , Moin Saleem 4 , Peter W. Mathieson 4 ,<br />
Jennifer Michaelson 2 , Chaim Putterman 1 . 1 Albert Einstein<br />
College of Medicine, Bronx, NY; 2 Biogen Idec, Cambridge,<br />
MA; 3 University of Regensburg, Regensburg, Germany;<br />
4<br />
University of Bristol, Bristol, United Kingdom.<br />
(131)-131. Differential Regulation of Cytokines by MKK3 and<br />
MKK6 in Synoviocytes: Complementary Signaling Pathways.<br />
Deepa R. Hammaker, David L. Boyle, Gary S. Firestein.<br />
UCSD School of Medicine, La Jolla, CA.<br />
(132)-132. Antagonizing RAGE Inhibits Immune Complex<br />
Induced IFNα Gene Signature in Human PBMC. Bo Chen,<br />
Su-Yau Mao, Yihong Yao, Chew-Shun Chang, Gary P.<br />
Sims, Partha Chowdhury, Laurent Audoly, Ronald Herbst,<br />
Herren Wu, Bahija Jallal, Peter Kiener, Anthony J. Coyle.<br />
MedImmune, Inc., Gaithersburg, MD.<br />
(133)-133. SIGLEC1, a Biomarker for Type-I-Interferon,<br />
Monitors Disease Activity and IFN-suppressive Therapy in SLE.<br />
Robert Biesen 1 , Cemal Demir 1 , Fidan Barchudarowa 1 ,<br />
Marta Steinbrich-Zoellner 2 , Marina Backhaus 1 , Joachim<br />
R. Gruen 2 , Thomas Haeupl 1 , Gerd-Ruediger Burmester 1 ,<br />
Andreas Radbruch 2 , Falk Hiepe 1 , Andreas Gruetzkau 2 .<br />
1<br />
Charité� Universit�ätsmedizin Berlin, Humboldt<br />
University of Berlin, Berlin, Germany; 2 German Arthritis<br />
Research Center, Berlin, Germany.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 79
Poster Session A<br />
(134)-134. TGF-β Superfamily Members and Cytokine<br />
Transcription Factor Genes in Scleroderma Lung Disease. Jan<br />
Lin 1 , Michael Kean 2 , Michael Roth 2 , James Wang 1 , James<br />
Chen 3 , Lillian F. Zhang 3 , Robert Elashoff 4 , Jonathan<br />
Goldin 5 , Philip Clements 1 , Donald Tashkin 2 , Daniel Furst 1 ,<br />
Ram R. Singh 1 . 1 Rheumatology, UCLA School of Medicine,<br />
Los Angeles, CA; 2 Pulmonary/Critical Care, UCLA School<br />
of Medicine, Los Angeles, CA; 3 UCLA, Los Angeles, CA;<br />
4<br />
Biomathematics, UCLA, Los Angeles, CA; 5 Radiology,<br />
UCLA School of Medicine, Los Angeles, CA.<br />
(135)-135. Anti-IL-1α/β Dual Variable Domain Immunoglobulin<br />
(DVD-Ig), a Novel Inhibitor of IL-1α and IL-1β is Efficacious<br />
in Mouse Collagen-Induced Arthritis Model. Anwar Murtaza,<br />
Shaughn Bryant, Suzanne Mathieu, Chengbin Wu, Tariq<br />
Ghayur, Lisa Olson, Lisa Schopf. Abbott Bioresearch<br />
Center, Worcester, MA.<br />
(136)-136. Y-320, a New Class of Immunomodulator, Inhibits<br />
IL-17 Production II. Y-320 Ameliorates Type II Collagen-Induced<br />
Arthritis in Mice and Monkeys. Noriko Sato, Koichi Oshita,<br />
Hirotoshi Kataoka, Noriyasu Seki, Kyoko Shimano, Kunio<br />
Sugahara, Kenji Chiba. Research Laboratory III, Immunology,<br />
Mitsubishi Pharma Corporation, Yokohama, Japan.<br />
(137)-137. Induction of Wnt Expression by Innate Immune<br />
Mechanisms in Inflamed Synovium. Jinseok Kim, Nicole Flores,<br />
Emily Grauel, Sasha Gardne, Maripat Corr. University of<br />
California, San Diego, La Jolla, CA.<br />
(138)-138. Enhanced Activation of Mitogen-Activated Protein<br />
Kinases in Rheumatoid Arthritis Synovial Tissue is Selectively<br />
Associated with Angiogenesis and Erosive Joint Disease. Daphne<br />
de Launay 1 , Tom Smeets 1 , Marjolein Vinkenoog 1 , Dion<br />
Groot 1 , David Trollinger 2 , Paul P. Tak 1 , Kris A. Reedquist 1 .<br />
1<br />
Academic Medical Centre, Amsterdam, The Netherlands;<br />
2<br />
Array BioPharma, Boulder, CO, Boulder, CO.<br />
(139)-139. IL-17 Induces MCP-1 Production Through PI3K and<br />
ERK Pathways in Peripheral Blood Differentiated Macrophages.<br />
Shiva Shahrara, Bo Shi, Richard Pope. Northwestern<br />
University, Feinberg School of Medicine, Chicago, IL.<br />
(140)-140. A Role of IL-15 in Maintaining IL-7Rαlow Memory<br />
CD8+ T Cells in Humans via Recovering the PI3K/AKT<br />
Pathway. Hang-Rae Kim, Kyung-A Hwang, Insoo Kang. Yale<br />
University School of Medicine, New Haven, CT.<br />
(141)-141. Evaluation of Gender Differences in T Cell Gene<br />
Expression by cDNA Microarray Analysis. Anura Hewagama,<br />
Dipak R. Patel, Faith M. Strickland, Bruce Richardson.<br />
University of Michigan, Ann Arbor, MI.<br />
(142)-142. Identification and Characterization of a Differentially<br />
Expressed Novel Gene Family in Activated Rheumatoid<br />
Arthritis Monocytes. Bruno Stuhlmuller 1 , Lorena Matinez-<br />
Gamboa 1 , Dr. Nikolaus Machuy 2 , Thomas Haupl 1 , Thomas<br />
Rudel 2 , Gerd R. Burmester 1 . 1 Rheumatology and clinical<br />
Immunology; Charite University Hospital, Berlin, Germany;<br />
2<br />
Max-Planck Institute of Infection Biology, Berlin, Germany.<br />
(143)-143. Role of Hypoxia and cAMP in the Transdifferentiation<br />
of Human Fetal Cardiac Fibroblasts in Amplifying the<br />
Scarring Effect of Anti-Ro Antibodies in Congenital Heart<br />
Block. Marguerita O’Mahoney, Peter Izmirly, Ping Zheng,<br />
Lawrence Gardner, Jiri Zavadil, Robert M. Clancy, Jill P.<br />
Buyon. NYU School of Medicine, New York, NY.<br />
(144)-144. Signaling Pathways Involved in Trail- Induced Ra<br />
Synovial Fibroblast Cell Death, Proliferation, and Survival.<br />
Rachel Audo 1 , Hahne Michael 2 , Bernard Combe 3 , Jacques<br />
Morel 3 . 1 Institut de Génétique Moléculaire de Montpellier<br />
(CNRS), Montpellier, France; 2 Institut Génétique<br />
Moléculaire de Montpellier (CNRS), Montpellier, France;<br />
3<br />
Teaching hospital Lapeyronie, Montpellier, France.<br />
(145)-145. Protein Deacetylase Inhibitors Suppress Inflammatory<br />
Cytokine Production by Human Macrophages and Induce<br />
Apoptosis. Alek Grabiec, Sarah Krausz, Marjolein E. Sanders,<br />
Dion Groot, Paul P. Tak, Kris A. Reedquist. Academic<br />
Medical Centre / University of Amsterdam, Amsterdam,<br />
The Netherlands.<br />
(146)-146. Immunoregulatory Role of RANKL-stimulated<br />
Dendritic Cells on Autoimmune Arthritis in MRL/lpr Mice.<br />
Takashi Izawa 1 , Naozumi Ishimaru 2 , Keiji Moriyama 3 ,<br />
Yoshio Hayashi 2 . 1 Department of Orthodontics and<br />
Dentofacial Orthopedics, Institute of Health Biosciences,<br />
Tokushima University, Graduate School, Tokushima,<br />
Japan; 2 Department of Oral Molecular Pathology, Institute<br />
of Health Biosciences, Tokushima University, Graduate<br />
School, Tokushima, Japan; 3 Department of Maxillofacial<br />
Orthognathics, Tokyo Medical and Dental University,<br />
Graduate School, Tokyo, Japan.<br />
(147)-147. The Adipokine Visfatin and its Influence on the<br />
Inflammatory State in Rheumatoid Arthrits. Florian MP Meier 1 ,<br />
Anette Knedla 1 , Stephanie Lefèvre 1 , Klaus Frommer 1 ,<br />
Andreas Schäffler 2 , Christa Büchler 2 , Jürgen Steinmeyer 3 ,<br />
Henning Stürz 4 , Steffen Gay 5 , Ulf Müller-Ladner 1 , Elena<br />
Neumann 1 . 1 Dept Int Med and Rheumatology, Justus-<br />
Liebig-University of Gießen, Bad Nauheim, Germany;<br />
2<br />
Internal Med I, University of Regensburg, Regensburg,<br />
Germany; 3 Dept Exp Orthopedics, Justus-Liebig-University<br />
Gießen, Gießen, Germany; 4 Dept Orthopedics, Justus-<br />
Liebig-University Gießen, Gießen, Germany; 5 Ctr Exp<br />
Rheumatology, USZ, Zürich, Switzerland.<br />
80 (Permanent Board Number)-Abstract Number
(148)-148. Differential Activation of c-Jun N-terminal Kinase<br />
(JNK) In Synoviocytes by MKK4 and MKK7. Toshio<br />
Yoshizawa, Deepa Hammaker, David L. Boyle, Gary S.<br />
Firestein. UCSD School of Medicine, La Jolla, CA.<br />
(149)-149. Elucidation of Promoters for Disease-Regulated Gene<br />
and Cell-Based Therapy for Rheumatoid Arthritis. Jeroen Geurts,<br />
Onno J. Arntz, Annemiek van Raaij, Miranda B. Bennink,<br />
Nozomi Takahashi, Leo A.B. Joosten, Wim B. van den<br />
Berg, Fons A.J. van de Loo. Radboud University Nijmegen<br />
Medical Centre, Nijmegen, The Netherlands.<br />
(150)-150. Conditional Expression of IL-10 in Th1, Tr1 and Th2<br />
lymphocytes. Hyun-Dong Chang, Jun Dong, Inka Albrecht,<br />
Juliana Koeck, Susan Brandenburg, Alexander Scheffold,<br />
Andreas Thiel, Andreas Radbruch. German Rheumatism<br />
Research Center Berlin, Berlin, Germany.<br />
(151)-151. The B Lymphocyte Factor (BLyS) in Castleman’s<br />
Disease. Damien Sène, Guislaine Carcelain, Aurélien Delluc,<br />
Marie Claude Diemert, Frédéric Charlotte, Claire Deback,<br />
Zahir Amoura, Jean Charles Piette, Patrice Cacoub. Pitie<br />
Salpetriere Hospital, Paris, Paris, France.<br />
(152)-152. Up-regulation of 150kDa Adenosine Deaminase that<br />
Act on RNA(ADAR1) Gene Expression and Altered Editing<br />
of ADAR2 Gene Transcripts in Physiologically Activated T<br />
Lymphocytes. Dama Laxminarayana 1 , Islam U. Khan 1 ,<br />
Banabihari Giri 1 , Charles E. Samuel 2 . 1 Section on<br />
Rheumatology and Immunology, Department of Internal<br />
Medicine, Wake Forest University School of Medicine,<br />
Winston Salem, NC; 2 Department of Molecular, Cellular<br />
and Developmental Biology, University of California, Santa<br />
Barbara, CA.<br />
(153)-153. DC-STAMP as a Surface Marker of Erosive vs Non-<br />
Erosive Arthritis. Kofi A. Mensah, Yahui Chiu, Colleen<br />
Hock, Christopher T. Ritchlin, Edward M. Schwarz.<br />
University of Rochester, Rochester, NY.<br />
(154)-154. In Active, Early Rheumatoid Arthritis, CXCR4+<br />
T Cells in Peripheral Blood are Up-Regulated, Partly Correlates<br />
to Disease Activity and a Potential Predictor of the Response<br />
to Methotrexate Treatment. Ib Hansen 1 , Torkell Ellingsen 1 ,<br />
Bjarne K. Møller 2 , Jan Krog 1 , Kim Hørslev-Petersen 3 , Merete<br />
L. Hetland 4 , Kristian Stengaard-Pedersen 1 . 1 Aarhus University<br />
Hospital - NBG, Århus, Denmark; 2 Aarhus University<br />
Hospital - Skejby, Århus, Denmark; 3 King Christian X’s<br />
Rheumatism Hospital, Gråsten, Denmark; 4 Copenhagen<br />
University Hospital in Hvidovre, Hvidovre, Denmark.<br />
(155)-155. Analysis of TWEAK Stimulation of Synovial<br />
Fibroblasts from RA and OA Patients. Timothy S. Zheng 1 ,<br />
Shawn Weng 1 , Suzanne Szak 1 , Linda Burkly 1 , Norm Allair 1 ,<br />
David Lee 2 . 1 Biogen Idec, Inc., Cambridge, MA; 2 Brigham<br />
Women’s Hospital, Boston, MA.<br />
(156)-156. The Anti-Inflammatory Adenosine A2a Receptor<br />
(a2aR) Modulates Production of Il-10 and Il-12 Via cAMP/<br />
PKA-Dependent and Independent Pathways. Khoa D. Nguyen,<br />
George G. Holz, Bruce N. Cronstein. NYU School of<br />
Medicine, New York, NY.<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Education<br />
(157)-157. Clinical and Professional Activity Engagement and<br />
Confidence of Nurse and Therapy Rheumatology Practitioners<br />
Entering a Post-Qualification Rheumatology Course. Alison<br />
Hammond. Derbyshire Royal Infirmary, Derby, United<br />
Kingdom.<br />
(158)-158. Pediatric Musculoskeletal (pMSK) Teaching in UK<br />
Medical Schools. Sharmila Jandial, Tim Rapley, Helen E.<br />
Foster. Newcastle University, Newcastle upon Tyne, United<br />
Kingdom.<br />
(159)-159. Identifying Patients Who Need Low Literacy Materials<br />
to Support Anti-Rheumatic Drug Decision Making. Richard<br />
W. Martin 1 , Lois A. Bader 2 , Andrew J. Head 1 , Emily J.<br />
Tubergen 3 , Margaret Holmes-Rovner 4 . 1 Michigan State<br />
University, College of Human Medicine, Grand Rapids,<br />
MI; 2 Michigan State University, College of Education, E.<br />
Lansing, MI; 3 Calvin College, Grand Rapids, MI; 4 Michigan<br />
State University, College of Human Medicine, E. Lansing, MI.<br />
(160)-160. Health Literacy in the General Population: Do Your<br />
Patients Actually Understand You?. Rachelle Buchbinder 1 ,<br />
Melissa Barber 1 , Margaret Staples 1 , Richard Osborne 2 .<br />
1<br />
Cabrini Hospital and Monash University, Malvern,<br />
Victoria, Australia; 2 AFV Centre for Rheumatic Diseases,<br />
University of Melbourne, Parkville, Victoria, Australia.<br />
(161)-161. Treatment Adherence and Use of Reminders in<br />
Patients with Rheumatic Disease. Maria A. Lopez-Olivo 1 ,<br />
Michael A. Kallen 1 , Marsha N. Richardson 1 , Araceli Garcia-<br />
Gonzalez 1 , Vanessa L. Cox 1 , Martin Lidsky 1 , Bernand<br />
Ng 1 , Donald Marcus 1 , John D. Reveille 2 , Maria Suarez-<br />
Almazor 1 . 1 UT MD Anderson Cancer Center, Houston,<br />
TX; 2 University of Texas Health Science Center at Houston,<br />
Houston, TX.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 81
Poster Session A<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Improving Quality of Care by Design, Redesign,<br />
and Innovation<br />
(162)-162. Benefits of Reporting Bone Density Results Directly<br />
to Patients. Teresa A. Fama 1 , Priscilla Carr 2 , Edward Leib 1 .<br />
1<br />
University of Vermont, Burlington, VT; 2 Central Vermont<br />
Medical Center, Berlin, VT.<br />
(163)-163. Maintenance of Improvement Seen at 6 Months<br />
over 5 Years in Patients with Rheumatoid Arthritis Treated in<br />
Standard Care According to a Policy of “Tight Control” using a<br />
Multidimensional Health Assessment Questinnaire (MDHAQ)<br />
and Routine Assessment of Patient Index Data (RAPID3) Scores<br />
at Each Visit. Theodore Pincus 1 , Christopher Swearingen 2 .<br />
1<br />
NYU-Hospital for Joint Diseases, New York, NY; 2 Medical<br />
University of South Carolina, Charleston, SC.<br />
(164)-164. Physician Estimate of Global Status in Patients<br />
with Rheumatoid Arthritis: Analysis of Intra-Observer and Inter-<br />
Observer Reliability. Theodore Pincus 1 , Martin Bergman 2 ,<br />
Yusuf Yazici 1 . 1 NYU-Hospital for Joint Diseases, New York,<br />
NY; 2 Rheumatology, Ridley Park, PA.<br />
(165)-165. Waiting Times for a Rheumatology Consultation<br />
in Canada. Robert J. McKendry. Rheumatology Research<br />
Associates, Ottawa, ON, Canada.<br />
(166)-166. Role Delineation of Rheumatology Physician<br />
Assistants. Roderick S. Hooker, Bavana V. Rangan, Jean Luc<br />
Seignon. Department of Veterans Affairs, Dallas, TX.<br />
(167)-167. Quality of Care for Veterans Diagnosed with<br />
Rheumatoid Arthritis. Dinesh Khanna, Alex Brown.<br />
University of Cincinnati, Cincinnati, OH.<br />
(168)-168. Variability of Disease Activity in Cryopyrin-Associated<br />
Periodic Syndromes (CAPS): Design of a Daily Health Assessment<br />
Form (DHAF) for Clinical Research. Hal Hoffman 1 , Scott<br />
Mellis 2 , Imogene Grimes 2 , Pavel Belomestnov 2 , Rebecca<br />
Schumacher 3 , Kimberly Harp 3 , David Stein 2 , Fred<br />
Wolfe 3 . 1 UCSD Division of Rheumatology,Allergy and<br />
Immunology, La Jolla, CA; 2 Regeneron Pharmaceuticals,<br />
Tarrytown, NY; 3 Data Bank for Rheumatic Diseases,<br />
Wichita, KS.<br />
(169)-169. A Proposed Model of Organizing an Ankylosing<br />
Spondylitis Out-Patient Clinic Based on the Use of Non-Medical<br />
Health Workers and a Custom-Made Clinical Computer Decision<br />
Support and Report System. Glenn Haugeberg 1 , Hanne<br />
Vestaby 1 , Knut Mikkelsen 2 , Erik Rodevand 3 , Johan Fredrik<br />
Skomsvoll 3 , Villy Johnsen 1 , Dag Magne Soldal 1 . 1 Sørlandet<br />
Hospital, Kristiansand, Norway; 2 Lillehammer Hospital<br />
for Rheumatic Diseases, Lillehammer, Norway; 3 St.Olavs<br />
Hospital, Trondheim, Norway.<br />
(170)-170. Development and Validation of a U.S. Lupus Specific<br />
Patient Reported Outcome Measure. Meenakshi Jolly 1 , A.<br />
Simon Pickard 2 , C. Wilke 2 , H. W. Lin 2 , S. Khandelwal 1 ,<br />
R. Rodby 1 , J. A. Block 1 . 1 Rush University Medical Center,<br />
Chicago, IL; 2 University Of Illinois at Chicago, Chicago, IL.<br />
(171)-171. Satisfaction with Care and Health Status in Lupus.<br />
M. Jolly 1 , A. S. Pickard 2 , C. Wilke 2 , S. Khandelwal 1 , R.<br />
Rodby 1 , Louis Fogg 1 , J. A. Block 1 . 1 Rush University Medical<br />
Center, Chicago, IL; 2 University Of Illinois at Chicago,<br />
Chicago, IL.<br />
(172)-172. Evaluation of a National Community-Based<br />
Educational Intervention to Improve Primary Health Care<br />
Management of Arthritis: Impact on Patients. Elizabeth Badley,<br />
Dr., Sydney Lineker, Ms., Paula Veinot, Ms., Kunyong Xu,<br />
Mr., Mary Bell, Dr.. Toronto Western Research Institute,<br />
Toronto, ON, Canada.<br />
(173)-173. A New Composite Measure for Assessing RA<br />
Activity in Clinical Practice. Roy M. Fleischmann 1 , Michael<br />
H. Schiff 2 , Edward C. Keystone 3 , Philip J. Mease 4 , Orrin<br />
M. Troum 5 , Michael E. Weinblatt 6 . 1 University of Texas<br />
Southwestern Medical Center at Dallas, Dallas, TX; 2 Denver<br />
Arthritis Clinic, PC, Denver, CO; 3 University of Toronto,<br />
Toronto, ON, Canada; 4 Seattle Rheumatology Associates,<br />
Seattle, WA; 5 Keck School of Medicine of the University<br />
of Southern California, Santa Monica, CA; 6 Brigham and<br />
Women’s Hospital, Boston, MA.<br />
(174)-174. Factors Predicting Work Loss and Productivity<br />
Impairment Using Worker Productivity and Impairment<br />
Questionnaire in Patients with Rheumatoid Arthritis. B. Tang 1 ,<br />
M. Rahman 1 , H. Thompson 1 , O. Dabbous 1 , A. Naim 1 , C.<br />
Han 2 . 1 Centocor, Inc., Horsham, PA; 2 Centocor Research<br />
and Development, Inc., Malvern, PA.<br />
(175)-175. Educating Physicians in Training about Billing<br />
Resulted in Improved Reimbursement at a Urban Safety-Net<br />
Hospital. Joel Hirsh, Edward Gardner. Denver Health<br />
Medical Center, Denver, CO.<br />
(176)-176. An Internet-Based Wellness Intervention for<br />
Fibromyalgia: Statistical vs. Clinical Outcomes. Joan C.<br />
Rogers 1 , Margo B. Holm 1 , Terence W. Starz 2 . 1 University<br />
of Pittsburgh, Pittsburgh, PA; 2 University of Pittsburgh<br />
Medical Center, Pittsburgh, PA.<br />
(177)-177. Introduction of Safety Technologies to Physician-<br />
Performed Procedures in Rheumatology. Courtney R. Johnson,<br />
Kye S. Park, Gautam R. Moorjani, Adrian A. Michael,<br />
Wilmer L. Sibbitt, Jr., Arthur D. Bankhurst. University of<br />
New Mexico Health Sciences Center, Albuquerque, NM.<br />
(178)-178. Development of the <strong>ACR</strong> Early Inflammatory Arthritis<br />
Screening Tool. Mary J. Bell. Sunnybrook Health Sciences<br />
Centre, Toronto, ON, Canada.<br />
82 (Permanent Board Number)-Abstract Number
(179)-179. Are Joint and Soft Tissue Injections Painful? A<br />
French National Prospective Survey of Rheumatological Practice<br />
Concerning 8446 Patients. Serge Perrot 1 , Catherine Payen-<br />
Champenois 2 , Coralie Poncet 3 . 1 Internal Medicine, Hotel<br />
Dieu, Paris 5 Descartes University, Paris, France; 2 BMS,<br />
Rueil-Malmaison, France; 3 BMS, Rueil Malmaison, France.<br />
(180)-180. Development of a Cytokine-Based Laboratory Test<br />
of Disease Activity for Rheumatoid Arthritis Patients. Nicholas<br />
Knowlton 1 , Mary Turner 1 , Christopher Sutton 2 , Thuan<br />
Nguyen 1 , Patrick Floyd 2 , Parima Pathipvanich 1 , Toni<br />
Woodard 1 , Mary Nguyen 1 , Liberty Gonzeles 1 , Amber<br />
Martinez 1 , Christine Codding 3 , Larry Willis 4 , Eugene<br />
Arthur 4 , Don Flinn 4 , Craig Carson 5 , Anna Kumar 5 , Robert<br />
Hynd 4 , Michael Centola 1 . 1 Oklahoma Medical Research<br />
Foundation, Oklahoma City, OK; 2 Rigen Inc., Oklahoma<br />
City, OK; 3 Codding Clinic, Oklahoma City, OK; 4 McBride<br />
Clinic, Oklahoma City, OK; 5 Oklahoma Arthritis Center,<br />
Oklahoma City, OK.<br />
(181)-181. Performance Analysis of a Fully Automated Anti-CCP<br />
Assay at an Independent Field Site. Stephanie J. Ott, Daya<br />
Parsa, Mathangi Sritharan, Ronald Whisler, Michael Bissell.<br />
The Ohio State University, Columbus, OH.<br />
(182)-182. Social Isolation in Rheumatic Patients- The Doctor<br />
and Patient Perspectives. Florian Berghea 1 , Mihaela Minea 1 ,<br />
Alina Stoica 1 , Cosmin Constantinescu 1 , Camelia E.<br />
Berghea 2 , Andra R. Balanescu 1 , Maria Iacob 3 , Violeta<br />
M. Vlad 1 , Violeta Bojinca 1 , Bogdan Stanescu 1 , Simona<br />
Libianu 1 , Denisa Predeteanu 1 , Ruxandra M. Ionescu 1 .<br />
1<br />
RCRD Research Center, Bucharest, Romania; 2 Carol<br />
Davila University of Medicine, Bucharest, Romania; 3 ATM,<br />
Bucharest, Romania.<br />
(183)-183. Effect of Depression and Social Support on the Self-<br />
Reported Adherence in Patientes with Rheumatic Diseases. Maria<br />
A. Lopez-Olivo 1 , Michael A. Kallen 1 , Marsha Richardson 1 ,<br />
Araceli Garcia-Gonzalez 1 , Vanessa L. Cox 1 , Martin Lidsky 1 ,<br />
Bernard Ng 1 , Donald Marcus 1 , Maria Suarez-Almazor 1 , John<br />
D. Reveille 2 . 1 UT MD Anderson Cancer Center, Houston,<br />
TX; 2 University of Texas Health Science Center at Houston,<br />
Houston, TX.<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Osteoarthritis: Clinical Aspects I<br />
(184)-184. Medial-Wedge Insole is Effective in the Treatment<br />
of Valgus Knee Osteoarthritis. Priscilla T. Rodrigues, Ana F.<br />
Ferreira, Rosa M R Pereira, Eloísa Bonfá, Eduardo F. Borba,<br />
Ricardo Fuller. Rheumatology Division, University of São<br />
Paulo, São Paulo, Brazil.<br />
(185)-185. The Rationale for the Differences in Lateral Wedge<br />
Outcomes for Knee Osteoarthritis in Japanese and Western<br />
Studies. Yoshitaka Toda, Noriko Tsukimura. Toda<br />
Orthopedic Rheumatology Clinic, Osaka, Japan.<br />
(186)-186. The Effects of Common Footwear on Dynamic Joint<br />
Loading in Osteoarthritis (OA) of the Knee. Mondira Sengupta,<br />
Rachel A. Mikolaitis, Robert M. Trombley, Joel A. Block,<br />
Najia Shakoor. Rush University Medical Center, Chicago, IL.<br />
(187)-187. Specialized Footwear Effectively Reduces Peak<br />
Dynamic Loads in Osteoarthritis of the Knee. Najia Shakoor,<br />
Roy Lidtke, Mondira Sengupta, Robert Trombley, Joel A.<br />
Block. Rush Medical College, Chicago, IL.<br />
(188)-188. Custom Shoe Inserts Induce Beneficial Long-Term<br />
Gait Adaptations in Medial Knee Osteoarthritis. Laura E.<br />
Thorp, Markus A. Wimmer, Dale R. Sumner, Roy Lidtke,<br />
Joel A. Block. Rush University Medical Center, Chicago, IL.<br />
(189)-189. Reduced Vibratory Perception at the Lower Extremity<br />
in Osteoarthritis of the Hip. Kristin J. Lee, Lisa Maskala-Streff,<br />
Rachel Mikolaitis, Joel A. Block, Najia Shakoor. Rush<br />
Medical College, Chicago, IL.<br />
(190)-190. Generalized Vibratory Perception Deficits in<br />
Osteoarthritis of the Knee. Kristin J. Lee, Marsha Teodori, Joel<br />
A. Block, Najia Shakoor. Rush Medical College, Chicago, IL.<br />
(191)-191. Hip Abductor Strengthening Reduces Medial Knee<br />
Loads and Palliates Knee Pain. Markus A. Wimmer, Laura<br />
E. Thorp, Kharma C. Foucher, Dale R. Sumner, Najia<br />
Shakoor, Joel A. Block. Rush University Medical Center,<br />
Chicago, IL.<br />
(192)-192. Site-specific Prevalence of Osteoarthritis (OA) in<br />
Two Prehispanic Mexican Populations. A Palaeopathologic<br />
Study. Rolando Espinosa-Morales 1 , Angelica Pena Ayala 1 ,<br />
Maria I. Segura-Esquivel 2 , L.R. Couoh-Hernandez 3 , J.<br />
Mansilla-Lory 3 , L.M. Amezcua-Guerra 2 , I. Leboreiro 3 , M.<br />
Martinez-Lavin 2 , Carlos Pineda 1 . 1 Instituto Nacional de<br />
Rehabilitacion, Distrito Federal, Mexico; 2 Instituto Nacional<br />
de Cardiologia, Distrito Federal, Mexico; 3 Museo Nacional<br />
de Antropologia e Historia, Distrito Federal, Mexico.<br />
(193)-193. How Do Pain and Disability Vary with<br />
Compartmental Distribution and Severity of Radiographic Knee<br />
Osteoarthritis?. Rachel Duncan, George Peat, Elaine Thomas,<br />
Elaine Hay, Peter Croft. Primary Care Musculoskeletal<br />
Research Centre, Keele, United Kingdom.<br />
(194)-194. Tibiofemoral Osteoarthritis Has Greater Impact on<br />
Pain and Function than Patellofemoral Osteoarthritis. Carina<br />
A. Thorstensson 1 , Maria L.E. Andersson 1 , Ingemar F.<br />
Petersson 2 . 1 Spenshult Hospital for Rheumatic Diseases,<br />
Oskarström, Sweden; 2 Clinical Sciences, Dept of<br />
Orthopaedics, Lund, Sweden.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 83
Poster Session A<br />
(195)-195. Psychological Factors and their Relation with<br />
Osteoarthritis (OA) Pain Flares. B. Wise 1 , N. Wang 1 , J. Niu 1 ,<br />
YQ Zhang 1 , JM Jordan 2 , E. Choy 3 , DJ Hunter 1 . 1 BUSM,<br />
Boston, MA; 2 UNC, Chapel Hill, NC; 3 King’s College,<br />
London, United Kingdom.<br />
(196)-196. Strength Does Not Alter Risk for Incident Knee<br />
Pain or Stiffness in the MOST Study. Neil A. Segal 1 , James<br />
C. Torner 1 , Jingbo Niu 2 , David Felson 2 , Leena Sharma 3 ,<br />
Michael Nevitt 4 , Cora Lewis 5 , for the Multicenter<br />
Osteoarthritis Study Group. 1 University of Iowa, Iowa City,<br />
IA; 2 BUSM, Boston, MA; 3 NWU, Chicago, IL; 4 UCSF, San<br />
Francisco, CA; 5 UAB, Birmingham, AL.<br />
(197)-197. Synovitis is Associated with Knee Pain in Those<br />
Without X-ray Knee OA. KR Baker 1 , AJ Grainger 2 , J. Niu 1 ,<br />
M. Clancy 1 , PG Conaghan 2 , L. Hughes 3 , JC Torner 4 , DT<br />
Felson 1 . 1 BUSM, Boston, MA; 2 U Leeds, Leeds, United<br />
Kingdom; 3 UAB, Birmingham, AL; 4 U Iowa, Iowa City, IA.<br />
(198)-198. Adipose Tissue Measures and Knee Pain Severity:<br />
The MOST Study. Laura B. Hughes 1 , Jingbo Niu 2 , Yuqing<br />
Zhang 2 , Mary T. Chang 3 , Michael CA Nevitt 4 , Cora E.<br />
Lewis 1 . 1 The University of Alabama at Birmingham,<br />
Birmingham, AL; 2 Boston University School of Medicine,<br />
Boston, MA; 3 The University of California San Francisco,<br />
San Francisco, CA; 4 Univeristy of California San Francisco<br />
San Francisco, CA.<br />
(199)-199. Low Vitamin D Levels are Associated with Greater<br />
Pain and Slow Walking Speed in Patients with Knee Osteoarthritis<br />
(KOA). Jun Wang 1 , Melynn Nuite 1 , Laura M. Wheeler 1 ,<br />
Prutha Badiani 1 , Johane Joas 1 , Erica L. McAdams 1 , Fletcher<br />
Jeremiah 1 , Michael P. Lavalley 2 , Bess Dawson-Hughes 3 ,<br />
Timothy E. McAlindon 1 . 1 Tufts-New England Medical<br />
Center, Boston, MA; 2 Boston University School of Public<br />
Health, Boston, MA; 3 Jean Mayer USDA HNRC on Aging,<br />
Boston, MA.<br />
(200)-200. Pre-Radiographic MRI Findings are Associated with<br />
Onset of Knee Pain: the MOST Study. M. Javaid 1 , J. Lynch 1 , I.<br />
Tolstykh 1 , A. Guermazi 2 , Roemer F 2 , J. Curtis 3 , N. Lane 1 ,<br />
D. Felson 2 , M. Nevitt 1 . 1 UCSF, San Francisco, CA; 2 BUSM,<br />
Boston, MA; 3 UAB, Birmingham, AL.<br />
(201)-201. Measures of Proximal Hip Geometry are Associated<br />
with Prevalent and Incident Radiographic Hip Osteoarthritis<br />
Independently of aBMD. M. Javaid 1 , N. Lane 1 , K. Chaganti 2 ,<br />
D. Mackey 1 , L. Lui 1 , N. Arden 3 , T. Beck 4 , S. Cummings 1 , M.<br />
Nevitt 1 . 1 UCSF, San Francisco, CA; 2 HSS, New York, NY;<br />
3<br />
MRC ERC, Southampton, United Kingdom; 4 JHUSM,<br />
Baltimore, MD.<br />
(202)-202. Strong Association of Meniscal Maceration and<br />
Bone Marrow Lesions in Osteoarthritis. G. Lo 1 , D. Hunter 2 ,<br />
M. Nevitt 3 , J. Lynch 3 , T. McAlindon 1 . 1 Tufts University,<br />
Boston, MA; 2 Boston University, Boston, MA; 3 UCSF, San<br />
Francisco, CA.<br />
(203)-203. Strong Association Between Tibial Plateau Bone<br />
Mineral Density and Cartilage Damage. G. Lo 1 , C. Dumoulin-<br />
Richez 2 , M. Nuite 1 , L. Wheeler 1 , P. Badiani 1 , J. Joas 1 , E.<br />
McAdams 1 , B. Dawson-Hughes 3 , B. Caron 3 , T. McAlindon 1 .<br />
1<br />
Tufts University, Boston, MA; 2 Centre Hospitalier<br />
Universitaire de Bordeaux, Bordeaux, France; 3 Human<br />
Nutrition Research Center on Aging, Boston, MA.<br />
(204)-204. Meniscal Status and Its Correlation with Joint Effusion<br />
in Knees without Radiographic Osteoarthritis Evaluated by MRI.<br />
Frank W. Roemer, Ali Guermazi, David J. Hunter, Jingbo<br />
Niu, Yuqing Q. Zhang, Martin Englund, David T. Felson.<br />
Boston University, Boston, MA.<br />
(205)-205. Advanced Femorotibial Cartilage Damage and Its<br />
Correlation to Osteophytosis and Radiographic Osteoarthritis<br />
Assessed by MRI. Frank W. Roemer, Ali Guermazi, David J.<br />
Hunter, Tuhina Neogi, Jingbo Niu, David T. Felson. Boston<br />
University Medical School, Boston, MA.<br />
(206)-206. Cartilage Loss in Men and Women with X-Ray Defined<br />
End-Stage Knee Osteoarthritis. S. Amin 1 , J. Niu 2 , A. Guermazi 2 ,<br />
M. Grigoryan 3 , D. J. Hunter 2 , D. T. Felson 2 . 1 Mayo Clinic,<br />
Rochester, MN; 2 Boston University, Boston, MA; 3 UCSF,<br />
San Francisco, CA.<br />
(207)-207. Stepping Outside Of The Joint Margin: Is Ligament<br />
Pathology a Precursor to Knee OA?. Peter C. Grayson, Margaret<br />
Clancy, Piran Aliabadi, Burton Sack, David T. Felson.<br />
Boston University Medical Center, Boston, MA.<br />
(208)-208. Prevalence of Bone Attrition in Knee Radiographs<br />
and MRI in a Community Based Cohort. S. Reichenbach 1 , A.<br />
Guermazi 1 , J. Niu 1 , T. Neogi 1 , DJ Hunter 1 , F. Roemer 2 , CE<br />
McLennan 3 , G. Hernandez-Molina 1 , DT Felson 1 . 1 Clinical<br />
Epidemiology, BUSM, Boston, MA; 2 Klinikum Augsburg,<br />
Augsburg, Germany; 3 Hebrew Senior Life, Boston, MA.<br />
(209)-209. Magnetic Resonance Imaging Prevalence of Different<br />
Features of Knee Osteoarthritis in Persons with Normal Knee<br />
X-Rays. Ali Guermazi, David J. Hunter, Frank W. Roemer,<br />
Jingbo Niu, Tuhina Neogi, Christine E. McLennan, David<br />
T. Felson. Boston University School of Medicine, Boston, MA.<br />
(210)-210. Do Meniscal Tears, Laxity, and Malalignment Predict<br />
Subsequent Cartilage Loss in Osteoarthritic Knees?. Dipali<br />
Kapoor 1 , Felix Eckstein 2 , Dorothy Dunlop 1 , Jing Song 1 ,<br />
September Cahue 1 , Martin Hudelmaier 2 , Pottumarthi<br />
Prasad 1 , Meredith Marshall 1 , Ali Guermazi 3 , Leena Sharma 1 .<br />
1<br />
Northwestern University, Chicago, IL; 2 Paracelsus Medical<br />
University, Salzburg, Austria; 3 Boston University, Boston, MA.<br />
(211)-211. The Longitudinal Relationship between Specific<br />
Physical Tasks and Cartilage Loss by MRI in Persons with Knee<br />
Osteoarthritis. Alison Chang 1 , Jing Song 1 , Felix Eckstein 2 ,<br />
Dorothy Dunlop 1 , September Cahue 1 , Pottumarthi Prasad 1 ,<br />
Martin Hudelmaier 2 , Meredith Marshall 1 , Leena Sharma 1 .<br />
1<br />
Northwestern University, Chicago, IL; 2 Paracelsus Medical<br />
University, Salzburg, Austria.<br />
84 (Permanent Board Number)-Abstract Number
(212)-212. MRI-Based Identification of Which Tibiofemoral Joint<br />
Surfaces Lose Cartilage Concurrently - Has X-ray Led us Astray?.<br />
Leena Sharma 1 , Jing Song 1 , Felix Eckstein 2 , September<br />
Cahue 1 , Martin Hudelmaier 2 , Meredith Marshall 1 ,<br />
Pottumarthi Prasad 1 , Dorothy Dunlop 1 . 1 Northwestern<br />
University, Chicago, IL; 2 Paracelsus Medical University,<br />
Salzburg, Austria.<br />
(213)-213. Clinical Risk Factors, Symptoms and Signs Can<br />
Identify Persons with Radiographic Knee Osteoarthritis: the<br />
MOST Study. J. R. Curtis 1 , J. Niu 2 , D. Felson 2 , M. Nevitt 3 ,<br />
K. G. Saag 1 , N. Segal 4 , C. Lewis 1 . 1 UAB, Birmingham,<br />
AL; 2 BUSM, Boston, MA; 3 UCSF, San Francisco, CA;<br />
4<br />
University of Iowa, Iowa city, IA.<br />
(214)-214. Repetitive Activities Impact the Risk for Incident<br />
and Progressive Radiographic Osteoarthritis. J. R. Curtis 1 , D.<br />
Felson 2 , J. Hietpas 3 , M. Nevitt 3 , J. Niu 2 , C. Lewis 1 . 1 UAB,<br />
Birmingham, AL; 2 BUSM, Boston, MA; 3 UCSF, San<br />
Francisco, CA.<br />
(215)-215. Change in Cartilage Morphometry: A Sample of the<br />
Progression Cohort of the Osteoarthritis Initiative (OAI). DJ<br />
Hunter 1 , J. Niu 1 , YQ Zhang 1 , S. Totterman 2 , J. Tamez 2 ,<br />
C. Dabrowski 3 , R. Davies 3 , MP Hellio Le Graverand-<br />
Gastineau 4 , M. Luchi 5 , Y. Tymofyeyev 6 , C. Beals for the OAI<br />
Investigators 6 . 1 Boston University Medical Center, Boston,<br />
MA; 2 VirtualScopics, Rochester, NY; 3 GSK, Collegeville,<br />
PA; 4 Pfizer, Ann Arbor, MI; 5 Novartis, East Hanover, NJ;<br />
6<br />
MERCK, Rahway, NJ.<br />
(216)-216. Knee Malalignment: Risk Factor for, or Part of<br />
Disease Progression. D. J. Hunter 1 , J. Niu 1 , DT Felson 1 , M.<br />
LaValley 1 , WF Harvey 1 , P. McCree 1 , A. Guermazi 1 , S.<br />
Amin 2 , D. Gale 3 , YQ Zhang 1 . 1 Boston University Medical<br />
Center, Boston, MA; 2 Mayo Clinic, Rochester, MN;<br />
3<br />
VirtualScopics, Rochester, NY.<br />
(217)-217. Cross Sectional Analysis of dGEMRIC Measurements<br />
in a Multicenter, Multivendor MRI Study at 3.0 T- The<br />
A9001140 Study. Nitya Krishnan 1 , Bradley Wyman 2 , Robert<br />
Buck 3 , Marie-Pierre Hellio 3 , Brandon Mikulis 1 , Jose Tamez 4 ,<br />
Saara Totterman 4 , Charles McKenzie 1 , Deborah Burstein 1 .<br />
1<br />
Beth Israel Deaconess Medical Center, Boston, MA;<br />
2<br />
Pfizer Global Research and Development, Groton, CT;<br />
3<br />
Pfizer Global Research and Development, Ann Arbor, MI;<br />
4<br />
VirtualScopics, Rochester, NY.<br />
(218)-218. Six Month Longitudinal Change in dGEMRIC<br />
Measurements in a Multicenter, Multivendor MRI Study at 3.0<br />
T- The A9001140 Study. Bradley Wyman 1 , Robert Buck 1 ,<br />
Marie-Pierre Hellio 1 , Nitya Krishnan 2 , Charles McKenzie 2 ,<br />
Saara Totterman 3 , Cecil Charles 4 , Deborah Burstein 2 , Jose<br />
Tamez 3 . 1 Pfizer, Inc, Groton, CT; 2 Beth Israel Deaconess<br />
Medical Center, Boston, MA; 3 VirtualScopics, Rochester,<br />
NY; 4 Duke Image Analsyis Laboratory, Durham, NC.<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Pediatric Rheumatology: Clinical and Therapeutic Aspects I<br />
(219)-219. Neonatal-Onset Multisystem Inflammatory Disease<br />
(NOMID) and Weight Gain with IL-1 Blocking Therapy:<br />
Adiponectin’s Role in Control?. Patrick Kicker 1 , Francesco<br />
Celi 2 , Valentina Congedo 2 , Nicole Plass 1 , Tuyet-Hang<br />
Pham 1 , Raphaela Goldbach-Mansky 1 . 1 National Institute of<br />
Arthritis and Musculoskeletal and Skin Diseases, Bethesda,<br />
MD; 2 National Institute of Diabetes and Digestive and<br />
Kidney Diseases, Bethesda, MD.<br />
(220)-220. Safety and Efficacy Experience with Rilonacept (IL-1<br />
Trap) in Adolescents with Cryopyrin-Associated Periodic Syndromes<br />
(CAPS). Hal Hoffman 1 , Martin Throne 2 , Stephen Pollard 3 ,<br />
Imogene Grimes 4 , David Stein 4 , Scott Mellis 4 , Steve<br />
Weinstein 4 . 1 UCSD Division of Rheumatology,Allergy and<br />
Immunology, La Jolla, CA; 2 Radiant Research, Atlanta, GA;<br />
3<br />
Family Allergy &Asthma Research Assoc, Louisville, KY;<br />
4<br />
Regeneron Pharmaceuticals, Tarrytown, NY.<br />
(221)-221. Immunogenicity of Abatacept During a Doubleblind<br />
Randomized Withdrawal Study in Patients with Juvenile<br />
Idiopathic Arthritis (JIA). L. H. Sigal, J. Manning, S. Sinisi, H.<br />
Haggerty, A. J. Block. Bristol-Myers Squibb, Princeton, NJ.<br />
(222)-222. Alendronate Treatment of Pediatric Patients<br />
with Connective Tissues Disorders. A Ten Year Follow-Up<br />
Study. Rolando Cimaz 1 , Martina Biggioggero 2 , Antonella<br />
Boncompagni 3 , Fabrizia Corona 4 , Loredana Lepore 5 ,<br />
Francesco Zulian 6 , Francesca Nacci 7 , Matilde Beltramelli 4 ,<br />
Fernanda Falcini 1 , Maria Luisa Bianchi 2 . 1 Pediatric<br />
Rheumatology, Firenze, Italy; 2 Istituto Auxologico Italiano<br />
IRCCS, Milano, Italy; 3 Gaslini IRCCS, Genova, Italy;<br />
4<br />
Pediatric Rheumatology, Milano, Italy; 5 IRCCS Burlo<br />
Garofolo, Trieste, Italy; 6 Pediatric Rheumatology, Padova,<br />
Italy; 7 Rheumatology, Firenze, Italy.<br />
(223)-223. Pediatric Lupus Erythematosus: Long-Term Follow-Up<br />
and Prognostic Impact of Antiphospholipid Antibodies. Rolando<br />
Cimaz 1 , Elodie Descloux 2 , Isabelle Durieu 2 . 1 Pediatric<br />
Rheumatology, Firenze, Italy; 2 Internal Medicine, CHU,<br />
Lyon, France.<br />
(224)-224. Effective Treatment with IV Pamidronate in<br />
Chronic Recurrent Multifocal Osteomyelitis( CRMO)-Resolution<br />
of Pain, Normalization of Radiologic Abnormalities, and<br />
Improvement of Elevated Urine-N-Telopeptide (uNTX) : Case<br />
Series with 10 Patients. Paivi M. Miettunen, Deepak Kaura,<br />
Wei Xingchang, Walid Abou Reslan, James D. Kellner.<br />
University of Calgary, Calgary, AB, Canada.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 85
Poster Session A<br />
(225)-225. Etenercept is an Effective Therapeutic Option for<br />
Children with Juvenile Idiopathic Enthesitis Related Arthritis-<br />
Results from the German Etanercept Rergistry. Ivan Foeldvari 1 ,<br />
Gerd Ganser 2 , Johannes Roth 3 , Ralf Trauzeddel 4 , Dagmar<br />
Moebius 5 , Angelika Thon 6 , Renate Haefner 7 , Kristhina<br />
Mathony 8 , Angela Wierk 1 , Gerd Horneff 9 , For the Members<br />
of the German Etanercept Registry. 1 Hamburger Zentrum<br />
fur Kinder und Jugendrheumatologie, Hamburg, Germany;<br />
2<br />
St. Joseph Stift, Sendenhorst, Germany; 3 University<br />
Childrens Hospital, Berlin, Germany; 4 Klinikum Buch,<br />
Berlin, Germany; 5 Carl-Thiem- Klinikum, Cottbus,<br />
Germany; 6 University Childrens Hospital, Hannover,<br />
Germany; 7 Zentrum fur Kinder und Jugendrheumatologie,<br />
Garmisch-Partenkirchen, Germany; 8 University Childrens<br />
Hospital, Halle, Germany; 9 Kinderklinik St. Augustin,<br />
Sankt Augustin, Germany.<br />
(226)-226. Loss of Efficacy During Long-Term Infliximab Therapy<br />
for Sight-Threatening Childhood Uveitis. Gabriele Simonini 1 ,<br />
Fernanda Falcini 1 , Roberto Caputo 2 , Cinzia De Libero 2 ,<br />
Teresa Giani 1 , Maurizio de Martino 1 , Rolando Cimaz 1 .<br />
1<br />
Rheumatology Unit-Department of Pediatrics, Firenze,<br />
Italy; 2 Ophtalmologic Unit-Department of Pediatrics,<br />
Firenze, Italy.<br />
(227)-227. Development and Initial Validation of a New<br />
Composite Disease Activity Score for Juvenile Idiopathic Arthritis.<br />
Rosa Vitale 1 , Alessandro Consolaro 1 , Giovanni Filocamo 1 ,<br />
Bianca Lattanzi 1 , Elena Tsitsami 1 , Anna Baszo 1 , Clara<br />
Malattia 1 , Antonella Buoncompagni 1 , Angela Pistorio 1 ,<br />
Nicolino Ruperto 1 , Alberto Martini 2 , Angelo Ravelli 2 .<br />
1<br />
IRCCS G Gaslini, Genova, Italy; 2 IRCCS G Gaslini and<br />
Università di Genova, Genova, Italy.<br />
(228)-228. Outcomes in the Initial Treatment of Knee<br />
Monoarthritis in Juvenile Idiopathic Arthritis: Results of a<br />
Decision Analysis Model. T. Beukelman 1 , J. Guevara 1 , D. A.<br />
Albert 2 . 1 Children’s Hospital of Philadelphia, Philadelphia,<br />
PA; 2 Dartmouth-Hitchcock Medical Center, Lebanon, NH.<br />
(229)-229. Localized Scleroderma Disease Activity Index<br />
(LoSDAI) and Global Assessments: A Pilot Study of Outcome<br />
Instruments. Thaschawee Arkachaisri, Julie Spangler, Sally<br />
Pino. University of Pittsburgh, Pittsburgh, PA.<br />
(230)-230. Thermography-Based Quantitative Measure of Disease<br />
Activity in Localized Scleroderma: A Proof-of-Concept Study.<br />
Thaschawee Arkachaisri, Sally Pino, Julie Spangler, Steve J.<br />
Spalding. Children’s Hospital of Pittsburgh, University of<br />
Pittsburgh, Pittsburgh, PA.<br />
(231)-231. Outcome of Prospectively Followed Cohort from<br />
PRIDE (PR Interval and Dexamethasone Evaluation) in<br />
Congenital Heart Block (CHB). Deborah M. Friedman 1 , Mimi<br />
Kim 2 , Joshua Copel 3 , Claudine Davis 4 , Jill P. Buyon 4 . 1 St.<br />
Barnabas Medical Center, Livingston, NJ; 2 Albert Einstein<br />
College of Medicine, New York, NY; 3 Yale University<br />
School of Medicine, New Haven, CT; 4 New York University<br />
School of Medicine, New York, NY.<br />
(232)-232. Long-Term Psychosocial and Employment Outcomes of<br />
Children with Systemic Lupus Erythematosus. Aimee O. Hersh,<br />
Emily von Scheven, Pantelis Panopalis, Jinoos Yazdany,<br />
JoAnn Gillis, Laura Trupin, Laura Julian, Patricia Katz,<br />
Edward Yelin. University of California San Francisco, San<br />
Francisco, CA.<br />
(233)-233. Macrophage Activation Syndrome (MAS) in Juvenile<br />
Systemic Lupus Erythematosus (JSLE): An Underrecognized<br />
Complication?. Alessandro Parodi 1 , Sergio Davì 1 , Ilaria Sala 1 ,<br />
Alejandra Beatriz Pringe 2 , Paivi Miettunen 3 , Brigitte Bader-<br />
Meunier 4 , Graciela Espada 5 , Seza Ozen 6 , Dowain Wright 7 ,<br />
Claudia Saad Magalhães 8 , Raju Khubchandani 9 , Alexei<br />
Grom 10 , Nicolino Ruperto 1 , Alberto Martini 11 , Angelo<br />
Ravelli 11 . 1 IRCCS G Gaslini, Genova, Italy; 2 Hospital<br />
General de Ninos Pedro de Elizalde, Buenos Aires,<br />
Argentina; 3 Department of Pediatrics, Calgary, AB, Canada;<br />
4<br />
Hopital Necker Enfants Malades, Paris, France; 5 Hospital<br />
de Ninos Ricardo Gutierrez, Buenos Aires, Argentina;<br />
6<br />
Hacettepe University Children’s Hospital, Ankara, Turkey;<br />
7<br />
Children’s Hospital Central California, Madera, CA;<br />
8<br />
Hospital das Clinicas - Faculdade de Medicina de Botucatu,<br />
UNESP, Botucatu, Brazil; 9 Jaslok Hospital and Research<br />
Centre, Mumbay, India; 10 Cincinnati Children’s Hospital<br />
Medical Center, Cincinnati, OH; 11 IRCCS G Gaslini and<br />
Università di Genova, Genova, Italy.<br />
(234)-234. Urinary Proteomics: New Biological Markers for<br />
Systemic Lupus Erythematosus (SLE) Renal Disease. Michiko<br />
Suzuki 1 , Kristina Wiers 1 , Kathleen Haines 2 , Marissa<br />
Klein-Gitelman 3 , Judyann Olson 4 , Kathleen O’Neil 5 ,<br />
Kathleen Onel 6 , Murray Passo 1 , Nora Singer 7 , Lori Tucker 8 ,<br />
Shannen Nelson 1 , Prasad Devarajan 1 , Hermine I. Brunner 1 .<br />
1<br />
Cincinnati Children’s Hospital Medical Center, Cincinnati,<br />
OH; 2 Hackensack University Medical Center, Hackensack,<br />
NJ; 3 Children’s Memorial Hospital/NW Univ, Chicago,<br />
IL; 4 Medical College of Wisconsin, Milwaukee, WI; 5 OK<br />
University Health Science Center, Oklahmoma City, OK;<br />
6<br />
University of Chicago/La Rabida Children’s, Chicago, IL;<br />
7<br />
Rainbow Babies & Childrens Hospital, Cleveland, OH; 8 BC<br />
Children’s Hospital, Vancouver, BC, Canada.<br />
86 (Permanent Board Number)-Abstract Number
(235)-235. Neutrophil Gelatinase Associated Lipocalin (NGAL)<br />
in Plasma and Urine Change with Disease Activity in Pediatric<br />
Lupus (pSLE). Kristina Wiers 1 , Michiko Suzuki 1 , Kathleen<br />
Haines 2 , Marisa Klein-Gitelman 3 , Judyann Olson 4 ,<br />
Kathleen O’Neil 5 , Karen Onel 6 , Murray Passo 1 , Nora<br />
Singer 7 , Lori Tucker 8 , Jun Ying 9 , Shannen Nelson 1 , Prasad<br />
Devarajan 1 , Hermine Brunner 1 . 1 Cincinnati Children’s<br />
Hospital Medical Center, Cincinnati, OH; 2 Hackensack<br />
University Medical Center, Hackensack, NJ; 3 Children’s<br />
Memorial Hospital/NW Univ, Chicago, IL; 4 Medical<br />
College of Wisconsin, Milwaukee, WI; 5 OK University<br />
Health Science Center, Oklahoma City, OK; 6 University<br />
of Chicago/La Rabida Childrens, Chicago, IL; 7 Rainbow<br />
Babies & Childrens Hospital, Cleveland, OH; 8 BC<br />
Childrens Hospital, Vancouver, BC, Canada; 9 University of<br />
Cincinnati, Cincinnati, OH.<br />
(236)-236. Health-Related Quality of Life (HRQoL) and Its<br />
Relationship to Patient Disease Course in Pediatric Systemic<br />
Lupus Erythematosus (pSLE). Kristina Wiers 1 , Marisa S.<br />
Klein-Gitelman 2 , Gloria C. Higgins 3 , Shannen Nelson 1 , T.<br />
Brent Graham 1 , Jamie Meyers-Eaton 1 , Sivia K. Lapidus 4 ,<br />
Jay Nocton 5 , Karen Onel 6 , Judyann C. Olson 5 , Marilynn<br />
Punaro 7 , Hermine I. Brunner 1 . 1 Cincinnati Children’s<br />
Hospital Medical Center, Cincinnati, OH; 2 Children’s<br />
Memorial Hospital, Chicago, IL; 3 Columbus Children’s<br />
Hospital, Columbus, OH; 4 Alfred DuPont Children’s<br />
Hospital, Wilmington, NJ; 5 Ped/MACC Fund Research<br />
Ctr, Milwaukee, WI; 6 LaRabida Children’s Hospital,<br />
Chicago, IL; 7 Texas Scottish Rite Hospital, Dallas, TX.<br />
(237)-237. Pediatric Class IV Lupus Nephritis: Time to<br />
Renal Remission Predicts Renal Pathology after One Year of<br />
Cyclophosphamide Infusions. J. Frankovich, J. Hsu, P. Chira,<br />
T. Holmes, M. Troxell, L. Siddiqui, C. Sandborg. Stanford<br />
University, Stanford, CA.<br />
(238)-238. Pediatric Class IV Lupus Nephritis (LN): Predictors<br />
of Renal Flare. J. Hsu, J. Frankovich, P. Chira, T. Holmes,<br />
M. Troxell, L. Siddiqui, C. Sandborg. Stanford University,<br />
Stanford, CA.<br />
(239)-239. Cachectic Obesity in Pediatric Systemic Lupus<br />
Erythematosus. Tracey B. Wright 1 , Justine Shults 2 , Mary<br />
B. Leonard 1 , Babette S. Zemel 1 , Leslie Burnley 1 , Jon M.<br />
Burnham 1 . 1 The Children’s Hospital of Philadelphia,<br />
Philadelphia, PA; 2 University of Pennsylvania School of<br />
Medicine, Philadelphia, PA.<br />
(240)-240. Comparison of Inflammatory Mediator Profiles in<br />
Synovial Fluid from Pediatric Patients with Acute and Chronic<br />
Lyme Arthritis. Paul T. Fawcett, Carlos D. Rose, Victoria<br />
L. Maduskuie, AnneMarie C. Brescia. Alfred I. duPont<br />
Hospital for Children, Wilmington, DE.<br />
(241)-241. Gene Expression Profiles in an Expanded Cohort of<br />
Pediatric Lyme Arthritis. AnneMarie C. Brescia, Carlos D.<br />
Rose, Suzanne M. McCahan, Timothy Stetson, Paul T.<br />
Fawcett. AI duPont Hospital for Children, Wilmington, DE.<br />
(242)-242. Bone Morbidity in Glucocorticoid-treated Children<br />
with Chronic Rheumatic Disease (CRD). D. A. Cabral 1 , B.<br />
Lang 2 , P. B. Dent 3 , J. Ellsworth 4 , A. M. Huber 2 , C. LeBlanc 5 ,<br />
P. M. Miettunen 6 , K. Oen 7 , S. E. Ramsey 2 , C. Saint-Cyr 8 ,<br />
R. Scuccimarri 9 , J. Hay 10 , M. Matzinger 5 , N. Shenouda 5 ,<br />
L. M. Ward 5 , and the STOPP Consortium. 1 U of British<br />
Columbia, Vancouver, BC, Canada; 2 Dalhousie Univ,<br />
Halifax, NS, Canada; 3 McMaster Univ, Hamilton, ON,<br />
Canada; 4 U of Alberta, Edmonton, AB, Canada; 5 U of<br />
Ottawa, Ottawa, ON, Canada; 6 U of Calgary, Calgary, AB,<br />
Canada; 7 U of Manitoba, Winnipeg, MB, Canada; 8 U de<br />
Montréal, Montréal, PQ, Canada; 9 McGill Univ, Montréal,<br />
PQ, Canada; 10 Brock Univ, St. Catharines, ON, Canada.<br />
(243)-243. Fitness and Fatigue in Pediatric SLE. Kristin M.<br />
Houghton, James E. Potts, Lori B. Tucker. BC Children’s<br />
Hospital, Vancouver, BC, Canada.<br />
(244)-244. Anti-NR-2 Antibodies are Prevalent in Childhood-<br />
Onset SLE (cSLE), but Do Not Predict Neurocognitive<br />
Dysfunction. Deborah M. Levy 1 , Cynthia Aranow 2 , Alexandra<br />
I. Barsdorf 3 , Betty Diamond 2 . 1 Morgan Stanley Children’s<br />
Hospital of New York, Columbia University Medical<br />
Center, New York, NY; 2 The Feinstein Institute for Medical<br />
Research, Manhasset, NY; 3 Columbia University Medical<br />
Center, New York, NY.<br />
(245)-245. Adapted Versions of the Sharp-Van Der Heijde<br />
Score are Reliable and Valid for Assessment of Radiographic<br />
Progression in Juvenile Idiopathic Arthritis. Juliana Sato 1 , Maka<br />
Ioseliani 1 , Ximena Norambuena 1 , Angela Pistorio 1 , Federica<br />
Rossi 1 , Nicolino Ruperto 1 , Silvia Magni-Manzoni 2 , Nicola<br />
Ullmann 1 , Alberto Martini 1 , Angelo Ravelli 1 . 1 IRCCS G<br />
Gaslini, Genova, Italy; 2 IRCCS Policlinico San Matteo,<br />
Pavia, Italy.<br />
(246)-246. Early Diagnosis of Temporomandibular Joint<br />
Involvement in Juvenile Idiopathic Arthritis: A Pilot Study<br />
Comparing Clinical Examination and Ultrasound to Magnetic<br />
Resonance Imaging. Rotraud K. Saurenmann 1 , Lukas Müller 2 ,<br />
Timo Peltomäki 2 , Dominik Ettlin 2 , Thomas Schraner 3 ,<br />
Isabel Bolt 1 , Christian J. Kellenberger 3 . 1 Rheumatology,<br />
Zürich University Children’s Hospital, Zürich, Switzerland;<br />
2<br />
Clinic for Orthodontics and Pediatric Dentistry, University<br />
of Zürich, Zürich, Switzerland; 3 Diagnostic Imaging, Zürich<br />
University Childrens Hospital, Zürich, Switzerland.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 87
Poster Session A<br />
(247)-247. High Prevalence of Temporomandibular Joint<br />
Arthritis at Disease Onset in Children with Juvenile Idiopathic<br />
Arthritis as Detected by MRI but not by Ultrasound. Pamela F.<br />
Weiss, Bita Arabshahi, Ann Johnson, Larissa T. Bilaniuk,<br />
Chris Feudtner, Randy Q. Cron. Childrens Hospital of<br />
Philadelphia, Philadelphia, PA.<br />
(248)-248. High prevalence of Algic-Dysfunctional Pathology of<br />
Masticatory Muscles in Children with Juvenile Idiopathic Arthritis<br />
(JIA). Claudia Bracaglia, Antonio Pietrobattista, Alfredo<br />
Niccoli, Paola Sabrina Buonuomo, Elisabetta Cortis,<br />
Alberto G. Ugazio. Ospedale Pediatrico Bambino Gesù<br />
IRCCS, Roma, Italy.<br />
(249)-249. Different Pattern of Il-1β Secretion and Response<br />
to Anti Il-1 Treatment in Patients with Systemic Onset Juvenile<br />
Idiopathic Arthritis (SoJIA). Marco Gattorno 1 , Giacomo<br />
Brisca 1 , Francesca Ferlito 1 , Sara Tassi 2 , Sonia Carta 2 ,<br />
Laura Delfino 1 , Maria Antonietta Pelagatti 1 , Antonella<br />
Buoncompagni 1 , Denise Lasigliè 1 , Stefania Viola 1 , Anna<br />
Loy 1 , Angelo Ravelli 1 , Anna Rubartelli 2 , Alberto Marini 1 .<br />
1<br />
G. Gaslini, Genoa, Italy; 2 Institute for Cancer Research,<br />
Genoa, Italy.<br />
(250)-250. Is Ultrasound a Valid Method for Assessment of<br />
Intra-Articular Cartilage Thickness in Children. Anne Helene<br />
Spannow 1 , Elisabeth Stenboeg 1 , Mogens Pfeiffer-Jensen 2 ,<br />
Troels Herlin 1 . 1 Aarhus University Hospital, Section Skejby,<br />
Aarhus N, Denmark; 2 Aarhus University Hospital, Section<br />
Norrebrogade, Aarhus C, Denmark.<br />
(251)-251. Chronic Parotitis: An Underdiagnosed Feature of<br />
Juvenile Dermatomyositis. María M. Katsicas, Blanca Balancini,<br />
Carina Kadzielski, Ricardo Russo. Hospital de Pediatría<br />
Prof Dr J P Garrahan, Buenos Aires, Argentina.<br />
(252)-252. Clinical and Metabolic Characteristics of Acquired<br />
Lipodystrophy (LD) in Juvenile Dermatomyositis (JDM). G.<br />
Mamyrova, C. A. Bingham, E. A. Oral, K. Rother, E.<br />
Cochran, N. Sebring, J. Pandey, L. James-Newton, T.<br />
O’Hanlon, I. Targoff, L. Imundo, F. Miller, L. Rider.<br />
NIEHS, NIH, DHHS, Bethesda, MD.<br />
(253)-253. Long-Term Outcome and Quality of Life in Children<br />
with Chronic Recurrent Multifocal Osteomyelitis. Charlotte<br />
Catalano-Pons 1 , Aurélie Comte 2 , Julien Wipff 3 , Pierre<br />
Quartier 4 , Albert Faye 5 , Dominique Gendrel 1 , Agnès<br />
Duquesne 6 , Rolando Cimaz 6 , Chantal Job-Deslandre 3 .<br />
1<br />
Hôpital Saint Vincent de Paul, Paris, France; 2 Hôpital Saint<br />
Jacques, Besançon, France; 3 Hôpital Cochin, Paris, France;<br />
4<br />
Hôpital Necker, Paris, France; 5 Hôpital Robert Debré,<br />
Paris, France; 6 Hôpital Edouard Herriot, Lyon, France.<br />
(254)-254. Mortality Outcomes in Pediatric Rheumatology<br />
Conditions. Philip J. Hashkes 1 , Michael S. Lauer 1 , Bridget<br />
M. Wright 1 , Sarah Worley 1 , Phil Roettcher 2 , Suzanne L.<br />
Bowyer 2 . 1 Cleveland Clinic Foundation, Cleveland, OH;<br />
2<br />
Riley Hospital, Indianapolis, IN.<br />
(255)-255. The Interaction of the RGD Sequence of Vitronectin<br />
with Integrin in Membrane Attack Complex (MAC) Mediated<br />
Synovial Damage in Juvenile Idiopathic Arthritis (JIA). Melinda<br />
R. Reed, Anil K. Chauhan, Terry L. Moore. Saint Louis<br />
University, St. Louis, MO.<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
RA New and Established Therapies: Efficacy and Safety I<br />
(256)-256. Initial versus Delayed Treatment with Infliximab plus<br />
Methotrexate in Patients with Recent Onset Rheumatoid Arthritis:<br />
Results from the BeSt Study. Sjoerd M. Van Der Kooij 1 , Jeska<br />
K. de Vries-Bouwstra 2 , Yvonne P.M. Goekoop-Ruiterman 1 ,<br />
Andreas H. Gerards 3 , Dirkjan van Schaardenburg 4 , Patrick<br />
E.H. Seys 5 , Ferdinand C. Breedveld 1 , Ben A.C. Dijkmans 4 ,<br />
Cornelia F. Allaart 1 . 1 LUMC, Leiden, The Netherlands;<br />
2<br />
VUMC, Amsterdam, The Netherlands; 3 Vlietland Hospital,<br />
Schiedam, The Netherlands; 4 VUMC, JBI, Amsterdam,<br />
The Netherlands; 5 Franciscus Hospital, Roosendaal, The<br />
Netherlands.<br />
(257)-257. Extended Follow-up of the Long-term Safety<br />
of Rituximab in Rheumatoid Arthritis. Ronald F. van<br />
Vollenhoven 1 , Paul Emery 2 , Clifton O. Bingham III 3 ,<br />
Edward Keystone 4 , Maria Greenwald 5 , Larry W. Moreland 6 ,<br />
Marianne Sweetser 7 , Karen Rowe 8 , Bridget Wagner 9 , Fabio<br />
Magrini 8 . 1 Karolinska University Hospital, Stockholm,<br />
Sweden; 2 Leeds General Infirmary, Leeds, United Kingdom;<br />
3<br />
Johns Hopkins University, Baltimore, MD; 4 University<br />
of Toronto, Toronto, ON, Canada; 5 Desert Medical<br />
Advances, Palm Desert, CA; 6 University of Alabama School<br />
of Medicine, Birmingham, AL; 7 Biogen Idec, Cambridge,<br />
MA; 8 Roche Products Ltd, Welwyn Garden City, United<br />
Kingdom; 9 Genentech, Inc, South San Francisco, CA.<br />
(258)-258. Evaluation of the Clinical Relevance of Different<br />
Reporting Techniques Used to Assess Disease Activity in RA<br />
Clinical Trials from the Patient’s Perspective: New Insights<br />
from the Abatacept database. M. Dougados 1 , N. Schmidely 2 ,<br />
C. Lafosse 2 , P. van Riel 3 , G. Wells 4 , M. Le Bars 2 . 1 Rene<br />
Descartes University, Paris, France; 2 Bristol-Myers Squibb,<br />
Rueil-Malmaison, France; 3 University Hospital Nijmegan,<br />
Nijmegen, The Netherlands; 4 University of Ottawa, Ottowa,<br />
ON, Canada.<br />
(259)-259. Relationship Between Serum Concentrations of the<br />
Interleukin-6 Receptor Inhibitor Tocilizumab and C-Reactive<br />
Protein Reduction in RA Patients: 6 Months’ Data from a Phase<br />
3 Study. Nicolas Frey 1 , Susan Grange 1 , Thasia Woodworth 2 .<br />
1<br />
F. Hoffmann-La Roche Ltd, Basel, Switzerland; 2 Roche<br />
Products, Ltd., Nutley, NJ.<br />
88 (Permanent Board Number)-Abstract Number
(260)-260. Why do Women with Early RA Respond Less<br />
Well to MTX then Men? Gender as a Determinant of<br />
Clinical Response in the Initial Open-label Phase of the Swefot<br />
Clinical Trial. R. F. Van Vollenhoven 1 , S. Ernestam 1 , L.<br />
Cöster 2 , C. Dackhammar 3 , K. Forslind 4 , P. Geborek 5 ,<br />
H. Hellström 6 , L. Ljung 7 , R. Oding 8 , I. F. Petersson 5 , A.<br />
Teleman 9 , J. Theander 10 , Å. Thörner 11 , B. Törnqvist 12 ,<br />
E. Waltbrand 13 , A. Zickert 14 , M. Wörnert 1 , J. Bratt 1 .<br />
1<br />
Karolinska University Hospital, Stockholm, Sweden;<br />
2<br />
Linköping University Hospital, Linköping, Sweden;<br />
3<br />
Mölndal University Hospital, Mölndal, Sweden; 4 Lasarettet,<br />
Helsingborg, Sweden; 5 University Hospital, Lund, Sweden;<br />
6<br />
Lasarettet, Falun, Sweden; 7 University Hospital, Umeå,<br />
Sweden; 8 Centrallasarettet, Västerås, Sweden; 9 Spenshult,<br />
Oskarström, Sweden; 10 Centralsjukhuset, Kristianstad,<br />
Sweden; 11 Mälarsjukhuset, Eskilstuna, Sweden; 12 University<br />
Hospital, Örebro, Sweden; 13 Lasarettet, Borås, Sweden;<br />
14<br />
Danderyds Hospital, Stockholm, Sweden.<br />
(261)-261. Immunoglobulin Levels and Infection Rates in Patients<br />
with Rheumatoid Arthritis (RA) Treated With Repeated Courses<br />
of Rituximab. M. Genovese 1 , P. Emery 2 , E. Ruderman 3 , E.<br />
Keystone 4 , D. Furst 5 , R. Van Vollenhoven 6 , M. Sweetser 7 ,<br />
F. Magrini 8 , E. Tindall 9 , T. Shaw 8 , D. Yocum 9 . 1 Stanford<br />
University, Palo Alto, CA; 2 University of Leeds, Leeds,<br />
United Kingdom; 3 Northwestern University, Chicago, IL;<br />
4<br />
University of Toronto, Toronto, NU, Canada; 5 University<br />
of California in Los Angeles, Los Angeles, CA; 6 Karolinska<br />
University Hospital, Stockholm, Sweden; 7 Biogen Idec,<br />
Cambridge, MA; 8 Roche Products Ltd, Welwyn Garden City,<br />
United Kingdom; 9 Genentech, South San Francisco, CA.<br />
(262)-262. Safety of TNF Inhibitors and Non-Biologic DMARDs<br />
in Rheumatoid Arthritis Patients Previously Treated with<br />
Rituximab. M. C. Genovese 1 , F. C. Breedveld 2 , P. Emery 3 , L.<br />
W. Moreland 4 , E. Keystone 5 , E. L. Matteson 6 , Y. Baptiste 7 ,<br />
L. Burke 7 , W. Reiss 8 , M. Sweetser 9 , T. Shaw 7 . 1 Stanford,<br />
CA; 2 Leiden U, The Netherlands; 3 Leeds Gen Infirmary,<br />
United Kingdom; 4 U of Alabama, AL; 5 U Toronto,<br />
ON, Canada; 6 Mayo, MN; 7 Roche, United Kingdom;<br />
8<br />
Genentech, CA; 9 Biogen Idec, MA.<br />
(263)-263. Abstract Withdrawn<br />
(264)-264. Reduction of Oxidized LDL Levels and Raised<br />
Atheroprotective Natural Antibodies Against Phosphorylcholine<br />
Induced by Gluten-Free Vegan Diet in Patients with Rheumatoid<br />
Arthritis are Partly Dependant on Decreased Disease Activity.<br />
Ann-Charlotte Elkan, Beatrice Sjöberg, Björn Kolsrud, Bo<br />
Ringertz, Ingiäld Hafström, Johan Frostegård. Karolinska<br />
Institute, Stockholm, Sweden.<br />
(265)-265. Efficacy of Etanercept in Early Versus Long-Term<br />
Rheumatoid Arthritis: Posthoc Analysis of 3-year TEMPO Data.<br />
D. van der Heijde 1 , L. Klareskog 2 , R. Pedersen 3 , J. Wajdula 3 ,<br />
S. Fatenejad 3 . 1 Leiden University Medical Center, Leiden,<br />
The Netherlands; 2 Karolinska Institut, Stockholm, Sweden;<br />
3<br />
Wyeth Research, Collegeville, PA.<br />
(266)-266. Repeated Treatment Courses of Rituximab Produce<br />
Sustained Efficacy in Rheumatoid Arthritis Patients with an<br />
Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs.<br />
Paul Emery 1 , Daniel E. Furst 2 , Gianfranco Ferraccioli 3 ,<br />
James Udell 4 , Ronald F. van Vollenhoven 5 , Karen Rowe 6 ,<br />
Sunil Agarwal 7 , Tim Shaw 6 . 1 Leeds General Infirmary,<br />
Leeds, United Kingdom; 2 University of California at Los<br />
Angeles, Los Angeles, CA; 3 Catholic University, Rome,<br />
Italy; 4 Arthritis Group, Philadelphia, PA; 5 Karolinska<br />
University Hospital, Stockholm, Sweden; 6 Roche Products<br />
Ltd, Welwyn Garden City, United Kingdom; 7 Genentech,<br />
Inc., South San Francisco, CA.<br />
(267)-267. Consistent Inhibition of Structural Damage Progression<br />
by Rituximab in Medically Important Subgroups of Patients<br />
with an Inadequate Response to TNF Inhibitors: Week 56<br />
REFLEX Results. S. Cohen 1 , M. Dougados 2 , M. Genovese 3 ,<br />
G. Burmester 4 , M. Greenwald 5 , T. Kvien 6 , M. Cravets 7 , T.<br />
Shaw 8 , D. Hagerty 9 . 1 Radiant Research, Dallas, TX; 2 Hopital<br />
Cochin, Paris, France; 3 Stanford, Palo Alto, CA; 4 Charité<br />
– University of Medicine Berlin, Berlin, Germany; 5 Desert<br />
Medical Advances, Palm Desert, CA; 6 Diakonhjemmet<br />
Hospital, Oslo, Norway; 7 Biogen Idec, Inc., San Diego,<br />
CA; 8 Roche Products Ltd, Welwyn Garden City, United<br />
Kingdom; 9 Biogen Idec, San Diego, CA.<br />
(268)-268. Anti-tnf Treatment with Adalimumab Reduces Hand<br />
Bone Loss in Early Rheumatoid Arthritis (RA): Explorative<br />
Analyses from the Premier Study. Mari Hoff 1 , Tore K.<br />
Kvien 2 , Johan Kälvesten 3 , Jakob Algulin 3 , Aake Elden 4 ,<br />
Glenn Haugeberg 5 . 1 Dept of Rheumatology, St. Olav’s<br />
Hospital, Trondheim, Norway; 2 Dept of Rheumatology,<br />
Diakonhjemmet Hospital, Oslo, Norway; 3 SECTRA,<br />
Linköping, Sweden; 4 ABBOTT, Oslo, Norway; 5 Dept of<br />
Rheumatology, Sørlandet Hospital, Kristiansand, Norway.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 89
Poster Session A<br />
(269)-269. Results from a Randomized, Blinded, Single-dose,<br />
Placebo- and Anakinra-Controlled Study to Evaluate the Safety,<br />
Tolerability, Pharmacokinetics and Pharmacodynamics of AMG<br />
108 (a Fhuman Monoclonal Antibody to IL-1R type I) in Healthy<br />
Volunteers. C. Banfield 1 , M. Vincent 1 , C. Tankersley 1 , M.<br />
Wong 1 , M. Plant 1 , B. Varnum 1 , Y-N Sun 1 , S. Shakib 2 .<br />
1<br />
Amgen, Thousand oaks, CA; 2 Royal Adelaide Hospital,<br />
South Australia, Australia.<br />
(270)-270. The Efficacy and Safety of 3 Oral Doses of ERB-<br />
041 in Subjects with Rheumatoid Arthritis on a Background of<br />
Methotrexate Therapy. Alan Brodsky 1 , Maurizio Cutolo 2 ,<br />
Damon L. Bass 3 , Andrew DerMovsesian 3 , Patti Shott 3 , Nate<br />
Haring 3 , Maria Alicia Lazaro 4 , Gabriel Herrero-Beaumont 5 ,<br />
Laurence Paolozzi 6 . 1 Arthritis Care and Diagnostic Center,<br />
Dallas, TX; 2 University of Genova, Genova, Italy; 3 Wyeth<br />
Research, Collegeville, PA; 4 Fundacion CIDEA, Buenos<br />
Aires, Argentina; 5 Fundacion Jimenez Diaz-Capio, Madrid,<br />
Spain; 6 Wyeth Pharmaceuticals France, Paris, France.<br />
(271)-271. Vascular Endothelial Dysfunction in Patients<br />
with Rheumatoid Arthritis can be Reversed by Adalimumab<br />
Treatment. Elda Chryssochoou 1 , Christos Papamichael 1 ,<br />
Athanasios Protogerou 1 , Kalliope Fragiadaki 2 , Kimon S.<br />
Stamatelopoulos 1 , Dimitrios Kontoyiannis 1 , Christina G.<br />
Katsiari 2 , Myron Mavrikakis 1 , Petros P. Sfikakis 2 . 1 Dept.<br />
of Therapeutics, Alexandra Hospital, Athens University<br />
Medical School, Athens, Greece; 2 1st Department of<br />
Propeudetic and Internal Medicine, Athens University<br />
Medical School, Athens, Greece.<br />
(272)-272. Improved Clinical and Simplified Disease Activity<br />
Index (CDAI, SDAI) Scores with Rituximab in Patients with<br />
Rheumatoid Arthritis (RA) and an Inadequate Response to TNF<br />
Inhibitors. Josef Smolen 1 , Arthur Kavanugh 2 , Hans Peter<br />
Tony 3 , Maria Greenwald 4 , Salvatore De Vita 5 , Richard<br />
Brasington 6 , Daniel Aletaha 1 , Anne Marie White 7 , Eva<br />
Hessey 7 . 1 Medical University of Vienna, Vienna, Austria;<br />
2<br />
UCSD, La Jolla, CA; 3 Universitätsklinikum Wurzburg,<br />
Wurzburg, Germany; 4 Desert Medical Advances,<br />
Palm Desert, CA; 5 University of Udine, Udine, Italy;<br />
6<br />
Washington School of Medicine, St Louis, MO; 7 Roche<br />
Products Ltd, Welwyn Garden City, United Kingdom.<br />
(273)-273. Good Quality of Life as Assessed by SF-36 in Patients<br />
with Early Rheumatoid Arthritis Treated with a Combination of<br />
Three DMARDs and Prednisolone with or without Infliximab.<br />
Kari Puolakka 1 , Hannu Kautiainen 2 , Kari Eklund 3 , Markku<br />
Kauppi 2 , Pekka Hannonen 4 , Oili Kaipiainen-Seppänen 5 ,<br />
Riitta Luosujärvi 3 , Eeva Moilanen 6 , Marjatta Leirisalo-<br />
Repo 3 , the Neo-RACo Trial Group. 1 Lappeenranta Central<br />
Hospital, Lappeenranta, Finland; 2 Rheumatism Foundation<br />
Hospital, Heinola, Finland; 3 Helsinki University Central<br />
Hospital, Helsinki, Finland; 4 Jyväskylä Central Hospital,<br />
Jyväskylä, Finland; 5 Kuopio University Hospital, Kuopio,<br />
Finland; 6 University of Tampere, Tampere, Finland.<br />
(274)-274. Characterization of Golimumab (CNTO 148), a<br />
Novel Monoclonal Antibody Specific for Human TNFα. David<br />
Shealy, Ann Cai, Tom Nesspor, Mike Brigham-Burke,<br />
Audrey Baker, Kim Staquet, Eilyn Lacy, Cheryl Blasie, Dana<br />
Wang, Paul Dal Monte, Bernie Scallon, Jill Giles-Komar.<br />
Centocor Research and Development, Inc., Malvern, PA.<br />
(275)-275. Monitoring the Effects of Leflunomide by Dynamic<br />
Magnetic Resonance Imaging in Patients with Active Rheumatoid<br />
Arthritis: Correlation with Changes in Biochemical Markers.<br />
Ayse Karan 1 , Hale Karapolat 2 , Yesim Kirazli 2 , Remide<br />
Arkun 3 , Nurten Eskiyurt 4 , Ahmet Yilmaz 5 , Sureyya Ergin 5 ,<br />
Feride Gogus 6 , Vesile Sepici 6 , Alp Cetin 7 , Zafer Hascelik 7 ,<br />
Aynur Terzibasioglu 8 , Fikret Tuzun 8 , Patrick Garnero 9 . 1 IU,<br />
Istanbul, Turkey; 2 EU, Izmir, Turkey; 3 EU, Radiology, Izmir,<br />
Turkey; 4 lU, Istanbul, Turkey; 5 AU, Ankara, Turkey; 6 GU,<br />
Ankara, Turkey; 7 HU, Ankara, Turkey; 8 CMF, Istanbul, Turkey;<br />
9<br />
INSERM and Synarc Molecular Markers, Lyon, France.<br />
(276)-276. Chronic Dosing with Diclofenac versus Etoricoxib or<br />
Celecoxib: Differences in Pharmacodynamic Profiles of COX-1<br />
and COX-2 Inhibition. J. I. Schwartz 1 , A. L. Dallob 1 , P. J.<br />
Larson 1 , J. L. Miller 1 , J. E. Royalty 2 , P. F. Cavanaugh, Jr 1 ,<br />
J. A. Wagner 1 . 1 Merck Research Laboratories, Rahway, NJ;<br />
2<br />
Covance GFI Research, Evansville, IN.<br />
(277)-277. Certolizumab Pegol 400 mg Every 4 Weeks as<br />
Monotherapy Rapidly Reduces Disease Activity in Active<br />
Rheumatoid Arthritis. Edward Keystone 1 , David Mason 2 ,<br />
Roy Fleischmann 3 . 1 University of Toronto, Toronto, ON,<br />
Canada; 2 UCB Inc, Smyrna, GA; 3 University of Texas<br />
Southwestern Medical Center, Dallas, TX.<br />
(278)-278. The Effect of Adalimumab on Clinical and<br />
MRI Outcome Measures in Psoriatic Arthritis. Allen P.<br />
Anandarajah 1 , Robert Ory 2 , D. Salonen 3 , Changyong Feng 1 ,<br />
Melissa McIlraith 4 , Christopher T. Ritchlin 1 . 1 University of<br />
Rochester Medical Center, Rochester, NY; 2 University of<br />
Washington, Seattle, WA; 3 University of Toronto, Toronto,<br />
ON, Canada; 4 Abbott Pharmaceuticals, Chicago, IL.<br />
(279)-279. Anti TNF-α Agents in Adult Onset Still Disease. A<br />
4 Year Follow-up Study. Matteo Colina, Marcello Govoni,<br />
Francesco De Leonardis, Francesco Trotta. University of<br />
Ferrara, Ferrara, Italy.<br />
(280)-280. Contemporary Use of Abatacept in Rheumatoid<br />
Arthritis. Teresa Simon 1 , Kaleb Michaud 2 , Kimberly Ray 1 ,<br />
Frederick Wolfe 3 . 1 Global Epidemiology, Bristol-Myers<br />
Squibb, Hopewell, NJ; 2 University of Nebraska Medical<br />
Center, Omaha, NE; 3 National Data Bank for Rheumatic<br />
Diseases, Wichita, KS.<br />
(281)-281. Are COX-2’s Safe to Use in Patients on Warfarin?.<br />
Gerald D. Levy, Craig Cheetham, Fang Niu. Southern<br />
California Permanente Medical Group, Downey, CA.<br />
90 (Permanent Board Number)-Abstract Number
(282)-282. TNF Inhibitors (TNF-I) and Risk of Malignancy<br />
in 8,072 RA Patients Followed Over 15,495 Patient Years.<br />
J. Greenberg 1 , V. Strand 2 , E. Keystone 3 , J. Curtis 4 , E.<br />
Maury 5 , G. Reed 6 , J. Kremer 7 , A. Nasir 1 , J. Henderson 8 , A.<br />
Kavanaugh 9 , M. Hochberg 5 . 1 NYU Hosp Jt Diseases, NY,<br />
NY; 2 Stanford Univ, Palo Alto, CA; 3 Univ of Toronto,<br />
Toronto, ON, Canada; 4 Univ Alabama, Birmingham, AL;<br />
5<br />
Univ of Maryland, Baltimore, MD; 6 U Mass, Worcester,<br />
MA; 7 Albany Med College, Albany, NY; 8 Corrona, Albany,<br />
NY; 9 UC San Diego, San Diego, CA.<br />
(283)-283. Definitive Results of the National French Prospective<br />
RATIO 3-Year Observatory on Lymphomas in Patients Treated<br />
with TNF Blockers : No Increase of Non Hodgkin’s Lymphomas<br />
but Slight Increase of EBV-Positive Hodgkin’s and Hodgkin Like’s<br />
Lymphomas. Xavier Mariette 1 , Florence Tubach 2 , Philippe<br />
Ravaud 2 , Jean-Marie Berthelot 3 , Thierry Schaeverbeke 4 ,<br />
Michel Bardet 5 , Patricia Rince 1 , Marc Lemann 6 , Dominique<br />
Salmon 7 , Olivier Hermine 8 , RATIO, Martine Raphael 1 .<br />
1<br />
Bicetre Hospital, Le Kremlin Bicetre, France; 2 Bichat<br />
Hospital, Paris, France; 3 Nantes Hospital, Nantes, France;<br />
4<br />
Pellegrin Hospital, Bordeaux, France; 5 La Source Hospital,<br />
Orléans, France; 6 St Louis Hospital, Paris, France; 7 Cochin<br />
Hospital, Paris, France; 8 Necker Hospital, Paris, France.<br />
(284)-284. Influence of Infliximab on the Myocardial Function of<br />
Patients with Rheumatic Diseases-12 Month Follow-Up. Gerhard<br />
Witzmann, Monika Schoels, Jeanette Wolf, Josef Smolen.<br />
Community Hospital Hietzing, Vienna, Austria.<br />
(285)-285. Tuberculosis in Japanese Patients with Rheumatoid<br />
Arthritis Treated with Infliximab: Findings from the Post<br />
Marketing Surveillance Trial. O. Dabbous 1 , K. Gilmer 1 , Y.<br />
Tatsuki 2 , P. Shane 1 , M. Togo 2 , Y. Nogami 2 , B. Tang 1 , H.<br />
Thompson 1 , M. Rahman 1 . 1 Centocor, Inc., Horsham, PA;<br />
2<br />
Tanabe Seiyaku Co., Ltd., Osaka, Japan.<br />
(286)-286. Increasing Cholesterol after Start of Adalimumab<br />
Treatment in Patients with Rheumatoid Arthritis, but no Negative<br />
Effect on the ApoB/apoA1 Lipoprotein Ratio. Ulf Bergström,<br />
Lennart TH Jacobsson, Käth Nilsson, Carl Turesson.<br />
Malmö University Hospital, Malmö, Sweden.<br />
(287)-287. TNF-α Antagonists and Risk of Severe Infections in<br />
Patients with Secondary Amyloidosis Complicating Inflammatory<br />
Artropathies. Rosario Garcia-Vicuña 1 , Alejandro Olivé 2 ,<br />
María C. Castro 3 , Ángela Herranz-Varela 1 , María-Victoria<br />
Irigoyen 4 , Elena Riera 2 , Esther Vicente 1 , Inmaculada<br />
Ureña 4 , Ángeles Belmonte-López 4 , Antonio Fernández-<br />
Nebro 4 . 1 Hospital de La Princesa, Madrid, Spain; 2 Hospital<br />
Universitario Germans Trías i Pujol, Barcelona, Spain;<br />
3<br />
Hospital Universitario Reina Sofía, Córdoba, Spain;<br />
4<br />
Hospital Regional Universitario Carlos Haya, Málaga, Spain.<br />
(288)-288. Infusion-Associated Events in Patients with<br />
Rheumatoid Arthritis Receiving Rituximab: Preliminary<br />
Results from SUNRISE. Andrew Chubick 1 , A. Deodhar 2 ,<br />
C. Codding 3 , M. Greenwald 4 , A. Kaell 5 , N. Gaylis 6 , B.<br />
Wagner 7 , M. Yin 7 , A. Kelman 7 . 1 Baylor Univ Med Ctr,<br />
Dallas, TX; 2 Oregon Health & Science Univ, Portland,<br />
OR; 3 Health Res of OK, Oklahoma City, OK; 4 Desert Med<br />
Advances, Palm Desert, CA; 5 Rheum Assoc, Port Jefferson,<br />
NY; 6 Arth & Rheum Dis, Aventura, FL; 7 Genentech, South<br />
San Francisco, CA.<br />
(289)-289. Daily and Cumulative Threshold Glucocorticoid<br />
Dose Associated with Cardiovascular and All-Cause Mortality<br />
in Rheumatoid Arthritis. Inmaculada del Rincón, Samvel<br />
Pogosian, Agustin Escalante. University of Texas Health<br />
Science Center, San Antonio, TX.<br />
(290)-290. Sequencing of DMARD Therapy in a Cohort of Newly<br />
Diagnosed Rheumatoid Arthritis (RA) Patients in the U.S.: An<br />
Analysis of 16,752 RA Patients, 1998 - 2006. Yusuf Yazici 1 ,<br />
Nianwen Shi 2 , Svetlana Krasnokutsky 1 , Inesa Vulfova 1 , Ani<br />
John 3 . 1 New York University, New York, NY; 2 Thomson<br />
Healthcare, Cambridge, MA; 3 Roche Laboratories Inc,<br />
Nutley, NJ.<br />
(291)-291. The Effectiveness and Cost-Effectiveness of Anti-<br />
TNF Therapy in the Community. Frederick Wolfe 1 , Kaleb<br />
Michaud 2 , Michael Luggen 3 . 1 National Data Bank for<br />
Rheumatic Diseases, Wichita, KS; 2 University of Nebraska<br />
Medical Center, Omaha, NE; 3 University of Cincinnati<br />
Medical Center, Cincinnati, OH.<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
RA: Clinical Aspects I<br />
(292)-292. Targeting the IL-6 Receptor with the Monoclonal<br />
Antibody Tocilizumab Significantly Improves Quality of Life<br />
in Patients with Rheumatoid Arthritis. Josef Smolen 1 , Josef<br />
Rovensky 2 , Cesar Ramos-Remus 3 , Melanie Lucero 4 , Thasia<br />
Woodworth 5 , Rieke Alten 6 . 1 Medical University of Vienna<br />
and Hietzing Hospital, Vienna, Austria; 2 National Institute<br />
of Rheumatic Diseases, Piestany, Slovakia; 3 Research Unit<br />
for Chronic Diseases, Guadalajara, Mexico; 4 Hoffmann-<br />
La Roche Inc., Basel, Switzerland; 5 Roche Products Ltd,<br />
Welwyn, United Kingdom; 6 Schlosspark Clinic, University<br />
Medicine, Berlin, Germany.<br />
(293)-293. High Proportion of Remission Can be Achieved Using<br />
Initial Early Optimal DMARD Therapy in Patients with New<br />
Onset Inflammatory Arthritis. Vivian Bykerk, Shahin Jamal,<br />
Chistopher Kitamura, Hong Chen, Edward Keystone.<br />
University of Toronto, Toronto, ON, Canada.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 91
Poster Session A<br />
(294)-294. Change Over Time in the Safety, Efficacy, and<br />
Remission Profiles of Patients With Rheumatoid Arthritis<br />
Receiving Adalimumab for Up to 7 Years. Michael E.<br />
Weinblatt 1 , Edward C. Keystone 2 , Daniel E. Furst 3 , Arthur<br />
F. Kavanaugh 4 , John L. Perez 5 , Oscar G. Segurado 6 .<br />
1<br />
Brigham & Womens Hospital, Boston, MA; 2 University of<br />
Toronto, Toronto, ON, Canada; 3 UCLA Medical School,<br />
Los Angeles, CA; 4 UCSD Center for Innovative Therapy,<br />
La Jolla, CA; 5 Abbott Laboratories, Parsippany, NJ; 6 Abbott<br />
Laboratories, Abbott Park, IL.<br />
(295)-295. Comparable Response Rates Between First and Second<br />
anti-TNFα Therapies in Rheumatoid Arthritis Patients under<br />
Treatment with anti-TNF agents. Prodromos Sidiropoulos 1 ,<br />
Irini Flouri 1 , Alexandros Drosos 2 , Kyriaki Boki 3 , Ioannis<br />
Papadopoulos 4 , Fotini Skopouli 5 , Florentia Kanakoudi 6 ,<br />
Dimitrios Karras 7 , Iraklis Kritikos 1 , Pierre Geborek 8 ,<br />
Dimitrios Boumpas 1 . 1 University of Crete, Heraklion,<br />
Greece; 2 University of Ioannina, Ioannina, Greece;<br />
3<br />
Sismanoglio Hospital, Athens, Greece; 4 Kavala Hospital,<br />
Kavala, Greece; 5 University of Athens, Athens, Greece;<br />
6<br />
University of Thessaloniki, Thessaloniki, Greece; 7 NIMITS<br />
hospital, Athens, Greece; 8 University of Lund, Lund, Sweden.<br />
(296)-296. Long-term Safety and Efficacy of Tocilizumab (anti-<br />
IL-6 Receptor Monoclonal Antibody) in Monotherapy, in Patients<br />
with Rheumatoid Arthritis. Norihiro Nishimoto 1 , Nobuyuki<br />
Miyasaka 2 , Kazuyuki Yamamoto 3 , Shinichi Kawai 4 , Tsutomu<br />
Takeuchi 5 , Junichi Azuma 1 , Tadamitsu Kishimoto 1 . 1 Osaka<br />
University, Osaka, Japan; 2 Tokyo Medical & Dental<br />
University, Tokyo, Japan; 3 University of Tokyo, Tokyo,<br />
Japan; 4 Toho University Omori Medical Center, Tokyo,<br />
Japan; 5 Saitama Medical Center/School, Saitama, Japan.<br />
(297)-297. Switching between Anti-TNFs: A Comparison of<br />
Maximum Efficacy with Each Treatment - Data from the STURE<br />
Registry. Ronald F. Van Vollenhoven 1 , Joel K. Joelsson 2 ,<br />
Cheryl Cullinane Carli 1 , Lars Klareskog 1 . 1 Karolinska<br />
University Hospital, Stockholm, Sweden; 2 University of<br />
Iceland, Reykjavik, Iceland.<br />
(298)-298. Disease Activity in the Early Course of Treatment<br />
Predicts Long-Term Response to Therapy in Rheumatoid Arthritis<br />
Patients. Daniel Aletaha 1 , Julia Funovits 1 , Edward C. Keystone 2 ,<br />
Josef Smolen 1 . 1 Medical University of Vienna, Vienna, Austria;<br />
2<br />
University of Toronto, Toronto, ON, Canada.<br />
(299)-299. Effectiveness of Switch to a Second AntiTNFα in<br />
Primary Nonresponders, Secondary Nonresponders and Failure<br />
Due to Adverse Events. Marlies Blom 1 , Wietske Kievit 1 , Jaap<br />
Fransen 1 , Ina H. Kuper 2 , Mart AFJ van de Laar, Prof 2 ,<br />
Dirk-Jan RAM de Rooij 3 , Carla MA De Gendt 4 , Tim L.<br />
Jansen 5 , Piet LM van Oijen 6 , Herman LM Brus 7 , Piet LCM<br />
van Riel, Prof 1 . 1 Radboud University Nijmegen Medical<br />
Center, Nijmegen, The Netherlands; 2 Medisch Spectrum<br />
Twente, Enschede, The Netherlands; 3 Sint Maartenskliniek,<br />
Nijmegen, The Netherlands; 4 Rijnstate Hospital,<br />
Arnhem, The Netherlands; 5 Medical Center Leeuwarden,<br />
Leeuwarden, The Netherlands; 6 Jeroen Bosch Hospital, Den<br />
Bosch, The Netherlands; 7 Twee Steden Hospital, Tilburg,<br />
The Netherlands.<br />
(300)-300. Predictors of Drug Free Remission in Patients with<br />
Recent-Onset Rheumatoid Arthritis Receiving Das-Guided<br />
Treatment in the BeSt Study. Karen Visser 1 , Sjoerd M. van<br />
der Kooij 1 , Melek Güler-Yüksel 1 , Irene Speyer 2 , J. M. de<br />
Jonge-Bok 3 , Ferdinand C. Breedveld 1 , Ben A. Dijkmans 4 ,<br />
Cornelia F. Allaart 1 . 1 LUMC, Leiden, The Netherlands;<br />
2<br />
Bronovo, The Hague, The Netherlands; 3 Groene Hart,<br />
Gouda, The Netherlands; 4 VUMC and JBI, Amsterdam,<br />
The Netherlands.<br />
(301)-301. Clinical and Laboratory Features after Orthopedic<br />
Surgery in Tocilizumab-Treating Patients with Rheumatoid<br />
Arthritis. Makoto Hirao 1 , Jun Hashimoto 1 , Hideki Tsuboi 1 ,<br />
Hideko Nakahara 2 , Naoko Yoshio 2 , Hideki Yoshikawa 1 ,<br />
Norihiro Nishimoto 2 . 1 Osaka University Graduate School<br />
of Medicine, Suita, Japan; 2 Graduate School of Frontier<br />
Bioscience, Osaka University, Suita, Japan.<br />
(302)-302. Factors Influencing Functional Disability in Patients<br />
with RA Who Are in Remission Following 5 Years of Treatment<br />
with Adalimumab (ADA) Plus Methotrexate (MTX). Edward C.<br />
Keystone 1 , Arthur F. Kavanuagh 2 , Kaushik Patra 3 , Eric H.<br />
Sasso 4 . 1 Univ. of Toronto, Toronto, ON, Canada; 2 UCSD, La<br />
Jolla, CA; 3 Abbott, Parsippany, NJ; 4 Abbott, Abbott Park, IL.<br />
(303)-303. Evaluating the Effectiveness and Safety of Etanercept<br />
in Subjects with Rheumatoid Arthritis Who Have Failed<br />
Infliximab Therapy: EMBARK, an Open-Label Observational<br />
Study. Clifton O. Bingham, III 1 , Akgun Ince 2 , Boulos<br />
Haraoui 3 , Edward C. Keystone 4 , Yun Chon 5 , Scott<br />
Baumgartner 5 . 1 Johns Hopkins, Baltimore, MD; 2 St Louis<br />
University, Saint Louis, MO; 3 Université de Montréal,<br />
Montréal, PQ, Canada; 4 University of Toronto, Toronto,<br />
ON, Canada; 5 Amgen Inc, Thousand Oaks, CA.<br />
(304)-304. Increased Independence in RA Patients: A<br />
Multidimensional Assessment from the ATTAIN Trial. Afton L.<br />
Hassett 1 , Tracy Li 2 , Steven Buyske 3 , Shantal V. Savage 1 , Ross<br />
Maclean 2 , Monique A. Gignac 4 . 1 UMDNJ-Robert Wood<br />
Johnson Medical School, New Brunswick, NJ; 2 Bristol-<br />
Myers Squibb Company, Princeton, NJ; 3 Rutgers University,<br />
Piscataway, NJ; 4 University of Toronto, Toronto, ON, Canada.<br />
(305)-305. Patients with Rheumatoid Arthritis Who are Non-<br />
Responders to Etanercept Plus Methotrexate Therapy at Week<br />
12 Achieve a Response at Week 24 and Sustain the Gain in<br />
Response. Arthur Kavanaugh 1 , Lars Klareskog 2 , Desiree<br />
van der Heijde 3 , Juan Li 4 , Shao-Lee Lin 4 , David Chang 5 ,<br />
Bruce Freundlich 5 , Michele Hooper 4 . 1 UCSD, La Jolla,<br />
CA; 2 Karolinska Instituet, Stockholm, Sweden; 3 Leiden<br />
University Medical Center, Leiden, The Netherlands;<br />
4<br />
Amgen Inc., Thousand Oaks, CA; 5 Wyeth Pharmaceuticals,<br />
Collegeville, PA.<br />
92 (Permanent Board Number)-Abstract Number
(306)-306. Anti-TNF Treatment: Reasons for Concern and<br />
Discontinuation among Rheumatoid Arthritis Patients. Arthur<br />
Kavanaugh 1 , Gabriel Farkas 2 , Niti Goel 3 . 1 UCSD, La Jolla,<br />
CA; 2 Columbia University, New York City, NY; 3 UCB, Inc,<br />
Smyrna, GA.<br />
(307)-307. Response to Infliximab Therapy is Related to<br />
Pretreatment Tissue Inflammation Levels in Rheumatoid Arthritis<br />
Patients: Results from Large-Scale Gene Expression Profiling.<br />
Tineke T. van der Pouw Kraan, Sr. 1 , Carla A. Wijbrandts,<br />
Ph.D 2 , Lisa G. van Baarsen, Ph.D 1 , François Rustenburg 1 ,<br />
Josefien M. Baggen 1 , Cornelis L. Verweij, Prof Dr 1 , Paul<br />
P. Tak, Prof Dr 2 . 1 VUmc, Amsterdam, The Netherlands;<br />
2<br />
Academic Medical Center/University of Amsterdam,<br />
Amsterdam, The Netherlands.<br />
(308)-308. Differences in Selection Criteria and Clinical<br />
Outcomes to Anti-TNFα Therapy in Patients with Rheumatoid<br />
Arthritis in Two European Countries. Beáta J. Radovits 1 , Chin<br />
Teck Ng 2 , Wietske Kievit 1 , Jaap Fransen 1 , Piet LCM van<br />
Riel*, Prof 1 , Douglas J. Veale, Prof 2 , Oliver FitzGerald,<br />
Prof 2 , Barry Bresnihan, Prof 2 , * representing the DREAM<br />
study group. 1 Radboud University Nijmegen Medical<br />
Center, Nijmegen, The Netherlands; 2 St. Vincent’s<br />
University Hospital, Dublin, Ireland.<br />
(309)-309. Safety and Pharmacodynamics of Repeat<br />
Administration of TRU-015, a CD20-Directed SMIP<br />
Therapeutic, in Subjects with Rheumatoid Arthritis. Daniel<br />
Burge 1 , Richard Martin 2 , Daniel Wallace 3 , Thomas<br />
Littlejohn 4 , Stephen <strong>Book</strong>binder 5 , Jeannette Bannink 1 ,<br />
Cathy Shu 6 . 1 Trubion, Seattle, WA; 2 Arth Ed & Treatment<br />
Ctr, Grand Rapids, MI; 3 Wallace Rheum Study Ctr, LA,<br />
CA; 4 Piedmont Med Res, Winston-Salem, NC; 5 Ocala<br />
Rheum Res Ctr, Ocala, FL; 6 Wyeth, Collegeville, PA.<br />
(310)-310. Hepatotoxicity Associated with Non-Biologic<br />
DMARDs: Implications for Evaluation of New Rheumatic Disease<br />
Therapies. Jeffrey R. Curtis 1 , G. Reed 2 , J. Greenberg 3 , G. G.<br />
Teng 1 , J. Kremer 4 . 1 UAB, Birmingham, AL; 2 University of<br />
Massachusetts, Worchester, MA; 3 NYU-HJD, New York,<br />
NY; 4 Albany Medical College, Albany, NY.<br />
(311)-311. Efficacy of Low Dose Prednisone (1-4 mg/day) in<br />
Patients with Rheumatoid Arthritis: A Randomized Controlled<br />
Placebo Controlled Double-Blind Withdrawal Trial. Theodore<br />
Pincus 1 , Christopher Swearingen 2 . 1 NYU-Hospital for Joint<br />
Diseases, New York, NY; 2 Medical University of South<br />
Carolina, Charleston, SC.<br />
(312)-312. Efficient Management of Disease Activity in Patients<br />
with Early RA Significantly Reduces Long-Term Functional<br />
Disability. Eiichi Tanaka 1 , Ajitha Mannalithara 2 , Eisuke<br />
Inoue 3 , Masako Hara 3 , Taisuke Tomatsu 3 , Naoyuki<br />
Kamatani 3 , Gurkirpal Singh 1 , Hisashi Yamanaka 3 . 1 Division<br />
of Gastroenterology and Hepatology, Stanford University<br />
School of Medicine, and Institute of Clinical Outcomes<br />
Research and Education, Palo Alto, CA; 2 Institute of<br />
Clinical Outcomes Research and Education, Palo Alto,<br />
CA; 3 Institute of Rheumatology, Tokyo Women’s Medical<br />
University, Tokyo, Japan.<br />
(313)-313. Managing RA Disease Activity Efficiently without<br />
Long-Term Corticosteroid Use Results in Better Functional<br />
Outcomes in Patients with Early RA. Eiichi Tanaka 1 , Ajitha<br />
Mannalithara 2 , Eisuke Inoue 3 , Noriko Iikuni 3 , Masako<br />
Hara 3 , Taisuke Tomatsu 3 , Naoyuki Kamatani 3 , Gurkirpal<br />
Singh 1 , Hisashi Yamanaka 3 . 1 Division of Gastroenterology<br />
and Hepatology, Stanford University School of Medicine,<br />
and Institute of Clinical Outcomes Research and Education,<br />
Palo Alto, CA; 2 Institute of Clinical Outcomes Research and<br />
Education, Palo Alto, CA; 3 Institute of Rheumatology, Tokyo<br />
Women’s Medical University, Tokyo, Japan.<br />
(314)-314. Treatment with Anti-TNFalpha Antagonists in<br />
Patients with Rheumatoid Arthritis Results in a Significant<br />
Decrease of Concomitant Glucocorticoid Therapy. Lydia<br />
Naumann, Jacqueline Detert, Gerd-Rüdiger Burmester,<br />
Frank Buttgereit. Charité - Universitätsmedizin Berlin,<br />
Berlin, Germany.<br />
(315)-315. Etanercept Therapy in Patients with Positive Hepatitis<br />
C Serology. Augustine M. Manadan 1 , Saulat Mushtaq 2 ,<br />
Winston Sequeira 1 , Joel A. Block 1 . 1 Rush University<br />
Medical Center, Chicago, IL; 2 Saint Joesph’s Hospital,<br />
Chicago, IL.<br />
(316)-316. Absence of Transaminase Elevation During<br />
Concomitant Methotrexate and Isoniazid Therapy. Augustine M.<br />
Manadan 1 , Anupama Poliyedath 2 , Winston Sequeira 1 , Joel<br />
A. Block 1 . 1 Rush University Medical Center, Chicago, IL;<br />
2<br />
John H. Stroger Jr Hospital of Cook County, Chicago, IL.<br />
(317)-317. Reduction of Bone Damage by Calcineurin-Inhibitors<br />
in Patients with Rheumatoid Arthritis. Katsunori Suzuki,<br />
Kazuyoshi Saito, Shigeru Iwata, Norifumi Sawamukai,<br />
Yoshiya Tanaka. First department of Internal Medicine,<br />
University of Occupational and Environmental Health,<br />
Japan, Kitakyushu, Japan.<br />
(318)-318. A Comparison of the Lifetime Health Benefits of<br />
Etanercept Versus Abatacept Following anti-TNF Treatment in<br />
Patients With Rheumatoid Arthritis. Matthew Taylor 1 , Paul<br />
Trueman 1 , Peter Conway 2 , Alan V. Reynolds 3 . 1 University of<br />
York, York, United Kingdom; 2 Wyeth Europa, Maidenhead,<br />
United Kingdom; 3 Wyeth UK, Taplow, United Kingdom.<br />
(319)-319. Lifetime Health Benefits of Etanercept Compared<br />
Against Abatacept Following Failure of Methotrexate. Matthew<br />
Taylor 1 , Paul Trueman 1 , Peter Conway 2 , Alan V. Reynolds 3 .<br />
1<br />
University of York, York, United Kingdom; 2 Wyeth<br />
Europa, Maidenhead, United Kingdom; 3 Wyeth UK,<br />
Taplow, United Kingdom.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 93
Poster Session A<br />
(320)-320. Early Treatment with and Time on First Disease<br />
Modifying Anti-Rheumatic Drug Predicts Long Term Functional<br />
Outcome in Patients with Inflammatory Polyarthritis. Tracey<br />
M. Farragher 1 , Mark Lunt 1 , Stephanie C. Manning 1 ,<br />
Diane Bunn 2 , Deborah P.M Symmons 1 . 1 arc Epidemiology<br />
Unit, The University of Manchester, Manchester, United<br />
Kingdom; 2 Norfolk Arthritis Register, Norfolk and Norwich<br />
University Hospital, Norwich, United Kingdom.<br />
(321)-321. The Relationship between Function and Radiological<br />
Damage in Early Rheumatoid Arthritis (ra) - A Longitudinal<br />
Analysis from the Eras Cohort. Josh Dixey 1 , Adam Young 2 ,<br />
Charis Emmett 3 , Gouri Koduri 4 , Peter Jones 5 , Keeranur<br />
Jayakumar 4 , Csilla Sollymossy 4 , Csilla Sollymossy 4 . 1 Robert<br />
Jones & Agnus Hunt Orthopaedic Hospital, Oswestry,<br />
Stropshire, United Kingdom; 2 St Albans City Hospital, St<br />
Albans, Hertfordshire, United Kingdom; 3 Department of<br />
Maths Keele University, Keele, United Kingdom; 4 St Albans<br />
City Hospital, HERTS, United Kingdom; 5 Keele University,<br />
Keele, United Kingdom.<br />
(322)-322. Association of TNF-α -308 G/A Polymorphism with<br />
Responsiveness to TNF- α Blockers in Rheumatoid Arthritis:<br />
A Meta-Analysis. Young Ho Lee, Young Hee Rho, Seong<br />
Jae Choi, Jin Hyun Woo, Jong Dae Ji, Gwan Gyu Song.<br />
Division of Rheumatolgy, Korea University Medical Center,<br />
Seoul, Republic of Korea.<br />
(323)-323. The Outcome of Aggressive Biologic Therapy in<br />
Clinical Practice: Measurement by DAS Remission and Minimal<br />
Disease Activity (MDA).. Timothy Shaver 1 , Shadi Shahouri 1 ,<br />
James Anderson 1 , David Weidensaul 1 , Ruth Busch 1 , Kaleb<br />
Michaud 2 , Frederick Wolfe 3 . 1 Arthritis and Rheumatology<br />
Clinics of Kansas, Wichita, KS; 2 University of Nebraska<br />
Medical Center, Omaha, NE; 3 National Data Bank for<br />
Rheumatic Diseases, Wichita, KS.<br />
(324)-324. Tapering Infliximab Dosages after Temporary Dose<br />
Increase Does Not Affect Treatment Survival in an Established<br />
RA Population. Bert Vander Cruyssen 1 , Renee Westhovens 2 ,<br />
Patrick Durez 3 , Filip Van den Bosch 1 , Herman Mielants 1 ,<br />
Luc De Clerck 4 , Anne Peretz 5 , Michel Malaise 6 , Leon<br />
Verbruggen 7 , Lode Dewulf 8 , Nathan Vastesaeger 9 , Wim<br />
Noel 9 , Luc Boullart 1 , Filip De Keyser 1 . 1 University Hospital<br />
Ghent, Ghent, Belgium; 2 University Hospitals KU Leuven,<br />
Leuven, Belgium; 3 Cliniques Universitaires Saint Luc,<br />
Brussels, Belgium; 4 University Hospital Antwerp, Antwerp,<br />
Belgium; 5 University Hospital Brugmann, Brussels, Belgium;<br />
6<br />
University Hospital Liege, Liege, Belgium; 7 Free University<br />
Hospital Brussels, Brussels, Belgium; 8 Schering Plough,<br />
Kenilworth, NJ; 9 Centocor, Leiden, The Netherlands.<br />
(325)-325. Spontaneous Amelioration in Early, Dmard Naive<br />
Patients with Rheumatoid Arthritis: Role of Antibody Profiles<br />
and Carriage of the Hla Shared Epitope in Predicting Decrease of<br />
Disease Activity.. Bert Vander Cruyssen 1 , Andre Miltenburg 2 ,<br />
Filip Van den Bosch 1 , Ruth Wittoek 1 , Jos Houbiers 2 ,<br />
Annemieke Boots 2 , Filip De Keyser 1 . 1 Ghent University,<br />
Gent, Belgium; 2 Organon, Oss, The Netherlands.<br />
(326)-326. Clinical Predictors of Persistent Arthritis after Six<br />
Months in Patients with Arthritis of Less Than 16 Weeks<br />
Duration. Maria D. Mjaavatten 1 , Anne J. Haugen 2 ,<br />
Halvor Nygaard 3 , Knut Helgetveit 4 , Tore K. Kvien 1 .<br />
1<br />
Diakonhjemmet Hospital, Oslo, Norway; 2 Sykehuset<br />
Østfold Sarpsborg, Sarpsborg, Norway; 3 Lillehammer<br />
Hospital for Rheumatic Diseases, Lillehammer, Norway;<br />
4<br />
Martina Hansen’s Hospital, Sandvika, Norway.<br />
(327)-327. Different Relationships Exist between Radiographic<br />
Progression and Clinical Status for Adalimumab (ADA) Plus<br />
Methotrexate (MTX) vs. ADA or MTX Monotherapy: Subanalysis<br />
of PREMIER. Paul Emery 1 , Mark Genovese 2 , Ronald Van<br />
Vollenhoven 3 , Kaushik Patra 4 , Eric Sasso 5 . 1 Leeds General<br />
Infirmary, Leeds, United Kingdom; 2 Stanford University,<br />
Palo Alto, CA; 3 Karolinska University Hospital, Stockholm,<br />
Sweden; 4 Abbott Laboratories, Parsippany, NJ; 5 Abbott<br />
Laboratories, Abbott Park, IL.<br />
(328)-328. Anxiety is Correlated with Clinical Conditions of<br />
Rheumatoid Arthritis and Improved by Anti-TNF Alpha Therapy.<br />
Yasushi Miura 1 , Yoshitada Sakai 2 , Shinya Hayashi 2 , Koji<br />
Tateishi 2 , Masayasu Takahashi 2 , Shunichi Shiozawa 3 ,<br />
Masahiro Kurosaka 2 . 1 Dept. of Orthopedic Sciences, Faculty<br />
of Health Sciences, Kobe Univ. School of Med., Kobe,<br />
Japan; 2 Dept. of Orthopaedic Surgery, Kobe Univ. Graduate<br />
School of Med., Kobe, Japan; 3 Dept. of Rheumatology,<br />
Faculty of Health Sciences, Kobe Univ. School of Med.,<br />
Kobe, Japan.<br />
(329)-329. Improvement of Depressive States Seen in Patients<br />
with Rheumatoid Arthritis by Infliximab Treatment: Potential<br />
Involvements of Inflammatory Cytokines and Hormones. Yusuke<br />
Miwa, Kuninobu Wakabayashi, Tsuyoshi Odai, Takeo<br />
Isozaki, Mizuho Matsunawa, Nobuyuki Yajima, Masao<br />
Negishi, Hirotsugu Ide, Tsuyoshi Kasama, Michio Hosaka.<br />
Division of Rheumatology and Clinical immunology,<br />
Tokyo, Japan.<br />
(330)-330. Differential Swollen and Tender Joint Count Responses<br />
Following Anti-TNF Therapy in Rheumatoid and Psoriatic<br />
Arthritis. Chin Teck Ng 1 , Laure Brulhart 1 , Mary B. Codd 2 ,<br />
Barry Bresnihan 1 , Oliver FitzGerald 1 , Douglas J. Veale 1 .<br />
1<br />
St. Vincent’s University Hospital, Dublin, Ireland; 2 UCD<br />
School of Medicine & Medical Science, Dublin, Ireland.<br />
94 (Permanent Board Number)-Abstract Number
(331)-331. A Single Centre Experience of Treating Rheumatoid<br />
and Psoriatic Arthritis with Biologics Therapy in the Republic of<br />
Ireland. Chin Teck Ng, Laure Brulhart, Eliza K. Pontifex,<br />
Ceara AE Walsh, Alexia Grier, Miriam Molloy, Eileen<br />
O’Flynn, Oliver FitzGerald, Barry Bresnihan, Douglas J.<br />
Veale. St. Vincent’s University Hospital, Dublin, Ireland.<br />
(332)-332. Clinical Factors Associated with the Use of Rituximab<br />
in Patients with Initial Treatment Failure to Tnf Inhibitors in Ra<br />
and Physician Election, First Year Data from the Mirar Study.<br />
Juan J. Gómez-Reino 1 , Raimon Sanmartí 2 , Rosa Roselló 3 ,<br />
Jose A. González 4 , Manuel Rodríguez 5 , Ángel Azpeitia 6 ,<br />
Carles Iglesias 7 , Mirar Study Group. 1 Hospital Universitario<br />
Santiago de Compostela, Santiago de Compostela, Spain;<br />
2<br />
Hospital Clínic i Provincial, Barcelona, Spain; 3 Hospital<br />
San Jorge, Huesca, Spain; 4 Hospital General, Elche, Spain;<br />
5<br />
Hospital Cristal Piñor, Orense, Spain; 6 Roche Farma S.A,<br />
Barcelona, Spain; 7 Salutis Research S.L, Barcelona, Spain.<br />
(333)-333. Variation in the Proportion of Patients in Standard<br />
Care in 58 Clinical Sites in 21 Countries who Meet DAS28 >5.1<br />
Critreria for High Diesase Activity; Data From the QUEST-RA<br />
Database. T. Sokka 1 , Theodore Pincus 2 , Bernard Combe<br />
Combe 3 , Kai Immonen 4 , Troels Mork Hansen 5 , Sergio<br />
Toloza 6 , Gianfranco Ferraccioli 7 , Susan MM Verstappen 8 ,<br />
Witold Tlustochowicz 9 , Wojciech Romanowski 10 , Jaime<br />
Calvo-Alen 11 , Patricia Minnock 12 , Selda Celik 13 , Martin<br />
Bergman 14 , Pál Géher 15 , Ilona Ujfalussy 16 , Jolanta<br />
Dadoniene 17 , Marika Tammaru 18 , Rolf Kuuse 18 , Riina<br />
Kallikorm 18 , Rolf Oding 19 , Margareth Liveborn 19 , Ann-<br />
Carin Holmqvist 20 , On Behalf of the QUEST-RA Group.<br />
1<br />
Jyväskylä Central Hospital, Jyväskylä, Finland; 2 New York<br />
University Hospital for Joint Diseases, New York, NY;<br />
3<br />
Hôpital Lapeyronie, Montpellier, France; 4 North Karelia<br />
Central Hospital, Joensuu, Finland; 5 Copenhagen University<br />
Hospital at Herlev, Herlev, Denmark; 6 Hospital San Juan<br />
Bautista, Catamarca, Argentina; 7 Catholic University of<br />
Sacred Heart, Rome, Italy; 8 University Medical Center<br />
Utrecht, Utrecht, The Netherlands; 9 Military Institute<br />
of Medicine, Warshaw, Poland; 10 Poznan Rheumatology<br />
Center in Srem, Srem, Poland; 11 Hospital Sierrallana<br />
Ganzo, Torrelavega, Spain; 12 Our Lady’s Hospice, Dublin,<br />
Ireland; 13 Cerrahpasa Medic Faculty, Istanbul, Turkey;<br />
14<br />
Taylor Hospital, Ridley Park, PA; 15 Semmelweis University<br />
of Medical Sciences, Budapest, Hungary; 16 Polyclinic of<br />
the Hospitaller Brothers of St. John of God, Budapest,<br />
Hungary; 17 Institute of Experimental and Clinical Medicine<br />
at Vilnius, Vilnius, Lithuania; 18 Tartu University Hospital,<br />
Tartu, Estonia; 19 Centrallasarettet, Västerås, Sweden;<br />
20<br />
Hudiksvall Medical Clinic, Hudiksvall, Sweden<br />
(334)-334. Infusion Reactions with Infliximab: Rapid versus 2<br />
Hours Infusion. Perez-Pampin Eva, Dr, Arca-Barca Beatriz,<br />
Dr, Fernandez-Aguado Sabela, Dr, Mera-Varela Antonio,<br />
Dr, Juan J. Gomez-Reino. Hospital Clinico Universitario,<br />
Santiago, Spain.<br />
(335)-335. Predicting Response to Anti-TNF Therapy in Patients<br />
with Inflammatory Arthritis Using Measures of Autonomic<br />
Reactivity: an Exploratory, Double-Blind Study with Heart Rate<br />
Variability. Andrew J. Holman. Pacific Rheumatology<br />
Research, Inc., Renton, WA.<br />
(336)-336. Alcohol Consumption is Related with Better Response<br />
to DMARD Therapy for Early Rheumatoid Arthritis in Men But<br />
Not in Women. Kari Puolakka 1 , Hannu Kautiainen 2 , Timo<br />
Möttönen 3 , Marjatta Leirisalo-Repo 4 . 1 Lappeenranta Central<br />
Hospital, Lappeenranta, Finland; 2 Rheumatism Foundation<br />
Hospital, Heinola, Finland; 3 Turku University Central<br />
Hospital, Turku, Finland; 4 Helsinki University Central<br />
Hospital, Helsinki, Finland.<br />
(337)-337. Population Analysis of Denosumab Pharmacokinetics<br />
(PK) and Pharmacodynamics (PD) in Patients With Rheumatoid<br />
Arthritis (RA). Mark Peterson, Wayne Tsuji, Richard<br />
Newmark. Amgen Inc., Thousand Oaks, CA.<br />
(338)-338. Functional and Work Outcomes Improve in RA<br />
Patients Who Receive Timely Comprehensive Occupational<br />
Therapy. Alyssa M. Macedo, Stephen P. Oakley, Gabriel S.<br />
Panayi, Bruce W. Kirkham. Guy’s and St. Thomas’ NHS<br />
Foundation Trust, London, United Kingdom.<br />
(339)-339. Prescription Practice Of Biologics In Rheumatoid<br />
Arthritis Is Changing Over Time. Does That Affect The<br />
EULAR Treatment Response? Results From The Nationwide<br />
DANBIO Registry. Merete L. Hetland 1 , Ulrik Tarp 1 , Jan<br />
Pødenphant 1 , Vibeke Ringsdal 1 , Annette Hansen 1 , Janne<br />
Unkerskov 2 . 1 DANBIO Registry and University Hospitals<br />
at Hvidovre, Herlev, Århus and Aalborg, On behalf of all<br />
Depts of Rheumatology, Denmark; 2 Institute for Rational<br />
Pharmacotherapy, Danish Medicines Agency, Denmark.<br />
(340)-340. Tight Control in the Treatment of Rheumatoid<br />
Arthritis: A New Paradigm. Marije F. Bakker, Johannes WG<br />
Jacobs, Johannes WJ Bijlsma. University Medical Center<br />
Utrecht, Rheumatology & Clinical Immunology, Utrecht,<br />
The Netherlands.<br />
(341)-341. Contemporary Trends in Rheumatoid Arthritis Disease<br />
Activity Reduction and Medication Use. Kerri L. Batra, Jing<br />
Cui, Roberta Glass, Daniel H. Solomon, Nancy E. Maher,<br />
Michael E. Weinblatt, Nancy A. Shadick. Brigham &<br />
Women’s Hospital, Boston, MA.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 95
Poster Session A<br />
(342)-342. Leflunomide is an acceptable Combination Partner<br />
for TNF Inhibitors if Methotrexate is not Tolerated - Results from<br />
the German Biologics Register. Angela Zink 1 , Anja Strangfeld 1 ,<br />
Peter Herzer 2 , Christina Bungartz 1 , Ulrich von Hinueber 3 ,<br />
Siegfried Wassenberg 4 , Joachim Listing 1 . 1 German Rheumatism<br />
Research Center, Berlin, Germany; 2 Private Practice,<br />
Munich, Germany; 3 Private Practice, Hildesheim, Germany;<br />
4<br />
Evangelisches Fachkrankenhaus, Ratingen, Germany.<br />
(343)-343. Effect of Rheumatoid Factor (RF) Levels on Response<br />
to Standard Dmard-Combination Treatment in Patients with<br />
Rheumatoid Arthritis (RA). Ashima Makol 1 , Anand N. Malaviya 2 .<br />
1<br />
Michigan State University, East Lansing, Michigan, MI;<br />
2<br />
’A&R Clinic’, Vasant Kunj, New Delhi, India.<br />
(344)-344. Safety Outcomes from a Large Japanese Post-<br />
Marketing Surveillance for Etanercept. Takao Koike 1 , Masayoshi<br />
Harigai 1 , Shigeko Inokuma 1 , Kazuhiko Inoue 1 , Naoki<br />
Ishiguro 1 , Jyunnosuke Ryu 1 , Tsutomu Takeuchi 1 , Yoshiya<br />
Tanaka 1 , Hisashi Yamanaka 1 , Michio Suzukawa 2 , Koichi<br />
Fujii 2 , Bruce Freundlich 3 . 1 Japan College of Rheumatology<br />
Etanercept Post-Marketing Surveillance Committee, Tokyo,<br />
Japan; 2 Wyeth KK, Medical Affairs, Tokyo, Japan; 3 Wyeth<br />
Research, Global Medical Affairs, Collegeville, PA.<br />
(345)-345. Should Local Anesthesia be used with Arthrocentesis<br />
and Joint Procedures?. Courtney R. Johnson, Kye S. Park,<br />
Gautam R. Moorjani, Adrian A. Michael, Wilmer L. Sibbitt,<br />
Jr., Arthur D. Bankhurst. University of New Mexico Health<br />
Sciences Center, Albuquerque, NM.<br />
(346)-346. Effect of Progressive Resistance Training in Cachectic<br />
Rheumatoid Arthritis Patients. Andrew B. Lemmey, Samuele<br />
M. Marcora, Kathryn Chester, Sally Wilson, Francesco<br />
Casanova, Peter J. Maddison. University of Wales, Bangor,<br />
Bangor, United Kingdom.<br />
(347)-347. The Safety of Re-infusion of Infliximab in RA<br />
Patients: Results from the Post-Marketing Surveillance (PMS) in<br />
Japan. Toshiro Yano 1 , Masanori Togo 1 , Seiichi Murakami 1 ,<br />
Tsutomu Takeuchi 2 , Takao Koike 3 . 1 Tanabe Seiyaku Co.,<br />
LTD., Osaka, Japan; 2 Rheumatology/Clinical Immunology,<br />
Saitama Medical Center/University, Kawagoe, Japan;<br />
3<br />
Department Medicine II, Hokkaido University, Graduate<br />
School of Medicine, Sapporo, Japan.<br />
(348)-348. Failure of Adalimumab in Patients with Rheumatoid<br />
Arthritis. Nicola Gullick, Chulanie Da Silva, Bruce Kirkham.<br />
Guy’s & St Thomas’ NHS Foundation Trust, London,<br />
United Kingdom.<br />
(349)-349. Study of Relationship between Disase Activity and<br />
Autoantibodies in Patients with Rheumatoid Arthritis during<br />
Infliximab Therapy. Ran Matsudaira, Fumio Sekiya, Masakazu<br />
Matsushita, Naoto Tamura, Yoshinari Takasaki. Juntendo<br />
University School of Medicine, Tokyo, Japan.<br />
(350)-350. Adverse Events on Patients Diagnosed with Rheumatoid<br />
Arthitis under Anti-tnf Treatment. P. De Abreu, M. Laiño, P.<br />
Granados, B. Varas, A. Burguet, A. Bardal, P. Castro, A. Zea.<br />
University Hospital Ramón y Cajal, Madrid, Spain.<br />
(351)-351. The Value of Convenience: Are Patients Willing to<br />
Trade-Off Other Attributes of Treatment for Better Convenience?.<br />
F. R. Johnson 1 , A. B. Hauber 2 , S. Ozdemir 1 , M. Bala 3 .<br />
1<br />
RTI International, Research Triangle Park, NC; 2 Health<br />
Preference Assessment, Doylestown, PA; 3 Centocor<br />
Research & Development, Inc., Malvern, PA.<br />
(352)-352. Acupuncture for Pain Relief in Patients with<br />
Rheumatoid Arthritis: A Systematic Review. Chenchen Wang,<br />
Paola De Pablo, Timothy McAlindon. Tufts-New England<br />
Medical Center, Boston, MA.<br />
(353)-353. Early Achievement of <strong>American</strong> College of<br />
Rheumatology (acr) 70% Improvement Criteria at 6 Weeks<br />
Predicts Therapeutic Efficacy at 2 Years in Active Rheumatoid<br />
Arthritis (ra) Patients Treated by Infliximab with Concomitant<br />
Use of Low Dose Methotrexate (mtx): A Japanese Regional<br />
Experience from Prospective Observational Study. Nozomi<br />
Iwanaga 1 , Atsushi Kawakami 1 , Keita Fujikawa 1 , Toshiyuki<br />
Aramaki 1 , Kunihiro Ichinose 1 , Mami Tamai 1 , Kazuhiko<br />
Arima 1 , Shin-ya Kawashiri 1 , Makoto Kamachi 1 , Hideki<br />
Nakamura 1 , Tomoki Origuchi 2 , Hiroaki Ida 1 , Katsumi<br />
Eguchi 1 . 1 Nagasaki University School of medicine, Nagasaki,<br />
Japan; 2 Nagasaki University School of Health Sciences,<br />
Nagasaki, Japan.<br />
(354)-354. The Utility of an Early Arthritis Clinic for Improving<br />
Time to Treatment. Shahin Jamal, Vivian P. Bykerk, Shabbir<br />
M. Alibhai, Elizabeth Badley, Claire Bombardier. University<br />
of Toronto, Toronto, ON, Canada.<br />
(355)-355. Disease Activity at Baseline and Early Treatment<br />
Response Predict Long-Term Success of Therapy In Rheumatoid<br />
Arthritis - Results from an Observational Study. Monika<br />
Schoels 1 , Julia Funovits 2 , Jutta Müllner 1 , Josef S.<br />
Smolen 1 , Daniel Aletaha 2 . 1 2nd Department of Internal<br />
Medicine, KH Hietzing, Vienna, Austria; 2 Department of<br />
Rheumatology, Medical University, Vienna, Austria.<br />
(356)-356. The Efficacy of Infliximab Treatment in 5,000<br />
Patients with Rheumatoid Arthritis: Results from the Post<br />
Marketing Surveillance Study in Japan. Yoshihiko Tatsuki 1 ,<br />
Masanori Togo 1 , Seiichi Murakami 1 , Tsutomu Takeuchi 2 ,<br />
Takao Koike 3 . 1 Tanabe Seiyaku Co., LTD., Osaka, Japan;<br />
2<br />
Rheumatology/Clinical Immunology, Saitama Medical<br />
Center/University, Kawagoe, Japan; 3 Department Medicine<br />
II, Hokkaido University, Graduate School of Medicine,<br />
Sapporo, Japan.<br />
96 (Permanent Board Number)-Abstract Number
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
RA: Human Etiology and Pathogenesis I<br />
(357)-357. Mast Cell-Derived Tryptase Induces Immortality of<br />
RA Synovial Fibroblast by Rho-Mediated Anti-Apoptotic Signaling.<br />
Sawamukai Norifumi, Kazuyoshi Saito, Kunihiro Yamaoka,<br />
Kazuhisa Nakano, Katsunori Suzuki Suzuki, Shigeru<br />
Iwata, Yoshiya Tanaka. University of Occupational and<br />
Environmental Health, Japan, Kitakyushu, Japan.<br />
(358)-358. Detailed Analysis of Lymphocyte Aggregates and<br />
Germinal Centers in the Synovium of Patients with Rheumatoid<br />
Arthritis in Relationship to Clinical and Histologic Signs of<br />
Inflammation. Rogier M. Thurlings 1 , Carla A. Wijbrandts 1 ,<br />
Reina E. Mebius 2 , Tineke Cantaert 1 , Dominique Baeten 1 ,<br />
Paul P. Tak 1 . 1 Academic Medical Center/ University of<br />
Amsterdam, Amsterdam, The Netherlands; 2 VU Medical<br />
Center, Amsterdam, The Netherlands.<br />
(359)-359. Smoking Upregulates Peptidylarginine 2 Enzyme<br />
Expression and Citrullination. D. Makrygiannakis 1 , M.<br />
Hermansson 1 , A. K. Ulfgren 1 , A. P. Nicholas 2 , A. JW<br />
Zendman 3 , A. Eklund 1 , J. Grunewald 1 , M. Skold 1 , L.<br />
Klareskog 1 , A. I. Catrina 1 . 1 Karolinska Institutet, Stockholm,<br />
Sweden; 2 University of Alabama, Birmingham, AL;<br />
3<br />
Radboud University, Nijmegen, The Netherlands.<br />
(360)-360. Biomarkers for Pre-Clinical Rheumatoid Arthritis in<br />
Women from Two Cohort Studies. Elizabeth W. Karlson, Lori<br />
B. Chibnik, Shelley S. Tworoger, Nancy A. Shadick, JoAnn<br />
E. Manson, Karen H. Costenbader. Brigham & Women’s<br />
Hospital, Boston, MA.<br />
(361)-361. The Role of Aryl Hydrocarbon Receptor in RA.<br />
Shu Kobayashi 1 , Hiroshi Okamoto 1 , Taisuke Tomatsu 1 ,<br />
Katsunori Ikari 1 , So Tsukahara 1 , Yoshiaki Toyama 2 , Shigeki<br />
Momohara 1 . 1 Tokyo Women’s Medical University, Tokyo,<br />
Japan; 2 Keio University, Tokyo, Japan.<br />
(362)-362. Cell Cycle Defects of Hematopoietic Progenitor Cells<br />
in Rheumatoid Arthritis. I. Colmegna, L. Qian, H. Fujii, J.<br />
J. Goronzy, C. M. Weyand. Lowance Center for Human<br />
Immunology, Emory University School of Medicine,<br />
Atlanta, GA.<br />
(363)-363. Adrenomedullin Inhibits the Bone Destruction Via<br />
Inhibition of Osteoclastogenesis in Inflammatory Arthritis. Wan-<br />
Hee Yoo 1 , Yun-Kyung Hong 1 , Hee-Jin Yoon 1 , Hak-Yong<br />
Lee 1 , Yong-Mi Kim 1 , Sang-Il Lee 2 . 1 Chonbuk National<br />
University Medical School and Research Institute of<br />
Clinical Medicine, Jeonju, Republic of Korea; 2 College of<br />
Medicine, Gyeongsang National University, Jinju, Republic<br />
of Korea.<br />
(364)-364. Deficient GADD45beta Expression Contributes<br />
to Persistent c-Jun N-terminal Kinase (JNK) Activation in<br />
Rheumatoid Arthritis (RA). Camilla I. Svensson 1 , Deepa R.<br />
Hammaker 1 , Tomoyuki Inoue 1 , Salvatore Papa 2 , Guido<br />
Franzos 2 , Gary S. Firestein 1 . 1 UCSD School of Medicine, La<br />
Jolla, CA; 2 University of Chicago, Chicago, IL.<br />
(365)-365. Intra-Articular Fms-Like Tyrosine Kinase 3 Ligand<br />
Expression is a Driving Force in Induction and Progression<br />
of Arthritis. Mats I. Dehlin 1 , Maria Bokarewa 1 , Robert<br />
Rottapel 2 , Mattias Magnusson 1 , Andrej Tarkowski 1 . 1 Dept<br />
of Rheumatology and Inflammation Research, Göteborg<br />
University, Gothenburg, Sweden; 2 Dept of Immunology,<br />
University of Toronto, Toronto, ON, Canada.<br />
(366)-366. Ectopic Lymphoid Neogenesis is not Functionally<br />
Competent to Drive Humoral Autoimmunity in Rheumatoid<br />
Synovitis. Tineke Cantaert 1 , Yiping Zhang 2 , Trieneke<br />
Timmer 3 , Bernard Vandooren 1 , Rogier Thurlings 1 , Tineke<br />
van der Pouw-Kraan 3 , Theo Out 1 , Paul P. Tak 1 , Dominique<br />
Baeten 1 . 1 Academic Medical Center/University of<br />
Amsterdam, Amsterdam, The Netherlands; 2 Department<br />
of Neurology, University of California Irvine, Irvine, CA;<br />
3<br />
Molecular Cell Biology and Immunology, VU Medical<br />
Center, Amsterdam, The Netherlands.<br />
(367)-367. The Four and a Half Lim Only Protein 2 (FHL2)<br />
is Involved in Balancing MMP-13 Expression and in Invasive<br />
Behaviour of RASF. Lars H. Meyer, Katja Neugebauer,<br />
Eva-Maria Schnäker, Berno Dankbar, Christina Wunrau,<br />
Noreen Pundt, Viktor Wixler, Thomas Pap. University of<br />
Muenster, Muenster, Germany.<br />
(368)-368. Rheumatoid Arthritis Patients Who Lack the<br />
RA-Associated HLA Shared Epitope May Acquire the SE<br />
as Microchimerism from Pregnancy. Zhen Yan, VK Gadi,<br />
Laurence S. Loubiere, Tessa M. Robinson, J Lee Nelson.<br />
Fred Hutchinson and U of WA, Seattle, WA.<br />
(369)-369. Heparin-Binding Domain Of VEGF165 Suppresses<br />
Synoviocyte Survival and Angiogenesis. Jin-Sun Kong, Seung-Ah<br />
Yoo, Hyun-Jin Kim, Seung-Ki Kwok, Hyun-Sook Kim, Chul-<br />
Soo Cho, Wan-Uk Kim. Department of Internal Medicine,<br />
School of Medicine, Catholic University of Korea, Seoul,<br />
Republic of Korea.<br />
(370)-370. Morphological Alteration and Proliferation of Synovial<br />
Fibroblast-like Cells in 3-Dimensional Culture are Induced by<br />
Platelet-derived Growth Factor and Inhibited by Imatinib Mesylate.<br />
Hideto Kameda, Miyuki Suzuki, Hironobu Ishigami, Hiroya<br />
Sakai, Tohru Abe, Tsutomu Takeuchi. Saitama Medical<br />
Center, Kawaoe, Japan.<br />
(371)-371. Expression of the Interleukin 17 Gene in Patients with<br />
Rheumatoid Arthritis. Mika Kohno, Akito Tsutsumi, Hiroto<br />
Matsui, Makoto Sugihra, Mizuko Mamura, Takeshi Suzuki,<br />
Daisuke Goto, Isao Matsumoto, Satoshi Ito, Takayuki<br />
Sumida. Graduate School Comprehensive Human Science,<br />
University of tsukuba, Tsukuba, Japan.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 97
Poster Session A<br />
(372)-372. Rheumatoid Arthritis (RA) Inflammatory Activity is<br />
Associated with Osteopontin (OPN), a Marker of Cardiovascular<br />
Risk. Laura Bazzichi 1 , Alessandra Rossi 2 , Francesca De<br />
Feo 1 , Tiziana Giuliano 1 , Camillo Giacomelli 2 , Mario<br />
Lanza 2 , Arianna Consensi 1 , Anna Maria Mazzone 3 , Stefano<br />
Bombardieri 1 . 1 Department of Internal Medicine, University<br />
of Pisa, Pisa, Italy; 2 Department of Psychiatry, Neurobiology,<br />
Pharmacology and Biotechnology, Pisa, Italy; 3 Department<br />
of Cardiology and Cardiac Surgery, CNR Institute of<br />
Clinical Physiology, Ospedale Pasquinucci, Massa, Italy.<br />
(373)-373. Association of the Immunoglobulin Enhancer<br />
HS1,2A and of the PTPN22 C1858T Polymorphisms with Early<br />
Rheumatoid Arthritis Phenotypes. Barbara Tolusso 1 , Anna<br />
L. Fedele 1 , Silvia Bosello 1 , Claudia Mattioli 2 , Vincenzo<br />
Giambra 2 , Elisa Gremese 1 , Ilaria Cuoghi 1 , Alessia Morelli 1 ,<br />
Donatello Pietrapertosa 1 , Alessandro Michelutti 1 , Maria C.<br />
Papalia 1 , Michele Totaro 1 , Domenico Frezza 2 , Gianfranco<br />
Ferraccioli 1 . 1 Catholic University of the Sacred Heart,<br />
Rome, Italy; 2 Tor Vergata University, Rome, Italy.<br />
(374)-374. Smoking, Low Level of Formal Education and<br />
Infrequent Alcohol Consumption Are Independent Predictors of<br />
Rheumatoid Arthritis. Ulf Bergström, Lennart TH Jacbsson,<br />
Jan-Åke Nilsson, Göran Berglund, Carl Turesson.<br />
University Hospital Malmö, Malmö, Sweden.<br />
(375)-375. Desumoylation Decreases Levels of Histone<br />
Acetylation in Rheumatoid Arthritis Synovial Fibroblasts. Hanna<br />
Maciejewska 1 , Hossein Hemmatazad 1 , Renate E. Gay 1 , Beat<br />
Michel 1 , Michel Neidhart 1 , Christoph Kolling 2 , Steffen<br />
Gay 1 , Thomas Pap 3 , Astrid Juengel 1 . 1 University Hospital,<br />
Zurich, Switzerland; 2 Schulthess Clinic, Zurich, Switzerland;<br />
3<br />
University Hospital, Munster, Germany.<br />
(376)-376. Constitutive Upregulation of the TGF-β Pathway<br />
in Rheumatoid Arthritis Synovial Fibroblasts. Raimund W.<br />
Kinne 1 , Andreas Beyer 2 , Dirk Koczan 3 , Thomas Wilhelm 2 ,<br />
Hans-Jürgen Thiesen 3 , Dirk Pohlers 1 . 1 Experimental<br />
Rheumatology Unit, Department of Orthopedics, Friedrich<br />
Schiller University Jena, Eisenberg, Germany; 2 Leibniz<br />
Institute for Age Research, Fritz Lipmann Institute, Jena,<br />
Germany; 3 Institute of Immunology, University of Rostock,<br />
Rostock, Germany.<br />
(377)-377. Smoking is Associated with Anti-ccp Positive Ra in<br />
a Dose Dependent Manner Results from the Swedish Eira Study.<br />
Henrik Källberg 1 , Leonid Padyukov 2 , Camilla Bengtsson 1 ,<br />
Johan Rönnelid 3 , Lars Klareskog 2 , Lars Alfredsson 1 , The<br />
EIRA study group. 1 Institute of Environmental Medicine,<br />
Karolinska Institutet, Stockholm, Stockholm, Sweden;<br />
2<br />
Rheumatology Unit, Department of Medicine, Karolinska<br />
Institutet/Karolinska Hospital, Stockholm, Sweden;<br />
3<br />
Uppsala University, Akademiska Sjukhuset, Uppsala,<br />
Sweden, Uppsala, Sweden.<br />
(378)-378. Rheumatoid Arthritis Synovial Fibroblasts Induce the<br />
Differentiation of Monocytes into Macrophages. Maria C. Lebre 1 ,<br />
Ana S. Jorge 2 , Armin Soumillion 2 , Saïda Aarrass 3 , Paul P.<br />
Tak 4 . 1 Academic Medical Center/University of Amsterdam,<br />
K0-134, Amsterdam, The Netherlands; 2 Academic Medical<br />
Center/University of Amsterdam, K0-126, Amsterdam,<br />
The Netherlands; 3 Academic Medical Center/University<br />
of Amsterdam, G1-111, Amsterdam, The Netherlands;<br />
4<br />
Academic Medical Center/University of Amsterdam, F4-<br />
218, Amsterdam, The Netherlands.<br />
(379)-379. HLA DRB1 Alleles, PTPN22 Polymorphism and<br />
Citrullinated Antibodies in Multi-case Families with RA from<br />
Northern Sweden. Lisbeth Ärlestig, Heidi Kokkonen, Solbritt<br />
Rantapää Dahlqvist. Dept of Rheumatology, Umea, Sweden.<br />
(380)-380. Higher Frequency of Shared Epitope Alleles among<br />
Anti-CCP Positive Early Arthritis and Established RA Patients<br />
Compared to Anti-CCP Positive Arthralgia Patients. Wouter<br />
H. Bos 1 , Jennie Ursum 1 , Geertje M. Bartelds 1 , Gert-Jan<br />
Wolbink 1 , Michael T. Nurmohamed 1 , Rob J. van der Stadt 1 ,<br />
Jakob B.A. Crusius 2 , Irene E. van der Horst-Bruinsma 2 , Niek<br />
de Vries 3 , Paul-Peter Tak 3 , Ben A.C. Dijkmans 2 , Dirkjan van<br />
Schaardenburg 1 . 1 Jan van Breemen Institute, Amsterdam,<br />
Netherlands; 2 VU Medical Centre, Amsterdam, Netherlands;<br />
3<br />
Academic Medical Centre, Amsterdam, Netherlands.<br />
(381)-381. Altered Cytokine and Chemokine Release of<br />
Stimulated B Cells from Patients with Rheumatoid Arthritis.<br />
Matthias Wahle 1 , Eva Heß 2 , Holm Häntzschel 2 ,<br />
Christoph Baerwald 2 . 1 J.W. Goethe University Hospital,<br />
Frankfurt, Germany; 2 University Hospital, Leipzig, Germany.<br />
(382)-382. Recruitment of B Cells into the Periphery Associates<br />
with Disease Severity in Patients with Rheumatoid Arthritis. Yoe<br />
Kie Onno Teng, N. Levarht, I.M. Bajema, R.E.M. Toes,<br />
T.W.J. Huizinga, J. van Laar. Leiden University Medical<br />
Center, Leiden, The Netherlands.<br />
(383)-383. Osteoblastic function of meschenchymal stem<br />
cell derived from Rheumatoid Arthritis. Daiki Morimoto,<br />
Tetsuya Tomita, Hideki Yoshikawa. Department of<br />
Orthopaedics,Osaka University Graduate School of<br />
Medicine, Suita-shi, Japan.<br />
(384)-384. Rheumatoid Arthritis Synovial Fluid Cells Express<br />
TH-17 Cells. Shiva Shahrara, QiQuan Huang, Rudina<br />
Sobkoviak, Richard M. Pope. Northwestern University,<br />
Feinberg School of Medicine, Chicago, IL.<br />
(385)-385. Risk of Rheumatoid Arthritis and Polymorphisms<br />
in Genes Coding for Mannose Binding Lectin and Surfactant<br />
Protein D. Søren Jacobsen 1 , Merete Pedersen 2 , Hans Ole<br />
Madsen 1 , Mette Klarlund 1 , Morten Frisch 2 , Peter Garred 1 .<br />
1<br />
Copenhagen University Hospital at Rigshospitalet,<br />
Copenhagen, Denmark; 2 Statens Serum Institut,<br />
Copenhagen, Denmark.<br />
98 (Permanent Board Number)-Abstract Number
(386)-386. Functional Promoter Single Nucleotide Polymorphism<br />
of Matrix Metalloproteinase-1 is Related with MRI-Bone Marrow<br />
Edema of Rheumatoid Arthritis Patients. Kazuhiko Arima 1 ,<br />
Mami Tamai 1 , Yuta Kochi 2 , Naoki Iwamoto 1 , Toshiyuki<br />
Aramaki 1 , Keita Fujikawa 1 , Hideki Nakamura 1 , Tomoki<br />
Origuchi 3 , Hiroaki Ida 1 , Atsushi Kawakami 1 , Masataka<br />
Uetana 4 , Kazuhiko Yamamoto 5 , Katsumi Eguchi 1 . 1 First<br />
Department of Internal Medicine, Graduate School of<br />
Biomedical Sciences, Nagasaki University, Nagasaki, Japan;<br />
2<br />
Laboratory for Rheumatic Diseases, SNP Research Center,<br />
RIKEN, Yokohama, Japan; 3 Nagasaki University School of<br />
Health Sciences, Nagasaki, Japan; 4 Department of Radiology<br />
and Radiation Research, Nagasaki University, Nagasaki,<br />
Japan; 5 Department of Allergy and Rheumatology, the<br />
University of Tokyo, Tokyo, Japan.<br />
(387)-387. Tristetraprolin (TTP) Gene Polymorphisms in Patients<br />
with Rheumatoid Arthritis and Healthy Individuals. Takeshi<br />
Suzuki, Akito Tsutsumi, Makoto Sugihara, Mika Kohno,<br />
Daisuke Goto, Isao Matsumoto, Satoshi Ito, Takayuki<br />
Sumida. Graduate School of Comprehensive Human<br />
Science, University of Tsukuba, Tsukuba, Japan.<br />
(388)-388. TNF-α Promoter -308 A/G Polymorphisms and the<br />
Susceptibility to Rheumatoid Arthritis: A Meta-Analysis. Young<br />
Ho Lee, Young Hee Rho, Seong Jae Choi, Jin Hyun Woo,<br />
Jong Dae Ji, Gwan Gyu Song. Division of Rheumatolgy,<br />
Korea University Medical Center, Seoul, Republic of Korea.<br />
(389)-389. Upregulated Expression of the Novel Sumo Specific<br />
Protease SENP7 in RA Synovial Fibroblasts. Marvin A. Peters,<br />
Noreen Pundt, Katja Neugebauer, Thomas Pap. University<br />
Hospital Munster, Munster, Germany.<br />
(390)-390. Synovial Differences Between Anti-CCP Positive<br />
and Anti-CCP Negative Rheumatoid Arthritis. Maikel van<br />
Oosterhout, Ingeborg M. Bajema, Eleonora WN Levarht,<br />
Rene EM Toes, Tom WJ Huizinga, Jacob M. van Laar. Leiden<br />
University Medical Center, Leiden, The Netherlands.<br />
(391)-391. Apoptosis Activity is Modulated Differentially by<br />
TNFα and IL-1β in Human Synovial Fibroblasts. A Mechanism<br />
Independently of Prostaglandins. Beatriz Caramés, Marcos Lires-<br />
Deán, Berta Cillero-Pastor, Carlos Vaamonde, Beatriz Lema,<br />
Francisco J. Blanco, María J. López-Armada. Osteoarticular<br />
and Aging Research Laboratory. Biomedical Research<br />
Center, CHU “Juan Canalejo”, A Coruña, Spain.<br />
(392)-392. Establishment of a Novel TEER Assay to Determine<br />
the Invasive Potential of Synovial Fibroblasts from Different<br />
Patients with Rheumatoid Arthritis. Christina Wunrau 1 ,<br />
Marvin A. Peters 1 , Noreen Pundt 1 , Eva-Maria Schnaeker 2 ,<br />
Berno Dankbar 1 , Thomas Pap 1 . 1 University Hospital<br />
Muenster, Muenster, Germany; 2 University Muenster,<br />
Muenster, Germany.<br />
(393)-393. Increased Expression and Impaired Function of<br />
<strong>Program</strong>med Death (PD)-1 in Synovial Membrane and Synovial<br />
Fluid T-Lymphocytes of Patients with Rheumatoid Arthritis:<br />
Implication for the Homeostatic Control of the Inflammation<br />
Within the Joint. Amalia P. Raptopoulou 1 , Giorgos Bertsias 1 ,<br />
Dimitrios Makrygiannakis 2 , Charalampos Linardakis 1 ,<br />
Heraklis D. Kritikos 1 , Eleni Koutala 1 , Anca I. Catrina 2 ,<br />
Dimitrios T. Boumpas 1 , Prodromos Sidiropoulos 1 .<br />
1<br />
University of Crete, Heraklion, Greece; 2 Department<br />
of Medicine, Rheumatology Unit, Karolinska University<br />
Hospital, Karolinska Institutet, Stockholm, Sweden.<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
SLE: Animal Models<br />
(394)-394. Targeting CD70 in MRL/lpr Mice: A Novel<br />
Therapeutic Approach for Lupus. Matlock Jeffries, Amr H.<br />
Sawalha. University of Oklahoma Health Sciences Center,<br />
Oklahoma City, OK.<br />
(395)-395. Raloxifene Modulates Disease Activity in NZB/W<br />
F1 Lupus Prone Mice. Gabriel Rosenfeld, Yu Zhang, Juana<br />
Gonzalez, Subhrajit Saha, Elena Peeva. Albert Einstein<br />
College of Medicine, Bronx, NY.<br />
(396)-396. Interferon Alpha Induces Anti-Sm Autoantibody de<br />
novo Under Inducible Expression of Interferon Alpha in Transgenic<br />
Mice. Chiaki Uchimura, Yasushi Miura, Masanori Haruna,<br />
Kenichirou Onuma, Chieri Akiyama, Yuichi Taniguchi,<br />
Shunichi Shiozawa. Department of Rheumatology, Kobe<br />
Univercity FHS School of Medicine, Kobe, Japan.<br />
(397)-397. A Novel Interferon-Producing Cell Subset Involved<br />
in the Pathogenesis of Murine Lupus. Pui Y. Lee, Jason S.<br />
Weinstein, Dina C. Nacionales, Philip O. Scumpia, Yi Li,<br />
Nico van Rooijen, Lyle Moldawer, Minoru Satoh, Westley<br />
Reeves. University of Florida, Gainesville, FL.<br />
(398)-398. Deficiency of the Type I Interferon Receptor Protects<br />
Mice from Experimental Lupus. Dina C. Nacionales, Kindra<br />
M. Kelly-Scunpia, Pui Y. Lee, Jason S. Weinstein, Eric<br />
Sobel, Minoru Satoh, Westley H. Reeves. University of<br />
Florida, Gainesville, FL.<br />
(399)-399. Altered Dendritic Cell Differentiation and Activation<br />
in Lupus Prone NZM 2328 Mice Lacking the Type I Interferon<br />
Receptor. Susan Kovats 1 , Noam Jacob 2 , Hemant Agrawal 1 ,<br />
Esther Carreras-Margalef 1 , Sandra Bajana-Miranda 1 , Chaim<br />
O. Jacob 2 . 1 Oklahoma Medical Research Foundation,<br />
Oklahoma City, OK; 2 University of Southern California<br />
Keck School of Medicine, Los Angeles, CA.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 99
Poster Session A<br />
(400)-400. Epistatic Interactions Between NZB Susceptibility Loci<br />
on Chromosomes 1 and 13 Lead to Expansion of an Activated<br />
Dendritic Cell Population and Increased Production of Pathogenic<br />
Autoantibodies. Yui-Ho Cheung, Christina Loh, Joan E.<br />
Wither. Toronto Western Hospital Research Institute,<br />
Toronto, ON, Canada.<br />
(401)-401. Macrophages Contribute To Sle Development In<br />
Bim-/- lpr Mice. Jack Hutcheson 1 , John C. Scatizzi 1 , Chandra<br />
Mohan 2 , Harris Perlman 1 . 1 St. Louis University, Saint Louis,<br />
MO; 2 University of Texas - Southwestern, Dallas, TX.<br />
(402)-402. B Cells Transgenic for Dna Encoding Ig Consensus<br />
Peptide Protect (NZB X NZW)F1 Lupus-prone Mice from Renal<br />
Disease. Francesca Ferrera 1 , Bevra H. Hahn 2 , Marta Rizzi 1 ,<br />
Francesco Indiveri 1 , Gilberto Filaci 1 , Antonio La Cava 2 .<br />
1<br />
University of Genoa, Genoa, Italy; 2 UCLA David Geffen<br />
School of Medicine, Los Angeles, CA.<br />
(403)-403. Naturally Occurring CD4+CD25+ T Cells Regulate<br />
Lupus-Like Disease in (NZB X NZW)F1 Mice and Directly<br />
Suppress Autoantibody-Producing B Cells. Antonio La Cava,<br />
Bevra H. Hahn. UCLA David Geffen School of Medicine,<br />
Los Angeles, CA.<br />
(404)-404. Nasal Anti-cd3 Monoclonal Antibody Suppresses<br />
Murine Lupus By Inducing Il-10 Producing Foxp3+cd4+cd25-<br />
lap+ T Regulatory Cells. Henry Y. Wu, Howard L. Weiner.<br />
Harvard Medical School, Boston, MA.<br />
(405)-405. Breakdown of Peripheral Homeostasis of CD4+foxp3+<br />
T Cells Drives Uncontrolled CD4+ T Cell Activation in Murine<br />
Lupus. Jens Y. Humrich 1 , Henner Morbach 2 , Philipp<br />
Enghard 1 , Reinmar Undeutsch 1 , Stefan Rosenberger 1 ,<br />
Gerd-Rüdiger Burmester 1 , Gabriela Riemekasten 1 . 1 Charité<br />
University Hospital Berlin, Berlin, Germany; 2 University<br />
Hospital of Wuerzburg, Wuerzburg, Germany.<br />
(406)-406. Cyclophosphamide Reduces the Cellular Infiltrate in<br />
the Inflamed Kidneys Rather than Affecting Auto-Antibody Levels<br />
in a Murine Model of Lupus Nephritis. Jens Y. Humrich 1 ,<br />
Philipp Enghard 1 , Stefanie Schürer 1 , Gretel Wittenburg 1 ,<br />
Reinmar Undeutsch 1 , Claudia Berek 2 , Gabriela Riemekasten 1 .<br />
1<br />
Charité University Hospital Berlin, Berlin, Germany;<br />
2<br />
German Rheumatism Research Center, Berlin, Germany.<br />
(407)-407. Multiple Subsets Of CD8+ T Cells Inhibit<br />
Autoimmunity after Induction Of Immune Tolerance by the<br />
Anti-Dna-Based Peptide Pconsensus. Ram P. Singh, Antonio<br />
La Cava, Bevra H. Hahn. UCLA David Geffen School of<br />
Medicine, Los Angeles, CA.<br />
(408)-408. Expansion of Dendritic Cells Drives Abnormal T cell<br />
Activation in Lupus-prone New Zealand Black Chromosome 13<br />
Congenic Mice. Christina Loh, Evelyn Pau, Nan-Hua Chang,<br />
Joan E. Wither. Toronto Western Hospital Research<br />
Institute, Toronto, ON, Canada.<br />
(409)-409. Adoptive Transfer Reconstitutes Anti-RNP<br />
Autoimmunity with Selective Induction of Nephritis or<br />
Pneumonitis. Eric L. Greidinger 1 , YunJuan Zang 1 , Irina<br />
Fernandez 2 , Kimberly Jaimes 3 , Laisel Martinez 3 , Robert W.<br />
Hoffman 1 . 1 University of Miami Medical School, Miami,<br />
FL; 2 Miami VA Foundation for Medical Research, Miami,<br />
FL; 3 Miami VA Medical Center, Miami, FL.<br />
(410)-410. The Role of Lipocalin-2 in the Pathogenesis of Lupus<br />
Nephritis. Milena Pitashny 1 , Xiaoping Qing 1 , Thorsten<br />
Berger 2 , Zeguo Zhao 1 , Tak W. Mak 2 , Chaim Putterman 1 .<br />
1<br />
Albert Einstein College of Medicine, Bronx, NY; 2 The<br />
Campbell Family Institute for Breast Cancer Research,<br />
Toronto, ON, Canada.<br />
(411)-411. Progesterone Prolongs the Survival of Female<br />
NZB/W Mice. Grant C. Hughes, Kang Zhang, David A.<br />
Martin, Keith B. Elkon, Edward A. Clark. University of<br />
Washington, Seattle, WA.<br />
(412)-412. Analysis of T Cells Infiltrating in Kidneys of MRL/<br />
lpr Mouse by Laser-Microdissection Method. Yingge Wang,<br />
Satoshi Ito, Yusuke Chino, Daisuke Goto, Isao Matsumoto,<br />
Akito Tsutsumi, Takayuki Sumida. Division of Clinical<br />
Immunology, Major of Advanced Biomedical Applications,<br />
Graduate School of Comprehensive Human Science,<br />
University of Tsukuba, Tsukuba, Japan.<br />
(413)-413. Inhibition of TWEAK/Fn14 Interactions Ameliorates<br />
Renal Disease in Nephrotoxic Serum Nephritis. Sean Campbell 1 ,<br />
Zeguo Zhao 1 , Hua-Xin Gao 1 , Linda Burkly 2 , Jennifer<br />
Michaelson 2 , Chaim Putterman 1 . 1 Albert Einstein College<br />
of Medicine, Bronx, NY; 2 Biogen-IDEC, Cambridge, MA.<br />
(414)-414. FTY720 Inhibits Lupus Nephritis in the IFNα-<br />
Accelerated NZB/W F1 Lupus Model by Altering Cellular<br />
Phenotype in the Secondary Lymphoid Organs and Trafficking<br />
to the Kidney. Melissa Matzelle, Christian Goess, Jamie<br />
Erickson, Donna McCarthy, Yu Tian, Annette Schwartz,<br />
Lisa Olson, Li Chun Wang. Abbott Bioresearch Center,<br />
Worcester, MA.<br />
(415)-415. Poly (ADP-ribose) Polymerase-1 (PARP-1) Activation<br />
Plays a Fundamental Role in the Pathogenesis of Autoimmune<br />
Nephritis. Neelakshi R. Jog 1 , George C. Scott 1 , Lorenza<br />
Frisoni 1 , Shileen K. Bynum 1 , Joudy-Ann Dinnall 2 , Jaya<br />
Vas 3 , Stefania Gallucci 2 , Marc Monestier 3 , Michael<br />
Madaio 3 , Roberto Caricchio 1 . 1 University of Pennsylvania,<br />
Philadelphia, PA; 2 Children’s Hospital of Philadelphia,<br />
Philadelphia, PA; 3 Temple University, Philadelphia, PA.<br />
(416)-416. Sp1 Transcriptional Factor as a Target for Lupus<br />
Kidney Disease Therapy. Isaac Snowhite 1 , Sabiha Shahnaz 1 ,<br />
Anh Nghiem 1 , Phill Ruiz 2 , Nilamadhab Mishra 1 . 1 Wake<br />
Forest University School of Medicine, Winston Salem, NC;<br />
2<br />
University of Miami, Miami, FL.<br />
100 (Permanent Board Number)-Abstract Number
(417)-417. Role of Aldosterone Blockade in Murine Lupus:<br />
Potential Mechanisms for Improvement in Glomerulonephritis.<br />
Seetha U. Monrad, Paul D. Killen, Marc R. Anderson,<br />
Amanda Bradke, Mariana J. Kaplan. University of<br />
Michigan, Ann Arbor, MI.<br />
(418)-418. Disparate Effects of the Src-Kinase Lyn on Immature<br />
and Mature B cells May Contribute to Development of Lupus-<br />
Like Autoantibody Production. Andrew J. Gross 1 , Anil K.<br />
Panigrahi 2 , Nina L. Prak 2 , Anthony L. DeFranco 1 . 1 Univ<br />
California, San Francisco, San Francisco, CA; 2 University of<br />
Pennsylvania, Philadelphia, PA.<br />
(419)-419. Contributions of BAFF and DNA-containing Immune<br />
Complexes on the Generation of DNA-Reactive B Cells. Daisuke<br />
Kawabata, Jeganathan Venkatesh, Christine M. Grimaldi,<br />
Betty Diamond. Autoimmune Disease Center, The<br />
Feinstein Institute for Medical Research, Manhasset, NY.<br />
(420)-420. Estrogen Receptor Alpha Deficiency Abrogates<br />
Renal Disease in the NZM 2410 Lupus Prone Mouse. John<br />
L. Svenson 1 , Kenneth Korach 2 , Jakie EuDaly 1 , Gary S.<br />
Gilkeson 1 . 1 Medical Univ. of South Carolina, Charleston,<br />
SC; 2 NIEHS, RTP, NC.<br />
(421)-421. Generation and Characterization of a Human 60kD<br />
Ro mouse: Amelioration of Diabetes and Delayed Mortality in<br />
NOD Mice Immunized with Ro Peptide. T. F. Gross, J. R.<br />
Anderson, Y. Wang, M. Zhu, J. M. Guthridge, K. M. Kaufman,<br />
J. B. Harley, J. A. James. OMRF, Oklahoma City, OK.<br />
(422)-422. Maternal MHC Regulates Generation of Pathogenic<br />
Antibodies While Fetal MHC Determines Susceptibility in an<br />
Experimental Congenital Heart Block Model. Linn Strandberg, Aurelie<br />
Ambrosi, Maja Jagodic, Stina Salomonsson, Kristina Bechanovic,<br />
Lars Ottosson, Sven-Erik Sonesson, Tomas Olsson, Marie<br />
Wahren-Herlenius. Karolinska Institutet, Stockholm, Sweden.<br />
(423)-423. Decreased Expression of Fli-1 in Bone Marrow Derived<br />
Hematopoietic Cells Significantly Affect Disease Development in<br />
MRL/lpr Wice. John Zhang, Ivan Molano, Gary Gilkeson.<br />
Medical University of South Carolina, Charleston, SC.<br />
(424)-424. Anti-dsDNA Antibody Production and Immune<br />
Deposits Precede Proteinuria and Antinucleosome Antibody<br />
Formation in (NZBxNZW)F1 Lupus Mice. Manar Kalaaji 1 ,<br />
Johannes C Nossent 2 , Leif Jørgensen 3 , Randi Olsen 4 , Ole<br />
Petter Rekvig 5 . 1 Department of Biochemistry, Institute of<br />
Medical Biology/Medical Faculty, University of Tromsø,<br />
Tromsø, Norway; 2 Department of Rheumatology, Institute<br />
of Clincal Medicine, Tromsø, Norway; 3 Department of<br />
pathology, Institute of Medical Biology/Medical Faculty,<br />
Tromsø, Norway; 4 Department of Electron Microscopy,<br />
Institute of Medical Biology/Medical Faculty, Tromsø,<br />
Norway; 5 Department of Biochemistry, Institute of Medical<br />
Biology/Medical Faculty, Tromsø, Norway.<br />
(425)-425. Accelerated Disease Onset and Progression in<br />
Two Separate Mouse Models of SLE: Benchmarking of High-<br />
Throughput SLE Modeling. Kai Fu, Robin Bolek, Jeffrey<br />
Browning, Catherine Hession, Susan Kalled, Julie Kujawa,<br />
Frank Lutterodt, Jorge-Sanchez Salazar, Henry Hess. Biogen<br />
Idec, Cambridge, MA.<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
SLE: Clinical Aspects and Treatment I<br />
(426)-426. Progressive Normalization of Autoantibody,<br />
Immunoglobulin, and Complement Levels Over 2.5 Years of<br />
Belimumab (Fully Human Monoclonal Antibody to BLyS)<br />
Therapy in Systemic Lupus Erythematosus (SLE) Patients. W.<br />
Stohl 1 , W. Chatham 2 , J. McKay 3 , M. H. Weisman 4 , J. T.<br />
Merrill 5 , M. Petri 6 , J. Condemi 7 , C. Aranow 8 , J. McCune 9 ,<br />
K. Diskin 10 , J. Zhong 10 , L. Pineda 10 , W. Freimuth 10 ,<br />
LBSL02/99 Study Grp. 1 USC, LA, CA; 2 UAB, Birm, AL;<br />
3<br />
OK Ctr for Arth Ther & Res, Tulsa, OK; 4 Cedars-Sinai,<br />
LA, CA; 5 OMRF, OK City, OK; 6 JHU, Balt, MD; 7 AAIR<br />
Res Ctr, Roch, NY; 8 Columbia U, NY, NY; 9 U of Mich,<br />
Ann Arbor, MI; 10 HGS, Rockville, MD.<br />
(427)-427. Safety Profile of Belimumab (Fully Human<br />
Monoclonal Antibody to BLyS) in Patients with Systemic Lupus<br />
Erythematosus (SLE) Treated During a Placebo-Controlled Trial<br />
and in a Long-Term Continuation Study. J. T. Merrill 1 , D. J.<br />
Wallace 2 , W. Stohl 3 , R. Furie 4 , E. Ginzler 5 , S. Stern 6 , J.<br />
Lisse 7 , E. Lee 8 , A. McCain 9 , L. Pineda 10 , J. Ronniger 10 , W.<br />
Freimuth 10 , LBSL02/99 Study Grp. 1 OMRF, OK City, OK;<br />
2<br />
Cedars-Sinai UCLA, LA, CA; 3 USC, LA, CA; 4 NSLIJHS,<br />
Lake Success, NY; 5 SUNY Downstate, Brooklyn, NY; 6 KY<br />
Ctr for Better Bone & Joint Hlth, Louisville, KY; 7 UA<br />
AHSC, Tucson, AZ; 8 Boling Clin Trials, Upland, CA;<br />
9<br />
Texas Res Ctr, Sugar Land, TX; 10 HGS, Rockville, MD.<br />
(428)-428. Safety of MEDI-545, an Anti-Interferon-α Monoclonal<br />
Antibody, in MI-CP126, a Phase 1 Study in Systemic Lupus<br />
Erythematosus (SLE). Joan T. Merrill 1 , Robert Levin 2 ,<br />
Vishala Chindalore 3 , Seth Berney 4 , Lupus Interferon Skin<br />
Activity Study Investigators, Gabriel Robbie 5 , Barbara<br />
White 5 , Lan Zeng 5 , Wendy White 5 , Gregory Dennis 5 .<br />
1<br />
Oklahoma Medical Research Foundation, Oklahoma<br />
City, OK; 2 Clinical Research of West Florida, Clearwater,<br />
FL; 3 Pinnacle Research Group, Anniston, AL; 4 LSUHSC,<br />
Shreveport, LA; 5 MedImmune, Inc., Gaithersburg, MD.<br />
(429)-429. Neutralization of Type I IFN Inducible Genes in<br />
Phase I Trial of Anti-IFNα mAb for the Treatment of SLE: Utility<br />
as Pharmacodynamic Markers. Yihong Yao, Laura Richman,<br />
Melissa de los Reyes, Anmarie Boutrin, Nancy Huddy,<br />
Martha Wester, Barbara White, Anthony J. Coyle, Peter<br />
Kiener, Bahija Jallal. MedImmune Inc, Gaithersburg, MD.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 101
Poster Session A<br />
(430)-430. Direct Quantitation of Interferon-Related Transcripts<br />
in Whole Blood of SLE Patients Without RNA Isolation<br />
and Reverse Transcriptase Real-Time PCR Using Panomics<br />
QuantiGene®Plex Technology: Applications in a Phase I Clinical<br />
Trial. Jonathan Zmuda, Yihong Yao, Jonathan W. Hirsch,<br />
Christopher A. Morehouse, Melissa de los Reyes, Peter<br />
Kiener, Bahija Jallal, Wendy I. White, Barbara White.<br />
MedImmune Inc, Gaithersburg, MD.<br />
(431)-431. Efficacy, Toxicity and Tolerability of Mycophenolate<br />
Mofetil in Patients with Lupus Nephritis, Based on Dose/Weight<br />
Ratio. Lucía Silva-Fernández 1 , Rashmi S. Nadig 2 , Hans Von<br />
Gizycki 2 , Ellen M. Ginzler 2 . 1 Hospital Universitario Puerta<br />
de Hierro, Madrid, Spain; 2 SUNY Downstate Medical<br />
Center, Brooklyn, NY.<br />
(432)-432. Pharmacokinetic Study and Development of a Simple<br />
Sampling Strategy to Assess Mycophenolate Mofetil Exposure in<br />
Systemic Lupus Erythematosus. Zahir Amoura 1 , Noel Zahr 2 ,<br />
Jean Debord 3 , Julien Haroche 1 , Jean-Sébastien Hulot 2 ,<br />
François Saint-Marcoux 3 , Pierre Marquet 3 , Philippe Lechat 2 ,<br />
Jean-Charles Piette 1 . 1 Service de Médecine Interne, Hopital<br />
Pitié Salpétrière, Paris, France; 2 Service de Pharmacologie<br />
Clinique, Hopital Pitié Salpétrière, Paris, France; 3 Service<br />
de Pharmacologie et Toxicologie, Hopital Universitaire de<br />
Limoges, Limoges, France.<br />
(433)-433. Treatment of Active Sle-Associated Glomerulonephritis<br />
(gn) with the Innovative Immunosuppressant 15-deoxyspergualin<br />
(dsg; Gusperimus). Hanns-Martin Lorenz 1 , Wilhelm<br />
Schmitt 2 , Ulf Müller-Ladner 3 , Ingeborg Hauser 4 , Falk<br />
Hiepe 5 , Vladimir Tesar 6 , Heike Wöhling 7 , Peter Heinzel 8 .<br />
1<br />
University of Heidelberg, Heidelberg, Germany; 2 University<br />
of Heidelberg, Mannheim, Germany; 3 University of<br />
Giessen, Bad Nauheim, Germany; 4 University of Frankfurt,<br />
Frankfurt, Germany; 5 University of Berlin, Berlin,<br />
Germany; 6 University of Prague, Prague, Czech Republic;<br />
7<br />
Dabio GmbH, Höhenkirchen, Germany; 8 Euro Nippon<br />
Kayaku, Frankfurt, Germany.<br />
(434)-434. Efficacy and Favourable Safety Profile of Short-Term<br />
Open Label Infliximab for SLE, but Severe Adverse Events<br />
Under Long-Term TNF Blockade. Martin Aringer 1 , Frederic<br />
Houssiau 2 , Winfried B. Graninger 3 , Eva Feierl 4 , Günter<br />
Steiner 4 , Josef S. Smolen 4 . 1 University Medical Center Carl<br />
Gustav Carus,Technical University of Dresden, Dresden,<br />
Germany; 2 Rheumatology, Cliniques universitaires Saint-<br />
Luc, Catholic University of Louvain, Brussels, Belgium;<br />
3<br />
Department of Rheumatology, Internal Medicine,<br />
Medical University of Graz, Graz, Austria; 4 Department of<br />
Rheumatology, Internal Medicine III, Medical University of<br />
Vienna, Vienna, Austria.<br />
(435)-435. Dose Dependent Reduction in Anti-dsDNA Antibody<br />
Levels Observed in the Abetimus LJP 394-90-14 Phase 3 Trial.<br />
Michael J. Tansey 1 , Tenshang Joh 1 , Martthew D. Linnik 1 ,<br />
Bevra H. Hahn 2 . 1 La Jolla Pharmaceutical Company, La<br />
Jolla, CA; 2 UCLA, Los Angeles, CA.<br />
(436)-436. Levels Of Urine CXCL16,MCP-1 And Serum<br />
sTNFR1 Correlate With Renal Disease Activity in SLE. Kok<br />
Ooi Kong 1 , Bernard PL Leung 2 , Weng Giap Law 1 , Bernard<br />
YH Thong 1 , Faith Chia 1 , Tsui Yee Lian 1 , Tang Ching Lau 1 ,<br />
Hiok Hee Chng 1 , Chandra Mohan 3 , Hwee Siew Howe 1 .<br />
1<br />
Tan Tock Seng Hospital, Singapore, Singapore; 2 National<br />
University of Singapore, Singapore, Singapore; 3 University<br />
of Texas, Dallas, TX.<br />
(437)-437. Reliability of Shorter than 24-hr Timed Urine<br />
Collections in Estimating 24-hr Total Urine Protein Excretion in<br />
Patients with Lupus Nephritis. Martina Ziegenbein 1 , Michelle<br />
Petri 1 , Kathryn A. Carson 2 , Brad H. Rovin 3 , Derek M. Fine 1 .<br />
1<br />
Johns Hopkins University, Baltimore, MD; 2 Johns Hopkins<br />
University, Bloomberg School of Public Health, Baltimore,<br />
MD; 3 Ohio State University, Columbus, OH.<br />
(438)-438. Urine Osteoprotegrin (OPG) in Lupus Nephritis<br />
(LN). Adnan Kiani 1 , Huaizhong Hu 2 , Ganesh Vasudevan 2 ,<br />
Catherine Chen 1 , Kristen Johnson 1 , Sukhminder Singh 1 ,<br />
Laurence Magder 3 , Stuart Knechtle 2 , Michelle Petri 1 .<br />
1<br />
Johns Hopkins University, Baltimore, MD; 2 Renovar Inc,<br />
Madison, WI; 3 University of Maryland, Baltimore, MD.<br />
(439)-439. Urine Monocyte Chemoattractant Protein-1 (MCP-1)<br />
in Lupus Nephritis (LN). Adnan Kiani 1 , Huaizhong Hu 2 ,<br />
Ganesh Vasudevan 2 , Catherine Chen 1 , Kristen Johnson 1 ,<br />
Sukhminder Singh 1 , Laurence Magder 3 , Stuart Knechtle 2 ,<br />
Michelle Petri 1 . 1 Johns Hopkins University, Baltimore,<br />
MD; 2 Renovar Inc, Madison, WI; 3 University of Maryland,<br />
Baltimore, MD.<br />
(440)-440. High Dose Cyclophosphamide Versus Traditional<br />
Regimen in Lupus Nephritis (LN). Tarek Abou-Khamis 1 ,<br />
Laurence Magder 2 , Richard Jones 3 , Robert Brodsky 3 ,<br />
Michelle Petri 3 . 1 Good Samaritan Hospital, Baltimore, MD;<br />
2<br />
University of Maryland, Baltimore, MD; 3 Johns Hopkins<br />
University, Baltimore, MD.<br />
(441)-441. Rituximab in the Treatment of Resistant Systemic<br />
Lupus Erythematosus: Failure of Therapy in Rapidly Progressive<br />
Crescentic Lupus Nephritis. Shirish R. Sangle, Rachel J.<br />
Davies, Lubna Aslam, Myles J. Lewis, Rose Wedgwood,<br />
Graham RV Hughes, Ian C. Abbs, David P. D’Cruz.<br />
Lupus Research Unit, The Rayne Institute, King’s College<br />
School of Medicine, St Thomas’ Hospital, London, United<br />
Kingdom.<br />
102 (Permanent Board Number)-Abstract Number
(442)-442. Expression of Endothelial Protein C Receptor (EPCR)<br />
in Peritubular Capillaries (PTC) of Renal Cortex Reflects<br />
Thwarted Cytoprotection and Associates with Progression of<br />
Disease in Lupus Nephritis. Peter Izmirly, Laura Barisoni,<br />
Tania Rivera, Joseph M. Weisstuch, David T. Liu, Howard<br />
M. Belmont, Chung-E Tseng, Anca D. Askanase, Jill P.<br />
Buyon, Robert Clancy. NYU School of Medicine, New<br />
York, NY.<br />
(443)-443. The Prognostic and Pathogenetic Significance of<br />
Severe Focal Segmental Lupus Glomerulonephritis. Melvin M.<br />
Schwartz 1 , Stephen M. Korbet 1 , Robert S. Katz 2 , Edmund<br />
J. Lewis 1 . 1 Rush University Medical College, Chicago, IL;<br />
2<br />
Rheumatology Associates, Rush University Medical Center,<br />
Chicago, IL.<br />
(444)-444. Risk and Predictors of Arterial Thromboembolism<br />
in Lupus and Non-Lupus Primary Glomerulonephritis: A<br />
Comparative Study. Chi Chiu Mok, Ka Hang Tong, Chi<br />
Hung To, Yui Pong Siu, Ling Yin Ho, Tak Cheung Au.<br />
Tuen Mun Hospital, Hong Kong, Hong Kong.<br />
(445)-445. N-Terminal Pro-Brain Natriuretic Peptide in Systemic<br />
Lupus Erythematosus: Relationship with Inflammation and<br />
Cardiovascular Risk Factors. Cecilia P. Chung 1 , Annette<br />
Oeser 1 , Joseph F. Solus 1 , Ingrid Avalos 1 , Daniel Kurnik 1 ,<br />
Paolo Raggi 2 , C. Michael Stein 1 . 1 Vanderbilt University,<br />
Nashville, TN; 2 Emory University, Atlanta, GA.<br />
(446)-446. Accelerated Atherosclerosis in Women with SLE and<br />
Pro-Inflammatory HDL May be Explained in Part by Reduced<br />
ApoJ Activity. Maureen A. McMahon 1 , Jennifer Grossman 1 ,<br />
Brian Skaggs 1 , Michael Li 1 , John Fitzgerald 1 , Christina<br />
Charles 1 , Nagesh Ragavendra 1 , Dan Wallace 2 , Michael<br />
Weisman 2 , Weiling Chen 1 , Bevra H. Hahn 1 . 1 University of<br />
California Los Angeles, Los Angeles, CA; 2 Cedars-Sinai, Los<br />
Angeles, CA.<br />
(447)-447. The Relationship of Asymmetric Dimethylarginine and<br />
Homocysteine with Arterial Stiffness in SLE and RA patients.<br />
Michelle Perna 1 , Deborah R. Alpert 1 , John P. Cooke 2 , Mary<br />
J. Roman 3 , Jane E. Salmon 1 . 1 Hospital for Special Surgery,<br />
New York, NY; 2 Stanford University, Stanford, CA; 3 Weill<br />
Medical College Cornell University, New York, NY.<br />
(448)-448. High-Sensitivity C-Reactive Protein as a Predictor<br />
of Cardiovascular Disease in Patients with Systemic Lupus<br />
Erythematosus: A Case-Control Study. Shin-Seok Lee 1 , Laurence<br />
S. Magder 2 , Michelle Petri 3 . 1 Chonnam National University<br />
Medical School, Gwangju, Republic of Korea; 2 University<br />
of Maryland School of Medicine, Baltimore, MD; 3 Johns<br />
Hopkins University School of Medicine, Baltimore, MD.<br />
(449)-449. Predictors of Progression in Atherosclerosis over Two<br />
Years in SLE. Michelle Petri 1 , Adnan Kiani 1 , Wendy Post 1 ,<br />
Laurence Magder 2 . 1 Johns Hopkins University, Baltimore,<br />
MD; 2 University of Maryland, Baltimore, MD.<br />
(450)-450. The Association between Reference Laboratory<br />
Values and the Classification of SLE. Michelle Petri 1 , Daniel<br />
J. Wallace 2 , Michael Weisman 2 , Dafna Gladman 3 , Paul<br />
Fortin 3 , Murray Urowitz 3 , Victoria Werth 4 , Melissa<br />
Costner 5 , Caroline Gordon 6 , Graciela S. Alarcón 7 , Rosalind<br />
Ramsey-Goldman 8 , Peter Maddison 9 , Ann Clarke 10 ,<br />
Susan Manzi 11 , Sang-Cheol Bae 12 , Joan T. Merrill 13 , Ellen<br />
Ginzler 14 , John Hanly 15 , Ola Nived 16 , Gunnar Sturfelt 16 ,<br />
Jorge Sanchez-Guerrero 17 , Ian Bruce 18 , Cindy Aranow 19 ,<br />
David Isenberg 20 , Asad Zoma 21 . 1 Johns Hopkins University,<br />
Baltimore, MD; 2 SLICC, Los Angeles, CA; 3 SLICC,<br />
Toronto, ON, Canada; 4 Univ. Penn., Philadelphia, PA;<br />
5<br />
UTSW, Dallas, TX; 6 SLICC, Birmingham, United<br />
Kingdom; 7 SLICC, Birmingham, AL; 8 SLICC, Chicago,<br />
IL; 9 SLICC, Bangor, United Kingdom; 10 SLICC, Montreal,<br />
PQ, Canada; 11 SLICC, Pittsburgh, PA; 12 SLICC, Seoul,<br />
Republic of Korea; 13 SLICC, Oklahoma City, OK; 14 SLICC,<br />
Brooklyn, NY; 15 SLICC, Halifax, NS, Canada; 16 SLICC,<br />
Lund, Sweden; 17 SLICC, Mexico City, Mexico; 18 SLICC,<br />
Manchester, United Kingdom; 19 SLICC, New York,<br />
NY; 20 SLICC, London, United Kingdom; 21 SLICC, East<br />
Kilbride, United Kingdom.<br />
(451)-451. Diagnostic Value of Transthoracic Compared With<br />
Transesophageal Echocardiography for Detection of Libman-<br />
Sacks Vegetations. Karen S. Sopko, Gautam R. Moorjani,<br />
Wilmer L. Sibbitt, Jr, Clifford R. Qualls, Carlos A. Roldan.<br />
University of New Mexico School of Medicine and VAMC,<br />
Albuquerque, NM.<br />
(452)-452. Transverse Versus Longitudinal Myeltis in SLE. Julius<br />
Birnbaum, Douglas Kerr, Michelle Petri. Johns Hopkins<br />
University, Baltimore, MD.<br />
(453)-453. Frequency of and Risk Factors for Incident Ischemic<br />
Stroke in Systemic Lupus Erythematosus (SLE). Julius Birnbaum,<br />
Jason Rhodes, Michelle Petri. Johns Hopkins University,<br />
Baltimore, MD.<br />
(454)-454. Aspirin Therapy in Conjunction with Selective<br />
Serotonin Reuptake Inhibitors (SSRI) for the Treatment of<br />
Major Depression in Systemic Lupus Erythematosus. Jamal<br />
A. Mikdashi, Stacy Kennedy, Eric Weintraub, Barry<br />
Handwerger. University of Maryland, School of Medicine,<br />
Baltimore, MD.<br />
(455)-455. The Neurometabolism of Neuropsychiatric Systemic<br />
Lupus Erythematosus: Pre-Mortem MR Spectroscopy Paired with<br />
Post-Mortem Brain Histopathology. Courtney R. Johnson,<br />
Carlos A. Roldan, William M. Brooks, Mario Kornfeld,<br />
Wilmer L. Sibbitt, Jr., Arthur D. Bankhurst. University of New<br />
Mexico Health Sciences Center, Albuquerque, NM.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 103
Poster Session A<br />
(456)-456. Fatigue is associated with Cerebral White Matter<br />
Hyperintensities in Systemic Lupus Erythematosus. Erna Harboe,<br />
Dr, Ole J. Greve, Dr, Mona Beyer, Dr, Anne B. Tjensvoll,<br />
Dr, Lasse G. Gøransson, Dr, Stian Maroni, Psychol, Roald<br />
Omdal, Dr. Stavanger University Hospital, Stavanger, Norway.<br />
Presentation numbers 457-491 are unassigned presentation numbers.<br />
(492)-492. Relationship between Memory Impairment and<br />
Abnormal Hippocampal Neurometabolites in Patients with SLE.<br />
Elizabeth Kozora 1 , David Arciniegas 2 , Mark Brown 2 , Maria<br />
D. Devore 1 , Christopher M. Filley 2 , Alexander Grimm 2 ,<br />
David Miller 2 , Lening Zhang 1 , Christy Wingrove 1 , Sterling<br />
West 2 . 1 National Jewish Medical and Research Center,<br />
Denver, CO; 2 University of Colorado Health Sciences<br />
Center, Denver, CO.<br />
(493)-493. Hydroxychloroquine Protects Lupus Patients from<br />
Developing Seizures: Data from a Large Multiethnic Cohort.<br />
Luis A. González 1 , Rosa M. Andrade 1 , Monica Fernández 1 ,<br />
Mandar Apte 1 , Luis M. Vilá 2 , Gerald McGwin, Jr 1 , John D.<br />
Reveille 3 , Graciela S. Alarcón 1 . 1 University of Alabama at<br />
Birmingham, Birmingham, AL; 2 University of Puerto Rico,<br />
San Juan, Puerto Rico; 3 University of Texas Health Science<br />
Center at Houston, Houston, TX.<br />
(494)-494. Impact of a Common Polymorphism in Platelet<br />
Protein gpIIb on Immune Thrombocytopenia and Neurologic<br />
Manifestations of Patients with SLE. Kenaz Thomas, Eric<br />
Finley, Stan Kamp, Kathleen O’Brien, Sandra Wilson,<br />
Joy Hutcheson, Joan T. Merrill. Oklahoma Med Research<br />
Found, Oklahoma City, OK.<br />
(495)-495. Anti-U1RNP Antibodies in Cerebrospinal Fluid are<br />
Associated with Active Central Nervous System Involvements<br />
in Patients with Systemic Lupus Erythematosus and Mixed<br />
Connective Tissue Disease. Takeshi Sato 1 , Takao Fujii 1 ,<br />
Yoshimasa Fujita 2 , Mikiko Hashimoto 1 , Yoshitaka Imura 1 ,<br />
Hajime Yoshifuji 1 , Takaki Nojima 1 , Koichiro Omura 1 ,<br />
Takashi Usui 1 , Tsuneyo Mimori 1 . 1 Kyoto University, Kyoto,<br />
Japan; 2 National Utano Hospital, Kyoto, Japan.<br />
(496)-496. Serum Perforin, A Novel Apoptosis Marker, Was<br />
Increased in Patients with Systemic Lupus Erythematosus (SLE)<br />
and it May Have Different Clinical Significance in SLE from<br />
Serum Granzyme B. Nobuo Negoro, Satoru Asai, Naoki<br />
Sugimoto, Kae Teramoto, Makio Furukawa, Katsuyuki<br />
Kawakami. Osaka City University Medical School, Osaka, Japan.<br />
(497)-497. April: A Predictive Factor of Response to Treatment<br />
in Systemic Lupus Erythematosus?. Jacques Morel 1 , Camille<br />
Roubille 1 , Lourdes Planelles 2 , Cecilia Rocha 2 , Michael<br />
Hahne 2 , Bernard Combe 1 . 1 Teaching hospital Lapeyronie,<br />
Montpellier, France; 2 Institut de Génétique Moléculaire de<br />
Montpellier (CNRS), Montpellier, France.<br />
(498)-498. April: A Protective Factor in Systemic Lupus<br />
Erythematosus?. Jacques Morel 1 , Camille Roubille 1 , Lourdes<br />
Planelles 2 , Cecilia Rocha 2 , Michael Hahne 2 , Bernard<br />
Combe 1 . 1 Teaching hospital Lapeyronie, Montpellier,<br />
France; 2 Institut de Génétique Moléculaire de Montpellier<br />
(CNRS), Montpellier, France.<br />
(499)-499. Haplotypes of IRF5 and Sle: Associations with<br />
Disease Features and Sequelae. Elizabeth E. Brown 1 , Jeffrey C.<br />
Edberg 1 , Michelle Petri 2 , John D. Reveille 3 , Luis M. Vilá 4 ,<br />
Rosalind Ramsey-Goldman 5 , Graciela S. Alarcón 1 , Robert<br />
P. Kimberly 1 . 1 University of Alabama at Birmingham,<br />
Birmingham, AL; 2 John Hopkins University School of<br />
Medicine, Baltimore, MD; 3 University of Texas-Houston<br />
Health Science Center, Houston, TX; 4 University of Puerto<br />
Rico, San Juan, Puerto Rico; 5 Northwestern University<br />
School of Medicine, Chicago, IL.<br />
(500)-500. Reactivity of Antibodies to Cyclic Citrullinated Peptide<br />
(CCP) and Unmodified Arginine Peptide in SLE as a Marker of<br />
Destructive/Deforming Arthritis. Prasanthi Kakumanu, Sonali<br />
Narain, Eric S. Sobel, Mark S. Segal, Paulette C. Hahn,<br />
Westley H. Reeves, Minoru Satoh. University of Florida,<br />
Gainesville, FL.<br />
(501)-501. SLE Patients from Multiplex and Simplex Families<br />
in a Large Multi-ethnic Cohort Have Similar Clinical Profiles.<br />
Andrea L. Sestak 1 , Swapan K. Nath 1 , Jennifer A. Kelly 1 ,<br />
Judith A. James 1 , Joel M. Guthridge 1 , Gail R. Bruner 1 ,<br />
Joanne M. Tesiram 1 , John B. Harley 2 . 1 Oklahoma Medical<br />
Research Foundation, Oklahoma City, OK; 2 Oklahoma<br />
Medical Research Foundation, OU Health Sciences Center,<br />
VA Medical Center, Oklahoma City, OK.<br />
(502)-502. Work Disability in Systemic Lupus Erythematosus.<br />
Ali M. AlDhanhani 1 , Jiandong Su 2 , Murray Urowitz 2 ,<br />
Dafna Gladman 2 , Paul R. Fortin 2 . 1 University of Toronto,<br />
Toronto, ON, Canada; 2 University of Toronto Lupus<br />
Clinic, Centre for Prognosis Studies in the Rheumatic<br />
Diseases, Toronto Western Hospital, University Health<br />
Network; Department of Medicine, University of Toronto,<br />
Toronto, ON, Canada.<br />
(503)-503. Systemic Lupus Erythematosus (SLE) Patients with<br />
Renal Damage Incur Higher Health Care Costs. A. E. Clarke 1 ,<br />
P. Panopalis 2 , M. Petri 3 , S. Manzi 4 , D. A. Isenberg 5 , C.<br />
Gordon 6 , J-L Senecal 7 , L. Joseph 1 , Y. St. Pierre 1 , T. Li 8 .<br />
1<br />
McGill University Health Centre, Montreal, PQ, Canada;<br />
2<br />
UCSF, San Francisco, CA; 3 John Hopkins University<br />
School of Medicine, Baltimore, MD; 4 University of<br />
Pittsburgh, Pittsburgh, PA; 5 University College London,<br />
London, United Kingdom; 6 University of Birmingham,<br />
Birmingham, United Kingdom; 7 Université de Montréal,<br />
Montréal, PQ, Canada; 8 Bristol-Myers Squibb, Princeton, NJ.<br />
104 (Permanent Board Number)-Abstract Number
(504)-504. Cost of Illness: Systemic Lupus Erythematosus Versus<br />
Lupus Nephritis. D. F. Eisenberg, N. Zhao, B. Hsu, Y. Wu,<br />
K. Renahan, C. Han, M. Bala. Centocor Research &<br />
Development, Inc., Malvern, PA.<br />
(505)-505. The Georgia Lupus Registry: Accuracy of Hospital<br />
Discharge Data in Identifying Systemic Lupus Erythematosus.<br />
S. Sam Lim 1 , Ahmed Jamal 2 , Rana Bayakly 2 , Leuy Tong 1 ,<br />
Cristina Drenkard 1 . 1 Emory University, Atlanta, GA;<br />
2<br />
Georgia Department of Human Resources, Atlanta, GA.<br />
(506)-506. The Georgia Lupus Registry: Predictors of Capturing<br />
SLE Utilizing Hospital Discharge Data. Cristina Drenkard 1 ,<br />
Ahmed Jamal 2 , Rana Bayakly 2 , S. Sam Lim 1 . 1 Emory<br />
University, Atlanta, GA; 2 Georgia Department of Human<br />
Resources, Atlanta, GA.<br />
(507)-507. Numerical Scoring for Classic BILAG Index. Chee-<br />
Seng Yee 1 , L. Cresswell 2 , V. Farewell 3 , D. Isenberg 4 , A.<br />
Rahman 4 , L. Teh 5 , B. Griffiths 6 , I. Bruce 7 , Y. Ahmad 8 ,<br />
A. Prabu 1 , M. Akil 9 , N. McHugh 10 , D. D’Cruz 4 , M.<br />
Khamashta 4 , P. Maddison 11 , C. Gordon 1 . 1 University<br />
of Birmingham, Birmingham, United Kingdom; 2 MRC<br />
Biostatistic Unit, Cambridge, United Kingdom; 3 MRC<br />
Biostatistics Unit, Cambridge, United Kingdom; 4 BILAG,<br />
London, United Kingdom; 5 BILAG, Blackburn, United<br />
Kingdom; 6 BILAG, Newcastle, United Kingdom; 7 BILAG,<br />
Manchester, United Kingdom; 8 MRI, Manchester, United<br />
Kingdom; 9 BILAG, Sheffield, United Kingdom; 10 BILAG,<br />
Bath, United Kingdom; 11 BILAG, Bangor, United Kingdom.<br />
(508)-508. BILAG-2004 Index for Assessment of SLE Disease<br />
Activity Is Sensitive to Change. Chee-Seng Yee 1 , V. Farewell 2 ,<br />
D. Isenberg 3 , A. Rahman 3 , L. Teh 4 , B. Griffiths 5 , I. Bruce 6 ,<br />
Y. Ahmad 7 , A. Prabu 1 , M. Akil 8 , N. McHugh 9 , D. D’Cruz 3 ,<br />
M. Khamashta 3 , P. Maddison 10 , C. Gordon 1 . 1 University<br />
of Birmingham, Birmingham, United Kingdom; 2 MRC<br />
Biostatistics Unit, Cambridge, United Kingdom; 3 BILAG,<br />
London, United Kingdom; 4 BILAG, Blackburn, United<br />
Kingdom; 5 BILAG, Newcastle, United Kingdom; 6 BILAG,<br />
Manchester, United Kingdom; 7 MRI, Manchester, United<br />
Kingdom; 8 BILAG, Sheffield, United Kingdom; 9 BILAG,<br />
Bath, United Kingdom; 10 BILAG, Bangor, United Kingdom.<br />
(509)-509. SLEDAI-2000 Index Does Not Capture SLE Disease<br />
Activity Requiring Increase in Therapy as well as BILAG-2004<br />
Index. Chee-Seng Yee 1 , V. Farewell 2 , D. Isenberg 3 , A.<br />
Rahman 3 , I. Bruce 4 , Y. Ahmad 5 , L. Teh 6 , B. Griffiths 7 , M.<br />
Akil 8 , A. Prabu 1 , N. McHugh 9 , D. D’Cruz 3 , M. Khamashta 3 ,<br />
P. Maddison 10 , C. Gordon 1 . 1 University of Birmingham,<br />
Birmingham, United Kingdom; 2 MRC Biostatistic Unit,<br />
Cambridge, United Kingdom; 3 BILAG, London, United<br />
Kingdom; 4 BILAG, Manchester, United Kingdom; 5 MRI,<br />
Manchester, United Kingdom; 6 BILAG, Blackburn,<br />
United Kingdom; 7 BILAG, Newcastle, United Kingdom;<br />
8<br />
BILAG, Sheffield, United Kingdom; 9 BILAG, Bath, United<br />
Kingdom; 10 BILAG, Bangor, United Kingdom.<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
SLE: Human Etiology and Pathogenesis I<br />
(510)-510. Pre-Clinical Humoral Autoimmunity and Altered<br />
Immunity to Epstein-Barr Virus in Presumed Healthy Primary<br />
Female Relatives of Systemic Lupus Erythematosus (SLE) Patients.<br />
Brian D. Poole, Hermancia S. Eugene, Lauren L. Curley,<br />
Benjamin F. Bruner, John B. Harley, Judith A. James. Oklahoma<br />
Medical Research Foundation, Oklahoma City, OK.<br />
(511)-511. Analysis of Gene Expression Pathways in SLE PBMC.<br />
Kyriakos A. Kirou, Christina Lee, Sandhya George, Mary K.<br />
Crow. Hospital for Special Surgery, New York, NY.<br />
(512)-512. Lupus Immune Complexes Containing RNA-<br />
Associated Autoantibodies are More Potent Inducers of Interferon<br />
than those Containing Anti-DNA Autoantibodies. Jing Hua 1 ,<br />
Jane Tian 2 , Kyriakos A. Kirou 1 , Anthony J. Coyle 2 , Mary<br />
K. Crow 1 . 1 Hospital for Special Surgery, New York, NY;<br />
2<br />
MedImmune, Inc., Gaithersburg, MD.<br />
(513)-513. Lupus Families Reveal Age- and Sex- Related Patterns<br />
of Interferon Alpha Expression. Timothy B. Niewold 1 , Jeremy<br />
E. Adler 2 , Thomas J.A. Lehman 2 , John B. Harley 3 , Mary K.<br />
Crow 2 . 1 University of Chicago, Chicago, IL; 2 Mary Kirkland<br />
Center for Lupus Research, Hospital for Special Surgery,<br />
New York, NY; 3 Oklahoma Medical Research Foundation,<br />
Oklahoma City, OK.<br />
(514)-514. Genetic Association with Interferon Regulatory Factor<br />
5 (IRF5) and Systemic Lupus Erythematosus in Multiple Ethnic<br />
Groups. Jennifer A. Kelly 1 , Jeffrey C. Edberg 2 , Kenneth M.<br />
Kaufman 3 , Jeff Kilpatrick 1 , Gail R. Bruner 1 , Joan T. Merrill 4 ,<br />
Judith A. James 4 , Miranda C. Marion 5 , Carl D. Langefeld 5 ,<br />
Michelle A. Petri 6 , John D. Reveille 7 , Rosalind Ramsey-<br />
Goldman 8 , Luis M. Vilá 9 , Graciela S. Alarcón 2 , Robert P.<br />
Kimberly 2 , John B. Harley 3 . 1 Oklahoma Medical Research<br />
Foundation (OMRF), OKC, OK; 2 Univ of Alabama at<br />
Birmingham, Birmingham, AL; 3 OMRF; U.S. Dept of<br />
Veterans Affairs Medical Center; Univ of Oklahoma<br />
Health Sciences Center, OKC, OK; 4 OMRF; Univ of<br />
Oklahoma Health Sciences Center, OKC, OK; 5 Wake<br />
Forest Univ, Winston-Salem, NC; 6 Johns Hopkins Univ<br />
School of Medicine, Baltimore, MD; 7 Univ of Texas Health<br />
Science Center, Houston, TX; 8 Northwestern Univ School<br />
of Medicine, Chicago, IL; 9 Univ of Puerto Rico Medical<br />
Sciences Campus, San Juan, Puerto Rico.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 105
Poster Session A<br />
(515)-515. Regulation of the Type I Interferon Production in<br />
Plasmacytoid Dendritic Cells Induced by snRNP-Containing<br />
Immune Complexes. Maija-Leena Eloranta 1 , Tanja Lövgren 1 ,<br />
Linda Mathsson 2 , Johan Ronnelid 2 , Berthold Kastner 3 ,<br />
Gunnar V. Alm 4 , Lars Rönnblom 1 . 1 Dept. of Medical<br />
Sciences, Uppsala University, Uppsala, Sweden; 2 Unit<br />
of Clinical Immunology, Uppsala University, Uppsala,<br />
Sweden; 3 Max Planck Institute of Biophysical Chemistry,<br />
Gottingen, Germany; 4 Dept. Molecular Biosciences, SLU,<br />
Uppsala, Sweden<br />
(516)-516. Normal Response of SLE Lymphocytes to Interleukin-2<br />
(IL-2) and other Gamma-Chain Cytokines. Eva Feierl 1 , Thomas<br />
Karonitsch 1 , Carl Walter Steiner 1 , Guenter Steiner 1 ,<br />
Clemens Scheinecker 1 , Josef S. Smolen 1 , Martin Aringer 2 .<br />
1<br />
Medical University of Vienna, Vienna, Austria; 2 University<br />
Clinical Centre Carl Gustav Carus Technical University of<br />
Dresden, Dresden, Germany.<br />
(517)-517. Autoantibodies to hnRNP A2 (RA33) are Associated<br />
with Lupus Arthritis. Eva Feierl 1 , Milos Kudra 1 , Thomas<br />
Karonitsch 1 , Guenter Steiner 1 , Josef S. Smolen 1 , Martin<br />
Aringer 2 . 1 Medical University of Vienna, Vienna, Austria;<br />
2<br />
University Centre Carl Gustav Technical University of<br />
Dresden, Dresden, Germany.<br />
(518)-518. TNF and INTERLEUKIN-18 (IL-18) in Systemic<br />
Lupus Erythematosus: Activity-Associated Upregulation in Serum<br />
and Renal Tissue. Martin Aringer 1 , Iain B. McInnes 2 , Günter<br />
Steiner 3 , Afschin Soleiman 4 , Sabina Stöckl-Hiesleitner 5 ,<br />
Elisabeth Hoefler 6 , Brigitte Meyer 3 , Walter Ulrich 5 , Josef<br />
S. Smolen 3 . 1 University Medical Center Carl Gustav<br />
Carus,Technical University of Dresden, Dresden, Germany;<br />
2<br />
Centre for Rheumatic Diseases, University of Glasgow,<br />
Glasgow, United Kingdom; 3 Department of Rheumatology,<br />
Internal Medicine III, Medical University of Vienna,<br />
Vienna, Austria; 4 Department of Pathology, Medical<br />
University of Vienna, Vienna, Austria; 5 Department of<br />
Pathology, Hietzing Hospital, Vienna, Austria; 6 Department<br />
of Medicine II, Hietzing Hospital, Vienna, Austria.<br />
(519)-519. Analysis of Regulatory T Cell Subsets in Patients<br />
with Autoimmune Diseases. Michael M. Bonelli, Anastasya<br />
Savitskaya, Karolina von Dalwigk, Alfred Rapp, Josef S.<br />
Smolen, Clemens Scheinecker. Medical university of vienna,<br />
Vienna, Austria.<br />
(520)-520. Thymus Recent Emigrants Rate is Associated with<br />
Disease Activity in Systemic Lupus Erythematosus. Queila F.<br />
Vieira, Cristiane Kayser, Daniela V. Horvath, Esper Kallas,<br />
Luis E. Andrade. Universidade Federal de São Paulo, São<br />
Paulo, Brazil.<br />
(521)-521. Multiplex Autoantigen Arrays Reveal Conserved<br />
Specific IgG autoantibody Profiles in SLE Twins. Gregg J.<br />
Silverman 1 , R. Srikrishnan 1 , Rufus W. Burlingame 2 , K.<br />
Germar 1 , K. Andrews 1 , Ellen M. Ginzler 3 , Betty P. Tsao 4 .<br />
1<br />
UCSD, La Jolla, CA; 2 INOVA Diagnostics, San Diego, CA;<br />
3<br />
SUNY Downstate Medical Center, Brooklyn, NY; 4 UCLA,<br />
Los Angeles, CA.<br />
(522)-522. Linking Interferon-alpha and Premature Atherosclerosis<br />
in Systemic Lupus Erythematosus. Michael F. Denny 1 , Seth<br />
Thacker 1 , Hemal Mehta 1 , Emily C. Somers 1 , Todd Dodick 1 ,<br />
Jennifer Johnson 1 , Franck J. Barrat 2 , W. Joseph McCune 1 ,<br />
Mariana J. Kaplan 1 . 1 University of Michigan, Ann Arbor,<br />
MI; 2 Dynavax Technologies, Berkeley, CA.<br />
(523)-523. Production of Type I Interferon by Circulating<br />
Monocyte-like Cells with Deficient Production by Plasmacytoid<br />
Dendritic Cells in Sle. Haoyang Zhuang, Yi Li, Pui Lee, Dina<br />
Nacionales, Kindra Kelly-Scumpia, Jason S. Weinstein,<br />
Mark Segal, Minoru Satoh, Eric Sobel, Westley H. Reeves.<br />
University of Florida, Gainesville, FL.<br />
(524)-524. PRKR (Interferon-Inducible Double-Stranded RNA<br />
Dependent Protein Kinase) Controls Immunoglobulin and<br />
Interferon-Induced Gene Expression in SLE PBMC. Bernard<br />
R. Lauwerys 1 , Ilse Gutierrez-Roelens 1 , Benoit J. Van den<br />
Eynde 2 , Frederic A. Houssiau 1 . 1 Cliniques Universitaires<br />
Saint-Luc, Universite catholique de Louvain, Brussels, Belgium;<br />
2<br />
Ludwig Institute for Cancer Research, Brussels, Belgium.<br />
(525)-525. Gene Expression in the Bone Marrow vs the<br />
Peripheral Blood in Human Systemic Lupus Erythematosus: Bone<br />
Marrow Better Differentiates Active from Inactive Patients and<br />
Displays Apoptosis and Granulopoiesis Signature. Magdalene<br />
Nakou 1 , Nicholas Knowlton 2 , Eleni Papadaki 1 , Amalia<br />
Raptopoulou 1 , Prodromos Sidiropoulos 1 , Heraklis Kritikos 1 ,<br />
Michael Centola 3 , Dimitrios T. Boumpas 1 . 1 University of<br />
Crete, Heraklion, Crete, Greece; 2 OMRF, Oklahoma, OK;<br />
3<br />
OMRF, Oklahoma City, OK.<br />
(526)-526. UVBExposure And TNF-a Induce 52 Kda Ro/ssa<br />
Surface Expression On Human Keratinocytes Independent Of<br />
Apoptosis. Bjorn Hostmann, Velia Gerl, P. Grossmann, C.<br />
Johnen, K. Bräutigam, G. Hausdorf, A. Waka, M. Rosowski,<br />
A. Radbruch, Falk Hiepe. Universitiy Medicine Charité,<br />
Berlin, Germany.<br />
(527)-527. Onset of Systemic Lupus Erythematosus among<br />
Cigarette Smokers. Rachna Aggarwal 1 , David M. Thompson 1 ,<br />
Bahram Namjou 2 , R. Hal Scofield 1 . 1 University of Oklahoma<br />
Health Sciences Center, Oklahoma City, OK; 2 Oklahoma<br />
Medical Research Foundation, Oklahoma City, OK.<br />
(528)-528. Male Only Systemic Lupus Erythematosus Families.<br />
Rachna Aggarwal 1 , Eun Sim Shin 1 , Shibo Li 1 , R. Hal<br />
Scofield 2 . 1 University of Oklahoma Health Sciences<br />
Center, Oklahoma City, OK; 2 Oklahoma Medical Research<br />
Foundation, Oklahoma City, OK.<br />
106 (Permanent Board Number)-Abstract Number
(529)-529. Autoantibody Subsets and Cytokine Profile in Systemic<br />
Lupus Erythematosus. Biji T. Kurien, Philip Alex, Gemma<br />
Wallis, Michael Centola, R. Hal Scofield. Oklahoma<br />
Medical Research Foundation, Oklahoma City, OK.<br />
(530)-530. Defective Expression of Inhibitory Molecule<br />
<strong>Program</strong>med Cell Death Ligand-1 on Monocytes and Myeloid<br />
Dendritic Cells in Active Systemic Lupus Erythematosus. Neelufar<br />
Mozaffarian 1 , Alice Wiedeman 2 , Anne M. Stevens 2 .<br />
1<br />
University of Washington, Seattle, WA; 2 Children’s<br />
Hospital and Regional Medical Center, Seattle, WA.<br />
(531)-531. Galectin-3 Expression Level was Correlated with<br />
Histological Activity Index, Anti-dsDNA Antibody Titer, and<br />
Complement Levels in Lupus Nephritis. Eun Ha Kang 1 , Hee<br />
Jung Ryu 1 , Jung Hwa Lee 1 , Kyung Chul Moon 2 , Eun Young<br />
Lee 1 , Yun Jong Lee 1 , Eun Bong Lee 1 , Curie Ahn 3 , Yeong<br />
Wook Song 1 . 1 Division of Rheumatology Department of<br />
Internal Medicine Seoul National University Hospital,<br />
Seoul, Republic of Korea; 2 Department of Pathology Seoul<br />
National University Hospital, Seoul, Republic of Korea;<br />
3<br />
Division of Nephrology Department of Internal Medicine<br />
Seoul National University Hospital, Seoul, Republic of Korea.<br />
(532)-532. Urinary Lipocalin-2 is Associated with Renal Disease<br />
Activity in Human Lupus Nephritis. Milena Pitashny 1 , Noa<br />
Schwartz 1 , Xiaoping Qing 1 , Bernard Hojaili 1 , Cynthia<br />
Aranow 2 , Meggan Mackay 2 , Chaim Putterman 1 . 1 Albert<br />
Einstein College of Medicine, Bronx, NY; 2 Columbia<br />
University, New York, NY.<br />
(533)-533. Defective Expression of Ras Guanine Nucleotide<br />
Releasing Protein 1 in a Subset of Patients with Systemic Lupus<br />
Erythematosus. Shinsuke Yasuda 1 , Richard L. Stevens 2 ,<br />
Tomoko Terada 1 , Tetsuya Horita 1 , Hiroshi Kataoka 1 , Toko<br />
Hashimoto 1 , Jun Fukae 1 , Tatsuya Atsumi 1 , Takao Koike 1 .<br />
1<br />
Hokkaido University Graduate School of Medicine,<br />
Sapporo, Japan; 2 Brigham and Women’s Hospital and<br />
Harvard Medical School, Boston, MA.<br />
(534)-534. Restoration of DNA Methylation in Lupus B-Cells<br />
Using Anti-IL-6 Receptor Antibodies. Soizic Garaux, Christelle<br />
Le Dantec, Sandrine Jousse, Christophe Jamin, Alain Saraux,<br />
Pierre Youinou. Brest Medical School Hospital, Brest, France.<br />
(535)-535. Low Serum 25 OH Vitamin D Concentrations in<br />
Patients with Systemic Lupus Erythematosus are Aassociated with<br />
Increased Disease Activity. Howard Amital 1 , Hedi Orbach 2 ,<br />
Gisele Zandman-Goddard 3 , Emese Kiss 4 , Andrea Doria 5 ,<br />
Tali Vishne 1 , Zoltan Szekanecz 4 , Yehuda Shoenfeld 6 . 1 Meir<br />
Medical Center, Kfar Saba, Israel; 2 Department of Internal<br />
Medicine ‘B’, Wolfson Medical Center, Holon,, Israel;<br />
3<br />
Department of Medicine ‘C’, Wolfson Medical Center,<br />
Holon, Israel; 4 Division of Rheumatology, University of<br />
Debrecen, Debrecen, Hungary; 5 Division of Rheumatology,<br />
Italy, Hospital of Padova, Italy; 6 Department of Internal<br />
Medicine B and The Center of Autoimmune Diseases,<br />
Sheba Medical Center, Tel-Hashomer, Israel.<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Genetics, Genomics and Proteomics I<br />
(536)-536. The HLA-DRB1*13 Alleles Reveal Opposite Effects<br />
on Risk of Developing Anti-CCP Positive and Anti-CCP Negative<br />
Rheumatoid Arthritis Independent of SE Alleles. Emeli Lundström 1 ,<br />
Henrik Källberg 1 , Johan Rönnelid 2 , Lars Alfredsson 1 , Lars<br />
Klareskog 1 , Leonid Padyukov 1 . 1 Karolinska Institutet,<br />
Stockholm, Sweden; 2 University of Uppsala, Uppsala, Sweden.<br />
(537)-537. Whole Genome Association Study of Quantitative<br />
CCP Titer in Rheumatoid Arthritis. Jing Cui 1 , Elizabeth<br />
W. Karlson 1 , Anita L. DeStefano 2 , Nancy E. Maher 1 ,<br />
Roberta Glass 1 , Elena Izmailova 3 , Ronenn Roubenoff 4 ,<br />
Michael E. Weinblatt 1 , Alex Parker 5 , Robert M. Plenge 1 ,<br />
Nancy A. Shadick 1 . 1 Brigham Women’s Hospital, Boston,<br />
MA; 2 Boston University, Boston, MA; 3 Millennium<br />
Pharmaceutical, Boston, MA; 4 Biogen Idec, Inc., Boston,<br />
MA; 5 Amgen Inc., Boston, MA.<br />
(538)-538. Association Between ß2-Adrenergic Receptor Polymorphisms<br />
Together with the Hla-drb1 Shared Epitope and Rheumatoid Arthritis in<br />
Conjunction with Anti-ccp Antibodies. Olga Malysheva, Uta Wagner,<br />
Matthias Wahle, Ulf Wagner, Matthias Pierer, Christoph<br />
Baerwald. University Hospital, Leipzig, Germany.<br />
(539)-539. A Dense Snp Mapo of the Extended Hla Region<br />
Defines Anti-Citrulline Positive and Negative Rheumatoid<br />
Arthritis as Distinct Groups and Reveals Novel Genetic Risk<br />
Factors for Anti-Citrulline Positive Subset of the Disease. Leonid<br />
Padyukov 1 , Bo Ding 1 , Mark Seielstad 2 , Robert M. Plenge 3 ,<br />
C. I. Amos 4 , P. K. Gregersen 5 , Lars Alfredsson 1 , Lars<br />
Klareskog 1 . 1 Karolinska Institutet, Stockholm, Sweden;<br />
2<br />
Genome Institute of Singapore, Singapore, Singapore;<br />
3<br />
The Broad Institute, MIT and Harvard,, Cambridge, MA;<br />
4<br />
University of Texas, Houston, TX; 5 The Feinstein Institute<br />
for Medical Research, Manhasset, NY.<br />
(540)-540. Biomarker Identification for Rheumatoid Arthritis<br />
using a Collagen-Induced Arthritis Rat Model. Shuzo Tagashira,<br />
Hatsuo Furuichi, Yosuke Nagasaka, Yutaka Ueda, Toru<br />
Kimura, Fumio Nishikaku. Dainippon Sumitomo Pharma<br />
Co., Ltd., Osaka, Japan.<br />
(541)-541. Association of Haplotypes of MMP1 and MMP3<br />
Polymorphisms with Erosive Status in Early Rheumatoid<br />
Arthritis. Arnaud Constantin 1 , Pierre-Antoine Gourraud 2 ,<br />
Jean-Frédéric Boyer 3 , Delphine Nigon 1 , Bruno Faucon 4 ,<br />
Bénédicte Jamard 1 , Jean-Luc Davignon 4 , Alain Cantagrel 1 .<br />
1<br />
Rangueil University Hospital, Toulouse Cedex 9, France;<br />
2<br />
INSERM U558, Toulouse, France; 3 JE 2510, Paul Sabatier<br />
University, Toulouse Cedex 9, France; 4 JE 2510, Paul<br />
Sabatier University, Toulouse, France.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 107
Poster Session A<br />
(542)-542. Influence of a Matrix Metalloproteinase 3 Promoter<br />
Polymorphism to Serum Titer of MMP-3 in a Japanese<br />
Rheumatoid Arthritis Cohort. So Tsukahara, Katsunori Ikari,<br />
Taisuke Tomatsu, Mikiko Shinozaki, Masako Hara, Hisashi<br />
Yamanaka, Shigeki Momohara, Naoyuki Kamatani. Tokyo<br />
Women’s Med Univ, Tokyo, Japan.<br />
(543)-543. Genetic Influence of the Protein Tyrosine Phosphatase<br />
Nonreceptor 22 1858T and HLA-Shared Epitope Alleles on<br />
Diagnosis and Prognosis of Early Rheumatoid Arthritis. Vincent<br />
GOEB 1 , Philippe Dieudé 2 , Romain Daveau 3 , Othmane<br />
Mejjad 1 , Alain Daragon 1 , Sophie Pouplin 1 , Patrice<br />
Fardellone 4 , Daniele Gilbert 3 , François Tron 3 , Xavier Le<br />
Loët 1 , François Cornélis 5 , Olivier Vittecoq 1 . 1 Rheumatology<br />
Department and Inserm U519, Rouen University Hospital,<br />
Rouen, France; 2 Rheumatology Department, Bichat<br />
Claude Bernard University Hospital, APHP, Paris, France;<br />
3<br />
Immunology Department and Inserm U519, Rouen<br />
University Hospital, Rouen, France; 4 Rheumatology<br />
Department, Amiens University Hospital, Amiens,<br />
France; 5 GenHotel, University of Evry-Paris VII, Faculty of<br />
Lariboisière-Saint Louis, APHP, Evry-Genopole, Paris, France.<br />
(544)-544. Inflammatory Cytokines Induce Aberrant Splicing<br />
of Dbl Proto-oncogene as Rheumatoid Arthritis Disease Gene.<br />
Koichiro Komai, Yui Imanishi, Mayumi Ito, Akira<br />
Hashiramoto, Shunichi Shiozawa. Div. of Rheumatology,<br />
FHS., Sch. of Med., Kobe Univ., Kobe, Japan.<br />
(545)-545. A Genome-Wide SNP Association Study Identifies<br />
Novel Risk Loci for Rheumatoid Arthritis. Bo Ding 1 , Mark<br />
Seielstad 2 , Leonid Padyukov 1 , Lars Alfredsson 1 , Lars<br />
Klareskog 1 , EIRA Study Group. 1 Karolinska Institutet,<br />
Stockholm, Sweden; 2 Genome Institute of Singapore,<br />
Singapore, Singapore.<br />
(546)-546. Association of a Single-Nucleotide Polymorphism in<br />
PDCD1 with Rheumatoid Arthritis Susceptibility in Koreans.<br />
Tae-Un Han 1 , Il Kim 2 , Sang-Cheol Bae 2 , Changwon Kang 1 .<br />
1<br />
Dept. of Biological Sciences, Korea Advanced Institute<br />
of Science and Technology, Daejeon, Republic of Korea;<br />
2<br />
Dept. of Internal Medicine, Division of Rheumatology,<br />
Hanyang University College of Medicine and the Hospital<br />
for Rheumatic Diseases, Seoul, Republic of Korea.<br />
(547)-547. Gene Expression Profiling Reveals an Increased Foxo3a<br />
mRNA Expression in Peripheral Blood of Rheumatoid Arthritis<br />
Patients as an Indication of Polymorphonuclear Cell Activation.<br />
Alexandre Pachot, Fanny Turrel, Myew-Ling Toh, Marie-<br />
Angélique Cazalis, Hubert Marotte, Bruno Mougin, Pierre<br />
Miossec. Joint Unit Hospices Civils de Lyon - bioMérieux,<br />
Lyon, France.<br />
(548)-548. Analysis of Genetic Effects of Interferon Regulatory<br />
Factor 5 (IRF5) on Rheumatoid Arthritis in a Korean Population.<br />
Yun Jung Kim 1 , Il Kim 1 , Hee Sun Kim 1 , Ji On Kim 2 , Joon<br />
Seol Bae 2 , Hyoung Doo Shin 2 , Tae-Hwan Kim 1 , Sang-Cheol<br />
Bae 1 . 1 The Hospital for Rheumatic Diseases, Hanyang<br />
University Medical Center, Seoul, Republic of Korea;<br />
2<br />
Department of Genetic Epidemiology, SNP Genetics, Inc,<br />
Seoul, Republic of Korea.<br />
(549)-549. Common and Disease-Specific Biomarkers Identified<br />
from Peripheral Blood Gene Expression Profiling of Rheumatoid<br />
Arthritis and Inflammatory Bowel Disease. Philip Alex 1 ,<br />
Mark Barton Frank 2 , R. Craig Cadwell 2 , Jeanette Osban 2 ,<br />
Philip Miner, Jr. 3 , Eugene Arthur 4 , Larry Willis 4 , Robert<br />
Hynd 4 , Don Flinn 4 , Xuhang Li 1 , Michael Centola 2 .<br />
1<br />
Gastroenterology, Johns Hopkins Medicine, Baltimore,<br />
MD; 2 Oklahoma Medical Research Foundation, Oklahoma<br />
City, OK; 3 Oklahoma Foundation for Digestive Research,<br />
Oklahoma University Heath Science Campus, Oklahoma<br />
City, OK; 4 McBride Clinic, Oklahoma City, OK.<br />
(550)-550. Characterization of New Specific Biomarkers of<br />
Rheumatoid Arthritis in Several Biological Materials by a<br />
Proteomic Approach. Athan C. Baillet, Candice Trocme,<br />
Sylvie Berthier, Laurent Grange, Francoise Morel, Philippe<br />
Gaudin. Universitary Hospital, Grenoble cedex 9, France.<br />
(551)-551. Biomarkers of Rheumatoid Arthritis Disease Activity:<br />
A Translational Approach. Elena S. Izmailova 1 , Michael<br />
Pickard 1 , Nancy Paz 1 , Michael Fitzgerald 1 , Jigna Narang 1 ,<br />
Nancy E. Maher 2 , Aileen Healy 1 , Bruce Jaffee 1 , Nancy A.<br />
Shadick 2 , Ronenn Roubenoff 3 , Michael E. Weinblatt 2 , Alex<br />
Parker 1 . 1 Millennium Pharmaceuticals Inc., Cambridge,<br />
MA; 2 Brigham and Women’s Hospital, Boston, MA;<br />
3<br />
Biogen Idec, Cambridge, MA.<br />
(552)-552. Investigation of Genetic Variants within Candidate<br />
Genes of the TNF Signalling Pathway on the Response to<br />
Anti-TNF Agents in a UK Cohort of RA Patients. John<br />
Bowes 1 , Catherine Potter 1 , Kimme Hyrich 1 , BRAGGSS,<br />
Ann Morgan 2 , Anthony G. Wilson 3 , John Isaacs 4 , Jane<br />
Worthington 1 , Anne Barton 1 . 1 University of Manchester,<br />
Manchester, United Kingdom; 2 University of Leeds, Leeds,<br />
United Kingdom; 3 University of Sheffield, Sheffield,<br />
United Kingdom; 4 Newcastle University, Newcastle, United<br />
Kingdom.<br />
(553)-553. Association of RF and Anti-CCP Positivity, but not<br />
Carriage of Shared Epitope or PTPN22 Susceptibility Variants,<br />
with Response to Anti-TNF Treatment in RA. Catherine Potter 1 ,<br />
Kimme Hyrich 1 , BRAGGSS, Ann Morgan 2 , Anthony G.<br />
Wilson 3 , John Isaacs 4 , Jane Worthington 1 , Anne Barton 1 .<br />
1<br />
University of Manchester, Manchester, United Kingdom;<br />
2<br />
University of Leeds, Leeds, United Kingdom; 3 University<br />
of Sheffield, Sheffield, United Kingdom; 4 Newcastle<br />
University, Newcastle, United Kingdom.<br />
108 (Permanent Board Number)-Abstract Number
(554)-554. Proteomic Analysis of Serum From RA Patients Under<br />
Anti-TNF-α Therapy. Ravi C. Dwivedi, Hani S. El-Gabalawy,<br />
Oleg Krohkin, John A. Wilkins. University of Manitoba,<br />
Winnipeg, MB, Canada.<br />
(555)-555. Association of STAT4 (rs7574865) with RA in the<br />
Korean Population- Asian and Caucasian Populations Share<br />
Common Risk Alleles. Hye-Soon Lee 1 , Elaine F. Remmers 2 ,<br />
Julie M. Le 2 , Daniel L. Kastner 2 , Dae-Hyun Yoo 3 , Sang-<br />
Cheol Bae 3 , Peter K. Gregersen 1 . 1 The Feinstein Institute for<br />
Medical Research, Manhasset, NY; 2 Genetics and Genomics<br />
Branch, National Institute of Arthritis and Musculoskeletal<br />
and Skin Diseases, National Institute of Health, Bethesda,<br />
MD; 3 Hanyang University of College of Medicine and the<br />
Hospital for Rheumatic Diseases, Seoul, Republic of Korea.<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Spondylarthropathies and Psoriatic Arthritis:<br />
Pathogenesis, Etiology<br />
(556)-556. Investigation of Chromosome 3q21 in Psoriatic Arthritis.<br />
Pauline Ho, Jane Worthington, Ian N. Bruce, Anne Barton.<br />
The University of Manchester, Manchester, United Kingdom.<br />
(557)-557. Association of Interleukin-23R Variants with Psoriatic<br />
Arthritis. Proton Rahman 1 , Robert D. Inman 2 , Walter P.<br />
Maksymowych 3 , Jeff P. Reeve 3 , Lynette Peddle 1 , Dafna D.<br />
Gladman 2 . 1 Memorial University of Newfoundland, St.<br />
John’s, NF, Canada; 2 University of Toronto, Toronto, ON,<br />
Canada; 3 University of Alberta, Edmonton, AB, Canada.<br />
(558)-558. Polymorphism in an IL18 Promotor Influences Disease<br />
Susceptibility in Caucasian Patients with Ankylosing Spondylitis.<br />
Dirk Elewaut 1 , Bert Vandercruyssen 1 , Jeff Reeve 2 , Walter<br />
Macksymowych 3 . 1 University Hospital Gent, Gent, Belgium;<br />
2<br />
University of Alberta, Alberta, AB, Canada; 3 University of<br />
Alberta, Edmonton, AB, Canada.<br />
(559)-559. IL23R Genes do not Distinguish Acute Anterior<br />
Uveitis in Patients with Ankylosing Spondylitis. John D.<br />
Reveille 1 , Xiaodong Zhou 1 , Michael H. Weisman 2 , Michael<br />
M. Ward 3 , John C. Davis 4 , Tammy M. Martin 5 , James<br />
T. Rosenbaum 5 , Panos Deloukas 6 , Andrew Keniry 6 ,<br />
Rhian Gwilliam 6 , Ralph McGinnis 6 , Jennifer J. Pointon 7 ,<br />
Paul Wordsworth 7 , Matthew A. Brown 8 . 1 University of<br />
Texas Health Science Center at Houston, Houston, TX;<br />
2<br />
Cedars-Sinai Medical Center, Los Angeles, CA; 3 National<br />
Institute of Arthritis and Musculoskeletal and Skin<br />
Diseases,, Bethesda, MD; 4 University of California-San<br />
Francisco, San Francisco, CA; 5 Oregon Health and Science<br />
University, Portland, OR; 6 Wellcome Trust Sanger Institute,<br />
Cambridge, United Kingdom; 7 University of Oxford,<br />
Oxford, United Kingdom; 8 University of Queensland,<br />
Brisbane, Australia.<br />
(560)-560. Genetic Studies Of The Interleukin-1A, CTGF,<br />
DRB1, DQA1, DQB1, DPB1, HLA-B And HLA-A In<br />
Multiplex Ankylosing Spondylitis (as) Families. Xiaodong Zhou 1 ,<br />
Momiao Xiong 2 , Michael H. Weisman 3 , Robert D. Inman 4 ,<br />
Muhammad A. Khan 5 , H Ralph Schumacher 6 , Tammy M.<br />
Martin 7 , James T. Rosenbaum 7 , Walter P. Maksymowych 8 ,<br />
Li Luo 2 , Laura Diekman 1 , Reveille D. John 1 . 1 University of<br />
Texas Houston Medical School, Houston, TX; 2 University<br />
of Texas School Public Health at Houston, Houston, TX;<br />
3<br />
Cedars-Sinai Medical Center - Los Angeles, Los Angeles,<br />
TX; 4 University of Toronto, Toronto, ON, Canada; 5 Case-<br />
Western Reserve University, Cleveland, OH; 6 University<br />
of Pennsylvania, Philadelphia, PA; 7 Oregon Health and<br />
Science University, Portland, OR; 8 University of Alberta,<br />
Edmonton, AB, Canada.<br />
(561)-561. Distinctive Immunopathology in Early Synovitis of Behçet<br />
Disease Compared with Psoriatic Arthritis. Juan D. Cañete 1 ,<br />
Raquel Celis 1 , Jose A Gómez-Puerta 1 , Raimon Sanmartí 1 ,<br />
Gertru Sánchez 1 , Ivon Vázquez 1 , Conchita Moll 1 , Antonio<br />
Palacin 1 , Dominique Baeten 2 . 1 Hospital Clinic of Barcelona,<br />
Barcelona, Spain; 2 Clinical Immunology and Rheumatology,<br />
University of Amsterdam, Amsterdam, The Netherlands.<br />
(562)-562. Profound Proinflammatory Cytokine Response<br />
Mediated by Synovial Fibroblast and Natural Killer Cell<br />
Interaction in Rheumatoid Arthritis and Spondyloarthritis. Antoni<br />
T. Chan 1 , Andrew D. Filer 2 , Greg Parsonage 2 , Simon<br />
Kollnberger 1 , Roger Gundle 3 , Christopher D. Buckley 2 , Paul<br />
Bowness 1 . 1 Weatherall Institute of Molecular Medicine,<br />
University of Oxford, Oxford, United Kingdom; 2 MRC<br />
Centre for Immune Regulation, University of Birmingham,<br />
Birmingham, United Kingdom; 3 Nuffield Orthopaedic Centre,<br />
Windmill Road, Headington, Oxford, United Kingdom.<br />
(563)-563. A Genomewide Non-Synonymous SNP Scan for<br />
Clinical Characteristics of Ankylosing Spondylitis - The Wellcome<br />
Trust Case-Control Consortium. Matthew A. Brown 1 , Linda<br />
A. Bradbury 1 , Jennifer J. Pointon 2 , B. Paul Wordsworth 2 ,<br />
Wellcome Trust Case-Control Consortium. 1 Diamantina<br />
Institute of Cancer, Immunology and Metabolic Medicine,<br />
Woolloongabba, Brisbane, Australia; 2 Botnar Research<br />
Centre, University of Oxford, Oxford, United Kingdom.<br />
(564)-564. Biomechanical Uncoupling of Bone Erosion and New<br />
Bone Formation in Spondyloarthropathy. Dennis McGonagle 1 ,<br />
Richard Wakefield 1 , Ai Lyn Tan 1 , Hechmi Toumi 2 , Koji<br />
Hayashi 3 , Maria A. D’Agostino 4 , Paul Emery 1 , Michael<br />
Benjamin 2 . 1 University of Leeds, Leeds, United Kingdom;<br />
2<br />
Cardiff University, Cardiff, United Kingdom; 3 Nara<br />
Medical University, Nara, Japan; 4 UVSQ University,<br />
Boulogne-Billancourt, France.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 109
Poster Session A<br />
(565)-565. Non-MHC Genes Implied in Spondylarthropathies.<br />
Cédric Julien 1 , Brigitte Nedelec 1 , Stéphane Meziti 2 ,<br />
Marc Delpech 1 , Saddek Laoussadi, Sr. 3 , & All EUROAS<br />
Consortium member Teams. 1 Institut Cochin INSERM-<br />
U567 & University Paris 5, Paris, France; 2 Assistance<br />
Publique Hopitaux de Paris, Paris, France; 3 Assistance<br />
Publique Hopitaux de Paris, Pole Osteo-articulaire (Pr<br />
Kahan) & Institut Cochin INSERM-U567 & University<br />
Paris 5, Paris, France.<br />
(566)-566. Dendritic Cell (DCs) Functional Defect Correlates<br />
with Sponyloarthritis (SpA) Phenotype in HLA-B27/human<br />
Beta-2-microglobulin (hb2m) Transgenic Rat Lines. Ingrid Fert 1 ,<br />
Simon Glatigny 1 , Cécile Poulain 1 , Nimman Satumtira 2 ,<br />
Martha L. Dorris 2 , Joel D. Taurog 2 , Maxime Breban 1 .<br />
1<br />
INSERM U567, Paris, France; 2 Univ TX Southwestern<br />
Med Ctr, Dallas, TX.<br />
(567)-567. Preferential Expansion of CD8+ T Cells in Ankylosing<br />
Spondylitis (AS) Demonstrated by a Novel Humanized Mouse<br />
Model. Nan-Hua Chang 1 , Joan Wither 1 , John Dick 2 , Robert<br />
D. Inman 1 . 1 Toronto Western Hospital, Toronto, ON,<br />
Canada; 2 University Health Network, Toronto, ON, Canada.<br />
(568)-568. A New Hypotheis-driven Approach Towards<br />
Identifying Candidate Biomarkers in AS. Like Zhao 1 , Feng<br />
Huang 2 , Beren Tomooka 3 , William H. Robinson 3 , David<br />
T. Yu 1 . 1 UCLA, Los Angeles, CA; 2 Chinese PLA General<br />
Hospital, Beijing, China; 3 Stanford University School of<br />
Medicine, Stanford, CA.<br />
(569)-569. Analyses with a Promoter Reporter Construct and<br />
its Mutant Showed that the Responses of the HLA-B27 Gene to<br />
Cytokines are Both Cytokine-Specific and Time-Dependent. Like<br />
Zhao 1 , Kaisa Granfors 2 , David TY Yu 1 . 1 UCLA, Los Angeles,<br />
CA; 2 National Public Health Institute, Turku, Finland.<br />
(570)-570. HLA-B27 Homozygosity Has no Influence on Clinical<br />
Manifestations and Disease Severity in Ankylosing Spondylitis.<br />
Tae-Jong Kim, IL Kim, Hyun-Joo Lee, Nara Lee, Tae-Hwan<br />
Kim. Hanyang University College of Medicine, and The<br />
Hospital for Rheumatic Diseases, Seoul, Republic of Korea.<br />
(571)-571. Analysis of T Cell Response to Versican in Ankylosing<br />
Spondylitis. Tae-Jong Kim 1 , Tae-Hwan Kim 1 , Hyun-Joo<br />
Lee 1 , Kyung-sun Na 1 , Shuiliang Shi 2 , A Robin Poole 2 ,<br />
Robert D. Inman 3 . 1 The Hospital for Rheumatic Diseases,<br />
Hanyang University, Seoul, Republic of Korea; 2 Joint<br />
Diseases Laboratory, Shriners Hospitals for Children,<br />
McGill University, Quebec, PQ, Canada; 3 Toronto Western<br />
Hospital, the University of Toronto, Toronto, ON, Canada.<br />
(572)-572. Osteoclasts are Derived from Distinct Monocyte<br />
Subsets in Psoriatic Arthritis Patients and Healthy Individuals.<br />
Yahui Chiu, Edward Schwarz, Kofi Mensah, Robert<br />
Durham, Tianmeng Shao, Christopher T. Ritchlin.<br />
University of Rochester Medical Center, Rochester, NY.<br />
(573)-573. Association of the Platelet Endothelial Cell Adhesion<br />
Molecule-1 Gene Polymorphism with Ankylosing Spondylitis.<br />
Seung-Cheol Shim 1 , Dong-Hyuk Sheen 1 , Mi-Kyoung Lim 1 ,<br />
Jin-Wuk Hur 1 , Yeong-Shil Joo 1 , Soo-Cheon Chae 2 , Hun-<br />
Taeg Chung 2 , Tae-Hwan Kim 3 . 1 Eulji University, Daejeon,<br />
Republic of Korea; 2 Wonkwang University, Iksan, Republic<br />
of Korea; 3 Hanyang University, Seoul, Republic of Korea.<br />
(574)-574. In Ankylosing Spondylitis Patients HLA-B27<br />
Expression Influence Susceptibility to Disease but not Disease<br />
Severity or the Occurrence of Acute Anterior Uveitis. Alberto<br />
Cauli, Grazia Dessole, Alessandra Vacca, Antonella<br />
Mamelli, Giovanni Porru, Valentina Ibba, Valentina Mura,<br />
Matteo Piga, Silvia Sanna, Giuseppe Passiu, Alessandro<br />
Mathieu. IInd chair of Rheumatology, Cagliari, Italy.<br />
(575)-575. The Abundant Synovial Expression of the RANK-<br />
RANKL-OPG System in Spondyloarthritis is Disconnected from<br />
Systemic and Local Inflammation. Bernard Vandooren 1 ,<br />
Tineke Cantaert 2 , Troy Noordenbos 2 , Paul P. Tak 2 ,<br />
Dominique Baeten 2 . 1 Ghent University Hospital,<br />
Ghent, Belgium; 2 Division of Clinical Immunology and<br />
Rheumatology, Academic Medical Centre/University of<br />
Amsterdam, Amsterdam, The Netherlands.<br />
(576)-576. Chondrocyte-Mediated Antigen-Presentation and<br />
Antigen-Specific Lysis of Chondrocytes by CD8+ T Cells. Maren<br />
Kuhne, Gundula Schulze-Tanzil, Thilo John, Joachim<br />
Sieper, Heiner Appel. Charite Berlin, CBF, Berlin,<br />
Germany.<br />
(577)-577. Histomorphological and Immunhistochemical Analysis<br />
of New Bone Formation in Zygapophyseal Joints of Patients<br />
with Ankylosing Spondylitis in Comparison to Osteoarthritis and<br />
Controls. Heiner Appel 1 , Christoph Loddenkemper 1 , René<br />
Heydrich 1 , Axel Hempfing 2 , Joachim Sieper 1 . 1 Charite<br />
Berlin, CBF, Berlin, Germany; 2 Werner Wicker Klinik, Bad<br />
Wildungen, Germany.<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Spondylarthropathies and Psoriatic Arthritis: Treatment I<br />
(578)-578. Adalimumab Reduces the Incidence of Uveitis Flares<br />
in Patients with Ankylosing Spondylitis (AS). M. Rudwaleit 1 ,<br />
E. N. Griep 2 , P. Holck 3 , M. Kron 4 , S. Kary 4 , H. Kupper 4 .<br />
1<br />
Charité University Hospital, Berlin, Germany; 2 Medisch<br />
Centrum Leeuwarden, Leeuwarden, The Netherlands;<br />
3<br />
Regionshospitalet Silkeborg, Silkeborg, Denmark; 4 Abbott<br />
GmbH & Co. KG, Ludwigshafen, Germany.<br />
(579)-579. Correlation of Biomarkers with Clinical Parameters<br />
in AS Patients without and during Treatment with TNFalpha<br />
Blocking Reagents. Heiner Appel, Louise Janssen, Martin<br />
Rudwaleit, Joachim Sieper. Charite Berlin, CBF, Berlin,<br />
Germany.<br />
110 (Permanent Board Number)-Abstract Number
(580)-580. Changes in Markers of Bone Metabolism and Bone<br />
Mineral Density in Patients with Active Ankylosing Spondylitis<br />
During Treatment with Tnf-Blockade. Monique Efde 1 , Anneke<br />
Spoorenberg 1 , George A.W. Bruyn 1 , Tim L.Th.A. Jansen 1 ,<br />
Johan Bijzet 2 , Marcel D. Posthumus 2 , Elisabeth Brouwer 2 ,<br />
Eveline vander Veer 2 . 1 MCL, Leeuwarden, The Netherlands;<br />
2<br />
UMCG, Groningen, The Netherlands.<br />
(581)-581. 2-Year Safety and Efficacy Results From the<br />
Adalimumab Trial Evaluating Long-Term Efficacy and Safety<br />
in Ankylosing Spondylitis (ATLAS). Désirée van der Heijde 1 ,<br />
Michael H. Schiff 2 , Joachim Sieper 3 , Alan Kivitz 4 , Ben AC<br />
Dijkmans 5 , Philip J. Mease 6 , Hartmut Kupper 7 , Robert<br />
L. Wong 8 , John C. Davis 9 , for the ATLAS Study Group.<br />
1<br />
University of Leiden, Leiden, The Netherlands; 2 Denver<br />
Arthritis Clinic, Denver, CO; 3 Charité Universitätsmedizin<br />
Berlin, Berlin, Germany; 4 Center for Clinical Research,<br />
Duncansville, PA; 5 VU Medical Centre, Amsterdam,<br />
The Netherlands; 6 Swedish Medical Center, Seattle, WA;<br />
7<br />
Abbott GmbH & Co KG, Ludwigshafen, Germany;<br />
8<br />
Abbott Laboratories, Parsippany, NJ; 9 University of<br />
California, San Francisco, San Francisco, CA.<br />
(582)-582. Prediction of Persistent Partial Remission in Active<br />
Ankylosing Spondylitis Treated with Infliximab over 3 Years.<br />
Giovanni La Montagna, Domenico Malesci. Rheumatology<br />
Unit - Second University of Naples, Napoli, Italy.<br />
(583)-583. Analysis of Risk Factors for Radiographic Progression<br />
in Psoriatic Arthritis (PsA): Subanalysis of ADEPT. D.<br />
Gladman 1 , P. J. Mease 2 , E. HS Choy 3 , C. T. Ritchlin 4 , R.<br />
J. Perdok 5 , E. H. Sasso 5 . 1 University of Toronto, Toronto,<br />
ON, Canada; 2 Swedish Medical Center, Seattle, WA;<br />
3<br />
King’s College, London, United Kingdom; 4 University of<br />
Rochester, Rochester, NY; 5 Abbott, Abbott Park, IL.<br />
(584)-584. Psoriasis Patients with or without Psoriatic Arthritis<br />
Experience Improvements in Skin and in Patient-Reported<br />
Outcomes upon Treatment with Adalimumab: Results from the<br />
First 16 Weeks of REVEAL. A. Menter 1 , S. Tyring 2 , S. R.<br />
Smith 3 , Y. Gu 4 , M. Okun 4 , M. K. Willian 4 . 1 Baylor Research<br />
Institute, Dallas, TX; 2 Univ. of Texas Health Science<br />
Center, Houston, TX; 3 Therapeutics Clinical Research, San<br />
Diego, CA; 4 Abbott, Abbott Park, IL.<br />
(585)-585. To what Degree do the BASDAI and BASFI<br />
Questionnaires Address the Most Essential Symptoms and<br />
Disabilities of Patients with Ankylosing Spondylitis?. Walter<br />
P. Maksymowych 1 , Chris Miller 2 , Melissa Velez 2 , Laurie<br />
Savage 2 . 1 University of Alberta, Edmonton, AB, Canada;<br />
2<br />
Spondylitis Association of America, Los Angeles, CA.<br />
(586)-586. Perceived Locus of Control and Coping as Major<br />
Factors Influencing Attainment of the Patient Acceptable<br />
Symptom State (PASS) in Ankylosing Spondylitis. Walter P.<br />
Maksymowych 1 , Barbara Conner-Spady 1 , Lionel Schachna 2 ,<br />
Annelies Boonen 3 . 1 University of Alberta, Edmonton, AB,<br />
Canada; 2 Austin Health, Heidelberg, Australia; 3 University<br />
of Maastricht, Maastricht, The Netherlands.<br />
(587)-587. Development of Diagnostic Criteria for Inflammatory<br />
Back Pain in Ankylosing Spondylitis Based on a Simple 2-Item<br />
Questionnaire. Stephanie O. Keeling, Barbara Conner-Spady,<br />
Anthony S. Russell, Walter P. Maksymowych. University of<br />
Alberta, Edmonton, AB, Canada.<br />
(588)-588. Diagnostic Criteria for Inflammatory Back Pain in<br />
Ankylosing Spondylitis: Does Sex, Symptom Duration, and Pain<br />
Level Influence the Diagnostic Value of Criteria Based on the<br />
History?. Stephanie O. Keeling, Barbara Conner-Spady,<br />
Anthony S. Russell, Walter P. Maksymowych. University of<br />
Alberta, Edmonton, AB, Canada.<br />
(589)-589. Scoring of Radiographic Progression Over 2 Years with<br />
the mSASSS in Ankylosing Spondylitis: Does Training Improve<br />
Reliability?. Anne Powell, Stephanie O. Keeling, Robert GS<br />
Lambert, Anthony S. Russell, Walter P. Maksymowych.<br />
University of Alberta, Edmonton, AB, Canada.<br />
(590)-590. Changes in Plasma IL-6, VEGF, YKL-40 and COMP<br />
in Spondyloarthritis Patients During Treatment with TNFα<br />
Inhibitors. Susanne J. Pedersen, Inge J Sørensen, Julia S<br />
Johansen, Ole R Madsen, Niels Tvede, Michael S Hansen,<br />
Gorm Thamsborg, Lis S Andersen, Ole Majgaard, Anne<br />
Gitte Loft, JonErlendsson, Karsten Asmussen, Annette<br />
Hansen, Mikkel Østergaard. University Hospitals at Herlev,<br />
Hvidovre, Gentofte, Rigshospitalet, Glostrup, Gråsten,<br />
Vejle, Horsens, and Bispebjerg, Denmark.<br />
(591)-591. Rates of IBD in Patients Receiving Etanercept and<br />
Placebo in AS. J. Wajdula, S. Sridharan, T. Fletcher, D.<br />
MacPeek, E. Meier. Wyeth Pharmaceutical, Collegeville, PA.<br />
(592)-592. Evaluation of the Efficacy and Safety of Repeated<br />
Intra-Articular Etanercept Injections in Resistant Knee Joint<br />
Synovitis. Ugo Fiocco, Paolo Sfriso, Roberto Nardacchione,<br />
Federica Sovran, Elena Scagliori, Luisella Cozzi, Maristella<br />
Vezzù, Davide Bertolini, Francesca Oliviero, Costantino<br />
Botsios, Antonio Piccoli, Antonio Di Maggio, Leopoldo<br />
Rubaltelli, Leonardo Punzi. University of Padova, Padova, Italy.<br />
(593)-593. Onset of Psoriatic Arthritis in Patients Treated with<br />
Efalizumab for Severe Cutaneous Psoriasis. Manuelle Viguier 1 ,<br />
Pascal Richette 2 , Morad Lahfa 1 , François Aubin 3 , Emmanuel<br />
Delaporte 4 , Christophe Bedane 5 , Marie Beylot-Barry 6 , Louis<br />
Dubertret 1 , Thomas Bardin 2 , Hervé Bachelez 1 . 1 Hopital<br />
Saint Louis, Paris, France; 2 Hopital Lariboisière, Paris,<br />
France; 3 Université Franche Comté, Besançon, France;<br />
4<br />
Hopital Claude Huriez, Lille, France; 5 CHU Dupuytren,<br />
Limoges, France; 6 Hopital du Haut Lévêque, Pessac, France.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 111
Poster Session A<br />
(594)-594. Adalimumab Improves Peripheral Arthritis and<br />
Enthesitis in Addition to Axial Signs and Symptoms in Patients<br />
with Ankylosing Spondylitis (AS): The RHAPSODY Trial.<br />
J. Sieper 1 , E. Rødevand 2 , O. Zamani 3 , P. Järvinen 4 , W.<br />
Spieler 5 , M. Kron 6 , R. Carcereri 6 , S. Kary 6 , H. Kupper 6 .<br />
1<br />
Charité Universitätsmedizin Berlin, Berlin, Germany;<br />
2<br />
St. Olavs Hospital, Trondheim, Norway; 3 SMZ-Süd-<br />
Kaiser-Franz-Josef-Spital, Vienna, Austria; 4 Kiljava Medical<br />
Research, Hyvinkää, Finland; 5 unknown, Zerbst, Germany;<br />
6<br />
Abbott GmbH & Co. KG, Ludwigshafen, Germany.<br />
(595)-595. Prevalence of Enthesitis and Utility of Two Enthesitis<br />
Index in Ankylosing Spondylitis and Psoriatic Arthritis. José<br />
L. Fernández-Sueiro, J. Pinto, S. Pértega, A. Willisch,<br />
C. Fernández, N. Oreiro, F. Galdo, F. Blanco. Hospital<br />
Universitario Juan Canalejo, La Coruña, Spain.<br />
(596)-596. Factors Associated to Employment in Ankylosing<br />
Spondylitis and Psoriatic Arthritis. José L. Fernández-Sueiro 1 , A.<br />
Willisch 2 , S. Pértega 1 , J. Pinto 1 , J. Mosquera 1 , N. Oreiro 1 , F.<br />
Galdo 1 , F. Blanco 1 . 1 Hospital Universitario Juan Canalejo,<br />
La Coruña, Spain; 2 Hospital Cirstal Piñor, Orense, Spain.<br />
(597)-597. Clinical and Radiographic Differences between<br />
Primary Ankylosing Spondylitis, Psoriatic Spondylitis and<br />
Spondylitis Associated with Inflammatory Bowel Disease. Finbar<br />
D. O’Shea, Vinod Chandran, Catherine T. Schentag, David<br />
Salonen, Dafna D. Gladman, Robert D. Inman. Toronto<br />
Western Hospital, Toronto, ON, Canada.<br />
(598)-598. Sacroiliac Joint Osteoarthritis in Females is a Distinct<br />
Clinical Entity Unrelated to Spinal Osteoarthritis. Finbar D.<br />
O’Shea 1 , David Salonen 1 , Carlo Ammendolia 1 , Eleanor<br />
Boyle 1 , Cindy Peterson 2 , William Hsu 2 , Robert D. Inman 1 .<br />
1<br />
Toronto Western Hospital, Toronto, ON, Canada; 2 Canadian<br />
Memorial Chiropractor College, Toronto, ON, Canada.<br />
(599)-599. Ankylosing Spondylitis (AS) is a Progressive Disease<br />
Without Burn-Out in the Majority of Patients. Millicent A.<br />
Stone 1 , Derek Gordon 2 , Raj Sengupta 1 , Emma Pomeroy 1 ,<br />
Rebecca Mogg 1 , Andrew Keat 3 . 1 Royal National Hospital<br />
for Rheumatic Diseases, Bath, United Kingdom; 2 Rutgers<br />
University, Rutgers, NJ; 3 Northwick Park Hospital, Harrow,<br />
United Kingdom.<br />
(600)-600. Enthesis Inflammation in Recurrent Acute Anterior<br />
Uveitis without Spondyloarthropathie. Santiago Muñoz,<br />
Eugenio De Miguel, Tatiana Cobo, Armelle Schlincker,<br />
Ventura Hidalgo, Sandra Falçao, Emilio Martín Mola.<br />
Hospital Universitario La Paz, Madrid, Spain.<br />
(601)-601. Strict Adherence to BASDAI Scores May Mislead<br />
the Treatment Decisions in Patients with Ankylosing Spondylitis.<br />
Anurag Bharadwaj, Mike Batley, Anthony Hammond.<br />
Maidstone Hospital, Maidstone, United Kingdom.<br />
(602)-602. TNF Alpha Gene Promoter Polymorphisms at Position<br />
-308 and Ankylosing Spondylitis Severity. Patricia Pinto 1 , Elsa<br />
Sousa 2 , Joana Caetano-Lopes 2 , Catarina Resende 2 , Carlos<br />
M. Rosa 3 , Helena Canhao 2 , Francisco Ventura 4 , Jose A.<br />
Pereira Silva 3 , Mario Viana Queiroz 3 , Joao E. Fonseca 2 .<br />
1<br />
Rheumatology Research Unit, Instituto de Medicina<br />
Molecular, Faculdade de Medicina de Lisboa and Hospital<br />
São João, Porto, Portugal; 2 Rheumatology Research Unit,<br />
Instituto de Medicina Molecular, Faculdade de Medicina<br />
de Lisboa and Hospital Santa Maria, Lisbon, Portugal;<br />
3<br />
Rheumatology Department, Hospital Santa Maria, Lisbon,<br />
Portugal; 4 Rheumatology Department, Hospital São João,<br />
Porto, Portugal.<br />
(603)-603. A Pilot Study with Referred Patients Suffering Early<br />
Spondyloarthropathies: Results of ESPIDEP Study. Martina<br />
Steinerova, Santiago Muñoz-Fernández, Tatiana Cobo-<br />
Ibañez, Eugenio de Miguel- Mendieta, Alejandro Balsa<br />
Criado, Emílio Martín-Mola. Hospital La Paz, Madrid,<br />
Madrid, Spain.<br />
(604)-604. Erythrocyte Sedimentation Rate Predict Progression of<br />
Enthesis Lesion in Spondyloarthropathies. Eugenio De Miguel,<br />
Santiago Muñoz, Tatiana Cobo, Martina Steinerova, Emilio<br />
Martín Mola. Hospital Universitario La Paz, Madrid, Spain.<br />
(605)-605. Comparison of 4 Functional indexes in Psoriatic<br />
Arthritis Using Rasch Analyses. Ying Ying Leung 1 , Lai Shan<br />
Tam 2 , Emily Wai-lin Kun 1 , Kwok Wah Ho 3 , Edmund Kwok-<br />
Ming Li 2 . 1 Tai Po Hospital, Hong Kong SAR, Hong Kong;<br />
2<br />
Chinese University of Hong Kong, Hong Kong SAR, Hong<br />
Kong; 3 Department of Statistics, Chinese University of<br />
Hong Kong, Hong Kong SAR, Hong Kong.<br />
(606)-606. The Psoriatic Arthritis Cost Evaluation (PACE)<br />
Study: A Cost-of-Illness Study on Tumor Necrosis Factor Inhibitors<br />
in Psoriatic Arthritis Patients with Inadequate Response to<br />
Conventional Therapy. Ignazio Olivieri 1 , Simona de Portu 2 ,<br />
Carlo Salvarani 3 , Alberto Cauli 4 , Ennio Lubrano 5 , Antonio<br />
Spadaro 6 , Fabrizio Cantini 7 , Maria S. Cutro 1 , Alessandro<br />
Mathieu 4 , Marco Matucci Cerinic 8 , Nicola Pappone 5 ,<br />
Leonardo Punzi 9 , Raffaele Scarpa 10 , Lorenzo G. Mantovani 2 ,<br />
for the PACE investigators. 1 Rheumatology Department of<br />
Lucania, Potenza, Italy; 2 Faculty of Pharmacy, University<br />
Federico II of Naples, Naples, Italy; 3 Rheumatology<br />
Unit, Arcispedale S. Maria Nuova, Reggio Emilia, Italy;<br />
4<br />
Rheumatology Unit, University of Cagliari, Cagliari, Italy;<br />
5<br />
Rheumatology Unit, Maugeri Foundation IRCCS, Telese<br />
Terme, Italy; 6 Rheumatology Unit, University of Rome<br />
“La Sapienza”, Rome, Italy; 7 Rheumatology Unit, Prato<br />
Hospital, Prato, Italy; 8 Rheumatology Unit, University of<br />
Florence, Florence, Italy; 9 Rheumatology Unit, University<br />
of Padova, Padova, Italy; 10 Rheumatology Unit, University<br />
Federico II of Naples, Naples, Italy.<br />
112 (Permanent Board Number)-Abstract Number
(607)-607. Determinants of Willingness to Pay for 8 Qol Domains<br />
in Psoriatic Arthritis Patients. Stephanie Hu 1 , M. Elaine<br />
Husni 2 , Elizabeth Holt 3 , Abrar Qureshi 4 . 1 Harvard Medical<br />
School, Boston, MA; 2 Cleveland Clinic, Cleveland, OH;<br />
3<br />
Department of Epidemiology, Tulane School of Public<br />
Health and Tropical Medicine, New Orleans, LA; 4 Brigham<br />
and Women’s hospital, Boston, MA.<br />
(608)-608. The PASE Questionnaire: Pilot-Testing a Psoriatic<br />
Arthritis Screening and Evaluation Tool. M. Elaine Husni 1 ,<br />
Darel S. Cohen 2 , Elinor Mody 2 , Kathryn H. Meyer 1 ,<br />
Qureshi Abrar 2 . 1 Cleveland Clinic, Cleveland, OH;<br />
2<br />
Brigham and Women’s Hospital, Boston, MA.<br />
(609)-609. Cardiovascular Risk Factors in Patients with Psoriatic<br />
Arthritis Compared to Healthy Controls. Lai-Shan Tam,<br />
Brian Tomlinson, Tanya Chu, Martin Li, Katy Y. Leung,<br />
Catherine L. Kwok, Tracy Zhu, Tracey Yu, Tena K. Li,<br />
Edmund K. Li. Chinese University of Hong Kong, Hong<br />
Kong, Hong Kong.<br />
(610)-610. Patient and Physician Perception of Disease<br />
in Psoriatic Arthritis (PsA). A Multicentre GRAPPA and<br />
OMERACT Study. Alberto Cauli, Dafna Gladman,<br />
Alessandro Mathieu, Ignazio Olivieri, Ilona Ujfalussy,<br />
Raffaele Scarpa, Paul P. Tak, Antonio Marchesoni, William<br />
Taylor, Antonio Spadaro, José Luis Fernández-Sueiro,<br />
Carlo Salvarani, Philip Helliwell, Ennio Lubrano, Joachim<br />
Kalden, Carneiro Sueli, John A. Flynn, Giovanni Porru,<br />
Gael Hewitt, Salvatore D’Angelo, Cathy Shentag, Arno WR<br />
van Kuijk, Alessandra Vacca, Rosario Peluso, Mariagrazia<br />
Catanoso, WJ Parsons, Emanuela Porcedda, Mathias<br />
Gruenke, Roberta Porceddu, Philip Mease. GRAPPA study<br />
group, Seattle, WA.<br />
(611)-611. 10 Year Cardiovascular Risk in Patients with Psoriatic<br />
Arthritis. Sangita Agarwal, Nicola Gullick, Dr., Alyssa<br />
Macedo, Ms., Stephen Oakley, Dr., Bruce Kirkham, Dr..<br />
Guy’s and St. Thomas’ NHS Foundation Trust, London,<br />
United Kingdom.<br />
(612)-612. Association of Radiographic Damage with Functional<br />
Limitations in Ankylosing Spondylitis: Differences between<br />
Patients with Early and Long-Standing Disease. Michael M.<br />
Ward 1 , John D. Reveille 2 , Thomas Learch 3 , John C. Davis 4 ,<br />
Michael H. Weisman 5 . 1 National Institute of Arthritis and<br />
Musculoskeletal and Skin Diseaes, NIH, Bethesda, MD;<br />
2<br />
University of Texas, Houston, TX; 3 University of Southern<br />
California, Los Angeles, CA; 4 University of California-<br />
San Francisco, San Francisco, CA; 5 Cedars-Sinai Medical<br />
Center, Los Angeles, CA.<br />
(613)-613. Ultrasonography In The Berlin’S Algorithm For The<br />
Diagnosis Of Early Spondyloarthropathy.. Tatiana Cobo-Ibáñez,<br />
Santiago Muñoz-Fernández, Eugenio De Miguel-Mendieta,<br />
Martina Steiner, Alejandro Balsa, Emilio Martín-Mola.<br />
Hospital Universitario La Paz, Madrid, Spain.<br />
(614)-614. Clinical Tests for Sacroiliitis and Spinal Mobility -<br />
no Helpful Tools for Diagnosing Axial Spondyloarthritis (SpA)<br />
Early. Henning C. Brandt, In-Ho Song, Inge Spiller, Heiner<br />
Appel, Janis Vahldiek, Joachim Sieper, Martin Rudwaleit.<br />
University Medicine Berlin, Charité Campus Benjamin<br />
Franklin, Department of Rheumatology, Berlin, Germany.<br />
(615)-615. Do We Really Need to Evaluate Entire Cervical<br />
Spines for Squaring Score in Modified Stoke Ankylosing Spondylitis<br />
Spinal Score?. Tae-Jong Kim 1 , Hee Sun Kim 1 , Kyung-Bin Joo 2 ,<br />
Seong-Jun Kim 3 , Tae-Hwan Kim 1 . 1 Hanyang University<br />
College of Medicine, and The Hospital for Rheumatic<br />
Diseases, Seoul, Republic of Korea; 2 Department of<br />
Radiology, The Hospital for Rheumatic Diseases, Hanyang<br />
University, Seoul, Republic of Korea; 3 Department of<br />
Radiology, Hanyang University GURI Hospital, Guri,<br />
Republic of Korea.<br />
(616)-616. Worker Productivity in Ankylosing Spondylitis: Absenteeism<br />
and Presenteeism. Annelies Boonen 1 , Walter Maksymowych 2 .<br />
1<br />
University Hospital Maastricht, Maastricht, The Netherlands;<br />
2<br />
University of Alberta, Edmonton, AB, Canada.<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Clinical Osteoporosis and Metabolic Bone Disease I<br />
(617)-617. BMD Response to Teriparatide in Patients Previously<br />
Treated with a Bisphosphonate versus Treatment Naïve<br />
Patients. Elizabeth A. File, Chad L. Deal. Cleveland Clinic<br />
Foundation, Cleveland, OH.<br />
(618)-618. Reduction of Bone Turnover Markers with Annual<br />
Infusion of Zoledronic Acid 5 mg in Postmenopausal Osteoporosis:<br />
Influence of Age, Renal Function, Concomitant Therapy, and<br />
Duration of Treatment. P. D. Delmas 1 , D. M. Black 2 , S.<br />
Boonen 3 , D. C. Bauer 2 , F. Cosman 4 , C. Mautalen 5 , I. A.<br />
Skripnikova 6 , E. F. Eriksen 7 , P. Mesenbrink 8 , H. Hu 8 , R.<br />
Eastell 9 . 1 INSERM Research Unit 831, University of Lyon,<br />
Lyon, France; 2 University of California, San Francisco, CA;<br />
3<br />
Universitaire Ziekenhuizen K.U., Leuven, Belgium; 4 Helen<br />
Hayes Hospital, West Haverstraw, NY; 5 Hospital de Clinicas<br />
University of Buenos Aires, Buenos Aires, Argentina;<br />
6<br />
Russian Ministry of Health, Moscow, Russian Federation;<br />
7<br />
Novartis Pharma AG, Basel, Switzerland; 8 Novartis<br />
Pharmaceuticals Corp, East Hanover, NJ; 9 University of<br />
Sheffield, Sheffield, United Kingdom.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 113
Poster Session A<br />
(619)-619. The Effects of Zoledronic Acid 5 mg Once-Yearly<br />
on Bone Remodeling and Structure in Osteoporotic Women are<br />
Consistent Across Age. R. R. Recker 1 , P. Delmas 2 , I. Reid 3 ,<br />
S. Boonen 4 , J. Halse 5 , P. Garcia 6 , J. Supronik 7 , E. M.<br />
Lewiecki 8 , L. Ochoa 9 , P. Miller 10 , F. Hartl 11 , J. A. Gasser 12 ,<br />
P. Mesenbrink 13 , H. Hu 13 , E. F. Eriksen 11 . 1 Creighton<br />
University Osteoporosis Research Center, Omaha, NE;<br />
2<br />
University of Lyon, INSERM Research Unit 831, Lyon,<br />
France; 3 University of Auckland, Auckland, New Zealand;<br />
4<br />
Universitaire Ziekenhuizen K.U., Leuven, Belgium;<br />
5<br />
Osteoporoseklinikken, Oslo, Norway; 6 University Hospital,<br />
Monterrey, Mexico; 7 Sniadecki Hospital, Bialystok,<br />
Poland; 8 New Mexico Clinical Research & Osteoporosis<br />
Center, Albuquerque, NM; 9 OSTEOSOL COMOP,<br />
Col. Hipodromo, Mexico; 10 Colorado Center for Bone<br />
Research, Lakewood, CO; 11 Novartis Pharma AG, Basel,<br />
Switzerland; 12 Musculoskeletal Diseases, Novartis Institutes<br />
for BioMedical Research, Basel, Switzerland; 13 Novartis<br />
Pharmaceuticals Corp, East Hanover, NJ.<br />
(620)-620. Relationship Between Annual Cumulative Exposure<br />
to Ibandronate, BMD Increases, and Clinical Fracture<br />
Reductions. Anthony Sebba 1 , Ronald D. Emkey 2 , William<br />
A. Blumentals 3 , Phillip N. Sambrook 4 . 1 University of South<br />
Florida, Tampa, FL; 2 Emkey Arthritis and Osteoporosis<br />
Clinic, Wyomising, PA; 3 Roche, Inc, Nutley, NJ; 4 University<br />
of Sydney, Sydney, Australia.<br />
(621)-621. Use of Ibandronate Results in Reduced Clinical and<br />
Nonvertebral Fracture Risk in Postmenopausal Osteoporosis.<br />
Ronald D. Emkey 1 , Steven T. Harris 2 , Paul D. Miller 3 ,<br />
William A. Blumentals 4 . 1 Emkey Arthritis and Osteoporosis<br />
Clinic, Wyomissing, PA; 2 University of California, San<br />
Francisco, San Francisco, CA; 3 Colorado Center for Bone<br />
Research, Lakewood, CO; 4 Roche Laboratories, Inc, Nutley, NJ.<br />
(622)-622. Monthly Ibandronate Use is Associated with Reduced<br />
Serious GI Event Risk Versus Weekly Bisphosphonates. Stuart<br />
L. Silverman 1 , William A. Blumentals 2 , Steven T. Harris 3 .<br />
1<br />
Cedars-Sinai Medical Center, Beverly Hills, CA; 2 Roche<br />
Laboratories, Inc, Nutley, NJ; 3 University of California, San<br />
Francisco, San Francisco, CA.<br />
(623)-623. Determinants of Femoral Neck Bone Loss in the<br />
HORIZON-PFT Study: Impact of Zoledronic Acid Therapy. R.<br />
Eastell 1 , D. Black 2 , S. Boonen 3 , S. Cummings 2 , P. Delmas 4 ,<br />
L. Palermo 2 , E. Eriksen 5 , P. Mesenbrink 6 , K. Lippuner 7 , C.<br />
Zerbini 8 , A. Skag 9 , P. J. Cauley 10 . 1 University of Sheffield,<br />
Sheffield, United Kingdom; 2 University of California, San<br />
Francisco, CA; 3 Universitaire Ziekenhuizen K.U., Leuven,<br />
Belgium; 4 University of Lyon, INSERM Research Unit 831,<br />
Lyon, France; 5 Novartis Pharma AG, Basel, Switzerland;<br />
6<br />
Novartis Pharmaceuticals Corp, East Hanover, NJ;<br />
7<br />
Poliklinik für Osteoporose der Medizinischen Fak. und des<br />
Inselspitals der Univ., Bern, Switzerland; 8 Hosp. Heliópolis,<br />
São Paulo, Brazil; 9 Senter for kliniske studier AS, Bergen,<br />
Norway; 10 University of Pittsburgh, Pittsburgh, PA.<br />
(624)-624. Effects of Low Dose Corticosteroids on the Bone<br />
Mineral Density of Patients with Rheumatoid Arthritis: A Meta-<br />
Analysis. Young Ho Lee, Young Hee Rho, Seong Jae Choi,<br />
Jin Hyun Woo, Jong Dae Ji, Gwan Gyu Song. Division of<br />
Rheumatolgy, Korea University Medical Center, Seoul,<br />
Republic of Korea.<br />
(625)-625. BMD Response to Teriparatide or Alendronate<br />
Therapy in Patients with Glucocorticoid-Induced Osteoporosis.<br />
Chris Recknor 1 , Robert Adler 2 , Noemi Casas 3 , Jean-Pierre<br />
Devogelaer 4 , Kyoungah See 5 , Mayme Wong 5 , Kelly Krohn 5 .<br />
1<br />
United Osteoporosis Centers, Gainesville, GA; 2 McGuire<br />
VA Medical Center, Richmond, VA; 3 Clinica Reina Sofia,<br />
Bogata, Colombia; 4 St. Luc University Hospital, Brussels,<br />
Belgium; 5 Eli Lilly and Company, Indianapolis, IN.<br />
(626)-626. Long-Term Prevention of Glucocorticoid-Induced<br />
Vertebral Fractures with Alendronate Versus Alfacalcidol: An<br />
Extension of the STOP-Study. Jos N. Hoes 1 , Johannes WG<br />
Jacobs 1 , Harry Mj Hulsmans 2 , Ron NJ De Nijs 1 , Johannes<br />
WJ Bijlsma 1 . 1 University Medical Center Utrecht, Utrecht,<br />
The Netherlands; 2 Haga Hospital, The Hague, Netherlands.<br />
(627)-627. The Direct Assessment of Non-vertebral Fracture in<br />
Community Experience (DANCE) Study: Baseline Demographics<br />
and Reasons for Initiating Teriparatide Therapy. Kelly Krohn 1 ,<br />
Anthony Sebba 2 , Radames Sierra-Zorita 3 , Paul Miller 4 , Peiqi<br />
Chen 1 , Kathleen Taylor 1 , Mayme Wong 1 . 1 Eli Lilly and<br />
Company, Indianapolis, IN; 2 Arthritis Associates, Palm<br />
Harbor, FL; 3 University of Puerto Rico School of Medicine,<br />
Hato Rey, PR; 4 Colorado Center for Bone Research,<br />
Lakewood, CO.<br />
(628)-628. Relative Importance of Dietary Calcium Intake and<br />
Serum 25-hydroxyvitamin D Status in Regard to Total Hip Bone<br />
Density Among Adults Age 20+. Heike A. Bischoff-Ferrari 1 ,<br />
Douglas P. Kiel 2 , John E. Orav 3 , Ruifeng Li 3 , Donna<br />
Spiegelman 3 , Walter C. Willett 3 . 1 University Hospital<br />
Zurich, Zurich, Switzerland; 2 Harvard University, Boston,<br />
MA; 3 Harvard School of Public Health, Boston, MA.<br />
(629)-629. Impact of Poor Adherence to Bisphosphonates<br />
Therapy on Hip Fracture Risk in Osteoporotic Women.<br />
Veronique Rabenda 1 , Valérie Fabri 2 , Raf Mertens 2 ,<br />
Johan Vanoverloop 2 , André Deswaef 3 , Gert Verpooten 4 ,<br />
Carine Vannecke 3 , Katrien Thorre 5 , Jean-Yves<br />
Reginster 1 . 1 University of Liege, Liege, Belgium; 2 Agence<br />
Intermutualiste, Bruxelles, Belgium; 3 INAMI, Bruxelles,<br />
Belgium; 4 University of Gand, Gand, Belgium; 5 Mutualite<br />
libre, Bruxelles, Belgium.<br />
114 (Permanent Board Number)-Abstract Number
(630)-630. The Impact of GI Medication Usage with Regard to<br />
Discontinuation and Restart Behavior with Oral Bisphosphonates<br />
in Three Large U.S. Physician Groups. M. B. Nichol 1 , W.<br />
W. Chan 2 , T. Dow 1 , K. H. Kahler 2 , S. Bamford 3 , L. D.<br />
Marks 4 , C. Parise 4 , G. Darah 5 . 1 JMRG Consulting, Encino,<br />
CA; 2 Novartis Pharmaceuticals Corp., East Hanover, NJ;<br />
3<br />
Physician Associates, Pasadena, CA; 4 Sutter Medical<br />
Group, Sacramento, CA; 5 ProMedica, Toledo, OH.<br />
(631)-631. Patient Knowledge and Beliefs about Osteoporosis:<br />
Factors Associated with Initiation of Treatment. Robert Yood 1 ,<br />
Kathleen Mazor 2 , Susan E. Andrade 2 , Srinivas Emani 1 ,<br />
Wing Chan 3 , Kristijan Kahler 3 . 1 Fallon Clinic, Worcester,<br />
MA; 2 Meyers Primary Care Institute, Worcester, MA;<br />
3<br />
Novartis Pharmaceuticals Corp., East Hanover, NJ.<br />
(632)-632. Predictors of Bone Mineral Density (BMD) in a Large<br />
Cohort of Children with Juvenile Idiopathic Arthritis. Fernanda<br />
Falcini, Stefano Stagi, Serena Capannini, Laura Ricci,<br />
Gabriele Simonini, Teresa Giani, Rolando Cimaz, Maurizio<br />
de Martino. A. Meyer Children’s Hospital, Firenze, Italy.<br />
(633)-633. Implementation of Guidelines for Osteoporosis and<br />
Fall Prevention in Patients with a Recent Clinical Fracture<br />
Reduces the Risk for New Clinical Fractures within One<br />
Year. Piet Geusens, Sven van Helden, Arie Kruseman,<br />
Eveline Pijpers, Sjef van der Linden. University Hospital,<br />
Maastricht, The Netherlands.<br />
(634)-634. Anti-TNF Treatment in Rheumatoid Arthritis Patients<br />
Does Not Alter the 1-year Change in Hand, Spine and Hip<br />
Bone Mineral Density Compared to Control Patients. Pernille<br />
Bøyesen 1 , Espen A. Haavardsholm 1 , Glenn Haugeberg 2 ,<br />
Tore K. Kvien 1 . 1 Diakonhjemmet sykehus, Oslo, Norway;<br />
2<br />
Sørlandet hospital, Kristiansand, Norway.<br />
(635)-635. Longitudinal Patterns in Bone Mass Measurement<br />
among U.S. Medicare Beneficiaries. Jeffrey R. Curtis 1 , L.<br />
Carbone 2 , H. Cheng 1 , B. Hayes 3 , A. J. Laster 4 , R. Mathews 1 ,<br />
K. G. Saag 1 , R. Sepanski 3 , B. Tanner 5 , C. Womack 3 , E.<br />
Delzell 1 . 1 UAB, Birmingham, AL; 2 VA Medical Center,<br />
Memphis, TN; 3 University of Tennessee, Memphis, TN;<br />
4<br />
Arthritis & Osteoporosis Consultants of the Carolinas,<br />
Charlotte, NC; 5 Vanderbilt, Nashville, TN.<br />
(636)-636. Bisphosphonates Adherence and Fracture Risk: Time-<br />
Dependent Relationships from 103,038 Bisphosphonate Users<br />
in the U.S.. J. R. Curtis 1 , A. O. Westfall 1 , W. Chan 2 , H.<br />
Cheng 1 , E. Delzell 1 , K. G. Saag 1 . 1 UAB, Birmingham, AL;<br />
2<br />
Novartis, East Hanover, NJ.<br />
(637)-637. Bone Turnover and Loss is Significantly Associated<br />
with Inflammatory Biomarkers in Older Adults: A Longitudinal<br />
Study. Changhai Ding 1 , Venkat Parameswaran 2 , Ray<br />
Udayan 2 , John Burgess 2 , Graeme Jones 1 . 1 University of<br />
Tasmania, Hobart, Australia; 2 Royal Hobart Hospital,<br />
Hobart, Australia.<br />
(638)-638. The Relationship Between Erosions and Osteoporosis<br />
in Rheumatoid Arthritis. Daniel H. Solomon 1 , Joel S.<br />
Finkelstein 2 , Ellen Gravallese 3 , Meryl S. LeBoff 1 , Carl<br />
Winalski 4 , David Lee 1 , Roberta Glass 1 , Liljana Kaci 1 ,<br />
Colleen Corcoran 1 , Margaret Stedman 1 , Michael E.<br />
Weinblatt 1 , Nancy Shadick 1 . 1 Brigham and Women’s<br />
Hospital, Boston, MA; 2 Massachusetts General Hospital,<br />
Boston, MA; 3 University of Massachussetts, Worcester, MA;<br />
4<br />
Cleveland Clinic Foundation, Cleveland, OH.<br />
(639)-639. Bone Mineral Density (BMD) Measured by<br />
Digital X-Ray Radiogrammetry (DXR) and Dual Energy<br />
X-ray Absorptiometry (DEXA) in Patients with Recent Onset<br />
Rheumatoid Arthritis (RA) after 1 Year of Treatment in the Best<br />
Study. M. Güler-Yüksel 1 , C.F. Allaart 1 , F.C. Breedveld 1 ,<br />
B.A.C. Dijkmans 2 , W.F. Lems 2 . 1 Leiden University Medical<br />
Center, Leiden, The Netherlands; 2 VU Medical Center,<br />
Amsterdam, The Netherlands.<br />
(640)-640. Genetic Variation of XPD in Osteoporosis. Eun<br />
Young Lee 1 , Eun Bong Lee 1 , Miook Cho 2 , Audrey<br />
Moshfeghian 2 , Christopher Chung 2 , Shanique Leonard 2 ,<br />
Jung Yoon Park 2 , LeeAnn Zarazabal 2 , Yousin Suh 2 , Yeong<br />
Wook Song 1 . 1 Seoul National University College of<br />
Medicine, Seoul, Republic of Korea; 2 University of Texas<br />
Health Science Center, San Antonio, TX.<br />
Thursday, November 8<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Imaging of Rheumatic Diseases<br />
(641)-641. dGEMRIC of the First Carpometacarpal (1CMC)<br />
Joint: Initial Results. Ashley Williams, Sanjay K. Shetty,<br />
Charles Day, Deborah Burstein, Charles McKenzie. Beth<br />
Israel Deaconess Medical Center, Boston, MA.<br />
(642)-642. The Prevalence of Hallux Valgus in the Community-<br />
Dwelling Elderly and its Association with Foot Pain. Young-Il<br />
Seo 1 , Suho Kim 1 , Seung Hum Kim 2 , Nam Han Cho 2 ,<br />
Hyun Ah Kim 1 . 1 Hallym University Sacred Heart Hospital,<br />
Anyang, Republic of Korea; 2 Department of Clinical<br />
epidemiology, Ajou University, College of Medicine,<br />
Suwon, Republic of Korea.<br />
(643)-643. What is the Utility of the MRI in Predicting<br />
Radiographic Erosions in the Rheumatoid Foot?. Matthew L.<br />
Mundwiler 1 , Douglas H. Brown 2 , Jeffrey M. Silverman 2 ,<br />
Daniel E. Furst 3 , Dinesh Khanna 4 , Michael Leibling 5 ,<br />
James S. Louie 6 , Daniel J. Wallace 1 , Michael H. Weisman 1 .<br />
1<br />
Cedars-Sinai Medical Center, Los Angeles, CA; 2 Landmark<br />
Imaging, Los Angeles, CA; 3 Geffen UCLA School of<br />
Medicine, Los Angeles, CA; 4 University of Cincinnati,<br />
Cincinnati, OH; 5 Harbor UCLA Medical Center, Torrance,<br />
CA; 6 AMGEN, Inc., Thousand Oaks, CA.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 115
Poster Session A<br />
(644)-644. Photoacoustic Tomography-a New Imaging Technology<br />
for Inflammatory Arthritis- as Applied to B27 Transgenic Rat<br />
Joints. David L. Chamberland 1 , Xueding Wang 1 , Joel<br />
D. Taurog 2 . 1 University of Michigan, Ann Arbor, MI;<br />
2<br />
University of Texas Southwestern, Dallas, TX.<br />
(645)-645. Ultrasonographic Erosions on Metacarpal and<br />
Metatarsal Heads in Ra Patients: How to Optimise the Exam<br />
in Clinical Pratice?. Damien Loeuille 1 , Ghislaine Gill 2 ,<br />
Jean Philippe Sommier 2 , Christine Batot-Michel 2 , Anne<br />
Christine Rat 2 , Virginie Hoenen-Clavert 2 , Jacques Pourel 1 ,<br />
Alain Blum 3 , Isabelle Chary-Valckenaere 1 . 1 Rheumatology<br />
and UMR CNRS 7561, Vandoeuvre les Nancy, France;<br />
2<br />
Rheumatology, Vandoeuvre les Nancy, France; 3 Radiology<br />
and UMR CNRS 7561, Nancy, France.<br />
(646)-646. Utility of Ultrasound in the Diagnosis of Giant Cell<br />
Arteritis. Eugenio De Miguel, Concepción Castillo, Emilio<br />
Martín Mola. Hospital Universitario La Paz, Madrid, Spain.<br />
(647)-647. Non-Invasive Diagnostic and Functional Evaluation<br />
of Cardiac Involvement in Patients with Systemic Sclerosis.<br />
Alessandra Vacca 1 , Pietro Garau 1 , Roberta Montisci 2 ,<br />
Alberto Cauli 1 , Antonella Mameli 1 , Matteo Piga 1 , Martina<br />
Piras 1 , Silvia Sanna 1 , Massimo Ruscazio 2 , Giuseppe Passiu 1 ,<br />
Luigi Meloni 2 , Sabino Iliceto 3 , Alessandro Mathieu 1 . 1 IInd<br />
chair of Rheumatology, University of Cagliari, Cagliari,<br />
Italy; 2 Chair of Cardiovascular Diseases, University of<br />
Cagliari, Cagliari, Italy; 3 Cardiology Division, University of<br />
Padua, Padua, Italy.<br />
(648)-648. Long term Patient Repositioning Reproducibility of<br />
Joint Space Width (JSW) Measurements on Hand Radiographs.<br />
Gesa Neumann 1 , Paola dePablo 1 , Axel Finckh 2 , Lori B.<br />
Chibnik 1 , Frederick Wolfe 3 , Jeffrey Duryea 1 . 1 Brigham and<br />
Women’s Hospital, Harvard Medical School, Boston, MA;<br />
2<br />
University of Geneva, Geneva, Switzerland; 3 National Data<br />
Bank for Rheumatic Diseases, Wichita, KS.<br />
(649)-649. Power Doppler Sonography Scoring System Is an<br />
Adaptable Aid to Evaluate Disease Activity and Treatment<br />
Response.. Atsushi Ihata, Yohei Kirino, Ryusuke Yoshimi,<br />
Maasa Hama, Kaoru Takase, Akiko Suda, Atsuhisa Ueda,<br />
Mitsuhiro Takeno, Yoshiaki Ishigatsubo. Yokohama City<br />
University Graduate School of Medicine, Yokohama, Japan.<br />
(650)-650. Impact of B-mode-, Power Doppler-, and Contrast<br />
Enhanced- Ultrasonography in RA Patients on Anti- TNFα<br />
Therapy. André Hensch 1 , Kay-Geert Hermann 2 , Alexander<br />
K. Scheel 3 , Jacqueline Detert 1 , Gerd-Ruediger Burmester 1 ,<br />
Marina Backhaus 1 . 1 Department of Rheumatology and<br />
Clinical Immunology Charité, 10117 Berlin, Germany;<br />
2<br />
Department of Radiology Charité, 10117 Berlin, Germany;<br />
3<br />
Rheumatology, University Frankfurt, 60596 Frankfurt A.<br />
M., Germany.<br />
(651)-651. Dyanamic Contrast Enhanced MRI of Bone Marrow<br />
Oedema in Rheumatoid Arthritis shows an Early Response<br />
to AntiTNFalpha Therapy. Richard Hodgson 1 , Andrew<br />
Grainger 2 , Theresa Barnes 1 , Sylvia Connolly 3 , Philip<br />
O’Connor 2 , Robert Moots 1 . 1 University of Liverpool,<br />
Liverpool, United Kingdom; 2 Chapel Allerton Hospital,<br />
Leeds, United Kingdom; 3 Whiston Hospital, St Helens,<br />
United Kingdom.<br />
(652)-652. Comparative Study of MR Imaging Findings in Wrist<br />
and Hands in Early Psoriatic Arthritis and Rheumatoid Arthritis.<br />
Javier Narvaez, Jose Antonio Narvaez, Joan Miquel Nolla, Jose<br />
Valverde. Hospital Universitari de Bellvitge, Barcelona, Spain.<br />
(653)-653. MRI RAMRIS Scores in Rheumatoid Arthritis:<br />
Experience in a Large Community Based Rheumatology Practice.<br />
John R. Tesser 1 , Lisa Ballehr 2 , Randy Jay 1 , Barbara Keske 1 ,<br />
Maurisa Konya 1 , Scott Brown 1 , Paul Caldron 1 , John Starr 1 ,<br />
Eric Peters 1 , Ralph Bennett 1 , Areena Swarup 1 , Ramina<br />
Jajoo 1 , Jill Bolignese 1 , Sheetal Chhaya 1 , Mike D’Onofrio 3 .<br />
1<br />
AZ Arthritis & Rheumatology Ass, Paradise Valley, AZ;<br />
2<br />
NAOI, Mesa, AZ; 3 ASU, Tempe, AZ.<br />
(654)-654. Hand Bone Mineral Density in Rheumatoid Arthritis<br />
Highly Correlates with Bone Mineral Density of Spine and Femur<br />
and Depends on Disease Activity and Disease Duration. Lydia<br />
Naumann, Marina Backhaus, Monique Jonas, Christian<br />
Scheurig, Susan Meier, Kay-Geert Hermann, Gerd-Rüdiger<br />
Burmester, Frank Buttgereit. Charité - Universitätsmedizin<br />
Berlin, Berlin, Germany.<br />
(655)-655. Scoring of Spinal Inflammation in Ankylosing<br />
Spondylitis by the SPARCC MRI Method: Comparison of Limited<br />
versus Total Spine Assessment. Walter P. Maksymowych 1 ,<br />
David C. Salonen 2 , Robert D. Inman 2 , Paul L. Filipow 1 ,<br />
Robert GW Lambert 1 . 1 University of Alberta, Edmonton,<br />
AB, Canada; 2 University of Toronto, Toronto, ON, Canada.<br />
(656)-656. [(18)F]FDG PET(or PET/CT) is More Usefull for<br />
Monitoring of Therapeutic Responsiveness in Takayasu Arteritis<br />
(TA) than MRI. Maasa Hama, Youhei Kirino, Akiko Suda,<br />
Atsushi Ihata, Mitsuhiro Takeno, Atsuhisa Ueda, Yoshiaki<br />
Ishigatsubo. Yokohama City University Graduate School of<br />
Medicine, Yokohama, Japan.<br />
(657)-657. Twelve Month Longitudinal Change in Regional<br />
Cartilage Morphology in a Multicenter, Multivendor MRI Study<br />
at 3.0 Tesla - The A9001140 Study. Marie Pierre Hellio-<br />
Le Graverand 1 , Brad Wyman 1 , Robert Buck 1 , Wolfgang<br />
Wirth 2 , Martin Hudelmaier 3 , Felix Eckstein 3 , for the<br />
A9001140 Investigators. 1 Pfizer GRD, Ann Arbor, MI;<br />
2<br />
Chondrometrics GmbH, Ainring, Germany; 3 Paracelsus<br />
Medical University, Salzburg, Austria.<br />
116 (Permanent Board Number)-Abstract Number
(658)-658. Longitudinal Change and Pattern of Patellar<br />
Cartilage Loss in Osteoarthritis Patients with Neutral, Valgus,<br />
and Varus Knee Alignment. Felix Eckstein 1 , Manuela Kunz 1 ,<br />
Martin Hudelmaier 1 , Wolfgang Wirth 2 , September<br />
Cahue 3 , Meredith Marshall 3 , Leena Sharma 3 . 1 Paracelsus<br />
Medical University, Salzburg, Austria; 2 Chondrometrics<br />
GmbH, Ainring, Germany; 3 Feinberg School of Medicine,<br />
Northwestern University, Chicago, IL.<br />
(659)-659. Change in Femorotibial Cartilage Volume and<br />
Subregional Cartilage Thickness over 1 Year-Data from the<br />
Osteoarthritis Initiative Progression Subcohort. Felix Eckstein 1 ,<br />
Susanne Maschek 2 , Wolfgang Wirth 2 , Brad Wyman 3 ,<br />
Martin Hudelmaier 1 , Michael Nevitt 4 , Marie-Pierre Hellio<br />
Le Graverand 3 , and the OAI Investigators group. 1 Paracelsus<br />
Medical University, Salzburg, Austria; 2 Chondrometrics<br />
GmbH, Ainring, Germany; 3 Pfizer GRD, Ann Arbor, MI;<br />
4<br />
University of California, San Franzisco, CA.<br />
(660)-660. The Relationship Between Cartilage and Synovitis<br />
in Osteoarthritis: A MRI Study Using Optimal Contrast-<br />
Enhanced Synovial Detection. Philip G. Conaghan 1 , Elizabeth<br />
MA Hensor 1 , Laura A. Rhodes 1 , Paul Emery 1 , Andrew J.<br />
Grainger 2 . 1 University Of Leeds, Leeds, United Kingdom;<br />
2<br />
Leeds Teaching Hospitals, Leeds, United Kingdom.<br />
(661)-661. Quantitative MRI can Accurately Assess the<br />
Progression of Knee Structural Changes in an Osteoarthritis<br />
Experimental Dog Model. Christelle Boileau 1 , Johanne Martel-<br />
Pelletier 1 , François Abram 2 , Jean-Pierre Raynauld 1 , Éric<br />
Troncy 3 , Marc-André D’Anjou 3 , Maxim Moreau 4 , Jean-<br />
Pierre Pelletier 1 . 1 Osteoarthritis Research Unit, University of<br />
Montreal Hospital Centre, Notre-Dame Hospital, Montreal,<br />
PQ, Canada; 2 ArthroVision Inc., Montreal, PQ, Canada;<br />
3<br />
Companion Animal Research Group, Veterinary Teaching<br />
Hospital Center, University of Montreal, St-Hyacinthe, PQ,<br />
Canada; 4 Companion Animal Research Group, Veterinary<br />
Teaching Hospital Center, St-Hyacinthe, PQ, Canada.<br />
(662)-662. The Development of a Preliminary Ultrasonographic<br />
Scoring System for Features of Hand Osteoarthritis : Work<br />
from the DICHOA Group. Helen I. Keen 1 , Frédéric Lavie 2 ,<br />
Richard J. Wakefield 1 , Maria-Antonietta D’Agostino, 3 ,<br />
Hilde Berner Hammer 4 , Elizabeth MA Hensor 1 , Adrian<br />
Pendleton 5 , David Kane 6 , Henri Guerini 2 , Claudia<br />
Schueller-Weidekamm 7 , Sally Doherty 5 , Marion C.<br />
Kortekaas 8 , Fraser N. Birrel 9 , Margreet Kloppenburg 8 , Iain<br />
Watt 10 , Joseph S. Smolen 7 , Emmanuel Maheu 11 , Maxime<br />
Dougados 2 , Philip G. Conaghan 1 . 1 University Of Leeds,<br />
Leeds, United Kingdom; 2 Cochin Hospital, Paris, France;<br />
3<br />
Ambroise Pare Hospital, Boulogne-Billancourt, France;<br />
4<br />
Diakonhjemmet Hospital, Oslo, Norway; 5 University of<br />
Nottingham, Nottingham, United Kingdom; 6 Adelaide<br />
and Meath Hospital, Dublin, Ireland; 7 Medical University<br />
Hospital, Vienna, Austria; 8 Leiden University Medical<br />
Center, Leiden, The Netherlands; 9 University of Newcastle<br />
upon Tyne, Newcastle upon Tyne, United Kingdom;<br />
10<br />
Leiden University Medical Centre, Leiden, The<br />
Netherlands; 11 Hôpital Saint Antoine, Paris, France.<br />
(663)-663. Assessment of Disease Activity in Rheumatoid<br />
Arthritis Using a Novel Folate Targeted Radiopharmaceutical<br />
FolatescanTM. Eric Matteson 1 , Val J. Lowe 1 , Franklyn G.<br />
Prendergast 1 , Cynthia S. Crowson 1 , William J. Sandborn 1 ,<br />
Jay H. Ryu 1 , Brian G. Weinshenker 1 , Kevin G. Moder 1 ,<br />
David E. Morgenstern 2 , Richard A. Messmann 3 , Philip S.<br />
Low 4 . 1 Mayo Clinic College of Medicine, Rochester, MN;<br />
2<br />
Endocyte Inc, West Lafayette, IN; 3 Endocyte Inc, West<br />
Lafayette, LA; 4 Endocyte Inc, West Layfayette, IA.<br />
(664)-664. Software Tool to Score Erosions on Digital Hand<br />
Radiographs for Rheumatoid Arthritis Assessment. Jeffrey Duryea 1 ,<br />
Carl Winalski 2 , Frederick Wolfe 3 , Lori B. Chibnik 1 . 1 Brigham<br />
and Women’s Hospital, Harvard Medical School, Boston,<br />
MA; 2 Cleveland Clinic, Cleveland, OH; 3 National Data<br />
Bank for Rheumatic Diseases, Wichita, KS.<br />
Poster Session A<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 117
irt symposia<br />
Industry Roundtable-Supported Symposia<br />
6:30 – 9:30 p m<br />
Westin Boston Waterfront, Grand Ballroom A-E<br />
Tackling the Controversies of Biologic Therapy in<br />
Rheumatoid Arthritis and Spondyloarthropathy:<br />
Application of Emerging Clinical Data into Daily<br />
Treatment Decisions<br />
Sponsored by The Chicago Medical School at the Rosalind<br />
Franklin University of Medicine and Science<br />
Supported by an educational grant from Abbott Laboratories<br />
PHYSICIAN ACCREDITATION<br />
The Chicago Medical School at the Rosalind Franklin<br />
University of Medicine & Science is accredited by the<br />
Accreditation Council for Continuing Medical Education<br />
(ACCME) to sponsor continuing medical education for<br />
physicians.<br />
CREDIT DESIGNATION<br />
Rosalind Franklin University of Medicine & Science<br />
designates this educational activity for a maximum of<br />
2 AMA PRA Category 1 Credit(s) TM . Physicians should<br />
only claim credit commensurate with the extent of their<br />
participation in the activity.<br />
LEARNING OBJECTIVES<br />
Upon completion of this session, the participants should be able to:<br />
∙ Compare and contrast the efficacy and safety of TNF<br />
antagonists and other biologic agents in achieving remission<br />
and/or modifying the natural history of RA, especially<br />
in halting radiographic progression of disease, preserving<br />
function and quality of life, and improving productivity<br />
∙ Outline the latest clinical data suggesting that certain<br />
TNF antagonists may prevent endothelial dysfunction,<br />
the first step in the pathway to atherosclerosis and<br />
cardiovascular disease<br />
∙ Describe the latest clinical data showing the safety and<br />
efficacy of TNF antagonists in treating spondyloarthropathy,<br />
including extraarticular manifestations of disease<br />
∙ Define the benefit/risk ratio for biologic agents used to<br />
treat patients with RA<br />
6:30 p m<br />
Registration and Dinner<br />
7:00 p m<br />
Welcome and Introduction<br />
Paul Emery, MD; University of Leeds; Leeds, West<br />
Yorkshire, England<br />
7:10 p m<br />
Changing Expectations in Rheumatoid Arthritis:<br />
Achieving Remission vs Clinical Improvement<br />
Josef Smolen, MD; University of Vienna; Vienna, Austria<br />
7:30 p m<br />
Beyond <strong>ACR</strong> Scores: Radiographic Inhibition Leads<br />
to Downstream Effects on Quality of Life and Productivity<br />
Paul Emery, MD; University of Leeds; Leeds, West<br />
Yorkshire, England<br />
7:45 p m<br />
The Role of TNF Antagonists in Managing<br />
Cardiovascular Risk<br />
Paul Ridker, MD; Brigham and Women’s Hospital; Boston, MA<br />
8:00 p m<br />
Optimal Management of the Spondyloarthropathies And<br />
Their Associated Comorbidities: What Have the Clinical<br />
Data Taught Us?<br />
Muhammad Asim Khan, MD; Case Western Reserve<br />
University; Cleveland, OH<br />
8:15 p m<br />
Are We Doing More Good than Harm? A Benefit/Risk<br />
Analysis of Biologic Therapy in RA<br />
Arthur Kavanaugh, MD; University of California, San<br />
Diego School of Medicine; La Jolla, CA<br />
8:30 p m<br />
Point-Counterpoint – A Roundtable Discussion & Debate<br />
of Key Issues in Patient Management of RA and SpA<br />
Faculty Panel<br />
9:00 p m<br />
Questions & Answers Session<br />
118 Thursday, November 8, <strong>2007</strong>
Industry Roundtable-Supported Symposia<br />
6:30 – 9:30 p m<br />
Westin Copley Place Boston, <strong>American</strong> Ballroom,<br />
North-Center-South<br />
Challenging Current RA Treatment: Do Disparities Exist?<br />
Sponsored by the Academy for Healthcare Education Inc.<br />
Supported by an educational grant from Amgen, Inc. and Wyeth<br />
Pharmaceuticals<br />
PHYSICIAN ACCREDITATION<br />
The Academy for Healthcare Education, Inc. is accredited<br />
by the Accreditation Council for Continuing Medical<br />
Education (ACCME) to sponsor continuing medical<br />
education for physicians.<br />
CREDIT DESIGNATION<br />
The Academy for Healthcare Education, Inc. designates this<br />
educational activity for a maximum of 2 AMA PRA Category 1<br />
Credit(s) TM . Physicians should only claim credit commensurate<br />
with the extent of their participation in the activity.<br />
LEARNING OBJECTIVES<br />
Upon completion of this session, the participants should be able to:<br />
∙ Describe standards of practice for prescribing biologic<br />
therapy for patients with RA<br />
∙ Discuss socioeconomic, race and gender issues influencing<br />
the initiation of DMARDs and biologics in RA<br />
∙ Identify ways to improve patient counseling through<br />
an improved understanding of the patients’ perspective<br />
on RA therapies, perceived self-efficacy and/or<br />
personal limitations<br />
6:30 p m<br />
Registration and Dinner<br />
7:15 p m<br />
Welcome and Introduction<br />
Allan Gibofsky, MD, JD; Weill Medical College of Cornell<br />
University; New York, NY<br />
7:20 p m<br />
Biological Drug Use: Are Standards of Practice Met?<br />
Clifton Bingham, III, MD; Johns Hopkins University;<br />
Baltimore, MD<br />
7:40 p m<br />
Panel/Audience Challenge<br />
7:50 p m<br />
Management of Early RA: Are There Gender Differences?<br />
Stephen Paget, MD; Weill Medical College of Cornell<br />
University; New York, NY<br />
8:10 p m<br />
Panel/Audience Challenge<br />
8:20 p m<br />
Will Improving the Physician/Patient Dialogue<br />
Improve Care?<br />
Kate Lorig, RN, DrPH; Stanford University School of<br />
Medicine; Palo Alto, CA<br />
8:35 p m<br />
Panel/Audience Challenge<br />
8:45 p m<br />
Inequality in Quality: Does Socioeconomic Status Matter<br />
in Severity and Outcomes?<br />
Theodore Pincus, MD; New York University Hospital; New<br />
York, NY<br />
irt symposia<br />
9:05 p m<br />
Panel/Audience Challenge and Closing Remarks<br />
CME credit for Industry-Supported Symposia provided by sponsor listed. 119
irt symposia<br />
Industry Roundtable-Supported Symposia<br />
6:30 – 9:30 p m<br />
Sheraton Boston Hotel, Grand Ballroom,<br />
Independence Ballroom and Liberty A-B-C<br />
Biological Therapies in RA and SLE – Applying Lessons<br />
from Clinical Trials to the Clinic<br />
Sponsored by Discovery Institute of Medical Education<br />
Supported by an educational grant from Genentech, Inc.<br />
PHYSICIAN ACCREDITATION<br />
The Discovery Institute of Medical Education is accredited<br />
by the Accreditation Council for Continuing Medical<br />
Education (ACCME) to sponsor continuing medical<br />
education for physicians.<br />
CREDIT DESIGNATION<br />
The Discovery Institute of Medical Education designates<br />
this educational activity for a maximum of 2 AMA PRA<br />
Category 1 Credit(s) TM . Physicians should only claim credit<br />
commensurate with the extent of their participation in<br />
the activity.<br />
LEARNING OBJECTIVES<br />
Upon completion of this session, the participants should be able to:<br />
∙ Explain to a colleague the current evidence based<br />
guidelines on the use of B- and T-cell targeted therapies<br />
in RA<br />
∙ Understand current issues in the design of clinical trials in<br />
rheumatology: the importance of patient selection criteria<br />
and end points<br />
∙ Weigh the use of targeted therapies against their side<br />
effects and clinical outcomes in patients with SLE<br />
∙ Appreciate the broad implications of clinical studies over<br />
the past 10 years on clinical practice for patients with RA<br />
and SLE<br />
6:30 p m<br />
Registration and Dinner<br />
7:30 p m<br />
Opening Remarks<br />
Vibeke Strand, MD; Stanford University; Portola Valley, CA<br />
7:35 p m<br />
Narrowing the Gap between Clinical Trials and Clinical<br />
Practice: Issues in Clinical Trial Design and Measurement<br />
in Standard Care<br />
Theodore Pincus, MD; New York University Hospital; New<br />
York, NY<br />
8:00 p m<br />
Biologic Therapies for RA: What Have We Learned<br />
in the Past Decade? Where Do We Go From Here?<br />
Vibeke Strand, MD; Stanford University; Portola Valley, CA<br />
8:25 p m<br />
Applying Evidence-Based Guidelines on Targeted<br />
Therapies for RA<br />
Edward Keystone, MD; Mount Sinai Hospital; Toronto,<br />
Ontario<br />
8:50 p m<br />
Biologic Therapies for SLE: Update on Clinical Trials<br />
Inaki Sanz, MD; University of Rochester Medical Center;<br />
Rochester, NY<br />
9:15 p m<br />
Expert Panel Discussion<br />
9:25 p m<br />
Closing Remarks<br />
Vibeke Strand, MD; Stanford University; Portola Valley, CA<br />
120 Thursday, November 8, <strong>2007</strong>
Industry Roundtable-Supported Symposia<br />
6:30 – 9:30 p m<br />
Boston Convention & Exhibition Center,<br />
Room 52 A-B<br />
Balancing Pain Relief Risks & Benefits in Arthritis &<br />
Fibromyalgia: An Interactive Patient Case Symposium<br />
Jointly sponsored by Beth Israel Medical Center-St. Luke’s<br />
Roosevelt Hospital Center and Health Education Alliance, Inc.<br />
Supported by an educational grant from Pfizer Inc<br />
PHYSICIAN ACCREDITATION<br />
Beth Israel Medical Center-St. Luke’s Roosevelt Hospital<br />
Center (BIMC-SLRHC) and Health Education Alliance,<br />
Inc. BIMC-SLRHC are accredited by the Accreditation<br />
Council for Continuing Medical Education (ACCME) to<br />
sponsor continuing medical education for physicians.<br />
CREDIT DESIGNATION<br />
BIMC-SLRHC designates this educational activity for a<br />
maximum of 2 AMA PRA Category 1 Credits. Participants<br />
should only claim credit commensurate with the extent of<br />
their participation in the activity.<br />
LEARNING OBJECTIVES<br />
Upon completion of this session, the participants should be able to:<br />
∙ Discuss the relative CV and GI risk of nonsteroidal antiinflammatory<br />
drugs (NSAIDs), including COX-2 selective<br />
inhibitors<br />
∙ Identify an individual patient’s level of potential CV or GI<br />
risk based on family history, medical history, and primary<br />
complaint(s)<br />
∙ Weigh the benefits of treating arthritis pain against the<br />
risk therapy may pose to patients with some level of CV<br />
or GI risk<br />
∙ Counsel patients to help them better understand their<br />
own level of treatment benefit and risk, and make<br />
informed decisions about their pain relief therapy<br />
∙ Explain the evolution in understanding of fibromyalgia as<br />
a sensory syndrome<br />
∙ List the various approaches which can be undertaken to<br />
relieve chronic pain caused by fibromyalgia<br />
6:30 p m<br />
Registration and Dinner<br />
7:00 p m<br />
Introduction<br />
Lee Simon, MD; Harvard Medical School; Boston, MA<br />
7:05 p m<br />
The Role of COX-2 Inhibitors in Arthritis (Including<br />
Two Interactive Video Patient Case Presentations)<br />
Lee Simon, MD; Harvard Medical School; Boston, MA<br />
7:45 p m<br />
Assessing the CV and GI Risk of NSAIDS/COX-2 Inhibitors<br />
Jeffery Boone, MD; University of Colorado College of<br />
Medicine; Denver, CO<br />
8:05 p m<br />
Advances in the Management of Fibromyalgia Syndrome<br />
(Including Two Interactive Video Patient Case Presentations)<br />
Lesley Arnold, MD; University of Cincinnati College of<br />
Medicine; Cincinnati, OH<br />
8:45 p m<br />
Questions & Answers Session/Closing Remarks<br />
Faculty Panel<br />
irt symposia<br />
CME credit for Industry-Supported Symposia provided by sponsor listed. 121
time locatioN EVENT<br />
Friday · agenda at-a-glance<br />
6:00—8:00 a m Carson Beach REF 5K Run/Walk<br />
7:00 a m—5:00 pm East Registration <strong>ACR</strong>/<strong>ARHP</strong> Registration<br />
7:45—8:45 a m Grand Ballroom East <strong>ACR</strong> Immunology Updates for Clinicians<br />
7:45—8:45 a m Convention Center (various locations) <strong>ACR</strong> State-of-the-Art<br />
7:45—8:45 a m Convention Center (various locations) <strong>ARHP</strong> Concurrent Sessions<br />
7:45—9:15 a m Convention Center (various locations) <strong>ACR</strong> Meet the Professor Sessions<br />
7:45—9:45 a m Convention Center (various locations) <strong>ACR</strong> Workshops<br />
8:00—9:30 a m Exhibit Hall A-B <strong>ACR</strong>/<strong>ARHP</strong> Coffee and Tea Break<br />
8:00 a m—4:30 pm Exhibit Hall A-B <strong>ACR</strong>/<strong>ARHP</strong> Poster Session B<br />
8:00 a m—4:30 pm Exhibit Hall A-B exhibits<br />
9:15—10:15 a m Hall C <strong>ACR</strong> Medical Aspects of Rheumatic Diseases<br />
9:15—10:15 a m Room 210 <strong>ACR</strong> State-of-the-Art<br />
9:15—10:15 a m Meet in the Registration Area <strong>ARHP</strong> Special Session: How to Decipher a Poster<br />
9:15—10:15 a m Convention Center (various locations) <strong>ARHP</strong> Concurrent Sessions<br />
9:15—10:15 a m Room 261 <strong>ARHP</strong> Concurrent Abstract Session<br />
10:30 a m—12:30 pm Convention Center (various locations) <strong>ACR</strong> Workshops<br />
10:45—11:45 a m Room 258 <strong>ARHP</strong> General Session II<br />
11:00 a m—Noon Room 253 <strong>ACR</strong> Practice Issues<br />
11:00 a m—12:30 pm Hall C <strong>ACR</strong> Plenary Session II<br />
11:00 a m—12:30 pm Grand Ballroom East <strong>ACR</strong> Special Session: Curbside Consults<br />
11:00 a m—12:30 pm Room 157 <strong>ACR</strong> Special Session: Workforce Issues<br />
Noon—2:00 pm Westin Waterfront Hotel, Grand Ballroom A-B <strong>ARHP</strong> Special Session: Networking at Noon<br />
12:45—2:15 pm Room 255 encore Theater<br />
12:45—2:15 pm Convention Center (various locations) <strong>ACR</strong> Meet the Professor Sessions<br />
12:45—2:15 pm Room 104 <strong>ACR</strong> Special Session: Young Investigators<br />
1:15—3:15 pm Convention Center (various locations) <strong>ACR</strong> Workshops<br />
2:30—4:00 pm Room 205 <strong>ACR</strong> Basic Science Symposium<br />
2:30—4:00 pm Convention Center (various locations) <strong>ACR</strong> Clinical Symposia<br />
<strong>ACR</strong><br />
CLINICAL PRACTICE<br />
BASIC AND<br />
TRANSLATIONAL<br />
RESEARCH<br />
DUAL INTEREST TO<br />
CLINICIANS AND<br />
RESEARCHERS<br />
PEDIATRICS<br />
FELLOWS-IN-TRAINING<br />
<strong>ARHP</strong><br />
CLINICAL PRACTICE<br />
PEDIATRICS<br />
FELLOWS-IN-TRAINING<br />
PLAN YOUR SCHEDULE USING EDUCATIONAL TRACKS TO ENHANCE<br />
YOUR MEETING EXPERIENCE<br />
The <strong>ACR</strong> and <strong>ARHP</strong> have designed educational tracks to help you maximize the scheduling of your time and<br />
meeting experience by emphasizing primary areas of interest. There are five tracks for <strong>ACR</strong> and three tracks for<br />
<strong>ARHP</strong>. Designated sessions include the main symposia, lectures and select <strong>ACR</strong> Meet the Professor Sessions and<br />
Workshops. However, the concurrent abstract sessions and poster discussions are not included.<br />
Those sessions that are predominantly translational in content are designed to be of interest to both clinicians and<br />
researchers. These are indicated as “C/R”. Sessions with mainly pediatric content are indicated as “P”, and may be<br />
of interest to both pediatric and adult rheumatologists.<br />
As the annual meeting has a variety of session types scheduled concurrently, use these suggested tracks as a tool to<br />
assist you in developing your own individualized schedule for the meeting.<br />
Track Indicator Example<br />
Please use the following as an example to identify the available tracks.<br />
C R C/R P F<br />
CLINICAL<br />
PRACTICE<br />
BASIC AND<br />
TRANSLATIONAL<br />
RESEARCH<br />
DUAL INTEREST TO<br />
CLINICIANS AND<br />
RESEARCHERS<br />
PEDIATRICS<br />
FELLOWS-IN-<br />
TRAINING<br />
PM - PAIN MANAGEMENT<br />
The <strong>ACR</strong> designates certain sessions for pain management credit as required by the Medical Board of California<br />
(AB487). This designation is identified by the icon shown and will be placed next to the session title.<br />
122
2:30—4:00 pm Convention Center (various locations) <strong>ACR</strong> Concurrent Abstract Sessions<br />
2:30—4:00 pm Room 253 <strong>ACR</strong> CORC Forum<br />
2:30—4:00 pm Room 257 <strong>ACR</strong>/<strong>ARHP</strong> Combined Clinical Symposium<br />
2:30—4:00 pm Room 151 <strong>ACR</strong> Special Session: Clinician Scholar Educator Awards<br />
2:30—4:00 pm Convention Center (various locations) <strong>ARHP</strong> Concurrent Sessions<br />
2:30—4:00 pm Room 261 <strong>ARHP</strong> Concurrent Abstract Session<br />
2:30—4:15 pm Grand Ballroom West <strong>ACR</strong> Mini-Symposium<br />
4:00—6:00 pm Convention Center (various locations) <strong>ACR</strong> Workshops<br />
4:30—6:00 pm Convention Center (various locations) <strong>ACR</strong> Basic Science Symposia<br />
4:30—6:00 pm Hall C <strong>ACR</strong> Clinical Symposium<br />
4:30—6:00 pm Convention Center (various locations) <strong>ACR</strong> Concurrent Abstract Sessions<br />
4:30—6:00 pm Room 104 <strong>ACR</strong>/<strong>ARHP</strong> Combined Concurrent Abstract Session<br />
4:30—6:00 pm Convention Center (various locations) <strong>ACR</strong> Meet the Professor Sessions<br />
4:30—6:00 pm Convention Center (various locations) <strong>ARHP</strong> Concurrent Sessions<br />
6:15—7:30 pm Convention Center (various locations) <strong>ACR</strong> Study Groups: Session I<br />
6:15—7:45 pm Room 255 encore Theater<br />
7:30—8:00 pm North Lobby <strong>ACR</strong> Study Group Reception<br />
7:45—9:15 pm Convention Center (various locations) <strong>ACR</strong> Study Groups: Session II<br />
friday<br />
FRIDAY, November 9, <strong>2007</strong><br />
REF 5K Run/Walk<br />
6:00—8:00 a m<br />
The REF thanks UCB, Inc., for its support of the <strong>2007</strong> REF 5K Run/Walk.<br />
The rheumatologists are coming!<br />
It’s not quite the midnight ride of Paul Revere, but we’ll<br />
definitely let Boston know that the <strong>ACR</strong> and <strong>ARHP</strong><br />
have arrived. Start the day with an early morning run/<br />
walk along the city’s beautiful waterfront and make a<br />
stand for the future of rheumatology. A pre-run warm up<br />
and refreshments will be offered at an indoor pavilion<br />
at Carson Beach. Participants may register on-site in the<br />
<strong>ACR</strong>/<strong>ARHP</strong> Registration area until 5:00 pm, Thursday,<br />
November 8. Complimentary shuttle service will be provided<br />
from convention hotels to the run course.<br />
<strong>ACR</strong>/<strong>ARHP</strong> Registration<br />
7:00 a m—5:00 p m<br />
East Registration<br />
<strong>ACR</strong> Immunology Updates for Clinicians c/r<br />
7:45—8:45 a m<br />
Grand Ballroom East<br />
Genetics of Autoimmunity: A Clinician’s Guide<br />
Moderator:<br />
Franak Batliwalla, PhD; Feinstein Institute for Medical<br />
Research; Manhasset, NY<br />
Speaker:<br />
Susan A. Boackle, MD; University of Colorado Health<br />
Sciences Center; Aurora, CO<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify the multigenic origins of autoimmune diseases<br />
∙ Describe the technology that has led to the identification<br />
of particular gene loci associated with autoimmunity<br />
∙ Interpret the roles of the SLam family, CR2, CTLA4,<br />
and PTPN22<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
123
FRIDAY<br />
<strong>ACR</strong> State-of-the-Art R<br />
7:45—8:45 a m<br />
Room 253<br />
Bioimaging: Visualizing the Immune Response<br />
Moderator:<br />
Kurt Redlich, MD; Medical University Vienna; Vienna, Austria<br />
Speaker:<br />
Jackson G. Egen, PhD; National Institute of Allergy and<br />
Infectious Diseases; Bethesda, MD<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize and interpret the novel imaging technology<br />
employed in characterizing the immune response<br />
∙ Evaluate the current limitations of these methods<br />
∙ Identify a variety of potential future applications of<br />
these methods<br />
<strong>ACR</strong> State-of-the-Art C<br />
7:45—8:45 a m<br />
Hall C<br />
Clinicopathologic Conference (CPC): A 57-Year-Old Man<br />
with Polyarthritis<br />
Moderators:<br />
Elena M. Massarotti, MD; New England Medical Center;<br />
Boston, MA<br />
Peter A. Merkel, MD, MPH; Boston University; Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Develop a rational clinical approach to the diagnosis of<br />
polyarthritis in a middle aged man<br />
∙ Differentiate the causes of polyarthritis utilizing the clinical<br />
findings and available diagnostic data<br />
∙ Review the pathophysiology of polyarthritis<br />
7:45 a m<br />
Case Presentation<br />
Eugene Y. Kissin, MD; Boston University; Boston, MA<br />
8:00 a m<br />
Case Presentation<br />
Michael E. Weinblatt, MD; Brigham and Women’s<br />
Hospital; Boston, MA<br />
8:30 a m<br />
Panel Discussion<br />
<strong>ARHP</strong> Concurrent Session c<br />
7:45—8:45 a m<br />
Room 156<br />
Rheumatic Disease Update: Adult and Juvenile<br />
Dermatomyositis/Polymyositis<br />
Moderator:<br />
Sandra J. Watcher, BSN; Childrens Hospital of Los Angeles;<br />
Los Angeles, CA<br />
Speaker:<br />
Lisa G. Rider, MD; National Institute of Environmental<br />
Health Sciences; Bethesda, MD<br />
Upon completion of this session, participants should be able to:<br />
∙ Review clinical features and prognoses of adult and<br />
juvenile myositis and its subsets<br />
∙ Describe the pathogenesis of these disorders<br />
∙ Distinguish disease activity from damage in patients with<br />
myositis<br />
∙ Review current approaches to medical management and<br />
physical therapy of these conditions<br />
<strong>ARHP</strong> Concurrent Session C<br />
7:45—8:45 a m<br />
Room 261<br />
Alternative Therapies for Arthritis and Fibromyalgia<br />
Moderator:<br />
Carlo A. Marra, PharmD; University of British Columbia;<br />
Vancouver, British Columbia<br />
Speaker:<br />
Donald R. Miller, PharmD; North Dakota State University;<br />
Fargo, ND<br />
Upon completion of this session, participants should be able to:<br />
∙ List the most common alternative therapies used in<br />
arthritis and fibromyalgia<br />
∙ Describe the quality of evidence for each alternative<br />
therapy discussed<br />
∙ Counsel patients on the appropriateness of using<br />
each therapy<br />
<strong>ARHP</strong> Concurrent Session C<br />
7:45—8:45 a m<br />
Room 259<br />
Arthrogenic Muscle Inhibition<br />
Moderator:<br />
Jennifer M. Hootman, PhD; Centers for Disease Control;<br />
Atlanta, GA<br />
Speaker:<br />
Christopher D. Ingersoll, PhD, ATC; University of Virginia;<br />
Charlottesville, VA<br />
p<br />
124<br />
= Recorded Sessions (order form on page 430)
Upon completion of this session, participants should be able to:<br />
∙ Describe the neurophysiological mechanisms of<br />
arthrogenic muscle inhibition<br />
∙ Realize the consequences of arthrogenic muscle inhibition<br />
on function and mobility<br />
∙ Assess the emerging evidence relating arthrogenic muscle<br />
inhibition to the development of osteoarthritis<br />
<strong>ARHP</strong> Concurrent Session<br />
7:45—8:45 a m<br />
Room 257<br />
What’s New and Noteworthy in <strong>2007</strong>: A Review of<br />
Rheumatology Research for Health Professionals?<br />
Moderator:<br />
Betty B. Loflin, RN, MSN, CFNP; Arthritis Associates of<br />
Mississippi; Jackson, MS<br />
Speakers:<br />
Teresa J. Brady, PhD, OT; Centers for Disease Control and<br />
Prevention; Atlanta, GA<br />
Carol A. Oatis, PT, PhD; Arcadia University; Glenside, PA<br />
Susan M. Oliver, MSc; Royal College of Nursing UK;<br />
Barnstaple, England<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify important research advances published in the<br />
rheumatology nursing, public health and rehabilitation<br />
arenas in the past 12 months<br />
∙ Describe the significance of these advances to the<br />
individual practitioner<br />
∙ Describe the significance of these advances to<br />
rheumatology research<br />
<strong>ACR</strong> Meet the Professor Sessions<br />
7:45—9:15 a m<br />
Admission to the Meet the Professor Sessions is by ticket only. To verify the<br />
session for which you are registered, refer to the registration codes below in<br />
parentheses. Meet the Professor sessions include beverages only.<br />
Crystal: Management of Gout (059)<br />
Room 107 A<br />
Michael A. Becker, MD; University of Chicago Medical<br />
Center; Chicago, IL<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the management of gout in patients with renal<br />
insufficiency or organ transplants<br />
∙ Identify strategies to treat patients who are intolerant of<br />
approved therapies<br />
∙ List agents in development for the treatment of<br />
hyperuricemia and gout<br />
Infections in Patients on TNF Therapy (060)<br />
Room 107 B<br />
John J. Cush, MD; Arthritis Care & Research Center;<br />
Dallas, TX<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the commonly encountered infections in patients<br />
using anti-TNF therapies<br />
∙ Discuss the indications for stopping anti-TNF therapies<br />
∙ Review the management of infections in patients using<br />
anti-TNF therapies<br />
Myopathy: Adult Inflammatory Myopathy (071)<br />
Room 162 B<br />
Robert L. Wortmann, MD; University of Oklahoma College<br />
of Medicine; Tulsa, OK<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the clinical manifestations of inflammatory<br />
myopathies including important extra-muscle manifestations<br />
∙ Discuss diagnostic pearls for the evaluation of someone<br />
suspected of having an inflammatory myopathy<br />
∙ Discuss the treatment paradigm for inflammatory myopathies<br />
∙ Use cases to reinforce objectives 1-3<br />
Osteoporosis: Pitfalls in Bone Density Testing (063) F<br />
Room 109 A<br />
Maria W. Greenwald, MD; Annenberg Health Sciences<br />
Center; Palm Desert, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the indications for bone densitometry<br />
∙ List common pitfalls in bone densitometry interpretation<br />
Pediatrics: Pediatric Rheumatology for Adult<br />
Rheumatologists (070) P F<br />
Room 162 A<br />
Emily Von Scheven, MD; University of California–San<br />
Francisco; San Francisco, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Diagnose the various forms of arthritis that are unique<br />
to children<br />
∙ Recognize how the evaluation of children with rheumatic<br />
diseases may be different from that of adults<br />
∙ Describe current treatments of arthritis in children<br />
Pulmonary Hypertension in the Rheumatic Diseases (061) C<br />
Room 107 C<br />
Harrison W. Farber, MD; Boston University; Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the prevalence of PHT in the rheumatic diseases<br />
∙ Discuss the pathogenesis of PHT in these disorders<br />
∙ Describe the indications for treatment, available treatment<br />
options and how to document therapeutic response<br />
FRIDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
125
FRIDAY<br />
RA: Biological Agents (064)<br />
Room 109 B<br />
Edward C. Keystone, Dr., MD; Mount Sinai Hospital;<br />
Toronto, Ontario<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify biologic agents in use for the treatment of<br />
rheumatoid arthritis<br />
∙ Describe the risk/benefit profiles of biologic agents<br />
RA: Difficult RA (062)<br />
Room 108<br />
Roy M. Fleischmann, MD; University of Texas Southwest<br />
Medical Center; Dallas, TX<br />
Upon completion of this session, participants should be able to:<br />
∙ Define difficult to treat rheumatoid arthritis<br />
∙ Develop effective management plans for complicated<br />
rheumatoid arthritis patients<br />
Rheumatology Practice 101: Starting Out in<br />
Practice for the Graduating Fellow (058) F<br />
Room 106<br />
Herbert S.B. Baraf, MD; Arthritis and Rheumatism<br />
Associates, P.C.; Wheaton, MD<br />
Upon completion of this session, participants should be able to:<br />
∙ Assess contracts with managed care companies and<br />
negotiating opportunities<br />
∙ Evaluate how to buy in to an existing practice, hire a new<br />
associate, or meet the needs of a retiring partner<br />
∙ Discuss the pros and cons of adding ancillary services<br />
(e.g. infusion center, densitometry service etc), an office<br />
manager or practice administrator<br />
Safety/Efficacy of Alternative Therapies (066)<br />
Room 160 A<br />
Donald M. Marcus, MD; Baylor College of Medicine;<br />
Houston, TX<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the use of alternative therapies in patients with<br />
rheumatic diseases<br />
∙ Describe the safety profiles of alternative therapies<br />
Scleroderma: Systemic Sclerosis (065)<br />
Room 159<br />
Lauren H. Kim, MD; Oregon Health and Science<br />
University; Portland, OR<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the classification of systemic sclerosis and its<br />
impact on treatment and prognosis<br />
∙ Apply cardiopulmonary testing to determine the relative<br />
contributions of alveolitis, fibrosis and vasculopathy<br />
∙ Formulate a therapeutic regimen to improve quality of life<br />
and organ-specific symptomatology<br />
SLE: CNS Lupus (068)<br />
Room 160 C<br />
C. Michael Neuwelt, MD; University of California–San<br />
Francisco and Stanford University; San Leandro, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize manifestations of central nervous system lupus<br />
∙ Select appropriate diagnostic tests in patients with central<br />
nervous system lupus<br />
∙ Formulate a treatment plan<br />
SLE: Lupus Nephritis (067)<br />
Room 160 B<br />
W. Joseph McCune, MD; University of Michigan; Ann<br />
Arbor, MI<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify lupus nephritis in early stages<br />
∙ Recognize poor prognostic factors<br />
∙ Evaluate lupus nephritis therapy<br />
Vasculitis: CNS Vasculitis (069)<br />
Room 161<br />
John H. Stone, MD, MPH; Massachusetts General<br />
Hospital / UpToDate; Sudbury, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss an approach to the evaluation of a patient referred<br />
with possible central nervous system (CNS) vasculitis<br />
∙ Review the major entities in the differential diagnosis<br />
of primary angiitis of the CNS<br />
∙ Develop a consistent therapeutic approach to the treatment<br />
of vasculitis involving the brain and/or spinal cord<br />
<strong>ACR</strong> Workshops<br />
7:45—9:45 a m<br />
Admission to the Workshop sessions is by ticket only. To verify the session<br />
for which you are registered, refer to the registration codes below in<br />
parentheses. Workshops include beverages only.<br />
Creating Presentations Using PowerPoint: Advanced (072)<br />
Room 213<br />
Steve Blevins, BA, BS, MBA; <strong>American</strong> College of<br />
Rheumatology; Atlanta, GA<br />
Upon completion of this session, participants should be able to:<br />
∙ Use advanced slide transition techniques<br />
∙ Integrate audio, video and narration into slides<br />
∙ Create presentations that can be published on a local<br />
website and be viewed in a browser<br />
Knee Braces and Foot Orthosis for Knee Osteoarthritis (074)<br />
Room 209<br />
Howard J. Hillstrom, PhD; Hospital for Special Surgery;<br />
New York, NY<br />
Kelly D. Krohn, MD; Eli Lilly and Company; Indianapolis, IN<br />
126<br />
= Recorded Sessions (order form on page 430)
Upon completion of this session, participants should be able to:<br />
∙ Review the biomechanical rationale for the use of knee<br />
braces and foot orthoses for knee OA<br />
∙ Discuss the clinical data to support these modalities<br />
∙ Apply these modalities to their patients<br />
Musculoskeletal Ultrasonography: Basic (073)<br />
Equipment provided by Biosound Esaote Ultrasound<br />
Room 211<br />
George A.W. Bruyn, MD, PhD; Medisch Centrum<br />
Leeuwarden; Loenga, Netherlands<br />
Wolfgang A. Schmidt, MD; Medical Center for<br />
Rheumatology Berlin-Buch; Berlin, Germany<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the indications for ultrasound in rheumatic diseases<br />
∙ Discuss the techniques of ultrasonography<br />
∙ Recognize normal and abnormal anatomical structures<br />
Synovial Fluid Analysis and Crystal Identification (075)<br />
Room 212<br />
H. Ralph Schumacher, Jr., MD; Veteran’s Affairs Medical<br />
Center; Philadelphia, PA<br />
Lan X. Chen, MD, PhD; University of Pennsylvania;<br />
Philadelphia, PA<br />
Gilda M. Clayburne, MLT; Veteran’s Affairs Medical<br />
Center; Philadelphia, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Prepare synovial fluid samples for microscopic examination<br />
∙ Identify various components of synovial fluid<br />
∙ Recognize crystals in synovial fluid<br />
Late-Breaking and Fellows-in-Training Posters<br />
For a complete listing of the Late Breaking and Fellows-in-Training<br />
abstracts, see the <strong>Program</strong> <strong>Book</strong> Supplement.<br />
Exhibits<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
<strong>ACR</strong> Medical Aspects of Rheumatic Diseases C<br />
9:15—10:15 a m<br />
Hall C<br />
¹<br />
Pulmonary Hypertension<br />
Moderator:<br />
Marcy B. Bolster, MD; Medical University of South<br />
Carolina; Charleston, SC<br />
Speaker:<br />
Nicholas Hill, MD; Tufts New England Medical Center;<br />
Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the pathogenesis and treatable causes of<br />
pulmonary hypertension<br />
∙ Describe the value of early detection of pulmonary<br />
hypertension<br />
∙ Describe indications for treatment, treatment options, and<br />
how to document therapeutic response<br />
10:05 a m<br />
Discussion<br />
FRIDAY<br />
<strong>ACR</strong>/<strong>ARHP</strong> Coffee and Tea Break<br />
8:00—9:30 a m<br />
Exhibit Hall A-B<br />
<strong>ACR</strong>/<strong>ARHP</strong> Poster Session B<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Admission to <strong>ACR</strong> poster sessions is by name badge only.<br />
Poster presenters will be available from 9:00—11:00 a m.<br />
Please note the numbering system for the poster sessions<br />
will include two sets of numbers. The first number is the<br />
permanent poster board number and will remain the same<br />
during all the poster sessions [e.g.:(1), (2)]. The next number<br />
will refer to the abstract number being presented, and this<br />
will change for each of the poster sessions.<br />
Abstracts #769–1275<br />
For complete listing of the abstracts presented in this poster session, see<br />
pages 164--200.<br />
<strong>ACR</strong> State-of-the-Art R<br />
9:15—10:15 a m<br />
Room 210<br />
MicroRNAs and Gene Regulation<br />
Moderator:<br />
William Robinson, MD, PhD; Stanford University;<br />
Stanford, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the field of microRNAs and the molecular<br />
mechanisms by which they regulate gene expression<br />
∙ Describe what is known about the role of microRNAs in<br />
human disease<br />
∙ Discuss potential therapeutic applications of microRNAs<br />
to rheumatic and inflammatory diseases<br />
Biology and Therapeutic Potential of Short RNAs<br />
Nobel Laureate Phillip A. Sharp, PhD; Massachusetts<br />
Institute of Technology; Cambridge, MA<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
127
FRIDAY<br />
<strong>ARHP</strong> Special Session<br />
9:15—10:15 a m<br />
Registration Area by the B1 Escalators<br />
Poster Introduction: How to Decipher a Poster<br />
Moderator:<br />
Nadine T. James, RN, MSN, PhD; University of Southern<br />
Mississippi; Hattiesburg, MS<br />
Take this opportunity to learn how to decipher a poster.<br />
Using pre-selected posters, experienced researchers will lead<br />
a discussion about the research with the posters’ authors.<br />
All <strong>ACR</strong> and <strong>ARHP</strong> attendees are welcome to participate<br />
and should meet in the Registration Area by the B1<br />
escalators at 9:10 a m. Look for the ‘<strong>ARHP</strong>’ signs.<br />
<strong>ARHP</strong> Concurrent Session C<br />
9:15—10:15 a m<br />
Room 259<br />
Manual Tender Point Survey: A Demonstration of a<br />
Standardized Approach to Assessing Tender Points<br />
Moderator:<br />
Donah Z. Crawford, BS, MA; The Arthritis Group;<br />
Philadelphia, PA<br />
Speakers:<br />
Jane S. Brandenstein, BS, PT; University of Pittsburgh;<br />
Pittsburgh, PA<br />
Terence W. Starz, MD; University of Pittsburgh Medical<br />
Center; Pittsburgh, PA<br />
Sukran Timbil, MD; Beth Israel Deaconess Medical Center;<br />
Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Review pathophysiologic mechanisms of tender points in<br />
fibromyalgia<br />
∙ Describe the elements of the Manual Tender Point Survey<br />
(MTPS) including pressure application, identification of<br />
survey sites, procedural guidelines and patient instructions<br />
∙ Demonstrate the MTPS with active participation by<br />
the attendees<br />
Upon completion of this session, participants should be able to:<br />
∙ Summarize the findings and recommendations of the<br />
Institute of Medicine Reports<br />
∙ Examine the implications of medication errors in<br />
rheumatology practice<br />
∙ Describe quality improvement and its role in patient safety<br />
∙ Describe the role of technology in improving patient safety<br />
<strong>ARHP</strong> Concurrent Session<br />
9:15—10:15 a m<br />
Room 260<br />
Multivariable Analysis: Taking the Mystery Out of the<br />
Regression Model “Black Box”<br />
Moderator:<br />
Geri B. Neuberger, RN, EdD; University of Kansas Medical<br />
Center; Kansas City, KS<br />
Speakers:<br />
Kerry Broe, MPH; Institute for Aging Research; Boston, MA<br />
Marian T. Hannan, MPH, DSc; Harvard Medical School;<br />
Boston, MA<br />
Robert R. McLean, DSc, MPH; Hebrew SeniorLife; Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Define the basic principles behind multivariable regression<br />
∙ Identify the different types of regression models and<br />
describe the assumptions and limitations of each<br />
∙ Interpret the results of multivariable regression from a<br />
common statistical software package<br />
∙ Communicate the results from multivariable analysis<br />
∙ Reflect whether a study‘s conclusions are warranted given<br />
the information presented on the multivariable analysis<br />
<strong>ARHP</strong> Concurrent Abstract Session<br />
9:15—10:15 a m<br />
Room 261<br />
Emotional Well-Being (Abstracts #1276-1279)<br />
Moderator:<br />
Monique A. Gignac, PhD; Toronto Western Research<br />
Institute; Toronto, Ontario<br />
<strong>ARHP</strong> Concurrent Session<br />
9:15—10:15 a m<br />
Room 257<br />
Improving Patient Safety: Prevention of Medication<br />
Errors in Rheumatology Practice<br />
Moderator:<br />
Patricia J. Cornell, BSc; Poole Hospital; Poole Dorset, England<br />
Speaker:<br />
Kam M. Nola, PharmD, MS; Tennessee Pharmacist<br />
Association; Nashville, TN<br />
9:15 a m<br />
1276. Rheumatoid Arthritis Health Outcomes Are More Strongly<br />
Linked with Mutuality than with Physical Affection. Shelley<br />
Kasle 1 , Alex J. Zautra 2 . 1 University of Arizona, Tucson, AZ;<br />
2<br />
Arizona State University, Phoenix, AZ<br />
9:30 a m<br />
1277. Depression in SLE: Relationships with Traditional and<br />
Disease-Specific Cardiovascular Risk. Laura J. Julian 1 , Pantelis<br />
Panopalis 1 , Jinoos Yazdany 1 , Laura Trupin 1 , JoAnn Zell<br />
Gillis 2 , Ed Yelin 1 , Patricia Katz 1 . 1 University of California<br />
San Francisco, San Francisco, CA; 2 National Jewish Medical<br />
and Research Center, Denver, CO<br />
128<br />
= Recorded Sessions (order form on page 430)
9:45 a m<br />
1278. Long-term Patterns and Predictors of Serious Depression<br />
in a Longitudinal Study of Individuals with Rheumatoid<br />
Arthritis. Anne Morris, Edward H. Yelin, Patricia P. Katz.<br />
University of California, San Francisco, San Francisco, CA<br />
10:00 a m<br />
1279. Psychiatric Comorbidity in Chronic Lyme Disease: Initial<br />
Findings from the Living with Lyme Disease Study. Afton L.<br />
Hassett 1 , Diane C. Radvanski 1 , Shantal V. Savage 1 , Steven<br />
Buyske 2 , Leonard H. Sigal 3 . 1 UMDNJ-Robert Wood<br />
Johnson Medical School, New Brunswick, NJ; 2 Rutgers<br />
University, Piscataway, NJ; 3 Bristol-Myers Squibb Company,<br />
Princeton, NJ<br />
<strong>ACR</strong> Workshops<br />
10:30 a m—12:30 p m<br />
Admission to the Workshop sessions is by ticket only. To verify the session<br />
for which you are registered, refer to the registration codes below in<br />
parentheses. Workshops include beverages only.<br />
Histopathology of Vasculitis (076)<br />
Room 212<br />
Allen Burke, MD; Gaithersburg, MD<br />
Fabio Tavora, MD; Johns Hopkins School of Medicine;<br />
Baltimore, MD<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe histological features of normal blood vessels<br />
∙ Distinguish pathologic reactions to vascular injury<br />
∙ Identify histological features of major vasculitic syndromes<br />
Joint Injection Techniques (078)<br />
Room 209<br />
Atul A. Deodhar, MD, MRCP; Oregon Health and Science<br />
University; Portland, OR<br />
Kenneth S. O’Rourke, MD; Wake Forest University;<br />
Winston-Salem, NC<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss indications and contraindications for joint<br />
aspirations and injections<br />
∙ Identify and avoid common mistakes in joint injection<br />
procedures<br />
∙ Perform common joint and soft tissue injections on upper<br />
and lower extremities<br />
Patient Questionnaires: Use in Clinical Trials of RA and<br />
OA (079)<br />
Room 213<br />
Theodore Pincus, MD; NYU-Hospital for Joint Diseases;<br />
New York, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Use patient questionnaires to monitor and document<br />
patient status in everyday rheumatology practice<br />
∙ Recognize how questionnaires can identify incomplete<br />
responses to therapies, and a need for changes in tight<br />
control of inflammation<br />
∙ Increase awareness of the significance of patient<br />
questionnaire data in the prognosis of long-term outcomes<br />
such as work disability and mortality in individual patients<br />
Peripheral MRI in Clinical Practice (077)<br />
Equipment provided by Esaote S.p.A.<br />
Room 211<br />
John V. Crues, III, MD; Radnet, Inc.; Los Angeles, CA<br />
Ewa Olech, MD; Oklahoma Medical Research Foundation;<br />
Oklahoma City, OK<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the logistics of implementation of peripheral MRI<br />
in the outpatient setting<br />
∙ Recognize the merits and pitfalls of this technology<br />
<strong>ARHP</strong> General Session II<br />
10:45—11:45 a m<br />
Room 258<br />
The <strong>ARHP</strong> thanks Roche for providing an educational grant in support<br />
of this session.<br />
A Critical Unmet Need of Patients with<br />
Rheumatic Diseases: Intervention for Work<br />
Disability: <strong>ARHP</strong> Distinguished Lecturer<br />
Moderator:<br />
Mary E. Christenson, PT, MS; Regis<br />
University; Denver, CO<br />
Speaker:<br />
Saralynn H. Allaire, ScD, RN, CRC; Boston University;<br />
Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the types and extent of work disability associated<br />
with major rheumatic diseases<br />
∙ Judge the effectiveness of interventions for rheumatic<br />
disease work disability<br />
∙ Identify interventions health professionals can undertake<br />
to address rheumatic disease work disability<br />
FRIDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
129
FRIDAY<br />
<strong>ACR</strong> Practice Issues C<br />
11:00 a m—Noon<br />
Room 253<br />
PM<br />
Avoiding the Legal Pain of Pain Management<br />
Moderator:<br />
Timothy Laing, MD; University of Michigan Medical<br />
Center; Ann Arbor, MI<br />
Speaker:<br />
Jennifer Bolen, JD; The J. Bolen Group; Lenoir City, TN<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the legal issues surrounding chronic pain<br />
management issues including dispensing large numbers of<br />
controlled substances<br />
∙ Assess the ethical problems in patients receiving chronic<br />
opioid therapy for chronic pain<br />
<strong>ACR</strong> Plenary Session II C/r<br />
11:00 a m—12:30 p m<br />
Hall C<br />
Discovery <strong>2007</strong>: Pathogenesis and Treatment of<br />
Inflammatory Arthritis (Abstracts #1280-1284)<br />
Moderators:<br />
Jeffrey N. Katz, MD, MS; Brigham and Women’s Hospital;<br />
Boston, MA<br />
Rosalind Ramsey-Goldman, MD, DrPH; Northwestern<br />
University; Chicago, IL<br />
11:00 a m<br />
Introductory Talk: SLE<br />
Daniel L. Kastner, MD, PhD; National Institutes of Health;<br />
Bethesda, MD<br />
11:45 a m<br />
1282. Preliminary Evidence for Sustained Bioactivity of IL-1<br />
Trap (Rilonacept), A Long Acting IL-1 Inhibitor, In Systemic<br />
Juvenile Idiopathic Arthritis (SJIA). Daniel J. Lovell 1 , Edward<br />
H. Giannini 1 , Yukiko Kimura 2 , Suzanne Li 2 , Philip J.<br />
Hashkes 3 , Andreas O. Reiff 4 , Carol A. Wallace 5 , Karen B.<br />
Onel 6 , Yi Wei 7 , Wen Fury 7 , Douglas R. Nadler 7 , Stephanie<br />
Biedermann 7 , Gregory Osgood 7 , Joanne H. Papadopoulos 7 ,<br />
Allen R. Radin 7 . 1 Children’s Hospital Medical Center,<br />
Cincinnati, OH; 2 Hackensack University Medical<br />
Center, Hackensack, NJ; 3 Cleveland Clinic Foundation,<br />
Cleveland, OH; 4 Children’s Hospital of LA, Los Angeles,<br />
CA; 5 Children’s Hospital and Regional Medical Center,<br />
Seattle, WA; 6 La Rabida Children’s Hospital, Chicago, IL;<br />
7<br />
Regeneron Pharmaceuticals, Inc., Tarrytown, NY<br />
Noon<br />
1283. HLA-B27 Misfolding Activates the IL-23/IL-17<br />
Axis via the Unfolded Protein Response in Transgenic Rats:<br />
Evidence for a Novel Mechanism of Inflammation. Robert A.<br />
Colbert 1 , Matthew J. Turner 1 , Monica L. DeLay 1 , Judith A.<br />
Smith 2 , Erin I. Klenk 1 , Dawn P. Sowders 1 , Shuzhen Bai 1 .<br />
1<br />
Cincinnati Childrens Hospital Medical Center, Cincinnati,<br />
OH; 2 University of Wisconsin School of Medicine,<br />
Madison, WI<br />
12:15 p m<br />
1284. TLR2, but Not TLR4, Variants are Associated with<br />
Reactive Arthritis. Robert D. Inman 1 , Sherry Rohekar 2 ,<br />
Reena Riarrh 1 , Rose Bilotta 3 , HingWo Tsui 1 , Florence WL<br />
Tsui 1 . 1 Toronto Western Hospital, Toronto, ON, Canada;<br />
2<br />
University of Western Ontario, London, ON, Canada;<br />
3<br />
Ministry of Health, Toronto, ON, Canada<br />
11:15 a m<br />
1280. Crucial Role of ASC-Dependent Inflammasome in Murine<br />
Arthritis. Mahir Karababa 1 , Laeticia Kolly 1 , Jürg Tschopp 2 ,<br />
Alexander So 1 , Nathalie Busso 1 . 1 CHUV-RMR, Lausanne,<br />
Switzerland; 2 université Lausanne, Lausanne, Switzerland<br />
11:30 a m<br />
1281. Gene Expression Profiling of Peripheral Blood from<br />
Untreated New Onset Systemic Juvenile Idiopathic Arthritis<br />
Patients Reveals Molecular Heterogeneity That May Predict<br />
Macrophage Activation Syndrome.. Ndate Fall 1 , Michael<br />
Barnes 1 , Sherry Thornton 1 , Lorie Luyrink 1 , Olson Judyann 2 ,<br />
Norman Ilowite 3 , Thomas Griffin 1 , David D. Sherry 4 , Susan<br />
Thompson 1 , David N. Glass 1 , Robert A. Colbert 1 , Alexei A.<br />
Grom 1 . 1 Childrens Hospital Medical Center, Cincinnati,<br />
OH; 2 Medical College of Wisconsin, Milwaukee, WI;<br />
3<br />
Albert Einstein College of Medicine, Bronx, NY;<br />
4<br />
Childrens Hospital of Philadelphia, Cincinnati, PA<br />
<strong>ACR</strong> Special Session ARS C<br />
11:00 a m—12:30 p m<br />
Grand Ballroom East<br />
Curbside Consults—Ask the Professors<br />
Moderator:<br />
Brian F. Mandell, MD, PhD; The Cleveland Clinic;<br />
Cleveland, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Compare their own personal management approaches<br />
to selected clinical problems with those of academic<br />
“expert” consultants<br />
∙ Discuss the role of medications and renal insufficiency in<br />
the management of hyperuricemia<br />
∙ List treatment options for refractory thrombocytopenia in<br />
a patient with antiphospholipid antibodies<br />
∙ Evaluate treatment options in a patient receiving anti-TNF<br />
therapy who develops a positive PPD or a carcinoma<br />
∙ Discuss the treatment of a patient found to have<br />
asymptomatic aortitis at the time of valve surgery<br />
130<br />
= Recorded Sessions (order form on page 430)
11:00 a m<br />
Case 1: What do you do with ASA and HCTZ in a patient with gout?<br />
N. Lawrence Edwards, MD; University of Florida; Gainesville, FL<br />
11:08 a m<br />
Case 2: Does allopurinol dosing need to be adjusted in a patient<br />
with renal insufficiency?<br />
N. Lawrence Edwards, MD; University of Florida; Gainesville, FL<br />
11:16 a m<br />
Case 3: Should I treat a patient with asymptomatic aortitis?<br />
Gary S. Hoffman, MD, MS; Cleveland Clinic/Lerner<br />
College of Medicine; Cleveland, OH<br />
11:24 a m<br />
Case 4: How should I approach a patient with Wegener’s granulomatosis<br />
in clinical remission with persistent active urinary sediment?<br />
Gary S. Hoffman, MD, MS; Cleveland Clinic/Lerner<br />
College of Medicine; Cleveland, OH<br />
11:32 a m<br />
Case 5: How should I manage potential exposure to TB in a<br />
patient on anti-TNF therapy?<br />
John J. Cush, MD; Arthritis Care and Research Center;<br />
Dallas, TX<br />
11:40 a m<br />
Case 6: Should anti-TNF therapy be continued in a patient who<br />
develops cancer?<br />
John J. Cush, MD; Arthritis Care and Research Center;<br />
Dallas, TX<br />
11:56 a m<br />
Case 7: How should an asymptomatic patient with a lupus<br />
anticoagulant be treated?<br />
Michael D. Lockshin, MD; Cornell Medical Center; New<br />
York, NY<br />
12:04 p m<br />
Case 8: How should thrombocytopenia be treated in a patient with<br />
antiphospholipid antibodies?<br />
Michael D. Lockshin, MD; Cornell Medical Center; New<br />
York, NY<br />
12:12 p m<br />
Panel Discussion<br />
<strong>ACR</strong> Special Session C<br />
11:00 a m—12:30 p m<br />
Room 157<br />
<strong>ACR</strong> Workforce Issues: The Future of Our Enterprise<br />
Moderators:<br />
David I. Daikh, MD, PhD; University of California,<br />
Veteran’s Affairs Medical Center; San Francisco, CA<br />
Chad L. Deal, MD; Cleveland Clinic Foundation;<br />
Cleveland, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Review and update the U.S. Rheumatology workforce<br />
projections, implications for training and non-physician<br />
clinicians<br />
∙ Review future financing in health care and how it will<br />
affect rheumatologists<br />
∙ Discuss issues of practice redesign, practice efficiency,<br />
the scope of rheumatology practice, chronic disease<br />
management and the quality movement<br />
11:00 a m<br />
The Future of Specialty Care in the United States, the Looming<br />
Shortage and Possible Responses<br />
Richard Cooper, MD; University of Pennsylvania;<br />
Philadelphia, PA<br />
11:25 a m<br />
The Value of Health: Your Money or Your Life, Strong Medicine<br />
for America’s Healthcare System<br />
David M. Cutler, PhD; Harvard University; Cambridge, MA<br />
11:45 a m<br />
The Future of Rheumatology Practice and Practice Redesign<br />
J. Timothy Harrington, Jr., MD; University of Wisconsin;<br />
Madison, WI<br />
12:05 p m<br />
Panel Discussion<br />
<strong>ARHP</strong> Special Session<br />
Noon—2:00 p m<br />
Westin Waterfront Hotel, Grand Ballroom A-B<br />
The <strong>ARHP</strong> thanks Roche for providing an educational grant in support of<br />
this session.<br />
A ticket is required and will be provided with your name badge.<br />
Networking at Noon<br />
Sit down with your colleagues, enjoy a light lunch and<br />
participate in an open discussion on various pre-selected<br />
research, practice and clinical topics. Each roundtable<br />
discussion will be facilitated by a rheumatology expert.<br />
All <strong>ARHP</strong> attendees are welcome to participate in this<br />
exciting opportunity.<br />
<strong>ARHP</strong> Business <strong>Meeting</strong><br />
Election of <strong>2007</strong> Officers<br />
Installation of 38th President<br />
Kimberly F. Kimpton, PT; Health Mark, Denver, CO<br />
This is a tentative listing of the topics and facilitators and is subject to change.<br />
∙ Adolescent Transition: Sharon M. Ramey, MSW<br />
∙ Advocacy and Access to Care: Kam M. Nola, PharmD, MS<br />
∙ Ankylosing Spondylitis: Lori C. Guthrie, RN-C, BSN, CCRC<br />
∙ Clinical Trials: Beverly K. Barham, BSN<br />
FRIDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
131
FRIDAY<br />
∙ Dissemination of Evidence Based Physical Activity<br />
<strong>Program</strong>s: Basia Belza, PhD, RN<br />
∙ Diversity/Cultural Issues: Jillian A. Rose, MSW<br />
∙ Educational Technology and Internet Applications:<br />
Laura E. Ray, MA, MLS<br />
∙ Enhancing Patient Adherence: Susan J. Bartlett, PhD<br />
∙ Epidemiology/Public Health: Jennifer M. Hootman, PhD<br />
∙ Forms Exchange: Norma L. Liburd, RNC, MN<br />
∙ International Rheumatology – Clinical: Susan M. Oliver,<br />
MSc and Patricia J. Cornell, BSc<br />
∙ International Rheumatology – Research: Maura D. Iversen,<br />
PT, DPT, SD, MPH<br />
∙ IRB and Ethical Issues: Marian T. Hannan, DSc, MPH<br />
∙ Low Back Pain: Jane S. Brandenstein, BS, PT<br />
∙ Medications for Rheumatic Diseases: Carlo A. Marra, BSc,<br />
PharmD, PhD<br />
∙ NP Issues—Adult: Leslie D. McDowell, ANP, MSN<br />
∙ NP Issues—Pediatric: Laurie E. Ebner-Lyon, RN, MSN, APN<br />
∙ Obesity, Arthritis and Weight Loss: Heidi C. Sitton<br />
∙ Office Nurse: Lee Anderson, AA, RN and Lisa M. Robbins, RN<br />
∙ PA Issues: Donald R. Flinn, PA-C<br />
∙ Pain Management: Gail C. Davis, RN, EdD<br />
∙ Pediatrics: Elizabeth L. Roth-Wojcicki, RN, MS, CPNP<br />
∙ Physical Activity and Fitness in Osteoarthritis: Elizabeth A.<br />
Schlenk, PhD, RN and Nadine T. James, RN, MSN, PhD<br />
∙ Physical Therapy Competency/Advance Practice in<br />
Rheumatology: Marie D. Westby, BSc, PT and Linda Li,<br />
BSc, PT, PhD<br />
∙ Qualitative Research: Laura Robbins, DSW<br />
∙ Rheumatic Disease Emergencies: Gail R. McIlvain-<br />
Simpson, MSN, RN, CS<br />
∙ Rheumatoid Arthritis: Benjamin J. Smith, PA-C<br />
∙ Rural Health: Mary E. Christenson, PT, MS<br />
∙ Sleep Improvement: Pamela J. Degotardi, PhD<br />
∙ Treatment Modalities and the Fibromyalgia Patient:<br />
Betsy Jacobson, BA<br />
∙ Treatment of the OA Thumb: Kathryn L. Lowenstein, OTR/L<br />
∙ Volunteering /Mentoring <strong>ARHP</strong>: Diana G. Fox, PsyD and<br />
Lisa M. Kastanek, RN, CCRC<br />
Encore Theater<br />
12:45—2:15 p m<br />
Room 255<br />
Clinical Symposium - Challenges in the<br />
Management of Lupus<br />
Please see page 69 for hours of operation and a tentative list of sessions.<br />
¹<br />
<strong>ACR</strong> Meet the Professor Sessions<br />
12:45—2:15 p m<br />
Admission to the Meet the Professor Sessions is by ticket only. To verify the<br />
session for which you are registered, refer to the registration codes below in<br />
parentheses. Meet the Professor sessions include beverages only.<br />
Allergy for Rheumatologists (091)<br />
Room 161<br />
John S. Sundy, MD, PhD; Duke University Medical Center;<br />
Durham, NC<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize immunologic disorders that are common to<br />
allergy and rheumatology practices<br />
∙ Review the presentations of autoimmune chronic urticaria,<br />
systemic mastocytosis, and common variable immune deficiency<br />
∙ Discuss upper airway and sinus disorders in allergic and<br />
rheumatic diseases<br />
Caring for the Young Adult with Rheumatic Disease (080)<br />
(Trainees Only) F<br />
Room 106<br />
Stacy P. Ardoin, MD; Duke University Medical Center;<br />
Durham, NC<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the unique challenges of caring for young adults<br />
with chronic rheumatic disease<br />
∙ Discuss special issues related to the use of medications<br />
commonly used to treat rheumatic disease<br />
∙ List strategies for managing the health system, insurance<br />
and vocational transition<br />
Crystal: Pseudogout (089)<br />
Room 160 B<br />
Anthony M. Reginato, MD, PhD; Massachusetts General<br />
Hospital; Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the pathophysiology of calcium pyrophosphate disease<br />
∙ Describe disease associations with CPPD<br />
∙ List agents used for the treatment of pseudogout<br />
Dermatological Manifestations of Rheumatic Diseases<br />
(082)(Trainees Only) F<br />
Room 107 B<br />
Jeffrey P. Callen, MD; University Louisville; Louisville, KY<br />
Upon completion of this session, participants should be able to:<br />
∙ List the diagnostic criteria for skin diseases with<br />
rheumatologic implications<br />
∙ Develop a differential diagnosis for these conditions<br />
∙ Construct a strategy for management of skin disease seen<br />
in patients with rheumatologic diseases<br />
132<br />
= Recorded Sessions (order form on page 430)
Neuroradiology of CNS Vasculitis/Vasculopathy (085)<br />
Room 109 A<br />
Mahesh V. Jayaraman, MD; Rhode Island Hostpital/ Brown<br />
University; Providence, RI<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the neuroradiologic modalities available to<br />
evaluate CNS vascular disease<br />
∙ Review the utility of each procedure relative to the clinical<br />
presentation<br />
∙ Recognize the relative utility and limitations of each test<br />
Pediatrics: Difficult to Treat Juvenile Idiopathic Arthritis<br />
(084) (Trainees Only) F P<br />
Room 108<br />
Gloria C. Higgins, PhD, MD; Columbus Children’s<br />
Hospital; Columbus, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss treatment options for the systemic JIA patient with<br />
persistent systemic manifestations<br />
∙ Discuss treatment options for the JIA patient with<br />
persistent arthritis<br />
∙ Discuss treatment options for the child with low bone<br />
density who needs corticosteroid treatment<br />
∙ Discuss one or more difficult cases prepared by an attendee<br />
Pregnancy in Rheumatic Diseases (088)<br />
Room 160 A<br />
Ann L. Parke, MD; St Francis Hospital and Medical Center;<br />
Hartford, CT<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the effects of pregnancy on the activity of<br />
rheumatic diseases<br />
∙ Recognize the challenging management issues unique<br />
to pregnancy<br />
Pregnancy, Fertility and Medication in Rheumatic<br />
Diseases (081)<br />
Room 107 A<br />
Bonnie L. Bermas, MD; Brigham and Womens Hospital;<br />
Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the effects of pregnancy on the activity of<br />
rheumatic diseases<br />
∙ Recognize the challenging management issues unique<br />
to pregnancy<br />
RA: Biological Agents (086)<br />
Room 109 B<br />
Edward C. Keystone, Dr., MD; Mount Sinai Hospital;<br />
Toronto, ON<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify biologic agents in use for the treatment of<br />
rheumatoid arthritis<br />
∙ Describe the risk/benefit profiles of biologic agents<br />
RA: Early Rheumatoid Arthritis (087)<br />
Room 159<br />
Jeffrey R. Lisse, MD; University of Arizona; Tucson, AZ<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify the clinical syndrome of rheumatoid arthritis early<br />
in its course<br />
∙ Determine which modalities are of use in diagnosis and<br />
determining prognosis<br />
∙ Evaluate which therapeutic regimens yield the best longterm<br />
outcomes<br />
Sarcoidosis (083)<br />
Room 107 C<br />
W. Winn Chatham, MD; University of Alabama-<br />
Birmingham; Birmingham, AL<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the various musculoskeletal manifestations<br />
of sarcoidosis<br />
∙ Describe the pathophysiology of sarcoidosis<br />
∙ Design treatment strategies for bone and joint sarcoidosis<br />
∙ Recognize neurologic and other organ manifestations<br />
of sarcoidosis<br />
Scleroderma: Systemic Sclerosis (090)(Trainees Only) F<br />
Room 160 C<br />
Richard M. Silver, MD; Medical University of South<br />
Carolina; Charleston, SC<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the classification of systemic sclerosis and its<br />
impact on treatment and prognosis<br />
∙ Apply cardiopulmonary testing to determine the relative<br />
contributions of alveolitis, fibrosis and vasculopathy<br />
∙ Formulate a therapeutic regimen to improve quality of life<br />
and organ-specific symptomatology<br />
<strong>ACR</strong> Special Session f<br />
12:45—2:15 p m<br />
Room 104<br />
Young Investigators Session: The New Triple Threat:<br />
Successful Academic Investigator, Balanced Family Life,<br />
Financial Solvency: A Roadmap for Success<br />
Moderator:<br />
Lisa A. Mandl, MD, MPH; Hospital for Special Surgery;<br />
New York, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Employ concrete strategies to attain a successful work/<br />
family balance<br />
∙ Utilize existing NIH programs, as well as institutional startup<br />
packages to ensure the first five years post-fellowship are<br />
financially viable<br />
∙ Optimize the first post-fellowship years to increase the<br />
likelihood of a successful NIH grant application<br />
FRIDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
133
FRIDAY<br />
12:45 p m<br />
Introduction<br />
12:55 p m<br />
Successfully Balance Family and Career<br />
Elizabeth W. Karlson, MD; Brigham and Womens Hospital;<br />
Boston, MA<br />
1:25 p m<br />
Maintain Financial Solvency the First Five Years Post-Fellowship<br />
John A. Peyman, PhD; DAIT, NIAID, NIH, DHHS;<br />
Bethesda, MD<br />
1:55 p m<br />
Discussion<br />
<strong>ACR</strong> Workshops<br />
1:15—3:15 p m<br />
Admission to the Workshop sessions is by ticket only. To verify the session<br />
for which you are registered, refer to the registration codes below in<br />
parentheses. Workshops include beverages only.<br />
Basic Statistical Concepts for the Medical Researcher (094)<br />
Room 212<br />
Christopher H. Schmid, PhD; Tufts-New England Medical<br />
Center; Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify factors influencing sample size and power<br />
∙ Interpret confidence intervals, odds ratio and relative risk<br />
∙ Recognize factors that confound study results<br />
Musculoskeletal Ultrasonography: Basic (092)<br />
(Trainees Only) F<br />
Equipment provided by Biosound Esaote Ultrasound<br />
Room 211<br />
George A. W. Bruyn, MD, PhD; Medisch Centrum<br />
Leeuwarden; Loenga, Netherlands<br />
Wolfgang A. Schmidt, MD; Medical Center for<br />
Rheumatology Berlin-Buch; Berlin, Germany<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the indications for ultrasound in rheumatic<br />
diseases<br />
∙ Discuss the techniques of ultrasonography<br />
∙ Recognize normal and abnormal anatomical structures<br />
Patient Questionnaires to Monitor Status and Document<br />
Improvement in Standard Care: Practical Considerations (095)<br />
Room 213<br />
Theodore Pincus, MD; NYU-Hospital for Joint Diseases;<br />
New York, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Use patient questionnaires to monitor and document<br />
patient status in everyday rheumatology practice<br />
∙ Recognize how questionnaires can identify incomplete<br />
responses to therapies, and a need for changes in tight<br />
control of inflammation<br />
∙ Increase awareness of the significance of patient<br />
questionnaire data in the prognosis of long-term outcomes<br />
such as work disability and mortality in individual patients<br />
Redesigning your Rheumatology Practice: Practical<br />
Approaches (093)<br />
Room 209<br />
J. Timothy Harrington, Jr., MD; University of Wisconsin;<br />
Madison, WI<br />
Eric D. Newman, MD; Geisinger Medical Center; Danville, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the importance and advantages of redesigning<br />
practice processes<br />
∙ Discuss the basics of rapid cycle process improvement (an<br />
essential method for clinical improvement)<br />
∙ Create a practice improvement project<br />
<strong>ACR</strong> Basic Science Symposium R<br />
2:30—4:00 p m<br />
Room 205<br />
Bone Remodeling: New Targets in the Rheumatic Diseases<br />
Moderators:<br />
Steven R. Goldring, MD; Hospital for Special Surgery; New<br />
York, NY<br />
Debra J. Zack, MD, PhD; Amgen Inc; Thousand Oaks, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify the role of the wnt / ß catenin pathway in<br />
determining bone density<br />
∙ Recognize the effects of the bone morphogenic proteins on<br />
bone remodeling<br />
∙ Describe the effects of SOST/sclerostin on osteocyte<br />
function and bone formation<br />
2:30 p m<br />
Targeting the Wnt Pathway for Treatment of Inflammatory<br />
Arthritis<br />
Georg Schett, MD; Institute for Clinical Immunology;<br />
Erlangen, Germany<br />
2:55 p m<br />
The Role of the BMP Pathway in Bone Remodeling in<br />
Inflammatory Arthritis<br />
Rik J. Lories, MD, PhD; Katholieke Universiteit Leuven;<br />
Leuven, Belgium<br />
134<br />
= Recorded Sessions (order form on page 430)
3:20 p m<br />
Role of Sclerostin and Osteocytes in Regulation of Bone<br />
Remodeling<br />
Teresita Bellido, PhD; University of Arkansas for Medical<br />
Sciences; Little Rock, AR<br />
3:45 p m<br />
Discussion<br />
<strong>ACR</strong> Clinical Symposium C<br />
2:30—4:00 p m<br />
Hall C<br />
Doing the Right Thing: Evidence and Guidelines for<br />
Rheumatoid Arthritis Treatment<br />
Moderator:<br />
John Esdaile, MD, MPH; Arthritis Research Center of<br />
Canada; Vancouver, British Columbia<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the new <strong>ACR</strong> Process for developing guidelines<br />
∙ Discuss the components in developing a truly evidence<br />
based guideline<br />
∙ Explain of the important new aspects of the <strong>2007</strong> <strong>ACR</strong><br />
Guidelines for treating RA<br />
2:30 p m<br />
Introduction<br />
John Esdaile, MD, MPH; Arthritis Research Center of<br />
Canada; Vancouver, British Columbia<br />
2:35 p m<br />
Methods to Develop Evidence-Based Guidelines<br />
Paul G. Shekelle, MD, PhD; RAND Corporation; Santa<br />
Monica, CA<br />
2:55 p m<br />
Assembling the Evidence Base with<br />
Jeremy Anuntiyo, MD; UCLA; Los Angeles, CA, U.S.<br />
Catherine L. Finney, MD; UCLA; Los Angeles, CA<br />
Nivedita M. Patkar, MD, MSPH; University of Alabama at<br />
Birmingham; Birmingham, AL<br />
Gim Gee Teng, MBBS, MD; Singapore, Singapore<br />
3:15 p m<br />
RA Treatment Guidelines<br />
Kenneth G. Saag, MD, MSc; University of Alabama at<br />
Birmingham; Birmingham, AL<br />
3:35 p m<br />
Questions and Answers<br />
<strong>ACR</strong> Clinical Symposium ARS C<br />
2:30—4:00 p m<br />
Grand Ballroom East<br />
¹<br />
Therapeutic Decisions in Systemic Vasculitis<br />
Moderator:<br />
Eric L. Matteson, MD; Mayo Clinic; Rochester, MN<br />
Upon completion of this session, participants should be able to:<br />
∙ List and compare options to induce remission in ANCAassociated<br />
vasculitis<br />
∙ Discuss the issues of cyclophosphamide retreatment in<br />
patients with ANCA-associated vasculitis who relapse<br />
∙ Review the outcome with stenting and vascular bypass in<br />
patients with large vessel arteritis<br />
2:30 p m<br />
Induction of Remission and Predicting Relapse in ANCA-<br />
Associated Vasculitis<br />
Alexandra Villa-Forte, MD, MPH; Universidade do Estado<br />
do Rio de Janeiro; Rio de Janeiro, RJ, Brazil<br />
3:00 p m<br />
Treating Relapses in ANCA-Associated Vasculitis<br />
Carol Langford, MD, MHS; Cleveland Clinic Foundation;<br />
Cleveland, OH<br />
3:30 p m<br />
Assessment of Disease Activity and the Use of Vascular<br />
Interventions in Patients with Large Vessel Arteritis<br />
Paul A. Bacon, MD; University of Birmingham;<br />
Birmingham, England<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 258<br />
B-Cell Biology and Targets in Autoimmune Disease<br />
(Abstracts #1285-1290)<br />
Moderators:<br />
M. Eric Gershwin, MD; University of California at Davis;<br />
Davis, CA<br />
Andrew C. Chan, MD, PhD; Genentech Inc; South San<br />
Francisco, CA<br />
2:30 p m<br />
1285. Inhibition of AID Suppressed Autoimmune Disease in<br />
BXD2 Mice. Hui-Chen Hsu 1 , PingAr Yang 1 , Qi Wu 1 ,<br />
Godwin Job 1 , John D. Mountz 2 . 1 University of Alabama at<br />
Birmingham, Birmingham, AL; 2 University of Alabama at<br />
Birmingham and Birmingham VAMC, Birmingham, AL<br />
FRIDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
135
FRIDAY<br />
2:45 p m<br />
1286. Shared Signaling Networks that Fire up in Lupus B Cells<br />
from Genetically Distinct Mouse Models - Implications for Disease<br />
Pathogenesis and Therapy. Tianfu Wu, Xiangmei Qin, Chun<br />
Xie, Madhavi Bhaskarabhatla, Joseph Zhou, Chandra<br />
Mohan. UT Southwestern Medical Center, Dallas, TX<br />
3:00 p m<br />
1287. Genetic Association of LYN in Systemic Lupus<br />
Erythematosus. Joel M. Guthridge 1 , Jennifer A. Kelly 1 ,<br />
Kenneth M. Kaufman 1 , Yuehua Zhou 1 , Yukon Wang 1 ,<br />
Nicolas Dominguez 1 , Ling Guo 2 , Christian Burell 1 , Isaac<br />
Harley 1 , Jeff Kilpatrick 1 , Joshua W. Cavett 1 , Swapan<br />
K. Nath 1 , Judith A. James 1 , John B. Harley 1 . 1 OMRF,<br />
Oklahoma City, OK; 2 OUHSC, Oklahoma City, OK<br />
3:15 p m<br />
1288. Differences in Proliferation Rates of Human B cell Subsets<br />
by In Vivo Labeling of Young Healthy Subjects. Eun-Hyung<br />
Lee 1 , Marc Hellerstein 2 , Hulin Wu 1 , Inaki Sanz 1 . 1 University<br />
of Rochester Medical Center, Rochester, NY; 2 University of<br />
California at Berkeley, Berkeley, CA<br />
3:30 p m<br />
1289. Autoantibody Profiling in Pre-Disease RA<br />
Samples. Wolfgang J. Hueber 1 , Beren H. Tomooka 1 , Kevin<br />
Deane 2 , Lezlie A. Parrish 2 , V. Michael Holers 2 , William<br />
H. Robinson 1 . 1 Stanford University & VAPAHCS, Palo<br />
Alto, CA; 2 University of Colorado Health Sciences Center,<br />
Denver, CO<br />
3:45 p m<br />
1290. Synovial Tissue Response to Rituximab: Mechanism of<br />
Action and Identification of Biomarkers of Response. Rogier M.<br />
Thurlings, Koen Vos, Carla A. Wijbrandts, Danielle M.<br />
Gerlag, Paul P. Tak. Academic Medical Center/ University<br />
of Amsterdam, Amsterdam, The Netherlands<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 102<br />
Eclectic Rheumatology (Abstracts #1291-1296)<br />
Moderator:<br />
Dennis W. Boulware, MD; Kaiser Permanente Medical<br />
Center;<br />
Honolulu, HI<br />
N. Lawrence Edwards, MD; University of Florida;<br />
Gainesville, FL<br />
2:30 p m<br />
1291. Sustained Efficacy of Rilonacept (IL-1 Trap) in Patients<br />
with Cryopyrin-Associated Periodic Syndromes (CAPS). Hal<br />
Hoffman 1 , Fred Wolfe 2 , Arthur Kavanaugh 1 , Alan Kivitz 3 ,<br />
Imogene Grimes 4 , Steve Weinstein 4 , Scott Mellis 4 . 1 UCSD<br />
Division of Rheumatology,Allergy and Immunology, La<br />
Jolla, CA; 2 University of Kansas, Wichita, KS; 3 Altoona<br />
Center for Clinical Research, Duncansville, PA; 4 Regeneron<br />
Pharmaceuticals, Tarrytown, NY<br />
2:45 p m<br />
1292. Increased Short-Term Mortality Outcomes Following<br />
Primary Knee and Hip Arthroplasty Among Patients with Lupus:<br />
A Case for Improved Pre-Operative Risk Stratification. Robyn T.<br />
Domsic, Eswar Krishnan. University of Pittsburgh Medical<br />
Center, Pittsburgh, PA<br />
3:00 p m<br />
1293. Intra-articular Botulinum Toxin A is Effective for Chronic<br />
Inflammatory Arthritis Pain but not Acute Inflammatory<br />
Arthritis Pain as Measured by Spontaneous and Evoked Pain<br />
Behaviors. Hollis E. Krug, Paul Lobitz, Peter Majeski, Maren<br />
L. Mahowald. Univ of Minn and VAMC, Minneapolis, MN<br />
3:15 p m<br />
1294. TNF Receptor-Associated Periodic Syndrome (TRAPS) in<br />
Japan: Its Prevalence and the Characteristics of Japanese Patients<br />
with TRAPS. Hiroaki Ida 1 , Toshiyuki Aramaki 1 , Kunihiro<br />
Ichinose 1 , Atsushi Kawakami 1 , Kiyoshi Migita 2 , Katsumi<br />
Eguchi 1 . 1 Graduate School of Biochemical Sciences, Nagasaki<br />
University, Nagasaki, Japan; 2 Clinical Research Center, NHO<br />
Nagasaki Medical Center, Nagasaki, Japan<br />
3:30 pm<br />
1295. Performance of the Polymyalgia Rheumatica Activity Score<br />
for Diagnosing Flares. Aymeric Binard 1 , Michel De Bandt 2 ,<br />
Jean M. Berthelot 3 , Alain Saraux 1 . 1 CHU Brest, Brest,<br />
France; 2 Hospital, Aulnay sous bois, France; 3 CHU Nantes,<br />
Nantes, France<br />
3:45 pm<br />
1296. Treatment with Eprodisate Results in a Significant Delay<br />
in the Progression to Dialysis/End-Stage Renal Disease in Amyloid<br />
A Amyloidosis Patients: Analysis Including Retrieved Follow-up<br />
Data. Peter D. Gorevic 1 , Philip N. Hawkins 2 , Martha Skinner 3 ,<br />
Evgeni L. Nasonov 4 , Irena Butrimiene 5 , Merrill D. Benson 6 ,<br />
Anna Filipowicz-Sosnowska 7 , Giampaolo Merlini 8 , Bouke<br />
Hazenberg 9 , Denis Garceau 10 , Wendy Hauck 10 , Helen J.<br />
Lachmann 2 , Laura Dember 3 , & the EFAAT group. 1 Mt Sinai<br />
Med Ctr, New York, NY; 2 Natl Amyloid Ctr Royal Free Hosp,<br />
London, United Kingdom; 3 Boston Univ, Boston, MA; 4 Rus<br />
Acad Med Sci Inst Rheum, Moscow, Russian Federation;<br />
5<br />
VU Inst Exp Clin Med, Vilnius, Lithuania; 6 Indiana Univ,<br />
136<br />
= Recorded Sessions (order form on page 430)
Indianapolis, IN; 7 Inst Rheum, Warsaw, Poland; 8 Amyloid Ctr<br />
IRCCS S Matteo, Pavia, Italy; 9 Univ Med Ctr, Groningen, The<br />
Netherlands; 10 Neurochem Inc., Montreal, PQ, Canada<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 pm<br />
Room 157<br />
IL-17 and Related Cytokines in Rheumatic Disease<br />
(Abstracts #1297-1302)<br />
Moderators:<br />
John O’Shea, MD; NIAMS-NIH; Bethesda, MD<br />
Wim B. Van Den Berg, PhD; Radboud University Nijemgen<br />
Medical Center; Nijmegen, The Netherlands<br />
2:30 pm<br />
1297. IL-23 Induces Th17 Polarization in Splenic T Cells<br />
From Type II Collagen-Immunized DBA-1 Mice and is Critical<br />
for Th17 Specific IL-22 Expression. Anne-Marie Mus, Ferry<br />
Cornelissen, Patrick Asmawidjaja, Rudi Hendriks, Erik<br />
Lubberts. Erasmus MC, Rotterdam, The Netherlands<br />
2:45 pm<br />
1298. Exacerbating and Suppressing Roles of TLR2 and TLR4<br />
During Experimental autoimmune Arthritis Mediated by Skewed<br />
Treg and Th17 cell Balance. Shahla Abdollahi-Roodsaz 1 , Leo A.<br />
Joosten 1 , Mieke F. Roelofs 1 , Timothy R. Radstake 1 , Martin J.H.<br />
Nicklin 2 , Marije I. Koenders 1 , Wim B. van den Berg 1 . 1 Radboud<br />
University Medical Centre, Nijmegen, Netherlands;<br />
2<br />
University of Sheffield, Sheffield, United Kingdom<br />
3:00 p m<br />
1299. Synergistic Effect of TH17 Cells And IL-17 on the<br />
Formation of Autoreactive Germinal Centers in Autoimmune<br />
BXD2 Mice. John D. Mountz 1 , PingAr Yang 2 , Qi Wu 2 ,<br />
John Yi 2 , John Wang 2 , Andrea L. Stanus 2 , Albert Tousson 2 ,<br />
Robinna G. Lorenz 1 , Robert H. Carter 1 , Jay K. Kolls 3 ,<br />
Hui-Chen Hsu 2 . 1 University of Alabama at Birmingham<br />
and Birmingham VAMC, Birmingham, AL; 2 University<br />
of Alabama at Birmingham, Birmingham, AL; 3 Children’s<br />
Hospital of Pittsburgh, Pittsburgh, PA<br />
3:15 p m<br />
1300. IL-17 Synergy with TNF Causes Striking Cartilage Erosion<br />
In Vivo. Marije I. Koenders, Isabel Devesa-Giner, Leo<br />
A.B. Joosten, Wim B. van den Berg. Radboud University<br />
Nijmegen Medical Center, Nijmegen, The Netherlands<br />
3:30 p m<br />
1301. IL-27 is Critical for the Development of Proteoglycan-<br />
Induced Arthritis and the Production of IFN-y. Yanxia Cao, Paul<br />
D. Doodes, Yumei Wang, Alison Finnegan. Rush University<br />
Medical Center, Chicago, IL<br />
3:45 p m<br />
1302. Transcriptional and Cellular Control of Th17 Cells in<br />
Humans. Hayley G. Evans, Tesha Suddason, Ian Jackson,<br />
Graham M. Lord, Leonie S. Taams. Kings College London,<br />
London, United Kingdom<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 153<br />
SLE: Animal Models (Abstracts #1309-1314)<br />
Moderators:<br />
Joan Wither, MD PhD; University of Toronto;<br />
Toronto, Ontario<br />
Charles S. Viam, MD; Uniformed Services University<br />
Health Sciences; Bethesda, MD<br />
2:30 p m<br />
1309. Nucleosome-Containing Immune Complexes Activate<br />
a TLR-Independent Anti-Viral Genetic <strong>Program</strong> in Myeloid<br />
Dendritic Cells. David A. Martin 1 , Kang Zhang 1 , Justin<br />
Kenkel 1 , Marc Monestier 2 , Keith B. Elkon 1 . 1 University of<br />
Washington, Seattle, WA; 2 Temple University School of<br />
Medicine, Philadelphia, PA<br />
2:45 p m<br />
1310. Antimalarials are More Effective at Inhibiting Toll-Like<br />
Receptor 9 than at Inhibiting Antigen Presentation. Risini<br />
Weeratna 1 , Ming Liu 1 , Shawn Makinen 1 , Grayson Lipford 2 ,<br />
Arthur M. Krieg 2 . 1 Coley Pharmaceutical Group, Ottawa,<br />
ON, Canada; 2 Coley Pharmaceutical Group, Wellesley, MA<br />
3:00 p m<br />
1311. Identification and Characterization of Separable<br />
Populations of Effector CD4+ T Cells in Murine Lupus: B-Helper<br />
T Cells and T Inflammatory Cells. Joseph Craft, Jared<br />
Odegard, Leah Eardley, Amanda Poholek, Benjamin Marks.<br />
Yale, New Haven, CT<br />
3:15 p m<br />
1312. Elevated Levels of B cell Activating Factor (BAFF)<br />
Contribute to the Breach of B cell Tolerance in the NZB Mouse<br />
Model of Lupus. Nan-Hua Chang, Evelyn Pau, Yui-Ho<br />
Cheung, Christina Loh, Valerie Roy, Yong-Chun Cai, Joan<br />
E. Wither. Toronto Western Hospital Research Institute,<br />
Toronto, ON, Canada<br />
3:30 p m<br />
1313. Histone Deacetylase 2 (HDAC2) Regulates B Cells<br />
Activation in Lupus. Isaac Snowhite 1 , Aldona Ziolkowska 1 ,<br />
Phill Ruiz 2 , Nilamadhab Mishra 1 . 1 Wake Forest University<br />
School of Medicine, Winston Salem, NC; 2 University of<br />
Miami, Miami, FL<br />
FRIDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
137
FRIDAY<br />
3:45 p m<br />
1314. Identification of Kallikreins as Pathogenic Players and<br />
Candidate Genes in Immune and Lupus Nephritis. Quan-Zhen<br />
Li, Kui Liu, Li Li, Jinchun Zhou, Qiu Ye, Mei Yan, Ward<br />
E. Wakeland, Chandra Mohan. UT Southwestern Medical<br />
Center, Dallas, TX<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 210<br />
SLE: Novel Therapies (Abstracts #1315-1320)<br />
Moderators:<br />
Ronald Van Vollenhoven, MD, PHD; Karolinska University<br />
Hospital; Stockholm, Sweden<br />
Jennifer Grossman, MD; University of California–Los<br />
Angeles; Los Angeles, CA<br />
2:30 p m<br />
1315. MEDI-545, an Anti-Interferon Alpha Monoclonal<br />
Antibody, Shows Evidence of Clinical Activity in Systemic Lupus<br />
Erythematosus. Daniel J. Wallace 1 , Michelle Petri 2 , Nancy<br />
Olsen 3 , Kyriakos Kirou 4 , Gregory Dennis 5 , Yihong Yao 5 ,<br />
Bahija Jallal 5 , Anthony Coyle 5 , Lan Zeng 5 , Lupus Interferon<br />
Skin Activity Study (LISA) Investigators, Barbara White 5 .<br />
1<br />
Cedars-Sinai/UCLA School of Medicine, Los Angeles,<br />
CA; 2 Johns Hopkins School of Medicine, Baltimore,<br />
MD; 3 University of Texas Southwestern Medical Center,<br />
Dallas, TX; 4 Hospital for Special Surgery, New York, NY;<br />
5<br />
MedImmune, Inc., Gaithersburg, MD<br />
2:45 p m<br />
1316. Novel Combined Response Endpoint and Systemic Lupus<br />
Erythematosus (SLE) Flare Index (SFI) Demonstrate Belimumab<br />
(Fully Human Monoclonal Antibody to BLyS) Improves or<br />
Stabilizes SLE Disease Activity and Reduces Flare Rate Over<br />
2.5 Years of Therapy. M. Petri 1 , R. Furie 2 , E. Ginzler 3 , D. J.<br />
Wallace 4 , W. Stohl 5 , V. Strand 6 , A. Weinstein 7 , J. McKay 8 ,<br />
J. Zhong 9 , V. Fernandez 9 , W. Freimuth 9 , LBSL02/99 Study<br />
Grp. 1 JHU, Balt, MD; 2 NSLIJHS, Lake Success, NY; 3 SUNY<br />
Downstate, Brooklyn, NY; 4 Cedars-Sinai UCLA, LA, CA;<br />
5<br />
USC, LA, CA; 6 Stanford U, Palo Alto, CA; 7 Wash Hosp<br />
Ctr, Wash, DC; 8 OK Ctr for Arth Ther & Res, Tulsa, OK;<br />
9<br />
HGS, Rockville, MD<br />
3:00 p m<br />
1317. A Randomised Placebo-Controlled Interventional Trail of<br />
Omega-3-Polyunsaturated Fatty Acids on Disease Activity and<br />
Endothelial Function in Systemic Lupus Erythematosus. Stephen<br />
A. Wright 1 , Fiona M. O’Prey 2 , Michelle T. McHenry 1 ,<br />
William J. Leahey 2 , Adrian B. Devine 2 , Emeir M. Duffy 3 ,<br />
Dennis G. Johnston 2 , Michael B. Finch 1 , Gary E. McVeigh 2 ,<br />
Aubrey L. Bell 1 . 1 Musgrave Park Hospital, Belfast, United<br />
Kingdom; 2 Queens University Belfast, Belfast, United<br />
Kingdom; 3 University of Ulster, Belfast, United Kingdom<br />
3:15 p m<br />
1318. Peptide Mimotope of DNA Blocks Toll Like Receptor<br />
(TLR) 9 Activation. Ilan Ben-Zvi, Cynthia Aranow, Meggan<br />
Mackay, Betty Diamond. The Feinstein Institute for Medical<br />
Research, Manhasset, NY<br />
3:30 p m<br />
1319. Memantine in Systemic Lupus Erythematosus: A<br />
Randomized Double-Blind Placebo-Controlled Trial. Mohammad<br />
Naqibuddin, Margaret Sampedro, Kathryn A. Carson,<br />
Michelle Petri. Johns Hopkins University, Baltimore, MD<br />
3:45 p m<br />
1320. Efficacy of Fulvestrant-an Estrogen Receptor Blocker-in<br />
Human SLE: A One-Year Double-Blind Placebo-Controlled<br />
Trial; Clinical, Serological, Bone Density, and Molecular<br />
Studies. Nabih I. Abdou 1 , V. Rider 2 , C. Greenwell 1 , X.<br />
Li 2 , B. Kimler 3 . 1 The Center for Rheumatic Disease,<br />
Allergy, Immunology, Kansas City, MO; 2 Dept of Biology,<br />
Pittsburg State University, Pittsburg, KS; 3 Dept of Radiation<br />
Oncology, KU Med Center, Kansas City, KS<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 104<br />
Spondylarthropathies and Psoriatic Arthritis:<br />
Pathogenesis, Etiology (Abstracts #1321-1326)<br />
Moderators:<br />
Dominique Baeten, MD; Academic Medical Center/<br />
University of Amsterdam; Amsterdam, The Netherlands<br />
Tammy M. Martin, PhD; Oregon Health and Science<br />
University; Portland, OR<br />
2:30 p m<br />
1321. The IL23R Gene is a Major Determinant of Susceptibility<br />
to but not Severity of Ankylosing Spondylitis. John D. Reveille 1 ,<br />
Xiaodong Zhou 1 , Michael M. Ward 2 , Lon R. Cardon 3 ,<br />
Linda A. Bradbury 4 , John C. Davis 5 , Panos Deloukas 6 ,<br />
David M. Evans 3 , Andrew Keniry 6 , Rhian Gwilliam 6 , Ralph<br />
McGinnis 6 , Jenny J. Pointon 7 , Laurie Savage 8 , Wellcome<br />
Trust Case-Control Consortium, Thomas L. Learch 9 ,<br />
Michael H. Weisman 9 , Paul Wordsworth 7 , Matthew A.<br />
Brown 4 . 1 University of Texas Health Science Center at<br />
Houston, Houston, TX; 2 National Institute of Arthritis<br />
and Musculoskeletal and Skin Diseases, Bethesda, MD;<br />
3<br />
Wellcome Trust Centre for Human Genetics, Oxford,<br />
United Kingdom; 4 University of Queensland, Brisbane,<br />
Australia; 5 University of California-San Francisco,<br />
San Francisco, CA; 6 Wellcome Trust Sanger Institute,<br />
Cambridge, United Kingdom; 7 University of Oxford,<br />
Oxford, United Kingdom; 8 Spondylitis Association of<br />
America, Sherman Oaks, CA; 9 Cedars-Sinai Medical<br />
Center, Los Angeles, CA<br />
138<br />
= Recorded Sessions (order form on page 430)
2:45 p m<br />
1322. Association of Interleukin-23R Variants with Ankylosing<br />
Spondylitis. Proton Rahman 1 , Robert D. Inman 2 , Dafna<br />
D. Gladman 2 , Jeff P. Reeve 3 , Lynette Peddle 1 , Walter P.<br />
Maksymowych 3 . 1 Memorial University of Newfoundland, St.<br />
John’s, NF, Canada; 2 University of Toronto, Toronto, ON,<br />
Canada; 3 University of Alberta, Edmonton, AB, Canada<br />
3:00 p m<br />
1323. A Genomewide Non-Synonymous SNP Scan for<br />
Susceptibility to Ankylosing Spondylitis - The Welcome Trust<br />
Case-Control Consortium. Matthew A. Brown 1 , Linda A.<br />
Bradbury 1 , Jennifer J. Pointon 2 , B. Paul Wordsworth 2 ,<br />
Wellcome Trust Case-Control Consortium. 1 Diamantina<br />
Institute of Cancer, Immunology and Metabolic Medicine,<br />
Woolloongabba, Brisbane, Australia; 2 Botnar Research<br />
Centre, University of Oxford, Oxford, United Kingdom<br />
3:15 p m<br />
1324. Identification of 2 Single Nucleotide Polymorphims (SNPs)<br />
Associated with Spondyloarthritis (SpA) in the SPA2 Locus<br />
(9q31-34). Elena Zinovieva 1 , Catherine Bourgain 2 , Corine<br />
Miceli-Richard 3 , Roula Said-Nahal 4 , Diana Zelenika 5 , Simon<br />
Heath 5 , Mark Lathrop 5 , Gilles Chiocchia 1 , Maxime Breban 1 .<br />
1<br />
Institut Cochin-INSERM U567/CNRS UMR8104/<br />
IFR116, Paris, France; 2 INSERM U535, Villejuif,<br />
France; 3 INSERM EMI 0109, Paris, France; 4 Ambroise<br />
Paré Hospital, Boulogne, France; 5 Centre National de<br />
Génotypage, Evry, France<br />
3:30 p m<br />
1325. Evidence for Altered Cytoskeleton Mobilization Pathway<br />
in Splenic Dendritic Cells (DC) from HLA-B27/human Beta-2-<br />
microglobulin Transgenic Rats (B27-rats). Maarten Dhaenens 1 ,<br />
Ingrid Fert 2 , Saskia Haerinck 1 , Cécile Poulain 2 , Cécile<br />
Hacquard-Bouder 2 , Claudine André 2 , Dirk Elewaut 3 , Dieter<br />
Deforce 1 , Maxime Breban 2 . 1 Laboratory of Pharmaceutical<br />
Biotechnology, Ghent University, Belgium; 2 INSERM<br />
U567, Paris, France; 3 Department of Rheumatology,<br />
University Hospital Ghent, Belgium<br />
3:45 p m<br />
1326. Neither Deletion of CD8 Nor Alternation of the B27<br />
Peptide Repertoire Prevents Spondyloarthritis in HLA-B27/hb2m<br />
Rats. Joel D. Taurog, Martha L. Dorris, Nimman Satumtira.<br />
UT Southwestern Med Ctr, Dallas, TX<br />
<strong>ACR</strong> CORC Forum C<br />
2:30—4:00 p m<br />
Room 253<br />
Building a Stronger Physician Practice<br />
Moderators:<br />
Peter D. Kent, MD; Park Nicollet; Minneapolis, MN<br />
Gail R. McIlvain-Simpson, MSN, APRN, BC; AI duPont<br />
Hospital for Children; Wilmington, DE<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss what to do if they are being sued and information<br />
on purchasing malpractice insurance<br />
∙ Utilize clinical research studies in different ways to increase<br />
their bottom line beyond relative value units<br />
∙ Integrate NP/PAs in a rheumatology practice setting to<br />
develop profitability<br />
2:30 p m<br />
A Malpractice Suit – Now What!<br />
Robert J. Conroy, JD, MPA, MPH; Kern Augustine Conroy<br />
and Schoppmann, P.C.; Bridgewater, NJ<br />
2:55 p m<br />
Clinical Research Studies for Small Offices<br />
E. Robert Harris, MD; Uuniversity of Californina-<br />
LosAngeles; Whittier, CA<br />
3:20 p m<br />
Business Aspects of NP/PAs<br />
Kori A. Dewing, MN, ARNP; Seattle Rheumatology<br />
Associates; Seattle, WA<br />
3:45 p m<br />
Discussion<br />
<strong>ACR</strong>/<strong>ARHP</strong> Combined Clinical Symposium C P<br />
2:30—4:00 p m<br />
Room 257<br />
Practical Pediatric Rheumatology Rehabilitation: What<br />
You Wished You Had Learned in Training<br />
Moderators:<br />
Helen M. Emery, MD; Children’s Hospital; Seattle, WA<br />
Doreen M. Stiskal, PT, PhD; Seton Hall University; South<br />
Orange, NJ<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify how common functional and fitness limitations<br />
impact the activities of children with a rheumatic disease<br />
∙ Discuss sports participation and mobility issues in a child<br />
or adolescent with rheumatic disease<br />
∙ Advocate for educational and vocational rights for children<br />
with rheumatic diseases<br />
FRIDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
139
FRIDAY<br />
2:30 p m<br />
Introduction and Overview<br />
Helen M. Emery, MD; Children’s Hospital; Seattle, WA<br />
2:50 p m<br />
Educational Rights<br />
Harry L. Gewanter, MD; Pediatric & Adolescent Health<br />
Partners; Midlothian, VA<br />
3:10 p m<br />
Exercise and Fitness in Children with Rheumatic Disease<br />
Susan E. Klepper, PhD, PT; Columbia University; New<br />
York, NY<br />
3:30 p m<br />
Mobility and Gait Issues in the School Aged Child<br />
Doreen M. Stiskal, PT, PhD; Seton Hall University; South<br />
Orange, NJ<br />
3:50 p m<br />
Panel Discussion<br />
<strong>ACR</strong> Special Session<br />
2:30—4:00 p m<br />
Room 151<br />
<strong>ACR</strong> Clinician Scholar Educator Awards<br />
Moderators:<br />
David I. Daikh, MD, PhD; University of California,<br />
Veteran’s Affairs Medical Center; San Francisco, CA<br />
Joan Marie Von Feldt, MD; University of Pennsylvania;<br />
Philadelphia, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss novel approaches to curriculum development for<br />
medical students and residents in the musculoskeletal and<br />
rheumatic diseases<br />
∙ Recognize the value of web-based formats for medical<br />
education<br />
∙ Describe new approaches to teaching diagnostic skills for<br />
musculoskeletal and rheumatic diseases<br />
∙ Identify the essential components of scholarship in<br />
education and educational research<br />
2:30 p m<br />
Quest for the Rheumatologic Diagnosis<br />
Robert A. Kalish, MD; New England Medical Center;<br />
Boston, MA<br />
2:45 p m<br />
Enhanced Rheumatology Curriculum for Medical Residents at the<br />
Johns Hopkins Hospital<br />
Don R. Martin, MD; Johns Hopkins University; Baltimore, MD<br />
3:00 p m<br />
A Web-Based Educational <strong>Program</strong> for Medical Students and<br />
Pediatric Residents on Pediatric Rheumatology<br />
Charles H. Spencer, MD; LaRabida Children’s Hospital/<br />
University of Chicago; Chicago, IL<br />
3:15 p m<br />
Educational Scholarship<br />
Terry M. Wolpaw, MD; Case; Cleveland, OH<br />
3:50 p m<br />
Panel Discussion<br />
<strong>ARHP</strong> Concurrent Session C<br />
2:30—4:00 p m<br />
Room 260<br />
Gait Analysis: Hip, Knee and Foot Effects on Gait and<br />
How to Assess Them<br />
Moderator:<br />
Noel Heath, BMR, OT; St. Joseph’s Care Group; Thunder<br />
Bay, Ontario<br />
Speakers:<br />
K. Douglas Gross, PT, ScD; Boston University; Boston, MA<br />
Carol A. Oatis, PT, PhD; Arcadia University; Glenside, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ List the primary functional tasks for swing and for stance<br />
∙ Describe the primary kinematic behaviors of the hip, knee<br />
and foot during gait<br />
∙ Identify common deviations in stance and swing associated<br />
with hip, knee and foot dysfunction<br />
∙ Use clinically feasible assessments of gait deviations<br />
∙ Identify interventions for gain deviations<br />
<strong>ARHP</strong> Concurrent Session<br />
11:00 a m—Noon<br />
Room 259<br />
Statistics: The Ideas Behind the Formulas<br />
Moderator:<br />
Sonali Narain, MD, MPH; University of Florida; Gainesville, FL<br />
Speaker:<br />
Dorothy D. Dunlop, PhD; Northwestern University;<br />
Chicago, IL<br />
Upon completion of this session, participants should be able to:<br />
∙ Set up and interpret hypothesis tests including defining<br />
the population, the role of probability and statistics and<br />
how alpha and beta errors influence hypothesis tests<br />
∙ Identify factors influencing statistical power such as alpha<br />
error, sample size, and a clinically meaningful difference<br />
∙ Interpret confidence intervals including p-values<br />
140<br />
= Recorded Sessions (order form on page 430)
<strong>ARHP</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 261<br />
Fibromyalgia Perspectives (Abstracts #1327-1332)<br />
Moderator:<br />
Janet E. Jeffrey, RN PhD; York University; Toronto,<br />
Ontario<br />
2:30 p m<br />
1327. Affect Balance and Catastrophizing in Patients with<br />
Fibromyalgia (FM). Afton L. Hassett 1 , Laura E. Simonelli 1 ,<br />
Diane C. Radvanski 1 , Shantal V. Savage 1 , Leonard H.<br />
Sigal 2 . 1 UMDNJ-Robert Wood Johnson Medical School, New<br />
Brunswick, NJ; 2 Bristol-Myers Squibb Company, Princeton, NJ<br />
2:45 p m<br />
1328. The Language of Pain among FMS Patients: McGill Pain<br />
Questionnaire Descriptors over Five Years. Susan Reisine, Judith<br />
Fifield, Stephen Walsh, Deborah Dauser, Micha Abeles. U<br />
Connecticut, Farmington, CT<br />
3:00 p m<br />
1329. Educational Needs and Concerns of People with Fibromyalgia.<br />
Alison Hammond. Derbyshire Royal Infirmary, Derby, England<br />
<strong>ACR</strong> Mini-Symposium<br />
2:30—4:15 p m<br />
Grand Ballroom West<br />
RA Pathogenesis: Molecular Mechanisms<br />
(Abstracts #1303-1308)<br />
Moderators:<br />
Nobuyuki N. Miyasaka, MD; Tokyo Med & Dent<br />
University; Tokyo, Japan<br />
Richard M. Pope, MD; Northwestern University Feinberg;<br />
Chicago, IL<br />
2:30 PM<br />
Introductory Talk<br />
New Therapeutic Targets in Rheumatoid Arthritis<br />
Gary S. Firestein, MD; University of California, San Diego;<br />
La Jolla, CA; Recipient, Arthritis Foundation 2006 Lee C.<br />
Howley Sr. Prize for Arthritis Research<br />
2:45 p m<br />
1303. Rheumatoid Arthritis-Specific Autoantibodies to an<br />
Immunodominant Epitope in Citrullinated a-Enolase Cross-React<br />
with Bacterial Enolase. Karin Lundberg, Benjamin Fisher,<br />
Andrew Kinloch, Patrick Venables. Kennedy Institute of<br />
Rheumatology, Imperial College London, London, England<br />
3:15 p m<br />
1330. Correlating Pain Medication Use and Pain Severity<br />
Measures in Fibromyalgia. Joan C. Rogers 1 , Margo B. Holm 1 ,<br />
Terence W. Starz 2 . 1 University of Pittsburgh, Pittsburgh, PA;<br />
2<br />
University of Pittsburgh Medical Center, Pittsburgh, PA<br />
3:30 p m<br />
1331. Effectiveness of Physical Exercise on Decrease of Pain in<br />
Patients with Fibromyalgia. Andrea H. Kayo 1 , Carla Munhoz<br />
Sanches 1 , Rafael Montenegro-Rodrigues 1 , Maria Stella<br />
Peccin 2 , Virginia Fernandes Moça Trevisani 1 . 1 University<br />
of Santo Amaro - UNISA, São Paulo, Brazil; 2 Federal<br />
University of Sao Paulo - UNIFESP, São Paulo, Brazil<br />
3:45 p m<br />
1332. Employment Status and Changes in Pain Levels Measured<br />
by the McGill Pain Questionnaire (MPQ) among Women with<br />
Fibromyalgia (FMS) over Five Years. Susan Reisine, Judith<br />
Fifield, Stephen Walsh, Deborah Dauser. U Connecticut,<br />
Farmington, CT<br />
3:00 p m<br />
1304. Osteoclast-Associated-Receptor (OSCAR) and Its Role in<br />
Rheumatoid Arthritis. Sonja Herman 1 , Karin Polzer 1 , Jochen<br />
Zwerina 1 , Kurt Redlich 2 , Clemens Scheinecker 2 , Georg<br />
Schett 1 . 1 Internal Medicine 3, Erlangen, Germany; 2 Internal<br />
Medicine III, Vienna, Austria<br />
3:15 p m<br />
1305. Synergy Between IL-32 and Bacterial Fragments Results in<br />
Chronic Destructive Arthritis. Bas Heinhuis 1 , Leo A. Joosten 1 ,<br />
Calin Popa 1 , Fons A. van de Loo 1 , Charles A. Dinarello 2 ,<br />
Wim B. van den Berg 1 . 1 UMC Nijmegen, Nijmegen, The<br />
Netherlands; 2 Div. of Infectious diseases, University of<br />
Colorado, Denver, CO<br />
FRIDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
141
FRIDAY<br />
3:30 p m<br />
1306. Synovial Expression of Cadherin-11 is Regulated by TNF<br />
alpha in Human Arthritis. Bernard Vandooren 1 , Tineke<br />
Cantaert 2 , Mariette Ter Borg 2 , Rodger Kuhlman 2 , Danielle<br />
Gerlag 2 , Kris Reedquist 2 , Paul P. Tak 2 , Dominique Baeten 2 .<br />
1<br />
Ghent University Hospital, Ghent, Belgium; 2 Division<br />
of Clinical Immunology and Rheumatology, Academic<br />
Medical Centre/University of Amsterdam, Amsterdam, The<br />
Netherlands<br />
3:45 p m<br />
1307. Syndecan-4, a Highly Expressed Cell Surface Receptor of RA<br />
Synovial Fibroblasts, Regulates Cytokine Induced MMP Synthesis<br />
via ERK Activation. Katja Neugebauer 1 , Christine Herzog 1 ,<br />
Noreen Pundt 1 , Lars H. Meyer 1 , George Kollias 2 , Perry J.<br />
Blackshear 3 , Georg Schett 4 , Thomas Pap 1 , Echtermeyer<br />
Frank 1 . 1 University Hospital Muenster, Muenster, Germany;<br />
2<br />
Institute of Immunology, Vari, Greece; 3 National<br />
Institute of Environmental Health Sciences, Durham, NC;<br />
4<br />
Department of Rheumatology, Erlangen, Germany<br />
4:00 p m<br />
1308. Lymphoid Architecture in the Rheumatoid Synovium<br />
is Protective of Auto-Antibody Production: Results From<br />
ARISE. Sanna Rosengren 1 , Nathan Wei 2 , Kenneth<br />
Kalunian 1 , Arthur Kavanaugh 1 , David L. Boyle 1 . 1 UCSD, La<br />
Jolla, CA; 2 Arthritis and Osteoporosis Center of Maryland,<br />
Frederick, MD<br />
<strong>ACR</strong> Workshops<br />
4:00—6:00 p m<br />
Admission to the Workshop sessions is by ticket only. To verify the session<br />
for which you are registered, refer to the registration codes below in<br />
parentheses. Workshops include beverages only.<br />
EMG/Nerve Conduction Interpretation for<br />
Rheumatology (097)<br />
Room 211<br />
Hans Carlson, MD; Oregon Health and Science University;<br />
Portland, OR<br />
Upon completion of this session, participants should be able to:<br />
∙ Explain the physiologic basis for normal and abnormal<br />
electrodiagnostic findings<br />
∙ Discuss the key elements of the electrodiagnostic study in<br />
relation to the diagnostic question<br />
∙ Recognize strong vs weak electrophysiologic evidence of<br />
clinicopathologic findings<br />
Histopathology of Vasculitis (096)<br />
Room 212<br />
Allen Burke, MD; Gaithersburg, MD<br />
Fabio Tavora, MD; Johns Hopkins School of Medicine;<br />
Baltimore, MD<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe histological features of normal blood vessels<br />
∙ Distinguish pathologic reactions to vascular injury<br />
∙ Identify histological features of major vasculitic syndromes<br />
Osteoporosis: Focus on DXA Interpretation (098)<br />
Room 209<br />
Edward S. Leib, MD; University of Vermont College of<br />
Medicine; Burlington, VT<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the basic principles of DXA interpretation and the<br />
ISCD guidelines for DXA interpretation<br />
∙ Identify some of the pitfalls of DXA interpretation and the<br />
clinical pearls associated with these unusual situations<br />
∙ Create a report based on the lumbar spine and hip bone<br />
densitometry results<br />
Practice Improvement Module (PIM) (099)<br />
All participants will receive a $75 discount on <strong>ACR</strong>’s practice improvement<br />
module – AIM. Discounts apply to enrollments after November <strong>2007</strong>.<br />
Room 213<br />
Audrey B. Uknis, MD; Temple University School of<br />
Medicine; Philadelphia, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the process to complete a practice improvement<br />
module<br />
∙ Discuss how quality measures are utilized in a practice<br />
improvement module<br />
∙ Identify practice strengths and area for improvement<br />
∙ Develop and implement a quality improvement plan<br />
∙ Summarize the role of a practice improvement module in<br />
relationship to health plan recognition programs, ACGME<br />
requirements and ABIM’s Maintenance of Certification program<br />
<strong>ACR</strong> Basic Science Symposium R<br />
4:30—6:00 p m<br />
Room 253<br />
Ion Channels in Inflammation<br />
Moderators:<br />
Iain B. McInnes, PhD; University of Glasgow; Glasgow,<br />
Scotland<br />
Stanford L. Peng, MD, PhD; Roche Palo Alto; Palo Alto, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Interpret the basic biology of ion channels in cell biology<br />
∙ Distinguish the diverse functions of ion channels in<br />
regulating immune and inflammatory pathways<br />
∙ Recognize the therapeutic potential in modulating ion<br />
channels in autoimmune and inflammatory diseases<br />
142<br />
= Recorded Sessions (order form on page 430)
4:30 p m<br />
Kv1.3 in Inflammation Biology<br />
K. George Chandy, MBBS, PhD; University of California<br />
Irvine; Irvine, CA<br />
5:00 p m<br />
CRAC in Inflammation<br />
Jean-Pierre Kinet, MD; Beth Israel Deaconess Medical<br />
Center and Harvard Medical School; Boston, MA<br />
5:30 p m<br />
ATP-Gated Receptors in Inflammation<br />
Annmarie Surprenant, PhD; University of Manchester;<br />
Manchester, England<br />
<strong>ACR</strong> Basic Science Symposium R<br />
4:30—6:00 p m<br />
Room 205<br />
Osteoarthritis: Degradation and Disease<br />
Moderators:<br />
Joel A. Block, MD; Rush University Medical Center;<br />
Chicago, IL<br />
Upon completion of this session, participants should be able to:<br />
∙ Assess the controversies regarding the roles of the subchondral<br />
bone in OA onset and progression<br />
∙ Integrate recent findings about the aggrecanases and<br />
cartilage homeostasis into the current paradigm of<br />
OA disease<br />
∙ Summarize the current thought concerning the etiology of<br />
pain in OA<br />
<strong>ACR</strong> Clinical Symposium ARS<br />
4:30—6:00 p m<br />
Hall C<br />
Issues in Biologic Therapy<br />
Moderators:<br />
Leonard H. Calabrese, DO; Cleveland Clinic Foundation;<br />
Cleveland, OH<br />
Peter J. Embi, MD, MS; University of Cincinnati;<br />
Cincinnati, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Review how to adjust biologics therapy when faced with<br />
complex circumstances like surgery, infections etc<br />
∙ Enumerate unusual complications associated with the use<br />
of various biologic therapies and their prevalence<br />
∙ Develop an algorithm for management of patients with<br />
inadequate response to anti-TNF therapy<br />
4:30 p m<br />
How to Use Biologics in Special Circumstances<br />
Peter C. Taylor, MA, PhD; Faculty of Medicine, Imperial<br />
College, London; London, England<br />
4:55 p m<br />
Unusual Complications of Biologics: What Do They Tell Us?<br />
Deborah P. Symmons, MD; University of Manchester;<br />
Manchester, England<br />
5:20 p m<br />
Management of RA After Inadequate Response to Anti-TNF agents<br />
Edward C. Keystone, Dr., MD; Mount Sinai Hospital;<br />
Toronto, Ontario<br />
C<br />
FRIDAY<br />
4:30 p m<br />
The Role of Sub-chondral Bone in OA<br />
David B. Burr, PhD; Indiana University; Indianapolis, IN<br />
4:55 p m<br />
The Aggrecanases in OA<br />
Amanda J. Fosang, PhD; Melbourne University and<br />
Murdoch Childrens Research Institute; Melbourne,<br />
Victoria, Australia<br />
5:20 p m<br />
The Origins of Pain in OA<br />
Jason J. McDougall, PhD; University of Calgary; Calgary,<br />
Alberta<br />
5:45 p m<br />
Discussion<br />
5:45 p m<br />
Discussion<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Grand Ballroom West<br />
Antiphospholipid Syndrome: Mechanisms of Vascular<br />
Pathology (Abstracts #1333-1338)<br />
Moderators:<br />
Joan T. Merrill, MD; Oklahoma Medical Research<br />
Foundation; Oklahoma City, OK<br />
Pier Luigi Meroni, MD; University of Milan; Milan, Italy<br />
4:30 p m<br />
1333. Differential Clinical Manifestations of the Antiphospholipid<br />
Syndrome May e Predicted by Different Intracellular Signalling<br />
Pathways. Anastasia Lambrianides 1 , Christopher Carroll 1 ,<br />
Wendy Heywood 1 , Kevin Mills 1 , David Latchman 1 , David<br />
Isenberg 1 , Silvia Pierangeli 2 , Paul Townsend 1 , Anisur<br />
Rahman 1 , Ian Giles 1 . 1 University College London, London,<br />
United Kingdom; 2 University of Texas, Galveston, TX<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
143
4:45 p m<br />
1334. CD45 Exon 6 A138G Single Nucleotide Polymorphism is<br />
Associated with Antiphospholipid Syndrome, Not Systemic Lupus<br />
Erythematosus. Tetsuya Horita, Hisako Nakagawa, Hiroshi<br />
Kataoka, Shinsuke Yasuda, Tatsuya Atsumi, Takao Koike.<br />
Hokkaido University, Sapporo, Japan<br />
5:00 p m<br />
1335. Tissue Factor: An Inflammatory Mediator in<br />
Antiphospholipid Antibody-Induced Pregnancy Loss. Patricia<br />
Redecha 1 , Rachel Tilley 2 , Michael Tencati 2 , Jane Salmon 1 ,<br />
Nigel Mackman 2 , Guillermina Girardi 1 . 1 Hospital for<br />
Special Surgery, New York, NY; 2 The Scripps Research<br />
Institute, La Jolla, CA<br />
5:15 p m<br />
1336. Role of p38 Mitogen Activated Protein Kinase in<br />
Antiphospholipid Antibody-Mediated Thrombosis And Endothelial<br />
Cell Activation. Mariano Vega-Ostertag 1 , Zurina Romay-<br />
Penabad 2 , Dardo E. Ferrara 3 , Xiaowei Liu 1 , Margaret<br />
Colden-Stanfield 1 , Silvia S. Pierangeli 4 . 1 Morehouse School<br />
of Medicine, Atlanta, GA; 2 University of Texas Medical<br />
Branch, Galveston, TX; 3 Emory University, Atlanta, GA;<br />
4<br />
Professor, Galveston, TX<br />
4:30 p m<br />
1339. Combination TNF-Inhibitor-Methotrexate Therapy is<br />
Superior yo Methotrexate Monotherapy in Reducing the Risk<br />
of Acute Myocardial Infarction in Patients with Rheumatoid<br />
Arthritis. Gurkirpal Singh 1 , Shweta Vadhavkar 2 , Alka<br />
Mithal 2 , George Triadafilopoulos 1 . 1 Stanford University<br />
School of Medicine, Palo Alto, CA; 2 Institute of Clinical<br />
Outcomes Research and Education (ICORE), Palo Alto, CA<br />
4:45 p m<br />
1340. The Effect of Rheumatic Disease Treatment on the<br />
Risk of Myocardial Infarction: Increased Risk from Rofecoxib,<br />
Valdecoxib and Celecoxib; Decreased Risk from Anti-TNF<br />
Therapy. Frederick Wolfe 1 , Kaleb Michaud 2 . 1 National Data<br />
Bank for Rheumatic Diseases, Wichita, KS; 2 University of<br />
Nebraska Medical Center, Omaha, NE<br />
5:00 p m<br />
1341. HLA-DRB1 Shared Epitope Alleles are Independently<br />
Associated with the Severity of Coronary Calcification in<br />
Rheumatoid Arthritis. Jon Giles 1 , Wendy Post 1 , Roger<br />
Blumenthal 1 , Moyses Szklo 1 , Michelle Petri 1 , Allan Gelber 1 ,<br />
Robert Detrano 2 , Joan Bathon 1 . 1 Johns Hopkins University,<br />
Baltimore, MD; 2 UCLA-Irvine, Irvine, CA<br />
FRIDAY<br />
5:30 p m<br />
1337. Beta2GPI-Dependent aPL React with Endometrial/<br />
Decidual Cells and Affect Their Function: Study with Inhibitory<br />
Molecules. M. Orietta Borghi 1 , Elena Raschi 1 , Silvia Scurati 1 ,<br />
Claudia Grossi 1 , Pojen P. Chen 2 , Silvia S. Pierangeli 3 , Pier<br />
Luigi Meroni 1 . 1 University of Milan- Istituto Auxologico,<br />
Milan, Italy; 2 Dept Rheumatology University of California,<br />
Los Angeles, CA; 3 University of Texas, Galveston, TX<br />
5:45 p m<br />
1338. A Possible Novel Therapeutic Strategy for Antiphospholipid<br />
Syndrome Using an NF-kappaB Inhibitor. Tetsuo Kubota 1 ,<br />
Yasuko Fukuya 1 , Rieko Hashimoto 1 , Hidenori Suzuki 2 ,<br />
Toshihiro Nanki 1 , Masayoshi Harigai 1 , Nobuyuki Miyasaka 1 ,<br />
Kazuo Umezawa 3 . 1 Tokyo Medical and Dental University,<br />
Tokyo, Japan; 2 Tokyo Metropolitan Institute of Medical<br />
Science, Tokyo, Japan; 3 Keio University, Yokohama, Japan<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Grand Ballroom West<br />
Biologic Therapies and RA Comorbidity<br />
(Abstracts #1339-1344)<br />
Moderator:<br />
Sherine Gabriel, MD; Mayo Clinic; Rochester, MN<br />
Ted R. Mikuls, MD; University of Nebraska Medical<br />
Center; Omaha, NE<br />
5:15 p m<br />
1342. TNF-α Antagonists and Heart Failure Hospitalization in<br />
Elderly Patients with Rheumatoid Arthritis. Soko Setoguchi,<br />
Sebastian Schneeweiss, Jerry Avorn, Jeffery N. Katz, Michael<br />
E. Weinblatt, Daniel H. Solomon. Brigham and Women’s<br />
Hospital, Boston, MA<br />
5:30 p m<br />
1343. Rheumatoid Arthritis, Interstitial Lung Disease, Mortality<br />
and Anti-TNF Therapy: Results from the BSR Biologics Register<br />
(BSRBR). William G. Dixon, Kath D. Watson, Mark Lunt,<br />
Kimme L. Hyrich, BSR Control Centre Consortium, Deborah<br />
pm Symmons, on behalf of the BSR Biologics Register. The<br />
University of Manchester, Manchester, United Kingdom<br />
5:45 p m<br />
1344. Are Cancers Occurring in RA Patients Treated with TNF-<br />
Antagonists Particularly Aggressive? Pauline Raaschou, Johan<br />
Askling, Fredrik Granath, Michael Fored, ARTIS Study<br />
Group. Karolinska Institute, Stockholm, Sweden<br />
144<br />
= Recorded Sessions (order form on page 430)
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 151<br />
Education (Abstracts #1345-1350)<br />
Moderators:<br />
Maria-Louise Barilla-LaBarca, MD; North Shore Long Island<br />
Jewish Health System; Lake Success, NY<br />
Richard Brasington, MD; Washington University School of<br />
Medicine; St. Louis, MO<br />
4:30 p m<br />
1345. Geriatric Rheumatology Educational Continuity Clinic<br />
(GRECC) Module Improve Quality of Care of Musculoskeletal<br />
Conditions in the Elderly. Jamal A. Mikdashi. University of<br />
Maryland, School of Medicine, Baltimore, MD<br />
4:45 p m<br />
1346. Pilot Testing of Instruments to Assess Knowledge of<br />
Synovial Fluid (SF) Analysis. Lan X. Chen 1 , Brian Mandell 2 ,<br />
Hans-Peter Brezinsek 3 , H. Ralph Schumacher 1 . 1 University<br />
of pennsylania, Philadelphia, PA; 2 Cleveland Clinic,<br />
Cleveland, OH; 3 Medical University, Graz, Austria<br />
5:00 p m<br />
1347. The Evolution of an Osteoporosis Fellowship Curriculum:<br />
From Concept to Implementation. Thomas P. Olenginski,<br />
Thomas Harrington. Geisinger Medical Center, Danville, PA<br />
5:15 p m<br />
1348. Teaching Rheumatology Fellows Communication and<br />
Teaching Skills: A Pilot <strong>Program</strong>. Patience H. White 1 ,<br />
Larrie Greenberg 1 , Raymond Flores 2 , Jim Katz 1 , Arthur<br />
Weinstein 3 . 1 George Washington University, washington<br />
DC, DC; 2 University of Maryland, Baltimore, MD;<br />
3<br />
Washington Hospital Center and Georgetown University,<br />
washington DC, DC<br />
5:30 p m<br />
1349. The Fourth Annual New York City Rheumatology<br />
Objective Structured Clinical Examination (NYC ROSCE):<br />
Utility for Rating Trainee Professionalism. Jessica R. Berman 1 ,<br />
Michael H. Pillinger 2 , Anne Bass 1 , Theodore Fields 1 ,<br />
Stephen Paget 1 , Elena Weinstein 3 , Deana Lazaro 4 . 1 Hospital<br />
for Special Surgery, New York, NY; 2 NYU School of<br />
Medicine, New York, NY; 3 Albert Einstein College of<br />
Medicine, New York, NY; 4 Brooklyn VA Medical Center,<br />
New York, NY<br />
5:45 p m<br />
1350. Evaluation of a Knee and Shoulder Arthrocentesis<br />
Training <strong>Program</strong> for Primary Care Providers (PCPs). H Ralph<br />
Schumacher 1 , Lan X. Chen 1 , Lesley Glick 2 . 1 University<br />
of Pennsylvania and Veteran’s Affairs Medical Center,<br />
Philadelphia, PA; 2 Phase Five Communications Inc., New<br />
York, NY<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 102<br />
Infection-Related Rheumatic Disease (Abstracts #1351-1356)<br />
Moderators:<br />
Allen C. Steere, MD; Massachusetts General Hospital;<br />
Boston, MA<br />
Linda Bockenstedt, MD; Yale University School of<br />
Medicine; New Haven, CT<br />
1351. Abstract Withdrawn<br />
4:30 p m<br />
1352. Borrelia burgdorferi Outer-Surface Protein C (OspC) Type<br />
K Strains More Often Infect the Joints of Patients with Lyme<br />
Arthritis than Type A Strains. Kathryn L. Jones, Gail C.<br />
McHugh, Lisa J. Glickstein, Allen C. Steere. Massachusetts<br />
General Hospital, Boston, MA<br />
4:45 p m<br />
1353. Diagnoses in Consecutive Patients Referred to a Tertiary<br />
Care Lyme Disease Clinic in the Northeast United States. Celina<br />
Crisman 1 , Robert A. Kalish 2 . 1 Columbia University School<br />
of Medicine, New York, NY; 2 Tufts-New England Medical<br />
Center, Boston, MA<br />
5:00 p m<br />
1354. Clinical Features of Subjects Having a Positive PBMC<br />
PCR Testing for Chlamydia in Suspected Chronic Reactive<br />
Arthritis. John D. Carter 1 , Luis R. Espinoza 2 , Robert D.<br />
Inman 3 , Mitchel Seleznick 1 , Kevin Sneed 1 , Louis Ricca 1 ,<br />
Joanne Valeriano 1 , Frank B. Vasey 1 , Cynthia Oszust 4 , Jessica<br />
Snelgrove 4 , Alan P. Hudson 4 . 1 University of South Florida,<br />
Tampa, FL; 2 Louisiana State University, New Orleans, LA;<br />
3<br />
University of Toronto, Toronto, ON, Canada; 4 Wayne<br />
State University, Detroit, MI<br />
FRIDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
145
FRIDAY<br />
5:15 p m<br />
1355. A Comparison of the Phenotypic Manifestations of<br />
Chlamydia Trachomatis vs Chlamydophila Pneumoniae-Induced<br />
Reactive Arthritis. John D. Carter 1 , Espinoza R. Luis 2 , Robert<br />
D. Inman 3 , Mitchel Seleznick 1 , Kevin Sneed 1 , Louis Ricca 1 ,<br />
Joanne Valeriano 1 , Frank B. Vasey 1 , Cynthia Oszust 4 , Jessica<br />
Snelgrove 4 , Herve C. Gerard 4 , Alan P. Hudson 4 . 1 University<br />
of South Florida, Tampa, FL; 2 Louisiana St University, New<br />
Orleans, LA; 3 Univ of Toronto, Toronto, ON, Canada;<br />
4<br />
Wayne St Univ, Detroit, MI<br />
5:30 p m<br />
1356. Increased Angiogenesis and Cell Proliferation as Features<br />
of the Synovium in Chronic Pyogenic Arthritis. Frank Pessler 1 ,<br />
Cesar Diaz-Torne 2 , Lie Dai 3 , Carmen Gomez-Vaquero 4 ,<br />
Michele Paessler 5 , Einhorn Eugene 6 , Lan X. Chen 1 ,<br />
H. Ralph Schumacher 1 . 1 University of Pennsylvania,<br />
Philadelphia, PA; 2 Hospital de la Santa Creu I Sant Pau,<br />
Barcelona, Spain; 3 2nd Affiliated Hospital, Sun Yat-sen<br />
University, Guangzhou, China; 4 Hospital Universitari de<br />
Bellvitge, Barcelona, Spain; 5 The Children’s Hospital of<br />
Philadelphia, Philadelphia, PA; 6 Philadelphia VA Medical<br />
Center, Philadelphia, PA<br />
5:45 p m<br />
Discussion<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 210<br />
Pathogenesis of Sjögren’s Syndrome<br />
(Abstracts #1357-1362)<br />
Moderators:<br />
H. M. Moutsopoulos, MD, FACP, FRCP; National<br />
University of Athens; Athens, Greece<br />
Mary K. Crow, MD; Hospital for Special Surgery; New<br />
York, NY<br />
4:45 p m<br />
1358. Coordinate Expression of Defensive Regulators of L1<br />
Endogenous Retroelements in Primary Sjögren’s Syndrome. Clio<br />
P. Mavragani 1 , Kate Moffit 1 , Efstathia K. Kapsogeorgou 1 ,<br />
Haralampos M. Moutsopoulos 2 , Mary K. Crow 1 . 1 Hospital<br />
for Special Surgery, New York, NY; 2 Department of<br />
Pathophysiology, School of Medicine, University of Athens,<br />
Athens, Greece<br />
5:00 p m<br />
1359. Interferon-Alpha Induces Up-Regulation and Nuclear<br />
Tranlocation of the Ro52 Autoantigen. Linn Strandberg 1 ,<br />
Aurelie Ambrosi 1 , Wei Zhou 1 , Lars Ottosson 1 , Maija-Leena<br />
Eloranta 2 , Alexander Espinosa 1 , Åse Elfving 1 , Edward<br />
Greenfield 3 , Vijay K. Kuchroo 3 , Marie Wahren-Herlenius 1 .<br />
1<br />
Karolinska Institutet, Stockholm, Sweden; 2 Uppsala<br />
Universitet, Uppsala, Sweden; 3 Harvard Medical School,<br />
Boston, MA<br />
5:15 p m<br />
1360. Reovirus-1 (a dsRNA Virus) and Poly (I:C) Induce High<br />
Expression of BAFF mRNA and Protein by Salivary Epithelial<br />
Cells Through TLR3 / Type I-interferon - Dependant and -<br />
Independent Pathways. Marc Ittah 1 , Corinne Miceli-Richard 1 ,<br />
Jacques-Eric Gottenberg 1 , Jérémie Sellam 1 , Pierre Eid 2 ,<br />
Christine Lepajolec 1 , Pierre Lebon 3 , Xavier Mariette 1 .<br />
1<br />
Bicetre Hospital, Le Kremlin Bicetre, France; 2 CNRS-UPR<br />
9045, Villejuif, France; 3 Saint-Vincent de Paul Hospital,<br />
Paris, France<br />
5:30 p m<br />
1361. Differential Expression of SS-A/Ro 60kDa and SS-B/La,<br />
but not SS-A/Ro 52kDa, mRNA and Protein in Minor Salivary<br />
Glands from Patients with Primary Sjögren’s Syndrome. Karin<br />
Spät Albino Barcellos 1 , Suely Nonogaki 2 , Milvia Maria<br />
Simões Silva Enokihara 1 , Miriam Scarpin Teixeira 1 , Luis<br />
Eduardo Coelho Andrade 1 . 1 São Paulo Federal University,<br />
São Paulo, Brazil; 2 Adolpho Lutz Institute, São Paulo, Brazil<br />
4:30 p m<br />
1357. Toll-like Receptor-3 Triggering of Salivary Gland<br />
Epithelial Cell lines (SGEC) Induces Significant Anoikis that<br />
is More Pronounced in Cells Derived from Primary Sjögren’s<br />
Syndrome (pSS) Patients. Maria P. Spachidou, Efstathia K.<br />
Kapsogeorgou, Christos I. Maratheftis, Haralampos M.<br />
Moutsopoulos, Menelaos N. Manoussakis. Medical School,<br />
University of Athens, ATHENS, Greece<br />
5:45 p m<br />
1362. FOXP3+ T Regulatory Cells (Tregs) in the Autoimmune<br />
Lesions of Sjögren’s Syndrome (SS): Correlation with the Number<br />
of the Infiltrating Dendritic Cells and Macrophages. Maria<br />
I. Christodoulou 1 , Efstathia K. Kapsogeorgou 1 , Niki M.<br />
Moutsopoulos 2 , Haralampos M. Moutsopoulos 1 . 1 Medical<br />
School of Athens, Athens, Greece; 2 NIDCR/NIH,<br />
Bethesda, MD<br />
146<br />
= Recorded Sessions (order form on page 430)
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 153<br />
SLE: Human Etiology and Pathogenesis<br />
(Abstracts #1363-1368)<br />
Moderators:<br />
Inaki Sanz, MD; University of Rochester Medical Center;<br />
Rochester, NY<br />
Martin Aringer, MD; University Medical Center Carl<br />
Gustav Carus, TU Dresden; Dresden, Germany<br />
4:30 p m<br />
1363. Anti-Lymphocyte Autoantibodies in SLE Revisited. Chau-<br />
Ching Liu, Jean Lin, Susan Manzi, Joseph M. Ahearn.<br />
University of Pittsburgh School of Medicine, Pittsburgh, PA<br />
4:45 p m<br />
1364. Prevalence, Clustering and Specificity of Select SLE<br />
Autoantibodies in a Large, Ethnically Diverse Collection of<br />
Patients and Unaffected Family Members. B. F. Bruner 1 , R.<br />
Lu 2 , D. Wiist, Jr. 2 , D. L. Kamen 3 , G. S. Gilkeson 3 , J. M.<br />
Guthridge 2 , J. B. Harley 2 , J. A. James 2 . 1 OUHSC, Oklahoma<br />
City, OK; 2 OMRF, Oklahoma City, OK; 3 MUSC,<br />
Charleston, SC<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 258<br />
Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s:<br />
Clinical Aspects and Therapeutics I (Abstracts #1369-1374)<br />
Moderators:<br />
Murray Baron, MD; McGill University; Montreal, Quebec<br />
Maureen D. Mayes, MD, MPH; University of Texas -<br />
Houston; Houston, TX<br />
4:30 p m<br />
1369. Nephrogenic Systemic Fibrosis Develops Following<br />
Gadopentetate Dimeglumine Exposure. Jonathan Kay 1 , Anna<br />
Kagan 1 , Lori B. Chibnik 2 , Whitney A. High 3 , Rosalynn M.<br />
Nazarian 1 , Hani H. Abujudeh 1 . 1 Massachusetts General<br />
Hospital, Boston, MA; 2 Brigham & Women’s Hospital,<br />
Boston, MA; 3 University of Colorado School of Medicine,<br />
Denver, CO<br />
4:45 p m<br />
1370. Use of the Exercise Echocardiogram in the Diagnosis of<br />
Pulmonary Hypertension in Systemic Sclerosis. Victoria K.<br />
Shanmugam, Tunay Kuru, Richard Morrissey, Virginia D.<br />
Steen. Georgetown University Hospital, Washington, DC<br />
5:00 p m<br />
1365. Oxidative Damage of PKCδ Impairs ERK Pathway<br />
Signaling in Lupus T Cells. Gabriela Gorelik 1 , Amr H.<br />
Sawalha 2 , Ailing Wu 1 , Bruce Richardson 1 . 1 University<br />
of Michigan, Ann Arbor, MI; 2 University of Oklahoma,<br />
Oklahoma City, OK<br />
5:15 p m<br />
1366. Platelets Modulate Immune Complex-Mediated Ifn-Alpha<br />
Secretion by Plasmacytoid Dendritic Cells in Sle. Pierre Duffau 1 ,<br />
Julien Seneschal 2 , Carole Nicco 3 , Claire Goulevestre 3 ,<br />
Jean-François Viallard 1 , Jean-Luc Pellegrin 1 , Jean-François<br />
Moreau 2 , Frederic Batteux 3 , Patrick Blanco 2 . 1 Chu<br />
Bordeaux, Pessac, France; 2 Chu Bordeaux, Bordeaux,<br />
France; 3 Institut Cochin, Paris, France<br />
5:30 p m<br />
1367. Sublytic Membrane Attack Complex (MAC) in Association<br />
with Circulating Immune Complexes (CIC) Induces Histone<br />
Dephosphorylation in SLE. Anil K. Chauhan, Terry L. Moore.<br />
Saint Louis University, Saint Louis, MO<br />
5:00 p m<br />
1371. Assessment of Heart Involvement in Systemic Sclerosis by<br />
Cardiac Magnetic Resonance Imaging in 50 Patients. Anne-<br />
Lise Hachulla 1 , David Launay 2 , Virginia Gaxotte 1 , Marc<br />
Lambert 2 , Sandrine Morell-Dubois 2 , Christophe Lions 1 ,<br />
Viviane Queyrel 2 , Hilaire Charlanne 2 , Pierre-Yves Hatron 2 ,<br />
Jean-Paul Beregi 1 , Eric Hachulla 2 . 1 Service de Radiologie et<br />
D’Imagerie Cardio-Vasculaire; Hôpital Cardiologique, Lille,<br />
France; 2 Service de Médecine Interne, Centre National de<br />
Référence «Atteinte Vasculaire de la Sclérodermie», Hôpital<br />
Claude-Huriez, Lille, France<br />
5:15 p m<br />
1372. Effects of New Oral Treatments on Exercise Capacity<br />
in Connective Tissue Disease Related Pulmonary Arterial<br />
Hypertension: A Meta-analysis of Randomized Controlled<br />
Trials. Jérôme Avouac, Julien Wipff, André Kahan,<br />
Yannick Allanore. Rheumatology A Department, Cochin<br />
Hospital, Paris, France<br />
FRIDAY<br />
5:45 p m<br />
1368. The Anti-DNA Ig Consensus Peptide pCONS Facilitates<br />
Regulatory T-Cell Activity in SLE Patients. Bevra H. Hahn,<br />
Marissa Anderson, Antonio La Cava. UCLA, Los Angeles, CA<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
147
FRIDAY<br />
5:30 p m<br />
1373. High Nt-pro Brain Natriuretic Peptide and Low Carbon<br />
Monoxide Lung Diffusion Capacity are Independent Predictors of<br />
the Occurrence of Pre-capillary Pulmonary Arterial Hypertension<br />
in Patients with Systemic Sclerosis. Yannick Allanore 1 , Didier<br />
Borderie 2 , Jérôme Avouac 1 , Djamila Zerkak 1 , Christophe<br />
Meune 3 , Julien Wipff 1 , Eric Hachulla 4 , Luc Mouthon 5 , Loic<br />
Guillevin 5 , Olivier Meyer 6 , Ohvanesse Ekindjian 2 , André<br />
Kahan 1 . 1 Department of Rheumatology A, Paris Descartes<br />
University, Medical Faculty, Cochin hospital, AP-HP, Paris,<br />
France; 2 Department of Biochemistry A, Cochin hospital,<br />
AP-HP, Paris, France; 3 Department of Cardiology, Paris<br />
Descartes University, Medical Faculty, Cochin hospital,<br />
AP-HP, Paris, France; 4 Department of Internal Medicine<br />
Lille II University, Claude Huriez Hospital, Lille, France;<br />
5<br />
Department of Internal Medicine, Paris Descartes<br />
University, Medical Faculty, Cochin hospital, AP-HP, Paris,<br />
France; 6 Department of Rheumatology, Paris VII University,<br />
Bichat Hospital, AP-HP, Paris, France<br />
5:45 p m<br />
1374. Definition of Digital Ulcers in Scleroderma - Can<br />
Rheumatologists Agree?. A. L. Herrick 1 , C. Roberts 1 , A.<br />
Tracey 1 , A. Silman 1 , M. E. Anderson 2 , M. Goodfield 3 ,<br />
N. McHugh 4 , L. Muir 5 , C. P. Denton 6 . 1 University of<br />
Manchester, Manchester, United Kingdom; 2 University<br />
of Liverpool, Liverpool, United Kingdom; 3 Leeds General<br />
Infirmary, Leeds, United Kingdom; 4 RNHRD, Bath, United<br />
Kingdom; 5 Hope Hospital, Salford, United Kingdom;<br />
6<br />
Royal Free Hospital, London, United Kingdom<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 156<br />
T-Cell Modulation in Autoimmunity<br />
(Abstracts #1375-1380)<br />
Moderators:<br />
Andras Perl, MD, PhD; State University of New York;<br />
Syracuse, NY<br />
I-Cheng Ho, MD, PhD; Brigham and Women’s Hospital;<br />
Boston, MA<br />
4:30 p m<br />
1375. Activation of T Cell Receptor Signaling by the Terminal<br />
Complement Complex: A Direct Link Between Innate and<br />
Adaptive Immunity. Anil K. Chauhan, Terry L. Moore. Saint<br />
Louis University, Saint Louis, MO<br />
4:45 p m<br />
1376. Expansion of Perforin/Granzyme-B+, CD8+ T Cells<br />
Expressing Activation Markers Correlates with Disease Activity<br />
in Systemic Lupus Erythematosus (SLE) and Mixed Connective<br />
Tissue Disease (MCTD). Sandra M. Crespo-Pagnussat,<br />
Marcos Maldonado, Emily Triana, Judith Pignac-Kobinger,<br />
Magdalena Perez, James Slusher, Eric L. Greidinger, Robert<br />
W. Hoffman. University of Miami, Miami, FL<br />
5:00 p m<br />
1377. 14-kd Protein Binds to the Conservative Region in TCR<br />
Zeta mRNA 3’UTR and Regulates the Production of TCR Zeta<br />
and TCR/CD3 Complex. Kensei Tsuzaka 1 , Yuka Itami 2 ,<br />
Chika Kumazawa 2 , Yumiko Setoyama 1 , Keiko Yoshimoto 1 ,<br />
Katsuya Suzuki 1 , Tohru Abe 1 , Tsutomu Takeuchi 1 . 1 Saitama<br />
Medical Center, Saitama Medical University, Kawagoe,<br />
Saitama, Japan; 2 Research Center for Genomic Medicine,<br />
Saitama Medical University, Hidaka, Saitama, Japan<br />
5:15 p m<br />
1378. CD4+ Memory Cells Escape Suppression by T Regulatory<br />
Cells. Sheetal S. Vora, Stesha Dunker, Benedetta Bonacci,<br />
Sreelatha Reddy, James W. Verbsky. Medical College of<br />
Wisconsin, Milwaukee, WI<br />
5:30 p m<br />
1379. CD25+IL-7RNeg-Defined FoxP3+ CD4 T Cells are Potent<br />
Suppressors of IL-7R+ T Cells and are Increased in the Synovial<br />
Fluid of RA Patients. Sarita AY Hartgring, Kim MG Jacobs,<br />
Johannes WJ Bijlsma, Floris PJG Lafeber, Joel AG van<br />
Roon. University Medical Center Utrecht, Rheumatology &<br />
Clinical Immunology, Utrecht, The Netherlands<br />
5:45 p m<br />
1380. Systemic Delivery of Adenovirus Encoding Suppressor of<br />
Cytokine Signaling-3 Markedly Ameliorates Collagen-Induced<br />
Arthritis by Down-Regulating Th17. Sharon Veenbergen,<br />
Miranda B. Bennink, Onno J. Arntz, Leo AB Joosten, Wim<br />
B. van den Berg, Fons AJ van de Loo. Radboud University<br />
Nijmegen Medical Centre, Nijmegen, The Netherlands<br />
<strong>ACR</strong>/<strong>ARHP</strong> Combined Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 104<br />
Building Resilience: Kids and Joints<br />
(Abstracts #1381-1386)<br />
Moderators:<br />
Carol J. Henderson, PhD, RD; Hatton Research Institute;<br />
Cincinnati, OH<br />
Marisa S. Klein-Gitelman, MD, MPH; Children’s Memorial<br />
Hospital; Chicago, IL<br />
148<br />
= Recorded Sessions (order form on page 430)
4:30 p m<br />
1381. Functional Status Over Time of Referrals to a Pediatric<br />
Rheumatology Center. Helen M. Emery, Sharon P. Goodwin.<br />
Childrens Hosp & Regional Med, Seattle, WA<br />
4:45 p m<br />
1382. Stress and Coping in Children and Adolescents with<br />
Fibromyalgia. Christopher J. Libby 1 , David S. Glenwick 1 ,<br />
Pamela J. Degotardi 2 . 1 Fordham University, Bronx, NY;<br />
2<br />
Queens College, Flushing, NY<br />
5:00 p m<br />
1383. Electronic Momentary Assessment of Child Pain, Parent<br />
Responses, and Emotion in Children with Arthritis. Mark<br />
Connelly 1 , Kelly K. Anthony 2 , Karen M. Gil 3 , Rebecca<br />
Sarniak 3 , Maggie A. Hood 2 , Janet Wootton 2 , Laura E.<br />
Schanberg 2 . 1 Children’s Mercy Hospital, Kansas City, MO;<br />
2<br />
Duke University Medical Center, Durham, NC; 3 University<br />
of North Carolina, Chapel Hill, NC<br />
5:15 p m<br />
1384. Utilizing a Lupus Teen/Parent Support Group for Pediatric<br />
Medical Education. Jillian Rose 1 , Roberta Horton 1 , Stephen<br />
Paget 1 , Susan Flics 1 , Betsy Pfeffer 2 , Philip Kahn 2 , Andrew<br />
Eichenfield 2 , Deborah M. Levy 2 , Lisa Imundo 2 . 1 Hospital for<br />
Special Surgery, New York, NY; 2 Morgan Stanley Children’s<br />
Hospital of New York-Presbyterian, Columbia University<br />
Medical Center, New York, NY<br />
5:30 p m<br />
1385. Access to Pediatric Rheumatology Subspecialty Care in<br />
British Columbia, Canada: A Prospective Patient Audit. Natalie<br />
Shiff, Reem Abdwani, David Cabral, Kristin Houghton,<br />
Peter Malleson, Ross Petty, Victor Espinosa, Lori Tucker.<br />
British Columbia Children’s Hospital, University of British<br />
Columbia, Vancouver, BC, Canada<br />
5:45 p m<br />
1386. Complementary and Alternative Medicine Use in<br />
Juvenile Idiopathic Arthritis Patients in the Canadian Maritime<br />
Provinces. Adam M. Huber, Anna Kubow, Bianca A. Lang,<br />
Suzanne E. Ramsey, Anthony Otley. IWK Health Centre,<br />
Halifax, NS, Canada<br />
<strong>ACR</strong> Meet the Professor Sessions<br />
4:30—6:00 p m<br />
Admission to the Meet the Professor Sessions is by ticket only. To verify the<br />
session for which you are registered, refer to the registration codes below in<br />
parentheses. Meet the Professor sessions include beverages only.<br />
Ankylosing Spondylitis: <strong>2007</strong> Update (106)<br />
Room 109 B<br />
Muhammad Asim Khan, MD, MACP; Case Western<br />
Reserve University; Cleveland, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the natural history of ankylosing spondylitis<br />
∙ Describe clinical and radiographic outcome measures used<br />
in ankylosing spondylitis trials<br />
∙ Review the scientific data on biologic agents as possible<br />
disease modifying agents in the treatment of AS<br />
Antiphospholipid Syndrome (112) F<br />
Room 162 A<br />
Daniel J. Wallace, MD; Rheum Arthritic Disorder; Los<br />
Angeles, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Analyze the therapeutic alternatives for the different<br />
manifestations of APS, including the benefit/risk, adverse<br />
effects and limitations<br />
∙ Discuss the laboratory tests used to confirm APS<br />
∙ Analyze the therapeutic alternatives for the different<br />
manifestations of APS, including the benefit/risk, adverse<br />
effects and limitations<br />
Fibromyalgia (107) PM<br />
Room 159<br />
Gary E. Myerson, MD; Arthritis and Rheumatology of GA;<br />
Atlanta, GA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the most recent thoughts regarding the<br />
pathophysiology of fibromyalgia and related disorders<br />
∙ Prescribe a treatment program for the typical fibromyalgia<br />
patient and serve as a consultant to that patient and the<br />
primary care provider<br />
∙ Describe the principles of a comprehensive treatment<br />
program for the more challenging fibromyalgia patient<br />
Immunology: Basic Immunology for Clinical<br />
Rheumatology (102) F<br />
Room 107 B<br />
Michael P. Davey, MD, PhD; Portland Veterans Affairs<br />
Medical Center; Portland, OR<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe how the immune system functions in normal<br />
individuals<br />
∙ Identify abnormalities of immune regulation that lead to<br />
autoimmunity<br />
FRIDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
149
FRIDAY<br />
Inflammatory Eye Disease: Focus on Uveitis (110)<br />
Room 160 C<br />
Sergio Schwartzman, MD; Hospital for Special Surgery; New<br />
York, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the clinical manifestations of inflammatory eye<br />
disease encountered by rheumatologists<br />
∙ Discuss diagnostic pearls for the evaluation of someone<br />
with inflammatory eye disease<br />
∙ Discuss the treatment paradigms used for the inflammatory<br />
eye diseases<br />
∙ Use cases to reinforce objectives 1-3<br />
Myopathy: Issues in Diagnosis and Treatment (108)<br />
Room 160 A<br />
Chester V. Oddis, MD; University of Pittsburgh; Pittsburgh, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Distinguish inflammatory myopathies from other<br />
muscles diseases<br />
∙ Plan a diagnostic work-up for a patient with signs and<br />
symptoms of muscle disease<br />
∙ Design a treatment program for a patient with myositis<br />
∙ Use cases to reinforce objectives 1-3<br />
RA: Outcome Measures in Clinical Practice (109)<br />
Room 160 B<br />
James R. O’Dell, MD; University of Nebraska Medical<br />
Center; Omaha, NE<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss outcome measures used in rheumatoid arthritis<br />
∙ Integrate outcome measures into an office-based practice<br />
RA: Safety of Novel Therapies (105)<br />
Room 109 A<br />
Arthur Kavanaugh, MD; Center for Innovative Therapy;<br />
La Jolla, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the management of patients with refractory<br />
rheumatoid arthritis<br />
∙ Identify novel treatment options for those failing<br />
conventional therapies<br />
Raynaud’s and Digital Ischemia (113)<br />
Room 162 B<br />
Fredrick M. Wigley, MD; Johns Hopkins University;<br />
Baltimore, MD<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the pathogenesis<br />
∙ Describe the appropriate diagnostic evaluation for<br />
this condition<br />
∙ Review treatment options and means of evaluating treatment<br />
Reactive Arthritis: An Update (103)<br />
Room 107 C<br />
Robert D. Inman, MD; Toronto Western Hospital;<br />
Toronto, Ontario<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize various causes of reactive arthritis<br />
∙ Discuss mechanisms of disease pathogenesis<br />
∙ Describe current treatment options for reactive arthritis<br />
Scleroderma Mimics (111)<br />
Room 161<br />
Virginia D. Steen, MD; Georgetown University Medical<br />
Center; Washington, DC<br />
Upon completion of this session, participants should be able to:<br />
∙ Generate a differential diagnosis for conditions simulating<br />
scleroderma<br />
∙ Formulate strategies to distinguish these various conditions<br />
∙ Discuss why these various conditions may have similar<br />
manifestations<br />
Sjögren’s: Controversies in Sjögren’s Syndrome (101)<br />
Room 107 A<br />
Steven E. Carsons, MD; Winthrop-University Hospital;<br />
Mineola, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss new diagnostic criteria for Sjögrens Syndrome<br />
∙ Describe new therapies for Sjögrens Syndrome<br />
∙ Identify systemic manifestations of Sjögrens Syndrome<br />
SLE: Novel Treatments (104)<br />
Room 108<br />
David A. Isenberg, MD; University College; London, England<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss current concepts of SLE pathogenesis<br />
∙ Describe the development of targeted therapies<br />
∙ Review recent clinical trial data<br />
Vasculitis: An Update (100)<br />
Room 106<br />
Simon Carette, MD; Toronto Western Hospital; Toronto,<br />
Ontario<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the various forms of vasculitis classified by<br />
affected vessel size<br />
∙ Utilize the various available tests with emphasis on ANCA<br />
∙ Identify current and novel therapeutic modalities<br />
150<br />
= Recorded Sessions (order form on page 430)
<strong>ARHP</strong> Concurrent Session C<br />
4:30—6:00 p m<br />
Room 260<br />
Beyond Fatigue and Pain: Addressing Concerns of<br />
Rheumatoid Arthritis Patients Outside of What is<br />
Traditionally Covered in the Physician Visit<br />
Moderator:<br />
Nancy E. Maher, MPH; Brigham and Women’s Hospital;<br />
Boston, MA<br />
Speakers:<br />
Jenny E. Heller, MPhil; Brigham and Women’s Hospital;<br />
Cambridge, MA<br />
Nancy A. Shadick, MD, MPH; Brigham and Women’s<br />
Hospital; Boston, MA<br />
Melanie Zibit, MEd, MBA; Brigham and Women’s<br />
Hospital; Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe concerns identified by RA patients in focus<br />
groups and discussions as most problematic and<br />
understand these concerns in-depth<br />
∙ Develop new approaches for dealing with patient concerns<br />
∙ Identify ways for health professionals, including but not<br />
limited to the attending physician, to provide support for<br />
patients around these issues<br />
∙ Apply the knowledge and ideas from the session to their<br />
own practice - before, during and after the office visit<br />
<strong>ARHP</strong> Concurrent Session C<br />
4:30—6:00 p m<br />
Room 259<br />
Young Patients with Old Knees: Treatment and Prevention<br />
of Knee Osteoarthritis (OA) in the Middle-Aged<br />
Moderator:<br />
Nadine M. Fisher, EdD; State University of New York;<br />
Buffalo, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify young and middle-aged patients at risk of knee OA<br />
∙ Formulate treatment plans for young and middle-aged<br />
patients with knee OA<br />
∙ Discuss the role of muscle function and exercise in<br />
prevention of knee OA<br />
4:30 p m<br />
Introduction: The Role of Joint-Related versus Muscular Aspects in<br />
Development and Prevention of OA<br />
Ewa M. Roos, PT, PhD; University of Southern Denmark;<br />
Odense, Denmark<br />
4:35 p m<br />
Epidemiology of OA, Risk Factors, The Role of The Meniscus<br />
Martin Englund, MD, PhD; Boston University; Boston, MA<br />
4:55 p m<br />
Exercise as Prevention and Treatment of Knee OA<br />
Ewa M. Roos, PT, PhD; University of Southern Denmark;<br />
Odense, Denmark<br />
5:15 p m<br />
Surgical Treatment Options for Young and Middle-Aged with Knee OA<br />
Annette W. Dahl, PhD; Lund University Hopital; Lund, Sweden<br />
<strong>ARHP</strong> Concurrent Session<br />
4:30—6:00 p m<br />
Room 257<br />
Improving Patient Outcomes: Implications for<br />
Rheumatology Practice<br />
Moderator:<br />
Kristine M. Lohr, MD; University of Kentucky; Lexington, KY<br />
Speaker:<br />
Karen L. Smarr, PhD; Harry S. Truman Memorial Veterans<br />
Affairs Hospital; Columbia, MO<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss how self-report questionnaires enhance clinical<br />
outcomes and relate to the Quality Movement<br />
∙ Review the advantages and disadvantages of public domain<br />
outcome measures used in rheumatology<br />
∙ Discuss practical strategies to include outcome measures<br />
in practice<br />
FRIDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
151
FRIDAY<br />
<strong>ACR</strong> Study Groups and Reception<br />
6:15—9:15 p m<br />
Study Groups are not eligible for CME credit.<br />
6:15-7:30 p m<br />
Study Groups: Session I (various locations)<br />
7:30-8:00 p m<br />
Reception in North Lobby<br />
7:45-9:15 p m<br />
Study Groups: Session II (various locations)<br />
Session I<br />
<strong>ACR</strong> Study Group<br />
6:15—7:30 p m<br />
Room 153<br />
<strong>ACR</strong>-EULAR Exchange<br />
Moderator:<br />
Randy Q. Cron, MD, PhD; Children’s Hospital of<br />
Alabama; Birmingham, AL<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the role of endothelium in autoimmunity<br />
∙ Describe how vascular permeability contributes to organ<br />
specific autoimmunity<br />
6:15 p m<br />
Cell Migration and Autoimmunity<br />
Ulrich Andrian, MD, PhD; Harvard; Boston, MA<br />
6:45 p m<br />
Vascular Permeability and Autoimmunity<br />
Umar Mahmood, MD, PhD; Harvard; Boston, MA<br />
7:05 PM<br />
Dysregulation of Major Endothelial Cell Signalling Pathways in<br />
Systemic Sclerosis<br />
Falk Moritz, MD; Center of Exploratory Rheumatology;<br />
Zurich, Switzerland<br />
7:18 p m<br />
C3 Deficiency Does Not Protect Against Coronary Arteritis or<br />
Aortitis Induced by Candida Albicans Water Soluble Fraction (CAWS)<br />
Nora G. Singer, MD; Rainbow Babies and Children’s<br />
Hospital; Cleveland, OH<br />
<strong>ACR</strong> Study Group<br />
6:15—7:30 p m<br />
Room 157<br />
Autoantibodies in Diagnosis and Follow up of<br />
Rheumatic Diseases<br />
Moderators:<br />
Pier Luigi Meroni, MD; University of Milan; Milan, Italy<br />
Eng M. Tan, MD; Scripps Research Institute; La Jolla, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Review reliable and new autoantibodies in scleroderma<br />
∙ Develop a practical guide in using complement assays in<br />
aiding clinical diagnosis<br />
∙ Discuss predictive/pathogenic versus protective<br />
autoantibodies focusing on anti-DNA<br />
6:15 p m<br />
Scleroderma Autoantibody Profile in <strong>2007</strong>: Diagnostic Specificity<br />
and Clinical Significance<br />
Westley H. Reeves, MD; University of Florida; Gainesville, FL<br />
6:40 p m<br />
Complement Assays: More Than Just C4 And C3<br />
John P. Atkinson, MD; Washington University; St. Louis, MO<br />
7:05 p m<br />
Lupus Autoantibodies - Predictive/Pathogenic versus Protective<br />
Yehuda Shoenfeld, MD; Sheba Medical Center; Tel-<br />
Hashomer, Israel<br />
<strong>ACR</strong> Study Group<br />
6:15—7:30 p m<br />
Room 156<br />
Behçet’s Disease<br />
Moderator:<br />
Sebahattin Yurdakul, MD; Cerrahpasa Medical Faculty;<br />
Istanbul, Turkey<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the autoinflammatory characteristics of Behçets Disease<br />
∙ Discuss the association of arthritis with acne like lesions in<br />
Behçets Disease<br />
∙ Discuss the limitations of available therapies and current<br />
evidence with anti TNF agents in Behçets Disease<br />
6:15 p m<br />
Pathogenesis of Behçet’s Disease<br />
Ahmet Gul, MD; Istanbul University; Istanbul, Turkey<br />
6:41 p m<br />
Clusters of Disease Expression in Behçet’s Disease<br />
Erdal Diri, MD; University of North Dakota, Trinity Health<br />
Group; Minot, ND<br />
Study Groups are not eligible for CME credit.<br />
152<br />
= Recorded Sessions (order form on page 430)
7:05 p m<br />
Anti TNF Therapy in Behçet’s Disease<br />
Petros Sfikakis, MD; Athens University Medical School;<br />
Athens, Greece<br />
7:05 p m<br />
Rheumatoid Arthritis in African <strong>American</strong>s<br />
S. Louis Bridges Jr., MD, PhD; University of Alabama-<br />
Birmingham; Birmingham, AL<br />
<strong>ACR</strong> Study Group<br />
6:15—7:30 p m<br />
Room 257<br />
Crystal Arthropathies<br />
Moderator:<br />
N. Lawrence Edwards, MD; University of Florida;<br />
Gainesville, FL<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss how delphi and nominal group process aid in<br />
development of clinical criteria<br />
∙ Participate in the finalizing of acute flare criteria for gout<br />
∙ Discuss the new cellular and cytokine control of acute<br />
gouty flares<br />
6:15 p m<br />
A Concensus Discussion on Criteria for Gout Flares<br />
Kenneth G. Saag, MD, MSc; University of Alabama-<br />
Birmingham; Birmingham, AL<br />
6:52 p m<br />
Update on the “On/Off” Mechanisms of Gout Inflammation<br />
Robert Terkeltaub, MD; University California–San Diego/<br />
Veterans Affairs Medical Center; San Diego, CA<br />
<strong>ACR</strong> Study Group<br />
6:15—7:30 p m<br />
Room 160 A<br />
Ethnic Minority<br />
Moderator:<br />
Edward L. Treadwell, MD; East Carolina University School<br />
of Medicine; Greenville, NC<br />
Upon completion of this session, participants should be able to:<br />
∙ Generate awareness of health disparities<br />
∙ Investigate areas of new research<br />
∙ Review evidence based outcome measures in ethnic populations<br />
6:15 p m<br />
Screening African <strong>American</strong> Men for Osteoporosis<br />
John S. Richards, MBBS; Veteran’s Affairs Medical Center;<br />
Washington, DC<br />
<strong>ACR</strong> Study Group<br />
6:15—7:30 p m<br />
Room 102<br />
Musculoskeletal Ultrasound<br />
Moderators:<br />
Marina Backhaus, MD; Charite University Hospital; Berlin,<br />
Germany<br />
Gurjit S. Kaeley, MBBS, MRCP; ROAD Clinic; University<br />
Place, WA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the protocols developed by OMERACT (Outcome<br />
Measures in Rheumatoid Arthritis Clinical Trials)<br />
ultrasound group for evaluation of Rheumatoid Arthritis<br />
∙ Apply the OMERACT recommendations to daily<br />
rheumatology practice<br />
∙ Review problems and pitfalls of powers Doppler use in<br />
musculoskeletal ultrasound practice<br />
∙ Describe major areas of interest for North <strong>American</strong><br />
Rheumatologists interested in Musculoskeletal Ultrasound<br />
over the last year<br />
6:15 p m<br />
Report of OMERACT Ultrasound Interest Group, Recommendations<br />
for initial and Sequential Evaluation of Rheumatoid Arthritis<br />
Maria A. D Agostino, MD; Hopital Ambroise Pare;<br />
Boulogne Cedex, France<br />
6:40 p m<br />
Uses and Limitations of Power in Daily Rheumatology<br />
Hvidovre Hospital<br />
Marcin Szkudlarek, MD; University of Copenhagen<br />
Hvidovre Hospital; Hvidovre, Denmark<br />
7:05 p m<br />
MSK-USS.org (<strong>American</strong> Rheumatology Focus Group for<br />
Ultrasound) Presentation. Report on Activity Since <strong>ACR</strong> 2006,<br />
discussion on goals for upcoming year.<br />
Gurjit S. Kaeley, MBBS, MRCP; ROAD Clinic; University<br />
Place, WA<br />
FRIDAY<br />
6:40 p m<br />
Studying Minority Populations with Connective Tissue Diseases<br />
Grace C. Wright, MD, PhD; Veteran’s Affairs Medical<br />
Center; Washington, DC<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
153
FRIDAY<br />
<strong>ACR</strong> Study Group<br />
6:15—7:30 p m<br />
Room 151<br />
Neuro Endocrine Immunology<br />
Moderators:<br />
Johannes W. J. Bijlsma, MD, PhD; University Medical<br />
Center Utrecht; Utrecht, Netherlands<br />
Maurizio E. Cutolo, MD; University of Genova; Genova, Italy<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify the pro- and anti-inflammatory role of hormones<br />
in rheumatic diseases<br />
∙ Recognize that hormonal changes can variably affect<br />
different rheumatic diseases in pregnancy<br />
∙ Determine that differential effects of hormones depend on<br />
concentration or dosage of hormones<br />
∙ Determine that differential effects of hormones depend on<br />
timing of administration in relation to immune responses<br />
∙ Determine that differential effects of hormones depend on<br />
differentially involved immune cell targets<br />
6:15 p m<br />
The Pro- Anti-inflammatory Aspects of Pregnancy in Different<br />
Rheumatic Diseases<br />
Michael D. Lockshin, MD; Cornell Medical Center; New<br />
York, NY<br />
6:35 p m<br />
The Pro- Anti-Inflammatory Role of Adipolines in Rheumatic<br />
Diseases<br />
Ulf Muller-Ladner, MD; Univ.Giessen/Kerckhoff-Clinic;<br />
Bad Nauheim, Germany<br />
6:55 p m<br />
The Immunostimulating and Immunosuppressive Roles of Cortisol<br />
in Rheumatic Diseases<br />
Frank Buttgereit; Universitatsklinikum Charite; Berlin,<br />
Germany<br />
<strong>ACR</strong> Study Group<br />
6:15—7:30 p m<br />
Room 259<br />
Patient Perspective in Outcomes Research<br />
Moderators:<br />
Ingemar F. Petersson, MD, PhD; Spenshults Hospital for<br />
Rheumatic; Oskarstrom, Sweden<br />
Pamela Richards; Bristol, England<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the significance of patient core set in rheumatoid<br />
arthritis<br />
∙ Discuss the progress being made in this direction<br />
∙ Identify the statistical and methodological challenges to<br />
establishing its validity<br />
6:15 p m<br />
Introduction<br />
6:18 p m<br />
Item Response Theory and the Revolution in Self-Reported Outcomes<br />
- How Will It Make A Difference to How We Measure Things?<br />
Martin van de Laar, MD, PhD; Medisch Spectrum Twente;<br />
Enschede, Netherlands<br />
Upon completion of this session, participants should be able to:<br />
∙ Evaluate how statistics can help us to understand the<br />
patient’s perspective<br />
∙ Discuss new ways of involving the patient’s perspective in<br />
clinical decision making<br />
6:33 p m<br />
What Patients See Compared to What Researchers See<br />
Tessa Sanderson, BSc; University of West England, Bristol<br />
Royal Infirmary; Bristol, England<br />
Upon completion of this session, participants should be able to:<br />
∙ Determine the patient’s perspective of well-being<br />
∙ Discuss the potential response-shift in views that may occur<br />
as chronic illness progresses<br />
7:15 p m<br />
Panel Discussion<br />
6:45 p m<br />
Progress Towards a Patient Core Set? - Report From EULAR<br />
Working Group<br />
Tore K. Kvien, MD; Diakonhjemmet Hospital; Oslo, Norway<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss how patients can be involved in the process<br />
of identifying dimensions of health perceived to be of<br />
importance to them<br />
∙ Review the evidence of different dimensions of health as<br />
reliable and responsive measures in research and clinical<br />
practice<br />
Study Groups are not eligible for CME credit.<br />
154<br />
= Recorded Sessions (order form on page 430)
7:00 p m<br />
Core Sets - Two (or More) Sides of the Same Coin?<br />
John R. Kirwan, MD; University of Bristol; Bristol, England<br />
Upon completion of this session, participants should be able to:<br />
∙ Explore the concept of two ways of expressing disease<br />
outcome which use different outcome measures but<br />
provide similar information<br />
∙ Identify the challenges and approaches to demonstrating<br />
that this approach can meet the requirements of the<br />
OMERACT filter<br />
7:10 p m<br />
Discussion<br />
7:25 p m<br />
Summary and Conclusion<br />
<strong>ACR</strong> Study Group<br />
6:15—7:30 p m<br />
Grand Ballroom East<br />
Pediatric Rheumatology: Update on Juvenile Scleroderma<br />
Moderators:<br />
Ronald M. Laxer, MD; Hospital for Sick Children; Toronto,<br />
Ontario<br />
Lisa G. Rider, MD; National Institute of Environmental<br />
Health Sciences; Bethesda, MD<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the demographic, clinical, immunologic and<br />
natural history of disease characteristics of different subsets<br />
of scleroderma in children<br />
∙ Compare these to adult onset systemic sclerosis and discuss<br />
the implications of these differences for patient evaluation<br />
and treatment<br />
∙ Discuss recent effects to standardize the classification of<br />
juvenile scleroderma<br />
6:15 p m<br />
Update on Juvenile Scleroderma, Clinical Features and<br />
Classification<br />
Francesco Zulian, MD; University of Padua; Padua, Italy<br />
6:45 p m<br />
A Comparison of Systemic Sclerosis with Onset in Childhood<br />
vs. Adulthood<br />
Thomas A. Medsger, Jr., MD; University of Pittsburgh;<br />
Pittsburgh, PA<br />
<strong>ACR</strong> Study Group<br />
6:15—7:30 p m<br />
Room 205<br />
Polymyalgia Rheumatica<br />
Moderator:<br />
Bhaskar Dasgupta, MD; Southend University Hospital;<br />
Essex, England<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify classification criteria in pmR- prospective<br />
validation study progress<br />
∙ Discuss ultrasound sub study progress<br />
∙ Discuss recent developments in analysis of temporal artery<br />
histology especially with relevance to intimal hyperplasia<br />
and neovascularization<br />
∙ Discuss new therapy trials in resistant pmR and GCA<br />
6:15 p m<br />
Classification Criteria: Clinical Project Update<br />
Eric L. Matteson, MD; Mayo Clinic; Rochester, MN<br />
6:35 p m<br />
Classification Criteria: Ultrasound Update<br />
Wolfgang A. Schmidt, MD; Medical Center for<br />
Rheumatology Berlin-Buch; Berlin, Germany<br />
6:55 p m<br />
Newer Therapy Studies in Polymyalgia Rheumatica /Giant Cell<br />
Arteritis<br />
Bhaskar Dasgupta, MD; Southend University Hospital;<br />
Essex, England<br />
<strong>ACR</strong> Study Group<br />
6:15—7:30 p m<br />
Room 261<br />
Psoriatic Arthritis<br />
Moderator:<br />
Christopher T. Ritchlin, MD; University of Rochester<br />
Medical Center; Rochester, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss how analyses of skin and joint samples can be<br />
incorporated into clinical trials<br />
∙ Identify domains and important instruments for PSA<br />
studies<br />
∙ Discuss the dermatology perspective in relation to stain<br />
assessments in PSA trials<br />
FRIDAY<br />
7:15 p m<br />
Pediatric Rheumatology Section Business <strong>Meeting</strong><br />
Suzanne L. Bowyer, MD; James Whitcomb Riley Hospital;<br />
Indianapolis, IN<br />
6:15 p m<br />
Clinical Trial and Implementation in PSA: The Translational<br />
Perspective<br />
Paul P. Tak, MD, PhD; Academic Medical Center;<br />
Amsterdam, Netherlands<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
155
FRIDAY<br />
6:40 p m<br />
Clinical Trials in PSA: Lessons Learned and the Path Forward<br />
Philip J. Mease, MD; Swedish Medical Center; Seattle, WA<br />
7:05 p m<br />
Evaluation of the Skin and Joints in PSA: The Dermatologic<br />
Perspective<br />
Bruce Strober, MD, PhD; New York University Medical Center;<br />
New York, NY<br />
<strong>ACR</strong> Study Group<br />
6:15—7:30 p m<br />
Room 260<br />
Rehabilitative Rheumatology<br />
Moderators:<br />
Geri B. Neuberger, RN, EdD; University of Kansas Medical<br />
Center; Kansas City, KS<br />
Kenneth S. O’Rourke, MD; Wake Forest University;<br />
Winston-Salem, NC<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the physiologic and biomechanical rationale<br />
supporting prescriptive exercise therapy for individuals<br />
with knee osteoarthritis<br />
∙ Describe the process of motivational interviewing and its<br />
use in practice and research<br />
∙ Identify methods to integrate exercise for arthritis into<br />
existing community programs<br />
6:15 p m<br />
Exercise Prescription for Older Adults with Knee OA:<br />
Biochemicanical and Physiologic Considerations<br />
Stephen P. Messier, PhD; Wake Forest University; Winston-<br />
Salem, NC<br />
<strong>ACR</strong> Study Group<br />
6:15—7:30 p m<br />
Room 159<br />
Scleroderma Skin Score—How I Do It<br />
Moderator:<br />
Daniel E. Furst, MD; University of California–Los Angeles<br />
Medical School; Los Angeles, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Establish the usefulness and reasons to do a modified<br />
Rodman skin score (mRSS)<br />
∙ Explain how to do a modified Rodman skin score<br />
∙ Perform a mRSS under the supervision of experts (limited<br />
to 50 rheumatologists)<br />
6:15 p m<br />
Demonstration of mRSS<br />
Daniel E. Furst, MD; University of California–Los Angeles<br />
Medical School; Los Angeles, CA<br />
6:35 p m<br />
Uses of mRSS<br />
Maureen D. Mayes, MD, MPH; University of Texas–<br />
Houston; Houston, TX<br />
6:55 p m<br />
Supervision of Hands-On mRSS<br />
James R. Seibold, MD; University of Michigan; Ann Arbor, MI<br />
7:15 p m<br />
Demonstrations<br />
Philip J. Clements, MD, MPH; University of California–Los<br />
Angeles; Los Angeles, CA<br />
Robert W. Simms, MD; Boston University Arthritis Center;<br />
Boston, MA<br />
6:40 p m<br />
Promoting Exercise through Existing Community <strong>Program</strong>s<br />
Basia Belza, PhD, RN; University of Washington; Seattle, WA<br />
7:05 p m<br />
Motivational Interviewing for Individualized Exercise<br />
Rowland W. Chang, MD, MPH; Northwestern University;<br />
Chicago, IL<br />
Linda S. Ehrlich-Jones, PhD, RN; Rehabilitation Institute of<br />
Chicago; Chicago, IL<br />
<strong>ACR</strong> Study Group<br />
6:15—7:30 p m<br />
Room 258<br />
Sjögren’s Syndrome<br />
Moderator:<br />
John B. Harley, MD, PhD; University of Oklahoma Health<br />
<strong>Scientific</strong> Center; Oklahoma City, OK<br />
Upon completion of this session, participants should be able to:<br />
∙ Develop a deeper understanding of cellular inter<br />
relationships and their role in innate and adaptive<br />
immune mechanisms in Sjögrens Syndrome<br />
∙ Realize the role of functional autoantibodies and their<br />
potential as diagnostic and prognostic biomarkers<br />
∙ Identify perspectives upon biologic therapies<br />
Study Groups are not eligible for CME credit.<br />
156<br />
= Recorded Sessions (order form on page 430)<br />
6:15 p m<br />
Recent Findings in Oral Pathology of Sjögren’s Syndrome<br />
Roland Jonsson, DDS, PhD; University of Bergen;<br />
Bergen, Norway
6:40 p m<br />
The Role of Functional Autoantibodies in Sjögren’s Syndrome<br />
Thomas P. Gordon, MD, PhD, FRACP; Flinders Medical<br />
Centre; Bedford Park, Australia<br />
7:05 p m<br />
Novel Therapeutic Approaches in Sjögren’s Syndrome: What<br />
About Biologics?<br />
Philip L. Cohen, MD; University of Pennsylvania;<br />
Philadelphia, PA<br />
<strong>ACR</strong> Study Group<br />
6:15—7:30 p m<br />
Room 104<br />
Skin Diseases<br />
Moderator:<br />
M. Kari Connolly, MD; University of California–San<br />
Francisco; San Francisco, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize skin manifestations of select rheumatic diseases<br />
∙ Review a range of treatment options for these patients<br />
<strong>ACR</strong> Study Group<br />
6:15—7:30 p m<br />
Room 253<br />
Spondylarthopathies<br />
Moderator:<br />
John D. Reveille, MD; University of Texas Health Sciences<br />
Center at Houston; Houston, TX<br />
Upon completion of this session, participants should be able to:<br />
∙ Learn recent breakthroughs in genetics of spondyloarthritis<br />
∙ Understand the effect of nongenetic factors on SpA<br />
pathogenesis<br />
∙ Understand the interaction of genetic and nongenetic factors<br />
6:15 p m<br />
The Genetic Basis of Spondyloarthritis<br />
Matthew A. Brown, MD; Princess Alexanda Hospital;<br />
Brisbame, Queensland, Australia<br />
6:40 p m<br />
Environmental Triggers of Spondyloarthritis<br />
Robert D. Inman, MD; Toronto Western Hospital;<br />
Toronto, Ontario<br />
6:15 p m<br />
Acral Skin Lesions in Lupus Erythematosus<br />
Melissa I. Costner, MD; UT Southwestern Medical Center;<br />
Dallas, TX<br />
6:25 p m<br />
Tumid Lupus Erythematosus<br />
Victoria P. Werth, MD; University of Pennsylvania;<br />
Philadelphia, PA<br />
6:35 p m<br />
Unusual Presentations of Dermatomyositis<br />
David Fiorentino, MD, PhD; Stanford Medical Center;<br />
Stanford, CA<br />
6:45 p m<br />
Radiation-Induced Generalized Morphea<br />
M. Kari Connolly, MD; University of California–San<br />
Francisco; San Francisco, CA<br />
6:55 p m<br />
Multicentric Reticulohistiocytosis - Treatment with Infliximab<br />
Jeffrey P. Callen, MD; University Louisville; Louisville, KY<br />
7:05 p m<br />
Calciphylaxis-Like Disease in the Dialysis Unit<br />
Jan P. Dutz, MD; British Columbia University; Vancouver,<br />
British Columbia<br />
7:15 p m<br />
Refractory Raynaud’s Phenomenon<br />
Andrew G. Franks, Jr., MD; New York University Medical<br />
Center; New York, NY<br />
7:05 p m<br />
The Role of the Gut in Spondyloarthritis<br />
Dominique Baeten, MD; University of Ghent; Gent, Belgium<br />
<strong>ACR</strong> Study Group<br />
6:15—7:30 p m<br />
Room 210<br />
Systemic Lupus Erythematosus<br />
Moderators:<br />
Jill P. Buyon, MD; New York University; New York, NY<br />
Joan T. Merrill, MD; Oklahoma Medical Research Found;<br />
Oklahoma City, OK<br />
Upon completion of this session, participants should be able to:<br />
∙ Evaluate diagnostic tools for evaluating CNS Lupus<br />
∙ Evaluate the pathology of CNS Lupus<br />
∙ Generate awareness of the blood-brain barrier, and tissue<br />
injury resulting from autoantibodies<br />
6:15 p m<br />
Cognitive Dysfunction in SLE: Prevalence and Significance<br />
Melanie J. Harrison, MD, MSCE; Wyeth Pharmaceuticals;<br />
Collegeville, PA<br />
6:30 p m<br />
Prevalence and Manifestations of CNS Lupus: Evidence from the<br />
International SLICC Study<br />
John G. Hanly, MD; Queen Elizabeth II Health Services<br />
Center; Halifax, NS<br />
FRIDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
157
6:45 p m<br />
Pathogenesis of CNS Lupus: Clues for Advances in Care<br />
Betty Diamond, MD; Feinstein Institute of Medical<br />
Research; Manhassett, NY<br />
7:00 p m<br />
Discussion<br />
<strong>ACR</strong> Study Group Reception<br />
7:30—8:00 p m<br />
North Lobby<br />
Encore Theater<br />
6:15—7:45 p m<br />
Room 255<br />
Medical Aspects of Rheumatic Disease - Pulmonary<br />
Hypertension<br />
Please see page 69 for hours of operation and a tentative list of sessions.<br />
8:35 p m<br />
The Challenges and Opportunities for Practice Redesign in the<br />
Academic Clinic<br />
J. Timothy Harrington, Jr., MD; University of Wisconsin;<br />
Madison, WI<br />
<strong>ACR</strong> Study Group<br />
7:45—9:15 p m<br />
Room 253<br />
Antiphospholipid Antibody<br />
Moderator:<br />
Silvia S. Pierangeli, PhD; University of Texas Medical<br />
Branch; Galveston, TX<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss current and future aspects of APS with respect to<br />
pathogenesis, diagnosis and treatment<br />
∙ Assess the neurological manifestation of APS<br />
∙ Explore the new insights in obstetrical complications of APS<br />
∙ Discuss difficult and challenging clinical cases of APS<br />
FRIDAY<br />
Session II<br />
<strong>ACR</strong> Study Group<br />
7:45—9:15 p m<br />
Room 151<br />
Academic Clinical Practice<br />
Moderator:<br />
Walter G. Barr, MD; Northwestern University; Chicago, IL<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the diversity of academic rheumatology practices in<br />
the United States<br />
∙ Identify the best practices to evaluate the performance of<br />
an academic practice<br />
∙ Identify the challenges and opportunities of practice<br />
redesign<br />
7:45 p m<br />
Challenging Cases of APS<br />
Doruk Erkan, MD; Hospital for Special Surgery; New York, NY<br />
8:00 p m<br />
CNS Involvement in APS<br />
Yehuda Shoenfeld, MD; Sheba Medical Center; Tel-<br />
Hashomer, Israel<br />
8:30 p m<br />
Antiphospholid Syndrome: The Evolving Obstetric Story<br />
D. Ware Branch, MD; University of Utah; Salt Lake City, UT<br />
9:00 p m<br />
The Antiphospholipid Antibody-Brain Connection<br />
Robin L. Brey, MD; University of Texas Health Science<br />
Center; San Antonio, TX<br />
7:45 p m<br />
A Profile of Academic Rheumatology Practices in the United States<br />
in <strong>2007</strong><br />
W. Winn Chatham, MD; University of Alabama–<br />
Birmingham; Birmingham, AL<br />
8:10 p m<br />
What Are the Appropriate Metrics to Judge the Performance of an<br />
Academic Rheumatology Practice?<br />
Bethany Chiaramonte; Northwestern University, Feinberg;<br />
Chicago, IL<br />
Study Groups are not eligible for CME credit.<br />
158<br />
= Recorded Sessions (order form on page 430)
<strong>ACR</strong> Study Group<br />
7:45—9:15 p m<br />
Room 210<br />
B-Cell Targeted Therapy in SLE<br />
Moderator:<br />
Ronald Van Vollenhoven, MD, PhD; Karolinska Hospital;<br />
Stockholm, Sweden<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the efficacy and safety data currently out on<br />
rituximab in SLE so as to be able to form a risk/benefit<br />
assessment for this off-label therapy applicable to patients<br />
seen in practice<br />
∙ Discuss practical aspects and controversies surrounding<br />
this therapy, including dosing and combination<br />
possibilities, prevention of adverse events, appropriate<br />
follow-up, etc.<br />
∙ Discuss several other B-cell therapies currently “on the<br />
horizon” for the treatment of SLE<br />
7:45 p m<br />
Welcome Introduction<br />
7:52 p m<br />
Experiences with Rituximab in Severe SLE at UCL – Focus on<br />
Clinical and Serological Results<br />
David A. Isenberg, MD; University College; London, England<br />
8:09 p m<br />
Experiences with Rituximab in SLE at University of Rochester –<br />
Focus on B- cells<br />
Ignacio Sanz, MD; University of Rochester; Rochester, NY<br />
8:26 p m<br />
Safety Issues with Rituximab in SLE<br />
Ronald Van Vollenhoven, MD, PhD; Karolinska Hospital;<br />
Stockholm, Sweden<br />
8:43 p m<br />
Other B-Cell Therapies on the Horizon<br />
Vibeke Strand, MD; Stanford University; Portola Valley, CA<br />
8:55 p m<br />
Panel Discussion<br />
<strong>ACR</strong> Study Group<br />
7:45—9:15 p m<br />
Room 261<br />
Clinician Scholar Educator<br />
Moderator:<br />
Joan Marie Von Feldt, MD; University of Pennsylvania;<br />
Philadelphia, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss and apply the method of step-back consultation for<br />
leader educators<br />
∙ Share ideas and pool resources in order to transmit<br />
enthusiasm and knowledge of Rheumatology to a new<br />
generation of Physicians<br />
∙ Facilitate the academic development of new CSE awardees<br />
∙ Promote collaboration of educators in the development of<br />
innovating teaching methods and projects<br />
7:45 p m<br />
CSE Awardee #1<br />
8:150 p m<br />
CSE Awardee #2<br />
8:45 p m<br />
CSE Awardee #3<br />
<strong>ACR</strong> Study Group<br />
7:45—9:15 p m<br />
Room 153<br />
Degos Disease and Related Vasculopathy<br />
Moderator:<br />
J. Patrick Whelan, MD, PhD; Massachusetts General<br />
Hospital; Boston, M<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the unforgettable pathogenous rash<br />
∙ Discuss all literature on treatment for an often fatal disease<br />
∙ Determine the state of research on causation and<br />
pathophysiology<br />
7:45 p m<br />
The Neurologic Catastrophe of Degos Disease<br />
Verne S. Caviness, Jr., MD; Harvard Medical School;<br />
Boston, MA<br />
FRIDAY<br />
8:45 p m<br />
Genetic Considerations in Degos Disease<br />
Constantine A. Stratakis, MD, MDSci; NICHD/ National<br />
Institutes of Health; Bethesda, MD<br />
8:45 p m<br />
Clinical Heterogeneity in Degos Disease<br />
Athanasios Theodoridis, MD; Dessam Medical Center;<br />
Dessam, Germany<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
159
FRIDAY<br />
<strong>ACR</strong> Study Group<br />
7:45—9:15 p m<br />
Room 157<br />
Geriatric Rheumatology<br />
Moderators:<br />
Yuri R. Nakasato, MD; University of North Dakota,<br />
MeritCare Broadway Health Center; Fargo, ND<br />
Raymond L. Yung, MB, ChB; East Ann Arbor Health and<br />
Geriatrics Center; Ann Arbor, MI<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe how genetic factors predispose and influence the<br />
severity and course of elderly onset RA<br />
∙ Outline a systemic approach for musculoskeletal<br />
disability and evaluate the deleterious consequences of<br />
musculoskeletal aging of bones and muscles<br />
7:45 p m<br />
Elderly Onset Rheumatoid Arthritis (EORA)<br />
Veena K. Ranganath, MD; University of Californai–Los<br />
Angeles; Los Angeles, CA<br />
8:15 p m<br />
A Model of Musculoskeletal Disability<br />
Luigi Ferrucci, MD, PhD; National Institute on Aging,<br />
National Institutes of Health; Balitmore, MD<br />
8:45 p m<br />
Osteopenia and Sarcopenia<br />
Nancy E. Lane, MD; University of California at Davis<br />
Medical Center; Sacramento, CA<br />
<strong>ACR</strong> Study Group<br />
7:45—9:15 p m<br />
Room 259<br />
Inflammation<br />
Moderator:<br />
Dorian O. Haskard, DM; Imperial College; London, England<br />
Upon completion of this session, participants should be able to:<br />
∙ Review basic molecular mechanisms of apoptic cell uptake<br />
by macrophages<br />
∙ Discuss the macrophage signaling mechanisms induced by<br />
apoptotic cells that result in anti-inflammatory responses<br />
∙ Distinguish the mechanisms that allow macrophages to<br />
resist programmed cell death in chronic synovitis<br />
8:15 p m<br />
Macrophage Signaling Events Triggered by Apoptotic Cells<br />
Jerrold S. Levine, MD; University of Illinois; Chicago, IL<br />
8:45 p m<br />
Molecular Mechanisms of Macrophage Survival in Chronic<br />
Synovitis<br />
Richard M. Pope, MD; Northwestern University Feinberg;<br />
Chicago, IL<br />
<strong>ACR</strong> Study Group<br />
7:45—9:15 p m<br />
Room 104<br />
Interstitial Lung Disease in the Rheumatic Diseases<br />
Moderators:<br />
Paul F. Dellaripa, MD; Brigham and Women’s Hospital;<br />
Boston, MA<br />
Kristin B. Highland, MD; Medical University of South<br />
Carolina; Charleston, SC<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss emerging data regarding the natural history of ILD<br />
in RA and other rheumatic diseases<br />
∙ Discuss important concepts regarding pathophysiology that<br />
lead to ILD in a subset of patients with rheumatic diseases<br />
∙ Discuss the controversies regarding treatment options in<br />
this group of patients<br />
7:45 p m<br />
The Natural History of ILD in RA<br />
Eric L. Matteson, MD; Mayo Clinic; Rochester, MN<br />
8:15 p m<br />
Pathogenesis of Interstitial Lung Disease in Rheumatic Diseases<br />
Kevin K. Brown, MD; National Jewish Medical and<br />
Research Center; Denver, CO<br />
8:45 p m<br />
Treatment Options in ILD and the Rheumatic Diseases<br />
Athol U. Wells, MD; Royal Brompton Hospital; Chelsea,<br />
London, England<br />
7:45 p m<br />
Molecular Mechanisms of Apoptotic Cell Recognition and<br />
Removal<br />
Keith B. Elkon, MD; University of Washington; Seattle, WA<br />
Study Groups are not eligible for CME credit.<br />
160<br />
= Recorded Sessions (order form on page 430)
<strong>ACR</strong> Study Group<br />
7:45—9:15 p m<br />
Room 260<br />
Joint Hypermobility Syndrome<br />
Moderator:<br />
Jaime F. Bravo, MD; Clinica Arauco and San Juan de Dios<br />
Hospital; Santiago, Chile<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the importance and frequency of JHS<br />
∙ Determine how to suspect the diagnosis: Typical face,<br />
marfanoid habitus, and family history<br />
∙ Discuss Beighton and Brighton criteria for the diagnosis<br />
of JHS<br />
7:45 p m<br />
Preparing a Slide Collection on the Hereditary Diseases of the<br />
Connective Tissues (HDCT)<br />
Jaime F. Bravo, MD; Clinica Arauco and San Juan de Dios<br />
Hospital; Santiago, Chile<br />
<strong>ACR</strong> Study Group<br />
7:45—9:15 p m<br />
Room 258<br />
Latin <strong>American</strong> Study Group<br />
Moderator:<br />
Luis J. Jara Quezada, MD; Hosp Esp Centro Medico<br />
LaRaza; Mexico City, Mexico<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the distinct epidemiological and clinical<br />
characteristics of lupus in Mexico<br />
∙ Identify common susceptibility gene variants that may<br />
represent risk factors for autoimmunity<br />
∙ Discuss the clinical and therapeutic experience of APS<br />
in Brazil<br />
7:45 p m<br />
Introduction<br />
Michael D. Lockshin, MD; Cornell Medical Center; New<br />
York, NY<br />
8:15 p m<br />
Revision of the Joint Hypermobility Syndrome (JHS)<br />
Criteria (Beighton and Brighton)<br />
Rodney Grahame, MD; University College, London<br />
Hospitals; London, England<br />
8:45 p m<br />
Discussion of the Rotes and Hospital del Mar JHS Criteria<br />
Antonio Buldbena, MD; Institut Atención Psiquiátrica,<br />
Hospital del Mar, University; Barcelona, Spain<br />
Discussions<br />
Alan J. Hakim, MD; Whipps Cross University Hospital;<br />
London, England<br />
Lars Remvig, MD; Copenhagen University Hospital;<br />
Copenhagen, Denmark<br />
7:55 p m<br />
Lupus: Mexican Experience<br />
Mary-Carmen Amigo, MD; ABC Medical Center; Mexico<br />
City, Mexico<br />
8:15 p m<br />
Multiple Autoimmune Disease in Latin America<br />
Juan-Manuel Anaya, MD; CIB; Medellin, Colombia<br />
8:35 p m<br />
Antiphospholipid Syndrome: Brazilian Experience<br />
Roger A. Levy, MD, PhD; University Estado Do Rio De<br />
Janeiro; Rio de Janeiro, Brazil<br />
<strong>ACR</strong> Study Group<br />
7:45—9:15 p m<br />
Room 257<br />
Magnetic Resonance Imaging (MRI)<br />
Moderator:<br />
Mikkel Ostergaard, MD, PhD, DMSc; Copenhagen<br />
University Hospital at Hvidovre; Hvidovre, Denmark<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify the histopathological background of MRI bone<br />
oedema (osteitis), based on animal models and humans<br />
∙ Discuss the clinical significance of MRI bone marrow<br />
(osteitis) in RA and spondyloarthritis<br />
FRIDAY<br />
7:45 p m<br />
MRI Bone Marrow Oedema in Rheumatological Diseases - An<br />
Introduction<br />
Mikkel Ostergaard, MD, PhD, DMSc; Copenhagen<br />
University Hospital at Hvidovre; Hvidovre, Denmark<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
161
FRIDAY<br />
7:55 p m<br />
Lessons from RA and OA Clinical Studies - The Clinical<br />
Significance of MRI Bone Marrow Oedema<br />
Fiona M. McQueen, MD; University of Auckland;<br />
Auckland, NZ<br />
8:15 p m<br />
Lessons from Spondyloarthritis Clinical Studies - The Clinical<br />
Significance of MRI Bone Marrow Oedema<br />
Joachim Sieper, MD; Charite Campus Benjamin Frankl;<br />
Berlin, Germany<br />
8:35 p m<br />
MRI Bone Marrow Oedema - Lessons From Histopathological<br />
Studies in Animal Models and Humans<br />
Georg Schett, MD; Institute for Clinical Immunology;<br />
Erlangen, Germany<br />
8:52 p m<br />
Panel Discussion<br />
<strong>ACR</strong> Study Group<br />
7:45—9:15 p m<br />
Room 156<br />
Metabolic Bone<br />
Moderator:<br />
Ellen M. Field, MD; Gateway Professional Center;<br />
Bethlehem, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Review pathophysiology and microarchitectural aspects of<br />
glucocorticoid induced osteoporosis<br />
∙ Discuss importance of diagnosis and treatment<br />
∙ Discuss importance of prevention of glucocorticoid<br />
induced osteoporosis<br />
∙ Discuss pathogenesis and epidemiology of glucocorticoid<br />
induced osteoporosis<br />
7:45 p m<br />
Clinical Update on Glucocorticoid Induced Osteoporosis -<br />
Diagnosis, Treatment and Prevention<br />
Kenneth G. Saag, MD, MSc; University of Alabama at<br />
Birmingham; Birmingham, AL<br />
8:25 p m<br />
Pathogenesis, Epidemiology and Microarchitectural Damage in<br />
Glucocorticoid Induced Osteoporosis<br />
Willem Lems, MD, PhD; Free University Hospital;<br />
Amsterdam, Netherlands<br />
<strong>ACR</strong> Study Group<br />
7:45—9:15 p m<br />
Room 205<br />
Scleroderma<br />
Moderator:<br />
Robert A. Lafyatis, MD; E5 Arthritis Center-BUSM;<br />
Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Understand the latest investigation information on fibrosis<br />
∙ Understand current methods for evaluating and treating<br />
skin and lung fibrosis<br />
7:45 p m<br />
Pathogenesis of Dermal Fibrosis<br />
John Varga, MD; Northwestern University Feinberg School;<br />
Chicago, IL<br />
8:15 p m<br />
Pulmonary Fibrosis in Systemic Sclerosis<br />
Richard M. Silver, MD; Medical University of South<br />
Carolina; Charleston, SC<br />
8:45 p m<br />
Discussion<br />
<strong>ACR</strong> Study Group<br />
7:45—9:15 p m<br />
Room 102<br />
WHO ILAR COPCORD (Community Oriented <strong>Program</strong><br />
for Control of Rheumatic Diseases)<br />
Moderators:<br />
Abraham G. Kutzbach, MD;<br />
Hans Rasker, Professor, MD; Enschede, THE<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the achievements and scope of WHO ILAR<br />
COPCORD<br />
∙ Discuss the epidemiology of MSK pain with special<br />
reference to community beliefs and perceptions<br />
∙ Discuss how to conduct a COPCORD survey<br />
7:45 p m<br />
COPCORD<br />
Arvind A. Chopra, MD, DNB; PCRD-Hermes Doctor<br />
House; Pune, India<br />
Study Groups are not eligible for CME credit.<br />
162<br />
= Recorded Sessions (order form on page 430)
7:55 p m<br />
COPCORD Bhigwan Model<br />
Manjit Saluja, BSc; Center for Rheumatic Diseases; Camp,<br />
Pune, India<br />
8:10 p m<br />
COPCORD Asian Snapshots: India<br />
Alakendu Ghosh, MD;<br />
8:22 p m<br />
COPCORD Asian Snapshots: China<br />
Sheng-Ming Dai, MD; Shanghai, Peoples Rep/China<br />
8:46 p m<br />
COPCORD Asian Snapshots: Other Perspectives<br />
Syed A. Haq, FCPS, MD; Bangabandhuk Sheikh Mujib<br />
Med; Dhaka, Bangladesh<br />
9:00 p m<br />
Collate Data, Future Agenda<br />
Arvind A. Chopra, MD, DNB; PCRD-Hermes Doctor<br />
House; Pune, India<br />
8:34 p m<br />
COPCORD Asian Snapshots: Iran<br />
Fereydoun Davatchi, MD; Tehran University for Medical<br />
Sciences; Tehran, Iran<br />
><br />
Do you have a strong interest in a particular<br />
area of rheumatology and would like to<br />
create a forum to network with others<br />
who share your same interests?<br />
FRIDAY<br />
Submit Your Application for a Study Group<br />
for the 2008 Annual <strong>Meeting</strong><br />
Then consider submitting an application to coordinate a study group for the 2008 <strong>ACR</strong><br />
Annual <strong>Scientific</strong> <strong>Meeting</strong> in San Franciso.<br />
Go to www.rheumatology.org/annual/08meeting.asp for complete guidelines and<br />
to submit your application online. Applications must be submitted online no later than<br />
November 16 using the official application and must include a copy of the final program and<br />
a budget in order to be considered complete.<br />
The <strong>ACR</strong> will approve 20 study groups annually. Approval of additional applications will<br />
be at the <strong>ACR</strong>’s discretion, and additional study groups may be added depending on space<br />
availability. CME credits are not provided for study groups.<br />
We look forward to receiving your application!<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
163
Poster Session b<br />
Friday, November 9<br />
8:00 a m—4:30 pm<br />
Exhibit Hall A-B<br />
Cytokines, Mediators and Gene Regulation II<br />
(1)-769. Interferons Limit Cell Cycle Progression in Rheumatoid<br />
Arthritis Fibroblast-like Synoviocytes and Induce Expression of the<br />
Cell Cycle Inhibitor p21Waf1/Cip1. Trieneke C.G. Timmer 1 ,<br />
Pia V. Kasperkovitz 1 , Sonja I. Gringhuis 1 , Bert van het Hof 1 ,<br />
Tom W.J. Huizinga 2 , Cornelis L. Verweij 1 . 1 VU Medical<br />
Center, Amsterdam, The Netherlands; 2 LUMC, Leiden,<br />
The Netherlands.<br />
(2)-770. IL-20 and IL-24 in Rheumatoid Arthritis and<br />
Spondyloarthropathy. Tue W. Kragstrup 1 , Kristian Otkjaer 2 ,<br />
Christian Holm 1 , Annette Jørgensen 3 , Marianne Hokland 1 ,<br />
Lars Iversen 2 , Bent Deleuran 4 . 1 Institute of Medical<br />
Microbiology and Immunology, Aarhus University, Aarhus,<br />
Denmark; 2 Department of Dermato-Venereology, Aarhus<br />
University Hospital, Aarhus, Denmark; 3 Department of<br />
Rheumatology, Aarhus University Hospital, Aarhus, Denmark;<br />
4<br />
Institute of Medical Microbiology and Immunology, Aarhus<br />
University and Department of Rheumatology, Aarhus<br />
University Hospital, Aarhus, Denmark.<br />
(3)-771. The Effects of the Alpha 7 Nicotinic Acetylcholine<br />
Receptor on Fibroblast-Like Synoviocytes from Rheumatoid<br />
Arthritis Patients: A Possible Link between the Neurological<br />
System and Inflammation. Marjolein A. van Maanen 1 , Esmerij<br />
P. van der Zanden 1 , Wouter J. de Jonge 1 , Margriet J.<br />
Vervoordeldonk 2 , Paul P. Tak 1 . 1 Academic Medical Center,<br />
Amsterdam, The Netherlands; 2 Arthrogen BV, Amsterdam,<br />
The Netherlands.<br />
(4)-772. Expression of MicroRNA-146 in Rheumatoid Arthritis<br />
Synovial Tissue. Tomoyuki Nakasa 1 , Shigeru Miyaki 2 ,<br />
Keiichiro Nishida 3 , Mitsuo Ochi 4 , Hiroshi Asahara 5 .<br />
1<br />
Department of Regenerative Biology and Medicine,<br />
National Research Institute for Child Health and<br />
Development, Tokyo, Japan; 2 Department of regenerative<br />
Biology and Medicine, National Research Institute for<br />
Child Health and Development, Tokyo, Japan; 3 Department<br />
of Human Morphology, Okayama University, Okayama,<br />
Japan; 4 Department of Orthopaedic Surgery, Hiroshima<br />
University, Hiroshima, Japan; 5 Department of Molecular<br />
and Experimental Medicine, the Scripps Research Institute,<br />
San Diego, CA.<br />
(5)-773. Nuclear Orphan Receptor Nurr1 is a Target of<br />
Macrophage Migration Inhibitory Factor in Rheumatoid<br />
Fibroblast-like Synoviocytes. Jennifer A. Ralph, Eric F. Morand.<br />
Monash University, Melbourne, Victoria, Australia.<br />
(6)-774. The Cell Cycle Inhibitor p21 is a Regulator of IL-1β<br />
Maturation in Macrophages and Prevents Endotoxic Shock. John<br />
C. Scatizzi, Jack Hutcheson, Harris Perlman. Saint Louis<br />
University, St. Louis, MO.<br />
(7)-775. Slug Suppression Induces Apoptosis of Fibroblast-Like<br />
Synoviocytes Via Puma Transactivation. Hoon-Suk Cha 1 , Eun-<br />
Kyung Bae 2 , Jinhee Kim 2 , Kwang-Sung Ahn 2 , Joong Kyung<br />
Ahn 1 , Chan Hong Jeon 3 , Eun-Mi Koh 1 . 1 Samsung Medical<br />
Center, Sungkyunkwan University School of Medicine,<br />
Seoul, Republic of Korea; 2 Samsung Biomedical Research<br />
Institute, Seoul, Republic of Korea; 3 Soonchunhyang<br />
University College of Medicine, Seoul, Republic of Korea.<br />
(8)-776. Cyclooxygenase (COX)-2 Inhibitor-Mediated Disruption<br />
of Reverse Cholesterol Transport is Corrected by Adenosine A2A<br />
Receptor (A2AR)Activation. Allison B. Reiss 1 , Hongwei<br />
Zhang 1 , Sari D. Edelman 1 , Steven E. Carsons 1 , Patricia<br />
Fernandez 2 , Edwin S. Chan 2 . 1 Winthrop University<br />
Hospital, Mineola, NY; 2 NYU School of Medicine, New<br />
York, NY.<br />
(9)-777. Adiponectin Stimulates Production of Interleukin-8 from<br />
Rheumatoid Synovial Fibroblasts. Kanako Kitahara, Natsuko<br />
Kusunoki, Terutaka Kakiuchi, Toru Suguro, Shinichi<br />
Kawai. Toho University School of Medicine, Tokyo, Japan.<br />
(10)-778. Inhibition by Hyaluronan of Nitric Oxide Production<br />
through Nuclear Factor-κB Down-Regulation in Rheumatoid<br />
Chondrocytes Stimulated with COOH-Terminal Heparin-Binding<br />
Fibronectin Fragment. Tadashi Yasuda. Tenri University,<br />
Tenri, Japan.<br />
(11)-779. Identification of Genomic Targets in Fibroblast-like<br />
Synoviocytes Downstream of p38 Mitogen-Activated Protein Kinase<br />
Pathway Mediating Tumor Necrosis Factor α-Signaling. Jai M.<br />
Shin, Cindy Zer, George Sachs. UCLA, Los Angeles, CA.<br />
(12)-780. Interferon-gamma (IFNγ) Blocks Adenosine Receptor-<br />
Mediated Induction of Collagen Production in Hepatic Stellate<br />
Cells. Eric Block, Bruce N. Cronstein. NYU School of<br />
Medicine, New York, NY.<br />
(13)-781. Microarray Analysis of Human Telomerase Transduced<br />
Osteoarthritis Fibroblast-like Synoviocytes. Yubo Sun 1 , Bryan<br />
Loeffler 1 , Gary Firestein 2 , David Mauerhan 1 , Helen Gruber 1 ,<br />
Edward Hanley 1 . 1 Carolinas Medical Center, Charlotte, NC;<br />
2<br />
University of California San Diego, La Jolla, CA.<br />
(14)-782. IL-1 Induces Rapid Chondrocyte PGE2 Synthesis via<br />
Nuclear Translocation of Constitutive cPGES to Interact with<br />
COX-1. Nada Marjanovic, Jean Y. Park, Mukundan Attur,<br />
Hayf Al-Mussawir, Mandar Dave, Adam Mor, Aryeh M.<br />
Abeles, Michael H. Pillinger, Steven B. Abramson. NYU<br />
School of Medicine, New York, NY.<br />
164 (Permanent Board Number)-Abstract Number
(15)-783. Aminopeptidase N is a Useful Marker in Pulmonary<br />
and Pleural Involvements of Collagen Vascular Diseases. Kenji<br />
Tani, Keiko Sato, Jun Kishi, Saburo Sone. Tokushima<br />
University, Tokushima, Japan.<br />
(16)-784. Downregulation of the Endothelin System in GianT-<br />
Cell Arteritis Lesions. Ester Lozano, Marta Segarra, Ana<br />
García-Martínez, Marc Corbera-Bellalta, Georgina Espigol,<br />
José Hernández-Rodríguez, María C. Cid. Hospital Clinic,<br />
University of Barcelona, IDIBAPS, Barcelona, Spain.<br />
(17)-785. Down Regulation of Heme Oxygenase 1 by Tumor<br />
Necrosis Factor and Lipopolysaccharide Amplify Inflammatory<br />
Responses in Human Peripheral Monocytes. Yohei Kirino,<br />
Mitsuhiro Takeno, Shuji Murakami, Masayoshi Kobayashi,<br />
Haruko Ideguchi, Shigeru Ohno, Atsuhisa Ueda, Yoshiaki<br />
Ishigatsubo. Yokohama City University Graduate School of<br />
Medicine, Department of Internal Medicine and Clinical<br />
Immunology, Yokohama, Japan.<br />
(18)-786. IL-17 Differentially Modulates Monocyte Chemattractant<br />
Chemokines in Rheumatoid Arthritis Synovial Tissue Fibroblasts<br />
and Peripheral Blood Differentiated Macrophages. Shiva Shahrara,<br />
Richard Pope. NorthwesternUniversity Feinberg School of<br />
Medicine, Chicago, IL.<br />
(19)-787. Inhibition of Systemic LPS-Induced Cytokine Release in<br />
Mice is Independent of the α7 Nicotinic Acetylcholine Receptor.<br />
Kelly R. Long 1 , Robert C. Chott 1 , Donald E. Frail 1 , Lisa M.<br />
Olson 2 . 1 Pfizer, Chesterfield, MO; 2 Abbott, Worcester, MA.<br />
(20)-788. Reelin, A Serine Protease of The Extracellular Matrix, is<br />
Expressed by Fibroblast-like Synoviocytes and is Secreted into Synovial<br />
Fluid. Laura Pattacini, Bruno Casali, Alberto Magnani, Luigi<br />
Boiardi, Davide Nicoli, Enrico Farnetti, Carlo Salvarani.<br />
Arcispedale S Maria Nuova, Reggio Emilia, Italy.<br />
(21)-789. Association of the -14035 A/T Promoter Polymorphism<br />
of the IL-15 Gene with the IL-15 Production in Patients with<br />
Rheumatoid Arthritis: A Possible New Prognostic Factor of<br />
the Disease Progression. Petr Nemec 1 , Monika Pavkova -<br />
Goldbergova 2 , Martina Stouracova 3 , Jindra Gatterova 4 ,<br />
Anna Vasku 2 , Miroslav Soucek 5 . 1 Rheumatology Unit,<br />
2nd Dept. of Internal Medicine, St. Anne’s University<br />
Hospital, Brno, Czech Republic; 2 Institute of Pathological<br />
Physiology, Faculty of Medicine Masaryk University, Brno,<br />
Czech Republic; 3 Institute of Clinical Immunology and<br />
Allergology, St. Anne’s University Hospital, Brno, Czech<br />
Republic; 4 Institute of Rheumatology, Prague, Czech<br />
Republic; 5 2nd Dept. of Internal Medicine, St. Anne’s<br />
University Hospital, Brno, Czech Republic.<br />
(22)-790. Association between Bioactive Circulating TNF Level<br />
and TNFGene Polymorphism at -308 in Rheumatoid Arthritis: Link<br />
to Response to Anti-TNF Treatment. Hubert Marotte, Béatrice<br />
Arnaud, Jennifer Diasparra, Alexandre Pachot, Bruno<br />
Mougin, Pierre Miossec. Hospices Civils de Lyon-bioMérieux<br />
Research Unit on Rheumatoid Arthritis, Lyon, France.<br />
(23)-791. The Activity of STAT-1, STAT-3, STAT-6 and iNOS<br />
in Peripheral Blood Leucocytes in Patients with Rheumatoid<br />
Arthritis. Beata Nowak 1 , Marta Madej 1 , Magdalena A.<br />
Sokalska-Jurkiewicz 1 , Anna Czarny 2 , Ewa Zaczyńska 2 , Piotr<br />
Wiland 1 , Jacek Szechiński 1 . 1 Medical University of Wrocław,<br />
Wrocław, Poland; 2 Polish Academy of Sciences,Institute of<br />
Immunology and Experimental Therapy, Wrocław, Poland.<br />
(24)-792. IL-15, IL-15rα, IL-18 and IL-18rα Expression Levels<br />
Specifically Correlate to IL-7 and IL-7rα Expression Levels in RA<br />
Patients with Persistent Arthritis of the Knee. Joel AG van Roon,<br />
Marion JG Wenting-van Wijk, Kim MG Jacobs, Johannes<br />
WJ Bijlsma, Floris PJG Lafeber. University Medical Center<br />
Utrecht, Rheumatology & Clinical Immunology, Utrecht,<br />
The Netherlands.<br />
(25)-793. The Function of CD1d Variants in Patients with<br />
Autoimmune Disease. Daisuke Goto, Yohei Yoshiga, Seiji<br />
Segawa, Isao Matsumoto, Satoshi Ito, Akito Tsutsumi,<br />
Takayuki Sumida. University of Tsukuba, Tsukuba, Japan.<br />
(26)-794. Adiponectin Induces Cyclooxygenase-2 and Membrane-<br />
Associated Prostaglandin E Synthase-1 Expressions in Rheumatoid<br />
Synovial Fibroblasts. Natsuko Kusunoki, Kanako Kitahara,<br />
Toru Suguro, Shinichi Kawai. Toho University School of<br />
Medicine, Tokyo, Japan.<br />
(27)-795. Activation of Stat-1, Stat-3, Stat-6 and iNOS in Early<br />
Arthritis. Magdalena A. Sokalska-Jurkiewicz 1 , Beata Nowak 1 ,<br />
Marta Madej 1 , Anna Czarny 2 , Ewa Zaczynska 2 , Piotr<br />
Wiland 1 , Jacek Szechinski 1 . 1 Wroclaw Medical University,<br />
Wroclaw, Poland; 2 Polish Academy of Sciences, Institute of<br />
Immunology and Experimental Therapy, Wroclaw, Poland.<br />
(28)-796. NURR1 Promotes an Aggressive Synoviocyte<br />
Phenotype by Inducing MMP-13 Gene Expression and Enhancing<br />
Proliferation. Kimberlee S. Mix, Jason P. McMorrow, Evelyn<br />
P. Murphy. University College Dublin, Dublin, Ireland.<br />
(29)-797. Acute Serum Amyloid A Upregulates TNFα Expression in<br />
RA Synovial Tissue Explants & Induces Cell Migrational Processes.<br />
Mary Connolly, Jennifer McCormick, Ronan Mullan, Barry<br />
Bresnihan, Oliver FitzGerald, Douglas Veale, Ursula Fearon.<br />
St. Vincent’s University Hospital, Dublin, Ireland.<br />
Poster Session B<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 165
Poster Session b<br />
Friday, November 9<br />
8:00 a m—4:30 pm<br />
Exhibit Hall A-B<br />
Epidemiology and Health Services Research II<br />
(30)-798. Michigan Lupus Epidemiology & Surveillance<br />
(MILES) <strong>Program</strong>: Preliminary Prevalence Estimates for SLE in<br />
Southeastern Michigan, 2002-2005. Emily C. Somers 1 , Emily<br />
E. Lewis 1 , Sheeja Francis 1 , Peter DeGuire 2 , Diane Shaltis 1 ,<br />
Elizabeth Curry 1 , Lauren Levy 1 , Carol VanHuysen 1 , Wendy<br />
Marder 1 , Patricia Cagnoli 1 , Thomas Kallarackal-Maliakal 1 ,<br />
James Leisen 3 , J. Patricia Dhar 4 , W. Joseph McCune 1 .<br />
1<br />
University of Michigan Health System, Ann Arbor, MI;<br />
2<br />
Michigan Department of Community Health, Lansing, MI;<br />
3<br />
Henry Ford Health, Detroit, MI; 4 Wayne State University,<br />
Detroit, MI.<br />
(31)-799. Systemic Lupus Erythematosus Mortality Rates Trends<br />
in a Developing Country. Emilia I. Sato 1 , Deborah CC Souza 1 ,<br />
Augusto H. Santo 2 . 1 Universidade Federal de Sao Paulo,<br />
Sao Paulo - Capital, Brazil; 2 Universidade de Sao Paulo, Sao<br />
Paulo - Capital, Brazil.<br />
(32)-800. Lower-Than-Median Normal Range Serum Prolactin<br />
Levels (
(43)-815. Prevalence of Rheumatic Musculoskeletal Disorders<br />
(RMSK) in a West India Urban Population: A Bone and Joint<br />
Decade (BJD) India ‘Burden of Disease’ Project. Vaijayanti<br />
Lagu-Joshi, Ekta Chanchani, Manjit Saluja, Anuradha<br />
Venugopalan, Arvind Chopra. Center for Rheumatic<br />
Diseases, Pune, India.<br />
(44)-816. Prevalence of Rheumatic Diseases and Disability in<br />
an Urban Marginal Latin <strong>American</strong> Population: A Community<br />
Based Study Using the Copcord Model Approach. Rocio<br />
Gamboa 1 , Mariela Medina 1 , Eduardo Acevedo 1 , Cesar<br />
Pastor 1 , Mariano Cucho 1 , Cesar Gutierrez 2 , Cesar Sanchez 1 ,<br />
Risto Perich 1 , Jose Alfaro 1 , Alfredo Sanchez 1 , Manuel<br />
Ugarte 1 , Karina La Madrid 1 , Francisco Zevallos 1 , Omar<br />
Barrientos 3 . 1 HNGAI, Lima, Peru; 2 UNMSM., Lima, Peru;<br />
3<br />
CS Tambo Viejo, Lima, Peru.<br />
(45)-817. Racial/ethnic Differences In Disability Among Older<br />
Adults: The Case Of Spanish Speakers. Huan J. Chang, Manasi<br />
Tirodkar, Jing Song, Rowland W. Chang, Dorothy D.<br />
Dunlop. Northwestern University, Chicago, IL.<br />
(46)-818. Prevalence of Pediatric Arthritis, United States, 2001-<br />
2004. Jeffrey J. Sacks 1 , Charles Helmick 1 , Yao-Hua Luo 1 ,<br />
Norman Ilowite 2 . 1 CDC, Atlanta, GA; 2 Albert Einstein<br />
College of Medicine, Bronx, NY.<br />
(47)-819. Cancer Risk Among Patients with Rheumatoid Arthritis<br />
(RA) Treated with Common RA Medications: An Analysis of a Large<br />
Cohort of U.S.. W. Dong, T. Dube, M. Taylor, B. Wagner, D.<br />
Yocum, P. Napalkov. Genentech, South San Francisco, CA.<br />
(48)-820. Observed and Expected Malignancies in the<br />
Rheumatoid Arthritis Abatacept Clinical Development <strong>Program</strong>:<br />
An Updated Epidemiological Assessment. T. A. Simon 1 , A. L.<br />
Smitten 2 , M. Meng 1 , S. Suissa 3 , for the Epidemiology Study<br />
Group, J. Askling 4 , J. Franklin 5 , M. Hochberg 6 , D. Lacaille 7 ,<br />
F. Wolfe 8 . 1 Bristol-Myers Squibb, Hopewell, NJ; 2 Duke<br />
Univ Sch of Med, Durham, NC; 3 McGill Univ, Montreal,<br />
PQ, Canada; 4 Karolinska Inst, Stockholm, Sweden; 5 ARC<br />
Epidem Unit, Manchester, United Kingdom; 6 Univ of<br />
Maryland, Baltimore, MD; 7 Univ of British Columbia,<br />
Vancouver, BC, Canada; 8 Nat’l Data Bank for Rheum<br />
Diseases, Wichita, KS.<br />
(49)-821. Observed and Expected Hospitalized Infections in<br />
the Abatacept Clinical Development <strong>Program</strong>: An Updated<br />
Epidemiological Assessment. T. A. Simon 1 , A. L. Smitten 2 , M.<br />
Meng 1 , for the Epidemiology Study Group, J. Franklin 3 , J.<br />
Askling 4 , D. Lacaille 5 , F. Wolfe 6 , S. Suissa 7 , M. Hochberg 8 .<br />
1<br />
Bristol-Myers Squibb, Hopewell, NJ; 2 Duke Univ School<br />
of Medicine, Durham, NC; 3 ARC Epidemiology Unit,<br />
Manchester, United Kingdom; 4 Karolinska Institute,<br />
Stockholm, Sweden; 5 Univ of British Columbia, Vancouver,<br />
BC, Canada; 6 National Data Bank for Rheumatic Diseases,<br />
Wichita, KS; 7 McGill Univ, Montreal, PQ, Canada; 8 Univ<br />
of Maryland, Baltimore, MD.<br />
Presentation numbers 822–824 are assigned to Genetics, Genomics and<br />
Proteomics II category. See page 168.<br />
(50)-825. Serious Infection among Patients with Rheumatoid<br />
Arthritis (RA) Treated with Common RA Medications: Analysis<br />
of a Large U.S. Cohort. P. Napalkov, T. Dube, M. Taylor, B.<br />
Wagner, D. Yocum, W. Dong. Genentech, San Francisco, CA.<br />
(51)-826. Use of Cyclooxygenase-2 Inhibitors in Patients with<br />
Myocardial Infarction and its Impact on Cardiovascular Outcome.<br />
Alain Vanasse, Josiane Courteau, Artur J. De-Brum Fernandes.<br />
Université de Sherbrooke, Sherbrooke, PQ, Canada.<br />
(52)-827. Upper and Lower Gastrointestinal Perforations Among<br />
RA Patients Treated with Methotrexate Alone or in Combination.<br />
Ani K. John 1 , Thasia Woodworth 2 , Randall Stevens 3 , Kathy<br />
Schulman 4 , Susan Sacks 3 . 1 Roche Laboratories Inc., Nutley,<br />
NJ; 2 Roche Products, Ltd., Welwyn, United Kingdom;<br />
3<br />
Hoffmann La Roche, Nutley, NJ; 4 Thompson Healthcare,<br />
Cambridge, MA.<br />
(53)-828. Rheumatoid Arthritis and Cardiovascular Disease in<br />
a Chinese Population; Findings from the Guangzhou Biobank<br />
Cohort Study. Peymane Adab 1 , Johanna Barlow 1 , Elizabeth<br />
Rankin 2 , K. K. Cheng 1 , G. Neil Thomas 3 , C. Q. Jiang 4 , W.<br />
S. Zhang 4 , T. H. Lam 3 . 1 The University of Birmingham,<br />
Birmingham, United Kingdom; 2 University Hospital<br />
Birmingham, Birmingham, United Kingdom; 3 The<br />
University of Hong Kong, Hong Kong, China; 4 Guangzhou<br />
Number 12 People’s Hospital, Guangzhou, China.<br />
(54)-829. Breast Feeding and Risk of Rheumatoid Arthritis;<br />
Findings from Guangzhou Biobank Cohort Study. Peymane<br />
Adab 1 , Yee Wah Tsang 1 , Elizabeth Rankin 2 , K. K. Cheng 1 ,<br />
C. Q. Jiang 3 , X. Q. Lao 4 , G. Neil Thomas 4 , W. S. Zhang 3 ,<br />
T. H. Lam 4 . 1 The University of Birmingham, Edgbaston,<br />
Birmingham, United Kingdom; 2 University Hospital<br />
Birmingham, Birmingham, United Kingdom; 3 Guangzhou<br />
Number 12 People’s Hospital, Guangzhou, China; 4 The<br />
University of Hong Kong, Hong Kong, China.<br />
(55)-830. Adalimumab (HUMIRA®) Improves Rheumatoid<br />
Arthritis Outcomes in an Open-Label Extension Study Compared<br />
with a Registry-Based DMARD Control Group. Michael T.<br />
Halpern 1 , Mary Cifaldi 2 , Tore Kvien 3 . 1 Emory University,<br />
Atlanta, GA; 2 Abbott Laboratories, Abbott Park, IL;<br />
3<br />
Diakonhjemmet Hospital, Oslo, Norway.<br />
(56)-831. A Meta-Analysis of the Adverse Events of<br />
Glucocorticoids. Jos N. Hoes, Suzan MM Verstappen,<br />
Johannes WJ Bijlsma, Geert JMG Van der Heijden,<br />
Johannes WG Jacobs. University Medical Center Utrecht,<br />
Utrecht, The Netherlands.<br />
(57)-832. Early Revisions of Total Knee Replacement: Impact of<br />
Time Since Surgery, Provider Volume and Patient’s Risk. Elena<br />
Losina, Elizabeth A. Wright, Jeffrey N. Katz. Brigham and<br />
Women’s Hospital, Boston, MA.<br />
Poster Session B<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 167
Poster Session b<br />
(58)-833. Effect of Socio-Demographic Factors on Time to<br />
Surgical Consultation and Hip/ Knee Replacement Surgery<br />
for Osteoarthritis Patients in British Columbia, Canada. M<br />
Mushfiqur Rahman 1 , Jacek A. Kopec 2 , Philippe Finès 3 ,<br />
William Flanagan 3 , Eric C. Sayre 1 , Donald S. Garbuz 2 ,<br />
Nelson V. Greidanus 2 , Jaafar Aghajanian 1 , Aslam H. Anis 2 ,<br />
Jolanda Cibere 2 , Joanne M. Jordan 4 , Elizabeth M. Badley 5 .<br />
1<br />
Arthritis Research Centre of Canada, Vancouver, BC,<br />
Canada; 2 University of British Columbia, Vancouver,<br />
BC, Canada; 3 Statistics Canada, Ottawa, ON, Canada;<br />
4<br />
University of North Carolina at Chapel Hill, Chapel Hill,<br />
NC; 5 University of Toronto, Toronto, ON, Canada.<br />
(59)-834. Total Joint Replacement Surgery of Hip and Knee<br />
in the Biologics Era. A Time-Trend Analysis From 1997-2005.<br />
Miguel Angel Descalzo 1 , Loreto Carmona 1 , Aurelio Tobias 2 .<br />
1<br />
Spanish Foundation of Rheumatology, Madrid, Spain;<br />
2<br />
National School of Public Health, Madrid, Spain.<br />
(60)-835. The Utilisation of Knee Arthroscopy in England and<br />
Ontario: Inequalities, Changes Over Time, and Relationship<br />
to Total Knee Joint Replacement. Gillian A. Hawker 1 , Jun<br />
Guan 2 , Andy Judge 3 , Paul Dieppe 3 . 1 University of Toronto,<br />
Toronto, ON, Canada; 2 ICES, Toronto, ON, Canada;<br />
3<br />
MRC HSRC, Bristol, United Kingdom.<br />
(61)-836. Age-Related Ethnic Disparities in Arthritis Related Hip<br />
and Knee Surgeries. Dorothy D. Dunlop, Larry M. Manheim,<br />
Jing Song, Rowland W. Chang. Northwestern University,<br />
Chicago, IL.<br />
(62)-837. Impact of Body Mass on Hospital Resource Use in Total<br />
Hip Arthroplasty. John A. Batsis, James M. Naessens, Mark T.<br />
Keegan, Paul M. Huddleston, III, Amy E. Wagie, Jeanne M.<br />
Huddleston. Mayo Clinic, Rochester, MN.<br />
Friday, November 9<br />
8:00 a m—4:30 pm<br />
Exhibit Hall A-B<br />
Genetics, Genomics and Proteomics II<br />
(63)-811. A Genetic Screen of the Type 1 Interferon Pathway in<br />
Human Systemic Lupus Erythematosus. Robert R. Graham 1 ,<br />
Leela R.L. Davies 1 , Christopher Lessard 2 , Noel Burtt 1 ,<br />
Timothy W. Behrens 3 , Deborah S. Cunninghame Graham 4 ,<br />
Timothy J. Vyse 4 , Kathy Moser 2 , David Altshuler 1 , Patrick<br />
M. Gaffney 2 . 1 Broad Institute of Harvard and MIT,<br />
Cambridge, MA; 2 Oklahoma Medical Research Foundation,<br />
Oklahoma City, OK; 3 Genentech, San Francisco, CA;<br />
4<br />
Imperial College, London, United Kingdom.<br />
(64)-812. The MEFV Gene Mutations may Increase the Risk<br />
of Pleuritis and Pericarditis in Patients with Systemic Lupus<br />
Erythematosus. Burak Erer 1 , Fulya Cosan 1 , Basar Oku 1 , Duran<br />
Ustek 2 , Orhan Aral 1 , Ahmet Gul 1 . 1 Istanbul University, Istanbul<br />
Faculty of Medicine, Istanbul, Turkey; 2 Istanbul University,<br />
Institute for Experimental Medicine, Istanbul, Turkey.<br />
(65)-813. Association Of DNase IV Polymorphism With Autoantibodies<br />
In Systemic Lupus Erythematosus Patients. Il Kim 1 , Hee Sun Kim 1 ,<br />
Hye Ryeon Yun 1 , Hyoung Doo Shin 2 , Byung Lae Park 2 , Hyun<br />
Sub Cheong 2 , Sang-Cheol Bae 1 . 1 The Hospital for Rheumatic<br />
Diseases, Hanyang University Medical Center, Seoul, Republic<br />
of Korea; 2 Department of Genetic Epidemiology, SNP<br />
Genetics, Inc., Seoul, Republic of Korea.<br />
(66)-814. Antibody Microarray-Based Serum Protein Profiling<br />
of Systemic Lupus Erythematosus and Systemic Sclerosis. Dirk<br />
M. Wuttge 1 , Anders Carlsson 2 , Johan Ingvarsson 2 , Anders<br />
A. Bengtsson 1 , Roger Hesselstrand 1 , Gunnar Sturfelt 1 ,<br />
Carl AK Borrebaeck 2 , Christer Wingren 2 . 1 Department<br />
of Rheumatology, Lund University Hospital, Sweden;<br />
2<br />
Department of Immunotechnology and CREATE Health,<br />
Lund University, Lund, Sweden.<br />
Presentation numbers 815–821 are assigned to Epidemiology and<br />
Health Services Research II category. See page 167.<br />
(67)-822. The Foxo3a Gene Polymorphism is Associated with<br />
Ankylosing Spondylitis. Seung-Cheol Shim 1 , Dong-Hyuk<br />
Sheen 1 , Mi-Kyoung Lim 1 , Jin-Wuk Hur 1 , Yeong-Shil Joo 1 ,<br />
Soo-Cheon Chae 2 , Hun-Taeg Chung 2 , Tae-Hwan Kim 3 .<br />
1<br />
Eulji university, Daejeon, Republic of Korea; 2 Wonkwang<br />
university, Iksan, Republic of Korea; 3 Hanyang university,<br />
Seoul, Republic of Korea.<br />
(68)-823. Reactivation of Rheumatoid Arthritis after Pregnancy is<br />
Accompanied by Increased Phagocyte and Recurring Lymphocyte<br />
Gene Activity in the Peripheral Blood. Thomas Haeupl 1 ,<br />
Monika Oestensen 2 , Andreas Gruetzkau 3 , Andreas<br />
Radbruch 3 , Gerd-R. Burmester 1 , Peter Villiger 2 . 1 Charite,<br />
Berlin, Germany; 2 Inselspital, Bern, Switzerland; 3 DRFZ,<br />
Berlin, Germany.<br />
(69)-824. Studies on the Genetic Association of MHC Class<br />
I Chain-related Gene A (MICA) with Japanese Patients with<br />
Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus<br />
(SLE). Kohsuke Yoshida 1 , Koichiro Komai 1 , Aya Mashida 1 ,<br />
Miki Murata 2 , Kazuko Shiozawa 2 , Shunichi Shiozawa 1 .<br />
1<br />
Dept. of Rheumatology, FHS School of Med., Kobe Univ.,<br />
Kobe, Japan; 2 Rheumatic Diseases Center, Konan Kakogawa<br />
Hospital, Kakogawa, Japan.<br />
Presentation numbers 825–837 are assigned to Epidemiology and<br />
Health Services Research II category. See page 167.<br />
(70)-838. Investigating CD45 as an SLE Susceptibility Gene.<br />
Sharon A. Chung, Ludmila Pawlikowska, Catherine Chu,<br />
Jorge R. Oksenberg, Pui-Yan Kwok, Lindsey A. Criswell.<br />
University of California, San Francisco, CA.<br />
168 (Permanent Board Number)-Abstract Number
(71)-839. Polymorphisms in the Osteopontin (SPP1) Gene are<br />
Associated with Increased Risk of Developing SLE in Males.<br />
Shizhong Han 1 , Isaac Harley 1 , Andrea L. Sestak 1 , Xana<br />
Kim-Howard 1 , Kenneth M. Kaufman 2 , Gail R. Bruner 1 , Joel<br />
M. Guthridge 1 , Gary S. Gilkeson 3 , John B. Harley 4 , Judith<br />
A. James 1 , Swapan K. Nath 1 . 1 Oklahoma Medical Research<br />
Fopundation, Oklahoma City, OK; 2 VAMC, Oklahoma<br />
City, OK; 3 Medical University of South Carolina,<br />
Charleston, SC; 4 Oklahoma Medical Research Foundation,<br />
VAMC, OUHSC, Oklahoma City, OK.<br />
(72)-840. Anti-IFN-α Antibody Neutralization of Early and Late<br />
Transcriptional Responses in PBMC Stimulated with Serum from<br />
SLE Patients. Wendy L. Trigona, Yihong Yao, Christopher<br />
Morehouse, Melissa de los Reyes, Bo Chen, Jonathan Zmuda,<br />
Jonathan W. Hirsch, Anthony J. Coyle, Peter Kiener, Wendy<br />
I. White, Bahija Jallal. MedImmune Inc, Gaithersburg, MD.<br />
(73)-841. Abnormal Histone Modification Patterns in Lupus<br />
CD4+ T Cells. Nan Hu, Xiangning Qiu, Yongqi Luo, Jun<br />
Yuan, Wenzhi Lei, Xiaoqin Yang, Yaping Li, Guiyin Zhang,<br />
Yin Zhou, Yuwen Su, Qianjin Lu. 2nd Xiangya Hospital,<br />
Central South University, Changsha, China.<br />
(74)-842. BAK1 Polymorphism Influences the Risk of Developing<br />
Autoimmune Rheumatic Diseases. Angelica M. Delgado-Vega 1 ,<br />
John Castiblanco 2 , Adriana Rojas-Villaraga 1 , Juan-Manuel<br />
Anaya 1 . 1 Corporación para Investigaciones Biológicas-<br />
Universidad del Rosario, Medellin, Colombia; 2 Corporación<br />
para Investigaciones Biológicas, Medellin, Colombia.<br />
(75)-843. Association of Killer Immunoglobulin-like Receptor Gene<br />
3DL1/3DS1 Polymorphism with Behçet’s Disease is Stronger in<br />
Male Patients. Julide Duymaz Tozkir, F. Aytul Uyar, Guher<br />
Saruhan Direskeneli, Ahmet Gul. Istanbul University,<br />
Istanbul Faculty of Medicine, Istanbul, Turkey.<br />
(76)-844. Three Dimensional (3-D) Model of the PRYSPRY<br />
Domain of Pyrin: Implications for Disease Severity in Familial<br />
Mediterranean Fever (FMF) and Exploration of Alternative<br />
Pathogenetic Mechanism. George N. Goulielmos 1 , Elias<br />
Eliopoulos 2 , Eleni Petraki 1 , Eleni Fragouli 1 , Prodromos<br />
Sidiropoulos 3 , Debora Gumucio 4 , Dimitrios T. Boumpas 1 .<br />
1<br />
Medical School, University of Crete, Heraklion, Crete,<br />
Greece; 2 Dept. of Agricultural Biotechnology, Agricultural<br />
Univ. of Athens, Greece; 3 Dept. of Rheumatology, Clinical<br />
Immunology and Allergy, University Hospital of Heraklion,<br />
Crete, Greece; 4 Center for Organogenesis, University of<br />
Michigan, Michigan, MI.<br />
(77)-845. Association between Metabolic Enzyme Genotype of<br />
Azathioprine and Drug Tolerance in Patients with Rheumatic Diseases.<br />
Zhong-Ping Zhan 1 , Xiu-Yan Yang 1 , Liu-Qin Liang 1 , Yi-Xi Wang 2 ,<br />
Ming Huang 2 . 1 The First Affiliated Hospital of Sun Yat-Sen<br />
University, Guangzhou, China; 2 School of Pharmaceutical<br />
Sciences, Sun Yat-Sen University, Guangzhou, China.<br />
(78)-846. Peripheral Blood Leukocyte Gene Expression as<br />
Biomarkers of Disease in Knee Osteoarthritis (OA). Svetlana<br />
Krasnokutsky 1 , Mukundan Attur 1 , Ilana Belitskaya-Levy 2 ,<br />
Jeffrey Greenberg 1 , Jonathan Samuels 1 , Stephen Smiles 1 ,<br />
Sicy H. Lee 1 , Jyoti Patel 1 , Hayf E. Al-Mussawir 1 , Steven B.<br />
Abramson 1 . 1 NYUHospital for Joint Diseases, New York,<br />
NY; 2 NYU School of Medicine, Division of Biostatistics,<br />
New York, NY.<br />
(79)-847. Differential Proteome of Mesenchymal Stem Cells from<br />
Osteoarthritis Patients. Raquel Rollín Toledo 1 , Juan Antonio<br />
López 2 , Emilio Camafeita 2 , Enrique Calvo 2 , Fernando<br />
Marco 1 , Benjamín Fernández-Gutiérrez 1 . 1 Hospital Clínico<br />
San Carlos, Madrid, Spain; 2 Unidad de Proteómica. CNIC,<br />
Madrid, Spain.<br />
(80)-848. Mapping the Sequence of the Human Tpl2 to a<br />
Structural Model: Implications to Signaling Defects. Elias<br />
Eliopoulos 1 , Irene Kyrmizi 2 , Dimitrios T. Boumpas 3 , George<br />
N. Goulielmos 3 . 1 Dept. of Agricultural Biotechnology,<br />
Agricultural Univ. of Athens, Athens, Greece; 2 Dept. of<br />
Rheumatology, Clinical Immunology and Allergy, Univ.<br />
Hospital of Heraklion, Heraklion, Greece; 3 Medical School,<br />
Univ. of Crete, Heraklion, Crete, Greece.<br />
(81)-849. Haplotype-Based Gene Mapping within Two Major<br />
Loci on Chromosomes 3 and 19 for Murine Proteoglycan-Induced<br />
Arthritis (PGIA) Identified Several Sub-Loci 2 Mb in Size.<br />
Vyacheslav A. Adarichev, Tibor T. Glant. Rush University<br />
Medical Center, Section of Molecular Medicine, Chicago, IL.<br />
(82)-850. Fine Mapping across the MHC with 2,095 SNPs<br />
Identifies at least Two Regions of Susceptibility Independent of<br />
the DRB1 Locus. Hye-Soon Lee 1 , Wentian Li 1 , Annette<br />
Lee 1 , Franak Batliwalla 1 , Frederick Wolfe 2 , Robert M.<br />
Plenge 3 , Michael F. Seldin 4 , Christopher I. Amos 5 , Daniel<br />
L. Kastner 6 , Lindsey A. Criswell 7 , Peter K. Gregersen 1 .<br />
1<br />
The Feinstein Institute for Medical Research, Manhasset,<br />
NY; 2 National Data Bank for Rheumatic Diseases,<br />
Wichita, KS; 3 Broad Institute of MIT and Harvard,<br />
Cambridge, MA; 4 Department of Biochemistry and<br />
Molecular Medicine, Rowe <strong>Program</strong> in Human Genetics,<br />
University of California, Davis, CA; 5 Department of<br />
Epidemiology, The University of Texas M. D. Anderson<br />
Cancer Center, Houston, TX; 6 National Institute of<br />
Arthritis and Musculoskeletal and Skin Diseases, Bethesda,<br />
MD; 7 Department of Medicine, Rosalind Russell Medical<br />
Research Center for Arthritis, University of California, San<br />
Francisco, CA.<br />
Poster Session B<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 169
Poster Session b<br />
Friday, November 9<br />
8:00 a m—4:30 pm<br />
Exhibit Hall A-B<br />
Miscellaneous Rheumatic and Inflammatory Diseases I<br />
(83)-851. The A3 Adenosine Receptor is Over-Expressed in Auto-<br />
Immune Inflammatory Diseases: Possible Therapuetic Target<br />
and Biological Marker. Avivt Ochaion 1 , Sara Bar Yehuda 1 ,<br />
Shira Cohen 1 , Renana Patoka 1 , Luis Del Valle 2 , Georginia<br />
Perez-Liz 2 , Josef Ophir 3 , Ronit Musberg-Galili 4 , Tatiana<br />
Reitblat 5 , Alex Reitblat 6 , Howard Amital 7 , Pnina Fishman 1 .<br />
1<br />
Can-Fite BioPharma, Petach Tikva, Israel; 2 Department<br />
of Neuroscience, Neuropathology Core & Center for<br />
NeuroVirology, Temple University School of Medicine,<br />
Philadelphia, PA; 3 Edith Wolfson Medical Center, Holon,<br />
Israel; 4 Department of Neurology, Rabin Medical Center,<br />
Petach Tikva, Israel; 5 The Barzilai Medical Center, shkelon,<br />
Israel; 6 The Barzilai Medical Center, Ashkelon, Israel; 7 Internal<br />
Department D, Meir Medical Center, Kfar Saba, Israel.<br />
(84)-852. Elevated BAFF and APRIL Levels in Cerebrospinal<br />
Fluids in Patients with Neuro-behçet’s Disease. Yoshiko Sumita,<br />
Yohko Murakawa, Tomoko Sugiura, Mayuko Moriyama,<br />
Masahiro Kondo, Makoto Kawakami, Shuhei Yamaguchi.<br />
Department of Rheumatology, Shimane University Faculty<br />
of Medicine, Izumo, Japan.<br />
(85)-853. Pulmonary Vascular Involvement in Behçet’s Syndrome<br />
(BS). Emire Seyahi 1 , Melike Melikoglu 1 , Canan Akman 2 ,<br />
Vedat Hamuryudan 1 , Harun Ozer 2 , Gulen Hatemi 1 , Hasan<br />
Tuzun 3 , Izzet Fresko 1 , Sebahattin Yurdakul 1 , Hasan Yazici 1 .<br />
1<br />
Cerrahpasa Medical Faculty, Rheumatology Department,<br />
Istanbul, Turkey; 2 Cerrahpasa Medical Faculty, Department<br />
of Radiology, Istanbul, Turkey; 3 Cerrahpasa Medical<br />
Faculty, Department of Thoracic Surgery, Istanbul, Turkey.<br />
(86)-854. Excessive Expression of Toll-like Receptor 4 Associated<br />
with Down-regulation of Heme Oxygenase 1 Accelerates Inflammatory<br />
Responses in Behçet’s Disease. Yohei Kirino, Mitsuhiro Takeno,<br />
Reikou Watanabe, Shuji Murakami, Masayoshi Kobayashi,<br />
Haruko Ideguchi, Shigeru Ohno, Atsuhisa Ueda, Yoshiaki<br />
Ishigatsubo. Yokohama City University Graduate School of<br />
Medicine, Department of Internal Medicine and Clinical<br />
Immunology, Yokohama, Japan.<br />
(87)-855. Natural Killer Cells Control a Pathogenic Th1 Response<br />
in Patients with Behçet’s Disease. Yukie Yamaguchi 1 , Hayato<br />
Takahashi 2 , Takashi Satoh 2 , Nobuhisa Mizuki 1 , Kazuo<br />
Takahashi 1 , Zenro Ikezawa 1 , Masataka Kuwana 2 . 1 Yokohama<br />
City University Graduate School of Medicine, Yokohama,<br />
Japan; 2 Keio University School of Medicine,Tokyo, Japan,<br />
Tokyo, Japan.<br />
(88)-856. Defective TNF-Receptor Type 1 Function in the TNF-<br />
Receptor Associated Periodic Syndrome (TRAPS). Anna Simon 1 ,<br />
Ravikanth Maddipati 1 , Heiyoung Park 1 , Hirsh Komarow 2 ,<br />
Adrian A. Lobito 1 , Adrianna J. Jackson 1 , Heleen D. de<br />
Koning 1 , Beverly Barham 1 , Daniel L. Kastner 1 , Richard<br />
M. Siegel 1 . 1 NIAMS, NIH, Bethesda, MD; 2 NIAID, NIH,<br />
Bethesda, MD.<br />
(89)-857. Efficacy of the Treatment with Anakinra in TRAPS<br />
Patients. A Pilot Study. Marco Gattorno 1 , Maria Antonietta<br />
Pelagatti 1 , Antonella Meini 2 , Nicoletta Solari 1 , Laura Obici 3 ,<br />
Roberto Barcellona 4 , Sandro Plebani 2 , Gian Paolo Merlini 3 ,<br />
Alberto Martini 1 . 1 G. Gaslini Institute, Genoa, Italy;<br />
2<br />
Clinica Pediatrica, Brescia, Italy; 3 IRCCS S. Matteo, Pavia,<br />
Italy; 4 UO Pediatria, Sciacca (Ag), Italy.<br />
(90)-858. The Platelet Inhibitory Effects of the Combination of<br />
Naproxen Sodium or Acetaminophen with Low Dose Aspirin.<br />
Kay Brune 1 , Marc C. Hochberg 2 , Michael Schiff 3 , John<br />
Oldenhof 4 , Reinhard Schuller 4 , Steve Zlotnick 5 . 1 Friedrich-<br />
Alexander-University Erlangen-Nuremberg, Erlangen,<br />
Germany; 2 University of Maryland School of Medicine,<br />
Baltimore, MD; 3 Denver Arthritis Clinic, Denver, CO;<br />
4<br />
DecisionLine Clinical Research, Toronto, ON, Canada;<br />
5<br />
Bayer HealthCare, Morristown, NJ.<br />
(91)-859. Risk Factors of Drug Interaction between Warfarin<br />
and Nonsteroidal Anti-Inflammatory Drugs. Eun Bong Lee 1 ,<br />
Ah Jeong Kim 2 , Kyung Hee Choi 2 , Eun Young Lee 1 , Hyuk<br />
Ahn 1 . 1 Seoul National University College of Medicine,<br />
Seoul, Republic of Korea; 2 Seoul National University<br />
Hospital, Seoul, Republic of Korea.<br />
(92)-860. Analgesic and Anti-inflammatory Activity Of PC-<br />
NSAIDs in Rodent Models of Acute Joint Inflammation.. Lenard<br />
M. Lichtenberger 1 , Jim Romero 1 , Elizabeth J. Dial 1 , Junhui<br />
Du 2 , Susan Carlton 2 . 1 The University of Texas Medical<br />
School at Houston, Houston, TX; 2 The University of Texas<br />
Medical Branch, Galveston, TX.<br />
(93)-861. Adalimumab as a Novel Therapy for Refractory<br />
Sarcoidosis: Preliminary Results of a 52-Week Trial. Nadera<br />
J. Sweiss 1 , Imre Noth 1 , Robert P. Baughman 2 , Michael<br />
Ellman 1 , James Curran 1 , Kyle Hogarth 1 , Mary Strek 1 , Mary<br />
Strek 1 , Maria-Luisa Alegre 1 , Marcus Clark 1 , Amy Hires 1 ,<br />
Philip Caligiuri 1 , Aileen L. Pangan 3 . 1 University of Chicago,<br />
Chicago, IL; 2 University of Cincinnati Medical Center,<br />
Cincinnati, OH; 3 Abbott Laboratories, Abbott Park, IL.<br />
(94)-862. Clinical Presentation and Treatment Outcomes of<br />
Progressive Neurosarcoidosis: Novel Role for TNF inhibition.<br />
Stephen Goutman 1 , James Curran 1 , James Brorson 1 ,<br />
Helene Rubeiz 1 , Thomas Kelly 1 , Saima Chohan 1 , Avertano<br />
Noronha 1 , Amy Hires 1 , May Azem 2 , Richard Keating 1 , Kyle<br />
Hogarth 1 , Edward Naureckas 1 , Rebecca Shilling 1 , Nadera<br />
J. Sweiss 1 . 1 University of Chicago, Chicago, IL; 2 Cleveland<br />
Clinic, Cleveland, OH.<br />
170 (Permanent Board Number)-Abstract Number
(95)-863. TNF Inhibition As Novel Therapy for Refractory<br />
Sarcoidosis: Long Term Follow up. Nadera J. Sweiss 1 , Robert<br />
P. Baughman 2 , Tara Adkinari 1 , James Curran 1 , Stephen<br />
Goutman 1 , Bernard Rubin 3 , Saima Chohan 1 , Amy Hires 1 ,<br />
Michael Ellman 1 . 1 University of Chicago, Chicago, IL;<br />
2<br />
University of Cincinnati Medical Center, Cincinnati, OH;<br />
3<br />
University of Texas, Fort Worth, TX.<br />
(96)-864. Plasmacytoid Dendritic Cells and IFN-alpha are<br />
Correlated with Depression in Sarcoidosis Patients. Pauline F.<br />
McHugh, Stephen J. Oliver. New York University School of<br />
Medicine, New York, NY.<br />
(97)-865. Tumor Necrosis Factor α Antagonists in the Treatment<br />
of Secondary Amyloidosis. Gulen Hatemi, Koray Tascilar,<br />
Sebahattin Yurdakul, Huri Ozdogan. Istanbul University,<br />
Cerrahpasa Medical School, Division of Rheumatology,<br />
Istanbul, Turkey.<br />
(98)-866. Regression of AL Amyloid Deposition in Fat Tissue of<br />
Patients Achieving a Complete Response of the Free Light Chain<br />
in Serum. Ingrid I. van Gameren, Bouke P. Hazenberg, Johan<br />
Bijzet, Edo Vellenga, Martin H. van Rijswijk. University<br />
Medical Centre Groningen, Groningen, The Netherlands.<br />
(99)-867. Utility of Elevated Acute Phase Reactants in the<br />
Treatment of Retroperitoneal Fibrosis. Marina N. Magrey,<br />
Elaine Husni, Leonard H. Calabrese. Cleveland Clinic,<br />
Cleveland, OH.<br />
(100)-868. Retroperitoneal Fibrosis: Single Center Experience of a<br />
Large Case Series. Marina N. Magrey, Elaine Husni, Leonard<br />
H. Calabrese. Cleveland Clinic, Cleveland, OH.<br />
(101)-869. Beneficial Effects of Early Adjunctive Treatment<br />
Using Rituximab during Acute Refractory Thrombocytopenic<br />
Thrombotic Purpura. Pascale Poullin 1 , Gilles Kaplanski 1 ,<br />
Nicolas Schleinitz 1 , Karin Mazodier 1 , Hervé Chambost 2 ,<br />
Jean-Robert Durand 1 , Jean-Robert Harle 1 , Patrice Lefevre 1 .<br />
1<br />
Hôpital Conception, Marseille, France; 2 Hôpital Timone,<br />
Marseille, France.<br />
(102)-870. Frequent Occurrence of Systemic Rheumatic Disease<br />
Autoantibodies in Thrombotic Thrombocytopenic Purpura Patient<br />
Sera. Douglas W. Warden 1 , James N. George 1 , Sarah K.<br />
Vesely 1 , Judith A. James 2 . 1 OUHSC, Oklahoma City, OK;<br />
2<br />
Oklahoma Medical Research Foundation, Oklahoma City, OK.<br />
(103)-871. Utility of NK Cell Lymphocytopenia and<br />
Increased Levels of Serum IL-18 in the Diagnosis of Reactive<br />
Hemophagocytic LymphoHistiocytosis in Adults.. Karin<br />
Mazodier 1 , Catherine Farnarier 2 , Nicolas Schleinitz 1 ,<br />
Emmanuelle Bernit 1 , Véronique Veit 1 , Corinne Brunet 1 ,<br />
Anderson Londou 2 , Jean-Marc Durand 1 , Charles A.<br />
Dinarello 3 , Jean-Robert Harle 1 , Gilles Kaplanski 1 . 1 Hôpital<br />
Conception, Marseille, France; 2 Hôpital Sainte-Marguerite,<br />
Marseille, France; 3 University of Colorado Health Science<br />
Center, Denver, CO.<br />
(104)-872. Activation of the Type I Interferon Pathway in<br />
Autoimmune Thyroid Disease. Clio P. Mavragani 1 , Stamatina<br />
Danielides 2 , Timothy B. Niewold 1 , Haralampos M.<br />
Moutsopoulos 2 , Mary K. Crow 1 . 1 Hospital for Special<br />
Surgery, New York, NY; 2 Department of Pathophysiology,<br />
School of Medicine, University of Athens, Athens, Greece.<br />
(105)-873. Etanercept but Not Infliximab or Adalimumab<br />
Induces Apoptosis of Fibroblasts-like Synoviocytes. Ori Elkayam,<br />
Jacob N. Ablin, Dan Caspi. Tel Aviv Medical Center, Tel<br />
Aviv, Israel.<br />
(106)-874. Safety and Efficacy of IL-1 Trap in Patients with<br />
Familial Cold Autoinflammatory Syndrome. Sharukh Shroff,<br />
Mildred Wilson, Beverly Barham, Tuyet Hang Pham,<br />
Scott Mellis, Steve Weinstein, Christopher Snyder, Daniel<br />
Kastner, Raphaela Goldbach-Mansky. NIH, Bethesda, MD.<br />
(107)-875. Inefficacy of Imatinib Mesylate in Erdheim-Chester<br />
Disease, Despite Platelet-Derived Growth Factor (PDGF)<br />
Receptor Beta Expression on Histiocytes. Julien Haroche 1 , Zahir<br />
Amoura 1 , Frédéric Charlotte 1 , Bertrand Wechsler 1 , Nicole<br />
Brousse 2 , Jean-Charles Piette 1 . 1 Hôpital Pitié-Salpêtrière, Paris,<br />
France; 2 Hôpital Necker-Enfants Malades, Paris, France.<br />
Friday, November 9<br />
8:00 a m—4:30 pm<br />
Exhibit Hall A-B<br />
Pediatric Rheumatology: Clinical and Therapeutic<br />
Aspects II<br />
(108)-876. B Cell Depletion for Autoimmune Thrombocytopenia<br />
& Autoimmune Hemolytic Anemia in Pediatric Systemic Lupus<br />
Erythematosus; A Single Center Experience. Sathish Kumar,<br />
Susanne Benseler, Earl Silverman. Hospital for Sick<br />
Children, Toronto, ON, Canada.<br />
(109)-877. Higher Mortality and Cyclophosphamide Use in SLE<br />
with Onset Prior to Eleventh Birthday. Catherine DiSipio, Lisa<br />
F. Imundo, Andrew H. Eichenfield, Philip J. Kahn, Deborah<br />
M. Levy. Morgan Stanley Children’s Hospital of New York,<br />
Columbia University Medical Center, New York, NY.<br />
(110)-878. Outcome of Pediatric Lupus Nephritis After IV<br />
Cyclophosphamide: 36 Month Follow-up of an Extended 9 Month<br />
Induction Protocol. Ankur A. Kamdar, M. J. Hicks, Karen<br />
W. Eldin, Marietta M. DeGuzman, Maria D. Perez, Robert<br />
W. Warren, Eileen D. Brewer, Arundhati S. Kale, Barry<br />
L. Myones. Baylor College of Medicine/Texas Childrens<br />
Hospital, Houston, TX.<br />
Poster Session B<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 171
Poster Session b<br />
(111)-879. Pregnancy Outcome in Juvenile Systemic Lupus<br />
Erythematosus (JSLE)): A Brazilian Multicentre Cohort Study.<br />
Clovis A. Silva 1 , Maria O. Hilário 2 , Marà lia V. FebrÒnio 1 ,<br />
Rozana G. Almeida 3 , Adriana R. Fonseca 3 , Edson M.<br />
Yamashita 2 , Marcos V. Ronchezel 4 , Luciene L. Campos 5 ,<br />
Simone Appenzeller 6 , Maria V. Quintero 7 , Ana B. Santos 3 ,<br />
Ana C. Medeiros 8 , Luciana M. Carvalho 9 , Tereza C.<br />
Robazzi 10 , Silvana P. Cardin 11 , Eloisa Bonfá 8 . 1 University<br />
of Sao Paulo - Pediatric Rheumatology Unit, Sao Paulo - SP,<br />
Brazil; 2 Federal University of Sao Paulo, Sao Paulo - SP,<br />
Brazil; 3 Federal University of Rio de Janeiro, Rio de Janeiro<br />
- RJ, Brazil; 4 Santa Casa of Sao Paulo, Sao Paulo - SP, Brazil;<br />
5<br />
State University of Rio de Janeiro, Rio de Janeiro - RJ,<br />
Brazil; 6 State University of Campinas, Campinas - SP, Brazil;<br />
7<br />
Santa Casa of Belo Horizonte, Belo Horizonte - MG, Brazil;<br />
8<br />
University of Sao Paulo, Sao Paulo - SP, Brazil; 9 University<br />
of Sao Paulo, Ribeirao Preto - SP, Brazil; 10 Hospital São<br />
Rafael, Salvador - BA, Brazil; 11 State of University of<br />
Botucatu, Botucatu - SP, Brazil.<br />
(112)-880. Early Mortality in Childhood Onset Systemic Lupus<br />
Erythematosus (SLE). Aurélie Klein 1 , Rolando Cimaz 2 ,<br />
Elie Azoulay 3 , Veronique Baudouin 4 , Elodie Descloux 2 ,<br />
Alexandre Belot 2 , Philippe Hubert 5 , Pierre Quartier 5 ,<br />
Stéphane Decramer 6 , Patrick Niaudet 5 , Brigitte Bader-<br />
Meunier 5 . 1 Hôpital Saint Jacques, Besançon, France;<br />
2<br />
Hôpital E. Herriot,, Lyon, France; 3 Hôpital Saint Louis,<br />
APHP, Paris, France; 4 Hôpital Robert Debré, APHP, Paris,<br />
France; 5 Hôpital Necker, APHP, Paris, France; 6 Hôpital<br />
Purpan, Toulouse, France.<br />
(113)-881. Pediatric Systemic Lupus Erythematosus (SLE) in<br />
Canada: 1000 Canadian Faces of SLE. L. B. Tucker 1 , A. Uribe 1 ,<br />
R. Petty 1 , E. Silverman 2 , G. Chedeville 3 , A. M. Huber 4 , C.<br />
Peschken 5 , 1000 Canadian Faces of SLE Investigators. 1 BC<br />
Children’s Hospital, Vancouver, BC, Canada; 2 Hosp Sick<br />
Kids, Toronto, ON, Canada; 3 Montreal Children’s Hosp,<br />
Montreal, PQ, Canada; 4 IWK Health Centre, Halifax, NS,<br />
Canada; 5 U Manitoba, Winnipeg, MB, Canada.<br />
(114)-882. Neurocognitive Function in Childhood-Onset Systemic<br />
Lupus Erythematosus (cSLE). Deborah M. Levy 1 , Alexandra<br />
I. Barsdorf 2 , Lisa F. Imundo 1 , Philip J. Kahn 1 , Andrew<br />
H. Eichenfield 1 , Candido Batres 1 , Gail S. Ross 3 , Cynthia<br />
Aranow 4 . 1 Morgan Stanley Children’s Hospital of New<br />
York, Columbia University Medical Center, New York,<br />
NY; 2 Columbia University Medical Center, New York, NY;<br />
3<br />
Cornell University, New York, NY; 4 The Feinstein Institute<br />
for Medical Research, Manhasset, NY.<br />
(115)-883. The Pediatric Automated Neuropsychological<br />
Assessment Metrics (Ped-ANAM) in Childhood-Onset Systemic<br />
Lupus Erythematosus (cSLE) - No Significant Practice Effect in<br />
First Three Trials. Deborah M. Levy 1 , Tresa M. Roebuck-<br />
Spencer 2 , Cynthia Aranow 3 , Hermine I. Brunner 4 . 1 Morgan<br />
Stanley Children’s Hospital of New York, Columbia<br />
University Medical Center, New York, NY; 2 National<br />
Rehabilitation Hospital, Washington, DC; 3 The Feinstein<br />
Institute for Medical Research, Manhasset, NY; 4 Cincinnati<br />
Children’s Hospital Medical Center, Cincinnati, OH.<br />
(116)-884. Relationship of Simple Measure of Impact of Lupus<br />
Erythematosus in Youngsters (SMILEY) to Change in Disease<br />
Activity and Damage over Time. Lakshmi Nandini Moorthy 1 ,<br />
Margaret Peterson 2 , Elizabeth Chalom 3 , Bettina Eulie 3 ,<br />
Karen Onel 4 , Maria Baratelli 1 , Melanie Harrison 2 , Philip<br />
Hashkes 5 , Deborah Bork 5 , Andreas Reiff 6 , Sandy Hong 6 ,<br />
Alexa Adams 2 , Laura Barinstein 7 , Emma MacDermott 2 ,<br />
Lilliana Barillas 2 , Sheila Angeles 2 , Jennifer Belasco 2 ,<br />
Ayman Mansour 2 , Kathleen Haines 8 , Doreen Tabussi 8 , Liza<br />
Vazquez 9 , Thomas J A Lehman 2 . 1 Robert Wood Johnson<br />
Med Sch-Univ of Med and Dentistry of NJ, New Brunswick,<br />
NJ; 2 Hospital For Special Surgery, New York, NY; 3 St.<br />
Barnabus Medical Center, Livingston, NJ; 4 La Rabida Chld<br />
Hosp, Chicago, IL; 5 CCF, Cleveland, OH; 6 Chld Hosp LA,<br />
Los Angeles, CA; 7 Maimonedes Medical Center, Brooklyn,<br />
NY; 8 Hackensack Univ. Med Ctr, Hackensack, NJ; 9 San<br />
Jorge Chlds Hosp, San Juan, Puerto Rico.<br />
(117)-885. Sensitivity & Specificity of Adult Lupus Flare<br />
Measures When Used in Pediatric Systemic Lupus Erythematosus.<br />
Hermine I. Brunner 1 , Gloria C. Higgins 2 , Jun Ying 3 ,<br />
Kristina Wiers 1 , T Brent Graham 1 , Sivia K. Lapidus 4 , Jay<br />
Nocton 5 , Karen Onel 6 , Marilynn Punaro 7 , Judyann Olson 5 ,<br />
Marisa Klein-Gitelman 8 . 1 Cincinnati Children’s Hospital<br />
Medical Center, Cincinnati, OH; 2 Columbus Children’s<br />
Hospital, Columbus, OH; 3 University of Cincinnati,<br />
Internal Medicine, Cincinnati, OH; 4 Alfred DuPont<br />
Children’s Hospital, Wilmington, NJ; 5 Ped/MACC Fund<br />
Research Ctr, Milwaukee, WI; 6 LaRabida Children’s<br />
Hospital, Chicago, IL; 7 Texas Scottish Rite Hospital, Dallas,<br />
TX; 8 Children’s Memorial Hospital, Cincinnati, IL.<br />
(118)-886. Anti-C1q Antibodies in Patients with Juvenile-onset<br />
Systemic Lupus Erythematosus. Adriana A. Jesus 1 , Cristovao L.<br />
Mangueira 2 , Morton A. Sheinberg 2 , Sueli Marie 3 , Magda S.<br />
Carneiro-Sampaio 1 , Clovis A. Silva 1 , Bernadete L. Liphaus 1 .<br />
1<br />
Instituto da Criança - Universidade de São Paulo, Sao<br />
Paulo, Brazil; 2 Hospital Israelita Albert Einstein, Sao Paulo,<br />
Brazil; 3 Departamento de Neurologia - Universidade de São<br />
Paulo, Sao Paulo, Brazil.<br />
(119)-887. Undiffrentiated Conective Tissue Disease in Children.<br />
Basil M. Fathalla, Donald P. Goldsmith. St. Christopher’s<br />
Hospital for Children / Drexel University College of<br />
Medicine, Philadelphia, PA.<br />
(120)-888. Vitamin D Deficiency in Children Evaluated for<br />
Musculoskeletal Symptoms. James E. Dowd, Billie Jo Coomer.<br />
Michigan Arthritis Research Center, Brighton, MI.<br />
(121)-889. Inpatient Utilization of Corticosteroids for Henoch<br />
Schönlein Purpura. Pamela F. Weiss, Jon M. Burnham, Ron<br />
Keren, Chris Feudtner. Childrens Hospital of Philadelphia,<br />
Philadelphia, PA.<br />
172 (Permanent Board Number)-Abstract Number
(122)-890. Familial ANCA-Positive Pulmonary Hemorrhage<br />
Syndrome. Polly J. Ferguson 1 , John P. Whelan 2 , Robert<br />
G. Zwerdling 3 . 1 University of Iowa, Iowa City, IA;<br />
2<br />
Massachusets General Hospital for Children, Boston, MA;<br />
3<br />
UMass Memorial Medical Center, Worcester, MA.<br />
(123)-891. Proposal for Diagnostic Guidelines for Incomplete<br />
and Atypical Kawasaki Disease (KD). Falcini F, Ricci L,<br />
Pistorio A, Zulian F, Calabri GB, VitaleA, Cuttica R,<br />
Oliveira S, Pietrogrande MC, Unsal U, Ozen S, Magni<br />
Manzoni S, Lepore L, Alessio M, Barcellona R, Manusia F,<br />
De Benedictis F, Martino S, Breda L, Stenboeg E, Pasic S,<br />
Boncompagni A, Siamopoulou-Mavridou A, Butbul Uziel<br />
J, Rigante D,Dressler F, Walsh J, Tove L, Meini A, Nukay<br />
A, for Paediatric Rheumatology European Study Group. A.<br />
Meyer Children Hospital, Firenze, Italy.<br />
(124)-892. Osteoprotegerin Deficiency (Juvenile Paget’s Disease):<br />
Responses to Oral and IV Bisphosphonates in 3 Children.<br />
Deborah Wenkert 1 , Marc Natter 2 , Mayumi Otsuka 3 , Natalya<br />
Fish 2 , Jorge Lopez-Benitez 2 , Morri Markowitz 4 , William H.<br />
McAlister 5 , Steven Mumm 5 , Michael P. Whyte 1 . 1 Shriners<br />
Hospitals for Children, St. Louis, MO; 2 Tufts-New Eng Med<br />
Ctr, Boston, MA; 3 N. Navajo Med Cntr, Shiprock, NM;<br />
4<br />
Montefiore Hospital, Bronx, NY; 5 Wash U Sch Med, St<br />
Louis, MO.<br />
(125)-893. Clinical Features of Blau Syndrome and Early-Onset<br />
Sarcoidosis with CARD15 (NOD2) Mutations. Ikuo Okafuji 1 ,<br />
Ryuta Nishikomori 1 , Nobuo Kanazawa 2 , Naotomo Kambe 3 .<br />
1<br />
Kyoto University Graduate School of Medicine, Kyoto,<br />
Japan; 2 Wakayama Medical University, Wakayama, Japan;<br />
3<br />
Chiba University Graduate School of Medicine, Chiba, Japan.<br />
(126)-894. Determination of in-vivo and in-vitro Production of<br />
Inflammatory Mediators in Pediatric Patients with Acute and<br />
Chronic Lyme Arthritis. Paul T. Fawcett, Carlos D. Rose,<br />
AnneMarie C. Brescia, Victoria L. Maduskuie, Marjorie M.<br />
Postell, Timothy Stetson, Phillip A. Stanek. Alfred I. duPont<br />
Hospital for Children, Wilmington, DE.<br />
(127)-895. Adalimumab for the Treatment of Patients With<br />
Juvenile Rheumatoid Arthritis: Safety and Efficacy After<br />
Conversion From Body-Surface-Area Dosing to Weight-Based<br />
Fixed Dosing. Daniel J. Lovell 1 , Nicolino Ruperto 2 , Steven<br />
Goodman 3 , Andreas Reiff 4 , Lawrence Jung 5 , Katerina<br />
Jarosova 2 , Christy Sandborg 5 , Ivan Foeldvari 2 , Jozef<br />
Rovensky 2 , Kirsten Minden 2 , Richard K. Vehe 5 , Gerd<br />
Horneff 2 , Melissa J. McIlraith 6 , John R. Medich 7 , Edward<br />
H. Giannini 5 , Alberto Martini 2 . 1 Cincinnati Children’s<br />
Hospital Medical Center, Cincinnati, OH; 2 PRINTO-<br />
IRCCS G Gaslini, Genova, Italy; 3 Arthritis Associates of<br />
South Florida, Del Ray Beach, FL; 4 Childrens Hospital<br />
of Los Angeles, Los Angeles, CA; 5 PRCSG, Cincinnati,<br />
OH; 6 Abbott GmbH and Co KG, Abbott Laboratories,<br />
Ludwigshafen, Germany; 7 Abbott Laboratories, Parsippany, NJ.<br />
(128)-896. Streptococcal Infection and Early Arthritis in Children.<br />
Oystein R. Riise 1 , Anja Lee 2 , Kai Handeland 1 , Karl-Olaf<br />
Wathne 2 , Peter Gaustad 1 , Berit Flato 1 . 1 Rikshospitalet-<br />
Radiumhospitalet Medical Centre, Oslo, Norway; 2 Ulleval<br />
University Hospital, Oslo, Norway.<br />
(129)-897. Comparison of Different Classification Criteria<br />
for Juvenile Onset Spondyloarthropathies. Adrianne Walker,<br />
Andrew S. Zeft, Bernadette McNally, Bronte Clifford, John<br />
F. Bohnsack, Sampath Prahalad. U of Utah, School of<br />
Medicine, Salt Lake City, UT.<br />
(130)-898. Long Term Outcome of Anti-TNF Therapy in<br />
Juvenile Spondyloarthropathy. Shirley ML Tse 1 , Ruben Burgos-<br />
Vargas 2 , Finbar D. O’Shea 3 , Robert D. Inman 3 , Ronald<br />
M. Laxer 1 . 1 Hospital for Sick Children, Toronto, ON,<br />
Canada; 2 Hospital General de Mexico, Mexico City, Mexico;<br />
3<br />
University Health Network, Toronto, ON, Canada.<br />
(131)-899. JIA- A Silent “Killer” of the Temporo-Mandibular<br />
Joints. Nikolay Tzaribachev 1 , Jan Fritz 2 , Ursula Holzer 1 ,<br />
Philippe L. Pereira 2 , Marius Horger 2 , Jasmin Kuemmerle-<br />
Deschner 1 . 1 University Children’s Hospital, Tuebingen,<br />
Germany; 2 University Hospital, Dept. for Radiology,<br />
Tuebingen, Germany.<br />
(132)-900. Growth Reconstitution in Juvenile Idiopathic Arthritis<br />
(JIA) upon Treatment with Etanercept is Related to Clinical<br />
Improvement and Gender. Gerd Horneff 1 , Ivan Foeldvari 2 ,<br />
Gerd Ganser 3 , Hartmut Michels 4 , Hermann Girschick 5 ,<br />
R.M. Kuester 6 , Angelika Thon 7 . 1 Asklepios Clinic Sankt<br />
Augustin, Sankt Augustin, Germany; 2 Office Pediatric<br />
Rheumatology, Hamburg, Germany; 3 Rheumazentrum,<br />
Sendenhorst, Germany; 4 Deutsches Kinderrheumazentrum,<br />
Garmisch-Partenkirchen, Germany; 5 University Clinics,<br />
Würzburg, Germany; 6 Rheumazentrum, Bad Bramstedt,<br />
Germany; 7 University Hospital, Hannover, Germany.<br />
(133)-901. Measurement of Biomarkers in Juvenile Idiopathic<br />
Arthritis Patients and Their Significant Association with Disease<br />
Severity: A Comparative Study. Brooke E. Gilliam, Anil K.<br />
Chauhan, Jason M. Low, Terry L. Moore. Saint Louis<br />
University, St. Louis, MO.<br />
(134)-902. Homocysteinemia and Altered Lipid Profile in Long<br />
Term Polyarticular Onset Juvenile Idiopathic Arthritis. Vivian<br />
AP Tizziani 1 , Roberta Gonçalves 1 , Sandra M. Gualandro 2 ,<br />
Ana R. Ribeiro 1 , Claudia Goldenstein-Schainberg 1 .<br />
1<br />
Rheumatology Division, Universtity of São Paulo, São<br />
Paulo, Brazil; 2 Hematology Division, Universtity of São<br />
Paulo, São Paulo, Brazil.<br />
(135)-903. Prevalence and Significance of Isotypes of Anti-Cyclic<br />
Citrullinated Peptide Antibodies in Juvenile Idiopathic Arthritis<br />
Patients. Reema H. Syed, Brooke E. Gilliam, Terry L. Moore.<br />
Saint Louis University, St. Louis, MO.<br />
Poster Session B<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 173
Poster Session b<br />
(136)-904. Advanced Bone Age in the Affected Side is<br />
Associated with Greater Radiographic Progression in Patients<br />
with Juvenile Idiopathic Arthritis and Unilateral Wrist Disease.<br />
Nicola Ullmann 1 , Clara Malattia 1 , Silvia Magni-Manzoni 2 ,<br />
Alessandro Consolaro 1 , Roberto Gastaldi 1 , Mohamad<br />
Maghnie 1 , Natasha Di Iorgi 1 , Michela Mocchi 1 , Giovanni<br />
Filocamo 1 , Cristina Ferrari 1 , Alberto Martini 3 , Angelo<br />
Ravelli 4 . 1 IRCCS G Gaslini, Genova, Italy; 2 IRCCS<br />
Policlinico San Matteo, Pavia, Italy; 3 IRCCS G Gaslini and<br />
Università di Genova, Genova, Italy; 4 IRCCS G Gaslini and<br />
Unversità di Genova, Genova, Italy.<br />
(137)-905. Referral Patterns to a Pediatric Rheumatologist Center.<br />
Helen M. Emery, Sharon P. Goodwin. Childrens Hosp &<br />
Regional Med, Seattle, WA.<br />
(138)-906. Sexuality of Male Patients with Polyarticular onset<br />
Juvenile Idiopathic Arthritis. Lilian A L Souza 1 , Andrea L.<br />
Gallinaro 1 , Sergio Kowalski 1 , Carmita Abdo 2 , Ricardo<br />
M. Suechiro 3 , Clóvis A. Silva 3 , Claudia Goldenstein-<br />
Schainberg 1 . 1 Rheumatology Division, Universtity of São<br />
Paulo, São Paulo, Brazil; 2 Psychiatry Division, Universtity<br />
of São Paulo, São Paulo, Brazil; 3 Pediatrics Division,<br />
Universtity of São Paulo, São Paulo, Brazil.<br />
(139)-907. Active Anti-Rheumatic Drug Treatment Improves<br />
the Outcome of Patients with Juvenile Idiopathic Arthritis and<br />
Amyloidosis. Kai Immonen 1 , Anneli H. Savolainen 2 , Hannu<br />
Kautiainen 2 , Markku S. Hakala 2 . 1 North-Karelia Central<br />
Hospital, Joensuu, Finland; 2 Rheumatism Foundation<br />
Hospital, Heinola, Finland.<br />
(140)-908. Symptoms at Presentation to Paediatric Rheumatology:<br />
Association with Delay from Disease Onset. Results from the<br />
Childhood Arthritis Prospective Study (CAPS). Kimme L.<br />
Hyrich 1 , Navid Adib 1 , Judith Thornton 1 , Mark Lunt 1 , Joyce<br />
Davidson 2 , Janet Gardner-Medwin 2 , Helen E. Foster 3 ,<br />
Eileen Baildam 4 , Lucy R. Wedderburn 5 , Wendy Thomson 1 .<br />
1<br />
University of Manchester, Manchester, United Kingdom;<br />
2<br />
Royal Hospital for Sick Children, Glasgow, United<br />
Kingdom; 3 University of Newcastle, Newcastle, United<br />
Kingdom; 4 Royal Liverpool Children’s Hospital, Liverpool,<br />
United Kingdom; 5 Institute of Child Health, London,<br />
United Kingdom.<br />
(141)-909. Predictors of Severe CHAQ in Children with<br />
Inflammatory Arthritis One Year after Presentation to Paediatric<br />
Rheumatology. Results from the Childhood Arthritis Prospective<br />
Study (CAPS). Kimme L. Hyrich 1 , Judith Thornton 1 , Mark<br />
Lunt 1 , Helen E. Foster 2 , Joyce Davidson 3 , Eileen Baildam 4 ,<br />
Janet Gardner-Medwin 3 , Lucy R. Wedderburn 5 , Wendy<br />
Thomson 1 . 1 University of Manchester, Manchester, United<br />
Kingdom; 2 University of Newcastle, Newcastle, United<br />
Kingdom; 3 Royal Hospital for Sick Children, Glasgow,<br />
United Kingdom; 4 Royal Liverpool Children’s Hospital,<br />
Liverpool, United Kingdom; 5 Institute of Child Health,<br />
London, United Kingdom.<br />
(142)-910. Do Interventional Procedures in Children with<br />
Suspected Juvenile Idiopathic Arthritis Contribute to Delay in<br />
Referral to Paediatric Rheumatology?. Anne-Marie McMahon,<br />
Michael S. Eltringham, Lesley J. Kay, Mario Abinun, Mark<br />
Friswell, Andrea Myers, Helen E. Foster. Newcastle upon<br />
Tyne NHS Trust, Newcastle, United Kingdom.<br />
(143)-911. Early Prediction of JIA in Recent Onset Childhood<br />
Arthritis. Kai S. Handeland 1 , Oystein R. Riise 1 , Karl-Olaf<br />
Wathne 2 , Britt Nakstad 3 , Berit Flato 1 . 1 Rikshospitalet-<br />
Radiumhospitalet Medical Center, Oslo, Norway; 2 Ullevaal<br />
University Hospital, Oslo, Norway; 3 Akershus University<br />
Hospital, Akershus, Norway.<br />
(144)-912. Revision of the Childhood Health Assessment<br />
Questionnaire (CHAQ) for the Improved Evaluation of Physical<br />
Functioning (PF) with Juvenile Idiopathic Arthritis (JIA). Daniel<br />
McLinden, Paula Melson, Hermine I. Brunner, Shannon<br />
Darnell, Sandy Kramer. Cincinnati Children’s Hospital<br />
Medical Center, Cincinnati, OH.<br />
(145)-913. Describing and Predicting Physical Functional<br />
Disability in Juvenile Idiopathic Arthritis: A Longitudinal<br />
Study. Silvia Magni-Manzoni 1 , Angela Pistorio 2 , Elena<br />
Labò 1 , Serena Panigada 2 , Pablo Garcia-Munitis 2 , Giovanni<br />
Filocamo 2 , Chiara Visconti 1 , Stefania Viola 2 , Alberto<br />
Martini 2 , Angelo Ravelli 2 . 1 IRCCS Policlinico San Matteo,<br />
Pavia, Italy; 2 IRCCS G Gaslini, Genova, Italy.<br />
Friday, November 9<br />
8:00 a m—4:30 pm<br />
Exhibit Hall A-B<br />
RA Animal Models: Novel Experimental Therapies<br />
(146)-914. B Cells Have Crucial Role as Autoantibody Producers<br />
in Arthritis Mediated by Glucose-6-phosphate Isomerase. Yoko<br />
Tanaka-Watanabe, Isao Matsumoto, Keiichi Iwanami, Aska<br />
Inoue, Daisuke Goto, Satoshi Ito, Akito Tsutsumi, Takayuki<br />
Sumida. University of Tsukuba, Tsukuba, Japan.<br />
(147)-915. Early and Long-Lasting Protection from Arthritis<br />
in TNF Alpha Transgenic Mice Immunized with a Human-<br />
TNFalpha Kinoid. Laure Delavallee 1 , Natacha Bessis 1 , Le<br />
Buannec Hélène 2 , Anne Denys 1 , Bernard Bizzini 3 , Daniel<br />
Zagury 2 , marie-christophe boissier 4 . 1 ERI18 and University<br />
of Paris 13, Bobigny, France; 2 Neovacs, Paris, France;<br />
3<br />
University of Paris 6, Paris, France; 4 ERI18 and University<br />
of Paris 13 and APHP, Bobigny, France.<br />
(148)-916. Regulation of Inflammatory Arthritis by Type I<br />
Interferon and IKKepsilon. Maripat Corr, David L. Boyle,<br />
Gary S. Firestein. UCSD School of Medicine, La Jolla, CA.<br />
(149)-917. Regulation of Pain Behavior by the p38-regulating<br />
Kinase MKK3. Linda S. Sorkin, Deepa Hammaker, Emily<br />
Vail, David Herman, HongBin Wei, David L. Boyle, Gary S.<br />
Firestein. UCSD School of Medicine, La Jolla, CA.<br />
174 (Permanent Board Number)-Abstract Number
(150)-918. Stimulation of the Nicotinic Acetylcholine Receptor<br />
Alpha7 Subunits with AR-R17779 Improves Collagen-Induced<br />
Arthritis in Mice. Marjolein A. van Maanen 1 , Maria C.<br />
Lebre 1 , Gregory J. LaRosa 2 , Daniel Elbaum 2 , Margriet J.<br />
Vervoordeldonk 3 , Paul P. Tak 1 . 1 Academic Medical Center,<br />
Amsterdam, The Netherlands; 2 Critical Therapeutics Inc.,<br />
Lexington, MA; 3 Arthrogen BV, Amsterdam, Netherlands.<br />
(151)-919. Enhanced Development and Function of FoxP3+<br />
Regulatory T Cells during Arthritis in K/BxN Mice. Kristen<br />
Monte, Christina Wilson, Fei F. Shih. Washington<br />
University School of Medicine, St Louis, MO.<br />
(152)-920. Drastic Inhibition of Leukocyte Recruitment and<br />
Synovitis by Anti-CD44 or Anti-Granulocyte Treatment in a<br />
Murine Model of Rheumatoid Arthritis. Katalin Mikecz, Eva<br />
Bajnok, Istvan Gal, Balint Farkas, Tibor T. Glant, Gabor<br />
Hutas. Rush University Medical Center, Chicago, IL.<br />
(153)-921. αvß3 Targeted Nanotherapy against Angiogenesis<br />
in Inflammatory Arthritis. Happy Chan, Ralph Fuhrhop,<br />
Sam Wickline, Greg Lanza, Christine Pham. Washington<br />
University School of Medicine, St. Louis, MO.<br />
(154)-922. Short-term Depletion of Regulatory T Cells Converts<br />
Self-Limiting Arthritis into a Chronic Disease. Oliver Frey,<br />
Andreas Reichel, Lisa Bruns, Thomas Kamradt. Institute of<br />
Immunology, Jena, Germany.<br />
(155)-923. DA.BN(Cia13e) Rats, Integrating a 6.7 Mbp Region<br />
of BN Chromosome 4 Into the DA Background, are Protected<br />
against Collagen-Induced Arthritis (CIA). Marie M. Griffiths 1 ,<br />
Elaine F. Remmers 2 , Grant W. Cannon 1 , Percio S. Gulko 3 ,<br />
Van Reese 1 , Tim Corsi 1 , Ronald L. Wilder 4 . 1 SLCVAHCS<br />
and Univ of Utah, Salt Lake City, UT; 2 NIH/NIAMS,<br />
Bethesda, MD; 3 Feinstein Institute Medical Research,<br />
Manhasset, NY; 4 MacroGenics, Rockville, MD.<br />
(156)-924. Inhibition of MCP-1 Ameliorates Rat Adjuvant<br />
Induced Arthritis. Shiva Shahrara 1 , Amanda E. I. Proudfoot 2 ,<br />
Christy C. Park 1 , Michael V. Volin 3 , Kenneth Haines 4 ,<br />
James M. Woods 3 , Christopher H. Aikens 5 , Richard M.<br />
Pope 1 . 1 Northwestern University, Feinberg School of<br />
Medicine, Chicago, IL; 2 Geneva Research Centre Merck<br />
Serono International, Geneva, Switzerland; 3 Midwestern<br />
University, Downers Grove, IL; 4 Yale University School<br />
of Medicine, New Haven, CT; 5 Saint Francis Hospital,<br />
Evanston, IL.<br />
(157)-925. Repeated Priming with Exogenous Antigen Inhibits<br />
Autoimmunity in MRL/lpr Mice via Reduction of Double<br />
Negative lpr T Cell. Ken Tsumiyama, Kenichi Uto, Akira<br />
Hashiramoto, Shunichi Shiozawa. Department of<br />
Rheumatology, Kobe University FHS School of Medicine,<br />
Kobe, Japan.<br />
(158)-926. Spinal p38 Map Kinase Regulates Peripheral Anti-<br />
Inflammatory Responses via the Vagus Nerve and Cholinergic<br />
Responses. Jean-Marc Waldburger 1 , David L. Boyle 1 , Megan<br />
Edgar 1 , Yaakov Levine 2 , Valentin A. Pavlov 2 , Mahendar<br />
Ochani 2 , Kevin J. Tracey 2 , Gary S. Firestein 1 . 1 UCSD School<br />
of Medicine, La Jolla, CA; 2 The Feinstein Institute for<br />
Medical Research, Manhasset, NY.<br />
(159)-927. The Nicotine Acetylcholine Receptor Alpha-7 Subunit<br />
and the Cholinergic Anti-inflammatory Pathway Influences<br />
Development of Collagen Induced Arthritis. Sipra Saha, Jianping<br />
Guo, Jon Lampa. Rheumatology unit, Karolinska Institute,<br />
Stockholm, Sweden.<br />
(160)-928. Anti-Inflammatory Effect of Curcumin in Collageninduced<br />
Arthritis Model. You Sun Lee 1 , Kwang-Sung Ahn 2 ,<br />
Eun-Kyung Bae 2 , Hyun Jung Kim 2 , Joong Kyong Ahn 3 ,<br />
Hoon-Suk Cha 3 , Chan-Hong Jeon 4 , Ji-Young Chai 5 , Eun-Mi<br />
Koh 3 . 1 Department of Medicine, Masan Samsung Medical<br />
Center, Sungkyunkwan University School of Medicine,<br />
Masan, Republic of Korea; 2 Center for Molecular Medicine,<br />
Samsung Biomedical Research Institute, Sungkyunkwan<br />
University School of Medicine, Seoul, Republic of Korea;<br />
3<br />
Department of Medicine, Samsung Medical Center,<br />
Sungkyunkwan University School of Medicine, Seoul,<br />
Republic of Korea; 4 Department of Internal Medicine,<br />
Soonchunhyang University College of Medicine, Bucheon,<br />
Republic of Korea; 5 Department of Medicine, Ulsan<br />
University Hospital, Ulsan, Republic of Korea.<br />
(161)-929. Effects of ARRY-797, a Selective, Potent p38<br />
Inhibitor, in in vivo Models of Inflammation and Arthritis. Jed<br />
Pheneger 1 , Mark Munson 1 , Laurence Burgess 1 , A. Dale<br />
Wright 1 , Jim Winkler 1 , Alison Bendele 2 , Lynelle Lopez 1 ,<br />
Kevin Koch 1 , Patrice Lee 1 . 1 Array BioPharma, Boulder, CO;<br />
2<br />
Bolder BioPath, Boulder, CO.<br />
(162)-930. Variant Death Receptor 3(DR3) Gene, Genetically<br />
Associated with Rheumatoid Arthritis, Inhibits TL1A-Induced<br />
Splenocyte Signaling and CD4-8- T Cell Subset in Thymus.<br />
Takako Kawazoe, Ken Tsumiyama, Akira Hashiramoto,<br />
Shunichi Shiozawa. Department of Rheumatology, Kobe<br />
University FHS School of Medicine, Kobe, Japan.<br />
(163)-931. Blocking of IL-23 by Anti-IL-23R Monoclonal<br />
Antibody Decreased Synovial Expressions of IL-17, IL-1β, IL-6 and<br />
TNF-α in Collagen-induced Arthritis. Joung-Wook Lee, Jun-Hee<br />
Lee, Mi-Ra Cho, Geun-Tae Kim, Seung-Hoon Baek, Sung-Il<br />
Kim. Pusan National University Hospital, Busan, Republic<br />
of Korea.<br />
Poster Session B<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 175
Poster Session b<br />
(164)-932. MR1-Restricted Vα19i T Cells Ameliorate Murine<br />
Models of Arthritis. Toru Yago, Ryosuke Tajima, Shinjiro<br />
Kaieda, Shinji Oki, Takashi Yamamura, Sachiko Miyake.<br />
Department of Immunology, national Institute of<br />
Neuroscience, NCNP, Tokyo, Japan.<br />
(165)-933. Local Overproduction of ApoA-1, a New<br />
Approach to Inhibit Arthritis Activity?. Janik Adriaansen,<br />
Stefan F.C. Vaessen, Catharina J. de Cortie, Margriet<br />
J. Vervoordeldonk, Jan A. Kuivenhoven, Paul P. Tak.<br />
Academic Medical Center/University of Amsterdam,<br />
Amsterdam, The Netherlands.<br />
(166)-934. Therapeutic Effects of Tnfα Antagonist, Il-6<br />
Antagonist and Ctla-4 Ig in Glucose-6-phosphate Isomerase<br />
Induced Arthritis. Isao Matsumoto, Keiichi Iwanami,<br />
Yoko Tanaka, Asuka Inoue, Daisuke Goto, Satoshi Ito,<br />
Akito Tsutsumi, Takayuki Sumida. Division of Clinical<br />
Immunology, Tsukuba University, Tsukuba city, Japan.<br />
(167)-935. Suppression of Inflammation in Experimental Arthritis<br />
Using βig-h3-Derived Peptides. Jin Hee Kang, Kyung Hoon<br />
Kim, Ju Chon Yeo, Eon Jeong Nam, In San Kim, Young<br />
Mo Kang. Kyungpook National University Hospital, Daegu,<br />
Republic of Korea.<br />
(168)-936. Suppression of Arthritis in a Murine Rheumatoid<br />
Arthritis Model Following Treatment with the Hepatocyte Growth<br />
Factor Antagonist Nk4. Sachi Tsunemi 1 , Tsuyoshi Iwasaki 1 ,<br />
Sachie Kitano 1 , Kunio Matsumoto 2 , Toshikazu Nakamura 2 ,<br />
Hajime Sano 1 . 1 Hyogo College of Medicine, Nishinomiya,<br />
Japan; 2 Osaka University Graduate School of Medicine,<br />
Suita, Japan.<br />
(169)-937. Treatment of Experimental Arthritis with PEG-PLA/<br />
PLA Nanoparticles Encapsulating Betamethasone Phosphate.<br />
Megumu Higaki, Tsutomu Ishihara, Eri Ayano, Tetsushi<br />
Kubota, Yutaka Mizushima. Jikei Univ. Sch Med, Tokyo, Japan.<br />
(170)-938. Single Mesenchymal Stem Cell Injection after Disease<br />
onset Suppressed Progression of Proteoglycan Induced Arthritis.<br />
Joost F. Swart 1 , Marieke J.G. Backer 1 , Henk Rozemuller 1 ,<br />
Femke Van Wijk 1 , Berent J. Prakken 1 , Femke Hauet-<br />
Broere 2 , Suzanne E. Berlo 2 , Nico M. Wulffraat 1 , Anton C.<br />
Martens 1 , Wietse Kuis 1 . 1 Wilhelmina Children’s Hospital/<br />
UMC Utrecht, Utrecht, The Netherlands; 2 Faculty of<br />
Veterinary Medicine, UMC Utrecht, Utrecht, Netherlands.<br />
(171)-939. Anti-Rheumatic Effect of a Selective Inhibitor of the<br />
Immunoproteasome. Tony Muchamuel, Monette Aujay, Mark<br />
Bennett, Maya Dajee, Susan Demo, Eileen Goldstein, Jing<br />
Jiang, Christopher Kirk, Evan Lewis, Francesco Parlati,<br />
Kevin Shenk, Jamie Shields, Peter Shwonek, Catherine<br />
Sylvain, Tina Woo. Proteolix, Inc., South San Francisco, CA.<br />
Friday, November 9<br />
8:00 a m—4:30 pm<br />
Exhibit Hall A-B<br />
RA New and Established Therapies: Efficacy and Safety II<br />
(172)-940. Inhibition of Radiographic Progression by Lyophilized<br />
Certolizumab Pegol Added to Methotrexate in Comparison with<br />
Methotrexate Alone in Patients with Rheumatoid Arthritis: The<br />
RAPID 1 Trial. Desiree van der Heijde 1 , Vibeke Strand 2 ,<br />
Edward Keystone 3 , Robert Landewé 1 . 1 University Hospital<br />
Maastricht, Maastricht, The Netherlands; 2 Stanford<br />
University, Portola Valley, CA; 3 University of Toronto,<br />
Toronto, ON, Canada.<br />
(173)-941. Efficacy and Rapid Response of Certolizumab Pegol<br />
Liquid Formulation in Combination with Methotrexate (MTX) in<br />
Patients with Active Rheumatoid Arthritis Despite MTX Therapy:<br />
Results from the RAPID 2 Study. Philip Mease 1 , David Mason 2 ,<br />
Arthur Kavanaugh 3 , Josef Smolen 4 . 1 Seattle Rheumatology<br />
Associates and University of Washington, Seattle, WA;<br />
2<br />
UCB Inc, Smyrna, GA; 3 University of San Diego, La Jolla,<br />
CA; 4 Division of Rheumatology, Medical University of<br />
Vienna, Vienna, Austria.<br />
(174)-942. The Efficacy of Abatacept in Patients with Active<br />
Rheumatoid Arthritis and an Inadequate Response to Anti-TNF<br />
Therapy: The ARRIVE Trial. M. Schiff 1 , C. Pritchard 2 , X.<br />
Zhou 3 , K. Bahrt 3 , M. C. Genovese 4 . 1 Denver Arthritis<br />
Clinic, Denver, CO; 2 Rheumatology Specialty Center,<br />
Willow Grove, PA; 3 Bristol-Myers Squibb, Princeton, NJ;<br />
4<br />
Stanford University, Palo Alto, CA.<br />
(175)-943. Response to Influenza Vaccine in Rheumatoid<br />
Arthritis Patients with an Inadequate Response to Anti-TNF<br />
Therapy Treated with Abatacept in the ARRIVE Trial. M.<br />
Schiff 1 , M. Saewert 2 , K. Bahrt 2 , M. C. Genovese 3 . 1 Denver<br />
Arthritis Clinic, Denver, CO; 2 Bristol-Myers Squibb,<br />
Princeton, NJ; 3 Stanford University, Palo Alto, CA.<br />
(176)-944. Denosumab-Mediated Increase of Hand Bone<br />
Mineral Density (BMD) in Patients with Rheumatoid Arthritis<br />
is Associated with Decreased Progression of Bone Erosion. A.<br />
Deodhar 1 , R. Dore 2 , J. Sharp 3 , D. Mandel 4 , J. Schechtman 5 ,<br />
W. Shergy 6 , R. Trapp 7 , P. Ory 3 , C. Peterfy 8 , L. Zhou 9 , W.<br />
Tsuji 9 , R. Newmark 9 . 1 Oregon Health & Science Univ,<br />
Portland, OR; 2 Robin K. Dore, MD, Inc., Anaheim, CA;<br />
3<br />
Univ of Washington, Seattle, WA; 4 Private Practice,<br />
Mayfield Village, OH; 5 Sun Valley Arthritis Center,<br />
Glendale, AZ; 6 Rheumatology Associates of North Alabama,<br />
Huntsville, AL; 7 The Arthritis Cntr, Springfield, IL; 8 Synarc<br />
Inc, San Francisco, CA; 9 Amgen Inc., Thousand Oaks, CA.<br />
176 (Permanent Board Number)-Abstract Number
(177)-945. Effectiveness and Safety of Adalimumab<br />
(HUMIRA®) After Failure of Etanercept or Infliximab Treatment<br />
in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or<br />
Ankylosing Spondylitis. Gerd Burmester 1 , Martin Rudwaleit 2 ,<br />
Frank van den Bosch 3 , M. Kron 4 , Sonja Kary 5 , Hartmut<br />
Kupper 5 . 1 University Medicine Berlin, Berlin, Germany;<br />
2<br />
Charité University Hospital, Berlin, Germany; 3 University<br />
Hospital, Ghent, Belgium; 4 Abbott GmbH & Co KG,<br />
Ludwigshafen, Germany; 5 Abbott GmbH & Co. KG,<br />
Ludwigshafen, Germany.<br />
(178)-946. Certolizumab Pegol Results in Clinically Meaningful<br />
Improvements in Physical Function and Health-Related Quality<br />
of Life in Patients with Active Rheumatoid Arthritis Despite<br />
Treatment with Methotrexate. Vibeke Strand 1 , Dorothy<br />
L. Keininger 2 , Enkeleida Tahiri-Fizgerald 3 . 1 Stanford<br />
University, Portola Valley, CA; 2 UCB, Braine-l’Alleud,<br />
Belgium; 3 Msource, Kraainem, Belgium.<br />
(179)-947. Preliminary Safety and Efficacy of LTβR-Ig<br />
(BG9924) in the Treatment of Rheumatoid Arthritis (RA). A.<br />
Baldassare 1 , J. Fiechtner 2 , A. Filipowicz-Sosnowska 3 , S.<br />
Jeka 4 , J. O’Gorman 5 , M. Weaver 5 , E. Beckman 5 . 1 Arthritis<br />
Consultants, St. Louis, MO; 2 Michigan State University,<br />
Lansing, MI; 3 Institute of Rheumatology, Warsaw, Poland;<br />
4<br />
NZOZ, Torun, Poland; 5 Biogen Idec, Cambridge, MA.<br />
(180)-948. New Modified-Release (MR) Prednisone Tablet Shows<br />
Sustained Reduction of Morning Stiffness and Interleukin-6 (IL-6)<br />
in Patients with Rheumatoid Arthritis (RA). Frank Buttgereit 1 ,<br />
Gisela Doering 2 , Achim Schaeffler 3 , Stephan Witte 3 , Jacek<br />
Szechinski 4 , Rieke Alten 5 . 1 Charité University Hospital,<br />
CCM, Berlin, Germany; 2 Merck KGaA, Darmstadt,<br />
Germany; 3 Nitec Pharma AG, Reinach, Switzerland; 4 Med.<br />
Univ. Dept. of Rheumatology, Wroclaw, Poland; 5 Dept. Int.<br />
Med. II, Rheumatology Schlosspark-Clinic, Berlin, Germany.<br />
(181)-949. Comparing Ayurvedic (India) Herbal drugs<br />
and HCQS (hydroxychloroquin sulfate) in the Treatment of<br />
Rheumatoid Arthritis (RA): A Randomized, Double Blind, Multi-<br />
Centric Exploratory Drug Trial of 24 Weeks Duration. Arvind<br />
Chopra 1 , Gumdal Narasimulu 2 , Lata Bichile 3 , Rohini Handa 4 ,<br />
Ashwin Raut 5 , Manjit Saluja 1 , Sanjeev Sarmukkadam 1 ,<br />
Bhushan Patwardhan 6 . 1 Center for Rheumatic Diseases, Pune,<br />
India; 2 Nizam’s Institute of Medical Sciences, Hyderabad,<br />
India; 3 KEM Hospital & Medical College, Mumbai, India; 4 All<br />
India Institute of Medical Sciences, New Delhi, India; 5 SPARC,<br />
Mumbai, India; 6 School of Health Sciences, University of<br />
Pune, Pune, India.<br />
(182)-950. Maintained Efficacy and Safety of Abatacept in<br />
Rheumatoid Arthritis Patients Receiving Background Methotrexate<br />
through 5 Years of Treatment. R. Westhovens 1 , J. Kremer 2 ,<br />
L. Moreland 3 , P. Emery 4 , A. Russell 5 , T. Li 6 , R. Aranda 6 ,<br />
J-C Becker 6 , C. Joshi 7 , M. Dougados 8 . 1 UZ Gasthuisberg,<br />
Leuven, Belgium; 2 Center for Rheumatology, Albany, NY;<br />
3<br />
University of Alabama, Birmingham, AL; 4 University of<br />
Leeds, Leeds, United Kingdom; 5 University of Alberta<br />
Hospital, Edmonton, AB, Canada; 6 Bristol-Myers Squibb,<br />
Princeton, NJ; 7 Bristol-Myers Squibb, Mumbai, India; 8 Rene<br />
Descartes University, Paris, France.<br />
(183)-951. A Clinical Study of Very Low Dose Prednisolone and<br />
Paroxetine for Active RA. Edward Keystone 1 , Jude Rodrigues 2 ,<br />
Jiri Vencovsky 3 , Carter Thorne 4 , Marco Matucci-Cernic 5 ,<br />
Johannes Bijlsma 6 , Melissa Nichols 7 , Theresa Podrebarac 8 ,<br />
Josef S. Smolen 9 . 1 University of Toronto, Toronto,<br />
ON, Canada; 2 Clinical Research and Arthritis Center,<br />
Windsor, ON, Canada; 3 Institute of Rheumatology,<br />
Prague, Czech Republic; 4 Arthritis <strong>Program</strong> Research<br />
Group, Newmarket, ON, Canada; 5 University of Florence,<br />
Florence, Italy; 6 University Medical Center Utrecht,<br />
Utrecht, The Netherlands; 7 Combinatorx, Cambridge, MA;<br />
8<br />
CombinatoRx, Cambridge, MA; 9 University of Vienna,<br />
Vienna, Austria.<br />
(184)-952. Significantly Higher Disease Remission over 3<br />
Years with Etanercept and Methotrexate Versus Either Therapy<br />
Alone: Longitudinal Analysis of the TEMPO Results. D. van<br />
der Heijde 1 , R. Landewe 2 , R. Pedersen 3 , D. MacPeek 3 , R.<br />
Wajdula 3 . 1 Leiden University Medical Center, Leiden,<br />
The Netherlands; 2 University Hospital, Maastricht, The<br />
Netherlands; 3 Wyeth Research, Collegeville, PA.<br />
(185)-953. Denosumab Increases Bone Mineral Density in<br />
Patients with Glucocorticoid-Induced Bone Loss and Rheumatoid<br />
Arthritis. Nancy Lane 1 , Stanley Cohen 2 , Robin K. Dore 3 ,<br />
Lifen Zhou 4 , Wayne Tsuji 4 , Richard Newmark 4 . 1 University<br />
of California-Davis Medical Center, Sacramento, CA;<br />
2<br />
Metroplex Center for Clinical Research, Dallas, TX; 3 Robin<br />
K Dore, MD, Inc., Anaheim, CA; 4 Amgen, Inc., Thousand<br />
Oaks, CA.<br />
(186)-954. Single Dose Safety, Tolerability, Pharmacokinetics<br />
And Pharmacodynamics Of AZD056, A Novel P2X7 Receptor<br />
Antagonist, In Healthy Volunteers. Carol Astbury, Graham E.<br />
Blakey, Helen E. Spray, John H. Perrett, Peter Lawrence.<br />
AstraZeneca R&D, Loughborough, United Kingdom.<br />
(187)-955. Change in Bone Mineral Density in Rheumatoid<br />
Arthritis Patients after Adalimumab Therapy: A Beneficial Role<br />
for Prednisone Use?. Ruth Klaasen, Carla A. Wijbrandts,<br />
Danielle M. Gerlag, Paul P. Tak. Academical Medical<br />
Centre/University of Amsterdam, Amsterdam, Netherlands.<br />
(188)-956. Infliximab Dose Escalation in Rheumatoid<br />
Arthritis Patients in the START Trial: The Effect of Infliximab<br />
Pharmacokinetics and Immunogenicity. M. U. Rahman 1 ,<br />
I. Strusberg 2 , P. Geusens 3 , A. Berman 4 , C. Wagner 1 ,<br />
A. Fasanmade 1 , J. Han 1 , R. Westhovens 5 . 1 Centocor<br />
Research and Development, Inc., Malvern, PA; 2 Centro<br />
Reumatológico Strusberg, Cordoba, Argentina; 3 University<br />
Hospital Maastricht, Maastricht, The Netherlands; 4 Hospital<br />
Angel C. Padilla, Tucuman, Argentina; 5 UZ Gasthuisberg,<br />
Leuven, Belgium.<br />
Poster Session B<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 177
Poster Session b<br />
(189)-957. Efficacy and Safety of up to 10 Years of Etanercept<br />
(Enbrel®) Therapy in North <strong>American</strong> Patients With Early<br />
and Long-Standing Rheumatoid Arthritis. M. E. Weinblatt 1 ,<br />
M. C. Genovese 2 , L. W. Moreland 3 , J. M. Bathon 4 , J. M.<br />
Kremer 5 , R. M. Fleischmann 6 , M. H. Schiff 7 , Y. Chon 8 , S-L<br />
Lin 8 , S. W. Baumgartner 8 . 1 Brigham & Women’s Hosp,<br />
Boston, MA; 2 Stanford Univ Med Ctr, Palo Alto, CA;<br />
3<br />
Univ of Alabama, Birmingham, AL; 4 Johns Hopkins Univ,<br />
Baltimore, MD; 5 The Center for Rheumatology, Albany,<br />
NY; 6 St Paul Med Ctr, Dallas, TX; 7 Denver Arthritis Clinic,<br />
Denver, CO; 8 Amgen, Thousand Oaks, CA.<br />
(190)-958. The Rate of Infection Adverse Events (AE’s) is<br />
Increased as Disease Activity Increases in Rheumatoid Arthritis<br />
(RA). Daniel E. Furst 1 , Joel Kremer, Dr. 2 , Vibeke Strand,<br />
Dr. 3 , George Reed 4 , Jeffrey Greenberg 5 . 1 University of<br />
California at Los Angeles, Los Angeles, CA; 2 Albany<br />
Medical College, Albany, NY; 3 Stanford University, Palo<br />
Alto, CA; 4 University of Massachusetts, Worchester, MA;<br />
5<br />
NUY Hospital for Joint Diseases, New York, NY.<br />
(191)-959. Adalimumab Safety Profile in Global Clinical Trials<br />
and Reduction in Standardized Mortality Ratios (SMR) Across<br />
Multiple Indications. G. R. Burmester 1 , P. J. Mease 2 , B. AC<br />
Dijkmans 3 , K. B. Gordon 4 , D. J. Lovell 5 , R. Panaccione 6 ,<br />
J. L. Perez 7 , A. L. Pangan 7 . 1 Charité – U. Medicine Berlin,<br />
Berlin, Germany; 2 Swedish Medical Center, Seattle,<br />
WA; 3 VU Medical Centre & Jan van Breemen Institute,<br />
Amsterdam, The Netherlands; 4 Evanston Northwest<br />
Healthcare, Evanston, IL; 5 Cincinatti Childrens’ Hospital<br />
Medical Center, Cincinatti, OH; 6 U. of Calgary, Calgary,<br />
AB, Canada; 7 Abbott, Abbott Park, IL.<br />
(192)-960. Clinical Trial Safety Data of Events of Interest in<br />
Patients Receiving Etanercept (ENBREL®) across Approved<br />
Indications. K. B. Gordon 1 , A. B. Gottlieb 2 , E. H. Giannini 3 ,<br />
P. J. Mease 4 , J. Li 5 , E. Chi 5 , Y. Chon 5 , H. H. Weng 5 , S.<br />
Hamza 5 , J. Wajdula 6 , S. R. Stevens 5 , S-L Lin 5 . 1 Evanston<br />
Northwestern Healthcare and Northwestern Univ, Feinberg<br />
School of Med, Chicago, IL; 2 Tufts-New England Med<br />
Ctr, Boston, MA; 3 Cincinnati Children’s Hosp Med Ctr,<br />
Cincinnati, OH; 4 Seattle Rheumatology Assoc, Seattle, WA;<br />
5<br />
Amgen, Thousand Oaks, CA; 6 Wyeth, Collegeville, PA.<br />
(193)-961. Impact of 3 TNFα Blockers on Markers of<br />
Autoimmunity in Rheumatoid Arthritis and Spondylarthropathy.<br />
Hélène Bacquet, Fabienne Jouen, Muriel Quillard, Jean-<br />
Francois Ménard, Vincent Goëb, Thierry Lequerré, Othmane<br />
Mejjad, Alain Daragon, François Tron, Xavier Le Loët,<br />
Olivier Vittecoq. Rouen University Hospital, Rouen, France.<br />
(194)-962. Effect of Tumor Necrosis Factor alpha Blockade on<br />
Inflammatory and Haemostatic Biomarkers in Patients with<br />
Rheumatoid Arthritis. Francesca Ingegnoli 1 , Massimo Cugno 2 ,<br />
Ennio Favalli 1 , Amedeo Soldi 1 , Samantha Griffini 2 , Erika<br />
Bonanni 2 , Valentina Galbiati 1 , Flavio Fantini 1 . 1 Department<br />
of Rheumatology, University of Milano, Istituto G. Pini,<br />
Milano, Italy; 2 Department of Internal Medicine, University<br />
of Milano, IRCCS Ospedale Maggiore, Milano, Italy.<br />
(195)-963. High Association of Anti-DNA Antibotides and<br />
Lowered Platelet Counts in Arthritic Patients Treated With<br />
Infliximab: A 1-Year Follow-Up Study. Michael R. Lovy 1 ,<br />
Russell A. Goodman 2 . 1 Univeristy of Washington, Tacoma,<br />
WA; 2 Arthritis Associates of Puget Sound, Tacoma, WA.<br />
(196)-964. Effects of Folic Acid Supplementation on Both<br />
Efficacy and Safety During Low-Dose Methotrexate Treatment<br />
in Rheumatoid Arthritis. Alberto Sulli, Bruno Seriolo,<br />
Maria Elena Secchi, Sabrina Paolino, Monica Oliveri,<br />
Carmela Ferrone, Maurizio Cutolo. Research Laboratory<br />
and Division of Rheumatology, Department of Internal<br />
Medicine, University of Genova, Genova, Italy.<br />
(197)-965. Co-morbidity Twelve Years after COBRA<br />
Combination Therapy in Patients with Early Rheumatoid<br />
Arthritis. Lilian H D van Tuyl 1 , Alexandre E. Voskuyl 1 ,<br />
Willem F. Lems 1 , Robert B M Landewé 2 , Ben A C<br />
Dijkmans 1 , Maarten Boers 1 , On behalf of the COBRA study<br />
group. 1 VU University Medical Center, Amsterdam, The<br />
Netherlands; 2 University Hospital Maastricht, Maastricht,<br />
The Netherlands.<br />
(198)-966. Steroid Use among RA Patients Pre and Post TNF<br />
Inhibitor Therapy: Decreased Steroid Use with TNF Inhibitors but<br />
More Than a Third Of Patients Still Require High Maintenance<br />
Doses. Yusuf Yazici, Inessa Vulfova, Svetlana Krasnokutsky.<br />
NYU Hospital for Joint Diseases, New York, NY.<br />
(199)-967. Rituximab (rtx) Treatment of Active Rheumatoid Arthritis<br />
(ra) in Daily Practice in Germany: Interim Analysis of Effectiveness<br />
and Safety after 9 Months. Helmut Soerensen 1 , Hans Peter<br />
Tony 2 , Andrea Rubbert 3 , Hubertus von Wilmowsky 4 , Gunther<br />
Neeck 5 , Marc Breitbach 6 , Joerg Wendler 7 . 1 Rheumaprojekt<br />
Berlin Brandenburg, Berlin, Germany; 2 Universitätsklinikum,<br />
Wuerzburg, Germany; 3 Universitätsklinikum, Köln, Germany;<br />
4<br />
Bundesknappschaftskrankenhaus, Püttlingen, Germany;<br />
5<br />
Biomedro, Rostock, Germany; 6 Roche Pharma AG, Grenzach-<br />
Wyhlen, Germany; 7 Rheumapraxis, Erlangen, Germany.<br />
(200)-968. The Feasibility and Acceptability of Withdrawal of<br />
Non-Steroidal Anti-Inflammatory Drugs from Patients with Stable<br />
Rheumatoid Arthritis. Gayle McKellar, Rosemary Hampson,<br />
Ann Tierney, Hilary A. Capell, Rajan Madhok. Glasgow<br />
Royal Infirmary, Glasgow, United Kingdom.<br />
(201)-969. Duration of Use of Anti-TNF Therapy in Rheumatoid<br />
Arthritis. Frederick Wolfe 1 , Kaleb Michaud 2 . 1 National Data<br />
Bank for Rheumatic Diseases, Wichita, KS; 2 University of<br />
Nebraska Medical Center, Omaha, NE.<br />
(202)-970. Comparison of Switching Patterns Among Anti-Tumor<br />
Necrosis Factors in the Treatment of Rheumatoid Arthritis.<br />
B. Tang 1 , M. Rahman 1 , B. Meissner 2 , O. Dabbous 1 , H.<br />
Thompson 1 . 1 Centocor, Inc., Horsham, PA; 2 Xcenda, Palm<br />
Harbor, FL.<br />
178 (Permanent Board Number)-Abstract Number
(203)-971. Comparison of Therapeutic Persistence Among Anti-<br />
Tumor Necrosis Factors in the Treatment of Rheumatoid Arthritis.<br />
B. Tang 1 , O. Dabbous 1 , B. Meissner 2 , H. Thompson 1 , M.<br />
Rahman 1 . 1 Centocor, Inc., Horsham, PA; 2 Xcenda, Palm<br />
Harbor, FL.<br />
(204)-972. Clinical Evolution after Discontinuation of Anti-TNF<br />
Treatment in RA Patients in Remission. Elodie MILLASSEAU,<br />
Olivier BROCQ, Christine ALBERT, Christian GRISOT,<br />
Philippe FLORY, Christian ROUX, Liana EULLER-<br />
ZIEGLER. Archet Hospital, NICE, France.<br />
(205)-973. Long-Term Effectiveness During Infliximab or<br />
Etanercept Therapy: A Systematic Review of Observational<br />
Studies. Maria Suarez-Almazor 1 , Maria A. Lopez-Olivo 1 ,<br />
Chong Pak 1 , Becky Skidmore 2 . 1 UT MD Anderson Cancer<br />
Center, Houston, TX; 2 The Society of Obstetricians and<br />
Gynaecologists of Canada, Ottawa, ON, Canada.<br />
(206)-974. Route of Administration of Biologic Therapy: What<br />
do Patients Prefer?. Marian L. Burr, Premarani Sinnathurai,<br />
Amel Ginawi, Andrew J K Ostor. Addenbrooke’s Hospital,<br />
Cambridge, United Kingdom.<br />
(207)-975. Role of Hypoxia-Inducible Factor-1α in Hypoxia-<br />
Induced Expressions of IL-8, MMP-1 and -3 in Rheumatoid<br />
Fibroblast-Like Synoviocytes. Joong Kyong Ahn 1 , Jinhee Kim 2 ,<br />
Eun-Kyung Bae 2 , Kwang-Sung Ahn 2 , You Sun Lee 3 , Chan<br />
Hong Jeon 4 , Hoon-Suk Cha 1 , Eun-Mi Koh 1 . 1 Department<br />
of Medicine, Samsung Medical Center, Sungkyunkwan<br />
University School of Medicine, Seoul, Republic of Korea;<br />
2<br />
Center for Molecular Medicine, Samsung Biomedical<br />
Research Institute, Seoul, Republic of Korea; 3 Masan<br />
Samsung Medical Center, Masan, Republic of Korea;<br />
4<br />
Department of Medicine, Soonchunhyang University<br />
College of Medicine, Bucheon, Republic of Korea.<br />
Friday, November 9<br />
8:00 a m—4:30 pm<br />
Exhibit Hall A-B<br />
RA: Clinical Aspects II<br />
(208)-976. Cause Specific Mortality in Patients Receiving Anti-<br />
TNF Therapy for Rheumatoid Arthritis: Results from the British<br />
Society for Rheumatology Biologics Register (BSRBR). Kath D.<br />
Watson, William G. Dixon, Yvonne E. King, Deborah P M<br />
Symmons, Kimme L. Hyrich, on behalf of the BSR Biologics<br />
Register. The University of Manchester, Manchester, United<br />
Kingdom.<br />
(209)-977. Adverse Socioeconomic Circumstances Need Not<br />
Prejudice Rheumatoid Arthritis (RA) Outcomes: Results of a 5<br />
Year Prospective Study. Ann Tierney, Rosemary Hampson,<br />
Meng M. Chee, Gayle McKellar, Rajan Madhok, Hilary A.<br />
Capell. Royal Infirmary, Glasgow, United Kingdom.<br />
(210)-978. Prediction of Mortality Over 5-20 Years in 210<br />
Patients with Rheumatoid Arthritis From 1985-2005 According<br />
to a Multidimensional Health Assessment Questionnaire<br />
(MDHAQ), Swollen Joint Counts with 28, 42 or 66 Joints, Age<br />
and Gender. Theodore Pincus 1 , Shanthi Krishnaswami 2 ,<br />
Christopher Swearingen 3 . 1 NYU-Hospital for Joint Diseases,<br />
New York, NY; 2 Vanderbilt University, Nashville, TN;<br />
3<br />
Medical University of South Carolina, Charleston, SC.<br />
(211)-979. Gender Differences in Outcome at 5 Years:<br />
Results from a Prospective Disease Modifying Therapy Study in<br />
Rheumatoid Arthritis. Rosemary Hampson, Ann Tierney,<br />
Meng M. Chee, Gayle McKellar, Rajan Madhok, Hilary A.<br />
Capell. Royal Infirmary, Glasgow, United Kingdom.<br />
(212)-980. Women Have a More Severe Disease Than Men<br />
when Starting Their First Biological Treatment for RA. Maria<br />
Söderlin 1 , Pierre Geborek 2 , Ingemar Petersson 2 , Lars<br />
Erik Kristensen 3 . 1 Spenshult Rheumatology Hospital,<br />
Oskarström, Sweden; 2 Lund University Hospital, Lund,<br />
Sweden; 3 Lund University Hospital, Lund, Sweden.<br />
(213)-981. Does Vitamin D Level Influence RA Disease Activity<br />
and Function?. Uzma J. Haque, Kevin R. Fontaine, Joan<br />
M. Bathon, Susan J. Bartlett. Johns Hopkins University,<br />
Baltimore, MD.<br />
(214)-982. The Impact of Total Knee Replacement (TKR) on<br />
Patient Reported Pain and Health-Related Quality of Life in<br />
Subjects with Rheumatoid Arthritis (RA). Kaleb Michaud 1 , Ted<br />
R. Mikuls 1 , James R. O’Dell 1 , Kevin L. Garvin 1 , Edward<br />
V. Fehringer 1 , Frederick Wolfe 2 . 1 University of Nebraska<br />
Medical Center, Omaha, NE; 2 National Data Bank for<br />
Rheumatic Diseases, Witchita, KS.<br />
(215)-983. Large Joint Replacements and Arthrodeses in RA<br />
Patients Followed over 20 Years- Prevalence and Predictive<br />
Factors. Meliha C. Kapetanovic, Elisabet Lindqvist, Tore<br />
Saxne, Kerstin Eberhardt. Dept of Rheumatology, Clinical<br />
Scienses, Lund, Sweden.<br />
(216)-984. Determinants of Mortality Risk among Males with<br />
Rheumatoid Arthritis. Roderick S. Hooker 1 , Daisha J. Cipher 1 ,<br />
Bavana V. Rangan 1 , Salahuddin Kazi 1 , Ted Mikuls 2 , Grant<br />
W. Cannon 3 , Gail Kerr 4 , John S. Richards 4 . 1 Department<br />
of Veterans Affairs, Dallas, TX; 2 Department of Veterans<br />
Affairs, Omaha, NE; 3 Department of Veterans Affairs,<br />
Salt Lake City, UT; 4 Department of Veterans Affairs,<br />
Washington, DC.<br />
(217)-985. Lung Cancer after Exposure to Disease Modifying<br />
Anti-Rheumatic Drugs. S. Bernatsky, Ann Clarke, Samy<br />
Suissa. McGill University, Montreal, PQ, Canada.<br />
(218)-986. Hematological Malignancies after Drug Exposure in<br />
Rheumatoid Arthritis. S. Bernatsky, A. E. Clarke, S. Suissa.<br />
McGill University, Montreal, PQ, Canada.<br />
Poster Session B<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 179
Poster Session b<br />
(219)-987. Increasing RA Severity and Disease Comorbidities<br />
Are Associated with Decreasing Hemoglobin in the CORRONA<br />
Database. D. E. Furst 1 , H. Chang 2 , J. Greenberg 3 , V.<br />
Ranganath 4 , G. Reed 5 , ZE Ozturk 6 , J. Kremer 7 . 1 UCLA<br />
Medical School, Los Angeles, CA; 2 Tufts New England<br />
Medica Center, Boston, MA; 3 NYU Hospital of Joint<br />
Dieases, New York, NY; 4 University of California, Los<br />
Angeles, CA; 5 University of Massachusetts Medical School,<br />
Worcester, MA; 6 Roche Laboratories, Nutley, NJ; 7 Albany<br />
Medical College, Albany, NY.<br />
(220)-988. Anemia is an Independent Factor Associated with<br />
Physical Disability among Patients with Rheumatoid Arthritis.<br />
C. Han 1 , M. U. Rahman 1 , M. K. Doyle 1 , J. M. Bathon 2 ,<br />
J. Smolen 3 , A. Kavanaugh 4 , R. Westhovens 5 , D. Baker 1 ,<br />
M. Bala 1 . 1 Centocor Research and Development, Inc.,<br />
Malvern, PA; 2 Johns Hopkins University, Baltimore, MD;<br />
3<br />
Krankenhaus dr Stadt Wien-Lainz, Vienna, Austria;<br />
4<br />
University of California-San Diego, La Jolla, CA;<br />
5<br />
University Hospital Leuven, Leuven, Belgium.<br />
(221)-989. A Review of Lymphoma Occurring in Rheumatoid<br />
Arthritis Patients in the Consortium of Rheumatology Researchers<br />
of North America (CORRONA) Database. P. Callegari 1 ,<br />
O. Dabbous 1 , J. Kremer 2 , G. Reed 3 . 1 Centocor, Inc.,<br />
Horsham, PA; 2 Albany Medical College/The Center for<br />
Rheumatology, Albany, NY; 3 University of Massachusetts<br />
Medical School, Epidemiology and Biostatistics Unit,<br />
Worcester, MA.<br />
(222)-990. Female is a Risk Factor for Develolping AA-<br />
Amyloidosis in patients with Rheumatoid Arthritis. Mariko<br />
Kitahama, Yumi Koseki, Tadashi Sakurai, Naoyuki<br />
Kamatani, Chihiro Terai. Institute of Rheumatology, Tokyo<br />
Women’s Medical University, Tokyo, Japan.<br />
(223)-991. Incidence of Adverse Effects During Long-Term, Low-<br />
Dose Glucocorticoid Treatment of Rheumatoid Arthritis. Maurizio<br />
Mazzantini, Marica Doveri, Arianna Consensi, Rosaria<br />
Talarico, Massimiliano Cazzato, Rossella Neri, Stefano<br />
Bombardieri. Department of internal medicine, Pisa, Italy.<br />
(224)-992. Glucocorticoid Treatment is Associated with Increased<br />
Insulin Resistance in Subjects with Rheumatoid Arthritis (RA).<br />
Dimitrios A. Pappas, Alicia Rodriguez-Pla, Joan M. Bathon,<br />
Jon T. Giles. Johns Hopkins Hospital, Baltimore, MD.<br />
(225)-993. High Disease Activity Burden Predicts Severe<br />
Extra-Articular Manifestations in Early Rheumatoid Arthritis.<br />
Britt-Marie Nyhäll-Wåhlin 1 , Ingemar Petersson 2 , Jan-Åke<br />
Nilsson 3 , Lennart Jacobsson 3 , Carl Turesson 3 . 1 Department<br />
of Rheumatology, Falun Hospital, Falun, Sweden;<br />
2<br />
Department of Rheumatology, Lund University Hospital,<br />
Lund, Sweden; 3 Department of Rheumatology, Malmö<br />
University Hospital, Malmö, Sweden.<br />
(226)-994. Incidence of Malignancies in Japanese Rheumatoid<br />
Arthritis Patients in an Observational Cohort IORRA in<br />
Comparison to the Japanese Population Database. Toru Yamada,<br />
Eisuke Inoue, Ayako Nakajima, Masako Hara, Taisuke<br />
Tomatsu, Naoyuki Kamatani, Hisashi Yamanaka. Institute<br />
of Rheumatology, Tokyo Women’s Medical University,<br />
Tokyo, Japan.<br />
(227)-995. High Disease Activity is not an Additional Risk Factor<br />
for Myocardial Infarction in Rheumatoid Arthritis. Beáta J.<br />
Radovits 1 , Delia A. Diaconu 1 , Calin Popa 1 , Agnes Eijbouts 2 ,<br />
Piet LCM van Riel, Prof 1 , Roland FJM Laan, Prof 1 , Jaap<br />
Fransen 1 . 1 Radboud University Nijmegen Medical Center,<br />
Nijmegen, The Netherlands; 2 Sint Maartenskliniek,<br />
Nijmegen, The Netherlands.<br />
(228)-996. Body Composition is Associated with Radiographic<br />
Damage in Rheumatoid Arthritis. Jon Giles, William Scott,<br />
Joan Bathon. Johns Hopkins University, Baltimore, MD.<br />
(229)-997. Central Obesity is Increased in Men with Rheumatoid<br />
Arthritis (RA) and is Associated with Insulin Resistance (IR) and<br />
Subclinical Coronary Atherosclerosis. Jon Giles, Wendy Post,<br />
Roger Blumenthal, Moyses Szklo, Michelle Petri, Gelber Allan,<br />
Joan Bathon. Johns Hopkins University, Baltimore, MD.<br />
(230)-998. Rheumatoid Arthritis (RA) Modifies the Atherogenic<br />
Effect of Traditional Cardiovascular (CV) Risk Factors. Jon<br />
Giles 1 , Roger Blumenthal 1 , Wendy Post 1 , Moyses Szklo 1 ,<br />
Michelle Petri 1 , Allan Gelber 1 , Robert Detrano 2 , Joan<br />
Bathon 1 . 1 Johns Hopkins University, Baltimore, MD;<br />
2<br />
UCLA-Irvine, Irvine, CA.<br />
(231)-999. The Influence of Social Deprivation on Cardiovascular<br />
Risk Factors in a Cohort of Female Rheumatoid Arthritis Patients<br />
Living in an Inner City Area: The Value of the ASSIGN Score in<br />
Predicting Ten Year Risk. Gayle McKellar 1 , Anne McEntegart 2 ,<br />
Elaine Morrison 3 , Rosemary Hampson 1 , Ann Tierney 1 ,<br />
Hilary A. Capell 1 . 1 Glasgow Royal Infirmary, Glasgow, United<br />
Kingdom; 2 Stobhill Hospital, Glasgow, United Kingdom;<br />
3<br />
Southern General Hospital, Glasgow, United Kingdom.<br />
(232)-1000. Nodules and Rheumatoid Factor Status Both<br />
Independently Predict Early and Late Cardiovascular Disease<br />
Mortality in Inflammatory Polyarthritis: Results from a Primary-<br />
Care Based Cohort. Sophia M. Naz, Dr 1 , Tracey M. Farragher,<br />
Dr 1 , Diane K. Bunn, Mrs 2 , Deborah pm Symmons,<br />
Professor 1 , Ian N. Bruce, Dr 1 . 1 University of Manchester,<br />
Manchester, United Kingdom; 2 Dept of Rheumatology,<br />
Norfolk & Norwich University Hospital, United Kingdom.<br />
(233)-1001. Pro-inflammatory High-Density Lipoprotein<br />
(HDL) is Associated with Poor Disease Control and Increased<br />
Haptoglobin Content of HDL in Patients with Rheumatoid<br />
Arthritis. Christina Charles-Schoeman, Daniel E. Furst, Junji<br />
Watanabe, Sogol Amjadi, Michael Li, Maureen McMahon,<br />
Yousha Yaghoobzadeh, Harold Paulus, Alan M. Fogelman,<br />
Srinivasa T. Reddy. University of California, Los Angeles, CA.<br />
180 (Permanent Board Number)-Abstract Number
(234)-1002. Vascular Endothelial Function is Related to<br />
Endothelial Biomarkers in Early RA. Anna S�dergren 1 ,<br />
Kurt Boman 2 , Chatarina Eriksson 3 , Kjell Karp 4 , Elisabeth<br />
Lundstr�m 4 , Torgny Smedby 5 , Lisbet S�derlund 6 ,<br />
Solbritt Rantap��-Dahlqvist 1 , Solveig W�llberg<br />
Jonsson 1 . 1 Department of Rheumatology, Ume�, Sweden;<br />
2<br />
Department of Medicin, Skellefteå, Sweden; 3 Department<br />
of Clinical Immunology, Umeå, Sweden; 4 Dept of Clinical<br />
Physiology, Ume�, Sweden; 5 Dept of Rheumatology,<br />
Ï¿½stersund, Sweden; 6 Dept of Rheumatology, Lule�, Sweden.<br />
(235)-1003. Significant Increase of Intima Media Thickness in<br />
Only Eighteen Months among Patients with Early RA. Anna<br />
S�dergren 1 , Kurt Boman 2 , Chatarina Eriksson 3 , Kjell<br />
Karp 4 , Elisabet Lundstr�m 4 , Stefan Soderberg 5 , Lisbet<br />
S�derlund 6 , Solbritt Rantap��-Dahlqvist 1 , Solveig<br />
W�llberg Jonsson 1 . 1 Department of Rheumatology,<br />
Ume�, Sweden; 2 Department of Medicin, Skellefteå,<br />
Sweden; 3 Department of Clinical Immunology, Umeå,<br />
Sweden; 4 Dept of Clinical Physiology, Ume�, Sweden;<br />
5<br />
Department of Medicine, Umea, Sweden; 6 Dept of<br />
Rheumatology, Lule�, Sweden.<br />
(236)-1004. Management and Treatment of Heart Failure among<br />
Rheumatoid Arthritis Subjects Compared to Non-RA Subjects.<br />
John M. Davis, Veronique L. Roger, Cynthia S. Crowson,<br />
Hilal Maradit Kremers, Terry M. Therneau, Sherine E.<br />
Gabriel. Mayo Clinic, Rochester, MN.<br />
(237)-1005. Early Treatment Reduce the Cardiovascular Risk in<br />
Newly Diagnosed Rheumatoid Arthritis Patients. Athanasios N.<br />
Georgiadis 1 , Paraskevi V. Voulgari 1 , Maria I. Argyropoulou 1 ,<br />
Yannis Alamanos 2 , Moses Elisaf 1 , Alexandros D. Tselepis 3 ,<br />
Alexandros A. Drosos 1 . 1 Medical School, University of<br />
Ioannina, Ioannina, Greece; 2 Medical School, University<br />
of Patras, Patras, Greece; 3 Department of Chemistry,<br />
University of Ioannina, Ioannina, Greece.<br />
(238)-1006. Progression of Cardiovascular Co-Morbidity in<br />
Early RA. Lena Innala 1 , Anna SÃdergren 1 , Lotta Ljung 1 ,<br />
Staffan Magnusson 2 , Torgny Smedby 3 , Lisbet SÃderlund 4 ,<br />
Solbritt Rantapää-Dahlqvist 1 , Solveig Wållberg-<br />
Jonsson 1 . 1 Department of Rheumatology, Ume�, Sweden;<br />
2<br />
Department of Rheumatology, Sundsvall, Sweden;<br />
3<br />
Department of Rheumatology, Östersund, Sweden;<br />
4<br />
Department of Rheumatology, Sunderbyn, Luleå, Sweden.<br />
(239)-1007. Decreased Prevalence of the Metabolic Syndrome in<br />
Rheumatoid Arthritis. Alicia Rodriguez-Pla 1 , Jon Giles 1 , Roger<br />
Blumenthal 2 , Wendy Post 2 , Moyses Sklo 3 , Michelle Petri 1 ,<br />
Allan Gelber 1 , Robert Detrano 4 , Joan Bathon 1 . 1 Johns<br />
Hopkins University-Rheumatology, Baltimore, MD; 2 Johns<br />
Hopkins Hospital-Cardiology, Baltimore, MD; 3 Johns<br />
Hopkins Bloomberg School of Public Health, Baltimore,<br />
MD; 4 UC-Irvine, Irvine, CA.<br />
(240)-1008. Prevalence of the Metabolic Syndrome in U.S.<br />
Veterans with Rheumatoid Arthritis. Gail Kerr 1 , Iraj Sabahi 2 ,<br />
John Richards 3 , Bavana Rangan 4 , Daisha Cipher 5 , Roderick<br />
Hooker 4 , Ted Mikuls 6 . 1 VAMC, Georgetown, Howard<br />
Univ, Washington, DC; 2 Howard Univ, Washington, DC;<br />
3<br />
VAMC, Georgetown Univ, Washington, DC; 4 VAMC,<br />
Dallas, TX; 5 VAMC, Univ of North Texas, Fort Worth, TX;<br />
6<br />
VAMC, Univ of Nebraska, Omaha, NE.<br />
(241)-1009. Whole Body Composition Assesment by Dual Energy<br />
X-Ray Absorptiometry in Rheumatoid Arthritis. Delia Reina,<br />
Carmen Gómez-Vaquero, César Díaz-Torné, Elena Sirvent,<br />
Javier Narváez, Joan M. Nolla. Hospital Universitari de<br />
Bellvitge, Barcelona, Spain.<br />
(242)-1010. No Evidence for Increased Common Carotid Artery<br />
Intima-Media Thickness in Patients with Severe Extra-articular<br />
Rheumatoid Arthritis. Carl Turesson 1 , Göran Berglund 1 , Gunnar<br />
Sturfelt 2 , Jerker Persson 3 , Lennart TH Jacobsson 1 . 1 Malmö<br />
University Hospital, Malmö, Sweden; 2 Lund University<br />
Hospital, Malmö, Sweden; 3 Ystad Hospital, Ystad, Sweden.<br />
(243)-1011. HLA-DRB1*04 and HLA-C3 Associations with<br />
Extra-Articular Manifestations in Rheumatoid Arthritis are Not<br />
Explained by Linkage Disequilibrium with TNFA Alleles. Carl<br />
Turesson 1 , Joyce Carlson 1 , Eric L. Matteson 2 , Gunnar<br />
Sturfelt 3 , Lennart Truedsson 3 , Lennart TH Jacobsson 1 .<br />
1<br />
Malmö University Hospital, Malmö, Sweden; 2 Mayo Clinic<br />
College of Medicine, Rochester, MN; 3 Lund University<br />
Hospital, Lund, Sweden.<br />
(244)-1012. High Prevalence of Carotid Plaques in Rheumatoid<br />
Arthritis Iis not Associated with Autoantibodies. Ivânio<br />
A. Pereira 1 , Eduardo F. Borba 2 , Rufus Burlingame 3 ,<br />
L. E. Anjos 1 , Vilma S T Viana 2 , Elaine P. Leon 2 ,<br />
Margarete Vendramini 2 , Ieda M. Laurindo 2 . 1 Division<br />
of Rheumatology, Federal University of Santa Catarina,<br />
Florianópolis, Brazil; 2 Rheumatolgy Divison, University of<br />
São Paulo, São Paulo, Brazil; 3 INOVA, Inc., San Diego, CA.<br />
(245)-1013. Increase of Body Fat Mass in Rheumatoid Arthritis<br />
is Not Explained by Dietary Calorie Intake. Raissa G. Silva 1 ,<br />
Maria Guadalupe Pippa 1 , Andrea Barranjard Lomont 1 ,<br />
Karen S. Sarkis 2 , Fabio L. Cukier 1 , Lenise B. Pierucetti 1 ,<br />
Wagner Ikehara 1 , Luiz Latorre 1 , Cristiano A. Zerbini 1 .<br />
1<br />
Heliopolis Hospital, São Paulo, Brazil; 2 University of São<br />
Paulo, São Paulo, Brazil.<br />
(246)-1014. Prevalence of Cardiovascular Risk Factors in Patients<br />
with Rheumatoid Arthritis. Firdaus Fatima 1 , Uppuluri RK<br />
Rao 2 , Robert J. Moots 3 , Nicola J. Goodson 3 . 1 University<br />
Hospital Aintree, Liverpool, U K,Sri Deepti Rheumatology<br />
Center, Hyderabad, India; 2 Sri Deepti Rheumatology<br />
Center, Hyderabad, India; 3 University Hospital Aintree,<br />
Liverpool, United Kingdom.<br />
Poster Session B<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 181
Poster Session b<br />
(247)-1015. Prevalence of Traditional and Non-Traditional<br />
Cardiovascular Risk Factors in Rheumatic Diseases. Marco<br />
Antivalle, Alessandra Mutti, Luca Bertani, Giovanna<br />
Randisi, Donatella Ventura, Alberto Batticciotto, Fabiola<br />
Atzeni, Piercarlo Sarzi-Puttini. L. Sacco University Hospital,<br />
Milano, Italy.<br />
(248)-1016. Incidence of Interstitial Pneumonitis in RA Patients<br />
Based on the Large Observational Cohort Study IORRA in Japan.<br />
Kumi Shidara, Hoshi Daisuke, Eisuke Inoue, Toru Yamada,<br />
Masako Hara, Taisuke Tomatsu, Naoyuki Kamatani, Hisashi<br />
Yamanaka. Tokyo Women’s Medical University, Tokyo, Japan.<br />
(249)-1017. High Prevalence of Moderate to Severe Periodontal<br />
Disease in Rheumatoid Arthritis Patients. Clifton O. Bingham<br />
III, Jon T. Giles, Patricia E. Jones, Joan M. Bathon, Susan J.<br />
Bartlett. Johns Hopkins University, Baltimore, MD.<br />
(250)-1018. Rheumatoid Arthrits and Sarcopenia: Determinants<br />
Factors. Maria G. Pippa, Raissa G. Silva, Luis C. Latorre,<br />
Andreia B. Lomonte, Maria J. Nunes, Cristiano A. Zerbini.<br />
Hospital Heliopolis, Sao Paulo, Brazil.<br />
(251)-1019. Bone Loss in Early Rheumatoid Arthritis after Two<br />
Years of Follow up. Jussara A. L. Kochen, Silvia Carolina<br />
Torres, Lissiane K.N. Guedes, Sergio C. Kowalski, Ieda M<br />
M Laurindo. Rheumatology Division, University of São<br />
Paulo, São Paulo, Brazil.<br />
(252)-1020. Prevalence of Vertebral Fractures in Elderly Patients<br />
with Early Rheumatoid Arthritis. Jennie Ursum 1 , Karin<br />
Britsemmer 1 , Dirkjan van Schaardenburg 1 , Paul T. Lips 2 ,<br />
Ben A. Dijkmans 2 , Willem F. Lems 2 . 1 Jan van Breemen<br />
Institute, Amsterdam, The Netherlands; 2 VU Medical<br />
Centre, Amsterdam, The Netherlands.<br />
(253)-1021. Divergent Results of Screening Tests for M.tuberculosis<br />
Infection among Candidates for Anti-TNF Therapy Call for New<br />
Screening Guidelines. Bolette Soborg 1 , Morten Ruhwald 2 , Merete<br />
Lund Hetland 3 , Søren Jacobsen 4 , A. B. Andersen 5 , Dorte V.<br />
Jensen 6 , Pernille Ravn 2 . 1 Int. Ref. Lab. of Mycobacteriology,<br />
Statens Serum Institut, Copenhagen, Denmark; 2 Dept. of<br />
Infec. Dis. Univ. Hosp. of Hvidovre, Hvidovre, Denmark;<br />
3<br />
Dept of Rheum. Univ. Hosp. of Hvidovre, Hvidovre,<br />
Denmark; 4 Copenhagen University Hospital at Rigshospitalet,<br />
Copenhagen, Denmark; 5 Dept. of Infect. Dis. Univ. Hosp.<br />
of Rigshospitalet, Copenhagen, Denmark; 6 Dept. of Rheum.<br />
Horsholm Hosp., Horsholm, Denmark.<br />
(254)-1022. Tuberculosis Incidence Low in Double-Blind and<br />
Open-Label Etanercept Studies in Patients With Rheumatoid<br />
Arthritis. J. Wajdula 1 , D. MacPeek 1 , S. Lin 2 , S. Hamza 2 , S.<br />
Fatenejad 1 . 1 Wyeth Research, Collegeville, PA; 2 Amgen,<br />
Thousand Oaks, CA.<br />
(255)-1023. Extended Follow-up of Patients with at Positive<br />
Tuberculin Skin Test Treated With Etanercept. Augustine M.<br />
Manadan 1 , Anupama Poliyedath 2 , Winston Sequeira 1 , Joel<br />
A. Block 1 . 1 Rush University Medical Center, Chicago, IL;<br />
2<br />
John Stroger Jr Hospital of Cook County, Chicago, IL.<br />
(256)-1024. Drug-Specific, Time-Dependent Risks of Serious<br />
Bacterial Infections Associated with TNF-α Antagonists. J.<br />
R. Curtis 1 , N. Patkar 1 , A. Xie 1 , C. Martin 2 , K. G. Saag 1 .<br />
1<br />
UAB, Birmingham, AL; 2 Center for Healthcare Policy and<br />
Evaluation, Eden Prarie, MN.<br />
(257)-1025. The effect of Infliximab and timing of vaccination<br />
on the humoral response to influenza vaccination in patients<br />
with Rheumatoid Arthritis and Ankylosing Spondylitis.. Ori<br />
Elkayam 1 , Amir Bashkin 1 , Michal Mendelbaum 2 , Daphna<br />
Paran 1 , Irena Wigler 1 , Irena Litinsky 1 , Ilana Kaufman 1 ,<br />
David Levartovsky 1 , Ella Mendelson 2 , Dan Caspi 1 . 1 Tel Aviv<br />
Medical Center, Tel Aviv, Israel; 2 Sheba Medical Center,<br />
Tel Aviv, Israel.<br />
(258)-1026. Immune Response to Pneumococcal Vaccine in<br />
Patients with Rheumatoid Arthritis under IL-6 Receptor Inhibition<br />
Therapy with Tocilizumab. Tomomi Tsuru 1 , Kimio Terao 2 ,<br />
Midori Suzaki 3 , Hitoshi Nakashima 4 , Toshiaki Amamoto 3 ,<br />
Azusa Akiyama 2 , Takahiro Kakehi 5 , Norihiro Nishimoto 6 .<br />
1<br />
Medical Co.LTA, PS Clinic, Fukuoka, Japan; 2 Chugai<br />
Clinical Research Center Co., Ltd., Tokyo, Japan; 3 Medical<br />
Co.LTA, PS clinic, Fukuoka, Japan; 4 Kyusyu University,<br />
Fukuoka, Japan; 5 Chugai Pharmaceutical Co., Ltd., Tokyo,<br />
Japan; 6 Osaka University, Osaka, Japan.<br />
(259)-1027. Role of Quantiferon-Tb Gold Test in the<br />
Identification of Latent Tuberculosis Infection in Patients with<br />
Rheumatoid Arthritis and Ankylosing Spondylitis. Nevsun Inanc,<br />
Sibel Zehra Aydın, Pamir Atagündüz, Sule Yavuz, Haner<br />
Direskeneli. Marmara Medical School, Istanbul, Turkey.<br />
(260)-1028. The Use of the T-spot.TB Test to Diagnose Latent<br />
Tuberculosis Infection (LTBI) in Rheumatic Disease Patients on<br />
Immunosuppressive Therapy. Samuel M. Behar, Daniel Shin,<br />
Agnes Maier, Jon Coblyn, Simon Helfgott, Michael E.<br />
Weinblatt. Brigham and Women’s Hospital, Boston, MA.<br />
(261)-1029. Late Tuberculosis in Patients with Rheumatoid<br />
Arthritis and Anti-tnf Alfa Therapy. Four Cases in a Single<br />
Center. Agustí Sellas, Emma Beltran, Yolanda Leon, Juan<br />
José De Agustín, Cayetano Alegre, Pere Barceló. Hospital<br />
Vall d’Hebron, Barcelona, Spain.<br />
(262)-1030. Screening of Mycobacterium Tuberculosis by<br />
Immunological Diagnosis Using ELISPOT Technique before<br />
Anti-TNF Therapy. Mitsuhiro Takeno, Shuji Murakami,<br />
Yohei Kirino, Masayoshi Kobayashi, Reikou Watanabe,<br />
Shigeru Ohno, Makoto Kudo, Yuji Watanuki, Yoshiaki<br />
Ishigatsubo. Yokohama City University Graduate School of<br />
Medicine, Department of Internal Medicine and Clinical<br />
Immunology, Yokohama, Japan.<br />
182 (Permanent Board Number)-Abstract Number
(263)-1031. Comparison of Tuberculin Skin Test and<br />
Quantiferon®-TB Gold Test in Patients with Rheumatoid<br />
Arthritis Living in a Tuberculosis Endemic Population. Feride<br />
Gogus 1 , Zafer Günendi 1 , Resul Karakus 2 , Kenan Hizel 3 ,<br />
Fatma Atalay 1 . 1 Gazi University, Department of Physical<br />
Medicine and Rehabilitation, Division of Rheumatology,<br />
Ankara, Turkey; 2 Gazi University, Department of Immunology,<br />
Ankara, Turkey; 3 Gazi University, Department of Infectious<br />
Diseases and Clinical Microbiology, Ankara, Turkey.<br />
(264)-1032. Whole Blood Interferon-Gamma Assay is Useful<br />
to Assess the Risk of Latent Tuberculosis Infection in Patients<br />
with Rheumatoid Arthritis. Akira Suwa 1 , Michito Hirakata 2 ,<br />
Naoki Hasegawa 2 , Yuko Kaneko 2 , Shinji Sato 2 , Eiko Saito 1 ,<br />
Takayuki Wakabayashi 1 , Yasuo Suzuki 1 . 1 Tokai University,<br />
Isehara, Japan; 2 Keio University, Tokyo, Japan.<br />
(265)-1033. Definitive Results of the National French Prospective<br />
RATIO 3-Year Observatory on Tuberculosis in Patients Treated<br />
with TNF Blockers: The Risk Persists but Depends on the Drug.<br />
Florence Tubach 1 , Dominique Salmon 2 , Philippe Ravaud 1 ,<br />
Béatrice Pallot-Prades 3 , Philippe Goupille 4 , Thierry<br />
Schaeverbeke 5 , Philippe Dieudé 1 , Marc Lemann 6 , RATIO,<br />
Xavier Mariette 7 . 1 Bichat Hospital, Paris, France; 2 Cochin<br />
Hospital, Paris, France; 3 Saint-Etienne Hospital, Saint-<br />
Etienne, France; 4 Tours Hospital, Tours, France; 5 Pellegrin<br />
Hospital, Bordeaux, France; 6 St Louis Hospital, Paris,<br />
France; 7 Bicetre Hospital, Le Kremlin Bicetre, France.<br />
(266)-1034. Diverticular Disease in Rheumatoid Arthritis.<br />
Eliza F. Chakravarty 1 , Kaleb Michaud 2 , Frederick Wolfe 3 .<br />
1<br />
Stanford University, Palo Alto, CA; 2 University of<br />
Nebraska Medical Center, Omaha, NE; 3 National Data<br />
Bank for Rheumatic Diseases, Wichita, KS.<br />
(267)-1035. Small Bowel Enteropathy in Rheumatoid Arthritis<br />
- Capsule Endoscopy Study in Anemic Rheumatoid Arthritis<br />
Patients. Petr Bradna, Ilja Tacheci, Jan Bures, Stanislav<br />
Rejchrt, Tomas Soukup, Drahomira Bastecka, Tomas<br />
Douda, Jan Toms. Charles university Medical Faculty<br />
Hradec Kralove and University Hospital Hradec Kralove,<br />
Hradec Kralove, Czech Republic.<br />
(268)-1036. Epidemiology of Major Depression in Japanese<br />
Patients with Rheumatoid Arthritis Using Mini-International<br />
Neuropsychiatric Interview (MINI). Eri Sato 1 , Katsuji<br />
Nishimura 2 , Mikiko Shinozaki 1 , Noriko Iikuni 1 , Toru<br />
Yamada 1 , Ayako Nakajima 1 , Hiroshi Okamoto 1 , Masako<br />
Hara 1 , Taisuke Tomatsu 1 , Naoyuki Kamatani 1 , Hisashi<br />
Yamanaka 1 . 1 Institute of Rheumatology, Tokyo Women’s<br />
Medical University, Tokyo, Japan; 2 Department of<br />
Psychiatry,Tokyo Women’s Medical University, Tokyo, Japan.<br />
(269)-1037. Does Depression Influence Self-Reported Disability<br />
in RA? Evidence of a Gender Effect. Susan J. Bartlett, Jon T.<br />
Giles, Kevin R. Fontaine, Steffany Haaz, Joan M. Bathon.<br />
Johns Hopkins, Baltimore, MD.<br />
(270)-1038. Prevalence Of Vertebral Ankylosis In Patients<br />
With Rheumatoid Arthritis And Symptomatic Involvement Of<br />
The Cervical Spine.. Javier Narvaez, Jose Antonio Narvaez,<br />
Joan Miquel Nolla, Jose Valverde. Hospital Universitari de<br />
Bellvitge, Barcelona, Spain.<br />
(271)-1039. Descriptive Trend Analysis of Infections and<br />
Malignancies in the Abatacept Clinical Development <strong>Program</strong>.<br />
T. A. Simon 1 , A. Covucci 2 , M. Meng 2 , M. L. Skovron 1 .<br />
1<br />
Bristol-Myers Squibb, Hopewell, NJ; 2 Bristol-Myers Squibb,<br />
Princeton, NJ.<br />
Friday, November 9<br />
8:00 a m—4:30 pm<br />
Exhibit Hall A-B<br />
RA: Human Etiology and Pathogenesis II<br />
(272)-1040. Vasoactive Intestinal Peptide (VIP) and VIP<br />
Receptors Expression by Rheumatoid Synoviocytes. Irene<br />
Gutierrez-Cañas 1 , Yasmina Juarranz 2 , Begoña Santiago 1 ,<br />
Javier Leceta 2 , Carmen Martínez 2 , Rosa P. Gomariz 3 ,<br />
Jose L. Pablos 1 . 1 Hospital 12 de Octubre, Madrid, Spain;<br />
2<br />
Universidad Complutense, Madrid, Spain; 3 Universidad<br />
Computense, Madrid, Spain.<br />
(273)-1041. Decreased Th1 Response in Rheumatoid Arthritis:<br />
Contribution of IL-17 through Downregulation of IL-12Rβ2 and<br />
Cooperative Effects with TGF-β. Myew-Ling Toh, Masanori<br />
Kawashima, Arnaud Hot, Gonzales Gaelle, Phillippe<br />
Miossec, Saloua Zrioual, Pierre Miossec. Unité Mixte<br />
Hospices Civils de Lyon, Lyon, France.<br />
(274)-1042. Mannose Binding Lectin Gene Polymorphisms<br />
are Associated with Disease Activity and Functional Disability<br />
in Untreated, Anti-CCP Positive Early Rheumatoid Arthritis<br />
Patients. Søren Jacobsen 1 , Peter Garred 1 , Hans Ole<br />
Madsen 1 , Arne Svejgaard 1 , Niels Heegaard 2 , Merete Lund<br />
Hetland 3 , Kristian Stengaard-Pedersen 4 , Peter Junker 5 ,<br />
Tine Lottenburger 6 , Torkel Ellingsen 4 , Lis Smedegaard<br />
Andersen 7 , Ib Hansen 4 , Henrik Skjødt 3 , Henrik Skjødt 3 ,<br />
Jens Kristian Pedersen 6 , Ulrik Birk Lauridsen 3 , Anders<br />
Svendsen 6 , Ulrik Tarp 4 , Jan Pødenphant 8 , Gert Hansen 6 ,<br />
Hanne Lindegaard 5 , Anselmo de Carvalho 4 , Mikkel<br />
Østergaard 6 , Kim Hørslev-Petersen 6 . 1 Copenhagen University<br />
Hospital at Rigshospitalet, Copenhagen, Denmark; 2 Statens<br />
Serum Institut, Copenhagen, Denmark; 3 Copenhagen<br />
University Hospital at Hvidovre, Copenhagen, Denmark;<br />
4<br />
Aarhus University Hospital, Aarhus, Denmark; 5 Odense<br />
University Hospital, Odense, Denmark; 6 Graasten<br />
Rheumatism Hospital, Graasten, Denmark; 7 Rheumatism<br />
Hospital, Graasten, Denmark; 8 Copenhagen University<br />
Hospital at Herlev, Copenhagen, Denmark.<br />
Poster Session B<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 183
Poster Session b<br />
(275)-1043. Role of Placental Growth Factor and its Receptor<br />
Flt-1 in Rheumatoid Inflammation. Seung-Ah Yoo, Jin-Sun<br />
Kong, Hyun-Jin Kim, Seung-Ki Kwok, Hyun-Sook Kim,<br />
Chul-Soo Cho, Wan-Uk Kim. Department of Internal<br />
Medicine, School of Medicine, Catholic University of<br />
Korea, Seoul, Republic of Korea.<br />
(276)-1044. Fibrin Promotes Invasiveness of Rheumatoid Arthritis<br />
Synovial Fibroblasts by the Induction of Matrix Metalloproteinases 1<br />
and 3. Olga Sanchez-Pernaute 1 , Emmanuel Karouzakis 1 , Astrid<br />
Juengel 1 , Peter Kuenzler 1 , Renate E. Gay 1 , Christoph Kolling 2 ,<br />
Gabriel Herrero-Beaumont 3 , Steffen Gay 1 , Michel Neidhart 1 .<br />
1<br />
Center of Experimental Rheumatology, University Hospital,<br />
Zurich, Switzerland; 2 Department of Orthopedic Surgery,<br />
Schulthess Klinik, Zurich, Switzerland; 3 Rheumatology Section,<br />
Fundacion Jimenez Di az, Madrid, Spain.<br />
(277)-1045. Relationship of Serum Tweak Level to Cytokine<br />
Levels, Disease Activity and Response to Anti-tnf Treatment in<br />
Patients with Rheumatoid Arthritis. Min-Chan Park, Sang-Tae<br />
Choi, Ji-Hye Kim, Soo-Kon Lee. Yonsei University College<br />
of Medicine, Seoul, Republic of Korea.<br />
(278)-1046. Resequencing of the Human Major<br />
Histocompatibility Complex in Rheumatoid Arthritis Patients<br />
and Healthy Controls in Alaska Natives of Southeast Alaska.<br />
Elizabeth D. Ferucci 1 , Zhen Yan 2 , Dan E. Geraghty 2 , Yin<br />
Yang 2 , Anne P. Lanier 1 , Wade P. Smith 2 , Lue Ping Zhao 2 ,<br />
John A. Hansen 2 , J Lee Nelson 3 . 1 Alaska Native Tribal<br />
Health Consortium, Anchorage, AK; 2 Fred Hutchinson<br />
Cancer Research Center, Seattle, WA; 3 Fred Hutchinson<br />
Cancer Research Center, U of WA, Seattle, WA.<br />
(279)-1047. HLA Associations with T Cell Reactivity to Type<br />
II Collagen (CII) Epitopes in Patients with Rheumatoid Arthritis<br />
(RA). Arnold E. Postlethwaite 1 , Andrew H. Kang 1 , Laura<br />
D. Carbone 1 , Jerome M. Seyer 1 , Robert Endres 2 , Francis<br />
Ward 2 . 1 University of Tennessee Memphis, Memphis, TN;<br />
2<br />
Duke University Medical Center, Durham, NC.<br />
(280)-1048. Adrenomedullin, a Potent Antiapoptotic and<br />
Angiogenic Peptide, Regulates Adhesion and Migration of<br />
Rheumatoid Fibroblast-Like Synoviocytes (FLS). Marie-<br />
Dominique Ah Kioon, Carine Asensio, Benjamin Uzan,<br />
Hang-Korng Ea, Martine Cohen-Solal, Frédéric Lioté.<br />
INSERM U606, Paris, France.<br />
(281)-1049. HLA-DRB1*0901 is Associated with Anti-CCP<br />
Antibodies in Native <strong>American</strong> RA Patients and Their First<br />
Degree Relatives. Hani El-Gabalawy 1 , David Robinson 1 ,<br />
Donna Hart 1 , Brenda Elias 1 , Christine Peschken 1 , Marlis<br />
Schroeder 1 , Janet Markland 2 , J. Lee Nelson 3 , Marvin<br />
Fritzler 4 , Kiem Oen 1 . 1 University of Manitoba, Winnipeg,<br />
MB, Canada; 2 University of Saskachewan, Saskatoon,<br />
SK, Canada; 3 University of Washington, Seattle, WA;<br />
4<br />
University of Calgary, Calgary, AB, Canada.<br />
(282)-1050. A Single Nucleotide Polymorphism in IRF5<br />
Promoter Region is Associated With Rheumatoid Arthritis<br />
in Japanese Population. Kenichi Shimane 1 , Yuta Kochi 1 ,<br />
Akari Suzuki 1 , Ryo Yamada 1 , Kazuhiko Yamamoto 2 .<br />
1<br />
Laboratory for Rheumatic Diseases, SNP Research Center,<br />
RIKEN, Yokohama, Japan; 2 Department of Allergy and<br />
Rheumatology, Graduate School of Medicine, University of<br />
Tokyo, Tokyo, Japan.<br />
(283)-1051. In Early Rheumatoid Arthritis, B Lymphocyte<br />
Activation Biomarkers are Increased Independently of Baff and<br />
Correlate with Disease Activity and Early Radiological Lesions:<br />
Results from the French Multicenter Prospective Cohort of 813<br />
Patients with Early Arthritis (espoir). Jacques-Eric Gottenberg 1 ,<br />
Corinne Miceli-Richard 1 , Philippe Goupille 2 , Nathalie<br />
Rincheval 3 , Bernard Combe 3 , Xavier Mariette 1 . 1 Bicetre<br />
Hospital, Le Kremlin Bicetre, France; 2 Tours Hospital,<br />
Tours, France; 3 La Peyronie Hospital, Montpellier, France.<br />
(284)-1052. The T Allele of the PTPN22 1858C/T<br />
Polymorphism is Associated with Markers of Increased Disease<br />
Severity in Rheumatoid Arthritis. Melissa R. Snyder, Carlotta<br />
Nannini, Cynthia S. Crowson, Eric L. Matteson, Henry A.<br />
Homburger. Mayo Clinic College of Medicine, Rochester, MN.<br />
(285)-1053. Association of the Ifih1-gca-kcnh7 Chromosomal<br />
Region With Rheumatoid Arthritis. Jezabel Varade, Luis<br />
Rodriguez, Alfonso Martinez-Doncel, Juan A. Jover, Emilio<br />
Gomez de la Concha, Benjamin Fernandez-Gutierrez, Elena<br />
Urcelay. Hospital Clinico San Carlos, Madrid, Spain.<br />
(286)-1054. Novel Association of a SNP in the 5-Regulatory<br />
Region of the DNase II Gene with Susceptibility to Rheumatoid<br />
Arthritis in Male Patients. Manuela Rossol, Matthias Pierer,<br />
Sybille Arnold, Christoph Baerwald, Ulf Wagner. University<br />
of Leipzig, Department of Medicine IV, Leipzig, Germany.<br />
(287)-1055. Novel Splice Variants of RasGRP4 Frequently<br />
Expressed in Patients with Rheumatoid Arthritis. Toko<br />
Hashimoto 1 , Shinsuke Yasuda 1 , Hiroshi Kataoka 1 , Tetsuya<br />
Horita 1 , Tatsuya Atsumi 1 , Richard L. Stevens 2 , Takao<br />
Koike 1 . 1 Hokkaido University Graduate School of Medicine,<br />
Sapporo, Japan; 2 Brigham and Women’s Hospital and<br />
Harvard Medical School, Boston, MA.<br />
(288)-1056. Genetic Influence on the Loss of Peripheral Bone<br />
Density in Rheumatoid Arthritis - Association with HLA-DRB1.<br />
Agustin Escalante 1 , Johan Kälvesten 2 , Jakob Algulin 2 ,<br />
Inmaculada del Rincon 1 . 1 University of Texas Health Science<br />
Center, San Antonio, TX; 2 Sectra AB, Linköping, Sweden.<br />
(289)-1057. Statin-Induced Apoptosis of Synovial Fibroblasts<br />
is Associated with Increased Expression of Bim and PUMA.<br />
Alison M. Connor 1 , Stuart A. Berger 1 , Christopher J.<br />
Paige 1 , Nathalie Simard 1 , Edward C. Keystone 2 . 1 University<br />
Health Network, Toronto, ON, Canada; 2 Mt Sinai Hospital<br />
University of Toronto, Toronto, ON, Canada.<br />
184 (Permanent Board Number)-Abstract Number
(290)-1058. Production of Matrix Metalloproteinases in<br />
Rheumatoid Arthritis is Regulated by Phosphatidylinositol<br />
3-Kinase Gamma. Noreen Pundt 1 , Marvin A. Peters 1 , Inga<br />
Kühnel 1 , Christina Wunrau 1 , Katja Neugebauer 1 , Lars H.<br />
Meyer 1 , Georg Schett 2 , Silvia Hayer 3 , Anja Baier 4 , Tzvetanka<br />
Bondeva 5 , Steffen Gay 6 , Thomas Ruekle 7 , Montserrat<br />
Camps 7 , Matthias K. Schwarz 7 , Christian Rommel 7 ,<br />
Reinhard Wetzker 5 , Thomas Pap 1 . 1 University Hospital<br />
Muenster, Muenster, Germany; 2 University Hospital<br />
Erlangen, Erlangen, Germany; 3 University Vienna, Vienna,<br />
Austria; 4 University Hospital Magdeburg, Magdeburg,<br />
Germany; 5 University Hospital Jena, Jena, Germany;<br />
6<br />
University Hospital Zurich, Zurich, Austria; 7 Serono Pharm<br />
Res Inst., Geneva, Switzerland.<br />
(291)-1059. The Novel Chemokine Receptor CXCR7 is Expressed<br />
in Rheumatoid Arthritis Synovium. Yvonne Y. Rengel Colina 1 ,<br />
Renate E. Gay 1 , Christoph Kolling 2 , Beat A. Michel 1 ,<br />
Steffen Gay 1 , Caroline Ospelt 1 . 1 Center of Experimental<br />
Rheumatology, University Hospital Zurich and Zurich Center<br />
of Integrative Human Physiology (ZIHP), Zurich, Switzerland;<br />
2<br />
Schulthess Clinic, Zurich Switzerland, Zurich, Switzerland.<br />
(292)-1060. An Important Role for Aberrantly Glycosylated<br />
Mucin in the Pathogenesis of Rheumatoid Arthritis. Hidetaka<br />
Ishino 1 , Yutaka Kawahito 1 , Masahide Hamaguchi 1 , Noriko<br />
Takeuchi 2 , Daisaku Tokunaga 3 , Tatsuya Hojo 3 , Masataka<br />
Kohno 1 , Yasunori Tubouchi 1 , Aihiro Yamamoto 1 ,<br />
Masatoshi Kadoya 1 , Mikiko Niimi 1 , Takahiro Senoo 1 ,<br />
Toshikazu Yoshikawa 1 , Hiroshi Nakada 2 . 1 Inflammation<br />
and Immunology, Graduate School of Medical Science,<br />
Kyoto Prefectural University of Medicine, Kyoto, Japan;<br />
2<br />
Department of Biotechnology, Faculty of Engineering,<br />
Kyoto Sangyo University, Kyoto, Japan; 3 Department of<br />
Orthopaedics, Graduate School of Medical Science, Kyoto<br />
Prefectural University of Medicine, Kyoto, Japan.<br />
(293)-1061. Type I Diabetes Mellitus is Strongly Associated with<br />
Rheumatoid Arthritis. Katherine P. Liao 1 , Marie Gunnarsson 2 ,<br />
Henrik Kallberg 2 , Bo Ding 2 , Lars Klareskog 2 , Johan Askling 2 ,<br />
Lars Alfredsson 2 . 1 Brigham and Women’s Hospital, Boston,<br />
MA; 2 Karolinska Institute, Stockholm, Sweden.<br />
(294)-1062. Abnormal T Cell Differentiation at the Onset of<br />
Rheumatoid Arthritis is Associated with Persistently Aggressive and<br />
Erosive Disease. Ruediger B. Mueller 1 , Alla Skapenko 2 , Jorg<br />
Wendler 3 , Joachim R. Kalden 1 , Hendrik Schulze-Koops 2 .<br />
1<br />
University of Erlangen-Nuremberg, Erlangen, Germany;<br />
2<br />
Division of Rheumatology, Medizinische Poliklinik“<br />
Innenstadt, Ludwig Maximilians University Munich,<br />
Munich, Germany; 3 Rheumatologische Gemeinschaftspraxis,<br />
Moehrendorferstr. 1, Erlangen, Germany.<br />
(295)-1063. Long Distance Migration of RASF: Role of<br />
Extracellular Matrix. Stephanie Lefèvre 1 , Anette Knedla 1 ,<br />
Christoph Tennie 1 , Ingo H. Tarner 1 , Henning Stürz 2 ,<br />
Jürgen Steinmeyer 3 , Steffen Gay 4 , Ulf Müller-Ladner 1 , Elena<br />
Neumann 1 . 1 Internal Med and Rheumatology, Justus-Liebig-<br />
University of Gießen, Bad Nauheim, Germany; 2 Dept<br />
Orthopedics and Orthopedic Surgery, Justus-Liebig-University<br />
of Gießen, Gießen, Germany; 3 Dept Orthopedics and Exp<br />
Orthopedics, Justus-Liebig-University of Gießen, Gießen,<br />
Germany; 4 Ctr Exp Rheumatology, USZ, Zürich, Switzerland.<br />
(296)-1064. Can Pain Sensitivity SNPs be Replicated in<br />
Rheumatoid Arthritis (RA) Patients?. Roberta J. Glass, Jing<br />
Cui, Elizabeth W. Karlson, Nancy E. Maher, Michael E.<br />
Weinblatt, Nancy A. Shadick. Brigham and Women’s<br />
Hospital, Boston, MA.<br />
(297)-1065. Association and Expression Study of PRKCH Gene<br />
in a French Caucasian Population with Rheumatoid Arthritis.<br />
Vitor H. Teixeira, Laurent Jacq, Jeoiakim Moore, Sandra<br />
Lasbleiz, Pascal Hilliquin, François Cornélis, Elisabeth Petit-<br />
Teixeira. GenHotel-EA3886, 91 057 Evry, France.<br />
(298)-1066. Evidence of Epistasis Between Interleukin-1 and<br />
Selenoprotein-S with Susceptibility to RA. Ioanna Marinou 1 ,<br />
Marion C. Dickson 2 , Michael H. Binks 2 , Douglas S.<br />
Montgomery 2 , Kevin Walters 1 , Anthony G. Wilson 1 .<br />
1<br />
University of Sheffield, Sheffield, United Kingdom;<br />
2<br />
GlaxoSmithKline R&D, Stevenage, United Kingdom.<br />
(299)-1067. PDCD1 Gene Polymorphisms are Not Associated<br />
With Susceptibility or Severity of Rheumatoid Arthritis in<br />
Japanese. Noriko Iikuni 1 , Takuji Iwamoto 2 , Katsunori Ikari 1 ,<br />
Eisuke Inoue 1 , Taisuke Tomatsu 1 , Masako Hara 1 , Hisashi<br />
Yamanaka 1 , Shigeki Momohara 1 , Naoyuki Kamatani 1 .<br />
1<br />
Tokyo Women’s Medical University, Tokyo, Japan; 2 Keio<br />
University, Tokyo, Japan.<br />
(300)-1068. Receiver Operating Characteristic Curve Analysis: A<br />
Novel Approach to Evaluating Synovial Tissue Biomarkers. Alexis<br />
R. Ogdie 1 , H. Ralph Schumacher 1 , Xiaoxia Yu 2 , Cesar Diaz-<br />
Torne 3 , Lie Dai 4 , Lan Chen 1 , Frank Pessler 1 . 1 University<br />
of Pennsylvania, Philadelphia, PA; 2 Traditional Chinese<br />
Medicine - Western Medicine Hospital, Cangzhou, China;<br />
3<br />
Universitari de Bellvitge, Barcelona, Spain; 4 Sun Yat-sen<br />
University, Guangzhou, China.<br />
(301)-1069. Membrane Incorporation of Eicosapentaenoic<br />
and Docosahexaenoic Omega-3 Fatty Acids Alters the Profile<br />
of Prostaglandin Biosynthesis in Response to Proinflammatory<br />
Cytokine IL-1Beta in Rheumatoid Synovial Fibroblast. Lihua<br />
Yang, Fumiaki Kojima, Mohit Kapoor, Leslie J. Crofford.<br />
University of Kentukcy, Lexington, KY.<br />
Poster Session B<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 185
Poster Session b<br />
(302)-1070. Anti-Cyclic Citrullinated Peptide Antibody Isotypes<br />
in Rheumatoid Arthritis: Association with Disease Duration,<br />
Rheumatoid Factor Production and the Presence of Shared<br />
Epitope. Gabriella Lakos 1 , Lilla Soós 2 , Andrea Fekete 1 ,<br />
Zoltán Szabó 2 , Margit Zeher 3 , Ildikó F. Horváth 3 , Katalin<br />
Dankó 3 , Anikó Kapitány 1 , Ágnes Gyetvai 1 , Gyula Szegedi 1 ,<br />
Zoltán Szekanecz 2 . 1 University of Debrecen Medical Center,<br />
Third Department of Medicine, Laboratory of Immunology,<br />
Debrecen, Hungary; 2 University of Debrecen Medical<br />
Center, Third Department of Medicine, Rheumatology<br />
Division, Debrecen, Hungary; 3 University of Debrecen<br />
Medical Center, Third Department of Medicine, Division of<br />
Clinical Immunology, Debrecen, Hungary.<br />
(303)-1071. Anti-glucose-6-phosphate Isomerase, Anti-cyclic<br />
Citrullinated Peptide Antibodies and HLA-DRB1 Genotypes in<br />
Japanese Patients with Early Rheumatoid Arthritis. Takefumi<br />
Furuya 1 , Isao Matsumoto 2 , Naoyuki Tsuchiya 3 , Masayuki<br />
Hakoda 4 , Naomi Ichikawa 1 , Toru Yago 1 , Yuki Nanke 1 ,<br />
Takayuki Sumida 2 , Naoyuki Kamatani 1 , Shigeru Kotake 1 .<br />
1<br />
Institute of Rheumatology, Tokyo Women’s Medical<br />
University, Tokyo, Japan; 2 Clinical Immunology, University<br />
of Tsukuba, Tsukuba, Japan; 3 Doctoral <strong>Program</strong> in Social<br />
and Environmental Medicine, University of Tsukuba,<br />
Tsukuba, Japan; 4 Department of Nutritional Sciences,<br />
Yasuda Women’s University, Hiroshima, Japan.<br />
(304)-1072. Molecular Signature of the Rheumatoid Module and<br />
the Potential for Predicting Prognosis of Rheumatoid Arthritis.<br />
Paul A. Hessian, Ulrike Lehnigk, Pauline van der Wielen,<br />
Charlotta Sandler, John Highton, Les McNoe, Dong Ho<br />
Kim. University of Otago, Dunedin, New Zealand.<br />
(305)-1073. Environmental Factors Related to Development of<br />
Rheumatoid Arthritis. Heidi Kokkonen, Ewa Berglin, Solbritt<br />
Rantapää Dahlqvist. Dept of Rheumatology, Umea, Sweden.<br />
(306)-1074. Immature Dendritic Cells generated in GM-CSF<br />
and its Function in Inflammatory Arthritis. Koji Nomura,<br />
Tetsuya Tomita, Shoko Kuroda, Hideki Yoshikawa. Osaka<br />
University Graduate School of Medicine, Suita, Japan.<br />
(307)-1075. Heat Shock Protein Gp96 and its Role in<br />
Rheumatoid Arthritis. Qi-Quan Huang 1 , Adedamola<br />
Adebayo 1 , Christopher V. Nicchitta 2 , Richard M. Pope 1 .<br />
1<br />
Northwestern University, Feinberg School of Medicine,<br />
Chicago, IL; 2 Duke University, Durham, NC.<br />
(308)-1076. Polymorphisms in the Selenoprotein S Gene: Lack of<br />
Association with Rheumatoid Arthritis. Luis Rodriguez, Jezabel<br />
Varade, Alfonso Martinez-Doncel, Elena Urcelay, Emilio<br />
Gomez de la Concha, Juan A. Jover, Benjamin Fernandez-<br />
Gutierrez. Hospital Clinico San Carlos, Madrid, Spain.<br />
Friday, November 9<br />
8:00 a m—4:30 pm<br />
Exhibit Hall A-B<br />
Sjögren’s Syndrome<br />
(309)-1077. Development of Autoimmune Exocrinopathy<br />
Resembling Sjögren’s Syndrome in Rbap48 Transgenic Mice.<br />
Yoshio Hayashi, Sr., Naozumi Ishimaru. Tokushima<br />
University, Tokushima, Japan.<br />
(310)-1078. Lymphotoxin-Beta Receptor Axis Modulates HEV<br />
Status and Gene Expression Patterns in Exocrine Glands in<br />
the NOD Mouse Model of Sjögren’s Syndrome. Roy A. Fava 1 ,<br />
Sheryl G. Wood 1 , Anne Isine Bolstad 2 , Kathrine Skarstein 2 ,<br />
Margaret Gatumu 2 , Jadwiga Bienkowska 3 , Norm Allaire 3 ,<br />
Leila Reider 3 , Caitlin Buttaro 3 , Jeffrey L. Browning 3 . 1 VA<br />
Medical Center, White River Junction, VT; 2 University of<br />
Bergen, Bergen, Norway; 3 Biogen Idec, Cambridge, MA.<br />
(311)-1079. Expression of Proteasomal Immunosubunit Beta1i<br />
(LMP2) is Suppressed in Inflammatory Infiltrates of Minor<br />
Salivary Glands in Sjögren’s Syndrome. Sonja Scheffler, Lars<br />
Morawietz, Anja Dankof, Lorena Martinez Gamboa,<br />
Thomas Doerner, Gerd-Rüdiger Burmester, Eugen Feist.<br />
Charité University Hospital, Berlin, Germany.<br />
(312)-1080. Constricture of the Excretory Duct in Parotid Salivary<br />
Glands of a Mouse Model of Sjögren’s Syndrome that Exhibits Decreased<br />
Salivary Flow. Shannon M. Maier 1 , Biji T. Kurien 2 , Anil D’Souza 1 ,<br />
Sima Asfa 2 , R. Hal Scofield 2 . 1 University of Oklahoma Health<br />
Sciences Center, Oklahoma City, OK; 2 Oklahoma Medical<br />
Research Foundation, Oklahoma City, OK.<br />
(313)-1081. Persistance of Maternally Transfered Anti-Ro 274<br />
Peptide Antibodies in a Sjögrens Syndrome Mouse Model. Sima<br />
Asfa 1 , Anil D’souza 2 , Yaser Dorri 2 , Ali Khalili 2 , Biji T.<br />
Kurien 1 , R. Hal Scofield 1 . 1 Oklahoma Medical Research<br />
Foundation, Oklahoma City, OK; 2 University of Oklahoma<br />
Health Sciences Center, Oklahoma City, OK.<br />
(314)-1082. Human Chorionic Gonadotropin Prevents Sjögren’s-<br />
Like Exocrinopathy in Mice. Na Li 1 , Toshikatsu Shigihara 1 ,<br />
Athanasios G. Tzioufas 2 , Abner L. Notkins 2 , Ji-Won Yoon 1 ,<br />
Hee-Sook Jun 1 . 1 Chicago Medical School, North Chicago,<br />
IL; 2 National Institutes of Health, Bethesda, MD.<br />
(315)-1083. New Murine Model for Sjögren’s Syndrome<br />
Established by M3 Muscarinic Acethylcholine Receptor<br />
Immunization. Ei Wakamatsu, Yumi Nakamura, Isao<br />
Matsumoto, Hiroto Tsuboi, Daisuke Goto, Satoshi Ito,<br />
Akito Tsutsumi, Takayuki Sumida. Clinical Immunology,<br />
Advanced Biochemical Applications, Graduate School<br />
Comprehensive Human Science, University of Tsukuba,<br />
Tsukuba, Japan.<br />
186 (Permanent Board Number)-Abstract Number
(316)-1084. Novel Genetic Associations with Primary Sjögren’s<br />
Syndrome. Beth L. Cobb, John B. Harley. Oklahoma Medical<br />
Research Foundation, Oklahoma City, OK.<br />
(317)-1085. Association of an Irf-5 Gene Functional<br />
Polymorphism with SjöGren’S Syndrome. Corinne Miceli-<br />
Richard 1 , Pascale Loiseau 2 , Emmanuelle Comets 3 , Xavier<br />
Puechal 4 , Eric Hachulla 5 , Xavier Mariette 1 . 1 Hôpital Bicêtre,<br />
Le Kremlin Bicetre, France; 2 Hôpital Saint-Louis, Paris,<br />
France; 3 Hôpital Bichat, Paris, France; 4 Hôpital du Mans, Le<br />
Mans, France; 5 Centre Hosptalier de Lilles, Lilles, France.<br />
(318)-1086. Fcg Receptor IIa and IIIa Polymorphisms in Primary<br />
Sjögren Syndrome. Corinne Miceli-Richard 1 , Marc Ohresser 2 ,<br />
Eric Hachulla 3 , Xavier Puechal 4 , Hervé Watier 2 , Xavier<br />
Mariette 1 . 1 Bicetre Hospital, Le Kremlin Bicetre, France;<br />
2<br />
UPRES-EA 3853, Tours, France; 3 CHU Lilles, Lilles,<br />
France; 4 Hôpital du Mans, Le Mans, France.<br />
(319)-1087. Is Id3 Gene Involved in Human Primary Sjögren’s<br />
Syndrome ?. Jérémie Sellam 1 , Marc Ittah 1 , Frédéric Lavie 1 ,<br />
Alexis Proust 1 , Jacques-Eric Gottenberg 1 , Pascale Loiseau 2 ,<br />
Xavier Mariette 1 , Corinne Miceli-Richard 1 . 1 Bicetre<br />
Hospital, Le Kremlin Bicetre, France; 2 Saint-Louis Hospital,<br />
Paris, France.<br />
(320)-1088. Up-Regulation of Interferon Inducible 150kDa<br />
ADAR1 Gene Expression and Altered Editing of the Interferon<br />
Alpha Receptor 2 (IFNAR2) Gene Transcripts in Peripheral Blood<br />
Mononuclear Cells (PBMCs) of Primary Sjögren’s Syndrome (pSS)<br />
Patients. Dama Laxminarayana, Kenneth S. O’Rourke, Irene<br />
Olorenshaw. Section on Rheumatology and Immunology,<br />
Department of Internal Medicine, Wake Forest University<br />
School of Medicine, Winston Salem, NC.<br />
(321)-1089. Quantitative Levels of Anti-ssa, Anti-ssb, and Antirnp<br />
Antibodies in Primary SjöGren’S Syndrome: Correlation<br />
with Baff, B Cell Activation Markers, and Disease Activity.<br />
Jacques-Eric Gottenberg 1 , Sophie Candon 2 , Nadine Porcher-<br />
Vasseur 1 , Frederic Desmoulins 1 , Lucienne Chatenoud 2 ,<br />
Xavier Mariette 1 . 1 Bicetre Hospital, Le Kremlin Bicetre,<br />
France; 2 Necker Hospital, Paris, France.<br />
(322)-1090. Clinical and Immunological Expression of the<br />
Epidemiologic Subsets of Primary Sjögren’s Syndrome. Multicenter<br />
Study of 1000 Patients. Manuel Ramos-Casals 1 , Rosé Solans 2 ,<br />
José Rosas 3 , María Teresa Camps 4 , Antonio Gil 5 , Javier<br />
del Pino 6 , Jaime Calvo-Alen 7 , Juan Jiménez-Alonso 8 , María<br />
Luisa Micó 9 , Juan Beltrán 10 , Rafael Belenguer 11 , Lucio<br />
Pallarés 12 , The GEMESS Study Group. 1 Department<br />
of Autoimmune Diseases, Hospital Clinic, Barcelona,<br />
Spain; 2 Department of Internal Medicine, Vall d’Hebrón<br />
Hospital, Barcelona, Spain; 3 Rheumatology Unit,<br />
Hospital de Vilajoyosa, Alicante, Spain; 4 Department<br />
of Internal Medicine, Hospital Carlos Haya, Málaga,<br />
Spain; 5 Department of Internal Medicine, Hospital La<br />
Paz, Madrid, Spain; 6 Department of Internal Medicine<br />
and Rheumatology, Hospital Universitario de Salamanca,<br />
Salamanca, Spain; 7 Rheumatology Section, Hospital de<br />
Sierrallana, Torrelavega, Spain; 8 Department of Internal<br />
Medicine, Hospital Virgen de las Nieves, Granada, Spain;<br />
9<br />
Department of Internal Medicine, La Fe Hospital,<br />
Valencia, Spain; 10 Rheumatology Unit, Hospital General de<br />
Castellón, Castellón, Spain; 11 Rheumatology Unit, Hospital<br />
9 d’Octubre, Valencia, Spain; 12 Department of Internal<br />
Medicine, Son Dureta Hospital, Palma de Mallorca, Spain.<br />
(323)-1091. Longitudinal Analysis of Lymphocyte Subsets in<br />
Patients with Primary Sjögren’s Syndrome (pSS) Treated with<br />
Rituximab: Results from an Open-Label Clinical Trial. Marc<br />
C. Levesque 1 , Nina Luning Prak 2 , E. William St. Clair 1 ,<br />
Wenzhao Meng 2 , Yang Zhu Du 2 , Patrice D. McNair 1 , John<br />
F. Whitesides 1 , Garnett Kelsoe 1 , Susheel Reddy 3 , Philip<br />
L. Cohen 2 , Autoimmunity Centers of Excellence. 1 Duke<br />
University Medical Center, Durham, NC; 2 University of<br />
Pennsylvania, School of Medicine, Philadelphia, PA; 3 Rho,<br />
Inc., Chapel Hill, NC.<br />
(324)-1092. Objective Measures in Sjögren’s Syndrome are<br />
Strongly Associated with Each Other but not with Sicca Symptoms:<br />
Analysis of 564 Enrollees in the SICCA International Registry<br />
and Repository. T. Daniels 1 , J. S. Greenspan 1 , D. P. Cox 1 ,<br />
L. A. Criswell 1 , Y. DeSouza 1 , Y. Dong 2 , D. Greenspan 1 ,<br />
A. Heidenreich 3 , S. Johansen 4 , R. Jordan 1 , K. Kitagawa 5 ,<br />
H. Lanfranchi 3 , K. Sack 1 , M. Schiødt 4 , C. Shiboski 1 , S.<br />
Shiboski 1 , S. Sugai 5 , H. Umehara 5 , J. Whitcher 1 , A. Wu 1 ,<br />
S. Zhang 2 . 1 University of California, San Francisco, San<br />
Francisco, CA; 2 Peking Union Medical College, Beijing,<br />
China; 3 University of Buenos Aires, Buenos Aires,<br />
Argentina; 4 Copenhagen University Hospital, Glostrup,<br />
Denmark; 5 Kanazawa Medical University, Kanazawa, Japan.<br />
(325)-1093. Increased Psychiatric Comorbidity in Primary<br />
SS.-Association with Autoantibodies Against Neuropeptides.<br />
D. A. Karaiskos 1 , C. P. Mavragani 2 , M. Hamze Sinno 3 ,<br />
P. Dechellot 3 , S. O. Fetissov 3 , H. M. Moutsopoulos 1 .<br />
1<br />
University of Athens, Medical School, Athens, Greece;<br />
2<br />
Hospital for Special Syrgery, NY, NY; 3 University of Rouen,<br />
Faculty of Medicine, Rouen, France.<br />
(326)-1094. Safety and Efficacy of Rituximab in Sjögren’s<br />
Syndrome: Results of a Randomised, Placebo Controlled Pilot Study.<br />
Shouvik Dass 1 , Simon J. Bowman 2 , Edward M. Vital 1 , Kei<br />
Ikeda 1 , Colin T. Pease 1 , Paul Emery 1 . 1 University of Leeds,<br />
Leeds, United Kingdom; 2 Department of Rheumatology,<br />
Selly Oak Hospital, Birmingham, United Kingdom.<br />
(327)-1095. Pulmonary Arterial Hypertension (PAH) in<br />
Primary Sjögren’s Syndrome: Report of 9 Cases. David Launay 1 ,<br />
Eric Hachulla 1 , Pierre-Yves Hatron 1 , Xavier Jais 2 , Gérald<br />
Simonneau 2 , Marc Humbert 2 . 1 Hôpital Claude-Huriez, Lille,<br />
France; 2 Centre de Reference National sur l’HTAP, Service<br />
De Pneumologie Et Reanimation, Clamart, France.<br />
Poster Session B<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 187
Poster Session b<br />
(328)-1096. Effect of Nizatidine, a H2 Receptor Antagonist on<br />
the Xerostomia in Patients with Sjögren’s Syndrome. Fumitaka<br />
Shiozawa, Kuninobu Wakabayashi, Tsuyoshi Odai, Takeo<br />
Isozaki, Mizuho Matsunawa, Nobuyuki Yajima, Yusuke<br />
Miwa, Masao Negishi, Hirotsugu Ide, Tsuyoshi Kasama.<br />
Showa University, Tokyo, Japan.<br />
(329)-1097. The Effect of Modafinil on Fatigue and Cognitive<br />
Function in Patients with Sjögren’s Syndrome. Thomas C.<br />
Namey. Univ. of Tennessee, Knoxville, Knoxville, TN.<br />
(330)-1098. Fatigue, Discomfort, and Burden of Illness Among<br />
Sjögren’s Syndrome (SS) Patients in the United States. S. J.<br />
Bowman 1 , B. M. Segal 2 , P. C. Fox 3 , F. B. Vivino 4 , N.<br />
Murukutla 5 , T. V. Kamath 6 , M. Yin 6 , L. McLean 6 . 1 U Hosp<br />
Birmingham, United Kingdom; 2 U of MN, MN; 3 PC Fox<br />
Cnsltng, MD; 4 Penn Presb Med Ctr, PA; 5 Harris Interactive,<br />
NY; 6 Genentech, CA.<br />
(331)-1099. Prevalence of Sensory Symptoms in Primary Sjögren’s<br />
Syndrome (pSS) and Relationship of Neuropathic Symptoms to<br />
Depression and Fibromyalgia. B. M. Segal 1 , S. J. Bowman 2 , P.<br />
C. Fox 3 , F. B. Vivino 4 , N. Murukutla 5 , T. V. Kamath 6 , M.<br />
Yin 6 , L. McLean 6 . 1 U of MN, MN; 2 U Hosp Birmingham,<br />
United Kingdom; 3 PC Fox Cnsltng, MD; 4 Penn Presb Med<br />
Ctr, PA; 5 Harris Interactive, NY; 6 Genentech, CA.<br />
(332)-1100. Prevalence, Severity and Predictors of Fatigue in<br />
Primary Sjögren’s Syndrome. Barbara M. Segal, MD 1 , Tyson<br />
B. Rogers 1 , Joanlise M. Leon 1 , A. N.M. Nazmul-Hossain,<br />
DDS 1 , Eshrat S. Emamian, DDS 1 , Nelson L. Rhodus,<br />
DMD 1 , Kathy L. Moser, PhD 2 . 1 University of Minnesota,<br />
Minneapolis, MN; 2 Oklahoma Medical Research<br />
Foundation, Oklahoma City, OK.<br />
(333)-1101. Anti-Cyclic Citrullinated Peptide Antibodies in<br />
Primary Sjögren’s Syndrome may be Associated to Non-Erosive<br />
Synovitis. Piercarlo Sarzi-Puttini 1 , Fabiola Atzeni 1 , Nicola<br />
Lama 2 , Eleonora Bonacci 3 , CarloMaurizio Montecucco 3 ,<br />
Roberto Caporali 3 . 1 Rheumatology Unit, L. Sacco<br />
Hospital, University of Milan, Milan, Italy; 2 Dipartimento<br />
di Medicina Pubblica Clinica e Preventiva, University<br />
of Naples, Naples, Italy; 3 University of Pavia, IRCCS<br />
Policlinico S. Matteo, Pavia, Italy.<br />
(334)-1102. Rituximab Therapy for Primary Sjögren’s Syndrome<br />
(pSS): An Open-Label Trial. E. William St. Clair 1 , Marc C.<br />
Levesque 1 , Nina Luning Prak 2 , Frederick B. Vivino 2 , Chacko<br />
Alappatt 2 , Dennis Wallace 3 , Josiah Wedgwood 4 , Philip<br />
Cohen 2 , for the Autoimmunity Centers of Excellence.<br />
1<br />
Duke University Medical Center, Durham, NC; 2 University<br />
of Pennsylvania, Philadelphia, PA; 3 Rho, Inc., Chapel Hill,<br />
NC; 4 National Institute of Allergy and Infectious Disease,<br />
Bethesda, MD.<br />
(335)-1103. Etiology of Sleep Disturbance in Sjögren’s Syndrome.<br />
Emily W. Hung 1 , Lan X. Chen 1 , George A. Hermann 2 ,<br />
Frederick B. Vivino 1 . 1 University of Pennsylvania,<br />
Philadelphia, PA; 2 Albert Einstein Medical Center,<br />
Philadelphia, PA.<br />
Friday, November 9<br />
8:00 a m—4:30 pm<br />
Exhibit Hall A-B<br />
SLE: Clinical Aspects and Treatment II<br />
(336)-1104. Testicular Sertoli Cell Function in Male Systemic<br />
Lupus Erythematosus (SLE). Ricardo M. Suehiro 1 , Eduardo F.<br />
Borba 1 , Eloisa Bonfá 1 , Thelma S. Okay 2 , Marcelo Cocuzza 3 ,<br />
Pollyana M. Soares 1 , Clovis A. Silva 4 . 1 University of Sao<br />
Paulo - Division of Rheumatology, Sao Paulo - SP, Brazil;<br />
2<br />
University of Sao Paulo - Pediatric Department Laboratory,<br />
Sao Paulo - SP, Brazil; 3 University of Sao Paulo - Division of<br />
Urology, Sao Paulo - SP, Brazil; 4 University of Sao Paulo -<br />
Pediatric Rheumatology Unit, Sao Paulo - SP, Brazil.<br />
(337)-1105. Prevalence and Risk Factors for Human<br />
Papillomavirus Infection and Cervical Cytological Abnormalities<br />
in Korean Patients with Systemic Lupus Erythematosus. You-<br />
Hyun Lee 1 , Jung-Yoon Choe 2 , Ji-Young Kim 2 , Yong-Wook<br />
Park 3 , Shin-Seok Lee 3 , Young Mo Kang 4 , Eon Jeong Nam 4 ,<br />
Won Park 5 , Seong-Ryul Kwon 5 , Sang-Cheol Bae 6 , Yun Jung<br />
Kim 6 , Chang-Hee Suh 7 , Hyoun-Ah Kim 7 , Nam Wook Hur 8 ,<br />
Jisoo Lee 1 . 1 Ewha Womans University School of Medicine,<br />
Seoul, Republic of Korea; 2 Catholic University of Daegu,<br />
Daegu, Republic of Korea; 3 Chonnam National University,<br />
Gwangju, Republic of Korea; 4 Kyongpook National<br />
University, Daegu, Republic of Korea; 5 Inha University,<br />
Incheon, Republic of Korea; 6 Hanyang University, Seoul,<br />
Republic of Korea; 7 Ajou University, Suwon, Republic<br />
of Korea; 8 Biomedical Research Group Brain Korea 21,<br />
Hanyang University, Seoul, Republic of Korea.<br />
(338)-1106. Lupus, Cervical Neoplasia and Human Papilloma<br />
Virus. J. Patricia Dhar 1 , Lucie Gregoire 1 , Wayne Lancaster 1 ,<br />
Azedah Stark 2 , Ann Schwartz 1 , Daniel Schultz 3 , Lynnette<br />
Essenmacher 1 , Joel Ager 1 , Raj Bhan 4 , Chiodo Lisa 1 , Robert<br />
J. Sokol 5 . 1 Wayne State University School of Medicine,<br />
Detroit, MI; 2 Henry Ford Health Systems, Detroit, MI;<br />
3<br />
Henry Ford Heath Systems, Detroit, MI; 4 Detroit Medical<br />
Center, Detroit, MI; 5 Wayne State University School of<br />
Medicine and the C.S. Mott Center for Human Growth,<br />
Detroit, MI.<br />
(339)-1107. Estimating Age at Menopause in Patients with<br />
Systemic Lupus Erythematosus (SLE): Comparison Between Two<br />
Methods. Deshiré Alpízar-Rodríguez, Juanita Romero-Díaz,<br />
María del Carmen Cravioto, Jorge Sánchez-Guerrero.<br />
Instituto Nacional de Ciencias Médicas y Nutrición SZ,<br />
Mexico, City, Mexico.<br />
188 (Permanent Board Number)-Abstract Number
(340)-1108. Trend of Mortality of Systemic Lupus Erythematosus<br />
(SLE) in a Southern Chinese Population between 2000 and 2006.<br />
Chi Chiu Mok, Chi Hung To, Ling Yin Ho, Ka Lung Yu.<br />
Tuen Mun Hospital, Hong Kong, Hong Kong.<br />
(341)-1109. Subclinical Atherosclerosis in Chinese Patients with<br />
Systemic Lupus Erythematosus (sle): Prevalence, Risk Factors and<br />
Threshold for Screening. Chi Chiu Mok, Wai Lun Poon, Ling<br />
Yin Ho, Chi Hung To, Ka Lung Yu, Cheuk Sum Lam. Tuen<br />
Mun Hospital, Hong Kong, Hong Kong.<br />
(342)-1110. Ethnic Differences in Patient Perceptions of<br />
Systemic Lupus Erythematosus (SLE) Disease Activity in a<br />
Multiethnic Cohort: The 1000 Canadian Faces of Lupus Study.<br />
Christine A. Peschken 1 , Janet Pope 2 , Earl Silverman 3 ,<br />
Glinda S. Cooper 4 , The 1000 Canadian Faces of Lupus<br />
Investigators. 1 University Of Manitoba, Winnipeg, MB,<br />
Canada; 2 University of Western Ontario, London, ON,<br />
Canada; 3 University of Toronto, Toronto, ON, Canada;<br />
4<br />
Environmental Protection Agency, Washington, DC.<br />
(343)-1111. Autoantibody Prevalence in Lupus Patients and First-<br />
Degree Relatives from a Unique African <strong>American</strong> Population.<br />
Diane L. Kamen 1 , Mia Barron 1 , Tia M. Parker 1 , Gail R.<br />
Bruner 2 , Judith A. James 2 , R. H. Scofield 2 , John B. Harley 2 ,<br />
Gary S. Gilkeson 1 . 1 Medical University of South Carolina,<br />
Charleston, SC; 2 Oklahoma Medical Research Foundation,<br />
Oklahoma City, OK.<br />
(344)-1112. Physician Assessed Disease Activity Measurement<br />
or Patient Reported Lupus Flare. Meenakshi Jolly, J. A. Block.<br />
Rush University Medical Center, Chicago, IL.<br />
(345)-1113. Disease Activity, Body Image and Health Status<br />
in Lupus. Meenakshi Jolly 1 , A. S. Pickard 2 , R. Mikolaitis 1 ,<br />
C. Wilke 2 , S. Khandelwal 1 , R. Rodby 1 , J. A. Block 1 . 1 Rush<br />
University Medical Center, Chicago, IL; 2 University Of<br />
Illinois at Chicago, Chicago, IL.<br />
(346)-1114. Predictors for Remission and Frequency of Flares<br />
in Patients with Systemic Lupus Erythematosus (SLE) of Recent<br />
Onset. Leonardo Limón-Camacho, Juanita Romero-Díaz,<br />
Jorge Sánchez-Guerrero. Instituto Nacional de Ciencias<br />
Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico.<br />
(347)-1115. Disease Outcomes in the First 4 Years of SLE:<br />
Results from the SLICC Inception Cohort. Murray B. Urowitz,<br />
Dafna D. Gladman, Dominique Ibañez, Paul R. Fortin,<br />
Jorge Sanchez-Guerrero, Sang-Cheol Bae, Caroline P.<br />
Gordon, Ann E. Clarke, John G. Hanly, Daniel J. Wallace,<br />
David A. Isenberg, Joan T. Merrill, Ellen M. Ginzler,<br />
Graciela S. Alarcón, Kristjan Steinsson, Michelle A. Petri,<br />
Munther A. Khamashta, Ian Bruce, Mary Anne Dooley,<br />
Susan Manzi Rosalind Ramsey-Goldman, Gunnar K.<br />
Sturfelt, Ola Nived, Asad A. Zoma, Peter J. Maddison,<br />
Josep Font, Ronald van Vollenhoven, Cynthia B. Aranow,<br />
Kenneth C. Kalunian, Thomas Stoll, David Wofsy, Jill<br />
P. Buyon. Toronto Western Hospital, University Health<br />
Network, Toronto, ON, Canada.<br />
(348)-1116. Accumulation of Atherosclerotic Risk Factors over<br />
3 Years by Ethnicity in an International Inception Cohort.<br />
Murray Urowitz, Dafna D. Gladman, Dominique Ibaňez,<br />
Paul R. Fortin, Jorge Sanchez-Guerrero, Sang-Cheol Bae,<br />
Caroline P. Gordon, Ann E. Clarke, John G. Hanly, Daniel<br />
J. Wallace, David A. Isenberg, Joan T. Merrill, Ellen M.<br />
Ginzler, Graciela S. Alarcón, Kristjan Steinsson, Michelle<br />
Petri, Munther A. Khamashta, Ian Bruce, Mary Anne<br />
Dooley, Susan Manzi, Rosalind Ramsey-Goldman, Gunnar<br />
Sturfelt, Ola Nived, Asad A. Zoma, Peter Maddison, Josep<br />
Font, Ronald van Vollenhoven, Cynthia B. Aranow,<br />
Kenneth C. Kalunian, Thomas Stoll, David Wofsy, Jill<br />
P. Buyon. Toronto Western Hospital, University Health<br />
Network, Toronto, ON, Canada.<br />
(349)-1117. Vitamin D Insufficiency is Prevalent in SLE<br />
patients. Sergio Toloza, David E. Cole, Dafna D. Gladman,<br />
Dominique Ibañez, Murray B. Urowitz. Toronto Western<br />
Hospital, University Health Network, Toronto, ON, Canada.<br />
(350)-1118. The Characteristics of a Systemic Lupus<br />
Erythematosus (SLE) National Cohort. Kaleb Michaud 1 ,<br />
Robert Katz 2 , Michelle Petri 3 , Graciela S. Alarcón 4 , Eliza<br />
Chakravarty 5 , John Goldman 6 , Frederick Wolfe 7 , The<br />
Systemic Lupus Erythematosus in the CommunityStudy<br />
Group. 1 University of Nebraska Medical Center, Omaha,<br />
NE; 2 Rush Medical Center, Chicago, IL; 3 John Hopkins<br />
University, Baltimore, MD; 4 University of Alabama at<br />
Birmingham, Birmingham, AL; 5 Stanford University,<br />
Stanford, CA; 6 Emory University, Atlanta, GA; 7 National<br />
Data Bank for Rheumatic Diseases, Wichita, KS.<br />
(351)-1119. The Influence of Cigarette Smoking on Disease<br />
Activity and Damage Accrual in SLE. Tammy O. Utset,<br />
Amanda Schmitz. University of Chicago, Chicago, IL.<br />
(352)-1120. Patient and Clinician Perceptions of Importance<br />
Differ on Physical and Psychosocial Issues in Systemic Lupus<br />
Erythematosus (SLE). Mariko L. Ishimori 1 , Melissa<br />
Schoenwetter 1 , Daniel Aguilar 2 , Robert W. Dubois 2 ,<br />
Richard Hector 2 , Perry Nicassio 3 , Simcha Russak 2 , Richard<br />
M. Ress 1 , Daniel J. Wallace 1 , Debra Eisenberg 4 , Don<br />
Robinson, Jr. 4 , John A. Getsy 4 , Michael H. Weisman 1 .<br />
1<br />
Cedars-Sinai Medical Center, Los Angeles, CA; 2 Cerner<br />
LifeSciences, Los Angeles, CA; 3 UCLA Neuropsychiatric<br />
Institute, Los Angeles, CA; 4 Centocor, Inc., Malvern, PA.<br />
(353)-1121. Atorvastatin Does Not Increase Bone Mineral<br />
Density in SLE Patients. Lisa Christopher-Stine 1 , Adnan<br />
Kiani 1 , Laurence Magder 2 , Barbara Weiss 1 , Michelle Petri 1 .<br />
1<br />
Johns Hopkins University, Baltimore, MD; 2 University of<br />
Maryland, Baltimore, MD.<br />
(354)-1122. Effect of Mycophenolate Mofetil (MMF) on<br />
Cutaneous and Serositis Manifestations of SLE. Adnan Kiani 1 ,<br />
Ehtisham Akhter 1 , Laurence Magder 2 , Michelle Petri 1 .<br />
1<br />
Johns Hopkins University, Baltimore, MD; 2 University of<br />
Maryland, Baltimore, MD.<br />
Poster Session B<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 189
Poster Session b<br />
(355)-1123. Low Mycophenolic Acid Area under the Curve<br />
is Associated with Increased SLE Activity. Zahir Amoura 1 ,<br />
Noel Zahr 2 , Julien Haroche 1 , Jean Debord 3 , Nathalie<br />
Costedoat-Chalumeau 1 , Jean S. Hulot 2 , Patrice Cacoub 1 ,<br />
Pierre Marquet 3 , Philippe Lechat 2 , Jean-Charles Piette 1 .<br />
1<br />
Hopital Pitié Salpêtrière, Service de Médecine Interne,<br />
France; 2 Hopital Pitié Salpêtrière, Service de Pharmacologie<br />
Clinique, France; 3 Hopital Universitaire de Limoges, Service<br />
de Pharmacologie et Toxicologie, France.<br />
(356)-1124. Efficacy of Rituximab in Systemic Lupus<br />
Erythematosus: A Series of 22 Cases. Zahir Amoura 1 , Karin<br />
Mazodier 2 , Marc Michel 3 , Jean-François Viallard 4 , Du<br />
Le Thi Huong 1 , Nathalie Chalumeau 1 , Patrice Cacoub 1 ,<br />
Jean-Robert Harlé 2 , Jean-Luc Pellegrin 4 , Gilles Kaplanski 2 ,<br />
Bertrand Godeau 3 , Jean-Charles Piette 1 . 1 Service de<br />
Médecine Interne, Hopital Pitié Salpétrière, Paris, France;<br />
2<br />
Service de Médecine Interne, Hopital de La Conception,<br />
Marseille, France; 3 Service de Médecine Interne, Hopital<br />
Henri Mondor, Créteil, France; 4 Service de Médecine<br />
Interne, Hopital Haut-Lévêque, Bordeaux, France.<br />
(357)-1125. Relationship between Blood Hydroxychloroquine<br />
and Desethylchloroquine Concentrations and Cigarette Smoking<br />
in Treated Patients with Connective Tissue Diseases. Gaelle<br />
Leroux, Nathalie Costedoat, Zahir Amoura, Jean-Sebastien<br />
Hulot, Camille Frances, Guy Aymard, Philippe Lechat, Jean-<br />
Charles Piette. Hopital Pitié Salpetriere, Paris, France.<br />
(358)-1126. Management of Pulmonary Arterial Hypertension<br />
Associated with Systemic Lupus Erythematosus (SLE) or Mixed<br />
Connective Tissue Disease (MCTD): Immunosuppressive Therapy<br />
(IT) Alone or Combined with PAH Specific Therapies?. David<br />
Launay 1 , Xavier Jais 2 , Azzedine Yaici 2 , Olivier Sitbon 2 ,<br />
Jerôme Le Pavec 2 , Benjamin Sztrympf 2 , Colas Tchérakian 2 ,<br />
Abdul Monem Hamid 2 , Lara Achouh 2 , Gérald Simonneau 2 ,<br />
Marc Humbert 2 . 1 Hôpital Claude-Huriez, Lille, France;<br />
2<br />
Centre de reference national sur l’HTAP, Service De<br />
Pneumologie Et Reanimation, Clamart, France.<br />
(359)-1127. Influence of Periodontal Disease Treatment in<br />
Systemic Lupus Erythematosus Activity. Cristiana Fabbri 1 ,<br />
Eduardo F. Borba 1 , Eloisa Bonfá 1 , Lissiane K. Guedes 1 , Paulo<br />
Sergio R. D’Alleva 2 , Ricardo Fuller 1 . 1 Rheumatology Division,<br />
University of São Paulo, São Paulo, Brazil; 2 Odontology<br />
Division, University of São Paulo, São Paulo, Brazil.<br />
(360)-1128. The Immunosuppressive Therapy is Associated with<br />
Better Endothelial Function in SLE Patients. Gilda A. Ferreira 1 ,<br />
Tulio P. Navarro 1 , Rosa WS Telles 1 , Emilia I. Sato 2 .<br />
1<br />
Universidade Federal de Minas Gerais, Belo Horizonte,<br />
Brazil; 2 Universidade Federal de Sao Paulo, Sao Paulo -<br />
Capital, Brazil.<br />
(361)-1129. A Novel Subset of SLE Exhibiting a Lack of<br />
Negative Feedback of Endogenous Glucocorticoid (GC); Possible<br />
Definition for GC Resistance. Sayumi Baba, Tomoko Sugiura,<br />
Yasushi Kawaguchi, Satomi Higami, Chikako Fukasawa,<br />
Hisae Ichida, Makoto Soejima, Tokiko Kanno, Naoyuki<br />
Kamatani, Masako Hara. Institute of Rheumatology, Tokyo<br />
Women’s Medical University, Tokyo, Japan.<br />
(362)-1130. Prospective Evaluation over Five Years of<br />
Neuropsychiatric Events in Patients with Systemic Lupus<br />
Erythematosus. John G. Hanly, Grace McCurdy, Lisa<br />
Fougere, Jo-Anne Douglas, Qiufen Qi, Kara Thomson.<br />
Queen Elizabeth II Health Sciences Center and Dalhousie<br />
University, Halifax, NS, Canada.<br />
(363)-1131. Time to Seizure Occurrence and Seizure Damage in<br />
a Multi-Ethnic Lupus Cohort. Rosalind Ramsey-Goldman 1 ,<br />
Graciela S. Alarcón 2 , Gerald McGwin, Jr. 2 , Michelle Petri 3 ,<br />
Lius A. Vilá, 4 , Jeffrey C. Edberg 2 , John D. Reveille 5 , Robert<br />
P. Kimberly 2 . 1 Northwestern University, Chicago, IL;<br />
2<br />
University of Alabama at Birmingham, Birmingham, AL;<br />
3<br />
Johns Hopkins University, Baltimore, MD; 4 University<br />
of Puerto Rico, San Juan, PR; 5 University of Texas Health<br />
Science Center, Houston, TX.<br />
(364)-1132. A Difficult Diagnosis: Four Cases of Progressive<br />
Multifocal Leukoencephalopathy over Two Decades in One<br />
Rheumatological Unit. Andreas Jönsen, Anders A. Bengtsson,<br />
Gunnar Sturfelt, Ola Nived. Department of Clinical<br />
Sciences, LUND, Sweden.<br />
(365)-1133. Serum and Cerebrospinal Fluid (CSF) Autoantibodies<br />
in Patients with Neuropsychiatric Lupus Erythematosus (NPSLE).<br />
Hilda E. Fragoso-Loyo 1 , Javier Cabiedes 1 , Yemil Atisha-<br />
Fregoso 1 , Alejandro Orozco-Narváez 1 , Luis Dávila 1 , Betty<br />
Diamond 2 , Luis Llorente 1 , Jorge Sánchez-Guerrero 1 .<br />
1<br />
Instituto Nacional de Ciencias Médicas y Nutrición<br />
Salvador Zubirán, México, Distrito Federal, Mexico; 2 The<br />
Feinstein Institute for Medical Research, North Shore, LIJ<br />
Health System, New York, NY.<br />
(366)-1134. Impaired Implicit Learning and Memory Functions<br />
in Systemic Lupus Erythematosus. Julianna Ward, Egberdina<br />
J. van der Hulst, Mohammad Naqibuddin, Michelle Petri.<br />
Johns Hopkins University, Baltimore, MD.<br />
(367)-1135. Reduced C3 Binding to Streptococcus pneumoniae in<br />
Serum from Patients with Systemic Lupus Erythematosus. Fiona<br />
Goldblatt, Jose Yuste, David Isenberg, Anisur Rahman,<br />
Jeremy Brown. University College London Hospital,<br />
London, United Kingdom.<br />
190 (Permanent Board Number)-Abstract Number
(368)-1136. The Presence of Anti-La Autoantibody Is Associated<br />
with a Lower Risk of Nephritis and Seizures in Lupus Patients.<br />
Sanober Malik 1 , Gail R. Bruner 2 , Courtney Williams-<br />
Weese 2 , Lourdes Feo 2 , R. Hal Scofield 3 , John B. Harley 3 ,<br />
Amr H. Sawalha 3 . 1 University of Oklahoma Health Sciences<br />
Center, Oklahoma City, OK; 2 Oklahoma Medical Research<br />
Foundation, Oklahoma City, OK; 3 University of Oklahoma<br />
Health Sciences Center, Oklahoma Medical Research<br />
Foundation, Oklahoma City VAMC, Oklahoma City, OK.<br />
(369)-1137. Antibodies against the VRT101 Laminin Epitope<br />
Correlate with Human SLE Disease Activity and Can be Removed<br />
by Extracorporeal Immunoadsorption. Michal Heilweil-Harel 1 ,<br />
Howard Amital 2 , Rina Ulmansky 1 , Michael Harlev 3 , Elias<br />
Toubi 4 , Alon Hershko 1 , Yaakov Naparstek 1 . 1 Hadassah -<br />
Hebrew University Medical Center, Jerusalem, Israel; 2 Meir<br />
Medical Center - Tel-Aviv University, Kfar Saba, Israel;<br />
3<br />
Hebrew University-Hadassah Medical School, Jerusalem,<br />
Israel; 4 Bnei Zion Medical Center, Haifa, Israel.<br />
(370)-1138. Association of the FasL-844*TT/TC Alleles<br />
with Hemolytic Anemia in Patients with Systemic Lupus<br />
Erythematosus. Results from a Multiethnic U.S. Cohort. Sergio<br />
Durán 1 , Mandar Apte 1 , Graciela S. Alarcón 1 , Luis M. Vilá 2 ,<br />
Jeffrey C. Edberg 1 , Robert P. Kimberly 1 , John D. Reveille 3 .<br />
1<br />
University of Alabama at Birmingham, Birmingham,<br />
AL; 2 University of Puerto Rico, San Juan, Puerto Rico;<br />
3<br />
University of Texas-Houston Health Science Center,<br />
Houston, TX.<br />
(371)-1139. Angiotensin-Converting Enzyme Inhibitors May<br />
Prevent Renal Involvement in Patients with Systemic Lupus<br />
Erythematosus. Results from a Multiethnic U.S. Cohort. Sergio<br />
Durán 1 , Gerald McGwin, Jr 1 , Luis M. Vilá 2 , John D.<br />
Reveille 3 , Graciela S. Alarcón 1 . 1 University of Alabama at<br />
Birmingham, Birmingham, AL; 2 University of Puerto Rico,<br />
San Juan, Puerto Rico; 3 University of Texas-Houston Health<br />
Science Center, Houston, TX.<br />
(372)-1140. Seizures are Important Determinants of Damage<br />
Accrual but not of Mortality in Systemic Lupus Erythematosus<br />
(SLE): Data from a Large Multiethnic Cohort. Luis A.<br />
González 1 , Rosa M. Andrade 1 , Mónica Fernández 1 ,<br />
Mandar Apte 1 , Luis M. Vilá 2 , Gerald McGwin, Jr 1 , John D.<br />
Reveille 3 , Graciela S. Alarcón 1 . 1 University of Alabama at<br />
Birmingham, Birmingham, AL; 2 University of Puerto Rico,<br />
San Juan, Puerto Rico; 3 University of Texax Health Science<br />
Center at Houston, Houston, TX.<br />
(373)-1141. High Sensitivity C-Reactive Protein (hs-CRP) is<br />
Associated with Early Damage in Systemic Lupus Erythematosus<br />
(SLE). Data from a Multiethnic Cohort. Ana M. Bertoli 1 , Luis<br />
M. Vila 1 , John D. Reveille 2 , Graciela Alarcon 3 . 1 University<br />
of Puerto Rico, San Juan, Puerto Rico; 2 The University of<br />
Texas Health Science Center at Houston,, Houston, TX;<br />
3<br />
University of Alabama at Birmingham, Birmingham, AL.<br />
(374)-1142. Disease Activity and Alcohol Intake May Lead<br />
to Permanent Cognitive Impairment in Patients with Systemic<br />
Lupus Erythematosus (sle): Data from a Multiethnic Cohort.<br />
Martha L. Sanchez 1 , Jie S. Jhang 1 , Luis M. Vilá 2 , John D.<br />
Reveille 3 , Graciela S. Alarcón 1 . 1 University of Alabama at<br />
Birmingham, Birmingham, AL; 2 University of Puerto Rico,<br />
San Juan, Puerto Rico; 3 University of Houston Health<br />
Science Campus, Houston, TX.<br />
(375)-1143. Defining Low-Density Lipoprotein Cholesterol (ldl-c)<br />
Cut-Points For Coronary Artery Disease Risk Stratification in<br />
Systemic Lupus Erythematosus (sle). Mandana Nikpour, Sergio<br />
Toloza, Dominique Ibañez, Dafna D. Gladman, Murray<br />
B. Urowitz. Toronto Western Hospital, University Health<br />
Network, Toronto, ON, Canada.<br />
(376)-1144. Arterial Stiffness in Active Lupus Patients<br />
with Low CAD Risk. Aleksander S. Prokopowitsch 1 ,<br />
Luiz A. Bortolotto 2 , Eloisa Bonfa 1 , Eduardo F. Borba 1 .<br />
1<br />
Rheumatology Division, University of São Paulo, São<br />
Paulo, Brazil; 2 Heart Institute (INCOR), University of São<br />
Paulo, São Paulo, Brazil.<br />
(377)-1145. Increased Augmentation Index in Systemic Lupus<br />
Erythematosus: Relationship to Traditional Cardiovascular Risk<br />
Factors. Cecilia P. Chung, Annette Oeser, Ingrid Avalos,<br />
Daniel Kurnik, C. Michael Stein. Vanderbilt University,<br />
Nashville, TN.<br />
(378)-1146. Nuclear Magnetic Resonance Spectroscopy<br />
Lipoprotein Subclasses and Particle Size in Patients with Systemic<br />
Lupus Erythematosus: Relationship with Inflammation and<br />
Coronary Atherosclerosis. Cecilia P. Chung 1 , Annette Oeser 1 ,<br />
Ingrid Avalos 1 , Joseph F. Solus 1 , Mac Rae F. Linton 1 ,<br />
Sergio Fazio 1 , Paolo Raggi 2 , C. Michael Stein 1 . 1 Vanderbilt<br />
University, Nashville, TN; 2 Emory University, Atlanta, GA.<br />
(379)-1147. Premature Atherosclerosis in Young Women with<br />
SLE. Kok Ooi Kong, Tsui Yee Lian, Bernard YH Thong,<br />
Hiok Hee Chng, TTSH Lupus Study Group, Hwee Siew<br />
Howe. Tan Tock Seng Hospital, Singapore, Singapore.<br />
(380)-1148. Serum Amyloid A and Measures of Disease Activity<br />
and Cardiovascular Risk in Patients with Systemic Erythematosus.<br />
Young Hee Rho 1 , Annette Oeser 1 , Cecilia P. Chung 1 ,<br />
Joseph Solus 1 , Paolo Raggi 2 , C. Michael Stein 1 . 1 Vanderbilt<br />
University, Nashville, TN; 2 Emory University, Atlanta, GA.<br />
(381)-1149. Urine Levels of sVCAM-1, but not sICAM-1 and<br />
P-Selectin, Correlate with Active Urine Sediments in SLE. Kok<br />
Ooi Kong 1 , Bernard PL Leung 2 , Weng Giap Law 1 , Bernard<br />
YH Thong 1 , Faith Chia 1 , Tsui Yee Lian 1 , Tang Ching Lau 1 ,<br />
Hiok Hee Chng 1 , Chandra Mohan 3 , Hwee Siew Howe 1 .<br />
1<br />
Tan Tock Seng Hospital, Singapore, Singapore; 2 National<br />
University of Singapore, Singapore, Singapore; 3 University<br />
of Texas, Dallas, TX.<br />
Poster Session B<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 191
Poster Session b<br />
(382)-1150. Prognostic Factors of Lupus Nephritis other than<br />
Renal Pathology. Yuko Takahashi, Akitake Suzuki, Hiroyuki<br />
Yamashita, Junwa Kunimatsu, Atsushi Yanai, Arisa Shimizu,<br />
Kenji Itoh, Akio Mimori. International Medical Center of<br />
Japan, Tokyo, Japan.<br />
(383)-1151. Antiphospholipid Antibody Induced Deterioration Of<br />
Renal Function In Most Patients With Systemic Lupus Erythematosus.<br />
Tadashi Sakurai, Mariko Kitahama, Yumi Koseki, Naoyuki<br />
Kamatani, Chihiro Terai. Institute of Rheumatology, Tokyo<br />
Women’s Medical University, Tokyo, Japan.<br />
(384)-1152. Michigan Lupus Epidemiology & Surveillance<br />
(MILES) <strong>Program</strong>: Prevalence of Lupus Nephritis in Washtenaw<br />
County, 2002-2005. Emily E. Lewis 1 , Emily C. Somers 1 ,<br />
Wendy Marder 1 , Diane Shaltis 1 , Elizabeth Curry 1 , Lauren<br />
Levy 1 , Sheeja Francis 1 , Thomas Kallarackal-Malaikal 1 , Carol<br />
VanHuysen 1 , Patricia Cagnoli 1 , James Leisen 2 , J. Patricia<br />
Dhar 3 , Peter DeGuire 4 , W. Joseph McCune 1 . 1 University<br />
of Michigan Health System, Ann Arbor, MI; 2 Henry Ford<br />
Health System, Detroit, MI; 3 Wayne State University,<br />
Detroit, MI; 4 Michigan Department of Community Health,<br />
Lansing, MI.<br />
Friday, November 9<br />
8:00 a m—4:30 pm<br />
Exhibit Hall A-B<br />
Spondylarthropathies and Psoriatic Arthritis:<br />
Treatment II<br />
(385)-1153. Infliximab Improves Spinal Mobility in Patients with<br />
Ankylosing Spondylitis: Two-Year Findings from the ASSERT<br />
Clinical Trial. J. Braun 1 , C. Han 2 , H. Kellner 3 , A. Deodhar 4 ,<br />
R. Inman 5 , W. Xu 2 , D. Baker 2 , B. Tang 6 , M. Bala 2 , D.<br />
van der Heijde 7 . 1 Rheumazentrum Ruhrgebiet, Herne,<br />
Germany; 2 Centocor Research and Development, Inc.,<br />
Malvern, PA; 3 Ludwig-Maximilians-Universität, München,<br />
Germany; 4 Oregon Health & Sciences University, Portland,<br />
OR; 5 Toronto Western Hospital, Toronto, ON, Canada;<br />
6<br />
Centocor, Inc., Horsham, PA; 7 University Hospital<br />
Maastricht, Maastricht, The Netherlands.<br />
(386)-1154. Sustained Reduction in Spinal Inflammation<br />
in Patients with Ankylosing Spondylitis after Treatment with<br />
Infliximab. J. Braun 1 , R. Landewé 2 , K-G Hermann 3 , A.<br />
Deodhar 4 , D. Baker 5 , J. Han 5 , W. Xu 5 , P. Williamson 5 ,<br />
D. van der Heijde 2 . 1 Rheumazentrum Ruhrgebiet, Herne,<br />
Germany; 2 University Hospital Maastricht, Maastricht, The<br />
Netherlands; 3 Universitaetsmedizin Berlin, Berlin, Germany;<br />
4<br />
Oregon Health & Science University, Portland, OR;<br />
5<br />
Centocor Research and Development, Inc., Malvern, PA.<br />
(387)-1155. The Efficacy of Combination Methotrexate and<br />
Infliximab in Patients with Ankylosing Spondylitis: A Clinical<br />
and Magnetic Resonance Imaging Correlation. Edmund K. Li,<br />
Lai-Shan Tam, James F. Griffith. Prince of Wales Hospital,<br />
Hong Kong, Hong Kong.<br />
(388)-1156. Psoriasis Occurrence or Reactivation under Anti<br />
TNF aAlpha Therapy. A Case Series. Daniel Wendling 1 , Jean-<br />
Charles Balblanc 2 , Daniel Briançon 3 , Alain Brousse 4 , Anne<br />
Lohse 2 , Philippe Deprez 5 , François Aubin 1 . 1 University<br />
Teaching Hospital, Besançon, France; 2 Hospital, Belfort,<br />
France; 3 Hospital, Aix-les-Bains, France; 4 Hospital, Dole,<br />
France; 5 Office, Dole, France.<br />
(389)-1157. New Onset Uveitis in Ankylosing Spondylitis Patients<br />
Treated with Anti-TNF Therapy. Laura C. Coates, Dennis<br />
McGonagle, Alexander N. Bennett, Paul Emery, Helena<br />
Marzo-Ortega. University of Leeds, Leeds, United Kingdom.<br />
(390)-1158. Adalimumab Significantly Reduces Inflammation in<br />
the Spine and Sacroiliac Joints in Active Ankylosing Spondylitis.<br />
Hildrun Haibel 1 , Christian Althoff 2 , Kay-Geert Hermann 2 ,<br />
Jürgen Braun 3 , Harald Burckhardt 4 , Herbert Kellner 5 , Ina<br />
Kötter 6 , Ulf Müller-Ladner 7 , Wolfgang Spieler 8 , Henning<br />
Zeidler 9 , Elke Zeise 10 , Joachim Sieper 1 , Hartmut Kupper 10 ,<br />
Martin Rudwaleit 1 . 1 Charité - Campus Benjamin Franklin,<br />
Berlin, Germany; 2 Charité - Campus Mitte, Berlin,<br />
Germany; 3 Rheumazentrum Ruhrgebiet, Herne, Germany;<br />
4<br />
University of Frankfurt, Frankfurt, Germany; 5 Praxisklinik,<br />
München, Germany; 6 University of Tübingen, Tübingen,<br />
Germany; 7 University of Giessen, Giessen, Germany;<br />
8<br />
Rheumatology Zerbst, Zerbst, Germany; 9 Medical<br />
School, Hannover, Germany; 10 Abbott GmbH & Co KG,<br />
Wiesbaden, Germany.<br />
(391)-1159. Adalimumab is Effective and Well-Tolerated in<br />
Treating Ankylosing Spondylitis (AS) in Real-Life Clinical Practice:<br />
The RHAPSODY Trial. M. Rudwaleit 1 , P. Claudepierre 2 ,<br />
P. Wordsworth 3 , E. Loza 4 , I. Olivieri 5 , K. A. Boki 6 , J.<br />
Vanhoof 7 , I. Mantika 8 , M. Kron 9 , R. Carcereri 9 , R. Wong 10 ,<br />
H. Kupper 9 . 1 Charité University Hospital, Berlin, Germany;<br />
2<br />
Hopital Universitaire Créteil-Paris XII, Créteil, France;<br />
3<br />
Nuffield Orthopaedic Centre, Oxford, United Kingdom;<br />
4<br />
Hospital de Navarra, Pamplona, Spain; 5 Ospedale San<br />
Carlo di Potenza, Córdoba, Spain; 6 Sismanoglio Hospital,<br />
Athens, Greece; 7 University Hasselt, Hasselt, Belgium; 8 De<br />
Monfort University – Guilford University, Leicester, United<br />
Kingdom; 9 Abbott GmbH & Co. KG, Ludwigshafen,<br />
Germany; 10 Abbott, Parsippany, NJ.<br />
(392)-1160. Long-Term Spinal Mobility in Ankylosing Spondylitis<br />
(AS) Patients Treated with Adalimumab: 104-Week Results<br />
from ATLAS. D. van der Heijde 1 , M. H. Schiff 2 , J. Sieper 3 ,<br />
A. Kivitz 4 , B. AC Dijkmans 5 , P. J. Mease 6 , H. Kupper 7 ,<br />
R. Wong 8 , S. Ballal 8 , J. Davis for the ATLAS Study<br />
Group 9 . 1 Leiden University Medical Center, Leiden,<br />
The Netherlands; 2 Denver Arthritis Clinic, Denver, CO;<br />
192 (Permanent Board Number)-Abstract Number
3<br />
Charité Universitätsmedizin Berlin, Berlin, Germany;<br />
4<br />
Altoona Center for Clinical Research, Duncansville, PA;<br />
5<br />
VU Medical Centre and the Jan van Breemen Institute,<br />
Amsterdam, The Netherlands; 6 Swedish Medical Center,<br />
Seattle, WA; 7 Abbott GmbH & Co. KG, Ludwigshafen,<br />
Germany; 8 Abbott, Parsippany, NJ; 9 University of<br />
California, San Francisco, CA.<br />
(393)-1161. Long Term Efficacy and Safety, Including Reports of<br />
Ocular Inflammation, in Ankylosing Spondylitis Patients Treated<br />
with Etanercept for 4 Years. Ben A.C. Dijkmans 1 , J. Sieper 2 ,<br />
S. van der Linden 3 , E. Martin-Mola 4 , M. Leirisalo-Repo 5 , B.<br />
Freundlich 6 , A. Koenig 6 . 1 VU Medical Center, Amsterdam,<br />
The Netherlands; 2 Charité Campus Benjamin Franklin,<br />
Berlin, Germany; 3 University of Maastricht, Maastricht,<br />
The Netherlands; 4 Hospital la Paz, Madrid, Spain; 5 Helsinki<br />
University Central Hospital, Helsinki, Finland; 6 Wyeth<br />
Research, Collegeville, PA.<br />
(394)-1162. Evidence-Based Recommendations for the<br />
Management of Ankylosing Spondylitis: Results of the 3e<br />
Initiative in Rheumatology Involving a Broad Panel of Experts<br />
and Practicing Rheumatologists. In-Ho Song 1 , Gülen Hatemi 2 ,<br />
Prodromos Sidiropoulos 3 , Jerome Avouac 4 , Maxime<br />
Dougados 4 . 1 Charité Campus Benjamin-Franklin, Med.<br />
Clinic I, Rheumatology, Berlin, Germany; 2 Istanbul<br />
University, Cerrahpasa Medical School, Rheumatology,<br />
Istanbul, Turkey; 3 University of Crete, Rheumatology,<br />
Crete, Greece; 4 René Descartes University, Medicine<br />
Faculty, APHP Cochin Hospital, Rheumatology B<br />
Department, Paris, France.<br />
(395)-1163. Gait Parameters are Responsive to Change in<br />
Function Associated with TNFα Blockade in People with<br />
Ankylosing Spondylitis. Anthony C. Redmond, Nichol<br />
Barkham, Laura Coates, Helen I. Keen, Lorna Cawkwell,<br />
David Pickles, Alexander Fraser, Paul Emery. University of<br />
Leeds, Leeds, United Kingdom.<br />
(396)-1164. Complementary and Alternative Medicines in<br />
Ankylosing Spondylitis. Simon M. Chatfield 1 , Anthony<br />
Boers 1 , Belinda Martin 1 , Russell R. Buchanan 1 , Walter<br />
P. Maksymowych 2 , Lionel Schachna 1 . 1 Austin Spondylitis<br />
Centre, Heidelberg Victoria, Australia; 2 University of<br />
Alberta, Edmonton, AB, Canada.<br />
(397)-1165. CANaDian evaluation of Low DosE Infliximab in<br />
Ankylosing Spondylitis (CANDLE)-12 week Magnetic Resonance<br />
Imaging Evaluation of Spinal Inflammation with the SPARCC<br />
MRI Method. Walter P. Maksymowych 1 , David Salonen 2 ,<br />
Robert D. Inman 3 , Filipow L. Paul 1 , Robert GW Lambert 1 .<br />
1<br />
University of Alberta, Edmonton, AB, Canada; 2 University<br />
of Toronto, Toronto, ON, Canada; 3 Toronto Western<br />
Hospital, Toronto, ON, Canada.<br />
(398)-1166. How Should We Define the Patient Acceptable<br />
Symptom State (PASS): Acceptable for a Few Months or<br />
Acceptable for Life?. Walter P. Maksymowych 1 , Lionel<br />
Schachna 2 , Annelies Boonen 3 . 1 University of Alberta,<br />
Edmonton, AB, Canada; 2 Austin Health Centre,<br />
Heidelberg, Australia; 3 University of Maastricht, Maastricht,<br />
The Netherlands.<br />
(399)-1167. Linear Definition of the Edmonton Ankylosing<br />
Spondylitis Metrology Index (EDASMI) and Comparison with<br />
the BASMI 0-2 and 0-10 indices. Walter P. Maksymowych,<br />
Catherine Mallon, Sharon Morrow. University of Alberta,<br />
Edmonton, AB, Canada.<br />
(400)-1168. When B27-positive Boys Grow Up: The Differing<br />
Clinical Courses of Juvenile- and Adult-Onset Spondyloarthritis.<br />
Finbar D. O’Shea 1 , Eleanor Boyle 1 , Shirley ML Tse 2 , Ron<br />
M. Laxer 2 , Robert D. Inman 1 . 1 Toronto Western Hospital,<br />
Toronto, ON, Canada; 2 The Hospital for Sick Children,<br />
Toronto, ON, Canada.<br />
(401)-1169. The Oswestry Disability Questionnaire Assesses<br />
Activity and Function Domains in Ankylosing Spondylitis. Finbar<br />
D. O’Shea, Reena Riarh, Robert D. Inman. Toronto<br />
Western Hospital, Toronto, ON, Canada.<br />
(402)-1170. The Diagnostic Value of Scintigraphy in Assessing<br />
Sacroiliitis in Ankylosing Spondylitis and Patients with Clinically<br />
Probable Sacroiliitis- A Systematic Literature Research. In-Ho<br />
Song 1 , Jose Antonio Carrasco 2 , Martin Rudwaleit, Dr. 1 ,<br />
Joachim Sieper, Prof. 1 . 1 Charité Campus Benjamin-<br />
Franklin, Med. Clinic I, Rheumatology, Berlin, Germany;<br />
2<br />
Universitary Hospital “Reina Sofía”. Department of<br />
Rheumatology., Cordova, Spain.<br />
(403)-1171. Urinary CTX-II is Associated with Radiological<br />
Damage and Progression in Patients with Ankylosing Spondylitis.<br />
Debby Vosse 1 , Robert Landewé 1 , Patrick Garnero 2 , Desirée<br />
van der Heijde 1 , Sjef van der Linden 1 , Piet Geusens 1 .<br />
1<br />
Academic Hospital Maastricht, Maastricht, The Netherlands;<br />
2<br />
INSERM Research Unit 403, and Synarc, Lyon, France.<br />
(404)-1172. Mechanism of Action of Heat Shock Protein Derived<br />
Peptide Epitopes in Ankylosing Spondylitis. Elissa Keogh, Soha<br />
Araji, Salvatore Albani. UC San Diego, La Jolla, CA.<br />
(405)-1173. The Relationship of Clinical Features and Laboratory<br />
Measurements to Radiological Damage in a Turkish Cohort of<br />
Patients with Ankylosing Spondylitis- A Cross Sectional Study.<br />
Pamir Atagunduz, Sibel Z. Aydin, MD, Mehmet A. Ozturk,<br />
MD, Ozan Kocakaya, MD, Haner Direskeneli, MD.<br />
Marmara University School of Medicine, Department of<br />
rheumatology, Istanbul, Turkey.<br />
Poster Session B<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 193
Poster Session b<br />
(406)-1174. Infliximab in Severe Active Ankylosing Spondylitis<br />
with Spinal Ankylosis. Peter P. Cheung 1 , Kathleen E. Tymms 2 ,<br />
Beverley J. Wilson 2 , Bruce Shadbolt 1 , Andrew S. Brook 1 ,<br />
Annamma K. Dorai Raj 2 , Kenneth B. Khoo 2 . 1 Canberra<br />
Hospital, Canberra, Australian Capital Territory, Australia;<br />
2<br />
Canberra Rheumatology, Canberra, Australian Capital<br />
Territory, Australia.<br />
(407)-1175. Differences between HLA-B27 Positive and Negative<br />
Patients with Ankylosing Spondylitis. Data From a Large<br />
Registry of Patients. Luisa M. Rojas Vargas 1 , E. Muñoz 1 , X.<br />
Juanola 2 , P. Zarco 3 , JL Fernandez-Sueiro 4 , C. Gonzalez 5 , E.<br />
Collantes 1 . 1 Hospital Universitario Reina Sofía, Cordoba,<br />
Spain; 2 Bellvitge H, Barcelona, Spain; 3 Fundación Alcorcón,<br />
Madrid, Spain; 4 Juan Canalejo U.H., A Coruña, Spain;<br />
5<br />
Gregorio Marañon U.H., Madrid, Spain.<br />
(408)-1176. Persistent Disease Activity Patterns Predominate<br />
in Ankylosing Spondylitis (AS) and are Associated with Worse<br />
Clinical Outcomes. Millicent A. Stone 1 , Andrew Keat 2 , Emma<br />
Pomeroy 1 , Sarah Hickey 1 , Raj Sengupta 1 , Rebecca Mogg 1 ,<br />
Jennifer Richardson 1 , John Pauling 1 , Robert Inman 3 . 1 Royal<br />
National Hospital for Rheumatic Diseases, Bath, United<br />
Kingdom; 2 Northwick Park Hospital, Harrow, United<br />
Kingdom; 3 University of Toronto, Toronto, ON, Canada.<br />
(409)-1177. The changes of aortic root predict Ankylosing<br />
Spondylitis in Korean patients by Transesophageal<br />
Echocardiography. Sang-Hoon Lee 1 , Jae Gun Lee 1 , Suk-Tae<br />
Jang 2 , Eun-Sun Jin 2 , Il-Suk Sohn 2 , Jin-Man Cho 2 , Chong-<br />
Jin Kim 2 , Jong-Hoa Bae 2 , Young Deok Bae 3 , Yeon-Ah<br />
Lee 4 , Seung-Jae Hong 4 , Hyung-In Yang 1 . 1 Division of<br />
Rheumatology, Arthritis and Rheumatism Center, East-<br />
West Neo Medical Center of Kyung Hee University, Seoul,<br />
Republic of Korea; 2 Division of Cardiology, Cardiovascular<br />
Center, East-West Neo Medical Center of Kyung Hee University,<br />
Seoul, Republic of Korea; 3 Division of Rheumatology,<br />
Gangdong Seong Sim Medical Center of Hanlym University,<br />
Seoul, Republic of Korea; 4 Division of Rheumatology, Kyung<br />
Hee Medical Center, Seoul, Republic of Korea.<br />
(410)-1178. Clinical and Laboratory Findings of Patients with<br />
Familial Mediterranean Fever associated Ankylosing Spondylitis<br />
(FMF-AS). Selda Celik 1 , Gulen Hatemi 1 , Bennur Esen 2 ,<br />
Emire Seyahi 1 , Huri Ozdogan 1 . 1 Istanbul University<br />
Cerrahpasa Medical Faculty,Rheumatology Department,<br />
Istanbul, Turkey; 2 Istanbul University Cerrahpasa Medical<br />
Faculty,Internal Medicine, Istanbul, Turkey.<br />
(411)-1179. Impact of Ankylosing Spondylitis on Work and<br />
Family Life: Comparisons with the U.S. Population. Michael M.<br />
Ward 1 , John D. Reveille 2 , Thomas Learch 3 , John C. Davis 4 ,<br />
Michael H. Weisman 5 . 1 National Institute of Arthritis and<br />
Musculoskeletal and Skin Diseaes, NIH, Bethesda, MD;<br />
2<br />
University of Texas, Houston, TX; 3 University of Southern<br />
California, Los Angeles, CA; 4 University of California-<br />
San Francisco, San Francisco, CA; 5 Cedars-Sinai Medical<br />
Center, Los Angeles, CA.<br />
(412)-1180. Which Aspects of Functioning are Relevant for<br />
Patients with Ankylosing Spondylitis: Results of a Focus Group<br />
Interviews. Annelies Boonen 1 , Monique van Berkel 1 , Alarcos<br />
Cieza 2 , Gerold Stucki 2 , Désirée van der Heijde 1 . 1 University<br />
Hospital Maastricht, Maastricht, The Netherlands;<br />
2<br />
Maximilian University, Munich, Germany.<br />
(413)-1181. Adalimumab Is Effective in Treating Patients<br />
with Psoriatic Arthritis (PsA) in Real-Life Clinical Practice:<br />
The STEREO Trial. F. Van den Bosch 1 , B. Manger 2 , P. M.<br />
Goupille 3 , N. McHugh 4 , E. Rødevand 5 , P. Holck 6 , R. F.<br />
van Vollenhoven 7 , M. Leirisalo-Repo 8 , O. Fitzgerald 9 , C.<br />
Frank 10 , M. Kron 10 , M. Frank 10 , H. Kupper 10 . 1 UZ Gent,<br />
Gent, Belgium; 2 Universität Erlangen/Nürnberg, Erlangen,<br />
Germany; 3 Hopital Trousseau, Tours, France; 4 Royal National<br />
Hospital, Bath, United Kingdom; 5 St. Olavs Hospital,<br />
Trondheim, Norway; 6 Silkeborg Centralsygehus, Silkeborg,<br />
Denmark; 7 Karolinska University Hospital, Stockholm,<br />
Sweden; 8 Helsinki University Central Hospital, Helsinki,<br />
Finland; 9 St. Vincent’s University Hospital, Dublin, Ireland;<br />
10<br />
Abbott GmbH & Co. KG, Ludwigshafen, Germany.<br />
(414)-1182. Prediction of Time to Relapse After Withdrawal<br />
of Etanercept in Psoriatic Arthritis. Kurt L. De Vlam, Rik J.<br />
Lories, Sarah Janssen. University Hospital, Leuven, Belgium.<br />
(415)-1183. Health Related Quality of Life Following TNFα<br />
Inhibitors Improves More in Psoriatic Arthritis Compared to<br />
Rheumatoid Arthritis Patients. Laure Brulhart 1 , Chin Teck<br />
Ng 1 , Mary B. Codd 2 , Ceara AE Walsh 1 , Eliza K. Pontifex 1 ,<br />
Alexia Grier 1 , Miriam Molloy 1 , Eileen O’Flynn 1 , Barry<br />
Bresnihan 1 , Oliver FitzGerald 1 , Douglas J. Veale 1 . 1 St<br />
Vincent’s University Hospital, Dublin, Ireland; 2 UCD<br />
School of Medicine and Medical Science, Dublin, Ireland.<br />
(416)-1184. Bone Mineral Density and Prevalence of Osteoporosis<br />
and Fractures in Psoriatic Arthritis. Noemi Busquets, Jesus<br />
Rodríguez-Moreno, Carmen Gómez-Vaquero, Daniel<br />
Roig-Vilaseca, Javier Narváez, Joan M. Nolla. Hospital<br />
Universitari de Bellvitge, Barcelona, Spain.<br />
(417)-1185. Measures Associated with Disease Activity in Psoriatic<br />
Arthritis. Valerie P. Nell Duxneuner 1 , Tanja Stamm 2 , Daniel<br />
Aletaha 2 , Klaus P. Machold 2 , Harald Heinzl 2 , Stephan<br />
Pflugbeil 1 , Josef S. Smolen 2 . 1 Hietzing Hospital, Vienna,<br />
Austria; 2 Medical University, Vienna, Austria.<br />
194 (Permanent Board Number)-Abstract Number
(418)-1186. Composite Indices For Disease Activity in Ankylosing<br />
Spondylitis (AS) and Psoriatic Arthritis (PsA). Dafna D.<br />
Gladman, Robert D. Inman, Richard R. Cook, Desiree van<br />
der Heijde, Robert Landewe, Jurgen Braun, John C. Davis,<br />
Jr., Philip J. Mease, Jan Brandt, Ruben Burgos-Vargas,<br />
Vinod Chandran, Philip Helliwell, Arthur F. Kavanaugh,<br />
Finbar O’Shea, Muhammad Asim Khan, Nicolò Pipitone,<br />
Proton Rahman, John D. Reveille, Millicent Stone, William<br />
Taylor, Douglas Veale, Walter Maksymowych, The INSPIRE<br />
Study Group. Toronto Western Hospital, University Health<br />
Network, Toronto, ON, Canada.<br />
(419)-1187. Burden of Ankylosing Spondylitis and Psoriatic<br />
Arthritis on Work Capability, Physical Function and Quality Of<br />
Life. José L. Fernández-Sueiro 1 , A. Willisch 2 , S. Pértega 1 ,<br />
J. Pinto 1 , J. Mosquera 3 , N. Oreiro 1 , C, Fernández 1 , F.<br />
Galdo 1 , F. Blanco 1 . 1 Hospital Universitario Juan Canalejo,<br />
La Coruña, Spain; 2 Hospital Cirstal Piñor, Orense, Spain;<br />
3<br />
Hospital Montecelo, Pontevedra, Spain.<br />
(420)-1188. A Comparative Study of Axial Forms of Psoriatic<br />
Artritis with Primary Ankylosing Spondylitis. Are Activity<br />
Parameters of as Useful in Axial Psa?. José L. Fernández-<br />
Sueiro, J. Pinto, S. Pértega, A. Willisch, F. Galdo, F. Blanco.<br />
Hospital Universitario Juan Canalejo, La Coruña, Spain.<br />
(421)-1189. Utility of Radiological Criteria for the Classification<br />
and Evaluation of Axial Psoriatic Arthritis. José L. Fernández-<br />
Sueiro, J. Pinto, S. Pértega, A. Willisch, M. Freire, F.<br />
Galdo, F. Blanco. Hospital Universitario Juan Canalejo, La<br />
Coruña, Spain.<br />
(422)-1190. Radiographic Spinal Damage and Spinal Mobility<br />
Correlate Poorly in Psoriatic Spondylitis (Ps-Sp). Vinod<br />
Chandran, Finbar D. O’Shea, Catherine T. Schentag, David<br />
Salonen, Robert D. Inman, Dafna D. Gladman. University<br />
of Toronto, Toronto, ON, Canada.<br />
(423)-1191. Clinical Outcome Measures in Psoriatic arthritis<br />
(PsA): Comparing Enrollment and Response in a Biologics Study.<br />
Eliza K. Pontifex, Adrian Gibbs, Barry Bresnihan, Douglas<br />
J. Veale, Oliver FitzGerald. St Vincents University Hospital,<br />
Elm Park, Dublin 4, Ireland.<br />
(424)-1192. Osteoclast Precursor Numbers from Peripheral Blood<br />
Following Cytokine Stimulation are Increased in Psoriatic Arthritis<br />
Patients with Arthritis Mutilans Defined Radiographically. Jamie<br />
Lee 1 , Nicola Dalbeth 1 , Timothy Smith 1 , William Taylor 2 ,<br />
Quentin Reeves 1 , Elizabeth Robinson 1 , Peter Jones 3 ,<br />
Mikkel Østergaard 4 , Ian Reid 1 , Jillian Cornish 1 , Fiona<br />
M. McQueen 1 . 1 University of Auckland, Auckland, New<br />
Zealand; 2 University of Otago, Wellington, New Zealand;<br />
3<br />
University of Auckland, Rotorua, New Zealand; 4 University<br />
of Copenhagen, Copenhagen, Denmark.<br />
Friday, November 9<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s:<br />
Clinical Aspects and Therapeutics II<br />
(425)-1193. Scleroderma in a Population-based Sample: Evidence<br />
Suggests Increasing Incidence. S. Bernatsky, C. A. Pineau,<br />
L. Joseph, J.F. Boivin, Y. St. Pierre, A. E. Clarke. McGill<br />
University, Montreal, PQ, Canada.<br />
(426)-1194. Gastric Antral Vascular Ectasia (GAVE) in<br />
Patients with Systemic Sclerosis (SSc): a Systematic Review of the<br />
Literature. Lisa Davis, David Collier, Liron Caplan. Univ of<br />
Colorado at Denver & Health Science Center, Denver, CO.<br />
(427)-1195. Serum Interleukin-15 (IL-15) in Patients with<br />
Early Systemic Sclerosis. Dirk M. Wuttge, Marie Wildt,<br />
Pierre Geborek, Frank A. Wollheim, Agneta Scheja, Anita<br />
Åkesson. Department of Rheumatology, Lund University<br />
Hospital, Sweden.<br />
(428)-1196. Early Atherosclerosis in Systemic Sclerosis and Its<br />
Relation to Disease or Traditional Risk Factors. Martha E.<br />
Hettema 1 , Dan Zhang 1 , Karina de Leeuw 1 , Ymkje Stienstra 2 ,<br />
Andries J. Smit 2 , Cees GM Kallenberg 1 , Hendrika Bootsma 1 .<br />
1<br />
Rheumatology and Clinical Immunology, University Medical<br />
Center Groningen, The Netherlands; 2 Internal Medicine,<br />
University Medical Center Groningen, The Netherlands.<br />
(429)-1197. Assessment of Unmet Needs in the Design of<br />
Randomized Controlled Trials and the Lack of Generalizability for<br />
Scleroderma Treatment. Renata Villela 1 , Sai Yan Yuen 1 , Janet E.<br />
Pope 1 , The Canadian Scleroderma Research Group, Murray<br />
Baron 2 . 1 The University of Western Ontario, London, ON,<br />
Canada; 2 Jewish General Hospital, Montreal, PQ, Canada.<br />
(430)-1198. High Sensitivity C Reactive Protein as a Disease<br />
Marker in Systemic Sclerosis. Hala Y. Sadik 1 , Kathryn Edge 2 ,<br />
Nicola J. Goodson 1 , Robert J. Moots 1 , Ariane L. Herrick 2 ,<br />
Marina E. Anderson 1 . 1 University of Liverpool, Liverpool,<br />
United Kingdom; 2 University of Manchester, Manchester,<br />
United Kingdom.<br />
(431)-1199. Long-term Effects of Bosentan Treatment on Survival<br />
in Patients with Pulmonary Arterial Hypertension (PAH) Related<br />
to Connective Tissue Disease (CTD). Janet E. Pope 1 , Armando<br />
Gabrielli 2 , Hans-Hartmut Peter 3 , Christopher P. Denton 4 ,<br />
Loic Guillevin 5 . 1 St. Josephâ€s Healthcare, London, ON,<br />
Canada; 2 Azienda Ospedaliera Umberto I, Ancona, Italy;<br />
3<br />
Med. Universitätsklinik Freiburg, Freiburg, Germany;<br />
4<br />
Royal Free Hospital, London, United Kingdom; 5 Hopital<br />
Cochin, Paris, France.<br />
Poster Session B<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 195
Poster Session b<br />
(432)-1200. Correlations of Subjective Ratings of Dyspnea with<br />
Traditional Measures of Parenchymal Lung Disease in Systemic<br />
Sclerosis (SSc) with Interstitial Lung Disease (ILD). Ann J.<br />
Impens 1 , Elena Schiopu 1 , Kristine Phillips 1 , Christopher<br />
P. Denton 2 , Daniel E. First 3 , Loic Guillevin 4 , Lewis J.<br />
Rubin 5 , Athol U. Wells 6 , Marco Matucci-Cerinic 7 , Gabriela<br />
Riemekasten 8 , Paul Emery 9 , Harbajan Chada-Boreham 10 ,<br />
Pascal Charef 10 , Sebastien Roux 10 , Carol M. Black 2 , James R.<br />
Seibold 1 . 1 University of Michigan, Ann Arbor, MI; 2 Royal<br />
Free and University College Medical School, London,<br />
United Kingdom; 3 University of California, Los Angeles,<br />
CA; 4 Universite Rene Descartes, Paris, France; 5 University<br />
of California, San Diego, CA; 6 Royal Brompton Hospital,<br />
London, United Kingdom; 7 University of Florence,<br />
Florence, Italy; 8 Charite University Hospital, Berlin,<br />
Germany; 9 University of Leeds, Leeds, United Kingdom;<br />
10<br />
Actelion, Allschwil, Switzerland.<br />
(433)-1201. Time to Diagnosis in Systemic Sclerosis: Is Gender<br />
a Factor?. Marie Hudson, Brett Thombs, Canadian<br />
Scleroderma Research Group, Murray Baron. McGill<br />
University, Montreal, PQ, Canada.<br />
(434)-1202. Familial Clustering of Auto-immune Diseases in<br />
Patients with Systemic Sclerosis. Marie Hudson, Canadian<br />
Scleroderma Research Group, Murray Baron. McGill<br />
University, Montreal, PQ, Canada.<br />
(435)-1203. Early Detection of the Transition from Primary to<br />
Secondary Raynaud’s Phenomenon by Videocapillaroscopy. Maurizio<br />
E. Cutolo, Maria Elena Secchi, Matteo Grollero, Massimiliano<br />
Parodi, Carmen Pizzorni, Monica Olivieri, Bruno Seriolo,<br />
Alberto Sulli. University of Genova, Genova, Italy.<br />
(436)-1204. Influence of Sex and Race on Clinical and<br />
Immunological Manifestations In Systemic Sclerosis: Analysis<br />
Of 1139 Brazilian Patients. Percival D. Sampaio-Barros,<br />
Adriana B. Bortoluzzo, Blanca E.G.R. Bica, Débora<br />
Calderaro, Cristiane Kayser, Mauro W. Keiserman, Cláudia<br />
T.L. Borges, Izaias P. Costa, Sheila M. Fontenele, Eutilia<br />
A.M. Freire, Roger A. Levy, Sebastião C. Radominski,<br />
Maria-Cecília F. Salgado, Mittermayer B. Santiago, Mariade-Fátima<br />
L.C. Sauma, Telma L. Skare, José-Carlos M.<br />
Szajubok, Roberto A. Toledo, Adriana F. Zimmermann,<br />
Sueli C. S. Carneiro, Gustavo P. Costa, Angela L.B. Duarte,<br />
Sandra L. E. Ribeiro, João-Francisco Marques-Neto, Luis-<br />
Eduardo C. Andrade. Systemic Sclerosis Study Group of<br />
the Pronuclear Project (GEPRO) of the Brazilian Society of<br />
Rheumatology, Campinas, Brazil.<br />
(437)-1205. Efficacy of Complementary Cardiac MRI with Cine<br />
MRI, Pharmacological Stress Perfusion and Late Enhancement<br />
in Asymptomatic Patients with Systemic Sclerosis. Hitomi<br />
Kobayashi 1 , Yasuyuki Kobayashi 2 , Isamu Yokoe 1 , Hidehiro<br />
Yamada 2 , Shoichi Ozaki 2 . 1 Itabashi Chuo Medical Center,<br />
Tokyo, Japan; 2 St. Marianna University School of Medicine,<br />
Kawasaki, Japan.<br />
(438)-1206. N-Terminal Pro-Brain Natriuretic Peptide as<br />
a Diagnostic Marker of Pulmonary Artery Hypertension in<br />
Connective Tissue Disease. Akira Suwa 1 , Michito Hirakata 2 ,<br />
Tohru Sato 2 , Yuko Kaneko 2 , Shinji Sato 3 , Masataka<br />
Kuwana 2 , Eiko Saito 1 , Takayuki Wakabayashi 1 , Yasuo<br />
Suzuki 1 . 1 Tokai University, Isehara, Japan; 2 Keio University,<br />
Tokyo, Japan; 3 KeioUniversity, Tokyo, Japan.<br />
(439)-1207. Lupus Nephritis in Patients with Longstanding<br />
Limited Scleroderma: A Report of Two Patients. Firas Alkassab,<br />
Ruchdi K. Barakat, Regina R. Verani, Maureen D. Mayes,<br />
Akinsan K. Dosekun. Univ ot Texas at Houston, Houston, TX.<br />
(440)-1208. Pulmonary Hypertension (PH)-Assessment and<br />
Recognition of Outcomes in Scleroderma (Systemic Sclerosis,<br />
SSc): PHAROS. Elena Schiopu 1 , Vivien M. Hsu 2 , Laura K.<br />
Hummers 3 , Lee S. Shapiro 4 , Maureen D. Mayes 5 , Mary E.<br />
Csuka 6 , Chris T. Derk 7 , Lorinda S. Chung 8 , John Varga 9 ,<br />
Dan E. Furst 10 , Richard M. Silver 11 , Frederick M. Wigley 12 ,<br />
James R. Seibold 1 , Virginia D. Steen 13 . 1 University of<br />
Michigan, Ann Arbor, MI; 2 Robert Wood Johnson Medical<br />
School, New Brunswick, NJ; 3 Johns Hopkins Universtity,<br />
Baltimore, MD; 4 Rheumatology Center, Albany, NY;<br />
5<br />
University of Texas, Houston, TX; 6 Medical College of<br />
Wisconsin, Milwaukee, WI; 7 Jefferson Medical College,<br />
Philadelphia, PA; 8 Stanford University, Palo Alto, CA;<br />
9<br />
Northwestern University, Chicago, MI; 10 University of<br />
California, Los Angeles, CA; 11 Medical University South<br />
Carolina, Charleston, SC; 12 Johns Hopkins University,<br />
Baltimore, MD; 13 Georgetown University, Washington, DC.<br />
(441)-1209. Bosentan Increases Serum Il-12 Levels in Systemic<br />
Sclerosis Patients with Pulmonary Arterial Hypertension. Yasuhito<br />
Hamaguchi, Manabu Fujimoto, Minoru Hasegawa, Takashi<br />
Matsushita, Kazuhiko Takehara. Kanazawa University,<br />
Kanazawa, Japan.<br />
(442)-1210. Serum levels of Endoglin in patients with Systemic<br />
Sclerosis and Pulmonary Arterial Hypertension. Paola Ximena<br />
Coral Alvarado, Maria Fernanda Garces, Jorge Eduardo<br />
Caminos, Gerardo Quintana, Federico Rondon, Antonio<br />
Iglesias, Jose Felix Restrepo. University National of<br />
Colombia, Bogota, Colombia.<br />
(443)-1211. Improvement of Gastric Antral Vascular Ectasia<br />
(GAVE) in Systemic Sclerosis Patients With Cyclophosphamide.<br />
Marie S. O’Brien, Francesco Del Galdo, Sergio A. Jimenez,<br />
Nora Sandorfi. Thomas Jefferson University, Philadelphia, PA.<br />
(444)-1212. The Eustar Prospective Follow-Up Study of Systemic<br />
Sclerosis Patients with Barrett’s Esophagus: Baseline Analysis<br />
of Dysplasia. J. Wipff 1 , M. Masciocchi 2 , P. Caramaschi 3 ,<br />
CT Derk 4 , L. Mouthon 1 , D. Krasowska 5 , B. Granel 6 , LP<br />
Ananieva 7 , M. Matucci-Cerinic 8 , A. Kahan 1 , Y. Allanore 1 .<br />
1<br />
Cochin hospital, Paris, France; 2 Mangiagalli Regina Elena<br />
fundation, Milan, Italy; 3 Verona University, Verona, Italy;<br />
4<br />
Jefferson University, Philadelphia, PA; 5 Medical University,<br />
Lublin, Poland; 6 Mediterranean University, Marseille,<br />
196 (Permanent Board Number)-Abstract Number
France; 7 Academy of Medical Science, Moscow, Russian<br />
Federation; 8 Rheumatology, Brescia, Italy.<br />
(445)-1213. C-type Natriuretic Peptide (cnp) and Nt-pro-cnp in<br />
Raynaud’S Phenomenon: Disease Severity Markers?. Alessandra<br />
Della Rossa 1 , Elisa Vesprini 1 , Silvia Del Ry 2 , Maristella<br />
Maltinti 2 , Manuela Cabiati 2 , Daniela Giannessi 2 , Michele<br />
Emdin 2 , Laura Bazzichi 1 , Stefano Bombardieri 1 . 1 Università<br />
di Pisa, Pisa, Italy; 2 CNR, Institute of Clinical Physiology,<br />
Laboratory of Cardiovascular Biochemistry, Pisa, Italy.<br />
(446)-1214. Galectins -1 And -3 Expression in Lesional Skin of<br />
Patients with Progressive Systemic Sclerosis. Gabriela Mora 1 ,<br />
Mariana Rodríquez Zubieta 2 , Marcelo Maguna 1 , José<br />
Mordoh 2 . 1 Hospital Militar Central, Buenos Aires, Argentina;<br />
2<br />
Fundación Instituto Leloir, Buenos Aires, Argentina.<br />
(447)-1215. Stimulatory Antibodies to Vascular Receptors in<br />
Systemic Sclerosis. Gabriela Riemekasten 1 , Ivo Lukitsch 1 ,<br />
Dominik Müller 2 , Katrin Schmidt 1 , Melanie Näther 1 , Rebecca<br />
Widmer 1 , Harald Heidecke 3 , Maik Gollasch 1 , Duska Dragun 1 .<br />
1<br />
Charité University Hospital, Berlin, Germany; 2 Max<br />
Delbrueck Centre for Molecular Medicine, Berlin, Germany;<br />
3<br />
CellTrend GmbH, Luckenwalde, Germany.<br />
(448)-1216. A Transforming Growth Factor-β (TGFβ)-Responsive<br />
Gene Signature Predicts More Severe Skin Disease and Occurrence<br />
of Interstitial Lung Disease (ILD) in Diffuse Cutaneous Systemic<br />
Sclerosis (dcSSc). Jennifer L. Sargent 1 , Ausra Milano 1 , Swati<br />
Bhattacharyya 2 , John Varga 2 , Howard Y. Chang 3 , M. Kari<br />
Connolly 4 , Michael L. Whitfield 1 . 1 Dartmouth Medical<br />
School, Hanover, NH; 2 Northwestern University Feinberg<br />
School of Medicine, Chicago, IL; 3 Stanford University<br />
Medical School, Stanford, CA; 4 University of California,<br />
San Francisco, San Francisco, CA.<br />
(449)-1217. Severe Fibrosis and Increased Expression of Fibrogenic<br />
Cytokines in the Gastric Wall of Systemic Sclerosis Patients.<br />
Mirko Manetti 1 , Elena Neumann 2 , Anna Franca Milia 1 ,<br />
Ingo H. Tarner 2 , Paolo Bechi 1 , Marco Matucci-Cerinic 1 ,<br />
Lidia Ibba-Manneschi 1 , Ulf Müller-Ladner 2 . 1 University<br />
of Florence, Florence, Italy; 2 Justus-Liebig-University of<br />
Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany.<br />
(450)-1218. Autoantibody against Peroxiredoxin I, an Antioxidant<br />
Enzyme, in Patients with Systemic Sclerosis: Possible Association<br />
with Oxidative Stress. Yohei Iwata 1 , Fumihide Ogawa 1 ,<br />
Kazuhiro Komura 1 , Eiji Muroi 1 , Toshihide Hara 1 , Kazuhiro<br />
Shimizu 1 , Minoru Hasegawa 2 , Manabu Fujimoto 2 , Yasushi<br />
Tomita 3 , Shinichi Sato 1 . 1 Nagasaki University Graduate<br />
School of Biomedical Sciences, Nagasaki, Japan; 2 Kanazawa<br />
University Graduate School of Medical Science, Kanazawa,<br />
Japan; 3 Nagoya University Graduate School of Medicine,<br />
Nagoya, Japan.<br />
(451)-1219. Anti-p53 Antibody is a Novel Autoantibody Related<br />
to Limited Cutaneous Systemic Sclerosis. Toshihide Hara,<br />
Fumihide Ogawa, Eiji Muroi, Kazuhiro Komura, Shinichi<br />
Sato. Nagasaki University, Nagasaki, Japan.<br />
(452)-1220. Autoantibody Against One of the Antioxidant<br />
Repair Enzymes, Methionine Sulfoxide Reductase A (MSRA),<br />
in Systemic Sclerosis: Association with Pulmonary Fibrosis and<br />
Vascular Damage. Fumihide Ogawa, Kazuhiro Shimizu,<br />
Kazuhiro Komura, Toshihide Hara, Eiji Muroi, Shinichi<br />
Sato. Nagasaki University Graduate School of Biomedical<br />
Sciences, Nagasaki, Japan.<br />
(453)-1221. Autoantibody Profile In Systemic Sclerosis: Clinical<br />
Significance.. Beatriz E. Joven, Eugenia Enríquez, Raquel<br />
Almodovar, Desamparados Oliver-Miñarro, Estela Paz,<br />
Patricia E. Carreira. 12 Octubre Hospital, Madrid, Spain.<br />
(454)-1222. The Use of Non-Steroidal Anti-Inflammatories in<br />
Systemic Sclerosis. Helen Piercy, Robert J. Moots, Marina E.<br />
Anderson. University of Liverpool Academic Rheumatology<br />
Unit, Liverpool, United Kingdom.<br />
(455)-1223. Clinical Improvement in Systemic Sclerosis Patients<br />
Treated with Anti-CD20. Silvia Bosello, Maria De Santis,<br />
Gina Lama, Cristina Spanò, Barbara Tolusso, Gigliola Sica,<br />
Gianfranco Ferraccioli. Catholic University of the Sacred<br />
Heart, Rome, Italy.<br />
(456)-1224. Platelet Gel in the Treatment of Severe Scleroderma<br />
Skin Ulcers. Dilia Giuggioli, Michele Colaci, Marco<br />
Sebastiani, Maria T. Mariano, Clodoveo Ferri. University of<br />
Modena and Reggio Emilia, Modena, Italy.<br />
(457)-1225. Inhaled Iloprost for the Treatment of Raynaud’s<br />
Phenomenon. Angela Pakozdi, Kevin Howell, Helen Wilson,<br />
Samantha Fox, Leo Gonzalez, Carol M. Black, Christopher<br />
P. Denton. Royal Free Hospital, London, United Kingdom.<br />
Friday, November 9<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Vasculitis I<br />
(458)-1226. Is Really [18FDG] Pet-Scan a Reliable Way to Assess<br />
Disease Activity in Takayasu’s Arteritis ?. Laurent Arnaud,<br />
Julien Haroche, Zahir Amoura, Patrice Cacoub, Zoulika<br />
Malek, Frédéric Archambaud, Jean-Charles Piette. Hôpital<br />
Pitié-Salpêtrière, Paris, France.<br />
(459)-1227. Procalcitonin at the Onset of Giant Cell Arteritis<br />
and Polymyalgia Rheumatica : The GRACG Prospective Study.<br />
Jean Schmidt, Anne-Marie Bourgeois, Pierre Duhaut, Valéry<br />
Salle, Amar Smail, Denis Chatelain, Fay Betsou, Jean-Claude<br />
Maziere, Jean-Pierre Ducroix. Chu Nord, Amiens, France.<br />
(460)-1228. Fdg-Pet in the Large-Vessel Vasculitis: Role in<br />
Assessing the Disease Activity. Gianluigi Bajocchi 1 , Luigi<br />
Boiardi 1 , Annibale Versari 1 , Nicolò Pipitone 1 , Angelina<br />
Filice 1 , Alessandra Ghinoi 1 , Pierluigi Macchioni 1 ,<br />
Mariagrazia Catanoso 1 , Fulvia Rossi 1 , Giovanna Restuccia 1 ,<br />
Diana Salvo 1 , Lia Pulsatelli 2 , Carlo Salvarani 1 . 1 Arcispedale<br />
S Maria Nuova, Reggio Emilia, Italy; 2 Istituti Ortopedici<br />
Rizzoli, Bologna, Italy.<br />
Poster Session B<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 197
Poster Session b<br />
(461)-1229. The Role of 18FDG PET/CT Scanning in Assessing<br />
Flares and Disease Activity in Patients with Takayasu’s Arteritis.<br />
Yet Lin Loh, Shirish Sangle, David P. D’Cruz. Lupus<br />
Research Unit, The Rayne Institute, King’s College School of<br />
Medicine, St Thomas’ Hospital, London, United Kingdom.<br />
(462)-1230. Human Temporal Artery Culture on Matrigel: A<br />
Useful Method for Preclinical Assessment of Functional Changes<br />
after Intervention. Ana García-Martínez, Ester Lozano, Marta<br />
Segarra, José Hernández-Rodríguez, Georgina Espígol, Sergio<br />
Prieto, Maria Cinta Cid. Hospital Clínic, Barcelona, Spain.<br />
(463)-1231. -463 G/a Myloperoxidase Promoter Polymorphism<br />
in Giant Cell Arteritis. Luigi Boiardi, Bruno Casali, Enrico<br />
Farnetti, Nicolò Pipitone, Davide Nicoli, Pierluigi<br />
Macchioni, Luca Cimino, Gialuigi Bajocchi, Maria Grazia<br />
Catanoso, Laura Pattacini, Alessandra Ghinoi, Giovanna<br />
Restuccia, Carlo Salvarani. Arcispedale S Maria Nuova,<br />
Reggio Emilia, Italy.<br />
(464)-1232. Colchicine: Randomized Double-Blind Controlled<br />
Crossover Study in Behçet’s Disease. Fereydoun Davatchi, Bahar<br />
Sadeghi-Abdolahi, Arash Tehrani-Banihashemi, Farhad<br />
Shahram, Abdolhadi Nadji, Cheyda Chams-Davatchi,<br />
Hormoz Shams, Ahmad-Reza Jamshidi. Rheumatology<br />
Research Center, Medical Sciences/University of Tehran,<br />
Tehran, Iran (Islamic Republic of).<br />
(465)-1233. Evaluation and Revision of the International Study<br />
Group Criteria for Behçet’s Disease. Fereydoun Davatchi 1 ,<br />
Michael Schirmer 2 , Christos C. Zouboulis 3 , Samir Assad-<br />
Khalil 4 , Kenneth T. Calamia 5 . 1 Tehran University for<br />
Medical Sciences, Tehran, Iran (Islamic Republic of);<br />
2<br />
IInnsbruck Medical University, Innsbruck, Austria; 3 Dessau<br />
Medical Center, Dessau, Germany; 4 Alexandria University,<br />
Alexandria, Egypt; 5 Mayo Clinic, Jacksonville, FL.<br />
(466)-1234. Assessment of Disease Activity with MR Angiography<br />
Using an Intravascular Contrast Media (Gadofosveset) in Takayasu’s<br />
Arteritis. Lorenzo Dagna 1 , Elena Baldissera 2 , Francesco De<br />
Cobelli 2 , Maurizio Papa 1 , Alessandro Del Maschio 1 , Maria<br />
Grazia Sabbadini 1 . 1 Universita’ Vita-Salute San Raffaele, Milan,<br />
Italy; 2 San Raffaele <strong>Scientific</strong> Institute, Milan, Italy.<br />
(467)-1235. Cardiovascular Outcomes in Giant Cell Arteritis.<br />
Eamonn S. Molloy 1 , H. Lester Kirchner 2 , Patrick K.<br />
Murray 2 , Hoffman S. Gary 1 , Carol A. Langford 1 . 1 Cleveland<br />
Clinic, Cleveland, OH; 2 Case Western Reserve University,<br />
Cleveland, OH.<br />
(468)-1236. Noninfectious Ascending Aortitis: A Clinicopathologic<br />
Review of 64 Cases. Kimberly P. Liang, Vaidehi R. Chowdhary,<br />
Clement J. Michet, Dylan V. Miller, Thoralf M. Sundt, Eric L.<br />
Matteson, Kenneth J. Warrington. Mayo Clinic, Rochester, MN.<br />
(469)-1237. Primary Central Nervous System Vasculitis with<br />
Spinal Cord Involvement. Carlo Salvarani 1 , Robert D. Brown<br />
Jr. 2 , Kenneth Calamia 3 , Teresa Christianson 2 , John Huston<br />
III 2 , James F. Meschia 3 , Caterina Giannini 2 , Dylan V.<br />
Miller 2 , Gene G. Hunder 2 . 1 Hospital of Reggio Emilia,<br />
Reggio Emilia, Italy; 2 Mayo Clinic, Rochester, MN; 3 Mayo<br />
Clinic, Jacksonville, FL.<br />
(470)-1238. Primary Central Nervous System Vasculitis:<br />
Comparison of Patients with and without Cerebral Amyloid<br />
Angiopathy. Carlo Salvarani 1 , Robert D. Brown Jr. 2 , Kenneth<br />
Calamia 3 , Teresa Christianson 2 , John Huston III 2 , James F.<br />
Meschia 3 , Caterina Giannini 2 , Dylan V. Miller 2 , Gene G.<br />
Hunder 2 . 1 Hospital of Reggio Emilia, Reggio Emilia, Italy;<br />
2<br />
Mayo Clinic, Rochester, MN; 3 Mayo Clinic, Jacksonville, FL.<br />
(471)-1239. A High Frequency of Carotid Artery Involvement in<br />
Takayasu Detected by Intima Medial Thickness. Sivakumar M.<br />
Rajappa, Professor 1 , Sanjeev Sivakumar 1 , Paul A. Bacon,<br />
Professor 2 . 1 Cerebrovascular and Vasculitis Research<br />
Foundation, Chennai, India; 2 University of Birmingham,<br />
Birmingham, United Kingdom.<br />
(472)-1240. Features of Temporal Artery Biopsy and Diagnostic<br />
of Giant Cell Arteritis: The Multicentric, Prospective GRACG<br />
Study. Denis Chatelain 1 , Pierre Duhaut 1 , Robert Loire 2 ,<br />
Sylvie Bosshard 2 , Hélène Pellet 2 , Jean-Charles Piette 3 , Henri<br />
Sevestre 1 , Jean-Pierre Ducroix 1 . 1 Chu Nord, Amiens, France;<br />
2<br />
Recif, Lyon, France; 3 Pitié-Salpêtrière Hospital, Paris, France.<br />
(473)-1241. Evaluation of Long-Term Remissions after Treatment<br />
with Interferon-alfa2a for Ocular Behçet`s Disease. Ina Koetter,<br />
Manfred Zierhut, Nicole Stuebiger, Christoph Deuter.<br />
University Hospital, Tuebingen, Germany.<br />
(474)-1242. Cause of Death in Patients with Hepatitis C (HCV)-<br />
Mixed Cryoglobulinemia (MC) Vasculitis. Sami Scerra, Damien<br />
Sene, David Saadoun, Aurelien Delluc, Zahir Amoura, Jean<br />
Charles Piette, Patrice Cacoub. Hopital Pitie Salpetriere,<br />
Paris, France.<br />
(475)-1243. NKG2D Stimulated T Cell Autoreactivity in<br />
Polymyalgia Rheumatica and Giant Cell Arteritis. Christian<br />
Dejaco 1 , Christina Duftner 1 , Carlo Salvarani 2 , William<br />
Sterlacci 3 , Michael Schirmer 1 . 1 General Hospital of the<br />
Elisabethinen, Klagenfurt, Austria; 2 Arcispedale Santa Maria<br />
Nouva, Reggio Emilia, Italy; 3 Medical University Innsruck,<br />
Innsbruck, Austria.<br />
(476)-1244. Epidemiology of Behçet’s Disease (BD) in a<br />
Multiethnic French Population. Alfred D. Mahr 1 , Linda<br />
Belarbi 1 , Bertrand Wechsler 2 , Dominique Jeanneret 3 , Robin<br />
Dhote 4 , Olivier Fain 5 , François Lhote 6 , Jacky Ramanoelina 7 ,<br />
Joël Coste 1 , Loïc Guillevin 1 . 1 Hôpital Cochin, Paris, France;<br />
2<br />
Hôpital de la Pitié–Salpêtrière, Paris, France; 3 Service<br />
Médical Assurance-Maladie Ile-de-France, Bobigny, France;<br />
4<br />
Hôpital Avicenne, Bobigny, France; 5 Hôpital Jean-Verdier,<br />
Bondy, France; 6 Hôpital Delafontaine, Saint-Denis, France;<br />
7<br />
Hôpital Robert-Ballanger, Aulnay-sous-Bois, France.<br />
(477)-1245. CD24 A57V Genetic Variant Confers Susceptibility<br />
to Giant Cell Arteritis. Javier Martin 1 , Blanca Rueda 1 , Miguel<br />
A. Gonzalez-Gay 2 . 1 Instituto Biomedicina. CSIC, Granada,<br />
Spain; 2 Hospital Xeral-Calde, Lugo, Spain.<br />
198 (Permanent Board Number)-Abstract Number
(478)-1246. Clinical Manifestations and Ethnic Background<br />
of Patients with Behçet’s Syndrome in a U.S. Cohort. Yusuf Yazici,<br />
Nicole Moses. NYU Hospital for Joint Diseases, New York,<br />
NY.<br />
(479)-1247. Treatment of Venous Thrombosis Associated with<br />
Behçet’s Disease: Immunosuppressive Therapy Alone Versus<br />
Immunosuppressive Therapy Plus Anticoagulation. Joong Kyong<br />
Ahn 1 , You Sun Lee 2 , Chan Hong Jeon 3 , Hoon-Suk Cha 1 ,<br />
Eun-Mi Koh 1 . 1 Department of Medicine, Samsung Medical<br />
Center, Sungkyunkwan University School of Medicine,<br />
Seoul, Republic of Korea; 2 Masan Samsung Medical Center,<br />
Masan, Republic of Korea; 3 Department of Medicine,<br />
Soonchunhyang University College of Medicine, Bucheon,<br />
Republic of Korea.<br />
(480)-1248. The Long Term Prognosis of Behçet’s Syndrome among<br />
Men with Skin-Mucosa Involvement at Onset: Re-Evaluation of a<br />
Cohort of Patients Enrolled in a Controlled Trial. Gulen Hatemi,<br />
Vedat Hamuryudan, Koray Tascilar, Yilmaz Ozyazgan,<br />
Emire Seyahi, Cem Mat, Sebahattin Yurdakul, Hasan Yazici.<br />
Istanbul University, Cerrahpasa Medical School, Behçet<br />
Syndrome Research Center, Istanbul, Turkey.<br />
(481)-1249. Treatment of Rheumatoid Vasculitis with<br />
Rituximab : Data from the French Registry Air (Autoimmunity<br />
and Rituximab). Jacques-Eric Gottenberg 1 , Michel<br />
Debandt 2 , Jean-Marie Berthelot 3 , Jacques Morel 4 , Maxime<br />
Dougados 5 , Xavier Mariette 1 , for the Club Rhumatismes<br />
et Inflammation (CRI). 1 Bicetre Hospital, Le Kremlin<br />
Bicetre, France; 2 Robert Ballanger Hospital, Aulnay, France;<br />
3<br />
Nantes Hospital, Nantes, France; 4 La Peyronie Hospital,<br />
Montpellier, France; 5 Cochin Hospital, Paris, France.<br />
(482)-1250. Gender Predicts Prolonged Corticosteroid Use in<br />
Giant Cell Arteritis (GCA). Yaqoot Khan, Martin Feuerman,<br />
Steven E. Carsons, Elise Belilos. Winthrop University<br />
Hospital, SUNY Stony Brook, Mineola, NY.<br />
Friday, November 9<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
<strong>ARHP</strong><br />
(483)-1251. Integrated Care in Practice: Is Acupuncture a Useful<br />
Adjunct to Exercise-Based Physiotherapy for Older Adults with<br />
Clinical Knee Osteoarthritis?. Nadine E. Foster, Elaine Thomas,<br />
Panos Barlas, Jonathan Hill, Julie Young, Elizabeth Mason,<br />
Elaine M. Hay. Keele University, Keele, United Kingdom.<br />
(484)-1252. Complementary and Alternative Medicine Use in<br />
Arthritis: Does Medical Skepticism Matter?. Elizabeth Wiley-<br />
Exley, Thelma J. Mielenz, Edward C. Norton, Leigh F.<br />
Callahan. University of North Carolina, Chapel Hill, NC.<br />
(485)-1253. LupusLine Peer Phone Counseling Service: A<br />
<strong>Program</strong> Evaluation. Jennie Salomon, Jillian Rose, Roberta<br />
Horton, Stephen Paget, Susan Flics. Hospital for Special<br />
Surgery, New York, NY.<br />
(486)-1254. The Multidimensional Burden of Systemic Lupus<br />
Erythematosus: Mortality Risk and Quality of Life Measures Early<br />
in the Course of the Disease. Robert Campbell, Jr. 1 , Glinda S.<br />
Cooper 2 , Gary S. Gilkeson 3 . 1 Medical University of South<br />
Carolina, Charleston, SC; 2 US Environmental Protection<br />
Agency; Washington, DC, Washington, DC; 3 Ralph<br />
H. Johnson Veterans Administration Medical Center,<br />
Charleston, South Carolina and Medical University of<br />
South Carolina, Charleston, Charleston, SC.<br />
(487)-1255. An Assessment of Medical Costs Associated with<br />
Systemic Lupus Erythematosus and Lupus Nephritis. Tracy<br />
Li 1 , Sara Wang 2 , Ron Goetzel 2 , Ross Maclean 1 , Ron<br />
Ozminkowski 2 . 1 Bristol--Myers Squibb, Princeton, NJ;<br />
2<br />
Medstat, Ann Arbor, MI.<br />
(488)-1256. Socioeconomic Status in Outcomes of Systemic Lupus<br />
Erythematosus. Laura Trupin, M. Christine Tonner, Jinoos<br />
Yazdany, Laura J. Julian, Lindsey A. Criswell, Patricia P.<br />
Katz, Edward Yelin. UC San Francisco, San Francisco, CA.<br />
(489)-1257. Patient’s Descriptions of SLE-Related Fatigue.<br />
Susanne Pettersson, Elisabet Svenungsson, Iva Gunnarsson,<br />
Elisabet Welin Henriksson. Karolinska Institutet,<br />
Stockholm, Sweden.<br />
(490)-1258. The Multi-Dimensional Nature of Fatigue in<br />
Osteoarthritis. J. Denise Power, Elizabeth M. Badley, Gillian<br />
A. Hawker. University of Toronto, Toronto, ON, Canada.<br />
(491)-1259. Help-Seeking in Early Rheumatoid Arthritis (era):<br />
From Onset to Early-Post Diagnosis. Anne Townsend 1 , Paul<br />
M. Adam 2 , Susan Margaret Cox 1 , Linda Li 1 . 1 University of<br />
British Columbia, Vancouver, BC, Canada; 2 Mary Pack<br />
Arthritis Centre, Vancouver, BC, Canada.<br />
(492)-1260. Barriers to Arthritis Care in Michigan. Peter<br />
DeGuire 1 , Emily C. Somers 2 . 1 Michigan Dept of<br />
Community Health, Lansing, MI; 2 University of Michigan<br />
Health System, Ann Arbor, MI.<br />
(493)-1261. Do Wrist Splints Improve Grip Strength in Patients<br />
with Rheumatoid Arthritis?. Margaret SIBLEY. St George’s<br />
Hospital, London, United Kingdom.<br />
(494)-1262. Social Role Participation in Arthritis: Measuring<br />
What Matters. Monique Gignac 1 , Aileen Davis 1 , Elizabeth<br />
Badley 1 , Catherine Backman 2 , Diane Lacaille 2 , Pamela<br />
Montie 2 , Cristina Mattison 1 . 1 The Arthritis Community<br />
Research & Evaluation Unit, Toronto, ON, Canada; 2 The<br />
Arthritis Research Centre of Canada, Vancouver, BC, Canada.<br />
(495)-1263. Disparities in Patient-Reported Risk Communication<br />
about Arthritis Therapy at Community Pharmacies. Cynthia L.<br />
LaCivita 1 , Daniel J. Cobaugh 1 , Midge N. Ray 2 , Kenneth G.<br />
Saag 2 , Jeroan J. Allison 2 . 1 ASHP Research and Education<br />
Foundation, Bethesda, MD; 2 University of Alabama at<br />
Birmingham, Birmingham, AL.<br />
Poster Session B<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 199
Poster Session b<br />
(496)-1264. TNF-Antagonism as a Promising Therapy for<br />
Sclerosing Mesenteritis. Lisa R. Rothlein 1 , John Vavalle 2 ,<br />
Amy W. Shaheen 2 , Nicholas Shaheen 2 , Teresa K. Tarrant 3 .<br />
1<br />
Thurston Arthritis Research Center, Chapel Hill, NC;<br />
2<br />
Department of Medicine, UNC School of Medicine,<br />
Chapel Hill, NC; 3 Thurston Arthritis Research Center,<br />
UNC Department of Medicine, Chapel Hill, NC.<br />
(497)-1265. Feasibility and Safety of Administration of<br />
Rituximab in Rheumatology Clinical Practice: Local Policy and<br />
Procedure Development to Support Safe Practice. Louise Moore 1 ,<br />
Madeline O’Neill 1 , Eileen Shinners 1 , Douglas Veale 2 ,<br />
Oliver FitzGerald 2 , Barry Bresnihan 2 , Patricia Minnock 1 .<br />
1<br />
Our Lady’s Hospice, Harold’s Cross, Dublin, Ireland; 2 St<br />
Vincent’s University Hospital and Our Lady’s Hospice,<br />
Harold’s Cross, Dublin, Ireland.<br />
(498)-1266. Administration of Intravenous Cyclophosphamide<br />
in Rheumatology Clinical Practice: Local Policy and Procedure<br />
Development to Support Safe Practice. Madeline O’Neill 1 ,<br />
Louise Moore 1 , Eileen Shinners 1 , Douglas Veale 2 , Oliver<br />
FitzGerald 2 , Barry Bresnihan 2 , Patricia Minnock 1 . 1 Our<br />
Lady’s Hospice, Harold’s Cross, Dublin, Ireland; 2 St<br />
Vincent’s University Hospital and Our Lady’s Hospice,<br />
Harold’s Cross, Dublin, Ireland.<br />
(499)-1267. Reduced Infusion Times in Patients Receiving<br />
Intravenous Infliximab: A Protocol for Practice. Eileen Shinners 1 ,<br />
Madeline O’Neill 1 , Louise Moore 1 , Douglas Veale 2 , Oliver<br />
FitzGerald 2 , Barry Bresnihan 2 , Patricia Minnock 1 . 1 Our<br />
Lady’s Hospice, Harold’s Cross, Dublin, Ireland; 2 St<br />
Vincent’s University Hospital and Our Lady’s Hospice,<br />
Harold’s Cross, Dublin, Ireland.<br />
(500)-1268. Effect of Weight Lifting on Muscle Strength at<br />
9 Months in Early Osteoarthritis of the Knee. Scott Going 1 ,<br />
Shelley Kasle 1 , Michelle Cornett 1 , Hilary Flint-Wagner 2 , Erin<br />
Nelson 1 , Jill Wright 1 , Elionor Garcia 1 , Calvin Hammond 1 ,<br />
Christopher Beglin 1 , Jeffrey R. Lisse 1 . 1 University of Arizona,<br />
Tucson, AZ; 2 Idaho State University, Pocatello, ID.<br />
(501)-1269. Reliability of Knee Stiffness and Damping Coefficient<br />
Measurements Using Two Different Motion Analysis Systems.<br />
Michael Bruno 1 , Mariana Hinkel 1 , Carla Vey 2 , Carol A.<br />
Oatis 3 , Margery A. Lockard 4 . 1 Hospital of the University of<br />
Pennsylvania, Philadelphia, PA; 2 Physical Therapy Associates<br />
of Concord, MA, Concord, MA; 3 Arcadia University,<br />
Glenside, PA; 4 Temple University, Philadelphia, PA.<br />
(502)-1270. Dynamic Wedging: Effective Treatment for<br />
Knee OA. Yaron Bar-Ziv, Yiftah Beer, Yuval Ran, Shaike<br />
Benedict, Nahum Halperin. Assaf-Harofe Medical Center,<br />
Zerifin, Israel.<br />
(503)-1271. The Mediating Effect of Knee Pain on the<br />
Relationship of Biobehavioral Factors to Function in Patients with<br />
Knee Osteoarthritis. Kristen A. Scopaz, Sara R. Piva, G. Kelley<br />
Fitzgerald. University of Pittsburgh, Pittsburgh, PA.<br />
(504)-1272. When Patients are Diagnosed with Knee OA, What<br />
do they do and How Does it Impact on Quality of Life?. Carlo<br />
A. Marra, Lindsey Colley, Bridgette Oteng, Jolanda Cibere,<br />
John M. Esdaile, Louise Gastonguay, Jacek Kopec, Ross T.<br />
Tsuyuki, Judith A. Soon. University of British Columbia,<br />
Vancouver, BC, Canada.<br />
(505)-1273. Exercise Therapy Aiming at Neuromuscular Control<br />
in Osteoarthritis of the Knee: Proof of Concept. Joost Dekker 1 ,<br />
Wilfred Peter 2 , Mariet de Rooij 2 , Martin van der Esch 2 ,<br />
Marike van der Leeden 2 , Leo Roorda 2 , Willem Lems 1 ,<br />
Martijn Steultjens 1 . 1 VU University Medical Center,<br />
Amsterdam, The Netherlands; 2 Jan van Breemen Institute,<br />
Amsterdam, The Netherlands.<br />
(506)-1274. Joint Proprioception, Muscle Strength and Functional<br />
Ability in Patients with Osteoarthritis of the Knee. Martin van<br />
der Esch 1 , Martijn Steultjens 2 , Jaap Harlaar 2 , Dirk Knol 2 ,<br />
Willem Lems 2 , Joost Dekker 2 . 1 Jan van Breemen Institute,<br />
Amsterdam, The Netherlands; 2 VU University Medical<br />
Center, Amsterdam, The Netherlands.<br />
(507)-1275. Predicting Poor Functional Outcome in Community<br />
Dwelling Older Adults with Knee Pain: Prognostic Value of<br />
Generic, Clinical History, and Physical Examination Variables.<br />
Elaine Thomas, George Peat, Christian D. Mallen, Rosie<br />
Lacey, Peter Croft. Keele University, Keele, United Kingdom.<br />
200 (Permanent Board Number)-Abstract Number
Rheumatology Audioconference Series<br />
08<br />
REGISTER DIAL<br />
The <strong>ARHP</strong> Rheumatology Audioconference Series is designed to meet the educational needs<br />
of health professionals involved in the management of patients with arthritis and other<br />
rheumatic diseases. The series is a convenient, cost-effective way to experience leading<br />
content from experts in the field. We offer various ways to experience this excellent inservice<br />
educational tool. You can dial-in from your office or conference room and invite as<br />
many guests as you’d like to participate or dial-in from the comfort of your home.<br />
>>> If you cannot dial in to a session, you can purchase an audio CD of any session in the<br />
<strong>2007</strong> or 2008 series through the online registration at www.rheumatology.org/arhp/<br />
audioconferences.<br />
MembeR<br />
Non-member<br />
Individual sessions $45 each $60 each<br />
Save! Any 3 Sessions $110 $160<br />
Save more! Any 6 Sessions $200 $300<br />
REGISTRATION IS OPEN!<br />
Go to the <strong>ARHP</strong> Web site at www.rheumatology.org/arhp/audioconferences<br />
Sessions are scheduled from Noon – 1:00 pm Eastern Time, and registered participants will<br />
receive the speaker’s handout materials prior to the call, along with a toll-free phone number<br />
and instructions on how to join the call and participate in the Question/Answer period.<br />
Act Now!<br />
January 15:<br />
February 12:<br />
March 18:<br />
April 17:<br />
May 21:<br />
June 11:<br />
Promoting Safety among the Elderly: Self Confidence and Function<br />
Patricia A. Quigley, PhD, MPH, ARNP, CRRN, FAAN<br />
The Heart “Ache” of Lupus<br />
Susan Manzi, MD, MPH<br />
Hypermobility Syndromes: The True Collagen Disorders<br />
Eric P. Gall, MD, MACP, M<strong>ACR</strong><br />
The Pain Puzzle<br />
Michael A. Rapoff, PhD<br />
Non-surgical Management of Lumbar Spinal Stenosis<br />
Maura D. Iversen, PT, DPT, ScD, MPH<br />
The Impact of Public Health on Arthritis and other Rheumatic Diseases<br />
Teresa J. Brady, PhD
time locatioN EVENT<br />
saturday · agenda at-a-glance<br />
7:00 a m—5:00 pm East Registration <strong>ACR</strong>/<strong>ARHP</strong> Registration<br />
7:00—8:00 a m Room 151 <strong>ACR</strong> Special Session: Quality Town Hall <strong>Meeting</strong><br />
7:00—8:00 a m Room 52-B <strong>ARHP</strong> Special Session: <strong>Meeting</strong> Success<br />
7:45—8:45 a m Hall C <strong>ACR</strong> Medical Aspects of Rheumatic Diseases<br />
7:45—8:45 a m Grand Ballroom East <strong>ACR</strong> State-of-the-Art<br />
7:45—8:45 a m Convention Center (various locations) <strong>ARHP</strong> Concurrent Sessions<br />
7:45—9:15 a m Convention Center (various locations) <strong>ACR</strong> Meet the Professor Sessions<br />
7:45—9:15 a m Room 210 <strong>ACR</strong> Special Session: A&R at 50<br />
7:45—9:15 a m Room 156 ref Estate Planning Session<br />
7:45—9:45 a m Convention Center (various locations) <strong>ACR</strong> Workshops<br />
7:45—11:45 a m Room 261 <strong>ARHP</strong> Concurrent Session<br />
8:00—9:30 a m Exhibit Hall A-B <strong>ACR</strong>/<strong>ARHP</strong> Coffee and Tea Break<br />
8:00 a m—4:30 pm Exhibit Hall A-B <strong>ACR</strong>/<strong>ARHP</strong> Poster Session C<br />
8:00 a m—4:30 pm Exhibit Hall A-B exhibits<br />
9:15—10:15 a m Grand Ballroom East <strong>ACR</strong> Immunology Updates for Clinicians<br />
9:15—10:15 a m Hall C <strong>ACR</strong> REF Special Session: Klemperer Lecture<br />
9:15—10:15 a m Convention Center (various locations) <strong>ARHP</strong> Concurrent Sessions<br />
9:15—10:15 a m Room 260 <strong>ARHP</strong> Concurrent Abstract Session<br />
9:45—10:45 a m Meet in the Registration Area <strong>ARHP</strong> Special Session: How to Decipher a Poster<br />
10:30 a m—12:30 pm Convention Center (various locations) <strong>ACR</strong> Workshops<br />
10:45—11:45 a m Convention Center (various locations) <strong>ARHP</strong> Concurrent Sessions<br />
11:00 a m—Noon Room 253 <strong>ACR</strong> Practice Issues<br />
11:00 a m—12:30 pm Grand Ballroom East <strong>ACR</strong> Clinical Symposium<br />
11:00 a m—12:30 pm Hall C <strong>ACR</strong> Plenary Session III<br />
Noon—1:00 pm Room 154 <strong>ARHP</strong> Fitness Session: Tai Chi<br />
12:45—1:45 pm Room 102 <strong>ACR</strong> Special Session: Recertification Information<br />
12:45—2:15 pm Room 255 encore Theater<br />
12:45—2:15 pm Convention Center (various locations) <strong>ACR</strong> Meet the Professor Sessions<br />
1:15—3:15 pm Convention Center (various locations) <strong>ACR</strong> Workshops<br />
2:00—4:00 pm Convention Center (various locations) <strong>ACR</strong> Business <strong>Meeting</strong> and Late-Breaking Abstracts<br />
<strong>ACR</strong><br />
CLINICAL PRACTICE<br />
BASIC AND<br />
TRANSLATIONAL<br />
RESEARCH<br />
DUAL INTEREST TO<br />
CLINICIANS AND<br />
RESEARCHERS<br />
PEDIATRICS<br />
FELLOWS-IN-TRAINING<br />
<strong>ARHP</strong><br />
CLINICAL PRACTICE<br />
PEDIATRICS<br />
FELLOWS-IN-TRAINING<br />
PLAN YOUR SCHEDULE USING EDUCATIONAL TRACKS TO ENHANCE<br />
YOUR MEETING EXPERIENCE<br />
The <strong>ACR</strong> and <strong>ARHP</strong> have designed educational tracks to help you maximize the scheduling of your time and<br />
meeting experience by emphasizing primary areas of interest. There are five tracks for <strong>ACR</strong> and three tracks for<br />
<strong>ARHP</strong>. Designated sessions include the main symposia, lectures and select <strong>ACR</strong> Meet the Professor Sessions and<br />
Workshops. However, the concurrent abstract sessions and poster discussions are not included.<br />
Those sessions that are predominantly translational in content are designed to be of interest to both clinicians and<br />
researchers. These are indicated as “C/R”. Sessions with mainly pediatric content are indicated as “P”, and may be<br />
of interest to both pediatric and adult rheumatologists.<br />
As the annual meeting has a variety of session types scheduled concurrently, use these suggested tracks as a tool to<br />
assist you in developing your own individualized schedule for the meeting.<br />
Track Indicator Example<br />
Please use the following as an example to identify the available tracks.<br />
C R C/R P F<br />
CLINICAL<br />
PRACTICE<br />
BASIC AND<br />
TRANSLATIONAL<br />
RESEARCH<br />
DUAL INTEREST TO<br />
CLINICIANS AND<br />
RESEARCHERS<br />
PEDIATRICS<br />
FELLOWS-IN-<br />
TRAINING<br />
PM - PAIN MANAGEMENT<br />
The <strong>ACR</strong> designates certain sessions for pain management credit as required by the Medical Board of California<br />
(AB487). This designation is identified by the icon shown and will be placed next to the session title.<br />
202
2:30—4:00 pm Room 253 <strong>ACR</strong> Advocacy Issues<br />
2:30—4:00 pm Room 205 <strong>ACR</strong> Basic Science Symposium<br />
2:30—4:00 pm Convention Center (various locations) <strong>ACR</strong> Concurrent Abstract Sessions<br />
2:30—4:00 pm Hall C <strong>ACR</strong> Special Session: The Great Debate<br />
2:30—4:00 pm Convention Center (various locations) <strong>ARHP</strong> Concurrent Sessions<br />
2:30—4:00 pm Room 261 <strong>ARHP</strong> Concurrent Abstract Session<br />
4:00—6:00 pm Convention Center (various locations) <strong>ACR</strong> Workshops<br />
4:00—6:00 pm Room 213 <strong>ARHP</strong> Concurrent Session<br />
4:30—6:00 pm grand Ballroom West <strong>ACR</strong> Basic Science Symposium<br />
4:30—6:00 pm Hall C <strong>ACR</strong> Clinical Symposium<br />
4:30—6:00 pm Convention Center (various locations) <strong>ACR</strong> Concurrent Abstract Sessions<br />
4:30—6:00 pm Convention Center (various locations) <strong>ACR</strong> Meet the Professor Sessions<br />
4:30—6:00 pm Room 210 <strong>ACR</strong>/<strong>ARHP</strong> Combined Clinical Symposium<br />
4:30—6:00 pm Convention Center (various locations) <strong>ARHP</strong> Concurrent Sessions<br />
6:30—9:30 pm Various Locations industry Roundtable-Supported Symposia<br />
saturday, November 10, <strong>2007</strong><br />
<strong>ACR</strong>/<strong>ARHP</strong> Registration<br />
7:00 a m—5:00 p m<br />
East Registration<br />
<strong>ACR</strong> Special Session<br />
7:00—8:00 a m<br />
Room 151<br />
This session is not eligible for CME credit.<br />
Quality Town Hall <strong>Meeting</strong><br />
If you have an opinion you would like to share, a concern<br />
you would like the <strong>ACR</strong> leadership to address, or if you<br />
want to learn how the quality movement is affecting the<br />
way your colleagues practice, the <strong>ACR</strong> would like to extend<br />
a special invitation to you to join us for breakfast and<br />
participate in the Quality Initiatives Town Hall <strong>Meeting</strong>.<br />
This meeting offers an opportunity to engage in a discussion<br />
about the quality movement, which will have a significant<br />
influence on how medicine is taught, practiced and<br />
reimbursed. The discussion will also involve <strong>ACR</strong> initiatives<br />
in response to the quality movement that are designed to<br />
ensure rheumatology is appropriately represented.<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify the current trends and recent developments in<br />
the quality movement<br />
∙ Recognize the <strong>ACR</strong> initiatives and projects that have<br />
been developed in response to the quality movement<br />
∙ Better understand how the quality movement will impact<br />
rheumatology practices and reimbursement<br />
saturday<br />
<strong>ARHP</strong> Special Session<br />
7:00—8:00 a m<br />
Room 52-B<br />
<strong>Meeting</strong> Success: A Master Class on Leadership<br />
Moderator:<br />
Catherine L. Backman, PhD, OT(C); University of British<br />
Columbia; Vancouver, British Columbia<br />
Upon completion of this session, participants should be able to:<br />
∙ Summarize strategies for leading and participating in<br />
effective meetings, including: ways to engage diverse<br />
constituencies around common goals, efficient use of<br />
meeting mechanics, including setting the agenda, time<br />
management, inclusiveness/involving all participants,<br />
re-directing discussion and summarizing decisions<br />
and action plans, ways to manage disparate views and<br />
negotiate solutions that fulfill organizational goals, and<br />
ways to facilitate, lead and manage change<br />
∙ Identify strategies for different types and modes of<br />
meetings, including those conducted in-person and by<br />
conference call<br />
∙ Given a specific meeting scenario from your choice of<br />
clinical practice, academic, business or voluntary sectors,<br />
apply selected strategies and identify alternative strategies<br />
when plans go awry<br />
7:00 a m<br />
A Useful and Lighthearted Review of <strong>Meeting</strong> Mechanics<br />
7:15 a m<br />
Communication Strategies: Managing the Unexpected<br />
7:30 a m<br />
Facilitate Small Groups: Application of Strategies<br />
7:55 a m<br />
Summary<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 203
SATURDAY<br />
<strong>ACR</strong> Medical Aspects of Rheumatic Diseases C<br />
7:45—8:45 a m<br />
Hall C<br />
Hepatitis C<br />
Moderator:<br />
Marcy B. Bolster, MD; Medical University of South<br />
Carolina; Charleston, SC<br />
Speaker:<br />
Adrian Reuben, MD; MUSC;<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the natural history of Hepatitis C infection<br />
∙ Design a treatment plan based on specific host and viral<br />
factors and address the timing of therapy<br />
∙ Enumerate extra-hepatic manifestations of Hepatitis C infection<br />
8:30 a m<br />
Discussion<br />
<strong>ACR</strong> State-of-the-Art R<br />
7:45—8:45 a m<br />
Grand Ballroom East<br />
Inflammasomes to Fever—How the Cell Biology<br />
Explains Disease<br />
Moderator:<br />
Dhavalkumar D. Patel, MD, PhD; Novartis Institutes for<br />
BioMedical Research; Basel, Switzerland<br />
Speaker:<br />
Jurg Tschopp, PhD; University of Lausanne; Epalinges,<br />
Switzerland<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the biology of the inflammosome<br />
∙ Define the characteristics of genetic defects associated with<br />
periodic fevers<br />
∙ Assess which diseases may be caused by inflammasome defects<br />
<strong>ARHP</strong> Concurrent Session C<br />
7:45—8:45 a m<br />
Room 258<br />
Challenging Case Studies in Rheumatoid Arthritis<br />
Moderator:<br />
Leslie D. McDowell, ANP, MSN; Mountain Medical<br />
Associates; Clyde, NC<br />
Speaker:<br />
Howard W. Hauptman, MD; Baltimore, MD<br />
Upon completion of this session, participants should be able to:<br />
∙ Analyze historical data for a patient presenting with<br />
musculoskeletal symptoms<br />
∙ Describe elements of the diagnostic work-up that are<br />
important to assist the clinician to reach an accurate<br />
diagnosis of rheumatoid arthritis<br />
∙ Identify important clues in the physical exam of a patient<br />
with arthritis symptoms<br />
<strong>ARHP</strong> Concurrent Session<br />
7:45—8:45 a m<br />
Room 260<br />
Dissemination of the EnhanceFitness <strong>Program</strong> for<br />
People with Arthritis<br />
Moderator:<br />
Richard H. Osborne, PhD; The University of Melbourne;<br />
Melbourne, Australia<br />
Speakers:<br />
Basia Belza, PhD, RN; University of Washington; Seattle, WA<br />
Dina L. Jones, PT, PhD; West Virginia University;<br />
Morgantown, WV<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the structure and essential components of the<br />
EnhanceFitness (EF) program for older adults<br />
∙ Summarize the existing evidence supporting EF as an<br />
evidence-based, community-delivered physical activity<br />
program for older adults<br />
∙ Report selected current initiatives aimed at disseminating<br />
EF for people with arthritis<br />
<strong>ARHP</strong> Concurrent Session<br />
7:45—8:45 a m<br />
Room 257<br />
How Do You Know Your Patient Is Taking Medicines,<br />
Exercising and Following Other Regimens You Recommended?<br />
Moderator:<br />
Elizabeth A. Schlenk, PhD, RN; University of Pittsburgh;<br />
Pittsburgh, PA<br />
Speaker:<br />
Michael A. Rapoff, PhD; University of Kansas Medical<br />
Center; Kansas City, KS<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify the extent and consequences of nonadherence to<br />
regimens for adult and pediatric patients with chronic arthritis<br />
∙ Describe the assets and liabilities of strategies for assessing<br />
adherence<br />
∙ Identify ways to improve patient-report methods of<br />
assessing adherence<br />
204<br />
= Recorded Sessions (order form on page 430)
<strong>ACR</strong> Meet the Professor Sessions<br />
7:45—9:15 a m<br />
Admission to the Meet the Professor Sessions is by ticket only. To verify the<br />
session for which you are registered, refer to the registration codes below in<br />
parentheses. Meet the Professor sessions include beverages only.<br />
Antiphospholipid Syndrome (124)<br />
Room 160 C<br />
Silvia S. Pierangeli, PhD; University of Texas Medical<br />
Branch; Galveston, TX<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the diverse clinical subsets within the spectrum<br />
of APS<br />
∙ Discuss the laboratory tests used to confirm APS<br />
∙ Analyze the therapeutic alternatives for the different<br />
manifestations of APS, including the benefit/risk, adverse<br />
effects and limitations<br />
Behçet’s Disease (116)<br />
Room 107 B<br />
Fereydoun Davatchi, MD; Tehran University for Medical<br />
Sciences; Tehran, Iran<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the epidemiology and diagnostic evaluation of<br />
Behçets Syndrome<br />
∙ Discuss the epidemiology and diagnostic evaluation of<br />
Behçets Syndrome<br />
Crystal: Management of Gout (114)<br />
Room 106<br />
Michael A. Becker, MD; University of Chicago Medical<br />
Center; Chicago, IL<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the management of gout in patients with renal<br />
insufficiency or organ transplants<br />
∙ Identify strategies to treat patients who are intolerant of<br />
approved therapies<br />
∙ List agents in development for the treatment of<br />
hyperuricemia and gout<br />
Osteoarthritis: Novel Treatments (121)<br />
Room 159<br />
Timothy E. McAlindon, MD, MPH, MRCP; Tufts-NEMC;<br />
Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe basic pathophysiologic mechanisms in OA<br />
∙ Discuss multiple treatment options for OA<br />
∙ Recognize newer novel treatment strategies for OA<br />
Osteoporosis: Novel Treatments (117)<br />
Room 107 C<br />
Chad L. Deal, MD; Cleveland Clinic Foundation;<br />
Cleveland, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Briefly review bone physiology and immunology<br />
emphasizing potential areas amenable to intervention<br />
∙ Briefly discuss current therapies for osteoporosis and their<br />
limitations<br />
∙ Discuss newer treatments available and therapies just over<br />
the horizon for osteoporosis<br />
∙ Use cases where possible to reinforce objective 1-3<br />
Pediatrics: Difficult to Treat Juvenile Idiopathic<br />
Arthritis (120) P<br />
Room 109 B<br />
Gloria C. Higgins, PhD, MD; Columbus Childrens<br />
Hospital; Columbus, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss treatment options for the systemic JIA patient with<br />
persistent systemic manifestations<br />
∙ Discuss treatment options for the JIA patient with<br />
persistent arthritis<br />
∙ Discuss treatment options for the child with low bone<br />
density who needs corticosteroid treatment<br />
∙ Discuss one or more difficult cases prepared by an attendee<br />
Pediatrics: Pediatric Rheumatology for Adult<br />
Rheumatologists (118) F P<br />
Room 108<br />
Helen M. Emery, MD; Children’s Hospital; Seattle, WA<br />
Upon completion of this session, participants should be able to:<br />
∙ Diagnose the various forms of arthritis that are unique to<br />
children<br />
∙ Recognize how the evaluation of children with rheumatic<br />
diseases may be different from that of adults<br />
∙ Describe current treatments of arthritis in children<br />
Pregnancy in Rheumatic Diseases (123)<br />
Room 160 B<br />
Ann L. Parke, MD; St. Francis Hospital and Medical<br />
Center; Hartford, CT<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the effects of pregnancy on the activity of<br />
rheumatic diseases<br />
∙ Recognize the challenging management issues unique<br />
to pregnancy<br />
SATURDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 205
SATURDAY<br />
Psoriatic Arthritis (126)<br />
Room 162 A<br />
Christopher T. Ritchlin, MD; University of Rochester<br />
Medical Center; Rochester, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the molecular basis for the pathogenesis of<br />
psoriatic arthritis<br />
∙ Discuss the recent advances in the treatment of patients<br />
with psoriatic arthritis<br />
RA: Difficult RA (119)<br />
Room 109 A<br />
Roy M. Fleischmann, MD; University of Texas Southwest<br />
Medical Center; Dallas, TX<br />
Upon completion of this session, participants should be able to:<br />
∙ Define difficult to treat rheumatoid arthritis<br />
∙ Develop effective management plans for complicated<br />
rheumatoid arthritis patients<br />
Rheumatic Manifestations of HIV (125)<br />
Room 161<br />
John D. Reveille, MD; University of Texas Health Sciences<br />
Center at Houston; Houston, TX<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the rheumatic syndromes associated with<br />
HIV infection<br />
∙ Discuss treatment options for patients with rheumatic<br />
diseases and HIV infection<br />
Sjögren’s: Controversies in Sjögren’s Syndrome (115)<br />
Room 107 A<br />
Steven E. Carsons, MD; Winthrop-University Hospital;<br />
Mineola, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss new diagnostic criteria for Sjögrens Syndrome<br />
∙ Describe new therapies for Sjögrens Syndrome<br />
∙ Identify systemic manifestations of Sjögrens Syndrome<br />
SLE: Lupus Nephritis (122)<br />
Room 160 A<br />
W. Joseph McCune, MD; University of Michigan; Ann<br />
Arbor, MI<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify lupus nephritis in early stages<br />
∙ Recognize poor prognostic factors<br />
∙ Evaluate lupus nephritis therapy<br />
Vasculitis: CNS Vasculitis (127)<br />
Room 162 B<br />
John H. Stone, MD, MPH; Massachusetts General Hospital/<br />
UpToDate; Sudbury, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss an approach to the evaluation of a patient referred<br />
with possible central nervous system (CNS) vasculitis<br />
∙ Review the major entities in the differential diagnosis of<br />
primary angiitis of the CNS<br />
∙ Develop a consistent therapeutic approach to the treatment<br />
of vasculitis involving the brain and/or spinal cord<br />
<strong>ACR</strong> Special Session C/R<br />
7:45—9:15 a m<br />
Room 210<br />
Arthritis & Rheumatism at 50: The Best of the Past, the<br />
Best of the Future<br />
Moderator:<br />
Michael D. Lockshin, MD; Cornell Medical Center; New<br />
York, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Trace the evolution of academic and clinical rheumatology<br />
using highlighted publications from A&R<br />
∙ Recognize the seminal role that papers published in A&R have<br />
played in the development of current paradigms in rheumatology<br />
∙ Discuss the potential path of development of<br />
rheumatology based on current publications in A&R<br />
7:45 a m<br />
Introduction: Fifty years of A&R<br />
Michael Dr. Lockshin, MD<br />
7:50 a m<br />
Fifty Years of A&R: The Early Years<br />
Charles L. Christian, MD; University of Florida Medical<br />
Center; Amelia Island, FL<br />
8:00 a m<br />
50 Years of Rheumatoid Arthritis<br />
J. Claude Bennett, MD; Biocryst Pharmaceuticals;<br />
Birmingham, AL<br />
8:10 a m<br />
Fifty Years of A&R: Up to the Present<br />
Leslie J. Crofford, MD; University of Kentucky; Lexington, KY<br />
8:20 a m<br />
Panel Discussion<br />
Gary S. Firestein, MD; University of California, San Diego;<br />
La Jolla, CA<br />
Steven R. Goldring, MD; Hospital for Special Surgery; New<br />
York, NY<br />
David S. Pisetsky, MD, PhD; Duke University Medical<br />
Center; Durham, NC<br />
206<br />
= Recorded Sessions (order form on page 430)
REF Estate Planning Session<br />
7:45—9:15 a m<br />
Room 156<br />
This session is not eligible for CME credit.<br />
A description of this session can be found on page 29.<br />
<strong>ACR</strong> Workshops<br />
7:45—9:45 a m<br />
Admission to the Workshop sessions is by ticket only. To verify the session<br />
for which you are registered, refer to the registration codes below in<br />
parentheses. Workshops include beverages only.<br />
Joint Injection Techniques (129)(Trainees Only) F<br />
Room 209<br />
Atul A. Deodhar, MD, MRCP; Oregon Health and Science<br />
University; Portland, OR<br />
Kenneth S. O’Rourke, MD; Wake Forest University;<br />
Winston-Salem, NC<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss indications and contraindications for joint<br />
aspirations and injections<br />
∙ Identify and avoid common mistakes in joint injection procedures<br />
∙ Perform common joint and soft tissue injections on the<br />
upper and lower extremities<br />
Muscle Pathology in Rheumatic Diseases (130)<br />
Room 212<br />
Sakir Humayun Gultekin, MD; Oregon Health and Science<br />
University; Portland, OR<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the histological appearance of muscle in different<br />
rheumatic diseases<br />
∙ Recognize the histologic abnormalities of steroid<br />
myopathy, polymyositis, dermatomyositis, and inclusion<br />
body myositis<br />
Peripheral MRI in Clinical Rheumatology (128)<br />
Equipment provided by Esaote S.p.A.<br />
Room 211<br />
Philip G. Conaghan, MD, PhD; Chapel Allerton Hospital;<br />
Leeds, England<br />
Mikkel Ostergaard, MD, PhD, DMSc; Copenhagen<br />
University Hospital at Hvidovre; Hvidovre, Denmark<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the merits of joint assessment by peripheral MRI<br />
∙ Identify the pitfalls of peripheral MRI in musculoskeletal<br />
imaging<br />
Practice Improvement Module (PIM)(131)<br />
All participants will receive a $75 discount on <strong>ACR</strong>’s practice improvement<br />
module – AIM. Discounts apply to enrollments after November <strong>2007</strong>.<br />
Room 213<br />
Audrey B. Uknis, MD; Temple University; Philadelphia, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the process to complete a practice improvement<br />
module<br />
∙ Discuss how quality measures are utilized in a practice<br />
improvement module<br />
∙ Identify practice strengths and area for improvement<br />
∙ Develop and implement a quality improvement plan<br />
∙ Summarize the role of a practice improvement module in<br />
relationship to health plan recognition programs, ACGME<br />
requirem<br />
<strong>ARHP</strong> Concurrent Session F<br />
7:45—11:45 a m<br />
Room 261<br />
Any meeting registrant may attend this session. It is designated to be of<br />
interest to Fellows-in-Training.<br />
Arthritis Treatments: Methods for Evaluating Information<br />
Moderator:<br />
Patricia A. MacDonald, BSN, NP; TAP Pharmaceutical<br />
Products; Lake Forest, IL<br />
Speakers:<br />
John E. Hewett, PhD; University of Missouri; Columbia, MO<br />
Marian A. Minor, PhD, PT; University of Missouri;<br />
Columbia, MO<br />
Upon completion of this session, participants should be able to:<br />
∙ Review research designs to address a variety of research questions<br />
∙ Summarize types of variables, levels of measurement and<br />
descriptive statistics<br />
∙ Examine probability, statistical inference and selection of<br />
appropriate statistical method<br />
∙ Specify strategies to determine sample size and power calculations<br />
<strong>ACR</strong>/<strong>ARHP</strong> Coffee and Tea Break<br />
8:00—9:30 a m<br />
Exhibit Hall A-B<br />
SATURDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 207
SATURDAY<br />
<strong>ACR</strong>/<strong>ARHP</strong> Poster Session C<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Admission to <strong>ACR</strong> poster sessions is by name badge only.<br />
Poster presenters will be available from 9:00—11:00 a m.<br />
Please note the numbering system for the poster sessions<br />
will include two sets of numbers. The first number is the<br />
permanent poster board number and will remain the same<br />
during all the poster sessions [e.g.:(1), (2)]. The next number<br />
will refer to the abstract number being presented, and this<br />
will change for each of the poster sessions.<br />
Abstracts #1387-2050<br />
For complete listing of the abstracts presented in this poster session,<br />
see pages 240–279.<br />
Exhibits<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
<strong>ACR</strong> Immunology Updates for Clinicians C/R<br />
9:15—10:15 a m<br />
Grand Ballroom East<br />
T-Cell Subsets: The Family Grows<br />
Moderator:<br />
Terri M. Laufer, MD; University of Pennsylvania;<br />
Philadelphia, PA<br />
Speaker:<br />
David A. Fox, MD; University of Michigan Medical Center;<br />
Ann Arbor, MI<br />
Upon completion of this session, participants should be able to:<br />
∙ Review subsets of T-cells beyond the TH1 / TH2 paradigm<br />
∙ Recognize the different functions of T cell subpopulations<br />
∙ Assess the relevance of TH17 cells and regulatory T cells to<br />
the therapy of autoimmune diseases<br />
<strong>ACR</strong> REF Special Session C/R<br />
9:15—10:15 a m<br />
Hall C<br />
Paul Klemperer, MD, Memorial Lectureship<br />
Moderator:<br />
James R. O’Dell, MD; University of Nebraska<br />
Medical Center; Omaha, NE<br />
The Vocation of Medicine: Lessons from Real<br />
and Imagined Doctors<br />
Speaker:<br />
Paul H. Plotz, MD; National Institute of Arthritis,<br />
Musculoskeletal and Skin; Bethesda, MD<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize that the vocation of medicine is learned from<br />
many non-medical as well as medical teachers<br />
∙ Recognize that literature provides fertile and instructive<br />
models, both good and bad, of the interactions of doctors<br />
and patients<br />
<strong>ARHP</strong> Concurrent Session<br />
9:15—10:15 a m<br />
Room 258<br />
Rheumatic Disease Update: Polymyalgia Rheumatica/<br />
Giant Cell Arthritis<br />
Moderator:<br />
Benjamin J. Smith, PA-C; McIntosh Clinic; Thomasville, GA<br />
Speaker:<br />
Cornelia M. Weyand, MD, PhD; Emory University; Atlanta, GA<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the clinical spectrum of giant cell arteritis and<br />
polymyalgia rheumatica and appropriately use diagnostic<br />
tests/procedures<br />
∙ Assess therapeutic approaches to patients with GCA and pmR<br />
∙ Summarize the current pathogenic concepts of large vessel<br />
vasculitis and understand how the innate and adaptive<br />
immune system contributes to the development of vasculitis<br />
<strong>ARHP</strong> Concurrent Session C<br />
9:15—10:15 a m<br />
Room 257<br />
Sexuality and Disability: Moving Beyond the Limitations<br />
Moderator:<br />
Karen L. Smarr, PhD; Harry S Truman Mem VA Hospital;<br />
Columbia, MO<br />
Speaker:<br />
Renee C. Stucky, PhD; University of Missouri; Columbia, MO<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify barriers to intimacy for persons with chronic<br />
health conditions/disabilities<br />
∙ Describe the interplay between physical and psychological<br />
factors in intimacy with a chronic health condition<br />
∙ Recognize the emotional/psychological and behavioral<br />
factors effecting intimacy<br />
∙ Identify ways to assist persons with disability/chronic<br />
health conditions overcome barriers to intimacy and<br />
participate in active, fulfilling intimate relationships<br />
∙ Project comfort and knowledge about discussing these<br />
issues with patients<br />
208<br />
= Recorded Sessions (order form on page 430)
<strong>ARHP</strong> Concurrent Abstract Session<br />
9:15—10:15 a m<br />
Room 260<br />
Arthritis in the Community (Abstracts #2051-2054<br />
Moderator:<br />
Macia Chwalek, MS, RN, ANP; Lahey Clinic; Burlington, MA<br />
9:15 a m<br />
2051. Exercise for Knee Pain in Older Adults: What Does<br />
a Community Sample Think?. Melanie Holden 1 , Nadine<br />
Foster 1 , Elaine Nicholls 1 , Julie Young 1 , Michael Doherty 2 ,<br />
Elanie Hay 1 . 1 Keele University, Keele, United Kingdom;<br />
2<br />
University of Nottingham, Nottingham, United Kingdom<br />
9:30 a m<br />
2052. Associations Between the Perceived Neighborhood<br />
Physical Environment and Physical Activity Levels in Patients<br />
with Arthritis. Thelma Mielenz, Changfu Xiao, Leigh F.<br />
Callahan. The University of North Carolina at Chapel Hill,<br />
Chapel Hill, NC<br />
9:45 a m<br />
2053. Which Environmental Factors in the Community are<br />
Associated with Disability?: The MOST Study. D. White 1 ,<br />
D. T. Felson 1 , A. M. Jette 2 , M. P. LaValley 2 , C. E. Lewis 3 ,<br />
J. C. Torner 4 , M. C. Nevitt 5 , J. J. Keysor 6 , The MOST<br />
Investigators. 1 BUSM, Boston, MA; 2 BUSPH, Boston, MA;<br />
3<br />
UAB, Birmingham, AL; 4 UI, Iowa City, IA; 5 UCSF, San<br />
Francisco, CA; 6 BU, Boston, MA<br />
10:00 a m<br />
2054. Co-morbidities Among People with Doctor Diagnosed<br />
Arthritis in the United States. Louise Murphy, Joseph Sniezek,<br />
Julie Bolen, Charles G. Helmick, Kristina Theis, Jennifer<br />
Hootman, Teresa Brady, Jeffrey Sacks. Centers for Disease<br />
Control and Prevention, Atlanta, GA<br />
<strong>ARHP</strong> Special Session<br />
9:45—10:45 a m<br />
Registration Area by the B1 Escalators<br />
Poster Introduction: How to Decipher a Poster<br />
Moderator:<br />
Nadine T. James, RN, MSN, PhD; University of Southern<br />
Mississippi; Hattiesburg, MS<br />
Take this opportunity to learn how to decipher a poster.<br />
Using pre-selected posters, experienced researchers will lead<br />
a discussion about the research with the posters’ authors.<br />
All <strong>ACR</strong> and <strong>ARHP</strong> attendees are welcome to participate<br />
and should meet in the Registration Area by the B1<br />
escalators at 9:30 a m. Look for the ‘<strong>ARHP</strong>’ signs.<br />
<strong>ACR</strong> Workshops<br />
10:30 a m—12:30 p m<br />
Admission to the Workshop sessions is by ticket only. To verify the session<br />
for which you are registered, refer to the registration codes below in<br />
parentheses. Workshops include beverages only.<br />
Basic Ultrasonography: U.S. Perspective (132)<br />
Equipment provided by Biosound Esaote Ultrasound<br />
Room 211<br />
Amy M. Evangelisto, MD; Cooper University Hospital;<br />
Cherry Hill, NJ<br />
Gurjit S. Kaeley, MBBS, MRCP; ROAD Clinic; University<br />
Place, WA<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the indications for ultrasound in rheumatic diseases<br />
∙ Discuss the techniques of ultrasonography<br />
∙ Recognize normal and abnormal anatomical structures<br />
Excel Spreadsheets: Expanding Skills Beyond Those of<br />
Your Kids (133)<br />
Room 213<br />
Richard A. Furie, MD; North Shore Long Island Jewish<br />
Health System; Lake Success, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Create a spreadsheet despite having no prior knowledge of<br />
spreadsheet function or design<br />
∙ Design a graph using spreadsheet data<br />
∙ Distinguish between a database and a spreadsheet<br />
Musculoskeletal Imaging (134)<br />
Room 209<br />
Mark D. Murphey, MD; Armed Forces Institute of Pathology;<br />
Washington, DC<br />
Upon completion of this session, participants should be able to:<br />
∙ Use a pattern or target approach to radiographs in<br />
evaluation of arthritis<br />
∙ Recognize typical and unusual radiographic manifestations<br />
of common arthritides<br />
∙ Discuss the use of advanced imaging techniques<br />
(CT and MRI)<br />
<strong>ARHP</strong> Concurrent Session<br />
10:45—11:45 a m<br />
Room 257<br />
Facilitating Cognitive and Behavioral Change: Self-<br />
Management and Beyond<br />
Moderator:<br />
Susan J. Bartlett, PhD; Johns Hopkins Asthma and Allergy;<br />
Baltimore, MD<br />
Speaker:<br />
Stephen T. Wegener, PhD; Johns Hopkins University;<br />
Baltimore, MD<br />
SATURDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 209
SATURDAY<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify adaptive cognitions and behaviors related to<br />
improved outcomes for persons with chronic conditions<br />
∙ Review the range of interventions from self-management to<br />
cognitive-behavioral therapy (CBT)<br />
∙ Describe the barriers to self-management and CBT interventions<br />
<strong>ARHP</strong> Concurrent Session C<br />
10:45—11:45 a m<br />
Room 259<br />
Fall Prevention in Community-Living Older Adults<br />
Moderator:<br />
Linda S. Ehrlich-Jones, PhD, RN; Rehabilitation Institute of<br />
Chicago; Chicago, IL<br />
Speaker:<br />
Bonita Lynn Beattie, PT, MPT, MHA; National Council on<br />
Aging; Washington, DC<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the urgency of our “call to action” and the challenges<br />
we face addressing this growing public health issue among<br />
older adults both in the U.S. and internationally<br />
∙ List three compelling reasons for the need to integrate<br />
the fall prevention efforts of health care providers, public<br />
health agencies and the aging services network in order to<br />
affect meaningful change<br />
∙ Discuss the multifactorial nature of a fall event and why<br />
effective interventions must take a multidisciplinary<br />
approach that is individualized to an at risk older adult<br />
∙ Recognize the value of emerging state coalitions on fall<br />
prevention and the need to become involved in state and<br />
local activities promoting the reduction of older adult falls<br />
and fall related injuries<br />
<strong>ARHP</strong> Concurrent Session C<br />
10:45—11:45 a m<br />
Room 258<br />
Rheumatic Disease Update: Scleroderma<br />
Moderator:<br />
Benjamin J. Smith, PA-C; McIntosh Clinic; Thomasville, GA<br />
Speaker:<br />
Richard M. Silver, MD; Medical University of South<br />
Carolina; Charleston, SC<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the differential diagnosis and pathogenesis of<br />
systemic sclerosis (scleroderma)<br />
∙ Define a logical approach to the evaluation of patients<br />
with Raynaud(aposthrophe)s phenomenon, distinguishing<br />
primary from secondary forms<br />
∙ Describe an organ-based approach to the management of<br />
patients with scleroderma<br />
<strong>ACR</strong> Practice Issues C<br />
11:00 a m—Noon<br />
Room 253<br />
EMR in the Physician’s Office<br />
Moderator:<br />
Michele Meltzer, MD; Philadelphia, PA<br />
Speaker:<br />
Cynthia Dunn, RN, FACMPE; MGMA Health Care<br />
Consulting Group; Cocoa Beach, FL<br />
Upon completion of this session, participants should be able to:<br />
∙ Distinguish the current electronic medical records available<br />
∙ Discuss pointers on what to look for when buying EMRs<br />
and the pros and cons of having an EMR<br />
<strong>ACR</strong> Clinical Symposium C<br />
11:00 a m—12:30 p m<br />
Grand Ballroom East<br />
pm<br />
Practical Management of Challenging Pain Syndromes<br />
Moderator:<br />
Atul A. Deodhar, MD, MRCP; Oregon Health and Science<br />
University; Portland, OR<br />
Upon completion of this session, participants should be able to:<br />
∙ Develop a multi-disciplinary plan for the optimum<br />
treatment of fibromyalgia<br />
∙ Discuss the management of complex regional pain<br />
syndrome based on pathophysiology<br />
∙ Review options and key considerations when using opioids<br />
in chronic pain conditions<br />
11:00 a m<br />
Evidence-Based Management of Fibromyalgia<br />
Leslie J. Crofford, MD; University of KY; Lexington, KY<br />
11:25 a m<br />
Complex Regional Pain Syndrome<br />
David D. Sherry, MD; Children’s Hospital of Philadelphia;<br />
Philadelphia, PA<br />
11:45 a m<br />
Use and Abuse of Opioids in Chronic Pain<br />
David G. Borenstein, MD; Arthritis & Rheumatism<br />
Associates; Washington, DC<br />
12:10 p m<br />
Discussion<br />
210<br />
= Recorded Sessions (order form on page 430)
<strong>ACR</strong> Plenary Session III C/R<br />
11:00 a m—12:30 p m<br />
Hall C<br />
Discovery <strong>2007</strong>: Insights into Autoimmunity<br />
(Abstracts #2055-2059)<br />
Moderators:<br />
Gary S. Firestein, MD; University of California, San Diego;<br />
La Jolla, CA<br />
Susan Manzi, MD, MPH; University of Pittsburgh;<br />
Pittsburgh, PA<br />
11:00 a m<br />
Introductory Talk: Autoimmunity<br />
Jane E. Salmon, MD; Hospital for Special Surgery; New<br />
York, NY<br />
11:15 a m<br />
2055. Case-control Association Studies Identify a Variant Form<br />
of the Signal Transducer and Activator of Transcription 4 Gene<br />
(STAT4) as a Genetic Risk Factor for Rheumatoid Arthritis and<br />
Systemic Lupus Erythematosus. Elaine F. Remmers 1 , Robert<br />
M. Plenge 2 , Annette T. Lee 3 , Julie M. Le 1 , Hye-Soon Lee 3 ,<br />
Franak Batliwalla 3 , Wentian Li 3 , Robert R. Graham 2 ,<br />
Timothy W. Behrens 4 , John P. Carulli 5 , Leonid Padyukov 6 ,<br />
Lars Alfredsson 6 , Lars Klareskog 6 , Christopher I. Amos 7 ,<br />
Lindsey A. Criswell 8 , Michael F. Seldin 9 , Daniel L. Kastner 1 ,<br />
Peter K. Gregersen 3 . 1 NIAMS, Bethesda, MD; 2 Broad<br />
Institute of Harvard and MIT, Cambridge, MA; 3 Feinstein<br />
Institute for Medical Research, Manhasset, NY; 4 Genentech,<br />
Inc., San Francisco, CA; 5 Biogen Idec, Inc, Cambridge,<br />
MA; 6 Karolinska Institute, Stockholm, Sweden; 7 University<br />
of Texas, M D Anderson Cancer Center, Houston, TX;<br />
8<br />
University of California at San Francisco, San Francisco,<br />
CA; 9 University of California at Davis, Davis, CA<br />
11:30 a m<br />
2056. IFN-Regulated Chemokines are Reliable Biomarkers of<br />
Systemic Lupus Erythematosus Disease Activity. Jason W.<br />
Bauer 1 , Michelle Petri 2 , Franak M. Batliwalla 3 , Joseph<br />
Wilson 1 , Catherine Slattery 1 , Sukhminder Singh 2 , Hanna<br />
Tesfasyone 2 , Peter K. Gregersen 3 , Timothy W. Behrens 4 ,<br />
Emily C. Baechler 1 . 1 University of Minnesota, Minneapolis,<br />
MN; 2 Johns Hopkins University School of Medicine,<br />
Baltimore, MD; 3 The Feinstein Institute For Medical<br />
Research, Manhasset, NY; 4 Genentech, Inc., South San<br />
Francisco, CA<br />
Kingdom; 2 Hospital, Cordoba, Spain; 3 Hospital “Reina<br />
Sofia”, Cordoba, Spain<br />
Noon<br />
2058. Downregulation of Caveolin-1 (cav-1) in Systemic Sclerosis<br />
Plays a Key Role in the Fibrotic Process and can be Reversed by<br />
Cell Permeable Recombinant Cav-1 Peptides. Francesco Del<br />
Galdo, Jean-Francois Jasmin, Megan Musick, Cecilia De<br />
Almeida, Federica Sotgia, Michael P. Lisanti, Sergio A.<br />
Jimenez. Thomas Jefferson University, Philadelphia, PA<br />
12:15 p m<br />
2059. Anti-Ro52 Antibodies Inducing Heart Block Cross-React<br />
with Alpha-Enolase. Aurélie Ambrosi 1 , Linn Strandberg 1 ,<br />
Lars Ottosson 1 , Olle Kämpe 2 , Marie Wahren-Herlenius 1 .<br />
1<br />
Karolinska Institute, Stockholm, Sweden; 2 Uppsala<br />
University, Uppsala, Sweden<br />
<strong>ARHP</strong> Fitness Session<br />
Noon—1:00 p m<br />
Room 154<br />
Participants must sign a waiver to participate in this fitness session.<br />
Tai Chi<br />
Moderator:<br />
Debra Bancroft Rizzo, MSN, FNP; Rheumatic Disease<br />
Center; Glendale, WI<br />
Speaker:<br />
Jay Van Schelt, Master Trainer; Arthritis Foundation;<br />
Bristol, CT<br />
<strong>ACR</strong> Special Session<br />
12:45—1:45 p m<br />
Room 102<br />
This session is not eligible for CME credit.<br />
<strong>ACR</strong> Recertification Information Session<br />
Together with the ABIM, the <strong>ACR</strong> is pleased to offer a (Re)<br />
certification information session. Join us to gain practical<br />
tips on how to navigate the (re)certification process and<br />
a review of educational tools specifically designed for the<br />
rheumatologist to excel at this process.<br />
This session is designed for physicians, including general internists and<br />
internal medicine subspecialists, participating in the ABIM Maintenance<br />
of Certification program, preparing for the ABIM Board exam or ABIM<br />
Recertification exam.<br />
SATURDAY<br />
11:45 a m<br />
2057. Changes Operated in Protein Pattern of Monocytes<br />
from Patients with Antiphospholipid Syndrome Treated with<br />
Statins. Maria J. Cuadrado 1 , Chary Lopez-Pedrera 2 , Angeles<br />
Aguirre 2 , Vanesa Hernandez 3 , Paula Buendia 3 , Nuria<br />
Barbarroja 3 , Luis Aristide 3 , Francisco Velasco 3 , Munther<br />
A. Khamashta 1 . 1 St. Thomas’ Hospital, London, United<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 211
SATURDAY<br />
Encore Theater<br />
12:45—2:15 p m<br />
Room 255<br />
Clinical Symposium - Therapeutic Decisions in<br />
Systemic Vasculitis<br />
Please see page 69 for hours of operation and a tentative list of sessions.<br />
<strong>ACR</strong> Meet the Professor Sessions<br />
12:45—2:15 p m<br />
¹<br />
Admission to the Meet the Professor Sessions is by ticket only. To verify the<br />
session for which you are registered, refer to the registration codes below in<br />
parentheses. Meet the Professor sessions include beverages only.<br />
Ankylosing Spondylitis: Disease Modification (140)<br />
Room 109 A<br />
John C. Davis, Jr., MD, MPH; University of California-San<br />
Francisco; San Francisco, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the natural history of ankylosing spondylitis<br />
∙ Describe clinical and radiographic outcome measures used<br />
in ankylosing spondylitis trials<br />
∙ Review the scientific data on biologic agents as possible<br />
disease modifying agents in the treatment of ankylosing<br />
spondylitis<br />
Immunology: Basic Immunology for Clinical<br />
Rheumatology (139)(Trainees Only) F<br />
Room 108<br />
Michael P. Davey, MD, PhD; Portland Veterans Affairs<br />
Medical Center; Portland, OR<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe how the immune system functions in normal<br />
individuals<br />
∙ Identify abnormalities of immune regulation that lead to<br />
autoimmunity<br />
Infections in Patients on TNF Therapy (138)<br />
Room 107 C<br />
John J. Cush, MD; Arthritis Care and Research Center;<br />
Dallas, TX<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the commonly encountered infections in patients<br />
using anti-TNF therapies<br />
∙ Discuss the indications for stopping anti-TNF therapies<br />
∙ Review the management of infections in patients using<br />
anti-TNF therapies<br />
Opportunistic Infections in Rheumatic Diseases (135)<br />
Room 106<br />
Lindsey Baden, MD; Brigham and Women’s Hospital;<br />
Bosotn, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the common opportunistic infections in the<br />
immunosuppressed rheumatic disease patient<br />
∙ Discuss treatment options for patients with rheumatic<br />
disease and opportunistic infections<br />
∙ Discuss strategies to prevent infection in the rheumatic<br />
disease patient<br />
Pain: Overuse Syndromes (143) PM<br />
Room 160 A<br />
Geoffrey O. Littlejohn, MBBS, MD; Monash Medical<br />
Center; Melbourne, VIC, Australia<br />
Upon completion of this session, participants should be able to:<br />
∙ List common pitfalls in bone densitometry interpretation<br />
∙ Discuss the clinical features and management of patients<br />
with overuse syndromes<br />
Pain: Soft Tissue Rheumatism (137)(Trainees Only) F PM<br />
Room 107 B<br />
Hans Carlson, MD; Oregon Health and Science University;<br />
Portland, OR<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the commonly encountered soft tissue rheumatic<br />
complaints<br />
∙ Prescribe a treatment program for the commonly<br />
encountered soft tissue rheumatic complaints<br />
∙ Understand which conditions will respond to therapeutic<br />
injections and which should be treated conservatively<br />
Pediatrics: JIA for Adult Rheumatologists (145) F<br />
Room 160 C<br />
Marilynn G. Punaro, MD; Texas Scottish Rite Hospital;<br />
Dallas, TX<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the ILAR classification for JIA<br />
∙ Discuss current therapeutic strategies for JIA<br />
∙ Recognize the role of IL-1 in the pathogenesis of systemic<br />
onset JIA<br />
Pediatrics: Pediatric Scleroderma (146) P<br />
Room 161<br />
Egla C. Rabinovich, MD, MPH; Duke University Medical<br />
Center; Durham, NC<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe how pediatric scleroderma differs from adult disease<br />
∙ Recognize the different forms of pediatric scleroderma<br />
∙ Describe how to approach treatment of pediatric<br />
scleroderma<br />
212<br />
= Recorded Sessions (order form on page 430)
Polymyalgia Rheumatica (147)<br />
Room 162 A<br />
Robert F. Spiera, MD; Hospital for Special Surgery; New<br />
York, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe modern concepts of pathogenesis<br />
∙ Discuss evolving strategies in treatment<br />
RA: Challenging Cases (148)<br />
Room 162 B<br />
Gary W. Williams, MD, PhD; Scripps Clinic and Research<br />
Foundation; La Jolla, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss management of patients with refractory RA<br />
∙ Identify novel treatment options for those failing<br />
conventional therapies<br />
RA: Difficult Cases (136)(Trainees Only) F<br />
Room 107 A<br />
Clifton O. Bingham, III., MD; Johns Hopkins University;<br />
Baltimore, MD<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the management of patients with refractory<br />
rheumatoid arthritis<br />
∙ Identify novel treatment options for those failing<br />
conventional therapies<br />
∙ Develop effective management plans for complicated<br />
rheumatoid arthritis patients<br />
SLE: Difficult to Treat SLE (144)<br />
Room 160 B<br />
Susan Manzi, MD, MPH; University of Pittsburgh;<br />
Pittsburgh, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Utilize laboratory testing in the management of patients<br />
∙ Determine the most relevant and beneficial therapeutic<br />
approach<br />
∙ Determine the most relevant and beneficial therapeutic<br />
approach<br />
Vasculitis Mimics (141)<br />
Room 109 B<br />
Rafael G. Grau, MD; Indiana University; Indianapolis, IN<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the differential diagnosis of vasculitis<br />
∙ Identify other syndromes that mimic vasculitis<br />
Vasculitis: Update (142)(Trainess Only) F<br />
Room 159<br />
Carol Langford, MD, MHS; Cleveland Clinic Foundation;<br />
Cleveland, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the classification of vasculitis according to<br />
affected vessel size<br />
∙ Utilize the various available laboratory tests, with emphasis<br />
on ANCA testing<br />
∙ Identify current and novel therapeutic modalities<br />
<strong>ACR</strong> Workshops<br />
1:15—3:15 p m<br />
Admission to the Workshop sessions is by ticket only. To verify the session<br />
for which you are registered, refer to the registration codes below in<br />
parentheses. Workshops include beverages only.<br />
Digital Photography for Rheumatologists (149)<br />
Room 213<br />
Everett H. Allen, MD; Rheumatology Associates of South<br />
Texas; San Antonio, TX<br />
Upon completion of this session, participants should be able to:<br />
∙ Use a digital camera to capture clinical images<br />
∙ Incorporate digital photography into academic and clinical<br />
practices<br />
Osteoporosis: Focus on DXA Interpretation (151)<br />
(Trainees Only) F<br />
Room 209<br />
Chad L. Deal, MD; Cleveland Clinic Foundation;<br />
Cleveland, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Review the basic principles of DXA interpretation and the<br />
ISCD guidelines for DXA interpretation<br />
∙ Identify some of the pitfalls of DXA interpretation and the<br />
clinical pearls associated with these unusual situations<br />
∙ Create a report based on the lumbar spine and hip bone<br />
densitometry results<br />
Peripheral MRI in Clinical Practice (150)<br />
Equipment provided by Esaote S.p.A.<br />
Room 211<br />
John V. Crues, III, MD; Radnet, Inc.; Los Angeles, CA<br />
Ewa Olech, MD; Oklahoma Medical Research Foundation;<br />
Oklahoma City, OK<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the logistics of implementation of peripheral MRI<br />
in the outpatient setting<br />
∙ Recognize the merits and pitfalls of this technology<br />
SATURDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 213
SATURDAY<br />
Renal Histopathology in SLE and Vasculitis (152)<br />
(Trainees Only)<br />
Room 212<br />
Megan L. Troxell, MD, PhD; Oregon Health and Science<br />
University; Portland, OR<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify the pathologic changes that occur in lupus nephritis<br />
∙ Discuss the pathologic basis for the classification of lupus<br />
nephritis and how it relates to clinical management<br />
∙ Recognize the histological changes in the kidneys of<br />
patients with vasculitis<br />
<strong>ACR</strong> Concurrent Abstract Session C/R<br />
2:00—4:00 p m<br />
Grand Ballroom<br />
<strong>ACR</strong> Business <strong>Meeting</strong> and Late-Breaking Abstracts<br />
<strong>ACR</strong> Business <strong>Meeting</strong><br />
Election of Officers<br />
Election of <strong>ACR</strong> Board Members<br />
Installation of 71st <strong>ACR</strong> President<br />
David A. Fox, MD, FRCPC; University of Michigan<br />
Medical Center; Ann Arbor, MI<br />
Late-Breaking Abstracts<br />
Moderators:<br />
Joel A. Block, MD; Rush University Medical Center;<br />
Chicago, IL<br />
Ann E. Clarke, MD; Montreal General Hospital; Montreal,<br />
Quebec<br />
For the complete listing of the Late-Breaking abstracts, see the<br />
<strong>Program</strong> <strong>Book</strong> Supplement.<br />
<strong>ACR</strong> Advocacy Issues C<br />
2:30—4:00 p m<br />
Room 253<br />
Grassroots and the Legislative Landscape<br />
Moderator:<br />
Joseph Flood, MD; Musculosketal Medical Specialists, Inc.;<br />
Columbus, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Educate members on the importance of grassroot advocacy<br />
∙ Discuss Capitol Hill etiquette when contacting members<br />
of Congress<br />
∙ Review the legislative landscape as it relates to the<br />
rheumatology community<br />
2:30 p m<br />
Grassroots on Capitol Hill<br />
Ranny Cooper; Weber Shandwick; Washington, DC,<br />
3:30 p m<br />
The Legislative Landscape<br />
Marti Kendrick, JD; Patton Boggs, LLC; Washington, DC<br />
<strong>ACR</strong> Basic Science Symposium R<br />
2:30—4:00 p m<br />
Room 205<br />
The Aging Immune System<br />
Moderators:<br />
Anne Davidson, MB, BS, FRACP; Feinstein Institute for<br />
Medical Research; Manhasset, NY<br />
Andreas H. Radbruch, PhD; Deutsches Rheuma-<br />
Forschungszentrum Berlin (DRFZ); Berlin, Germany<br />
Upon completion of this session, participants should be able to:<br />
∙ Explain how aging affects the biology at the level of<br />
individual cells, as well as the organism<br />
∙ Assess the impact of age on immunocompetence and<br />
identify the implications for immunosuppressive therapy<br />
such as B cell depletion or cytokine blockade<br />
∙ Recognize the role of age-dependent immune defects for<br />
the increasing incidence of chronic inflammatory and<br />
autoimmune diseases with age<br />
2:30 p m<br />
Aging: What Role Might It Play?<br />
Huber R. Warner, PhD; University of Minnesota; St. Paul, MN<br />
2:55 p m<br />
B-Cell Development and Aging<br />
Michael P. Cancro, PhD; University of Pennsylvania School<br />
of medicine; Philadelphia, PA<br />
3:20 p m<br />
Premature Senescence of T-Cells in Rheumatoid Arthritis<br />
Cornelia M. Weyand, MD, PhD; Emory University; Atlanta, GA<br />
3:45 p m<br />
Discussion<br />
214<br />
= Recorded Sessions (order form on page 430)
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 157<br />
Biology and Pathology of Bone and Joint<br />
(Abstracts #2060-2065)<br />
Moderators:<br />
Edward Schwarz, PhD; University of Rochester Medical<br />
Center; Rochester, NY<br />
Richard F. Loeser, Jr., MD; Wake Forest University School<br />
of Medicine; Winston-Salem, NC<br />
2:30 p m<br />
2060. Identification of Foxo1a as a New Chondrogenic<br />
Transcription Factor in Mesenchymal Stromal Stem Cells. Danièle<br />
Noel 1 , Claire Bony 2 , C. Bouffi 2 , Christian Jorgensen 3 .<br />
1<br />
CHU Montpellier, Montpellier, France; 2 INSERM<br />
U844, Montpellier, France; 3 Unité Clinique d’Immuno-<br />
Rhumatologie-CHU Montpellier, Montpellier, France<br />
2:45 p m<br />
2061. Differential Role for Interleukin-1 in Induced Instability<br />
Osteoarthritis and Spontaneously Occurring Osteoarthritis in<br />
Mice. Arjen B. Blom, Peter L. van Lent, Peter M. van der Kraan,<br />
Leo A. Joosten, Wim B. van den Berg. Radboud University<br />
Nijmegen Medical Center, Nijmegen, The Netherlands<br />
3:00 p m<br />
2062. Systemic BMD and Risk of Incident and Progressive<br />
Tibiofemoral Radiographic OA in White Men and Women: The<br />
MOST Study. Michael C. Nevitt 1 , Yuqing Zhang 2 , M. Kassim<br />
Javaid 1 , Tuhina Neogi 2 , Jeffrey Curtis 3 , Charles E. McCulloch 1 ,<br />
Na Wang 2 , David T. Felson 2 . 1 UCSF, San Francisco, CA;<br />
2<br />
BUSM, Boston, MA; 3 UAB, Birmingham, AL<br />
3:15 p m<br />
2063. CCR2-Deficient Mice are Osteopetrotic Due to Impaired<br />
Osteoclast Development and Function. Nikolaus B. Binder 1 ,<br />
Birgit Tuerk 1 , Oskar Hoffmann 2 , Georg Schett 3 , Josef<br />
S. Smolen 1 , Kurt Redlich 1 . 1 Medical University Vienna,<br />
Vienna, Austria; 2 University of Vienna, Vienna, Austria;<br />
3<br />
University of Erlangen, Erlangen, Germany<br />
3:30 p m<br />
2064. RGS18 is a Novel Negative Regulator of Osteoclastogenesis<br />
by Modulating Extracellular Acidosis-Sensing Mechanism. Kaori<br />
Iwai, Masaru Ishii, Shiro Ohshima, Yukihiko Saeki.<br />
National Hospital Organization Osaka Minami Medical<br />
Center, Kawachinagano, Japan<br />
3:45 p m<br />
2065. Transgenic Disruption of Glucocorticoid Signalling in<br />
Mature Osteoblasts Attenuates KRN Serum-Induced Arthritis In<br />
Vivo. Frank Buttgereit 1 , Hong Zhou 2 , Timo Gaber 1 , Robert<br />
Kalak 2 , Rebecca Dragovic 2 , Doerte Huscher 3 , Rainer H.<br />
Straub 4 , James Modzelewski 2 , Colin R. Dunstan 2 , Markus J.<br />
Seibel 2 . 1 Charité University Hospital, CCM, Berlin, Germany;<br />
2<br />
Bone Research <strong>Program</strong>, ANZAC Research Institute,<br />
Sydney, Australia; 3 Deutsches Rheumaforschungszentrum,<br />
Berlin, Germany; 4 Dept. of Internal Medicine I, University<br />
Hospital, Regensburg, Germany<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 153<br />
Muscle Biology, Myositis and Myopathies: New<br />
Insights Regarding Mechanism and Clinical Assessment<br />
(Abstracts #2066-2071)<br />
Moderator:<br />
Robert L. Wortmann, MD; Dartmouth-Hitchcock<br />
MedicalCenter; Lebanon, NH<br />
Chester V. Oddis, MD; University of Pittsburgh School of<br />
Medicine; Pittsburgh, PA<br />
2:30 p m<br />
2066. Ectopic Lymphoid Microstructures are Central to the<br />
Pathogenesis of Juvenile Dermatomyositis. Consuelo M. López<br />
de Padilla 1 , Abbe N. Vallejo 2 , Ann M. Reed 1 . 1 Mayo<br />
Clinic, Rochester, MN; 2 Children’s Hospital of Pittsburgh,<br />
University of Pittsburgh School of Medicine, Pittsburgh, PA<br />
2:45 p m<br />
2067. High Mobility Group Box Chromosomal Protein 1<br />
(HMGB-1) a New Inducer of MHC Class I Expression in Muscle<br />
Fibers. Ingrid E. Lundberg 1 , Cecilia Grundtman 1 , Joseph<br />
Bruton 2 , Ulf Andersson 3 , Helena Erlandsson Harris 1 ,<br />
Håkan Westerblad 2 . 1 Rheumatology Unit, Department<br />
of Medicine, Karolinska Institutet, Stockholm, Sweden;<br />
2<br />
Department of Physiology, Karolinska Institutet,<br />
Stockholm, Sweden; 3 Department of Woman and Child<br />
Health, Karolinska Institutet, Stockholm, Sweden<br />
3:00 p m<br />
2068. Sera with Autoantibodies to the MJ Antigen React<br />
with NXP2. Ira N. Targoff 1 , Edward P. Trieu 2 , Mauricio<br />
Levy-Neto 2 , Noreen Fertig 3 , Chester V. Oddis 3 . 1 VAMC,<br />
University of Oklahoma HSC, and OMRF, Oklahoma City,<br />
OK; 2 Oklahoma Medical Research Found, Oklahoma City,<br />
OK; 3 University of Pittsburgh, Pittsburgh, PA<br />
SATURDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 215
3:15 p m<br />
2069. Effect of Retinoid on Experimental Autoimmune Myositis.<br />
Naho Ohyanagi 1 , Toshihiro Nanki 1 , Miwako Ishido 2 , Tetsuo<br />
Kubota 1 , Nobuyuki Miyasaka 1 . 1 Tokyo Medical and Dental<br />
University, Tokyo, Japan; 2 R&R, Inc., Tokyo, Japan<br />
3:30 p m<br />
2070. Autoantigen Microarray Analysis of Sera from Juvenile<br />
Dermatomyositis Patients: Association with an SLE-like Type<br />
I Interferon Signature. Imelda Balboni 1 , Pinakeen Patel 2 ,<br />
Cindy Limb 3 , Nicola Luera 3 , Gabrielle Morgan 4 , Paul J.<br />
Utz 3 , Virginia Pascual 2 , Lauren M. Pachman 4 . 1 Dept. of<br />
Pediatrics and Medicine, Stanford University, Stanford,<br />
CA; 2 Baylor Institute for Immunology Research, Dallas,<br />
TX; 3 Dept. of Medicine, Stanford University, Stanford, CA;<br />
4<br />
Dept. of Pediatrics, Northwestern University, Feinberg<br />
School of Medicine, Children’s Memorial Research Center,<br />
Chicago, IL<br />
3:45 p m<br />
2071. The Development of an Outcome Instrument for Cutaneous<br />
Dermatomyositis: Comparison of Inter-And Intra-Rater Reliability<br />
and Validity. Rhonda Q. Klein 1 , Carolyn C. Bangert 2 ,<br />
Melissa Costner 2 , M. Kari Connolly 3 , Elizabeth Dugan 4 ,<br />
Akiko Tanikawa 5 , Joyce Okawa 1 , Mathew Rose 1 , Steven S.<br />
Fakharzadeh 6 , David Fiorentino 7 , Lela A. Lee 8 , Richard D.<br />
Sontheimer 9 , Lynne Taylor 1 , Victoria P. Werth 6 . 1 UPenn,<br />
Philadelphia, PA; 2 UTSW, Dallas, TX; 3 UCSF, San<br />
Francisco, CA; 4 Wash Hosp Ctr, Washington, DC; 5 Keio<br />
Univ, Tokyo, Japan; 6 UPenn & VAMC, Philadelphia, PA;<br />
7<br />
Stanford Univ, Stanford, CA; 8 Univ Colorado, Denver,<br />
CO; 9 UOklahoma, Oklahoma City, OK<br />
3:00 p m<br />
2074. Persons with Patellofemoral Osteoarthritis Exhibit Altered<br />
Knee Kinematics During a Sit-to-Stand Task. Lisa T. Hoglund 1 ,<br />
Ann E. Barr 1 , Benjamin P. Heilman 1 , Howard J. Hillstrom 2 ,<br />
Margery A. Lockard 1 , William R. Reinus 1 , Jinsup Song 1 .<br />
1<br />
Temple University, Philadelphia, PA; 2 Hospital for Special<br />
Surgery, New York, NY<br />
3:15 p m<br />
2075. Older Men and Women with Knee Osteoarthritis Have<br />
Poorer Muscle Quality: Findings from Health ABC. Molly B.<br />
Conroy 1 , Eswar Krishnan 1 , Robert Boudreau 1 , Michael<br />
Nevitt 2 , C. Kent Kwoh 1 , Anne B. Newman 1 , Bret H.<br />
Goodpaster 1 . 1 University of Pittsburgh, Pittsburgh, PA;<br />
2<br />
University of California, San Francisco, CA<br />
3:30 p m<br />
2076. Knee OA: Less Knee Pain with Higher Hip Bone<br />
Density. Heike A. Bischoff-Ferrari 1 , Hans J. Hauselmann 2 ,<br />
Daniel Uebelhart 1 , Diana Frey 1 , Gerold Stucki 3 , Beat A.<br />
Michel 1 . 1 University Hospital Zurich, Zurich, Switzerland;<br />
2<br />
Hirslanden Clinics, Zurich, Switzerland; 3 University<br />
Hospital Munich, Munich, Germany<br />
3:45 p m<br />
2077. Strong Association of Bone Marrow Lesions and Effusion<br />
with Pain in Osteoarthritis. G. Lo 1 , T. McAlindon 1 , J.<br />
Niu 2 , Y. Zhang 2 , C. Beals 3 , C. Dabrowski 4 , M. Hellio 5 ,<br />
M. Luchi 6 , D. Hunter 2 . 1 Tufts University, Boston, MA;<br />
2<br />
Boston University, Boston, MA; 3 Merck, Rahway, NJ;<br />
4<br />
GalaxoSmithKline, Collegeville, PA; 5 Pfizer, Ann Arbor,<br />
MI; 6 Novartis, East Hanover, NJ<br />
SATURDAY<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 258<br />
Osteoarthritis: Clinical Aspects II (Abstracts #2072-2077)<br />
Moderators:<br />
Stephen P. Messier, PhD; Wake Forest University;<br />
Winston-Salem, NC<br />
Leena Sharma, MD; Northwestern University; Chicago, IL<br />
2:30 p m<br />
2072. Relationship Between Dynamic Loading, Muscle Strength,<br />
and Proprioception at the Knees of Subjects with Unilateral Hip<br />
Osteoarthritis (OA). Najia Shakoor, Robert M. Trombley,<br />
Joel A. Block. Rush Medical College, Chicago, IL<br />
2:45 p m<br />
2073. The Role of Rearfoot Mobility in the Long Term Response<br />
to Wedge Orthoses in Medial Knee OA. Roy Lidtke, Markus<br />
A. Wimmer, Kharma C. Foucher, Joel A. Block. Rush<br />
University Medical Center, Chicago, IL<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 104<br />
Pediatric Rheumatology: Determinants and Markers of<br />
Disease (Abstracts #2078-2083)<br />
Moderators:<br />
Nora G. Singer, MD; Case Western Reserve University;<br />
Cleveland, OH<br />
Anna Huttenlocher, MD; University of Wisconsin;<br />
Madison, WI<br />
2:30 p m<br />
2078. The Immunopathology of Early Untreated Juvenile<br />
Idiopathic Arthritis: Comparing Oligoarticular and Polyarticular<br />
Disease. Sarah Blelock 1 , David S. Gibson 1 , Susan A.<br />
Clarke 2 , Catherine McAllister 3 , Madeleine Rooney 1 .<br />
1<br />
Arthritis Research Group, Queen’s University Belfast,<br />
Belfast, United Kingdom; 2 Trauma and Orthopedics<br />
Research Group, Queen’s University Belfast, Belfast, United<br />
Kingdom; 3 Rheumatology Department, Musgrave Park<br />
Hospital, Belfast, United Kingdom<br />
216<br />
= Recorded Sessions (order form on page 430)
2:45 p m<br />
2079. A High Density SNP Genome-wide Association Study in<br />
Juvenile Idiopathic Arthritis. Susan D. Thompson 1 , Marc<br />
Sudman 1 , Miranda C. Marion 2 , Shweta Srivastava 1 , Mehdi<br />
Keddache 1 , Carl D. Langefeld 2 , David N. Glass 1 . 1 Cincinnati<br />
Children’s Hospital Medical Center, Cincinnati, OH;<br />
2<br />
Wake Forest University, Winston-Salem, NC<br />
3:00 p m<br />
2080. A Pooled DNA Microarray Study of Methotrexate-Treated<br />
JIA Patients. Tracey A. Weiler 1 , Mary H. Ryan 1 , Monica<br />
K. Tsoras 1 , Carl D. Langefeld 2 , John B. Harley 3 , David<br />
N. Glass 1 , Susan D. Thompson 1 . 1 Cincinnati Children’s<br />
Hospital Medical Center, Cincinnati, OH; 2 Wake Forest<br />
University, Winston Salem, NC; 3 OMRF, University of<br />
Oklahoma & JK Autoimmunity, Oklahoma City, OK<br />
3:15 p m<br />
2081. Serum Levels of Osteoprotegerin and Receptor Activator<br />
of Nuclear factor - kB Ligand in Children with Early Juvenile<br />
Idiopathic Arthritis: A 2-year Prospective Controlled Study.<br />
Gunhild Lien, Thor Ueland, Kristin Godang, Anne<br />
Marit Selvaag, Berit Flatø, Øystein Førre. Rikshospitalet-<br />
Radiumhospitalet Medical Center, Oslo, Norway<br />
3:30 p m<br />
2082. Validation of a Diagnostic Score for Molecular Analysis<br />
of Hereditary Autoinflammatory Syndromes in Children with<br />
Periodic Fever. Marco Gattorno 1 , Maria Pia Sormani 2 , Silvia<br />
Federici 1 , Maria Antonietta Pelagatti 1 , Antonella Meini 3 ,<br />
Andrea D’Osualdo 1 , Francesco Zulian 4 , Laura Obici 5 ,<br />
Luciana Breda 6 , Silvana Martino 7 , Alberto Tommasini 8 ,<br />
Patrica Woo 9 , Joost Frenkel 10 , Isabelle Kone-Paut 11 , Isabelle<br />
Touitou 12 , Maurizia Baldi 13 , Isabella Ceccherini 1 , Alberto<br />
Martini 1 . 1 Gaslini Institute, Genoa, Italy; 2 DISSAL, Genoa,<br />
Italy; 3 Clinica Pediatrica, Brescia, Italy; 4 Clinica Pediatrica,<br />
Padova, Italy; 5 IRCCS S. Matteo, Pavia, Italy; 6 Clinica<br />
Pediatrica, Chieti, Italy; 7 Clinica Pediatrica, Torino, Italy;<br />
8<br />
Clinica Pediatrica, Trieste, Italy; 9 Windeyer Institute for<br />
Medical Sciences, University College, London, United<br />
Kingdom; 10 Wilhelmina Children’s Hospital, Utrecht, The<br />
Netherlands; 11 Bicêtre University Hospital, Le Kremlin<br />
Bicêtre, France; 12 Hôpital A de Villeneuve, Montpellier,<br />
France; 13 Ospedale Galliera, Genoa, Italy<br />
3:45 p m<br />
2083. B Lymphocyte Stimulator (BLyS) Expression in Pediatric<br />
Systemic Lupus Erythematosus (pSLE) and Juvenile Idiopathic<br />
Arthritis (JIA). Sandy D. Hong 1 , Andreas Reiff 1 , Hai-Tao<br />
Yang 2 , Christopher D. Ward 3 , Thi-Sau Migone 3 , Katherine<br />
Marzan 1 , Bracha Shaham 1 , Bram Bernstein 1 , William<br />
Stohl 2 . 1 Childrens Hospital of Los Angeles, Los Angeles,<br />
CA; 2 University of Southern California, Los Angeles, CA;<br />
3<br />
Human Genome Sciences, Rockville, MD<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Grand Ballroom East<br />
RA New Treatments Clinical Trials II (Abstracts #2084-2089)<br />
Moderators:<br />
Daniel Aletaha, MD, MSc; Medical University of Vienna;<br />
Vienna, Austria<br />
Kathryn Hobbs, MD; Denver Arthritis Clinic; Denver, CO<br />
2:30 p m<br />
2084. Local Treatment for Inflammatory Arthritis: A Phase 1/2<br />
Clinical Study of Intra-Articular Administration of a Recombinant<br />
Adeno-Associated Vector Containing a TNF-α Antagonist<br />
Gene. Philip Mease 1 , Nathan Wei 2 , Edward Fudman 3 ,<br />
Alan Kivitz 4 , Pervin Anklesaria 5 , Alison Heald 5 . 1 Seattle<br />
Rheumatology Associates, Seattle, WA; 2 Arthritis and<br />
Osteoporosis Center of Maryland, Frederick, MD; 3 Austin<br />
Rheumatology Research, Austin, TX; 4 Altoona Center for<br />
Clinical Research, Duncansville, PA; 5 Targeted Genetics<br />
Corporation, Seattle, WA<br />
2:45 p m<br />
2085. Results of a Phase II Clinical Trial of a Novel P2X7<br />
Receptor Antagonist, AZD9056, in Patients with Active<br />
Rheumatoid Arthritis (CREATE Study). Iain B. McInnes 1 ,<br />
Noel J. Snell 2 , John H. Perrett 2 , Harsukh Parmar 2 , Millie M.<br />
Wang 2 , Carol Astbury 2 . 1 University of Glasgow, Glasgow,<br />
United Kingdom; 2 AstraZeneca R&D, Loughborough,<br />
United Kingdom<br />
3:00 p m<br />
2086. Ofatumumab, a Human CD20 Monoclonal Antibody,<br />
in the Treatment of Rheumatoid Arthritis: Early Results from<br />
an Ongoing, Double-Blind, Randomized, Placebo Controlled<br />
Clinical Trial. M. Østergaard 1 , B. Baslund 2 , W. Rigby 3 , B.<br />
Rojkovich 4 , C. Jorgensen 5 , J. Petersen 6 , H. Kastberg 6 , P.<br />
Dawes 7 , S. Sierakowski 8 . 1 Department of Rheumatology,<br />
Copenhagen University Hospital, Hvidovre at Hvidovre,<br />
Denmark; 2 Rigshospitalet, Copenhagen, Denmark;<br />
3<br />
Dartmouth - Hitchcock Medical Center, Lebanon, NH;<br />
4<br />
Polyclinic of the Hospitaller Brothers of St. John of God,<br />
Budapest, Hungary; 5 Lapeyronie Hospital, Montpellier,<br />
France; 6 Genmab A/S, Copenhagen, Denmark; 7 The<br />
Haywood Hospital, Stroke on Trent, United Kingdom;<br />
8<br />
Medical University of Bialystok, Bialystok, Poland<br />
SATURDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 217
SATURDAY<br />
3:15 p m<br />
2087. Loss of Radiographic Benefit after Discontinuation of<br />
Treatment with Methotrexate in Patients with Undifferentiated<br />
Arthritis. Karen Visser 1 , Henrike van Dongen 1 , Jill van<br />
Aken 1 , Leroy R. Lard 1 , Herman K. Ronday 2 , Harry M.J.<br />
Hulsmans 2 , Irene Speyer 3 , Marie-Louise Westedt 3 , Andre J.<br />
Peeters 4 , Cornelia F. Allaart 1 , Rene E.M. Toes 1 , Ferdinand<br />
C. Breedveld 1 , Thomas W.J. Huizinga 1 . 1 LUMC, Leiden,<br />
The Netherlands; 2 Haga, The Hague, The Netherlands;<br />
3<br />
Bronovo, The Hague, The Netherlands; 4 Reinier de Graaf,<br />
Delft, The Netherlands<br />
3:30 p m<br />
2088. Repeated Treatment Courses of Rituximab Produce<br />
Sustained Efficacy in Patients with Rheumatoid Arthritis and<br />
an Inadequate Response or Intolerance to One or More TNF<br />
Inhibitors. Edward C. Keystone 1 , Roy M. Fleischmann 2 , Paul<br />
Emery 3 , Andrew Chubick 4 , Maxime R. Dougados 5 , Andrew<br />
R. Baldassare 6 , Joan M. Bathon 7 , Eva Hessey 8 , David<br />
Hagerty 9 , Simon Cooper 8 . 1 University of Toronto, Toronto,<br />
ON, Canada; 2 Metroplex Clinical Research Center, Dallas,<br />
TX; 3 Leeds General Infirmary, Leeds, United Kingdom;<br />
4<br />
Baylor University Medical Center, Dallas, TX; 5 Hópital<br />
Cochin, Paris, France; 6 St Louis University, St Louis, MO;<br />
7<br />
Johns Hopkins University, Baltimore, MD, Canada; 8 Roche<br />
Products Ltd, Welwyn Garden City, United Kingdom;<br />
9<br />
Biogen Idec, San Diego, CA<br />
3:45 p m<br />
2089. Targeted Inhibition of the IL-6 Receptor with Tocilizumab<br />
Effectively Reduces Disease Activity in Patients with Rheumatoid<br />
Arthritis. Andre D. Beaulieu 1 , Andrea Rubbert-Roth 2 ,<br />
Thasia Woodworth 3 , Emma Alecock 3 , Rieke Alten 4 , Josef<br />
Smolen 5 . 1 Laval University, Quebec, PQ, Canada; 2 Medical<br />
Clinic I, University of Cologne, Cologne, Germany; 3 Roche<br />
Products Ltd, Welwyn, United Kingdom; 4 Schlosspark<br />
Clinic, University Medicine Berlin, Berlin, Germany;<br />
5<br />
Medical University of Vienna and Hietzing Hospital,<br />
Vienna, Austria<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 210<br />
SLE: Markers of Disease (Abstracts #2090-2095)<br />
Moderators:<br />
David P. D’Cruz, MD, MRCP; St Thomas Hosptial;<br />
London, England<br />
Karen H. Costenbader, MD, MPH; Brigham and Women’s<br />
Hospital; Boston, MA<br />
2:30 p m<br />
2090. Atorvastatin Treatment does not Reduce Cytokines or Cell<br />
Adhesion Molecules in SLE. Lisa Christopher-Stine 1 , Adnan<br />
Kiani 1 , Laurence Magder 2 , James Mahoney 1 , Wendy Post 1 ,<br />
Michelle Petri 1 . 1 Johns Hopkins University, Baltimore, MD;<br />
2<br />
University of Maryland, Baltimore, MD<br />
2:45 p m<br />
2091. Plasma Leptin Levels are Associated with Carotid Artery<br />
Plaque and Intima-Media Thickness (IMT) in Women with SLE<br />
and a Matched Population of Healthy Women. Maureen A.<br />
McMahon, Marissa Anderson, Jennifer Grossman, Nagesh<br />
Ragavendra, Michael Li, Weiling Chen, Antonio LaCava,<br />
Bevra Hahn. University of California Los Angeles, Los<br />
Angeles, CA<br />
3:00 p m<br />
2092. Resistin Levels are Elevated and Associated with Coronary<br />
Artery Calcification in SLE Patients Compared to Age, Gender,<br />
and Race Matched Controls. Megan Morales, Mohammed<br />
Qatanani, Andrew Cucchiara, Eleni Nackos, Mitchell<br />
A. Lazar, Karen Teff, Joan Marie Von Feldt. Univ of<br />
Pennsylvania, Philadelphia, PA<br />
3:15 p m<br />
2093. Antibodies to Apolipoprotein A1 are Associated with<br />
Persistent Disease Activity in Patients with Systemic Lupus<br />
Erythematosus. Sean G. O’Neill, Ian Giles, David A.<br />
Isenberg, Anisur Rahman. Centre for Rheumatology<br />
Research, University College London, London, England<br />
3:30 p m<br />
2094. Fetal Kinetocardiogram for Early Detection and Treatment<br />
of First-Degree AV Block in Fetuses Exposed to Maternal<br />
Autoantibodies - A Prospective Study. Uri Elhalal, Dror<br />
Mevorach, Zeev Perles, Amiram Nir, Azaria JTT Rein.<br />
Hadassah, Jerusalem, Israel<br />
3:45 p m<br />
2095. White Matter Inflammation Revealed By FDG-PET as<br />
a Marker of SLE Disease Activity. Michelle Petri 1 , Shalini<br />
Narayana 2 , Mohammad Naqibuddin 1 , Margaret Sampedro 1 ,<br />
Robin L. Brey 2 , Stephen L. Holliday 3 , Peter Kochunov 2 ,<br />
Crystal Franklin 2 , Daniel J. Wallace 4 , Michael H. Weisman 4 ,<br />
Peter T. Fox 2 . 1 Johns Hopkins University, Baltimore, MD;<br />
2<br />
UT Health Science Center at San Antonio, San Antonio,<br />
TX; 3 South Texas Veterans Health Care System, San<br />
Antonio, TX; 4 Cedars-Sinai Medical Center, Los Angeles, CA<br />
218<br />
= Recorded Sessions (order form on page 430)
<strong>ACR</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 156<br />
Spondylarthropathies and Psoriatic Arthritis: Treatment II<br />
(Abstracts #2096-2101)<br />
Moderators:<br />
Dafna D. Gladman, MD, FRCPC; Toronto Western<br />
Hospital; Toronto, Ontario<br />
Robert B. M. Landewé, MD; University Hospital<br />
Maastricht; Maastricht, The Netherlands<br />
2:30 p m<br />
2096. Recurrence Risk of Psoriatic Arthritis (PsA) and Psoriasis<br />
(Ps) in Relatives of Patients with PsA. Vinod Chandran 1 ,<br />
Fawnda J. Pellett 1 , Sutharshini Shanmugarajah 1 , Catherine<br />
T. Schentag 1 , John E. Brockbank 2 , Sergio Toloza 1 , Proton<br />
Rahman 3 , Dafna D. Gladman 1 . 1 University of Toronto,<br />
Toronto, ON, Canada; 2 Blackburn Royal Infirmary, East<br />
Lancashire, United Kingdom; 3 St. Claires Mercy Hospital,<br />
St. Johns, NF, Canada<br />
2:45 p m<br />
2097. Development and Validation of a Screening Questionnaire<br />
for Psoriatic Arthritis (PsA). Dafna D. Gladman 1 , Catherine<br />
T. Schentag 1 , Brian D.M. Tom 2 , Vinod Chandran 1 , Vernon<br />
T. Farewell 2 . 1 University of Toronto, Toronto, ON, Canada;<br />
2<br />
MRC Biostatistics Unit, Institute of Public Health,<br />
Cambridge, United Kingdom<br />
3:00 p m<br />
2098. International Multi-Centre Psoriasis and Psoriatic Arthritis<br />
Reliability Trial (GRAPPA-IMPART): Assessment of Skin, Joints,<br />
Nails and Dactylitis. Vinod Chandran 1 , Richard Cook 2 ,<br />
Philip Helliwell 3 , Arthur F. Kavanaugh 4 , Neil J. McHugh 5 ,<br />
Philip J. Mease 6 , Ignazio Olivieri 7 , Proton Rahman 8 , Carlo<br />
Salvarani 9 , Sergio Toloza 1 , Qian Zhou 2 , Dafna D. Gladman 1 .<br />
1<br />
University of Toronto, Toronto, ON, Canada; 2 University<br />
of Waterloo, Waterloo, ON, Canada; 3 University of Leeds,<br />
Leeds, United Kingdom; 4 UCSD Thorton Hospital,<br />
La Jolla, CA; 5 Royal National Hospital, Bath, United<br />
Kingdom; 6 Seattle Rheumatology Associate, Seattle, WA;<br />
7<br />
Rheumatology Dept. of Lucania, Potenza, Italy; 8 St. Claires<br />
Mercy Hospital, St. Johns, NF, Canada; 9 Arcispedale-Santa-<br />
Maria-Nuova, Reggio Emilia, Italy<br />
3:15 p m<br />
2099. Adiposity, Smoking and the Risk of Psoriasis in Women<br />
and Implications on Psoriatic Arthritis - Nurses’ Health Study<br />
II. Arathi R. Setty 1 , Abrar A. Qureshi 2 , M. Elaine Husni 3 ,<br />
Hyon K. Choi 4 . 1 Massachusetts General Hospital, Harvard<br />
Med School, Boston, MA; 2 Brigham and Women’s Hosp,<br />
Boston, MA; 3 Cleveland Clinic, Cleveland, OH; 4 Arthritis<br />
Research Ctr of Canada, Univ of British Columbia,<br />
Vancouver, BC, Canada<br />
3:30 p m<br />
2100. Risk of Myocardial Infarction in Patients with Psoriatic<br />
Arthritis. Hyon K. Choi 1 , M. Mushfiqur Rahman 1 , Jacek<br />
A. Kopec 1 , John Esdaile 1 , Jan P. Dutz 2 , Diane Lacaille 1 .<br />
1<br />
Arthritis Research Center of Canada, Vancouver, BC,<br />
Canada; 2 Division of Dermatology/Department of Medicine,<br />
University of British Columbia, Vancouver, BC, Canada<br />
3:45 p m<br />
2101. Random High-throuhgput Screening of Chemical Libraries<br />
for Modulators of the Gene Promoter Activity of HLA-B27<br />
Uncovered New Research Directions. Like Zhao, Robert<br />
Damoiseaux, David Ty Yu. UCLA, Los Angeles, CA<br />
<strong>ACR</strong> Special Session C<br />
2:30—4:00 p m<br />
Hall C<br />
The Great Debate: Describe the Strengths and Pitfalls of<br />
Peripheral MRI Assessment of Synovitis and Erosions in<br />
Inflammatory Arthritis<br />
Moderators:<br />
Arthur Kavanaugh, MD; University of California, San<br />
Diego School of Medicine; La Jolla, CA<br />
Sally W. Pullman-Mooar, MD; Philadelphia Veterans<br />
Administration Hospital; Wynnewood, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the strengths and pitfalls of peripheral MRI<br />
assessment of synovitis and erosions in inflammatory<br />
arthritis<br />
∙ Discuss the sensitivity and specificity of erosions seen on<br />
peripheral MRI that are not seen on plain radiography and<br />
their clinical significance<br />
∙ Review the arguments for and against using biologics in<br />
early inflammatory arthritis based on MRI imaging<br />
2:30 p m<br />
Pro Perspective<br />
Paul Emery, MA, MD; Leeds University; Leeds, England<br />
3:05 p m<br />
Con Perspective<br />
Michael H. Weisman, MD; Cedars Sinai Medical Center;<br />
Los Angeles, CA<br />
3:40 p m<br />
Panel Discussion<br />
SATURDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 219
SATURDAY<br />
<strong>ARHP</strong> Concurrent Session C<br />
2:30—4:00 p m<br />
Room 260<br />
Evidence for Realignment, Off-Loading and Restorative<br />
Therapies for the Treatment of Knee Osteoarthritis<br />
Moderator:<br />
Doreen M. Stiskal, PT, PhD; Seton Hall University; South<br />
Orange, NJ<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the standard of treatment provided by the<br />
realignment, off-loading and restorative therapies for the<br />
management of knee OA as described in the peer reviewed<br />
literature<br />
∙ Describe the difference between the clinical expertise<br />
versus documented scientific evidence for these treatments<br />
∙ Identify some of the key holes in our knowledge base for<br />
OA treatment<br />
2:30 p m<br />
Physical Rehabilitation Therapies<br />
Cheryl L. Riegger-Krugh, PT, ScD; University of Colorado<br />
at Denver and Health Sciences Center; Denver, CO<br />
2:55 p m<br />
Orthoses<br />
Howard J. Hillstrom, PhD; Hospital for Special Surgery;<br />
New York, NY<br />
3:20 p m<br />
Surgical Procedures<br />
Sherry I. Backus, PT, DPT, MA; Hospital for Special<br />
Surgery; New York, NY<br />
3:45 p m<br />
Panel Discussion<br />
<strong>ARHP</strong> Concurrent Session<br />
2:30—4:00 p m<br />
Room 257<br />
Motivational Interviewing: Facilitating Health Promotion<br />
in Arthritis<br />
Moderator:<br />
Joyce P. Carlone, MN, RN, CFNP; Emory University;<br />
Atlanta, GA<br />
Speakers:<br />
Jillian Bateman, OTD, OTR/L; Rehabilitation Institute of<br />
Chicago; Chicago, IL<br />
Linda S. Ehrlich-Jones, PhD, RN; Rehabilitation Institute of<br />
Chicago; Chicago, IL<br />
Trudy R. Mallinson, PhD; Rehabilitation Institute of<br />
Chicago; Chicago, IL<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the motivational interviewing process<br />
∙ Discuss the major components of an arthritis physical<br />
activity promotion program<br />
∙ Apply principles of motivational interviewing during role<br />
play of specific client situations<br />
<strong>ARHP</strong> Concurrent Session<br />
2:30—4:00 p m<br />
Room 259<br />
Rheumatic Disease Epidemiology for Clinical Practice: What<br />
We Know, What We Don’t Know and Why It Matters<br />
Moderator:<br />
Glinda S. Cooper, PhD; U.S. Environmental Protection<br />
Agency; Washington, DC<br />
Speakers:<br />
Eswar Krishnan, MD; University of Pittsburgh; Pittsburgh, PA<br />
Terence W. Starz, MD; University of Pittsburgh Medical<br />
Center; Pittsburgh, PA<br />
Molly T. Vogt, PhD; University of Pittsburgh; Pittsburgh, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Analyze U.S. and International epidemiologic information<br />
on rheumatic diseases including rheumatoid arthritis,<br />
osteoarthritis, systemic lupus erythematosus, gout, systemic<br />
sclerosis, fibromyalgia, spondylarthropathies and low back<br />
disorders<br />
∙ Review the criteria for epidemiologic identification of the<br />
various disorders and relate them to clinical practice<br />
∙ Describe the influence of rheumatic disease drug trials on<br />
pharmacologic prescribing<br />
∙ Evaluate the impact of rheumatic disease incidence on<br />
clinical practice activities<br />
<strong>ARHP</strong> Concurrent Abstract Session<br />
2:30—4:00 p m<br />
Room 261<br />
Improving Hand Function: From Pain to Evaluation to<br />
Splinting (Abstracts #2102-2107)<br />
Moderator:<br />
Kathryn L. Lowenstein, OTR/L; Arthritis Center; Palm<br />
Harbor, FL<br />
2:30 p m<br />
2102. Hand and Lower Limb Pain in Community Dwelling Older<br />
Adults: Onset and Effect on Physical Function Over a Three-year<br />
Period. Elaine Thomas, Krysia S. Dziedzic, Peter Croft.<br />
Keele University, Keele, United Kingdom<br />
220<br />
= Recorded Sessions (order form on page 430)
2:45 p m<br />
2103. Development of the Vienna Instrument of Functioning<br />
in Hand Osteoarthritis (VIF): A Cross-Sectional Study. Birgit<br />
Prodinger, Katharina Scheel, Daniel Aletaha, Josef Smolen,<br />
Klaus Machold, Tanja Stamm. Medical University of<br />
Vienna, Vienna, Austria<br />
3:00 p m<br />
2104. Responsiveness of the Michigan Hand Outcomes<br />
Questionnaire-Dutch Language Version in Patients with<br />
Rheumatic Diseases. Florus J. van der Giesen, R. G.H.H.<br />
Nelissen, J. H. Arendzen, Z. de Jong, R. Wolterbeek, T.<br />
P.M. Vliet Vlieland. Leiden University Medical Center,<br />
Leiden, The Netherlands<br />
3:15 p m<br />
2105. Clinical Effectiveness of Two Swan-Neck Finger Splints<br />
in Patients with Rheumatoid Arthritis; A Randomized, Cross-<br />
Over Trial. Florus J. van der Giesen 1 , W. J. van Lankveld 2 ,<br />
C. J.W. Kremers 2 , A. J. Peeters 3 , E. Stern 4 , S. le Cessie 1 ,<br />
R. G.H.H. Nelissen 1 , T. P. M. Vliet Vlieland 1 . 1 Leiden<br />
University Medical Center, Leiden, The Netherlands; 2 Sint<br />
Maartenskliniek, Nijmegen, The Netherlands; 3 Reinier<br />
de Graaf Gasthuis, Delft, The Netherlands; 4 University of<br />
Minnesota, Minneapolis, MN<br />
3:30 p m<br />
2106. Effectiveness of Splinting for the Treatment of Trigger<br />
Finger. Julie Colbourn 1 , Noel Heath 1 , Sherry Manary 2 ,<br />
Denette Pacifico 2 . 1 St. Joseph’s Care Group, Thunder<br />
Bay, ON, Canada; 2 St. Joseph’s Care Group/Thunder Bay<br />
Regional Hospital, Thunder Bay, ON, Canada<br />
3:45 p m<br />
2107. Determinants of the Use of Wrist Working Splints<br />
in Rheumatoid Arthritis. Martine M. Veehof, Erik Taal,<br />
Marjanne J. Willems, Mart AFJ van de Laar. University of<br />
Twente, Enschede, The Netherlands<br />
<strong>ACR</strong> Workshops<br />
4:00—6:00 p m<br />
Admission to the Workshop sessions is by ticket only. To verify the session<br />
for which you are registered, refer to the registration codes below in<br />
parentheses. Workshops include beverages only.<br />
Basic Ultrasonography: U.S. Perspective (153)<br />
Equipment provided by Biosound Esaote Ultrasound<br />
Room 211<br />
Amy M. Evangelisto, MD; Cooper University Hospital;<br />
Cherry Hill, NJ<br />
Gurjit S. Kaeley, MBBS, MRCP; ROAD Clinic; University<br />
Place, WA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss indications for use of musculoskeletal ultrasound<br />
∙ Recognize ultrasonographic appearances of various soft<br />
tissues and joints<br />
∙ Acquire basic images and recognize major pitfalls of ultrasound<br />
Musculoskeletal Imaging (155)(Trainees Only) F<br />
Room 209<br />
Mark D. Murphey, MD; Armed Forces Institute of<br />
Pathology; Washington, DC<br />
Upon completion of this session, participants should be able to:<br />
∙ Use a pattern or target approach to radiographs in<br />
evaluation of arthritis<br />
∙ Recognize typical and unusual radiographic manifestations<br />
of common arthritides<br />
∙ Discuss the use of advanced imaging techniques<br />
(CT and MRI)<br />
Renal Histopathology in SLE and Vasculitis (154)<br />
Room 212<br />
Megan L. Troxell, MD, PhD; Oregon Health & Science<br />
University; Portland, OR<br />
Upon completion of this session, participants should be able to:<br />
∙ Identify the pathologic changes that occur in lupus nephritis<br />
∙ Discuss the pathologic basis for the classification of lupus<br />
nephritis and how it relates to clinical management<br />
∙ Recognize the histological changes in the kidneys of<br />
patients with vasculitis<br />
SATURDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 221
<strong>ARHP</strong> Concurrent Session<br />
4:00—6:00 p m<br />
Room 213<br />
There is no charge to attend this session in the computer workshop room but<br />
participation is limited.<br />
Identifying and Navigating Web-Based Educational<br />
and Networking Resources for Rheumatology Health<br />
Professionals and Patients<br />
Moderator:<br />
Karla B. Jones, MS, RN, CPNP; Childrens Hospital;<br />
Columbus, OH<br />
Speakers:<br />
Ann Kunkel, BS; University of Kansas Medical Center;<br />
Oregon, MO<br />
Laura E. Ray, MA, MLS; Cleveland State University;<br />
Cleveland, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Review key rheumatology-related Web sites and methods<br />
for identifying such Web sites<br />
∙ Examine navigation methods for connecting to<br />
educational and networking resources on rheumatologyrelated<br />
Web resources<br />
∙ Discuss methods for incorporation rheumatology-related<br />
Web resources into professional and patient education and<br />
networking programs<br />
5:20 p m<br />
Genetic Epistasis<br />
Bruce C. Richardson, MD, PhD; University of Michigan;<br />
Ann Arbor, MI<br />
5:45 p m<br />
Discussion<br />
<strong>ACR</strong> Clinical Symposium C<br />
4:30—6:00 p m<br />
Hall C<br />
Why is My Patient with Myositis Not Getting Better?<br />
Moderator:<br />
John H. Stone, MD, MPH; Massachusetts General<br />
Hospital / UpToDate; Sudbury, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the role of histopathology in addressing the patient<br />
with refractory muscle disease<br />
∙ Differentiate the principal clinical features of metabolics<br />
opposed to inflammatory myopathies<br />
∙ Develop evidence-based treatment approaches to the<br />
patient with refractory myositis<br />
4:30 p m<br />
Refractory Myopathies: Looking for Clues under a Microscope<br />
Sakir Humayun Gultekin, MD; Oregon Health and Science<br />
University; Portland, OR<br />
SATURDAY<br />
<strong>ACR</strong> Basic Science Symposium C/R<br />
4:30—6:00 p m<br />
Grand Ballroom West<br />
Gender in Rheumatic Disease<br />
Moderator:<br />
Gary S. Gilkeson, MD; Medical University of South<br />
Carolina; Charleston, SC<br />
Upon completion of this session, participants should be able to:<br />
∙ Summarize the latest concepts regarding the role of sex<br />
versus gender on developmental biology<br />
∙ Discuss the effect of sex hormones on lymphocyte<br />
development and function<br />
∙ Define the complex interplay of epigenetics of the X and Y<br />
chromosomes on rheumatic diseases<br />
4:30 p m<br />
Sex Chromosomes and Rheumatic Disease<br />
Carmen Sapienza, PhD; Temple University Medical School;<br />
Philadelphia, PA<br />
5:00 p m<br />
Diagnosis and Treatment of Metabolic Myopathies<br />
Anthony Amato, MD; Brigham and Womens Hospital /<br />
Harvard Medical Scho; Boston, MA<br />
5:30 p m<br />
Approach to a Patient with Refractory Myositis<br />
Mark F. Gourley, MD; National Institutes of Health;<br />
Bethesda, MD<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 153<br />
Advances in Orthopedics (Abstracts #2108-2113)<br />
Moderators:<br />
Joseph Biundo; MD; Kenner Regional Medical Center;<br />
Kenner, LA<br />
Henning K. Zeidler, MD; MHH Rheumatologie<br />
Medizinische Hochschule Postfach Hanover, Germany<br />
4:55 p m<br />
Effects of Sex Hormones on B-Cell Tolerance<br />
Christine M. Grimaldi, PhD; Columbia University; New York, NY<br />
4:30 p m<br />
2108. Influence of Cytokine Inhibitors on Levels of Mmp-1 and<br />
Mmp-3 in Disc Herniation. An In-Vitro Analysis. Stéphane<br />
Genevay, Francoise Mezin, Axel Finckh, Enrico Tessitore,<br />
Pierre-Andre Guerne. University Hospital of Geneva,<br />
Geneva, Switzerland<br />
222<br />
= Recorded Sessions (order form on page 430)
4:45 p m<br />
2109. Cervical Spine Instability in Patient with Rheumatoid<br />
Arthritis (RA) Undergoing General Surgery. Maria A. Lopez-<br />
Olivo, Tayab R. Andrabi, Maria E. Suarez-Almazor. UT MD<br />
Anderson Cancer Center, Houston, TX<br />
4:30 p m<br />
2114. Total Joint Replacement Contributes to Declining Disability<br />
Rates in Seniors. James F. Fries, Eliza F. Chakravarty,<br />
Bharathi Lingala, Helen B. Hubert. Stanford University,<br />
Palo Alto, CA<br />
5:00 p m<br />
2110. Syndecan-4 is Highly Expressed in Synovial-like Interface<br />
Membranes from Aseptic Prosthesis Loosening and Regulates<br />
MMP-1 and MMP-3 in Prosthesis Loosening Fibroblasts. Steffen<br />
Drange 1 , Katja Neugebauer 2 , Marvin A. Peters 2 , Frank<br />
Echtermeyer 2 , Thomas Pap 2 . 1 Otto-von-Guericke University,<br />
Magdeburg, Germany; 2 University Hospital Munster,<br />
Munster, Germany<br />
5:15 p m<br />
2111. Use of Anti-TNF Agents in 15 Rheumatoid Arthritis<br />
Patients Undergoing Primary Total Elbow Arthroplasty. Daniel<br />
G. Arkfeld, Vickram Reehal, Sina Kasraeian, George Hatch,<br />
Steve Kang, Samy Metyas, John Itamura. University of<br />
Southern California, Los Angeles, CA<br />
5:30 p m<br />
2112. Initial Clinical Experience with the OrthoGlideTM<br />
Medial Knee Implant: A Novel, Minimally-Invasive Surgical<br />
Procedure for Patients with Osteoarthritis of the Knee. William<br />
Arnold, M.D. 1 , David Raab, MD 1 , David Trotter, MD 2 ,<br />
David Esposito, MD 3 , Jeffrey Felt, MD 4 . 1 Morton Grove, IL;<br />
2<br />
Hoffman Estates, IL; 3 Wilmington, NC; 4 Advanced Bio-<br />
Surfaces, Minnetonka, MN<br />
5:45 p m<br />
2113. Age and Gender are Predictors of Moderate or Severe Pain<br />
Post Total Knee Arthroplasty (TKA). Jasvinder A. Singh 1 ,<br />
Sherine E. Gabriel 2 , David Lewallen 2 . 1 Minneapolis VA<br />
Medical Center, Minneapolis, MN; 2 Mayo Clinic School of<br />
Medicine, Rochester, MN<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 156<br />
Epidemiology and Health Services Research: Primary,<br />
Secondary and Tertiary Prevention (Abstracts #2114-2119)<br />
Moderators:<br />
Loreto Carmona, MD, PhD; Fundacion Española de<br />
Reumatologia; Madrid, Spain<br />
Maria Suarez-Almazor, MD, PhD; UT MD Anderson<br />
Cancer Center; Houston, TX<br />
4:45 p m<br />
2115. Obesity as a Risk Factor for Incident and Progressive<br />
Radiographic Osteoarthritis in Neutral and Malaligned Knees:<br />
The Most Study. Jingbo Niu 1 , YQ Zhang 1 , J. Toner 2 , M.<br />
Nevitt 3 , CE Lewis 4 , P. Aliabadi 1 , B. Sack 1 , M. Clancy 1 , DT<br />
Fleson 1 . 1 BUSM, Boston, MA; 2 U Iowa, Iowa City, IA;<br />
3<br />
UCSF, San Francisco, CA; 4 UAB, Birmingham, AL<br />
5:00 p m<br />
2116. Bone Mineral Density and Prevalent Hip OA in Older<br />
Men. R. Krishna Chaganti 1 , Mohammed Javaid 2 , Neeta<br />
Parimi 3 , Michael Nevitt 4 , Thomas Lang 4 , Marcia Stefanick 5 ,<br />
Eric Orwoll 6 , Nancy Lane 7 . 1 Hospital for Special Surgery,<br />
New York,, NY; 2 MRC, ERC, University of Southampton,<br />
Southampton, United Kingdom; 3 SF Coordinating Center,<br />
San Francisco, CA; 4 UCSF, San Francisco, CA; 5 Stanford<br />
University, Palo Alto, CA; 6 OHSU, Portland, OR; 7 UC-<br />
Davis, Sacramento, CA<br />
5:15 p m<br />
2117. Impact of Adherence to Osteoporosis Medications on<br />
Fracture Rates: A Population-Based Study. Susan B. Jaglal 1 ,<br />
Deva Thiruchelvam 2 , Gillian A. Hawker 1 . 1 University of<br />
Toronto, Toronto, ON, Canada; 2 Institute for Clinical<br />
Evaluative Studies, Toronto, ON, Canada<br />
5:30 p m<br />
2118. Provision of Preventive Health Services in SLE. Jinoos<br />
Yazdany 1 , Pantelis Panopalis 1 , Joann Gillis 2 , Laura Trupin 1 ,<br />
Laura Julian 1 , Aimee Hersh 1 , Patricia Katz 1 , Edward Yelin 1 .<br />
1<br />
University of California, San Francisco, San Francisco, CA;<br />
2<br />
National Jewish Hospital, Denver, CO<br />
5:45 p m<br />
2119. No Evidence of Reduction in Premature Work Loss among<br />
Persons with Rheumatoid Arthritis (RA) Using Anti-TNF Alpha<br />
Agents. Saralynn Allaire 1 , Frederick Wolfe 2 , Jingbo Niu 1 ,<br />
Michael LaValley 3 . 1 Boston University School of Medicine,<br />
Boston, MA; 2 National Data Bank for Rheumatic Diseases,<br />
Wichita, KS; 3 Boston University School of Public Health,<br />
Boston, MA<br />
SATURDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 223
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 104<br />
Genetics, Genomics and Proteomics (Abstracts #2120-2125)<br />
Moderators:<br />
Lars Klareskog, MD, PhD; Karolinska Institute; Stockholm,<br />
Sweden<br />
Gregg Silverman, MD; University of Calfornia–San Diego;<br />
La Jolla, CA<br />
of Musculoskeletal Disease, Chapel Allerton Hospital,<br />
Leeds, United Kingdom; 4 Academic Unit of Molecular<br />
Vascular Medicine, University of Leeds, Leeds, United<br />
Kingdom; 5 Clinical and Academic Rheumatology, Kings<br />
College Hospital, London, United Kingdom; 6 Bone<br />
Research Group, Department of Medicine & Therapeutics,<br />
University of Aberdeen, Aberdeen, United Kingdom;<br />
7<br />
Division of Community Health Sciences, St George’s,<br />
University of London, London, United Kingdom<br />
SATURDAY<br />
4:30 p m<br />
2120. Whole Genome Association Studies of Rheumatoid<br />
Arthritis and Replication of Identified Susceptibility Loci. Xiayi<br />
Ke 1 , Wendy Thomson 1 , Anne Barton 1 , Steve Eyre 1 , Anne<br />
Hinks 1 , John Bowes 1 , Rachelle Donn 1 , Ian N. Bruce 1 ,<br />
Anthony G. Wilson 2 , Ann Morgan 3 , Paul Emery 3 , YEAR<br />
consortium, Angela Carter 3 , Sophia Steer 4 , Lynne Hocking 5 ,<br />
David M. Reid 5 , David Strachan 6 , Paul Wordsworth 7 , Jane<br />
Worthington 1 . 1 University of Manchester, Manchester,<br />
United Kingdom; 2 University of Sheffield, Sheffield, United<br />
Kingdom; 3 University of Leeds, Leeds, United Kingdom;<br />
4<br />
Kings College Hospital, London, United Kingdom;<br />
5<br />
University of Aberdeen, Aberdeen, United Kingdom;<br />
6<br />
University of London, London, United Kingdom; 7 Nuffield<br />
Orthopaedic Centre, Oxford, United Kingdom<br />
4:45 p m<br />
2121. Whole Genome Association Study Identifies Rheumatoid<br />
Arthritis Risk Locus Near TNFAIP3. Robert Plenge 1 , Chris<br />
Cotsapas 2 , Leela Davies 2 , Michael F. Seldin 3 , Leonid<br />
Padyukov 4 , Lars Klareskog 4 , Shaun Purcell 2 , Peter K.<br />
Gregersen 5 , Jonathan Coblyn 1 , Michael E. Weinblatt 1 ,<br />
Nancy A. Shadick 1 , Mark J. Daly 2 , David Altshuler 2 ,<br />
Epidemiological Investigation of Rheumatoid Arthritis<br />
(EIRA), North <strong>American</strong> Rheumatoid Arthritis Consortium<br />
(NARAC), Brigham Rheumatoid Arthritis Sequential Study<br />
(BRASS). 1 Brigham and Women’s Hospital, Boston, MA;<br />
2<br />
Broad Institute of MIT and Harvard, Cambridge, MA;<br />
3<br />
University of California at Davis, Davis, CA; 4 Karolinska<br />
Institutet, Stockholm, Sweden; 5 The Feinstein Institute for<br />
Medical Research, Manhasset, NY<br />
5:00 p m<br />
2122. Investigation in JIA Of RA Susceptibility SNPs Identified<br />
in the WTCCC WGAS Reveals Association with IL2RA/<br />
CD25. Wendy Thomson 1 , Anne Hinks 1 , Anne Barton 1 ,<br />
Xiayi Ke 1 , Steve Eyre 1 , John Bowes 1 , Rachelle Donn 1 ,<br />
Samantha Hider 1 , Ian N. Bruce 1 , Anthony G. Wilson 2 ,<br />
Ann Morgan 3 , Paul Emery 3 , YEAR consortium, BSPAR<br />
group, Angela Carter 4 , Sophia Steer 5 , Lynne Hocking 6 ,<br />
David M. Reid 6 , David Strachan 7 , Jane Worthington 1 .<br />
1<br />
University of Manchester, Manchester, United Kingdom;<br />
2<br />
School of Medicine & Biomedical Sciences, University<br />
of Sheffield, Sheffield, United Kingdom; 3 Academic Unit<br />
5:15 p m<br />
2123. MiR-155 is Abundantly Expressed in Rheumatoid<br />
Arthritis Synovium and is Regulated by Proinflammatory<br />
Cytokines and TLR Ligands. Joanna Stanczyk 1 , Deena<br />
M. Leslie 2 , Fabia Brentano 1 , Olga Sanchez-Pernaute 1 ,<br />
Christoph Kolling 3 , Renate E. Gay 1 , Beat A. Michel 1 ,<br />
Michael Detmar 2 , Steffen Gay 1 , Diego Kyburz 1 . 1 Center of<br />
Experimental Rheumatology, Zurich Center of Integrative<br />
Human Physiology (ZIHP), University of Zurich, Zurich,<br />
Switzerland; 2 Department of Chemistry and Applied<br />
Biosciences, Institute of Pharmaceutical Sciences, Swiss<br />
Federal Institute of Technology (ETH), Zurich, Switzerland;<br />
3<br />
Schulthess Clinic, Zurich, Switzerland<br />
5:30 p m<br />
2124. Genetic Variation in the CRP Promoter: Association<br />
with SLE. Jeffrey C. Edberg 1 , Jianming Wu 1 , Miranda<br />
Marion 2 , Carl D. Langefeld 2 , Gerald McGwin, Jr. 1 , Michelle<br />
Petri 3 , Rosalind Ramsey-Goldman 4 , Luis M. Vilá 5 , John D.<br />
Reveille 6 , Kenneth M. Kaufman 7 , Summer Frank 7 , John B.<br />
Harley 7 , Graciela Alarcón 1 , Robert P. Kimberly 1 . 1 University<br />
of Alabama at Birmingham, Birmingham, AL; 2 Wake Forest<br />
University School of Medicine, Winston-Salem, NC; 3 Johns<br />
Hopkins Univ, Baltimore, MD; 4 Northwestern University<br />
School of Medicine, Chicago, IL; 5 University of Puerto Rico<br />
Mecical Sciences Campus, San Juan, Puerto Rico; 6 University<br />
of Texas Health Science Center, Houston, TX; 7 Oklahoma<br />
Medical Research Foundation, Oklahoma City, OK<br />
5:45 p m<br />
2125. Genetic Association of Il-21 Polymorphisms with Systemic<br />
Lupus Erythematosus. Amr H. Sawalha 1 , Kenneth M.<br />
Kaufman 1 , Jennifer A. Kelly 2 , Adam J. Adler 2 , Teresa Aberle 2 ,<br />
Jeff Kilpatrick 2 , Edward K. Wakeland 3 , Quan-Zhen Li 3 ,<br />
Amy E. Wandstrat 3 , David S. Karp 3 , Judith A. James 2 , Joan<br />
T. Merrill 4 , Peter Lipsky 5 , John B. Harley 1 . 1 University of<br />
Oklahoma Health Sciences Center, Oklahoma Medical<br />
Research Foundation, Oklahoma City VAMC, Oklahoma<br />
City, OK; 2 Oklahoma Medical Research Foundation,<br />
Oklahoma City, OK; 3 University of Texas Southwestern<br />
Medical Center, Dallas, TX; 4 University of Oklahoma Health<br />
Sciences Center, Oklahoma Medical Research Foundation,<br />
Oklahoma City, OK; 5 National Institute of Arthritis and<br />
Musculoskeletal and Skin Diseases, Bethesda, MD<br />
224<br />
= Recorded Sessions (order form on page 430)
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 102<br />
Innate Immunity Leading to Rheumatic Disease (Abstracts<br />
#2126-2131)<br />
Moderators:<br />
Christine Pham, MD; Washington University School of<br />
Medicine; St. Louis, MO<br />
4:30 p m<br />
2126. Infliximab-Induced Reverse Signalling of Membrane TNF<br />
Leads to Increased Apoptosis in Monocytes of Patients with<br />
Rheumatoid Arthritis Compared to Healthy Donors. Undine<br />
Meusch, Manuela Rossol, Holm Häntzschel, Christoph<br />
Baerwald, Sunna Hauschildt, Ulf Wagner. University of<br />
Leipzig, Leipzig, Germany<br />
4:45 p m<br />
2127. The Leucine-Rich Repeat (LRR) Domain of Cryopyrin<br />
(NALP3) is Critical for Monosodium Urate (MSU) Crystal-<br />
Induced Inflammation. Hal Hoffman 1 , Peter Scott 2 , Amir<br />
Misaghi 1 , Robert Terkeltaub 2 , Ru L. Bryan 2 . 1 Dept. of<br />
Medicine, UCSD, San Diego, CA; 2 VAMC/UCSD, San<br />
Diego, CA<br />
5:00 p m<br />
2128. Coercion of Innate Immunity to Amplify the Adaptive<br />
Immune Response in the Cascade to Cardiac Injury in<br />
Congenital Heart Block: Implications for Prevention with<br />
Antimalarials. Robert M. Clancy 1 , Peter Izmirly 1 , Robert<br />
Kimberly 2 , Jeffrey Edberg 2 , Franck J. Barrat 3 , Marguerita<br />
O’Mahoney 1 , Jill P. Buyon 1 . 1 New York University School<br />
of Medicine, New York, NY; 2 University of Alabama,<br />
Birmingham, AL; 3 Dynavax Technologies Corporation,<br />
Berkley, CA<br />
5:15 pm<br />
2129. Mechanisms of IgG Activation of the Alternative Pathway<br />
of Complement. Nirmal K. Banda 1 , Allyson K. Wood 1 , Kazue<br />
Takahashi 2 , Pauline M. Rudd 3 , Louise Royle 4 , Gregory L.<br />
Stahl 5 , V. Michael Holers 1 , William P. Arend 1 . 1 University of<br />
Colorado at Denver and HSC, Aurora, CO; 2 Massachusetts<br />
General Hospital for Children, Boston, MA; 3 University<br />
College, Dublin, Ireland; 4 Universirty College, Dublin,<br />
Ireland; 5 Brigham and Women’s Hospital, Boston, MA<br />
5:30 p m<br />
2130. Differential Function of the NACHT-LRR (NLR) Members<br />
NOD1 and NOD2 in Arthritis. Leo A. Joosten 1 , Shahla<br />
Abdollahi-Roodsaz 1 , Stephen E. Girardin 2 , Mihai G. Netea 1 ,<br />
Wim B. van den Berg 1 . 1 UMC Nijmegen, Nijmegen, The<br />
Netherlands; 2 University of Toronto, Ontario, ON, Canada<br />
5:45 p m<br />
2131. IFN-α Production by Mouse Conventional Dendritic<br />
Cells and Human Monocytes Through TLR4 and IFN-β<br />
Synergy: Possible Mechanism for Lupus Flares During Bacterial<br />
Infection. Christophe Richez 1 , Kei Yasuda 1 , Jean M. van<br />
Seventer 1 , Shizuo Akira 2 , Ian R. Rifkin 1 . 1 Boston University,<br />
Boston, MA; 2 Osaka University, Osaka, Japan<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 253<br />
Novel Molecular Mediators and Treatments<br />
(Abstracts #2132-2137)<br />
Moderators:<br />
Richard M. Pope, MD; Northwestern University Medical<br />
School; Chicago, IL<br />
Richard M. Siegel, MD, PhD; National Institutes of Health;<br />
4:30 p m<br />
2132. Identification of TTP mRNA Targets in Human Dendritic<br />
Cells Reveals TTP as a Critical Regulator of Dendritic Cell<br />
Maturation. Jillian Emmons 1 , Davin Townley-Tilson 2 ,<br />
Kristen M. Deleault 1 , Stephen J. Skinner 1 , Michael L.<br />
Whitfield 3 , Seth A. Brooks 1 . 1 Dartmouth Medical School,<br />
Lebanon, NH; 2 DartmouthCollege, Hanover, NH;<br />
3<br />
Dartmouth College, Hanover, NH<br />
4:45 p m<br />
2133. TNFα-induced Macrophage Death Via Caspase and<br />
Cathepsin Pathways. Tri M. Tran 1 , Vladislav Temkin 1 ,<br />
Shi Bo 1 , Lisa J. Pagliari 1 , Christiane J. Ferran 2 , Richard<br />
M. Pope 1 . 1 Northwestern University Feinberg School of<br />
Medicine, Chicago, IL; 2 Beth Israel Deaconess Medical<br />
Center, Harvard Medical School, Boston, MA<br />
5:00 p m<br />
2134. Antagonizing Type-I Interferon Receptor Ameliorates Lupus<br />
Disease in Autoimmune NZB/W F1 Mice. Yan Xu 1 , Jing<br />
Zhang 1 , Kevin Schifferli 1 , Christopher J Groves 1 , Laurent<br />
Audoly 1 , Jack Gauldie 2 , Peter Kiener 1 , Anthony J Coyle 1 , Su-<br />
Yau Mao 1 . 1 MedImmune, Inc., Gaithersburg, MD; 2 Centre<br />
for Gene Therapeutics, Hamilton, ON, Canada<br />
5:15 p m<br />
2135. Antagonizing HMBG1 Blocks Inflammation and Tissue<br />
Damage in Experimental Arthritis. Su-Yau Mao, Yihong<br />
Yao, Brian Naiman, Chris Morehouse, LuAnn McKinney,<br />
Ling-Ling An, Herren Wu, Laurent Audoly, Peter Kiener,<br />
Anthony J. Coyle. MedImmune, Inc., Gaithersburg, MD<br />
SATURDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 225
5:30 p m<br />
2136. Ligands for Nuclear Receptors Retinoid X Receptor<br />
(RXR) and Peroxisome Proliferator Activated Receptor Gamma<br />
(PPARgamma) Inhibit Collagen Destruction by Chondrocytic<br />
Cells Stimulated with Interleukin-1ß (IL-1ß). Adam C.<br />
Schmucker, Peter S. Burrage, Michael B. Sporn, Constance<br />
E. Brinckerhoff. Dartmouth College, Hanover, NH<br />
5:45 p m<br />
2137. Combined Anti-Inflammatory Tri-Therapy Using a Novel<br />
Sirna Formulation Successfully Prevents and Cures Mice from<br />
Arthritis. Florence Apparailly 1 , Maroun Khoury 1 , Valérie<br />
Escriou 2 , A. Galy 3 , R. Yao 3 , C. Largeau 2 , D. Scherman 2 ,<br />
Christian Jorgensen 1 . 1 INSERM U844, Montpellier, France;<br />
2<br />
INSERM U640, Montpellier, France; 3 INSERM U790,<br />
EVRY, France<br />
5:00 p m<br />
2140. The Efficacy and Tolerability of a Once-a-Month<br />
Dosing Regimen of 150 mg Risedronate for the Treatment of<br />
Postmenopausal Osteoporosis - The Merit-OP Study. P. D.<br />
Delmas 1 , M. R. McClung 2 , J. R. Zanchetta 3 , A. Racewicz 4 ,<br />
C. Roux 5 , C. L. Benhamou 6 , Z. Man 7 , R. Eusebio 8 , J. F.<br />
Beary 8 , E. Matzkin 9 , D. E. Burgio 8 , S. Boonen 10 . 1 University<br />
of Lyon, Lyon, France; 2 Oregon Osteoporosis Center &<br />
Providence Medical Center, Portland, OR; 3 Instituto de<br />
Investigaciones (IDIM), Buenos Aires, Argentina; 4 Centrum<br />
Medyczne Specjalistyczny Gabinet Lekarski, Bialystok,<br />
Poland; 5 Cochin Hospital, Rene Descartes University,<br />
Paris, France; 6 Inserm Research Unit U658, Orléans,<br />
France; 7 Centro TIEMPO, Buenos Aires, Argentina; 8 P&G<br />
Pharmaceuticals, Mason, OH; 9 sanofi-aventis, Bridgewater,<br />
NJ; 10 Leuven University, Leuven, Belgium<br />
SATURDAY<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 258<br />
Osteoporosis Treatment and Epidemiologic Updates<br />
(Abstracts #2138-2143)<br />
Moderators:<br />
Anthony I. Sebba, MD; Palm Harbor, FL<br />
Piet Geusens; University Hospital; Maastricht, Netherlands<br />
4:30 p m<br />
2138. Teriparatide Stimulates Greater Increases in Bone Turnover<br />
Markers and Bone Mineral Density after Risedronate than after<br />
Alendronate: The OPTAMISE Study. J.P. Bilezikian 1 , M.<br />
Luckey 2 , K. Saag 3 , J. Adachi 4 , S.L. Greenspan 5 , S. Boonen 6 ,<br />
E. Seeman 7 , J. Stewart 8 , F. Cosman 9 , P. Miller 10 . 1 Columbia<br />
University College of Physicians and Surgeons, New York,<br />
NY; 2 St. Barnabas Osteoporosis Center, Livingston, NJ;<br />
3<br />
University of Alabama at Birmingham, Birmingham,<br />
AL; 4 St. Joseph’s Healthcare, Hamilton, ON, Canada;<br />
5<br />
University of Pittsburgh, Pittsburgh, PA; 6 Center for<br />
Metabolic Bone Disease, Leuven, Belgium; 7 Austin Health,<br />
Melbourne, Australia; 8 sanofi-aventis, Laval, PQ, Canada;<br />
9<br />
Helen Hayes Hospital, West Haverstraw, NY; 10 Colorado<br />
Center for Bone Research, Lakewood, CO<br />
4:45 p m<br />
2139. Bone Mineral Density Gains with Monthly Oral<br />
Ibandronate (150mg) and Weekly Oral Alendronate (70mg) After<br />
12 months: Results from the MOTION Study. E. Michael<br />
Lewiecki 1 , Robert R. Recker 2 , Farhad Sedarati 3 , Colin<br />
Neate 4 , Paul D. Miller 5 . 1 New Mexico Clinical Research &<br />
Osteoporosis Center, Albuquerque, NM; 2 Osteoporosis<br />
Research Center, Creighton University, Omaha, NE;<br />
3<br />
Hoffmann-La Roche Inc., Nutley, NJ; 4 Roche Products Ltd,<br />
Welwyn Garden City, United Kingdom; 5 Colorado Center<br />
for Bone Research, Lakewood, CO<br />
5:15 p m<br />
2141. Significant Reduction in Non-Vertebral Fractures With<br />
High- Versus Low-Dose Ibandronate: Results From a Meta-Analysis<br />
of Individual Patient Data. Stuart Silverman 1 , Jonathan D.<br />
Adachi 2 , Paul D. Miller 3 , George Wells 4 , Ann Cranney 5 ,<br />
SCIENCE Meta-analysis Group. 1 Cedars-Sinai/UCLA,<br />
Beverly Hills, CA; 2 McMaster University, Hamilton, ON,<br />
Canada; 3 Colorado Center for Bone Research, Lakewood,<br />
CO; 4 University of Ottawa, Ottawa, ON, Canada; 5 Ottawa<br />
Health Research Institute, Ottawa, ON, Canada<br />
5:30 p m<br />
2142. Bisphosphonate Use at the Time of Humerus Fracture is<br />
Associated with an Increased Risk of Non-Union. Daniel H.<br />
Solomon 1 , Marc C. Hochberg 2 , Helen Mogun 1 , Sebastian<br />
Schneeweiss 1 . 1 Brigham and Women’s Hospital, Boston,<br />
MA; 2 University of Maryland, Baltimore, MD<br />
5:45 p m<br />
2143. Regional Differences in Femoral Neck Cortical Thickness<br />
with Aging: Implications for Hip Fracture Risk. S. Amin, E.<br />
Atkinson, J. Camp, L. J. Melton, R. Robb, B. L. Riggs, S.<br />
Khosla. Mayo Clinic, Rochester, MN<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Room 205<br />
Pathogenesis of Systemic Sclerosis: Key Pathways and<br />
Molecular Targets for Therapy (Abstracts #2144-2149)<br />
Moderators:<br />
Marco Matucci Cerinic, MD, PhD, Professor; University of<br />
Florence; Florence, Italy<br />
Filemon Tan, MD, PhD; University of Texas–Houston;<br />
Houston, TX<br />
226<br />
= Recorded Sessions (order form on page 430)
4:30 p m<br />
2144. Novel Function of PPAR-γ: Endogenous Anti-Fibrotic<br />
that Ameliorates Murine Scleroderma and May be Defective in<br />
Systemic Sclerosis (SSc). Asish K. Ghosh 1 , Minghua Wu 1 ,<br />
Denisa S. Melichian 1 , Jennifer L. Sargent 2 , Ausra Milano 2 ,<br />
M. Kari Connolly 3 , Michael L. Whitfield 2 , John Varga 1 .<br />
1<br />
Northwestern University, Chicago, IL; 2 Dartmouth Medical<br />
School, Hanover, NH; 3 UCSF, San Francisco, CA<br />
5:45 p m<br />
2149. The Angiopoietin / Tie2 System in Systemic Sclerosis<br />
(SSc). Falk Moritz 1 , Lars C. Huber 1 , Jörg HW Distler 1 ,<br />
Astrid Juengel 1 , Beat A. Michel 1 , Margerita Pileckyte 2 ,<br />
Holm Häntzschel 3 , Steffen Gay 1 , Oliver Distler 1 . 1 University<br />
Hospital Zurich, Zurich, Switzerland; 2 University Hospital<br />
Kaunas, Kaunas, Lithuania; 3 University Hospital Leipzig,<br />
Leipzig, Germany<br />
4:45 p m<br />
2145. Clinical and Molecular Evidence for C-Kit Receptor as a<br />
Therapeutic Target in Systemic Sclerosis (SSc). Nicoletta Del<br />
Papa 1 , Nadia Quirici 2 , Laura Corti 2 , Daniela Graziani 3 ,<br />
Ester Fasoli 4 , Wanda Maglione 1 , Denise Comina 1 ,<br />
Cinzia Scavullo 2 , Umberto Gianelli 3 , Silvano Bosari 4 ,<br />
Armando Gabrielli 5 , Giorgio Lambertenghi Deliliers 6 .<br />
1<br />
G. Pini Hospital, Milano, Italy; 2 Fondazione Matarelli,<br />
University of Milan, Milano, Italy; 3 II Cattedra Anatomia<br />
Patologica, S. Paolo Hospital, Milano, Italy; 4 II Cattedra<br />
Anatomia Patologica, University of Milan, Milano, Italy;<br />
5<br />
Dipartimento di Scienze Mediche e Chirurgiche, Sezione<br />
di Clinica Medica, Universita Politecnica delle Marche,<br />
Ancona, Italy; 6 Ematologia I, Ospedale Maggiore Policlinico<br />
IRCCS, University of Milan, Milano, Italy<br />
5:00 p m<br />
2146. Imatinib Alleviates the Pro-Fibrotic Phenotype of<br />
Scleroderma Fibroblasts. Xu Shiwen 1 , Korsa Khan 1 ,<br />
Vin Rajkumar 1 , Yunliang Chen 2 , Michael Eastwood 2 ,<br />
Andrew Leask 3 , Carol Black 1 , Christopher Denton 1 ,<br />
David Abraham 1 . 1 Royal Free and University College<br />
Medical School, London, United Kingdom; 2 School of<br />
Biosciences,University of Westminster, London, United<br />
Kingdom; 3 Division of Oral Biology, University of Western<br />
Ontario, London, ON, Canada<br />
5:15 p m<br />
2147. Src Kinases Play a Major Role for the Production<br />
of Extracellular Matrix by Ssc Fibroblasts in vitro and in<br />
Dermal Fibrosis in vivo. Catherine Skhirtladse 1 , Oliver<br />
Distler 2 , Clara Dees 1 , Alfiya Akhmetshina 1 , Margarita<br />
Pileckyte 3 , Steffen Gay 2 , Georg Schett 1 , Jörg H.W. Distler 1 .<br />
1<br />
Department of Internal Medicine III, Erlangen, Germany;<br />
2<br />
Center of Experimental Rheumatology and Zurich Center<br />
of Integrative Human Physiology, Zurich, Switzerland;<br />
3<br />
Department of Rheumatology, Kaunas Medical University<br />
Hospital, Lithuania<br />
5:30 p m<br />
2148. Epigenetic Regulation in Scleroderma: High-Throughput<br />
Dna Methylation Profiling of Ssc Fibroblasts and Microvascular<br />
Endothelial Cells and the Central Role for Nos3 and Fli1<br />
Epigenetic Repression in the Emergence of Ssc Cellular<br />
Phenotype. Yongqing Wang, Bashar Kahaleh. University of<br />
Toledo, Toledo, OH<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
4:30—6:00 p m<br />
Grand Ballroom East<br />
Therapeutic and Diagnostic Strategies in RA<br />
(Abstracts #2150-2155)<br />
Moderators:<br />
Marc David Cohen, MD; Mayo Clinic Jacksonville;<br />
Jacksonville, FL<br />
Paul P. Tak, MD, PhD; Academic Medical Center/<br />
University of Amsterdam; Amsterdam, The Netherlands<br />
4:30 p m<br />
2150. Anti-CCP-Modified Criteria for the Classification of Early<br />
Rheumatoid Arthritis. Katherine P. Liao, Kerri L. Batra,<br />
Lori Chibnik, Anne H. Fossel, Peter H. Schur, Karen H.<br />
Costenbader. Brigham and Women’s Hospital, Boston, MA<br />
4:45 p m<br />
2151. Objectives Study in RA (OSRA): A RCT Defining the Best<br />
Clinical Target Control in RA. John P. Edmonds 1 , Marissa N.<br />
Lassere 1 , John T. Sharp 2 , Paul Bird 1 , Kerrie Carlton 1 , OSRA<br />
Study Group. 1 St George Hospital, Sydney, Australia;<br />
2<br />
University of Washington, Seattle, WA<br />
5:00 p m<br />
2152. Treatment Aims in Rheumatoid Arthritis: Response versus<br />
State. Daniel Aletaha, Julia Funovits, Josef S. Smolen.<br />
Medical University of Vienna, Vienna, Austria<br />
5:15 p m<br />
2153. Progression of Joint Damage in Different Disease Activity<br />
States of Early Rheumatoid Arthritis. Daniel Aletaha 1 , Julia<br />
Funovits 1 , Ferdinand C. Breedveld 2 , John Sharp 3 , Oscar<br />
Segurado 4 , Josef S. Smolen 1 . 1 Medical University of Vienna,<br />
Vienna, Austria; 2 Leiden University Medical Center,<br />
Leiden, The Netherlands; 3 University of Washington,<br />
Seattle, WA; 4 Abbott Laboratories, Abbott Park, IL<br />
5:30 p m<br />
2154. Frequency of Sustained Remission and Ability to Withdraw<br />
Therapy in an Observational Cohort of ERA Patients Starting<br />
with Initial DMARD Therapy. Vivian Bykerk, Shahin Jamal,<br />
Chistopher Kitamura, Hong Chen, Edward Keystone.<br />
University of Toronto, Toronto, ON, Canada<br />
SATURDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 227
SATURDAY<br />
5:45 p m<br />
2155. Increasing Body Mass Index is Associated with Reduced<br />
Rate of Remission in Early Rheumatoid Arthritis. Marjatta<br />
Leirisalo-Repo 1 , Timo Möttönen 2 , Pekka Hannonen 3 ,<br />
Markku Korpela 4 , Markku Kauppi 5 , Oili Kaipiainen-<br />
Seppänen 6 , Riitta Luosujärvi 1 , Hannu Kautiainen 5 , Reijo<br />
Luukkainen 7 , Toini Uutela 8 , Eeva Moilanen 9 . 1 Helsinki<br />
University Central Hospital, Helsinki, Finland; 2 Turku<br />
University Central Hospital, Turku, Finland; 3 Jyväskylä<br />
Central Hospital, Jyväskylä, Finland; 4 Tampere University<br />
Hospital, Tampere, Finland; 5 Rheumatism Foundation<br />
Hospital, Heinola, Finland; 6 Kuopio University Hospital,<br />
Kuopio, Finland; 7 Pori Central Hospital, Rauma, Finland;<br />
8<br />
Rovaniemi Central Hospital, Rovaniemi, Finland;<br />
9<br />
Tampere University, Tampere, Finland<br />
<strong>ACR</strong> Meet the Professor Sessions<br />
4:30—6:00 p m<br />
Admission to the Meet the Professor Sessions is by ticket only. To verify the<br />
session for which you are registered, refer to the registration codes below in<br />
parentheses. Meet the Professor sessions include beverages only.<br />
Myopathy: Adult Inflammatory Myopathy (169)<br />
Room 162 B<br />
Robert L. Wortmann, MD; University of Oklahoma College<br />
of Medicine; Tulsa, OK<br />
Upon completion of this session, participants should be able to:<br />
∙ Distinguish inflammatory myopathies from other<br />
muscles diseases<br />
∙ Plan a diagnostic work-up for a patient with signs and<br />
symptoms of muscle disease<br />
∙ Design a treatment program for a patient with myositis<br />
Myopathy: Issues in Diagnosis and Treatment (164)<br />
Room 160 A<br />
Chester V. Oddis, MD; University of Pittsburgh; Pittsburgh, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Distinguish inflammatory myopathies from other<br />
muscle diseases<br />
∙ Plan a diagnostic work-up for a patient with signs and<br />
symptoms of muscle disease<br />
∙ Design a treatment program for a patient with myositis<br />
∙ Use cases to reinforce objectives 1-3specific antibodies<br />
Osteoarthritis: Update <strong>2007</strong> (160)<br />
Room 108<br />
David J. Hunter, MBBS, PhD; New England Baptist<br />
Hospital; Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the potential causes and exacerbating factors of<br />
the disease<br />
∙ Discuss the appropriate use of laboratory testing and<br />
imaging modalities<br />
∙ Design an efficacious, safe and cost-effective therapeutic<br />
strategy<br />
Osteoporosis: Novel Treatments (158)<br />
Room 107 B<br />
Chad L. Deal, MD; Cleveland Clinic Foundation;<br />
Cleveland, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Briefly review bone physiology and immunology<br />
emphasizing potential areas amenable to intervention<br />
∙ Briefly discuss current therapies for osteoporosis and their<br />
limitations<br />
∙ Discuss newer treatments available and therapies just over<br />
the horizon for osteoporosis<br />
∙ Use cases where possible to reinforce objective 1-3<br />
Paget’s Disease (166)<br />
Room 160 C<br />
Margaret Seton, MD; Massachusetts General Hospital;<br />
Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the natural history of Paget’s disease<br />
∙ Recognize the indications for treatment<br />
∙ Discuss effective treatment of Paget’s disease<br />
Pain - Depression Interface in the Rheumatic Diseases<br />
(159)PM<br />
Room 107 C<br />
Don L. Goldenberg, MD; Newton-Wellesley Hospital;<br />
Newton, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the spectrum of chronic pain in the rheumatic<br />
diseases<br />
∙ Recognize the associations between pain and depression<br />
∙ Develop treatment strategies that may be effective in<br />
managing this interface<br />
228<br />
= Recorded Sessions (order form on page 430)
Pediatric Systemic Lupus (162)(Trainees Only) F P<br />
Room 109 B<br />
Deborah M. Levy, MD, MS; Columbia University Medical<br />
Center; New York, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss differences in presentation, disease course and<br />
treatment options between childhood-onset and adultonset<br />
Lupus<br />
∙ List recent and ongoing research efforts in childhood-onset<br />
Lupus<br />
∙ Describe important developmental issues in the care of<br />
children and adolescents with a chronic disease<br />
Pediatrics: Dermatomyositis (165) P<br />
Room 160 B<br />
Ann M. Reed, MD; Mayo Clinic; Rochester, MN<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss recent research developments regarding juvenile<br />
dermatomyositis<br />
∙ Describe the clinical assessment and management of<br />
juvenile dermatomyositis<br />
Pediatric Rheumatology for Adult Rheumatologists (167)<br />
(Trainees Only) F P<br />
Room 161<br />
Emily Von Scheven, MD; University of California–San<br />
Francisco; San Francisco, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Diagnose the various forms of arthritis that are unique to<br />
children<br />
∙ Recognize how the evaluation of children with rheumatic<br />
diseases may be different from that of adults<br />
∙ Describe current treatments of arthritis in children<br />
Pediatrics: Spondyloarthritis in Children (157) P<br />
Room 107 A<br />
Robert A. Colbert, MD, PhD; Cincinnati Childrens<br />
Hospital Medical; Cincinnati, OH<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe differences between spondyloarthritis in children<br />
and adults<br />
∙ Discuss the approach to diagnosis and treatment of<br />
children with spondyloarthritis<br />
Pediatrics: What to Do With Children With Joint Pain<br />
and Normal PE (163) p pm<br />
Room 159<br />
Michael L. Miller, MD; Childrens Memorial Hospital;<br />
Chicago, IL<br />
Upon completion of this session, participants should be able to:<br />
∙ Learn the differential diagnosis of arthralgia in the absence<br />
of arthritis, including infections, neurologic disorders, and<br />
malignancies<br />
∙ Understand the potential for psychosocial problems to<br />
manifest as arthralgia, and how to evaluate a child<br />
∙ Become acquainted with strategies for monitoring children<br />
with persisting symptoms but normal examinations, to<br />
avoid both misdiagnoses and<br />
missing diagnoses<br />
Raynaud’s and Digital Ischemia (168)<br />
Room 162 A<br />
Fredrick M. Wigley, MD; Johns Hopkins University;<br />
Baltimore, MD<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss the pathogenesis of RP and digital ischemia<br />
∙ Describe the appropriate diagnostic evaluation for this condition<br />
∙ Review treatment options and means of evaluating treatment<br />
Rheumatology Practice 101: Starting Out in Practice for<br />
the Graduating Fellow (156)(Trainees Only) F<br />
Room 106<br />
Herbert S.B. Baraf, MD; Arthritis and Rheumatism<br />
Associates, PC; Wheaton, MD<br />
Upon completion of this session, participants should be able to:<br />
∙ Assess contracts with managed care companies and<br />
negotiating opportunities<br />
∙ Evaluate how to buy in to an existing practice, hire a new<br />
associate, or meet the needs of a retiring partner<br />
∙ Discuss the pros and cons of adding ancillary services<br />
(e.g. infusion center, densitometry service etc), an office<br />
manager or practice administrator<br />
Spondylarthropathy: An Update (161)<br />
Room 109 A<br />
Robert D. Inman, MD; Toronto Western Hospital;<br />
Toronto, Ontario<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the challenge in the early diagnosis of SpA<br />
∙ Discuss mechanisms of disease pathogenesis<br />
∙ Decribe current treatment options for SpA<br />
SATURDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 229
<strong>ACR</strong>/<strong>ARHP</strong> Combined Clinical Symposium C<br />
4:30—6:00 p m<br />
Room 210<br />
Management of Psychiatric Illness in Children and<br />
Adolescents with Rheumatic Disease<br />
Moderators:<br />
Pamela J. Degotardi, PhD; Queens College; Flushing, NY<br />
Laura E. Schanberg, MD; Duke University Medical Center;<br />
Durham, NC<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the signs and symptoms of depression and<br />
other psychiatric co-morbidities common in childhood<br />
rheumatic diseases<br />
∙ List appropriate pharmacologic and cognitive therapy for<br />
childhood psychiatric illness<br />
∙ Discuss the controversy surrounding the pharmacologic<br />
treatment of psychiatric disease in childhood, particularly<br />
SSRIs and related medications<br />
4:30 p m<br />
Diagnosing Common Psychiatric Disorders in Children with<br />
Rheumatic Disease<br />
Jeff Bostic, MD, EdD; Massachusetts General Hospital;<br />
Boston, MA<br />
P<br />
5:10 p m<br />
Drug Management of Childhood Psychiatric Illness: What<br />
Rheumatology Caregivers Need to Know<br />
Eva Szigethy, MD; Childrens Hospital of Pittsburgh;<br />
Pittsburgh, PA<br />
5:50 p m<br />
Panel Discussion<br />
<strong>ARHP</strong> Concurrent Session C<br />
4:30—6:00 p m<br />
Room 259<br />
This lecture will be complemented with a 2-hour, hands-on<br />
laboratory session on Sunday, November 11 at 9:15 am. The<br />
lecture is not a pre-requisite to the laboratory session. Laboratory<br />
attendance is limited to 25 participants who are asked to bring<br />
their own splint scissors.<br />
Dynamic Stability for the Painful Thumb: It’s Not<br />
Just a Splint<br />
Moderator:<br />
Carole V. Dodge, OT; University of Michigan Medical<br />
Center; Ann Arbor, MI<br />
SATURDAY<br />
230<br />
= Recorded Sessions (order form on page 430)
Speakers:<br />
Jan Albrecht, OTR/L, CHT; University Orthopaedics Hand<br />
Center; North Mankato, MN<br />
Virginia O Brien, OTR/L, CHT; University of Minnesota<br />
Medical Center; Minneapolis, MN<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe normal and faulty thumb biomechanics and the<br />
elements of a full evaluation of thumb instability, pain and<br />
dysfunction<br />
∙ Identify a treatment program to restore dynamic stability<br />
that includes techniques of myofascial release, joint<br />
mobilization, muscle re-education and specific muscle<br />
strengthening to decrease pain and increase function<br />
∙ Describe specific custom splints, adaptive techniques<br />
and equipment to improve mechanical advantage with<br />
emphasis on helping patients recognize unstable postures<br />
and modify them during functional tasks<br />
<strong>ARHP</strong> Concurrent Session C<br />
4:30—6:00 p m<br />
Room 257<br />
Our Best Foot Forward: Practical Perspectives from the<br />
Front Line of Population-Based Foot Research<br />
Moderator:<br />
Lisa M. Kastanek, RN, CCRC; Arthritis Center of<br />
Nebraska; Lincoln, NE<br />
Speakers:<br />
K. Douglas Gross, PT, ScD; Boston University; Boston, MA<br />
Marian T. Hannan, MPH, DSc; Harvard Medical School;<br />
Boston, MA<br />
Carol A. Oatis, PT, PhD; Arcadia University; Glenside, PA<br />
Yuqing Zhang, DSc; Boston University; Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe current knowledge of the role of the foot in<br />
common conditions of lower extremity<br />
∙ State three key issues related to successful data collection<br />
of foot disorders from the Kinesiologist’s perspective<br />
∙ State the key issues of studying related data from the<br />
Biostatistician’s perspective<br />
∙ State key issues regarding practice data collection process<br />
from the Field Epidemiologist’s perspective<br />
∙ Contribute to the discussions on how to improve abilities<br />
to examine and collect timely collection of valid related<br />
foot data in population studies based on small group<br />
interaction with speakers<br />
<strong>ARHP</strong> Concurrent Session<br />
4:30—6:00 p m<br />
Room 260<br />
Research Mentor/Trainee Responsibilities: Making the<br />
Most of Mentorship<br />
Moderator:<br />
John E. Hewett, PhD; University of Missouri; Columbia, MO<br />
Speakers:<br />
Catherine L. Backman, PhD, OT(C); University of British<br />
Columbia; Vancouver, British Columbia<br />
Basia Belza, PhD, RN; University of Washington; Seattle, WA<br />
Jennifer M. Hootman, PhD; Centers for Disease Control;<br />
Atlanta, GA<br />
Nadine T. James, RN, MSN, PhD; University of Southern<br />
Mississippi; Hattiesburg, MS<br />
Marian A. Minor, PhD, PT; University of Missouri;<br />
Columbia, MO<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the roles of the mentor<br />
∙ Discuss mentor responsibilities<br />
∙ Discuss trainee responsibilities<br />
∙ Discuss overlapping roles of mentor/employer/teacher/<br />
advisor and trainee/employee/student/advisee<br />
∙ Discuss practical problems that can arise in mentoring<br />
∙ Incorporate principles of responsible conduct of research<br />
as a mentor or trainee<br />
Industry Roundtable-Supported Symposia<br />
6:30—9:30 p m<br />
Various Locations<br />
The REF would like to thank the supporting industry leaders<br />
that have made a significant multi-year commitment to the<br />
REF for participation in the Industry Roundtable. In<br />
appreciation for their commitment, these industry leaders have<br />
been invited to host a symposium. Please visit the organization’s<br />
exhibit booth or the industry-supported symposia booth<br />
for more information. The sponsoring organization is<br />
responsible for planning and providing CME credit for their<br />
respective symposium.<br />
Refer to page 280–282 for complete program information.<br />
SATURDAY<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 231
Poster Session c<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Antiphospholipid Syndrome I<br />
(1)-1387. Risk Factors for the First Thrombotic Event in<br />
Antiphospholipid Antibody Carriers: A Multicenter Retrospective<br />
Follow-up Study. Pier Luigi Meroni for the APS group-Italian<br />
Rheumatol Society. University of Milan, Milan, Italy.<br />
(2)-1388. Persistently Positive Antiphospholipid Antibodies are<br />
Related with the Appearance of Thrombosis During Follow-Up<br />
of Patients with Antiphospholipid Syndrome. Gerard Espinosa,<br />
Silvia Bucciarelli, Dolors Tassies, Albert Bove, Joan Plaza,<br />
Joan Carles Reverter, Ricard Cervera. Hospital Clinic,<br />
Barcelona, Spain.<br />
(3)-1389. Prothrombotic Genetic Factors are Not Associated with<br />
Thrombosis in Patients with Antiphospholipid Syndrome. Gerard<br />
Espinosa, Gisela Claver, Dolors Tassies, Joan Plaza, Albert<br />
Bove, Joan Carles Reverter, Ricard Cervera. Hospital Clinic,<br />
Barcelona, Spain.<br />
(4)-1390. Endogenous Thrombin Potential (ETP) in the<br />
Assessment of Hypercoagulability in SLE. Bijal M. Mehta 1 ,<br />
Adnan Kiani 2 , Catherine Chen 2 , Thomas S. Kickler 2 ,<br />
Michelle Petri 2 . 1 Good Samaritan Hospital, Baltimore, MD;<br />
2<br />
Johns Hopkins University, Baltimore, MD.<br />
(5)-1391. Impact of Hypertension and Hyperhomocysteinemia<br />
on Arterial Thrombosis in Primary Antiphoaspholipid Syndrome.<br />
Emilia I. Sato 1 , Alexandre WS Souza 1 , Jozelio F. Carvalho 2 ,<br />
Neusa P. Silva 1 , Vania D’Álmeida 1 , Maria A E Noguti 1 .<br />
1<br />
Universidade Federal de Sao Paulo, Sao Paulo - Capital, Brazil;<br />
2<br />
Universidade de Sao Paulo, Sao Paulo - Capital, Brazil.<br />
(6)-1392. Bone Mineral Density Decreases in the Presence of<br />
Anticardiolipin Antibodies. Lisa Christopher-Stine 1 , Adnan<br />
Kiani 1 , Laurence Magder 2 , Barbara Weiss 1 , Michelle Petri 1 .<br />
1<br />
Johns Hopkins University, Baltimore, MD; 2 University of<br />
Maryland, Baltimore, MD.<br />
(7)-1393. Leg ulcers in the Antiphospholipid Syndrome as<br />
a Form of Pyoderma Gangrenosum and Their Respond to<br />
Immunosuppressive Therapy and Anticoagulation. Carlos A.<br />
Canas, Gabriel J. Tobón, Carlos E. Durán. Fundación Valle<br />
del Lili, Cali, Colombia.<br />
(8)-1394. Coronary Artery Disease Associated with<br />
Antiphospholipid Syndrome. Report of 25 Cases. Laurent<br />
Perard 1 , Arnaud Hot 1 , Pascal seve 1 , Marie Simon 1 ,<br />
Christiane Broussole 1 , Jacques Ninet 1 , Jean Charles Piette 2 .<br />
1<br />
Hopital Edouard Herriot, Lyon, France; 2 Hopital Pitié<br />
Salpétrière, Paris, France.<br />
(9)-1395. Cardiac Valve Replacement in APS Patients.<br />
Jose G. Erdozain, Jr. 1 , Maria Victoria Egurbide 1 , Mary<br />
Carmen Amigo 2 , Maria Isabel Segura 2 , Gerard Espinosa 3 ,<br />
Jose Luis Pomar 4 , Ignacio Perez-Valero 5 , Munther A.<br />
Khamashta 5 . 1 Hospital de Cruces, Barakaldo (Vizcaya),<br />
Spain; 2 Departamento de Reumatología, Instituto Nacional<br />
de Cardiología I. Chávez, Mexico DF, Mexico; 3 Unidad<br />
de Enfermedades Autoinmunes and Cardiovascular<br />
Department, Hospital Clinic, Barcelona, Spain; 4 Unidad<br />
de Enfermedades Autoinmunes and Cardiovascular<br />
department, Hospital Clinic, Barcelona, Spain; 5 Lupus<br />
Research Unit, The Rayne Institute, King’s College London<br />
School of Medicine, London, United Kingdom.<br />
(10)-1396. A Longitudinal Study of Antiphospholipid Antibodies<br />
in Women at Risk of Preeclampsia. Maria Laura Bertolaccini 1 ,<br />
Veronica Murru 1 , Claire Cuckson 2 , Rishi Caleyachetty 1 ,<br />
Paul Seed 2 , Lucilla Poston 2 , Munther A. Khamashta 1 .<br />
1<br />
Lupus Research Unit, The Rayne Institute, King’s<br />
College London School of Medicine, London, United<br />
Kingdom; 2 Maternal and Fetal Research Unit, Department<br />
of Women’s Health, King’s College London School of<br />
Medicine, London, United Kingdom.<br />
(11)-1397. Relapsing Catastrophic Antiphospholipid Syndrome:<br />
Potential Role of Microangiopathic Hemolytic Anemia in Disease<br />
Relapses. Silvia Bucciarelli 1 , Gerard Espinosa 1 , Ricard<br />
Cervera 1 , Albert Bové 1 , Ronald Asherson 2 , Catastrophic<br />
Antiphospholipid Syndrome (CAPS) Registry Project<br />
Group. 1 Hospital Clinic, Barcelona, Spain; 2 University of<br />
the Witwatersrand, Johannesbrug, South Africa.<br />
(12)-1398. Practice Questions/Answers about Antiphospholipid<br />
Syndrome Pregnancies. Doruk Erkan 1 , Angela Tincani 2 , Pier<br />
Luigi Meroni 3 , Michael D. Lockshin 1 . 1 Hospital for Special<br />
Surgery, New York, NY; 2 University of Brescia, Brescia,<br />
Italy; 3 University of Milan, Milan, Italy.<br />
(13)-1399. Innate Immunity and Antiphospholipid Syndrome:<br />
Prevalence and Clinical Significance of Polymorphisms of Mannose-<br />
Binding Lectin (mbl) and Toll-Like Receptors (tlr) 2 and 4. Pilar<br />
Brito-Zerón 1 , Rafael Belenguer 2 , Dolors Tassies 3 , Natalia<br />
Soria 1 , Sandra Muñoz 1 , Albert Bové 1 , Francisco Lozano 4 ,<br />
Joan Carles Reverter 3 , Manuel Ramos-Casals 1 . 1 Laboratory<br />
of Basic Research in Autoimmune Diseases, IDIBAPS,<br />
Hospital Clinic, Barcelona, Spain; 2 Rheumatology Unit,<br />
Hospital 9 d’Octubre, Valencia, Spain; 3 Department of<br />
Hemotherapy and Hemostasis, Hospital Clínic, Barcelona,<br />
Spain; 4 Department of Immunology, Hospital Clinic,<br />
Barcelona, Spain.<br />
232 (Permanent Board Number)-Abstract Number
(14)-1400. Tyrosine Kinase 2 and Interferon Regulatory<br />
Factor 5 Gene Polymorphisms in Patients with Systemic Lupus<br />
Erythematosus and Antiphospholipid Syndrome. Hisako<br />
Nakagawa, Tetsuya Horita, Hiroshi Kataoka, Shinsuke<br />
Yasuda, Tatsuya Atsumi, Takao Koike. Hokkaido<br />
University, Sapporo, Japan.<br />
(15)-1401. Aminophospholipid Translocase (ATP10A)<br />
Polymorphisms and the Risk of Thrombosis in Patients with<br />
Antiphospholipid Antibodies. Olga Amengual, Tatsuya Atsumi,<br />
Tetsuya Horita, Hiroshi Kataoka, Shinsuke Yasuda, Takao<br />
Koike. Medicine II, Hokkaido University Graduate School<br />
of Medicine, Sapporo, Japan.<br />
(16)-1402. Factor XIII Val34Leu Polymorphism is Associated<br />
to the Risk of Thrombosis in Patients with Antiphospholipid<br />
Antibodies and High Fibrinogen Levels. Gerard Espinosa,<br />
Dolors Tassies, Gloria de la Red, Joan Plaza, Joan Carles<br />
Reverter, Ricard Cervera. Hospital Clinic, Barcelona, Spain.<br />
(17)-1403. Platelet Glycoprotein Ib-alpha, IIa/IIIa and IIb/IIIa<br />
Polymorphisms and Vascular Arterial Disease in Patients with the<br />
Antiphospholipid Syndrome or with Systemic Lupus Erythematosus.<br />
Sonia Jimenez, Dolors Tassies, Gerard Espinosa, Joan<br />
Plaza, Angeles Gracia-Criado, Ricard Cervera, Joan Carles<br />
Reverter. Hospital Clinic, Barcelona, Spain.<br />
(18)-1404. Pro-inflammatory Genotype as a Risk Factor for Aps<br />
Clinical Manifestations: A Case Report. Valentina De Angelis 1 ,<br />
Martina Biggioggero 1 , Elena Raschi 2 , Silvia Scurati 3 , Orietta<br />
Borghi 1 , Rolando Cimaz 4 , PierLuigi Meroni 1 . 1 University<br />
of Milan, Milan, Italy; 2 University of Milan- Istituto<br />
Auxologico Italiano, Milan, Italy; 3 University of Milan -<br />
Istituto Auxologico Italiano, Milan, Italy; 4 University of<br />
Lione, Lione, France.<br />
(19)-1405. Evidence for Interaction of B2-Glycoprotein I (β2GPI)<br />
with CD40 Ligand (CD40L): Their Role in the Pathogenesis of<br />
Antiphospholipid Syndrome (APS). Marina P. Sikara, Panayiotis<br />
G. Vlachoyiannopoulos. School of Medicine, University of<br />
Athens, Athens, Greece.<br />
(20)-1406. The P38 Mitogen-Activate Protein Kinase (mapk)<br />
Pathway Mediates the Induction of Tissue Factor Expression by<br />
a Phosphatidylserine-Dependent Monoclonal Antiprothrombin<br />
Antibody with Lupus Anticoagulant Activity. Kenji Oku,<br />
Tatsuya Atsumi, Olga Amengual, Hiroshi Kataoka,<br />
Tetsuya Horita, Shinsuke Yasuda, Takao Koike. Hokkaido<br />
University Graduate School of Medicine, Sapporo, Japan.<br />
(21)-1407. β2-Glycoprotein I Bound to Anionic Substance is<br />
a Preferential Target Recognized by Both Autoantibodies and<br />
Autoreactive T Cells in Patients with Antiphospholipid Syndrome.<br />
Masataka Kuwana 1 , Yuka Okazaki 1 , Kazuko Kobayashi 2 , Eiji<br />
Matsuura 2 . 1 Keio University School of Medicine, Tokyo,<br />
Japan; 2 Okayama University Graduate School of Medicine<br />
and Dentistry, Okayama, Japan.<br />
(22)-1408. Sequence Motifs in Human Monoclonal<br />
Antiphospholipid Antibodies Determine Their Ability to Bind but<br />
do not Effect the Function of Antigens Relevant to the Pathogenesis<br />
of Atherosclerosis in the Antiphospholipid Syndrome. I. Giles 1 ,<br />
A. Lambrianides 1 , S. O`Neill 1 , P. Chen 2 , D. Latchman 1 ,<br />
D. Isenberg 1 , A. Rahman 1 . 1 University College London,<br />
London, United Kingdom; 2 University College of Los<br />
Angeles, Los Angeles, CA.<br />
(23)-1409. INF alpha Accelerates Nephritis, But Not<br />
Antiphospholipid Syndrome In NZW/BXSB F1 Females.<br />
Philip J. Kahn 1 , Meera Ramanujam 2 , Haiou Tao 2 , Anne<br />
Davidson 2 . 1 Morgan Stanley Children’s Hospital of New<br />
York-Columbia Presbyterian, New York, NY; 2 Feinstein<br />
Institute of Medical Research-North Shore Medical Center,<br />
New York, NY.<br />
(24)-1410. Pathogenic Effects of A Dimer of β2glycoprotein<br />
I. Zurina Romay-Penabad 1 , R. T. Urbanus 2 , Guadalupe<br />
Montiel-Manzano 3 , M. T. Pennings 2 , Philip DeGroot 2 ,<br />
Silvia S. Pierangeli 1 . 1 Professor, Galveston, TX; 2 Utrecht<br />
University, Utrecht, The Netherlands; 3 University of Texas<br />
Medical Branch, Galveston, TX.<br />
(25)-1411. Decreased Paraoxonase Activity is Associated<br />
with Preclinical Atherosclerotic Vascular Changes in Primary<br />
Antiphospholipid Syndrome:. Marietta Charakida 1 , Joanna<br />
Batuca 2 , Shirish R. Sangle 3 , Jose Delgado Alves 2 , Julian P.<br />
Holcox 1 , Ann E. Donald 1 , Charles Mackworth-Young 4 ,<br />
Nigel J. Klein 1 , Graham RV Hughes 3 , David P. D’Cruz 3 ,<br />
John E. Deanfield 1 . 1 Great Ormond Street Hospital,<br />
London, United Kingdom; 2 Faculty of Medical Sciences,<br />
New University of Lisbon, Lisboa, Portugal; 3 Lupus<br />
Research Unit, The Rayne Institute, King’s College School<br />
of Medicine, St Thomas’ Hospital, London, United<br />
Kingdom; 4 Charing Cross Hospital, London, United<br />
Kingdom.<br />
(26)-1412. Effects of an Inhibitor of Nuclear Factor-Kappa<br />
B (NF-κB) on Thrombogenic Properties of Antiphospholipid<br />
Antibodies in vivo.. Guadalupe Montiel-Manzano 1 , Zurina<br />
Romay-Penabad 1 , Silvia S. Pierangeli 2 . 1 University of Texas<br />
Medical Branch, Galveston, TX; 2 Professor, Galveston, TX.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 233
Poster Session c<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
B-Cell Biology and Targets in Autoimmune Disease<br />
(27)-1413. Plasticity and Stability of Plasma Cell Memory and its<br />
Impact on Autoimmunity. Taketoshi Yoshida 1 , Henrik Mei 1 ,<br />
Andreas Gruetzkau 1 , Bimba F. Hoyer 2 , Thomas Häupl 2 ,<br />
Joachim Gruen 1 , Rudolf Manz 1 , Thomas Dörner 2 , Andreas<br />
Radbruch 1 , Falk Hiepe 2 . 1 German Arthritis Research<br />
Center, Berlin, Germany; 2 Charité - Universitaetsmedizin<br />
Berlin, Berlin, Germany.<br />
(28)-1414. Usage of Gene Expression Profiling Analysis to<br />
Investigate the Regulation of Autoreactive B Cells in Humans.<br />
Chungwen Wei, Inaki Sanz. University of Rochester,<br />
Rochester, NY.<br />
(29)-1415. C-reactive Protein Serum Amyloid P Component Bind<br />
to HnRNPA/B Proteins and other Autoantigens. Identification<br />
of a Short Polypeptide Binding Region. Karl Skriner 1 , Zoltan<br />
Konthur 2 , Gerd-Rüdiger Burmester 1 . 1 Charite, Berlin,<br />
Germany; 2 Max-Planck-Institut für Molekulare Genetik,<br />
Berlin, Germany.<br />
(30)-1416. Transglutaminated and Citrullinated Proteins<br />
are Targeted By Rheumatoid Arthritis Patient Sera. Karl<br />
Skriner 1 , Zoltan Konthur 2 , Thomas Häupl 1 , Gerd Rüdiger<br />
Burmester 1 . 1 Charite, Berlin, Germany; 2 Max-Planck-Institut<br />
für Molekulare Genetik, Berlin, Germany.<br />
(31)-1417. Generation of a Humanized Anti-CD19 Antibody<br />
with Superior Effector Function by Combining Fab and<br />
Fc Modifications. Ronald Herbst, Yue Wang, Nanette<br />
Mittereder, Christopher J. Groves, Gary P. Sims, Ellen<br />
Kuta, Daniel Rowe, Elizabeth Ward, Gianluca Carlesso,<br />
Michael Bowen, Robert M. Woods, Li Cheng, Kimberly<br />
Cook, Linda Xu, Thomas Tedder, Melissa Damschroeder,<br />
William Dall’Acqua, Peter Kiener, Herren Wu, Anthony J.<br />
Coyle. MedImmune, Inc., Gaithersburg, MD.<br />
(32)-1418. Using Flow Cytometric Analysis of Protein<br />
Phosphorylation to Study B Cell Receptor Signaling in Tolerized<br />
Human B Cells. Scott A. Jenks, Iñaki Sanz. University of<br />
Rochester, Rochester, NY.<br />
(33)-1419. The Cellular RNA Interference GW2-Ago2 Complex<br />
is an Autoimmune Target Associated with Cytokine Signaling<br />
Regulated by MiRNAs in Innate Immune Cells. Keigo Ikeda 1 ,<br />
Kaleb M. Pauley 1 , Marvin J. Fritzler 2 , Westley H. Reeves 3 ,<br />
Minoru Satoh 3 , Edward K.L. Chan 1 . 1 Department of Oral<br />
Biology, University of Florida, Gainesville, FL; 2 Faculty<br />
of Medicine, University of Calgary, Calgary, AB, Canada;<br />
3<br />
Division of Rheumatology and Clinical Immunology,<br />
Department of Medicine, and Department of Pathology,<br />
Immunology, and Laboratory Medicine, University of<br />
Florida, Gainesville, FL.<br />
(34)-1420. Identification of Anergic Human Naive B Cells<br />
Characterized by Low Surface IgM Expression. Tam D. Quach,<br />
Inaki Sanz. University of Rochester Medical Center,<br />
Rochester, NY.<br />
(35)-1421. Mechanisms of Prolactin-mediated Impairment of B<br />
Cell Tolerance Induction. Subhrajit Saha, Juana Gonzalez,<br />
Gabriel Rosenfeld, Elena Peeva. Albert Einstein College of<br />
Medicine, Bronx, NY.<br />
(36)-1422. Changes in B Cells and B Cell Subsets Induced by<br />
BAFF Neutralization in Vivo. Shelley S. Belouski, H. Erik<br />
Rasmussen, John K. Thomas, John Ferbas, Debra Jeske<br />
Zack. Amgen, Thousand Oaks, CA.<br />
(37)-1423. Mice Overexpressing BAFF Develop IgA-Associated<br />
Nephritis. Ann M. Ranger 1 , Cheryl Wilson 1 , Julie Kujawa 1 ,<br />
Irene Sizing 1 , Jennifer L. Gommerman 2 , Bruce A. Julian 3 ,<br />
Lea Novak 3 , Jan Novak 3 , Jeffrey L. Browning 1 . 1 Biogen Idec,<br />
Cambridge, MA; 2 University of Toronto, Toronto, ON,<br />
Canada; 3 University of Alabama, Birmingham, AL.<br />
(38)-1424. Immunologic Effects of BAFF Antagonism in the<br />
Treatment of Human SLE. Ramin Sabahi, Teresa Owen,<br />
Jennifer Barnard, Emily Cushing, R John Looney, Inaki<br />
Sanz, Jennifer Anolik. University of Rochester, Rochester, NY.<br />
(39)-1425. Development of nRNP Humoral Autoimmunity in<br />
Systemic Lupus Erythematosus. Brian D. Poole, Rebecca I.<br />
Schneider, Joel M. Guthridge, Cathy Velte, Morris Reichlin,<br />
John B. Harley, Judith A. James. Oklahoma Medical<br />
Research Foundation, Oklahoma City, OK.<br />
(40)-1426. Fli-1 in B Cell Proliferation and Systemic Lupus<br />
Erythematosus. Sarah G. Bradshaw, Xian K. Zhang,<br />
Dennis K. Watson, Ivan Molano, Gary Gilkeson. Medical<br />
University of South Carolina, Charleston, SC.<br />
(41)-1427. Cellular Origin of Autoreactive Antibodies in<br />
Systemic Lupus Erythematosus. Jennifer L. Huggins, Laura<br />
Miguel, Nataly Manjarrez-Orduno, Iñaki Sanz. University of<br />
Rochester, Rochester, NY.<br />
(42)-1428. The Autoimmune Response in Early Rheumatoid<br />
Arthritis is Directed Against Citrullinated Enzymes of the<br />
Glycolytic Pathway and Molecular Chaperonins. Vincent<br />
GOEB 1 , Marlene Thomas-L’Otellier 2 , Romain Daveau 2 ,<br />
Roland Charlionet 2 , Patrice Fardellone 3 , Francois Tron 2 ,<br />
Xavier Le Loët 1 , Daniele Gilbert 2 , Olivier Vittecoq 1 .<br />
1<br />
Rheumatology Department and Inserm U519, Rouen<br />
University Hospital, Rouen, France; 2 Immunology<br />
Department and Inserm U519, Rouen University Hospital,<br />
Rouen, France; 3 Rheumatology Department Amiens<br />
University Hospital, Amiens, France.<br />
234 (Permanent Board Number)-Abstract Number
(43)-1429. Auto-Antibodies against Serpin E2 Might<br />
Contribute to Joint Destruction in Rheumatoid Arthritis. Hanna<br />
Maciejewska, Mariam Al-Shamisi, Renate E. Gay, Beat<br />
Michel, Alexander Knuth, Michel Neidhart, Steffen Gay,<br />
Astrid Juengel. University Hospital, Zurich, Switzerland.<br />
(44)-1430. Higher Sensitivity and Extended Prognostic Values<br />
Concerning Future Radiological Progression of Antibodies Against<br />
Citrullinated Vimentin Compared to Antibodies Against Ccp<br />
in Rheumatoid Arthritis. Linda Mathsson 1 , Mohammed<br />
Mullazehi 1 , Marius C. Wick 2 , Olof SjÃberg 1 , Ronald van<br />
Vollenhoven 3 , Lars Klareskog 3 , Johan Rönnelid 1 . 1 Clinical<br />
Immunology, Uppsala University, Uppsala, Sweden;<br />
2<br />
Department of Radiology, Innsbruck Medical University,<br />
Innsbruck, Austria; 3 Unit of Rheumatology, Karolinska<br />
Institute, Stockholm, Sweden.<br />
(45)-1431. B-Cell Subsets as Predictors of Response in Patients<br />
with RA Treated with Rituximab. Petra Roll 1 , Christian<br />
Kneitz 1 , Thomas Dorner 2 , Hans-Peter Tony 1 . 1 University of<br />
Wuerzburg, Medizinische Klinik II, Wuerzburg, Germany;<br />
2<br />
University of Berlin, Charite, Berlin, Germany.<br />
(46)-1432. The Safety, Pharmacokinetics (PK) and<br />
Pharmacodynamic (PD) Effects of Repeated Doses of BR3-Fc<br />
in Patients with Rheumatoid Arthritis (RA). M. Shaw 1 , J.<br />
Del Giudice 2 , R. Trapp 3 , M. Burnette 4 , E. Beckman 5 , B.<br />
Anand 6 , M. Cheu 6 , M. Yin 6 , L. McLean 6 . 1 Altoona Center<br />
for Clinical Research, Duncansville, PA; 2 Arthritis &<br />
Osteoporosis Associates, LLP, Lubbock, TX; 3 The Arthritis<br />
Center, Springfield, IL; 4 Tampa Medical Group, PA, Tampa,<br />
FL; 5 Biogen Idec, Cambridge, MA; 6 Genentech, SF, CA.<br />
(47)-1433. Biomarker Discovery in Rheumatoid Arthritis through<br />
Autoantibody Profiling. Klaartje Somers, Piet Geusens, Piet<br />
Stinissen, Veerle Somers. Hasselt University, Biomedical<br />
Research Institute, Diepenbeek, Belgium.<br />
(48)-1434. Caspase Cleaved Fragments of Vimentin are<br />
Citrullinated in Synovial Tissue of Inflammatory Arthritides<br />
and Show Autoantibody Reactivity in Rheumatoid Arthritis. Kelly<br />
Tilleman 1 , Dirk Elewaut 2 , Tineke Cantaert 2 , Katleen Van<br />
Steendam 1 , Filip De Keyser 2 , Dieter Deforce 1 . 1 Gent University,<br />
Gent, Belgium; 2 Gent University Hospital, Gent, Belgium.<br />
(49)-1435. Structure/Function Mapping of SSA/Ro Apoptopes:<br />
Towards Understanding the Pathogenecity of Maternal Antibodies<br />
in CHB. Carolina Llanos 1 , Judith James 2 , Jill Buyon 1 , Robert<br />
Clancy 1 . 1 New York University, New York, NY; 2 Oklahoma<br />
Medical Research Foundation, Oklahoma City, OK.<br />
(50)-1436. Dominance of Type II Collagen Autoantibodies in<br />
Synovial Fluid of RA Patients. Omri Snir 1 , Mona Widhe 1 ,<br />
Caroline von Spee 1 , Rikard Holmdahl 2 , Lars Klareskog 1 ,<br />
Vivianne Malmström 1 . 1 Karolinska Institutet, Stockholm,<br />
Sweden; 2 Medical Inflammation Research, Lund University,<br />
Lund, Sweden.<br />
(51)-1437. Autoantibody Profiles Toward Specific Citrullinated<br />
Antigens in Serum and Synovial Fluid of RA Patients. Omri<br />
Snir 1 , Mona Widhe 1 , Caroline von Spee 1 , Karin Lundberg 2 ,<br />
Patrick Venables 2 , Rikard Holmdahl 3 , Lars Klareskog 4 ,<br />
Vivianne Malmström 4 . 1 Rheumatology Research, Dep<br />
Medicine, Karolinska Institutet, Stockholm, Sweden;<br />
2<br />
Kennedy Institute of Rheumatology, Imperial College,<br />
London, United Kingdom; 3 Medical Inflammation<br />
Research, Lund University, Lund, Sweden; 4 Karolinska<br />
Institutet, Stockholm, Sweden.<br />
(52)-1438. Circulating CD22+CD20-CD19+ Cells at Baseline<br />
May Predict the Clinical Response to Rituximab in Patients with<br />
Active RA. Kasia M. Owczarczyk 1 , Gunter Valet 2 , Doro<br />
Passon 1 , Tobias Roehrs 1 , Norma Jung 1 , Dirk Taubert 1 ,<br />
Andrea Rubbert 1 . 1 University Hospital Cologne, Cologne,<br />
Germany; 2 Max-Planck Institute of Biochemistry, Munich-<br />
Martinsried, Germany.<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Biology and Pathology of Bone and Joint<br />
(53)-1439. Systemic Blockade of Pro-Inflammatory Cytokines<br />
Reverses the Suppression of Chondrocyte Anabolism in Rheumatoid<br />
Arthritis. Bernard Vandooren 1 , Tineke Cantaert 2 , Marie-Jose Van<br />
Lierop 3 , Ebo Bos 3 , Leen De Rycke 2 , Eric Veys 1 , Filip De Keyser 1 ,<br />
Barry Bresnihan 4 , Frank P. Luyten 5 , Annemieke H. Boots 3 , Paul<br />
P. Tak 2 , Dominique Baeten 2 . 1 Rheumatology Department,<br />
Ghent University Hospital, Ghent, Belgium; 2 Division<br />
of Clinical Immunology and Rheumatology, Academic<br />
Medical Centre/University of Amsterdam, Amsterdam,<br />
The Netherlands; 3 Organon NV, Oss, The Netherlands;<br />
4<br />
Department of Rheumatology, St. Vincent’s University<br />
Hospital, Dublin, Ireland; 5 Division of Rheumatology,<br />
University Hospitals Leuven, Leuven, Belgium.<br />
(54)-1440. Temporal Decrease in Circulating Type IIA<br />
Procollagen N-Peptide (PIIANP) in Rheumatoid Arthritis.<br />
Anne F. Christensen 1 , Tine Lottenburger 2 , Hanne Merete<br />
Lindegaard 1 , Kim Horslev-Petersen 2 , Peter Junker 1 . 1 Odense<br />
University Hospital, Odense, Denmark; 2 Rheumatism<br />
Hospital, Grasten, Denmark.<br />
(55)-1441. CX3CL1 Expression in Osteoblasts of Patients with<br />
Rheumatoid Arthritis: Possible Roles of NF kappaB and STAT-1<br />
Pathways. Takeo Isozaki 1 , Mizuho Matsunawa 1 , Kuninobu<br />
Wakabayashi 1 , Tsuyoshi Odai 1 , Nobuyuki Yajima 1 , Yusuke<br />
Miwa 1 , Masao Negishi 1 , Hirotsugu Ide 1 , Tsuyoshi Kasama 1 ,<br />
Masakazu Tezuka 2 . 1 Showa University, Tokyo, Japan;<br />
2<br />
Denencyofu Central Hospital, Tokyo, Japan.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 235
Poster Session c<br />
(56)-1442. CD38-Negative Plasma Cells from Synovial Fluids of<br />
Rheumatoid Arthritis Patients have Potent Osteoclastogenic and<br />
Osteolytic Properties. Ji Hyeon Ju, Sook Hee Chang, Sung-<br />
Hwan Park, Ho-Youn Kim. The Catholic University of<br />
Korea, College of Medicine, Seoul, Republic of Korea.<br />
(57)-1443. IL-1 Mediates Toll Like Receptor 3-Enhanced<br />
Osteoclastogenesis. Ji Hyeon Ju, Kyoung-Woon Kim, Mi-La<br />
Cho, In Je Kim, Jang Uk Yoon, Sung-Hwan Park, Ho-<br />
Youn Kim. The Catholic University of Korea, College of<br />
Medicine, Seoul, Republic of Korea.<br />
(58)-1444. Risk Factors Of New Fractures After Vertebroplasty.<br />
Elisa Docampo 1 , Joan Calvet 1 , Joan Serra 2 , Manuel Ciria 1 ,<br />
Josep Blanch 1 , Luis Perez-Edo 1 , Jordi Carbonell 1 . 1 Servei De<br />
Reumatologia Hospital Del Mar i Hospital De L’Esperanca<br />
Imas, Barcelona, Spain; 2 CRC, Barcelona, Spain.<br />
(59)-1445. Change of a Conserved Glutamic Acid for Glycine<br />
in the ADAMTS14 Protease Associated with Susceptibility<br />
to Primary Knee Osteoarthritis. Antonio Gonzalez 1 , Zehra<br />
Mustafa 2 , Konstantinos N. Malizos 3 , Manuel Pombo-Suarez 1 ,<br />
Aspasia Tsezou 3 , John Loughlin 2 , Juan J. Gomez-Reino 1 .<br />
1<br />
Hospital Clinico Universitario de Santiago, Santiago de<br />
Compostela, Spain; 2 University of Oxford, Oxford, United<br />
Kingdom; 3 University of Thessaly, Larissa, Greece.<br />
(60)-1446. Tumor Necrosis Factor α but not Interleukin 1 β<br />
Potenciate Cell Death Induced by Ro 31-8220, a Protein Kinase<br />
Inhibitor, in Normal Human Articular Chondrocytes. María J.<br />
López-Armada, Beatriz Caramés, Marcos Lires-Deán, Berta<br />
Cillero-Pastor, Carlos Vaamonde, Beatriz Lema, Fausto<br />
Galdo, Francisco J. Blanco. Osteoarticular and Aging<br />
Research Laboratory. Biomedical Research Center, CHU<br />
“Juan Canalejo”, A Coruña, Spain.<br />
(61)-1447. Adipokines and Osteoarthritis: Visfatin Regulates<br />
Matrix Degrading Enzymes and Pge2 Synthesis in Cultured<br />
Chondrocytes. Marjolaine Gosset 1 , Francis Berenbaum 1 ,<br />
Colette Salvat 1 , Alain Sautet 1 , Audrey Pigenet 1 , Martin<br />
Holzenberger 2 , Claire Jacques 1 . 1 University Pierre & Marie<br />
Curie Paris VI, Paris, France; 2 INSERM U515, Paris, France.<br />
(62)-1448. Human Articular Chondrocytes Produce IL-7 in<br />
Response to Catabolic Stimuli: Potential Role in Aging and<br />
Osteoarthritis. Richard F. Loeser, Jr. 1 , David Long 1 , Simon<br />
Blake 2 , Xiao-Yu Song 2 , Michael Lark 2 . 1 Wake Forest<br />
University School of Medicine, Winston-Salem, NC;<br />
2<br />
Centocor, Malvern, PA.<br />
(63)-1449. The Thrombospondin-Related Protein, F-spondin, is<br />
Expressed in Embryonic Growth Plate Cartilage and can Enhance<br />
the Expression of Chondrocyte Maturation Markers. Glyn<br />
Palmer 1 , Mukundan Attur 1 , Yelena Nemelivsky 2 , Alejandro<br />
Piton 2 , Hayf E. Al-Mussawir 1 , Cristina Teixeira 2 , Steven B.<br />
Abramson 1 . 1 NYUHospital for Joint Diseases, New York,<br />
NY; 2 NYU College of Dentistry, Dept of Basic Sciences and<br />
Cranofacial Biology, New York, NY.<br />
(64)-1450. Hypoxia Up-Regulates Expression of Angiopoietin-<br />
Like (ANGPTL)-4 in Human Articular Chondrocytes: A<br />
Potential Role of ANGPTL4 in Cartilage Degradation. Minako<br />
Murata 1 , Kazuo Yudo 1 , Rie Karasawa 1 , Junji Chiba 2 ,<br />
Kusuki Nishioka 1 , Kazuhiko Inoue 2 , Tomohiro Kato 3 ,<br />
Kayo Masuko 3 . 1 Institute of Medical Science, St. Marianna<br />
University School of Medicine, Kawasaki, Japan; 2 Tokyo<br />
Women’s Medical University, Medical Center East,<br />
Tokyo, Japan; 3 Department of Biochemistry, St. Marianna<br />
University School of Medicine, Kawasaki, Japan.<br />
(65)-1451. Cell Death in Chondrocytes: Apoptosis or<br />
Autophagocytosis?. María del C. De Andrés, Emilia Maneiro,<br />
Angeles Bonilla, Fausto Galdo, Francisco J. Blanco.<br />
Osteoarticular and Aging Research Laboratory. Biomedical<br />
Research Center. Rheumatology Division. C.H.U. Juan<br />
Canalejo., A Coruña, Spain.<br />
(66)-1452. Dysfunction of Mitochondrial Respiratory Chain in<br />
Normal Chondrocyte. Inflammation and Matrix Degradation.<br />
Berta Cillero-Pastor, Ignacio Rego, Beatriz Caramés, Marcos<br />
Lires-Deán, Carlos Vaamonde, Beatriz Lema, Francisco J.<br />
Blanco, María J. López-Armada. Osteoarticular and Aging<br />
Research Laboratory. Biomedical Research Center. CH<br />
Universitario Juan Canalejo, A Coruña, Spain.<br />
(67)-1453. Toll Like Receptor 2 and 4 do not Aggravate Cartilage<br />
Pathology in Experimental Osteoarthritis. Arjen B. Blom,<br />
Peter M. van Lent, Leo A. Joosten, Wim B. van den Berg.<br />
Radboud University Nijmegen Medical Center, Nijmegen,<br />
The Netherlands.<br />
(68)-1454. Sphingosine-1-Phosphate Counteracts IL-1β in<br />
Articular Cartilage. Martin H. Stradner, Hannes Angerer,<br />
Verena Huber, Josef Hermann, Winfried B. Graninger.<br />
Medical University of Graz, Graz, Austria.<br />
(69)-1455. The Cartilage Turnover Marker Comp is Raised in<br />
Established RA Regardless of Inflammatory Activity. Thomas<br />
Skogh 1 , Jan Hed 2 , Charlotte Dahle 1 , Per Lewander 1 .<br />
1<br />
Linköping University, Linköping, Sweden; 2 AnaMar<br />
Medical, Linköping, Sweden.<br />
(70)-1456. Prevalence and Composition of Calcium Crystals<br />
in Advanced Osteoarthritis (OA) of the Knee. Martin<br />
Fuerst 1 , Lydia Lammers 2 , Fritz Schaefer 3 , Daniela Fuerst 3 ,<br />
Frank Echtermeyer 2 , Thomas Pap 2 , Wolfgang Ruether 1 .<br />
1<br />
Rheumaklinik Bad Bramstedt, Bad Bramstedt, Germany;<br />
2<br />
University Hospital Muenster, Muenster, Germany;<br />
3<br />
University Schleswig-Holstein, Kiel, Germany.<br />
236 (Permanent Board Number)-Abstract Number
(71)-1457. Subchondral Bone Changes and Cartilage<br />
Degeneration are Differentially Regulated; Comparison of Two<br />
Canine Models of Osteoarthritis. Femke Intema 1 , Yvonne<br />
H. Sniekers 2 , Sue Yocum 3 , Annemarie M. Zuurmond 4 ,<br />
Jeroen DeGroot 4 , Simon C. Mastbergen 1 , Harrie Weinans 2 ,<br />
Floris PJG Lafeber 1 . 1 University Medical Center Utrecht,<br />
Rheumatology & Clinical Immunology, Utrecht, The<br />
Netherlands; 2 Erasmus MC, Orthopedics, Rotterdam, The<br />
Netherlands; 3 Pfizer Inc PGRD, Ann Arbor, NJ; 4 TNO<br />
Quality of Life, Leiden, The Netherlands.<br />
(72)-1458. Scavenger Receptor Expression in Joint Tissues In A<br />
Murine Overuse-Induced Model Of Osteoarthritis. Anna Plaas 1 ,<br />
Wendy Anemaet 1 , Katalin Mikecz 1 , Barbara Osborn 2 . 1 Rush<br />
University Medical Center, Chicago, IL; 2 University of<br />
South Florida, Tampa, FL.<br />
(73)-1459. Study Comparing mRNA Expression of Selected Genes<br />
in Cartilage and Synovium in Age and Gender Matched Subjects<br />
with and without Knee Osteoarthritis. Candace R. Bramson 1 ,<br />
Debra Kellner 1 , Paul Juneau 1 , William J. Arnold 2 , David<br />
J. Raab 2 , Nathan Wei 3 . 1 Pfizer, Ann Arbor, MI; 2 Illinois<br />
Bone and Joint Institute, Des Plains, IL; 3 Arthritis and<br />
Osteoporosis Center of Maryland, Frederick, MD.<br />
(74)-1460. The “Alarmin” S100 A8: A Regulator of Chondrocyte<br />
Activation during Experimental Arthiritis? Peter L. Van Lent 1 ,<br />
Lilyanne Grevers 1 , Arjen B Blom 1 , Annet Sloetjes 1 , Thomas<br />
Vogl 2 , Wolfgang Nacken 2 , Johannes Roth 2 , Wim B van den<br />
Berg 1 . 1 University Medical Centre Nijmegen, Nijmegen,<br />
The Netherlands; 2 Inst of Experimental Dermatology,<br />
Muenster, Germany.<br />
(75)-1461. C-Reactive Protein as a Marker of Developing<br />
Knee Joint Osteoarthritis- A 12 Year Follow-Up. Maria LE<br />
Andersson 1 , Tore Saxne 2 , Ingemar F. Petersson 2 . 1 Spenshult<br />
Hospital for Rheumatic Diseases, Oskarstrom, Sweden;<br />
2<br />
Department of Rheumatology, Lund University Hospital,<br />
Lund, Sweden.<br />
(76)-1462. Protective Abilities of Interleukin-10 in Blood-Induced<br />
Joint Damage. Nathalie WD Jansen 1 , Joel AG van Roon 1 ,<br />
Goris Roosendaal 2 , Matthias Theobald 2 , Johannes WJ<br />
Bijlsma 1 , Floris PJG Lafeber 1 . 1 University Medical Center<br />
Utrecht, Rheumatology & Clinical Immunology, Utrecht,<br />
The Netherlands; 2 UMC Utrecht, Hematology, Utrecht,<br />
The Netherlands.<br />
(77)-1463. Hsp90 and p130cas: Novel Regulatory Factors of<br />
MMP-13 Expression in Human Osteoarthritic Chondrocytes.<br />
Zhiyong Fan 1 , Ginette Tardif 1 , David Hum 1 , François<br />
Mineau 1 , Nicolas Duval 2 , Jean-Pierre Pelletier 1 , Johanne<br />
Martel-Pelletier 1 . 1 Osteoarthritis Research Unit, Notre-<br />
Dame Hospital, University of Montreal Hospital Centre,<br />
Montreal, PQ, Canada; 2 Pavillon des Charmilles, Vimont,<br />
PQ, Canada.<br />
(78)-1464. Reciprocal Function of Two Tetraspanin Superfamily<br />
Proteins, Tspan-5 and NET-6 During Osteoclastogenesis. Junichi<br />
Kikuta 1 , Kaori Iwai 1 , Masaru Ishii 2 , Shiro Ohshima 1 ,<br />
Yukihiko Saeki 1 . 1 National Hospital Organization Osakaminami<br />
Medical Center, Kawachinagano, Japan; 2 National<br />
Institutes of Health, Bethesda, MD.<br />
(79)-1465. Elevated Transforming Growth Factor Beta<br />
1 Followed by High Intensity Treadmill Exercise Induces<br />
Ostearthritis in Murine Knee Joints. Wendy Anemaet, Anna<br />
Plaas, John Sandy, Katalin Mikecz. Rush University Medical<br />
Center, Chicago, IL.<br />
(80)-1466. Bone Turnover (Bone Quality) is Closely Associated<br />
with Disease Activity and Physical Disability in RA Patients.<br />
Daihei Kida, Yoshito Eto, Masami Tsukamoto, Tomotaro<br />
Sato, Atsushi Kaneko, Gintaro Ishihara, Hideki Sugishita,<br />
Kiwamu Saito. National Hospital Organization Nagoya<br />
Medical Center, Nagoya, Japan.<br />
(81)-1467. Statin Inhibits Catabolic Stress-Induced Chondrocyte<br />
Aging in Articular Cartilage. Kazuo Yudoh 1 , Satoe Karasawa 1 ,<br />
Kayo Masuko 2 , Hiroshi Nakamura 3 , Tomohiro Kato 4 .<br />
1<br />
Institute of Medical Science, St. Marianna University<br />
School of Medicine, Kawasaki City, Japan; 2 Dept.<br />
of Biochemistry, St. Marianna University School of<br />
Medicine, Kawasaki City, Japan; 3 Dept. of Joint disease<br />
and Rheumatism, Nippon Medical School, Tokyo, Japan;<br />
4<br />
Dept of Biochemistry, St. Marianna University School of<br />
Medicine, Kawasaki City, Japan.<br />
(82)-1468. Monitoring Bone Mineral Density During the<br />
Course of Teriparatide Therapy in a Community Setting. Kelly<br />
Krohn 1 , Guillermo Valenzuela 2 , Paul Miller 3 , Asad Rana 1 ,<br />
Mayme Wong 1 , Kathleen Taylor 1 . 1 Eli Lilly and Company,<br />
Indianapolis, IN; 2 140 SW 84th Ave Ste B, Plantation, FL;<br />
3<br />
Colorado Center for Bone Research, Lakewood, CO.<br />
(83)-1469. The Effect of Bone Mineral Density Measurement of<br />
Hip Bilateral in Clinical Practice. Jaqueline B. Lopes, Camille<br />
F. Danilevicius, Valéria F. Caparbo, Liliam Takayama, Rosa<br />
M. R. Pereira. Rheumatology Division, University of São<br />
Paulo, São Paulo, Brazil.<br />
(84)-1470. Low Energy Wrist Fracture in Elderly Females:<br />
Seasonal Variations and Associates with Osteoporotic Fractures.<br />
Glenn Haugeberg 1 , Ronny Andre Heie 2 , Gudrun Elise<br />
Rohde 1 , Odd Arild Agedal 1 , Halvar Mosdol 1 , Unni<br />
Syversen 3 , Dag Magne Soldal 1 , Villy Johnsen 1 . 1 Sørlandet<br />
Hospital, Kristiansand, Norway; 2 Nordland Hospital, Bodo,<br />
Norway; 3 St.Olavs Hospital, Trondheim, Norway.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 237
Poster Session c<br />
(85)-1471. Mitochondrial Proteomic Differential Expression<br />
Analysis of Osteoarthritis-Related Proteins in Human Articular<br />
Chondrocytes. Cristina Ruiz-Romero, Vanessa Carreira,<br />
Silvia Remeseiro, María del C. Fernández, Fausto Galdo,<br />
Francisco J. Blanco. Osteoarticular and Aging Research<br />
Lab, Proteomics Unit. Biomedical Research Center, CH<br />
Universitario Juan Canalejo, A Coruña, Spain.<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Cell-Cell Adhesion, Cell Trafficking and Angiogenesis<br />
(86)-1472. Stromal Cell Derived Factor/CXCL12-gamma<br />
Isoform is Expressed by Rheumatoid Fibroblasts and Displays<br />
Distinct Endothelial Binding and Pro-Angiogenic Properties. Elena<br />
Izquierdo 1 , Patricia Rueda 2 , Begoña Santiago 1 , Manuel J.<br />
del Rey 1 , Françoise Baleux 2 , Fernando Arenzana 2 , Jose L.<br />
Pablos 1 . 1 Hospital 12 de Octubre, Madrid, Spain; 2 Pasteur<br />
Institute, Paris, France.<br />
(87)-1473. Bovine Herpes Virus 1 Glycoprotein G: A Novel<br />
Broad Spectrum Chemokine Inhibitor. Zheng Liu 1 , Meera<br />
Ramanujam 2 , Martha Tepas 2 , Elif Alpoge 2 , Haiou Tao 2 ,<br />
Anne Davidson 2 . 1 Columbia University, New York, NY; 2 The<br />
Feinstein Institute for Medical Research, Manhasset, NY.<br />
(88)-1474. Unique Reciprocal Map Kinase Regulation in<br />
Thrombin-Induced Endothelial Pro-Inflammatory Activation. Paul<br />
Salers 1 , Catherine Farnarier 1 , Pierre Bongrand 2 , Françoise<br />
Dignat-George 1 , Gilles Kaplanski 1 . 1 UMR-S608, Marseille,<br />
France; 2 UMR-600, Marseille, France.<br />
(89)-1475. A Unique Role for Cytokine Inducible<br />
Fucosyltransferase 1 in Angiogenesis. Mohammad A. Amin 1 ,<br />
Bradley J. Rabquer 1 , Pawan Kumar 1 , Pamela J. Mansfield 1 ,<br />
Phillip L. Campbell 1 , Steven E. Domino 2 , Alisa E. Koch 3 .<br />
1<br />
University of Michigan, Ann Arbor, MI; 2 Veteran’s<br />
Administration and University of Michigan, Ann Arbor,<br />
MI; 3 Veteran’s Administration and University of Michigan,<br />
Ann Arbor, MI.<br />
(90)-1476. Increased Lymphangiogenesis in Joints of Mice with<br />
Inflammatory-Erosive Arthritis. Ruolin Guo, Qian Zhang, Yan<br />
Lu, Steve T. Proulx, Edward M. Schwarz, Brendan F. Boyce,<br />
Lianping Xing. Univesity of Rochester, Rochester, NY.<br />
(91)-1477. TNF Promotes Remodelling Of Cadherin-11<br />
Intercellular Junctions And Condensation Of Fibroblast-like<br />
Synoviocytes. Thomas Karonitsch, Verena Kallab, Irene<br />
Radda, Birgit Tuerk, Alfred Rapp, Clemens Scheinecker,<br />
Josef S. Smolen, Hans Kiener. Division of Rheumatology,<br />
Internal Medicine III, Medical University, Vienna, Austria.<br />
(92)-1478. Cas-l Associates with Adaptor Protein Nck. Role of<br />
Cas-l/nck Interaction in Beta1 Integrin- and Tcr-Mediated Cell<br />
Signaling and Migration. Yutaka Hashizume, Satoshi Iwata,<br />
Koji You, Kei Ohnuma, Osamu Hosono, Hiroshi Kawasaki,<br />
Hirotoshi Tanaka, Chikao Morimoto. Institute of Medical<br />
Science, The University of Tokyo, Tokyo, Japan.<br />
(93)-1479. Tpl2 Kinase is Part of the Integrin “Signalosome” in<br />
Adherent Primary Macrophage and Regulates the Integrin Induced<br />
ERK1/2 Activation and Effector Function. Marianna Ioannou,<br />
Irene Kyrmizi, Dimitrios T. Boumpas, Ioannis Tassiulas.<br />
University of Crete Medical School, Heraklion, Greece.<br />
(94)-1480. Junctional Adhesion Molecule-C Mediates Leukocyte<br />
Recruitment to the Rheumatoid Arthritis Synovium. Bradley<br />
J. Rabquer 1 , Angela Pakozdi 1 , James E. Michel 1 , Beat A.<br />
Imhof 2 , Alisa E. Koch 3 . 1 University of Michigan, Ann<br />
Arbor, MI; 2 Centre Medical Universitaire, Geneva,<br />
Switzerland; 3 Veteran’s Administration and University of<br />
Michigan, Ann Arbor, MI.<br />
(95)-1481. Roles of TSG-6-Hyaluronan Complexes in<br />
Extracellular Matrix Assembly and Inflammatory Cell<br />
Recruitment. Gabor Hutas 1 , Eva Bajnok 1 , Yanal M. Murad 1 ,<br />
Marianna Radacs 1 , Anthony J. Day 2 , Katalin Mikecz 1 . 1 Rush<br />
University Medical Center, Chicago, IL; 2 University of<br />
Manchester, Manchester, United Kingdom.<br />
(96)-1482. Effect of Hypoxia on CD4+ T-Cells During the<br />
Pathogenesis of Rheumatoid Arthritis. Timo Gaber 1 , Thomas<br />
Häupl 2 , Miriam Tschirschmann 3 , Grit Sandig 2 , Monique<br />
Fangradt 2 , René Dziurla 2 , Kerem Erekul 2 , Manuela<br />
Jakstadt 2 , Roland Lauster 3 , Gerd R. Burmester 2 , Frank<br />
Buttgereit 2 . 1 German Arthritis Research Center, DRFZ,<br />
Berlin, Germany; 2 Charité University Hospital, CCM,<br />
Berlin, Germany; 3 University for Technologies, Medical<br />
Biotechnology, Berlin, Germany.<br />
(97)-1483. Metalloelastase MMP12 Expression in GianT-<br />
Cell Arteritis Lesions. Marta Segarra, Ester Lozano, Ana<br />
García-Martínez, Montse Sánchez, Georgina Espígol, José<br />
Hernández-Rodríguez, Maria C. Cid. Hospital Clinic-<br />
IDIBAPS, Barcelona, Spain.<br />
238 (Permanent Board Number)-Abstract Number
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Epidemiology and Health Services Research III<br />
(98)-1484. Individualizing the Measure of Functional Impairment<br />
in Rheumatoid Arthritis (RA): Development of Patient-Specific<br />
Forms of the Health Assessment Questionnaire (HAQ). Raphaele<br />
SEROR, Florence Tubach, Gabriel Baron, Philippe Ravaud.<br />
Hopital Bichat, Paris, France.<br />
(99)-1485. An OARSI/OMERACT Initiative: The Development<br />
of Short Measures of Physical Function for Knee and Hip OA<br />
KOOS-Physical Function Shortform (KOOS-PS) and HOOS-<br />
Physical Function Shortform (HOOS-PS). Aileen M. Davis 1 ,<br />
Anthony V. Perruccio 1 , Mayilee Canizares 1 , Gillian A.<br />
Hawker 2 , Philip G. Conaghan 3 , Alan Tennant 4 , Maxime<br />
Dougados 5 , Joanne Jordan 6 , Ewa Roos 7 , Stefan Lohmander 7 .<br />
1<br />
Toronto Western Research Institute, Toronto, ON,<br />
Canada; 2 Women’s College Hospital, Toronto, ON,<br />
Canada; 3 Chapel Allerton Hospital, Leeds, United<br />
Kingdom; 4 University of Leeds, Leeds, United Kingdom;<br />
5<br />
Hopital Cochin, Paris, France; 6 University of North<br />
Carolina, Chapel Hill, NC; 7 University Hospital in Lund,<br />
Lund, Sweden.<br />
(100)-1486. Improved Precision of a Lower Extremity<br />
Osteoarthritis Functional Outcome Instrument. Alan M. Jette 1 ,<br />
Stephen M. Haley 1 , Pengsheng Ni 1 , Suzanne Olarsch 1 ,<br />
David J. Hunter 2 , David T. Felson 2 . 1 Boston University<br />
School of Public Health, Boston, MA; 2 Boston University<br />
School of Medicine, Boston, MA.<br />
(101)-1487. What Diseases Do Rheumatologists Treat? Analysis<br />
of a Large Community Based Practice. Molly Vogt, Terence<br />
W. Starz, Darlene Imling, William Grenzig, Nancy Dentel,<br />
Thaddeus Osial, Kent Kwoh. University of Pittsburgh<br />
Medical Center, Pittsburgh, PA.<br />
(102)-1488. Osteoarthritis or Rheumatoid Arthritis - Are<br />
Individuals Concerned in the General Population Able to<br />
Differentiate? Results from the German Rheumatoid Arthritis<br />
Population Survey (GRAPS). Gisela Westhoff 1 , Matthias<br />
Schneider 2 , Heiner Raspe 3 , Henning Zeidler 4 , Claus Runge 5 ,<br />
Timm Volmer 5 , Angela Zink 1 . 1 German Rheumatology<br />
Research Center, Berlin, Germany; 2 Heinrich Heine<br />
Universität Düsseldorf, Düsseldorf, Germany; 3 Universität<br />
Lübeck, Lübeck, Germany; 4 Medical University Hannover,<br />
Hannover, Germany; 5 Wyeth Pharma, Münster, Germany.<br />
(103)-1489. Effect of Abatacept Treatment on Patient Activity<br />
Participation in Rheumatoid Arthritis. Tracy Li 1 , George Wells 2 ,<br />
Rene Westhovens 3 , JC Becker 1 , Peter Tugwell 2 . 1 Bristol-<br />
-Myers Squibb, Princeton, NJ; 2 University of Ottawa,<br />
Ottawa, ON, Canada; 3 University of Ziekenhuizen Leuven,<br />
Leuven, Belgium.<br />
(104)-1490. Effect of Lupus on Sexual Health of Women.<br />
Meenakshi Jolly, J. A. Block, Roger Rodby. Rush University<br />
Medical Center, Chicago, IL.<br />
(105)-1491. Psychosocial Factors are Associated with Poor Mental<br />
and Physical Health-Related Quality of Life in Subjects with New<br />
Onset Chronic Widespread Pain. Barbara I. Nicholl 1 , Gary J.<br />
Macfarlane 2 , Richard Morriss 3 , David Ray 1 , Chris Dickens 1 ,<br />
John McBeth 1 . 1 University of Manchester, Manchester,<br />
United Kingdom; 2 University of Aberdeen, Aberdeen,<br />
United Kingdom; 3 University of Nottingham, Nottingham,<br />
United Kingdom.<br />
(106)-1492. The Impact of Demographic and Psychosocial<br />
Characteristics on Health-Related Quality of Life in Patients with<br />
Early Inflammatory Joint Complaints. Goedele A. Geuskens 1 ,<br />
Alex Burdorf 1 , Andrea W.M. Evers 2 , Johanna M.W. Hazes 1 .<br />
1<br />
Erasmus MC, University Medical Center Rotterdam,<br />
Rotterdam, The Netherlands; 2 Radboud University<br />
Nijmegen Medical Centre, Nijmegen, The Netherlands.<br />
(107)-1493. Prediction Models for Disease: The Effect of<br />
Associations between Markers on Calculating the Risk for<br />
Disease by Likelihood Ratio Products. Ruth Wittoek 1 , Filip<br />
De Keyser 1 , Annelies Boonen 2 , Kurt De Vlam 3 , Nathan<br />
Vastesaeger 4 , Herman Mielants 1 , Gust Verbruggen 1 , Bert<br />
Vander Cruyssen 1 . 1 University Hospital Ghent, Ghent,<br />
Belgium; 2 University Hospital Maastricht, Maastricht, The<br />
Netherlands; 3 University Hospital Leuven, Leuven, Belgium;<br />
4<br />
Schering Plough, Brussels, Belgium.<br />
(108)-1494. Ankylosing Spondylitis (AS) Patients on Adalimumab<br />
Show Sustained Improvement in Health-Related Quality of<br />
Life (HRQOL): 104-Week Results from ATLAS. D. van der<br />
Heijde 1 , M. P. Luo 2 , A. Kivitz 3 , M. H. Schiff 4 , J. Sieper 5 , B.<br />
AC Dijkmans 6 , J. Braun 7 , M. Dougados 8 , P. Wordsworth 9 ,<br />
R. Wong 10 , H. Kupper 11 , J. Davis for the ATLAS Study<br />
Group 12 . 1 Leiden University Medical Center, Leiden, The<br />
Netherlands; 2 Abbott, Abbott Park, IL; 3 Altoona Center<br />
for Clinical Research, Duncansville, PA; 4 Denver Arthritis<br />
Clinic, Denver, CO; 5 Charité Universitätsmedizin Berlin,<br />
Berlin, Germany; 6 VU Medical Centre and the Jan van<br />
Breemen Institute, Amsterdam, The Netherlands; 7 Ruhr<br />
University Bochum, Bochum, Germany; 8 Hôpital Cochin,<br />
Paris, France; 9 Nuffield Orthopaedic Centre, Oxford,<br />
United Kingdom; 10 Abbott, Parsippany, NJ; 11 Abbott<br />
GmbH & Co. KG, Ludwigshafen, Germany; 12 University of<br />
California, San Francisco, CA.<br />
(109)-1495. What Matters to People in Spondyloarthritis (SpA):<br />
Measuring the Importance of Valued Life Activities. Aileen<br />
Davis, Dr, Marvilyn Palaganas, Ms, Elizabeth Badley, Dr,<br />
Robert Inman, Dr, Dafna Gladman, Dr, Monique Gignac, Dr.<br />
Toronto Western Research Institute, Toronto, ON, Canada.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 239
Poster Session c<br />
(110)-1496. Investigating What Aspects of Sleep Improve<br />
in Rheumatoid Arthritis Patients Treated with Abatacept.<br />
George A. Wells 1 , Tracy Li 2 , John Kirwan 3 , Peter Tugwell 1 .<br />
1<br />
University of Ottawa, Ottawa, ON, Canada; 2 Bristol-Myers<br />
Squibb, Princeton, NJ; 3 Bristol Royal Infirmary, Bristol,<br />
United Kingdom.<br />
(111)-1497. Validation of the DAS28 Definition Based on CRP<br />
Compared with DAS28 Based on ESR Using Data from Patients<br />
with Rheumatoid Arthritis Treated with Abatacept. George A.<br />
Wells 1 , Jean-Claude Becker 2 , Julie Teng 2 , Piet van Riel 3 .<br />
1<br />
University of Ottawa, Ottawa, ON, Canada; 2 Bristol-Myers<br />
Squibb, Princeton, NJ; 3 Radboud University Nijmegen<br />
Medical Centre, Nijmegen, The Netherlands.<br />
(112)-1498. Abnormal Psychological Attachment is Associated<br />
with the Onset of Chronic Widespread Pain. Kelly A. Jones 1 ,<br />
John McBeth 1 , Gary J. Macfarlane 2 , Barbara I. Nicholl 1 ,<br />
David Ray 1 , Richard Morriss 3 , Chris Dickens 1 . 1 University<br />
of Manchester, Manchester, United Kingdom; 2 University<br />
of Aberdeen, Aberdeen, United Kingdom; 3 University of<br />
Nottingham, Nottingham, United Kingdom.<br />
(113)-1499. Understanding the Pain Experience in Hip and<br />
Knee OA. Gillian A. Hawker 1 , Lindsay Stewart 1 , Melissa<br />
R. French 1 , Jolanda Cibere 2 , Joanne M. Jordan 3 , Lyn<br />
March 4 , Maria Suarez-Almazor 5 , Paul Dieppe 6 . 1 University<br />
of Toronto, Toronto, ON, Canada; 2 University of British<br />
Columbia, Vancouver, BC, Canada; 3 University of North<br />
Carolina, Chapel Hill, NC; 4 IBJR, Sydney Uni, Sydney,<br />
Australia; 5 UT MD Anderson Cancer Center, Houston, TX;<br />
6<br />
MRC HSRC, Bristol, United Kingdom.<br />
(114)-1500. Common Sleep Habits of Older Community-Living<br />
People with Osteoarthritis. Brian J. Murray 1 , Cahyee Cheung 1 ,<br />
Melissa R. French 1 , Lucia Gagliese 2 , Aileen M. Davis 3 ,<br />
Gillian A. Hawker 1 . 1 University of Toronto, Toronto, ON,<br />
Canada; 2 York University, Toronto, ON, Canada; 3 Toronto<br />
Western Research Institute, Toronto, ON, Canada.<br />
(115)-1501. Efficacy of Etoricoxib in the Treatment of<br />
Osteoarthritis as Compared to Acetaminophen, Traditional<br />
NSAIDs and Cox-2 selective NSAIDs: A Bayesian Meta-analysis<br />
of Direct and Indirect Comparisons. Wiro B. Stam 1 , Sabine<br />
Gaugris 2 , Julie van Bavel 3 , Jeroen Jansen 1 . 1 Mapi Values,<br />
Houten, The Netherlands; 2 Merck & Co., Inc., Whitehouse<br />
Station, NJ; 3 MSD Australia, South Granville, New South<br />
Wales, Australia.<br />
(116)-1502. How Useful is the “Help from Others, Aids &<br />
Devices” in Scoring the Health Assessment Questionnaire (HAQ)?.<br />
T. Sokka 1 , H. Kautiainen 1 , T. Pincus 2 , H. Mäkinen 1 , V.<br />
Skakic 3 , A. Stankovic 3 , S. Toloza 4 , S. Kelly 5 , E. Choy 5 , F.<br />
Salaffi 6 , A. Stancati 6 , J. Devlin 7 , S. Alraqi 7 , J. Sibilia 8 , G.<br />
Burmester 9 , D. Zarowny-Wierzbinska 10 , S. Sadkiewicz 10 , On<br />
Behalf of the QUEST-RA Group. 1 Finland; 2 NY; 3 Serbia;<br />
4<br />
Argentina; 5 United Kingdom; 6 Italy; 7 Ireland; 8 France;<br />
9<br />
Germany; 10 Poland.<br />
(117)-1503. Predictors of Frequent Emergency Department Use<br />
among Persons with Systemic Lupus Erythematosus. Pantelis<br />
Panopalis 1 , Jinoos Yazdany 1 , Joann Gillis 2 , Laura Julian 1 ,<br />
Aimee Hersh 1 , Laura Trupin 1 , Patricia Katz 1 , Ed Yelin 1 .<br />
1<br />
University of California, San Francisco, San Francisco, CA;<br />
2<br />
National Jewish Medical and Research Center, Denver, CO.<br />
(118)-1504. Health Status in Inflammatory Arthritis Patients<br />
with “Worse Than Death” EQ-5D Scores. Mark Harrison 1 ,<br />
Linda Davies 1 , Nick Bansback 2 , Melanie McCoy 3 ,<br />
Andrew Hassell 4 , Deborah Symmons 1 . 1 The University of<br />
Manchester, Manchester, United Kingdom; 2 Centre for<br />
Health Evaluation and Outcome Sciences, Vancouver,<br />
BC, Canada; 3 The University of Western Australia, Perth,<br />
Australia; 4 University Hospital of North Staffordshire,<br />
Stoke-on-Trent, United Kingdom.<br />
(119)-1505. Ambulatory Medical Care Visits by Adults for<br />
Arthritis and Other Rheumatic Conditions (aorc) are Increasing,<br />
United States, 2002-2004 Vs. 1997. Charles Helmick,<br />
Jennifer Hootman, Yao-Hua Luo. CDC, Atlanta, GA.<br />
(120)-1506. Chronic Musculoskeletal Pain Predicts an Increased<br />
Risk for Hospital Care. Hans Lindgren, Stefan Bergman.<br />
Spenshult Hospital for Rheumatic Diseases, Oskarström,<br />
Sweden.<br />
(121)-1507. Description of Lifetime Physical Activity by Time,<br />
Energy and Joint Force in a Canadian Sample. C. Ratzlaff 1 , P.<br />
Doerfling 2 , J. Kopec 1 , G. Steininger 1 , J. Cibere 1 , M. Liang 3 ,<br />
D. McIntyre 1 , D. Wilson 1 , J. Esdaile 1 . 1 University of British<br />
Columbia, Vancouver, BC, Canada; 2 Arthritis Research<br />
Centre of Canada, Vancouver, BC, Canada; 3 Harvard<br />
School of Public Health, Boston, MA.<br />
(122)-1508. Investigation of Response Shift in Health Related<br />
Quality of Life scores Among Patients Undergoing Total Knee<br />
Replacement. Xu-Hao Zhang 1 , Shu-Chuen Li 2 , Ngai-Nung<br />
Lo 3 , Kwang-Ying Yang 3 , Seng-Jin Yeo 3 , Julian Thumboo 3 .<br />
1<br />
National University of Singapore, Singapore, Singapore;<br />
2<br />
University of Newcastle, Callaghan, Australia; 3 Singapore<br />
General Hospital, Singapore, Singapore.<br />
(123)-1509. The Development of a Rheumatic Disease Research<br />
Comorbidity Index for Use in Outpatients with RA, OA, SLE<br />
and Fibromyalgia (FMS). Kaleb Michaud 1 , Frederick Wolfe 2 .<br />
1<br />
University of Nebraska Medical Center, Omaha, NE;<br />
2<br />
National Data Bank for Rheumatic Diseases, Witchita, KS.<br />
240 (Permanent Board Number)-Abstract Number
(124)-1510. Valuation Of Health States for Scleroderma and<br />
Psoriatic Arthritis by the General Public: Community Weights<br />
for Future Decision and Cost-effectiveness Analyses. Dinesh<br />
Khanna 1 , Robert Kaplan 2 , Mark Eckman 1 , Shaari Ginsburg 1 ,<br />
Ron D. Hays 2 , Joel Tsevat 1 . 1 University of Cincinnati,<br />
Cincinnati, OH; 2 UCLA, Los Angeles, CA.<br />
(125)-1511. Respective Value of a Specific and of a Generic<br />
Questionnaire in the Measurement of Quality of Life in<br />
Osteoarthritis: Insights from Item Response Theory Modelling.<br />
Anne-Christine Rat 1 , Emmanuel Ecosse 2 , Joel Coste 2 ,<br />
Stéphanie Boini 1 , Jacques Pouchot 3 , Francis Guillemin 1 .<br />
1<br />
CIC-EC Inserm CIE6, CHU Nancy, Nancy, France;<br />
2<br />
Département de Santé Publique, Hôpital Cochin, Paris,<br />
France; 3 Service de Médecine Interne, HEGP, Paris, France.<br />
(126)-1512. Baseline Disease Activity Determines the Level<br />
of Improvement Needed to Experience a Minimal and Major<br />
Response in Rheumatoid Arthritis. Daniel Aletaha 1 , Julia<br />
Funovits 1 , Josef S. Smolen 1 , Tore K. Kvien 2 . 1 Medical<br />
University of Vienna, Vienna, Austria; 2 Diakonnehmet<br />
Hospital, Oslo, Norway.<br />
(127)-1513. Most TNF Inhibitor Trials in Rheumatoid Arthritis<br />
(RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) are<br />
Undeservedly Called “Efficacy And Safety” Trials: Type II Error in<br />
Reporting Safety Data. Yusuf Yazici 1 , Nicole Moses 1 , Hasan Yazici 2 .<br />
1<br />
NYU Hospital for Joint Diseases, New York, NY; 2 Cerrahpasa<br />
Medical Faculty, Istanbul University, Istanbul, Turkey.<br />
(128)-1514. Household Income and Quality of Life in Patients<br />
with Rheumatoid Arthritis: Results from a Mestizo Population<br />
with Full Health-Care Coverage. Augusto Garcia-Poma 1 ,<br />
Maria I. Segami 1 , Henry N. Terrazas 1 , Cecilia P. Chung 2 .<br />
1<br />
Universidad Nacional Mayor de San Marcos, Lima, Peru;<br />
2<br />
Vanderbilt University, Nashville, TN.<br />
(129)-1515. The Cutoff Points of Antinuclear Antibody with<br />
High Negative and Positive Predictive Values. Analysis of 5655<br />
Cases. Hisanori Shimizu, Yukio Matsui, Masato OKADA.<br />
St. Luke’s International Hospital, Tokyo, Japan.<br />
(130)-1516. Improving the Health Assessment Questionaire: The<br />
HAQ-100. James F. Fries 1 , Bonnie Bruce 1 , Matthias Rose 2 .<br />
1<br />
Stanford University School of Medicine, Palo Alto, CA;<br />
2<br />
QualityMetric, Lincoln, RI.<br />
(131)-1517. NSAIDs in the Management of Musculoskeletal<br />
Conditions: A Comparative Meta-Analysis of the Efficacy/Safety<br />
Profile of Piroxicam. Florent F. Richy 1 , Carmalo Scarpignato 2 ,<br />
Angel Lanas 3 , Gurkirpal Singh 4 , Jean-Yves Reginster 1 .<br />
1<br />
University of Liège, Sart-Tilman, Belgium; 2 University of<br />
Parma, Parma, Italy; 3 University of Zaragoza, Sart-Tilman,<br />
Spain; 4 Standford University, Standford, CA.<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Fibromyalgia: Etiology and Treatment II<br />
(132)-1518. Functioning of the Hypothalamic Pituitary Adrenal<br />
and Growth Hormone Axes are Associated with the Presence<br />
of Multiple Chronic Pain Syndromes. John McBeth 1 , Vishal<br />
Aggarwal 1 , David Ray 1 , Gary J. Macfarlane 2 . 1 University<br />
of Manchester, Manchester, United Kingdom; 2 Aberdeen<br />
University, Aberdeen, United Kingdom.<br />
(133)-1519. Inappropriate Antibiotic Treatment in “Chronic<br />
Lyme Disease”. Afton L. Hassett 1 , Diane C. Radvanski 1 ,<br />
Shantal V. Savage 1 , Lakshmi N. Moorthy 1 , Leonard H.<br />
Sigal 2 . 1 UMDNJ-Robert Wood Johnson Medical School,<br />
New Brunswick, NJ; 2 Bristol-Myers Squibb Company,<br />
Princeton, NJ.<br />
(134)-1520. Fibromyalgia Patients Reading Self-Help Journals and<br />
in Internet Self-Help Groups: Are They Different from Patients in<br />
Clinical Practice?. Robert Katz 1 , Kaleb Michaud 2 , Frederick<br />
Wolfe 3 . 1 Rush Medical Center, Chicago, IL; 2 University<br />
of Nebraska Medical Center, Omaha, NE; 3 National Data<br />
Bank for Rheumatic Diseases, Wichita, KS.<br />
(135)-1521. Heritability in Fibromyalgia. Robert S. Katz.<br />
Rheumatology Associates, Rush University Medical Center,<br />
Chicago, IL.<br />
(136)-1522. Pregabalin Therapy for Durability of Meaningful<br />
Relief of Fibromyalgia. Susan Simpson 1 , James P. Young,<br />
Jr 1 , George Haig 1 , Jeannette Barrett 2 . 1 Pfizer Global<br />
Research and Development, Ann Arbor, MI; 2 Pfizer Global<br />
Pharmaceuticals, New York, NY.<br />
(137)-1523. Efficacy and Safety of Pregabalin as Long-Term<br />
Treatment of Pain Associated with Fibromyalgia: A 1-Year,<br />
Open-Label Study. Hana Florian 1 , James P. Young, Jr 1 ,<br />
George Haig 1 , Jeannette Barrett 2 . 1 Pfizer Global Research<br />
and Development, Ann Arbor, MI; 2 Pfizer Global<br />
Pharmaceuticals, New York, NY.<br />
(138)-1524. Pregabalin Monotherapy for Management of<br />
Fibromyalgia: Analysis of Two Double-blind, Randomized, Placebo-<br />
Controlled Trials. Rachel Duan 1 , Hana Florian 1 , James P.<br />
Young 1 , Susan Martin 1 , George Haig 1 , Jeannette Barrett 2 .<br />
1<br />
Pfizer Global Research and Development, Ann Arbor, MI;<br />
2<br />
Pfizer Global Pharmaceuticals, New York, NY.<br />
(139)-1525. Composite Responder Endpoints for Fibromyalgia<br />
Trials - Experience with Milnacipran. R. Michael Gendreau 1 ,<br />
David A. Williams 2 , Robert H. Palmer 3 , Philip Mease 4 ,<br />
Daniel J. Clauw 2 . 1 Cypress Bioscience, Inc., San Diego, CA;<br />
2<br />
University of Michigan, Ann Arbor, MI; 3 Forest Research<br />
Institute, Jersey City, NJ; 4 Seattle Rheumatology Associates,<br />
Seattle, WA.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 241
Poster Session c<br />
(140)-1526. One-Year Durability of Response to Milnacipran<br />
Treatment for Fibromyalgia. Don Goldenberg 1 , Daniel J.<br />
Clauw 2 , Robert H. Palmer 3 , Philip Mease 4 , R. Michael<br />
Gendreau 5 . 1 Newton-Wellesley Hospital, Newton, MA;<br />
2<br />
University of Michigan, Ann Arbor, MI; 3 Forest Research<br />
Institute, Jersey City, NJ; 4 Seattle Rheumatology Associates,<br />
Seattle, WA; 5 Cypress Bioscience, Inc., San Diego, CA.<br />
(141)-1527. Catastrophizing and Fatigue are Associated with<br />
Poorer Perceived Physical Function Relative to Objective Activity<br />
Measures in Fibromyalgia. Michael C. Hsu 1 , Michael E.<br />
Geisser 1 , Angela K. Lyden 2 , David A. Williams 2 , Daniel J.<br />
Clauw 2 . 1 Phys Med & Rehab, University of Michigan, Ann<br />
Arbor, MI; 2 Rheumatology, University of Michigan, Ann<br />
Arbor, MI.<br />
(142)-1528. The Change of Regional Cerebral Glucose<br />
Metabolism in Fibromyalgia Patients after One-Year Duloxetine<br />
Treatment. Jonathan JH Chen 1 , Chung-Ming Huang 1 , Chia-<br />
Horng Kao 1 , Sun-Sen Sun 1 , Kuo-Yang Yen 1 , Shen-Yu Su 1 ,<br />
Jiun-Yi Wang 2 . 1 China Medical University Hospital, Taichung,<br />
Taichung, Taiwan; 2 Asia University, Taichung, Taiwan.<br />
(143)-1529. Coping Styles in Fibromyalgia: Effect of Co-Morbid<br />
Posttraumatic Stress Disorder (PTSD). Jacob N. Ablin 1 , Hagit<br />
Cohen 2 , Lily Neumann 3 , Zeev Kaplan 4 , Dan Buskila 5 .<br />
1<br />
Institute of rheumatology, Tel - Aviv Sourasky medical<br />
center and Sackler faculty of medicine, Tel - Aviv university,<br />
Tel - Aviv, Israel; 2 Ministry of Health Mental Health Center,<br />
and Stress Research Unit, Beer Sheva, Israel; 3 Epidemiology<br />
Department, Faculty of Health Sciences, Ben-Gurion<br />
University of the Negev, Beer Sheva, Israel; 4 Ministry of<br />
Health Mental Health Center, Anxiety and Stress Research<br />
Unit, Beer Sheva, Israel; 5 4Rheumatic Disease Unit,<br />
Department of Medicine, Soroka Medical Center, Beer<br />
Sheva, Israel.<br />
(144)-1530. What Characterises Persons Who Never Report<br />
Musculoskeletal Pain? A 4-year Population-Based Cohort Study.<br />
Gareth T. Jones 1 , John McBeth 2 , Elizabeth A. Jones 1 ,<br />
Richard K. Morriss 3 , Chris Dickens 4 , Gary J. Macfarlane 1 .<br />
1<br />
Aberdeen Pain Research Collaboration (Epidemiology<br />
Group), University of Aberdeen, United Kingdom;<br />
2<br />
Arthritis Research Campaign Epidemiology Unit, The<br />
University of Manchester, United Kingdom; 3 School of<br />
Community Health Sciences, University of Nottingham,<br />
United Kingdom; 4 Department of Psychiatry, The<br />
University of Manchester, United Kingdom.<br />
(145)-1531. Fibromyalgia: The Early Years. Symptoms in<br />
Childhood Before the Diagnosis. Robert S. Katz 1 , Sharon<br />
Ferbert 2 , Frank Leavitt 3 . 1 Rheumatology Associates,<br />
Rush University Medical Center, Chicago, IL; 2 AFFTER<br />
Fibromyalgia Organization, Chicago, IL; 3 Rush University<br />
Medical Center, Chicago, IL.<br />
(146)-1532. Fibromyalgia Patients Report Many Symptoms Other<br />
Than Pain and Fatigue. Robert S. Katz 1 , Sharon Ferbert 2 ,<br />
Frank Leavitt 3 . 1 Rheumatology Associates, Rush University<br />
Medical Center, Chicago, IL; 2 AFFTER Fibromyalgia<br />
Organization, Chicago, IL; 3 Rush University Medical<br />
Center, Chicago, IL.<br />
(147)-1533. Association of Fibromyalgia with Coronary<br />
Angiography. Jacob N. Ablin 1 , Natella Beilinson 2 , Valerie<br />
Aloush 1 , Ori Elkayam 1 , Ariel Finkelstein 3 . 1 Institute of<br />
rheumatology, Tel - Aviv Sourasky medical center, Tel<br />
- Aviv, Israel; 2 Internal medicine f, Tel - Aviv Sourasky<br />
medical center, Tel - Aviv, Israel; 3 Institute of cardiology, Tel<br />
- Aviv Sourasky medical center, Tel - Aviv, Israel.<br />
(148)-1534. Patients with Fibromyalgia Have Greater Difficulty<br />
Coping with Their Illness than Patients with Other Rheumatic<br />
Diseases. Robert S. Katz 1 , Susan Shott 2 , Nancy Helmke 3 ,<br />
Alexandra Small 3 , Ben Small 3 , Robin Moss 3 . 1 Rheumatology<br />
Associates, Rush University Medical Center, Chicago,<br />
IL; 2 Rush University Medical Center, Chicago, IL;<br />
3<br />
Rheumatology Associates, Chicago, IL.<br />
(149)-1535. Chronic Widespread Pain.- A Comparisation between<br />
those who Meet Criteria for Fibromyalgia and Those Who do<br />
Not. Lars Cöster 1 , Sally Kendall 2 , Björn Gerdle 3 , Chris<br />
Henriksson 4 , Karl G. Henriksson 3 , Ann Bengtsson 1 . 1 Dep of<br />
Rheumatology, Linköping, Sweden; 2 Multidisciplinary Pain<br />
Centre, Copenhagen, Denmark; 3 Dep of Rehabilitation<br />
Medicine, Linköping University, Sweden; 4 Dep of Social<br />
and Welfare Studies, Linköping University, Sweden.<br />
(150)-1536. The Impact of Concomitant Fibromyalgia on HAQ<br />
and DAS28 Evaluation in Patients with Rheumatoid Arhritis.<br />
Aline Ranzolin, Jairo Guarienti, Marcele Rizzatti, Daniel<br />
P. Feldman, Ricardo M. Xavier, João Carlos T. Brenol.<br />
Universidade Federal do Rio Grande do Sul, Porto Alegre/<br />
RS, Brazil.<br />
(151)-1537. Electronic Diaries Have Superior Discrimination<br />
Compared to Paper-Based Pain Assessment in Individuals with<br />
Fibromyalgia. David A. Williams 1 , R. Michael Gendreau 2 ,<br />
Daniel J. Clauw 1 . 1 University of Michigan, Ann Arbor, MI;<br />
2<br />
Cypress Bioscience, Inc., San Diego, CA.<br />
(152)-1538. What Level of Symptom Relief Do Fibromyalgia<br />
Patients Expect During a Rheumatology Office Visit?. Roland<br />
Staud, Erin O’Brien, Jason G. Craggs, Donald D. Price,<br />
Michael E. Robinson. University of Florida, Gainesville, FL.<br />
(153)-1539. Fibromyalgia Symptom Reporting and Application<br />
for Disability Insurance: Is it Possible to Fake Fibromyalgia<br />
Symptoms for Financial Benefit?. Nandini Natarajan 1 , Harvey<br />
Moldofsky 2 . 1 Dalhousie University, Halifax, NS, Canada;<br />
2<br />
University of Toronto, Toronto, ON, Canada.<br />
242 (Permanent Board Number)-Abstract Number
(154)-1540. Characteristics of Fibromyalgia in Muslim Bedouin<br />
Women in Primary Care Clinic. Roni Peleg 1 , Jacob Ablin 2 ,<br />
Aya Peleg 3 , Lily Neumann 4 , Rasmia Abu Rabia 5 , Dan<br />
Buskila 6 . 1 Ben Gurion University of the Negev, Beer Sheva,<br />
Israel; 2 Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel;<br />
3<br />
Department of Epidemiology and Evaluation of Health<br />
Services, Beer Sheva, Israel; 4 Department of Epidemiology<br />
and Evaluation of Health Services., Beer Sheva, Israel;<br />
5<br />
Kuseife Clinic, Clalit Health Services, Southern region,<br />
Kuseife, Israel; 6 Rheumatic Disease Unit, Soroka Medical<br />
Center Beer-Sheva, Israel. Faculty of Health Sciences, Ben<br />
Gurion University of the Negev, Beer Sheva, Israel.<br />
(155)-1541. Clinical and Biochemical features of Atypical<br />
and Melancholic Depression Subtypes in Fibromyalgia Patients.<br />
Rebecca Ross, Kim Jones, Dorothy Eldredge, Robert Bennett.<br />
Oregon Health & Science University, Portland, OR.<br />
(156)-1542. The Synovium in Gulf War Veterans’ Illness:<br />
Quantitative Histopathologic Comparisons to OA and Normal<br />
Synovium. Frank Pessler 1 , Lan X. Chen 2 , Carmen Gomez-<br />
Vaquero 3 , Necati Cakir 2 , Cesar Diaz-Torne 4 , Eugene<br />
Einhorn 5 , H. Ralph Schumacher 2 . 1 The Children’s<br />
Hospital of Philadelphia, Philadelphia, PA; 2 University<br />
of Pennsylvania, Philadelphia, PA; 3 Hospital Universitari<br />
de Bellvitge, Barcelona, Spain; 4 Hospital de la Santa Creu<br />
I Sant Pau, Barcelona, Spain; 5 Philadelphia VA Medical<br />
Center, Philadelphia, PA.<br />
(157)-1543. Duloxetine 60-120 mg Versus Placebo in the Treatment<br />
of Fibromyalgia Syndrome. Amy Chappell 1 , Laurence Bradley 2 ,<br />
Curtis Wiltse 1 , Deborah N. D’Souza 1 , Michael Spaeth 3 .<br />
1<br />
Lilly Research Laboratories, Indianapolis, IN; 2 University<br />
of Alabama at Birmingham, Birmingham, AL; 3 Practice for<br />
Internal Medicine/Rheumatology, Graefelfing, Germany.<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Clinical Osteoporosis and Metabolic Bone Disease II<br />
(158)-1544. Comparable Adherence Between Monthly Oral<br />
and Quarterly Intravenous Ibandronate in Patients Who<br />
Discontinued Previous Bisphosphonates because of Gastrointestinal<br />
Intolerance. Henry G. Bone 1 , Marc K. Drezner 2 , Joseph D.<br />
Kohles 3 , D. Sudhaker Rao 4 . 1 Michigan Bone and Mineral<br />
Clinic, Detroit, MI; 2 Department of Medicine, University<br />
of Wisconsin and GRECC, Wm. S. Middleton VAMC,<br />
Madison, WI; 3 Roche Laboratories, Inc, Nutley, NJ; 4 Henry<br />
Ford Hospital, Detroit, MI.<br />
(159)-1545. Tolerability of Monthly Ibandronate and Weekly<br />
Alendronate in Women With Postmenopausal Osteoporosis:<br />
Results From the MOTION Study. Ronald Emkey 1 , Michael<br />
Bolognese 2 , Sergio Ragi-Eis 3 , Farhad Sedarati 4 , Christine<br />
Leigh 5 , Sol Epstein 6 . 1 Radiant Research, Wyomissing, PA;<br />
2<br />
Bethesda Health Research, Bethesda, MD; 3 CEDOES<br />
Diagnóstico e Pesquisa, Vitoria, Brazil; 4 Hoffmann-La Roche<br />
Inc., Nutley, NJ; 5 Roche Products Ltd, Welwyn Garden<br />
City, United Kingdom; 6 Mt Sinai School of Medicine New<br />
York and Doylestown Hospital, Doylestown, PA.<br />
(160)-1546. Rapid Suppression of Serum CTX within Three<br />
Days of Treatment Initiation with Montly Oral Ibandronate.<br />
Stuart L. Silverman 1 , Elizabeth Barrett-Connor 2 , Christine<br />
Simonelli 3 , Joseph D. Kohles 4 , Gorana Dasic 5 , Neil Binkley 6 .<br />
1<br />
Cedars-Sinai Medical Center, Beverly Hills, CA; 2 University<br />
of California at San Diego, San Diego, CA; 3 Health East<br />
Osteoporosis Care, Woodbury, MN; 4 Roche Laboratories,<br />
Inc, Nutley, NJ; 5 GlaxoSmithKline, Research Triangle Park,<br />
NC; 6 University of Wisconsin, Madison, WI.<br />
(161)-1547. Oral Ibandronate (150mg) Administered Monthly<br />
Provides Similar Improvements in Hip Bone Mineral Density as<br />
Oral Alendronate (70mg) Administered Weekly in Postmenopausal<br />
Osteoporosis. Jean Y. Reginster 1 , Joao LC Borges 2 , Chris<br />
Recknor 3 , Farhad Sedarati 4 , Colin Neate 5 , Felicia Cosman 6 .<br />
1<br />
University of Liège, Liège, Belgium; 2 Universidade Catolica<br />
de Brasilia, Brasilia, Brazil; 3 United Osteoporosis Centers,<br />
Gainesville, GA; 4 Hoffmann-La Roche Inc., Nutley, NJ;<br />
5<br />
Roche Products Ltd, Welwyn Garden City, United<br />
Kingdom; 6 Helen Hayes Hospital, New York, NY.<br />
(162)-1548. Treatment With Intravenous Pamidronate is a Good<br />
Alternative For Oral Bisphosphonates in Case of Gastrointestinal<br />
Side Effects or Contraindications. Danielle A. Eekman 1 ,<br />
Marijn Vis 2 , Irene E.M. Bultink 1 , Harm J.G.M. Derikx 2 ,<br />
Ben A.C. Dijkmans 1 , Willem F. Lems 1 . 1 VU University<br />
Medical Center, Amsterdam, The Netherlands; 2 Slotervaart<br />
Hospital, Amsterdam, The Netherlands.<br />
(163)-1549. Bone Metabolism in Primary Senile Osteoporosis.<br />
Effects of Two Different Calcium Supplementation. Manuel<br />
CIRIA 1 , Lluis Perez-Edo 1 , Josep Blanch 1 , Pilar Lisbona 1 ,<br />
Monica Coll 2 , Jordi Carbonell 1 . 1 Hospital del Mar,<br />
Barcelona, Spain; 2 Hospital de Mataró, Barcelona, Spain.<br />
(164)-1550. High Dose Oral Vitamin D3 in Rheumatologic<br />
Patients with Severe Vitamin D Deficiency. Cord von Restorff 1 ,<br />
Heike A. Bischoff-Ferrari 2 , Robert Theiler 1 . 1 Triemli<br />
Hospital, Zurich, Switzerland; 2 University Hospital Zurich,<br />
Zurich, Switzerland.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 243
Poster Session c<br />
(165)-1551. Management Scheme for Glucocorticoid-Induced<br />
Osteoporosis (gio) in Rheumatoid Arthritis (ra) Based on a<br />
Two-Year Longitudinal Cohort Study. Ikuko Tanaka 1 , Hisaji<br />
Oshima 2 . 1 Fujita Health University School of Medicine,<br />
Toyoake, Japan; 2 National Hospital Organization Tokyo<br />
Medical Center, Tokyo, Japan.<br />
(166)-1552. How Quickly Do Oral Bisphosphonates Work,<br />
and are There Differences between Them?. J. R. Curtis, A.<br />
O. Westfall, H. Cheng, E. Delzell, K. G. Saag. UAB,<br />
Birmingham, AL.<br />
(167)-1553. Identifying Clinical Vertebral Fractures Using Administrative<br />
Claims Data: A Validation Study. J. R. Curtis 1 , A. Mudano 1 , D.<br />
Solomon 2 , Y. Kim 1 , K. G. Saag 1 . 1 UAB, Birmingham, AL;<br />
2<br />
Brigham and Women’s Hospital, Boston, MA.<br />
(168)-1554. Longitudinal Patterns of Adherence with<br />
Bisphosphonates. J. R. Curtis 1 , A. O. Westfall 1 , W. Chan 2 , H.<br />
Cheng 1 , E. Delzell 1 , K. G. Saag 1 . 1 UAB, Birmingham, AL;<br />
2<br />
Novartis, East Hanover, NJ.<br />
(169)-1555. Comparative Gastrointestinal Safety of Weekly Oral<br />
Bisphosphonates for the Treatment of Osteoporosis. Suzanne M.<br />
Cadarette, Jeffrey N. Katz, M. Alan Brookhart, Margaret R.<br />
Stedman, Til Stürmer, Raisa Levin, Daniel H. Solomon.<br />
Brigham and Women’s Hospital, Boston, MA.<br />
(170)-1556. Improved Persistence at 12 Months with Monthly<br />
Bisphosphonate Therapy Compared to Weekly Bisphosphonates:<br />
Results from Two Retrospective Databases. Joyce A. Cramer 1 ,<br />
Stuart L. Silverman 2 , Chaitanya Sarawate 3 , Carolyn Harley 4 ,<br />
William A. Blumentals 5 , Sara Poston 6 , E. M. Lewiecki 7 .<br />
1<br />
Yale University School of Medicine, West Haven,<br />
CT; 2 Cedars-Sinai Medical Center, Beverly Hills, CA;<br />
3<br />
HealthCore, Inc., Wilmington, DE; 4 i3 Innovus, Eden<br />
Prairie, MN; 5 Roche, Inc, Nutley, NJ; 6 GlaxoSmithKline,<br />
Research Triangle Park, NC; 7 NM Clin Res & Osteoporosis<br />
Center, Albuquerque, NM.<br />
(171)-1557. Undertreatment with Anti-Osteoporotic Drugs<br />
after Hip Fracture. Veronique Rabenda 1 , Valérie Fabri 2 ,<br />
Raf Mertens 2 , Johan Vanoverloop 2 , André Deswaef 3 ,<br />
Gert Verpooten 4 , Carine Vannecke 3 , Katrien Thorre 5 , JY<br />
Reginster 1 . 1 University of Liege, Liege, Belgium; 2 Agence<br />
Intermutualiste, Bruxelles, Belgium; 3 INAMI, Bruxelles,<br />
Belgium; 4 University of Gand, Gand, Belgium; 5 Mutualite<br />
Libre, Bruxelles, Belgium.<br />
(172)-1558. A Beneficial Roll of Etanercept on Bone Metabolism.<br />
Daihei Kida, Yoshito Eto, Masami Tsukamoto, Tomotaro<br />
Sato, Atsushi Kaneko, Gintaro Ishihara, Hideki Sugishita,<br />
Kiwamu Saito. National Hospital Organization Nagoya<br />
Medical Center, Nagoya, Japan.<br />
(173)-1559. Prevalence with Seasonal Variation of<br />
Hypovitaminosis D, and Male Hypogonadism, in Prednisonetreated<br />
Patients with Rheumatic Disease. Damandeep S. Walia 1 ,<br />
Harchetan Singh 1 , Kate Jennings 1 , Fred Wolfe 2 , Barbara<br />
P. Lukert 1 , Donald D. Smith 1 , Ernesto N. Levy 3 , Kent<br />
A. Huston 4 , Herbert B. Lindsley 1 . 1 University of Kansas<br />
Medical Center, Kansas City, KS; 2 University of Kansas<br />
School of Medicine, Wichita, KS; 3 Penn State/Div Rheum<br />
HO38, Hershey, PA; 4 Center for Rheumatic Diseases,<br />
Kansas City, MO.<br />
(174)-1560. Association of Low Levels of 25 Hydroxyvitamin D<br />
and Moderate/Severe Vertebral Fractures in Community-Dwelling<br />
Elderly Women. Jaqueline B. Lopes 1 , Camille F. Danilevicius 1 ,<br />
Liliam Takayama 1 , Valéria F. Caparbo 1 , Paulo R. Menezes 2 ,<br />
Rosa M. R. Pereira 1 . 1 Rheumatology Division, University<br />
of São Paulo, São Paulo, Brazil; 2 Preventive Medicine<br />
Department, University of São Paulo, São Paulo, Brazil.<br />
(175)-1561. High Prevalence of Vertebral Fractures in Epileptic<br />
Patients Taking Anti-Epileptic Drugs. Antonio A. Lazzari,<br />
Philip Dussault, Manisha Thakore, Samuel A. Davis. Boston<br />
Div. VA New England Health Care System, Boston, MA.<br />
(176)-1562. Prevalence of Osteoporosis and Risk Factors for Low<br />
Energy Hip Fracture in Southern Norway. Glenn Haugeberg,<br />
Mikkel Hoiberg, Gudrun Elise Rohde, Odd Arild Agedal,<br />
Halvar Mosdol, Villy Johnsen, Dag Magne Soldal. Sørlandet<br />
Hospital, Kristiansand, Norway.<br />
(177)-1563. Correlation of Isokinetic Knee and Trunk Muscular<br />
Strength with Bone Mineral Content in Female Soccer Players.<br />
Michelle F. Saccol 1 , Natalia C. Oliveira 1 , Rosa M. R.<br />
Pereira 1 , Ana Lucia Pinto 1 , Liliam Takayama 1 , Julia M.<br />
D. Greve 2 , Fernanda R. Lima 1 . 1 Rheumatology Division,<br />
University of São Paulo, São Paulo, Brazil; 2 Orthopedic<br />
Institute, University of São Paulo, São Paulo, Brazil.<br />
(178)-1564. Bisphosphonate Use Increases in Patients at<br />
High Risk for Fracture Following an Integrated Osteoporosis<br />
Educational Intervention: Canadian Quality Circle (CQC)<br />
National Project. Alexandra Papaioannou 1 , George<br />
Ioannidis 1 , Brent Kvern 2 , Lehana Thabane 1 , Amiran<br />
Gafni 1 , Anthony Hodsman 3 , Dan Johnstone 4 , Lena<br />
Salach 5 , Famida Jiwa 6 , Jonathan D. Adachi 1 . 1 McMaster<br />
University, Hamilton, ON, Canada; 2 University of<br />
Manitoba, Winnipeg, MB, Canada; 3 University of Western<br />
Ontario, London, ON, Canada; 4 Procter and Gamble<br />
Pharmaceuticals, Toronto, ON, Canada; 5 Ontario College<br />
of Family Physicians, Toronto, ON, Canada; 6 Osteoporosis<br />
Canada, Toronto, ON, Canada.<br />
244 (Permanent Board Number)-Abstract Number
(179)-1565. The Impact of Incident Fractures on Health<br />
Related Quality of Life Depends on Fracture Site: The<br />
Canadian Multicentre Osteoporosis Study (CaMos). Alexandra<br />
Papaioannou 1 , George Ioannidis 1 , Courtney Kennedy 1 ,<br />
Laura Pickard 1 , Alan Tenenhouse 2 , Jacques P. Brown 3 ,<br />
Robert Josse 4 , Anna M. Sawka 4 , Stephanie M. Kaiser 5 ,<br />
Tassos Anastassiades 6 , Wilma Hopman 6 , Jonathan D.<br />
Adachi 1 . 1 McMaster University, Hamilton, ON, Canada;<br />
2<br />
McGill University, Montreal, ON, Canada; 3 Laval<br />
University, Sainte-Foy, PQ, Canada; 4 University of Toronto,<br />
Toronto, ON, Canada; 5 Dalhousie University, Halifax, NS,<br />
Canada; 6 Queen’s University, Kingston, ON, Canada.<br />
(180)-1566. An Osteoporosis Educational Intervention Increases<br />
the use of X-ray Ordering in High Risk Patients with Height<br />
Loss or Kyphosis: Canadian Quality Circle (CQC) National<br />
Project. Jonathan D. Adachi 1 , George Ioannidis 1 , Lehana<br />
Thabane 1 , Amiran Gafni 1 , Brent Kvern 2 , Alexandra<br />
Papaioannou 1 , Anthony Hodsman 3 , Dan Johnstone 4 , Lena<br />
Salach 5 , Famida Jiwa 6 . 1 McMaster University, Hamilton,<br />
ON, Canada; 2 University of Manitoba, Winnipeg, MB,<br />
Canada; 3 University of Western Ontario, London, ON,<br />
Canada; 4 Procter and Gamble Pharmaceuticals, Toronto,<br />
ON, Canada; 5 Ontario College of Family Physicians,<br />
Toronto, ON, Canada; 6 Osteoporosis Canada, Toronto,<br />
ON, Canada.<br />
(181)-1567. Validation of the Osteoporosis Self-Assessment<br />
Tool in Men with Rheumatoid Arthrtis. John S. Richards 1 ,<br />
Justin Peng 2 , Daisha Cipher 3 , Bavana Rangan 4 , Roderick<br />
S. Hooker 5 , Ted Mikuls 6 , Grant W. Cannon 7 , Salahuddin<br />
Kazi 5 , Gail Kerr 1 . 1 VAMC and Georgetown University,<br />
Washington, DC; 2 Georgetown University, Washington,<br />
DC; 3 VAMC and University of North Texas Health Science<br />
Center, Fort Worth, TX; 4 VAMC, Dallas, TX; 5 VAMC and<br />
University of Texas, Dallas, TX; 6 VAMC and University of<br />
Nebraska, Omaha, NE; 7 VAMC and University of Utah,<br />
Salt Lake City, UT.<br />
(182)-1568. Bone Mineral Density, Anti-histamine Therapy, and<br />
Proton Pump Inhibitors : An Analysis of NHANES III. Mitsuyo<br />
Kinjo 1 , Soko Setoguchi 2 , Daniel H. Solomon 2 . 1 Teine<br />
Keijinkai Hospital, Teine-ku Sapporo city, Japan; 2 Brigham<br />
and Women’s Hospital, Harvard Medical School, Boston, MA.<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Infection Related Rheumatic Disease<br />
(183)-1569. Fuctional CCR5 Receptor Protects Patients from<br />
High Synovial Chlamydia Trachomatis Burden but Differentially<br />
Protects Against Induction of Inflammatory Arthritis in ReA and<br />
UO Patients. Alan P. Hudson 1 , Cynthia Oszust 1 , Jason P.<br />
Guthrie 2 , Judith A. Whittum-Hudson 1 , Jessica Snelgrove 1 ,<br />
John D. Carter 2 , H Ralph Schumacher 3 , Herve C. Gerard 1 .<br />
1<br />
Wayne State University School of Medicine, Detroit,<br />
MI; 2 University of South Florida School of Medicine,<br />
Tampa, FL; 3 University of Pennsylvania Medical School,<br />
Philadelphia, PA.<br />
(184)-1570. Patients Infected with Chlamydia Trachomatis<br />
Frequently Have Ocular, Not Genital, Serovars of the Organism<br />
in Synovial Tissue. Alan P. Hudson 1 , H Ralph Schumacher 2 ,<br />
Judith A. Whittum-Hudson 1 , John D. Carter 3 , Herve C.<br />
Gerard 1 . 1 Wayne State University School of Medicine,<br />
Detroit, MI; 2 University of Pennsylvania Medical School,<br />
Philadelphia, PA; 3 University of South Florida School of<br />
Medicine, Tampa, FL.<br />
(185)-1571. The Chikungunya (CHIK) Arthritis & Rheumatism<br />
-An Untold Suffering. Arvind Chopra, Vaijayanti Lagu-Joshi,<br />
Anuradha Venugopalan. Center for Rheumatic Diseases,<br />
Pune, India.<br />
(186)-1572. Serum Procalcitonin for Discrimination between<br />
Septic and Non-Septic Arthritis. Thomas Hügle 1 , Beat Müller 1 ,<br />
Stephan Regenass 2 , Gerd Laifer 1 , Alan Tyndall 2 , Thomas<br />
Daikeler 1 . 1 University hospital of Basel, Basel, Switzerland;<br />
2<br />
Felix-Platter hospital Basel, Basel, Switzerland.<br />
(187)-1573. Mucocutaneous Leishmaniasis Presenting as<br />
Wegener’s Granulomatosis. Qingping Yao 1 , Sheetal Desai 1 ,<br />
Noah Craft 2 , Ernest Brahn 1 . 1 Division of Rheumatology,<br />
UCLA School of Medicine, Los Angeles, CA; 2 Harbor-<br />
UCLA Divisions of Dermatology and Adult Infectious<br />
Diseases, UCLA School of Medicine, Los Angeles, CA.<br />
(188)-1574. Skeletal Tuberculosis. Study of 53 Cases. Emma<br />
Garcia-Melchor, Lourdes Mateo, Elisabet Garcia-Casares,<br />
Susana Holgado, Sonia Mínguez, Alejandro Olivé, Xavier<br />
Tena, Jerónima Cañellas. Hospital Universitari Germans<br />
Trias i Pujol, Badalona, Spain.<br />
(189)-1575. Serial C-reactive protein Measurements in Adult<br />
Patients with Septic Arthritis as a Marker for Clinical Outcome.<br />
Shobha R. Wani, Tam T. Ly, Kalonji R. Collins, Maria<br />
E. Ruiz, Paul J. DeMarco, Christopher E. Collins, Arthur<br />
Weinstein. Washington Hospital Center, Washington, DC.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 245
Poster Session c<br />
(190)-1576. Diagnosis of Latent Tuberculosis Infection by T<br />
Spot-tb Compared to Other Modalities of Screening in Patients<br />
with Inflammatory Arthritis (ia): Influence of Disease and<br />
Treatments. Herve Dintinger 1 , Anne Kennel de March 2 ,<br />
Felicie Constantino 1 , Anne Christine Rat 1 , Marie-Christine<br />
Bene 3 , Damien Loeuille 1 , Jacques Pourel 1 , Gilbert Faure 2 ,<br />
Isabelle Chary-Valckenaere 1 . 1 Rheumatology, CHU de<br />
Nancy, France; 2 Immunology, CHU de Nancy, France;<br />
3<br />
Immunology, Vandoeuvre les Nancy, France.<br />
(191)-1577. Clinical Significance of Mannose-Binding Lectin<br />
(mbl)-Deficient Genotypes in HCV Patients with Systemic<br />
Autoimmune Diseases. Manuel Ramos-Casals 1 , Pilar Brito-<br />
Zerón 1 , Sandra Muñoz 1 , Albert Bové 1 , Xavier Forns 2 , José<br />
M. Sánchez-Tapias 2 , Francisco Lozano 3 . 1 Laboratory of Basic<br />
Research in Autoimmune Diseases, IDIBAPS, Hospital<br />
Clinic, Barcelona, Spain; 2 Department of Hepatology,<br />
Hospital Clinic, Barcelona, Spain; 3 Department of<br />
Immunology, Hospital Clinic, Barcelona, Spain.<br />
(192)-1578. Comparison of an Interferon-γ assay with Tuberculin<br />
Skin Testing for the detection of Tuberculosis Infection in<br />
Rheumatoid Arthritis patients in a TB endemic population. Dario<br />
Ponce de Leon 1 , Eduardo Acevedo 1 , Sergio Alvizuri 1 , Cesar<br />
Gutierrez 2 , Mariano Cucho 1 , Jose Alfaro 1 , Risto Perich 1 ,<br />
Alfredo Sanchez 1 , Cesar Pastor 1 , Cesar Sanchez 1 , Mariela<br />
Medina 1 , Rocio Gamboa 1 , Manuel Ugarte 1 . 1 HNGAI, Lima,<br />
Peru; 2 Universidad San Marcos, Lima, Peru.<br />
(193)-1579. Epstein-Barr Virus-Induced Gene Expression Changes<br />
in SLE Patient B Cells. Brian D. Poole, Joel M. Guthridge,<br />
John B. Harley, Judith A. James. Oklahoma Medical<br />
Research Foundation, Oklahoma City, OK.<br />
(194)-1580. Concomitant Septic Arthritis and Crystal<br />
Arthopathy: A Case Series. Avnit Ahuja 1 , David E. Feinstein 2 ,<br />
Rajesh Kataria 3 , Marguerite L. McGarvey 4 , Charles H.<br />
Pritchard 5 , Lawrence H. Brent 1 . 1 Albert Einstein Medical<br />
Center, Philadelphia, PA; 2 Cooper University Hospital,<br />
Camden, NJ; 3 Southern Ohio Medical Center, Portsmouth,<br />
OH; 4 Hahnemann University Hospital-Drexel, Philadelphia,<br />
PA; 5 Abington Memorial Hospital, Abington, PA.<br />
(195)-1581. Impact of Clinical, Demographic and Disease<br />
Activity Features in Influenza Vaccination Responses in SLE.<br />
Sherry R. Crowe 1 , Joel M. Guthridge 1 , Valerie Skaggs 2 ,<br />
Courtney L. Quine 1 , Virginia Roberts 1 , Gillian M. Air 2 ,<br />
Linda F. Thompson 1 , Judith A. James 1 . 1 OMRF, Oklahoma<br />
City, OK; 2 OUHSC, Oklahoma City, OK.<br />
(196)-1582. Sacroiliitis in a Patient with Multiple Infections.<br />
Markus Rihl 1 , Katrin Achilles-Mehr Bakhsh 1 , Annette D.<br />
Wagner 2 , Herbert Rosenthal 3 , Franz-Christoph Bange 4 ,<br />
Torsten Witte 1 , Reinhold E. Schmidt 1 , Henning Zeidler 5 .<br />
1<br />
Div. of Clin. Immunology and Rheumatology, Hannover<br />
Medical School, Hannover, Germany; 2 Div. of Nephrology,<br />
Hannover Medical School, Hannover, Germany; 3 Dep. of<br />
Radiology, Hannover Medical School, Hannover, Germany;<br />
4<br />
Dep. of Microbiology and Hospital Epidemiology,<br />
Hannover Medical School, Hannover, Germany;<br />
5<br />
Rheumatologikum Hannover, Hannover, Germany.<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Innate Immunity and Rheumatic Disease<br />
(197)-1583. Murine Dendritic Cell Type I IFN Production<br />
Induced by Human IgG-RNA Immune Complexes is IRF5- and<br />
IRF7-dependent, and is Required for IL-6 Production. Christophe<br />
Richez 1 , Kei Yasuda 1 , Joseph W. Maciaszek 1 , Neerja<br />
Agrawal 1 , Shizuo Akira 2 , Ann Marshak-Rothstein 1 , Ian R.<br />
Rifkin 1 . 1 Boston University, Boston, MA; 2 Osaka University,<br />
Osaka, Japan.<br />
(198)-1584. mPGES-1 is Required For PGE2 Production in<br />
Murine Dendritic Cells, but not for Maturation or Migration.<br />
Seetha U. Monrad 1 , Mohit Kapoor 2 , Fumiaki Kojima 2 ,<br />
Emma L. Kuan 3 , Sujata Sarkar 1 , Gwendalyn J. Randolph 3 ,<br />
Leslie J. Crofford 2 . 1 University of Michigan, Ann Arbor,<br />
MI; 2 University of Kentucky, Lexington, KY; 3 Mount Sinai<br />
School of Medicine, New York, NY.<br />
(199)-1585. Myeloid Dendritic Cells Display Downregulation of<br />
C-type Lectin Receptors and Aberrant Lectin Uptake in Systemic<br />
Lupus Erythematosus. Seetha U. Monrad, Kristine M. Rea,<br />
Mariana J. Kaplan. University of Michigan, Ann Arbor, MI.<br />
(200)-1586. PAR2 Signalling Promotes Myeloid Dendritic Cell<br />
Differentiation and Maturation. Mahir Karababa 1 , Giancarlo<br />
Ramelli 1 , Isabelle Miconnet 2 , Alexander So 1 , Nathalie<br />
Busso 1 . 1 CHUV-RMR, Lausanne, Switzerland; 2 CHUV-IAL,<br />
Lausanne, Switzerland.<br />
(201)-1587. Regulation of Dendritic Cell Differentiation by<br />
Estrogen Receptor Ligands. Esther Carreras-Margalef, Sean<br />
Turner, Susan Kovats. Oklahoma Medical Research<br />
Foundation, Oklahoma City, OK.<br />
(202)-1588. Susceptibility and Resistance of Monocytes/<br />
Macrophages to CD4+CD25+Foxp3+ Regulatory T Cell-Mediated<br />
Suppression. Machteld M. Tiemessen, Ann L. Jagger, Hayley<br />
G. Evans, Susan John, Leonie S. Taams. King’s College<br />
London, London, United Kingdom.<br />
246 (Permanent Board Number)-Abstract Number
(203)-1589. Bip Downregulates Dendritic Cell Maturation<br />
Leading to Generation Of Regulatory T Cells. Valerie M.<br />
Corrigall, Stephen J. Thompson, Gabriel S. Panayi. King’s<br />
College London School of Medicine, London, United Kingdom.<br />
(204)-1590. Toll-like Receptor Signaling Activates NR4A Orphan<br />
Nuclear Receptors in Synoviocytes and Chondrocytes. Kimberlee<br />
S. Mix 1 , Mukundan Attur 2 , Steven B. Abramson 2 , Evelyn<br />
P. Murphy 1 . 1 University College Dublin, Dublin, Ireland;<br />
2<br />
NYU Hospital for Joint Diseases, New York, NY.<br />
(205)-1591. Fibrin Triggers an Innate Immune Response<br />
in Rheumatoid Arthritis Synovial Fibroblasts Acting as an<br />
Endogenous Ligand of Toll Like Receptor 4. Olga Sanchez-<br />
Pernaute 1 , Fabia Brentano 1 , Caroline Ospelt 1 , Christoph<br />
Kolling 2 , Beat A. Michel 1 , Renate E. Gay 1 , Gabriel Herrero-<br />
Beaumont 3 , Steffen Gay 1 , Michel Neidhart 1 . 1 Center of<br />
Experimental Rheumatology, University Hospital and<br />
Zurich Center for Integrative Human Physiology (ZIHP),<br />
Zurich, Switzerland; 2 Orthopaedic Surgery, Schulthess<br />
Klinic, Zurich, Switzerland; 3 Rheumatology Section,<br />
Fundacion Jimenez Diaz, Madrid, Spain.<br />
(206)-1592. Natural Antibody Mediated Downregulation of<br />
TLR-Induced Myeloid Dendritic Cell Maturation, Cytokine and<br />
Chemokine Responses. Sahil Khanna, Yifang Chen, Y-B Park,<br />
Ravi Kolla, Gregg J. Silverman. UCSD, La Jolla, CA.<br />
(207)-1593. Estrogen Receptor Expression Markedly Modulates<br />
the Inflammatory Response of Mesangial Cells to Toll Like<br />
Receptor Ligands. John L. Svenson, Gary S. Gilkeson.<br />
Medical Univ. of South Carolina, Charleston, SC.<br />
(208)-1594. Prevalence and Clinical Significance of<br />
Polymorphisms of Toll-like Receptors 2 and 4 in Patients With<br />
Primary Sjögren Syndrome. Pilar Brito-Zerón 1 , Natalia<br />
Soria 1 , Norma Nardi 1 , Alfonso Vargas 1 , Sandra Muñoz 1 ,<br />
Albert Bové 1 , Francisco Lozano 2 , Manuel Ramos-Casals 1 .<br />
1<br />
Laboratory of Basic Research in Autoimmune Diseases,<br />
IDIBAPS, Hospital Clinic, Barcelona, Spain; 2 Department<br />
of Immunology, Hospital Clinic, Barcelona, Spain.<br />
(209)-1595. Mannose-Binding Lectin Polymorphisms in Primary<br />
Sjögren’s Syndrome: Prevalence and Cinical Significance in 137<br />
Patients. Pilar Brito-Zerón 1 , Natalia Soria 1 , Norma Nardi 1 ,<br />
Alfonso Vargas 1 , Sandra Muñoz 1 , Francisco Lozano 2 ,<br />
Manuel Ramos-Casals 1 . 1 Laboratory of Basic Research<br />
in Autoimmune Diseases, IDIBAPS, Hospital Clinic,<br />
Barcelona, Spain; 2 Department of Immunology, Hospital<br />
Clinic, Barcelona, Spain.<br />
(210)-1596. Selective Toll-like Receptor 7/8/9 Antagonists for<br />
the Oral Treatment of Autoimmune Diseases. Grayson Lipford 1 ,<br />
Alexandra Forsbach 2 , Charles Zepp 1 , Toan Nguyen 1 , Risini<br />
Weeratna 3 , Mike McCluskie 3 , Jorg Vollmer 2 , Heather<br />
Davis 3 , Arthur M. Krieg 1 . 1 Coley Pharmaceutical Group,<br />
Wellesley, MA; 2 Coley Pharmaceutical GmbH, Langenfeld,<br />
Germany; 3 Coley Pharmaceutical Group, Kanata, ON, Canada.<br />
(211)-1597. Differential Induction of IL-23 Subunits by TLR<br />
Ligands in Rheumatoid Arthritis Synovial Fibroblasts and<br />
Monocytes. Fabia Brentano 1 , Caroline Ospelt 1 , Joanna<br />
Stanczyk 1 , Renate E. Gay 1 , Christoph Kolling 2 , Steffen Gay 1 ,<br />
Diego Kyburz 1 . 1 Center of Experimental Rheumatology and<br />
Zurich Center of Integrative Human Physiology (ZIHP),<br />
University Hospital of Zurich, Switzerland; 2 Schulthess<br />
Clinic, Zurich, Switzerland.<br />
(212)-1598. Induction and Activation of the Pattern Recognition<br />
Receptor Nod2 in Rheumatoid Arthritis. Caroline Ospelt 1 , Fabia<br />
Brentano 1 , Beat A. Michel 1 , Beat R. Simmen 2 , Renate E.<br />
Gay 1 , Steffen Gay 1 . 1 Center of Experimental Rheumatology,<br />
University Hospital Zurich and Zurich Center of Integrative<br />
Human Physiology (ZIHP), Zurich, Switzerland; 2 Schulthess<br />
Clinic, Zurich, Switzerland.<br />
(213)-1599. RNA Interference of MEFV Reveals Potential Genes<br />
Regulated by Pyrin. Geryl M. Wood 1 , James Balow, Jr. 1 , Hong-<br />
Wei Sun 1 , Nitza Shoham 2 , Daniel L. Kastner 1 . 1 National<br />
Institutes of Health, Bethesda, MD; 2 Allergy Immunology<br />
Laboratory, Meir Hospital, Israel.<br />
(214)-1600. Post-Translational Changes in the Anti-Apoptotic<br />
Protein, Mcl-1 Regulate Apoptosis in Inflammatory Cells. Andrew<br />
Cross, Luke Thomas, Robert Moots, Steven Edwards.<br />
University of Liverpool, Liverpool, United Kingdom.<br />
(215)-1601. Characterization of Null Mice Reveals New Roles<br />
for Pyrin in Innate Immunity. Jae Jin Chae 1 , Silvia Stojanov 1 ,<br />
P. Paul Liu 2 , Daniel L. Kastner 1 . 1 NIAMS, Bethesda, MD;<br />
2<br />
NHGRI, Bethesda, MD.<br />
(216)-1602. Endogenous LINE-1 (L1) Retrotransposon Elements:<br />
Candidate Triggers of Type I Interferon (IFN) Production in<br />
Autoimmune Disorders. Clio P. Mavragani 1 , Efstathia K.<br />
Kapsogeorgou 2 , Drew Pierce 1 , Surya Seshan 3 , Haralampos<br />
M. Moutsopoulos 2 , Mary K. Crow 1 . 1 Hospital for Special<br />
Surgery, New York, NY; 2 Department of Pathophysiology,<br />
School of Medicine, University of Athens, Athens, Greece;<br />
3<br />
Department of Pathology, Weill Medical College of<br />
Cornell University, New York, NY.<br />
(217)-1603. CD56bright NK and NKT Cells are Enriched at<br />
the Site of Inflammation, are Activated and are Associated with<br />
Increased Intracellular Cytokine Production. Ceara AE Walsh,<br />
Dr, Lucy Golden-Mason, Dr, Douglas J. Veale, Prof, Barry<br />
Bresnihan, Prof, Oliver FitzGerald, Prof, Ursula Fearon, Dr.<br />
St Vincent’s University Hospital, Dublin, Ireland.<br />
(218)-1604. Withdrawal of Anti-TNF-Alpha Therapy in<br />
Patients with Rheumatoid Arthritis in Clinical Remission: Can<br />
Maintenance of Remission be Predicted?. Ceara AE Walsh,<br />
Dr, Douglas J. Veale, Prof, Oliver FitzGerald, Prof, Ursula<br />
Fearon, Dr, Barry Bresnihan, Prof. St Vincent’s University<br />
Hospital, Dublin, Ireland.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 247
Poster Session c<br />
(219)-1605. FcγR and TLR-Induced ERK1/2 Activation and<br />
Cytokine Production in Primary Murine and Human Macrophages<br />
is Regulated by the Tpl2 Kinase. Irene Kyrmizi, Marianna<br />
Ioannou, Christiana Choulaki, Dimitrios T. Boumpas,<br />
Ioannis Tassiulas. University of Crete Medical School,<br />
Heraklion, Greece.<br />
(220)-1606. Cd19, A Critical Signal Transduction Molecule<br />
Of B Lymphocytes, Regulates Skin Wound Healing Through<br />
Controlling Toll-like Receptor Signaling And Cytokine Production<br />
By B Lymphocytes. Yohei Iwata 1 , Kazuhiro Komura 1 ,<br />
Fumihide Ogawa 1 , Toshihide Hara 1 , Kazuhiro Shimizu 1 ,<br />
Sangjae Bae 1 , Yasushi Tomita 2 , Thomas F. Tedder 3 , Shinichi<br />
Sato 1 . 1 Nagasaki University Graduate School of Biomedical<br />
Sciences, Nagasaki, Japan; 2 Nagoya University Graduate<br />
School of Medicine, Nagoya, Japan; 3 Duke University<br />
Medical Center, Durham, NC.<br />
(221)-1607. CD11b/CD18 Mediates Distinct Anti-Inflammatory<br />
Response and Post Transcriptional NFkB-Dependent Blockade<br />
Following Interaction but not Engulfment of iC3b-Opsonized<br />
Apoptotic Cells. Gil Amerilyo, Inna Reiner, Mizhir Atallah,<br />
Dror Mevorach. Hadassah, Jerusalem, Israel.<br />
(222)-1608. Apoptotic Cells Suppress Dendritic Cell Cytokine<br />
Production in a Complement Receptor 3 Independent Manner.<br />
Edward M. Behrens, Nidal Muvarak, Philip W. Zoltick,<br />
Alan W. Flake, Stefania Gallucci. Children’s Hospital of<br />
Philadelphia, Philadelphia, PA.<br />
(223)-1609. Role of Scavenger Receptors in the Clearance of<br />
Apoptotic Cells and Ox-LDL by CD14+ Cells of SLE Patients.<br />
Lina M. Yassin 1 , Luis A. Ramírez 1 , Juan DeSanctis 2 ,<br />
Mauricio Rojas 1 , Luis F. García 1 , Gloria M. Vásquez 1 .<br />
1<br />
Universidad de Antioquia, Medellín, Colombia;<br />
2<br />
Universidad Central de Venezuela, Caracas, Venezuela.<br />
(224)-1610. Steroids and Methotrexate do not Effect the Rate<br />
of Tuberculin Skin Test Positivity in Patients being Screened for<br />
Anti-TNF Therapy. Patricia Kavanagh, Bryan R. Whelan,<br />
Ann Cassidy, Norma Ferris, Suzanne Donnelly, Geraldine<br />
M. McCarthy, Conor J. McCarthy. Mater Hospital,<br />
Dublin, Ireland.<br />
(225)-1611. A Decrease in Natural Killer Cell Activity in<br />
Patients with Rheumatoid Arthritis during Treatment with<br />
Biologic Agents: One of the Risk Factors for Malignancy.<br />
Toshiyuki Aramaki 1 , Hiroaki Ida 1 , Hideki Nakamura 1 ,<br />
Tomoki Origuchi 1 , Atsushi Kawakami 1 , Naoki Matsuoka 2 ,<br />
Katsumi Eguchi 1 . 1 Nagasaki University Hospital of<br />
Medicine and Dentistry, Graduate School of Biomedical<br />
Sciences, Nagasaki, Japan; 2 Nagasaki Medical Hospital of<br />
Rheumatology, Nagasaki, Japan.<br />
(226)-1612. In Vivo Adjuvant Activity of the RNA Component<br />
of the Sm/RNP Lupus Autoantigen. Kindra M. Kelly-Scumpia,<br />
Dina C. Nacionales, Philip O. Scumpia, Jason S. Weinstein,<br />
Sonali Narain, Pui Y. Lee, Lyle L. Moldawer, Minoru Satoh,<br />
Westley H. Reeves. University of Florida, Gainesville, FL.<br />
(227)-1613. A Role for EBV in SLE. Timothy Quan,<br />
Robert M. Roman, Benjamin J. Rudenga, Joe Craft. Yale<br />
University, New Haven, CT.<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Metabolic and Crystal Arthropathies<br />
(228)-1614. Effect of Phosphate on Fibroblast-like Synoviocytes.<br />
Yubo Sun, David Mauerhan, Deepthi Chaturvedi, Bryan<br />
Loeffler, Helen Gruber, Edward Hanley. Carolinas Medical<br />
Center, Charlotte, NC.<br />
(229)-1615. Contrast Phase Microscopy Highly Improves<br />
Detection of Calcium Pyrophosphate Dihydrate (CPPD) Crystals<br />
in Synovial Fluid Samples. Joana Atxotegi, Belen Alvarez,<br />
Fernando Perez-Ruiz. Hospital de Cruces, Baracaldo, Spain.<br />
(230)-1616. Detection of Synovial Fluid Calcium Phosphate<br />
Crystals: A Route to Improved Diagnosis and Characterisation<br />
of Osteoarthritis. Gillian McMahon 1 , Aaron Hernandez-<br />
Santana 1 , Alexander Yavorsky 1 , Alastair Smith 2 , Geraldine<br />
McCarthy 3 . 1 Dublin City University, Dublin, Ireland;<br />
2<br />
University of Leeds, Leeds, United Kingdom; 3 Mater<br />
Misericordiae Hospital, Dublin, Ireland.<br />
(231)-1617. Metabolic Syndrome and Cardiovascular Risk in<br />
Patients with Diffuse Idiopathic Skeletal Hyperostosis (DISH).<br />
Reuven Mader, Irena Novofestovsky, Muhammed Adawi,<br />
Idit Lavi. Ha’Emek Medical Center, Afula, Israel.<br />
(232)-1618. Ultrasound Detects Calcium Pyrophosphate<br />
Dehydrate Crystal Deposition in Hyaline Cartilage more Readily<br />
than Conventional Radiography and MRI in Pyrophosphate<br />
Arthropathy. Ralf G. Thiele 1 , Naomi Schlesinger 2 . 1 University<br />
of Rochester, Rochester, NY; 2 UMDNJ/RWJMS, New<br />
Brunswick, NJ.<br />
(233)-1619. Sodium-Dependent Phosphate Cotransporter Type 1<br />
(NPT1) Sequence Polymorphisms in Patients with Gout. Wako<br />
Urano 1 , Atsuo Taniguchi 1 , Naohiko Anzai 2 , Yoshikatsu<br />
Kanai 2 , Mariko Yamanaka 1 , Hisashi Yamanaka 1 , Hitoshi<br />
Endou 3 , Naoyuki Kamatani 1 . 1 Institute of Rheumatology,<br />
Tokyo Women’s Medical University, Tokyo, Japan;<br />
2<br />
Department of Pharmacology and Toxicology, Kyorin<br />
University School of Medicine, Tokyo, Japan; 3 Department<br />
of Pharmacology and Toxicology, Kyorin University School<br />
of Medicine, Fuji Biomedix Co., Ltd., Tokyo, Japan.<br />
(234)-1620. Uric Acid Directly Promotes T Cell Autoreactivity.<br />
Ryan Webb 1 , Matlock Jeffries 2 , Amr H. Sawalha 3 .<br />
1<br />
Oklahoma Medical Research Foundation, Oklahoma City,<br />
OK; 2 University of Oklahoma Health Sciences Center,<br />
Oklahoma Medical Research Foundation, Oklahoma City,<br />
OK; 3 University of Oklahoma Health Sciences Center,<br />
Department of Veterans Affairs Medical Center, Oklahoma<br />
Medical Research Foundation, Oklahoma City, OK.<br />
248 (Permanent Board Number)-Abstract Number
(235)-1621. Blood Uric Acid (UA) Measurements Using a<br />
Handheld Electrochemical UA Meter are Comparable to Those<br />
Obtained with Current Analytical Standard. Faith D. Ottery 1 ,<br />
William Huang 1 , Royce W. Waltrip 1 , Allan N. Maroli 1 , David<br />
Wright 1 , Y. H. Lin 2 . 1 Savient Pharmaceuticals, Inc., East<br />
Brunswick, NJ; 2 Apex Biotechnology, Ltd, Hsinchu, Taiwan.<br />
(236)-1622. Urate-Lowering Pharmacotherapy with Febuxostat<br />
(FEB) or Allopurinol (ALLO) in African-<strong>American</strong> Subjects with<br />
Gout. M. A. Becker 1 , P. A. MacDonald 2 , E. J. Lloyd 2 , C.<br />
Lademacher 2 , N. Joseph-Ridge 2 . 1 University of Chicago,<br />
Chicago, IL; 2 TAP Pharmaceutical Products Inc, Lake<br />
Forest, IL.<br />
(237)-1623. Expression and Function of Cytokines in Gouty<br />
Arthritis. Jeffrey H. Ruth 1 , Monica D. Arendt 1 , Pamela J.<br />
Mansfield 1 , Alisa E. Koch 2 . 1 University of Michigan, Ann<br />
Arbor, MI; 2 Veterans Administration and University of<br />
Michigan, Ann Arbor, MI.<br />
(238)-1624. A Modified Delphi Exercise to Determine the Extent<br />
of Consensus with OMERACT Outcome Domains for Studies<br />
of Acute and Chronic Gout. William J. Taylor 1 , H. Ralph<br />
Schumacher, Jr 2 , Nicola Dalbeth 3 , for the other coauthors<br />
of the Omeract Gout StudyGroup. 1 University of Otago,<br />
Wellington, New Zealand; 2 University of Pennsylvania,<br />
Philadelphia, PA; 3 University of Auckland, Auckland,<br />
New Zealand.<br />
(239)-1625. Gout and the Risk of Type 2 Diabetes. Hyon<br />
K. Choi 1 , Kenneth H. Svendsen 2 , Eswar Krishnan 3 .<br />
1<br />
Arthritis Research Center of Canada, Vancouver, BC,<br />
Canada; 2 Division of Biostatistics, School of Public Health,<br />
University of Minnesota, Minneapolis, MN; 3 Department<br />
of Medicine/Division of Rheumatology, University of<br />
Pittsburgh,, Pittsburgh, PA.<br />
(240)-1626. Diagnosis of Gout in the Rheumatology, Hospital-<br />
Based Setting Lies Far from that Recommended: Results from the<br />
GEMA (Gout Evaluation Of Management) Study. Fernando<br />
Perez-Ruiz 1 , Eliseo Pascual 2 , Loreto Carmona 3 , Miguel<br />
A. Gonzalez-Gay 4 , Eugenio de Miguel 5 , Inmaculada<br />
Ureña 6 , GEMA Study Group, Fundación Española de<br />
Reumatologia. 1 Hospital de Cruces, Baracaldo, Spain;<br />
2<br />
Hospital General de Alicante, Alicante, Spain; 3 Fundación<br />
Española de Reumatologia, Madrid, Spain; 4 Hospital<br />
de Lugo, Lugo, Spain; 5 Hospital La Paz, Madrid, Spain;<br />
6<br />
Hopital Carlos Haya, Malaga, Spain.<br />
(241)-1627. Validation of Gout Clinical Diagnostic Criteria in<br />
VA Patients Compared with the Gold Standard of Synovial Fluid<br />
Crystal Analysis. Aarti Malik, H. Ralph Schumacher, Janet<br />
E. Dinnella, Gilda M. Clayburne. Veteran’s Affairs Medical<br />
Center, Philadelphia, PA.<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Miscellaneous Rheumatic and Inflammatory Diseases II<br />
(242)-1628. Anti-inflammatory Role of Endomorphins in<br />
Osteoarthritis, Rheumatoid Arthritis, and Adjuvant Arthritis.<br />
Rainer H. Straub 1 , Christine Wolff 1 , Alexander Faßold 1 ,<br />
Rafael Hofbauer 1 , Antonio Chover-Gonzalez 2 , Louise J.<br />
Richards 3 , David S. Jessop 3 . 1 University Hospital Regensburg,<br />
Regensburg, Germany; 2 University of Cadiz, Cadiz, Spain;<br />
3<br />
University of Bristol, Bristol, United Kingdom.<br />
(243)-1629. Castleman’s Disease: Main Characteristics in a<br />
Series of 37 Patients. Damien Sène, Zahir Amoura, Aurélien<br />
Delluc, Bertrand Wechsler, Frédéric Charlotte, Philippe<br />
Bossi, Sylvain Choquet, Jean Charles Piette, Patrice Cacoub.<br />
Pitie Salpetriere Hospital, Paris, Paris, France.<br />
(244)-1630. Eosinophilic Fasciitis: Clinical, Biological,<br />
Histological and Therapeutic Features from a Series of 28 Patients.<br />
Damien Sène 1 , David Lebeau 1 , Camille Francès 2 , Bertrand<br />
Wechsler 1 , Zahir Amoura 1 , Thierry Maisonobe 1 , Stéphane<br />
Barete 1 , Olivier Benveniste 1 , Patrice Cacoub 1 , Jean Charles<br />
Piette 1 . 1 Pitie Salpetriere Hospital, Paris, Paris, France;<br />
2<br />
Tenon Hospital, Paris, Paris, France.<br />
(245)-1631. Pamidronate: An Effective Tool in Treating Tarsal<br />
Arthropathy. Sathish Kallankara, Tim J. Gillott, Tim J. Tait.<br />
Department of Rheumatology,Diana Princess of Wales<br />
Hospital, Grimsby, United Kingdom.<br />
(246)-1632. Subclinical Inflammation in Myocardium of<br />
Patients with Inflammatory Rheumatic Diseases (IRD). Cecilia<br />
Grundtman 1 , Ivana Hollan 2 , Knut Mikkelsen 2 , Øystein<br />
T. Førre 2 , Kjell Saatvedt 3 , Ingrid Lundberg 4 . 1 Karolinska<br />
institute, Stockholm, Sweden; 2 Revmatismesykehuset,<br />
Lillehammer, Norway; 3 Rikshospitalet University Hospital,<br />
Oslo, Norway; 4 Karolinska Institute, Stockholm, Sweden.<br />
(247)-1633. Clinical Study of 1124 Cases of Ehlers-Danlos<br />
Syndrome (Classic EDS, JHS and Vascular EDS). Jaime F.<br />
Bravo 1 , Carlos Wolff 2 . 1 Clinica Arauco Salud and San Juan<br />
de Dios Hospital, Santiago, Chile; 2 University of Chile, San<br />
Juan de Dios Hospital. Santiago, Chile.<br />
(248)-1634. Interferon-Inducible Gene Expression in Peripheral<br />
Blood Mononuclear Cells is the Same in Mixed Connective Tissue<br />
Disease Patients as in Lupus Patients. Maria F. Carpintero 1 ,<br />
Kimberly Jaimes 2 , Judith Pignac-Kobinger 1 , Magdalena<br />
Perez 1 , Robert W. Hoffman 1 , Eric L. Greidinger 1 .<br />
1<br />
University of Miami Medical School, Miami, FL; 2 Miami<br />
VAMC, Miami, FL.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 249
Poster Session c<br />
(249)-1635. PTPN22 Gene Polymorphism in Inflammatory<br />
Rheumatological Disorders in Turkey. Nilufer Sahin, MD 1 ,<br />
Nevsun Inanc, MD 1 , Muge Bicakcigil, MD 1 , Haner<br />
Direskeneli, MD 1 , Guher Saruhan Direskeneli, MD 2 .<br />
1<br />
Marmara University Medical School, Istanbul, Turkey;<br />
2<br />
Istanbul Medical Faculty, Istanbul, Turkey.<br />
(250)-1636. Analysis of the Serum Reactivity against Possible<br />
Target Proteins for Anti-endotheial Cell Antibodies from Sera<br />
of Mixed Connective Tissue Disease Patients with Pulmonary<br />
Hypertension. Akihisa Kamataki 1 , Nobuhito Sasaki 1 , Akira<br />
Hatakeyama 2 , Takashi Sawai 1 . 1 Iwate Medical University,<br />
Morioka, Japan; 2 Tohoku Rosai Hospital, Japan Labor<br />
Health and Welfare Organization, Sendai, Japan.<br />
(251)-1637. Antinociceptive and Anti-Inflammatory Effects of<br />
Achyrantes Japonica Bark Extract. Seong-Su Nah 1 , Young-<br />
Ok Kim 2 , Joo-Ho Chung 2 , Seung-Jae Hong 3 . 1 University<br />
of Ulsan College of Medicine, Asan Medical Center,<br />
Seoul, Republic of Korea; 2 Kohwang Medical Research<br />
Institute, Kyung Hee University, Seoul, Republic of Korea;<br />
3<br />
Department of Rheumatology, KyungHee University,<br />
Seoul, Republic of Korea.<br />
(252)-1638. Clinical Characteristics of Patients Presenting<br />
with Oligoarthritis in a Very Early Arthritis Clinic in Norway:<br />
Predictors of Persistent Arthritis at Six Month Follow-Up. Maria<br />
D. Mjaavatten 1 , Halvor Nygaard 2 , Knut Helgetveit 3 , Anne<br />
J. Haugen 4 , Tore K. Kvien 1 . 1 Diakonhjemmet hospital,<br />
0319 Oslo, Norway; 2 Lillehammer Hospital for Rheumatic<br />
Diseases, Lillehammer, Norway; 3 Martina Hansen’s<br />
Hospital, Sandvika, Norway; 4 Sykehuset Østfold Sarpsborg,<br />
Sarpsborg, Norway.<br />
(253)-1639. Sialylation Differences between Different Commercial<br />
Preparations of Intravenous Immune Globulin (IVIG):<br />
Implications for Efficacy. John Axford 1 , Owen Fraser 1 , Sujoy<br />
Khan 2 , Azita Alavi 1 , Edward Tarelli 3 , Carrock Sewell 2 . 1 The<br />
Sir Joseph Hotung Centre for Musculoskeletal Diseases, St<br />
George’s University, London, United Kingdom; 2 Lincoln<br />
University Centre for Immunoglobulin Therapy, Lincoln,<br />
United Kingdom; 3 Medical Biomics Centre, St George’s<br />
University, London, United Kingdom.<br />
(254)-1640. Evaluation of Immunohistological Changes After<br />
Intra-Articular Etanercept Treatment for Diffuse Pigmented<br />
Villonodular Knee Synovitis. Paolo Sfriso, Ugo Fiocco,<br />
Roberto Nardacchione, Elena Scagliori, Federica Sovran,<br />
Antonio Di Maggio, Elisa Pagnin, Costantino Botsios,<br />
Francesca Lunardi, Luca Braghetto, Leonardo Punzi.<br />
University of Padova, Padova, Italy.<br />
(255)-1641. CARD15 Analysis in a Patient with Multi-System<br />
Inflammation. Allyson Chambers, Marie O’Brien, Sergio A.<br />
Jimenez, Charlene J. Williams. Thomas Jefferson University,<br />
Philadelphia, PA.<br />
(256)-1642. Relapsing Polychondritis in 19 Patients from<br />
Colombia. Carlos Enrique Toro Gutierrez, MD 1 , Mario<br />
Andres Quintana, MD 1 , Carlos Alberto Cañas, MD 2 , Carlo<br />
Vinicio Caballero, MD 3 , Ruben Dario Mantilla, MD 4 ,<br />
Constanza LaTorre, MD 4 , Noemi Casas, MD 4 , Federico<br />
Rondon, MD 1 , Jose Felix Restrepo, MD 1 , Antonio Iglesias<br />
Gamarra, MD 1 . 1 Universidad Nacional de Colombia,<br />
Bogota, Colombia; 2 Fundacion Clinica Valle del Lili, Cali,<br />
Colombia; 3 Universidad del Norte, Barranquilla, Colombia;<br />
4<br />
Clinica CAYRE, Bogota, Colombia.<br />
(257)-1643. Progressive Multifocal Leukoencephalopathy in<br />
Rheumatic Diseases. Eamonn S. Molloy, Deren Huang,<br />
Richard M. Ransohoff, Leonard H. Calabrese. Cleveland<br />
Clinic, Cleveland, OH.<br />
(258)-1644. Clinical Characteristics of Fasciitis Paniculitis<br />
Syndrome in Comparison with Eosinophilic Fasciitis. Makoto<br />
Soejima, Tomoko Sugiura, Yasushi Kawaguchi, Takashi Kato,<br />
Sayumi Baba, Tokiko Kanno, Hisae Ichida, Ayako Nakajima,<br />
Naoyuki Kamatani, Masako Hara. Institute of Rheumatology,<br />
Tokyo Women’s Medical University, Tokyo, Japan.<br />
(259)-1645. Clinical Characteristics and Outcome of 10<br />
Consecutive Patients with Adult Onset Still Disease Associated<br />
Macrophage Activation Syndrome. Arnaud Hot, Myew-Ling<br />
Toh, Brigitte Coppéré, Laurent Perard, Marie Hélène<br />
Girard Madoux, Marie Simon, Hélène Desmurs-Clavel,<br />
Martine French, Jacques Ninet. Hopital Edouard Herriot,<br />
Lyon, France.<br />
(260)-1646. Long-Term Outcome of Local Corticosteroid Injection<br />
vs. Surgery in Carpal Tunnel Syndrome: An Observational<br />
Extension of a Randomized Clinical Trial. Domingo Ly-Pen 1 ,<br />
José-Luis Andreu 2 , Isabel Millán 3 , Gemma de Blas 4 , Alberto<br />
Sánchez-Olaso 5 . 1 Centro de Salud Gandhi, Madrid, Spain;<br />
2<br />
Rheumatology Unit. Hospital Universitario Puerta de<br />
Hierro, Madrid, Spain; 3 Biostatistics. Hospital Universitario<br />
Puerta de Hierro, Madrid, Spain; 4 Neurophysiology Unit.<br />
Hospital Universitario Ramón y Cajal., Madrid, Spain;<br />
5<br />
Plastic Surgery Unit. Hospital Universitario Ramón y<br />
Cajal., Madrid, Spain.<br />
(261)-1647. Myeloid DC Function and BDNF in Sarcoidosis.<br />
Sneha Mathew 1 , Arne Fishoeder 2 , Nina Bhardwaj 1 , Stephen<br />
J. Oliver 1 . 1 New York University School of Medicine, New<br />
York, NY; 2 Charite Hospital, Berlin, Germany.<br />
250 (Permanent Board Number)-Abstract Number
(262)-1648. Off-Label Use of Biological Therapies in Systemic<br />
Autoimmune Diseases. Description of 1140 Registered Cases<br />
(International Registry of Biological Agents in SAD, iBIOGEAS).<br />
Manuel Ramos-Casals 1 , Francisco J. García-Hernández 2 ,<br />
Agustín Martínez-Berriotxoa 3 , Lucio Pallarés 4 , Albert<br />
Selva-O’Callaghan 5 , José Luis Callejas 6 , Agustín Colodro 7 ,<br />
Francisco Medrano 8 , María Luisa Micó 9 , The BIOGEAS<br />
Study Group. 1 Department of Autoimmune Diseases,<br />
Hospital Clinic, Barcelona, Spain; 2 Colagenosis Unit,<br />
Department of Internal Medicine, Virgen del Rocío<br />
Hospital, Sevilla, Spain; 3 Department of Internal Medicine,<br />
Hospital de Cruces, Bizcaia, Spain; 4 Department of Internal<br />
Medicine, Son Dureta Hospital, Palma de Mallorca, Spain;<br />
5<br />
Department of Internal Medicine, Vall d’Hebrón Hospital,<br />
Barcelona, Spain; 6 Unit of Systemic Autoimmune Diseases,<br />
San Cecilio Hospital, Granada, Spain; 7 Department<br />
of Internal Medicine, University Hospital of Albacete,<br />
Albacete, Spain; 8 Department of Internal Medicine,<br />
Complejo Hospitalario de Jaén, Jaén, Spain; 9 Department of<br />
Internal Medicine, La Fe Hospital, Valencia, Spain.<br />
(263)-1649. Development of a Screening Tool for Inflammatory<br />
Arthritis Referrals Using the Sensitivity and Specificity of Pain<br />
Diagrams for Diagnosis in Rheumatic Diseases in a Large<br />
Referral Cohort. Angela Caines, Janet E. Pope, Andrew E.<br />
Thompson, Gillian M. Ouimet. St. Joseph’s Health Care<br />
London, London, ON, Canada.<br />
(264)-1650. Cardiac Magnetic Resonance Imaging in Churg-<br />
Strauss Syndrome. David W. McCarey, Nicola L. Walker,<br />
Darshan Kumar, Susan M. Fraser. Southern General<br />
Hospital, Glasgow, United Kingdom.<br />
(265)-1651. Prevalence of Anti-Agalactosyl IgG Antibodies and<br />
Anti-CCP Antibodies In Non-Rheumatoid Arthritis Diseases.<br />
Hee Jung Ryu, Jin Hyun Kim, Jae Ki Koh, Eun Young Lee,<br />
Eun Bong Lee, Yeong Wook Song. Department of Internal<br />
Medicine, Seoul National University, College of Medicine,<br />
Seoul, Republic of Korea.<br />
(266)-1652. Focal Hypertrophic Myositis of the Calf Following S1<br />
Radiculopathy: A New Case and Systematic Literature Review.<br />
Xavier Puéchal, Raphaël Gross, Céline Degive, Emmanuelle<br />
Dernis, Monique Plat, Odile Dubourg. Department of<br />
Rheumatology, Le Mans, France.<br />
(267)-1653. Non-Steroidal Anti-Inflammatory Drug (NSAID)<br />
Prescription Preferences among Chronic Rofecoxib Users after<br />
Rofecoxib Withdrawal. Merih Birlik 1 , Yusuf Savran 1 , Gercek<br />
Can 1 , Sedat Capar 2 , Servet Akar 1 , Ismail Sari 1 , Fatos Onen 1 ,<br />
Nurullah Akkoc 1 . 1 Dokuz Eylul University School of<br />
Medicine, Izmir, Turkey; 2 Dokuz Eylul University Art and<br />
Science Faculty,Statistics, Izmir, Turkey.<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Muscle Biology, Myositis and Myopathies<br />
(268)-1654. Frequency of Metabolic Myopathies in the<br />
Biochemical Analysis of Muscle Disease. Alan N. Baer 1 ,<br />
Georgirene D. Vladutiu 2 . 1 Johns Hopkins University,<br />
Baltimore, MD; 2 University at Buffalo, SUNY, Buffalo, NY.<br />
(269)-1655. Abnormal Glucose and Lipid Metabolism and<br />
Impaired Growth and Development are Frequent Endocrine<br />
Findings in Juvenile Myositis. K. Coyle, K. Rother, M. Weise,<br />
A. Ahmed, F. Miller, L. Rider. NIH, DHHS, Bethesda, MD.<br />
(270)-1656. Changes in Fiber Type Characteristics in Patients<br />
with Polymyositis and Dermatomyositis; a Feature Occurring<br />
in the Chronic, Rather Than Early State of Disease. Ingela M.<br />
Loell 1 , Maryam Dastmalchi 1 , Ingrid E. Lundberg 1 , Mona<br />
Esbjörnsson 2 . 1 Medicine, Stockholm, Sweden; 2 Clinical<br />
Physiology, Stockholm, Sweden.<br />
(271)-1657. Idiopathic Inflammatory Myopathies in a Large<br />
Population-based Sample: Incidence and Patient Characteristics. S.<br />
Bernatsky, C. A. Pineau, L. Joseph, J.F. Boivin, Y. St. Pierre,<br />
A. E. Clarke. McGill University, Montreal, PQ, Canada.<br />
(272)-1658. Race is a Major Predictor of Death in Patient’s<br />
with Idiopathic Inflammatory Myopathies (IIM). Shari<br />
Diamond 1 , Douglas Rosing 2 , Mehmooda Naeem 3 , Laura<br />
James-Newton 2 , Frederick Miller 2 , Mark Gourley 2 . 1 George<br />
Washington University, Washington, DC; 2 NIH, Bethesda,<br />
MD; 3 NIH, Bethesdsa, MD.<br />
(273)-1659. Towards an Abbreviated Cutaneous Assessment<br />
Tool (CAT) in Juvenile Dermatomyositis. Adam M. Huber 1 ,<br />
Elizabeth M. Dugan 2 , Peter A. Lachenbruch 2 , Frederick W.<br />
Miller 2 , Lisa G. Rider 2 . 1 IWK Health Centre, Halifax, NS,<br />
Canada; 2 NIEHS, NIH, DHHS, Bethesda, MD.<br />
(274)-1660. Clinical Features of Hemophagocytic Syndrome in<br />
Patients with Dermatomyositis. Nobuyuki Yajima, Kuninobu<br />
Wakabayashi, Tsuyoshi Odai, Takeo Isozaki, Mizuho<br />
Matsunawa, Yusuke Miwa, Masao Negishi, Hirotsugu Ide,<br />
Tsuyoshi Kasama. Showa University, Tokyo, Japan.<br />
(275)-1661. Pulmonary Involment in Inflamatory Myopathies.<br />
M. Pilar Ahijado-Guzman, Beatriz E. Joven, Carmen Torres,<br />
F.Javier Gomez-Reino, Maria Galindo, Patricia E. Carreira.<br />
12 Octubre Hospital, Madrid, Spain.<br />
(276)-1662. Successful Treatment of Refractory Interstitial<br />
Pneumonia in Patients with Amyopathic Dermatomyositis by<br />
Combination Immunosuppressive Therapy. Naoaki Hashimoto,<br />
Hideki Kuno, Masayasu Kitano, Masahiro Sekiguchi,<br />
Takanori Kuroiwa, Kiyoshi Matsui, Tsuyoshi Iwasaki, Hajime<br />
Sano. Hyogo College of Medicine, Nishinomiya, Japan.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 251
Poster Session c<br />
(277)-1663. Clinical Classification of Dermatomyositis Using<br />
Myositis-Specific Autoantibodeis and Newly Found Autoantibodies<br />
in Patients with Dermatomyositis. Shinji Sato 1 , Kana Hoshino 1 ,<br />
Takashi Sato 1 , Yukie Yamaguchi 1 , Akira Suwa 2 , Michito<br />
Hirakata 1 , Masataka Kuwana 1 . 1 Keio University School<br />
of Medicine, Tokyo, Japan; 2 Tokai University School of<br />
Medicine, Kanagawa, Japan.<br />
(278)-1664. Myositis-Specific Autoantibodies are Associated<br />
with Specific Histopathological Features on Muscle Biopsies.<br />
Tetsuya Takada 1 , Michito Hirakata 1 , Yumiko Katsuki 1 , Yuko<br />
Kaneko 1 , Shinji Sato 1 , Masataka Kuwana 1 , Akira Suwa 2 ,<br />
Tadayuki Ishihara 3 . 1 Keio University School of Medicine,<br />
Tokyo, Japan; 2 Tokai University School of Medicine,<br />
Isehara, Japan; 3 Hakone National Hospital, Odawara, Japan.<br />
(279)-1665. Clinical Features of Japanese Patients with Anti-<br />
Asparaginyl tRNA Synthetase Autoantibodies: The Immunogenetic<br />
Backgrounds. Michito Hirakata 1 , Akira Suwa 2 , Tetsuya<br />
Takada 1 , Yuko Kaneko 1 , Shinji Sato 1 , Masataka Kuwana 1 .<br />
1<br />
Keio University School of Medicine, Tokyo, Japan; 2 Tokai<br />
University School of Medicine, Isehara, Japan.<br />
(280)-1666. HLA-DPB1*0101 Discriminates Between Anti-Jo-1<br />
and Anti-pm-Scl Antibody Positive UK Caucasians with Idiopathic<br />
Inflammatory Myopathy (IIM). Hector Chinoy 1 , Debbie<br />
Payne 2 , Kay V. Poulton 3 , Noreen Fertig 4 , Chester V. Oddis 4 ,<br />
William E. Ollier 2 , Robert G. Cooper 1 . 1 The University of<br />
Manchester Rheumatic Diseases Centre, Salford, United<br />
Kingdom; 2 Centre for Integrated Genomic Medical<br />
Research, The University of Manchester, Manchester,<br />
United Kingdom; 3 Transplantation Laboratory, Manchester<br />
Royal Infirmary, Manchester, United Kingdom; 4 Division<br />
of Rheumatology & Clinical Immunology, University of<br />
Pittsburgh School of Medicine, Pittsburgh, PA.<br />
(281)-1667. Increased Serum BAFF Levels in Patients with<br />
Inflammatory Myopathies. Olga Krystufkova 1 , Therese<br />
Vallerskog 2 , Sevim B. Helmers 2 , Herman Mann 1 , Ivana<br />
Putova 1 , Vivianne Malmstrom 2 , Christina Trollmo 2 ,<br />
Jiri Vencovsky 1 , Ingrid E. Lundberg 2 . 1 Institute of<br />
Rheumatology, Prague, Czech Republic; 2 Rheumatology<br />
Unit, Department of Medicine, Karolinska University<br />
Hospital, Solna, Karolinska Institutet, Stockholm, Sweden.<br />
(282)-1668. Identification of NADH-Tetrazolium Reductase<br />
(NADH-TR) as a Marker of Microvascular Regeneration in<br />
Dermatomyositis. Christina Charles-Schoeman, Anthony<br />
Verity. University of California, Los Angeles, CA.<br />
(283)-1669. Comparison of Transgenic Mice as an Animal Model<br />
for Calcinosis in Juvenile Dermatomyositis (JDM). Yongdong<br />
Zhao 1 , Lyudnila Spevak 2 , Annette L. Urganus 1 , William<br />
Tse 1 , Adele L. Boskey 2 , Lauren M. Pachman 1 . 1 Childrens<br />
Memorial Research Center, Northwestern University,<br />
Chicago, IL; 2 Hospital for Special Surgery, Cornell<br />
University-Weill Medical College, New York, NY.<br />
(284)-1670. Amelioration of Experimental Arthritis by a Calpaininhibitory<br />
Compound. Hajime Yoshifuji, Takashi Usui,<br />
Yoshinaga Ito, Mikiko Hashimoto, Tsuneyo Mimori. Kyoto<br />
University, Kyoto, Japan.<br />
(285)-1671. Human Cytomegalovirus- A Possible Activator<br />
of the Immune System in Polymyositis and Dermatomyositis.<br />
Andreas E. R. Fasth 1 , Afsar Rahbar 2 , Maryam Dastmalchi 1 ,<br />
Cecilia Söderberg-Naucler 2 , Christina Trollmo 1 , Ingrid E.<br />
Lundberg 1 , Vivianne Malmström 1 . 1 Rheumatology Unit,<br />
Department of Medicine, Karolinska Institutet, Stockholm,<br />
Sweden; 2 Center for Molecular Medicine, Karolinska<br />
Institutet, Stockholm, Sweden.<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Osteoarthritis: Clinical Aspects II<br />
(286)-1672. Does Syringe Size Matter in Physician-Performed<br />
Procedures, Including Arthrocentesis? Adrian A. Michael, Jr.,<br />
Courtney R. Johnson, Kye S. Park, Gautam R. Moorjani,<br />
Wilmer L. Sibbitt, Arthur D. Bankhurst. University of New<br />
Mexico Health Sciences Center, Albuquerque, NM.<br />
(287)-1673. Artist (Osteoarthritis Intervention Standardized) A<br />
Cluster Randomised Controlled Trial Comparing Standardized<br />
Consultation to Usual Care for Patients with Knee Osteoarthritis<br />
in Primary Care Setting. Philippe Ravaud 1 , René-Marc Flipo 2 ,<br />
Thao Pham 3 , Bruno Giraudeau 4 , Carine Roy 1 . 1 Groupe<br />
Hospitalier Bichat-Claude Bernard, Paris, France; 2 Service<br />
de Rhumatologie - Chu de Lille, Lille, France; 3 Service de<br />
Rhumatologie - Hôpital de la Conception, Marseille, France;<br />
4<br />
Inserm Cic 202, Tours, France.<br />
(288)-1674. Efficacy and Safety of Diclofenac Sodium Gel 1% in<br />
Patients with Osteoarthritis of the Hand: A Prospective, 8-Week,<br />
Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Phase<br />
3 Trial. Roy Altman 1 , Josef Zacher 2 , Renée Liliane Dreiser 3 ,<br />
Chester Fisher 4 , Walter F. Chase 5 , Donatus S. Dreher 6 .<br />
1<br />
n/a, Agua Dulce, CA; 2 HELIOS Klinikum Berlin - Buch,<br />
Berlin, Germany; 3 N/a, Paris, France; 4 Health Research<br />
of Hampton Roads, Inc., Newport News, VA; 5 Walter F.<br />
Chase, MD, PA, Austin, TX; 6 Novartis Consumer Health<br />
S.A., Nyon, Switzerland.<br />
(289)-1675. Efficacy and Safety of Diclofenac Sodium Gel 1%<br />
in Patients With Osteoarthritis of the Knee: A Prospective, 12-<br />
Week, Randomized, Double-Blind, Vehicle-Controlled, Multicenter,<br />
Phase 3 Trial. H. Richard Barthel 1 , Douglas Haselwood 2 ,<br />
Parimal Parikh 3 , Morris Gold 4 . 1 Santa Barbara, CA; 2 MED<br />
Investigations, Inc., Fair Oaks, CA; 3 Best Clinical Trial,<br />
LLC, New Orleans, LA; 4 Novartis Consumer Health,<br />
Parsippany, NJ.<br />
252 (Permanent Board Number)-Abstract Number
(290)-1676. Joint Distraction in the Treatment of Severe Knee<br />
Osteoarthritis; the First Clinical Results. Femke Intema 1 ,<br />
Peter M. van Roermund 2 , Johannes WJ Bijlsma 1 , Anne<br />
CA Marijnissen 1 , Floris PJG Lafeber 1 . 1 University Medical<br />
Center Utrecht, Rheumatology & Clinical Immunology,<br />
Utrecht, The Netherlands; 2 UMC Utrecht, Orthopedics,<br />
Utrecht, The Netherlands.<br />
(291)-1677. Randomized, Double-Blind Trial to Assess<br />
the Efficacy of Hyaluronan in Thumb Carpometacarpal<br />
Osteoarthritis. Karen Ebina, Carla Gonçalves, Fernanda R.<br />
Lima, Ricardo Fuller. Rheumatology Division, University of<br />
Sao Paulo, Sao Paulo, Brazil.<br />
(292)-1678. Efficacy and Safety of Naproxcinod Compared to<br />
Placebo and Naproxen in Patients with Osteoarthritis of the Knee:<br />
Results from a 13-Week Randomized Double-Blind Trial. Thomas<br />
Schnitzer 1 , Alan Kivitz 2 , Bruce Rankin 3 , Chester Fisher 4 ,<br />
Richard Fishman 5 , Howard Marker 6 , Hayet Frayssinet 7 ,<br />
Brigitte Duquesroix 7 . 1 Northwestern University, Chicago,<br />
IL; 2 Altoona Center for Clinical Research, Duncansville,<br />
PA; 3 University Clinical Research Deland, Deland, FL;<br />
4<br />
Health Research of Hampton Roads, Newport News, VA;<br />
5<br />
Palm Beach Research Center, Pico Rivera, CA; 6 Sarah<br />
Cannon Research Institute, LLC, Memphis, TN; 7 NicOx,<br />
Sophia-Antipolis, France.<br />
(293)-1679. A Randomized, Double-Blind, Placebo-Controlled<br />
Trial of Lumiracoxib in Patients with Primary Hip Osteoarthritis<br />
using Celecoxib as a Positive Control. Thomas Schnitzer 1 , I<br />
Dan Dattani 2 , Bruno Seriolo 3 , Hartmut Schneider 4 , Sue<br />
Yu 5 , Lillian Tseng 5 , Peter Sallstig 6 , Rosemary Rebuli 6 , Tom<br />
Maxwell 7 . 1 Northwestern Center for Clinical Research,<br />
Chicago, IL; 2 Prairie Clinical Research Group, Saskatoon,<br />
SK, Canada; 3 Clinica Reumatologica, D.I.M.I. e Specialità<br />
Mediche, Università di Genova, Genova, Italy; 4 Facharzt<br />
für Orthopädie/Sportmedizin, Kurstraβe 9, 61231,<br />
Bad Nauheim, Germany; 5 Novartis Pharmaceuticals<br />
Corporation, East Hanover, NJ; 6 Novartis Pharma AG,<br />
Basel, Switzerland; 7 Little Common Surgery, Cooden Sea<br />
Road, United Kingdom.<br />
(294)-1680. Reduced Intestinal Injury with Lumiracoxib<br />
Compared to Naproxen Plus Proton Pump Inhibitor. C. Hawkey 1 ,<br />
C. Ell 2 , B. Simon 3 , J. Albert 4 , M. Keuchel 5 , M. McAlindon 6 ,<br />
J. Hugot 7 , U. Arulmani 7 , V. Yu 8 , G. Krammer 7 , R. Rebuli 7 ,<br />
E. Toth 9 . 1 Wolfson Digestive Diseases,Queen’s Medical<br />
Centre, Nottingham, United Kingdom; 2 Department<br />
of Internal Medicine II, HSK, Wiesbaden, Germany;<br />
3<br />
Department of Internal Medicine, Kreiskrankenhaus<br />
Schwetzingen, Germany; 4 Martin-Luther-University of<br />
Halle-Wittenberg, Halle, Germany; 5 Asklepios Klinik<br />
Altona, Hamburg, Germany; 6 Royal Hallamshire Hospital,<br />
Sheffield, United Kingdom; 7 Novartis Pharma AG, Basel,<br />
Switzerland; 8 Novartis Pharmaceuticals Corporation, East<br />
Hanover, NJ; 9 Department of Medicine, Malmo University<br />
Hospital, Malmo, Sweden.<br />
(295)-1681. Improved Blood Pressure Control with Lumiracoxib<br />
Compared with Ibuprofen: A Randomized Trial in Osteoarthritis<br />
Patients with Controlled Hypertension. Thomas M.<br />
MacDonald 1 , Jean-Yves Reginster 2 , Thomas W. Littlejohn 3 ,<br />
Dominik Richard 4 , Karine Lheritier 4 , Gerhard Krammer 4 .<br />
1<br />
Ninewells Hospital and Medical School, Dundee, United<br />
Kingdom; 2 CHU Polyclinique, Liège, Belgium; 3 Piedmont<br />
Medical Research Associates Inc., Winston-Salem, NC;<br />
4<br />
Novartis Pharma AG, Basel, Switzerland.<br />
(296)-1682. Tapentadol Extended Release (ER) is Effective for<br />
the Relief of Chronic Pain Due to Osteoarthritis (OA) of the<br />
Knee. Christine Rauschkolb-Loeffler 1 , Akiko Okamoto 1 ,<br />
Achim Steup 2 , Claudia Lange 2 . 1 Johnson and Johnson,<br />
Pharmaceutical Research and Development, Titusville, NJ;<br />
2<br />
Grünenthal GmbH, Aachen, Germany.<br />
(297)-1683. COX-2 Inhibition in Osteoarthritis: Effects on<br />
Cartilage, a Clinical Ex vivo Approach. Simon C. Mastbergen 1 ,<br />
Magriet A. Huisman 2 , Tineke N. De Boer 1 , Astrid A. Polak 2 ,<br />
Johannes WJ Bijlsma 1 , Floris PJG Lafeber 1 . 1 University<br />
Medical Center Utrecht, Rheumatology & Clinical<br />
Immunology, Utrecht, The Netherlands; 2 Sint Franciscus<br />
Gasthuis, Orthopaedics, Rotterdam, The Netherlands.<br />
(298)-1684. Results from a Randomized Controlled Trial of<br />
AMG 108 (a fully human monoclonal antibody to IL-1R type<br />
I) in Patients With Osteoarthritis of the Knee. S. Cohen 1 , S.<br />
Proudman 2 , A. Kivitz 3 , F. Burch 4 , JP Donohue 5 , L. Ni 6 , B.<br />
Appleton 6 . 1 St Paul Univ Hosp, Dallas, TX; 2 Royal Adelaide<br />
Hosp, South Australia, Australia; 3 3Altoona Center for<br />
Clinical Research, Duncansville, PA; 4 Radiant Research,<br />
San Antonio, TX; 5 Beth Israel Deaconess Med Ctr, Boston,<br />
MA; 6 Amgen, Thousand Oaks, CA.<br />
(299)-1685. Xylosan Polysulphate as a Symptom Modifying<br />
Osteoarthritis Drug in Patients with Finger Joint Arthritis.. Bert<br />
J. Vander Cruyssen 1 , Qolam Reza Mahrban Moqadam 1 ,<br />
Sara Groeneboer 1 , David Cullis-Hill 2 , Peter Ghosh 3 ,<br />
Gust Verbruggen 1 . 1 Ghent University, Gent, Belgium;<br />
2<br />
Arthropharm, Bondi Junction, Australia; 3 Institute of<br />
Nutraceutical Research, Broovale, Australia.<br />
(300)-1686. Vitamin K in Hand Osteoarthritis: Results from a<br />
Randomized Clinical Trial. T. Neogi 1 , DT Felson 1 , R. Sarno 2 ,<br />
S. Steptoe 2 , N. Palermo 2 , SL Booth 2 . 1 BUSM, Boston, MA;<br />
2<br />
Tufts University, Boston, MA.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 253
Poster Session c<br />
(301)-1687. Polymerized-type I Collagen: A Disease Modifier<br />
Drug for the Treatment of Patients with Knee Osteoarthritis.<br />
Janette Furuzawa-Carballeda, Olga Muñoz-Chable, Salvador<br />
I. Macías-Hernández, Andrés Agualimpia-Janning. Instituto<br />
Nacional de Ciencias Médicas y Nutrición Salvador<br />
Zubirán, Mexico D.F., Mexico.<br />
(302)-1688. Intra-Articular Botulinum Toxin Type A (IA-<br />
BoNT/A) for Refractory Knee pain: randomized Controlled Trial<br />
in Patients with Rheumatoid Arthritis (RA) and Osteoarthritis<br />
(OA). Maren L. Mahowald, Jasvinder A. Singh, Elizabeth<br />
Goelz, Anton Kushnaryov, Hollis E. Krug. Mpls VAMC/<br />
Univ MN, Minneapolis, MN.<br />
(303)-1689. Civamide Cream, 0.075% Provides Safe and<br />
Continued Relief of Osteoarthritis Pain of the Knee in a Year<br />
Long Study. S. B. Phillips 1 , T. J. Schnitzer 2 , J. R. Lisse 3 ,<br />
D. M. Haselwood 4 , W. T. Ellison 5 , J. E. Ervin 6 , R. D.<br />
Gordon 7 , Civamide Cream Study Group, H. B. Fezatte 1 , J.<br />
E. Bernstein 1 . 1 Winston Laboratories, Inc., Vernon Hills,<br />
IL; 2 Feinberg School of Medicine, Northwestern University,<br />
Chicago, IL; 3 University of Arizona, Tucson, AZ; 4 Med.<br />
Investigations, Fair Oaks, CA; 5 Radiant Research, Greer,<br />
SC; 6 Center for Pharmaceutical Research, Kansas City, MO;<br />
7<br />
Arthritis Regional Research Center, Mercerville, NJ.<br />
(304)-1690. Similar Clinically Meaningful Response to Therapy<br />
in Osteoarthritis Patients Treated Daily with Either Etoricoxib 30<br />
mg or Ibuprofen 2400 mg. Judith Boice, Amy T. Ko, Sean P.<br />
Curtis. Merck Research Laboratories, Rahway, NJ.<br />
(305)-1691. Comparison of the Lyon Schuss and Fixed Flexion<br />
Radiographic Techniques; Long-Term Reproducibility in Normal<br />
Knees and Sensitivity to Change in Joint Space Width in<br />
Osteoarthritis. Marie-Pierre Hellio Le Graverand 1 , Eric<br />
Vignon 2 , Kenneth Brandt 3 , Steve Mazzuca 3 , Robert Buck 1 ,<br />
Brad Wyman 1 , Mark Tengowski 1 , and the A9001140<br />
Investigators. 1 Pfizer Global Research and Development,<br />
Ann Arbor, MI; 2 Universite Claude Bernard, Lyon, France;<br />
3<br />
Indiana University School of Medicine, Indianapolis, IN.<br />
(306)-1692. Adequacy of Performance of a Modified Protocol<br />
for the Lyon Schuss (LS) Knee Radiograph: Reproducibility of<br />
Positioning and Sensitivity to Joint Space Narrowing (JSN) in<br />
Knee Osteoarthritis (OA). Marie-Pierre Hellio Le Graverand 1 ,<br />
Steven A. Mazzuca 2 , Eric Vignon 3 , 9001140 Study Group.<br />
1<br />
Pfizer Global Research and Development, Ann Arbor, MI;<br />
2<br />
Indiana University School of Medicine, Indianapolis, IN;<br />
3<br />
Universite Claude Bernard, Lyon, France.<br />
(307)-1693. Progression of Joint Space Narrowing in Knee<br />
Osteoarthritis (OA): An Analytic Literature Synthesis. Parastu S.<br />
Emrani 1 , Jeffrey N. Katz 1 , Courtenay L. Kessler 1 , William M.<br />
Reichmann 1 , Elizabeth A. Wright 1 , Timothy E. McAlindon 2 ,<br />
Elena Losina 1 . 1 Brigham and Women’s Hospital, Boston,<br />
MA; 2 Tufts-New England Medical Center, Boston, MA.<br />
(308)-1694. A New Approach Yields High Rates of X-Ray<br />
Progression in Knee Osteoarthritis (OA). D. T. Felson 1 , M. C.<br />
Nevitt 2 , M. Yang 1 , J. Niu 1 , J. C. Torner 3 , C. E. Lewis 4 , B.<br />
Sack 1 , P. Aliabadi 1 , Y. Zhang 1 . 1 Boston University School<br />
of Medicine, Boston, MA; 2 Univ California, San Francisco,<br />
San Francisco, CA; 3 Univ of Iowa, Iowa City, IA; 4 Univ<br />
Alabama, Birmingham, Birmingham, AL.<br />
(309)-1695. Automated Radiographic Analysis Measurements<br />
in the Medial Tibiofemoral Compartment of the Knee: Intra-<br />
Operator Reproducibility. Tony Lacey 1 , Jane Haslam 1 , Alan<br />
Brett 1 , Mark W. Tengowski 2 . 1 Optasia Medical Ltd,<br />
Cheadle, United Kingdom; 2 Pfizer Global Research &<br />
Development, Ann Arbor, MI.<br />
(310)-1696. Biological Variability of Biochemical Markers<br />
of Bone, Cartilage and Synovial Tissue in Patients with Knee<br />
Osteoarthritis. Patrick Garnero. Synarc, Inserm Unit 664,<br />
Lyon, France.<br />
(311)-1697. Changes in Outcome Measures for Impairments,<br />
Activity Limitation and Participation Restriction Over Two<br />
Years in Osteoarthritis in the Lower Extremities. Stella Botha-<br />
Scheepers, Iain Watt, Frits R. Rosendaal, Ferdinand C.<br />
Breedveld, Margreet Kloppenburg. Leiden University<br />
Medical Center, Leiden, The Netherlands.<br />
(312)-1698. Early Non-Response after Total Hip Replacement<br />
Due to Primary Hip OA. Heike A. Bischoff-Ferrari 1 , Stefan<br />
Schaeren 2 , Juerg Huber 3 , Emanuel Gautier 4 , Brigitte Jolles 5 ,<br />
Walter Dick 2 , Robert Theilet 6 . 1 University Hospital Zurich,<br />
Zurich, Switzerland; 2 University Hospital Basel, Basel,<br />
Switzerland; 3 Kantonal Hospital Aarau, Aarau, Switzerland;<br />
4<br />
Hôpitale Cantonale Fribourg, Fribourg, Switzerland;<br />
5<br />
University Hospital Lausanne, Lausanne, Switzerland;<br />
6<br />
Triemli Hospital, Zurich, Switzerland.<br />
(313)-1699. Veterans With Total Knee or Total Hip Arthroplasty<br />
(TKA, THA) have Poor Physical Health Related Quality<br />
Of Life (HRQoL): A Population-based Study. Jasvinder A.<br />
Singh 1 , Terrence Gioe 1 , Jeff Sloan 2 . 1 Minneapolis VA<br />
Medical Center, Minneapolis, MN; 2 Mayo Clinic School of<br />
Medicine, Rochester, MN.<br />
254 (Permanent Board Number)-Abstract Number
(314)-1700. Creating Comprehensive Item Banks to Improve<br />
Outcome Measurement in OA Research. Alan M. Jette 1 ,<br />
Stephen M. Haley 1 , Pengsheng Ni 1 , Suzanne Olarsch 1 ,<br />
David T. Felson 2 , David J. Hunter 2 . 1 Boston University<br />
School of Public Health, Boston, MA; 2 Boston University<br />
School of Medicine, Boston, MA.<br />
(315)-1701. OAQoL: Development and Preliminary Validation<br />
of a Needs-Based Quality of Life Measure for Osteoarthritis.<br />
Anne-Maree Keenan 1 , Stephen P. McKennan 2 , Lyndan<br />
C. Doward 2 , Philip G. Conaghan 1 , Paul Emery 1 , Alant<br />
Tennant 1 . 1 University of Leeds, Leeds, United Kingdom;<br />
2<br />
Galen, Manchester, United Kingdom.<br />
(316)-1702. Preliminary Psychometric Testing of a New<br />
Osteoarthritis Pain Measure. Gillian A. Hawker 1 , Melissa R.<br />
French 1 , Jolanda Cibere 2 , Joanne M. Jordan 3 , Aileen M.<br />
Davis 1 , Lyn March 4 , Maria Suarez-Almazor 5 , Paul Dieppe 6 .<br />
1<br />
University of Toronto, Toronto, ON, Canada; 2 University<br />
of British Columbia, Vancouver, BC, Canada; 3 University<br />
of North Carolina, Chapel Hill, NC; 4 IBJR, Sydney Uni,<br />
Sydney, Australia; 5 UT MD Anderson Cancer Center,<br />
Houston, TX; 6 MRC HSRC, Bristol, United Kingdom.<br />
(317)-1703. Symptomatic Knee Osteoarthritis is a Risk Factor<br />
for Widespread Pain. J. R. Curtis 1 , G. G. Teng 1 , D. Felson 2 ,<br />
M. Nevitt 3 , J. Niu 2 , K. G. Saag 1 , N. Segal 4 , C. Lewis 1 . 1 UAB,<br />
Birmingham, AL; 2 BUSM, Boston, MA; 3 UCSF, San<br />
Francisco, CA; 4 University of Iowa, Iowa City, IA.<br />
(318)-1704. A Majority of Middle-Aged People with Chronic<br />
Knee Pain Developed Knee Osteoarthritis over 12 Years. Carina<br />
A. Thorstensson 1 , Hanna Jönsson 1 , Maria L.E. Andersson 1 ,<br />
Ingemar F. Petersson 2 . 1 Spenshult Hospital for Rheumatic<br />
Diseases, Oskarström, Sweden; 2 Clinical Sciences, Dept of<br />
Orthopaedics, Lund, Sweden.<br />
(319)-1705. Radiographic Hand Osteoarthritis (OA) in Patients<br />
with Early Rheumatoid Arthritis (RA). M. Güler-Yüksel 1 , C.F.<br />
Allaart 1 , M. Kloppenburg 1 , I. Watt 1 , F.C. Breedveld 1 , B.A.C.<br />
Dijkmans 2 , W.F. Lems 2 . 1 Leiden University Medical Center,<br />
Leiden, The Netherlands; 2 VU Medical Center, Amsterdam,<br />
The Netherlands.<br />
(320)-1706. Do Increasing Obesity and Varus Angulation<br />
Increase the Progression of Knee Osteoarthritis?. Eric Vignon 1 ,<br />
Kenneth Brandt 2 , Steve Mazzuca 2 , Robert Buck 3 , Brad<br />
Wyman 3 , Mark Tengowski 3 , Marie-Pierre Hellio Le<br />
Graverand 3 , and the A9001140 Investigators. 1 Universite<br />
Claude Bernard, Lyon, France; 2 Indiana University School<br />
of Medicine, Indianapolis, IN; 3 Pfizer Global Research and<br />
Development, Ann Arbor, MI.<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Pediatric Rheumatology: From Genes to Cells<br />
(321)-1707. Disease-Associated CIAS1 Mutations Induce<br />
Monocyte Death, Revealing Low-Level Mosaicism in Mutation-<br />
Negative Cryopyrin-Associated Periodic Syndrome Patients.<br />
Megumu Saito 1 , Ryuta Nishikomori 1 , Naotomo Kambe 2 ,<br />
Akihiro Fujisawa 3 , Hideaki Tanizaki 3 , Tomoki Kawai 1 ,<br />
Hidemasa Sakai 1 , Ikuo Okafuji 1 , Takakazu Yoshioka 1 ,<br />
Souichi Adachi 1 , Toshio Heike 1 , Yoshiki Miyachi 3 ,<br />
Tatsutoshi Nakahata 1 . 1 Department of Pediatrics, Kyoto<br />
University Graduate School of Medicine, Kyoto City, Japan;<br />
2<br />
Department of Dermatology, Chiba University Graduate<br />
School of Medicine, Chiba City, Japan; 3 Department<br />
of Dermatology, Kyoto University Graduate School of<br />
Medicine, Kyoto City, Japan.<br />
(322)-1708. Seasonal Clustering of Symptom Onset in the Juvenile<br />
Spondyloarthropathies. Andrew S. Zeft, Adrian Walker,<br />
Bernadette McNally, Bronte Clifford, John F. Bohnsack,<br />
Sampath Prahalad. University of Utah, Salt Lake City, UT.<br />
(323)-1709. Gene Expression Patterns in Peripheral Blood<br />
Mononuclear Cells Identify Biological Differences Between JIA<br />
Subtypes. Michael G. Barnes 1 , Susan D. Thompson 1 , Alexei<br />
A. Grom 1 , Lorie K. Luyrink 1 , Shweta Srivastava 1 , Bruce J.<br />
Aronow 1 , David Sherry 2 , Judyann Olson 3 , Beth Gottlieb 4 ,<br />
Norman Ilowite 5 , Robert A. Colbert 1 , David N. Glass 1 ,<br />
Thomas A. Griffin 1 . 1 Cincinnati Children’s Hospital<br />
Medical Center, Cincinnati, OH; 2 Children’s Hospital of<br />
Pittsburgh, Pittsburgh, PA; 3 Medical College of Wisconsin,<br />
Milwaukee, WI; 4 Schneider Children’s Hopsital, New Hyde<br />
Park, NY; 5 Albert Einstein College of Medicine, Bronx, NY.<br />
(324)-1710. A Systems Biology Approach to JIA: Gene Expression<br />
Profiling Detects Only Small Differences between Children with<br />
Pauciarticular and Polyarticular Disease. James N. Jarvis 1 ,<br />
Nicholas Knowlton 2 , M. Barton Frank 2 , Amita Aggarwal 3 ,<br />
Kaiyu Jiang 1 , Yanmin Chen 1 , Ryan McKee 1 , Julie L.<br />
McGhee 4 , Kathleen M. O’Neil 1 , Brad Chaser 1 , Michael<br />
Centola 2 . 1 U. of Oklahoma Health Sci Ctr, Oklahoma<br />
City, OK; 2 OK Med Research Found, Oklahoma City, OK;<br />
3<br />
Sanjay Gandhi Postgraduate Inst for Med, Lucknow, India;<br />
4<br />
St. Louis Children’s Hospital, St. Louis, MO.<br />
(325)-1711. The Biological Meaning of Clinical Remission in<br />
JIA: A Systems Biology Approach. James N. Jarvis 1 , Nicholas<br />
Knowlton 2 , M. Barton Frank 2 , Amita Aggarwal 3 , Kaiyu<br />
Jiang 1 , Yanmin Chen 1 , Ryan McKee 1 , Julie L. McGhee 4 ,<br />
Kathleen M. O’Neil 1 , Brad Chaser 1 , Michael Centola 2 . 1 U<br />
of Oklahoma College of Med, Oklahoma City, OK; 2 OK<br />
Med Research Found, Oklahoma City, OK; 3 Sanjay Gandhi<br />
Postgraduate Inst for Med, Lucknow, India; 4 St. Louis<br />
Children’s Hospital, St. Louis, MO.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 255
Poster Session c<br />
(326)-1712. Tumor Necrosis Factor Alpha -308 GA/AA<br />
Genotypes are Associated with the Polyarticular Subtype of Juvenile<br />
Idiopathic Arthritis. Ana Filipa SP Mourao 1 , Joana Caetano-<br />
Lopes 2 , Paula Costa 3 , Artur Sousa 3 , Joao Cavaleiro 2 , Jose<br />
Teles 2 , Helena Canhao 4 , Maria J. Santos 5 , Patricia Pinto 6 ,<br />
Iva Brito 6 , Paulo J. Nicola 7 , Jose A. Melo Gomes 8 , Jaime<br />
Branco 9 , Jose Teixeira da Costa 10 , Joao Gomes Pedro 3 ,<br />
Mario Viana Queiroz 10 , Joao E. Fonseca 4 . 1 Rheumatology<br />
Research Unit, Instituto de Medicina Molecular, Faculdade<br />
de Medicina da Universidade de Lisboa and Hospital Egas<br />
Moniz, Lisbon, Portugal; 2 Rheumatology Research Unit,<br />
Instituto de Medicina Molecular, Faculdade de Medicina<br />
da Universidade de Lisboa, Lisbon, Portugal; 3 Pediatrics<br />
Department, Hospital de Santa Maria, Lisbon, Portugal;<br />
4<br />
Rheumatology Research Unit, Instituto de Medicina<br />
Molecular, Faculdade de Medicina da Universidade de<br />
Lisboa and Hospital de Santa Maria, Lisbon, Portugal;<br />
5<br />
Rheumatology Department, Hospital Garcia de Orta,<br />
Lisbon, Portugal; 6 Rheumatology Department, Hospital de<br />
São João, Porto, Portugal; 7 Epidemiology Unit, Preventive<br />
Medicine Institute, Faculdade de Medicina, University<br />
of Lisbon., Lisbon, Portugal; 8 Portuguese Institute<br />
of Rheumatology, Lisbon, Portugal; 9 Rheumatology<br />
Department, Hospital Egas Moniz, Lisbon, Portugal;<br />
10<br />
Rheumatology Department, Hospital de Santa Maria,<br />
Lisbon, Portugal.<br />
(327)-1713. Effect on Anti-TNF Agents on Gene Expression in<br />
Children with Juvenile Arthritis. Lakshmi Nandini Moorthy 1 ,<br />
Gunter Schemmann 2 , Mary K. Crow 3 , Emmanuel<br />
Zachariah 1 , Margaret Peterson 3 , Thomas Lehman 3 , Daniel<br />
Notterman 1 . 1 Robert Wood Johnson Med Sch-Univ of Med<br />
and Dentistry of NJ, New Brunswick, NJ; 2 UMDNJ, New<br />
Brunswick, NJ; 3 Hospital For Special Surgery, New York, NY.<br />
(328)-1714. Mutations of the HLH-Associated Gene UNC13D<br />
(MUNC13-4) in a Patient with Systemic Onset Juvenile<br />
Idiopathic Arthritis. Melissa M. Hazen 1 , Amy L. Woodward 2 ,<br />
Inga Hofmann 3 , Barbara A. Degar 3 , Alexandra Filipovich 4 ,<br />
Bryce Anthony Binstadt 5 . 1 Children’s Hospital Boston,<br />
Boston, MA; 2 Indiana University School of Medicine,<br />
Indianapolis, IN; 3 Dana Farber Cancer Center, Boston, MA;<br />
4<br />
Cincinnati Children’s Hospital Medical Center, Cincinnati,<br />
OH; 5 University of Minnesota, Minneapolis, MN.<br />
(329)-1715. Synovial Fluid Proteins Differentiate Between<br />
Subtypes of Juvenile Idiopathic Arthritis. Margalit E.<br />
Rosenkranz 1 , Brendan Giles 2 , Paul R. Reynolds 2 , David<br />
C. Wilson 1 , Anthony D. Marinov 1 , Suzanne D. Clutter 1 ,<br />
Alisha Preuss 3 , Patrick Grof-Tisza 3 , David Kirchner 3 , Kumar<br />
Kolli 3 , Raphael Hirsch 1 . 1 Children’s Hospital of Pittsburgh,<br />
Pittsburgh, PA; 2 University of Pittsburgh, Pittsburgh, PA;<br />
3<br />
Windber Research Institute, Windber, PA.<br />
(330)-1716. Characterization of Protein Expression Profiles in<br />
Circulating Immune Complexes (CICs) from Juvenile Idiopathic<br />
Arthritis (JIA). Jason M. Low 1 , Anil K. Chauhan 1 , David S.<br />
Gibson 2 , Madeleine E. Rooney 2 , Terry L. Moore 1 . 1 Saint<br />
Louis University, St. Louis, MO; 2 Queen’s University,<br />
Belfast, United Kingdom.<br />
(331)-1717. Il-17 Levels are Elevated in Synovial Fluid of Patients<br />
with JIA and It Induces Production of Cytokines and MMPs by<br />
Fibroblast like Synoviocytes. Amita Aggarwal, Shilpi Agarwal,<br />
Ramnath Misra. Sanjay Gandhi Postgraduate Institute of<br />
Medical SCiences, Lucknow, India.<br />
(332)-1718. Serum and Synovial Fluid Concentrations of<br />
Interleukin-23 and Interleukin-17 in Juvenile Idiopathic Arthritis.<br />
Sampath Prahalad, April Whiting, Bronte Clifford,<br />
Bernadette McNally, Andrew Zeft, John Bohnsack. U of<br />
Utah, School of Medicine, Salt Lake City, UT.<br />
(333)-1719. Synovial Fluid T Cells are Resistant to rAd Based<br />
Suppression of Proliferation. Emma Sala Soriano, Katy R. Newton,<br />
Siobhan Burns, Lucy Wedderburn. University College<br />
London, Insitute of Child Health, London, United Kingdom.<br />
(334)-1720. Role of Vγ9Vδ2+ γδ T Cells in Juvenile Idiopathic<br />
Arthritis. Yackov Berkun 1 , Anna Bendersky 2 , Shay Padeh 1 ,<br />
Maya Gerstein 1 , Ilan Bank 3 . 1 Safra Children’s Hospital,<br />
Sheba Medical Center, Tel-Hashomer, Israel; 2 Sackler<br />
School of Medicine, Tel-Aviv, Israel; 3 Laboratory for<br />
Immunoregulation, Sheba Medical Center, Sackler Medical<br />
School, Tel-Hashomer, Israel.<br />
(335)-1721. Clonal Expansion of Synovial B Cells and<br />
Differentiation into Plasma Cells in Juvenile Idiopathic Arthritis.<br />
Henner Morbach, Nadine Suffa, Petra Richl, Hermann<br />
Josef Girschick. Children`s Hospital, University of<br />
Würzburg, Würzburg, Germany.<br />
(336)-1722. Decreased Proportion of Thymic Recent Emigrants in<br />
Juvenile Idiopathic Arthritis. Daniela V. Horvath 1 , Cristiane<br />
Kayser 1 , Queila F. Vieira 1 , Karin S. Barcellos 1 , Clovis A A<br />
Silva 2 , Maria O E Hilario 1 , Luis E. Andrade 1 . 1 Universidade<br />
Federal de São Paulo, São Paulo, Brazil; 2 Universidade de<br />
São Paulo, São Paulo, Brazil.<br />
(337)-1723. Study of Thymic Size and Function in Children and<br />
Adolescents with Treatment Refractory Systemic Sclerosis Eligible<br />
for Immunoablative Therapy. Andreas Reiff 1 , Paul Krogstad 2 ,<br />
Sheila Moore 1 , Bracha Shaham 1 , Kenneth Weinberg 3 .<br />
1<br />
Childrens Hospital Los Angeles, Los Angeles, CA; 2 UCLA,<br />
Los Angeles, CA; 3 University of Stanford, Stanford, CA.<br />
256 (Permanent Board Number)-Abstract Number
(338)-1724. Pathway Analysis of Genes Differentially Expressed<br />
in Peripheral Blood Mononuclear Cells from Children with Stable,<br />
Flaring or Improving Systemic Lupus Erythematosus. Kathleen<br />
M. O’Neil 1 , Igor Dozmorov 2 , Justin Neff 1 , Lauren M.<br />
Kickingbird 1 , James N. Jarvis 1 , Craig Cadwell 2 , Michael<br />
Centola 2 , Mark Barton Frank 2 . 1 University of Oklahoma,<br />
Oklahoma City, OK; 2 Oklahoma Medical Research<br />
Foundation, Oklahoma City, OK.<br />
(339)-1725. Gene Expression Profiles in Neutrophils of Children<br />
with SLE: Abnormal Regulation of Apoptosis-Related Genes<br />
Suggests Role for Neutrophils in SLE. Kathleen M. O’Neil 1 ,<br />
Ann B. Nguyen 1 , Mark Barton Frank 2 , Craig Cadwell 2 ,<br />
James N. Jarvis 1 , Michael Centola 2 , Igor Dozmorov 2 .<br />
1<br />
University of Oklahoma, Oklahoma City, OK; 2 Oklahoma<br />
Medical Research Foundation, Oklahoma City, OK.<br />
(340)-1726. Low Expression of Fas and Bcl-2 Proteins on<br />
Peripheral Monocytes from Juvenile-Onset Systemic Lupus<br />
Erythematosus. Bernadete L. Liphaus 1 , Maria H. B. Kiss 2 ,<br />
Solange Carrasco 3 , Claudia Goldenstein-Schainberg 3 ,<br />
Clóvis A A Silva 1 . 1 Instituto da Criança - Universidade<br />
de São Paulo, São Paulo, Brazil; 2 Departamento de<br />
Pediatria - Universidade de São Paulo, São Paulo, Brazil;<br />
3<br />
Departamento de Reumatologia - Universidade de São<br />
Paulo, São Paulo, Brazil.<br />
(341)-1727. Ro52 Autoantibodies Specific for Amino Acid 200-<br />
239 Bind Cardiomyocytes and Induce Atrioventricular Block in<br />
Rat Pups. Vijole Dzikaite, Linn Strandberg, Aurelie Ambrosi,<br />
Jeo Park, Erik Herlenius, Lars Ottosson, Stina Salomonsson,<br />
Sven-Erik Sonesson, Marie Wahren. Karolinska Institutet,<br />
Stockholm, Sweden.<br />
(342)-1728. Inhibition of Matrix Metalloproteinase-9 Activity<br />
Improves Coronary Outcome in a Murine Model of Kawasaki<br />
Disease. Andrew C. Lau, Trang T. Duong, Shinya Ito, Rae<br />
S.M. Yeung. Hospital for Sick Children, Toronto, ON,<br />
Canada.<br />
(343)-1729. Elastin Signalling in a Mouse Model of Kawasaki<br />
Disease. Nicholas J. Peake, Rae S.M. Yeung. Hospital for<br />
Sick Children, Toronto, ON, Canada.<br />
(344)-1730. HMG-CoA Reductase Inhibition Reduces T-Cell<br />
Proliferation and MMP-9 Gene Expression in a Superantigenic<br />
Mouse Model of Kawasaki Disease. Shawn Blankier, Andrew<br />
C. Lau, Brian W. McCrindle, Shinya Ito, Rae S.M. Yeung.<br />
The Hospital for Sick Children, Toronto, ON, Canada.<br />
(345)-1731. Mannose Binding Lectin (MBL) Polymorphisms and<br />
Age at Onset of Kawasaki Disease (KD). Fernanda Falcini,<br />
Maria Moriondo, Laura Ricci, Cristina Massai, Giovanni<br />
Battista Calabri, Gabriele Simonini, Rolando Cimaz, Chiara<br />
Azzari. A. Meyer Children’s Hospital, Firenze, Italy.<br />
(346)-1732. Absence of Killer Ig-like Inhibitory Receptor with the<br />
Associated HLA Ligand in Juvenile Dermatomyositis. Kelly T.<br />
McNallan, Molly S. Wagner, Cynthia S. Crowson, Ann M.<br />
Reed. Mayo Clinic, Rochester, MN.<br />
(347)-1733. Gene Expression Profiling in Neutrophils and<br />
PBMC in Juvenile Dermatomyositis. Shirley Wang 1 , Nicholas<br />
Knowlton 2 , Amita Aggarwal 1 , Timothy McGhee 1 , Kaiyu<br />
Jiang 1 , Yanmin Chen 1 , M. Barton Frank 2 , Michael Centola 2 ,<br />
James N. Jarvis 1 . 1 OUHSC, Oklahoma City, OK; 2 OMRF,<br />
Oklahoma City, OK.<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Post-Surgical Rehabilitation and Low Back Pain<br />
(348)-1734. Analgesic Effectiveness, Tolerability and Safety<br />
of Celecoxib Versus Tramadol Hydrochloride in Patients<br />
with Chronic Low Back Pain. John B. O’Donnell 1 , Evan<br />
F. Ekman 2 , William M. Spalding 3 , Dorothy McCabe 3 .<br />
1<br />
Department of Orthopaedic Surgery, Union Memorial<br />
Hospital, Baltimore, MD; 2 Southern Orthopaedic Sports<br />
Medicine, Columbia, SC; 3 Pfizer Inc, New York, NY.<br />
(349)-1735. Gender and Arthroplasty Type Affects the Prevalence<br />
of Moderate or Severe Pain Post Total Hip Arthroplasty (THA).<br />
Jasvinder A. Singh 1 , Sherine E. Gabriel 2 , David Lewallen 3 .<br />
1<br />
Minneapolis VA Medical Center, Minneapolis, MN; 2 Mayo<br />
Clinic School of Medicine, Rochester, MN; 3 Mayo CLinic<br />
School of Medicine, Rochester, MN.<br />
(350)-1736. Regional Variation in Home Health Care after Joint<br />
Replacement Surgery and Hip Fracture. John D. FitzGerald, W.<br />
John Boscardin, Susan L. Ettner. UCLA, Los Angeles, CA.<br />
(351)-1737. Self Assessed Health Status and Outcome Following<br />
Primary Hip and Knee Arthroplasty. M. Elaine Husni, Boris<br />
Bershadsky, Wael Barsoum, George Muschler. Cleveland<br />
Clinic, Cleveland, OH.<br />
(352)-1738. Role of Social Support and Depression on Pain<br />
and Function in Patients Undergoing Total Knee Arthroplasty<br />
(TKA). Maria A. Lopez-Olivo 1 , Michael A. Kallen 1 , Chong<br />
Pak 1 , Sherwin J. Siff 2 , Glenn C. Landon 2 , David Eldestein 2 ,<br />
Maria E. Suarez-Almazor 1 . 1 UT MD Anderson Cancer<br />
Center, Houston, TX; 2 St. Luke’s Episcopal Health System,<br />
Houston, TX.<br />
(353)-1739. Bone Tartrate Resistant Acid Phosphatase Serum<br />
Levels in Patients with Spinal Cord Injury Patients. Andrea<br />
Fonseca, fonseca 1 , Cristovao Mangueira 1 , Valeria Leite 2 ,<br />
Ricardo Golmia, Golmia 1 , Marcelo Ares, Ares 2 , Morton<br />
Aaron Scheinberg, Scheinberg 2 . 1 Albert Einstein Hospital<br />
and Research Institute, Sao Paulo, Brazil; 2 Hospital Abreu<br />
Sodre, Sao Paulo, Brazil.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 257
Poster Session c<br />
(354)-1740. Do Patients Expectations of Joint Replacement<br />
Surgery Influence Post-Operative Health Status and out of Pocket<br />
Costs. Lyn MARCH 1 , Marita Cross 1 , A. Barcenilla 1 , P.<br />
Brooks 2 , H. Lapsley 3 , D. Parker 4 , M. Coolican 5 , A. Ellis 1 ,<br />
Mervyn Cross 6 , L. Pinczewski 7 , B. Courtenay 8 . 1 University of<br />
Sydney, St Leonards, Australia; 2 University of Queensland,<br />
Brisbane, Australia; 3 CONROD, University of Queensland,<br />
Brisbane, Australia; 4 Sydney Orthopaedic Research<br />
Institute, Chatswood, Australia; 5 SORI, Chatswood,<br />
Australia; 6 Australian Institute of Musculoskeletal Science,<br />
Crows Nest, Australia; 7 AIMS, Crows Nest, Australia; 8 St<br />
Vincents Clinic, University of NSW, Darlinghurst, Australia.<br />
(355)-1741. Combing Information Obtained from Musculoskeletal<br />
Ultrasound, Color Doppler, and Conventional Radiography to<br />
Prevent Disability in Patients with Recent Shoulder Complaints.<br />
mohammed kamel 1 , Hazem Eid 2 , Loay Aglan 2 . 1 AlAzhar<br />
University & Dr.fakhry Hospital, Alkhobar, Saudi Arabia;<br />
2<br />
Dr.fakhry & AlRajhi Hospital, Alkhobar, Saudi Arabia.<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
RA Animal Models: Clues to Pathogenesis<br />
(356)-1742. Engagement of Nod2 Exacerbates Proteoglycan (PG)-<br />
Induced Arthritis in T Cell Receptor Transgenic Mice. Holly L.<br />
Rosenzweig 1 , Monica M. Jann 2 , Tibor T. Glant 3 , Tammy M.<br />
Martin 1 , Steve R. Planck 1 , Peter J. van Kooten 4 , Willem van<br />
Eden 4 , James T. Rosenbaum 1 , Michael P. Davey 2 . 1 Oregon<br />
Health & Science University, Portland, OR; 2 Veteran<br />
Affairs Medical Center, Portland, OR; 3 Rush University<br />
Medical Center, Chicago, IL; 4 Utrecht University, Utrecht,<br />
The Netherlands.<br />
(357)-1743. Analysis of Clonally Expanded Regulatory T Cells<br />
in the Arthritis Site. Keishi Fujio, Akiko Okamoto, Hirofumi<br />
Shoda, Mihoko Shibuya, Yumi Yamaguchi, Nelson Tsuno,<br />
Koki Takahashi, Kazuhiko Yamamoto. Tokyo University,<br />
Tokyo, Japan.<br />
(358)-1744. The Role of PLAD of TNF Receptor in Inflammatory<br />
Arthritis. Guo-Min Deng. BIDMC, Harvard Medical School,<br />
Boston, MA.<br />
(359)-1745. Effects of Quantitative Trait Loci on Chromosomes<br />
1, 4 and 10 on the Severity of Adjuvant-Induced Arhtritis. Grant<br />
W. Cannon 1 , Elaine F. Remmers 2 , Tim Corsi 1 , Ronald<br />
L. Wilder 3 , Marie M. Griffiths 1 . 1 VA and University of<br />
Utah, Salt Lake City, UT; 2 NIH/NIAMS, Bethesda, MD;<br />
3<br />
MacroGenics, Rockville, MD.<br />
(360)-1746. Arthritogenic CD4 T Cells in Citrulline-Induced<br />
Arthritis. David Yue, William Brintnell, Shashi Uniyal, Bosco<br />
Chan, Anthony M. Jevnikar, David A. Bell, Ewa Cairns.<br />
University of Western Ontario, London, ON, Canada.<br />
(361)-1747. Uncoupling of the HPA Axis and the Sympathetic<br />
Nervous System in Rheumatoid Arthritis is Linked to Marked<br />
Changes of Norepinephrine Content in the Hypothalamus.<br />
Christine Wolff 1 , Peter Härle 1 , Johannes Wildmann 2 ,<br />
Hugo O. Besedovsky 2 , Rainer H. Straub 1 , Adriana del<br />
Rey 2 . 1 University Medical Center, Regensburg, Germany;<br />
2<br />
Medical Faculty, Marburg, Germany.<br />
(362)-1748. Efficacy of a Novel CXCR2 Antagonist, SCH<br />
527123, in an Acute Murine Model of Joint Inflammation.<br />
Shu-Cheng Chen, Yongliang Sun, David Kinsley, Loretta<br />
A. Bober, Arthur G. Taveras, Satwant K. Narula, Daniel<br />
Lundell, Jay S. Fine. Schering-Plough Research Institute,<br />
Kenilworth, NJ.<br />
(363)-1749. CXCL13 (BLC) Regulates Both Active and Passive<br />
Inflammatory Arthritis. Achal Pashine, Ying Yu, Christopher<br />
Del Nagro, Yong Kim, Joseph Dal Porto, Elsie M. Eugui,<br />
Anthony M. Manning, Stanford L. Peng. Roche Palo Alto,<br />
Palo Alto, CA.<br />
(364)-1750. Synovitis and Focal Erosion in Inflamed Joints<br />
is Triggered by Activation and Translocation of B Cells in the<br />
Draining Lymph Node. Steven T. Proulx 1 , Christopher<br />
T. Ritchlin 1 , David J. Shealy 2 , Lianping Xing 1 , Edward<br />
M. Schwarz 1 . 1 University of Rochester, Rochester, NY;<br />
2<br />
Centocor R&D, Inc., Radnor, PA.<br />
(365)-1751. Glucosamine Prevents Systemic and Femoral Lesion<br />
Inflammation in an Experimental Model of Atherosclerosis<br />
Associated to Chronic Arthritis. Raquel Largo 1 , M Esther<br />
Marcos 1 , Olga Sanchez-Pernaute 1 , Juan Moreno-Rubio 1 ,<br />
Luis Ortega 2 , Jesus Egido 1 , Gabriel Herrero-Beaumont 1 .<br />
1<br />
Fundacion Jimenez Diaz, Madrid, Spain; 2 Hospital Clinico<br />
San Carlos, Madrid, Spain.<br />
(366)-1752. Collagen-Polyvynilpirrolidone Down-Regulates<br />
Inflammation in Collagen Induced Arthritis in a Murine Model.<br />
Perla Macip-Rodríguez 1 , David Cruz-Robles 2 , Virgina Soto-<br />
Abraham 2 , María I I. V 1 , Leonardo Limón-Camacho 1 ,<br />
Janette Furuzawa-Carballeda 1 . 1 Instituto Nacional de<br />
Ciencias Medicas y Nutricion Salvador Zubiran, Mexico<br />
City, Mexico; 2 Instituto Nacional de Cardiología Ignacio<br />
Chávez, Mexico City, Mexico.<br />
(367)-1753. Exploring the Role of TIARP (TNFα Induced<br />
Adipose Related Protein) in Autoimmune Arthritis Mediated<br />
Driven by Glucose-6-phosphate Isomerase. Asuka Inoue, Isao<br />
Matsumoto, Keiichi Iwanami, Yoko Tanaka-Watanabe,<br />
Daisuke Goto, Satoshi Ito, Akito Tsutsumi, Takayuki<br />
Sumida. Division of Clinical Immunology, Major of<br />
Advanced Biological Applications, Graduate School<br />
Comprehensive Human Science, University of Tsukuba,<br />
Tsukuba, Japan.<br />
(368)-1754. Effects of the Novel Immunosuppressant FTY720 in<br />
a Murine Rheumatoid Arthritis Model. Tsuyoshi Iwasaki, Sachi<br />
Tsunemi, Sachie Kitano, Hajime Sano. Hyogo College of<br />
Medicine, Nishinomiya, Japan.<br />
258 (Permanent Board Number)-Abstract Number
(369)-1755. The Role of Sulfotransferases in Autoimmune<br />
Inflammatory Arthritis. Hanayo Arata-kawai 1 , Kenji<br />
Uchimura 1 , David M. Lee 2 , Steven D. Rosen 1 . 1 University of<br />
California, San Francisco, San Francisco, CA; 2 Brigham and<br />
Women’s Hospital, Harvard Medical School, Boston, MA.<br />
(370)-1756. Macrophage Migration Inhibitory Factor Upregulates<br />
Monocyte Chemoattractant Protein-1 and Interleukin-1β in<br />
Inflammatory Arthritis. Mohammad A. Amin 1 , Jeffrey H.<br />
Ruth 1 , Pamela J. Mansfield 1 , Angela Pakozdi 1 , Lanie L.<br />
Santos 2 , Eric E. Morand 2 , John R. David 3 , Alisa E. Koch 4 .<br />
1<br />
University of Michigan, Ann Arbor, MI; 2 Monash Institute<br />
of Medical Research, Monash University, Clayton, Victoria,<br />
Australia; 3 Harvard School of Public Health, Boston, MA;<br />
4<br />
Veteran’s Administration and University of Michigan, Ann<br />
Arbor, MI.<br />
(371)-1757. Active Involvement of “Alarmins” S100a8 and A9<br />
in Regulation of Joint Inflammation and Cartilage Destruction<br />
during Antigen-Induced Arthritis.. Peter L. Van Lent 1 , Arjen B<br />
Blom 1 , Annet Sloetjes 1 , Thomas Vogl 2 , Wolfgang Nacken 2 ,<br />
Johannes Roth 3 , Wim B van den Berg 1 . 1 University Medical<br />
Centre Nijmegen, Nijmegen, The Netherlands; 2 Inst of<br />
Experimental Dermatology, Muenster, Germany; 3 Inst of<br />
Experimental Dermatology, Leiden, Germany.<br />
(372)-1758. Antibodies Against an HSP Epitope Suppress<br />
Autoimmune Arthritis By Modulation of Cytokine Regulation.<br />
Rina Ulmansky, Alon Hershko, Eli Moallem, Yaakov<br />
Naparstek. Hadassah - Hebrew University Medical Center,<br />
Jerusalem, Israel.<br />
(373)-1759. A Novel Role For Natural Killer T Cells As<br />
Activators And Producers Of Interleukin-17 In The Pathogenesis<br />
Of Collagen-induced Arthritis. Yohei Yoshiga, Daisuke Goto,<br />
Seigi Segawa, Isao Matsumoto, Satoshi Ito, Akito Tsutsumi,<br />
Takayuki Sumida. University of Tsukuba, Ibaraki, Japan.<br />
(374)-1760. The Role of RORγt in Regulating Gene Expression<br />
of the Arthritis Promoting Cytokine, IL-17. Cong-Qiu Chu 1 ,<br />
Xizhang Sun 1 , Zuoming Sun 2 , Karol Bomsztyk 1 , Keith B.<br />
Elkon 1 . 1 University of Washington, Seattle, WA; 2 University<br />
of Illinois, Chicago, IL.<br />
(375)-1761. The Rheumatoid Arthritis Associated Autoantigen<br />
hnRNP-A2 (RA33) is a Major Stimulator of Autoimmunity in<br />
Rats with Pristane-Induced Arthritis. Guenter Steiner 1 , Markus<br />
Hoffmann 1 , Jonatan Tuncel 2 , Karl Skriner 3 , Makiyeh<br />
Tohidast-Akrad 4 , Rikard Holmdahl 5 . 1 Medical University of<br />
Vienna, Vienna, Austria; 2 Lund Universityf, Lund, Sweden;<br />
3<br />
Charité University Hospital, Berlin, Germany; 4 Ludwig<br />
Boltzmann Institute for Rheumatology, Vienna, Austria;<br />
5<br />
Lund University, Lund, Sweden.<br />
(376)-1762. TNF-Induced Structural Joint Damage is Mediated<br />
by Interleukin-1. Jochen Zwerina 1 , Kurt Redlich 2 , Karin<br />
Polzer 1 , Leo Joosten 3 , Gerhard Kronke 1 , Joerg Distler 1 ,<br />
Noreen Pundt 4 , Thomas Pap 4 , Clemens Scheinecker 2 , Josef<br />
Smolen 2 , Wim van den Berg 3 , Georg Schett 1 . 1 University<br />
of Erlangen, Erlangen, Germany; 2 Medical University of<br />
Vienna, Vienna, Austria; 3 Radboud University Nijmegen<br />
Medical Centre, Nijmegen, The Netherlands; 4 University of<br />
Muenster, Muenster, Germany.<br />
(377)-1763. Reduction of Incidence and Severity of Collagen-<br />
Induced Arthritis is Correlated to a Marked Reduction of Serum<br />
Anti-Collagen Antibodies Levels in Microsomal Prostaglandin E<br />
Synthase-1 Null Mice. Fumiaki Kojima, Mohit Kapoor, Lihua<br />
Yang, Erica L. Fleishaker, Leslie J. Crofford. University of<br />
Kentukcy, Lexington, KY.<br />
(378)-1764. IL-17 Increased the Expression of Toll-like receptor-2,<br />
4, 9 via IL-1β and IL-6 Production in Autoimmune Arthritis.<br />
Jun-Hee Lee 1 , Hye-Joa Oh 2 , Mi-Ra Cho 1 , Joung-Wook Lee 1 ,<br />
Seung-Hoon Baek 1 , Geun-Tae Kim 1 , Mi-La Cho 2 , Ho-Youn<br />
Kim 2 , Sung-Il Kim 1 . 1 Pusan National University Hospital,<br />
Busan, Republic of Korea; 2 The Rheumatism Research<br />
Center at the Catholic University of Korea, Seoul, Republic<br />
of Korea.<br />
(379)-1765. Differential Gene Expression by Chondrocytes from<br />
Rats Immunized with IFA and Type II Collagen: An Analysis<br />
by Microarray. Xiu Ye 1 , Ivan C. Gerling 1 , Jian Yang 1 , Dana<br />
R. Marshall, Dr 2 , Michael A. Cremer 1 . 1 University of<br />
Tennessee Health Sciences Center, Memphis, TN; 2 Meharry<br />
Medical College, Nashville, TN.<br />
(380)-1766. Development and Phenotyping of Three Informative<br />
DA.BN(CIA-QTL) Congenic Rat Lines: DA.BN(Cia5),<br />
DA.BN(Cia11) and DA.BN(Cia12). Marie M. Griffiths 1 ,<br />
Elaine F. Remmers 2 , Grant W. Cannon 1 , Percio S. Gulko 3 ,<br />
Van Reese 1 , Tim Corsi 1 , Ronald L. Wilder 4 . 1 SLCVAHCS<br />
and Univ of Utah, Salt Lake City, UT; 2 NIH/NIAMS,<br />
Bethesda, MD; 3 Feinstein Institute Medical Research,<br />
Manhasset, NY; 4 MacroGenics, Rockville, MD.<br />
(381)-1767. Rat’s Models of Collagen Induced Arthritis (CIA)<br />
and Adjuvant Induced Arthritis (AIA) Reveal Distinct Pathways<br />
in Arthritis Development. Svetlana Oestergaard 1 , Marina<br />
Stolina 2 , Denise Dwyer 2 , Rasmus H. Nielsen 1 , Per Qvist 1 ,<br />
Morten A. Karsdal 1 . 1 Nordic Bioscience, Herlev, Denmark;<br />
2<br />
Amgen Inc., Thousand Oaks, CA.<br />
(382)-1768. Initiation and Amplification of Complement<br />
Activation by the Alternative Pathway is Sufficient for<br />
Development of Collagen Antibody Induced Arthritis in Mice.<br />
Nirmal K. Banda 1 , Kazue Takahashi 2 , Allyson K. Wood 1 ,<br />
V. Michael Holers 1 , William P. Arend 1 . 1 University of<br />
Colorado HSC, Denver, CO; 2 Massachusetts General<br />
Hospital for Children, Boston, MA.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 259
Poster Session c<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
RA Treatment: Novel Targets, Mechanisms of Action and<br />
Predictors of Response<br />
(383)-1769. TNF-α Knockdown Using Polymeric/siRNA<br />
Nanoparticles as a Treatment Strategy for Collagen Type II<br />
Induced Arthritis in Mice. Kenneth A. Howard 1 , Søren R.<br />
Paludan 1 , Mark Behlke 2 , Bent W. Deleuran 1 , Besenbacher<br />
Flemming 1 , Jørgen Kjems 1 . 1 University of Aarhus, Aarhus,<br />
Denmark; 2 Integrated DNA Technologies, Iowa, IA.<br />
(384)-1770. Bim-BH3 Peptide Mimetic Therapy is Effective<br />
at Preventing Development of Inflammatory Arthritis. John<br />
C. Scatizzi, Jack Hutcheson, Harris Perlman. Saint Louis<br />
University, St. Louis, MO.<br />
(385)-1771. Efficacy and Tolerability of Novel JAK inhibitors<br />
in Animal Models of Rheumatoid Arthritis. Jordan Fridman,<br />
Peggy Scherle, Robert Collins, Yanlong Li, Stacey Shepard,<br />
Rick Sparks, Ari Arvanitis, Guoen Shi, Andrew Combs,<br />
James Rodgers, Claire Neilan, Nancy Contel, Patrick Haley,<br />
Swamy Yeleswaram, Robert Newton, Steven Friedman, Kris<br />
Vaddi. Incyte Corporation, Wilmington, DE.<br />
(386)-1772. Antagonism of the P2X7 Receptor Attenuates Joint<br />
Destruction in a Model of Arthritis. Simon Cruwys, Anita<br />
Midha, Elizabeth Rendall, Margaret McCormick, Alexander<br />
Nicol, Martyn Foster, Martin Braddock. AstraZeneca R&D,<br />
Loughborough, United Kingdom.<br />
(387)-1773. Parthenolide Ameliorates the Arthritis and Joint<br />
Destruction in the Murine Model of Rheumatoid Arthritis.<br />
Koji Nomura, Tetsuya Tomita, Shoko Kuroda, Hideki<br />
Yoshikawa. Osaka University Graduate School of Medicine,<br />
Suita, Japan.<br />
(388)-1774. Methotrexate (MTX) Exerts Anti-atherogenic Effects<br />
on Cholesterol Efflux from Monocytes/Macrophages via Activation<br />
of the Adenosine A2A Receptor. Soumya Rao 1 , Hongwei<br />
Zhang 1 , Edwin S. Chan 2 , Steven E. Carsons 1 , Allison B.<br />
Reiss 1 . 1 Winthrop University Hospital, Mineola, NY; 2 NYU<br />
School of Medicine, New York, NY.<br />
(389)-1775. Downregulation of Macrophage Migration Inhibitory<br />
Factor (MIF) By Anti-TNF-Therapy in Rheumatoid Arthritis<br />
Patients. Carla A. Wijbrandts, Sander I. van Leuven, Hido<br />
D. Boom, Danielle M. Gerlag, Erik G. S. Stroes, John<br />
J. P. Kastelein, Paul P. Tak. Academic Medical Center/<br />
University of Amsterdam, Amsterdam, The Netherlands.<br />
(390)-1776. TWEAK and TWEAK Ligand/FN14 Expression<br />
in Rheumatoid Arthritis Synovial Tissue and Clinical Response to<br />
TNF Blockade. Carla A. Wijbrandts 1 , Arno W.R van Kuijk 1 ,<br />
Dion Groot 1 , Tom J. M. Smeets 1 , Marjolein Vinkenoog 1 ,<br />
Timothy S. Zheng 2 , Kris A. Reedquist 1 , Paul P. Tak 1 .<br />
1<br />
Academic Medical Center/University of Amsterdam,<br />
Amsterdam, The Netherlands; 2 Biogen Idec, 14 Cambridge<br />
Center, Cambridge, MA.<br />
(391)-1777. Anti-Tumor Necrosis Factor Therapy in Rheumatoid<br />
Arthritis Alters CD80 Expression on B-Lymphocytes. Joerg-<br />
Andres Rump 1 , Susanne Usadel 2 , Hartwig Schoenborn 2 ,<br />
Guido Wolff-Vorbeck 3 . 1 Medical University Clinic Freiburg,<br />
Freiburg, Germany; 2 Private Practice, Freiburg, Germany;<br />
3<br />
Surgical University Clinic Freiburg, Freiburg, Germany.<br />
(392)-1778. Anti-Inflammatory Effects of a Novel Class of 5-HT2<br />
Receptor Binding Compounds. Anders Sjödin 1 , Anna-Carin<br />
Ryde 1 , Niklas Palmqvist 1 , Helena Arozenius 1 , Gunilla<br />
Ekström 1 , Suzanne Kalliomäki 1 , Lars Ekblad 1 , Christina<br />
Wenglén 1 , Arne Boman 2 , Elisabeth Seifert 2 , Torbjörn<br />
Lundstedt 3 , Per Lek 2 . 1 AnaMar Medical AB, Lund, Sweden;<br />
2<br />
AcurePharma AB, Uppsala, Sweden; 3 Department of<br />
Pharmaceutical Chemistry, Uppsala University, Uppsala,<br />
Sweden.<br />
(393)-1779. Characterization of Anti-arthritic Effect of a Novel<br />
Small Molecule AP-1 Inhibitor T-5224.. Tetsuya Yamamoto 1 ,<br />
Yukihiko Aikawa 1 , Akira Hashiramoto 2 , Kimiko Morimoto 1 ,<br />
Hisaaki Chaki 1 , Hirokazu Narita 1 , Shuichi Hirono 3 ,<br />
Shunichi Shiozawa 2 . 1 Research Laboratories, Toyama<br />
Chemical Co., Ltd., Toyama, Japan; 2 Department of<br />
Rheumatology, Kobe University FHS School of Medicine,<br />
Kobe, Japan; 3 Department of Pharmaceutical Sciences,<br />
School of Pharmacy, Kitasato University, Tokyo, Japan.<br />
(394)-1780. Resveratrol Induces the Apoptosis in Synovial<br />
Fibroblasts of Rheumatoid Arthritis. JuKyoung Song 1 , JaeHee<br />
Hwang 1 , HeeSun Byun 2 , YunJong Lee 3 , GangMin Hur 2 ,<br />
SeongWook Kang 1 . 1 Department of Internal Medicine,<br />
Chungnam National University Hospital, Dae-jeon,<br />
Republic of Korea; 2 Department of Pharmacology, Cancer<br />
Research Institute, Research Institute for Medical Sciences,<br />
Chungnam National University, Dae-jeon, Republic of<br />
Korea; 3 Department of Internal Medicine, Seoul National<br />
University Hospital, Seoul, Republic of Korea.<br />
(395)-1781. Tacrolimus Overcomes Treatment-Unresponsiveness<br />
Mediated by P-glycoprotein on Lymphocytes in Refractory<br />
Rheumatoid Arthritis. Katsunori Suzuki, Kazuyoshi Saito,<br />
Shizuyo Tsujimura, Shigeru Iwata, Norifumi Sawamukai,<br />
Yoshiya Tanaka. First department of Internal Medicine,<br />
University of Occupational and Environmental Health,<br />
Japan, Kitakyushu, Japan.<br />
260 (Permanent Board Number)-Abstract Number
(396)-1782. Interferon Gamma Decreases Interleukin 1β<br />
Mediated Cartilage Loss in Rheumatoid Arthritis by Inhibiting<br />
MMP Production. Charlotte E. Page 1 , Shaun Smale 1 , Sarah<br />
Lauder 2 , Sara Carty 1 , Anwen S. Williams 2 . 1 University<br />
Hospital of Wales, Cardiff, United Kingdom; 2 Cardiff<br />
University, Cardiff, United Kingdom.<br />
(397)-1783. Epigallocatechin-3-gallate (EGCG) Downregulates<br />
PGE2 Mediated Production of Interleukin-6 (IL-6) in Rheumatoid<br />
Arthritis Synovial Fibroblasts. Salahuddin Ahmed 1 , Kevin<br />
Kwan 1 , Angela Pakozdi 1 , Alisa E. Koch 2 . 1 University of<br />
Michigan, Ann Arbor, MI; 2 Veterans Administration Health<br />
Care System and the University of Michigan, Ann Arbor, MI.<br />
(398)-1784. Rheumatoid Arthritis Synovial T Cells are Resistant<br />
to Glucocorticoid Induced Apoptosis. Dimitrios Makrygiannakis,<br />
Cecilia Grundtman, Erik af Klint, Omri Snir, Lars Klareskog,<br />
Anca Irinel Catrina. Department of Rheumatology, Karolinska<br />
University Hospital, Karolinska Institutet, Stockholm, Sweden.<br />
(399)-1785. In Untreated, Active, Early Rheumatoid Arthritis<br />
Up-regulated Density Of CCR7 On Monocytes And CD4+<br />
T-lymphocytes Is Differentially Influenced By Clinically Effective<br />
Dmard: The CCR7 Density On Monocytes Is Normalized But<br />
It Remains Up-regulated On CD4+ T-lymphocytes. Torkell<br />
Ellingsen 1 , Ib Hansen 1 , Jonas Thorsen 2 , Bjarne K. Møller 2 ,<br />
Ulrik Tarp 1 , Merete Hetland 3 , Kim Hørslev-Petersen 4 ,<br />
Kristian Stengaard-Pedersen 1 . 1 Dept of Rheumatology,<br />
Århus University Hospital, Århus, Denmark; 2 Dept of<br />
Clinical Immunology, Århus University Hospital, Århus,<br />
Denmark; 3 Dept of Rheumatology, Hvidovre University<br />
Hospital, Århus, Denmark; 4 Dept of Rheumatology, King<br />
Christian X Hospital, Gråsten, Denmark.<br />
(400)-1786. In Untreated, Active, Early Rheumatoid Arthritis<br />
Patients CD26 Density on Monocytes and CD4+ Lymphocytes<br />
Correlate to CRP and DAS28 and on Monocytes the CD26<br />
Density was Unaffected by a Clinically, Effective DMARD<br />
Treatment. Torkell Ellingsen 1 , Ib Hansen 1 , Jonas Thorsen 2 ,<br />
Bjarne Kuno Møller 2 , Ulrik Tarp 1 , Merete Hetland 3 , Kim<br />
Hørslev-Petersen 4 , Kristian Stengaard-Pedersen 1 . 1 Dept<br />
of Rheumatology, Århus, Denmark; 2 Dept of Clinical<br />
Immunology, Århus, Denmark; 3 Dept of Rheumatology,<br />
Hvidovre, Denmark; 4 Dept of Rheumatology, King<br />
Christian X’s Hospital, Gråsten, Denmark.<br />
(401)-1787. CF502 Targets the A3 Adenosine Receptor to Induce<br />
Anti-Inflammatory Effect Via Down-Regulation of the NF-KappaB<br />
Signaling Pathway. Sara Bar Yehuda 1 , Avivit Ochaion 1 ,<br />
Kenneth A. Jacobson 2 , Bhalchandra V. Joshi 2 , Zhan-Guo<br />
Gao 2 , Shira Cohen 1 , Renana Patoka 1 , Faina Barer 1 , Luis<br />
Del Valle 3 , Georginia Perez-Liz 3 , Pnina Fishman 1 . 1 Can-Fite<br />
BioPharma, Petach Tikva, Israel; 2 National Institute of<br />
Diabetes & Digestive & Kidney Diseases, National Institutes<br />
of Health, Bethesda, MD; 3 Department of Neuroscience,<br />
Neuropathology Core & Center for NeuroVirology, Temple<br />
University School of Medicine, Philadelphia, PA.<br />
(402)-1788. Anti-Rheumatic Effect of ZSTK474, a Novel<br />
Phosphoinositide 3-kinase Inhibitor, by Inhibiting Osteoclast<br />
Formation. Shouko Tohyama 1 , Naoto Tamura 1 , Kazukiko<br />
Haruta 2 , Takeo Karakida 3 , Shigeyuki Mori 2 , Testuo<br />
Watanabe 2 , Shin-ichi Yaguchi 2 , Michiko Tajima 1 , Makoto<br />
Fukae 3 , Takao Yamori 4 , Yoshinari Takasaki 1 . 1 Depatment<br />
of Internal Medicine and Rheumatology, Juntendo<br />
University School of Medicine, Tokyo, Japan; 2 Central<br />
Research Laboratory, Zenyaku Kogyo Co., Ltd, Tokyo,<br />
Japan; 3 Department of Biochemistry, School of Dental<br />
Medicine, Tsurumi University, Yokohama, Japan; 4 Division<br />
of Molecular Pharmacology, Cancer Chemotherapy Center,<br />
Japanese Foundation for Cancer Research, Tokyo, Japan.<br />
(403)-1789. Microparticles in Peripheral Blood Decrease in<br />
Patients with Active Rheumatoid Arthritis by Leukocytapheresis.<br />
Kunihiko Umekita 1 , Toshihiko Hidaka 2 , Shiro Ueno 1 ,<br />
Ichiro Takajyo 1 , Yasufumi Kai 1 , Masayuki Kuroki 1 ,<br />
Yasuhiro Nagatomo 1 , Akihiko Okayama 1 . 1 Department<br />
of Rheumatology, Infectious Diseases and Laboratory<br />
Medicine, University of Miyazaki, Miyazaki, Japan; 2 Institute<br />
of Rheumatology, Zenjinkai Shimin-No-Mori Hospital,<br />
Miyazaki, Japan.<br />
(404)-1790. Inhibitory Effects of Melittin on the Production<br />
of Lipopolysaccaharide-induced Matrixmetalloproteinase 3 in<br />
Human Rheumatoid Arthritic Fibroblast Like Synoviocytes.<br />
Seong-Su Nah, Chang-Keun Lee, Yong Gil Kim, Ji Seon Oh,<br />
Hee-Bom Moon, Bin Yoo. University of Ulsan College of<br />
Medicine, Asan Medical Center, Seoul, Republic of Korea.<br />
(405)-1791. Effects of Hormone Replacement Therapy on Resistin<br />
in Rheumatoid Arthritis. Helena Forsblad d’Elia, Rille Pullerits,<br />
Hans Carlsten, Maria Bokarewa. Department of Rheumatology<br />
and Inflammation Research, Göteborg, Sweden.<br />
(406)-1792. Simvastatin Inhibits Production of Pentraxin 3<br />
and Monocyte Chemoattractant Protein-1 in Fibroblast-Like<br />
Synoviocytes from Patients with Rheumatoid Arthritis. Kazuhiro<br />
Yokota 1 , Toshiko Ishibashi 1 , Yu Asanuma 1 , Yasufumi<br />
Shindo 1 , Yoshihiro Yoshida 1 , Haruhiko Akiba 1 , Kyoichi<br />
Nakajima 1 , Kojiro Sato 1 , Yuji Akiyama 1 , Yoon Taek Kim 2 ,<br />
Toshihide Mimura 1 . 1 Department of Rheumatology and<br />
Applied Immunology, Saitama Medical University, Saitama,<br />
Japan; 2 Department of Orthopedic Surgery, Saitama<br />
Medical University, Saitama, Japan.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 261
Poster Session c<br />
(407)-1793. Preparation of a TAT-PTD CDKI Fusion Protein<br />
that efficiently Inhibits Proliferation and MMP-3 Production of<br />
Rheumatoid Synovial Fibroblasts. Makoto Nakasato, Yoshinori<br />
Nonomura, Nobuyuki Miyasaka, Hitoshi Kohsaka.<br />
Graduate School, Tokyo Medical and Dental University,<br />
Tokyo, Japan.<br />
(408)-1794. Differential Peripheral Blood Gene Expression Profile<br />
of Rheumatoid Arthritis in Response to Anti-TNF Treatment.<br />
Franak Batliwalla 1 , Wentian Li 1 , Jadwiga Bienkowska 2 , Aarti<br />
Damle 1 , Houman Khalili 1 , Wolfgang Hueber 3 , Normad<br />
Allaire 4 , Margaret Mcrann 4 , William Robinson 3 , Marlena<br />
Kern 1 , John Carulli 4 , Peter K. Gregersen 1 . 1 The Feinstein<br />
Institute for Medical Research, Manhasset, NY; 2 Biogen<br />
Idec Inc, Cambridge, MA; 3 Stanford University, Palo Alto,<br />
CA; 4 Biogen Idec, Cambridge, MA.<br />
(409)-1795. Genotypes Coding for High-Affinity Variants of Fc<br />
Gamma Receptors IIA (CD32A) y IIIA (CD16A) are Associated<br />
with Poorer <strong>ACR</strong> Response to Therapy with Infliximab in Patients<br />
with Rheumatoid Arthritis. Juan D. Cañete 1 , Belén Suarez 2 , M<br />
Victoria Hernández 1 , Raimon Sanmartí 1 , Ignacio Rego 3 , José<br />
A Pinto 3 , Conchita Moll 1 , Francisco J Blanco 3 , Francisco<br />
Lozano 4 . 1 Arthritis Unit/Rheumatology Dept/Hospital<br />
Clinic of Barcelona, Barcelona, Spain; 2 Immunology<br />
Dept, Hospital Clinic of Barcelona, Barcelona, Spain;<br />
3<br />
Rheumatology Dept/Hospital Juan Canalejo, Coruña,<br />
Spain; 4 Immunology Dept/Hospital Clínic of Barcelona,<br />
Barcelona, Spain.<br />
(410)-1796. Global Gene Expression Profiles in the Synovium<br />
of Rheumatoid Arthritis Patients Treated with Adalimumab.<br />
Valerie Badot 1 , Christine Galant 2 , Adrien Nzeusseu<br />
Toukap 2 , Benoit J. Van den Eynde 3 , Patrick Durez 2 , Frederic<br />
A. Houssiau 2 , Bernard R. Lauwerys 2 . 1 CHU Brugmann,<br />
Brussels, Belgium; 2 Cliniques Universitaires Saint-Luc,<br />
Universite Catholique de Louvain, Brussels, Belgium;<br />
3<br />
Ludwig Institute for Cancer Research, Brussels, Belgium.<br />
(411)-1797. Anti-cyclic Citrullinated Peptide Antibodies and<br />
High Il-15 Serum Levels are Better Predictors than Rheumatoid<br />
Factor for Intensive Treatment in Early Arthritis Patients. Ana M.<br />
Ortiz 1 , Isidoro González-Álvaro 1 , Rosario Garcia-Vicuña 1 ,<br />
Inmaculada Carvajal 2 , Santos Castañeda 1 . 1 Rheumatology<br />
Service. Hospital de la Princesa, Madrid, Spain;<br />
2<br />
Rheumatology. Sanatorio Nuestra Señora del Rosario,<br />
Madrid, Spain.<br />
(412)-1798. Utilization of Host Resistance Models (HRMs) in the<br />
Prediction of Human Safety of Abatacept (ABA): A Translational<br />
Approach. H. G. Haggerty 1 , S. G. Nadler 2 , T. A. Simon 3 , M.<br />
Corbo 2 . 1 Bristol-Myers Squibb, Syracuse, NJ; 2 Bristol-Myers<br />
Squibb, Princeton, NJ; 3 Bristol-Myers Squibb, Hopwell, NJ.<br />
(413)-1799. Influence of Genetic Variation in the TNF, LTA<br />
and LST-1 Genes on the Response to Treatment of Rheumatoid<br />
Arthritis with Anti-TNF Therapy in a Large Cohort of UK<br />
Patients. James Maxwell 1 , Catherine Potter 2 , Kimme Hyrich 2 ,<br />
BRAGGSS 3 , Anne Barton 2 , Jane Worthington 2 , John<br />
Isaacs 4 , Ann Morgan 5 , Anthony G. Wilson 1 . 1 University<br />
of Sheffield, Sheffield, United Kingdom; 2 University of<br />
Manchester, Manchester, United Kingdom; 3 Biologics<br />
in Rheumatoid Arthritis Genetics and Genomics Study<br />
Syndicate, United Kingdom; 4 University of Newcastle,<br />
Newcastle, United Kingdom; 5 University of Leeds, Leeds,<br />
United Kingdom.<br />
(414)-1800. HLG-G 14bp Polymorphisms Are Not Associated<br />
with Methotrexate Response in Rheumatoid Arthritis. Lisa K.<br />
Stamp 1 , Mei Zhang 1 , John O’Donnell 2 , Peter Chapman 2 ,<br />
Chris Frampton 1 , Murray Barclay 1 , Martin Kennedy 1 ,<br />
Rebecca Roberts 1 . 1 University of Otago, Christchurch,<br />
New Zealand; 2 Christchurch Hospital, Christchurch, New<br />
Zealand.<br />
(415)-1801. Synovial Markers of Response to Adalimumab<br />
in Severe Rheumatoid Arthritis. Adrien Nzeusseu-Toukap 1 ,<br />
Bernard R. Lauwerys 1 , Christine Galant 1 , Ivan Theate 1 ,<br />
Benoit J. Van den Eynde 2 , Valerie Badot 3 , Patrick Durez 1 ,<br />
Frederic A. Houssiau 1 . 1 Cliniques Universitaires Saint-<br />
Luc, Universite catholique de Louvain, Brussels, Belgium;<br />
2<br />
Ludwig Institute for Cancer Research, Brussels, Belgium;<br />
3<br />
CHU Brugmann, Brussels, Belgium.<br />
(416)-1802. An In Silico Model of Rheumatoid Arthritis Predicts<br />
Key Pathways of Bone Erosion and Candidate Biomarkers of<br />
Therapeutic Efficacy. Kosmas Kretsos 1 , Nadine Defranoux 2 ,<br />
Sirid A. Kellermann 1 , Daniel L. Young 1 . 1 Entelos Inc.,<br />
Foster City, CA; 2 721 Hallam St., San Francisco, CA.<br />
(417)-1803. Remission of Rheumatoid Arthritis is Predicted by<br />
Baseline Variables Including Low Disease Activity, Less Joint<br />
Damage, and Better Physical Function. R. Landewe 1 , D. van der<br />
Heijde 2 , R. Pedersen 3 , D. MacPeek 3 , J. Wajdula 3 . 1 University<br />
Hospital, Maastrict, The Netherlands; 2 Leiden University<br />
Medical Center, Leiden, The Netherlands; 3 Wyeth<br />
Research, Collegeville, PA.<br />
(418)-1804. High Remission During Treatment of Patients with<br />
Early Rheumatoid Arthritis by Monitoring with DAS28 or a<br />
Biochemical Marker of Cartilage Degradation, CTX-II: A Pilot<br />
Study. Lilian H D van Tuyl 1 , Willem F. Lems 1 , Alexandre<br />
E. Voskuyl 1 , Pit J S M Kerstens 2 , Patrick Garnero 3 , Ben<br />
A C Dijkmans 1 , Maarten Boers 1 . 1 VU University Medical<br />
Center, Amsterdam, The Netherlands; 2 Jan van Breemen<br />
Institute, Amsterdam, The Netherlands; 3 INSERM Unit<br />
664 and Synarc, Lyon, France.<br />
262 (Permanent Board Number)-Abstract Number
(419)-1805. Biologic Drugs Targeting the TNF-α and IL-6<br />
Pathways Induces Fibroblast-like Synoviocytes Apoptosis.<br />
Laura Pattacini, Bruno Casali, Luigi Boiardi, Davide<br />
Nicoli, Enrico Farnetti, Nicolò Pipitone, Carlo Salvarani.<br />
Arcispedale S Maria Nuova, Reggio Emilia, Italy.<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
RA: Clinical Aspects III<br />
(420)-1806. Validation of a Disease Activity Score Using Patient<br />
Derived Joint Counts. A. Kavanaugh 1 , H. H. Weng 2 , Y. Chon 2 ,<br />
S-L Lin 2 . 1 UCSD, Division of Rheumatology, Allergy and<br />
Immunology, La Jolla, CA; 2 Amgen, Thousand Oaks, CA.<br />
(421)-1807. Relationship Between Residual Functional Disability<br />
and Residual Disease Activity in Patients With Early Rheumatoid<br />
Arthritis Who Achieved a Remission-like State in the PREMIER<br />
Study. Arthur Kavanaugh 1 , Michael Weinblatt 2 , Edward<br />
Keystone 3 , Kaushik Patra 4 , Eric Sasso 5 . 1 USCD Center for<br />
Innovative Therapy, La Jolla, CA; 2 Brigham & Women’s<br />
Hospital, Boston, MA; 3 University of Toronto, Toronto,<br />
ON, Canada; 4 Abbott Laboratories, Parsippany, NJ; 5 Abbott<br />
Laboratories, Abbott Park, IL.<br />
(422)-1808. Is there a Gender Bias in Prescribing Anti-TNFs to<br />
Patients with RA? Joel K. Joelsson 1 , Cheryl Cullinane Carli 2 ,<br />
Lars Klareskog 2 , Ronald F. Van Vollenhoven 2 . 1 University<br />
of Reykjavik, Medicine, Iceland; 2 Karolinska University<br />
Hospital, Stockholm, Sweden.<br />
(423)-1809. An Index Based on Only Patient Reported Outcome<br />
(PRO) Measures, Without Formal Joint Counts, Routine<br />
Assessment of Patient Index Data (RAPID) Classifies Patients into<br />
4 Severity Categories which are Similar to Disease Activity Score<br />
(DAS28) and Clinical Disease Activity Index (CDAI) Categories<br />
in 4 Adalimumab Clinical Trials. Theodore Pincus 1 , Oscar<br />
Segurado 2 . 1 NYU-Hospital for Joint Diseases, New York,<br />
NY; 2 Abbott Immunology, Abbott Park, IL.<br />
(424)-1810. Recognition of Remission or Near Remission Status<br />
at the Conclusion of the AIM and ATTAIN Abatacept Clinical<br />
Trials according to an Index of Only the 3 Patient Measures in the<br />
Rheumatoid Arthritis (RA) Core Data Set, Without Joint Counts,<br />
Routine Assessment of Patient Index Data 3 (RAPID3): Similar<br />
Results to Disease Activity Score (DAS28). Theodore Pincus 1 ,<br />
Martin Bergman 2 , Yusuf Yazici 3 , Patricia Hines 4 , Ross<br />
Maclean 4 . 1 NYU-Hospital for Joint Diseases, New York, NY;<br />
2<br />
Rheumatology, Ridley Park, PA; 3 Hospital for Joint Diseases,<br />
New York, NY; 4 Bristol-Myers-Squibb, Princeton, NJ.<br />
(425)-1811. Real-Time Assessment of Disease Activity in<br />
Rheumatoid Arthritis (RADARA): Use of Threshold Criteria<br />
Improves Specificity of Composite Clinical Outcome Measures.<br />
Steven Call 1 , Daisha Ciphers 2 , Rod Hooker 3 , Salahuddin<br />
Kazi 3 , Ted Mikuls 4 , Gail Kerr 5 , John Richards 5 , Grant W.<br />
Cannon 1 . 1 VAMC and Univ of Utah, SLC, UT; 2 VAMC and<br />
Univ. of Texas, Dallas, TX; 3 VAMC and UT Southwestern,<br />
Dallas, TX; 4 VAMC and Univ of Nebraska, Omaha, NE;<br />
5<br />
VAMC and Georgetown Univ, Washington, DC.<br />
(426)-1812. Validity of the Rheumatoid Arthritis Disease Activity<br />
Index in Early Inflammatory Arthritis. Bindee Kuriya, Claire<br />
Bombardier, Vivian P. Bykerk. University of Toronto,<br />
Toronto, ON, Canada.<br />
(427)-1813. Evaluation of the Onset of Clinical Response in<br />
Abatacept-Treated Rheumatoid Arthritis Patients Using the<br />
Simplified Disease Activity Index and the Clinical Disease<br />
Activity Index. D. Aletaha 1 , M. Schiff 2 , K. Tsai 3 , J. Smolen 4 .<br />
1<br />
Department of Internal Medicine, Medical University<br />
of Vienna, Vienna, Austria; 2 Denver Arthritis Clinic,<br />
Denver, CO; 3 Bristol-Myers Squibb, Princeton, NJ; 4 Medical<br />
University of Vienna, Vienna, Austria.<br />
(428)-1814. Novel Approach to Assess Patient Derived Measures<br />
in Rheumatoid Arthritis. Susan J. Lee 1 , Omeed Saghafi 1 ,<br />
Ricky Huang 2 , Steven Skoczen 2 , Arthur Kavanaugh 1 ,<br />
Leslie Lenert 2 . 1 UCSD, San Diego, CA; 2 San Diego VA<br />
Healthcare, San Diego, CA.<br />
(429)-1815. Digital X-ray Radiogrammetry: A Promising<br />
Predictor of Joint Destruction in Early Ra. Kristina Forslind 1 ,<br />
Annelies Boonen 2 , Ingiäld Hafström 3 , Kristina Albertsson 3 ,<br />
Björn Svensson 4 . 1 Rheumatology, Helsingborgs Lasarett,<br />
Helsingborg, Sweden; 2 Rheumatology, University Hospital,<br />
Maastricht, The Netherlands; 3 Rheumatology, Karolinska<br />
University Hospital Huddinge, Stockholm, Sweden;<br />
4<br />
Rheumatology. University of Lund, Lund, Sweden.<br />
(430)-1816. Measuring Radiological Disease Progression in Early<br />
Rheumatoid Arthritis - The Effect of Scoring Methods. Keeranur<br />
Jayakumar 1 , Adam Young 1 , A. Boonen 2 , Gouri Koduri 1 ,<br />
D. van der Heijdel 2 . 1 St Albans City Hospital, St Albans,<br />
Hertfordshire, United Kingdom; 2 Maastricht University<br />
Hospital, Maastricht, Netherlands Antilles.<br />
(431)-1817. Defining Change in Disease Activity Parameters<br />
Associated with Loss of Response Over Time in RA Patients.<br />
Daniel E. Furst 1 , Hong Chang 2 , Veena Ranganath 1 , George<br />
Reed 3 , Dinesh Khanna 4 , Joel Kremer 5 , Jeffrey Greenberg 6 .<br />
1<br />
University of California at Los Angeles, Los Angeles, CA;<br />
2<br />
Albany Medical College, New York, NY; 3 University of<br />
Massachusetts, Worcester, MA; 4 University of Cincinnati,<br />
Cincinnati, CT; 5 Albany Medical College, Albany, NY;<br />
6<br />
NYU Hopsital for Joint Diseases, NY, NY.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 263
Poster Session c<br />
(432)-1818. Extra-articular Manifestations in a Community<br />
Based Sample of Patients with Rheumatoid Arthritis: Incidence<br />
and Relation to Treatment with TNF Inhibitors. Carl Turesson 1 ,<br />
Cecilia Jacobsson 1 , Pierre Geborek 2 , Jan-Åke Nilsson 1 , Käth<br />
Nilsson 1 , Marita Brissard 1 , Lennart TH Jacobsson 1 . 1 Malmö<br />
University Hospital, Malmö, Sweden; 2 Lund University<br />
Hospital, Lund, Sweden.<br />
(433)-1819. The Disease Activity Score (DAS) with Extended<br />
Joint Counts in Rheumatoid Arthritis: Update and Validation<br />
of the Original DAS Formula. Jaap Fransen, Bea Radovits,<br />
George Borm, Piet LCM Van Riel. Radboud University<br />
Nijmegen Medical Centre, Nijmegen, The Netherlands.<br />
(434)-1820. Does Training of Patients Using a Computer Assisted<br />
Patient Reported Outcome Tool in Rheumatoid Arthritis Persist<br />
Between Visits?. Gerald D. Levy, Craig T. Cheetham, Allison<br />
Cheatwood, Fang Niu. Southern California Permanente<br />
Medical Group, Downey, CA.<br />
(435)-1821. Patient-Reported Outcomes (PROs) in Assessment<br />
of Patients with Rheumatoid Arthritis (RA) Seen in Standard<br />
Rheumatology Care in 21 Countries in the QUEST-RA Study.<br />
T. Sokka 1 , Theodore Pincus 2 , Bernard Combe Combe 3 ,<br />
Kai Immonen 4 , Troels Mork Hansen 5 , Sergio Toloza 6 ,<br />
Gianfranco Ferraccioli 7 , Susan MM Verstappen 8 , Witold<br />
Tlustochowicz 9 , Wojciech Romanowski 10 , Jaime Calvo-<br />
Alen 11 , Patricia Minnock 12 , Selda Celik 13 , Martin Bergman 14 ,<br />
Pál Géher 15 , Ilona Ujfalussy 16 , Jolanta Dadoniene 17 , Marika<br />
Tammaru 18 , Rolf Kuuse 18 , Riina Kallikorm 18 , Rolf Oding 19 ,<br />
Margareth Liveborn 19 , Ann-Carin Holmqvist 20 , On Behalf<br />
of the QUEST-RA Group. 1 Jyväskylä Central Hospital,<br />
Jyväskylä, Finland; 2 New York University Hospital for Joint<br />
Diseases, New York, NY; 3 Hôpital Lapeyronie, Montpellier,<br />
France; 4 North Karelia Central Hospital, Joensuu, Finland;<br />
5<br />
Copenhagen University Hospital at Herlev, Herlev, Denmark;<br />
6<br />
Hospital San Juan Bautista, Catamarca, Argentina; 7 Catholic<br />
University of Sacred Heart, Rome, Italy; 8 University Medical<br />
Center Utrecht, Utrecht, The Netherlands; 9 Military Institute<br />
of Medicine, Warshaw, Poland; 10 Poznan Rheumatology<br />
Center in Srem, Srem, Poland; 11 Hospital Sierrallana Ganzo,<br />
Torrelavega, Spain; 12 Our Lady’s Hospice, Dublin, Ireland;<br />
13<br />
Cerrahpasa Medic Faculty, Istanbul, Turkey; 14 Taylor<br />
Hospital, Ridley Park, PA; 15 Semmelweis University of Medical<br />
Sciences, Budapest, Hungary; 16 Polyclinic of the Hospitaller<br />
Brothers of St. John of God, Budapest, Hungary; 17 Institute<br />
of Experimental and Clinical Medicine at Vilnius, Vilnius,<br />
Lithuania; 18 Tartu University Hospital, Tartu, Estonia;<br />
19<br />
Centrallasarettet, Västerås, Sweden; 20 Hudiksvall Medical<br />
Clinic, Hudiksvall, Sweden<br />
(436)-1822. Development of a Health Care Utilization Database<br />
Index for Rheumatoid Arthritis Severity. Gladys Ting 1 , Sebastian<br />
Schneeweiss 1 , Richard Scranton 2 , Jeffrey N. Katz 1 , Michael<br />
E. Weinblatt 1 , Melissa Young 2 , Jerry Avorn 1 , Daniel H.<br />
Solomon 1 . 1 Brigham and Women’s Hospital, Boston, MA;<br />
2<br />
VA Healthcare System, Boston, MA.<br />
(437)-1823. Quality of Healthcare for Patients with Rheumatoid<br />
Arthritis has Improved: Results from the German Rheumatoid<br />
Arthritis Population Survey (GRAPS). Gisela Westhoff 1 ,<br />
Matthias Schneider 2 , Heiner Raspe 3 , Henning Zeidler 4 ,<br />
Claus Runge 5 , Timm Volmer 5 , Angela Zink 1 . 1 German<br />
Rheumatology Research Center, Berlin, Germany;<br />
2<br />
Heinrich Heine University Düsseldorf, Düsseldorf,<br />
Germany; 3 University of Lübeck, Lübeck, Germany;<br />
4<br />
Medical University Hannover, Hannover, Germany;<br />
5<br />
Wyeth Pharma, Münster, Germany.<br />
(438)-1824. The Impact of Foot Compromise in Patients with<br />
Rheumatoid Arthritis. Adriana Rojas-Villarraga 1 , Javier<br />
Bayona 2 , Zuluaga Natalia 2 , Mejia Santiago 2 , Maria-Eugenia<br />
Hincapie 1 , Juan-Manuel Anaya 1 . 1 Corporación para<br />
Investigaciones Biológicas, Medellin, Colombia; 2 Clinica<br />
Universitaria Bolivariana, Medellin, Colombia.<br />
(439)-1825. Would prior testing of Anti-Cyclic Citrullinated<br />
Antibodies (anti CCP) Help with Decision Making at the First<br />
Visit to an Early Arthritis Clinic?. Joegi Thomas, Ruth Slack,<br />
Tracey Catchpole, Per Johansen, David O’Reilly. West<br />
Suffolk Hospital UK, Bury St Edmunds, United Kingdom.<br />
(440)-1826. The Significance of the Second and Third<br />
Generations of Anti-Cyclic Citrullinated Peptides Antibodies<br />
among Various Serological Tests for Rheumatoid Arthritis.<br />
Kanako Kitahara 1 , Shinichiro Nishio 1 , Yoshie Kusunoki 1 ,<br />
Kenji Takagi 1 , Takamasa Nozaki 2 , Hirotake Inomata 2 ,<br />
Masami Takei 2 , Shigemasa Sawada 2 , Shinichi Kawai 1 . 1 Toho<br />
University School of Medicine, Tokyo, Japan; 2 Nihon<br />
University School of Medicine, Tokyo, Japan.<br />
(441)-1827. Prediction of Therapy Outcome of Etanercept Treated<br />
Patients with Rheumatoid Arthritis (RA) Based on Pre-Treatment<br />
Anti-Cyclic Citrullinated Peptide (CCP) Antibody Levels. Susanne<br />
Drynda 1 , Helga Wollenberg 2 , Susann Dube 2 , Joern Kekow 1 .<br />
1<br />
University of Magdeburg, Magdeburg, Germany; 2 Clinic of<br />
Rheumatology, Vogelsang/Gommern, Germany.<br />
(442)-1828. Two Novel Assays-Third Generation Cyclic<br />
Citrullinated Peptides and Antibodies Against Modified<br />
Citrullinated Vimentin in the Diagnosis of Rheumatoid Arthritis<br />
and Relation with Disease Activity. Muge Bıcakcigil 1 , Nilgun<br />
Mutlu 2 , Demet Tasan 3 , Ayhan Kayan 3 , Sule Yavuz 4 , Inci<br />
Özden 5 . 1 Division of Rheumatology, Department of Internal<br />
Medicine, Faculty of Medicine, University of Yeditepe,<br />
Istanbul, Turkey; 2 Department of Biochemistry, Faculty<br />
of Medicine, University of Yeditepe, Istanbul, Turkey;<br />
3<br />
Division of Rheumatology, Department of Internal<br />
264 (Permanent Board Number)-Abstract Number
Medicine, Dr. Lutfi Kirdar Kartal Education and Research<br />
Hospita, Istanbul, Turkey; 4 Division of Rheumatology,<br />
Department of Internal Medicine, Faculty of Medicine,<br />
University of Marmara, Istanbul, Turkey; 5 1 Department of<br />
Biochemistry, Faculty of Medicine, University of Yeditepe,<br />
Istanbul, Turkey.<br />
(443)-1829. Discrepancies between Acpa Tests: Do All Anticitrullinated<br />
Protein/Peptide Antibody (acpa) Tests Measure<br />
the Same?. Bert J. Vander Cruyssen 1 , Leonor Nogueira 2 ,<br />
Jens Van Praet 1 , Mireille Sebag 2 , Cyril Clavel 2 , Vincent<br />
Christian 2 , Dieter Deforce 1 , Guy Serre 2 , Dirk Elelwaut 1 ,<br />
Filip De Keyser 1 . 1 Ghent University, Gent, Belgium;<br />
2<br />
UMR 5165 “Laboratory of Epidermis Differentiation and<br />
Rheumatoid Autoimmunity”, Toulouse, France.<br />
(444)-1830. Anti-CCP Antibody : Is it a Marker of Structural<br />
Joint Damage in Early Rheumatoid Arthritis?. Sung-Hoon Park,<br />
Jung-Yoon Choe, Sung-Kyu Kim, Ji-Young Kim. Catholic<br />
University of Daegu, School of Medicine, Daegu, Republic<br />
of Korea.<br />
(445)-1831. The Value of Antibodies to Mutated Citrullinated<br />
Vimentin in Early Arthitis. Jennie Ursum 1 , Markus M. Nielen 1 ,<br />
Dirkjan van Schaardenburg 1 , Ann R. van der Horst 2 , Rob<br />
J. van der Stadt 1 , Ben A. Dijkmans 3 , Dörte Hamann 2 . 1 Jan<br />
van Breemen Institute, Amsterdam, Netherlands; 2 Sanquin<br />
Diagnostics, Amsterdam, Netherlands; 3 VU Medical Centre,<br />
Amsterdam, Netherlands.<br />
(446)-1832. Sensitivity and Specificity of Second- and Third-<br />
Generation Cyclic Citrullinated Peptide Antibody Assays. Melissa<br />
R. Snyder, Gregory L. Jacob, Henry A. Homburger. Mayo<br />
Clinic College of Medicine, Rochester, MN.<br />
(447)-1833. Anti-CCP and Rheumatoid Factor Expression<br />
in Rheumatoid Arthritis; an Investigation of the Effect of<br />
Rheumatoid Factor on the ELISA quantitation of IgG anti-CCP.<br />
Charlotte M. Prior, Norma Ferris, Gerry O’Toole, Mary<br />
Codd, Suzanne Donnelly, Conor J. McCarthy, Geraldine<br />
M. McCarthy. Mater Misericordiae University Hospital,<br />
Dublin, Ireland.<br />
(448)-1834. Patients with Undifferentiated Arthritis Showing<br />
High Titer of Anti-CCP2 Antibodies Develop RA within One<br />
Year. Yukihiko Saeki, Eriko Kudo-Tanaka, Shiro Ohshima,<br />
Masato Matsushita, Takio Narukawa, Yoshinori Katada,<br />
Mitsuko Umeshita-Sasai, Kunio Miyatake. NHO Osaka-<br />
Minami Medical Center, Osaka, Japan.<br />
(449)-1835. Sera from Patients with Pulmonary Tuberculosis<br />
are Frequently Positive in Anti-CCP ELISA but also React with<br />
Unmodified Arginine-Containing Peptide. Prasanthi Kakumanu 1 ,<br />
Hajime Yamagata 2 , Eric S. Sobel 1 , Westley H. Reeves 1 ,<br />
Edward K.L Chan 1 , Minoru Satoh 1 . 1 University of Florida,<br />
Gainesville, FL; 2 National Hospital Organisation Murayama<br />
Medical Center, Musashi-Murayama, Tokyo, Japan.<br />
(450)-1836. Rheumatoid Disease Process and/or Therapy<br />
Differentially Impact on IgM and IgA Rheumatoid Factor Responses<br />
in Affected Native <strong>American</strong>s When Compared to Unaffected<br />
High Risk Relatives. Marianna M. Newkirk 1 , Thomas Jacob 2 ,<br />
David Robinson 2 , Donna Hart 2 , Brenda Elias 2 , Christine<br />
Peschken 2 , Janet Markland 2 , Hani El-Gabalawy 2 . 1 McGill<br />
University Health Centre, Montreal, PQ, Canada; 2 University<br />
of Manitoba, Winnipeg, MB, Canada.<br />
(451)-1837. The Inova CCP3.1 IgA/IgG ELISA Represents<br />
Significant Improvement in the Laboratory Diagnosis of<br />
Rheumatoid Arthritis. Zoltán Szekanecz 1 , Judit Tumpek 2 ,<br />
Zoltán Szabó 1 , Lilla Soós 1 , Margit Zeher 3 , Ildikó F.<br />
Horváth 3 , Katalin Dankó 3 , Sándor Sipka 2 , Gabriella Lakos 2 .<br />
1<br />
University of Debrecen Medical Center, Third Department<br />
of Medicine, Rheumatology Division, Debrecen, Hungary;<br />
2<br />
University of Debrecen Medical Center, Third Department<br />
of Medicine, Laboratory of Immunology, Debrecen,<br />
Hungary; 3 University of Debrecen Medical Center, Third<br />
Department of Medicine, Division of Clinical Immunology,<br />
Debrecen, Hungary.<br />
(452)-1838. No Association between Levels of Auto-Antibodies<br />
and the Improvement of RA during Pregnancy. Yaël A. de Man,<br />
Liesbeth E. Bakker, B. C.M. Dufour-van den Goorbergh,<br />
Sonja P.R. Tillemans, Herbert Hooijkaas, Johanna M.W.<br />
Hazes, Radboud J.E.M. Dolhain. Erasmus MC, University<br />
Medical Center Rotterdam, Rotterdam, The Netherlands.<br />
(453)-1839. A Novel Imaging Technology for Joint Assessment<br />
in Arthritis: Results of a Feasibility Study. Steven J. Spalding 1 ,<br />
Robert Boudreau 2 , Joseph Enama 2 , Paul Rosen 1 , C. Kent<br />
Kwoh 2 , Raphael Hirsch 1 , Eswar Krishnan 2 . 1 Children’s<br />
Hospital of Pittsburgh, Pittsburgh, PA; 2 University of<br />
Pittsburgh, Pittsburgh, PA.<br />
(454)-1840. Prognostic Evaluation of Undifferentiated Arthritis<br />
(UA) at Baseline Through Magnetic Resonance Imaging (MRI)-<br />
Detection of Early Join Damages and Serologic Variables:<br />
Results from the Prospective Clinical Study. Mami Tamai 1 ,<br />
Atsushi Kawakami 1 , Masataka Uetani 1 , Seiichiro Takao 1 ,<br />
Kazuhiko Arima 1 , Keita Fujikawa 1 , Naoki Iwamoto 1 , Shinya<br />
Kawashiri 1 , Nozomi Iwanaga 1 , Yasumori Izumi 1 , Fumiko<br />
Tanaka 1 , Kouichiro Aratake 1 , Makoto Kamachi 1 , Mingguo<br />
Huang 1 , Hideki Nakamura 1 , Tomoki Origuchi 2 , Hiroaki<br />
Ida 1 , Hiroaki Ida 1 , Kiyoshi Aoyagi 1 , Katsumi Eguchi 1 .<br />
1<br />
Graduate School of Biomedical Sciences, Nagasaki<br />
University, Nagasaki, Japan; 2 Nagasaki University School of<br />
Health Sciences, Nagasaki University, Nagasaki, Japan.<br />
(455)-1841. Ultrasound at Presentation Predicts Clinical<br />
Outcome in Very Early Inflammatory Patients. Jane E. Freeston,<br />
Richard J. Wakefield, Philip G. Conaghan, Elizabeth M A<br />
Hensor, Paul Emery. Academic Unit of Musculoskeletal<br />
Disease, University of Leeds, United Kingdom.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 265
Poster Session c<br />
(456)-1842. How Can Synovitis Detection by Ultrasonography<br />
Modify DAS28?. Andrea B. Lomonte 1 , Andrea P. Golmia 1 ,<br />
Kátia R. Ortiz 2 , William F. Lin 2 , Wanda C. Caldana 2 , Maria<br />
J. Nunes 1 , Luiza H. Ribeiro 1 , Mariana G. Waisberg 1 , Luiz<br />
C. Latorre 1 , Cristiano A. Zerbini 1 . 1 Heliopolis Hospital,<br />
São Paulo - S.P., Brazil; 2 Radiology Department, Centro de<br />
Medicina Diagnóstica Fleury, São Paulo - S.P., Brazil.<br />
Presentation numbers 1843-1849 are unassigned presentation numbers.<br />
(464)-1850. Cricoarytenoid (ca) and Laryngeal Rheumatoid<br />
Arthritis (RA): Their Clinical, Functional and Imaging Findings.<br />
Espinosa-Morales Rolando, Angelica H. Pena, Rembao<br />
Hilda, Martinez Elisa, Ramirez Agustin, Hernandez<br />
Xochiquetzal, Pineda Carlos. Instituto Nacional de<br />
Rehabilitacion, Distrito Federal, Mexico.<br />
Presentation numbers 1851-1862 are unassigned presentation numbers.<br />
(477)-1863. Validation of the self-report of Rheumatoid Arthritis<br />
and Systemic Lupus Erythematosus: The Women’s Health<br />
Initiative. Brian Walitt 1 , Florina Constantinescu 2 , James<br />
Katz 3 , Arthur Weinstein 1 , Hong Wang 4 , Rohini Khorana 4 ,<br />
Judith Hsia 3 , Barbara Howard 4 . 1 Washington Hospital<br />
Center, Washington, DC; 2 Virginia Commonwealth<br />
University, Richmond, VA; 3 George Washington<br />
University, Washington, DC; 4 MedStar Research Institute,<br />
Washington, DC.<br />
(478)-1864. The Association between NT-proBNP and Measures<br />
of Disease Activity in 238 Patients with Rheumatoid Arthritis: A<br />
10-year Longitudinal Study. Sella A. Provan, Tore K. Kvien,<br />
Petter Mowinckel. Diakonhjemmet hospital, Oslo, Norway.<br />
Presentation numbers 1865-1876 are unassigned presentation numbers.<br />
(491)-1877. High Levels of Serum Cartilage Oligomeric Matrix<br />
Protein (comp) in Early Rheumatoid Arthritis (ra) Associate with<br />
Anti-Cyclic Citrullinated Peptide (ccp)-Negative and Anti-Collagen<br />
Type Ii (cii) Positive Disease and with Low Level Activity During<br />
Follow-up. Mohammed Mullazehi 1 , Lars Klareskog 2 , Marius<br />
C. Wick 3 , Ronald F. van Vollenhoven 2 , Johan Rönnelid 1 .<br />
1<br />
Department of Clinical Immunology, Uppsala University,<br />
Uppsala, Sweden; 2 Department of Rheumatology, Karolinska<br />
Institute, Stockholm, Sweden; 3 Department of Radiology,<br />
Innsbruck Medical University, Innsbruck, Austria.<br />
(492)-1878. Genome-Wide Phararmacogenomics in Anti-<br />
TNF Therapy of Rheumatoid Arthritis: Implications for Their<br />
Efficacy and Adverse Reactions. Tsukasa Matsubara 1 , Keiko<br />
Funahashi 1 , Sayumi Toriyama 2 , Hitomi Itoh 2 , Masaaki<br />
Muramatsu 2 , Mitsuru Emi 2 , Satoru Koyano 2 . 1 Research<br />
Institute of Joint Disease, Kobe, Japan; 2 HuBit Genomix,<br />
Inc., Tokyo, Japan.<br />
(493)-1879. Circulating Survivin is a Negative Predictor of<br />
Remission in Early Ra. Björn Svensson 1 , Ingiäld Hafström 2 ,<br />
Kristina Forslind 3 , Kristina Albertsson 2 , Andrej Tarkowski 4 ,<br />
Maria Bokarewa 4 . 1 Rheumatology, University of Lund,<br />
Lund, Sweden; 2 Rheumatology, Karolinska University<br />
Hospital Huddinge, Stockholm, Sweden; 3 Rheumatology,<br />
Helsingborg Hospital, Helsingborg, Sweden; 4 Rheumatology<br />
and Inflammation Research, Sahlgrenska University<br />
Hospital, Göteborg, Sweden.<br />
(494)-1880. Serum Cytokine Levels Determined by Multiplex Assays<br />
and Clinical Characteristics in Patients with Rheumatoid Arthritis.<br />
John M. Davis, Keith L. Knutson, Michael A. Strausbauch,<br />
Cynthia S. Crowson, Peter J. Wettstein, Terry M. Therneau,<br />
Sherine E. Gabriel. Mayo Clinic, Rochester, MN.<br />
(495)-1881. Serum IL-6 and YKL-40 Levels in Early Rheumatoid<br />
Arthritis are Associated with Disease Activity, Treatment<br />
Response and Radiographic Outcome. L. S. Knudsen 1 , J. S.<br />
Johansen 1 , I. J. Christensen 2 , M. L. Hetland 3 , S. Jacobsen 4 ,<br />
M. Østergaard 1 , H. J. Nielsen 3 , K. Steengaard-Pedersen 5 ,<br />
P. Junker 6 , T. Lottenburger 7 , T. Elligsen 5 , L. S. Andersen 7 ,<br />
I. Hansen 5 , H. Skjødt 3 , J. K. Pedersen 7 , U. B. Lauridsen 3 ,<br />
A. Svendsen 6 , U. Tarp 5 , J. Pødenphant 1 , G. Hansen 7 , H.<br />
Lindegaard 6 , K. Hørslev-Pedersen 7 . 1 Herlev Hospital, Herlev,<br />
Denmark; 2 Finsen laboratory, Copenhagen Biocenter,<br />
Copenhagen, Denmark; 3 Hvidovre Hospital, Hvidovre,<br />
Denmark; 4 Rigshospital, Copenhagen, Denmark; 5 Århus<br />
Hospital, Århus, Denmark; 6 Odense Hospital, Odense,<br />
Denmark; 7 Gigthospital, Gråsten, Denmark.<br />
(496)-1882. Patients with Destructive Joint-Disease Have<br />
Increased MMP-Mediated Aggrecan Degradation. Eren U.<br />
Sumer 1 , Gerd Hein 2 , Andreas Mueller 2 , Morten A. Karsdal 1 ,<br />
Claus Christiansen 3 , Per Qvist 1 . 1 Nordic Bioscience, Herlev,<br />
Denmark; 2 Rheumatologie & Osteologie, Friedrich-Schiller-<br />
Universität, Jena, Germany; 3 Center of Clinical and Basic<br />
Research, Ballerup, Denmark.<br />
(497)-1883. A Transmembrane Polymorphism in FcγRIIb<br />
(FCGR2B) Is Associated with Rheumatoid Factor Production and<br />
Disease Severity in Taiwanese RA Patients. Ji-Yih Chen 1 , Chin-<br />
Man Wang 1 , Chung-Chun Ma 1 , Huei-Huang Ho 1 , Yeong-<br />
Jian Jan Wu 1 , Shue-Fen Luo 1 , Shin-Ning Kuo 1 , Jianming<br />
Wu 2 . 1 Chang Gung Memorial Hospital, Kwei Shan,<br />
Taoyuan, Taiwan; 2 University of Alabama at Birmingham,<br />
Birmingham, AL.<br />
(498)-1884. Higher Levels of Leptin in Obese Patients Correlate<br />
with Rheumatoid Arthritis Activity. Daniel X. Xibille 1 , Juan<br />
González-Rivera 2 , Mariana Alvarez-Fuentes 3 , Jose Luis<br />
Montiel 2 . 1 Hospital General de Cuernavaca, Cuernavaca,<br />
Mexico; 2 Faculty of Farmacy, Universidad Autónoma del<br />
Estado de Morelos, Cuernavaca, Mexico; 3 Instituto Nacional<br />
de Salud Publica, Cuernavaca, Mexico.<br />
(499)-1885. The Effect of Hormone Replacement Therapy on<br />
Soluble RAGE Levels in Postmenopausal RA Patients. Rille<br />
Pullerits, Helena Forsblad d’Elia, Andrej Tarkowski, Hans<br />
Carlsten. Sahlgrenska Academy at Göteborg University,<br />
Gothenburg, Sweden.<br />
266 (Permanent Board Number)-Abstract Number
(500)-1886. Synovial PPARγ Expression as a Tissue Biomarker in<br />
Rheumatoid Arthritis. Dai Lie, Lu Meng, Zhang Bai-Yu, Zheng<br />
Dong-hui, Mo Ying-Qian. The Second Affiliated Hospital,<br />
Sun Yat-sen University, Guangzhou, China.<br />
(501)-1887. Usefulness of Multiple Single Nucleotide<br />
Polymorphisms Detection by a DNA Array in the Prediction of<br />
Functional Impairment and Remission Status in Rheumatoid<br />
Arthritis. José-Luis Andreu 1 , Jokin del Amo 2 , Alejandro<br />
Balsa 3 , Francisco Blanco 4 , Raimon Sanmartí 5 , Rafael<br />
Cáliz 6 , Lucía Silva 1 , Eduard Graell 5 , Antonio Martínez 2 ,<br />
Dora Pascual-Salcedo 7 , Diego Tejedor 2 , Natividad Oreiro 4 ,<br />
María-Dolores Collado 6 , Laureano Simón 2 , Juan Mulero 1 .<br />
1<br />
Rheumatology Department. Hospital Universitario Puerta<br />
de Hierro, Madrid, Spain; 2 Progenika Biopharma SA, Derio,<br />
Spain; 3 Rheumatology Department. Hospital Universitario<br />
La Paz, Madrid, Spain; 4 Rheumatology Department.<br />
Hospital Universitario Juan Canalejo, A Coruña, Spain;<br />
5<br />
Rheumatology Department. Hospital Clinic, Barcelona,<br />
Spain; 6 Rheumatology Department. Hospital Universitario<br />
Virgen de las Nieves, Granada, Spain; 7 Immunology<br />
Department. Hospital Universitario La Paz, Madrid, Spain.<br />
(502)-1888. Rheumatoid Arthritis and Access to Care in the GTA.<br />
Shahin Jamal, Shabbir M. Alibhai, Elizabeth Badley, Claire<br />
Bombardier. University of Toronto, Toronto, ON, Canada.<br />
(503)-1889. Evaluation of Selected Rheumatoid Arthritis Activity<br />
Scores for Office Based Assessment. Kerri L. Batra, Jing Cui,<br />
Roberta Glass, Nancy E. Maher, Daniel H. Solomon, Nancy<br />
A. Shadick. Brigham & Women’s Hospital, Boston, MA.<br />
(504)-1890. Characterization of Synovial Tissue and Plasma<br />
Biomarkers and their Relationship to Rheumatoid Arthritis Disease<br />
Activity. Seth Sadis 1 , Robert Buck 1 , Roberto Guzman 1 ,<br />
Robert Dunstan 1 , Nathan Wei 2 , Justus Fiechtner 3 ,<br />
Bernhardt G. Zeiher 1 . 1 Pfizer Global Research and<br />
Development, Ann Arbor, MI; 2 Arthritis and Osteoporosis<br />
Center, Frederick, MD; 3 Fiechtner Research, Lansing, MI.<br />
(505)-1891. Rheumatoid Arthritis Diagnosis: A Comparative<br />
Study of Second and Third Generation Anti-Cyclic Citrullinated<br />
Peptide (CCP) Antibody Elisas. Lisiane Enriconi dos Anjos<br />
Vieira 1 , Ivanio Alves Pereira 1 , Eleonora D’dorsi 1 , Edelton<br />
Flávio Morato 1 , Rufus Burlingame 2 . 1 Federal University<br />
of Santa Catarina State, Florianopolis, Brazil; 2 Inova<br />
Diagnostics, Inova Diagnostics, CA.<br />
(506)-1892. Can we Predict Structural Damage Progression at<br />
2 Years in Very Early Arthritis ? Value of Bone and Cartilage<br />
Markers in the Conservatively Treated Community-Based<br />
Inceptive VErA Cohort. Othmane Mejjad 1 , Claire Fèvre 1 ,<br />
Michel Brazier 2 , Alain Daragon 3 , Romain Daveau 4 , Patrick<br />
Boumier 5 , Alain Gayet 6 , François Tron 4 , Charles Zarnitzky 7 ,<br />
Olivier Vittecoq 8 , Patrice Fardellone 9 , Xavier Le Loët 8 .<br />
1<br />
Rheumatology, CHU, Rouen, France; 2 Pharmacology,<br />
CHU, Amiens, France; 3 Rheumatology, CHU, INSERM<br />
U 519, rouen, France; 4 Immunology laboratory, INSERM<br />
U 519, rouen, France; 5 College of Rheumatology Picardie,<br />
Amiens, France; 6 College of Rheumatology Haute Normandie,<br />
rouen, France; 7 Rheumatology, Groupe Hospitalier, Le Havre,<br />
France; 8 Rheumatology, CHU, INSERM U 519, Rouen, France;<br />
9<br />
Rheumatology, CHU, Amiens, France.<br />
(507)-1893. Comparison of Anti-Mutated Citrullinated Vimentin<br />
with Anti-Cyclic Citrullinated Peptide and Rheumatoid Factors<br />
for the Diagnosis of Rheumatoid Arthritis. Jungsoo S. Song,<br />
Geumborae B. Park, Aeja J. Park. Chung-Ang University<br />
Hospital, Seoul, Republic of Korea.<br />
(508)-1894. Usefulness of Magnetic Resonance Imaging of the<br />
Hand Versus Anti-Cyclic Citrullinated Peptide Antibody Test to<br />
Confirm Diagnosis in Patients with Clinical Suspicion of Early<br />
Rheumatoid Arthritis in the Absence of Rheumatoid Factor and<br />
Radiographic Erosions. Javier Narvaez, Elena Sirvent, Jose<br />
Antonio Narvaez, Jordi Bas Minguet, Carmen Gomez<br />
Vaquero, Delia Reina, Joan Miquel Nolla, Jose Valverde.<br />
Hospital Universitari de Bellvitge, Barcelona, Spain.<br />
(509)-1895. Relationship between Biomarkers for Cartilage and<br />
Bone and Joint Counting in Patients with Rheumatoid Arthritis.<br />
Andrea P. Golmia 1 , Andrea B. Lomonte 1 , Kátia R. Ortiz 2 ,<br />
William F. Lin 2 , Wanda C. Caldana 2 , Maria J. Nunes 1 ,<br />
Luiza H. Ribeiro 1 , Mariana G. Waisberg 1 , Luiz C. Latorre 1 ,<br />
Cristiano A. Zerbini 1 . 1 Heliopolis Hospital, São Paulo -<br />
S.P., Brazil; 2 Radiology Department, Centro de Medicina<br />
Diagnóstica Fleury, São Paulo - S.P., Brazil.<br />
(510)-1896. Serum CX3CL1 Levels are Predictive of the Response<br />
to Infliximab Therapy in Patients with Rheumatoid Arthritis.<br />
Tsuyoshi Odai, Kuninobu Wakabayashi, Takeo Isozaki,<br />
Mizuho Matsunawa, Nobuyuki Yajima, Yusuke Miwa,<br />
Masao Negishi, Hirotsugu Ide, Tsuyoshi Kasama. Showa<br />
University, Tokyo, Japan.<br />
(511)-1897. Usage of High Sensitivity CRP Test Together with<br />
Anti-Cyclic Citrullinated Peptide Antibody Significantly Raised<br />
the Predictive Value for Rheumatoid Arthritis. Nobuhide<br />
Hayashi 1 , Seiji Kawano 1 , Daisuke Sugiyama 2 , Goh Tsuji 2 ,<br />
Takashi Nakazawa 2 , Kunihiro Nishimura 2 , Akio Morinobu 2 ,<br />
Shunichi Kumagai 2 . 1 Kobe University Hospital, Kobe,<br />
Japan; 2 Kobe University Graduate School of Medicine,<br />
Kobe, Japan.<br />
(512)-1898. Anti-Cyclic Citrulline Peptide Antibodies (Anti-<br />
CCP) and Anti-Citrullinated Vimentin in Patients with Systemic<br />
Rheumatic Diseases Different to Rheumatoid Arthritis (RA).<br />
Eugenia González-Díaz de Rábago, Francisco Javier López-<br />
Longo, Inmaculada De la Torre, D. Oliver-Miñarro, Marta<br />
García Castro, Maria Dolores Casas González, MAria<br />
Carpena, Irene Diez-Merchán, Elena Becerra, Carlos Manuel<br />
González-Fernández, Indalecio Monteagudo, Silvia Sanchez-<br />
Ramón, Margarita Rodríguez-Mahou, Luis Carreño. hospital<br />
general universitario Gregorio Marañon, Madrid, Spain.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 267
Poster Session c<br />
(513)-1899. Increased Concentration of Plasma Pentraxin 3 in<br />
Rheumatoid Arthritis: Relationship to Chronic Inflammation,<br />
Bone Destruction and Atherosclerosis. Yu Asanuma, Kojiro<br />
Sato, Kazuhiro Yokota, Yasushi Shindo, Yoshihiro Yoshida,<br />
Haruhiko Akiba, Kyoichi Nakajima, Yuji Akiyama, Toshihide<br />
Mimura. Saitama Medical University, Saitama, Japan.<br />
(514)-1900. Anti Cyclic Citrullinated Peptide Antibodies<br />
(anti-CCP) and Rheumatoid Factor in Established Rheumatoid<br />
Arthritis: A Real World Experience. Elena M. Massarotti, Grace<br />
Lo, Paola DePablo, Jun Wang, Timothy E. McAlindon.<br />
Tufts New England Medical Center, Boston, MA.<br />
(515)-1901. Antibodies to Citrullinated Human Fibrin Synthetic<br />
Peptides: Diagnostic Value in Rheumatoid Arthritis. Isabel<br />
Haro 1 , María L. Pérez 1 , María Gómara 1 , Guadalupe Ercilla 2 ,<br />
Eduard Graell 2 , Juan D. Cañete 3 , Raimon Sanmarti 2 .<br />
1<br />
Departament of Peptide and Protein Chemistry, IIQAB-<br />
CSIC, Barcelona, Spain; 2 Rheumatology Service. Hospital<br />
Clínic, Barcelona, Spain; 3 Rheumatology Service. Hospital<br />
Clínic, BARCELONA, Spain.<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
SLE: Clinical Aspects and Treatment III<br />
(516)-1902. An Acute and Extreme Increase in Serum True<br />
Lap (leucine Aminopeptidase) Level is an Indicator of a Unique<br />
Type of Exacerbation in Systemic Lupus Erythematosus.<br />
Shigeko Inokuma, Hajime Kono, Akira Yoshida, Hisanori<br />
Nakayama, Yuko Matsuzaki, Yoji Miyakuni, Shoko Takagi,<br />
Mikako Mori, Junko Maruyama. Tokyo Metropolitan<br />
Komagome Hospital, Tokyo, Japan.<br />
(517)-1903. A Practical, Reliable Methodology for<br />
Measuring Anti-DNA Antibodies in the Diagnosis of Systemic<br />
Lupus Erythematosus (SLE): ELISA, Farr or C. luciliae<br />
Immunoflorescence (CL-IFA)? Laura McCloskey 1 , Paul<br />
Christner 1 , Dana Jacobs-Kosmin 2 , Troy Jaskowski 3 , Harry<br />
Hill 3 , Marius Teodorescu 4 . 1 Thomas Jefferson University,<br />
Philadelphia, PA; 2 Albert Einstein Medical Center,<br />
Philadelphia, PA; 3 ARUP Laboratories, Salt Lake City, UT;<br />
4<br />
TheraTest Laboratories, Lombard, IL.<br />
(518)-1904. The Cutaneous Lupus Erythematosus Disease<br />
Activity and Severity Index (CLASI) Reliability and Validity<br />
Assessment: Expansion for Rheumatology and Dermatology and<br />
Evaluation with Spectroscopy. Michael S. Krathen 1 , Jonathan<br />
Dunham 1 , Elizabeth Gaines 1 , Gary Grove 2 , Jacqueline<br />
Junkins-Hopkins 1 , Ellen Kim 1 , Kolaskinski L. Sharon 1 ,<br />
Carrie Kovarik 1 , Jennifer Kwan-Morley 1 , Joyce Okawa 1 , Kate<br />
Propert 1 , Nicole Rogers 3 , Mathew Rose 1 , Preethi Thomas 1 ,<br />
Andrea B. Troxel 1 , Abby VanVoorhees 1 , Joan Von Feldt 1 ,<br />
Anita A. Weber 1 , Victoria P. Werth 1 . 1 University of<br />
Pennsylvania, Philadelphia, PA; 2 cyberDERM Inc, Broomall,<br />
PA; 3 Tulane University, New Orleans, LA.<br />
(519)-1905. Prevalence of Anti-Cyclic Citrullinated Peptide<br />
Antibodies and Rheumatoid Factor in Patients with Systemic<br />
Lupus Erythematosus. Ewa Olech 1 , Linda A. Zacharias 2 ,<br />
Stan Kamp 1 , Joy Hutcheson 1 , Sandra Wilson 1 , Fredonna<br />
Carthen 1 , Joan T. Merrill 1 . 1 Oklahoma Medical Research<br />
Foundation, Oklahoma City, OK; 2 Oklahoma Health<br />
Sciences Center, Oklahoma City, OK.<br />
(520)-1906. Assessment of KLH Specific T and B Cell Responses<br />
in Healthy Volunteers (HV) and in Subjects with Systemic Lupus<br />
Erythematosus (SLE) Immunized with KLH. John Ferbas 1 ,<br />
Shelley Belouski 1 , Arunan Kaliyaperumal 1 , Vibha Jawa 1 ,<br />
Mark Dalphin 1 , Fanesca Young 1 , Malcolm Boyce 2 , Bernard<br />
Colaço 3 , Neil McHugh 4 , Vanessa Boyce 4 , Richard Nicholl 1 ,<br />
Gerald Siu 1 , James Chung 1 . 1 Amgen, Thousand Oaks,<br />
CA; 2 Hammersmith Medicines Research, London, United<br />
Kingdom; 3 Central Middlesex Hospital, London, United<br />
Kingdom; 4 Royal National Hospital for Rheumatological<br />
Diseases, Bath, United Kingdom.<br />
(521)-1907. Performance of a Multiplex Flow Immunoassay ANA<br />
Screen in Patients with a Diagnosis of SLE. Timothy Bouck,<br />
Bob Miyake, Michael Nasello, Marilyn Menegus, Jennifer H.<br />
Anolik. Univ of Rochester, Rochester, NY.<br />
(522)-1908. Depression, Anxiety, Anger, Fatigue and Quality of<br />
Life in Systemic Lupus Erythematosus: Relationship to the Disease<br />
Activity and Damage. Sang Tae Choi 1 , Jee In Kang 2 , Eun-Jin<br />
Kang 1 , Sang-Won Lee 1 , Min-Chan Park 1 , Yong-Beom Park 1 ,<br />
Soo-Kon Lee 1 . 1 Department of Internal medicine, Yonsei<br />
University College of Medicine, Seoul, Republic of Korea;<br />
2<br />
Department of Psychiatry, Yonsei University College of<br />
Medicine, Seoul, Republic of Korea.<br />
(523)-1909. Serious Cardiovascular Disease (CVD) and<br />
Infections in Patients with Systemic Lupus Erythematosus (SLE)<br />
in a Large U.S. Managed Care Plan Stratified by Therapeutic<br />
Intensity. Stephen P. Motsko 1 , Bao-Anh Nguyen-Khoa 1 , Pavel<br />
Napalkov 2 , Wei Dong 2 , Ruby M. Vendiola 1 , Earl Goehring,<br />
Jr. 1 , Judith K. Jones 1 . 1 The Degge Group, Ltd., Arlington,<br />
VA; 2 Genentech, Inc., S San Francisco, CA.<br />
(524)-1910. Does Smoking Influence Clinical And Laboratory<br />
Features In Patients With Systemic Lupus Erythematosus?<br />
Nikolaos G. Papadopoulos, Georgios Tsiaousis,<br />
Panagiota Partala, Aikaterini Pavlitou-Tsiontsi, Vasiliki<br />
K. Galanopoulou. Papageorgiou General Hospital,<br />
Thessaloniki, Greece.<br />
(525)-1911. Ethnicity and Adherence to Medications in<br />
Patients with Systemic Lupus Erythematosus (SLE). Sharon<br />
A. Chambers 1 , Rosalind Raine 2 , Anisur Rahman 1 , David<br />
Isenberg 1 . 1 University College London Hospitals, London,<br />
United Kingdom; 2 University College London, London,<br />
United Kingdom.<br />
268 (Permanent Board Number)-Abstract Number
(526)-1912. Autoantibodies and Clinical Associations in a Large,<br />
Ethnically Diverse SLE Patient Collection: Leucopenia is Strongly<br />
Associated with All Ten Lupus Autoantibodies. B. F. Bruner 1 , J. M.<br />
Guthridge 2 , J. A. Kelly 2 , J. B. Harley 2 , J. A. James 2 . 1 OUHSC,<br />
Oklahoma City, OK; 2 OMRF, Oklahoma City, OK.<br />
(527)-1913. Michigan Lupus Epidemiology & Surveillance<br />
(MILES) <strong>Program</strong>: False Positive Diagnosis of ANA Negative<br />
Lupus by the <strong>ACR</strong> Criteria and Boston Weighted Criteria as<br />
Compared to Rheumatologist Classification in a Population Based<br />
Cohort. Sheeja Francis 1 , Emily C. Somers 1 , Emily Lewis 1 ,<br />
Wendy Marder 1 , Diane Shaltis 1 , Elizabeth Curry 1 , Thomas<br />
Kallarackal-Maliakal 1 , Carol VanHuysen 1 , Patricia Cagnoli 1 ,<br />
Lauren Levy 1 , James Leisen 2 , J. Patricia Dhar 3 , Peter<br />
DeGuire 4 , W. Joseph McCune 1 . 1 University of Michigan<br />
Health System, Ann Arbor, MI; 2 Henry Ford Health<br />
System, Detroit, MI; 3 Wayne State University, Detroit, MI;<br />
4<br />
Michigan Department of Community Health, Lansing, MI.<br />
(528)-1914. Psychological Factors Associated with Functional<br />
Disability in Patients with Systemic Lupus Erythematosus. Thomas<br />
N. Hyphantis, Kaliopi Palieraki, Paraskevi V. Voulgari,<br />
Marina Bai, Niki Tsifetaki, Aliki I. Venetsanopoulou,<br />
Venetsanos Mavreas, Alexandros A. Drosos. Medical School,<br />
University of Ioannina, Ioannina, Greece.<br />
(529)-1915. The Relationship between Clinical, Neuropsychiatric,<br />
Immunological Variables and Health-Related Quality of Life of<br />
Chinese Patients with Systemic Lupus Erythematosus. Lai-Shan<br />
Tam, Tena K. Li, Edmund K. Li. Chinese University of<br />
Hong Kong, Hong Kong, Hong Kong.<br />
(530)-1916. Performance of the SLAQ in SLE and Non-SLE<br />
Subjects in a Longitudinal Databank. Robert Katz 1 , Michelle<br />
Petri 2 , Elizabeth W. Karlson 3 , Graciela S. Alarcón 4 ,<br />
Eliza Chakravarty 5 , John Goldman 6 , Frederick Wolfe 7 ,<br />
Systemic Lupus Erythematosus in the Community<br />
Study Group. 1 Rush Medical Center, Chicago, IL; 2 John<br />
Hopkins University, Baltimore, MD; 3 Brigham and<br />
Women’s Hospital, Boston, MA; 4 University of Alabama<br />
at Birmingham, Birmingham, AL; 5 Stanford University,<br />
Stanford, CA; 6 Emory University, Atlanta, GA; 7 National<br />
Data Bank for Rheumatic Diseases, Wichita, KS.<br />
(531)-1917. Problems in Functioning from the Perspective of<br />
Patients with Chronic Phases of Systemic Lupus Erythematodes<br />
Based on the International Classification of Functioning,<br />
Disability and Health. Bettina Bauernfeind 1 , Josef Smolen 1 ,<br />
Gerold Stucki 2 , Martin Aringer 3 , Tanja Stamm 1 . 1 Vienna<br />
Medical University, Vienna, Austria; 2 Ludwid-Maximilians-<br />
University, Munich, Germany; 3 Fakultät Carl Gustav Carus<br />
der Technischen Universität Dresden, Dresden, Germany.<br />
(532)-1918. The Relationship between Demographic and Clinical<br />
Parameters and Health-Related Quality of Life (HRQoL) in<br />
patients with Systemic Lupus Erythematosus (SLE). Kathleen<br />
McElhone 1 , J. Abbott 2 , J. Shelmerdine 3 , I. Bruce 3 , Y.<br />
Ahmad 3 , C. Gordon 4 , K. Peers 4 , D. Isenberg 5 , A. Ferenkeh-<br />
Koroma 5 , B. Griffiths 6 , M. Akil 7 , P. Maddison 8 , Lee-Suan<br />
Teh 1 . 1 Royal Blackburn Hospital, Blackburn, United<br />
Kingdom; 2 Faculty of Health, UCLAN, Preston, United<br />
Kingdom; 3 Manchester Royal Infirmary, Manchester,<br />
United Kingdom; 4 University of Birmingham, Birmingham,<br />
United Kingdom; 5 Middlesex Hospital, London, United<br />
Kingdom; 6 Freeman Hospital, Newcastle, United Kingdom;<br />
7<br />
Hallamshire Hospital, Sheffield, United Kingdom; 8 Ysbyty<br />
Gwynedd, Bangor, United Kingdom.<br />
(533)-1919. Systemic Lupus Erythematosus (SLE) Patients of<br />
Hispanic-Texan Ethnicity are at Increased Risk of Premature<br />
Gonadal Failure (PGF): Data from a Large Multiethnic Cohort.<br />
Luis A. González 1 , Sergio Durán 1 , Gerald McGwin, Jr 1 ,<br />
Mandar Apte 1 , Luis M. Vilá 2 , John D. Reveille 3 , Graciela<br />
S. Alarcón 1 . 1 University of Alabama at Birmingham,<br />
Birmingham, AL; 2 University of Puerto Rico, San Juan,<br />
Puerto Rico; 3 University of Texas Health Science Center at<br />
Houston, Houston, TX.<br />
(534)-1920. Mammographic Abnormalities in Patients with<br />
SLE. Veena Rao, Hiro Abe, Tammy O. Utset. University of<br />
Chicago, Chicago, IL.<br />
(535)-1921. Prevalence of Menopausal Symptoms in Patients<br />
with Systemic Lupus Erythematosus (SLE). Deshiré Alpízar-<br />
Rodríguez, Juanita Romero-Díaz, María del Carmen<br />
Cravioto, Jorge Sánchez-Guerrero. Instituto Nacional de<br />
Ciencias Médicas y Nutrición SZ, Mexico, City, Mexico.<br />
(536)-1922. Ovarian Preservation by GnRH-Agonists during<br />
Chemotherapy: A Meta-Analysis. Megan E.B. Clowse, Millie<br />
A. Behera, Carey K. Anders, Phyllis C. Leppert, Lori A.<br />
Bastian. Duke University, Durham, NC.<br />
(537)-1923. Endothelial Vasculopathy as Reflected by Circulating<br />
Endothelial Cells (CEC) Associates with Abnormal Intimal Media<br />
Thickness in Systemic Lupus Erythematosus. Tania Rivera,<br />
Peter Izmirly, Harmony Reynolds, Paul Tunick, Jill P.<br />
Buyon, Robert M. Clancy. New York University School of<br />
Medicine, New York, NY.<br />
(538)-1924. Anticardiolipin Antibodies are Associated with<br />
Higher Risk of Thrombosis in Systemic Lupus Erythematosus: A<br />
Descriptive Study. Simon Y. Tian 1 , Zhaleh Shariati 2 , Raja<br />
Bobba 3 , Dafna Gladman 2 , Murray Urowitz 2 , Paul R. Fortin 2 .<br />
1<br />
UHN - Toronto Western Research Institute, University<br />
of Toronto, Toronto, ON, Canada; 2 University of<br />
Toronto Lupus Clinic, Centre for Prognosis Studies in the<br />
Rheumatic Diseases, Toronto Western Hospital, University<br />
Health Network, Toronto, ON, Canada; 3 McMaster<br />
University, Hamilton, ON, Canada.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 269
Poster Session c<br />
(539)-1925. Soft Coronary Plaque in Systemic Lupus<br />
Erythematosus (SLE). Michelle Petri, Adnan Kiani, Jens<br />
Vogel-Claussen, David A. Bluemke. Johns Hopkins<br />
University, Baltimore, MD.<br />
(540)-1926. A Low, Rather than a High, Asymmetric<br />
Dimethylarginine is a Risk Factor for Cardiovascular Disease in<br />
Patients with Systemic Lupus Erythematosus. Shin-Seok Lee 1 ,<br />
James A. Mahoney 2 , Laurence S. Magder 3 , Michelle Petri 2 .<br />
1<br />
Chonnam National University Medical School, Gwangju,<br />
Republic of Korea; 2 Johns Hopkins University School of<br />
Medicine, Baltimore, MD; 3 University of Maryland School<br />
of Medicine, Baltimore, MD.<br />
(541)-1927. MCP-1 Is Not Associated with Cardiovascular<br />
Disease in Patients with Systemic Lupus Erythematosus. Shin-<br />
Seok Lee 1 , James A. Mahoney 2 , Laurence S. Magder 3 ,<br />
Michelle Petri 2 . 1 Chonnam National University Medical<br />
School, Gwangju, Republic of Korea; 2 Johns Hopkins<br />
University School of Medicine, Baltimore, MD; 3 University<br />
of Maryland School of Medicine, Baltimore, MD.<br />
(542)-1928. Relationship Between Inflammatory Cytokines<br />
and Cell Adhesion Molecules and Changes in Measures of<br />
Atherosclerosis. Lisa Christopher-Stine 1 , Adnan Kiani 1 ,<br />
Laurence Magder 2 , James Mahoney 1 , Wendy Post 1 ,<br />
Michelle Petri 1 . 1 Johns Hopkins University, Baltimore, MD;<br />
2<br />
University of Maryland, Baltimore, MD.<br />
(543)-1929. Mycophenolate Mofetil (MMF) and Atherosclerosis<br />
in SLE. Adnan Kiani 1 , Laurence Magder 2 , Michelle Petri 1 .<br />
1<br />
Johns Hopkins University, Baltimore, MD; 2 University of<br />
Maryland, Baltimore, MD.<br />
(544)-1930. Factors Associated with Vascular Events in a<br />
Multiethnic Lupus Cohort. Ana M. Bertoli 1 , Luis M. Vila 1 ,<br />
Graciela Alarcon 2 , Gerald McGwin, Jr. 2 , Michelle Petri 3 ,<br />
Rosalind Ramsey-Goldman 4 , John D. Reveille 5 , Robert P.<br />
Kimberly 2 . 1 University of Puerto Rico, San Juan, Puerto<br />
Rico; 2 University of Alabama at Birmingham, Birmingham,<br />
AL; 3 Johns Hopkins University, Baltimore, MD;<br />
4<br />
Northwestern University, Chicago, IL; 5 University of Texas<br />
Health Science Center at Houston, Houston, TX.<br />
(545)-1931. Cardiovascular Events in Patients with Biopsy-Proven<br />
Lupus Nephropathy: Predictive Clinical and Immunological<br />
Factors at Diagnosis. Manuel Ramos-Casals 1 , Albert Bové 1 ,<br />
Pilar Brito-Zerón 1 , Natalia Soria 1 , Gerard Espinosa 1 , Ricard<br />
Cervera 1 , Manel Solé 2 , Alexandre Darnell 3 , Antoni Sisó 4 .<br />
1<br />
Department of Autoimmune Diseases, Hospital Clinic,<br />
Barcelona, Spain; 2 Department of Pathology, Hospital<br />
Clinic, Barcelona, Spain; 3 Department of Nephrology,<br />
Hospital Clinic, Barcelona, Spain; 4 Centre d’Assistència<br />
Primària ABS Les Corts, Barcelona, Spain.<br />
(546)-1932. Risk Factors for Clinical Coronary Events in Patients<br />
with SLE: a Multicentre Case-Control Study. Sahena Haque 1 ,<br />
Donna Taylor-Fesler 1 , Caroline Gordon 2 , Veronica Toescu 3 ,<br />
David Isenberg 2 , Anisur Rahman 2 , Aubrey Bell 3 , Peter<br />
Lanyon 3 , Neil McHugh 2 , David GI Scott 2 , Paul Emery 2 , Lee<br />
Suan Teh 2 , Jacqueline Andrews 3 , Hazem Youssef 3 , Bridget<br />
Griffiths 3 , John McLaren 3 , Ian N. Bruce 1 . 1 University of<br />
Manchester, Manchester, United Kingdom; 2 British Isles<br />
Lupus Assessment Group, London, United Kingdom; 3 BSR<br />
Lupus Special Interest Group, London, United Kingdom.<br />
(547)-1933. Antiphospholipid Antibodies and Increased Bleeding<br />
Complications Following Renal Biopsy: A Single Centre Study.<br />
Ahlem Chaib 1 , Nadia Mellilo 2 , Shirish R. Sangle 1 , Tarun<br />
Sabharwal 3 , Fahim Tungekar 4 , Ian C. Abbs 5 , Munther A.<br />
Khamashta 1 , David P. D’Cruz 1 . 1 Lupus Research Unit,<br />
The Rayne Institute, King’s College School of Medicine, St<br />
Thomas’ Hospital, London, United Kingdom; 2 Department<br />
of Rheumatology, d’Avanzo Hospital, University of Foggia,,<br />
Foggia, Italy; 3 Radiology Department, St Thomas’ Hospital,<br />
London, United Kingdom; 4 Histopathology Department, St<br />
Thomas’ Hospital, London, United Kingdom; 5 Department<br />
of Renal Medicine, King’s College School of Medicine, St<br />
Thomas’ Hospital, London, United Kingdom.<br />
(548)-1934. Prognostic Factors for Relapse after Induction<br />
Therapy in the First Episode of Lupus Nephritis. Eva Salgado,<br />
Javier Garcà a, Rebeca Belmonte, Paz Martinez- Vidal,<br />
Marà a Galindo, Isabel Mateo, Patricia Carreira. Hospital 12<br />
de Octubre, Madrid, Spain.<br />
(549)-1935. Comparison of Renal Biopsies: High-Dose<br />
Cyclophosphamide Therapy vs. NIH Cyclophosphamide in Lupus<br />
Nephritis (LN). Surabhi Agarwal 1 , Mark Haas 2 , Richard<br />
Jones 2 , Robert Brodsky 2 , Laurence Magder 3 , Michelle Petri 2 .<br />
1<br />
Good Samaritan Hospital, Baltimore, MD; 2 Johns Hopkins<br />
University, Baltimore, MD; 3 University of Maryland,<br />
Baltimore, MD.<br />
(550)-1936. Lack of Association between High Avidity AntidsDNA,<br />
Anti-chromatin Antibodies and Anti-C1q Antibodies with<br />
Renal Proteinuria Flares. Ehtisham Akhter 1 , Roger Budd 2 ,<br />
Michelle Petri 1 . 1 Johns Hopkins University, Baltimore, MD;<br />
2<br />
The Binding Site, Birmingham, United Kingdom.<br />
(551)-1937. A Simple Exercise Advice Intervention Improves<br />
Health-Related Quality of Life (HRQOL) in Patients with<br />
Systemic Lupus Erythematosus (SLE). Karen J. Donaldson 1 ,<br />
Joanna Goodall 2 , Joanne Steel 2 , Emma Ninan 2 , John<br />
Brockbank 1 , Kathleen McElhone 1 , Lee-Suan Teh 1 .<br />
1<br />
Rheumatology Department, Royal Blackburn Hospital,<br />
Blackburn, United Kingdom; 2 Physiotherapy Department,<br />
Royal Blackburn Hospital, Blackburn, United Kingdom.<br />
270 (Permanent Board Number)-Abstract Number
(552)-1938. A Pilot Study on Tacrolimus Treatment in Patients<br />
with Systemic Lupus Erythematosus without Renal Involvement.<br />
Yoshie Kusunoki, Kenji Takagi, Kimiko Akimoto,<br />
Shinichiro Nishio, Nahoko Matsumoto, Shinichi Kawai.<br />
Toho University School of Medicine, Tokyo, Japan.<br />
(553)-1939. Long-Term Follow Up of Rituximab (Anti-CD20)<br />
Therapy for Refractory Systemic Lupus Erythematosus. Yoshiya<br />
Tanaka, Mikiko Tokunaga, Masao Nawata, Katsunori<br />
Suzuki, Shigeru Iwata, Kunihiro Yamaoka, Kazuyoshi Saito.<br />
University of Occupational & Environmental Health,<br />
Japan, Kitakyushu, Japan.<br />
(554)-1940. Intravenous Immunoglobulin for Steroid-Resistant<br />
Neutropenia Associated with Systemic Lupus Erythematosus.<br />
Jennifer A. McCallum, Karina D. Torralba. University of<br />
Arkansas for Medical Sciences, Central Arkansas Veterans<br />
Healthcare System, Little Rock, AR.<br />
(555)-1941. Intrathecal Immunoglobulin Production in<br />
Systemic Lupus Erythematosus Patients with Neuropsychiatric<br />
Manifestations. Mo Yin Mok 1 , Eric YT Chan 2 , Woon Sing<br />
Wong 1 , Chak Sing Lau 1 . 1 The Univerity of Hong Kong,<br />
Department of Medicine, Hong Kong, Hong Kong; 2 The<br />
Univerity of Hong Kong, Department of Pathology, Hong<br />
Kong, Hong Kong.<br />
(556)-1942. Long-Term Clinical Outcomes of Synchronized<br />
Therapy with Plasmapheresis and Intravenous Cyclophosphamide<br />
Pulse Therapy in the Treatment of Steroid-Resistant Lupus<br />
Nephritis. Ken Yamaji 1 , Shin Onuma 1 , Hitoshi Ogasawara 1 ,<br />
Hiroshi Tsuda 2 , Yoshinari Takasaki 1 . 1 Juntendo University,<br />
Tokyo, Japan; 2 Juntendo Tokyo Koto Geriatric Medical<br />
Center, Tokyo, Japan.<br />
(557)-1943. Clinical Features of SLE with Interstitial Cystitis<br />
(Lupus Cystitis); A Subgroup of Lupus with Interstitial Cystitis,<br />
Hydronephrosis and Gastro-enteropathy. Kazuhiro Kurasawa 1 ,<br />
Kotaro Kumano 1 , Yuko Maezawa 2 , Noriaki Nakagawa 2 ,<br />
Yasuhiko Kita 3 , Takao Sugiyama 4 , Katsuhiko Takabayashi 2 .<br />
1<br />
Dokkyo University, School of Medicine, Mibu, Tochigi,<br />
Japan; 2 Chiba University, School of Medicine, Chiba,<br />
Japan; 3 Yokohama Rosai Hospital, Yokohama, Japan; 4 NHO<br />
Shimoshizu Hospital, Yotukaido, Chiba, Japan.<br />
(558)-1944. Thrombotic Thrombocytopenic Purpura in Systemic<br />
Lupus Erythematosus: Focus on Clinical Characteristics and Risk<br />
Factor for Mortality. Seung-Ki Kwok, Hyun-Jin Kim, Ji Hyeon<br />
Ju, Chong-Hyeon Yoon, Chul-Soo Cho, Ho-Youn Kim,<br />
Sung-Hwan Park. The Catholic University of Korea, Seoul,<br />
Republic of Korea.<br />
(559)-1945. Thrombotic Thrombocytopenic Purpura in the<br />
Setting of Systemic Lupus Erythematosus: Sorting out the Clinical<br />
Dilemma. Douglas W. Warden 1 , Andrea L. Sestak 2 , Jean<br />
Morrisey 2 , Stuart B. Glenn 2 , John B. Harley 2 , Judith A.<br />
James 2 . 1 OUHSC, Oklahoma City, OK; 2 OMRF, Oklahoma<br />
City, OK.<br />
(560)-1946. Posterior Reversible Encephalopathy Syndrome<br />
During Systemic Lupus Erythematosus: Four New Cases and<br />
Review of the Literature. Jérémie sellam 1 , Gaelle Leroux 2 ,<br />
Nathalie Costedoat-Chalumeau 2 , Du Lê Thi Huong 2 , Alain<br />
Combes 3 , Nathalie Tieulé 3 , Julien Haroche 2 , Zahir Amoura 2 ,<br />
Ania Nieskowska 3 , Jean Chastre 3 , Didier Dormont 4 , Jean-<br />
Charles Piette 2 . 1 Rheumatology, Le Kremlin Bicêtre, France;<br />
2<br />
Internal Medicine, Paris, France; 3 Intensive Care Unit,<br />
Paris, France; 4 Neuroradiology, Paris, France.<br />
(561)-1947. Risk Factors of Vertebral Fractures in Systemic<br />
Lupus Erythematosus (SLE) - An Observational Study. Katarina<br />
Almehed 1 , Helena Forsblad d’Elia 1 , Göran Kvist 2 , Hetényi<br />
Szabolcs 3 , Claes Ohlsson 1 , Hans Carlsten 1 . 1 Sahlgrenska<br />
Academy at Göteborg University, Sweden, Goteborg,<br />
Sweden; 2 Department of Rheumatology, Borås, Sweden;<br />
3<br />
Sahlgrenska University Hospital, Dpt of Radiology,<br />
Goteborg, Sweden.<br />
(562)-1948. Gastrointestinal Manifestations of Lupus:<br />
Retrospective Case Review Demonstrates Greater Than Expected<br />
Prevalence and Limited Utility of Traditional Diagnostic<br />
Evaluations. Jessica R. Berman 1 , Brian R. Landzberg 2 .<br />
1<br />
Hospital for Special Surgery, New York, NY; 2 New York-<br />
Presbyterian Hospital Weill Medical College of Cornell<br />
University, New York, NY.<br />
(563)-1949. Correlation of Vitamin D Deficiency with Skin<br />
Pigment Among African <strong>American</strong>s with Systemic Lupus<br />
Erythematosus. Diane L. Kamen, Tia M. Parker, Carol L.<br />
Wagner, Bruce W. Hollis, Gary S. Gilkeson. Medical<br />
University of South Carolina, Charleston, SC.<br />
(564)-1950. Associated Factors and Outcome of Herpes Zoster in<br />
Systemic Lupus Erythematosus (SLE) Patients. Ana C. Medeiros,<br />
Patrícia Martin, Ana R. Ribeiro, Roberta Gonçalves,<br />
Eduardo F. Borba. Rheumatology Division, University of<br />
São Paulo, São Paulo, Brazil.<br />
(565)-1951. Hepatitis C Virus Infection in Egyptian Patients<br />
with Systemic Lupus Erythematosus. M.Salah Eldin Abdel<br />
Baky, Khalid F. Elhasanein, Abdel Azeem M. Alhefny,<br />
Dahlia Abdel-Mohsen, Reem A. Habib, Samah A. Albakry.<br />
Department of Medicine-Rheumatology Division, Ain<br />
Shams University, Cairo, Egypt.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 271
Poster Session c<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
SLE: Human Etiology and Pathogenesis II<br />
(566)-1952. Lower Expression Levels of the PD1 Immunoreceptor<br />
in SLE Patients and Lower Frequency of CD25+ CD4 T-Cells.<br />
Helga Kristjansdottir 1 , Kristjan Steinsson, Prof. 1 , Iva<br />
Gunnarsson 2 , Thuridur Thorsteinsdottir 1 , Marta E.<br />
Alarcon-Riquelme 3 . 1 Center for Rheumatology Research,<br />
Landspitali-University Hospital, Reykjavik, Iceland;<br />
2<br />
Karolinska University Hospital, Stockholm, Sweden;<br />
3<br />
Department of Genetics and Pathology, Rudbeck<br />
Laboratory, Uppsala University, Uppsala, Sweden.<br />
(567)-1953. APCs Along with IFNα in Active SLE Patients<br />
Render the Dysfunction of CD4+CD25+ Regulatory T Cells. Bing<br />
Yan, Shunle Chen, Nan Shen, shuang ye. Renji Hospital,<br />
Shanghai, China.<br />
(568)-1954. CXCR3+ CD4+ T Cells Infiltrate the Inflamed<br />
Kidneys in Sle Patients and can be Monitored in the Urine.<br />
Philipp Enghard, Jens Humrich, Reinmar Undeutsch,<br />
Robert Biesen, Gerd-Rüdiger Burmester, Gabriela<br />
Riemekasten. Charité, Berlin, Germany.<br />
(569)-1955. Leptin and Regulatory T Cells in Human SLE.<br />
Antonio La Cava 1 , Giuseppe Matarese 2 , Jeremy Anuntiyo 3 ,<br />
Bevra H. Hahn 1 . 1 UCLA David Geffen School of Medicine,<br />
Los Angeles, CA; 2 Federico II University of Naples, Naples,<br />
Italy; 3 UCLA David Geffen School of Medicine and VA<br />
Greater Los Angeles Healthcare System, Los Angeles, CA.<br />
(570)-1956. Increase in CD4+CD28null Lymphocytes may be<br />
Associated with Endothelial Dysfunction and Early Atherosclerosis<br />
in Patients with Systemic Lupus Erythematosus. Andrejous Recio-<br />
Mayoral 1 , John Axford 2 , Zal Behnam 1 , Christina Babonian 1 ,<br />
Juan-Carlos Kaski 1 . 1 Cardiac and Vascular Sciences, St<br />
George’s University of London, London, United Kingdom;<br />
2<br />
Sir Joseph Hotung Centre for Musculoskeletal Diseases, St<br />
George’s, London, United Kingdom.<br />
(571)-1957. Molecular Modeling of 4-hydroxy-2-nonenal Modified<br />
Ro 60 Peptide Sequences. Biji T. Kurien 1 , Anil D’Souza 2 ,<br />
Simon Terzyan 1 , R. Hal Scofield 1 . 1 Oklahoma Medical<br />
Research Foundation, Oklahoma City, OK; 2 University of<br />
Oklahoma Health Sciences Center, Oklahoma City, OK.<br />
(572)-1958. Patients with Neuropsychiatric Lupus (NPSLE)<br />
Display High Interferogenic Activity in Their Cerebrospinal<br />
Fluid. Deanna Santer 1 , Taku Yoshio 2 , Daniel Kim 1 ,<br />
Thomas Moeller 1 , Seiji Minota 2 , Keith Elkon 1 . 1 University<br />
of Washington, Seattle, WA; 2 Jichi Medical University,<br />
Tochigi, Japan.<br />
(573)-1959. Proton Magnetic Resonance Spectroscopy Reveals<br />
Abnormalities In The Basal Ganglia Of Patients With<br />
Neuropsychiatric Lupus. Pamela L. Peterson 1 , Franklyn A. Howe 2 ,<br />
John Axford 1 . 1 The Sir Joseph Hotung Centre, University of<br />
London, London, United Kingdom; 2 Basic Medical Sciences,<br />
University of London, London, United Kingdom.<br />
(574)-1960. Autoantibodies and Neuropsychiatric Events at<br />
Diagnosis of Systemic Lupus Erythematosus. J. G. Hanly 1 , M.<br />
B. Urowitz 2 , F. Siannis 1 , V. Farewell 1 , C. Gordon 1 , S. C.<br />
Bae 1 , D. Isenberg 1 , M. A. Dooley 1 , A. Clarke 1 , S. Bernatsky 1 ,<br />
D. Gladman 1 , P. R. Fortin 1 , S. Manzi 1 , K. Steinsson 1 , I.<br />
Bruce 1 , E. Ginzler 1 , C. Aranow 1 , D. J. Wallace 1 , R. Ramsey-<br />
Goldman, R. Van Vollenhoven, G. Sturfelt, O. Nived 1 , J.<br />
Sanchez-Guerrero, G.S. Alarcón, M. Petri, M. Khamashta 1 ,<br />
A. Zoma, J. Font, K. Kalunian 1 , J. Douglas, Q. Qi 1 , J.T.<br />
Merrill 3 . 1 Dalhousie University, Halifax, NS, Canada;<br />
2<br />
University of Toronto, Toronto, ON, Canada; 3 Oklahoma<br />
Medical Research Foundation, Oklahoma, OK.<br />
(575)-1961. Association of Diffuse Psychiatric/Neuropsychological<br />
Syndromes with Cerebrospinal Fluid Antibodies against the<br />
Epitopes Other Than C-Terminal 22 Amino Acids of Ribosomal<br />
P0 Protein in Systemic Lupus Erythematosus. Shunsei Hirohata 1 ,<br />
Taku Yoshio 2 . 1 Kitasato University School of Medicine,<br />
Kanagawa, Japan; 2 Jichi Medical University, Tochigi, Japan.<br />
(576)-1962. Cerebrospinal Fluid (CSF) TWEAK: A Novel<br />
Biomarker for Neuropsychiatric SLE? Estelle Trysberg 1 , Linda<br />
Burkly 2 , Lihe Su 2 , Jennifer Michaelson 2 , Chaim Putterman 3 .<br />
1<br />
Sahlgrenska University Hospital, Göteborg, Sweden;<br />
2<br />
Biogen Idec, Cambridge, MA; 3 Albert Einstein College of<br />
Medicine, Bronx, NY.<br />
(577)-1963. Activation of IKK-related Kinases and Interferon<br />
Regulatory Factors in Peripheral Blood Cells of Patients with<br />
Systemic Lupus Erythematosus. Susan E. Sweeney, Kenneth C.<br />
Kalunian. UCSD, La Jolla, CA.<br />
(578)-1964. Increased Skin Autofluorescence is not Reflected by<br />
Elevated Plasma Levels of Advanced Glycation Endproducts in<br />
Systemic Lupus Erythematosus. Hans L. Nienhuis 1 , Karina<br />
de Leeuw 1 , Johan Bijzet 1 , Andries J. Smit 1 , Casper G.<br />
Schalkwijk 2 , Cees G.M. Kallenberg 1 , Marc Bijl 1 . 1 University<br />
Medical Center Groningen, Groningen, Netherlands;<br />
2<br />
University Hospital Maastricht, Maastricht, Netherlands.<br />
(579)-1965. High Expression of Ro52 in Skin Lesions in<br />
Cutaneous Lupus Erythematosus. Vilija Barkauskaite 1 , Linn<br />
Strandberg 1 , Filippa Nyberg 2 , Marie Wahren-Herlenius 1 .<br />
1<br />
Karolinska Institutet, Stockholm, Sweden; 2 Karolinska<br />
Institutet at Danderyds Hospital, Stockholm, Sweden.<br />
272 (Permanent Board Number)-Abstract Number
(580)-1966. TRAIL is Upregulated in Tubules from Lupus<br />
Nephritis Patients and Promotes Proliferation of Proximal Tubular<br />
Epithelial Cells through MAP Kinases and PI3-Kinase/Akt<br />
Activation. Valentina Zernetkina, Vinh Nguyen, Cornelia<br />
Cudrici, Florin Niculescu, Cinthia Drachenberg, Violeta Rus.<br />
University of Maryland School of Medicine, Baltimore, MD.<br />
(581)-1967. Studies of Previously Associated Genes in a Large,<br />
Multi-Ethnic <strong>American</strong> SLE Cohort. Andrea L. Sestak 1 ,<br />
Kenneth M. Kaufman 2 , Jennifer A. Kelly 1 , John B. Harley 2 .<br />
1<br />
Oklahoma Medical Research Foundation, Oklahoma City,<br />
OK; 2 Oklahoma Medical Research Foundation, OU Health<br />
Sciences Center, VA Medical Center, Oklahoma City, OK.<br />
(582)-1968. A SNP in IRF5 Intron 1 Defines a Protective<br />
Haplotype against SLE in Japanese. Aya Kawasaki 1 , Chieko<br />
Kyogoku 2 , Risa Miyashita 3 , Jun Ohashi 3 , Katsushi<br />
Tokunaga 3 , Makio Kusaoi 4 , Yoshinari Takasaki 4 , Hiroshi<br />
Hashimoto 4 , Timothy W. Behrens 2 , Naoyuki Tsuchiya 1 .<br />
1<br />
Doctoral <strong>Program</strong> in Social and Environmental Medicine,<br />
University of Tsukuba, Tsukuba, Japan; 2 Center for<br />
Immunology, University of Minnesota, Minneapolis, MN;<br />
3<br />
Department of Human Genetics, The University of Tokyo,<br />
Tokyo, Japan; 4 Department of Internal Medicine and<br />
Rheumatology, Juntendo University, Tokyo, Japan.<br />
(583)-1969. CD14 Promoter Gene Polymorphism C-260T in<br />
Relation to Patients with Systemic Erythematosus Lupus. Yi<br />
Li, Pui Lee, Dina Nacionales, Haoyang Zhuang, Kindra<br />
Scumpia, Jason Weinstein, Eric Sobel, Mark S. Segal,<br />
Westley H. Reeves, Hanno B. Richards. University of<br />
Florida, Gainesville, FL.<br />
(584)-1970. High Circulating Plasma Cells Levels are Found in<br />
Both Active and Inactive Systemic Lupus Erythematosus. Alexis<br />
Mathian 1 , Zahir Amoura 1 , Christophe Parizot 1 , Karim<br />
Dorgham 2 , Salim Trad 1 , Makoto Miyara 1 , Julien Haroche 1 ,<br />
Patrice Debre 3 , Guy Gorochov 3 , Jean-Charles Piette 1 .<br />
1<br />
Hopital Pitié Salpétrière, Paris, France; 2 INSERM U543,<br />
Paris, France; 3 Hopital Pitié Salpétrière et INSERM U543,<br />
Paris, France.<br />
(585)-1971. Total Number of Risk Alleles in Four Susceptibility<br />
Genes as a Marker for Genetic Risk to SLE. Naoyuki Tsuchiya 1 ,<br />
Aya Kawasaki 1 , Yoshinari Takasaki 2 , Hiroshi Hashimoto 2 ,<br />
Jun Ohashi 3 . 1 Doctoral Proram in Social and Environmental<br />
Medicine, Graduate School of Comprehensive Human<br />
Sciences, University of Tsukuba, Tsukuba, Japan;<br />
2<br />
Department of Internal Medicine and Rheumatology,<br />
Juntendo University, Tokyo, Japan; 3 Department of Human<br />
Genetics, Graduate School of Medicine, The University of<br />
Tokyo, Tokyo, Japan.<br />
(586)-1972. High Density SNP Screening of the Major<br />
Histocompatibility Complex in Systemic Lupus Erythematosus<br />
Families. Lisa F. Barcellos 1 , Suzanne L. Clark 1 , Patricia P.<br />
Ramsay 1 , Hong Quach 1 , Michael F. Seldin 2 , John B. Harley 3 ,<br />
Kathy L. Moser 3 , Tim W. Behrens 4 , Patrick M. Gaffney 3 ,<br />
Lindsey A. Criswell 5 . 1 UC Berkeley, Berkeley, CA; 2 UC<br />
Davis, Davis, CA; 3 OMRF, Oklahoma City, OK; 4 Genentech,<br />
So. San Francisco, CA; 5 UCSF, San Francisco, CA.<br />
(587)-1973. Analysis of Genetic Variation in PDCD1: A New<br />
Regulatory 5’ SNP as the Unique SLE Associated Polymorphism<br />
in European Caucasians. Antonio Gonzalez 1 , Isabel Ferreiros-<br />
Vidal 1 , Elisa Alonso-Perez 1 , Marian Suarez-Gestal 1 ,<br />
Manuel Calaza 1 , Josep Ordi-Ros 2 , Eva Balada 2 , Chryssa<br />
Papasteriades 3 , Iris Kappou-Rigatou 3 , Sergio Migliaresi 4 ,<br />
Fotini N. Skopouli 5 , Maria Mavromati 5 , Francisca<br />
Gonzalez-Escribano 6 , Sandra D’Alfonso 7 , Javier Martin 8 ,<br />
Gian Domenico Sebastiani 9 , Sarka Ruzickova 10 , Ctibor<br />
Dostal 10 , Patricia Carreira 11 , Emöke Endreffy 12 , Attila<br />
Kovacs 12 , Reinhold E. Schmidt 13 , Torsten Witte 13 , Maurizio<br />
Marchini 14 , Juan J. Gomez-Reino 1 . 1 Hospital Clinico<br />
Universitario de Santiago, Santiago de Compostela, Spain;<br />
2<br />
Hospital Vall d’Hebron, Barcelone, Spain; 3 Evangelismos<br />
Hospital, Athens, Greece; 4 Second University of Naples,<br />
Naples, Italy; 5 Athens University Medical School, Athens,<br />
Greece; 6 Hospital Virgen del Rocio, Seville, Spain;<br />
7<br />
Eastern Piedmont University, Novara, Italy; 8 Instituto de<br />
Parasitologia y Biomedicina Lopez-Neyra, Granada, Spain;<br />
9<br />
Ospedale S. Camillo - Forlanini, Roma, Italy; 10 Institute<br />
of Rheumatology, Prague, Czech Republic; 11 Hospital 12<br />
de Octubre, Madrid, Spain; 12 University of Szeged, Szeged,<br />
Hungary; 13 Hannover Medical School, Hannover, Germany;<br />
14<br />
University of Milan and Fondazione IRCCS Ospedale<br />
Maggiore Policlinico, Milan, Italy.<br />
(588)-1974. Questioning the Functional Relevance of the PD1.3<br />
SNP, a Putative Regulatory SNP of PDCD1 Associated with<br />
Systemic Lupus Erythematosus. Antonio Gonzalez 1 , Marian<br />
Suarez-Gestal 1 , Isabel Ferreiros-Vidal 1 , Jose Antonio Ortiz 2 ,<br />
Juan J. Gomez-Reino 1 . 1 Hospital Clinico Universitario de<br />
Santiago, Santiago de Compostela, Spain; 2 Instituto de<br />
Neurociencias de Alicante, Alicante, Spain.<br />
(589)-1975. Systemic Lupus Erythematosus is Associated with<br />
Normal Circulating Endothelial Progenitor Cell Levels but<br />
Impaired EPC Migration Behaviour. Johannes C. Grisar,<br />
Carl W. Steiner, Michael Bonelli, Thomas Karonitsch,<br />
Günter Steiner, Josef S. Smolen. Division of Rheumatology,<br />
Medical University of Vienna, Austria.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 273
Poster Session c<br />
(590)-1976. The ATP-Binding Cassette Transporter 2 (TAP2)<br />
Gene is Strongly Associated with Systemic Lupus Erythematosus<br />
(SLE). Paula S. Ramos 1 , LeeAnn Bera 1 , Patrick M. Gaffney 2 ,<br />
Kathy L. Moser 2 . 1 University of Minnesota, Minneapolis,<br />
MN; 2 Oklahoma Medical Research Foundation, Oklahoma<br />
City, OK.<br />
(591)-1977. Hypomethylation of CD19+ B Lymphocytes in<br />
Patients with Systemic Lupus Erythematosus is Associated with<br />
Serum Levels of Anti-ds DNA Antibody. In Je Kim 1 , Seung<br />
Ki Kwok 1 , Mi-Kyung Park 1 , Young Ok Jung 2 , Mi-La Cho 1 ,<br />
Chul-Soo Cho 1 , Ho-Youn Kim 1 , Sung-Hwan Park 1 . 1 The<br />
Catholic University of Korea, College of Medicine, Seoul,<br />
Republic of Korea; 2 Hallym University, College of Medicine,<br />
Seoul, Republic of Korea.<br />
(592)-1978. Altered Tolerizing Dendritic Cells in Patients<br />
with Systemic Lupus Erythematosus. Yackov Berkun, Inna<br />
Reiner, Daphna Paran, Dan Caspi, Yakov Naparstek, Dror<br />
Mevorach. Hadassah, Jerusalem, Israel.<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
T-Cells in Autoimmunity<br />
(593)-1979. FOXP3 Represses Effector CD4 T Cell Function<br />
Via Inhibition of Activation Induced NFAT2 Transcription.<br />
Randy Q. Cron 1 , Andrew D. Wells 1 , Troy R. Torgerson 2 .<br />
1<br />
Childrens Hosp of Philadelphia, Philadelphia, PA;<br />
2<br />
University of Washington, Seattle, WA.<br />
(594)-1980. Role of Annexin-1 in the Regulation of T Cell<br />
Proliferation. Yuan H. Yang, Jiro Yamana, Michelle Leech,<br />
Pam Hall, Devi Ngo, Eric Morand. Monash University<br />
Department of Medicine, Melbourne, Australia.<br />
(595)-1981. Possible Involvement of Mmp-9 in the Production<br />
of Baff in T Cells. Keiko Yoshimoto 1 , Yumiko Setoyama 1 ,<br />
Kensei Tsuzaka 1 , Yoko Ogawa 2 , Kazuo Tsubota 2 , Tohru Abe 1 ,<br />
Tsutomu Takeuchi 1 . 1 Saitama Medical University, Medical<br />
Center, Kawagoe, Japan; 2 Keio University, Tokyo, Japan.<br />
(596)-1982. In vivo Function of Interleukin-4-Induced Tregs. Alla<br />
Skapenko 1 , Joachim R. Kalden 2 , Peter E. Lipsky 3 , Hendrik<br />
Schulze-Koops 1 . 1 University of Munich, Munich, Germany;<br />
2<br />
University of Erlangen, Erlangen, Germany; 3 NIAMS,<br />
Bethesda, MD.<br />
(597)-1983. Galectin-8 and Function-Blocking Autoantibodies<br />
Against Gal-8 Modulate an Apoptotic Pathway in T Cells.<br />
Claudia Metz, Andrés Norambuena, Lucas Vicuña, Antonia<br />
Silva, Loreto Massardo, Sergio Jacobelli, Alfonso González,<br />
Andrea Soza. Pontificia Universidad Católica de Chile,<br />
Santiago, Chile.<br />
(598)-1984. Functional Blocking and Targeted Depletion of<br />
Activated Lymphocytes by Fucosylated and Non-fucosylated<br />
of Fully Human anti-CD70 IgG1. Marco Coccia, Diane<br />
Feingersh, Hadia Lemar, Ben Preston, Alison Witte,<br />
Jonathan Terrett, Michael Yellin, Mark Selby, Alan<br />
Korman. Medarex, Inc, Milpitas, CA.<br />
(599)-1985. Tolerogenic Dendritic Cells Differentially Regulate<br />
Naïve and Memory T Cells. Bethan Sayers, Amy Anderson,<br />
Muzlifah Haniffa, Julie Diboll, John D. Isaacs, Catharien<br />
Hilkens. University of Newcastle, Newcastle upon Tyne,<br />
United Kingdom.<br />
(600)-1986. Abstract Withdrawn<br />
(601)-1987. Fully Differentiated Th1, Th2 and Th17 T-effector<br />
Lymphocytes Can Induce Pathologically Distinct Types of Organspecific<br />
Autoimmune Disease and are Differentially Susceptible<br />
to Control by Regulatory T-Cells (Treg). Georg H. Stummvoll 1 ,<br />
Richard J. DiPaolo 2 , Todd S. Davidson 2 , Eva NI Huter 2 ,<br />
Jerrold M. Ward 3 , Ethan M. Shevach 2 . 1 Medical University<br />
of Vienna, Vienna, Austria; 2 Laboratory of Immunology,<br />
Cellular Immunology Section, NIAID, NIH, Bethesda,<br />
MD; 3 Comparative Medicine Branch, Infectious Disease<br />
Pathogenesis Section, NIAID, NIH, Bethesda, MD.<br />
(602)-1988. Epitope-Specific Immune Tolerance can Maintain the<br />
Disease Control Induced by Conventional Methotrexate-Etanercept<br />
Combination Therapy in Rat Adjuvant Arthritis. Negar<br />
Ghahramani, Elissa Keogh, Annick van de Ven, Salvatore<br />
Albani. University of California San Diego, La Jolla, CA.<br />
(603)-1989. A Novel Bcl-2 Inhibitor is Highly Efficacious in a<br />
Collagen-Induced Mouse Model of Arthritis. Philip D. Bardwell 1 ,<br />
Donna McCarthy 1 , Shaughn Bryant 1 , Suzanne Mathieu 1 ,<br />
Steven W. Elmore 2 , Saul H. Rosenberg 2 , Jijie Gu 1 , Tariq<br />
Ghayur 1 , Anwar Murtaza 1 . 1 Abbott Bioresearch Center,<br />
Worcester, MA; 2 Abbott Laboratories, Abbott Park, IL.<br />
(604)-1990. Dissecting the Roles Played by DCs in Mediating<br />
Inflammatory Arthropathies. Robert A. Benson 1 , Sarah<br />
Jongbloed 2 , Mohammad B. Nickdel 1 , Paola Conigliaro 1 ,<br />
Catherine M. Rush 1 , Paul Garside 1 , Iain B. McInnes 2 , James M.<br />
Brewer 1 . 1 University of Strathclyde, Glasgow, United Kingdom;<br />
2<br />
University of Glasgow, Glasgow, United Kingdom.<br />
(605)-1991. IL-7-induced Immune Activation due to Elevated<br />
Expression of the IL-7 Receptor in RA Joints can be Inhibited by<br />
Soluble Human IL-7 Receptor. Sarita AY Hartgring, Marion<br />
JG Wenting, Kim MG Jacobs, Johannes WJ Bijlsma, Floris<br />
PJG Lafeber, Joel AG van Roon. University Medical Center<br />
Utrecht, Rheumatology & Clinical Immunology, Utrecht,<br />
The Netherlands.<br />
274 (Permanent Board Number)-Abstract Number
(606)-1992. Kinetics of Immune Tolerization in a Clinical<br />
Trial on Epitope-Specific Therapy in Rheumatoid Arthritis<br />
(RA). Eva C. Koffeman 1 , Diana Amox 1 , Elissa A. Keogh 1 ,<br />
Adriana Tremoulet 1 , Peter Zeiseniss 1 , Courtney Gosch 1 ,<br />
Samantha Friend 1 , Xiao Zhang 2 , Gary Cutter 2 , Salvatore<br />
Albani 1 . 1 University California San Diego, San Diego, CA;<br />
2<br />
University of Alabama, Birmingham, AL.<br />
(607)-1993. Disturbancies in T and B Cell Homeostasis<br />
are Associated with Disease Duration and Disease-Specific<br />
Autoantibody Levels in Rheumatoid Arthritis. Zoltán Szekanecz 1 ,<br />
Andrea Fekete 2 , Lilla Soós 1 , Zoltán Szabó 1 , Peter Szodoray 1 ,<br />
Sándor Baráth 2 , Gabriella Lakos 2 . 1 University of Debrecen<br />
Medical Center, Third Department of Medicine,<br />
Rheumatology Division, Debrecen, Hungary; 2 University of<br />
Debrecen Medical Center, Third Department of Medicine,<br />
Laboratory of Immunology, Debrecen, Hungary.<br />
(608)-1994. Increased IL-4+ CD8+ T Cells in Peripheral Blood<br />
and Autoreactive CD8+ T Cell Lines of Patients with Ankylosing<br />
Spondylitis and Rheumatoid Arthritis. Han J. Baek 1 , L. Zhang 2 ,<br />
L. B. Jarvis 3 , JS Hill Gaston 3 . 1 Gachon University Gil<br />
Medical Center, Incheon, Republic of Korea; 2 Changzheng<br />
Hospital, Shanghai, China; 3 University of Cambridge,<br />
Cambridge, United Kingdom.<br />
(609)-1995. Dendritic Cell Stimulation Induces IL-4+CD8+ T<br />
Cells in AS Patients and HLA-B27+ Subjects. Libin Zhang 1 ,<br />
Lorna B. Jarvis 2 , Han J. Baek 3 , JS Hill Gaston 2 . 1 Changzheng<br />
Hospital, Shanghai, China; 2 University of Cambridge,<br />
Cambridge, United Kingdom; 3 Gachon University Gil<br />
Medical Center, Incheon, Republic of Korea.<br />
(610)-1996. Decreased Expression of the Glycosylated Syndecan 4<br />
Accompanied with Down-regulation of TCR Zeta in SLE Patient<br />
T Cells. Kensei Tsuzaka 1 , Yuka Itami 2 , Chika Kumazawa 2 ,<br />
Yumiko Setoyama 1 , Keiko Yoshimoto 1 , Katsuya Suzuki 1 ,<br />
Tohru Abe 1 , Tsutomu Takeuchi 1 . 1 Saitama Medical Center,<br />
Saitama Medical University, Kawagoe, Saitama, Japan;<br />
2<br />
Research Center for Genomic Medicine, Saitama Medical<br />
University, Hidaka, Saitama, Japan.<br />
(611)-1997. TNF-α and IL-6 Inhibit Anti-osteoclastogenic Effect of<br />
Human CD4+CD25+ Regulatory T Cells In Vitro. Yong-Gil Kim,<br />
Ji-Seon Oh, Seong-Su Nah, Chang-Keun Lee, Bin Yoo, Hee-<br />
Bom Moon. Asan Medical Center, Seoul, Republic of Korea.<br />
(612)-1998. Regulatory T Cells Suppress Osteoclast Formation- A<br />
New Link Between the Immune System and Bone. Mario M.<br />
Zaiss 1 , Jochen Zwerina 1 , Karin Polzer 1 , Alla Skapenko 2 ,<br />
Hendrik Schulze-Koops 2 , Nikki Horwood 3 , Andrew<br />
Cope 4 , Georg Schett 1 . 1 University of Erlangen-Nurenberg,<br />
Erlangen, Germany; 2 University of Munich, Division of<br />
Rheumatology, Munich, Germany; 3 Kennedy Institute<br />
of Rheumatology, London, United Kingdom; 4 Kennedy<br />
Institue of Rheumatology, London, United Kingdom.<br />
(613)-1999. Upregulation of MicroRNA-16 (mir-16) may<br />
Explain Aberrant Apoptosis in Human Lupus. Nilamadhab<br />
Mishra 1 , Kerri keiger 2 , Emmanuel Labourier 2 . 1 Wake Forest<br />
University School of Medicine, Winston Salem, NC;<br />
2<br />
Ambion Inc, Austin, TX.<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
Vasculitis II<br />
(614)-2000. PTPN22 and IRF5 Alleles in Wegener’s<br />
Granulomatosis (WG). Jeffrey C. Edberg 1 , James Kelley 1 , Gary<br />
S. Hoffman 2 , Peter A. Merkel 3 , E. William St. Clair 4 , Ulrich<br />
Specks 5 , Paul F. Dellarippa 6 , Robert F. Spiera 7 , Miranda<br />
C. Marion 8 , Carl D. Langefeld 8 , Ann B. Begovich 9 , John<br />
H. Stone 10 , for the WGGER Research Group. 1 University<br />
of Alabama at Birmingham, Birmingham, AL; 2 Cleveland<br />
Clinic, Cleveland, OH; 3 Boston University School of<br />
Medicine, Boston, MA; 4 Duke University, Durham, NC;<br />
5<br />
Mayo Clinic, Rochester, MN; 6 Harvard Medical School;,<br />
Boston, MA; 7 Hospital for Special Surgery, New York, NY;<br />
8<br />
Wake Forest University, Winston-Salem, NC; 9 Celera,<br />
Alameda, CA; 10 Johns Hopkins University, Baltimore, MD.<br />
(615)-2001. Pathogenesis of Allergic Granulomatous Angitis in<br />
the Experimental Model with Mice. Nobuhito Sasaki, Kohei<br />
Yamauchi, Hiroshi Inoue, Akio Kamataki, Takashi Sawai.<br />
Iwate Medical Universtiy, Morioka Iwate, Japan.<br />
(616)-2002. Cryofibrinogen in Patients with Hepatitis C Virus<br />
(HCV)-Mixed Cryoglobulinemia (MC) Vasculitis. aurelien<br />
delluc, David Saadoun, pascale ghillani, damien sene, zahir<br />
amoura, jean charles piette, patrice cacoub. hopital pitie<br />
salpetriere, paris, France.<br />
(617)-2003. Selective p38mapk Isoform Expression and Activation<br />
in Anca-Associated Crescentic Glomerulonephritis. Karin Polzer 1 ,<br />
Afschin Soleiman 2 , Wolfgang Baum 1 , Joerg Distler 1 ,<br />
Roland Axmann 1 , Kurt Redlich 2 , Gerhard Kroenke 1 , Georg<br />
Schett 1 , Jochen Zwerina 1 . 1 University of Erlangen, Erlangen,<br />
Germany; 2 Medical University of Vienna, Vienna, Austria.<br />
(618)-2004. Persistent Hematuria after Induction of Remission<br />
in Patients with Glomerulonephritis Due to Wegener’s<br />
Granulomatosis. Marina N. Magrey, Curry Koening, Gary S.<br />
Hoffman. Cleveland Clinic, Cleveland, OH.<br />
(619)-2005. Elevated Serum Levels of Soluble CX3CL1 in<br />
Patients with Systemic Vasculitis: Potential Involvement in<br />
Microscopic Polyangiitis. Mizuho Matsunawa, Kuninobu<br />
Wakabayashi, Tsuyoshi Odai, Takeo Isozaki, Nobuyuki<br />
Yajima, Yusuke Miwa, Masao Negishi, Hirotsugu Ide,<br />
Tsuyoshi Kasama. Showa University, Tokyo, Japan.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 275
Poster Session c<br />
(620)-2006. Cryoglobulinemic Vasculitis in Patients with<br />
Chronic HCV Infection. Influence of HCV-RNA Load, HCV<br />
Genotype and HIV Coinfection. Manuel Ramos-Casals 1 ,<br />
Xavier Forns 2 , Pilar Brito-Zerón 3 , Alfonso Vargas 1 ,<br />
Martín Ruiz 1 , Montserrat Laguno 1 , Jordi Yagüe 4 , Josep<br />
M. Gatell 5 , José M. Sánchez-Tapias 2 . 1 Department of<br />
Autoimmune Diseases, Hospital Clinic, Barcelona, Spain;<br />
2<br />
Department of Hepatology, Hospital Clinic, Barcelona,<br />
Spain; 3 Laboratory of Basic Research in Autoimmune<br />
Diseases, IDIBAPS, Hospital Clinic, Barcelona, Spain;<br />
4<br />
Department of Immunology, Hospital Clinic, Barcelona,<br />
Spain; 5 Department of Infectious Diseases, Hospital Clinic,<br />
Barcelona, Spain.<br />
(621)-<strong>2007</strong>. Association of Cigarette Smoking with Organ<br />
Damage in Primary Systemic Vasculitis. Aladdin Mohammad,<br />
Mårten Segelmark. Lund University, Lund, Sweden.<br />
(622)-2008. Renal Disease Associated with Mixed<br />
Cryoglobulinemia Vasculitis Unrelated to Hcv Infection.<br />
Patrice Cacoub 1 , David Saadoun 1 , Jeremie Sellam 1 , Marie<br />
Matignon 2 , Magali Colombat 2 , Beatrice Mougenot 2 ,<br />
Philippe Vanhille 2 , Olivier Moranne 2 , Pierre Ronco 2 ,<br />
Emmanuelle Plaisier 2 . 1 Hopital Pitie Salpetriere, Paris,<br />
France; 2 Hopital Tenon, Paris, France.<br />
(623)-2009. Efficacy of Rituximab in Limited Wegener’s<br />
Granulomatosis with Refractory Granulomatous Manifestations.<br />
Philip Seo 1 , Ulrich Specks 2 , Karina A. Keogh 3 . 1 The Johns<br />
Hopkins Vasculitis Center, Baltimore, MD; 2 Division of<br />
Pulmonary and Critical Care Medicine, Department of<br />
Medicine, Mayo Clinic College of Medicine, Rochester,<br />
MN; 3 Division of Pulmonary and Critical Care Medicine,<br />
Department of Medicine, Mayo Clinic College of Medicine,,<br />
Rochester, MN.<br />
(624)-2010. The Anca Target Antigen Bactericidal/Permeability-<br />
Increasing Protein (BPI) Co-Localizes with Gram-Negative<br />
Bacterial Outer Membrane Blebs in Lamp-1+ Compartments of<br />
Dendritic Cells. Hendrik Schultz 1 , Yoko Nakano 1 , Janet R.<br />
Hume 2 , De Sheng Zhang 1 , Theresa L. Gioannini 1 , Jerrold P.<br />
Weiss 1 . 1 University of Iowa Hospitals and Clinics and Iowa<br />
City VAMC, Iowa City, IA; 2 Dept. of Pediatrics, University<br />
of Arkansas for Medical Sciences, Little Rock, AR.<br />
(625)-2011. Identification of Targets of the Anti-Endothelial Cell<br />
Antibodies in Patients with Systemic Vasculitis: By a Proteomic<br />
Approach. Rie Karasawa, Seido Ooka, Kayo Masuko, Shoichi<br />
Ozaki, Kusuki Nishioka, Kazuo Yudoh, Tomohiro Kato. St.<br />
Marianna University School of Medicine, Kawasaki, Japan.<br />
(626)-2012. The Effect of Low-Dose Corticosteroids on Risk of<br />
Relapse in ANCA-Associated Vasculitis: A Systematic Review<br />
and Meta-Analysis of Clinical Trials. Michael Walsh 1 , Peter A.<br />
Merkel 2 , Alfred D. Mahr 2 , David Jayne 1 . 1 Addenbrooke’s<br />
Hospital, Cambridge, United Kingdom; 2 Boston University<br />
School of Medicine, Boston, MA.<br />
(627)-2013. Venous Thromboembolic Events in Patients with<br />
Different Systemic Necrotizing Vasculitides: Systematic Study<br />
on the French Vasculitis Study Group (FVSG) Patient Cohort.<br />
Yves Allenbach, Christian Pagnoux, Raphaèle Seror,<br />
Luis Teixeira, Philippe Guilpain, Loïc Guillevin, French<br />
Vasculitis Study Group. Hôpital Cochin, National Referral<br />
Center for Necrotizing Vasculitides, Paris, France.<br />
(628)-2014. Prevalence of Alpha 1-Antitrypsin (AAT) Deficiency<br />
in Wegener’s Granulomatosis (WG). Alfred D. Mahr 1 , Jeffrey<br />
C. Edberg 2 , John H. Stone 3 , Paul F. Dellaripa 4 , Gary S.<br />
Hoffman 5 , U. Specks 6 , Robert F. Spiera 7 , E. William<br />
St. Clair 8 , Farshid N. Rouhani 9 , Mark L. Brantly 9 ,<br />
Peter A. Merkel 1 , for the WGGER Research Group.<br />
1<br />
Boston University School of Medicine, Boston, MA;<br />
2<br />
University of Alabama, Birmingham, AL; 3 Johns Hopkins<br />
University, Baltimore, MD; 4 Lahey Clinic, Burlington,<br />
MA; 5 Cleveland Clinic, Cleveland, OH; 6 Mayo Clinic,<br />
Rochester, MN; 7 Hospital for Special Surgery, New York,<br />
NY; 8 Duke University, Durham, NC; 9 University of Florida,<br />
Gainesville, FL.<br />
(629)-2015. Regulatory T-Cells in Hepatitis C Virus-Induced<br />
Mixed Cryoglobulinemia Vasculitis. Dan A. Landau 1 , Michelle<br />
Rosenzwajg 2 , David Saadoun 1 , David Klatzmann 2 , Patrice<br />
Cacoub 1 . 1 Laboratoire de Biologie et Thérapeutique des<br />
Pathologies Immunitaires, CNRS/UPMC UMR 7087 and<br />
Service de Médecine Interne, Hôpital Pitié-Salpêtrière,<br />
Paris, France; 2 Laboratoire de Biologie et Thérapeutique<br />
des Pathologies Immunitaires, CNRS/UPMC UMR 7087,<br />
Paris, France.<br />
(630)-2016. Relapse of Hepatitis C Virus-Associated Mixed<br />
Cryoglobulinemia Vasculitis in Patients with Sustained Viral<br />
Response. Dan A. Landau 1 , David Saadoun 1 , Philippe<br />
Halfon 2 , Michele Martinot 3 , Elena Fois 4 , Jean-Charles<br />
Piette 1 , Patrice Cacoub 1 . 1 Université Pierre et Marie Curie-<br />
Paris 6, CNRS, UMR 7087 and Hôpital Pitié-Salpêtrière,<br />
Service de Médecine Interne, Paris, France; 2 Laboratoire<br />
Alphabio, Marseille, France; 3 Laboratoire de Virologie,<br />
Hopital Beaujon, Clichy, France; 4 Hôpital Cochin, Service<br />
de Médecine Interne, Paris, France.<br />
(631)-2017. The Incidence of Wegener’s Granulomatosis and<br />
Churg Strauss Syndrome in the UK General Practice Database.<br />
Richard Watts 1 , Abdullah Al-Taiar 1 , Jane Skinner 1 , David<br />
Scott 2 , Alex MacGregor 1 . 1 University of East Anglia,<br />
Norwich, United Kingdom; 2 Norfolk and Norwich<br />
University Hospital NHS Trust, Norwich, United Kingdom.<br />
276 (Permanent Board Number)-Abstract Number
(632)-2018. Limited Utility of Rapamycin in Severe, Refractory<br />
Wegener’s Granulomatosis (WG). Curry L. Koening, Jose<br />
Hernandez-Rodriguez, Eamonn S. Molloy, Tiffany Clark,<br />
Carol A. Langford, Gary S. Hoffman. Cleveland Clinic,<br />
Cleveland, OH.<br />
(633)-2019. Clinical and Angiographic Features, Treatment<br />
and Prognosis of Takayasu’s Arteritis: A Prospective Nationwide<br />
Survey in Turkey. Muge Bıcakcigil, Sevil Kamalı, Murat Inanc,<br />
Kenan Aksu, Izzet Fresko, Gökhan Keser, Nurullah Akkoc,<br />
Yasar Karaarslan, Sedat Kiraz, Hüseyin Özer, Ercan Tunç,<br />
Eftal Yucel, Haner Direskeneli. Turkish Takayasu’s Arteritis<br />
Study Group, Turkey, Turkey.<br />
(634)-2020. Relapses in Rituximab-Treated Wegener’s<br />
Granulomatosis Patients Despite Peripheral B Cell Depletion.<br />
Eamonn S. Molloy, Curry L. Koening, Jose Hernandez-<br />
Rodriguez, Tiffany M. Clark, Carol A. Langford, Gary S.<br />
Hoffman. Cleveland Clinic, Cleveland, OH.<br />
(635)-2021. Long Term Visual Outcome in Patients with Behçet’s<br />
Disease. Sergio Migliaresi 1 , Gennaro Iaccarino 2 , Ambrogio<br />
Petrillo 1 , Nicola Rosa 2 , Gabriele Valentini 1 . 1 Rheumatology<br />
Unit. Second University of Naples, Naples, Italy; 2 Eye<br />
Department. Second University of Naples, Naples, Italy.<br />
(636)-2022. Clinical and Histological Characterization of<br />
Vasculitis Involving the Breast. Jose Hernandez-Rodriguez,<br />
Carmela D. Tan, Eamonn S. Molloy, Curry L. Koening,<br />
Atul Khasnis, E.Rene Rodriguez, Gary S. Hoffman.<br />
Cleveland Clinic Foundation, Cleveland, OH.<br />
(637)-2023. Comparison of Predictors of Relapse in ANCA<br />
Vasculitis in 2 Independent Cohorts. Christian Pagnoux 1 ,<br />
Hyunsook Chin 2 , Susan L. Hogan 2 , Loïc Guillevin 1 , Ronald<br />
J. Falk 2 , Patrick H. Nachman 2 . 1 Hôpital Cochin, National<br />
Referral Center for Necrotizing Vasculitides, Paris, France;<br />
2<br />
UNC Kidney Center, University of North Carolina,<br />
Chapel Hill, NC.<br />
(638)-2024. Severe Cardiac Involvement in Churg-Strauss<br />
Syndrome. Philippe Guilpain 1 , Pascal Cohen 1 , Christian<br />
Pagnoux 1 , Denis Duboc 2 , Olivier Vignaux 3 , Jean-François<br />
Viallard 4 , Olivier Fain 5 , Luc Mouthon 1 , Jean-François<br />
Cordier 6 , Loïc Guillevin 1 . 1 French Vasculitis Study Group.<br />
Hôpital Cochin, National Referral Center, Paris, France;<br />
2<br />
Department of Cardiology, Hôpital Cochin, Paris, France;<br />
3<br />
Department of Radiology, Hôpital Cochin, Paris, France;<br />
4<br />
Hôpital Haut Lévêque, Bordeaux, France; 5 Hôpital Jean<br />
Verdier, Bondy, France; 6 Hôpital Louis-Pradel, Lyon, France.<br />
(639)-2025. Rituximab Combined with Peg-Interferon-Ribavirin<br />
in Refractory Hcv-Associated Cryoglobulinemia Vasculitis. David<br />
Saadoun, Mathieu Resche-Rigon, Damien Sene, Laurent<br />
Perard, Jean Charles Piette, Patrice Cacoub. Hopital Pitie<br />
Salpetriere, Paris, France.<br />
Saturday, November 10<br />
8:00 a m—4:30 p m<br />
Exhibit Hall A-B<br />
<strong>ARHP</strong><br />
(640)-2026. Managing Arthritis and Employment: Making<br />
Arthritis-Related Work Transitions to Remain Employed.<br />
Monique Gignac 1 , Diane Lacaille 2 , Aslam Anis 2 , Elizabeth<br />
Badley 1 . 1 The Arthritis Community Research & Evaluation<br />
Unit, The Toronto Western Research Institute, Toronto,<br />
ON, Canada; 2 The Arthritis Research Centre of Canada,<br />
Vancouver, BC, Canada.<br />
(641)-2027. Improved Quality of Life for Neonatal Onset<br />
Multisystem Inflammatory Disease (NOMID) Patients: A<br />
Comparison of Before and After Treatment on Anakinra. Nicole<br />
Plass, Christopher Snyder, Raphaela Goldbach-Mansky.<br />
national institute of health, bethesda, MD.<br />
(642)-2028. The Evaluation of Hand Impairment and Activity<br />
Limitation in Children with Juvenile Idiopathic Arthritis.<br />
Christine M. O’Brien 1 , Brian M. Feldman 1 , Susan B. Jaglal 2 ,<br />
A. M. Davis 3 . 1 The Hospital for Sick Children, Toronto,<br />
ON, Canada; 2 The University of Toronto, Toronto, ON,<br />
Canada; 3 Toronto Western Research Institute, Toronto,<br />
ON, Canada.<br />
(643)-2029. Perceived Parenting Ability in Mothers with<br />
Scleroderma. Janet L. Poole 1 , Cindy Mendelson 2 , Kelly<br />
Willer 1 . 1 1 University of New Mexico, Albuquerque, NM;<br />
2<br />
University of New Mexico, Albuquerque, NM.<br />
(644)-2030. Predicting Factors on Physical Activity in Patients<br />
with Fibromyalgia. Bak Won SooK 1 , Sang-Sook Han 1 , Youn-<br />
Jung Kim 1 , Mi Jung Seo 2 , Sung Hee Park 3 , Sang-Sook<br />
Han 1 , Hyung-In Yang 3 . 1 College of Nursing Science, Kyung<br />
Hee University, Seoul, Republic of Korea; 2 Arthritis &<br />
Rheumatism Center, East-West Neo Medical Center of<br />
Kyung Hee University, Seoul, Republic of Korea; 3 Arthritis<br />
& Rheumatism Center, East-West Neo Medical Center of<br />
Kyung Hee University, Seoul, Republic of Korea, Seoul,<br />
Republic of Korea.<br />
(645)-2031. Short Term Out Patient Rehabilitation Improves<br />
Activity and Participation in Life in Patients with Inflammatory<br />
Arthritides. Elisabeth Mogard 1 , Ann B. Bremander 2 .<br />
1<br />
Department of Rheumatology, Lund University Hospital,<br />
Lund, Sweden; 2 Research and Development Center,<br />
Spenshult, Oskarström, Sweden.<br />
(646)-2032. Ranking of Age- and Sex-Specific Population Associated<br />
Fraction of Arthritis and Fibromyalgia Across Two Health<br />
Outcomes. Anthony V. Perruccio, J. Denise Power, Elizabeth<br />
M. Badley. University of Toronto, Toronto, ON, Canada.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 277
Poster Session c<br />
(647)-2033. The Contribution of Pain, Affective Distress and<br />
Functional Disability to Sleep Difficulty/Disruption among Older<br />
Adults with Arthritis:/Findings from the Behavioral Risk Factor<br />
Surveillance System, 2004. Carl W. Miller 1 , Nadine T. James 1 ,<br />
Kathleen C. Brown 2 , Mary G. Umlauf 2 . 1 USM, Hattiesburg,<br />
MS; 2 UAB, Birmingham, AL.<br />
(648)-2034. Developing a Better Understanding of Patients’<br />
Knowledge of Arthritis Signs, Symptoms, Treatment and Outcomes<br />
in an Early Arthritis Center: A Pilot Qualitative Study. Karen<br />
Golan, Jamie Weiss, Lisa C. Vasanth, Stephen A. Paget,<br />
Theodore Fields, Melanie J. Harrison. Hospital for Special<br />
Surgery, New York, NY.<br />
(649)-2035. Depression and Responsiveness to Non-<br />
Pharmacological Therapies. Susan J. Bartlett, Steffany Haaz,<br />
Joan M. Bathon. Johns Hopkins, Baltimore, MD.<br />
(650)-2036. Prevalence and Course of Forefoot Impairments<br />
and Walking Disability during the First 8 Years of Rheumatoid<br />
Arthritis. Marike van der Leeden 1 , Martijn Steultjens 2 ,<br />
Rutger Dahmen 1 , Jennie Ursum 1 , Dirkjan van<br />
Schaardenburg 1 , Leo Roorda 1 , Joost Dekker 2 . 1 Jan van<br />
Breemen Institute, Amsterdam, The Netherlands; 2 VU<br />
University Medical Center, Amsterdam, The Netherlands.<br />
(651)-2037. The Role of Illness Perceptions in Determining<br />
Outcome in Low Back Pain Patients Presenting to Family<br />
Practice. Elaine Thomas, Annette Bishop, Chris Main,<br />
Elaine M. Hay, Nadine E. Foster. Keele University, Keele,<br />
United Kingdom.<br />
(652)-2038. Bone Health and Osteoporosis: A Report of<br />
the Surgeon General (SGR) Reaches Diverse Audiences with<br />
Multipronged Outreach Effort. Janet S. Austin, Trish Reynolds,<br />
Kelli L. Carrington. NIAMS, Bethesda, MD.<br />
(653)-2039. C-reactive Protein (CRP), Bone Mineral Density<br />
(BMD) And Hip Fracture Risk In Elderly Men And Women: The<br />
Framingham Study. Robert R. McLean 1 , Ronenn Roubenoff 2 ,<br />
Marian T. Hannan 1 , L. Adrienne Cupples 3 , Douglas P.<br />
Kiel 1 . 1 Hebrew SeniorLife & Harv Med Sch, Boston, MA;<br />
2<br />
Biogen Idec, Cambridge, MA; 3 BU Sch of Public Health,<br />
Boston, MA.<br />
(654)-2040. Application of Medical Simulation in Rheumatology<br />
Health Professional Education. Maura D. Iversen. MGH<br />
Institute of Health Professions, Boston, MA.<br />
(655)-2041. A Preliminary Needs Assessment for the Development<br />
of an Education and Support <strong>Program</strong> for Early and Newly<br />
Diagnosed RA Patients. Dayna Kurtz, Adena Batterman,<br />
Roberta Horton, Theodore Fields, Stephen Paget. Hospital<br />
for Special Surgery, New York, NY.<br />
(656)-2042. Item Response Theory Analysis of CDC Healthy<br />
Days Core and Healthy Days Symptoms Modules in Patients with<br />
Arthritis. Thelma Mielenz 1 , Michael C. Edwards 2 , Robert<br />
F. DeVellis 1 , Leigh F. Callahan 1 . 1 The University of North<br />
Carolina at Chapel Hill, Chapel Hill, NC; 2 The Ohio State,<br />
Columbus, OH.<br />
(657)-2043. Is it Possible to Ascertain Damage in Lupus Utilizing<br />
a Self-Reported Questionnaire? Preliminary Data on the Lupus<br />
Damage Index Questionnaire (LDIQ). Martha L. Sanchez 1 ,<br />
Karen H. Costenbader 2 , Elizabeth W. Karlson 2 , Graciela<br />
S. Alarcón 1 , Frederick Wolfe 3 . 1 University of Alabama at<br />
Birmingham, Birmingham, AL; 2 Lupus Center Brigham and<br />
Women’s Hospital, Boston, MA; 3 National Data Bank for<br />
Rheumatic Diseases, Wichita, KS.<br />
(658)-2044. Advancements in Prioritization for Joint Replacement<br />
Surgery: The Hip and Knee Questionnaire Captures Patient-<br />
Reported Indicators More Efficiently Than the New Zealand<br />
Priority Criteria. Richard H. Osborne 1 , Rachelle Buchbinder 2 ,<br />
Catherine L. Hill 3 , Ilana N. Ackerman 1 , Lainie Wengier 2 .<br />
1<br />
The University of Melbourne, Parkville, Victoria, Australia;<br />
2<br />
Monash University and Cabrini Hospital, Malvern,<br />
Victoria, Australia; 3 The Queen Elizabeth Hospital,<br />
Woodville, South Australia, Australia.<br />
(659)-2045. Standardizing Visual Analogue Scales to Measure<br />
Fatigue in Rheumatoid Arthritis. Joanna K. Nicklin 1 , John R.<br />
Kirwan 2 , Fiona Cramp 1 , Sarah Hewlett 1 . 1 University of the<br />
West of England, Bristol, United Kingdom; 2 University of<br />
Bristol, Bristol, United Kingdom.<br />
(660)-2046. Confirmatory Factor Analysis of the AIMS2-SF in<br />
Patients with Rheumatoid Arthritis. Peter M. ten Klooster 1 ,<br />
Martine M. Veehof 1 , Erik Taal 1 , Piet L.C.M. van Riel 2 ,<br />
Mart A.F.J. van de Laar 1 . 1 University of Twente, Enschede,<br />
The Netherlands; 2 Radboud University Nijmegen Medical<br />
Centre, Nijmegen, The Netherlands.<br />
278 (Permanent Board Number)-Abstract Number
(661)-2047. The STAR/ETIC Project-The Benefit of a<br />
Common European Register in Rheumatological Team Care.<br />
Ann B. Bremander 1 , Margreth Grotle 2 , Sofia Hagel 3 ,<br />
Kare Birger Hagen 2 , Mari Klokkerud 2 , Ida Lochting 2 ,<br />
Elisabeth Lindquist 3 , Lennart TH Jacobsson 4 , Britta<br />
Strömbeck 5 , John Verhoef 6 , Thea Vliet Vlieland 6 , Ingemar<br />
F. Petersson 7 . 1 Research and Development Center,<br />
Spenshult, Oskarström, Sweden; 2 National Resource<br />
Centre for Rehabilitation in Rheumatology (NRCRR),<br />
Diakonhjemmets Sykehus, Oslo, Norway; 3 Department<br />
of Rheumatology, Lund University Hospital, Lund,<br />
Sweden; 4 Dpartment of Rheumatology, Malmö University<br />
Hospital, Malmö, Sweden; 5 Department of Rheumatology,<br />
Malmö University Hospital, Malmö, Sweden; 6 Dept of<br />
Rheumatology, Leiden University Medical Center (LUMC),<br />
Leiden, The Netherlands; 7 Department of Orthopaedics,<br />
Lund University, Lund, Sweden.<br />
(662)-2048. Evaluation of the Factor Structure of the Arthritis<br />
Body Experience Scale (ABES) in a Cohort of People with<br />
Rheumatoid Arthritis (RA), Fibromyalgia (FM) and Osteoarthritis<br />
(OA). Josephine E. A. Boyington 1 , Robert DeVellis 2 , Jack<br />
Shreffler 2 , Britta Schoster 2 , Leigh F. Callahan 2 . 1 Shaw<br />
University, Raleigh, NC; 2 University of North Carolina,<br />
Chapel Hill, NC.<br />
(663)-2049. Don’t Always Believe What You Are Told: A<br />
Comparison of Self-Reported with Measured Weight and Height.<br />
Melynn Nuite 1 , Jun Wang 1 , Laura M. Wheeler 1 , Jeremiah<br />
Fletcher 1 , Prutha Badiani 1 , Erica L. McAdams 1 , Johane P.<br />
Joas 1 , Michael P. LaValley 2 , Bess Dawson-Hughes 3 , Timothy<br />
E. McAlindon 1 . 1 Tufts-New England Medical Center, Boston,<br />
MA; 2 Boston University School of Public Health, Boston,<br />
MA; 3 Jean Mayer USDA HNRC on Aging, Boston, MA.<br />
(664)-2050. Development and Psychometric Evaluation of the<br />
Rheumatology Exercise Barriers Scale. Elizabeth A. Schlenk,<br />
Susan E. Simms, Lisa K. Tamres, Jacqueline Dunbar-Jacob.<br />
University of Pittsburgh, Pittsburgh, PA.<br />
Poster Session c<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 279
Industry Roundtable-Supported Symposia<br />
6:30 – 9:30 p m<br />
Westin Boston Waterfront, Grand Ballroom A-E<br />
Strategies to Improve Outcomes in Rheumatoid Arthritis:<br />
Understanding the Role of Newer Biologic Agents<br />
Sponsored by education / outcomes / science<br />
Supported by an educational grant from Bristol-Myers Squibb Company<br />
PHYSICIAN ACCREDITATION<br />
education / outcomes / science is accredited by the<br />
Accreditation Council for Continuing Medical Education<br />
(ACCME) to sponsor continuing medical education for<br />
physicians.<br />
CREDIT DESIGNATION<br />
education | outcomes | science designates this educational<br />
activity for a maximum of 2 AMA PRA Category 1 Credits TM .<br />
Physicians should only claim credit commensurate with the<br />
extent of their participation in the activity.<br />
LEARNING OBJECTIVES<br />
Upon completion of this session, the participants should be able to:<br />
∙ Review current clinical evidence from trials evaluating<br />
newer biologic agents in RA and describe its clinical<br />
implications<br />
∙ Outline appropriate measures of treatment success and<br />
failure in RA<br />
∙ Identify appropriate patient selection criteria for the<br />
newer biologic agents in RA<br />
∙ Describe how and when newer biologic agents should be<br />
implemented in RA treatment<br />
6:30 p m<br />
Registration and Dinner<br />
7:30 p m<br />
Introduction<br />
Michael Schiff, MD; University of Colorado; Denver, CO<br />
7:40 p m<br />
Optimizing Early and Aggressive Intervention in RA<br />
Eric Ruderman, MD; Feinberg School of Medicine;<br />
Chicago, Illinois<br />
Lee Simon, MD; Harvard Medical School; Boston, MA<br />
8:10 p m<br />
How to Integrate New Treatment/Why and When to<br />
Switch<br />
Marc Cohen, MD; Mayo Clinic; Jacksonville, FL<br />
Alvin Wells, MD, PhD; Rosalind Franklin University of<br />
Medicine & Science; Oak Creek, WI<br />
8:40 p m<br />
Measures of Treatment Success and Failure in RA<br />
Kathryn Hobbs, MD; University of Colorado Health<br />
Sciences Center; Denver, CO<br />
Eric Ruderman, MD; Feinberg School of Medicine;<br />
Chicago, IL<br />
9:10 p m<br />
Questions & Answers<br />
All Faculty<br />
irt symposia<br />
280 Saturday, November 10, <strong>2007</strong>
Industry Roundtable-Supported Symposia<br />
6:30 – 9:30 p m<br />
Sheraton Boston Hotel, Grand Ballroom,<br />
Independence Ballroom and Liberty A-B-C<br />
Pathology and Treatment of Rheumatoid Arthritis: Focus<br />
on IL-6<br />
Sponsored by University of Kentucky Pharmacy College of Medicine<br />
Supported by an educational grant from Roche<br />
PHYSICIAN ACCREDITATION<br />
The University of Kentucky College of Medicine is<br />
accredited by the Accreditation Council for Continuing<br />
Medical Education (ACCME) to sponsor continuing<br />
medical education for physicians.<br />
CREDIT DESIGNATION<br />
The University of Kentucky College of Medicine designates<br />
this educational activity for a maximum of 2 AMA PRA<br />
Category 1 Credit(s) TM . Physicians should only claim credit<br />
commensurate with the extent of their participation in<br />
the activity.<br />
LEARNING OBJECTIVES<br />
Upon completion of this session, the participants should be able to:<br />
∙ Describe the role of IL-6 in the cytokine network<br />
associated with RA pathogenesis<br />
∙ Explain how IL-6 contributes to cardiovascular disease,<br />
and anemia of chronic disease, the principal systemic<br />
complications of RA<br />
∙ Discuss the relative benefits and challenges associated with<br />
the clinical use of the first direct IL-6 receptor inhibitor,<br />
tocilizumab, on articular and systemic manifestations of RA<br />
6:30 p m<br />
Registration and Dinner<br />
7:30 p m<br />
Welcome and Introductions<br />
Arthur Kavanaugh, MD; University of California, San Diego<br />
School of Medicine; La Jolla, CA<br />
7:40 p m<br />
Role of IL-6 in the Pathogenesis of Rheumatoid Arthritis<br />
Gary Firestein, MD; University of California, San Diego<br />
School of Medicine; La Jolla, CA<br />
8:00 p m<br />
Systemic Inflammation and Cardiovascular Disease in<br />
Rheumatoid Arthritis<br />
Joan Bathon, MD; Johns Hopkins School of Medicine;<br />
Baltimore, MD<br />
8:20 p m<br />
Hematological Effects of IL-6 – Effects on Bone Marrow<br />
and the Anemia of Chronic Disease<br />
Daniel Furst, MD; University of California at Los Angeles;<br />
Los Angeles, CA<br />
8:40 p m<br />
Proof of Concept: Tocilizumab, an IL-6 Receptor Antagonist,<br />
for the Treatment of Rheumatoid Arthritis<br />
Arthur Kavanaugh, MD; University of California San Diego;<br />
La Jolla, CA<br />
9:00 p m<br />
Panel Discussion<br />
Arthur Kavanaugh, MD; University of California San Diego;<br />
La Jolla, CA<br />
irt symposia<br />
CME credit for Industry-Supported Symposia provided by sponsor listed. 281
Industry Roundtable-Supported Symposia<br />
6:30 – 9:30 p m<br />
Westin Copley Place Boston,<br />
<strong>American</strong> Ballroom North-Center-South<br />
Rheumatoid Arthritis: The Next Generation of<br />
Biologic Agents<br />
Sponsored by the Center for Bio-Medical Communication<br />
Supported by an educational grant from UCB, Inc.<br />
PHYSICIAN ACCREDITATION<br />
The Center for Bio-Medical Communication, Inc. is<br />
accredited by the Accreditation Council for Continuing<br />
Medical Education (ACCME) to sponsor continuing<br />
medical education for physicians.<br />
CREDIT DESIGNATION<br />
CBC designates this educational activity for a maximum<br />
of 2 AMA PRA Category 1 Credits TM . Physicians should<br />
only claim credit commensurate with the extent of their<br />
participation in the activity.<br />
LEARNING OBJECTIVES<br />
Upon completion of this session, the participants should be able to:<br />
∙ Provide details on the pathophysiology of RA and the<br />
rationale for biological therapy<br />
∙ Differentiate the mechanism of action of the biological<br />
agents that have shown efficacy in RA<br />
∙ Compare the efficacy, safety and tolerability of<br />
conventional versus newer agents for RA<br />
∙ Identify therapeutic options for individual patients<br />
with significant RA symptoms despite conventional<br />
biologic therapy<br />
6:30 p m<br />
Registration and Dinner<br />
7:30 p m<br />
Welcome, Introduction, and Overview<br />
Edward Keystone, MD; Mount Sinai Hospital; Toronto,<br />
Ontario<br />
7:40 p m<br />
Evolution in Therapy for Rheumatoid Arthritis: Matching<br />
Pathophysiology with Biology<br />
Philip Mease, MD; University of Washington School of<br />
Medicine; Seattle, Washington<br />
8:05 p m<br />
Pathways and Molecules: Differentiating the Therapeutic<br />
Mechanisms of Action for Successful Patient Outcomes<br />
Edward Keystone, MD; Mount Sinai Hospital; Toronto,<br />
Ontario<br />
8:30 p m<br />
The Increasing Individualization of Therapy for Managing<br />
Rheumatoid Arthritis<br />
Katherine Siminovitch, MD; Mount Sinai Hospital;<br />
Toronto, Ontario<br />
8:55 p m<br />
Challenging Cases and Clinical Comparisons/Q & A<br />
Entire Faculty<br />
Chaired by: Michael Schiff, MD; University of Colorado<br />
School of Medicine; Denver, Colorado<br />
9:25 p m<br />
Closing Remarks<br />
irt symposia<br />
282 Saturday, November 10, <strong>2007</strong>
The Rheumatologist is an official publication of the <strong>American</strong><br />
College of Rheumatology and the Association of Rheumatology<br />
Health Professionals serving those dedicated to rheumatology<br />
care. Launched in 2006, The Rheumatologist focuses on news,<br />
trends and issues instrumental in shaping rheumatology.<br />
The Rheumatologist<br />
>> Go to <strong>ACR</strong> Central to receive the latest issue<br />
and learn more about The Rheumatologist.<br />
...just one of the many benefits of<br />
membership, join <strong>ACR</strong> or <strong>ARHP</strong> today!
time locatioN EVENT<br />
sunday · agenda at-a-glance<br />
7:00 a m—1:00 pm East Registration <strong>ACR</strong>/<strong>ARHP</strong> Registration<br />
7:30—9:00 a m Exhibit Hall A-B <strong>ACR</strong>/<strong>ARHP</strong> Coffee and Tea Break<br />
8:00—9:00 a m grand Ballroom East <strong>ACR</strong> Immunology Updates for Clinicians<br />
8:00—9:00 a m Room 253 <strong>ACR</strong> Practice Issues<br />
8:00—9:00 a m Hall C <strong>ACR</strong> Special Session: Rheumatology Roundup<br />
8:00—9:00 a m Convention Center (various locations) <strong>ARHP</strong> Concurrent Sessions<br />
9:15—10:45 a m Grand Ballroom East <strong>ACR</strong> Basic Science Symposium<br />
9:15—10:45 a m Convention Center (various locations) <strong>ACR</strong> Clinical Symposia<br />
9:15—10:45 a m Convention Center (various locations) <strong>ACR</strong> Concurrent Abstract Sessions<br />
9:15—10:45 a m Room 257 <strong>ARHP</strong> Concurrent Session<br />
9:15—10:45 a m Room 261 <strong>ARHP</strong> Concurrent Abstract Session<br />
9:15—11:30 a m Room 260 <strong>ARHP</strong> Concurrent Session<br />
11:00 a m—Noon Convention Center (various locations) <strong>ARHP</strong> Concurrent Sessions<br />
11:00 a m—Noon Convention Center (various locations) <strong>ARHP</strong> Concurrent Abstract Session<br />
11:00 a m—12:30 pm Room 210 <strong>ACR</strong> Basic Science Symposium<br />
11:00 a m—12:30 pm Convention Center (various locations) <strong>ACR</strong> Clinical Symposia<br />
11:00 a m—12:30 pm Convention Center (various locations) <strong>ACR</strong> Concurrent Abstract Sessions<br />
1:00—4:00 pm Various Locations <strong>ACR</strong> Industry-Supported Post-Conference Symposia<br />
sunday<br />
<strong>ACR</strong><br />
CLINICAL PRACTICE<br />
BASIC AND<br />
TRANSLATIONAL<br />
RESEARCH<br />
DUAL INTEREST TO<br />
CLINICIANS AND<br />
RESEARCHERS<br />
PEDIATRICS<br />
FELLOWS-IN-TRAINING<br />
<strong>ARHP</strong><br />
CLINICAL PRACTICE<br />
PEDIATRICS<br />
FELLOWS-IN-TRAINING<br />
PLAN YOUR SCHEDULE USING EDUCATIONAL TRACKS TO ENHANCE<br />
YOUR MEETING EXPERIENCE<br />
The <strong>ACR</strong> and <strong>ARHP</strong> have designed educational tracks to help you maximize the scheduling of your time and<br />
meeting experience by emphasizing primary areas of interest. There are five tracks for <strong>ACR</strong> and three tracks for<br />
<strong>ARHP</strong>. Designated sessions include the main symposia, lectures and select <strong>ACR</strong> Meet the Professor Sessions and<br />
Workshops. However, the concurrent abstract sessions and poster discussions are not included.<br />
Those sessions that are predominantly translational in content are designed to be of interest to both clinicians and<br />
researchers. These are indicated as “C/R”. Sessions with mainly pediatric content are indicated as “P”, and may be<br />
of interest to both pediatric and adult rheumatologists.<br />
As the annual meeting has a variety of session types scheduled concurrently, use these suggested tracks as a tool to<br />
assist you in developing your own individualized schedule for the meeting.<br />
Track Indicator Example<br />
Please use the following as an example to identify the available tracks.<br />
C R C/R P F<br />
CLINICAL<br />
PRACTICE<br />
BASIC AND<br />
TRANSLATIONAL<br />
RESEARCH<br />
DUAL INTEREST TO<br />
CLINICIANS AND<br />
RESEARCHERS<br />
PEDIATRICS<br />
FELLOWS-IN-<br />
TRAINING<br />
PM - PAIN MANAGEMENT<br />
The <strong>ACR</strong> designates certain sessions for pain management credit as required by the Medical Board of California<br />
(AB487). This designation is identified by the icon shown and will be placed next to the session title.<br />
284
Sunday, November 11, <strong>2007</strong><br />
<strong>ACR</strong>/<strong>ARHP</strong> Registration<br />
7:00 a m—1:00 p m<br />
East Registration<br />
<strong>ACR</strong>/<strong>ARHP</strong> Coffee and Tea Break<br />
7:30—9:00 a m<br />
Exhibit Hall A-B<br />
<strong>ACR</strong> Immunology Updates for Clinicians C/R<br />
8:00—9:00 a m<br />
Grand Ballroom East<br />
Innate Immunity<br />
Moderator:<br />
David M. Lee, MD, PhD; Brigham and Women’s Hospital;<br />
Boston, MA<br />
Speaker:<br />
Steven A. Porcelli, MD; Albert Einstein College of<br />
Medicine; Bronx, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the elements of the innate immune system<br />
∙ Identify the cellular and soluble mediators of the innate<br />
immune system<br />
∙ Assess the role of innate immunity in the normal<br />
host defense<br />
<strong>ACR</strong> Practice Issues C<br />
8:00—9:00 a m<br />
Room 253<br />
Coding is Your Friend<br />
Moderator:<br />
Faye N. Hant, DO; Medical University of South Carolina;<br />
Charleston, SC<br />
Speaker:<br />
Valerie G. Rock, CPC-A, ACS-EM; Gates, Moore and<br />
Company; Atlanta, GA<br />
Upon completion of this session, participants should be able to:<br />
∙ Differentiate proper coding guidelines for a rheumatology<br />
practice regarding infusions and injections<br />
∙ Discuss and interpret evaluation and management codes<br />
frequently used by rheumatologists<br />
∙ Discuss new codes that may affect practicing rheumatologists<br />
<strong>ACR</strong> Special Session C/R<br />
8:00—9:00 a m<br />
Hall C<br />
Rheumatology Roundup is supported by an educational grant from Novartis.<br />
Rheumatology Roundup: Highlights from the <strong>2007</strong><br />
<strong>ACR</strong> Annual <strong>Scientific</strong> <strong>Meeting</strong><br />
Moderator:<br />
Atul A. Deodhar, MD, MRCP; Oregon Health and<br />
Science University; Portland, OR<br />
Speakers:<br />
John J. Cush, MD; Arthritis Care and Research Center;<br />
Dallas, TX<br />
Arthur Kavanaugh, MD; Center for Innovative Therapy;<br />
La Jolla, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ List research highlights from the scientific presentations<br />
at the meeting<br />
∙ Discuss the clinical impact of selected research reports<br />
presented at the meeting<br />
<strong>ARHP</strong> Concurrent Session C<br />
8:00—9:00 a m<br />
Room 257<br />
Driving Simulation’s Role in Arthritis Research and Practice<br />
Moderator:<br />
Sharon L. Marcheschi, RN, BSN; Northwestern Medical<br />
Faculty Foundation; Chicago, IL<br />
Speaker:<br />
Erica B. Stern, PhD,OTR/L; University of Minnesota;<br />
Minneapolis, MN<br />
Upon completion of this session, participants should be able to:<br />
∙ Develop an informed perspective on PC-based commercial<br />
driving simulators: comparing and contrasting their<br />
attributes, uses and limitations for arthritis research and<br />
clinical care<br />
∙ Describe the types of data that can be generated through<br />
driving simulation and potential use in arthritis research<br />
∙ Contrast the use of driving simulation to study driving<br />
behaviors (e.g., lane maintenance; adherence to rules of the<br />
road); study abstract cognitive-motor skills (e.g., complex/<br />
simple reaction time, memory impulsivity, inattention,<br />
impaired problem solving); train persons in driving<br />
adaptations and improve insight and self-awareness of<br />
abilities/deficits<br />
∙ Describe existing arthritis-related research using driving<br />
simulation<br />
∙ Using cases, discuss how driving simulation could be<br />
used in arthritis research related to diagnoses (e.g.,<br />
osteoarthritis, SLE, fibromyalgia, rheumatoid arthritis,<br />
juvenile arthritis) and research questions (e.g., assessment<br />
medical therapies’s cognitive, emotional or motor effects)<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted. 285
sunday<br />
<strong>ARHP</strong> Concurrent Session C<br />
8:00—9:00 a m<br />
Room 261<br />
Physical Therapy Management of Pediatric<br />
Rheumatology Issues<br />
Moderator:<br />
Susan E. Klepper, PhD, PT; Columbia University; New York, NY<br />
Speaker:<br />
Lisa C. Mangino, PT, DPT, MS; Lenox Baker Childrens<br />
Hospital; Durham, NC<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe when a referral to physical therapy is indicated<br />
∙ Define physical therapy management issues in JRA<br />
∙ Define physical therapy management of dermatomyositis<br />
∙ Integrate specific treatment ideas to use in the clinic (e.g.,<br />
splinting, shoe lifts, etc.)<br />
<strong>ARHP</strong> Concurrent Session<br />
8:00—9:00 a m<br />
Room 259<br />
Chronic Disease Self Management Patient Education<br />
<strong>Program</strong>s: Clinical and Public Health Awareness<br />
Moderator:<br />
James A. Jenkins, PhD; Pacific Arthritis Care Center; Los<br />
Angeles, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the place and importance of high quality<br />
arthritis education and self-management programs<br />
∙ Discuss why evaluation of arthritis self-management<br />
programs have revealed mixed effects at the group and<br />
individual levels<br />
∙ Critically appraise the measurement properties of current<br />
evaluation tools<br />
∙ Prescript the skills and measures requested to evaluate and<br />
interpret outcomes<br />
∙ Integrate the range of patient education options (from clinical<br />
interviews, coaching, group-based programs, through to<br />
multimedia) into local clinical and community settings.<br />
8:00 a m<br />
Integration and Sustainability of Self-Management <strong>Program</strong>s at the<br />
Local and National Level<br />
Joanne E. Jordan, BA, BSc, MPH; Royal Melbourne Hospital,<br />
The University of Melbourne; Melbourne, Australia<br />
Upon completion of this session, participants should be able to:<br />
∙ Critically appraise current international policy and<br />
program trends with respect to the integration of chronic<br />
disease self-management education programs into the<br />
healthcare system<br />
∙ Identify and analyze barriers and enablers that have<br />
impacted on the viability and sustainability of integrating<br />
self-management programs into the healthcare system<br />
∙ Specify key actions required to advance self-management<br />
programs at the national and local setting<br />
8:30 a m<br />
Arthritis and Chronic Disease Education <strong>Program</strong>s: Evidence,<br />
Evaluation and Impact<br />
Richard H. Osborne, PhD; The University of Melbourne;<br />
Melbourne, Australia<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize the place and importance of high quality<br />
arthritis education and self-management programs<br />
∙ Discuss why evaluation of arthritis self-management<br />
programs have revealed mixed effects at the group and<br />
individual level<br />
∙ Critically appraise the measurement properties of current<br />
evaluation tools<br />
∙ Prescribe the skills and measures required to evaluate and<br />
interpret patient outcomes<br />
<strong>ACR</strong> Basic Science Symposium C/R<br />
9:15—10:45 a m<br />
Grand Ballroom East<br />
RA from Bench to Bedside<br />
Moderators:<br />
Gary S. Firestein, MD; University of California, San Diego;<br />
La Jolla, CA<br />
Michael E. Weinblatt, MD; Brigham and Women’s<br />
Hospital; Boston, MA<br />
Upon completion of this session, participants should be able to:<br />
∙ Interpret how animal models can give clues to the<br />
pathogenesis and treatment of RA<br />
∙ Summarize how genetic association studies are performed<br />
and how to interpret the data<br />
∙ Describe the association of anti-CCP antibodies with RA,<br />
as well as how these antibodies can be used as prognostic<br />
indicators<br />
286<br />
= Recorded Sessions (order form on page 430)
9:15 a m<br />
Innate Responses Bypass IL-1 in Animal Models: Implications<br />
for Therapy<br />
Maripat Corr, MD; UCSD; La Jolla, CA<br />
9:40 a m<br />
Use and Abuse of Genomics and Genetic Associations in RA<br />
Peter K. Gregersen, MD; Feinstein Institute for Medical<br />
Research; Manhasset, NY<br />
10:05 a m<br />
Citrullination and Anti-CCP Antibodies in RA<br />
Thomas Huizinga, MD; Leiden University Medical Center;<br />
Leiden, Netherlands<br />
10:30 a m<br />
Discussion<br />
<strong>ACR</strong> Clinical Symposium C<br />
9:15—10:45 a m<br />
Hall C<br />
Challenging Topics in Bone Disease<br />
Moderator:<br />
Marcy B. Bolster, MD; Medical University of South<br />
Carolina; Charleston, SC<br />
Upon completion of this session, participants should be able to:<br />
∙ Evaluate the risk of osteonecrosis of the jaw and<br />
benefits of stopping prolonged therapy in patients on<br />
bisphosphonates<br />
∙ Enumerate the common causes of misinterpretation of<br />
bone densitometry results<br />
∙ Discuss the causes and management of low bone mass in<br />
pre-menopausal women<br />
9:15 a m<br />
Controversies and Complications of Bisphosphonates Use<br />
Michael McClung, MD; Oregon Osteoporosis Center;<br />
Portland, OR<br />
9:40 a m<br />
Pitfalls in the Interpretation of Bone Densitometry<br />
Nancy E. Lane, MD; University of California at Davis<br />
Medical Center; Sacramento, CA<br />
10:10 a m<br />
Assessment Strategies for Premenopausal Low Bone Mass<br />
Clifford J. Rosen, MD; St. Joseph Hospital; Bangor, ME<br />
10:30 a m<br />
Panel Discussion<br />
<strong>ACR</strong> Clinical Symposium C<br />
9:15—10:45 a m<br />
Room 258<br />
Streptococcal Related Rheumatic Diseases<br />
Moderator:<br />
Beth S. Gottlieb, MD, MS; Schneider Childrens Hospital;<br />
New Hyde Park, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Discuss current concepts in the diagnosis and treatment of<br />
post-strep arthritis and acute rheumatic fever<br />
∙ Describe the controversy surrounding the diagnosis and<br />
treatment of PANDAS<br />
9:15 a m<br />
Immunobiology of Group A Strep Infections<br />
Edward L. Kaplan, MD; University of Minnesota;<br />
Minneapolis,, MN<br />
9:40 a m<br />
Post-Strep Arthritis/Acute Rheumatic Fever<br />
Stanford T. Shulman, MD; Children’s Memorial Hospital;<br />
Chicago, IL<br />
10:05 a m<br />
Pediatric Autoimmune Neuropsychiatric Disorders Associated with<br />
Streptococcal Disease (PANDAS)<br />
Susan Swedo, MD; Bethesda, MD<br />
10:30 a m<br />
Panel Discussion<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
9:15—10:45 a m<br />
Room 210<br />
The Epidemiology of SLE (Abstracts #2156-2161)<br />
Moderators:<br />
Eliza F. Chakravarty, MD; Stanford University; Palo Alto, CA<br />
Ann E. Clarke, MD; Montreal General Hospital;<br />
Montreal, Quebec<br />
9:15 a m<br />
2156. Outcomes after Acute Myocardial Infarction in Systemic<br />
Lupus Erythematosus. Mansi Shah 1 , Eswar Krishnan 2 , Amber<br />
Shah 1 . 1 Reading Hopsital, Wyomissing, PA; 2 University of<br />
Pittsburgh, Pittsburgh, PA<br />
P<br />
sunday<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
287
sunday<br />
9:30 a m<br />
2157. Atherosclerotic Vascular Events in a Multinational<br />
Inception Cohort of Sle: Description and Attribution. Murray B.<br />
Urowitz, Dafna D. Gladman, Dominique Ibañez, Paul R.<br />
Fortin, Jorge Sanchez-Guerrero, Sang-Cheol Bae, Carolyn P.<br />
Gordon, Ann E. Clarke, John G. Hanly, Daniel J. Wallace,<br />
David A. Isenberg, Joan T. Merrill, Ellen M. Ginzler,<br />
Graciela S. Alarcon, Kristjan Steinsson, Michelle A. Petri,<br />
Munther A. Khamashta, Ian Bruce, Mary Ann Dooley,<br />
Susan Manzi, Rosalind Ramsey-Goldman, Gunnar Sturfelt,<br />
Ola Nived, Asad A. Zoma, Peter Maddison, Josep Font,<br />
Ronald van Vollenhoven, Cynthia B. Aranow, Kenneth<br />
C. Kalunian, Thomas Stoll, David Wofsy, Jill P. Buyon.<br />
Toronto Western Hospital, University Health Network,<br />
Toronto, ON, Canada<br />
9:45 a m<br />
2158. Estimates of Increased Risk of Coronary Heart Disease<br />
(CHD) in Systemic Lupus Erythematosus (SLE). Laurence<br />
Magder 1 , Michelle Petri 2 . 1 University of Maryland,<br />
Baltimore, MD; 2 Johns Hopkins University, Baltimore, MD<br />
10:00 a m<br />
2159. Differences in Subclinical Cardiovascular Disease<br />
in African-<strong>American</strong> and Caucasian Women with SLE: A<br />
Combined Analysis with SOLVABLE (Chicago) and HEARTS<br />
(Pittsburgh). Elisa Y. Rhew 1 , Susan M. Manzi 2 , David<br />
McPherson 3 , Alan R. Dyer 1 , George T. Kondos 4 , Daniel<br />
Edmundowicz 2 , Kim Sutton-Tyrrell 2 , Rosalind Ramsey-<br />
Goldman 1 . 1 Northwestern University, Chicago, IL;<br />
2<br />
University of Pittsburgh, Pittsburgh, PA; 3 University of<br />
Texas, Houston, TX; 4 University of Illinois, Chicago, IL<br />
10:15 a m<br />
2160. The 1000 Canadian Faces of Lupus: A look at the First<br />
Year. Christine A. Peschken 1 , Janet Pope 2 , Earl Silverman 3 ,<br />
Glinda S. Cooper 4 , Steven Katz 1 , The 1000 Canadian Faces<br />
of Lupus Investigators. 1 university of Manitoba, Winnipeg,<br />
MB, Canada; 2 University of Western Ontario, London, ON,<br />
Canada; 3 University of Toronto, Toronto, ON, Canada;<br />
4<br />
Environmental Protection Agency, Washington, DC<br />
10:30 a m<br />
2161. Cognitive Function Changes in Newly Diagnosed Systemic<br />
Lupus Erythematosus. Mohammad Naqibuddin 1 , Margaret<br />
Sampedro 1 , Kathryn A. Carson 1 , Daniel J. Wallace 2 , Michael<br />
H. Weisman 2 , Robin L. Brey 3 , Stephen L. Holliday 4 ,<br />
Michelle Petri 1 . 1 Johns Hopkins University, Baltimore, MD;<br />
2<br />
Cedars-Sinai Medical Center / David Geffen School of<br />
Medicine at UCLA, Los Angeles, CA; 3 UT Health Science<br />
Center at San Antonio, San Antonio, TX; 4 South Texas<br />
Veterans Health Care System, San Antonio, TX<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
9:15—10:45 a m<br />
Room 205<br />
Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s:<br />
Clinical Aspects and Therapeutics II (Abstracts #2162-2167)<br />
Moderator:<br />
Otylia Kowal-Bielecka, MD; Medical University of Bialystok;<br />
Bialystok, Poland<br />
Philip Clements; UCLA; Los Angeles, CA<br />
9:15 a m<br />
2162. Development of a Provisional Core Set of Response<br />
Measures for Clinical Trials of Systemic Sclerosis. Dinesh<br />
Khanna 1 , Daniel E. Lovell 2 , Edward Giannini 2 , Philip J.<br />
Clements 3 , Peter A. Merkel 4 , James R. Seibold 5 , Marco<br />
Matucci-Cerinic 6 , Christopher P. Denton 7 , Maureen D.<br />
Mayes 8 , Virginia D. Steen 9 , John Varga 10 , Daniel E. Furst 3 ,<br />
for the other coauthors of the Scleroderma Clinical Trials<br />
Consortium. 1 University of Cincinnati, Cincinnati, OH;<br />
2<br />
Cincinnati Childrens Medical Center, Cincinnati, OH;<br />
3<br />
UCLA, Los Angeles, CA; 4 Boston University, Boston,<br />
MA; 5 University of Michigan, Ann Arbor, MI; 6 University<br />
of Florence, Florence, Italy; 7 Royal Free Hospital, London,<br />
United Kingdom; 8 University of Texas, Houston, TX;<br />
9<br />
Georgetown University, Washington, DC; 10 Northwestern<br />
University, Chicago, IL<br />
9:30 a m<br />
2163. A Multi-Center Placebo-Controlled “In-Life” Study of<br />
MQX-503 in Patients with Raynaud Phenomenon. Lorinda<br />
Chung 1 , Murray Baron 2 , David Collier 3 , Mary Ellen Csuka 4 ,<br />
David Fiorentino 1 , Barry Gruber 5 , Vivien Hsu 6 , Bashar<br />
Kahaleh 7 , Richard Martin 8 , Maureen Mayes 9 , Janet Pope 10 ,<br />
Naomi Rothfield 11 , Joseph Shanahan 12 , Lee Shapiro 13 ,<br />
Robert Simms 14 , Edwin Smith 15 , Virginia Steen 16 , Sangeeta<br />
Sule 17 , Nadera Sweiss 18 , Elena Matthews 19 , Adam Gilbert 19 ,<br />
Frederick J. Dechow 20 , Fredrick M. Wigley 17 . 1 Stanford<br />
Univ, Stanford, CA; 2 McGill Univ, Montreal, PQ, Canada;<br />
3<br />
Univ of CO, Denver, CO; 4 Medical College of WI,<br />
Milwaukee, WI; 5 SUNY, Stony Brook, NY; 6 UMDNJ, New<br />
Brunswick, NJ; 7 Medical Univ of OH, Toledo, OH; 8 MSU,<br />
Grand Rapids, MI; 9 Univ of TX, Houston, TX; 10 Univ of<br />
Western Ontario, London, ON, Canada; 11 Univ of CT,<br />
Farmington, CT; 12 Duke Univ, Durham, NC; 13 Center for<br />
Rheumatology, Albany, NY; 14 BU, Boston, MA; 15 MUSC,<br />
Charleston, SC; 16 Georgetown Univ, Washington, DC;<br />
17<br />
Johns Hopkins Univ, Baltimore, MD; 18 Univ of Chicago,<br />
Chicago, IL; 19 Ockham Development Group, Inc., Cary,<br />
NC; 20 MediQuest Therapeutics, Inc., Bothell, WA<br />
288<br />
= Recorded Sessions (order form on page 430)
9:45 a m<br />
2164. Defining Appropriate Outcome Measures in Pulmonary<br />
Arterial Hypertension Related to Systemic Sclerosis: Delphi<br />
Consensus Study with Cluster Analysis. Oliver Distler 1 , David<br />
Pittrow 2 , Frank Behrens 3 , Doerte Huscher 4 , Christopher<br />
P. Denton 5 , Ivan Foeldvari 6 , Marc Humbert 7 , Marco<br />
Matucci-Cerinic 8 , Peter Nash 9 , Christian F. Opitz 10 , James<br />
R. Seibold 11 , Lewis J. Rubin 12 , Daniel E. Furst 13 . 1 Dept.<br />
of Rheum., Univ., Zurich, Switzerland; 2 Med. Faculty,<br />
Dresden, Germany; 3 Div. Rheum, University, Frankfurt,<br />
Germany; 4 German Rheum. Res. Centre, Berlin, Germany;<br />
5<br />
Royal Free Hospital, London, United Kingdom; 6 Pediatric<br />
Rheum. Clinic, Eilbek, Hamburg, Germany; 7 Hopital<br />
Antoine-Beclere, Université, Clamart, France; 8 Univ.,<br />
Medica I, Florence, Italy; 9 Rheum. Res. Unit, Sunshine<br />
Coast,, Queensl., Australia; 10 Med. Klinik DRK, Berlin,<br />
Germany; 11 Univ. Michigan, Ann Arbor, MI; 12 Div. Pulm.<br />
Med., Univ., La Jolla, CA; 13 Div. Rheumatol., UCLA, Los<br />
Angeles, CA<br />
10:00 a m<br />
2165. MQX-503, A Novel Topical Nitroglycerin Formulation,<br />
Improves Severity of Raynaud Phenomenon in a Heterogeneous<br />
Patient Population. Lorinda Chung 1 , Lee Shapiro 2 ,<br />
David Fiorentino 1 , Murray Baron 3 , Joseph Shanahan 4 ,<br />
Sangeeta Sule 5 , Vivien Hsu 6 , Naomi Rothfield 7 , Virginia<br />
Steen 8 , Richard Martin 9 , Edwin Smith 10 , Maureen Mayes 11 ,<br />
Robert Simms 12 , Janet Pope 13 , Bashar Kahaleh 14 , Mary Ellen<br />
Csuka 15 , Barry Gruber 16 , David Collier 17 , Nadera Sweiss 18 ,<br />
Elena Matthews 19 , Adam Gilbert 19 , Frederick J. Dechow 20 ,<br />
Jeff Gregory 20 , Fredrick M. Wigley 5 . 1 Stanford University,<br />
Stanford, CA; 2 Center for Rheumatology, Albany, NY; 3 McGill<br />
University, Montreal, PQ, Canada; 4 Duke University, Durham,<br />
NC; 5 Johns Hopkins University, Baltimore, MD; 6 UMDNJ,<br />
New Brunswick, NJ; 7 University of Connecticut, Farmington,<br />
CT; 8 Georgetown University, Washington D.C., DC; 9 MSU,<br />
Grand Rapids, MI; 10 MUSC, Charleston, SC; 11 University<br />
of Texas, Houston, TX; 12 Boston University, Boston, MA;<br />
13<br />
University of Western Ontario, London, ON, Canada;<br />
14<br />
Medical University of Ohio, Toledo, OH; 15 Medical College<br />
of Wisconsin, Milwaukee, WI; 16 SUNY, Stony Brook, NY;<br />
17<br />
University of Colorado, Denver, CO; 18 University of Chicago,<br />
Chicago, IL; 19 Ockham Development Group, Inc., Cary, NC;<br />
20<br />
MediQuest Therapeutics, Inc., Bothell, WA<br />
10:15 a m<br />
2166. Ambrisentan Therapy for Pulmonary Arterial Hypertension<br />
Associated with Connective Tissue Diseases. David Badesch, on<br />
behalf of the ARIES Study Group. University of Colorado<br />
HSC, Denver, CO<br />
10:30 a m<br />
2167. Addition of the Short Term Phosphodiesterase-5<br />
Inhibitor Sildenafil to Iloprost Therapy for Scleroderma Digital<br />
Vasculopathy. Angela Pakozdi, Kevin Howell, Carol M.<br />
Black, Christopher P. Denton. Royal Free Hospital,<br />
London, United Kingdom<br />
<strong>ARHP</strong> Concurrent Session<br />
9:15—10:45 a m<br />
Room 257<br />
Fundamental Regulatory Aspects of Clinical Research:<br />
Satisfying the FDA, HIPAA and the IRB Is Not Enough<br />
Moderator:<br />
Stacey Busch, RN, BSN, MA; Family Arthritis Center;<br />
Jupiter, FL<br />
Speakers:<br />
Donah Z. Crawford, BS, MA; The Arthritis Group;<br />
Philadelphia, PA<br />
Cindy A. Greenwell, RN; Center for Rheumatic Disease;<br />
Kansas City, MO<br />
Lisa M. Kastanek, RN, CCRC; Arthritis Center of<br />
Nebraska; Lincoln, NE<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe the legal and ethical regulations governing<br />
clinical trials<br />
∙ Define the role of the FDA, HIPAA and the IRB<br />
∙ Define the role and compliance requirement of the<br />
Occupational Safety and Health Administration (OSHA)<br />
and the International Air Transport Association (IATA)<br />
<strong>ARHP</strong> Concurrent Abstract Session<br />
9:15—10:45 a m<br />
Room 261<br />
SLE and Inflammatory Arthritis: Disease Activity and<br />
Outcomes Research (Abstracts #2168-2173)<br />
Moderator:<br />
Karen A. Orloff, BS, CCRC; State University of New York<br />
at Brooklyn; Brooklyn, NY<br />
9:15 a m<br />
2168. Factors Associated with the Development of Cognitive<br />
Impairment over the Course of Systemic Lupus Erythematosus<br />
(SLE): Data from a Multiethnic Cohort. Martha L. Sanchez 1 ,<br />
Jie S. Zhang 1 , Luis M. Vilá 2 , John D. Reveille 3 , Graciela<br />
S. Alarcón 1 . 1 University of Alabama at Birmingham,<br />
Birmingham, AL; 2 University of Puerto Rico, San Juan,<br />
Puerto Rico; 3 University of Texas-Houston Health Sciences<br />
Campus, Houston, TX<br />
sunday<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
289
9:30 a m<br />
2169. Reduced Fatigue and Improved Self-Perceived<br />
Social Function in Patients with Severe SLE Treated with<br />
Rituximab. Elisabet Welin Henriksson, Thorunn Jonsdottir,<br />
Iva Gunnarsson, Ronald F. van Vollenhoven. Karolinska<br />
Institutet, Stockholm, Sweden<br />
9:45 a m<br />
2170. Can a Patient Self-Reported Active Joint Count Replace<br />
a Physician’s Examination of the Joints for Inflammatory<br />
Activity? Catherine T. Schentag, Salman Chaudhry, Dafna<br />
D. Gladman. Toronto Western Hospital, University Health<br />
Network, Toronto, ON, Canada<br />
Speakers:<br />
Jan Albrecht, OTR/L, CHT; University Orthopaedics Hand<br />
Center; North Mankato, MN<br />
Virginia O Brien, OTR/L, CHT; University of Minnesota<br />
Medical Center; Minneapolis, MN<br />
Upon completion of this session, participants should be able to:<br />
∙ Explain the pros and cons of splints as a treatment tool for<br />
the at-risk or arthritic thumb<br />
∙ Fabricate 1-4 custom splints for thumb instability, pain<br />
and osteoarthritis<br />
∙ Demonstrate correct application of tape to enhance thumb<br />
biomechanics and to reduce pain and inflammation<br />
sunday<br />
10:00 a m<br />
2171. The Validity and Reliability of a Simple Activity<br />
Participation Measure for Rheumatoid Arthritis Clinical<br />
trials. Tracy Li 1 , George Wells 2 , Rene Westhovens 3 ,<br />
Peter Tugwell 2 . 1 Bristol--Myers Squibb, Princeton, NJ;<br />
2<br />
University of Ottawa, Ottawa, ON, Canada; 3 Universitaire<br />
Ziekenhuizen Leuven, Leuven, Belgium<br />
10:15 a m<br />
2172. Psychometric Properties of the Rheumatoid Arthritis Disease<br />
Activity Index (RADAI) in a Cohort of Consecutive Dutch RA<br />
Patients Starting Anti-TNF Blocking Treatment. Martine M.<br />
Veehof 1 , Peter M. ten Klooster 1 , Erik Taal 1 , Piet LCM<br />
van Riel 2 , Mart AFJ van de Laar 1 . 1 University of Twente,<br />
Enschede, The Netherlands; 2 Radboud University Nijmegen<br />
Medical Centre, Nijmegen, The Netherlands<br />
10:30 a m<br />
2173. The Sensitivity to Change of Lower vs. Higher Joint Counts<br />
in Rheumatoid Arthritis (RA) Trials. B. Zhang, M. Lavalley, D.<br />
T. Felson. BUSM, Boston, MA<br />
<strong>ARHP</strong> Concurrent Session<br />
9:15—11:30 a m<br />
Room 260<br />
This 2-hour, hands-on laboratory is a complement to the<br />
lecture which is held on Saturday, November 10 at 4:30 pm.<br />
The lecture was not a pre-requisite to the laboratory session.<br />
Hands-on practice of mobilization/stabilization techniques<br />
will precede the fabrication of up to 3 custom splints.<br />
Laboratory attendance is limited to 25 participants who are asked<br />
to bring their own splint scissors.<br />
Dynamic Stability for the Painful Thumb: Experiential<br />
Laboratory<br />
Moderator:<br />
Kathryn L. Lowenstein, OTR/L; Arthritis Center; Palm<br />
Harbor, FL<br />
<strong>ARHP</strong> Concurrent Session<br />
11:00 a m—Noon<br />
Room 257<br />
Fibromyalgia: An Innovative Approach to Understanding<br />
the Relationship Between Daily Activities and Symptoms<br />
Moderator:<br />
Susan T. Reisine, PhD; University of Connecticut;<br />
Farmington, CT<br />
Speakers:<br />
Margo B. Holm, PhD, OTR/L; University of Pittsburgh;<br />
Pittsburgh, PA<br />
Joan C. Rogers, PhD, OTR/L; University of Pittsburgh;<br />
Pittsburgh, PA<br />
Terence W. Starz, MD; University of Pittsburgh Medical<br />
Center; Pittsburgh, PA<br />
Upon completion of this session, participants should be able to:<br />
∙ Review pathophysiologic mechanisms of fibromyalgia<br />
∙ Describe activity and energy patterns over time (1 day, 1<br />
week, 6 weeks)<br />
∙ Illustrate the use of objective, sensor information<br />
combined with subjective, Internet self-monitoring<br />
to manage fibromyalgia symptoms and promote a<br />
healthy lifestyle<br />
290<br />
= Recorded Sessions (order form on page 430)
<strong>ARHP</strong> Concurrent Abstract Session<br />
11:00 a m—Noon<br />
Room 261<br />
Living the Good Life with Rheumatic Disease<br />
(Abstracts #2186-2189)<br />
Moderator:<br />
Christina H. Opava, PhD, RPT; Karolinska Institutet;<br />
Huddinge, Sweden<br />
11:00 a m<br />
2186. Initial Findings of an RCT of Yoga on Physical and<br />
Psychological Functioning in RA and OA. Steffany Haaz, Joan<br />
M. Bathon, Susan J. Bartlett. Johns Hopkins University,<br />
Baltimore, MD<br />
11:15 a m<br />
2187. Rheumatoid Arthritis Outcomes: Focus Groups Emphasize<br />
Lifestyle, Social and Self-image Effects of RA. Jenny E. Heller,<br />
Melanie J. Zibit, Nancy E. Maher, Kerri L. Batra, Michael<br />
E. Weinblatt, Nancy A. Shadick. Brigham and Women’s<br />
Hospital, Boston, MA<br />
11:30 a m<br />
2188. Daily Spiritual Experiences of Older Adults With and<br />
Without Arthritis: Relationships to Health Outcomes. Susan J.<br />
Bartlett, Jeanne McCauley, Steffany Haaz. Johns Hopkins,<br />
Baltimore, MD<br />
11:45 a m<br />
2189. Improved Health-Related Quality of Life after a<br />
One-Year Physical Activity <strong>Program</strong>me for Systemic Lupus<br />
Erythematosus. Carina Boström 1 , Brigitte Dupré 2 , The late<br />
Pia Tengvar 2 , Christina H. Opava 3 , Eva Jansson 4 , Ingrid E.<br />
Lundberg 5 . 1 Department of Neurobiology, Care Sciences<br />
and Society, Karolinska Institutet, Sweden; 2 Department<br />
of Medicine, Karolinska University Hospital, Sweden;<br />
3<br />
Department of Neurobiology, Care Sciences and Society,<br />
Karolinska University Hospital, Karolinska Institutet,<br />
Sweden; 4 Department of Laboratory Medicine, Karolinska<br />
University Hospital, Karolinska Institutet, Sweden;<br />
5<br />
Department of Medicine, Karolinska University Hospital,<br />
Karolinska Institutet, Sweden<br />
<strong>ACR</strong> Basic Science Symposium C/r<br />
11:00 a m—12:30 p m<br />
Room 210<br />
Inflammation, Atherosclerosis and the Rheumatic Diseases<br />
Moderators:<br />
Jorg J. Goronzy, MD, PhD; Emory University; Atlanta, GA<br />
Jane E. Salmon, MD; Hospital for Special Surgery; New<br />
York, NY<br />
Upon completion of this session, participants should be able to:<br />
∙ Recognize immune-mediated inflammation as a critical<br />
mechanism of tissue injury in atherosclerotic disease<br />
∙ Identify immune defects in patients with rheumatoid<br />
arthritis and systemic lupus erythematosus that sustain and<br />
complicate the inflammation of the atherosclerotic plaque<br />
∙ Realize cardiovascular disease as an intrinsic comorbidity<br />
of rheumatoid arthritis and systemic lupus erythematosus<br />
11:00 a m<br />
Inflammation and Atherosclerosis: Learning from Rheumatoid<br />
Arthritis and Lupus<br />
Charles Stein, MD; Vanderbilt; Nashville, TN<br />
11:25 a m<br />
Macrophages, Dendritic Cells and Atherosclerosis<br />
Gwendalyn J. Randolph, PhD; Mount Sinai; New York, NY<br />
11:50 a m<br />
Accelerated Atherosclerosis in Rheumatic Disease<br />
Dorian O. Haskard, DM; Imperial College; London, England<br />
12:15 p m<br />
Discussion<br />
sunday<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
291
sunday<br />
<strong>ACR</strong> Clinical Symposium C<br />
11:00 a m—12:30 p m<br />
Hall C<br />
Rheumatologic Skin Disease<br />
Moderators:<br />
Marcy B. Bolster, MD; Medical University of South<br />
Carolina; Charleston, SC<br />
Prakash Pispati, MD; Jaslok, Breach Candy and Saifee<br />
Hospitals; Mumbai, India<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe novel therapies and local wound care in the<br />
management of cutaneous vasculitis<br />
∙ Discuss the pathogenesis of nephrogenic fibrosing<br />
dermopathy and determine if patients with autoimmune<br />
disease are at a higher risk<br />
∙ Review the evaluation and management of patients with<br />
refractory digital ulcerations and/or calcinosis<br />
11:00 a m<br />
Cutaneous Vasculitis<br />
Warren W. Piette, MD; John Stroger, Jr. Hospital of Cook<br />
County; Chicago, IL<br />
11:25 a m<br />
Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy<br />
Jonathan Kay, MD; Massachusetts General Hospital;<br />
Boston, MA<br />
11:55 a m<br />
Digital Ulcerations and Calcinosis<br />
Marco Matucci Cerinic, Professor; University of Florence;<br />
Florence, Italy<br />
<strong>ACR</strong> Clinical Symposium<br />
11:00 a m—12:30 p m<br />
Grand Ballroom East<br />
Spondyloarthritis: Update on Pathogenesis and Treatment<br />
Moderator:<br />
John C. Davis, Jr., MD, MPH; University of California–San<br />
Francisco; San Francisco, CA<br />
Upon completion of this session, participants should be able to:<br />
∙ Describe our current understanding of the interaction<br />
between genes and the environment in the pathogenesis of<br />
spondyloarthritis<br />
∙ Review the central role of entheses in the pathophysiology<br />
of joint, nail, and bone inflammation in spondyloarthritis<br />
∙ Discuss the insights into the current and future treatment<br />
options for spondyloarthritis based on recent clinical trials<br />
11:00 a m<br />
The Role of Genes and Microbes in the Pathophysiology of<br />
Spondyloarthritis<br />
Robert D. Inman, MD; Toronto Western Hospital;<br />
Toronto, Ontario<br />
C<br />
11:30 a m<br />
Enthesis: From Anatomy to Molecules<br />
Dennis McGonagle, MB, I, PhD; Chapel Allenion Hosp;<br />
Leeds, England<br />
Noon<br />
Treatment Updates in Spondyloarthritis<br />
Christopher T. Ritchlin, MD; University of Rochester<br />
Medical Center; Rochester, NY<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
11:00 a m—12:30 p m<br />
Room 258<br />
Pediatric Rheumatic Diseases: New Developments in<br />
Diagnosis, Treatment and Natural History<br />
(Abstracts #2174-2179)<br />
Moderators:<br />
Kathleen M. O’Neil, MD; University of Oklahoma;<br />
Oklahoma City, OK<br />
Kiem Oen, MD; University of Manitoba; Winnipeg, Manitoba<br />
11:00 a m<br />
2174. Osteonecrosis in Children with Autoimmune Diseases - A<br />
Promising Treatment with Multipotent Mesenchymal Stromal<br />
Cells. Nikolay Tzaribachev 1 , Martin Vaegler 1 , Juergen<br />
Schäfer 2 , Maximilian Rudert 3 , Patrick Reize 4 , Ingo Mueller 1 .<br />
1<br />
University Children’s Hospital, Tuebingen, Germany;<br />
2<br />
University Hospital, Dept. Radiology, Tuebingen,<br />
Germany; 3 University Hospital, Munich, Germany;<br />
4<br />
University Hospital for Orthopaedics, Stuttgart, Germany<br />
11:15 a m<br />
2175. Cytokine Profile in Synovial Fluid (SF) as Major<br />
Duration Predictor of Intra-Articular Corticosteroid (IAC)<br />
Injection in Juvenile Arthritis. Andrea Taddio 1 , Marcella<br />
Montico 2 , Paul T. Fawcett 3 , Victoria L. Maduskuie 3 , Marco<br />
Cattalini 4 , Luca Ronfani 2 , AnneMarie C. Brescia 5 , Carlos<br />
D. Rose 5 . 1 Department of Sciences of Reproduction<br />
and Development, Institute of Child Health IRCCS<br />
Burlo Garofolo, University of Trieste, Trieste, Italy;<br />
2<br />
Epidemiology and Biostatistics Unit, Institute of Child<br />
Health IRCCS Burlo Garofolo, Trieste, Italy; 3 Immunology<br />
Laboratory, Department of Research; A. I. duPont<br />
Hospital for Children, Wilmington, DE; 4 Department<br />
of Pediatric Immunology and Rheumatology, Pediatric<br />
Clinic, University of Brescia, Brescia, Italy; 5 Division<br />
of Rheumatology A. I. duPont Hospital for Children,<br />
Department of Pediatrics, Thomas Jefferson University,<br />
Wilmington, DE<br />
292<br />
= Recorded Sessions (order form on page 430)
11:30 a m<br />
2176. Differential Gene Expression Profiles in Cultured Fibroblastlike<br />
Synoviocytes (FLS) from Children with Oligoarticular JIA<br />
Show Both Similarities and Remarkable Differences with RA<br />
FLS. AnneMarie C. Brescia, Carlos D. Rose, Suzanne M.<br />
McCahan, Timothy Stetson, Paul T. Fawcett. AI duPont<br />
Hospital for Children, Wilmington, DE<br />
11:45 a m<br />
2177. Paired Posterior-Anterior and Lateral DXA Detects Bone<br />
Mineral Density Deficits in Juvenile Idiopathic Arthritis. Sarah<br />
E. Dubner 1 , Justine Shults 1 , Mary B. Leonard 2 , Babette S.<br />
Zemel 2 , Harjeet Sembhi 2 , Jon M. Burnham 2 . 1 University of<br />
Pennsylvania School of Medicine, Philadelphia, PA; 2 The<br />
Children’s Hospital of Philadelphia, Philadelphia, PA<br />
Noon<br />
2178. The Long-Term Outcome of Juvenile Idiopathic<br />
Inflammatory Myopathies: A Multicenter, Multinational Study<br />
of 557 Patients. Lucia Trail 1 , Nicolino Ruperto 1 , Clarissa<br />
Pilkington 2 , Sue Maillard 3 , Elena Sala 1 , Sheila Oliveira 4 ,<br />
Ruben Cuttica 5 , Enrico Felici 1 , Ruben Burgos-Vargas 6 ,<br />
Vicente Baca 6 , Eunice Solis-Vallejo 7 , Silvia Magni-<br />
Manzoni 8 , Matilde Beltramelli 9 , Federica Rossi 1 , Claudia<br />
Saad Magalhães 10 , Francesco Zulian 11 , Marcia Bandeira 12 ,<br />
Maria Alessio 13 , Loredana Lepore 14 , Fernanda Falcini 15 ,<br />
Rosanna Podda 16 , Maria Giannina Alpigiani 1 , Roberto<br />
Barcellona 17 , Alberto Martini 1 , Angelo Ravelli 1 . 1 IRCCS G<br />
Gaslini, Genova, Italy; 2 Great Ormond St Hospital for Sick<br />
Children, London, United Kingdom; 3 JDRC-Institute of<br />
Child Health, London, United Kingdom; 4 Universidade<br />
Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 5 Hospital<br />
General de Ninos Pedro de Elizalde, Buenos Aires,<br />
Argentina; 6 Hospital General de México, Mexico City,<br />
Mexico; 7 Center Medical National La Raza, Mexico City,<br />
Mexico; 8 IRCCS Policlinico San Matteo, Pavia, Italy;<br />
9<br />
Clinica Pediatrica De Marchi, Milan, Italy; 10 Hospital das<br />
Clínicas - Faculdade de Medicina de Botucatu, UNESP,<br />
Botucatu, Brazil; 11 Clinica Pediatrica I, Padua, Italy;<br />
12<br />
Hospital Pequeno Principe, Curitiba Parana, Brazil;<br />
13<br />
Universita’ di Napoli Federico II, Naples, Italy; 14 IRCCS<br />
Burlo Garofolo, Trieste, Italy; 15 Azienda ospedaliera Meyer,<br />
Florence, Italy; 16 Ospedale Regionale Microcitemia, Cagliari,<br />
Italy; 17 Azienda Ospedaliera, Sciacca (AG), Italy<br />
12:15 p m<br />
2179. Register for Pediatric Patients with Antiphospholipid<br />
Syndrome: Clinical and Immunological Features of 107<br />
Children. T. Avcin 1 , R. Cimaz 2 , E. D. Silverman 3 ,<br />
R. Cervera 4 , M. Gattorno 5 , S. Garay 6 , Y. Berkun 7 , F.<br />
Sztajnbok 8 , C. A. Silva 9 , L. M. Campos 9 , C. S. Magalhaes 10 ,<br />
A. Ravelli 5 , A. Martini 5 , B. Rozman 1 , P. L. Meroni 11 .<br />
1<br />
University Children’s Hospital, Ljubljana, Slovenia; 2 Meyer<br />
Hospital, Florence, Italy; 3 The Hospital for Sick Children,<br />
Toronto, ON, Canada; 4 Hospital Clinic, Barcelona, Spain;<br />
5<br />
Istituto G. Gaslini, Genoa, Italy; 6 Hospital Sor Maria<br />
Ludovica, La Plata, Australia; 7 Safra Children’s Hospital,<br />
Tel-Hashomer, Israel; 8 Universidade do Estado do Rio de<br />
Janeiro, Rio de Janeiro, Brazil; 9 University of Sao Paulo, Sao<br />
Paulo, Brazil; 10 Faculdade de Medicina de Botucatu, Sao<br />
Paulo, Brazil; 11 University of Milan, Milan, Italy<br />
<strong>ACR</strong> Concurrent Abstract Session<br />
11:00 a m—12:30 p m<br />
Room 253<br />
Predictors of Disease Severity and RA Treatment<br />
Response (Abstracts #2180-2185)<br />
Moderators:<br />
Joan Bathon, MD; Johns Hopkins University; Baltimore, MD<br />
Arthur F. Kavanaugh, MD; University of California–San<br />
Diego; San Diego, CA<br />
11:00 a m<br />
2180. MRI Bone Oedema is the Strongest Predictor of Subsequent<br />
Radiographic Progression in Early RA. Results from a 2 Year<br />
Randomized Controlled Trial (CIMESTRA). Merete Lund<br />
Hetland, Bo Ejbjerg, Mikkel Østergaard, Søren Jacobsen,<br />
Aage Vestergaard, Anne Grethe Jurik, Kristian Stengaard-<br />
Pedersen, Peter Junker, Tine Lottenburger, Ib Hansen,<br />
Lis Smedegaard Andersen, Ulrik Tarp, Henrik Skjødt,<br />
Jens Kristian Pedersen, Ole Majgaard, Anders J. Svendsen,<br />
Torkell Ellingsen, Gert Hansen, Hanne Lindegaard,<br />
Jørgen Vallø, Trine Torfing, Henrik S. Thomsen, Kim<br />
Hørslev-Petersen. University Hospitals, Copenhagen, South-<br />
Denmark and Århus, Denmark<br />
11:15 a m<br />
2181. A Genome-Wide SNP Chip Analysis Revealed Genes<br />
Regulating the Severity of Rheumatoid Arthritis. Tsukasa<br />
Matsubara 1 , Keiko Funahashi 1 , Sayumi Toriyama 2 , Masaaki<br />
Muramatsu 2 , Mitsuru Emi 2 , Satoru Koyano 2 . 1 Research<br />
Institute of Joint Disease, Kobe, Japan; 2 HuBit Genomix,<br />
Inc., Tokyo, Japan<br />
11:30 a m<br />
2182. Diagnostic and Prognostic Accuracy of Anti-Cyclic<br />
Citrullinated Peptide Antibody and Rheumatoid Factor for Early<br />
Rheumatoid Arthritis. A Meta-Analysis. Kunihiro Nishimura 1 ,<br />
Daisuke Sugiyama 2 , Akio Morinobu 2 , Schunichi Kumagai 2 .<br />
1<br />
Kobe University/ Harvard School of Public Health, Kobe,<br />
Japan; 2 Kobe University, Kobe, Japan<br />
sunday<br />
All sessions are in the Boston Convention and Exhibition Center unless otherwise noted.<br />
293
11:45 a m<br />
2183. Serum Cytokine Profiles Identify a Subset of Patients<br />
with Early Inflammatory Arthritis Responsive to Early DMARD<br />
Therapy. Carol A. Hitchon 1 , Thuan Nguyen 2 , Adarshdip<br />
Brar 1 , Keng Wong 1 , Nicholas Knowlton 2 , Michael Centola 2 ,<br />
Hani S. El-Gabalawy 1 . 1 University of Manitoba, Winnipeg,<br />
MB, Canada; 2 Oklahoma Medical Research Foundation,<br />
Oklahoma City, OK<br />
Noon<br />
2184. The Association of Cigarette Smoking with Disease<br />
Characteristics in African <strong>American</strong>s with Early Rheumatoid<br />
Arthritis. Ted R. Mikuls 1 , Laura B. Hughes 2 , Andrew<br />
O. Westfall 2 , George Howard 2 , Graciela S. Alarcón 2 , V.<br />
M. Holers 3 , Doyt L. Conn 4 , Edwin A. Smith 5 , Gary S.<br />
Gilkeson 5 , Desiree van der Heijde 6 , Beth Jonas 7 , Leigh<br />
F. Callahan 7 , S. L. Bridges, Jr 2 . 1 University of Nebraska<br />
Medical Center, Omaha, NE; 2 University of Alabama at<br />
Birmingham, Birmingham, AL; 3 University of Colorado,<br />
Denver, CO; 4 Emory University, Atlanta, GA; 5 Medical<br />
University of South Carolina, Charleston, SC; 6 Leiden<br />
University, Leiden, The Netherlands; 7 University of North<br />
Carolina, Chapel Hill, NC<br />
12:15 p m<br />
2185. High 10-year Cardiovascular Risk in Newly Diagnosed<br />
Rheumatoid Arthritis (RA) Patients. Hilal Maradit Kremers,<br />
Cynthia S. Crowson, Terry M. Therneau, Veronique L.<br />
Roger, Sherine E. Gabriel. Mayo Clinic, Rochester, MN<br />
<strong>ACR</strong> Industry-Supported Post-Conference Symposia<br />
1:00—4:00 p m<br />
Various Locations<br />
The <strong>ACR</strong> is pleased to present the Industry-Supported Post-<br />
Conference Symposia. We invite you to visit the supporting<br />
organization’s booth for more information. The sponsoring<br />
organization is responsible for planning and providing CME<br />
credit for their respective symposium.<br />
Refer to page 296–301 for complete program information.<br />
sunday<br />
294<br />
= Recorded Sessions (order form on page 430)
www.rheumatology.org—Rheumatology’s Home on the Web 295
Industry-Supported Post-Conference Symposia<br />
1:00 – 4:00 p m<br />
Boston Convention & Exhibition Center,<br />
Room 107 A-B-C<br />
The Prevention and Management of Infections in Patients<br />
Receiving TNF Inhibitors<br />
Sponsored by the University of Texas Southwestern Medical Center<br />
at Dallas<br />
Supported by an educational grant from Abbott Laboratories,<br />
Centocor, Inc. and Wyeth Pharmaceuticals<br />
PHYSICIAN ACCREDITATION<br />
The University of Texas Southwestern Medical Center<br />
at Dallas is accredited by the Accreditation Council for<br />
Continuing Medical Education (ACCME) to sponsor<br />
continuing medical education for physicians.<br />
CREDIT DESIGNATION<br />
The University of Texas Southwestern Medical Center at<br />
Dallas designates this educational activity for a maximum<br />
of 1.75 AMA PRA Category 1 Credit(s) TM . Physicians should<br />
only claim credit commensurate with the extent of their<br />
participation in the activity.<br />
LEARNING OBJECTIVES<br />
Upon completion of this session, the participants should be able to:<br />
∙ Identify infectious risks that accompany rheumatoid<br />
arthritis and other rheumatic diseases<br />
∙ Assess the potential risk of bacterial infections in patients<br />
treated with TNF inhibitors<br />
∙ Recognize the measures needed to reduce risk of infection<br />
in patients receiving TNF inhibitors<br />
∙ Interpret guidelines for the screening, prevention and<br />
treatment of mycobacterial infections in patients on<br />
TNF inhibitors<br />
∙ Utilize recently proposed guidelines for the prevention and<br />
management of infections in TNF inhibitor treated patients<br />
1:00 p m<br />
Registration and Lunch<br />
1:30 p m<br />
Introductions<br />
1:35 p m<br />
Are Bacterial Infections Increased in Patients Receiving<br />
TNF Inhibitors<br />
Arthur Kavanaugh, MD; University of California, San<br />
Diego School of Medicine; San Diego, CA<br />
1:55 p m<br />
Managing Common and Non-Serious Infections in<br />
Patients Receiving TNF Inhibitors<br />
John Cush, MD; University of Texas Southwestern Medical<br />
Center; Dallas, TX<br />
2:10 p m<br />
Avoiding and Treating Serious Infections in Patients<br />
on TNF Inhibitors<br />
Edward Keystone, MD; University of Toronto; Toronto, Ontario<br />
2:30 p m<br />
Screening Prevention and Management of Mycobacterial<br />
Infections When Using TNF Inhibitors<br />
Jerrold Ellner, MD; New Jersey Medical School; Newark, NJ<br />
2:50 p m<br />
Evidence Based Guidelines for the Prevention and<br />
Management of Infections in Patients Receiving TNF<br />
Inhibitors: Results of an Expert Consensus Panel 2006<br />
John Cush, MD; University of Texas Southwestern Medical<br />
Center; Dallas, TX<br />
3:00 p m<br />
Questions & Answers<br />
PC Symposia<br />
296<br />
Sunday, November 11, <strong>2007</strong>
Industry-Supported Post-Conference Symposia<br />
1:00 – 4:00 p m<br />
Westin Boston Waterfront, Grand Ballroom B<br />
Practical Approaches to Vascular Complications in<br />
Systemic Sclerosis (SSc)<br />
Sponsored by Medical Education Resources<br />
Supported by an educational grant from Actelion Pharmaceuticals<br />
U.S., Inc.<br />
PHYSICIAN ACCREDITATION<br />
Medical Education Resources is accredited by the Accreditation<br />
Council for Continuing Medical Education (ACCME) to<br />
sponsor continuing medical education for physicians.<br />
CREDIT DESIGNATION<br />
Medical Education Resources designates this educational<br />
activity for a maximum of 2 AMA PRA Category 1 Credit(s).<br />
Physicians should only claim credit commensurate with the<br />
extent of their participation in the activity.<br />
LEARNING OBJECTIVES<br />
Upon completion of this session, the participants should be able to:<br />
∙ Identify vasculopathies associated with systemic sclerosis<br />
(SSc), describe pathogenic pathways, and delineate clinical<br />
corollaries including potential treatment targets<br />
∙ Define key components of effective early diagnosis<br />
of pulmonary complications secondary to SSc, and<br />
implement critical risk assessment<br />
∙ Evaluate current strategies for early intervention in PAH<br />
and assess related new clinical trial evidence<br />
∙ Establish long-term goals and determine the potential utility<br />
of emerging combination treatment paradigms in PAH<br />
1:00 p m<br />
Registration and Lunch<br />
1:30 p m<br />
Welcome and Introduction<br />
Richard M. Silver, MD; Medical University of South<br />
Carolina; Charleston, SC<br />
1:35 p m<br />
Vasculopathies in Scleroderma: Basic Science Update<br />
and Clinical Corollaries<br />
Robert W. Simms, MD; Boston University School of<br />
Medicine; Boston, MA<br />
2:00 p m<br />
Early Diagnosis and Critical Risk Assessment in<br />
SSc-related Lung Complications<br />
Kristin B. Highland, MD; Medical University of South<br />
Carolina; Charleston, SC<br />
2:25 p m<br />
Early Intervention in PAH: Current Strategies and New<br />
Clinical Trial Evidence<br />
Richard N. Channick, MD, FCCP; UCSD Medical Center,<br />
La Jolla; La Jolla, CA<br />
2:50 p m<br />
Long-term Goals and Emerging Combination Treatment<br />
Paradigms in PAH<br />
Myung H. Park, MD, FACC; University of Maryland<br />
Medical Center; Baltimore, MD<br />
3:15 p m<br />
Panel Discussion<br />
3:25 p m<br />
Concluding Remarks<br />
Richard M. Silver, MD; Medical University of South<br />
Carolina; Charleston, SC<br />
PC Symposia<br />
CME credit for Industry-Supported Symposia provided by sponsor listed.<br />
297
Industry-Supported Post-Conference Symposia<br />
1:00 – 4:00 p m<br />
Westin Boston Waterfront, Commonwealth A-C<br />
Osteoarthritis and Synovitis: The Link Between<br />
Pathogenesis, Detection and Treatment<br />
Sponsored by Vindico Medical Education<br />
Supported by an educational grant from Bioiberica<br />
PHYSICIAN ACCREDITATION<br />
Vindico Medical Education is accredited by the Accreditation<br />
Council for Continuing Medical Education (ACCME) to<br />
provide continuing medical education for physicians.<br />
CREDIT DESIGNATION<br />
Vindico Medical Education designates this educational<br />
activity for a maximum of 2 AMA PRA Category 1 Credit(s).<br />
Physicians should only claim credit commensurate with the<br />
extent of their participation in the activity.<br />
LEARNING OBJECTIVES<br />
Upon completion of this session, the participants should be able to:<br />
∙ Review the pathophysiology of synovitis and osteoarthritis<br />
∙ Evaluate new imaging modalities for the diagnosis and<br />
tracking of the progression of osteoarthritis<br />
∙ Discuss effective treatment and management options for<br />
osteoarthritis and synovitis<br />
∙ Evaluate recent clinical trial data on therapeutic advances<br />
and modalities for treatment and management of<br />
osteoarthritis, including glucosamine and<br />
chondroitin sulfate<br />
1:00 p m<br />
Registration and Lunch<br />
1:30 p m<br />
Introduction<br />
Roland Moskowitz, MD; Case Western University;<br />
Cleveland, OH<br />
1:45 p m<br />
Pathophysiology of Osteoarthritis and Synovitis<br />
Warren Katz, MD; Boston University; Boston, MA<br />
2:00 p m<br />
Imaging of Osteoarthritis and Synovitis<br />
Philip Conaghan, MD, PhD; University of Leeds;<br />
Leeds, England<br />
2:15 p m<br />
Current Therapies for Osteoarthritis and Synovitis:<br />
Examining Recent Data<br />
Roland Moskowitz, MD; Case Western Reserve University;<br />
Cleveland, OH<br />
2:30 p m<br />
Pharmacology of Chondroitin Sulfate<br />
Carmelita Frondoza, MD; Johns Hopkins University;<br />
Baltimore, MD<br />
2:45 p m<br />
Clinical Review of Chondroitin Sulfate and Glucosamine<br />
in Osteoarthritis<br />
Patrick du Souich, MD, PhD; University of Montreal;<br />
Quebec, Canada<br />
3:00 p m<br />
Case Studies<br />
Steven Abramson, MD; New York University School of<br />
Medicine; New York, NY<br />
3:15 p m<br />
Questions & Answers<br />
PC Symposia<br />
298<br />
Sunday, November 11, <strong>2007</strong>
Industry-Supported Post-Conference Symposia<br />
1:00 – 4:00 p m<br />
Boston Convention & Exhibition Center,<br />
Room 52 B<br />
New Approaches to Understanding, Diagnosing, and<br />
Treating Fibromyalgia<br />
Sponsored by the University of Kentucky<br />
Supported by an educational grant from Forest Research Institute<br />
PHYSICIAN ACCREDITATION<br />
The University of Kentucky College of Medicine is<br />
accredited by the Accreditation Council for Continuing<br />
Medical Education (ACCME) to sponsor continuing<br />
medical education for physicians.<br />
CREDIT DESIGNATION<br />
The University of Kentucky College of Medicine<br />
designates this educational activity for a maximum of<br />
1.5 AMA PRA Category 1 Credit(s). Physicians should<br />
only claim credit commensurate with the extent of their<br />
participation in the activity.<br />
LEARNING OBJECTIVES<br />
Upon completion of this session, the participants should be able to:<br />
∙ Discuss new understandings of FMS, particularly CNS<br />
mechanisms underlying fibromyalgia<br />
∙ Utilize current approaches to diagnosis of FMS<br />
∙ Evaluate current and emerging pharmacologic treatments<br />
for patients with FMS<br />
∙ Design and implement effective multimodal management<br />
strategies for patients with FMS<br />
1:00 p m<br />
Registration and Lunch<br />
1:30 p m<br />
Welcome and Introductions<br />
1:35 p m<br />
Characterizing and Diagnosing FMS<br />
Daniel J. Clauw, MD; University of Michigan Medical<br />
Center; Ann Arbor, MI<br />
1:55 p m<br />
New Understandings of mechanisms Underlying FMS<br />
Don L. Goldenberg, MD; Tufts University School of<br />
Medicine; Boston, MA<br />
2:20 p m<br />
Multimodal Treatment of FMS<br />
Lee S. Simon, MD; Harvard Medical School; Boston, MA<br />
2:40 p m<br />
Questions & Answers<br />
PC Symposia<br />
CME credit for Industry-Supported Symposia provided by sponsor listed.<br />
299
Industry-Supported Post-Conference Symposia<br />
1:00 – 4:00 p m<br />
Westin Boston Waterfront, Grand Ballroom A<br />
Pulmonary Arterial Hypertension in Connective<br />
Tissue Disease: Current Concepts in Pathophysiology,<br />
Recognition and Treatment Stratagems<br />
Sponsored by education / outcomes / science<br />
Supported by an educational grant from Gilead Sciences<br />
Medical Affairs<br />
PHYSICIAN ACCREDITATION<br />
education / outcomes / science is accredited by the<br />
Accreditation Council for Continuing Medical Education<br />
(ACCME) to sponsor continuing medical education<br />
for physicians.<br />
CREDIT DESIGNATION<br />
education | outcomes | science will designate this educational<br />
activity for a maximum of 2 AMA PRA Category 1 Credit(s) TM .<br />
Physicians should only claim credit commensurate with the<br />
extent of their participation in the activity.<br />
LEARNING OBJECTIVES<br />
Upon completion of this session, the participants should be able to:<br />
∙ Describe new understandings of the pathogenesis of<br />
PAH associated with connective tissues disease, including<br />
diasolic dysfunction and endothelial dysfunction<br />
∙ Compare the efficacy and sensitivity of diagnostic tools of<br />
PAH in patients with connective tissue diseases<br />
∙ Understand the critical role of rheumatologists in<br />
initiating screening for, and early treatment of, PAH in<br />
patients with connective tissue disease<br />
∙ Differentiate the efficacy and safety profiles in the<br />
endothelin receptor antagonists armamentarium<br />
1:00 p m<br />
Registration and Lunch<br />
1:30 p m<br />
Welcome and Overview<br />
Daniel Furst, MD; David Geffen School of Medicine at<br />
UCLA; Los Angeles, CA<br />
1:35 p m<br />
The Pathogenesis of Pulmonary Arterial Hypertension<br />
Associated with Connective Tissue Disease: The Biological<br />
Basis for Early Intervention<br />
Robyn Barst, MD; Columbia University Medical Center;<br />
New York, NY<br />
2:00 p m<br />
Raising the Index of Suspicion of Pulmonary Arterial<br />
Hypertension in Patients with Connective Tissues Diseases<br />
James Seibold, MD; University of Michigan Medical School;<br />
Ann Arbor, MI<br />
2:25 p m<br />
Case Studies in the Diagnosis of PAH in Patients with<br />
Connective Tissue Disease<br />
Daniel Furst, MD; David Geffen School of Medicine at<br />
UCLA; Los Angeles, CA<br />
2:50 p m<br />
The Efficacy and Safety Profiles of Endothelin Receptor<br />
Antagonists in Slowing the Progression of Pulmonary<br />
Arterial Hypertension<br />
Adaani Frost, MD; Baylor College of Medicine; Houston, TX<br />
3:15 p m<br />
Questions & Answers<br />
Faculty Panel<br />
3:25 p m<br />
Concluding Remarks<br />
Daniel Furst, MD; David Geffen School of Medicine at<br />
UCLA; Los Angeles, CA<br />
PC Symposia<br />
300<br />
Sunday, November 11, <strong>2007</strong>
Industry-Supported Post-Conference Symposia<br />
1:00 – 4:00 p m<br />
Boston Convention & Exhibition Center,<br />
Room 160 A-B-C<br />
Opioid Analgesia in Patients With Rheumatologic<br />
Disorders: Strategies for Optimizing Analgesia and<br />
Minimizing Risk<br />
Sponsored by The Johns Hopkins University School of Medicine<br />
Supported by an educational grant from King Pharmaceuticals, Inc.<br />
PHYSICIAN ACCREDITATION<br />
The Johns Hopkins University School of Medicine is<br />
accredited by the Accreditation Council for Continuing<br />
Medical Education (ACCME) to sponsor continuing<br />
medical education for physicians.<br />
CREDIT DESIGNATION<br />
The Johns Hopkins University School of Medicine<br />
designates this educational activity for a maximum of<br />
1 AMA PRA Category 1 Credit(s). Physicians should<br />
only claim credit commensurate with the extent of their<br />
participation in the activity.<br />
LEARNING OBJECTIVES<br />
Upon completion of this session, the participants should be able to:<br />
∙ Identify patients who are appropriate candidates for<br />
opioid therapy<br />
∙ Discuss comprehensive assessment and treatment plans<br />
including risk management strategies for patients initiating<br />
an opioid regimen<br />
∙ Develop appropriate strategies for individualizing and<br />
monitoring adherence of opioid regimens to improve pain<br />
management outcomes and minimize risk<br />
∙ Evaluate investigational abuse-deterrent opioid formulations<br />
and discuss their potential utility in treatment of chronic<br />
non-cancer pain<br />
1:00 p m<br />
Registration & Lunch<br />
1:30 p m<br />
Introduction & Overview of Painful Rheumatologic<br />
Disorders and Their Current Management<br />
Joseph Markenson, MD; Weill Medical College of Cornell<br />
University; New York, NY<br />
1:45 p m<br />
When is Opioid Therapy Appropriate for<br />
Rheumatologic Disorders?<br />
Charles Argoff, MD; New York University School of<br />
Medicine; New York, NY<br />
2:05 p m<br />
Aberrant Drug-Taking Behaviors During Pain Management:<br />
What Do We Really Know and How Can We Address<br />
the Problem?<br />
Steven Passick, PhD; Weill Medical College of Cornell<br />
University; New York, NY<br />
2:30 p m<br />
Questions & Answers<br />
PC Symposia<br />
CME credit for Industry-Supported Symposia provided by sponsor listed.<br />
301
Boston Convention and exhibition Center:<br />
Exhibit Hall<br />
302 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!<br />
529-540<br />
541-552<br />
517-528<br />
505-516<br />
492-504<br />
478-491<br />
464-477<br />
457-463 229-240<br />
241-246<br />
217-228<br />
204-216<br />
190-203<br />
176-189<br />
162-175<br />
148-161<br />
141-147<br />
134-140<br />
445-456<br />
423-444<br />
401-422<br />
377-400<br />
353-376<br />
329-352<br />
305-328<br />
283-304<br />
259-282<br />
247-258<br />
B1<br />
B1<br />
B1<br />
A1<br />
EAST REGISTRATION<br />
HALL B<br />
SE LOBBY C<br />
SE LOBBY B2<br />
NE LOBBY B1<br />
(258)<br />
(259)<br />
(257)<br />
(260)<br />
(256)<br />
(261)<br />
(255)<br />
(262)<br />
(254)<br />
(263)<br />
(253)<br />
(264)<br />
(252)<br />
(265)<br />
(251)<br />
(266)<br />
(250)<br />
(267)<br />
(249)<br />
(268)<br />
(248)<br />
(269)<br />
(247)<br />
(270)<br />
(282)<br />
(281)<br />
(283)<br />
(280)<br />
(284)<br />
(279)<br />
(284)<br />
(278)<br />
(286)<br />
(277)<br />
(287)<br />
(276)<br />
(288)<br />
(275)<br />
(289)<br />
(274)<br />
(273)<br />
(290)<br />
(272)<br />
(291)<br />
(271)<br />
(292)<br />
(304)<br />
(305)<br />
(303)<br />
(306)<br />
(302)<br />
(307)<br />
(301)<br />
(308)<br />
(300)<br />
(309)<br />
(299)<br />
(310)<br />
(298)<br />
(311)<br />
(297)<br />
(312)<br />
(296)<br />
(313)<br />
(295)<br />
(314)<br />
(294)<br />
(315)<br />
(293)<br />
(316)<br />
(328)<br />
(329)<br />
(327)<br />
(330)<br />
(326)<br />
(331)<br />
(325)<br />
(332)<br />
(324)<br />
(333)<br />
(323)<br />
(334)<br />
(322)<br />
(335)<br />
(321)<br />
(336)<br />
(320)<br />
(337)<br />
(319)<br />
(338)<br />
(318)<br />
(339)<br />
(317)<br />
(340)<br />
(352)<br />
(353)<br />
(351)<br />
(354)<br />
(350)<br />
(355)<br />
(349)<br />
(356)<br />
(348)<br />
(357)<br />
(347)<br />
(358)<br />
(346)<br />
(359)<br />
(345)<br />
(360)<br />
(344)<br />
(361)<br />
(343)<br />
(362)<br />
(342)<br />
(363)<br />
(341)<br />
(364)<br />
(376)<br />
(377)<br />
(375)<br />
(378)<br />
(374)<br />
(379)<br />
(373)<br />
(380)<br />
(372)<br />
(381)<br />
(371)<br />
(382)<br />
(370)<br />
(383)<br />
(369)<br />
(384)<br />
(368)<br />
(385)<br />
(367)<br />
(386)<br />
(366)<br />
(387)<br />
(365)<br />
(388)<br />
(400)<br />
(401)<br />
(399)<br />
(402)<br />
(398)<br />
(403)<br />
(397)<br />
(404)<br />
(396)<br />
(405)<br />
(395)<br />
(406)<br />
(394)<br />
(407)<br />
(393)<br />
(408)<br />
(392)<br />
(409)<br />
(391)<br />
(410)<br />
(390)<br />
(411)<br />
(389)<br />
(412)<br />
(422)<br />
(423)<br />
(421)<br />
(424)<br />
(420)<br />
(425)<br />
(419)<br />
(426)<br />
(418)<br />
(427)<br />
(417)<br />
(428)<br />
(416)<br />
(429)<br />
(415)<br />
(430)<br />
(414)<br />
(431)<br />
(413)<br />
(432)<br />
(444)<br />
(445)<br />
(443)<br />
(446)<br />
(442)<br />
(447)<br />
(441)<br />
(448)<br />
(440)<br />
(449)<br />
(439)<br />
(450)<br />
(438)<br />
(451)<br />
(437)<br />
(452)<br />
(436)<br />
(453)<br />
(435)<br />
(454)<br />
(434)<br />
(455)<br />
(433)<br />
(456)<br />
(13<br />
(134)<br />
(13<br />
(135)<br />
(13<br />
(136)<br />
(13<br />
(137)<br />
(12<br />
(138)<br />
(12<br />
(139)<br />
(12<br />
(140)<br />
(147)<br />
(148)<br />
(146)<br />
(149)<br />
(145)<br />
(150)<br />
(143)<br />
(152)<br />
(142)<br />
(153)<br />
(141)<br />
(154)<br />
(161)<br />
(162)<br />
(160)<br />
(163)<br />
(159)<br />
(164)<br />
(157)<br />
(166)<br />
(156)<br />
(167)<br />
(155)<br />
(168)<br />
(175)<br />
(176)<br />
(174)<br />
(177)<br />
(173)<br />
(178)<br />
(172)<br />
(179)<br />
(171)<br />
(180)<br />
(170)<br />
(181)<br />
(169)<br />
(182)<br />
(189)<br />
(190)<br />
(188)<br />
(191)<br />
(187)<br />
(192)<br />
(186)<br />
(193)<br />
(185)<br />
(194)<br />
(184)<br />
(195)<br />
(183)<br />
(196)<br />
(203)<br />
(204)<br />
(202)<br />
(205)<br />
(201)<br />
(206)<br />
(199)<br />
(208)<br />
(198)<br />
(209)<br />
(197)<br />
(210)<br />
(216)<br />
(217)<br />
(215)<br />
(218)<br />
(214)<br />
(219)<br />
(213)<br />
(220)<br />
(211)<br />
(222)<br />
(228)<br />
(229)<br />
(227)<br />
(230)<br />
(226)<br />
(231)<br />
(225)<br />
(232)<br />
(223)<br />
(234)<br />
(240)<br />
(241)<br />
(239)<br />
(242)<br />
(238)<br />
(243)<br />
(236)<br />
(245)<br />
(235)<br />
(246)<br />
(55<br />
(547)<br />
(55<br />
(549)<br />
(55<br />
(550)<br />
(55<br />
(551)<br />
(55<br />
(552)<br />
(546)<br />
(535)<br />
(544)<br />
(537)<br />
(543)<br />
(538)<br />
(542)<br />
(539)<br />
(541)<br />
(540)<br />
(534)<br />
(523)<br />
(532)<br />
(525)<br />
(530)<br />
(527)<br />
(529)<br />
(528)<br />
(522)<br />
(511)<br />
(520)<br />
(513)<br />
(519)<br />
(514)<br />
(518)<br />
(515)<br />
(517)<br />
(516)<br />
(510)<br />
(499)<br />
(509)<br />
(500)<br />
(507)<br />
(502)<br />
(506)<br />
(503)<br />
(505)<br />
(504)<br />
(498)<br />
(485)<br />
(497)<br />
(486)<br />
(496)<br />
(487)<br />
(494)<br />
(489)<br />
(493)<br />
(490)<br />
(492)<br />
(491)<br />
(484)<br />
(471)<br />
(483)<br />
(472)<br />
(482)<br />
(473)<br />
(481)<br />
(474)<br />
(480)<br />
(475)<br />
(479)<br />
(476)<br />
(478)<br />
(477)<br />
(470)<br />
(457)<br />
(469)<br />
(458)<br />
(468)<br />
(459)<br />
(467)<br />
(460)<br />
(466)<br />
(461)<br />
(465)<br />
(462)<br />
(464)<br />
(463)<br />
(158)<br />
(165)<br />
(200)<br />
(207)<br />
(212)<br />
(221)<br />
(224)<br />
(233)<br />
(237)<br />
(244)<br />
(55<br />
(548)<br />
(545)<br />
(536)<br />
(533)<br />
(524)<br />
(521)<br />
(512)<br />
(508)<br />
(501)<br />
(495)<br />
(488)<br />
Exhibitor<br />
Lounge<br />
Brede ServiceDesk<br />
EXIT<br />
EXIT<br />
(144)<br />
(151)<br />
(531)<br />
(526)<br />
1066 1064 1062 1060 1058<br />
1072 1070<br />
151<br />
159<br />
167<br />
173<br />
175<br />
177<br />
179<br />
Eli Lilly<br />
and Company<br />
Eli Lilly<br />
and Company<br />
272<br />
274<br />
275<br />
276<br />
349<br />
358<br />
371<br />
373<br />
375<br />
377<br />
379<br />
449<br />
459<br />
463<br />
467<br />
469<br />
470<br />
474<br />
475<br />
476<br />
478<br />
54<br />
558<br />
559<br />
560<br />
562<br />
564<br />
566<br />
567<br />
Pfizer<br />
570<br />
573<br />
575<br />
577<br />
579<br />
64<br />
64<br />
651<br />
666<br />
667<br />
668<br />
669<br />
670<br />
671<br />
672<br />
673<br />
674<br />
675<br />
676<br />
677<br />
678<br />
679<br />
74<br />
74<br />
759<br />
761<br />
765<br />
766<br />
767<br />
768<br />
770<br />
771<br />
772<br />
773<br />
774<br />
775<br />
776<br />
777<br />
778<br />
779<br />
84<br />
850<br />
858<br />
859<br />
860<br />
862<br />
863<br />
865<br />
864<br />
866<br />
870<br />
871<br />
872<br />
874<br />
876<br />
877<br />
878<br />
94<br />
949<br />
958<br />
959<br />
960<br />
961<br />
962<br />
963<br />
964<br />
965<br />
967<br />
970<br />
971<br />
973<br />
977<br />
1<br />
P<br />
2<br />
3<br />
4<br />
5<br />
6<br />
8<br />
9<br />
10<br />
11<br />
12<br />
13<br />
14<br />
15<br />
16<br />
17<br />
CMR<br />
Hardwall<br />
Office<br />
Group<br />
Hardwall<br />
Office<br />
Briefcase/Material<br />
Pick-Up<br />
7<br />
11a<br />
11b<br />
972
www.rheumatology.org—Rheumatology’s Home on the Web 303<br />
Clinical Trials<br />
658-664<br />
644-657<br />
630-643<br />
616-629<br />
602-615<br />
589-601<br />
577-588<br />
565-576<br />
553-564<br />
541-552<br />
141-147<br />
134-140<br />
120-133<br />
106-119<br />
92-105<br />
78-91<br />
64-77<br />
50-63<br />
36-49<br />
22-35<br />
8-21<br />
1-7<br />
HALLA<br />
NE LOBBY A<br />
NE LOBBY B1<br />
(7)<br />
(8)<br />
(6)<br />
(9)<br />
(5)<br />
(10)<br />
(4)<br />
(11)<br />
(3)<br />
(12)<br />
(2)<br />
(13)<br />
(14) (1)<br />
(21)<br />
(22)<br />
(20)<br />
(23)<br />
(19)<br />
(24)<br />
(18)<br />
(25)<br />
(17)<br />
(26)<br />
(16)<br />
(27)<br />
(15)<br />
(28)<br />
(35)<br />
(36)<br />
(34)<br />
(33)<br />
(37)<br />
(38)<br />
(31)<br />
(40)<br />
(30)<br />
(41)<br />
(29)<br />
(42)<br />
(49)<br />
(50)<br />
(48)<br />
(51)<br />
(47)<br />
(52)<br />
(46)<br />
(53)<br />
(45)<br />
(54)<br />
(44)<br />
(55)<br />
(43)<br />
(56)<br />
(63)<br />
(64)<br />
(62)<br />
(65)<br />
(61)<br />
(66)<br />
(60)<br />
(67)<br />
(59)<br />
(68)<br />
(58)<br />
(69)<br />
(57)<br />
(70)<br />
(77)<br />
(78)<br />
(76)<br />
(79)<br />
(73)<br />
(82)<br />
(72)<br />
(83)<br />
(71)<br />
(84)<br />
(91)<br />
(92)<br />
(90)<br />
(93)<br />
(89)<br />
(94)<br />
(88)<br />
(95)<br />
(87)<br />
(96)<br />
(86)<br />
(97)<br />
(85)<br />
(98)<br />
(105)<br />
(106)<br />
(104)<br />
(107)<br />
(103)<br />
(108)<br />
(102)<br />
(109)<br />
(101)<br />
(110)<br />
(100)<br />
(111)<br />
(99)<br />
(112)<br />
(119)<br />
(120)<br />
(118)<br />
(121)<br />
(115)<br />
(124)<br />
(114)<br />
(125)<br />
(113)<br />
(126)<br />
(133)<br />
(134)<br />
(132)<br />
(135)<br />
(131)<br />
(136)<br />
(130)<br />
(137)<br />
(129)<br />
(138)<br />
(128)<br />
(139)<br />
(127)<br />
(140)<br />
(147)<br />
(148)<br />
(146)<br />
(149)<br />
(145)<br />
(150)<br />
(143)<br />
(152)<br />
(142)<br />
(153)<br />
(141)<br />
(154)<br />
(664)<br />
(651)<br />
(663)<br />
(652)<br />
(662)<br />
(653)<br />
(661)<br />
(654)<br />
(660)<br />
(655)<br />
(659)<br />
(656)<br />
(658)<br />
(657)<br />
(650)<br />
(637)<br />
(649)<br />
(638)<br />
(648)<br />
(639)<br />
(646)<br />
(641)<br />
(645)<br />
(642)<br />
(644)<br />
(643)<br />
(636)<br />
(623)<br />
(635)<br />
(624)<br />
(634)<br />
(625)<br />
(633)<br />
(626)<br />
(632)<br />
(627)<br />
(631)<br />
(628)<br />
(630)<br />
(629)<br />
(622)<br />
(609)<br />
(621)<br />
(610)<br />
(620)<br />
(611)<br />
(619)<br />
(612)<br />
(618)<br />
(613)<br />
(617)<br />
(614)<br />
(616)<br />
(615)<br />
(608)<br />
(595)<br />
(607)<br />
(596)<br />
(606)<br />
(597)<br />
(604)<br />
(599)<br />
(603)<br />
(600)<br />
(602)<br />
(601)<br />
(594)<br />
(583)<br />
(593)<br />
(584)<br />
(591)<br />
(586)<br />
(590)<br />
(587)<br />
(589)<br />
(588)<br />
(582)<br />
(571)<br />
(580)<br />
(573)<br />
(579)<br />
(574)<br />
(578)<br />
(575)<br />
(577)<br />
(576)<br />
(570)<br />
(559)<br />
(569)<br />
(560)<br />
(567)<br />
(562)<br />
(566)<br />
(563)<br />
(565)<br />
(564)<br />
(558)<br />
(547)<br />
(556)<br />
(549)<br />
(555)<br />
(550)<br />
(554)<br />
(551)<br />
(553)<br />
(552)<br />
(546)<br />
(535)<br />
(544)<br />
(537)<br />
(543)<br />
(538)<br />
(542)<br />
(539)<br />
(541)<br />
(540)<br />
(32)<br />
(39)<br />
(74)<br />
(81)<br />
(80) (75)<br />
(116)<br />
(123)<br />
(122) (117)<br />
(647)<br />
(640)<br />
(605)<br />
(598)<br />
(592)<br />
(585)<br />
(581)<br />
(572)<br />
(568)<br />
(561)<br />
(557)<br />
(548)<br />
(545)<br />
(536)<br />
EXIT<br />
ENTRANCE<br />
Exhibitor<br />
SuiteD<br />
Exhibitor<br />
SuiteC<br />
Exhibitor<br />
Lounge<br />
(144)<br />
(151)<br />
FOOD COURT<br />
101<br />
062 1060 1058<br />
109<br />
117<br />
123<br />
133<br />
135<br />
137<br />
139<br />
151<br />
59<br />
232<br />
233<br />
Abbott<br />
UCB<br />
Eli Lilly<br />
Company<br />
Eli Lilly<br />
and Company<br />
Smith &<br />
Nephew<br />
Orthopaedics<br />
234<br />
237<br />
239<br />
240<br />
241<br />
301<br />
317<br />
331<br />
332<br />
337<br />
338<br />
349<br />
431<br />
449<br />
459<br />
463<br />
501<br />
507<br />
509<br />
511<br />
513<br />
521<br />
537<br />
549<br />
558<br />
59<br />
560<br />
562<br />
Pfizer<br />
Pfizer<br />
601<br />
606<br />
608<br />
610<br />
614<br />
648<br />
649<br />
651<br />
737<br />
739<br />
741<br />
745<br />
747<br />
748<br />
749<br />
759<br />
761<br />
Genentech<br />
Centocor<br />
801<br />
827<br />
836<br />
838<br />
842<br />
844<br />
845<br />
846<br />
847<br />
848<br />
850<br />
858<br />
859<br />
860<br />
862<br />
863<br />
916<br />
943<br />
944<br />
946<br />
948<br />
949<br />
958<br />
959<br />
960<br />
961<br />
962<br />
963<br />
Exhibitor<br />
SuiteB1<br />
Exhibitor<br />
SuiteB2<br />
Exhibitor<br />
SuiteA<br />
Exhibitor<br />
SuiteB3<br />
Exhibitor<br />
SuiteC3<br />
Boards # 1 - 664<br />
EAST REGISTRATION<br />
SE LOBBY C<br />
SE LOBBY B2<br />
P<br />
3<br />
4<br />
5<br />
6<br />
8<br />
9<br />
10<br />
11<br />
12<br />
13<br />
14<br />
15<br />
16<br />
17<br />
CMR<br />
Hardwall<br />
Office<br />
Group<br />
Hardwall<br />
Office<br />
Briefcase /Material<br />
Pick-Up<br />
7<br />
11a<br />
11b
to Summer<br />
Street<br />
M<br />
W<br />
W M<br />
W M<br />
Boston Convention and exhibition Center:<br />
Street Level<br />
Viaduct<br />
Street<br />
Downtown<br />
Boston<br />
to South<br />
Station<br />
to<br />
Summer<br />
Street<br />
Summer<br />
Street<br />
Bar<br />
C 157 A 156<br />
C 156 Food<br />
Food<br />
109 109 108 107 B<br />
107 106<br />
Tastes of Boston<br />
105 B A C B A<br />
B B A<br />
107 W M<br />
B A C A<br />
Kitchen<br />
Food Court<br />
C<br />
Court<br />
104<br />
Court<br />
Kitchen<br />
Skybridge<br />
Skybridge<br />
Open to<br />
Open to<br />
Exhibit Hall C<br />
Exhibit Hall B<br />
below<br />
below<br />
162 162 161 160 160 160 159 158 157<br />
157<br />
156 155 154 153<br />
104<br />
B<br />
Open to<br />
Exhibit Hall A<br />
below<br />
C 153<br />
B<br />
104<br />
A<br />
153<br />
A<br />
KEY<br />
Restrooms<br />
Escalator<br />
Elevator<br />
103 102 102<br />
B A 101<br />
Business Center<br />
First Aid<br />
152 151<br />
B<br />
151<br />
A 150<br />
W M<br />
North Lobby Entrance<br />
Plaza<br />
W M<br />
to Stop<br />
Crosswalk<br />
Access<br />
The Westin Boston<br />
Waterfront<br />
304 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
Boston Convention and exhibition Center:<br />
Level Two<br />
Downtown<br />
Boston<br />
KEY<br />
Restrooms<br />
Escalator<br />
Elevator<br />
Open to<br />
Exhibit Hall C<br />
below<br />
W<br />
210<br />
C<br />
210<br />
M W<br />
M<br />
213 212 211 (Ballroom 210) 209 208<br />
B<br />
210<br />
A<br />
207<br />
206<br />
B<br />
206<br />
A<br />
205<br />
C<br />
205<br />
B<br />
205<br />
A<br />
204<br />
B<br />
204<br />
A<br />
Skybridge<br />
(Level 1)<br />
Skybridge<br />
(Level 1)<br />
Open to<br />
Exhibit Hall B<br />
below<br />
Open to<br />
Exhibit Hall A<br />
below<br />
261 260 259 259<br />
257 257 256<br />
255 254 254<br />
W M<br />
258 258 258<br />
W<br />
M<br />
253 253 253<br />
252 252<br />
B<br />
A<br />
C<br />
B<br />
A<br />
B<br />
A<br />
B<br />
A<br />
C<br />
B<br />
A<br />
B<br />
A<br />
203<br />
Boardroom<br />
Suite 201,202<br />
Bridge<br />
Lobby<br />
below<br />
East Boardroom<br />
251<br />
Skybridge<br />
Access<br />
The Westin Boston<br />
Waterfront<br />
Plaza<br />
below<br />
www.rheumatology.org—Rheumatology’s Home on the Web 305
M<br />
W<br />
Boston Convention and exhibition Center:<br />
Level Three<br />
Downtown<br />
Boston<br />
KEY<br />
Restrooms<br />
Escalator<br />
Elevator<br />
M<br />
W<br />
Grand<br />
Ballroom<br />
Hotel Access<br />
(Levels 1 & 2)<br />
The Westin Boston<br />
Waterfront<br />
306 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
exhibitor information<br />
Abbott<br />
Pharmaceuticals<br />
Booth # 301 and 507; Suite A<br />
200 Abbott Park Road<br />
Abbott Park, IL 60064<br />
p: 847-9376100 f: 847-938-1160<br />
Actelion Pharmaceuticals<br />
Pharmaceuticals<br />
Booth # 275<br />
5000 Shoreline Court<br />
Suite 200<br />
South San Francisco, CA 94080<br />
p: 650-624-6900 f: 650-952-0991<br />
www.actelion.com<br />
Active Ankle Systems, Inc.<br />
Therapeutic/Patient Aid Products<br />
Booth # 467<br />
233 Quartermaster Court<br />
Jeffersonville, IN 47130<br />
p: 812-258-0663 f: 812-258-0664<br />
www.activeankle.com<br />
Adelphi Group Products<br />
Market Research<br />
Booth # 846<br />
Adelphi Mill, Grimshaw Lane,<br />
Bollington Macclesfied<br />
Cheshire UK SK10 5JB<br />
p: +1625 577220 f: +1625 575853<br />
www.adelphigroup.com<br />
Advanced Bio-Surfaces, Inc.<br />
Other (Medical Devices)<br />
Booth # 566<br />
5909 Baker Road<br />
Suite 550<br />
Minnetonka, MN 55345<br />
p: 952-912-5400 f: 952-912-5410<br />
www.advbiosurf.com<br />
ALCiS Health, Inc.<br />
Other (External Topical Analgesic)<br />
Booth # 610<br />
2001 Gateway Place<br />
Suite 520W<br />
San Jose, CA 95110<br />
p: 408-437-1060 f: 408-437-1066<br />
www.alcis.com<br />
Alliance for Better Bone Heatlh<br />
Pharmaceuticals<br />
Booth # 109<br />
8700 Mason Montgomery Road<br />
Mason, OH 45040<br />
p: 513-622-1818 f: 513-983-0936<br />
www.actonel.com<br />
<strong>American</strong> Academy of<br />
Physician Assistants<br />
Non-Profit Organization<br />
Booth # 775<br />
950 N. Washington Street<br />
Alexandria, VA 22314<br />
p: 703-836-2272 f: 703-684-1924<br />
www.aapa.org<br />
<strong>American</strong> College of<br />
Physicians/Annals<br />
of Internal Medicine<br />
Publisher<br />
Booth # 972<br />
190 N. Independence Mall West<br />
Philadelphia, PA 19106<br />
p: 215-351-2629 f: 215-351-2619<br />
www.acponline.org<br />
<strong>American</strong> Express<br />
Other (Finance)<br />
Booth # 749<br />
161 6 th Avenue, 8 th Floor<br />
New York, NY 10013<br />
p: 212-206-4031 f: 212-206-4002<br />
www.open.com<br />
AquaMed<br />
Therapeutic/Patient Aid Products<br />
Booth # 765<br />
15395 Roosevelt Boulevard<br />
Clearwater, FL 33760<br />
p: 727-536-5566 f: 727-536-6633<br />
www.aquamed.com<br />
Arthritis Foundation<br />
Non-Profit Organization<br />
Booth # 567<br />
1330 West Peachtree Street<br />
Suite 100<br />
Atlanta, GA 30309<br />
p: 404-872-7100 f: 404-587-7782<br />
www.arthritis.org<br />
Arthritis Practitioner<br />
Publisher<br />
Booth # 175<br />
83 General Warren Boulevard<br />
Suite 100<br />
Malvern, PA 19355<br />
p: 610-560-0500 f: 610-560-0501<br />
www.arthritispractitioner.com<br />
Arthritis Self-Management<br />
Publisher<br />
Booth # 511<br />
150 West 22nd Street<br />
8 th Floor<br />
New York, NY 10011<br />
p: 212-989-0200 f: 212-989-4786<br />
Aspreva Pharmaceuticals Inc.<br />
Pharmaceuticals<br />
Booth # 159<br />
106 Allen Road<br />
Basking Ridge, NJ 07920<br />
p: 908-212-1042 f: 908-212-1029<br />
www.aspreva.com<br />
Autoimmune Related<br />
Diseases Association<br />
Non-Profit Organization<br />
Booth # 778<br />
22100 Gratiot Avenue<br />
Eastpointe, MI 48021<br />
p: 586-776-3900 f: 586-776-3903<br />
www.aarda.org<br />
Axis-Shield<br />
Diagnostic Equipment/Products<br />
Booth # 771<br />
The Technology Park<br />
Dundee, Scotland, UK DD21XA<br />
p: +441382422000<br />
f: +441382422088<br />
www.axis-shield.com<br />
Bayer HealthCare<br />
Pharmaceuticals<br />
Booth # 233<br />
36 Columbia Road<br />
Morristown, NJ 07962<br />
p: 973-254-4837 f: 973-254-4907<br />
www.bayer.com<br />
exhibitor Index<br />
www.rheumatology.org—Rheumatology’s Home on the Web 307
exhibitor Index<br />
exhibitor information<br />
Besse Medical<br />
Pharmaceuticals<br />
Booth # 944<br />
9075 Centre Pointe Drive<br />
Suite 140<br />
West Chester, OH 45069<br />
p: 800-543-2111 f: 513-682-3622<br />
www.besse.com<br />
The Binding Site<br />
Laboratory Equipment/Products<br />
Booth # 845<br />
5889 Oberlin Drive<br />
Suite 101<br />
San Diego, CA 92121<br />
p: 800-633-4484 f: 858-453-9189<br />
www.bindingsite.co.uk<br />
Bio-Imaging Technologies, Inc.<br />
Other (Imaging Core Lab Services)<br />
Booth # 549<br />
826 Newtown-Yardley Road<br />
Newtown, PA 18940<br />
p: 267-757-3000 f: 267-757-3010<br />
www.bioimaging.com<br />
BioMed Central<br />
Publisher<br />
Booth # 870<br />
Middlesex House, 34-42<br />
Cleveland Street<br />
London, UK W1T4LB<br />
p: +442073230323 f: +442076319926<br />
www.biomedcentral.com<br />
Biosound Esaote Ultrasound<br />
Diagnostic Equipment/Products<br />
Booth # 139<br />
8000 Castleway Drive<br />
Indianapolis, IN 46250<br />
p: 317-813-6000 f: 317-813-6600<br />
www.biosound.com<br />
Brigham and Women’s Hospital<br />
Orthopedics and Arthritis Center<br />
Non-Profit Organization<br />
Booth # 671<br />
850 Boylston Street<br />
Suite 130<br />
Chestnut Hill, MA 02467<br />
p: 617-732-9500 f: 617-732-9576<br />
www.brighamsandwomens.org/<br />
orthopedics<br />
Bristol-Myers Squibb<br />
Pharmaceuticals<br />
Booth # 537; Suite C<br />
PO Box 4500<br />
Princeton, NJ 08543<br />
p: 609-897-3746 f: 609-897-6722<br />
www.bms.com<br />
British Society for Rheumatology<br />
Non-Profit Organization<br />
Booth # 772<br />
Bride House<br />
18-20 Bride Lane<br />
London, UK EC4Y 8EE<br />
p: +442078420900 f: +442078420901<br />
www.rheumatology.org.uk<br />
Centocor, Inc.<br />
Biotech<br />
Booth # 827; Suite D<br />
800 Ridgeview Drive<br />
Horsham, PA 19044<br />
p: 610-651-6000 f: 610-651-6100<br />
www.centocor.com<br />
Centric Health Finance<br />
Other (Financial Services)<br />
Booth # 959<br />
4225 Executive Square<br />
Suite 200<br />
La Jolla, CA 92037<br />
p: 858-450-4227 f: 858-450-4229<br />
www.centrichf.com<br />
Chondrex, Inc.<br />
Laboratory Equipment/Products<br />
Booth # 739<br />
2607 151st Place NE<br />
Redmond, WA 98052<br />
p: 425-702-6365 f: 425-882-3094<br />
www.chondrex.com<br />
Clinical and Experimental<br />
Rheumatology<br />
Publisher<br />
Booth # 973<br />
Via Santa Maria 31<br />
Pisa, Italy 56126<br />
p: +39 050 40124 f: +39 050 502299<br />
www.clinexprheumatol.org<br />
Consortium of Rheumatology<br />
Researchers of North<br />
America, Inc.(CORRONA)<br />
Other (Data Registry)<br />
Booth # 133<br />
185 Barker Lane<br />
Fonda, NY 12068<br />
p: 518-853-1317 f: 518-853-3295<br />
www.corrona.org<br />
Coolibar<br />
Other (Sun Protective Clothing)<br />
Booth # 649<br />
2401 Edgewood Avenue South<br />
St. Louis Park, MN 55426<br />
p: 952-922-1445 f:952-922-1455<br />
www.coolibar.com<br />
CuraScript, Inc.<br />
Pharmaceuticals<br />
Booth # 964<br />
6272 Lee Vista Boulevard<br />
Orlando, FL 32822<br />
p: 407-852-4522 f: 407-852-4940<br />
www.curascript.com<br />
308<br />
Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
exhibitor information<br />
Datazoom Solutions Inc.<br />
Office Software/Equipment<br />
Booth # 135<br />
4 Robert Speck Parkway<br />
Suite 1500<br />
Mississauga, Ontario<br />
Canada L4Z 1S1<br />
p: 905-896-6970 f: 905-593-9087<br />
www.datazoomsolutons.com<br />
DePuy Mitek<br />
Pharmaceuticals<br />
Booth # 276<br />
325 Paramount<br />
Raynham, MA 02767<br />
p: 508-977-3993 f: 508-977-6976<br />
www.depuymitek.com<br />
Dermpath Diagnostics, A Division<br />
of Ameripath/Institute for<br />
Immunofluorescence<br />
Other (Laboratory Services)<br />
Booth # 1060<br />
7111 Fairway Drive<br />
Suite 400<br />
Palm Beach Gardens, FL 33418<br />
p: 866-467-7546 f: 954-633-3286<br />
www.dermpathdiagnostics.com<br />
Diagnostic Instruments, Inc.<br />
Diagnostic Equipment/Products<br />
Booth # 570<br />
211 Asquithview Lane<br />
Arnold, MD 21012<br />
p: 410-421-5550 f: 410-421-5540<br />
www.msultrasound.com<br />
Diamedix Corporation<br />
Diagnostic Equipment / Products<br />
Booth # 177<br />
2140 N. Miami Avenue<br />
Miami, FL 33127<br />
p: 305-324-2300 f: 305-324-2326<br />
www.diamedix.com<br />
DJO, Inc.<br />
Other (Bracing)<br />
Booth # 373<br />
1430 Decision Street<br />
Vista, CA 92081<br />
p: 760-734-3125 f: 760-734-3595<br />
www.djortho.com<br />
Eli Lilly and Company<br />
Pharmaceuticals<br />
Booth # 358 and 559<br />
Lilly Corporate Center<br />
Indianapolis, IN 46285<br />
p: 317-276-2000 f: 317-276-1118<br />
www.lilly.com<br />
Elsevier-Saunders/Mosby<br />
Publisher<br />
Booth # 858<br />
1600 JFK Boulevard<br />
Suite 1800<br />
Philadelphia, PA 19103<br />
p: 800-545-2522 f: 215-239-3494<br />
www.elsivierhealth.com<br />
Endo Pharmaceuticals<br />
Pharmaceuticals<br />
Booth # 977<br />
100 Endo Boulevard<br />
Chadds Ford, PA 19317<br />
p: 610-558-9800 f: 610-558-4162<br />
www.endo.com<br />
Enhancement, Inc.<br />
Therapeutic/Patient Aid Products<br />
Booth # 668<br />
PO Box 867<br />
Morro Bay, CA 93443<br />
p: 805-771-8640 f: 805-772-4717<br />
www.enhancementinc.com<br />
European League Against<br />
Rheumatism (EULAR)<br />
Non-Profit Organization<br />
Booth # 675<br />
Seestrasse 240<br />
Kilchberg/Zurich, Switzerland 8802<br />
p: +41447163031 ∙ f: +41447163039<br />
www.eular.org<br />
Exhibitchek<br />
Market Research<br />
Booth # 759<br />
20351 E. LaSalle Place<br />
Aurora, CO 80013<br />
p: 303-283-3952 f: 303-283-3369<br />
Fallene, Ltd.<br />
Other (Skin Care)<br />
Booth # 838<br />
2555 Industry Lane<br />
West Norristown, PA 19403<br />
p: 800-332-5536 f: 610-630-6202<br />
www.totalblock.com<br />
Federation of Clinical<br />
Immunology Societies (FOCIS)<br />
Non-Profit Organization<br />
Booth # 773<br />
11950 W. Lake Park Drive<br />
Suite 320<br />
Milwaukee, WI 53224<br />
p: 414-359-1670 f: 414-359-1671<br />
www.focisnet.org<br />
Ferring Pharmaceuticals Inc.<br />
Pharmaceuticals<br />
Booth # 463<br />
400 Rella Boulevard<br />
Suite 300<br />
Suffern, NY 10901<br />
p: 845-770-2643 f: 845-770-5611<br />
www.ferringusa.com<br />
Genentech<br />
Biotech<br />
Booth # 801<br />
1 DNA Way<br />
S. San Francisco, CA 94080<br />
p: 650-225-1000 f: 650-225-6000<br />
www.gene.com<br />
Genzyme<br />
Biotech, Therapeutic/Patient Aid<br />
Products<br />
Booth # 475<br />
55 Cambridge Parkway<br />
Cambridge, MA 02142<br />
p: 617-494-8484 f: 617-761-8789<br />
www.genzyme. Com<br />
exhibitor Index<br />
www.rheumatology.org—Rheumatology’s Home on the Web 309
exhibitor Index<br />
exhibitor information<br />
Gilead Sciences, Inc.<br />
Pharmaceuticals<br />
Booth # 877<br />
333 Lakeside Drive<br />
Foster City, CA 94404<br />
p: 650-574-3000 f: 650-578-9264<br />
www.gilead.com<br />
Hologic<br />
Diagnostic Equipment/Products<br />
Booth # 101<br />
35 Crosby Drive<br />
Bedford, MA 01730<br />
p: 781-999-7300 f: 781-280-0667<br />
www.hologic.com<br />
INOVA Diagnostics, Inc.<br />
Diagnostic Equipment/Products<br />
Booth # 338<br />
9900 Old Grove Road<br />
San Diego, CA 92131<br />
p: 858-586-9900 f: 858-586-9911<br />
www.inovadx.com<br />
GlaxoSmithKline Consumer<br />
Healthcare<br />
Pharmaceuticals<br />
Booth # 614<br />
16 West State Street<br />
Sherburne, NY 13460<br />
p: 607-674-2666 f: 607-674-6132<br />
www.gsk.com<br />
Gout & Uric Acid Education Society<br />
Non-Profit Organization<br />
Booth # 679<br />
875 N. Michigan Avenue<br />
Suite 3300<br />
Chicago, IL 60611<br />
p: 312-751-3511 f: 312-751-8191<br />
www.gouteducation.org<br />
Grifols USA<br />
Diagnostic Equipment/Products<br />
Booth # 958<br />
2410 Lillyvale Avenue<br />
Los Angeles, CA 90032<br />
p: 800-421-0008<br />
www.grifolsusa.com<br />
HakoMed USA Inc.<br />
Other (Medical Equipment<br />
Manufacturer)<br />
Booth # 842<br />
1024 Puuwai Street<br />
Honolulu, HI 96819<br />
p: 888-913-7900 f: 808-845-1013<br />
www.hakomed.com<br />
Health Education Alliance<br />
Other (CME)<br />
Booth # 878<br />
345 Hudson Street<br />
16 th Floor<br />
New York, NY 10014<br />
p: 646-823-1735 f: 212-727-2751<br />
Hospital for Special Surgery<br />
Non-Profit Organization<br />
Booth # 469<br />
535 East 70 th Street<br />
New York, NY 10021<br />
p: 212-606-1139 f: 212-606-1762<br />
www.hss.edu<br />
HRA Research<br />
Market Research<br />
Booth # 562<br />
400 Lanidex Plaza<br />
Parsippany, NJ 07054<br />
p: 973-240-1200 f: 973-463-1888<br />
www.hraresearch.com<br />
Immunodiagnostic Systems<br />
Diagnostic Equipment/Products<br />
Booth # 564<br />
PO Box 17063<br />
Fountain Hills, AZ 85269<br />
p: 480-836-7435 f: 480-836-7437<br />
www.idsinc.us.com<br />
Immunomedics, Inc.<br />
Biotech<br />
Booth # 272<br />
300 <strong>American</strong> Road<br />
Morris Plains, NJ 07950<br />
p: 973-605-8282 f: 973-605-5145<br />
www.immunomedics.com<br />
ImmunoVision, Inc.<br />
Biotech<br />
Booth # 179<br />
1820 Ford Avenue<br />
Springdale, AR 72764<br />
p: 800-541-0960 f: 479-751-7002<br />
www.Immunovision.com<br />
Institute for Clinical Care &<br />
Council for Osteoarthritis<br />
Pain Management<br />
Pharmaceuticals<br />
Booth # 237<br />
3400 West Chester Pike<br />
Suite 100<br />
Newtown Square, PA 19073<br />
p: 610-353-9100 f: 610-359-9101<br />
www.clincare.org<br />
Inverness Medical Professional<br />
Diagnostics<br />
Diagnostic Equipment/Products<br />
Booth # 239<br />
2 Research Way<br />
Princeton, NJ 08540<br />
p: 609-627-8000 f: 609-627-8035<br />
www.invernessmedicalpd.com<br />
Johns Hopkins Arthritis Center<br />
Website<br />
Non-Profit Organization<br />
Booth # 677<br />
5200 Eastern Avenue<br />
Suite 4100<br />
Baltimore, MD 21224<br />
p: 410-550-5907 f: 410-550-2072<br />
www.hopkins-arthritis.org<br />
Journal of Musculoskeletal Medicine<br />
Publisher<br />
Booth # 375<br />
330 Boston Post Road<br />
Darien, CT 06820<br />
p: 203-662-6400 f: 203-662-6775<br />
310<br />
Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
exhibitor information<br />
The Journal of Rheumatology<br />
Publisher<br />
Booth # 579<br />
365 Bloor Street E.<br />
Suite 901<br />
Toronto, Ontario, Canada M4W 3L4<br />
p: 416-967-5155 f: 416-967-7556<br />
www.jrheum.com<br />
La Lettre Du Rhumatologue<br />
Publisher<br />
Booth # 234<br />
Edimark Sante-2, Rue Sainte Marie<br />
Courbevoie Cedex, France 92418<br />
p: +33146676283 f: 33146676310<br />
www.edimark.fr<br />
Lippincott Williams & Wilkins<br />
Publisher<br />
Booth # 850<br />
31 Cove Road<br />
Salem, NH 03079<br />
p: 603-870-0099 f: 603-870-0099<br />
www.lww.com<br />
Lupus Alliance of America<br />
Non-Profit Organization<br />
Booth # 678<br />
3871 Harlem Road<br />
Buffalo, NY 14215<br />
p: 716-832-7580 f: 716-835-7251<br />
www.lupusalliance.org<br />
Lupus Clinical Trials Consortium, Inc.<br />
Non-Profit Organization<br />
Booth # 770<br />
221 East 48th Street<br />
New York, NY 10017<br />
p: 212-593-7227 f: 212-803-0059<br />
www.lupusclinicaltrials.org<br />
Lupus Foundation of America, Inc.<br />
Non-Profit Organization<br />
Booth # 667<br />
2000 L Street, NW<br />
Suite 710<br />
Washington, DC 20036<br />
p: 202-349-1155 f: 202-349-1156<br />
www.lupus.org<br />
Lupus Research Institute<br />
Non-Profit Organization<br />
Booth # 776<br />
330 Seventh Avenue<br />
Suite 1701<br />
New York, NY 10001<br />
p: 212-685-4118 f: 212-545-1843<br />
www.lupusresearchinstitute.org<br />
MBL International Corporation<br />
Diagnostic Equipment/Products<br />
Booth # 173<br />
15 B Constitution Way<br />
Woburn, MA 01801<br />
p: 781-939-6964 f: 781-939-6963<br />
www.mblintl.com<br />
Medical-Billing.com<br />
Other (Billing compay)<br />
Booth # 946<br />
74 Industrial Park Road<br />
Saco, ME 04072<br />
p: 207-286-9277 f: 207-286-9255<br />
www.medical-billing.com<br />
MediNotes Corporation<br />
Office Software/Equipment<br />
Booth # 748<br />
1025 Ashworth Road<br />
Suite 222<br />
West Des Moines, IA 50265<br />
p: 877-633-6683 f: 515-327-8856<br />
www.medinotes.com<br />
Mediquest Therapeutics, Inc.<br />
Pharmaceuticals<br />
Booth # 948<br />
22322 20 th Avenue, SE<br />
#100<br />
Bothell, WA 98021<br />
p: 425-398-9580 f: 425-398-9590<br />
www.mqti.com<br />
MedPage Today, LLC<br />
Publisher<br />
Booth # 240<br />
150 Clove Road<br />
Little Falls, NJ 07424<br />
p: 973-890-0985 f: 973-890-1327<br />
www.medpagetoday.com<br />
Merck Research Laboratories<br />
Pharmaceuticals<br />
Booth # 651<br />
126 East Lincoln Avenue<br />
RY33-600<br />
Rahway, NJ 07065<br />
www.merck.com<br />
Meso Scale Discovery<br />
Biotech<br />
Booth # 379<br />
9238 Gaither Road<br />
Gaithersburg, MD 20877<br />
p: 240-631-2522 f: 301-208-3890<br />
www.mesoscale.com<br />
MIR Preclinical Services<br />
Contract Research<br />
Booth # 747<br />
800 Technology Drive<br />
Ann Arbor, MI 48108<br />
p: 734-821-1063 f: 734-821-1066<br />
www.molecularimaging.com<br />
Munson Medical Center<br />
Recruitment<br />
Booth 777<br />
1105 Sixth Street<br />
MPB, Suite 212<br />
Traverse City, MI 49684<br />
p: 231-935-5889 f: 231-935-5885<br />
www.munsonhealthcare.org<br />
The Myositis Association<br />
Non-Profit Organization<br />
Booth # 674<br />
1233 20 th Street NW<br />
Suite 402<br />
Washington, DC 20036<br />
p: 202-887-0082 f: 202-466-8940<br />
www.myositis.org<br />
National Databank for<br />
Rheumatic Diseases<br />
Non-Profit Organization<br />
Booth # 575<br />
1035 North Emporia<br />
Suite 288<br />
Wichita, KS 67214<br />
p: 316-263-2125 f: 316-263-0761<br />
www.arthritis-research.org<br />
exhibitor Index<br />
www.rheumatology.org—Rheumatology’s Home on the Web 311
exhibitor Index<br />
exhibitor information<br />
National Fibromyalgia Association<br />
Non-Profit Organization<br />
Booth # 672<br />
2200 North Glassell Street<br />
Suite A<br />
Orange, CA 92865<br />
p: 714-921-0150 f: 714-921-6920<br />
www.FMAware.org<br />
National Institute of Allergy and<br />
Infectious Diseases<br />
Non-Proft Organization<br />
Booth # 874<br />
1000 Thomas Jefferson Street, NW<br />
Washington, DC 20007<br />
p: 202-403-5452 f: 202-403-5848<br />
Nature Publishing Group<br />
Publisher<br />
Booth # 866<br />
75 Varick Street, Floor 9<br />
New York, NY 10013<br />
p: 212-726-9636 f: 212-696-9006<br />
www.nature.com<br />
NeuMed<br />
Diagnostic Equipment/Products<br />
Booth # 836<br />
800 Silvia Street<br />
West Trenton, NJ 08628<br />
p: 609-896-3444 f: 609-896-2798<br />
www.neumedinc.com<br />
NeuroMetrix<br />
Diagnostic Equipment/Products<br />
Booth # 459<br />
62 Fourth Avenue<br />
Waltham, MA 02451<br />
p: 781-890-9989 f: 781-890-1556<br />
www.neurometrix.com<br />
New Balance Athletic Shoes<br />
Therapeutic/Patient Aid Products<br />
Booth # 332<br />
20 Guest Street<br />
Boston, MA 02135<br />
p: 800-343-4648 f: 617-746-6303<br />
www.newbalance.com<br />
NIAMS (National Institute of<br />
Arthritis & Musculoskeletal<br />
& Skin Diseases)<br />
Non-Profit Organization<br />
Booth # 573<br />
1 AMS Circle<br />
Bethesda, MD 20892<br />
p: 877-226-4267 f: 301-718-6366<br />
www.niams.nih.gov<br />
NicOx SA<br />
Biotech<br />
Booth # 949<br />
1681 Route Des Dolines<br />
BP 313<br />
Sophia Antipolis, France 06906<br />
p: +33497245300 f: +33497245399<br />
www.nicox.com<br />
Novartis Pharmaceuticals<br />
Pharmaceuticals<br />
Booth #123<br />
One Health Plaza<br />
East Hanover, NJ 07936<br />
p: 862-778-6299 f: 973-781-5488<br />
www.novartis.com<br />
Nutramax Laboratories, Inc.<br />
Nutritional Products<br />
Booth # 648<br />
2208 Lakeside Boulevard<br />
Edgewood, MD 21040<br />
p: 800-925-5187 f: 800-925-0361<br />
www.cosamin.com<br />
NYU Hospital for Joint Diseases<br />
Other (Academic Hospital)<br />
Booth # 859<br />
246 East 20 th Street<br />
New York, NY 10003<br />
p: 212-844-0223 f: 212-844-0226<br />
Oklahoma Medical Research<br />
Foundation (OMRF)<br />
Non-Profit Organization<br />
Booth # 673<br />
825 NE 13th Street<br />
Oklahoma City, OK 73104<br />
p: 405-271-6673 f: 405-271-3045<br />
www.omrf.ouhsc.edu<br />
ONI Medical Systems, Inc.<br />
Diagnostic Equipment/Products<br />
Booth # 745<br />
301 Ballardvale Street<br />
Suite 4<br />
Wilmington, MA 01887<br />
p: 978-658-0020 f: 978-658-0898<br />
www.onicorp.com<br />
Organization of Teratology<br />
Information Specialists (OTIS)<br />
Non-Profit Organization<br />
Booth # 670<br />
9500 Gilman Drive<br />
#0828<br />
La Jolla, CA 92093<br />
p: 877-311-8972 f: 619-294-6191<br />
www.otispregnancy.org/autoimmune<br />
OSSUR<br />
Other (Braces, Supports &<br />
Prosthetics)<br />
Booth # 137<br />
19762 Pauling<br />
Foothill Ranch, GA 92610<br />
p: 949-859-4407 f: 949-609-3108<br />
www.ossur.com<br />
OTN<br />
Physician Services<br />
Booth # 377<br />
401 Mason Road<br />
LaVergne, TN 37086<br />
p: 615-287-5200<br />
www.myotn.com<br />
Oxford University Press<br />
Publisher<br />
Booth # 509<br />
2001 Evans Road<br />
Cary, NC 27513<br />
p: 919-677-0977 f: 919-677-1714<br />
www.oxfordjournals.org<br />
Pacific Biometrics<br />
Contract Research<br />
Booth # 1070<br />
220 W. Harrison Street<br />
Seattle, WA 98119<br />
p: 206-298-0068<br />
www.pacbio.com<br />
312<br />
Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
exhibitor information<br />
Pan <strong>American</strong> League of<br />
Associations for<br />
Rheumatology (PANLAR)<br />
Non-Profit Organization<br />
Booth # 872<br />
Hermilio Hernandez 170<br />
San Isidro, Lima, Peru 27<br />
p: +511 4778693 f: +511 7447798<br />
www.panlar.org<br />
Pfizer Inc.<br />
Pharmaceuticals<br />
Booth # 521 and 349; Suite B1<br />
235 East 42nd Street<br />
MS 219/2/18<br />
New York, NY 10017<br />
p: 212-733-0677 f: 646-441-5558<br />
www.pfizer.com<br />
Pharmacare Specialty Pharmacy<br />
Pharmacy Services<br />
Booth # 274<br />
600 Penn Center Boulevard<br />
Pittsburgh, PA 15235<br />
p: 412-825-8149 f: 412-717-9339<br />
www.pharmacare.com<br />
Physician Select Vitamins<br />
Other<br />
Booth # 848<br />
10645 Richmond Avenue<br />
Suite 150<br />
Houston, TX 77042<br />
p: 713-787-9547 f: 713-787-9548<br />
www.psvitamins.com<br />
PriCara, Unit of Ortho-McNeil, Inc.<br />
Pharmaceuticals<br />
Booth # 863; 865<br />
1000 Route 202<br />
Raritan, NJ 08869<br />
p: 908-2186000 f: 908-203-0641<br />
www.pricara.com<br />
ProScan Reading Services<br />
Other (MRI Reading Services)<br />
Booth # 608<br />
5400 Kennedy Avenue<br />
Cincinnati, OH 45213<br />
p: 513-229-7115 f: 513-352-9332<br />
www.proscan.com<br />
Pulmonary Hypertension<br />
Association<br />
Non-Profit Organization<br />
Booth # 768<br />
801 Roeder Road<br />
Suite 400<br />
Silver Spring, MD 20910<br />
p: 301-565-3004 f: 301-565-3994<br />
www.phassociation.org<br />
Regeneron<br />
Pharmaceuticals<br />
Booth # 871<br />
777 Old Saw Mill River Road<br />
Tarrytown, NY 10591<br />
p: 914-345-7911 f: 914-593-1078<br />
www.regeneron.com<br />
Reina Imaging<br />
Diagnostic Equipment/Products<br />
Booth # 847<br />
6107 W. Lou Avenue<br />
Crystal Lake, IL 60014<br />
P815-823-0223 f: 815-823-0227<br />
www.reinadigital.com<br />
Rhematology Diagnostics<br />
Laboratory, Inc.<br />
Other (Reference Lab)<br />
Booth # 513<br />
10755 Venice Boulevard<br />
Los Angeles, CA 90034<br />
p: 310-253-5455 f: 310-253-5466<br />
www.rdlinc.com<br />
Rheumatology News<br />
Publisher<br />
Booth # 371<br />
60-B Columbia Road<br />
Morristown, NJ 07960<br />
p: 973-290-8228 f: 973-290-8250<br />
www.rheumatologynews.com<br />
Rheumatology Nurses Society<br />
Non-Profit Organization<br />
Booth # 876<br />
34 Mountain Boulevard<br />
Building A, Suite 201<br />
Warren, NJ 07059<br />
p: 908-222-5610<br />
www.rnsnetwork.org<br />
Rheuminations, Inc.<br />
Non-Profit Organization<br />
Booth # 470<br />
221 East 48th Street<br />
New York, NY 10017<br />
p: 212-593-5180 f: 212-803-0059<br />
www.dxlupus.org<br />
Road Back Foundation<br />
Non-Profit Organization<br />
Booth # 669<br />
PO Box 410184<br />
Cambridge, MA 02141<br />
p: 617-225-3993 f: 617-225-0933<br />
www.roadback.org<br />
Roche<br />
Pharmaceuticals<br />
Booth # 337, 449 and 916; Suite B2<br />
340 Kingsland Street<br />
Nutley, NJ 07110<br />
p: 973-235-5000 f: 973-562-2817<br />
www.roche.com<br />
RottaPharm<br />
Pharmaceuticals<br />
Booth # 501<br />
Rottapharm SpA<br />
Via Valosa di Sopra 9<br />
20052 Monza, Italy<br />
p: +390397390212 f: +390397390372<br />
www.donausa.com<br />
Rxperience<br />
Recruitment<br />
Booth # 970<br />
570 Taxter Road<br />
Elmsford, NY 10523<br />
p: 914-366-6000 f: 914-598-1550<br />
www.rxperience.com<br />
exhibitor Index<br />
www.rheumatology.org—Rheumatology’s Home on the Web 313
exhibitor Index<br />
exhibitor information<br />
sanofi-aventis<br />
Pharmaceuticals<br />
Booth # 151<br />
55 Corporate Drive<br />
Bridgewater, NJ 08807<br />
P800-981-2491<br />
www.sanofi-aventis.com<br />
Saunders/Mosby-Elsevier<br />
Publisher<br />
Booth # 606<br />
1600 JFK Boulevard<br />
Suite 1800<br />
Philadelphia, PA 19103<br />
p: 800-545-2522 f: 215-239-3494<br />
www.elsevierhealth.com<br />
Savient Pharmaceuticals<br />
Biotech<br />
Booth # 167<br />
1 Tower Center<br />
14 th Floor<br />
East Brunswick, NJ 08816<br />
p: 732-565-4665<br />
www.savientpharma.com<br />
Scandinavian Journal of<br />
Rheumatology<br />
Non-Profit Organization<br />
Booth # 577<br />
Norrebrogade 44<br />
Aarhus, Denmark DK-8000<br />
p: +4589494411 f: +4589494412<br />
www.scandjrheumatol.dk<br />
Schering-Plough Corporation<br />
Pharmaceuticals<br />
Booth # 943<br />
2000 Galloping Hill Road<br />
Kenilworth, NJ 07033<br />
p: 908-298-4000 f: 908-463-8460<br />
www.scheringplough.com<br />
Scius, LLC<br />
Other (CME)<br />
Booth # 779<br />
34 Mountain Boulevard<br />
Building A – Suite 201<br />
Warren, NJ 07059<br />
p: 908-222-4903 f: 908-222-4930<br />
www.sciuseducation.com<br />
Scleroderma Foundation<br />
Non-Profit Organization<br />
Booth # 766<br />
300 Rosewood Drive<br />
Suite 105<br />
Danvers, MA 01923<br />
p: 978-463-5843 f: 978-463-5809<br />
www.scleroderma.org<br />
Silver Ring Splint Company<br />
Therapeutic/Patient Aid Products<br />
Booth # 737<br />
PO Box 2856<br />
Charlottesville, VA 22902<br />
p: 888-311-7028 f: 888-456-8828<br />
(434-971-8828)<br />
www.silverringsplint.com<br />
Sjögren’s Syndrome Foundation<br />
Non-Profit Organization<br />
Booth # 774<br />
6707 Democracy Boulevard<br />
Suite 325<br />
Bethesda, MD 20817<br />
p: 301-530-4420 f: 301-530-4415<br />
www.sjogrens.org<br />
Smith & Nephew Orthopaedics<br />
Surgical Instruments/Supplies<br />
Booth # 431<br />
1450 Brooks Road<br />
Memphis, TN 38116<br />
p: 901-399-5265 f: 901-399-5187<br />
www.smith-nephew.com<br />
SonoSite<br />
Diagnostic Equipment/Products<br />
Booth # 741<br />
21919-30 th Drive SE<br />
Bothell, WA 98021<br />
p: 425-951-1200 f: 425-951-1201<br />
www.sonosite.com<br />
Spondylitis Association of America<br />
Non-Profit Organization<br />
Booth # 666<br />
PO Box 5872<br />
Sherman Oaks, CA 91413<br />
p: 818-981-1616 f: 818-981-9826<br />
www.spondylitis.org<br />
Springer<br />
Publisher<br />
Booth # 558<br />
233 Spring Street<br />
New York, NY 10013<br />
p: 212-460-1500 f: 201-348-4505<br />
www.springer.com<br />
Tanabe Seiyaku Co., LTD.<br />
Pharmaceuticals<br />
Booth # 844<br />
Biko-Hongo 2 BLD 1F,<br />
3-14-15 Hongo<br />
Bunkyo-KU, Tokyo, Japan 113-0033<br />
p: +81356840351 f: +81356840354<br />
TheraTest Labs<br />
Diagnostic Equipment/Products<br />
Booth # 117<br />
1111 North Main Street<br />
Lombard, IL 60148<br />
p: 630-627-6069 f: 630-627-4231<br />
www.theratest.com<br />
UCB, Inc.<br />
Biotech<br />
Booth # 317; Suite B3<br />
1950 Lake Park Drive<br />
Smyrna, GA 30080<br />
p: 770-437-5500<br />
www.ucb-group.com<br />
314<br />
Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
exhibitor information<br />
UpToDate<br />
Publisher<br />
Booth # 761<br />
95 Sawyer Road<br />
Waltham, MA 02453<br />
p: 781-392-2903 f: 781-642-8890<br />
www.uptodate.com<br />
US Nutrition/NBTY<br />
Nutritional Products<br />
Booth # 560<br />
90 Orville Drive<br />
Ronkonkoma, NY 11716<br />
p: 561-241-8900 f: 561-241-8222<br />
www.osteobiflex.com<br />
Vasculitis Foundation<br />
Non-Profit Organization<br />
Booth # 676<br />
PO Box 28660<br />
Kansas City, MO 64188<br />
p: 816-436-8211 f: 816-436-8211<br />
www.vasculitisfoundation.org<br />
Victory Pharma<br />
Pharmaceuticals<br />
Booth # 1072<br />
3700 Regency Parkway<br />
Suite 130<br />
Cary, NC 27518<br />
p: 919-459-3926 f: 919-459-3927<br />
www.victorypharma.com<br />
VirtualScopics, Inc.<br />
Other (Imaging Services for<br />
Clinical Trials)<br />
Booth # 1058<br />
350 Linden Oaks<br />
Rochester, NY 14625<br />
p: 585-249-6231 f: 585-218-7350<br />
www.virtualscopics.com<br />
Vitamin Health - Neoflex<br />
Nutritional Products<br />
Booth # 232<br />
PO Box 26<br />
Mobridge, SD 57601<br />
p: 1-800-NEOFLEX f: 888-748-6748<br />
www.neoflex.com<br />
VQ OrthoCare<br />
Therapeutic/Patient Aid Products<br />
Booth # 767<br />
18011 Mitchell South<br />
Irvine, CA92614<br />
p: 800-266-6969<br />
www.vqorthocare.com<br />
Wiley Blackwell<br />
Publisher<br />
Booth # 478<br />
111 River Street<br />
Hoboken, NJ 07030<br />
p: 201-748-6000 f: 201-748-6142<br />
www.wiley.com<br />
Wyeth<br />
Pharmaceuticals<br />
Booth # 601<br />
500 Arcola Road<br />
Collegeville, PA 19426<br />
p: 484-865-3358<br />
www.wyeth.com<br />
exhibitor Index<br />
www.rheumatology.org—Rheumatology’s Home on the Web 315
acknowledgements<br />
The <strong>ACR</strong>, the <strong>ARHP</strong> and the REF wish to thank the following organizations for providing support of the <strong>2007</strong> <strong>ACR</strong><br />
Annual <strong>Scientific</strong> <strong>Meeting</strong>.<br />
Abbott Laboratories<br />
Commemorative T-Shirt<br />
Conference Briefcase<br />
Conference Notebook<br />
Conference Shuttle Buses<br />
Fellows Scholarship <strong>Program</strong><br />
Industry Roundtable Symposium<br />
Actelion Pharmaceuticals, Inc.<br />
Post-Conference Symposium<br />
Amgen Inc., and Wyeth Pharmaceuticals<br />
Fellows Scholarship <strong>Program</strong><br />
Industry Roundtable Symposium<br />
Late-Breaking Abstract Supplement<br />
<strong>Program</strong> Pocket Planner<br />
<strong>Scientific</strong> <strong>Program</strong> <strong>Book</strong><br />
<strong>Scientific</strong> Syllabus<br />
Bioiberica<br />
Post-Conference Symposium<br />
Bristol-Myers Squibb Company<br />
Abstracts on <strong>ACR</strong> Web site and CD-ROM<br />
Conference Shuttle Buses<br />
Fellows Scholarship <strong>Program</strong><br />
Industry Roundtable Symposium<br />
Centocor, Inc.<br />
Post-Conference Symposium<br />
Forest Research Institute<br />
Post-Conference Symposium<br />
Genentech, Inc.<br />
Industry Roundtable Symposium<br />
Genentech, Inc. and Biogen Idec<br />
Fellows Scholarship <strong>Program</strong><br />
Message/Internet Center<br />
(The Message/Internet Center is co-supported by<br />
Genentech, Inc. and Biogen Idec)<br />
Gilead Sciences, Inc.<br />
Post-Conference Symposium<br />
King Pharmaceuticals, Inc.<br />
Post-Conference Symposium<br />
Novartis<br />
<strong>ARHP</strong> Clinical Focus Course<br />
Rheumatology Round-Up<br />
Pfizer Inc<br />
Industry Roundtable Symposium<br />
Roche<br />
<strong>ACR</strong> 2008 Calendar<br />
<strong>ARHP</strong> Clinical Focus Course<br />
<strong>ARHP</strong> General Sessions I & II<br />
<strong>ARHP</strong> Health Professionals Networking at Noon<br />
Industry Roundtable Symposium<br />
TAP Pharmaceutical Products, Inc.<br />
Recharging Area<br />
UCB, Inc.<br />
Conference Shuttle Buses<br />
REF 5K Run/Walk<br />
Registration Brochure<br />
Speaker Ready Room<br />
Industry Roundtable Symposium<br />
316 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
<strong>2007</strong> <strong>ACR</strong> Annual <strong>Meeting</strong> Leadership<br />
Officers<br />
President<br />
Neal S. Birnbaum, MD<br />
President-Elect<br />
David A. Fox, MD<br />
Vice President<br />
Sherine E. Gabriel, MD, MSc<br />
Secretary/Treasurer<br />
Stanley B. Cohen, MD<br />
Annual <strong>Meeting</strong><br />
Planning Committee<br />
Chair<br />
Brian F. Mandell, MD, PhD<br />
Basic Science Subchair<br />
Joel A. Block, MD<br />
Clinical Subchair<br />
Atul Deodhar, MD<br />
Meet the Professor/Workshop/<br />
Study Group Subchair<br />
Edward V. Lally, MD<br />
<strong>2007</strong> Abstract Selection Committee<br />
Co-Chairs<br />
Gary S. Firestein, MD; Basic Science<br />
Chair<br />
Susan Manzi, MD, MPH, Clinical Chair<br />
Basic Science Symposia<br />
Steven R. Goldring, MD<br />
Jorg J. Goronzy, MD<br />
Iain McInnes, PhD, MRCP<br />
Kurt Redlich, MD<br />
William Robinson, MD, PhD<br />
Clinical Symposia<br />
Mary-Carmen Amigo, MD, FACP<br />
Beth S. Gottlieb, MD<br />
Prakash Pispati, MD<br />
Sally W. Pullman-Mooar, MD<br />
Frontiers Course<br />
Debra J. Zack, MD, PhD<br />
Immunology Updates for Clinicians<br />
Anne Davidson, MBBS, FRACP<br />
Medical Aspects Lectures<br />
Marcy B. Bolster, MD<br />
Meet the Professors<br />
Laura E. Schanberg, MD<br />
Victoria K. Shanmugam, MD<br />
Practice Issues/CORC Forum<br />
John J. Cush, MD<br />
David I. Daikh, MD, PhD<br />
Karen S. Kolba, MD<br />
Review Course<br />
Mary Anne Dooley, MD, MPH<br />
John H. Stone, MD<br />
State-of-the-Art Lectures<br />
Dhavalkumar D. Patel, MD<br />
Study Groups<br />
Maria L. Barilla-LaBarca, MD<br />
Workshops<br />
John C. Davis, Jr., MD, MPH<br />
Peter J. Embi, MD<br />
Committee Liaisons<br />
<strong>ACR</strong> Executive Committee<br />
Neal S. Birnbaum, MD, <strong>ACR</strong> President<br />
Committee on Education<br />
Rosalind Ramsey-Goldman, MD,<br />
DrPH, Chair<br />
Richard A. Furie MD, <strong>Program</strong>s Subchair<br />
<strong>ARHP</strong> <strong>Program</strong> Committee<br />
Mary E. Christenson, PT, MS, Chair<br />
Committee on Research<br />
Gary S. Gilkeson, MD<br />
Committee on Training and Workforce Issues<br />
David I. Daikh, MD, PhD, Chair<br />
Professional <strong>Meeting</strong>s Committee<br />
Robert C. Fuhlbrigge MD, PhD, Chair<br />
Quality Measures Committee<br />
Jasvinder Singh, MD, MPH<br />
Corporate Relations Committee<br />
John J. Cush, MD, Chair<br />
<strong>2007</strong> <strong>ACR</strong> Abstract<br />
Selection Committee<br />
1. Cytokines, mediators, and<br />
gene regulation<br />
Richard M. Siegel, MD, PhD, Chair<br />
Andrew P. Cope, MD, PhD<br />
Lionel B. Ivashkiv, MD<br />
Andrew D. Luster, MD, PhD<br />
David Martin, MD<br />
Mehrad Matloubian, MD, PhD<br />
2. Cell-cell adhesion, cell trafficking<br />
and angiogenesis<br />
Alisa Koch, MD, Chair<br />
Robert M. Clancy, PhD<br />
Bruce N. Cronstein, MD<br />
Dorian O. Haskard, DM, FRCP<br />
Costantino Pitzalis, MD, PhD, FRCP<br />
Raymond Yung, MD<br />
3. Innate immunity and rheumatic disease<br />
John P. Atkinson, MD, Chair<br />
Gerd R. Burmester, MD<br />
Arthur M. Krieg, MD<br />
Harris R. Perlman, PhD<br />
Christine Pham, MD<br />
William Seaman, MD<br />
4. B-Cell biology and targets in<br />
autoimmune disease<br />
Joseph Holoshitz, MD, Chair<br />
Robert H. Carter, MD<br />
Betty Diamond, MD<br />
David A. Isenberg, MD, FRCP<br />
Yaakov Naparstek, MD<br />
Yehuda Shoenfeld, MD<br />
5. T-Cell biology and targets in<br />
autoimmune disease<br />
Stanford L. Peng, MD, PhD, Chair<br />
Eric M. Gershwin, MD<br />
I-Cheng Ho, MD, PhD<br />
George C. Tsokos, MD<br />
Andras Perl, MD, PhD<br />
6. Biology and pathology of bone<br />
and joint<br />
Steven R. Goldring, MD, Chair<br />
Francis Berenbaum, MD, PhD<br />
Pierre Miossec, MD, PhD<br />
Georg Schett, MD<br />
Edward M. Schwarz, PhD<br />
Robert Terkeltaub, MD<br />
www.rheumatology.org—Rheumatology’s Home on the Web 317
<strong>2007</strong> <strong>ACR</strong> Annual <strong>Meeting</strong> Leadership<br />
7. Osteoarthritis – clinical aspects<br />
Leena Sharma, MD, Chair<br />
Nigel K. Arden, MRCP<br />
Joel A. Block, MD<br />
Daniel O. Clegg, MD<br />
Timothy McAlindon, MD, MRP, MRCP<br />
Miriam N. Hannan, MD<br />
8. Osteoporosis and metabolic bone<br />
disease – clinical aspects and pathogenesis<br />
Kenneth G. Saag, MD, MSc, Chair<br />
Jeffrey R. Curtis, MD, MPH<br />
Chad L. Deal, MD<br />
Nancy E. Lane, MD<br />
Anthony I. Sebba, MD<br />
Stuart Silverman, MD<br />
9. Fibromyalgia and soft tissue disorders<br />
Robert S. Katz, MD, Chair<br />
Graciela S. Alarcon, MD, MPH<br />
Lan X. Chen, MD, PhD<br />
Daniel J. Clauw, MD<br />
Don L. Goldenberg, MD<br />
Daniel Wallace, MD<br />
10. Orthopedics, low back pain<br />
and rehabilitation<br />
David G. Borenstein, MD, Chair<br />
Joseph Biundo, MD<br />
Malcolm IV. Jayson, MD, FRCP<br />
Beth L. Jonas, MD<br />
Kenneth S. O’Rourke, MD<br />
Henning K. Zeidler, MD<br />
11. Pediatric rheumatology - clinical<br />
and therapeutic aspects<br />
Carlos D. Rose, MD, Chair<br />
Marisa S. Klein-Gitelman, MD, MPH<br />
Kathleen M. O’Neil, MD<br />
Kiem Oen, MD<br />
Ricardo A.G. Russo, MD<br />
Carine Wouters, MD<br />
12. Pediatric rheumatology<br />
pathogenesis and genetics<br />
Nora G. Singer, MD, Chair<br />
Randy Q. Cron, MD, PhD<br />
Leonard Dragone, MD, PhD<br />
Theresa Lu, MD, PhD<br />
Rae S.M. Yeung, MD, PhD<br />
13. Infection-related rheumatic disease<br />
Allen C. Steere, MD, Chair<br />
Linda Bockenstedt, MD<br />
Alan P. Hudson, PhD<br />
James Louie, MD<br />
John S.H. Gaston, MA, PhD, FRCP<br />
Jerry A. Green, MD<br />
14. Metabolic and crystal arthropathies<br />
H. Ralph. Schumacher Jr., MD, Chair<br />
Michael A. Becker, MD<br />
Hyon K. Choi, MD, DrPH<br />
Duncan A. Gordon, MD, FRCPC<br />
Fernando Perez-Ruiz, MD, PhD<br />
Ann K. Rosenthal, MD<br />
15. Muscle biology, myositis and myopathies<br />
Dana P. Ascherman, MD, Chair<br />
Ingrid Lundberg, MD, PhD<br />
Chester V. Oddis, MD<br />
Frederick W. Miller, MD, PhD<br />
Ann Reed, MD<br />
Robert L. Wortmann, MD<br />
16. Imaging of rheumatic diseases<br />
Barbara N. Weissman, MD, Chair<br />
Ronald Adler, MD<br />
Peter Ory, MD<br />
Hollis Peter, MD<br />
Joel Rubenstein, MD<br />
Carl Winalski, MD<br />
17. RA: clinical aspects<br />
Iain B. McInnes, PhD, MRCP, Co-Chair<br />
Ted R. Mikuls, MD, Co-Chair<br />
Joan Bathon, MD<br />
Ernest H.S. Choy, MD, FRCP<br />
Marc D. Cohen, MD<br />
Tom Huizinga, MD<br />
John D. Isaacs, MD, PhD<br />
Ulf Mueller-Ladner, MD<br />
Larry W. Moreland, MD<br />
Harold E. Paulus, MD<br />
Daniel H. Solomon, MD, MPH<br />
Douglas J. Veale, MD, FRCPI<br />
18. RA treatment - small molecules,<br />
biologics and gene therapy<br />
Clifton O. Bingham III, MD, Co-Chair<br />
Kathryn Hobbs, MD, Co-Chair<br />
Daniel Aletaha, MD, MS<br />
Claire Bombardier, MD, FRCPC<br />
John J. Cush, MD<br />
Mark C. Genovese, MD<br />
Susan J. Lee, MD<br />
Alan K. Matsumoto, MD<br />
Mikkel Ostergaard, MD<br />
Eric M. Ruderman, MD<br />
Nancy A. Shadick, MD, MPH<br />
Vibeke Strand, MD<br />
19. RA: human etiology and pathogenesis<br />
Richard M. Pope, MD, Chair<br />
Mary Corr, MD<br />
Diego Kyburz, MD<br />
Nobuyuki Miyasaka, MD<br />
Eric F. Morand, MD, PhD<br />
James Thomas, MD<br />
20. RA: animal models<br />
Ernest Brahn, MD, Chair<br />
Lars Klareskog, MD, PhD<br />
Harvinder S. Luthra, MD<br />
Linda Myers, MD<br />
Wim B. Van Den Berg, PhD<br />
Paul H. Wooley, PhD<br />
21. Systemic sclerosis, fibrosing syndromes,<br />
and Raynaud’s: clinical aspects<br />
and therapeutics<br />
Frank C. Arnett, MD, Chair<br />
Murray Baron, MD<br />
Marcy B. Bolster, MD<br />
Masataka Kuwana, MD, PhD<br />
Maureen D. Mayes, MD, MPH<br />
Fredrick M. Wigley, MD<br />
22. Systemic sclerosis, fibrosing syndromes,<br />
and Raynaud’s: pathogenesis,<br />
animal models and genetics<br />
Oliver Distler, MD, Chair<br />
Yannick Allanore, MD, PhD<br />
Christopher P. Denton, MD, PhD<br />
Jörg HW. Distler, MD<br />
Robert Lafyatis, MD<br />
Filemon K. Tan, MD, PhD<br />
318 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
<strong>2007</strong> <strong>ACR</strong> Annual <strong>Meeting</strong> Leadership<br />
23. Sjögren’s syndrome<br />
Haralampos M. Moutsopoulos, MD,<br />
FACP, Chair<br />
Mary K. Crow, MD<br />
Gabor G. Illei, MD<br />
Athanasios G. Tzioufas, MD<br />
Pierre Youinou, MD, DSc<br />
24. Antiphospholipid syndrome<br />
Joan T. Merrill, MD, Chair<br />
Ronald A. Asherson, MD, FRCP, FCP(S)<br />
Doruk Erkan, MD<br />
Kenneth C. Kalunian, MD<br />
Kevin M. Latinis, MD, PhD<br />
Barry L. Myones, MD<br />
25. SLE: clinical aspects and treatment<br />
Ann E. Clarke, MD, Co-Chair<br />
Jennifer M. Grossman, MD, Co-Chair<br />
Sasha R. Bernatsky, MD<br />
Ian N. Bruce, MD, FRCP<br />
Eliza F. Chakravarty, MD<br />
Karen H. Costenbader, MD, MPH<br />
David P. D’Cruz, MD, MRCP<br />
Christine A. Peschken, MD, MSc, FRCPC<br />
Joseph Shanahan, MD<br />
Ronald O. Van Vollenhoven, MD, PhD<br />
Jinoos Yazdany, MD, MPH<br />
26. SLE: human etiology and pathogenesis<br />
Jennifer H. Anolik, MD, PhD, Chair<br />
Martin Aringer, MD<br />
Lindsey A. Criswell, MD, MPH<br />
Mariana J. Kaplan, MD<br />
Richard J. Looney, MD<br />
Yoshiya Tanaka, MD, PhD<br />
27. SLE: animal models<br />
Chandra Mohan, MD, PhD, Chair<br />
Marina Botto, MD<br />
Roberto Caricchio, MD<br />
Antonio La Cava, MD, PhD<br />
Mark J. Mamula, PhD<br />
Barbara J. Vilen, PhD<br />
28. Spondylarthropathies and<br />
psoriatic arthritis: clinical aspects<br />
and treatment<br />
Dafna D. Gladman, MD, FRCPC, Chair<br />
John C. Davis, Jr., MD, MPH<br />
Robert B.M. Landewé, MD<br />
Walter P. Maksymowych, MD, FRCPC<br />
Millicent A. Stone, MB, MRCP, MSc<br />
29. Spondylarthropathies and psoriatic<br />
arthritis: pathogenesis, etiology, and<br />
animal models<br />
Robert A. Colbert, MD, PhD, Chair<br />
Dominique Baeten, MD, PhD<br />
Tibor T. Glant, MD, PhD<br />
Tammy M. Martin, PhD<br />
Dennis McGonagle, MB, FRCPI, PhD<br />
Christopher T. Ritchlin, MD<br />
30. Vasculitis<br />
John H. Stone, MD, MPH, Chair<br />
Lin A. Brown, MD<br />
Curry L. Koening, MD<br />
Carlo Salvarani, MD<br />
Robert Spiera, MD<br />
Steven R. Ytterburg, MD<br />
31. Epidemiology and health<br />
services research<br />
Michael M. Ward, MD, Co-Chair<br />
Maria E. Suarez-Almazor, MD,<br />
PhD, Co-Chair<br />
Loreto Carmona, MD, PhD<br />
John D. FitzGerald, MD, PhD<br />
Sherine E. Gabriel, MD, MSc<br />
Allan C. Gelber, MD<br />
Eswar Krishnan, MD<br />
Tore K. Kvien, MD<br />
Diane V. Lacaille, MD, FRCPC, MHSc<br />
Jaya K. Rao, MD, MHS<br />
Anthony D. Woolf, MBBS, FRCP<br />
Angela Zink, PhD<br />
32. Quality measures and innovations in<br />
practice management and care delivery<br />
Eric D. Newman, MD, Chair<br />
Larry G. Anderson, MD<br />
William T. Ayoub, MD<br />
John T. Harrington, Jr., MD<br />
Steven S. Overman, MD, MPH<br />
Kazi Salahuddin, MD<br />
33. Genetics, genomics and proteomics<br />
William Robinson, MD, PhD, Chair<br />
Sergio A. Jimenez, MD<br />
John B. Harley, MD, PhD<br />
Virginia Pascual, MD<br />
Gregg J. Silvermann, MD<br />
34. Education<br />
Richard Brasington, MD, Chair<br />
Maria Barilla-LaBarca, MD, Co-Chair<br />
Abby G. Abelson, MD<br />
Johannes WJ. Bijlsma, MD, PhD<br />
George V. Lawry II, MD<br />
Murray H. Passo, MD<br />
35. Miscellaneous rheumatic and<br />
inflammatory diseases<br />
Dennis W. Boulware, MD, Chair<br />
Walter G. Barr, MD<br />
N. Lawrence Edwards, MD<br />
Paul Katz, MD<br />
Eric Matteson, MD<br />
Wayne J. Wallis, MD<br />
<strong>2007</strong> Abstract<br />
Oversight Committee<br />
Jeffrey N. Katz, MD, Chair<br />
Mary Anne Dooley, MD, MPH<br />
Daniel E. Furst, MD<br />
www.rheumatology.org—Rheumatology’s Home on the Web 319
<strong>2007</strong> <strong>ARHP</strong> Annual <strong>Meeting</strong> Leadership<br />
Executive Committee<br />
President<br />
Karen L. Kerr, MSN, NP, CPNP,<br />
APRN-BC<br />
President-Elect<br />
Kimberly F. Kimpton, PT<br />
Secretary-Treasurer<br />
Pamela J. Degotardi, PhD<br />
Committee on Education<br />
Linda S. Ehrlich-Jones, PhD, RN<br />
Committee on Practice & Membership<br />
Cindy F. Mendelson, PhD, RN<br />
Committee on Research<br />
Nadine T. James, RN, MSN, PhD<br />
Nominations Committee<br />
Catherine L. Backman, PhD, OT(C)<br />
<strong>ACR</strong> Board Representative<br />
Lenore M. Buckley, MD, MPH<br />
Invited Guests<br />
Janet S. Austin, PhD<br />
Gail C. Davis, RN, EdD<br />
Deborah A. McCloskey, RN, BSN<br />
Carol A. Oatis, PT, PhD<br />
<strong>ARHP</strong> <strong>Program</strong> Committee<br />
Mary E. Christenson, PT, MS, Chair<br />
Benjamin J. Smith, PA-C, Chair elect<br />
Glinda S. Cooper, PhD<br />
Patricia J. Cornell, BSc<br />
Linda S. Ehrlich-Jones, PhD, RN<br />
Kathryn L. Lowenstein, OTR/L<br />
Nancy E. Maher, MPH<br />
Leslie D. McDowell, ANP, MSN<br />
Karen L. Smarr, PhD<br />
Sandra J. Watcher, RN, BSn<br />
<strong>ARHP</strong> Clinical Focus Course<br />
Task Force<br />
Benjamin J. Smith, PA-C, Chair<br />
Kori A. Dewing, MN, ARNP<br />
J. Cairn Marrale, NP, MS, PhD<br />
Gale F. Mason, NP, MSN, MPH<br />
Daniel E. Schaffer, MPAS<br />
Donna L. Willingham, MSN, CPNP<br />
<strong>2007</strong> <strong>ARHP</strong> Abstract<br />
Review Panels<br />
Education/Community <strong>Program</strong>s<br />
Gail C. Davis, RN, EdD<br />
Victoria Gall, PT, MEd<br />
Patricia A. MacDonald, RN, NP<br />
Laura Robbins, DSW<br />
Ben J. Smith, PA-C<br />
Linda S. Ehrlich-Jones, PhD, RN<br />
Epidemiology<br />
Leigh F, Callahan, PhD<br />
Jennifer M Hootman, PhD, ATC<br />
Louise Murphy, BS, PhD<br />
Richard H. Osborne, PhD<br />
Emily C. Somers, PhD, ScM<br />
Nancy E Maher, MPH<br />
Health Services Research<br />
Teresa J. Brady, PhD, OT<br />
Josh S. Brinks, BSN, MSN<br />
Maureen R. Gecht-Silver, MPH, OTR/L<br />
Nadine M. Fisher, EdD<br />
Mark A. Lyle, MSPT<br />
Mary E. Christensen, PT, MS<br />
Nursing<br />
Joyce P. Carlone, MN, RN, CS, FNP<br />
Julie A. D’Agostino, ANP, CS<br />
Jackie Hill, RN, MPhII, PhDG<br />
Deborah A. McCloskey, RN, BSN<br />
Leslie D. McDowell, ANP, MSN<br />
Lisa M. Robbins, RN<br />
Pediatrics<br />
Deanna L. Carman, BS, PT<br />
Laurie E. Ebner-Lyon, RN, ANP<br />
Norma L. Liburd, RNC, MN<br />
Paula G. Melson, BHS, MMSc<br />
Elizabeth L. Roth-Wojcicki, RN, MS, CPNP<br />
Sandra J. Watcher, RN, BSN<br />
Psychology/Social Sciences<br />
Kelly K. Anthony, PhD<br />
Susan J. Bartlett, PhD<br />
Pamela J. Degotardi, PhD<br />
Patricia Katz, PhD<br />
Kathleen M. Schiaffino, PhD<br />
Karen L. Smarr, PhD<br />
Rehabilitation Sciences<br />
Laura D. Bilek, PhD, PT<br />
Lori Cyr, BSc, OT<br />
Ewa M. Roos, PT, PhD<br />
Jennifer L. Trizuto, BS, MPT<br />
Susan J. Wright, OT<br />
Kathryn L. Lowenstein, OTR/L<br />
Research Methodology<br />
Saralynn H. Allaire, ScD, RN, CRC<br />
Beverly K. Barham, BSN<br />
Michael P. LaValley, PhD<br />
Geri B. Neuberger, RN, EdD<br />
Mildred E. Wilson, BSN, RN<br />
Glinda S. Cooper, PhD<br />
320 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
acr award recipients<br />
The <strong>2007</strong> Award recipients will be profiled in a central exhibit in the North Lobby of the Boston Convention and<br />
Exhibition Center. <strong>ACR</strong> and <strong>ARHP</strong> awards will be presented at 5:30 pm on Wednesday, November 7 immediately<br />
preceding the Opening Lecture. The <strong>ACR</strong> Masters will also be recognized on Wednesday evening.<br />
<strong>ACR</strong> Awards of Distinction<br />
Presidential Gold Medal<br />
The highest award bestowed by<br />
the <strong>ACR</strong> to an active or emeritus<br />
member in recognition of outstanding<br />
achievements in rheumatology over an<br />
entire career. Candidates will have<br />
made important contributions in<br />
multiple areas such as clinical medicine,<br />
research, education or administration.<br />
It is supported by an endowed fund<br />
created by the past presidents of<br />
the <strong>ACR</strong> and managed by the <strong>ACR</strong><br />
Research and Education Foundation.<br />
Edward D. Harris, Jr., MD<br />
George DeForest Barnett<br />
Professor Emeritus<br />
Stanford University School of Medicine<br />
Executive Secretary, Alpha Omega Alpha<br />
Menlo Park, California<br />
Distinguished Basic Investigator Award<br />
Awarded to a basic scientist making<br />
outstanding contributions to the field<br />
of rheumatology.<br />
Peter K. Gregersen, MD<br />
Investigator Head<br />
Robert S. Boas Center for Genomics<br />
and Human Genetics<br />
The Feinstein Institute for<br />
Medical Research<br />
Manhasset, New York<br />
Distinguished Clinician Scholar Award<br />
Awarded to a rheumatologist who has<br />
made outstanding contributions in<br />
clinical medicine, clinical scholarship,<br />
or education.<br />
W. Joseph McCune, MD<br />
Professor of Internal Medicine<br />
The University of Michigan<br />
Ann Arbor, Michigan<br />
Henry Kunkel Young Investigator Award<br />
Awarded to a young physician scientist,<br />
age 45 or under, who has made<br />
outstanding independent contributions<br />
to basic or clinical research in the field<br />
of rheumatology.<br />
Daniel H. Solomon, MD, MPH<br />
Associate Professor of Medicine<br />
Brigham and Women’s Hospital<br />
Boston, Massachusetts<br />
Distinguished Clinical Investigator Award<br />
This award is given to a clinical scientist<br />
making outstanding contributions to<br />
the field of rheumatology.<br />
Daniel J. Lovell, MD, MPH<br />
Professor of Pediatrics<br />
Children’s Hospital Medical Center<br />
Cincinnati, Ohio<br />
Paulding Phelps Award<br />
This award is given to a clinical<br />
rheumatologist for outstanding service<br />
to patients, community and the<br />
profession of medicine.<br />
Luis R. Espinoza, MD<br />
Section Chief, Professor of Medicine<br />
Louisiana State University Health<br />
Sciences Center<br />
New Orleans, Louisiana<br />
Distinguished Service Award<br />
This award is given to an <strong>ACR</strong><br />
member for outstanding and sustained<br />
service of the <strong>ACR</strong>.<br />
Maren L. Mahowald, MD<br />
University of Minnesota Medical<br />
School<br />
Minneapolis, Minnesota<br />
<strong>ACR</strong>/REF Excellence in<br />
Investigative Mentoring Award<br />
Through this mentoring award, the<br />
REF will honor an active <strong>ACR</strong> or<br />
<strong>ARHP</strong> member for their contributions<br />
to the rheumatology profession through<br />
outstanding and ongoing mentoring.<br />
Bevra H. Hahn, MD<br />
Chief of Rheumatology<br />
University of California, Los Angeles<br />
School of Medicine<br />
Los Angeles, California<br />
<strong>2007</strong> <strong>ACR</strong> Masters<br />
Recognition as a Master of the<br />
<strong>American</strong> College of Rheumatology<br />
is one of the highest honors the<br />
College bestows on an <strong>ACR</strong> member.<br />
This distinction is given to members,<br />
age 65 or older, who have made<br />
outstanding contributions to the field<br />
of rheumatology through scholarly<br />
achievement and/or service to their<br />
patients, students, and profession. The<br />
<strong>ACR</strong> has honored 207 members as<br />
Masters since 1987.<br />
Frank C. Arnett, Jr., MD<br />
Professor of Medicine<br />
University of Texas Medical School<br />
at Houston<br />
Houston, Texas<br />
Robert M. Bennett, MD, FRCP<br />
Professor of Medicine<br />
Oregon Health and Sciences University<br />
Portland, Oregon<br />
Lynn Bonfiglio<br />
Director of Membership<br />
<strong>American</strong> College of Rheumatology<br />
Atlanta, Georgia<br />
www.rheumatology.org—Rheumatology’s Home on on the Web 321
acr award recipients<br />
Jean-Michel Dayer, MD<br />
Professor of Medicine<br />
University of Geneva<br />
Geneva, Switzerland<br />
Raphael J. DeHoratius, MD<br />
Professor of Medicine<br />
Jefferson Medical College<br />
Philadelphia, Pennsylvaniaa<br />
C. Garrison Fathman, MD<br />
Professor of Medicine, Division Chief<br />
Stanford University<br />
Stanford, California<br />
Shu Man Fu, MD, PhD<br />
Margaret M. Trolinger Professor of<br />
Rheumatology<br />
University of Virginia<br />
Charlottesville, Virginia<br />
David N. Glass, MD<br />
Professor of Pediatrics<br />
Children’s Hospital Medical Center<br />
Cincinnati, Ohio<br />
Kate R. Lorig, DrPH<br />
Professor of Medicine<br />
Stanford University<br />
Palo Alto, California<br />
Anne-Marie Prieur, MD<br />
Hopital Enfants-Malades<br />
Paris, France<br />
Kenneth E. Sack, MD<br />
Professor of Clinical Medicine<br />
University of California, San Francisco<br />
San Francisco, California<br />
William E. Seaman, MD<br />
Professor of Medicine and<br />
Microbiology/Immunology<br />
University of California, San Francisco<br />
San Francisco, California<br />
John S. Sergent, MD<br />
Vice Chair for Education<br />
Vanderbilt University Medical Center<br />
Nashville, Tennessee<br />
Levinus B. Van de Putte, MD, PhD<br />
Chairman of the Department<br />
of Rheumatology<br />
University Hospital Nijmegen<br />
Nijmegen, The Netherlands<br />
Alan S. Wiik, MD, PhD<br />
Director of the Division of<br />
Autoimmunity<br />
State Seruminstitut<br />
Copenhagen, Denmark<br />
H. James Williams, MD*<br />
Professor of Medicine<br />
University of Utah School of Medicine<br />
Salt Lake City, Utah<br />
John B. Winfield, MD<br />
Herman and Louise Smith<br />
Distinguished Professor<br />
University of North Carolina Thurston<br />
Arthritis Research Center<br />
Chapel Hill, North Carolina<br />
Distinguished Fellow Awards<br />
These awards are given to clinical and<br />
research fellows in a rheumatology<br />
fellowship training program who have<br />
performed meritoriously in the areas of<br />
patient care, teaching, research and/or<br />
community service. These awards are<br />
made possible through support from<br />
the <strong>ACR</strong> Fellows Education Fund.<br />
This fund is supported by educational<br />
grants from Abbott Laboratories, Amgen,<br />
Inc. and Wyeth Pharmaceuticals, Bristol-<br />
Myers Squibb Company and Genentech, Inc.<br />
Edward Behrens, MD<br />
Children’s Hospital of Philadelphia<br />
Happy Chan, DO<br />
Washington University School of<br />
Medicine<br />
Julia Charles, MD, PhD<br />
University of California, San Francisco<br />
Sharon Chung, MD<br />
University of California, San Francisco<br />
Mazen Elyan, MD<br />
Case Western Metro Health Center<br />
Gim Gee Teng, MBBS<br />
University of Alabama at Birmingham<br />
Aimee Hersh, MD<br />
University of California, San Francisco<br />
Matthew Mundwiler, MD<br />
Cedars-Sinai Medical Center<br />
Victoria Shanmugam, MBBS<br />
Georgetown University<br />
Steve Spalding, MD<br />
Children’s Hospital of Pittsburgh<br />
* Elected in 2006<br />
322 Visit <strong>ACR</strong> Central for for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
arhp award recipients<br />
The <strong>2007</strong> Award recipients will be profiled in a central exhibit in the North Lobby of the Boston Convention and<br />
Exhibition Center. <strong>ACR</strong> and <strong>ARHP</strong> awards will be presented at 5:30 pm on Wednesday, November 7 immediately<br />
preceding the Opening Lecture. The <strong>ACR</strong> Masters will also be recognized on Wednesday evening.<br />
Lifetime Achievement Award<br />
The Lifetime Achievement Award is the<br />
highest honor <strong>ARHP</strong> bestows and is<br />
presented to a current or former<br />
member of the <strong>ARHP</strong> whose career has<br />
demonstrated a sustained and lasting<br />
contribution to the field of rheumatology<br />
and to health professional within<br />
rheumatology.<br />
Marian A. Minor, PhD, PT<br />
University of Missouri<br />
Columbia, MO<br />
<strong>ARHP</strong> Merit Awards<br />
Addie Thomas Service Award<br />
Presented in honor of the first president<br />
of the Arthritis Health Professionals<br />
Association and recognizes the member<br />
who has been an active volunteer<br />
involved with local, regional and<br />
national arthritis related activities.<br />
Janalee Taylor, RN, MSN, CNS<br />
Children’s Hospital and Medical Center<br />
Cincinnati, OH<br />
<strong>ARHP</strong> Distinguished Scholar Award<br />
Presented to an individual who<br />
demonstrates exceptional achievements<br />
in scholarly activities pertinent to the<br />
rheumatic diseases.<br />
Joan C. Rogers, PhD, OTR/L<br />
University of Pittsburgh<br />
Pittsburgh, PA<br />
Ann Kunkel Advocacy Award<br />
The new Ann Kunkel Advocacy Award<br />
recognizes health professionals with a<br />
history of advocating at local, regional<br />
and national levels with and on<br />
behalf of people living with arthritis.<br />
Individuals who receive this award are<br />
recognized as champions in promoting<br />
health policies, practices and research<br />
that address the needs of the arthritis<br />
community. It is named in honor of<br />
<strong>ARHP</strong> member Ann Kunkel, a patient<br />
educator in pediatric rheumatology<br />
whose enthusiasm and persistence<br />
as an advocate has inspired many<br />
members to join the effort to increase<br />
arthritis awareness.<br />
Amye L. Leong, MBA<br />
Healthy Motivation<br />
North Wales, PA<br />
Kathleen A. Arntsen, BA<br />
Lupus Foundation of Mid & Northern<br />
New York<br />
Verona, NY<br />
<strong>ARHP</strong> Master Clinician Award<br />
This award is presented to an individual<br />
who is engaged in clinical practice and<br />
demonstrates outstanding clinical<br />
expertise in the rheumatic diseases.<br />
(Formerly known as Clinical Master Award)<br />
Norma L. Liburd, RNC, MN<br />
University of South Florida<br />
St. Petersburg, FL<br />
Gail R. McIlvain-Simpson,<br />
MSN, APRN, BC<br />
A. I. duPont Hospital for Children<br />
Wilmington, DE<br />
<strong>ARHP</strong> Appreciation Award<br />
Membership Recruitment Award<br />
Presented to the member who has<br />
recruited the most members in the<br />
current year.<br />
To be announced<br />
President’s Award<br />
Presented to the member that has<br />
advanced the aims, ideals and goals of<br />
<strong>ARHP</strong> during the current year.<br />
Erica B. Stern, PhD, OTR/L<br />
University of Minnesota<br />
Minneapolis, MN<br />
<strong>ARHP</strong> Graduate Student<br />
Recognition Award<br />
Recognizes creative research or clinical<br />
project efforts that merge theory and<br />
clinical practice in assessing and/or<br />
improving the lives of patients with<br />
rheumatic diseases, broadly defined<br />
and encourages the interest of nonmedical<br />
graduate students in the field<br />
of rheumatology.<br />
Steffany Haaz, MFA<br />
Johns Hopkins University<br />
Baltimore, MD<br />
<strong>ARHP</strong> Mentor: Susan J. Bartlett, PhD<br />
Allen J. Lehman, MA<br />
University of British Columbia<br />
Vancouver, British Columbia<br />
<strong>ARHP</strong> Mentor: Catherine L. Backman,<br />
PhD, OT(C)<br />
Terri L. White, MS, RN, FNP-C<br />
Texas Woman’s University<br />
Robinson, TX<br />
<strong>ARHP</strong> Mentor: Gail C. Davis, RN, EdD<br />
www.rheumatology.org—Rheumatology’s Home on on the Web 323
acr, arhp + ref staff members<br />
Administration<br />
Executive Vice President<br />
Mark Andrejeski<br />
Human Resources Director<br />
Andrea Brinn, JD<br />
Senior Specialist, Administration & Governance<br />
Rachel Ullian<br />
Executive Assistant<br />
Katie Duggan<br />
Operations & Finance<br />
Vice President, Operations & Finance<br />
Colleen Merkel<br />
Controller<br />
Susan Parrish<br />
Senior Specialist, Accounting<br />
Chasity Steverson<br />
Accounting Coordinator, A/P<br />
Tawanda Hawk<br />
Accounting Assistant, A/R<br />
Donna Hunt<br />
Receptionist<br />
Felecia Moore<br />
Technology & Information Systems<br />
Vice President, Technology & Information Systems<br />
Steve Blevins<br />
Web <strong>Program</strong>mer<br />
Janet Chisholm<br />
Systems & Database Administrator<br />
Dotty Nordberg<br />
Network Administrator<br />
Michael Crozier<br />
Information Systems Specialist<br />
Vacant<br />
Education<br />
Vice President, Education<br />
Donna Hoyne<br />
Senior Director, Educational <strong>Program</strong>s<br />
Candace Spradley<br />
Senior Director, <strong>Meeting</strong>s & Conferences<br />
Ron Olejko<br />
Senior Specialist, Continuous Professional Development<br />
Julie Anderson<br />
Senior Specialist, Educational <strong>Program</strong>s<br />
Stacey Chandler<br />
Specialist, Educational Products<br />
Vacant<br />
<strong>Meeting</strong>s Planner<br />
Lucy Beckett<br />
Educational <strong>Program</strong>s Coordinator<br />
Teresa Montgomery<br />
Administrative Assistant, Annual <strong>Scientific</strong> <strong>Meeting</strong><br />
Karol Gaddis-Flowers<br />
Administrative Assistant<br />
Naama Davidai<br />
Corporate Relations<br />
Senior Director, Corporate Relations<br />
Susan Bernstein<br />
Socioeconomic & Government Affairs<br />
Vice President, Socioeconomic Affairs<br />
Tiffany Schmidt, JD, MBA<br />
Director, Government Affairs<br />
Kristin Wormley<br />
Director, Practice Management<br />
Antanya Chung<br />
Specialist, Government Affairs<br />
Aiken Hackett<br />
Reimbursement Specialist<br />
Melesia Collins<br />
Reimbursement Specialist<br />
Resaee Freeman<br />
Administrative Assistant<br />
Regina Adair<br />
Communications, Marketing<br />
& Membership<br />
Senior Director, Communications,<br />
Marketing and Membership<br />
Tammy J. Tilley<br />
Director, Membership<br />
Helen Anne Richards<br />
Senior Specialist, Communications & Marketing<br />
Erin Latimer<br />
Senior Specialist, Web Content<br />
Vacant<br />
Senior Graphic Designer<br />
Sandra Pulmano<br />
Member Services Coordinator<br />
Damian Smalls<br />
Research, Training & Quality Measures<br />
Senior Director, Research, Training<br />
& Quality Measures<br />
Amy Miller<br />
Senior Specialist, Research & Training<br />
LaTanya Batts<br />
Senior Specialist, Quality Measures<br />
Amy B. Miller<br />
Coordinator, Research, Training & Quality<br />
Crystal Livingston<br />
<strong>ARHP</strong><br />
Executive Director<br />
David Haag, MSM, CAE<br />
Senior Specialist, Educational <strong>Program</strong>s<br />
Joan “Happy” Tyree<br />
<strong>Program</strong> Services Specialist<br />
Ramona Hilliard<br />
Managing Editor, AC&R<br />
Nancy Parker<br />
Manuscript Editor, AC&R<br />
Lisa McAvoy<br />
Manuscript Editor, AC&R<br />
Lauren Vogelbaum<br />
Manuscript Editor, AC&R<br />
Rachel Whittaker<br />
Administrative Assistant<br />
Sharon Ross<br />
REF<br />
Executive Director<br />
Steven Echard, CAE<br />
Senior Director, Development<br />
Paula Reed<br />
Director, Major Gifts<br />
Elizabeth Jennette<br />
Director, Awards & Grants<br />
Seema Bajaj, MPA<br />
Senior Specialist, Annual Giving<br />
Samantha Rasnake<br />
Senior Specialist, Communications<br />
& Marketing<br />
Michelle Hatch<br />
Senior Specialist, Awards & Grants<br />
Victoria Anderson<br />
Development Coordinator<br />
Kymberly Burkhead<br />
Administrative Assistant<br />
Vacant<br />
Arthritis & Rheumatism Journal<br />
Senior Director & Managing Editor<br />
Jane Diamond<br />
Assistant Managing Editor<br />
Patricia Reichert<br />
Senior Manuscript Editor<br />
Lesley Allen<br />
Manuscript Editor<br />
Michelle Moran<br />
Manuscript Editor<br />
Michael Weinberg<br />
Manuscript Editor<br />
Pat Mabley<br />
Manuscript Editor<br />
Emily Wehby<br />
Editorial Coordinator<br />
Lee Sanford<br />
324 Visit <strong>ACR</strong> Central for for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
“<br />
My REF award has profoundly altered my professional life. It<br />
has enabled me to pursue an academic career, obtain a Masters<br />
in epidemiology and pursue other research interests. It is likely<br />
that the experiences made possible through REF support will<br />
serve as the foundation for the rest of my academic career.<br />
”<br />
– Brian T. Walitt, MD, Clinical Investigator Fellowship Award<br />
Ensuring the Future of Rheumatology.<br />
Today, due in large part to REF<br />
efforts, including an extensive awards<br />
and grants program, the number of<br />
fellows completing rheumatology<br />
training programs has increased by<br />
more than 50 percent.<br />
www.rheumatology.org—Rheumatology’s Home on the Web 325
acr research and education foundation<br />
2006-<strong>2007</strong> Board of Directors<br />
President<br />
James R. O’Dell, MD<br />
Vice President<br />
Leslie J. Crofford, MD<br />
Secretary/Treasurer<br />
Stanley B. Cohen, MD<br />
<strong>ACR</strong> Vice President<br />
Sherine E. Gabriel, MD, MSc<br />
Member-At-Large<br />
Michael Brenner, MD<br />
Member-At-Large<br />
Leonard H. Calabrese, DO<br />
Member-At-Large<br />
David I. Daikh, MD, PhD<br />
Member-At-Large<br />
Ellen M. Gravallese, MD<br />
Member-At-Large<br />
Stephen A. Paget, MD<br />
Member-At-Large<br />
Eric S. Schned, MD<br />
<strong>ARHP</strong> Representative<br />
Carol Oatis, PT, PhD<br />
Chair, <strong>Scientific</strong> Advisory Council<br />
V. Michael Holers, MD<br />
IRT Representative<br />
Jim Norton, PhD<br />
<strong>ACR</strong> Research Representative<br />
E. William St. Clair, MD<br />
Ex Officio Members<br />
<strong>ACR</strong> President<br />
Neal S. Birnbaum, MD<br />
<strong>ACR</strong> President-Elect<br />
David Fox, MD<br />
DAC Representative<br />
Katherine S. Upchurch, MD<br />
2006-<strong>2007</strong> Development<br />
Advisory Council<br />
Stanley B. Cohen, MD, Chair<br />
Diana L. Anderson, PhD<br />
Leslie J. Crofford, MD<br />
Ronald L. Kaufman, MD, MBA<br />
William N. Kelley, MD<br />
Peter A. Looram<br />
James R. O’Dell, MD<br />
Katherine S. Upchurch, MD<br />
Arthur L. Weaver, MD<br />
2006-<strong>2007</strong> <strong>Scientific</strong><br />
Advisory Council<br />
V. Michael Holers, MD, Chair<br />
David I. Daikh, MD, PhD<br />
Anne Davidson, MBBS, FRACP<br />
Judith James, MD<br />
David R. Karp, MD, PhD<br />
Daniel L. Kastner, MD, PhD<br />
Gary A. Koretzky, MD, PhD<br />
Michael A. Rapoff, PhD<br />
E. William St. Clair, MD<br />
Ilona S. Szer, MD<br />
Sterling G. West, MD<br />
326 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
<strong>ACR</strong> ref Award <strong>Program</strong>s + REcipients<br />
<strong>Program</strong>s For Students<br />
<strong>ACR</strong> REF/Abbott Medical/Graduate<br />
Student Achievement Awards<br />
Recognizes medical and graduate<br />
students for significant work in<br />
the field of rheumatology and<br />
is presented based on scores for<br />
abstracts submitted to the <strong>ACR</strong>/<br />
<strong>ARHP</strong> Annual <strong>Scientific</strong> <strong>Meeting</strong>.<br />
Students receive a $750 cash award<br />
and a travel package of up to $1,000<br />
for the annual meeting. Funding for<br />
this award is made possible through the<br />
Abbott Endowment for Rheumatology<br />
Development.<br />
Sarah E. Dubner<br />
University of Pennsylvania School of<br />
Medicine<br />
Jack Hutcheson<br />
St. Louis University<br />
Kindra M. Kelly-Scumpia<br />
University of Florida<br />
Pui Y. Lee<br />
University of Florida<br />
Jason M. Low, MS<br />
St. Louis University School of<br />
Medicine<br />
Ann B. Nguyen<br />
University of Oklahoma Health<br />
Sciences Center<br />
John C. Scatizzi<br />
St. Louis University<br />
Adam C. Schmucker<br />
Dartmouth College<br />
Puneet Tung<br />
University of Pennsylvania School of<br />
Medicine<br />
Muthiah Vaduganathan<br />
Northwestern University<br />
Cindy Zer<br />
The Regents of University of<br />
California, Los Angeles<br />
<strong>ACR</strong> REF/Abbott Medical Student<br />
Clinical Preceptorship<br />
Introduces students who are<br />
between the first and second year<br />
of medical school to the specialty<br />
of rheumatology by supporting<br />
a full-time clinical opportunity.<br />
Preceptorships offer a student<br />
stipend, a preceptor stipend and,<br />
upon acceptance, travel expenses<br />
to the <strong>ACR</strong>/<strong>ARHP</strong> Annual<br />
<strong>Scientific</strong> <strong>Meeting</strong>. Funding for this<br />
award is made possible through the<br />
Abbott Endowment for Rheumatology<br />
Development.<br />
David R. Carrier<br />
Preceptor: David George, MD<br />
Reading Hospital & Medical Center<br />
Jennifer C. Cooper, PharmD<br />
Preceptor: Robert V. Janson, MD<br />
Denver VA Medical Center<br />
Brandi D. Eastman<br />
Preceptor: Marcy Bolster, MD<br />
Medical University of South<br />
Carolina<br />
Brian H. Horner<br />
Preceptor: David H. Collier, MD<br />
University of Colorado School of<br />
Medicine<br />
Erin E. Meschter<br />
Preceptor: Thomas M. Harrington, MD<br />
Geisinger Medical Center<br />
Marisa C. Mizus<br />
Preceptor: Joan M. Bathon, MD<br />
John Hopkins University<br />
Elizabeth G. Riccardi<br />
Preceptor: Hom Neupane, MD<br />
Upstate Medical Center<br />
Megan L. Shparago<br />
Preceptor: R. Deaver Collins, Jr., MD<br />
Arthritis Associates of Mississippi<br />
An T. Tran<br />
Preceptor: Daniel George Arkfeld, MD<br />
University of Southern California<br />
<strong>ACR</strong> REF/Abbott Medical Student<br />
Research Preceptorship<br />
Introduces students who are<br />
between the first and second year<br />
of medical school to the specialty<br />
of rheumatology by supporting<br />
a full-time research opportunity.<br />
Preceptorships offer a student<br />
stipend, a preceptor stipend and,<br />
upon acceptance, travel expenses<br />
to the <strong>ACR</strong>/<strong>ARHP</strong> Annual<br />
<strong>Scientific</strong> <strong>Meeting</strong>. Funding for this<br />
award is made possible through the<br />
Abbott Endowment for Rheumatology<br />
Development.<br />
Aimee K. Angle-Zahn<br />
Preceptor: Jane E. Salmon, MD<br />
Hospital of Special Surgery<br />
Christopher P. Deibert<br />
Preceptor: Joseph M. Ahearn, MD<br />
University of Pittsburgh<br />
James M. Kelley<br />
Preceptor: Robert P. Kimberly, MD<br />
University of Alabama at Birmingham<br />
Robert W. Koschik II<br />
Preceptor: Thomas A. Medsger, Jr., MD<br />
University of Pittsburgh<br />
Eleni Nackos<br />
Preceptor: John M. Von Feldt, MD<br />
University of Pennsylvania<br />
Thomas M. Penoyar<br />
Preceptor: Peter A. Simkin, MD<br />
University of Washington School of<br />
Medicine<br />
Balvinder Rehal<br />
Preceptor: Nancy E. Lane, MD<br />
University of California at Davis<br />
Robert Lee Salazar<br />
Preceptor: Barry L. Myones, MD<br />
Texas Children’s Hospital - Baylor<br />
Xueyuan Shelly Wang<br />
Preceptor: Joan M. Von Feldt, MD<br />
University of Pennsylvania<br />
www.rheumatology.org—Rheumatology’s Home on on the Web 327
<strong>ACR</strong> ref Award <strong>Program</strong>s + REcipients<br />
Daniel M. Wells<br />
Preceptor: Leonard L. Dragone, MD, PhD<br />
National Jewish Medical &<br />
Research Center<br />
Sophie L. Woolston<br />
Preceptor: David Sherry, MD<br />
Children’s Hospital of Philadelphia<br />
Daniel C. Windels<br />
Preceptor: Susan A. Boackle, MD<br />
University of Colorado Health<br />
Services Center<br />
Jeremy J. Zimmermann<br />
Preceptor: Calvin B. Williams, MD<br />
Midwestern University<br />
<strong>ACR</strong> REF/Abbott Health Professional<br />
Graduate Student Research Preceptorship<br />
Introduces students to rheumatologyrelated<br />
health care by supporting fulltime<br />
research by a graduate student<br />
in the area of rheumatic diseases.<br />
Preceptorships offer a student<br />
stipend, a preceptor stipend and,<br />
upon acceptance, travel expenses to<br />
the <strong>ACR</strong>/<strong>ARHP</strong> Annual <strong>Scientific</strong><br />
<strong>Meeting</strong>. Funding for this award is made<br />
possible through the Abbott Endowment<br />
for Rheumatology Development.<br />
Steffany Haaz, MFA<br />
Preceptor: Susan J. Bartlett, PhD<br />
Johns Hopkins University<br />
Cynthia W. Karlson<br />
Preceptor: Michael Rapoff, PhD<br />
University of Kansas<br />
Deepak Kumar, PT<br />
Preceptor: Katherine T. Rudolph, PhD<br />
University of Delaware<br />
Mei Yang, MA<br />
Preceptor: Yuqing Zhang, DSc, MPH<br />
Boston University School of Medicine<br />
Haoyang Zhuang<br />
Preceptor: Westley H. Reeves, MD<br />
University of Florida<br />
PROGRAMS FOR RESIDENTS<br />
<strong>ACR</strong> REF/Amgen Pediatric<br />
Rheumatology Research Award<br />
Recognizes and promotes scholarship<br />
in the field of pediatric rheumatology<br />
and is presented based on scores for<br />
abstracts submitted to the <strong>ACR</strong>/<br />
<strong>ARHP</strong> Annual <strong>Scientific</strong> <strong>Meeting</strong>.<br />
Recipients receive a $1,000 cash<br />
award Funding for this award is made<br />
possible through an endowment provided<br />
by Amgen Inc.<br />
Alexis R. Ogdie, MD<br />
University of Pennsylvania<br />
<strong>ACR</strong> REF/Abbott Medical and Pediatric<br />
Resident Research Award<br />
Designed to motivate outstanding<br />
residents to pursue subspecialty<br />
training in rheumatology by providing<br />
them with an opportunity to attend<br />
the <strong>ACR</strong>/<strong>ARHP</strong> Annual <strong>Scientific</strong><br />
<strong>Meeting</strong>. Recipients will receive a<br />
$750 cash award and a travel package<br />
of up to $1,000 for the annual<br />
meeting. Funding for this award is made<br />
possible through the Abbott Endowment<br />
for Rheumatology Development.<br />
Kaleo C. Ede, MD<br />
The Regents of University of<br />
California, Los Angeles<br />
Melissa M. Hazen, MD<br />
Brigham and Women’s Hospital<br />
Frank C. Pessler, MD, PhD<br />
Philadelphia VA Medical Center<br />
<strong>ACR</strong> REF Resident Research<br />
Preceptorship<br />
Introduces residents to the specialty<br />
of rheumatology by supporting a fulltime<br />
research experience. This award<br />
is funded for one year at $15,000.<br />
Shannon M. Rylee, MD<br />
Preceptor: Ram Raj Singh, MD<br />
The Regents of the University of<br />
California – Los Angeles<br />
Korey L. Ullrich, MD<br />
Preceptor: John D. Reveille, MD<br />
University of Texas Health Services<br />
Center - Houston<br />
PROGRAMS FOR FELLOWS<br />
<strong>ACR</strong> REF Clinical Investigator<br />
Fellowship Award<br />
Supports a structured, formal training<br />
program on aspects of clinical<br />
investigations for rheumatology<br />
fellows or rheumatologists who are in<br />
the early stages of their career. This<br />
award is funded for two years at up to<br />
$90,000 per year.<br />
Elaine Husni, MD<br />
The Cleveland Clinic Foundation<br />
Veena K. Ranganath, MD<br />
UCLA School of Medicine<br />
Pamela F. Weiss, MD<br />
Children’s Hospital of Philadelphia<br />
328 Visit <strong>ACR</strong> Central for for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
<strong>ACR</strong> ref Award <strong>Program</strong>s + REcipients<br />
<strong>ACR</strong> REF/Lupus Research Institute<br />
Lupus Investigator Fellowship Award<br />
Encourages qualified physicians<br />
without significant prior research<br />
experience to develop research careers<br />
that emphasize better understanding<br />
of systemic lupus erythematosus and<br />
its prevalence. The award is funded<br />
for three years at $50,000 annually.<br />
Funding for this award is made possible<br />
through the financial support of the Lupus<br />
Research Institute.<br />
Eyal Muscal, MD<br />
Baylor College of Medicine<br />
<strong>ACR</strong> REF Physician Scientist<br />
Development Award<br />
Encourages qualified physicians<br />
without significant prior research<br />
experience to embark on careers in<br />
biomedical and/or clinical research in<br />
arthritis and the rheumatic diseases.<br />
This award is funded for three years at<br />
$50,000 annually.<br />
Alvina D. Chu, MD<br />
Stanford University<br />
Sharon A. Chung, MD<br />
The Regents of University of<br />
California – San Francisco<br />
Alison M. Gizinski, MD<br />
University of Colorado Health<br />
Sciences Center<br />
Jane L. Park, MD<br />
Stanford University Medical Center<br />
Victoria K. Shanmugam, MBBS,<br />
MRCP<br />
Georgetown University Hospital<br />
Tracey B. Wright, MD<br />
Children’s Hospital of Philadelphia<br />
Michael R. York, MD<br />
Boston University Medical Center<br />
PROGRAMS FOR YOUNG<br />
RHEUMATOLOGISTS<br />
<strong>ACR</strong> REF/Association of Subspecialty<br />
Professors Junior Career Development<br />
Award in Geriatric Medicine<br />
Provides support to academicians who<br />
are transitioning from fellowship to<br />
their first faculty appointment and<br />
who are interested in pursuing careers<br />
in the geriatric and gerontology<br />
aspects of rheumatology. This award<br />
is funded for two years at $75,000<br />
per year. Funding for this award is made<br />
possible through the financial support of<br />
the Association of Subspecialty Professors.<br />
Tuhina Neogi, MD, FRCPC<br />
Boston University School of Medicine<br />
<strong>Program</strong>s for<br />
Experienced Physicians<br />
<strong>ACR</strong> REF Academic Re-Entry Award<br />
Assists fully trained basic and clinical<br />
research scientists in resuming<br />
research careers in rheumatology<br />
after having taken time away from<br />
academic research. Awards are funded<br />
for two years at $50,000 per year.<br />
Diana Milojevic, MD<br />
The Regents of University of<br />
California – San Francisco<br />
<strong>ACR</strong> REF/Amgen Pediatric Rheumatology<br />
Visiting Professorship <strong>Program</strong><br />
Provides educational opportunities<br />
for medical students and residents<br />
in institutions where no established<br />
pediatric rheumatology expertise<br />
currently exists. Each visiting<br />
professor receives an honorarium and<br />
reimbursement for expenses. Funding<br />
for this award is made possible through an<br />
endowment provided by Amgen Inc.<br />
Visiting Professors and Institutions:<br />
Barbara S. Adams, MD<br />
University of Michigan – Ann Arbor<br />
Queens University - Kingston<br />
General Hospital<br />
Helen M. Emery, MD<br />
Children’s Hospital & Regional<br />
Medical Center<br />
Nassau University Medical Center<br />
Donald P. Goldsmith, MD<br />
St. Christopher Hospital for Children<br />
Lincoln Medical and Mental Health Center<br />
James D. Jarvis, MD<br />
Children’s Hospital Oklahoma<br />
The Children’s Hospital at Monmouth<br />
Medical Center<br />
Barry L. Myones, MD<br />
Baylor College of Medicine<br />
Orlando Regional Medical Center<br />
Murray Passo, MD<br />
Cincinnati Children’s Hospital<br />
Medical Center<br />
Vermont Children’s Hospital<br />
Laura Schanberg, MD<br />
Duke University Medical Center<br />
Gundersen Clinic<br />
<strong>ACR</strong> REF Clinician Scholar<br />
Educator Award<br />
Recognizes and supports<br />
rheumatologists who are dedicated<br />
to providing a high-quality clinical<br />
educational experience to future<br />
rheumatologists. This award is funded<br />
for three years at $50,000 annually.<br />
Abby G. Abelson, MD<br />
Cleveland Clinic Foundation<br />
Yukiko Kimura, MD<br />
Hackensack University Medical Center<br />
Sharon L. Kolasinski, MD<br />
Hospital of University of Pennsylvania<br />
www.rheumatology.org—Rheumatology’s Home on on the Web 329
<strong>ACR</strong> ref Award <strong>Program</strong>s + REcipients<br />
<strong>ACR</strong> REF Innovative Teaching Grant<br />
Supports the development of quality<br />
rheumatology training programs and<br />
teaching materials for students and<br />
residents. This award is funded for<br />
one year at $15,000.<br />
Daniel J. Lovell, MD, MPH<br />
Children’s Hospital Medical Center<br />
<strong>ACR</strong> REF Memorial Lectureships<br />
Endowed lectureships support<br />
rheumatology research and honor the<br />
lives of four outstanding physicians,<br />
Edmund L. Dubois, MD, Oscar S.<br />
Gluck, MD, Paul Klemperer, MD,<br />
and Marshall J. Schiff, MD. These<br />
lectureships highlight research<br />
on systemic lupus erythematosus,<br />
outstanding research in rheumatology,<br />
bone metabolism and the interface<br />
between rheumatology and<br />
orthopedics in musculoskeletal<br />
medicine, respectively. Dubois<br />
Lectureship recipients are awarded<br />
$750; Klemperer, Gluck and Schiff<br />
Lectureship recipients receive $1,500.<br />
Edmund L. Dubois, MD,<br />
Memorial Lectureship<br />
Presented by: Judith James, MD,<br />
PhD, Oklahoma Medical Research<br />
Foundation<br />
Oscar S. Gluck, MD,<br />
Memorial Lectureship<br />
Presented by: Steven Teitelbaum, MD,<br />
Washington University – St. Louis<br />
Funding for the Gluck Lectureship is<br />
provided in part by support from Merck &<br />
Company, Inc. and Eli Lilly and Company.<br />
Paul Klemperer, MD,<br />
Memorial Lectureship<br />
Presented by: Paul Plotz, MD,<br />
National Institute of Arthritis<br />
Marshall J. Schiff, MD,<br />
Memorial Lectureship<br />
Presented by: Regis O’Keefe, MD,<br />
University of Rochester Medical Center<br />
<strong>Program</strong>s for<br />
Health Professionals<br />
<strong>ACR</strong> REF Lawren H. Daltroy Fellowship<br />
in Patient-Clinician Communication<br />
Improves patient-clinician interactions<br />
through researching various aspects<br />
of patient-clinician communication<br />
leading to the development of more<br />
qualified and trained clinicians and.<br />
Awards are funded for one year at<br />
$7,000. Funding for this award is made<br />
possible through an endowment established<br />
by Rheuminations, Inc.<br />
No recipients awarded this year.<br />
<strong>ACR</strong> REF Health Professional<br />
Investigator Award<br />
Offers support to health professionals<br />
who are committed to a career in<br />
rheumatology-related research. This<br />
award is funded for two years at<br />
$50,000 annually.<br />
Nancy A. Baker, ScD, OTR/L<br />
University of Pittsburgh<br />
Chenchen Wang, MD, MSs<br />
Tufts New England Medical Center<br />
<strong>ACR</strong> REF Health Professional<br />
New Investigator Award<br />
Encourages health professionals new<br />
to the field of rheumatology to pursue<br />
a research career. This award is funded<br />
for two years at $50,000 annually.<br />
Thelma J. Mielenz, PT, PhD, OCS<br />
University of North Carolina, Chapel Hill<br />
Sara R. Piva, PhD, PT<br />
University of Pittsburgh<br />
Jennifer E. Stevens, MPT, PhD<br />
University of Colorado, Denver<br />
Health Sciences Center<br />
<strong>Program</strong>s for<br />
Institutions and <strong>Program</strong><br />
Directors<br />
<strong>ACR</strong> REF Paula de Merieux<br />
Rheumatology Fellowship Award<br />
Helps to ensure for a diverse and<br />
highly trained workforce to provide<br />
competent clinical care to those<br />
affected by the rheumatic diseases.<br />
This award is funded for one year at<br />
$25,000 to support the salary of one<br />
minority or woman trainee. Funding<br />
for this award is made possible by an<br />
endowment established by the Dr. Paula<br />
de Merieux estate.<br />
David D. Sherry, MD<br />
The Children’s Hospital of Philadelphia<br />
<strong>ACR</strong> REF/Abbott Resident<br />
Recruitment Dinner <strong>Program</strong><br />
Supports recruitment dinners<br />
designed to interest outstanding<br />
internal medicine and pediatric<br />
residents in rheumatology and<br />
encourage their entry into the field.<br />
Selected institutions receive a grant of<br />
$1,000. Funding for this award is made<br />
possible through the Abbott Endowment<br />
for Rheumatology Development.<br />
Helen M. Emery, MD<br />
Children’s Hospital and Regional<br />
Medical Center<br />
Sharon L. Kolasinski, MD<br />
Hospital of University of Pennsylvania<br />
330 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
<strong>ACR</strong> ref Award <strong>Program</strong>s + REcipients<br />
<strong>ACR</strong> REF/Amgen/Wyeth Rheumatology<br />
Fellowship Training Award<br />
Helps to ensure that a highly trained<br />
workforce is available to provide<br />
competent clinical care to those<br />
affected by the rheumatic disease.<br />
The award is funded for one year at<br />
$25,000 to support the salary of one<br />
trainee. Funding for this award is made<br />
possible through the financial support of<br />
Amgen Inc. and Wyeth Pharmaceuticals.<br />
Walter G. Barr, MD<br />
Northwestern University<br />
Ernest Brahn, MD<br />
UCLA School of Medicine<br />
Suzanne L. Bowyer, MD<br />
James Whitcomb Riley Hospital<br />
Richard Brasington, MD<br />
Washington University School<br />
of Medicine<br />
Doyt L. Conn, MD<br />
Emory University School of Medicine<br />
Mary E. Cronin, MD<br />
Medical College of Wisconsin<br />
Helen M. Emery, MD<br />
Children’s Hospital and Regional<br />
Medical Center<br />
Allan C. Gelber, MD<br />
Johns Hopkins University School<br />
of Medicine<br />
Samina Q. Hayat, MD<br />
Louisiana State University<br />
Lisa Imundo, MD<br />
Columbia University<br />
Beth L. Jonas, MD<br />
University of North Carolina,<br />
Chapel Hill<br />
Insoo Kang, MD<br />
Yale University School of Medicine<br />
David R. Karp, MD, PhD<br />
University of Texas Southwestern<br />
Medical Center<br />
Carlos J. Lozada, MD<br />
University of Miami Miller School of<br />
Medicine<br />
W. Neal Roberts, Jr., MD<br />
Virginia Commonwealth University<br />
Christy I. Sandborg, MD<br />
Stanford Medical Center<br />
Laura Schanberg, MD<br />
Duke University Medical Center<br />
Nora G. Singer, MD<br />
Rainbow Babies & Children’s<br />
Hospital<br />
Eric S. Sobel, MD, PhD<br />
University of Florida<br />
Virginia D. Steen, MD<br />
Georgetown University<br />
Robert Terkeltaub, MD<br />
University of California, San Diego<br />
Arthur Weinstein, MD<br />
Washington Hospital Center<br />
Sterling G. West, MD<br />
University of Colorado at Denver<br />
Health Sciences Center<br />
<strong>ACR</strong> REF New Initiatives in<br />
Rheumatology Award<br />
This award supports the<br />
initial development of a larger<br />
multidisciplinary initiative whose<br />
overall goal is to fundamentally<br />
improve clinical care, research<br />
and education in rheumatology.<br />
Recipient organizations receive one<br />
year of funding at $50,000.<br />
Childhood Arthritis & Rheumatology<br />
Research Alliance (CARRA)<br />
Stanford, CA<br />
www.rheumatology.org—Rheumatology’s Home on the Web 331
<strong>ACR</strong> Research and Education Foundation Honor Roll of Donors<br />
TThe <strong>ACR</strong> Research and Education Foundation is continually grateful for those who support our mission to<br />
improve patients’ lives by advancing the field of rheumatology. Contributions on all levels are appreciated and are<br />
important for continued success in providing quality education and training programs. It is with gratitude that we<br />
acknowledge those who have demonstrated their support of the REF. The following list includes donors who have given<br />
between July 1, 2006 and June 30, <strong>2007</strong> at the levels indicated. Great care has been taken in preparing this list. If we have<br />
misspelled or omitted your name, please bring it to our attention.<br />
CIRCLE OF LEADERSHIP<br />
The Circle of Leadership recognizes donors who demonstrate their commitment and leadership by contributing a minimum of<br />
$1,000 during the fiscal year (July 1 through June 30). Leadership support at this level provides the financial strength that creates<br />
a margin of excellence needed to enhance the kinds of training and educational opportunities that make the REF unique.<br />
Circle of Leadership contributors are recognized as follows. An * denotes Lifetime Giving Circle status:<br />
Benefactor ($25,000+):<br />
Anonymous *<br />
Ephraim Engleman, MD *<br />
Patron ($5,000 – $9,999):<br />
Melvin Britton, MD *<br />
Leslie Crofford, MD *<br />
John Cush, MD *<br />
Sharad Lakhanpal, MD<br />
Reuben and Mollie Gordon Foundation *<br />
Steward ($2,500 – $4,999):<br />
Diana Anderson, PhD<br />
Bevra Hahn, MD *<br />
Susan Krol<br />
Yongsuk Lertratanakul, MD<br />
William Palmer, MD *<br />
Lee Simon, MD *<br />
Warren Thoits<br />
Colleague ($1,000 – $2,499):<br />
John Abruzzo, MD<br />
William Arend, MD<br />
John Atkinson, MD<br />
Herbert S. Baraf, MD<br />
Joan Bathon, MD<br />
George Beall<br />
Neal Birnbaum, MD<br />
Charles Boniske, MD<br />
Mark Box, MD<br />
Earl Brewer, MD<br />
Alan Bridges, MD<br />
Leonard Calabrese, DO<br />
EP Charlton<br />
Mary Cronin, MD<br />
Bruce Cronstein, MD<br />
Mary Crow, MD *<br />
Raphael DeHoratius, MD<br />
Frederick Delafield, MD<br />
Gregory Dennis, MD<br />
Denver Arthritis Clinic<br />
Steven Echard, CAE<br />
Helen Emery, MD<br />
Steven Eyanson, MD<br />
P. Brent Ferrell, MD<br />
Roy Fleischmann, MD *<br />
David Fox, MD<br />
Allan Gelber, MD<br />
Joseph Golbus, MD<br />
Evelyn Hess, MD<br />
Gary Hoffman, MD<br />
V. Michael Holers, MD<br />
Rodanthi Kitridou, MD<br />
Alan Kivitz, MD<br />
Joel Kremer, MD *<br />
Ronald Lamont-Havers, MD<br />
Kristine Lohr, MD<br />
Lupus Support Group of the Ozarks<br />
Michael Maricic, MD *<br />
Joseph Markenson, MD *<br />
Alfonse Masi, MD, DrPH<br />
Gale McCarty, MD, FACP, F<strong>ACR</strong><br />
Audrey Nelson, MD<br />
Mark Niemer, MD<br />
Paul E. Phillips, MD<br />
Fred Robertson, MD<br />
Shaun Ruddy, MD<br />
Jane Salmon, MD<br />
Raymond Scalettar, MD, DSc<br />
Michael Schiff, MD *<br />
Eric Schned, MD<br />
Nora Singer, MD<br />
E. William St. Clair, MD<br />
Vibeke Strand, MD<br />
Donita Sullivan, MD<br />
Robert Thoburn, MD<br />
Elizabeth Tindall, MD<br />
Orrin Troum, MD<br />
Audrey Uknis, MD<br />
United Way<br />
Katherine Upchurch, MD<br />
Robbie Waits<br />
Sara Walker, MD<br />
Daniel Wallace, MD *<br />
Arthur Weaver, MD<br />
332 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
<strong>ACR</strong> Research and Education Foundation Honor Roll of Donors<br />
REF CLUB<br />
The REF Club recognizes donors who contribute between $250 and $999 during the fiscal year (July 1 through June 30).<br />
REF Club contributors are recognized as follows. An * denotes Lifetime Giving Circle status:<br />
Associate ($500 – $999):<br />
Kelli Allen, PhD<br />
Amgen Foundation<br />
Mark Andrejeski<br />
Alan Baer, MD<br />
Clifton Bingham, MD<br />
Block & Gratwick, P.A.<br />
Bradley Bloom, MD<br />
D. R. Boeckling<br />
Dennis Boulware, MD<br />
Gary Bryant, MD<br />
Lenore Buckley, MD, MPH<br />
Sophia Chang, MD<br />
W. Winn Chatham, MD<br />
Daniel Clauw, MD<br />
Stanley Cohen, MD *<br />
Jan de Vries, PhD<br />
Atul Deodhar, MD, MRCP<br />
James Engelbrecht, MD<br />
Robert Fuhlbrigge, MD, PhD<br />
Richard Furie, MD<br />
Sherine Gabriel, MD, MSc<br />
Ellen Ginzler, MD, MPH<br />
Emilio Gonzalez, MD<br />
Rafael Grau, MD<br />
J. Timothy Harrington, MD<br />
John Harris, MD<br />
Edward Harris, MD<br />
Caryn Hasselbring, MD<br />
Kathryn Hobbs, MD<br />
Kent Huston, MD<br />
Hugo Jasin, MD<br />
Gurjit Kaeley MBBS, MRCP<br />
Elizabeth Karlson, MD *<br />
Jonathan Kay, MD<br />
Lloyd Klickstein, MD, PhD<br />
Victor Labbate, MD<br />
Joseph Levinson, MD<br />
Caryn Libbey, MD<br />
Michael Lockshin, MD<br />
Ed Lynch<br />
David Mandel, MD<br />
Eric Matteson, MD<br />
Kevin McKown, MD<br />
Roland Moskowitz, MD<br />
Eileen Moynihan, MD<br />
James Norton, PhD<br />
Christy Park, MD<br />
Harold Paulus, MD<br />
Forrest Riordan, MD<br />
Kathryn Riordan, MD<br />
Christopher Ritchlin, MD<br />
Antony Rosen, MD<br />
Eric Ruderman, MD<br />
Richard Rynes, MD<br />
Fredrica Smith, MD<br />
Daniel Solomon, MD, MPH<br />
Chris Striebich, MD, PhD<br />
John Sundy, MD, PhD<br />
Michael Weinblatt, MD *<br />
Arthur Weinstein, MD<br />
David Wofsy, MD<br />
Sustainer ($250 – $499):<br />
Robert Ashman, MD<br />
Franc Barada, MD<br />
Walter Barr, MD<br />
Evan Beckman, MD<br />
Linda Bockenstedt, MD<br />
Marta Bognar, MD<br />
David Borenstein, MD<br />
Frederick Brandt, MD<br />
Richard Brasington, MD<br />
Jeffrey Brown, MD<br />
L. Frank Cavaliere, MD, FACP<br />
James Davis, MD<br />
Chad Deal, MD<br />
Paul Dellaripa, MD<br />
Rajiv Dixit, MD<br />
Robin Dore, MD<br />
Christine Evelyn, MD<br />
Martin Garber, DO<br />
Joann Gillis, MD<br />
Mary Goldring, PhD<br />
Mark Gourley, MD<br />
Jennifer Grossman, MD<br />
Michel Haniph<br />
Howard Hillstrom, PhD<br />
Jo Ann Hornsby, MD<br />
Norman Ilowite, MD<br />
Mary Johnson<br />
Johnson & Johnson<br />
Amy Joseph, MD<br />
David Karp, MD, PhD<br />
Ed Keystone, MD, FRCP(C)<br />
Karen Kolba, MD<br />
Neil Kramer, MD<br />
Saddek Laoussadi, MD<br />
Robert Lightfoot, MD<br />
Jeffrey Lisse, MD<br />
Mart Mannik, MD<br />
Susan Manzi, MD, MPH<br />
Donald Marcus, MD<br />
John Miller, MD, PhD<br />
Eileen Neumeier<br />
Chester Oddis, MD<br />
James R. O’Dell, MD<br />
Nancy Olsen, MD<br />
Murray Passo, MD<br />
Christian Pfirrmann, MD<br />
Michael Pick, MD<br />
Robert Rosenberg, MD<br />
Elliot Rosenstein, MD<br />
Joy Schechtman, DO<br />
H. Ralph Schumacher, MD<br />
John Sergent, MD<br />
Anne Sigsbee, MD<br />
Virginia Steen, MD<br />
Masao Tanaka, MD, PhD<br />
Claire Targoff, MD<br />
William Tidmore, MD<br />
Vedder Price Kaufman<br />
Thuan Vu, MD<br />
Daqing Wang, PhD<br />
Noranna Warner, MD<br />
Cody Wasner, MD<br />
Ulrich Weber, MD<br />
Melissa Weekley, MD<br />
Patience White, MD, MA<br />
Andrew Wong, MD<br />
Steven Ytterberg, MD<br />
Debra Zack, MD, PhD<br />
www.rheumatology.org—Rheumatology’s Home on the Web 333
<strong>ACR</strong> Research and Education Foundation Honor Roll of Donors<br />
HONORARY AND MEMORIAL GIFTS<br />
The following gifts were made in honor or in memory of the lives of patients, loved ones, friends and colleagues. These<br />
donations were made during the fiscal year (July 1, 2006 through June 30, <strong>2007</strong>):<br />
In Honor of<br />
Mark Andrejeski, Jim O’Dell, MD and Neal Birnbaum, MD<br />
by Joseph Golbus, MD<br />
Neal Birnbaum, MD by William Palmer, MD<br />
Lynn Bonfiglio by Raphael DeHoratius, MD<br />
Melvin Britton, MD by: EP Charlton; Williard Kauffman; Robert<br />
Nordman; Warren Thoits<br />
Mary Crow, MD by Jane Salmon, MD<br />
Maude David by Alix Maiden Baillie<br />
Teresa Fitzgerald and David Wofsy by Jane Diamond<br />
Margarita Gardiner, MD by: David Mariano; Glenda Patterson;<br />
Songlin Xue<br />
Sara McLinden by Jack Stevens<br />
Inna Pendrak by Margarita Gardiner, MD<br />
REF Staff by Steven Echard, CAE<br />
Shefali Saini by Margarita Gardiner, MD<br />
Mike Schiff, MD by Anonymous<br />
In Memory of<br />
Richard Anderson by William Palmer, MD<br />
Herman Backus by Joy Schechtman, DO<br />
Reuben Baldwin by Franc Barada, MD<br />
Eldred Bartley by: Auburn Housing Authority; Robert Coughlan;<br />
Philip Rioux; Joline Maurice Roy; Richard Whiting<br />
Marcie L. Bean by Sara Newell, MD<br />
Aileen Beson by Joy Schechtman, DO<br />
Bonita Bishop by Block & Gratwick, P.A.<br />
Ann Joseph Boeckling by D R Boeckling<br />
Kathryn L. Boese by William Palmer, MD<br />
Needham P. Broadwell by Franc Barada, MD<br />
Bruce Bromme, Jr. by Karen Kolba, MD<br />
Millie Bryant by Joy Schechtman, DO<br />
Erna Buie by Edith Hammock<br />
Evelyn Bull by Block & Gratwick, P.A.<br />
Anna R. Caffery by William Palmer, MD<br />
Elaine Centanni by Block & Gratwick, P.A.<br />
Raymond Chapman by Catherine Lee, MD<br />
April Claassen by William Palmer, MD<br />
Carol Colsell by Karen Kolba, MD<br />
Betty Corbett by Block & Gratwick, P.A.<br />
Barbara Cropley by Block & Gratwick, P.A.<br />
Louis Cyr by Block & Gratwick, P.A.<br />
Florence Daisy by Block & Gratwick, P.A.<br />
Anita Decormier by Block & Gratwick, P.A.<br />
Marilyn Downes by Joy Schechtman, DO<br />
Elizabeth Dudes by Susan Krol<br />
Gene Duncan by Sara Newell, MD<br />
Mary Duncan by Sara Newell, MD<br />
Winifred Dyer by Block & Gratwick, P.A.<br />
Rebecca Emory by Franc Barada, MD<br />
E. Dorris Everett by Catherine Lee, MD<br />
Dianne Falina by Block & Gratwick, P.A.<br />
Shirley Fisher by Joy Schechtman, DO<br />
Terry Foote by Catherine Lee, MD<br />
Paul Gervais by Block & Gratwick, P.A.<br />
Janet Gillespie by Joy Schechtman, DO<br />
Bruce Gilliland, MD by Block & Gratwick, P.A.<br />
Oscar Gluck, MD by Michael Maricic, MD<br />
Wilbur Grasser by Block & Gratwick, P.A.<br />
Lisa Hacker by Joy Schechtman, DO<br />
Teresa Hansen by Block & Gratwick, P.A.<br />
Hester Hanson by Block & Gratwick, P.A.<br />
Nettie Harder by William Palmer, MD<br />
Margaret Harris by Karen Kolba, MD<br />
Daniel Hathaway, MD by: Elie Gertner, MD, FRCPC; Thomas<br />
Harkcom, MD; Michelle Ochsendorf; Ellen Shammash, MD;<br />
Sou-Pan Wu, MD<br />
Nathan Hawley by Franc Barada, MD<br />
Helen Diane Hecken by Cardiovascular Association of Pennsylvania<br />
Diane Hencken by: Peter Kowey, MD; Jeannine McMenamin<br />
Shirley Howe by William Palmer, MD<br />
Jack Hubbard by William Palmer, MD<br />
Echelle Hutchinson by Karen Kolba, MD<br />
Ken Hyatt by Block & Gratwick, P.A.<br />
Richard Jacobs by Block & Gratwick, P.A.<br />
Marie Jenks by Block & Gratwick, P.A.<br />
Dorothy G. Jennings by: Judy Williams; Ollie Bennett; Walter<br />
Coker; Beverly Gregg; Robert Hooper; Shirley Lake; Leisure<br />
Years Club; Myrtle Leopard<br />
Sarah Kelsey by Block & Gratwick, P.A.<br />
Melvin Kennett by Joy Schechtman, DO<br />
Orville Kirby by William Palmer, MD<br />
Elmer Knowlton by Block & Gratwick, P.A.<br />
Deborah Kredich by Helen Emery, MD<br />
Bobby Jack Langston by Karen Kolba, MD<br />
Roger Lapierre by Block & Gratwick, P.A.<br />
334 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
<strong>ACR</strong> Research and Education Foundation Honor Roll of Donors<br />
In Memory of<br />
Gertrude Levitin by: Julie Baker-Stiner; Judith Bonner; Eagle<br />
Internal Medicine; Cheryl Madren<br />
Barbara Long by Sara Newell, MD<br />
Frances Lynch by Joy Schechtman, DO<br />
Agnes Malvone by Lucent Technologies<br />
Florence Matten by Denver Arthritis Clinic<br />
Roman Maxsimic by Block & Gratwick, P.A.<br />
Michael J. McAlister by William Palmer, MD<br />
Dianne McGrath by Block & Gratwick, P.A.<br />
James McKeen by Block & Gratwick, P.A.<br />
Phyllis McKinney by Joy Schechtman, DO<br />
Eva McMillen by William Palmer, MD<br />
Thomas McNalley by Block & Gratwick, P.A.<br />
Inez Mills by Block & Gratwick, P.A.<br />
Rothie Moore by Franc Barada, MD<br />
Verna Newcomb by Block & Gratwick, P.A.<br />
May Noel by: John & Elizabet Collins; Susan Williams;<br />
Franklin Sheppard<br />
Madeline Paul by Block & Gratwick, P.A.<br />
Carolyn Polyot by Block & Gratwick, P.A.<br />
Thomas C. Quinn by Jacqueline Litowski<br />
Carol Ragsdale by Helen Emery, MD<br />
Mary L. Ramos by Joy Schechtman, DO<br />
Robert Rau by Martin Garber, DO<br />
Eric Reed by Block & Gratwick, P.A.<br />
Michiko Rhoads by Block & Gratwick, P.A.<br />
Audrey Rotter by Catherine Lee, MD<br />
Howard Ruddloff by William Palmer, MD<br />
Richard Rush by Joy Schechtman, DO<br />
Sara Sage by Karen Kolba, MD<br />
Mary Lou Sharkey by William Palmer, MD<br />
Marietta Shaw by Joy Schechtman, DO<br />
Eugene Sherburne by Block & Gratwick, P.A.<br />
Hoyt Shuman by Block & Gratwick, P.A.<br />
Therese Sirois by Block & Gratwick, P.A.<br />
Madeline Smith by Block & Gratwick, P.A.<br />
Sadie Smith by Karen Kolba, MD<br />
Opal Soffietto by Karen Kolba, MD<br />
Sarah Spruce by Block & Gratwick, P.A.<br />
Virginia Stacy by Sara Newell, MD<br />
Ernest Stevenson by Joy Schechtman, DO<br />
David Stewart by Theodore Peterson<br />
Mildred Stone by Block & Gratwick, P.A.<br />
Helen Szulczewski by Joy Schechtman, DO<br />
Teresa Teran by Joy Schechtman, DO<br />
Herbert Tilley by Karen Kolba, MD<br />
Betty Tinnen by Franc Barada, MD<br />
Maggie VanAmburgh by Joy Schechtman, DO<br />
Rosalie Violette by Block & Gratwick, P.A.<br />
Irene Vitagliano by Martin Garber, DO<br />
Margaret Wain by Block & Gratwick, P.A.<br />
Stan Waits by Robbie Waits<br />
Mary Wallace by Joy Schechtman, DO<br />
Merle Watke by William Palmer, MD<br />
William Wilson by William Palmer, MD<br />
Siewyin Wong by Esther Eisenstein<br />
Mary Zieser by Joy Schechtman, DO<br />
Morris Ziff, MD, PhD by Evelyn Hess, MD<br />
REF Donors’ Lounge - Boardroom SUITE 201-202<br />
REF donors (Membership in the Lifetime Giving Circles, a $500 minimum donation made between July<br />
1, 2006 and June 30, <strong>2007</strong> or a $500 minimum donation on site at the annual meeting are required for<br />
entry) have Internet access in the REF Donors’ Lounge. The lounge is open on Saturday from Noon–6:00<br />
PM, Sunday–Tuesday from 7:00 AM–6:00 PM, and on Wednesday from 7:00 AM–12:30 PM.<br />
A REF Donor Ribbon is required for entry. Donors may pick up their ribbons at the Donors’ Booth, just<br />
outside the Donors’ Lounge.<br />
www.rheumatology.org—Rheumatology’s Home on the Web 335
REF WITHIN OUR REACH GRANT RECIPIENTS<br />
Within Our Reach, a national multi-year campaign, seeks<br />
to advance the future of rheumatologic research by<br />
accelerating RA research not normally funded by NIH<br />
or other peer-reviewed funding sources. Accelerating RA research<br />
will enhance practicing rheumatologists’ ability to characterize<br />
various causes of the disease, predict onset of the disease,<br />
individualize treatment based on patient’s characteristics and<br />
prevent joint damage and improve joint function.<br />
Within Our Reach has the capacity to improve RA patients’ quality of life, alleviate long-term effects of RA and, ultimately,<br />
ensure that future generations can enjoy life without RA.<br />
Innovative Basic Research<br />
Paul Anderson, MD, PhD<br />
K. Frank Austen Professor of<br />
Medicine; Brigham and Women’s<br />
Hospital<br />
Post-transcriptional Regulation of TNF<br />
alpha Production<br />
Robert H. Carter, MD<br />
Professor of Medicine and<br />
Microbiology; Director, Div.<br />
Clinical Immunology &<br />
Rheumatology; University of<br />
Alabama at Birmingham<br />
Autoantigen-specific B-Cells in<br />
Rheumatoid Arthritis<br />
Gary S. Firestein, MD<br />
Professor of Medicine; Chief, Div.<br />
of Rheumatology, Allergy and<br />
Immunology; Director, UCSD<br />
Clinical Investigation Institute;<br />
University of California - San<br />
Diego, School of Medicine<br />
Neural Regulation of Synovial Inflammation<br />
Richard A. Flavell, PhD, FRS<br />
Sterling Professor and Chairman;<br />
Investigator, Howard Hughes<br />
Medical Institute; Yale University<br />
School of Medicine<br />
Regulation of T cell Function in Collageninduced<br />
Arthritis by IL-10<br />
Gary Gilkeson, MD<br />
Professor of Medicine and Vice Chair<br />
for Research; Medical University of<br />
South Carolina<br />
Role of Sphingosine Kinase I in<br />
Inflammatory Arthritis<br />
Joseph Holoshitz, MD<br />
Associate Professor of Internal<br />
Medicine; University of Michigan -<br />
Ann Arbor<br />
Functional Characterization of the<br />
Rheumatoid Arthritis Shared Epitope<br />
Binding Receptor<br />
Elizabeth D. Mellins, MD<br />
Associate Professor; Stanford<br />
University School of Medicine<br />
MHC Association in Rheumatoid<br />
Arthritis: A Novel Hypothesis<br />
John D. Mountz, MD, PhD<br />
Professor, Department of Medicine;<br />
University of Alabama at Birmingham<br />
Novel IL-17 Induced Germinal Center<br />
Formation and Arthritis-inducing<br />
Autoantibodies<br />
Translational Research<br />
S. Louis Bridges, Jr., MD, PhD<br />
Associate Professor, Departments<br />
of Medicine and Microbiology;<br />
University of Alabama at Birmingham<br />
Genetics and Ethic Differences in C-Reactive<br />
Protein as a Biomarker of Radiographic<br />
Severity in Rheumatoid Arthritis<br />
David M. Lee, MD, PhD<br />
Assistant Professor of Medicine<br />
Brigham and Women’s Hospital<br />
IgG Glycosylation and Rheumatoid Arthritis<br />
Antony Rosen, MD<br />
Mary Betty Stevens Professor of<br />
Medicine; Professor of Cell Biology<br />
and Pathology; Director, Division<br />
of Rheumatology; Johns Hopkins<br />
University School of Medicine<br />
Anti-PADI4 Immune Responses in Rheumatoid<br />
Arthritis: Markers of Disease Propagation<br />
Cornelia M. Weyand, MD, PhD<br />
David Lowance Professor of Medicine;<br />
Director, Lowance Center for<br />
Human Immunology; Emory<br />
University<br />
Defects of Hematopoietic Stem Cell<br />
Function in Rheumatoid Arthritis<br />
Clinical Practice<br />
Joan M. Bathon, MD<br />
Professor of Medicine; Johns Hopkins<br />
Arthritis Center<br />
Rheumatoid Arthritis and Body Composition<br />
Harold E. Paulus, MD<br />
Professor Emeritus; University of<br />
California - Los Angeles<br />
Joint MRI to Validate Clinical Remission<br />
Criteria in Early Rheumatoid Arthritis<br />
Edward Yelin, PhD<br />
Professor of Medicine and Health<br />
Policy; University of California -<br />
San Francisco<br />
Disparities in Utilization and Outcomes<br />
in Rheumatoid Arthritis<br />
336 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
REF WITHIN OUR REACH THE SUMMIT OF LEADERSHIP<br />
While we continue to seek out new investors, the REF gratefully acknowledges the following donors who have<br />
demonstrated their commitment and support for the Within Our Reach campaign. This list was current as of<br />
August 22, <strong>2007</strong>:<br />
Pinnacle ($5 million +)<br />
Abbott Immunology<br />
<strong>American</strong> College of Rheumatology<br />
Bristol-Myers Squibb<br />
Partner ($1 million +)<br />
Genentech, Inc.<br />
Milestone ($250,000 - $499,999)<br />
J. Peter Cahill (in memory of Carol K.<br />
Cahill)<br />
Shirley and Hunter Enis<br />
Betsy and John McLinden<br />
Visionary ($100,000 - $249,000)<br />
Anonymous<br />
The Hersh Foundation<br />
Myles McDonough<br />
Sandra and Alan Williams<br />
Innovator ($50,000 - $99,999)<br />
Leslie J. Crofford, MD and Kevin<br />
McDonagh, MD<br />
Katherine S. Upchurch, MD<br />
Trailblazer ($25,000 - $49,999)<br />
Jeffrey G. Lawson, MD<br />
Greta and Max Spillar<br />
Pioneer ($10,000 – $24,999)<br />
Mark Andrejeski<br />
Stanley B. Cohen, MD<br />
David Fox, MD<br />
Stuart S. Kassan, MD<br />
Carolyn C. Lupton<br />
Donald E. Marshall<br />
James R. O’Dell, MD<br />
John Tesser, MD<br />
Founder ($1,000 - $9,999)<br />
Neal S. Birnbaum, MD<br />
Mary “Peggy” Crow, MD<br />
Joseph Flood, MD<br />
Emily Isaacs, MD<br />
Steven S. Overman, MD, MPH<br />
www.rheumatology.org—Rheumatology’s Home on the Web 337
2008 <strong>ACR</strong> Call for suggestionS<br />
Submission Deadline:<br />
Friday, November 16, <strong>2007</strong><br />
Electronic Submissions Only!<br />
Submit online at: www.rheumatology.org/cfp.asp<br />
The <strong>ACR</strong> Annual <strong>Meeting</strong> Planning Committee (AMPC) will<br />
meet in early December to select topics and speakers for the<br />
2008 Annual <strong>Scientific</strong> <strong>Meeting</strong> to be held in San Francisco, CA.<br />
The AMPC, which consists of 35 members, reviews all of the<br />
submitted suggestions prior to the planning meeting. The AMPC<br />
will notify invited speakers no later than the end of March. The<br />
action taken on a specific suggestion is dependent upon a variety<br />
of factors, including the committee’s perception of the topic’s<br />
popularity, speaker quality and/or needs assessments.<br />
To assist the <strong>ACR</strong> in choosing quality educational programs on<br />
topics of greatest interest to its members, the <strong>ACR</strong> requests<br />
members to submit suggestions for any of the following sessions:<br />
∙ Review Course: a day-long pre-meeting course that features 8<br />
speakers who provide updates related to the clinical aspects of<br />
rheumatology<br />
∙ Symposia: 90 minute sessions featuring 2–4 speakers who<br />
address modern concepts related to a single clinical or<br />
research theme<br />
a. Clinical Symposium<br />
b. Combined <strong>ACR</strong>/<strong>ARHP</strong> Symposium<br />
c. Pediatric Symposium<br />
d. Basic Science Symposium<br />
∙ Medical Aspects: 60 minute sessions featuring 1 speaker<br />
who discusses an internal medicine topics pertinent to the<br />
practicing rheumatologist<br />
∙ Practice Issues: 60 minute sessions featuring 1–2 speakers<br />
who discuss issues related to the practice of rheumatology<br />
∙ State-of-the-Art: 60 minutes session featuring 1 speaker who<br />
focuses on advances in basic or clinical investigation<br />
∙ Immunology Updates for Clinicians: a 60-minute session<br />
featuring 1 speaker who provides a basic overview of immunology<br />
∙ Special Lectures: 60 minute sessions honoring leaders in<br />
their respective fields. Please submit candidates names along<br />
with possible topics related to the respective award.<br />
a. Marshall J. Schiff, MD, Memorial Lectureship: a lecture<br />
devoted to a topic in orthopedics<br />
b. Paul Klemperer, MD, Memorial Lectureship: a lecture<br />
devoted to a topic in the broad area of rheumatology<br />
c. Oscar S. Gluck, MD, Memorial Lectureship: a lecture<br />
devoted to a topic in the area of bone and/or bone<br />
metabolism<br />
∙ Workshops: 2 hour sessions featuring “hands-on” learning in<br />
groups limited to 24 attendees<br />
∙ Meet the Professors: 90 minute sessions featuring an expert<br />
in the field and limited to 30 attendees<br />
∙ Study Groups: Please see page 163 for additional information<br />
on how to submit an application for a study group by the<br />
November 16 deadline.<br />
The <strong>ACR</strong> can only accept suggestions that are submitted<br />
electronically (in order to distribute the suggestions to the<br />
relevant committee members). Please see the <strong>ACR</strong> Web site<br />
at www.rheumatology.org/cfp.asp for submission rules and<br />
instructions. The <strong>ACR</strong> Annual <strong>Meeting</strong> Planning Committee<br />
reserves the right to:<br />
∙ accept all or part of any submitted suggestions<br />
∙ choose a moderator or speaker not listed on the suggestion<br />
∙ copyedit the title and/or learning objectives<br />
∙ adjust the requested session category to meet needs of the program<br />
Thank you for taking the time out of your busy schedule to<br />
submit a suggestion. The AMPC has a very difficult task<br />
to distill all of the suggestions (generally over 100) in an<br />
effort to create a meeting that has balanced, appealing and<br />
innovative sessions. Your suggestion helps guide the planning<br />
process as we strive to enhance the scientific program to<br />
benefit all attendees. Accepted suggestions may be presented<br />
in their entirety or they may undergo variable degrees of<br />
modification by AMPC members.<br />
The <strong>ACR</strong> greatly appreciates your submission and sincerely<br />
desires your continued participation and feedback in future<br />
meeting planning. We look forward to another outstanding<br />
Annual <strong>Scientific</strong> <strong>Meeting</strong>.<br />
338 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
2008 <strong>ARHP</strong> Call for Proposals<br />
Submission Deadline:<br />
Friday, November 16, <strong>2007</strong><br />
Electronic Submissions Only! Submit online at:<br />
www.rheumatology.org/annual/arhp/cfp<br />
The <strong>ARHP</strong> <strong>Program</strong> Subcommittee will meet in early<br />
January to plan the topics and speakers for the 2008 Annual<br />
<strong>Scientific</strong> <strong>Meeting</strong> to be held in San Francisco, CA.<br />
To assist the <strong>ARHP</strong> in providing quality educational<br />
programs on topics of greatest interest to its members, a Call<br />
for Proposals is announced. Members and non-members<br />
may submit a proposal for the annual scientific meeting.<br />
A proposal can be given in a lecture, symposium or handson,<br />
interactive workshop format. Sessions are scheduled<br />
as concurrent for 60 or 90 minutes and may be placed on<br />
the program on any day/time during the annual scientific<br />
meeting, unless stated otherwise.<br />
The <strong>ARHP</strong> Call for Abstracts for research, special interest and<br />
case report abstracts will be available online in March 2008.<br />
Abstract Deadline is May 1, 2008.<br />
Proposals Formats<br />
∙ Lecture—a single speaker<br />
∙ Symposium—should not exceed three speakers<br />
∙ Interaction—should emphasize inter-activity and should not<br />
exceed three speakers<br />
Proposals must contain the following information:<br />
∙ Proposals should be submitted to <strong>ARHP</strong> only. Only<br />
proposals from the <strong>ACR</strong> Pediatric and Rehabilitation<br />
Sections should be dually submitted through <strong>ACR</strong>.<br />
∙ Type of format<br />
∙ Title and/or topic of the session<br />
∙ Purpose of the session in no more than three sentences<br />
∙ No more than four learning objectives<br />
∙ Intended audience and skill level [Fundamental (basic),<br />
Intermediate, or Advanced]<br />
∙ Preferred length of presentation (60 or 90 minutes)<br />
∙ Name of coordinator, affiliation, complete mailing address,<br />
telephone and fax numbers and e-mail address.<br />
∙ Name(s) of speaker(s) (maximum of three) with titles of their<br />
presentations, affiliations, complete mailing addresses,<br />
telephone and fax numbers, and e-mail addresses.<br />
Coordinators must provide citations of each speaker’s<br />
education, experience and publications/research.<br />
∙ Coordinator must indicate on this submission whether<br />
all speakers have agreed to participate if the suggestion is<br />
accepted. Securing speakers prior to submission is strongly<br />
encouraged. If a speaker has not agreed, indicate this on<br />
the submission.<br />
∙ Content outline<br />
Presenters and Coordinator are responsible for their own<br />
travel and must pay the appropriate registration fee. No<br />
funds are available for honoraria. Presenters will be required<br />
to provide conflict of interest/disclosure statements if<br />
applicable. The coordinator will be notified regarding<br />
acceptance or rejection approximately 8-12 weeks after the<br />
suggestion deadline. The <strong>ARHP</strong> reserves the right to 1) accept<br />
all or part of any suggestion, 2) copy edit the title, purpose<br />
and objectives and 3) adjust the requested time to meet the<br />
needs of the program. Date and time of presentation cannot<br />
be guaranteed.<br />
<strong>ARHP</strong> Proposals Submission<br />
Submit <strong>ARHP</strong> Proposals to www.rheumatology.org/<br />
annual/arhp/cfp.<br />
If you have questions, contact:<br />
Happy Tyree, Senior Specialist, Educational <strong>Program</strong>s<br />
Association of Rheumatology Health Professionals<br />
1800 Century Place, Suite 250, Atlanta, GA 30345-4300<br />
Telephone: (404) 633–3777; Fax: (404) 633–1870<br />
E-mail: htyree@rheumatology.org<br />
www.rheumatology.org—Rheumatology’s Home on the Web 339
Speaker Index<br />
A<br />
Abramson, Steven B., MD<br />
Morning Keynote: Drug Safety in Rheumatic<br />
Diseases.................................. p. 31<br />
Disclosure: Abbott Laboratories 5, Bristol-<br />
Myers Squibb 5, Merck Pharmaceuticals 5,<br />
Novartis Pharmaceutical Corporation 5,<br />
Pfizer Inc 5<br />
Albrecht, Jan, OTR/L, CHT<br />
Dynamic Stability for the Painful Thumb:<br />
It’s Not Just a Splint................. p. 230<br />
Disclosure: Nothing to disclose.<br />
Dynamic Stability for the Painful Thumb:<br />
Experiential Laboratory............. p. 290<br />
Disclosure: Nothing to disclose.<br />
Aldridge, III., Julian M., MD<br />
Bone Health in Children and Adolescents<br />
with Rheumatic Disease............... p. 62<br />
Disclosure: Nothing to disclose.<br />
Ali, Yousaf, MD<br />
Career Choices in Rheumatology: Many<br />
Choices, Great Lifestyles!............. p. 52<br />
Disclosure: Abbott Laboratories 5<br />
Allaire, Saralynn H., ScD, RN, CRC<br />
Improving Employment Situations Among<br />
People with Arthritis................... p. 68<br />
Disclosure: Nothing to disclose.<br />
A Critical Unmet Need of Patients with<br />
Rheumatic Diseases: Intervention for<br />
Work Disability: <strong>ARHP</strong> Distinguished<br />
Lecturer................................ p. 129<br />
Disclosure: Nothing to disclose.<br />
Allen, Everett H., MD<br />
Digital Photography for Rheumatologists.<br />
.......................................... p. 213<br />
Disclosure: Nothing to disclose.<br />
Amato, Anthony, MD<br />
Why is My Patient With Myositis Not<br />
Getting Better?........................ p. 222<br />
Disclosure: Nothing to disclose.<br />
Amigo, Mary-Carmen, MD<br />
Latin <strong>American</strong> Study Group........ p. 161<br />
Disclosure: Non-CME Activity.<br />
Arnold, Lesley M., MD<br />
Fibromyalgia............................. p. 44<br />
Disclosure: Allergan 2, 5, Boehringer<br />
Ingelheim 2, 5, Cypress Biosciences, Inc.<br />
2, 5, Eli Lilly and Company 2, 5, 8, Forest<br />
Laboratories 2, 5, Pfizer Inc 2, 5, 8, Wyeth<br />
Pharmaceuticals 2, 5<br />
Atkinson, John P., MD<br />
Autoantibodies In Diagnosis and Follow Up<br />
of Rheumatic Diseases............... p. 152<br />
Disclosure: Non-CME Activity.<br />
Avorn, Jerry, MD<br />
Afternoon Keynote: The Coxib Experience:<br />
What Has (and Hasn’t) It Taught Us about<br />
Drug Risks?............................... p. 33<br />
Disclosure: Nothing to disclose.<br />
B<br />
Backman, Catherine L., PhD, OT(C)<br />
Research Mentor/Trainee Responsibilities:<br />
Making the Most of Mentorship..... p. 231<br />
Disclosure: Nothing to disclose.<br />
Backus, Sherry I., PT, DPT, MA<br />
Evidence for Realignment, Off-Loading and<br />
Restorative Therapies for the Treatment of<br />
Knee Osteoarthritis................... p. 220<br />
Disclosure: Nothing to disclose.<br />
Bacon, Paul A., MD<br />
Therapeutic Decisions in Systemic<br />
Vasculitis............................... p. 133<br />
Disclosure: Nothing to disclose.<br />
Baden, Lindsey, MD<br />
Opportunistic Infections in Rheumatic<br />
Diseases.................................. p. 44<br />
Disclosure: Nothing to disclose.<br />
Baeten, Dominique, MD<br />
Spondylarthopathies................. p. 157<br />
Disclosure: Non-CME Activity.<br />
Baker, Nancy A., ScD, OTR/L<br />
Developing a Research Career: Finding and<br />
Following a Path to Independence<br />
............................................ p. 59<br />
Disclosure: Nothing to disclose.<br />
Barr, Walter G., MD<br />
Radiology 101........................... p. 68<br />
Disclosure: Nothing to disclose.<br />
Barron, Hal<br />
Session III: Drug Policy and<br />
Regulation............................... p. 33<br />
Disclosure: Genentech and Biogen IDEC Inc 1, 3<br />
Barry, Frank P., PhD<br />
Session V: Clinical Applications...... p. 37<br />
Disclosure: Osiris Therapeutics Inc. 1, Smith<br />
& Nephew, Inc. 2<br />
Bateman, Jillian, OTD, OTR/L<br />
Motivational Interviewing: Facilitating<br />
Health Promotion in Arthritis....... p. 220<br />
Disclosure: Nothing to disclose.<br />
Beattie, Bonita Lynn, PT, MPT, MHA<br />
Fall Prevention in Community-Living Older<br />
Adults................................... p. 210<br />
Disclosure: Nothing to disclose.<br />
Becker, Michael A., MD<br />
Crystal: Management of Gout........ p. 51<br />
Disclosure: Savient Pharmaceutical 5, TAP<br />
Pharmaceuticals Inc. 5<br />
Crystal: Management of Gout...... p. 125<br />
Disclosure: Savient Pharmaceutical 5, TAP<br />
Pharmaceuticals Inc. 5<br />
Bellido, Teresita, PhD<br />
Bone Remodeling: New Targets in the<br />
Rheumatic Diseases.................. p. 134<br />
Disclosure: Nothing to disclose.<br />
Belza, Basia, PhD, RN<br />
Rehabilitative Rheumatology....... p. 156<br />
Disclosure: Non-CME Activity.<br />
Dissemination of the EnhanceFitness (TM)<br />
<strong>Program</strong> for People with Arthritis.. p. 204<br />
Disclosure: Nothing to disclose.<br />
Research Mentor/Trainee Responsibilities:<br />
Making the Most of Mentorship..... p. 231<br />
Disclosure: Nothing to disclose.<br />
Bennett, J Claude, MD<br />
Arthritis & Rheumatism at 50: The Best of<br />
the Past, the Best of the Future... p. 206<br />
Disclosure: Nothing to disclose.<br />
Anaya, Juan-Manuel, MD<br />
Latin <strong>American</strong> Study Group........ p. 161<br />
Disclosure: Non-CME Activity.<br />
Anuntiyo, Jeremy, MD<br />
Doing the Right Thing: Evidence and<br />
Guidelines for Rheumatoid Arthritis<br />
Treatment............................. p. 135<br />
Disclosure: Nothing to disclose.<br />
Ardoin, Stacy P., MD<br />
Caring for the Young Adult with Rheumatic<br />
Disease (Trainees Only).............. p. 132<br />
Disclosure: Nothing to disclose.<br />
Bansback, Nick<br />
Session II: Economics of Rheumatic<br />
Pharmacotherapy....................... p. 31<br />
Disclosure: Nothing to disclose.<br />
Baraf, Herbert S B., MD<br />
Rheumatology Practice 101: Starting Out<br />
in Practice for the Graduating Fellow.....<br />
.......................................... p. 126<br />
Disclosure: Nothing to disclose.<br />
Rheumatology Practice 101: Starting Out<br />
in Practice for the Graduating Fellow<br />
(Trainees Only)....................... p. 229<br />
Disclosure: Nothing to disclose.<br />
Bermas, Bonnie L., MD<br />
Pregnancy, Fertility and Medication in<br />
Rheumatic Diseases.................... p. 45<br />
Disclosure: Nothing to disclose.<br />
Pregnancy, Fertility and Medication in<br />
Rheumatic Diseases.................. p. 133<br />
Disclosure: Nothing to disclose.<br />
340
Bingham, III., Clifton O., MD<br />
RA: Difficult Cases...................... p. 67<br />
Disclosure: Abbott Immunology<br />
Pharmaceuticals 5, Abbott Laboratories<br />
2, Amgen 2, 5, Bristol-Myers Squibb 2,<br />
Genentech and Biogen IDEC Inc 2, Merck<br />
Pharmaceuticals 5, Novartis Pharmaceutical<br />
Corporation 5, Wyeth Pharmaceuticals 2<br />
RA: Difficult Cases (Trainees Only)<br />
.......................................... p. 213<br />
Disclosure: Abbott Immunology<br />
Pharmaceuticals 5, Abbott Laboratories<br />
2, Amgen 2, 5, Bristol-Myers Squibb 2,<br />
Genentech and Biogen IDEC Inc 2, Merck<br />
Pharmaceuticals 5, Novartis Pharmaceutical<br />
Corporation 5, Wyeth Pharmaceuticals 2<br />
Blevins, Steve, BA, BS, MBA<br />
Creating Presentations Using PowerPoint:<br />
Basic...................................... p. 52<br />
Disclosure: Nothing to disclose.<br />
Creating Presentations Using PowerPoint:<br />
Advanced.............................. p. 126<br />
Disclosure: Nothing to disclose.<br />
Blumenthal, David, MD, MPP<br />
<strong>ACR</strong>/<strong>ARHP</strong> Opening Lecture and Awards<br />
............................................ p. 40<br />
Disclosure: Nothing to disclose.<br />
Boackle, Susan A., MD<br />
Genetics of Autoimmunity: A Clinician’s<br />
Guide................................... p. 123<br />
Disclosure: Nothing to disclose.<br />
Bolen, Jennifer, JD<br />
Avoiding the Legal Pain of Pain<br />
Management........................... p. 130<br />
Disclosure: AIT Laboratories 8, Alpharma<br />
8, Cephalon 8, Endo Pharmaceuticals Inc.<br />
5, King Pharmaceuticals 5, 8, McMahon<br />
Publishing Group - Pain Medicine News - CME<br />
Zone 9, Ortho-McNeil Pharmaceuticals 8<br />
Bombardier, Claire, MD<br />
Session III: Drug Policy and<br />
Regulation............................... p. 35<br />
Disclosure: Nothing to disclose.<br />
Borenstein, David G., MD<br />
Practical Management of Challenging Pain<br />
Syndromes............................. p. 210<br />
Disclosure: Abbott Laboratories 5,<br />
Alpharma 5, Endo Pharmaceuticals Inc. 9,<br />
Pfizer Inc 8<br />
Bostic, Jeff, MD, EdD<br />
Management of Psychiatric Illness in<br />
Children and Adolescents with Rheumatic<br />
Disease................................. p. 230<br />
Disclosure: Forest Laboratories 5,<br />
GlaxoSmithKline 5<br />
Bowyer, Suzanne L., MD<br />
Pediatric Rheumatology: Update on<br />
Juvenile Scleroderma................ p. 155<br />
Disclosure: Non-CME Activity.<br />
Brady, Teresa J., PhD, OT<br />
The Evolution of CDC-Funded State Arthritis<br />
<strong>Program</strong>s................................. p. 50<br />
Disclosure: Nothing to disclose.<br />
What’s New and Noteworthy in <strong>2007</strong>: A<br />
Review of Rheumatology Research for<br />
Health Professionals................. p. 125<br />
Disclosure: Nothing to disclose.<br />
Branch, D. Ware, MD<br />
Antiphospholipid Antibody.......... p. 158<br />
Disclosure: Non-CME Activity.<br />
Brandenstein, Jane S., BS, PT<br />
Manual Tender Point Survey: A<br />
Demonstration of a Standardized Approach<br />
to Assessing Tender Points.......... p. 128<br />
Disclosure: Nothing to disclose.<br />
Bravo, Jaime F., MD<br />
Joint Hypermobility Syndrome..... p. 161<br />
Disclosure: Non-CME Activity.<br />
Breedveld, Ferdinand C., MD<br />
<strong>ACR</strong> Review Course..................... p. 41<br />
Disclosure: Abbott Laboratories 5,<br />
Centocor, Inc. 5, Schering-Plough 5, Wyeth<br />
Pharmaceuticals 5<br />
Brennan, John K.<br />
Speak Out: Using Your Voice to Improve<br />
Rheumatology Practice and Patient Care.<br />
............................................ p. 69<br />
Disclosure: Amgen 1, 3<br />
Brey, Robin L., MD<br />
Antiphospholipid Antibody.......... p. 158<br />
Disclosure: Non-CME Activity.<br />
Bridges, Jr., S. Louis, MD, PhD<br />
Ethnic Minority........................ p. 153<br />
Disclosure: Non-CME Activity.<br />
Broe, Kerry, MPH<br />
Multivariable Analysis: Taking the Mystery<br />
Out of the Regression Model “Black Box”<br />
.......................................... p. 128<br />
Disclosure: Nothing to disclose.<br />
Brown, Kevin K., MD<br />
Interstitial Lung Disease in the Rheumatic<br />
Diseases................................ p. 160<br />
Disclosure: Non-CME Activity.<br />
Brown, Matthew A., MD<br />
Spondylarthopathies................. p. 157<br />
Disclosure: Non-CME Activity.<br />
Bruyn, George AW., MD, PhD<br />
Musculoskeletal Ultrasonography:<br />
Basic...................................... p. 46<br />
Disclosure: Nothing to disclose.<br />
Musculoskeletal Ultrasonography:<br />
Advanced................................ p. 61<br />
Disclosure: Nothing to disclose.<br />
Musculoskeletal Ultrasonography:<br />
Basic.................................... p. 127<br />
Disclosure: Nothing to disclose.<br />
Musculoskeletal Ultrasonography:<br />
Basic (Trainees Only)................ p. 134<br />
Disclosure: Nothing to disclose.<br />
Buchbinder, Rachelle, MBBS, PhD, FRACP<br />
Health Literacy: Foundations for<br />
Improving Clinical Practice and Patient<br />
Outcomes................................ p. 60<br />
Disclosure: Nothing to disclose.<br />
Buldbena, Antonio, MD<br />
Joint Hypermobility Syndrome..... p. 161<br />
Disclosure: Non-CME Activity.<br />
Burke, Allen, MD<br />
Histopathology of Vasculitis........ p. 129<br />
Disclosure: Nothing to disclose.<br />
Histopathology of Vasculitis........ p. 143<br />
Disclosure: Nothing to disclose.<br />
Burr, David B., PhD<br />
Osteoarthritis: Degradation and Disease..<br />
.......................................... p. 154<br />
Disclosure: Amgen 1, 2, 5, 9, Eli Lilly<br />
and Company 2, 5, 9, GlaxoSmithKline 1,<br />
Proctor & Gamble Pharmaceuticals 2, 5,<br />
Roche Pharmaceuticals 9<br />
Buttgereit, Frank<br />
Neuro Endocrine Immunology......... p. 59<br />
Disclosure: Non-CME Activity.<br />
C<br />
Cahill, Janet, PT<br />
Advances in the Management of Total<br />
Hip Arthroplasty Patients: <strong>Meeting</strong> the<br />
Challenges of Reduced Length of Stay<br />
............................................ p. 66<br />
Disclosure: Nothing to disclose.<br />
Callen, Jeffrey P., MD<br />
Dermatological Manifestations of Rheumatic<br />
Diseases.................................. p. 66<br />
Disclosure: Nothing to disclose.<br />
Dermatological Manifestations of Rheumatic<br />
Diseases (Trainees Only)............ p. 132<br />
Disclosure: Nothing to disclose.<br />
Skin Diseases.......................... p. 157<br />
Disclosure: Non-CME Activity.<br />
Cancro, Michael P., PhD<br />
The Aging Immune System.......... p. 214<br />
Disclosure: Nothing to disclose.<br />
Speaker Index<br />
341
Speaker Index<br />
Canoso, Juan J., MD<br />
Rheumatology Physical Examination:<br />
Anatomical Correlates................. p. 46<br />
Disclosure: Nothing to disclose.<br />
Carette, Simon, MD<br />
Vasculitis: An Update.................. p. 46<br />
Disclosure: Nothing to disclose.<br />
Vasculitis: An Update................ p. 150<br />
Disclosure: Nothing to disclose.<br />
Carlson, Hans, MD<br />
Pain: Soft Tissue Rheumatism........ p. 44<br />
Disclosure: Nothing to disclose.<br />
EMG/Nerve Conduction Interpretation for<br />
Rheumatology......................... p. 142<br />
Disclosure: Nothing to disclose.<br />
Pain: Soft Tissue Rheumatism<br />
(Trainees Only)....................... p. 212<br />
Disclosure: Nothing to disclose.<br />
Carsons, Steven E., MD<br />
Sjögren’s: Controversies in<br />
Sjögren’s Syndrome.................. p. 150<br />
Disclosure: Daiichi Pharmaceutical<br />
Corporation 8<br />
Sjögren’s: Controversies in<br />
Sjögren’s Syndrome.................. p. 206<br />
Disclosure: Daiichi Pharmaceutical<br />
Corporation 8<br />
Caviness, Jr., Verne S., MD<br />
Degos Disease and Related Vasculopathy.<br />
.......................................... p. 159<br />
Disclosure: Non-CME Activity.<br />
Cerinic, Marco Matucci, Professor<br />
Rheumatologic Skin Disease........ p. 291<br />
Disclosure: Nothing to disclose.<br />
Chandy, K. George, MBBS, PhD<br />
Ion Channels in Inflammation....... p. 143<br />
Disclosure: Nothing to disclose.<br />
Chang, Rowland W., MD, MPH<br />
Rehabilitative Rheumatology....... p. 156<br />
Disclosure: Non-CME Activity.<br />
Chatham, W. Winn, MD<br />
<strong>ACR</strong>/ABIM Maintenance of Certification<br />
Learning Session for Recertification<br />
Module 30-R............................. p. 36<br />
Disclosure: Nothing to disclose.<br />
Sarcoidosis............................... p. 45<br />
Disclosure: Nothing to disclose.<br />
Sarcoidosis............................. p. 133<br />
Disclosure: Nothing to disclose.<br />
Academic Clinical Practice.......... p. 158<br />
Disclosure: Non-CME Activity.<br />
Chen, Lan X., MD, PhD<br />
Synovial Fluid Analysis and Crystal<br />
Identification (Trainees Only)........ p. 46<br />
Disclosure: Nothing to disclose.<br />
Synovial Fluid Analysis and Crystal<br />
Identification............................ p. 53<br />
Disclosure: Nothing to disclose.<br />
Synovial Fluid Analysis and Crystal<br />
Identification.......................... p. 127<br />
Disclosure: Nothing to disclose.<br />
Chiaramonte, Bethany<br />
Academic Clinical Practice.......... p. 158<br />
Disclosure: Non-CME Activity.<br />
Chopra, Arvind A., MD, DNB<br />
WHO ILAR COPCORD (Community Oriented<br />
<strong>Program</strong> for Control of Rheumatic<br />
Diseases)............................... p. 162<br />
Disclosure: Non-CME Activity.<br />
WHO ILAR COPCORD (Community Oriented<br />
<strong>Program</strong> for Control of Rheumatic<br />
Diseases)............................... p. 163<br />
Disclosure: Non-CME Activity.<br />
Chowdhary, Vaidehi R., MD<br />
Completing the Puzzle: Other Aspects of<br />
Rheumatic Diseases.................... p. 39<br />
Disclosure: Nothing to disclose.<br />
Christian, Charles L., MD<br />
Arthritis & Rheumatism at 50: The Best of<br />
the Past, the Best of the Future... p. 206<br />
Disclosure: Nothing to disclose.<br />
Clauw, Daniel J., MD<br />
<strong>ACR</strong> Review Course..................... p. 38<br />
Disclosure: Cypress Biosciences, Inc 5, Eli<br />
Lilly and Company 5, Forest Laboratories<br />
5, Pfizer Inc 5, Wyeth Pharmaceuticals 5<br />
Fibromyalgia: Etiology and<br />
Treatment............................... p. 58<br />
Disclosure: Cypress Biosciences, Inc 5, Eli<br />
Lilly and Company 5, Forest Laboratories<br />
5, Pfizer Inc 5, Wyeth Pharmaceuticals 5<br />
Clayburne, Gilda M., MLT<br />
Synovial Fluid Analysis and Crystal<br />
Identification (Trainees Only)........ p. 46<br />
Disclosure: Nothing to disclose.<br />
Synovial Fluid Analysis and Crystal<br />
Identification............................ p. 53<br />
Disclosure: Nothing to disclose.<br />
Synovial Fluid Analysis and Crystal<br />
Identification.......................... p. 127<br />
Disclosure: Nothing to disclose.<br />
Cleland, Joshua A., PT, DPT, PhD, OCS<br />
Arthritis and Manual Therapy: What Is<br />
The Evidence?”......................... p. 49<br />
Disclosure: Nothing to disclose.<br />
Clements, Philip J., MD, MPH<br />
Scleroderma Skin Score - How I Do It......<br />
.......................................... p. 156<br />
Disclosure: Non-CME Activity.<br />
Cohen, Philip L., MD<br />
Sjogren’s Syndrome.................. p. 159<br />
Disclosure: Non-CME Activity.<br />
Colbert, Robert A., MD, PhD<br />
Career Choices in Rheumatology: Many<br />
Choices, Great Lifestyles!............. p. 52<br />
Disclosure: Nothing to disclose.<br />
Pediatrics: Spondyloarthritis in Children.<br />
.......................................... p. 229<br />
Disclosure: Nothing to disclose.<br />
Conaghan, Philip G., MD, PhD<br />
Peripheral MRI in Clinical<br />
Rheumatology........................... p. 53<br />
Disclosure: Nothing to disclose.<br />
Peripheral MRI in Clinical Rheumatology<br />
.......................................... p. 207<br />
Disclosure: Nothing to disclose.<br />
Connolly, M. Kari, MD<br />
Skin Diseases.......................... p. 157<br />
Disclosure: Non-CME Activity.<br />
Conroy, Robert J., JD, MPA, MPH<br />
Building a Stronger Physician<br />
Practice................................ p. 139<br />
Disclosure: Nothing to disclose.<br />
Cooper, Ranny<br />
Grassroots and the Legislative Landscape.<br />
.......................................... p. 214<br />
Disclosure: Nothing to disclose.<br />
Cooper, Richard, MD<br />
<strong>ACR</strong> Workforce Issues: The Future of Our<br />
Enterprise.............................. p. 131<br />
Disclosure: Nothing to disclose.<br />
Corr, Maripat, MD<br />
RA from Bench to Bedside........... p. 287<br />
Disclosure: Nothing to disclose.<br />
Costner, Melissa I., MD<br />
Skin Diseases.......................... p. 157<br />
Disclosure: Non-CME Activity.<br />
Crawford, Donah Z., BS, MA<br />
Fundamental Regulatory Aspects of<br />
Clinical Research: Satisfying the FDA,<br />
HIPAA and the IRB Is Not Enough... p. 289<br />
Disclosure: Nothing to disclose.<br />
Crofford, Leslie J., MD<br />
Arthritis & Rheumatism at 50: The Best of<br />
the Past, the Best of the Future... p. 206<br />
Disclosure: Allergan 2, 5, Eli Lilly and<br />
Company 5, Johnson & Johnson 2, Pfizer<br />
Inc 2, 5, Wyeth Pharmaceuticals 2, 2, 5<br />
Practical Management of Challenging<br />
Pain Syndromes....................... p. 210<br />
Disclosure: Allergan 2, 5, Eli Lilly and<br />
Company 5, Johnson & Johnson 2, Pfizer<br />
Inc 2, 5, Wyeth Pharmaceuticals 2, 2, 5<br />
Crow, Mary K., MD<br />
The Year in Review..................... p. 44<br />
Disclosure: Nothing to disclose.<br />
342
Crues, III., John V., MD<br />
Peripheral MRI in Clinical Practice. p. 129<br />
Disclosure: MagnaVu 1, ONI Medical<br />
Systems, Inc. 1<br />
Peripheral MRI in Clinical Practice. p. 213<br />
Disclosure: MagnaVu 1, ONI Medical<br />
Systems, Inc. 1<br />
Cua, Daniel, PhD<br />
Th17 Cells: The New Kids on the<br />
Block...................................... p. 43<br />
Disclosure: Schering-Plough 3<br />
Cush, John J., MD<br />
Session I: Drug Safety and Effectiveness..<br />
............................................ p. 31<br />
Disclosure: Abbott Laboratories 5, 8,<br />
Amgen 5, Centocor, Inc. 5, Corrona 6,<br />
Genentech and Biogen IDEC Inc 2, 5,<br />
Novartis Pharmaceutical Corporation 5,<br />
Pfizer Inc 2, Roche Pharmaceuticals 2, 5,<br />
Sanofi-Aventis Pharmaceutical 5, Targeted<br />
Genetics 2, Wyeth Pharmaceuticals 5<br />
<strong>ACR</strong>/ABIM Maintenance of Certification<br />
Learning Session for Recertification<br />
Module 30-R............................. p. 36<br />
Disclosure: Abbott Laboratories 5, 8,<br />
Amgen 2, 5, Centocor, Inc. 5, Corrona<br />
6, Genentech and Biogen IDEC Inc 2, 5,<br />
Novartis Pharmaceutical Corporation 5,<br />
Pfizer Inc 5, Roche Pharmaceuticals 2, 5,<br />
Wyeth Pharmaceuticals 5<br />
Infections in Patients on TNF<br />
Therapy................................ p. 125<br />
Disclosure: Abbott Laboratories 5, 8,<br />
Amgen 5, Centocor, Inc. 5, Corrona 6,<br />
Genentech and Biogen IDEC Inc 2, 5,<br />
Novartis Pharmaceutical Corporation 5,<br />
Pfizer Inc 2, Roche Pharmaceuticals 2, 5,<br />
Sanofi-Aventis Pharmaceutical 5, Targeted<br />
Genetics 2, Wyeth Pharmaceuticals 5<br />
Curbside Consults - Ask the<br />
Professors.............................. p. 131<br />
Disclosure: Abbott Laboratories 5, 8,<br />
Amgen 5, Centocor, Inc. 5, Corrona 6,<br />
Genentech and Biogen IDEC Inc 2, 5,<br />
Novartis Pharmaceutical Corporation 5,<br />
Pfizer Inc 2, Roche Pharmaceuticals 2, 5,<br />
Sanofi-Aventis Pharmaceutical 5, Targeted<br />
Genetics 2, Wyeth Pharmaceuticals 5<br />
Curbside Consults -<br />
Ask the Professors.................... p. 131<br />
Disclosure: Abbott Laboratories 5, 8,<br />
Amgen 5, Centocor, Inc. 5, Corrona 6,<br />
Genentech and Biogen IDEC Inc 2, 5,<br />
Novartis Pharmaceutical Corporation 5,<br />
Pfizer Inc 2, Roche Pharmaceuticals 2, 5,<br />
Sanofi-Aventis Pharmaceutical 5, Targeted<br />
Genetics 2, Wyeth Pharmaceuticals 5<br />
Infections in Patients on TNF<br />
Therapy................................ p. 212<br />
Disclosure: Abbott Laboratories 5, 8,<br />
Amgen 5, Centocor, Inc. 5, Corrona 6,<br />
Genentech and Biogen IDEC Inc 2, 5,<br />
Novartis Pharmaceutical Corporation 5,<br />
Pfizer Inc 2, Roche Pharmaceuticals 2, 5,<br />
Sanofi-Aventis Pharmaceutical 5, Targeted<br />
Genetics 2, Wyeth Pharmaceuticals 5<br />
Rheumatology Roundup: Highlights<br />
from the <strong>2007</strong> <strong>ACR</strong> Annual <strong>Scientific</strong><br />
<strong>Meeting</strong>................................. p. 285<br />
Disclosure: Abbott Laboratories 5, 8,<br />
Amgen 5, Centocor, Inc. 5, Corrona 6,<br />
Genentech and Biogen IDEC Inc 2, 5,<br />
Novartis Pharmaceutical Corporation 5,<br />
Pfizer Inc 2, Roche Pharmaceuticals 2, 5,<br />
Sanofi-Aventis Pharmaceutical 5, Targeted<br />
Genetics 2, Wyeth Pharmaceuticals 5<br />
Cutler, David M., PhD<br />
<strong>ACR</strong> Workforce Issues: The Future of Our<br />
Enterprise.............................. p. 131<br />
Disclosure: Nothing to disclose.<br />
D<br />
D’Agostino, Maria A., MD<br />
Musculoskeletal Ultrasound......... p. 153<br />
Disclosure: Non-CME Activity.<br />
Dahl, Annette W., PhD<br />
Young Patients With Old Knees: Treatment<br />
and Prevention of Knee Osteoarthritis (OA)<br />
in the Middle-Aged................... p. 151<br />
Disclosure: Nothing to disclose.<br />
Dai, Sheng-Ming, MD<br />
WHO ILAR COPCORD (Community Oriented<br />
<strong>Program</strong> for Control of Rheumatic Diseases)<br />
.......................................... p. 163<br />
Disclosure: Non-CME Activity.<br />
Dasgupta, Bhaskar, MD<br />
Polymyalgia Rheumatica............ p. 155<br />
Disclosure: Non-CME Activity.<br />
Davatchi, Fereydoun, MD<br />
Behcet’s Disease........................ p. 66<br />
Disclosure: Roche Pharmaceuticals 9,<br />
Wyeth Pharmaceuticals 9<br />
WHO ILAR COPCORD (Community O<br />
riented <strong>Program</strong> for Control of<br />
Rheumatic Diseases)................. p. 163<br />
Disclosure: Non-CME Activity.<br />
Behcet’s Disease...................... p. 205<br />
Disclosure: Roche Pharmaceuticals 9,<br />
Wyeth Pharmaceuticals 9<br />
Davey, Michael P., MD, PhD<br />
Immunology: Basic Immunology for<br />
Clinical Rheumatology............... p. 149<br />
Disclosure: Nothing to disclose.<br />
Immunology: Basic Immunology for Clinical<br />
Rheumatology (Trainees Only)..... p. 212<br />
Disclosure: Nothing to disclose.<br />
Davis, Jr., John C., MD, MPH<br />
Ankylosing Spondylitis: Disease<br />
Modification........................... p. 212<br />
Disclosure: Abbott Laboratories 2, Amgen 2,<br />
Centocor, Inc. 2, Wyeth Pharmaceuticals 8<br />
Ankylosing Spondylitis: Disease<br />
Modification........................... p. 292<br />
Disclosure: Abbott Laboratories 2, Amgen<br />
2, Centocor, Inc. 2, Wyeth Pharmaceuticals 8<br />
Deal, Chad L., MD<br />
Osteoporosis: Novel Treatments... p. 205<br />
Disclosure: Nothing to disclose.<br />
Osteoporosis: Focus on DXA<br />
Interpretation (Trainees Only)..... p. 213<br />
Disclosure: Nothing to disclose.<br />
Osteoporosis: Novel Treatments... p. 228<br />
Disclosure: Nothing to disclose.<br />
Degotardi, Pamela J., PhD<br />
Improving Sleep: Non-Pharmalogical<br />
Strategies................................ p. 50<br />
Disclosure: Nothing to disclose.<br />
DeLoughery, Thomas, MD<br />
Completing the Puzzle: Other Aspects of<br />
Rheumatic Diseases.................... p. 39<br />
Disclosure: Aventis Pharmaceuticals 8,<br />
baxter 8, GlaxoSmithKline 8<br />
Deodhar, Atul A., MD, MRCP<br />
Joint Injection Techniques.......... p. 129<br />
Disclosure: Nothing to disclose.<br />
Joint Injection Techniques<br />
(Trainees Only)....................... p. 207<br />
Disclosure: Nothing to disclose.<br />
Dewing, Kori A., MN, ARNP<br />
Building a Stronger Physician<br />
Practice................................ p. 139<br />
Disclosure: Nothing to disclose.<br />
Diamond, Betty, MD<br />
Systemic Lupus Erythematosus..... p. 158<br />
Disclosure: Non-CME Activity.<br />
Diri, Erdal, MD<br />
Behcet’s Disease...................... p. 152<br />
Disclosure: Non-CME Activity.<br />
Distler, Oliver, MD<br />
Signal Transduction Pathways in<br />
Scleroderma............................. p. 53<br />
Disclosure: Nothing to disclose.<br />
Dunlop, Dorothy D., PhD<br />
Statistics: The Ideas Behind the<br />
Formulas............................... p. 140<br />
Disclosure: Nothing to disclose.<br />
Dunn, Cynthia, RN, FACMPE<br />
EMR in the Physician’s Office....... p. 210<br />
Disclosure: Nothing to disclose.<br />
Dutz, Jan P., MD<br />
Skin Diseases.......................... p. 157<br />
Disclosure: Non-CME Activity.<br />
Speaker Index<br />
343
Speaker Index<br />
E<br />
Edwards, N Lawrence, MD<br />
Curbside Consults - Ask the<br />
Professors.............................. p. 131<br />
Disclosure: Savient Pharmaceutical 2,<br />
TAP Pharmaceuticals Inc. 5<br />
Curbside Consults - Ask the<br />
Professors.............................. p. 131<br />
Disclosure: Savient Pharmaceutical 2,<br />
TAP Pharmaceuticals Inc. 5<br />
Egen, Jackson G., PhD<br />
Bioimaging: Visualizing the Immune<br />
Response............................... p. 124<br />
Disclosure: Nothing to disclose.<br />
Ehrlich-Jones, Linda S., PhD, RN<br />
<strong>ARHP</strong> Networking Forum.............. p. 46<br />
Disclosure: Nothing to disclose.<br />
Rehabilitative Rheumatology....... p. 156<br />
Disclosure: Non-CME Activity.<br />
Motivational Interviewing: Facilitating<br />
Health Promotion in Arthritis....... p. 220<br />
Disclosure: Nothing to disclose.<br />
Elkon, Keith B., MD<br />
Inflammation.......................... p. 160<br />
Disclosure: Non-CME Activity.<br />
Elston, Dirk M., MD<br />
Dermatopathology of Rheumatic<br />
Diseases.................................. p. 48<br />
Disclosure: Nothing to disclose.<br />
Dermatopathology of Rheumatic<br />
Diseases.................................. p. 61<br />
Disclosure: Nothing to disclose.<br />
Englund, Martin, MD, PhD<br />
Young Patients With Old Knees: Treatment<br />
and Prevention of Knee Osteoarthritis (OA)<br />
in the Middle-Aged................... p. 151<br />
Disclosure: Nothing to disclose.<br />
Erkan, Doruk, MD<br />
Antiphospholipid Antibody.......... p. 158<br />
Disclosure: Non-CME Activity.<br />
Esdaile, John, MD, MPH<br />
Still’s Disease and Febrile Illnesses.... p. 45<br />
Disclosure: Up To Date 7<br />
Evangelisto, Amy M., MD<br />
Basic Ultrasonography: U.S.<br />
Perspective............................ p. 209<br />
Disclosure: Nothing to disclose.<br />
Basic Ultrasonography: U.S.<br />
Perspective............................ p. 221<br />
Disclosure: Nothing to disclose.<br />
Evans, Christopher H., PhD, DSc<br />
Session III: Gene-Based Therapies... p. 37<br />
Disclosure: tissuegene 5<br />
F<br />
Farber, Harrison W., MD<br />
Pulmonary Hypertension in the<br />
Rheumatic Diseases.................. p. 125<br />
Disclosure: Actelion Pharmaceuticals US 2,<br />
8, 9, Gilead 8, 9<br />
Ferrucci, Luigi, MD, PhD<br />
Geriatric Rheumatology............. p. 160<br />
Disclosure: Non-CME Activity.<br />
RA: Difficult RA....................... p. 206<br />
Disclosure: Abbott Laboratories 1, 2,<br />
5, Amgen 2, 5, AstraZeneca 5, Biogen<br />
Idec 2, Celltech 2, 5, Centocor, Inc. 2,<br />
5, Genentech and Biogen IDEC Inc 2, 5,<br />
Hoffmann-La Roche, Inc. 2, 5, Wyeth<br />
Pharmaceuticals 2, 5<br />
Flood, Joseph, MD<br />
Speak Out: Using Your Voice to Improve<br />
Rheumatology Practice and Patient Care.<br />
............................................ p. 69<br />
Disclosure: Nothing to disclose.<br />
Folkman, Judah, MD<br />
Angiogenesis, Cell-Cell Adhesion, Migration<br />
and Vascular Biology in Arthritis and<br />
Inflammation............................ p. 57<br />
Disclosure: Nothing to disclose.<br />
Fosang, Amanda J., PhD<br />
Osteoarthritis: Degradation and Disease<br />
.......................................... p. 143<br />
Disclosure: Pfizer Inc 2<br />
Fox, David A., MD<br />
T-Cell Subsets: The Family Grows... p. 208<br />
Disclosure: Genentech 2<br />
Fox, Diana G., PsyD<br />
Improving Sleep: Non-Pharmalogical<br />
Strategies................................ p. 50<br />
Disclosure: Nothing to disclose.<br />
Franks, Jr., Andrew G., MD<br />
Skin Diseases.......................... p. 157<br />
Disclosure: Non-CME Activity.<br />
Embi, Peter J., MD, MS<br />
Designing a Website for Your<br />
Practice.................................. p. 46<br />
Disclosure: Nothing to disclose.<br />
Designing a Website for Your<br />
Practice.................................. p. 48<br />
Disclosure: Nothing to disclose.<br />
Emery, Helen M., MD<br />
Pediatrics: Pediatric Rheumatology<br />
for Adult Rheumatologists<br />
(Trainees Only)......................... p. 51<br />
Disclosure: Nothing to disclose.<br />
Practical Pediatric Rheumatology<br />
Rehabilitation: What You Wished You<br />
Had Learned in Training............. p. 140<br />
Disclosure: Nothing to disclose.<br />
Pediatrics: Pediatric Rheumatology for<br />
Adult Rheumatologists............... p. 205<br />
Disclosure: Nothing to disclose.<br />
Emery, Paul, MA, MD<br />
The Great Debate: Peripheral MRI Results<br />
Should Guide Early Intervention with<br />
Biologics in Rheumatoid Arthritis.. p. 219<br />
Disclosure: Nothing to disclose.<br />
Finney, Catherine L., M.D.<br />
Doing the Right Thing: Evidence and<br />
Guidelines for Rheumatoid Arthritis<br />
Treatment............................. p. 135<br />
Disclosure: Nothing to disclose.<br />
Fiorentino, David, MD, PhD<br />
Skin Diseases.......................... p. 157<br />
Disclosure: Non-CME Activity.<br />
Firestein, Gary S., MD<br />
RA Pathogenesis: Molecular<br />
Mechanisms............................ p. 141<br />
Disclosure: Biogen Idec 5, Bristol-Myers<br />
Squibb 5, Hoffmann-La Roche, Inc. 5<br />
Arthritis & Rheumatism at 50: The<br />
Best of the Past, the Best of the<br />
Future.................................. p. 206<br />
Disclosure: Nothing to disclose.<br />
Fleischmann, Roy M., MD<br />
RA: Difficult RA....................... p. 126<br />
Disclosure: Abbott Laboratories 1, 2,<br />
5, Amgen 2, 5, AstraZeneca 5, Biogen<br />
Idec 2, Celltech 2, 5, Centocor, Inc. 2,<br />
5, Genentech and Biogen IDEC Inc 2, 5,<br />
Hoffmann-La Roche, Inc. 2, 5, Wyeth<br />
Pharmaceuticals 2, 5<br />
Furie, Richard A., MD<br />
Excel Spreadsheets: Expanding Skills<br />
Beyond Those of Your Kids.......... p. 209<br />
Disclosure: Nothing to disclose.<br />
Furst, Daniel E., MD<br />
Scleroderma Skin Score - How I Do It... p. 156<br />
Disclosure: Non-CME Activity.<br />
G<br />
Gazit, Dan, DMD, PhD<br />
Session IV: Engineering Technologies......<br />
............................................ p. 37<br />
Disclosure: Nothing to disclose.<br />
Gewanter, Harry L., MD<br />
Practical Pediatric Rheumatology<br />
Rehabilitation: What You Wished You Had<br />
Learned in Training.................. p. 250<br />
Disclosure: Nothing to disclose.<br />
Ghosh, Alakendu, MD<br />
WHO ILAR COPCORD (Community Oriented<br />
<strong>Program</strong> for Control of Rheumatic<br />
Diseases)............................... p. 163<br />
Disclosure: Non-CME Activity.<br />
344
Goldenberg, Don L., MD<br />
Pain - Depression Interface in the<br />
Rheumatic Diseases.................... p. 66<br />
Disclosure: Nothing to disclose.<br />
Pain - Depression Interface in the<br />
Rheumatic Diseases.................. p. 228<br />
Disclosure: Nothing to disclose.<br />
Goldring, Steven R., MD<br />
Arthritis & Rheumatism at 50: The Best of<br />
the Past, the Best of the Future... p. 206<br />
Disclosure: Abbott Laboratories 9,<br />
Boehringer Ingelheim 2, Genzyme 5<br />
Gordon, Caroline P., MD<br />
Challenges in the Management of<br />
Lupus..................................... p. 53<br />
Disclosure: Arthritis Research Campaign<br />
(arc) 2, Aspreva 2<br />
Gordon, Thomas P., MD, PhD, FRACP<br />
Sjögren’s Syndrome.................. p. 157<br />
Disclosure: Non-CME Activity.<br />
Gourley, Mark F., MD<br />
Why is My Patient With Myositis Not Getting<br />
Better?................................. p. 222<br />
Disclosure: Nothing to disclose.<br />
Grahame, Rodney, MD,<br />
Joint Hypermobility Syndrome..... p. 161<br />
Disclosure: Non-CME Activity.<br />
Grau, Rafael G., MD<br />
Vasculitis Mimics...................... p. 213<br />
Disclosure: Nothing to disclose.<br />
Green, Douglas R., PhD<br />
Apoptosis: Death by A Thousand Cuts.. p. 47<br />
Disclosure: Nothing to disclose.<br />
Greenwald, Maria W., MD<br />
Osteoporosis: Pitfalls in Bone Density<br />
Testing (Trainees Only)................ p. 51<br />
Disclosure: Amgen 2, Aventis<br />
Pharmaceuticals 2, Eli Lilly and Company 2,<br />
GlaxoSmithKline 2, Merck Human Health 2,<br />
Pfizer Inc 2, Proctor and Gamble 2, Roche<br />
Pharmaceuticals 2, Wyeth Pharmaceuticals<br />
2, Xoma Corporation 2<br />
Osteoporosis: Pitfalls in Bone Density<br />
Testing................................. p. 125<br />
Disclosure: Amgen 2, Aventis<br />
Pharmaceuticals 2, Eli Lilly and Company 2,<br />
GlaxoSmithKline 2, Merck Human Health 2,<br />
Pfizer Inc 2, Proctor and Gamble 2, Roche<br />
Pharmaceuticals 2, Wyeth Pharmaceuticals<br />
2, Xoma Corporation 2<br />
Greenwell, Cindy A., RN<br />
Fundamental Regulatory Aspects of Clinical<br />
Research: Satisfying the FDA, HIPAA and the<br />
IRB Is Not Enough..................... p. 289<br />
Disclosure: AstraZeneca 2, Talecris<br />
Biotherapeutics 2, The Center for<br />
Rheumatic Disease/Allergy/Immunology 3<br />
Gregersen, Peter K., MD<br />
RA from Bench to Bedside........... p. 286<br />
Disclosure: Nothing to disclose.<br />
Grimaldi, Christine M., PhD<br />
Gender in Rheumatic Disease....... p. 220<br />
Disclosure: Nothing to disclose.<br />
Grisanti, Joseph M., MD<br />
Completing the Puzzle: Other Aspects of<br />
Rheumatic Diseases.................... p. 39<br />
Disclosure: Nothing to disclose.<br />
Gross, K. Douglas, PT, ScD<br />
Gait Analysis: Hip, Knee and Foot Effects on<br />
Gait and How to Assess Them...... p. 140<br />
Disclosure: Nothing to disclose.<br />
Our Best Foot Forward: Practical<br />
Perspectives from the Front Line of<br />
Population-Based Foot Research... p. 231<br />
Disclosure: Nothing to disclose.<br />
Guilak, Farshid, PhD<br />
Session IV: Engineering Technologies......<br />
............................................ p. 37<br />
Disclosure: Nothing to disclose.<br />
Gul, Ahmet, MD<br />
Behçet’s Disease...................... p. 152<br />
Disclosure: Non-CME Activity.<br />
Gultekin, Sakir Humayun, MD<br />
Muscle Pathology in Rheumatic<br />
Diseases................................ p. 207<br />
Disclosure: Nothing to disclose.<br />
Why is My Patient With Myositis Not<br />
Getting Better?........................ p. 222<br />
Disclosure: Nothing to disclose.<br />
H<br />
Hakim, Alan J., MD<br />
Joint Hypermobility Syndrome..... p. 161<br />
Disclosure: Non-CME Activity.<br />
Hanly, John G., MD<br />
Systemic Lupus Erythematosus..... p. 157<br />
Disclosure: Non-CME Activity.<br />
Hannan, Marian T., MPH, DSc<br />
Multivariable Analysis: Taking the Mystery<br />
Out of the Regression Model “Black Box”<br />
.......................................... p. 128<br />
Disclosure: Nothing to disclose.<br />
Our Best Foot Forward: Practical<br />
Perspectives from the Front Line of<br />
Population-Based Foot Research... p. 231<br />
Disclosure: Nothing to disclose.<br />
Haq, Syed A., FCPS, MD<br />
WHO ILAR COPCORD (Community Oriented<br />
<strong>Program</strong> for Control of Rheumatic Diseases)<br />
.......................................... p. 163<br />
Disclosure: Non-CME Activity.<br />
Harrington, Jr., J. Timothy, MD<br />
Redesigning Your Rheumatology<br />
Practice: Practical Approaches....... p. 48<br />
Disclosure: Abbott Laboratories 2, Corrona<br />
6, 9, Wisconsin Alumni Research Foundation 7<br />
<strong>ACR</strong> Workforce Issues: The Future<br />
of Our Enterprise..................... p. 131<br />
Disclosure: Abbott Laboratories 2, Corrona<br />
6, 9, Wisconsin Alumni Research Foundation 7<br />
Redesigning your Rheumatology Practice:<br />
Practical Approaches................. p. 134<br />
Disclosure: Abbott Laboratories 2, Corrona<br />
6, 9, Wisconsin Alumni Research Foundation 7<br />
Academic Clinical Practice.......... p. 158<br />
Disclosure: Non-CME Activity.<br />
Harris, E Robert, MD<br />
Building a Stronger Physician<br />
Practice................................ p. 139<br />
Disclosure: Nothing to disclose.<br />
Harrison, Melanie J., MD, MSCE<br />
Challenges in the Management of<br />
Lupus..................................... p. 53<br />
Disclosure: Amgen 5, Arthritis Foundation-<br />
New York Chapter 2, Mary Kirkland Center<br />
for Lupus Research 2, NIH 2, Pfizer Inc<br />
5, Rheuminations, Inc. 2, UCB 5, Wyeth<br />
Pharmaceuticals 3, 5<br />
Systemic Lupus Erythematosus..... p. 157<br />
Disclosure: Non-CME Activity.<br />
Hashkes, Philip J., MD, MSc<br />
Pediatrics: Periodic Fevers in Children<br />
............................................ p. 45<br />
Disclosure: Nothing to disclose.<br />
Haskard, Dorian O., DM<br />
Inflammation, Atherosclerosis and the<br />
Rheumatic Diseases.................. p. 291<br />
Disclosure: Nothing to disclose.<br />
Hauptman, Howard W., MD<br />
Challenging Case Studies in Rheumatoid<br />
Arthritis................................ p. 204<br />
Disclosure: Abbott Laboratories 8, Amgen<br />
8, Centocor, Inc. 8, Genentech and Biogen<br />
IDEC Inc 8, Pfizer Inc 8<br />
Heller, Jenny E.., MPhil<br />
Beyond Fatigue and Pain: Addressing<br />
Concerns of Rheumatoid Arthritis Patients<br />
Outside of What is Traditionally Covered in<br />
the Physician Visit.................... p. 151<br />
Disclosure: Biogen Idec 2, Bristol-Myers<br />
Squibb 2, Millenium Pharmaceuticals 2<br />
Hewett, John E., PhD<br />
Arthritis Treatments: Methods for<br />
Evaluating Information.............. p. 207<br />
Disclosure: Nothing to disclose.<br />
Speaker Index<br />
345
Speaker Index<br />
Higgins, Gloria C., PhD, MD<br />
Pediatrics: Difficult to Treat<br />
Juvenile Idiopathic Arthritis<br />
(Trainees Only)....................... p. 133<br />
Disclosure: Abbott Laboratories 2, Amgen 2<br />
Pediatrics: Difficult to Treat Juvenile<br />
Idiopathic Arthritis................... p. 205<br />
Disclosure: Abbott Laboratories 2, Amgen 2<br />
Hill, Nicholas, MD<br />
Pulmonary Hypertension............ p. 127<br />
Disclosure: Actelion Pharmaceuticals US 2,<br />
Encysive Pharmaceuticals 2, Pfizer Inc 2,<br />
United Therapeutics 2<br />
Hillstrom, Howard J., PhD<br />
Knee Braces and Foot Orthosis for<br />
Knee Osteoarthritis..................... p. 48<br />
Disclosure: Ossur Generation II 2<br />
Knee Braces and Foot Orthosis for<br />
Knee Osteoarthritis................... p. 126<br />
Disclosure: Ossur Generation II 2<br />
Evidence for Realignment, Off-Loading and<br />
Restorative Therapies for the Treatment of<br />
Knee Osteoarthritis................... p. 220<br />
Disclosure: Ossur Generation II 2<br />
Hoffman, Gary S., MD, MS<br />
Curbside Consults - Ask the Professors<br />
.......................................... p. 130<br />
Disclosure: Nothing to disclose.<br />
Curbside Consults - Ask the Professors<br />
.......................................... p. 130<br />
Disclosure: Nothing to disclose.<br />
Holm, Margo B., PhD, OTR/L<br />
Fibromyalgia: An Innovative Approach to<br />
Understanding the Relationship Between<br />
Daily Activities and Symptoms...... p. 290<br />
Disclosure: Nothing to disclose.<br />
Hootman, Jennifer M., PhD<br />
Research Mentor/Trainee Responsibilities:<br />
Making the Most of Mentorship..... p. 231<br />
Disclosure: Nothing to disclose.<br />
Houssiau, Frederic A., MD, PhD<br />
Challenges in the Management of<br />
Lupus..................................... p. 53<br />
Disclosure: Aspreva 5, Bristol-Myers<br />
Squibb 5, Human Genome Sciences, Inc. 5<br />
Huard, Johnny, PhD<br />
Session V: Clinical Applications...... p. 37<br />
Disclosure: Cook Myosite 5<br />
Regenerating Musculosketal Tissues<br />
............................................ p. 61<br />
Disclosure: Cook Myosite 5, 5<br />
Huber, Peter, MD, PhD<br />
Signal Transduction Pathways in<br />
Scleroderma............................. p. 53<br />
Disclosure: Nothing to disclose.<br />
Huizinga, Thomas, MD<br />
RA from Bench to Bedside........... p. 287<br />
Disclosure: Nothing to disclose.<br />
Hunter, David J., MBBS, PhD<br />
Osteoarthritis: Update <strong>2007</strong>.......... p. 51<br />
Disclosure: AstraZeneca 2, DJ Orthopedics<br />
2, Merck Pharmaceuticals 2, Pfizer Inc 2<br />
Osteoarthritis: Update <strong>2007</strong>........ p. 228<br />
Disclosure: AstraZeneca 2, DJ Orthopedics<br />
2, Merck Pharmaceuticals 2, Pfizer Inc 2<br />
Hyrich, Kimme L., MD, PhD<br />
Session I: Drug Safety and Effectiveness<br />
............................................ p. 31<br />
Disclosure: Nothing to disclose.<br />
Ingersoll, Christopher D., PhD, ATC<br />
Arthrogenic Muscle Inhibition....... p. 124<br />
Disclosure: Nothing to disclose.<br />
Inman, Robert D., MD<br />
Reactive Arthritis: An Update...... p. 150<br />
Disclosure: Abbott Laboratories 5, Amgen<br />
5, Centocor, Inc. 5, Pfizer Inc 2, Schering<br />
Canada 5<br />
Spondylarthopathies................. p. 157<br />
Disclosure: Non-CME Activity.<br />
Spondylarthropathy: An Update.... p. 229<br />
Disclosure: Abbott Laboratories 5,<br />
Amgen 5, Centocor, Inc. 5, Pfizer Inc 2,<br />
Schering Canada 5<br />
Spondyloarthritis: Update on<br />
Pathogenesis and Treatment....... p. 292<br />
Disclosure: Abbott Laboratories 5, Amgen<br />
5, Centocor, Inc. 5, Pfizer Inc 2, Schering<br />
Canada 5<br />
I<br />
Isenberg, David A., MD<br />
<strong>ACR</strong> Review Course..................... p. 38<br />
Disclosure: Amgen 6, Bristol-Myers Squibb<br />
9, 9, Celltech 6, Roche Pharmaceuticals 5,<br />
Serono 6, Teva Pharmaceuticals 6<br />
SLE: Novel Treatments (Trainees Only)<br />
............................................ p. 52<br />
Disclosure: Amgen 6, Bristol-Myers Squibb<br />
9, 9, Celltech 6, Roche Pharmaceuticals 5,<br />
Serono 6, Teva Pharmaceuticals 6<br />
SLE: Novel Treatments............... p. 150<br />
Disclosure: Amgen 6, Bristol-Myers Squibb<br />
9, 9, Celltech 6, Roche Pharmaceuticals 5,<br />
Serono 6, Teva Pharmaceuticals 6<br />
B-Cell Targeted Therapy in SLE.... p. 159<br />
Disclosure: Non-CME Activity.<br />
James, Judith A., MD, PhD<br />
REF Edmund L. Dubois, MD, Memorial<br />
Lectureship.............................. p. 67<br />
Disclosure: Nothing to disclose.<br />
J<br />
James, Nadine T., RN, MSN, PhD<br />
Research Mentor/Trainee Responsibilities:<br />
Making the Most of Mentorship..... p. 231<br />
Disclosure: Nothing to disclose.<br />
Jayaraman, Mahesh V., MD<br />
Neuroradiology of CNS Vasculitis/<br />
Vasculopathy.......................... p. 133<br />
Disclosure: Nothing to disclose.<br />
Jeffrey, Janet E., RN, PhD<br />
Fibromyalgia Perspectives.......... p. 141<br />
Disclosure: Nothing to disclose.<br />
Jones, Dina L., PT, PhD<br />
Dissemination of the EnhanceFitness (TM)<br />
<strong>Program</strong> for People with Arthritis.. p. 204<br />
Disclosure: Federal grant 2<br />
Jonsson, Roland, DDS, PhD<br />
Sjögren’s Syndrome.................. p. 156<br />
Disclosure: Non-CME Activity.<br />
Jordan, Joanne E., BA, BSc, MPH<br />
Health Literacy: Foundations for Improving<br />
Clinical Practice and Patient Outcomes<br />
............................................ p. 60<br />
Disclosure: Nothing to disclose.<br />
Chronic Disease Self Management Patient<br />
Education <strong>Program</strong>s: Clinical and Public<br />
Health Awareness.................... p. 286<br />
Disclosure: Nothing to disclose.<br />
Jordan, Joanne M., MD, MPH<br />
<strong>ACR</strong> Review Course..................... p. 38<br />
Disclosure: GlaxoSmithKline 2, 5, Novartis<br />
Pharmaceutical Corporation 5<br />
Jorgensen, Christian, MD, PhD<br />
Session III: Gene-Based Therapies... p. 37<br />
Disclosure: Nothing to disclose.<br />
Juliano, Karen, PT<br />
Advances in the Management of Total<br />
Hip Arthroplasty Patients: <strong>Meeting</strong> the<br />
Challenges of Reduced Length of Stay....<br />
............................................ p. 59<br />
Disclosure: Nothing to disclose.<br />
K<br />
Kaeley, Gurjit S., MBBS, MRCP<br />
Musculoskeletal Ultrasound......... p. 153<br />
Disclosure: Non-CME Activity.<br />
Basic Ultrasonography: US Perspective<br />
.......................................... p. 209<br />
Disclosure: Nothing to disclose.<br />
Basic Ultrasonography: US Perspective<br />
.......................................... p. 221<br />
Disclosure: Nothing to disclose.<br />
Kalish, Robert A., MD<br />
Rheumatology Physical Examination:<br />
Anatomical Correlates................. p. 46<br />
Disclosure: Nothing to disclose.<br />
<strong>ACR</strong> Clinician Scholar Educator Awards<br />
.......................................... p. 140<br />
Disclosure: Nothing to disclose.<br />
Kaplan, David, PhD<br />
Regenerating Musculosketal Tissues<br />
............................................ p. 61<br />
Disclosure: Nothing to disclose.<br />
346
Kaplan, Edward L., MD<br />
Streptococcal Related Rheumatic Diseases<br />
.......................................... p. 287<br />
Disclosure: Nothing to disclose.<br />
Karlson, Elizabeth W., MD<br />
Young Investigators Session: The New Triple<br />
Threat: Successful Academic Investigator,<br />
Balanced Family Life, Financial Solvency: A<br />
Roadmap for Success.........................<br />
p. 134<br />
Disclosure: Nothing to disclose.<br />
Karp, Jeffrey M., BEng, PhD<br />
Session II: Biomaterial Scaffolds..... p. 36<br />
Disclosure: Nothing to disclose.<br />
Kastanek, Lisa M., RN, CCRC<br />
Fundamental Regulatory Aspects of Clinical<br />
Research: Satisfying the FDA, HIPAA and the<br />
IRB Is Not Enough<br />
.......................................... p. 289<br />
Disclosure: Nothing to disclose.<br />
Kastner, Daniel L., MD, PhD<br />
Discovery <strong>2007</strong>: Pathogenesis<br />
and Treatment of Inflammatory<br />
Arthritis................................ p. 130<br />
Disclosure: Nothing to disclose.<br />
Kavanaugh, Arthur, MD<br />
RA: Safety of Novel Therapies........ p. 67<br />
Disclosure: Nothing to disclose.<br />
RA: Safety of Novel Therapies...... p. 150<br />
Disclosure: Nothing to disclose.<br />
Rheumatology Roundup: Highlights<br />
from the <strong>2007</strong> <strong>ACR</strong> Annual<br />
<strong>Scientific</strong> <strong>Meeting</strong>..................... p. 285<br />
Disclosure: Nothing to disclose.<br />
Kay, Jonathan, MD<br />
Rheumatologic Skin Disease........ p. 292<br />
Disclosure: Nothing to disclose.<br />
Kendrick, Marti, JD<br />
Grassroots and the Legislative Landscape.<br />
.......................................... p. 214<br />
Disclosure: Nothing to disclose.<br />
Kerr, Karen L., MSN, NP, CPNP<br />
<strong>ARHP</strong> Networking Forum.............. p. 46<br />
Disclosure: Nothing to disclose.<br />
Keystone, Dr., Edward C., MD<br />
Physical Examination Skills for Improved<br />
Detection of Synovitis and Cervical<br />
Thoracolumbar Disorders.............. p. 53<br />
Disclosure: Nothing to disclose.<br />
RA: Biological Agents................ p. 126<br />
Disclosure: Abbott Immunology<br />
Pharmaceuticals 5, Amgen 5, Bristol-Myers<br />
Squibb 5, 9, 9, Celltech 9, Centocor, Inc.<br />
5, Genentech and Biogen IDEC Inc 5, 8, 9,<br />
Hoffmann-La Roche, Inc. 5, 8, 9, Schering-<br />
Plough 9, UCB 8, 9, Wyeth Pharmaceuticals 5<br />
RA: Biological Agents................ p. 133<br />
Disclosure: Abbott Immunology<br />
Pharmaceuticals 5, Amgen 5, Bristol-Myers<br />
Squibb 9, 9, Centocor, Inc. 5, Genentech<br />
and Biogen IDEC Inc 5, 8, 9, Hoffmann-La<br />
Roche, Inc. 5, 8, 9, Schering-Plough 9, UCB<br />
5, 8, 9, Wyeth Pharmaceuticals 5<br />
Issues in Biologic Therapy........... p. 143<br />
Disclosure: Nothing to disclose.<br />
Khan, Muhammad Asim, MD, MACP<br />
Ankylosing Spondylitis: <strong>2007</strong><br />
Update................................... p. 50<br />
Disclosure: Abbott Laboratories 8, Amgen<br />
8, Centocor, Inc. 8, Schering Canada 8,<br />
Schering-Plough 8, Wyeth Pharmaceuticals 8<br />
Ankylosing Spondylitis: <strong>2007</strong><br />
Update................................. p. 149<br />
Disclosure: Abbott Laboratories 8, Amgen<br />
8, Centocor, Inc. 8, Schering Canada 8,<br />
Schering-Plough 8, Wyeth Pharmaceuticals 8<br />
Kim, Lauren H., MD<br />
Scleroderma: Systemic Sclerosis... p. 126<br />
Disclosure: Nothing to disclose.<br />
Kinet, Jean-Pierre, MD<br />
Ion Channels in Inflammation....... p. 143<br />
Disclosure: Synta Pharmaceuticals 1<br />
Kirwan, John R., MD<br />
Patient Perspective in Outcomes<br />
Research............................... p. 155<br />
Disclosure: Non-CME Activity.<br />
Kissin, Eugene Y., MD<br />
Clinicopathologic Conference (CPC): A<br />
57-Year-Old Man with Polyarthritis... p. 124<br />
Disclosure: Nothing to disclose.<br />
Klepper, Susan E., PhD, PT<br />
Practical Pediatric Rheumatology<br />
Rehabilitation: What You Wished You Had<br />
Learned in Training.................. p. 140<br />
Disclosure: Nothing to disclose.<br />
Kosman, Lisa, MS, PT<br />
Advances in the Management of<br />
Total Hip Arthroplasty Patients:<br />
<strong>Meeting</strong> the Challenges of Reduced<br />
Length of Stay........................... p. 59<br />
Disclosure: Nothing to disclose.<br />
Krishnan, Eswar, MD<br />
Rheumatic Disease Epidemiology for Clinical<br />
Practice: What We Know, What We Don’t<br />
Know and Why It Matters............ p. 220<br />
Disclosure: Nothing to disclose.<br />
Krohn, Kelly D., MD<br />
Knee Braces and Foot Orthosis for Knee<br />
Osteoarthritis......................... p. 148<br />
Disclosure: Nothing to disclose.<br />
Knee Braces and Foot Orthosis for Knee<br />
Osteoarthritis......................... p. 126<br />
Disclosure: Nothing to disclose.<br />
Kunkel, Ann, BS<br />
Identifying and Navigating Web-Based<br />
Educational and Networking Resources<br />
for Rheumatology Health Professionals<br />
and Patients........................... p. 222<br />
Disclosure: Nothing to disclose.<br />
Kvien, Tore K., MD<br />
Patient Perspective in Outcomes<br />
Research............................... p. 154<br />
Disclosure: Non-CME Activity.<br />
Lacaille, Diane V., MD,, MHSc<br />
Improving Employment Situations Among<br />
People with Arthritis................... p. 68<br />
Disclosure: Nothing to disclose.<br />
Laflamme, Michael A., MD, PhD<br />
Session I: Stem Cells................... p. 36<br />
Disclosure: Geron 2<br />
Lane, Nancy E., MD<br />
Geriatric Rheumatology............. p. 160<br />
Disclosure: Non-CME Activity.<br />
Challenging Topics in Bone Disease. . p. 287<br />
Disclosure: Nothing to disclose.<br />
Langford, Carol, MD, MHS<br />
<strong>ACR</strong>/ABIM Maintenance of<br />
Certification Learning Session for<br />
Recertification Module 30-R.......... p. 35<br />
Disclosure: Bristol-Myers Squibb 9,<br />
Genentech and Biogen IDEC Inc 2, 9<br />
Vasculitis: Update...................... p. 67<br />
Disclosure: Bristol-Myers Squibb 9,<br />
Genentech and Biogen IDEC Inc 2, 9<br />
Therapeutic Decisions in Systemic<br />
Vasculitis............................... p. 135<br />
Disclosure: Bristol-Myers Squibb 9,<br />
Genentech and Biogen IDEC Inc 2, 9<br />
Vasculitis: Update (Trainess Only)<br />
.......................................... p. 213<br />
Disclosure: Bristol-Myers Squibb 9,<br />
Genentech and Biogen IDEC Inc 2, 9<br />
Lanza, Robert, MD<br />
Session I: Stem Cells................... p. 36<br />
Disclosure: Advanced Cell Technology 3<br />
Lawry, II., George V., MD<br />
Career Choices in Rheumatology: Many<br />
Choices, Great Lifestyles!............. p. 52<br />
Disclosure: Nothing to disclose.<br />
Laxer, Ronald M., MD<br />
Management of Complications of Systemic<br />
Juvenile Idiopathic Arthritis.......... p. 47<br />
Disclosure: Nothing to disclose.<br />
L<br />
Speaker Index<br />
347
Speaker Index<br />
Leib, Edward S., MD<br />
Osteoporosis: Focus on DXA Interpretation<br />
............................................ p. 61<br />
Disclosure: Nothing to disclose.<br />
Osteoporosis: Focus on DXA Interpretation<br />
.......................................... p. 142<br />
Disclosure: Nothing to disclose.<br />
Lems, Willem, MD, PhD<br />
Metabolic Bone........................ p. 162<br />
Disclosure: Non-CME Activity.<br />
Leong, Amye L., MBA<br />
The Physician, The Patient, The Disease:<br />
Why Bother with Person-Centered Care?<br />
Keynote Address........................ p. 48<br />
Disclosure: Nothing to disclose.<br />
Speak Out: Using Your Voice to Improve<br />
Rheumatology Practice and Patient Care.<br />
............................................ p. 69<br />
Disclosure: Nothing to disclose.<br />
Levine, Jerrold S., MD<br />
Inflammation.......................... p. 160<br />
Disclosure: Non-CME Activity.<br />
Levy, Deborah M., MD, MS<br />
Pediatric Systemic Lupus.............. p. 45<br />
Disclosure: Pfizer Inc 2<br />
Pediatric Systemic Lupus (Trainees Only).<br />
.......................................... p. 229<br />
Disclosure: Pfizer Inc 2<br />
Levy, Roger A., MD, PhD<br />
Latin <strong>American</strong> Study Group........ p. 161<br />
Disclosure: Non-CME Activity.<br />
Lisse, Jeffrey R., MD<br />
RA: Early Rheumatoid Arthritis....... p. 52<br />
Disclosure: Abbott Immunology<br />
Pharmaceuticals 8, Amgen 2, 5, 8,<br />
Centocor, Inc. 2, 8, Genentech and Biogen<br />
IDEC Inc 8<br />
RA: Early Rheumatoid Arthritis..... p. 133<br />
Disclosure: Abbott Immunology<br />
Pharmaceuticals 5, 8, Amgen 2, 5, 8,<br />
Centocor, Inc. 2, 8, Genentech and Biogen<br />
IDEC Inc 8<br />
Littlejohn, Geoffrey O., MBBS, FRACP, MD<br />
Pain: Overuse Syndromes............ p. 212<br />
Disclosure: Nothing to disclose.<br />
Lockshin, Michael D., MD<br />
Curbside Consults - Ask the Professors<br />
.......................................... p. 131<br />
Disclosure: Nothing to disclose.<br />
Curbside Consults - Ask the Professors<br />
.......................................... p. 131<br />
Disclosure: Nothing to disclose.<br />
Neuro Endocrine Immunology....... p. 154<br />
Disclosure: Non-CME Activity.<br />
Latin <strong>American</strong> Study Group........ p. 161<br />
Disclosure: Non-CME Activity.<br />
Lories, Rik J., MD, PhD<br />
Bone Remodeling: New Targets in the<br />
Rheumatic Diseases.................. p. 134<br />
Disclosure: Nothing to disclose.<br />
Luyten, Frank P., MD, PhD<br />
Session V: Clinical Applications...... p. 37<br />
Disclosure: Tigenix 1<br />
M<br />
Maetzel, Andreas, MD<br />
Session II: Economics of Rheumatic<br />
Pharmacotherapy....................... p. 31<br />
Disclosure: Nothing to disclose.<br />
Mahmood, Umar, MD, PhD<br />
<strong>ACR</strong>-EULAR Exchange................ p. 152<br />
Disclosure: Non-CME Activity.<br />
Mallinson, Trudy R., PhD<br />
Motivational Interviewing: Facilitating<br />
Health Promotion in Arthritis....... p. 220<br />
Disclosure: Nothing to disclose.<br />
Mangino, Lisa C., PT, DPT, MS<br />
Physical Therapy Management of Pediatric<br />
Rheumatology Issues................. p. 286<br />
Disclosure: Nothing to disclose.<br />
Manzi, Susan, MD, MPH<br />
SLE: Difficult to Treat SLE............. p. 67<br />
Disclosure: Aspreva 9, Bristol-Myers<br />
Squibb 9, Centocor, Inc. 9, Food & Drug<br />
Administratiaon (FDA) Arthritis Advisory<br />
Board 9, Genelabs Technologies, Inc. 9,<br />
Genzyme Corporation 9, Human Genome<br />
Sciences, Inc. 9, StageMark, Inc 9<br />
SLE: Difficult to Treat SLE........... p. 213<br />
Disclosure: Aspreva 9, Bristol-Myers Squibb<br />
9, Centocor, Inc. 9, Genelabs Technologies,<br />
Inc. 9, Genzyme Corporation 9, Human<br />
Genome Sciences, Inc. 9, StageMark, Inc 9<br />
Marcus, Donald M., MD<br />
Safety/Efficacy of Alternative Therapies.<br />
.......................................... p. 126<br />
Disclosure: Nothing to disclose.<br />
Martin, Don R., MD<br />
<strong>ACR</strong> Clinician Scholar Educator Awards<br />
.......................................... p. 140<br />
Disclosure: Nothing to disclose.<br />
Martin, Ivan, PhD<br />
Session IV: Engineering Technologies......<br />
............................................ p. 37<br />
Disclosure: Nothing to disclose.<br />
Marty, Francisco M., MD<br />
Opportunistic Infections in Rheumatic<br />
Diseases.................................. p. 44<br />
Disclosure: Arrow Therapeutics 2, Astellas<br />
Pharma US 2, Basilea Pharmaceutica<br />
2, Berlex 5, Biogen Idec 5, Genzyme<br />
Corporation 5, Novartis Pharmaceutical<br />
Corporation 5, Schering-Plough 2,<br />
ViroPharma 2<br />
Massarotti, Elena M., MD<br />
<strong>ACR</strong>/ABIM Maintenance of Certification<br />
Learning Session for Recertification<br />
Module 30-R............................. p. 36<br />
Disclosure: Nothing to disclose.<br />
Matteson, Eric L., MD<br />
Polymyalgia Rheumatica............ p. 155<br />
Disclosure: Non-CME Activity.<br />
Interstitial Lung Disease in the Rheumatic<br />
Diseases................................ p. 160<br />
Disclosure: Non-CME Activity.<br />
Mayes, Maureen D., MD, MPH<br />
<strong>ACR</strong>/ABIM Maintenance of Certification<br />
Learning Session for Recertification<br />
Module 30-R............................. p. 36<br />
Disclosure: Actelion Pharmaceuticals US 5,<br />
Encysive Pharmaceuticals 5<br />
Scleroderma Skin Score - How I Do It<br />
.......................................... p. 156<br />
Disclosure: Non-CME Activity.<br />
McAlindon, Timothy E., MD, MPH, MRCP<br />
Osteoarthritis: Novel Treatments.... p. 66<br />
Disclosure: GELITA 5, Stryker 5<br />
Osteoarthritis: Novel Treatments.. p. 205<br />
Disclosure: GELITA 5, Stryker 5<br />
McCann, Barton C., MD, MPH<br />
Physician Fee Schedule: What is an RVU?.<br />
............................................ p. 52<br />
Disclosure: Johnson & Johnson 5<br />
McClung, Michael, MD<br />
Challenging Topics in Bone Disease<br />
.......................................... p. 287<br />
Disclosure: Amgen 2, 5, Eli Lilly and<br />
Company 2, 5, 8, Merck Pharmaceuticals<br />
2, 5, Novartis Pharmaceutical Corporation<br />
2, 5, Proctor & Gamble Pharmaceuticals<br />
2, 5, 8, Roche Pharmaceuticals 2, Sanofi-<br />
Aventis Pharmaceutical 2, 5, 8<br />
McCune, W Joseph, MD<br />
SLE: Lupus Nephritis................. p. 126<br />
Disclosure: Aspreva 2, DNAX 2, Genentech<br />
and Biogen IDEC Inc 2, Human Genome<br />
Sciences 2, TAP Pharmaceuticals Inc. 2<br />
SLE: Lupus Nephritis................. p. 206<br />
Disclosure: DNAX 2, Genelabs 2, Genentech<br />
and Biogen IDEC Inc 2, Human Genome<br />
Sciences 2, TAP Pharmaceuticals Inc. 2<br />
McDougall, Jason J., PhD<br />
Osteoarthritis: Degradation and Disease<br />
.......................................... p. 143<br />
Disclosure: Nothing to disclose.<br />
McGonagle, Dennis, MB, I, PhD<br />
Spondyloarthritis: Update on Pathogenesis<br />
and Treatment........................ p. 292<br />
Disclosure: Nothing to disclose.<br />
348
McInnes, Iain B., , PhD<br />
Psoriatic Arthritis....................... p. 45<br />
Disclosure: Abbott Immunology<br />
Pharmaceuticals 5, Schering-Plough 2, 5,<br />
Wyeth Pharmaceuticals 5<br />
Psoriatic Arthritis....................... p. 66<br />
Disclosure: Abbott Immunology<br />
Pharmaceuticals 5, Schering-Plough 2, 5,<br />
Wyeth Pharmaceuticals 5<br />
McLean, Robert R., DSc, MPH<br />
Multivariable Analysis: Taking the<br />
Mystery Out of the Regression<br />
Model “Black Box”.................... p. 128<br />
Disclosure: Nothing to disclose.<br />
McQueen, Fiona M., MD<br />
Magnetic Resonance Imaging (MRI)<br />
.......................................... p. 162<br />
Disclosure: Non-CME Activity.<br />
Mease, Philip J., MD<br />
Psoriatic Arthritis..................... p. 219<br />
Disclosure: Non-CME Activity.<br />
Medsger, Jr., Thomas A., MD<br />
Pediatric Rheumatology: Update on<br />
Juvenile Scleroderma................ p. 155<br />
Disclosure: Non-CME Activity.<br />
Messier, Stephen P., PhD<br />
Rehabilitative Rheumatology....... p. 156<br />
Disclosure: Non-CME Activity.<br />
Miller, Donald R., PharmD<br />
Alternative Therapies for Arthritis and<br />
Fibromyalgia........................... p. 124<br />
Disclosure: Nothing to disclose.<br />
Miller, Michael L., MD<br />
Pediatrics: What to Do with Children with<br />
Joint Pain and Normal PE............. p. 51<br />
Disclosure: Nothing to disclose.<br />
Pediatrics: What to Do With Children With<br />
Joint Pain and Normal PE........... p. 229<br />
Disclosure: Nothing to disclose.<br />
Minor, Marian A., PhD, PT<br />
Arthritis Treatments: Methods for<br />
Evaluating Information.............. p. 207<br />
Disclosure: Nothing to disclose.<br />
Research Mentor/Trainee Responsibilities:<br />
Making the Most of Mentorship..... p. 231<br />
Disclosure: Nothing to disclose.<br />
Moritz, Falk, MD<br />
<strong>ACR</strong>-EULAR Exchange................ p. 152<br />
Disclosure: Non-CME Activity.<br />
Moutsopoulos, Haralampos M., MD,<br />
Sjögren’s Syndrome: Update on a Systemic<br />
Disease................................... p. 62<br />
Disclosure: Nothing to disclose.<br />
Muller-Ladner, Ulf, MD<br />
Neuro Endocrine Immunology....... p. 154<br />
Disclosure: Non-CME Activity.<br />
Murphey, Mark D., MD<br />
Musculoskeletal Imaging............. p. 209<br />
Disclosure: Nothing to disclose.<br />
Musculoskeletal Imaging (Trainees Only)<br />
.......................................... p. 221<br />
Disclosure: Nothing to disclose.<br />
Murphy, Susan L., ScD, OTR<br />
Developing a Research Career: Finding and<br />
Following a Path to Independence... p. 59<br />
Disclosure: Nothing to disclose.<br />
Myerson, Gary E., MD<br />
Fibromyalgia............................. p. 66<br />
Disclosure: Eli Lilly and Company 8, Forest<br />
Laboratories 8, Pfizer Inc 8, Pricara 8,<br />
Wyeth Pharmaceuticals 8<br />
Fibromyalgia........................... p. 149<br />
Disclosure: Eli Lilly and Company 8, Forest<br />
Laboratories 8, Pfizer Inc 8, Pricara 8,<br />
Wyeth Pharmaceuticals 8<br />
N<br />
Neuwelt, C Michael, MD<br />
SLE: CNS Lupus.......................... p. 45<br />
Disclosure: Aspreva 2, Genentech and<br />
Biogen IDEC Inc 2, 9, Hoffmann-La Roche,<br />
Inc. 2, La Jolla Pharmaceutical 2, Teva<br />
Pharmaceuticals 2<br />
SLE: CNS Lupus........................ p. 126<br />
Disclosure: Aspreva 2, Biogen Idec<br />
2, Genentech and Biogen IDEC Inc 2,<br />
Hoffmann-La Roche, Inc. 2, La Jolla<br />
Pharmaceutical 2, Teva Pharmaceuticals 2<br />
Newman, Eric D., MD<br />
Redesigning your Rheumatology Practice:<br />
Practical Approaches................. p. 134<br />
Disclosure: Nothing to disclose.<br />
Nola, Kam M., PharmD, MS<br />
Improving Patient Safety: Prevention of<br />
Medication Errors in Rheumatology Practice<br />
.......................................... p. 128<br />
Disclosure: Nothing to disclose.<br />
O<br />
O’Brien, Virginia, OTR/L, CHT<br />
Dynamic Stability for the Painful Thumb:<br />
It’s Not Just a Splint................. p. 231<br />
Disclosure: Nothing to disclose.<br />
Dynamic Stability for the Painful Thumb:<br />
Experiential Laboratory............. p. 290<br />
Disclosure: Nothing to disclose.<br />
Oatis, Carol A., PT, PhD<br />
What’s New and Noteworthy in <strong>2007</strong>: A<br />
Review of Rheumatology Research for<br />
Health Professionals................. p. 125<br />
Disclosure: Nothing to disclose.<br />
Gait Analysis: Hip, Knee and Foot Effects on<br />
Gait and How to Assess Them...... p. 140<br />
Disclosure: Nothing to disclose.<br />
Our Best Foot Forward: Practical Perspectives<br />
from the Front Line of Population-Based Foot<br />
Research................................ p. 231<br />
Disclosure: Nothing to disclose.<br />
Oddis, Chester V., MD<br />
<strong>ACR</strong> Review Course..................... p. 39<br />
Disclosure: Genentech and Biogen IDEC Inc 5<br />
Myopathy: Issues in Diagnosis and<br />
Treatment............................. p. 150<br />
Disclosure: Nothing to disclose.<br />
Myopathy: Issues in Diagnosis and<br />
Treatment............................. p. 230<br />
Disclosure: Nothing to disclose.<br />
O’Dell, James R., MD<br />
RA: Outcome Measures in Clinical Practice<br />
.......................................... p. 150<br />
Disclosure: Nothing to disclose.<br />
O’Keefe, Regis J., M.D., Ph.D.<br />
REF Marshall J. Schiff, MD, Memorial<br />
Lectureship.............................. p. 59<br />
Disclosure: Nothing to disclose.<br />
Olech, Ewa, MD<br />
Peripheral MRI in Clinical Practice. p. 129<br />
Disclosure: Abbott Immunology<br />
Pharmaceuticals 5, 8, Biogen Idec 5, BioRad<br />
Laboratories 5, Bristol-Myers Squibb 2, 8,<br />
Centocor, Inc. 2, Genentech and Biogen<br />
IDEC Inc 2, 5, 8<br />
Peripheral MRI in Clinical Practice... p. 213<br />
Disclosure: Abbott Immunology<br />
Pharmaceuticals 5, 8, Biogen Idec 5, BioRad<br />
Laboratories 5, Bristol-Myers Squibb 2, 8,<br />
Centocor, Inc. 2, Genentech and Biogen<br />
IDEC Inc 2, 5, 8<br />
Oliver, Susan M., MSc<br />
What’s New and Noteworthy in <strong>2007</strong>: A<br />
Review of Rheumatology Research for<br />
Health Professionals................. p. 125<br />
Disclosure: Nothing to disclose.<br />
O’Rourke, Kenneth S., MD<br />
Joint Injection Techniques.......... p. 129<br />
Disclosure: Nothing to disclose.<br />
Joint Injection Techniques (Trainees Only)<br />
.......................................... p. 207<br />
Disclosure: Nothing to disclose.<br />
Speaker Index<br />
349
Speaker Index<br />
Osborne, Richard H., PhD<br />
Health Literacy: Foundations for Improving<br />
Clinical Practice and Patient Outcomes..<br />
............................................ p. 60<br />
Disclosure: Nothing to disclose.<br />
Chronic Disease Self Management Patient<br />
Education <strong>Program</strong>s: Clinical and Public<br />
Health Awareness.................... p. 286<br />
Disclosure: Nothing to disclose.<br />
Ostergaard, Mikkel, MD, PhD, DMSc<br />
Peripheral MRI in Clinical<br />
Rheumatology........................... p. 53<br />
Disclosure: Nothing to disclose.<br />
Magnetic Resonance Imaging (MRI)... p. 161<br />
Disclosure: Non-CME Activity.<br />
Peripheral MRI in Clinical<br />
Rheumatology......................... p. 207<br />
Disclosure: Nothing to disclose.<br />
P<br />
Parke, Ann L., MD<br />
Sjögren’s Syndrome: Update on a Systemic<br />
Disease................................... p. 62<br />
Disclosure: Nothing to disclose.<br />
Pregnancy in Rheumatic Diseases<br />
.......................................... p. 133<br />
Disclosure: Nothing to disclose.<br />
Pregnancy in Rheumatic Diseases.. p. 205<br />
Disclosure: Nothing to disclose.<br />
Patkar, Nivedita M., MD, MSPH<br />
Doing the Right Thing: Evidence and<br />
Guidelines for Rheumatoid Arthritis<br />
Treatment............................. p. 135<br />
Disclosure: Nothing to disclose.<br />
Peyman, John A.., PhD<br />
Young Investigators Session: The New<br />
Triple Threat: Successful Academic<br />
Investigator, Balanced Family Life,<br />
Financial Solvency:<br />
A Roadmap for Success.............. p. 133<br />
Disclosure: Nothing to disclose.<br />
Pierangeli, Silvia S., PhD<br />
Antiphospholipid Syndrome........... p. 66<br />
Disclosure: Nothing to disclose.<br />
Antiphospholipid Syndrome......... p. 205<br />
Disclosure: Nothing to disclose.<br />
Piette, Warren W., MD<br />
Rheumatologic Skin Disease........ p. 292<br />
Disclosure: Nothing to disclose.<br />
Pincus, Theodore, MD<br />
Patient Questionnaires: Use in Clinical<br />
Trials of RA and OA................... p. 129<br />
Disclosure: Bristol-Myers Squibb 2<br />
Patient Questionnaires to Monitor Status<br />
and Document Improvement in Standard<br />
Care: Practical Considerations..... p. 134<br />
Disclosure: Bristol-Myers Squibb 2<br />
Pisetsky, David S., MD, PhD<br />
Arthritis & Rheumatism at 50: The Best of<br />
the Past, the Best of the Future... p. 206<br />
Disclosure: Nothing to disclose.<br />
Plotz, Paul H., MD<br />
REF Paul Klemperer, MD, Memorial<br />
Lectureship............................ p. 208<br />
Disclosure: Nothing to disclose.<br />
Pope, Richard M., MD<br />
Inflammation.......................... p. 160<br />
Disclosure: Non-CME Activity.<br />
Porcelli, Steven A., MD<br />
Innate Immunity...................... p. 285<br />
Disclosure: Vaccinex, Inc. 5<br />
Prestwich, Glenn D., PhD<br />
Session II: Biomaterial Scaffolds..... p. 36<br />
Disclosure: Carbylan BioSurgery 1, Glycosan<br />
BioSystems 1, Sentrx Animal Care 1<br />
Punaro, Marilynn G., MD<br />
Pediatrics: JIA for Adult Rheumatologists.<br />
............................................ p. 51<br />
Disclosure: Nothing to disclose.<br />
Pediatrics: JIA for Adult Rheumatologists.<br />
.......................................... p. 212<br />
Disclosure: Nothing to disclose.<br />
R<br />
Rabinovich, Egla C., MD, MPH<br />
Bone Health in Children and Adolescents<br />
with Rheumatic Disease............... p. 62<br />
Disclosure: Nothing to disclose.<br />
Pediatrics: Pediatric Scleroderma<br />
.......................................... p. 212<br />
Disclosure: Nothing to disclose.<br />
Ramsey, Lee Ann B., BBA, GCPH<br />
The Evolution of CDC-Funded State<br />
Arthritis <strong>Program</strong>s...................... p. 50<br />
Disclosure: Nothing to disclose.<br />
Randolph, Gwendalyn J., PhD<br />
Inflammation, Atherosclerosis and the<br />
Rheumatic Diseases.................. p. 291<br />
Disclosure: Merck Pharmaceuticals 2<br />
Ranganath, Veena K., MD<br />
Geriatric Rheumatology............. p. 145<br />
Disclosure: Non-CME Activity.<br />
Rapoff, Michael A., PhD<br />
How Do You Know Your Patient Is Taking<br />
Medicines, Exercising and Following Other<br />
Regimens You Recommended?...... p. 204<br />
Disclosure: Nothing to disclose.<br />
Ray, Laura E., MA, MLS<br />
Research Beyond Google: Efficient<br />
and Effective Research on the Web for<br />
Clinicians and Educators............... p. 61<br />
Disclosure: Nothing to disclose.<br />
Identifying and Navigating Web-Based<br />
Educational and Networking Resources for<br />
Rheumatology Health Professionals and<br />
Patients................................ p. 222<br />
Disclosure: Nothing to disclose.<br />
Reed, Ann M., MD<br />
Pediatrics: Dermatomyositis........ p. 229<br />
Disclosure: Genentech and Biogen IDEC<br />
Inc 5<br />
Reeves, Westley H., MD<br />
Autoantibodies In Diagnosis and Follow Up<br />
of Rheumatic Diseases............... p. 152<br />
Disclosure: Non-CME Activity.<br />
Reginato, Anthony M., MD, PhD<br />
Crystal: Pseudogout.................. p. 152<br />
Disclosure: Nothing to disclose.<br />
Remvig, Lars, MD<br />
Joint Hypermobility Syndrome..... p. 161<br />
Disclosure: Non-CME Activity.<br />
Reuben, Adrian, MD<br />
Hepatitis C............................. p. 204<br />
Disclosure: Nothing to disclose.<br />
Reveille, John D., MD<br />
Rheumatic Manifestations of HIV... p. 206<br />
Disclosure: Nothing to disclose.<br />
Richards, John S., MBBS<br />
Ethnic Minority........................ p. 153<br />
Disclosure: Non-CME Activity.<br />
Richardson, Bruce C., MD, PhD<br />
Gender in Rheumatic Disease....... p. 220<br />
Disclosure: Nothing to disclose.<br />
Rider, Lisa G., MD<br />
Rheumatic Disease Update: Adult and<br />
Juvenile Dermatomyositis/Polymyositis<br />
.......................................... p. 124<br />
Disclosure: Nothing to disclose.<br />
Riegger-Krugh, Cheryl L., PT, ScD<br />
Evidence for Realignment, Off-Loading and<br />
Restorative Therapies for the Treatment of<br />
Knee Osteoarthritis................... p. 220<br />
Disclosure: Nothing to disclose.<br />
Ritchlin, Christopher T., MD<br />
Psoriatic Arthritis....................... p. 51<br />
Disclosure: Abbott Laboratories 5, Amgen<br />
5, Bristol-Myers Squibb 5, Centocor, Inc.<br />
2, 5, Roche Pharmaceuticals 5, Wyeth<br />
Pharmaceuticals 5<br />
Psoriatic Arthritis..................... p. 155<br />
Disclosure: Abbott Laboratories 5, Amgen<br />
5, Bristol-Myers Squibb 5, Centocor, Inc.<br />
2, 5, Roche Pharmaceuticals 5, Wyeth<br />
Pharmaceuticals 5<br />
350
Spondyloarthritis: Update on Pathogenesis<br />
and Treatment........................ p. 292<br />
Disclosure: Abbott Laboratories 5, Amgen<br />
5, Bristol-Myers Squibb 5, Centocor, Inc.<br />
2, 5, Roche Pharmaceuticals 5, Wyeth<br />
Pharmaceuticals 5<br />
Robey, Pamela G., PhD<br />
Session I: Stem Cells................... p. 36<br />
Disclosure: Nothing to disclose.<br />
Rock, Valerie G., CPC-A, ACS-EM<br />
Coding is Your Friend................ p. 285<br />
Disclosure: Nothing to disclose.<br />
Rogers, Joan C., PhD, OTR/L<br />
Fibromyalgia: An Innovative Approach to<br />
Understanding the Relationship Between<br />
Daily Activities and Symptoms...... p. 290<br />
Disclosure: Nothing to disclose.<br />
Roos, Ewa M., PT, PhD<br />
Young Patients With Old Knees: Treatment<br />
and Prevention of Knee Osteoarthritis (OA)<br />
in the Middle-Aged................... p. 151<br />
Disclosure: Nothing to disclose.<br />
Rosen, Clifford J., MD<br />
Challenging Topics in Bone Disease<br />
.......................................... p. 287<br />
Disclosure: Nothing to disclose.<br />
Rosenbaum, James T., MD<br />
<strong>ACR</strong> Review Course..................... p. 38<br />
Disclosure: Abbott Laboratories 2, 5,<br />
Allergan 2, Amgen 1, 5, Bausch & Lomb<br />
2, Celgene 5, Centocor, Inc. 2, Genentech<br />
and Biogen IDEC Inc 2, Lux 2, Novartis<br />
Pharmaceutical Corporation 5<br />
Russell, Sheryl S., PhD, APRN, BC<br />
Completing the Puzzle: Other Aspects of<br />
Rheumatic Diseases.................... p. 39<br />
Disclosure: Nothing to disclose.<br />
S<br />
Saag, Kenneth G., MD, MSc<br />
<strong>ACR</strong>/ABIM Maintenance of Certification<br />
Learning Session for Recertification<br />
Module 30-R................................. p. 36<br />
Disclosure: Amgen 2, Eli Lilly and Company<br />
2, 5, Merck Human Health 2, Merck<br />
Pharmaceuticals 5, 8, Novartis Pharmaceutical<br />
Corporation 2, 5, Roche Pharmaceuticals 2, 5,<br />
Savient 5, TAP Pharmaceuticals Inc. 5<br />
Doing the Right Thing: Evidence and Guidelines<br />
for Rheumatoid Arthritis Treatment...p. 135<br />
Disclosure: Amgen 2, Eli Lilly and Company<br />
2, 5, Merck Human Health 2, Merck<br />
Pharmaceuticals 5, 8, Novartis Pharmaceutical<br />
Corporation 2, 5, Roche Pharmaceuticals 2, 5,<br />
Savient 5, TAP Pharmaceuticals Inc. 5<br />
Crystal Arthropathies................ p. 153<br />
Disclosure: Non-CME Activity.<br />
Metabolic Bone........................ p. 162<br />
Disclosure: Non-CME Activity.<br />
Sah, Robert L., MD, ScD<br />
Regenerating Musculosketal Tissues<br />
............................................ p. 61<br />
Disclosure: Nothing to disclose.<br />
Salmon, Jane E., MD<br />
Discovery <strong>2007</strong>: Insights into Autoimmunity<br />
.......................................... p. 211<br />
Disclosure: Nothing to disclose.<br />
Saluja, Manjit, BSc<br />
WHO ILAR COPCORD (Community Oriented<br />
<strong>Program</strong> for Control of Rheumatic Diseases)<br />
p. 163<br />
Disclosure: Non-CME Activity.<br />
Sanderson, Tessa, BSc<br />
Patient Perspective in Outcomes Research<br />
.......................................... p. 154<br />
Disclosure: Non-CME Activity.<br />
Sanz, Ignacio, MD<br />
B-Cell Targeted Therapy in SLE.... p. 159<br />
Disclosure: Non-CME Activity.<br />
Sapienza, Carmen, PhD<br />
Gender in Rheumatic Disease....... p. 222<br />
Disclosure: Nothing to disclose.<br />
Schett, Georg, MD<br />
Bone Remodeling: New Targets in the<br />
Rheumatic Diseases.................. p. 134<br />
Disclosure: Nothing to disclose.<br />
Magnetic Resonance Imaging (MRI)<br />
.......................................... p. 162<br />
Disclosure: Non-CME Activity.<br />
Schmid, Christopher H., PhD<br />
Basic Statistical Concepts for the Medical<br />
Researcher............................. p. 134<br />
Disclosure: Averion 5, Kenyon and Kenyon<br />
5, Pfizer Inc 2, United Biosystems 5<br />
Schmidt, Wolfgang A., MD<br />
Musculoskeletal Ultrasonography:<br />
Basic...................................... p. 46<br />
Disclosure: Nothing to disclose.<br />
Musculoskeletal Ultrasonography:<br />
Advanced................................ p. 61<br />
Disclosure: Nothing to disclose.<br />
Musculoskeletal Ultrasonography:<br />
Basic.................................... p. 127<br />
Disclosure: Nothing to disclose.<br />
Musculoskeletal Ultrasonography:<br />
Basic (Trainees Only)................ p. 134<br />
Disclosure: Nothing to disclose.<br />
Polymyalgia Rheumatica............ p. 155<br />
Disclosure: Non CME Activity.<br />
Schneeweiss, Sebastian, MD, ScD<br />
Session IV: Methods in Drug Evaluation<br />
............................................ p. 35<br />
Disclosure: Merck Pharmaceuticals 2, Pfizer Inc 2<br />
Schumacher, Jr., H Ralph, MD<br />
Synovial Fluid Analysis and Crystal<br />
Identification (Trainees Only)........ p. 46<br />
Disclosure: Nothing to disclose.<br />
Synovial Fluid Analysis and Crystal<br />
Identification............................ p. 53<br />
Disclosure: Nothing to disclose.<br />
Synovial Fluid Analysis and Crystal<br />
Identification.......................... p. 127<br />
Disclosure: Nothing to disclose.<br />
Schur, Peter H., MD<br />
Completing the Puzzle: Other Aspects of<br />
Rheumatic Diseases.................... p. 39<br />
Disclosure: Nothing to disclose.<br />
Schwartzman, Sergio, MD<br />
Inflammatory Eye Disease: Focus on Uveitis<br />
............................................ p. 44<br />
Disclosure: Centocor, Inc. 8<br />
Inflammatory Eye Disease: Focus on Uveitis<br />
.......................................... p. 150<br />
Disclosure: Centocor, Inc. 8<br />
Seibold, James R., MD<br />
Scleroderma Skin Score - How I Do It<br />
.......................................... p. 156<br />
Disclosure: Non-CME Activity.<br />
Seligman, Paul, MD, MPH<br />
Session III: Drug Policy and Regulation<br />
............................................ p. 35<br />
Disclosure: Nothing to disclose.<br />
Seton, Margaret, MD<br />
Paget’s Disease....................... p. 228<br />
Disclosure: Nothing to disclose.<br />
Sfikakis, Petros, MD<br />
Behcet’s Disease...................... p. 153<br />
Disclosure: Non-CME Activity.<br />
Shadick, Nancy A., MD, MPH<br />
Beyond Fatigue and Pain: Addressing<br />
Concerns of Rheumatoid Arthritis Patients<br />
Outside of What is Traditionally Covered in<br />
the Physician Visit.................... p. 151<br />
Disclosure: Biogen Idec 2, Bristol-Myers<br />
Squibb 2, Millenium Pharmaceuticals 2<br />
Sharp, Phillip A., PhD<br />
MicroRNAs and Gene Regulation... p. 125<br />
Disclosure: Nothing to disclose.<br />
Shekelle, Paul G., MD, PhD<br />
Doing the Right Thing: Evidence and<br />
Guidelines for Rheumatoid Arthritis<br />
Treatment............................. p. 135<br />
Disclosure: Nothing to disclose.<br />
Sherry, David D., MD<br />
Practical Management of Challenging Pain<br />
Syndromes............................. p. 210<br />
Disclosure: Nothing to disclose.<br />
Speaker Index<br />
351
Speaker Index<br />
Shoenfeld, Yehuda, MD<br />
Autoantibodies In Diagnosis and Follow Up<br />
of Rheumatic Diseases............... p. 152<br />
Disclosure: Non-CME Activity.<br />
Antiphospholipid Antibody.......... p. 160<br />
Disclosure: Non-CME Activity.<br />
Shulman, Stanford T., MD<br />
Streptococcal Related Rheumatic Diseases<br />
.......................................... p. 287<br />
Disclosure: GlaxoSmithKline 8, Merck<br />
Pharmaceuticals 8, Quidel 6<br />
Siegel, Bernie, MD<br />
The Physician, The Patient, The Disease:<br />
Why Bother with Person-Centered Care?<br />
Keynote Address........................ p. 48<br />
Disclosure: Nothing to disclose.<br />
Sieper, Joachim, MD<br />
Magnetic Resonance Imaging (MRI)<br />
.......................................... p. 162<br />
Disclosure: Non-CME Activity.<br />
Silver, Richard M., MD<br />
Scleroderma: Systemic Sclerosis..... p. 45<br />
Disclosure: Actelion Pharmaceuticals US<br />
2, 8, Genentech and Biogen IDEC Inc 2, 8,<br />
Millenium Pharmaceuticals 5<br />
Scleroderma: Systemic Sclerosis<br />
(Trainees Only)....................... p. 133<br />
Disclosure: Actelion Pharmaceuticals US<br />
2, 8, Genentech and Biogen IDEC Inc 2, 8,<br />
Millenium Pharmaceuticals 5<br />
Scleroderma........................... p. 162<br />
Disclosure: Non-CME Activity.<br />
Rheumatic Disease Update:<br />
Scleroderma........................... p. 210<br />
Disclosure: Actelion Pharmaceuticals US<br />
2, 8, Genentech and Biogen IDEC Inc 2, 8,<br />
Millenium Pharmaceuticals 5<br />
Simkin, Peter A., MD<br />
Crystal: Management of Gout........ p. 51<br />
Disclosure: Nothing to disclose.<br />
Simms, Robert W., MD<br />
Scleroderma: Systemic Sclerosis..... p. 52<br />
Disclosure: Actelion Pharmaceuticals US 2,<br />
8, Encysive Pharmaceuticals 2, Mediquest<br />
2, Millenium Pharmaceuticals 5<br />
Scleroderma Skin Score - How I Do It... p. 156<br />
Disclosure: Non-CME Activity.<br />
Singer, Nora G., MD<br />
<strong>ACR</strong>-EULAR Exchange................ p. 152<br />
Disclosure: Non-CME Activity.<br />
Smarr, Karen L., PhD<br />
Improving Patient Outcomes: Implications<br />
for Rheumatology Practice.......... p. 151<br />
Disclosure: Nothing to disclose.<br />
Smith, Benjamin J., PA-C<br />
Completing the Puzzle: Other Aspects<br />
of Rheumatic Diseases................. p. 39<br />
Disclosure: Abbott Laboratories 5<br />
Sniezek, Joseph E., MD, MPH<br />
The Evolution of CDC-Funded State<br />
Arthritis <strong>Program</strong>s...................... p. 50<br />
Disclosure: Nothing to disclose.<br />
Solomon, Daniel H., MD, MPH<br />
Welcome and Introduction............ p. 31<br />
Disclosure: Nothing to disclose.<br />
Specks, Ulrich, MD<br />
<strong>ACR</strong> Review Course..................... p. 38<br />
Disclosure: Genentech and Biogen IDEC Inc 2<br />
Spencer, Charles H., MD<br />
<strong>ACR</strong> Clinician Scholar Educator Awards<br />
.......................................... p. 140<br />
Disclosure: Nothing to disclose.<br />
Spiera, Robert F., MD<br />
Polymyalgia Rheumatica.............. p. 66<br />
Disclosure: Regeneron 2<br />
Polymyalgia Rheumatica............ p. 213<br />
Disclosure: Regeneron 2<br />
St Clair, E William, MD<br />
The Year in Review..................... p. 44<br />
Disclosure: Amgen 2, Centocor, Inc.<br />
2, Genentech and Biogen IDEC Inc 2,<br />
5, Human Genome Sciences, Inc. 5,<br />
Medimmune 5, Xoma Corporation 5<br />
Sjögren’s Syndrome: Update on a<br />
Systemic Disease........................ p. 62<br />
Disclosure: Amgen 2, Genentech and<br />
Biogen IDEC Inc 2, 5, Human Genome<br />
Sciences, Inc. 5, Medimmune 5, Xoma<br />
Corporation 5<br />
Starz, Terence W., MD<br />
Manual Tender Point Survey: A<br />
Demonstration of a Standardized Approach<br />
to Assessing Tender Points.......... p. 128<br />
Disclosure: Jazz Pharmaceuticals, Inc 8<br />
Rheumatic Disease Epidemiology for<br />
Clinical Practice: What We Know, What We<br />
Don’t Know and Why It Matters.... p. 220<br />
Disclosure: Jazz Pharmaceuticals, Inc 8<br />
Fibromyalgia: An Innovative Approach to<br />
Understanding the Relationship Between<br />
Daily Activities and Symptoms...... p. 290<br />
Disclosure: Jazz Pharmaceuticals, Inc 8<br />
Steen, Virginia D., MD<br />
Scleroderma Mimics.................... p. 67<br />
Disclosure: Nothing to disclose.<br />
Scleroderma Mimics.................. p. 150<br />
Disclosure: Nothing to disclose.<br />
Steere, Allen C., MD<br />
Rheumatic Disease Update:<br />
Lyme Disease............................ p. 50<br />
Disclosure: Viramed 2<br />
Stein, Charles, MD<br />
Inflammation, Atherosclerosis and the<br />
Rheumatic Diseases.................. p. 291<br />
Disclosure: Nothing to disclose.<br />
Stern, Erica B., PhD, OTR/L<br />
Driving Simulation’s Role in Arthritis<br />
Research and Practice............... p. 285<br />
Disclosure: STISIM 2<br />
Stiskal, Doreen M., PT, PhD<br />
Practical Pediatric Rheumatology<br />
Rehabilitation: What You Wished You Had<br />
Learned in Training.................. p. 139<br />
Disclosure: Nothing to disclose.<br />
Stone, John H., MD, MPH<br />
Vasculitis: CNS Vasculitis............ p. 126<br />
Disclosure: Nothing to disclose.<br />
Vasculitis: CNS Vasculitis............ p. 206<br />
Disclosure: Nothing to disclose.<br />
Strand, Vibeke, MD<br />
B-Cell Targeted Therapy in SLE.... p. 159<br />
Disclosure: Non-CME Activity.<br />
Stratakis, Constantine A., MD, MDSci<br />
Degos Disease and Related Vasculopathy<br />
.......................................... p. 159<br />
Disclosure: Non-CME Activity.<br />
Strober, Bruce, MD, PhD<br />
Psoriatic Arthritis..................... p. 206<br />
Disclosure: Non-CME Activity.<br />
Stucky, Renee C., PhD<br />
Sexuality and Disability: Moving Beyond<br />
the Limitations........................ p. 208<br />
Disclosure: Nothing to disclose.<br />
Suissa, Samy, PhD<br />
Session IV: Methods in Drug<br />
Evaluation............................... p. 35<br />
Disclosure: Bristol-Myers Squibb 5, Merck<br />
Pharmaceuticals 5, Wyeth Pharmaceuticals 2<br />
Sundy, John S., MD, PhD<br />
Allergy for Rheumatologists........... p. 44<br />
Disclosure: Nothing to disclose.<br />
Allergy for Rheumatologists......... p. 132<br />
Disclosure: Nothing to disclose.<br />
Surprenant, Annmarie, PhD<br />
Ion Channels in Inflammation....... p. 142<br />
Disclosure: Nothing to disclose.<br />
Svec, Frank, MD, PhD<br />
Obesity................................... p. 47<br />
Disclosure: Nothing to disclose.<br />
Swedo, Susan, MD<br />
Streptococcal Related Rheumatic Diseases<br />
.......................................... p. 287<br />
Disclosure: Nothing to disclose.<br />
Symmons, Deborah P., MD, FFPH<br />
Issues in Biologic Therapy........... p. 143<br />
Disclosure: British Society for<br />
Rheumatology 2<br />
352
Szigethy, Eva, MD<br />
Management of Psychiatric Illness in<br />
Children and Adolescents with Rheumatic<br />
Disease................................. p. 230<br />
Disclosure: Nothing to disclose.<br />
Szkudlarek, Marcin, MD<br />
Musculoskeletal Ultrasound......... p. 153<br />
Disclosure: Non-CME Activity.<br />
T<br />
Tak, Paul P., MD, PhD<br />
Psoriatic Arthritis..................... p. 206<br />
Disclosure: Non-CME Activity.<br />
Tschopp, Jurg, PhD<br />
Inflammasomes to Fever - How the Cell<br />
Biology Explains Disease............. p. 204<br />
Disclosure: Nothing to disclose.<br />
Tuan, Rocky S., PhD<br />
Session II: Biomaterial Scaffolds..... p. 36<br />
Disclosure: Nothing to disclose.<br />
Tugwell, Peter, MD<br />
Session I: Drug Safety and Effectiveness<br />
............................................ p. 31<br />
Disclosure: Nothing to disclose.<br />
U<br />
Von Scheven, Emily, MD<br />
Pediatrics: Pediatric Rheumatology for<br />
Adult Rheumatologists................. p. 51<br />
Disclosure: Nothing to disclose.<br />
Pediatrics: Pediatric Rheumatology<br />
for Adult Rheumatologists<br />
(Trainees Only)....................... p. 229<br />
Disclosure: Nothing to disclose.<br />
Vunjak Novakovic, Gordana, PhD<br />
Session IV: Engineering Technologies......<br />
............................................ p. 37<br />
Disclosure: Nothing to disclose.<br />
W<br />
Taylor, Peter C., MA, PhD<br />
Issues in Biologic Therapy........... p. 143<br />
Disclosure: Celgene 5, Celltech 5, Centocor,<br />
Inc. 5, 8, GlaxoSmithKline 2, Novartis<br />
Pharmaceutical Corporation 5, Roche<br />
Pharmaceuticals 5, Schering-Plough 2, 5<br />
Teitelbaum, Steven L., MD<br />
REF Oscar S. Gluck, MD, Memorial<br />
Lectureship.............................. p. 43<br />
Disclosure: Nothing to disclose.<br />
Teng, Gim Gee, MBBS, MD<br />
Doing the Right Thing: Evidence and<br />
Guidelines for Rheumatoid Arthritis<br />
Treatment............................. p. 135<br />
Disclosure: Nothing to disclose.<br />
Terkeltaub, Robert, MD<br />
Crystal Arthropathies................ p. 153<br />
Disclosure: Non-CME Activity.<br />
Theis, Kristina, MPH<br />
Improving Employment Situations Among<br />
People with Arthritis................... p. 68<br />
Disclosure: Nothing to disclose.<br />
Uknis, Audrey B., MD<br />
Practice Improvement Module (PIM)<br />
.......................................... p. 142<br />
Disclosure: <strong>American</strong> Board of Internal<br />
Medicine 9<br />
Practice Improvement Module (PIM)<br />
.......................................... p. 207<br />
Disclosure: <strong>American</strong> Board of Internal<br />
Medicine 9<br />
V<br />
van de Laar, Martin, MD, PhD<br />
Patient Perspective in Outcomes Research<br />
.......................................... p. 154<br />
Disclosure: Non-CME Activity.<br />
Van Schelt, Jay, Master, Trainer<br />
Tai Chi.................................... p. 50<br />
Disclosure: Nothing to disclose.<br />
Tai Chi.................................. p. 211<br />
Disclosure: Nothing to disclose.<br />
Van Vollenhoven, Ronald, MD, PhD<br />
B-Cell Targeted Therapy in SLE.... p. 159<br />
Disclosure: Non-CME Activity.<br />
Wallace, Daniel J., MD<br />
Antiphospholipid Syndrome (Trainees Only)<br />
............................................ p. 51<br />
Disclosure: Nothing to disclose.<br />
Antiphospholipid Syndrome......... p. 149<br />
Disclosure: Nothing to disclose.<br />
Warman, Matthew, MD<br />
Bone Health in Children and Adolescents<br />
with Rheumatic Disease............... p. 62<br />
Disclosure: Nothing to disclose.<br />
Warner, Huber R., PhD<br />
The Aging Immune System.......... p. 214<br />
Disclosure: Nothing to disclose.<br />
Waters, Thomas R., PhD<br />
Improving Employment Situations Among<br />
People with Arthritis................... p. 68<br />
Disclosure: Nothing to disclose.<br />
Wegener, Stephen T., PhD<br />
Facilitating Cognitive and Behavioral<br />
Change: Self-Management and<br />
Beyond................................. p. 209<br />
Disclosure: Nothing to disclose.<br />
Speaker Index<br />
Theodoridis, Athanasios, MD<br />
Degos Disease and Related Vasculopathy.<br />
.......................................... p. 159<br />
Disclosure: Non-CME Activity.<br />
Timbil, Sukran, MD<br />
Manual Tender Point Survey: A<br />
Demonstration of a Standardized Approach<br />
to Assessing Tender Points.......... p. 128<br />
Disclosure: Nothing to disclose.<br />
Torgerson, Troy R., MD, PhD<br />
Immune Deficiency Syndromes....... p. 51<br />
Disclosure: Baxter Pharmaceuticals 2<br />
Troxell, Megan L., MD, PhD<br />
Renal Histopathology in SLE and Vasculitis<br />
(Trainees Only)....................... p. 214<br />
Disclosure: Nothing to disclose.<br />
Renal Histopathology in SLE and Vasculitis<br />
.......................................... p. 221<br />
Disclosure: Nothing to disclose.<br />
Varga, John, MD<br />
Signal Transduction Pathways in<br />
Scleroderma............................. p. 53<br />
Disclosure: Nothing to disclose.<br />
Scleroderma........................... p. 162<br />
Disclosure: Non-CME Activity.<br />
Villa-Forte, Alexandra, MD, MPH<br />
Therapeutic Decisions in Systemic Vasculitis<br />
.......................................... p. 135<br />
Disclosure: Nothing to disclose.<br />
Vogt, Molly T., PhD<br />
Rheumatic Disease Epidemiology for Clinical<br />
Practice: What We Know, What We Don’t<br />
Know and Why It Matters............ p. 220<br />
Disclosure: Nothing to disclose.<br />
von Andrian, Ulrich, MD, PhD<br />
<strong>ACR</strong>-EULAR Exchange................ p. 152<br />
Disclosure: Non-CME Activity.<br />
Weinblatt, Michael E., MD<br />
Clinicopathologic Conference (CPC): A 57-<br />
Year-Old Man with Polyarthritis.... p. 124<br />
Disclosure: Nothing to disclose.<br />
Weisman, Michael H., MD<br />
The Great Debate: Peripheral MRI Results<br />
Should Guide Early Intervention with<br />
Biologics in Rheumatoid Arthritis.. p. 219<br />
Disclosure: Nothing to disclose.<br />
Wells, Athol U., MD<br />
Interstitial Lung Disease in the Rheumatic<br />
Diseases................................ p. 160<br />
Disclosure: Non-CME Activity.<br />
Werth, Victoria P., MD<br />
Skin Diseases.......................... p. 157<br />
Disclosure: Non-CME Activity.<br />
353
Weyand, Cornelia M., MD, PhD<br />
Rheumatic Disease Update: Polymyalgia<br />
Rheumatica/Giant Cell Arthritis... p. 208<br />
Disclosure: Nothing to disclose.<br />
The Aging Immune System.......... p. 214<br />
Disclosure: Nothing to disclose.<br />
White, Andrew J., MD<br />
Completing the Puzzle: Other Aspects of<br />
Rheumatic Diseases.................... p. 39<br />
Disclosure: Nothing to disclose.<br />
Wortmann, Robert L., MD<br />
Myopathy: Adult Inflammatory Myopathy.<br />
.......................................... p. 125<br />
Disclosure: Nothing to disclose.<br />
Myopathy: Adult Inflammatory Myopathy<br />
.......................................... p. 228<br />
Disclosure: Nothing to disclose.<br />
Wright, Grace C., MD, PhD<br />
Ethnic Minority........................ p. 153<br />
Disclosure: Non-CME Activity.<br />
Speaker Index<br />
White, Barbara, MD<br />
Career Choices in Rheumatology: Many<br />
Choices, Great Lifestyles!............. p. 52<br />
Disclosure: Nothing to disclose.<br />
White, Patience H., MD, MA<br />
<strong>ACR</strong> Review Course..................... p. 38<br />
Disclosure: Nothing to disclose.<br />
Wigley, Fredrick M., MD<br />
Raynaud’s and Digital Ischemia.... p. 150<br />
Disclosure: Actelion Pharmaceuticals US<br />
2, Asahi Kasei Pharma Corporation 2,<br />
Mediquest 9<br />
Raynaud’s and Digital Ischemia.... p. 229<br />
Disclosure: Actelion Pharmaceuticals US<br />
2, Asahi Kasei Pharma Corporation 2,<br />
Mediquest 9<br />
Williams, Gary W., MD, PhD<br />
RA: Challenging Cases............... p. 213<br />
Disclosure: Nothing to disclose.<br />
RA: Challenging Cases............... p. 140<br />
Disclosure: Nothing to disclose.<br />
Zhang, Yuqing, DSc<br />
Our Best Foot Forward: Practical<br />
Perspectives from the Front Line of<br />
Population-Based Foot Research... p. 231<br />
Disclosure: Nothing to disclose.<br />
Z<br />
Zibit, Melanie, MEd, MBA<br />
Beyond Fatigue and Pain: Addressing<br />
Concerns of Rheumatoid Arthritis Patients<br />
Outside of What is Traditionally Covered in<br />
the Physician Visit.................... p. 151<br />
Disclosure: Nothing to disclose.<br />
Zink, Angela, PhD<br />
Session IV: Methods in Drug Evaluation...<br />
............................................ p. 35<br />
Disclosure: Nothing to disclose.<br />
Zulian, Francesco, MD<br />
Pediatric Rheumatology: Update on<br />
Juvenile Scleroderma................ p. 155<br />
Disclosure: Non-CME Activity.<br />
Wolpaw, Terry M., MD<br />
<strong>ACR</strong> Clinician Scholar Educator Awards<br />
............................................ p. 31<br />
Disclosure: Nothing to disclose.<br />
Wong, John B., MD<br />
Session II: Economics of Rheumatic<br />
Pharmacotherapy..................... p. 125<br />
Disclosure: Nothing to disclose.<br />
354
A<br />
Amigo, Mary-Carmen, MD<br />
Sjögren’s Syndrome: Update on a Systemic<br />
Disease..................................... p. 62<br />
Disclosure: Nothing to disclose.<br />
Austin, Janet S., PhD<br />
Improving Employment Situations Among<br />
People with Arthritis..................... p. 68<br />
Disclosure: Nothing to disclose.<br />
B<br />
Backhaus, Marina, MD<br />
Musculoskeletal Ultrasound............p. 153<br />
Disclosure: Nothing to disclose.<br />
Backman, Catherine L., PhD, OT(C)<br />
<strong>Meeting</strong> Success: A Master Class on<br />
Leadership................................p. 203<br />
Disclosure: Nothing to disclose.<br />
Bancroft Rizzo, Debra, MSN, FNP<br />
Tai Chi.....................................p. 211<br />
Disclosure: Nothing to disclose.<br />
Barr, Walter G., MD<br />
Academic Clinical Practice.............p. 158<br />
Disclosure: Nothing to disclose.<br />
Bartlett, Susan J., PhD<br />
Facilitating Cognitive and Behavioral Change:<br />
Self-Management and Beyond.........p. 209<br />
Disclosure: Nothing to disclose.<br />
Batliwalla, Franak, PhD<br />
Genetics of Autoimmunity: A Clinician’s<br />
Guide......................................p. 123<br />
Disclosure: Nothing to disclose.<br />
Bijlsma, Johannes W J., MD, PhD<br />
Neuro Endocrine Immunology..........p. 154<br />
Disclosure: Nothing to disclose.<br />
Birnbaum, Neal S., MD<br />
<strong>ACR</strong>/<strong>ARHP</strong> Opening Lecture and Awards....<br />
p. 40<br />
Disclosure: Nothing to disclose.<br />
Discovery <strong>2007</strong>: Advances in the<br />
Management of Arthritis and Osteoporosis.<br />
p. 49<br />
Disclosure: Nothing to disclose.<br />
Block, Joel A., MD<br />
Osteoarthritis: Degradation and Disease....<br />
p. 143<br />
Disclosure: Pfizer Inc 9<br />
Bolster, Marcy B., MD<br />
Pulmonary Hypertension...............p. 127<br />
Disclosure: Nothing to disclose.<br />
Hepatitis C................................p. 204<br />
Disclosure: Nothing to disclose.<br />
Challenging Topics in Bone Disease...p. 287<br />
Disclosure: Merck Pharmaceuticals 8,<br />
Proctor & Gamble Pharmaceuticals 2<br />
Rheumatologic Skin Disease...........p. 292<br />
Disclosure: Nothing to disclose.<br />
Borenstein, David G., MD<br />
Physical Activity in Musculoskeletal<br />
Disorders................................... p. 68<br />
Disclosure: Nothing to disclose.<br />
Bowyer, Suzanne L., MD<br />
Management of Complications of Systemic<br />
Juvenile Idiopathic Arthritis............ p. 47<br />
Disclosure: Nothing to disclose.<br />
Bravo, Jaime F., MD<br />
Joint Hypermobility Syndrome........p. 161<br />
Disclosure: Nothing to disclose.<br />
Busch, Stacey, RN, BSN, MA<br />
Fundamental Regulatory Aspects of Clinical<br />
Research: Satisfying the FDA, HIPAA and the<br />
IRB Is Not Enough........................p. 289<br />
Disclosure: Amgen 2<br />
Buyon, Jill P., MD<br />
Systemic Lupus Erythematosus........p. 157<br />
Disclosure: Nothing to disclose.<br />
C<br />
Calabrese, Leonard H., DO<br />
Issues in Biologic Therapy..............p. 143<br />
Disclosure: Abbott Laboratories 5, Amgen<br />
5, Genentech and Biogen IDEC Inc 5, Wyeth<br />
Pharmaceuticals 5<br />
Carlone, Joyce P., MN, RN, CFNP<br />
Motivational Interviewing: Facilitating<br />
Health Promotion in Arthritis..........p. 220<br />
Disclosure: Nothing to disclose.<br />
Carsons, Steven E., MD<br />
Sjögren’s Syndrome: Update on a Systemic<br />
Disease..................................... p. 62<br />
Disclosure: Daiichi Pharmaceutical Corporation 8<br />
Christenson, Mary E., PT, MS<br />
The Physician, The Patient, The Disease:<br />
Why Bother with Person-Centered Care?<br />
Keynote Address.......................... p. 48<br />
Disclosure: Nothing to disclose.<br />
Arthritis and Manual Therapy: What Is The<br />
Evidence?”................................. p. 48<br />
Disclosure: Nothing to disclose.<br />
A Critical Unmet Need of Patients with<br />
Rheumatic Diseases: Intervention for Work<br />
Disability: <strong>ARHP</strong> Distinguished Lecturer....<br />
p. 131<br />
Disclosure: Nothing to disclose.<br />
Chwalek, Marcia G., MS, RN, ANP<br />
Arthritis in the Community.............p. 209<br />
Disclosure: Nothing to disclose.<br />
Cohen, Stanley B., MD<br />
The Great Debate: Peripheral MRI Results<br />
Should Guide Early Intervention with<br />
Biologics in Rheumatoid Arthritis.....p. 219<br />
Disclosure: Nothing to disclose.<br />
Colbert, Robert A., MD, PhD<br />
Regenerating Musculosketal Tissues... p. 61<br />
Disclosure: Nothing to disclose.<br />
Connolly, M. Kari, MD<br />
Skin Diseases.............................p. 157<br />
Disclosure: Nothing to disclose.<br />
Cooper, Glinda S., PhD<br />
Rheumatic Disease Epidemiology for Clinical<br />
Practice: What We Know, What We Don’t<br />
Know and Why It Matters...............p. 220<br />
Disclosure: GlaxoSmithKline 5<br />
Cornell, Patricia J., BSc<br />
Improving Patient Safety: Prevention of<br />
Medication Errors in Rheumatology Practice<br />
.............................................p. 128<br />
Disclosure: Nothing to disclose.<br />
Crawford, Donah Z., BS, MA<br />
Manual Tender Point Survey: A<br />
Demonstration of a Standardized Approach<br />
to Assessing Tender Points.............p. 128<br />
Disclosure: Nothing to disclose.<br />
Cron, Randy Q., MD, PhD<br />
<strong>ACR</strong>-EULAR Exchange...................p. 152<br />
Disclosure: Nothing to disclose.<br />
Cutolo, Maurizio E., MD<br />
Neuro Endocrine Immunology..........p. 154<br />
Disclosure: Nothing to disclose.<br />
D<br />
Daikh, David I., MD, PhD<br />
<strong>ACR</strong> Workforce Issues: The Future of Our<br />
Enterprise.................................p. 131<br />
Disclosure: Nothing to disclose.<br />
<strong>ACR</strong> Clinician Scholar Educator<br />
Awards....................................p. 140<br />
Disclosure: Nothing to disclose.<br />
Dasgupta, Bhaskar, MD<br />
Polymyalgia Rheumatica...............p. 155<br />
Disclosure: Nothing to disclose.<br />
Davidson, Anne, MB, BS, FRACP<br />
Th17 Cells: The New Kids on the Block.....<br />
.............................................. p. 43<br />
Disclosure: Nothing to disclose.<br />
The Aging Immune System.............p. 214<br />
Disclosure: Nothing to disclose.<br />
Davis, Gail C., RN, EdD<br />
Health Literacy: Foundations for<br />
Improving Clinical Practice and Patient<br />
Outcomes.................................. p. 60<br />
Disclosure: Nothing to disclose.<br />
Davis, Jr., John C., MD, MPH<br />
Spondyloarthritis: Update on Pathogenesis<br />
and Treatment...........................p. 292<br />
Disclosure: Abbott Laboratories 2, Amgen<br />
2, Centocor, Inc. 2, Wyeth Pharmaceuticals 8<br />
Deal, Chad L., MD<br />
<strong>ACR</strong> Workforce Issues: The Future of Our<br />
Enterprise.................................p. 131<br />
Disclosure: Nothing to disclose.<br />
Speaker moderator Index<br />
355
Moderator Index<br />
Degotardi, Pamela J., PhD<br />
Management of Psychiatric Illness in<br />
Children and Adolescents with Rheumatic<br />
Disease....................................p. 230<br />
Disclosure: Nothing to disclose.<br />
Dellaripa, Paul F., MD<br />
Interstitial Lung Disease in the Rheumatic<br />
Diseases...................................p. 160<br />
Disclosure: Nothing to disclose.<br />
Deodhar, Atul A., MD, MRCP<br />
Practical Management of Challenging Pain<br />
Syndromes................................p. 210<br />
Disclosure: Nothing to disclose.<br />
Rheumatology Roundup: Highlights<br />
from the <strong>2007</strong> <strong>ACR</strong> Annual <strong>Scientific</strong><br />
<strong>Meeting</strong>....................................p. 285<br />
Disclosure: Centocor, Inc. 2, 5, 8,<br />
Genentech and Biogen IDEC Inc 2, 5, 8<br />
Dewing, Kori A., MN, ARNP<br />
Completing the Puzzle: Other Aspects of<br />
Rheumatic Diseases...................... p. 39<br />
Disclosure: Nothing to disclose.<br />
Dodge, Carole V., OT<br />
Dynamic Stability for the Painful Thumb:<br />
It’s Not Just a Splint....................p. 230<br />
Disclosure: Nothing to disclose.<br />
Dooley, Mary Anne, MD, MPH<br />
<strong>ACR</strong> Review Course....................... p. 38<br />
Disclosure: Nothing to disclose.<br />
E<br />
Edwards, N Lawrence, MD<br />
Crystal Arthropathies...................p. 153<br />
Disclosure: Non-CME Activity.<br />
Ehrlich-Jones, Linda S., PhD, RN<br />
Fall Prevention in Community-Living Older<br />
Adults......................................p. 210<br />
Disclosure: Nothing to disclose.<br />
Elkon, Keith B., MD<br />
Apoptosis: Death by A Thousand Cuts<br />
.............................................. p. 47<br />
Disclosure: Nothing to disclose.<br />
Embi, Peter J., MD, MS<br />
Issues in Biologic Therapy..............p. 143<br />
Disclosure: Nothing to disclose.<br />
Emery, Helen M., MD<br />
Practical Pediatric Rheumatology<br />
Rehabilitation: What You Wished You Had<br />
Learned in Training.....................p. 139<br />
Disclosure: Nothing to disclose.<br />
Esdaile, John, MD, MPH<br />
Doing the Right Thing: Evidence and<br />
Guidelines for Rheumatoid Arthritis<br />
Treatment................................p. 135<br />
Disclosure: Abbott Laboratories 5, Bristol-<br />
Myers Squibb 5, Up To Date 7<br />
Evans, Christopher H., PhD, DSc<br />
Session III: Gene-Based Therapies..... p. 37<br />
Disclosure: Nothing to disclose.<br />
F<br />
Field, Ellen M., MD<br />
Metabolic Bone...........................p. 162<br />
Disclosure: Nothing to disclose.<br />
Firestein, Gary S., MD<br />
Discovery <strong>2007</strong>: Insights into<br />
Autoimmunity............................p. 211<br />
Disclosure: Nothing to disclose.<br />
RA from Bench to Bedside..............p. 286<br />
Disclosure: Nothing to disclose.<br />
Fisher, Nadine M., EdD<br />
Physical Activity in Musculoskeletal<br />
Disorders................................... p. 68<br />
Disclosure: Nothing to disclose.<br />
Young Patients With Old Knees: Treatment<br />
and Prevention of Knee Osteoarthritis (OA)<br />
in the Middle-Aged......................p. 151<br />
Disclosure: Nothing to disclose.<br />
Flood, Joseph, MD<br />
Grassroots and the Legislative<br />
Landscape................................p. 214<br />
Disclosure: Nothing to disclose.<br />
Fox, David A., MD<br />
Discovery <strong>2007</strong>: Advances in the<br />
Management of Arthritis and Osteoporosis.<br />
p. 49<br />
Disclosure: Nothing to disclose.<br />
Furie, Richard A., MD<br />
The Year in Review....................... p. 44<br />
Disclosure: Nothing to disclose.<br />
Furst, Daniel E., MD<br />
Scleroderma Skin Score - How I Do It<br />
.............................................p. 156<br />
Disclosure: Nothing to disclose.<br />
G<br />
Gignac, Monique A., PhD<br />
Emotional Well-Being...................p. 128<br />
Disclosure: Nothing to disclose.<br />
Gilkeson, Gary S., MD<br />
Gender in Rheumatic Disease..........p. 222<br />
Disclosure: Nothing to disclose.<br />
Gilliland, William R., MD<br />
Career Choices in Rheumatology: Many<br />
Choices, Great Lifestyles!............... p. 52<br />
Disclosure: Nothing to disclose.<br />
Goldring, Steven R., MD<br />
Bone Remodeling: New Targets in the<br />
Rheumatic Diseases.....................p. 134<br />
Disclosure: Abbott Laboratories 9,<br />
Boehringer Ingelheim 2, Genzyme 5<br />
Goronzy, Jorg J., MD, PhD<br />
Inflammation, Atherosclerosis and the<br />
Rheumatic Diseases.....................p. 291<br />
Disclosure: Nothing to disclose.<br />
Gottlieb, Beth S., MD, MS<br />
Streptococcal Related Rheumatic<br />
Diseases...................................p. 287<br />
Disclosure: Nothing to disclose.<br />
Greco, Carol M., PhD<br />
Research Beyond Google: Efficient<br />
and Effective Research on the Web for<br />
Clinicians and Educators................. p. 61<br />
Disclosure: Nothing to disclose.<br />
Guilak, Farshid, PhD<br />
Session IV: Engineering<br />
Technologies.............................. p. 37<br />
Disclosure: Nothing to disclose.<br />
H<br />
Harley, John B., MD, PhD<br />
Sjögren’s Syndrome.....................p. 156<br />
Disclosure: Nothing to disclose.<br />
Haskard, Dorian O., DM<br />
Arthritis: An Angiogenesis-Dependent<br />
Disease..................................... p. 57<br />
Disclosure: Nothing to disclose.<br />
Inflammation.............................p. 291<br />
Disclosure: Non-CME Activity.<br />
Heath, Noel, BMR, OT<br />
Gait Analysis: Hip, Knee and Foot Effects on<br />
Gait and How to Assess Them.........p. 140<br />
Disclosure: Nothing to disclose.<br />
Henderson, Carol J., PhD, RD<br />
Building Resilience: Kids and<br />
Joints......................................p. 148<br />
Disclosure: Nothing to disclose.<br />
Henrickson, Michael, MD<br />
Coding is Your Friend...................p. 285<br />
Disclosure: Nothing to disclose.<br />
Hewett, John E., PhD<br />
Research Mentor/Trainee Responsibilities:<br />
Making the Most of Mentorship........p. 231<br />
Disclosure: Nothing to disclose.<br />
Highland, Kristin B., MD<br />
Interstitial Lung Disease in the Rheumatic<br />
Diseases...................................p. 160<br />
Disclosure: Nothing to disclose.<br />
Hootman, Jennifer M., PhD<br />
Arthrogenic Muscle Inhibition..........p. 124<br />
Disclosure: Nothing to disclose.<br />
J<br />
James, Nadine T., RN, MSN, PhD<br />
Poster Introduction: How to Decipher a<br />
Poster.....................................p. 128<br />
Disclosure: Nothing to disclose.<br />
Poster Introduction: How to Decipher a<br />
Poster.....................................p. 209<br />
Disclosure: Nothing to disclose.<br />
Jara Quezada, Luis J., MD<br />
Latin <strong>American</strong> Study Group...........p. 161<br />
Disclosure: Nothing to disclose.<br />
Jenkins, James A., PhD<br />
Chronic Disease Self Management Patient<br />
Education <strong>Program</strong>s: Clinical and Public<br />
Health Awareness.......................p. 286<br />
Disclosure: Nothing to disclose.<br />
356
Jones, Karla B., MS, RN, CPNP<br />
Identifying and Navigating Web-Based<br />
Educational and Networking Resources for<br />
Rheumatology Health Professionals and<br />
Patients...................................p. 222<br />
Disclosure: Nothing to disclose.<br />
K<br />
Kaeley, Gurjit S., MBBS, MRCP<br />
Musculoskeletal Ultrasound............p. 153<br />
Disclosure: Nothing to disclose.<br />
Kastanek, Lisa M., RN, CCRC<br />
Our Best Foot Forward: Practical<br />
Perspectives from the Front Line of<br />
Population-Based Foot Research......p. 231<br />
Disclosure: Nothing to disclose.<br />
Katz, Jeffrey N., MD, MS<br />
Discovery <strong>2007</strong>: Pathogenesis and<br />
Treatment of Inflammatory Arthritis. p. 130<br />
Disclosure: Nothing to disclose.<br />
Katz, Robert S., MD<br />
Fibromyalgia: Etiology and Treatment... p. 58<br />
Disclosure: Nothing to disclose.<br />
Kavanaugh, Arthur, MD<br />
Session II: Economics of Rheumatic<br />
Pharmacotherapy......................... p. 31<br />
Disclosure: Nothing to disclose.<br />
The Great Debate: Peripheral MRI Results<br />
Should Guide Early Intervention with<br />
Biologics in Rheumatoid Arthritis.....p. 219<br />
Disclosure: Nothing to disclose.<br />
Kent, Peter D., MD<br />
Building a Stronger Physician<br />
Practice...................................p. 139<br />
Disclosure: Nothing to disclose.<br />
Kerr, Karen L., MSN, NP, CPNP<br />
<strong>ACR</strong>/<strong>ARHP</strong> Opening Lecture and<br />
Awards..................................... p. 40<br />
Disclosure: Nothing to disclose.<br />
Klein-Gitelman, Marisa S., MD, MPH<br />
Building Resilience: Kids and<br />
Joints......................................p. 148<br />
Disclosure: Nothing to disclose.<br />
Klepper, Susan E., PhD, PT<br />
Physical Therapy Management of Pediatric<br />
Rheumatology Issues....................p. 286<br />
Disclosure: Nothing to disclose.<br />
Koch, Alisa E., MD<br />
Arthritis: An Angiogenesis-Dependent<br />
Disease..................................... p. 59<br />
Disclosure: Tap Pharma and Predix Pharma<br />
2; AstraZeneca, PLC 5; Genentech 5;<br />
Proctor and Gamble Pharma 5; Predix<br />
Pharma 5; Clinical Advisors, LLC 5; Gerson<br />
Lerhrman Group 5; Kirkland and Ellis LLP 5.<br />
Kolba, Karen S., MD<br />
Physician Fee Schedule: What is<br />
an RVU?.................................... p. 52<br />
Disclosure: Nothing to disclose.<br />
Kunkel, Ann, BS<br />
Speak Out: Using Your Voice to<br />
Improve Rheumatology Practice and<br />
Patient Care............................... p. 69<br />
Disclosure: Nothing to disclose.<br />
Kutzbach, Abraham G.., MD<br />
WHO ILAR COPCORD (Community<br />
Oriented <strong>Program</strong> for Control of<br />
Rheumatic Diseases)....................p. 162<br />
Disclosure: Nothing to disclose.<br />
L<br />
Lafyatis, Robert A., MD<br />
Scleroderma..............................p. 162<br />
Disclosure: Nothing to disclose.<br />
Laing, Timothy, MD<br />
Avoiding the Legal Pain of Pain<br />
Management..............................p. 130<br />
Disclosure: Nothing to disclose.<br />
Langford, Carol, MD, MHS<br />
<strong>ACR</strong>/ABIM Maintenance of Certification<br />
Learning Session for Recertification<br />
Module 30-R............................... p. 35<br />
Disclosure: Bristol-Myers Squibb 9,<br />
Genentech and Biogen IDEC Inc 2, 9<br />
Laufer, Terri M., MD<br />
T-Cell Subsets: The Family Grows....p. 208<br />
Disclosure: Nothing to disclose.<br />
Laxer, Ronald M., MD<br />
Pediatric Rheumatology: Update on<br />
Juvenile Scleroderma...................p. 155<br />
Disclosure: Non-CME Activity.<br />
Lee, David M., MD, PhD<br />
Innate Immunity.........................p. 285<br />
Disclosure: Nothing to disclose.<br />
Lockshin, Michael D., MD<br />
Arthritis & Rheumatism at 50: The Best of<br />
the Past, the Best of the Future......p. 206<br />
Disclosure: Nothing to disclose.<br />
Loflin, Betty B., RN, MSN, CFNP<br />
What’s New and Noteworthy in <strong>2007</strong>: A<br />
Review of Rheumatology Research for<br />
Health Professionals....................p. 125<br />
Disclosure: Abbott Laboratories 9, Bristol-<br />
Myers Squibb 8, Eli Lilly and Company 5,<br />
Genentech and Biogen IDEC Inc 8<br />
Lohr, Kristine M., MD<br />
Improving Patient Outcomes: Implications<br />
for Rheumatology Practice.............p. 151<br />
Disclosure: <strong>American</strong> College of Rheumatology<br />
6, Amgen 2, Centocor, Inc. 2, Merck<br />
Pharmaceuticals 1, Pfizer Inc 1, Schering-Plough<br />
1, University of Kentucky School of Medicine 3<br />
Lowenstein, Kathryn L., OTR/L<br />
Improving Hand Function: From Pain to<br />
Evaluation to Splinting..................p. 220<br />
Disclosure: Nothing to disclose.<br />
Dynamic Stability for the Painful Thumb:<br />
Experiential Laboratory................p. 230<br />
Disclosure: Nothing to disclose.<br />
Luyten, Frank P., MD, PhD<br />
Session V: Clinical Applications........ p. 37<br />
Disclosure: Tigenix 1<br />
Regenerating Musculosketal<br />
Tissues...................................... p. 61<br />
Disclosure: Tigenix 1<br />
M<br />
MacDonald, Patricia A., BSN, NP<br />
Arthritis Treatments: Methods for<br />
Evaluating Information.................p. 207<br />
Disclosure: Nothing to disclose.<br />
Maher, Nancy E., MPH<br />
Tai Chi...................................... p. 50<br />
Disclosure: Nothing to disclose.<br />
Beyond Fatigue and Pain: Addressing<br />
Concerns of Rheumatoid Arthritis Patients<br />
Outside of What is Traditionally Covered in<br />
the Physician Visit.......................p. 151<br />
Disclosure: Nothing to disclose.<br />
Mandell, Brian F., MD, PhD<br />
The Year in Review....................... p. 44<br />
Disclosure: Nothing to disclose.<br />
Curbside Consults - Ask the<br />
Professors.................................p. 130<br />
Disclosure: Nothing to disclose.<br />
Mandl, Lisa A., MD, MPH<br />
Young Investigators Session: The New Triple<br />
Threat: Successful Academic Investigator,<br />
Balanced Family Life, Financial Solvency:<br />
A Roadmap for Success.................p. 133<br />
Disclosure: Nothing to disclose.<br />
Manzi, Susan, MD, MPH<br />
Challenges in the Management<br />
of Lupus.................................... p. 53<br />
Disclosure: Nothing to disclose.<br />
Discovery <strong>2007</strong>: Insights into<br />
Autoimmunity............................p. 211<br />
Disclosure: Nothing to disclose.<br />
Marcheschi, Sharon L., RN, BSN<br />
Driving Simulation’s Role in Arthritis<br />
Research and Practice..................p. 285<br />
Disclosure: Nothing to disclose.<br />
Marra, Carlo A., BSc, PharmD, PhD<br />
Alternative Therapies for Arthritis and<br />
Fibromyalgia..............................p. 124<br />
Disclosure: Nothing to disclose.<br />
Massarotti, Elena M., MD<br />
Clinicopathologic Conference (CPC): A<br />
57-Year-Old Man with Polyarthritis...p. 124<br />
Disclosure: Nothing to disclose.<br />
Matteson, Eric L., MD<br />
Obesity..................................... p. 47<br />
Disclosure: Nothing to disclose.<br />
Therapeutic Decisions in Systemic<br />
Vasculitis..................................p. 135<br />
Disclosure: AMerican College of<br />
Rheumatology 2, Amgen 2, 9, Biogen-<br />
IDEC 9, Centocor, Inc. 2, 5, 9, Genentech<br />
and Biogen IDEC Inc 2, 9, Human Genome<br />
Sciences 9, Mayo Foundation 2, NIH 2,<br />
Wyeth Pharmaceuticals 9<br />
Speaker moderator Index<br />
357
Moderator Index<br />
McBeth, John, PhD<br />
Fibromyalgia: Etiology and Treatment<br />
.............................................. p. 58<br />
Disclosure: Nothing to disclose.<br />
McCloskey, Deborah A., RN, BSN<br />
Speak Out: Using Your Voice to<br />
Improve Rheumatology Practice and<br />
Patient Care............................... p. 69<br />
Disclosure: Nothing to disclose.<br />
McDowell, Leslie D., ANP, MSN<br />
Radiology 101............................. p. 68<br />
Disclosure: Nothing to disclose.<br />
Challenging Case Studies in Rheumatoid<br />
Arthritis...................................p. 204<br />
Disclosure: Nothing to disclose.<br />
McIlvain-Simpson, Gail R., MSN, APRN, BC<br />
Building a Stronger Physician Practice<br />
.............................................p. 139<br />
Disclosure: Nothing to disclose.<br />
McInnes, Iain B., PhD<br />
Ion Channels in Inflammation..........p. 142<br />
Disclosure: Abbott Immunology<br />
Pharmaceuticals 5, Schering-Plough 2, 5,<br />
Wyeth Pharmaceuticals 5<br />
Meltzer, Michele, MD<br />
EMR in the Physician’s Office..........p. 210<br />
Disclosure: Nothing to disclose.<br />
Mendelson, Cindy F., PhD, RN<br />
First-Time Attendee Orientation....... p. 43<br />
Disclosure: Nothing to disclose.<br />
<strong>ARHP</strong> Networking Forum................ p. 46<br />
Disclosure: Nothing to disclose.<br />
Merkel, Peter A., MD, MPH<br />
Clinicopathologic Conference (CPC): A<br />
57-Year-Old Man with Polyarthritis...p. 124<br />
Disclosure: Nothing to disclose.<br />
Meroni, Pier Luigi, MD<br />
Autoantibodies In Diagnosis and Follow Up<br />
of Rheumatic Diseases..................p. 152<br />
Disclosure: Nothing to disclose.<br />
Merrill, Joan T., MD<br />
Systemic Lupus Erythematosus........p. 157<br />
Disclosure: Nothing to disclose.<br />
Miyasaka, Nobuyuki N., MD<br />
RA Pathogenesis: Molecular<br />
Mechanisms...............................p. 141<br />
Disclosure: Nothing to disclose.<br />
N<br />
Nakasato, Yuri R., MD<br />
Geriatric Rheumatology................p. 160<br />
Disclosure: Nothing to disclose.<br />
Narain, Sonali, MD, MPH<br />
Statistics: The Ideas Behind the<br />
Formulas..................................p. 140<br />
Disclosure: Nothing to disclose.<br />
Neuberger, Geri B., RN, EdD<br />
Multivariable Analysis: Taking the<br />
Mystery Out of the Regression Model<br />
“Black Box”...............................p. 128<br />
Disclosure: Nothing to disclose.<br />
Rehabilitative Rheumatology..........p. 156<br />
Disclosure: Nothing to disclose.<br />
Nola, Kam M., PharmD, MS<br />
The Evolution of CDC-Funded State Arthritis<br />
<strong>Program</strong>s................................... p. 50<br />
Disclosure: Nothing to disclose.<br />
O<br />
O’Dell, James R., MD<br />
REF Oscar S. Gluck, MD, Memorial<br />
Lectureship................................ p. 43<br />
Disclosure: Nothing to disclose.<br />
REF Marshall J. Schiff, MD, Memorial<br />
Lectureship................................ p. 59<br />
Disclosure: Nothing to disclose.<br />
REF Edmund L. Dubois, MD, Memorial<br />
Lectureship................................ p. 67<br />
Disclosure: Nothing to disclose.<br />
REF Paul Klemperer, MD, Memorial<br />
Lectureship...............................p. 208<br />
Disclosure: Nothing to disclose.<br />
Oliver, Susan M., MSc<br />
Improving Sleep: Non-Pharmalogical<br />
Strategies.................................. p. 50<br />
Disclosure: Nothing to disclose.<br />
Opava, Christina H., PhD, RPT<br />
Living the Good Life with Rheumatic<br />
Disease....................................p. 291<br />
Disclosure: Nothing to disclose.<br />
Orloff, Karen A., BS, CCRC<br />
SLE and Inflammatory Arthritis: Disease<br />
Activity and Outcomes Research......p. 289<br />
Disclosure: Nothing to disclose.<br />
O’Rourke, Kenneth S., MD<br />
Rehabilitative Rheumatology..........p. 156<br />
Disclosure: Non-CME Activity.<br />
Osborne, Richard H., PhD<br />
Dissemination of the EnhanceFitness (TM)<br />
<strong>Program</strong> for People with Arthritis.....p. 204<br />
Disclosure: Nothing to disclose.<br />
Ostergaard, Mikkel, MD, PhD, DMSc<br />
Magnetic Resonance Imaging (MRI)...p. 161<br />
Disclosure: Non-CME Activity.<br />
P<br />
Patel, Dhavalkumar D., MD, PhD<br />
Inflammasomes to Fever - How the Cell<br />
Biology Explains Disease................p. 204<br />
Disclosure: Novartis Institutes of<br />
Biomedical Research 3<br />
Peng, Stanford L., MD, PhD<br />
Ion Channels in Inflammation..........p. 142<br />
Disclosure: Roche Pharmaceuticals 3<br />
Petersson, Ingemar F., MD, PhD<br />
Patient Perspective in Outcomes<br />
Research..................................p. 154<br />
Disclosure: Nothing to disclose.<br />
Pierangeli, Silvia S., PhD<br />
Antiphospholipid Antibody.............p. 158<br />
Disclosure: Non-CME Activity.<br />
Pispati, Prakash, MD<br />
Rheumatologic Skin Disease...........p. 292<br />
Disclosure: Nothing to disclose.<br />
Poole, Janet L., PhD, OTR<br />
Developing a Research Career: Finding and<br />
Following a Path to Independence..... p. 59<br />
Disclosure: Nothing to disclose.<br />
Pope, Richard M., MD<br />
RA Pathogenesis: Molecular<br />
Mechanisms...............................p. 141<br />
Disclosure: Nothing to disclose.<br />
Pullman-Mooar, Sally W., MD<br />
The Great Debate: Peripheral MRI Results<br />
Should Guide Early Intervention with<br />
Biologics in Rheumatoid Arthritis.....p. 219<br />
Disclosure: Nothing to disclose.<br />
R<br />
Radbruch, Andreas H., PhD<br />
The Aging Immune System.............p. 214<br />
Disclosure: Nothing to disclose.<br />
Ramsey-Goldman, Rosalind, MD, DrPH<br />
Discovery <strong>2007</strong>: Pathogenesis and<br />
Treatment of Inflammatory Arthritis<br />
.............................................p. 130<br />
Disclosure: Nothing to disclose.<br />
Rasker, Hans, Prof., MD<br />
WHO ILAR COPCORD (Community Oriented<br />
<strong>Program</strong> for Control of Rheumatic<br />
Diseases)..................................p. 162<br />
Disclosure: Nothing to disclose.<br />
Redlich, Kurt, MD<br />
Bioimaging: Visualizing the Immune<br />
Response..................................p. 124<br />
Disclosure: Nothing to disclose.<br />
Reisine, Susan T., PhD<br />
Fibromyalgia: An Innovative Approach to<br />
Understanding the Relationship Between<br />
Daily Activities and Symptoms.........p. 290<br />
Disclosure: Nothing to disclose.<br />
Reveille, John D., MD<br />
Spondylarthopathies....................p. 157<br />
Disclosure: Non-CME Activity.<br />
Richards, Pamela<br />
Patient Perspective in Outcomes<br />
Research..................................p. 154<br />
Disclosure: Nothing to disclose.<br />
Rider, Lisa G., MD<br />
Pediatric Rheumatology: Update on<br />
Juvenile Scleroderma...................p. 155<br />
Disclosure: Non-CME Activity.<br />
Ritchlin, Christopher T., MD<br />
Psoriatic Arthritis........................p. 155<br />
Disclosure: Non-CME Activity.<br />
358
Robinson, William, MD, PhD<br />
Signal Transduction Pathways in<br />
Scleroderma............................... p. 53<br />
Disclosure: Nothing to disclose.<br />
MicroRNAs and Gene Regulation......p. 127<br />
Disclosure: Nothing to disclose.<br />
Roth-Wojcicki, Elizabeth L., RN, MS, CPNP<br />
Rheumatic Disease Update: Lyme<br />
Disease..................................... p. 50<br />
Disclosure: Nothing to disclose.<br />
Saag, Kenneth G., MD, MSc<br />
Session IV: Methods in Drug Evaluation.. p. 35<br />
Disclosure: Amgen 2, Eli Lilly and<br />
Company 2, 5, Merck Human Health 2,<br />
Merck Pharmaceuticals 5, 8, Novartis<br />
Pharmaceutical Corporation 2, 5, Roche<br />
Pharmaceuticals 2, 5, Savient 5, TAP<br />
Pharmaceuticals Inc. 5<br />
S<br />
Salmon, Jane E., MD<br />
Inflammation, Atherosclerosis and the<br />
Rheumatic Diseases.....................p. 291<br />
Disclosure: Nothing to disclose.<br />
Schanberg, Laura E., MD<br />
Management of Psychiatric Illness in<br />
Children and Adolescents with Rheumatic<br />
Disease....................................p. 230<br />
Disclosure: Pfizer Inc 2, 5<br />
Schlenk, Elizabeth A., PhD, RN<br />
How Do You Know Your Patient Is Taking<br />
Medicines, Exercising and Following Other<br />
Regimens You Recommended?.........p. 204<br />
Disclosure: Nothing to disclose.<br />
Siegel, Jeffrey N., MD<br />
Session III: Drug Policy and<br />
Regulation................................. p. 35<br />
Disclosure: Nothing to disclose.<br />
Silman, Alan J., MD<br />
Session I: Drug Safety and<br />
Effectiveness.............................. p. 31<br />
Disclosure: Nothing to disclose.<br />
Smarr, Karen L., PhD<br />
Sexuality and Disability: Moving Beyond<br />
the Limitations...........................p. 208<br />
Disclosure: Nothing to disclose.<br />
Smith, Benjamin J., PA-C<br />
Completing the Puzzle: Other Aspects of<br />
Rheumatic Diseases...................... p. 39<br />
Disclosure: Abbott Laboratories 5<br />
Rheumatic Disease Update: Polymyalgia<br />
Rheumatica/Giant Cell Arthritis......p. 208<br />
Disclosure: Abbott Laboratories 5<br />
Rheumatic Disease Update:<br />
Scleroderma..............................p. 210<br />
Disclosure: Abbott Laboratories 5<br />
Stiskal, Doreen M., PT, PhD<br />
Practical Pediatric Rheumatology<br />
Rehabilitation: What You Wished You Had<br />
Learned in Training.....................p. 139<br />
Disclosure: Nothing to disclose.<br />
Evidence for Realignment, Off-Loading and<br />
Restorative Therapies for the Treatment of<br />
Knee Osteoarthritis......................p. 220<br />
Disclosure: Nothing to disclose.<br />
Stone, John H., MD, MPH<br />
<strong>ACR</strong> Review Course....................... p. 38<br />
Disclosure: Nothing to disclose.<br />
Why is My Patient With Myositis Not<br />
Getting Better?...........................p. 222<br />
Disclosure: Nothing to disclose.<br />
T<br />
Taal, Erik, PhD<br />
Considerations in Arthritis Self-Help<br />
<strong>Program</strong>s................................... p. 60<br />
Disclosure: Nothing to disclose.<br />
Tan, Eng M., MD<br />
Autoantibodies In Diagnosis and Follow Up<br />
of Rheumatic Diseases..................p. 152<br />
Disclosure: Nothing to disclose.<br />
Treadwell, Edward L., MD<br />
Ethnic Minority............................ p. 53<br />
Disclosure: Nothing to disclose.<br />
Trizuto, Jennifer L., BSPT, MPT<br />
Advances in the Management of Total<br />
Hip Arthroplasty Patients: <strong>Meeting</strong> the<br />
Challenges of Reduced Length<br />
of Stay...................................... p. 59<br />
Disclosure: Nothing to disclose.<br />
Trojanowska, Maria, PhD<br />
Signal Transduction Pathways in<br />
Scleroderma............................... p. 53<br />
Disclosure: Nothing to disclose.<br />
Tuan, Rocky S., PhD<br />
Session I: Stem Cells..................... p. 36<br />
Disclosure: Nothing to disclose.<br />
Session II: Biomaterial Scaffolds....... p. 36<br />
Disclosure: Nothing to disclose.<br />
V<br />
Weinblatt, Michael E., MD<br />
RA from Bench to Bedside..............p. 286<br />
Disclosure: Nothing to disclose.<br />
Whelan, J Patrick, MD, PhD<br />
Degos Disease and Related<br />
Vasculopathy.............................p. 159<br />
Disclosure: Nothing to disclose.<br />
Y<br />
Yung, Raymond L., MB, ChB<br />
Geriatric Rheumatology................p. 160<br />
Disclosure: Nothing to disclose.<br />
Yurdakul, Sebahattin, MD<br />
Behcet’s Disease.........................p. 152<br />
Disclosure: Nothing to disclose.<br />
Z<br />
Zack, Debra J., MD, PhD<br />
Bone Remodeling: New Targets in the<br />
Rheumatic Diseases.....................p. 134<br />
Disclosure: Amgen 1, 3<br />
Speaker moderator Index<br />
Van Vollenhoven, Ronald, MD, PhD<br />
B-Cell Targeted Therapy in SLE.......p. 159<br />
Disclosure: Nothing to disclose.<br />
Von Feldt, Joan Marie, MD<br />
<strong>ACR</strong> Clinician Scholar Educator<br />
Awards....................................p. 140<br />
Disclosure: Nothing to disclose.<br />
Clinician Scholar Educator.............p. 159<br />
Disclosure: Non-CME Activity.<br />
Von Scheven, Emily, MD<br />
Bone Health in Children and Adolescents<br />
with Rheumatic Disease................. p. 62<br />
Disclosure: Nothing to disclose.<br />
Watcher, Sandra J., BSN<br />
Rheumatic Disease Update: Adult and<br />
Juvenile Dermatomyositis/Polymyositis. p. 124<br />
Disclosure: Nothing to disclose.<br />
359
abstract moderator Index Clinical research conference - Abstract Author Index<br />
A<br />
Akimoto, K. CRC12<br />
Allantaz, F. CRC02<br />
Alten, R. CRC37<br />
Amano, K. CRC03<br />
Andersone, D. CRC37<br />
Arnold, S. CRC18<br />
B<br />
Baecklund, E. CRC37<br />
Baerwald, C. CRC18<br />
Bala, M. CRC33, CRC38, CRC44<br />
Baliga, V. P. CRC19<br />
Bienvenu, J. CRC02<br />
Biernat, J. CRC21<br />
Bodemer, C. CRC07<br />
Bossuyt, X. CRC02<br />
Bracaglia, C. CRC01<br />
Bresnihan, B. CRC37<br />
Bresson, J. CRC02<br />
Brzozowski, T. CRC21<br />
Bunn, D. CRC06<br />
Buonuomo, P. CRC01<br />
C<br />
Calderon, C. CRC44<br />
Callegari, P. CRC17<br />
Carsetti, R. CRC01<br />
Carter, J. D. CRC20<br />
Cazzato, M. CRC37<br />
Chopra, A. CRC24<br />
Chung, C. P. CRC45<br />
Cimaz, R. CRC02<br />
Cortis, E. CRC01<br />
Cruz Dominguez, P. CRC05<br />
D<br />
Dabbous, O. CRC13, CRC14, CRC17,<br />
CRC27, CRC28, CRC29, CRC30,<br />
CRC31, CRC34, CRC35, CRC36,<br />
CRC39, CRC40, CRC41, CRC42,<br />
CRC43, CRC47, CRC48, CRC49,<br />
CRC50<br />
Dalbeth, N. CRC23<br />
Delise, R. CRC47<br />
Desjonqueres, M. CRC02<br />
Dimic, A. CRC37<br />
Dinavahi, K. CRC09, CRC10<br />
Duquesne, A. CRC02<br />
E<br />
Eisenberg, D. F. CRC33, CRC44<br />
F<br />
Fantini, F. CRC16<br />
Farragher, T. M. CRC06<br />
Fernando, C. E. CRC04<br />
G<br />
Garcia-Poma, A. CRC45<br />
Gattinara, M. CRC16<br />
Gerloni, V. CRC16<br />
Ghodke, Y. CRC24<br />
Gilmer, K. CRC13, CRC14<br />
Gogus, F. CRC37<br />
Goregaonkar, A. CRC19<br />
Gossec, L. CRC37<br />
Gow, P. CRC23<br />
H<br />
Han, C. CRC30, CRC33, CRC36,<br />
CRC44<br />
Hatoum, H. T.. CRC26<br />
Hauber, A. B.. CRC38<br />
Hetland, M. CRC37<br />
Hilliard, R. CRC31, CRC35, CRC40,<br />
CRC47<br />
Hsu, B. CRC33<br />
Huisman, M. CRC37<br />
Hyrich, K. L. CRC11<br />
Insalaco, A. CRC01<br />
I<br />
J<br />
Johnson, F. R.. CRC38<br />
Joshi, K. CRC24<br />
Jung, N. CRC25<br />
K<br />
Kameda, H. CRC03<br />
Kassai, B. CRC02<br />
Katirji, B. CRC09<br />
Kautiainen, H. CRC37<br />
Kawai, S. CRC12<br />
Kolsun, K. CRC26<br />
Kone-Paut, I. CRC02<br />
Kremer, J. CRC17<br />
Kugel, M. CRC40<br />
Kusunoki, Y. CRC12<br />
Kuwata, S. CRC22<br />
L<br />
Ladhani, A. CRC20<br />
Lal, A. CRC04<br />
Landais, P. CRC02<br />
Lee, M. CRC31, CRC35, CRC47<br />
Lemelle, I. CRC02<br />
Lin, S. CRC26<br />
Lindsay, K. CRC23<br />
Logo, P. CRC23<br />
Lord, P. CRC11<br />
Lunt, M. CRC06, CRC11<br />
Luukkainen, R. CRC37<br />
M<br />
Malysheva, O. CRC18<br />
Manning, S. C. CRC06<br />
Mathiazhagan, K. J. CRC19<br />
Matsumoto, N. CRC12<br />
Medina, G. CRC05<br />
Meissner, B. CRC29, CRC39, CRC41,<br />
CRC42, CRC50<br />
Messiaen, C. CRC02<br />
Mogenet, A. CRC02<br />
Mouy, R. CRC07<br />
Müller, R. CRC37<br />
N<br />
Nagasawa, H. CRC03<br />
Naim, A. CRC27, CRC30, CRC31,<br />
CRC35, CRC36, CRC40, CRC41,<br />
CRC46, CRC47, CRC48<br />
Nair, K. V. CRC32, CRC46<br />
Naranjo, A. CRC37<br />
Nishi, E. CRC03<br />
Nishio, S. CRC12<br />
Nogami, Y. CRC13, CRC14<br />
O<br />
Obuchowicz, R. CRC21<br />
Ogawa, H. CRC03<br />
Okuyama, A. CRC03<br />
on behalf of the BSR Biologics<br />
Register, CRC11<br />
On Behalf of the Quest-RA Group,<br />
CRC37<br />
Onel, E. CRC26<br />
Owczarczyk, K. M. CRC25<br />
Ozdemir, S. CRC38<br />
360
P<br />
Passon, D. CRC25<br />
Patwardhan, B. CRC24<br />
Pawlik, W. W. CRC21<br />
Piantone, A. CRC44<br />
Pierer, M. CRC18<br />
Pillet, P. CRC02<br />
Pincus, T. CRC37<br />
Poddubnyy, D. CRC08<br />
Pohl, C. CRC37<br />
Pontikaki, I. CRC16<br />
Prieur, A. CRC07<br />
Pupek, M. CRC44<br />
Q<br />
Quartier, P. CRC02, CRC07<br />
Quimbo, R. CRC27, CRC28, CRC34,<br />
CRC43, CRC48<br />
R<br />
Rahman, M. CRC13, CRC14, CRC27,<br />
CRC28, CRC29, CRC30, CRC31,<br />
CRC32, CRC34, CRC35, CRC36,<br />
CRC39, CRC40, CRC41, CRC42,<br />
CRC43, CRC46, CRC47, CRC48,<br />
CRC49, CRC50<br />
Rambharose, J. CRC47<br />
Rebrov, A. CRC08<br />
Reed, G. CRC17<br />
Renahan, K. CRC33, CRC44<br />
Ricca, L. CRC20<br />
Richer, O. CRC02<br />
Roehrs, T. CRC25<br />
Rojkovich, B. CRC37<br />
Rubbert, A. CRC25<br />
S<br />
Saito, T. CRC22<br />
Sakuta, H. CRC22<br />
Saseen, J. CRC32<br />
Satyamoorthy, K. CRC24<br />
Segami, M. I. CRC45<br />
Seidel, W. CRC18<br />
Seitz, M. CRC15<br />
Sekiguchi, N. CRC03<br />
Sendur, R. CRC21<br />
Shah, R. R. CRC19<br />
Shane, P. CRC13, CRC14<br />
Sharma, A. CRC19<br />
Sierakowski, S. CRC37<br />
Singer, N. CRC09<br />
Skakic, V. CRC37<br />
Smith, H. R. CRC10<br />
Sokka, T. CRC37<br />
Song, Y. CRC22<br />
Stephenson, J. J. CRC27, CRC28,<br />
CRC34, CRC43, CRC48<br />
Stropuviene, S. CRC37<br />
Suzuki, K. CRC03<br />
Symmons, D. P.M. CRC06, CRC11<br />
T<br />
Takagi, K. CRC12<br />
Takei, H. CRC03<br />
Takeuchi, F. CRC22<br />
Takeuchi, T. CRC03<br />
Taneja, P. CRC19<br />
Tang, B. CRC13, CRC14, CRC27,<br />
CRC28, CRC29, CRC30, CRC31,<br />
CRC32, CRC34, CRC35, CRC36,<br />
CRC39, CRC40, CRC41, CRC42,<br />
CRC43, CRC46, CRC47, CRC48,<br />
CRC49, CRC50<br />
Tatsuki, Y. CRC13, CRC14<br />
Taubert, D. CRC25<br />
Terrazas, H. N. CRC45<br />
Thompson, H. CRC13, CRC14, CRC27,<br />
CRC28, CRC29, CRC30, CRC31,<br />
CRC34, CRC35, CRC36, CRC39,<br />
CRC40, CRC41, CRC42, CRC43,<br />
CRC47, CRC48, CRC49, CRC50<br />
Togo, M. CRC13, CRC14<br />
Toloza, S. CRC37<br />
Treluyer, J. CRC02<br />
Tsai, M. CRC09<br />
Tsuzaka, K. CRC03<br />
Ugazio, A. CRC01<br />
U<br />
V<br />
Valeriano, J. CRC20<br />
Valet, G. CRC25<br />
Van Den Bos, J. CRC32, CRC46<br />
Vanderpyl, J. CRC23<br />
Vasey, F. B. CRC20<br />
Vera-Lastra, O. L. CRC05<br />
W<br />
Wagner, U. CRC18<br />
Wahle, M. CRC18<br />
Watson, G. CRC40<br />
Watson, K. CRC11<br />
Woolf, A. CRC37<br />
Wu, Y. CRC33<br />
Yabuki, T. CRC22<br />
Yazici, Y. CRC37<br />
Young, T. CRC49<br />
Y<br />
Z<br />
Zhang, V. CRC32, CRC46<br />
Zhao, N. CRC33<br />
Ziskind, M. CRC40, CRC49<br />
Clinical research conference - Abstract Author Index abstract moderator Index<br />
361
Moderator Index<br />
abstract author Index<br />
A<br />
Aarrass, S 378<br />
Abbott, J 1918<br />
Abbs, IC 441, 1933<br />
Abdel Baky, M 1951<br />
Abdel-Mohsen, D 1951<br />
Abdo, C 906<br />
Abdollahi-Roodsaz, S<br />
1298, 2130<br />
Abdou, NI 1320<br />
Abdulahad, WH 703<br />
Abdwani, R 1385<br />
Abe, H 1920<br />
Abe, T 370, 1377, 1981,<br />
1996<br />
Abeles, AM 782<br />
Abeles, M 1328<br />
Aberle, T 2125<br />
Abinun, M 910<br />
Ablin, J 1540<br />
Ablin, JN 105, 873, 1529,<br />
1533<br />
Abou Reslan, W 224<br />
Abou-Khamis, T 440<br />
Abraham, D 45, 63, 2146<br />
Abraham, DJ 57<br />
Abram, F 661<br />
Abramson, SB 782, 846,<br />
1449, 1590<br />
Abrar, Q 608<br />
Abu Rabia, R 1540<br />
Abud, C 679, 680<br />
Abujudeh, HH 1369<br />
Acevedo, E 816, 1578<br />
Achilles-Mehr Bakhsh, K<br />
1582<br />
Achouh, L 1126<br />
Ackerman, IN 2044<br />
Adab, P 828, 829<br />
Adachi, J 666<br />
Adachi, J 2138<br />
Adachi, JD 1564, 1565,<br />
1566, 2141<br />
Adachi, S 1707<br />
Adam, PM. 1259<br />
Adami, S 738<br />
Adams, A 884<br />
Adang, EM 90<br />
Adarichev, VA 849<br />
Adawi, M 1617<br />
Adebayo, A 1075<br />
Adhikesavan, LG 669<br />
Adhikesavan, LG. 735<br />
Adib, N 908<br />
Adkinari, T 863<br />
Adler, AJ 2125<br />
Adler, JE. 513<br />
Adler, R 625<br />
Adriaansen, J 933<br />
af Klint, E 1784<br />
Agarwal, S 611<br />
Agarwal, S 1717<br />
Agarwal, S 266<br />
Agarwal, S 1935<br />
Agedal, OArild 1470, 1562<br />
Ager, J 1106<br />
Aggarwal, A 1710, 1711,<br />
1717, 1733<br />
Aggarwal, R 527, 528<br />
Aggarwal, V 1518<br />
Aghajanian, J 833<br />
Aglan, L 1741<br />
Agnew-Blais, JC 734<br />
Agrawal, H 399<br />
Agrawal, N 1583<br />
Agualimpia-Janning, A<br />
1687<br />
Aguilar, D 1120<br />
Aguirre, A 2057<br />
Agustin, R 1850<br />
Ah Kioon, M 1048<br />
Ahearn, JM 1363<br />
AHIJADO-GUZMAN, M 1661<br />
Ahmad, Y 507, 508, 509,<br />
1918<br />
Ahmed, A 1655<br />
Ahmed, S 711, 1783<br />
Ahn, C 531<br />
Ahn, H 859<br />
Ahn, J 928, 975, 1247<br />
Ahn, J 775<br />
Ahn, K 775, 928, 975<br />
Ahuja, A 1580<br />
Aikawa, Y 1779<br />
Aikens, CH. 924<br />
Air, GM 1581<br />
Akar, S 1653<br />
Åkesson, A 1195<br />
Akhmetshina, A 43, 2147<br />
Akhter, E 1122, 1936<br />
Akiba, H 1792, 1899<br />
Akil, M 507, 508, 509,<br />
1918<br />
Akimoto, K 1938, CRC12<br />
Akira, S 1583, 2131<br />
Akiyama, A 1026<br />
Akiyama, C 396<br />
Akiyama, Y 1792, 1899<br />
Akkoc, N 1653, 2019<br />
Akman, C 853<br />
Aksu, K 2019<br />
Al-Mussawir, H 782<br />
Al-Mussawir, HE 846, 1449<br />
Al-Shamisi, M 1429<br />
Al-Taiar, A 2017<br />
Alamanos, Y 1005<br />
Alappatt, C 1102<br />
Alarcon, G 1141, 1930,<br />
2124<br />
Alarcón, GS 450, 499, 514,<br />
1118, 1142, 1916, 2043,<br />
2184<br />
Alarcon, GS. 493, 1115,<br />
1116, 1131, 1138, 1139,<br />
1140, 1919, 2157, 2168<br />
Alarcon-Riquelme, ME<br />
1952<br />
Alavi, A 1639<br />
Albakry, SA 1951<br />
Albani, S 1172, 1988, 1992<br />
ALBERT, C 972<br />
Albert, DA. 228<br />
Albert, DA 686<br />
Albert, J 1680<br />
Albertsson, K 1815, 1879<br />
Albrecht, I 150<br />
Aldag, JC 800, 801<br />
AlDhanhani, AM 502<br />
Alecock, E 2089<br />
Alegre, C 1029<br />
Alegre, M 861<br />
Alesi, G 108<br />
Alessio, M 2178<br />
Aletaha, D 1813<br />
Aletaha, D 272, 298, 355,<br />
1185, 1512, 2103, 2152,<br />
2153<br />
Alex, P 529, 549<br />
Alfaro, J 816, 1578<br />
Alfredsson, L 377, 536,<br />
539, 545, 1061, 2055<br />
Algulin, J 268, 1056<br />
Alhefny, AM 1951<br />
Ali, F 708, 709<br />
Ali, N 709<br />
Aliabadi, P 1694, 2115<br />
Aliabadi, P 207<br />
Alibhai, SM 354, 1888<br />
Alivernini, S 23<br />
Alkassab, F 1207<br />
Allaart, C 639, 1705<br />
Allaart, CF. 256, 300, 697,<br />
2087<br />
Allair, N 155<br />
Allaire, N 1078<br />
Allaire, N 1794<br />
Allaire, S 729, 2119<br />
Allan, G 997<br />
Allanore, Y 1212<br />
Allanore, Y 61, 62, 1372,<br />
1373<br />
Allen, BL 711<br />
Allenbach, Y 2013<br />
Allison, JJ 1263<br />
Alm, GV 515<br />
Almehed, K 1947<br />
Almeida, RG 879<br />
Almodovar, R 6, 7, 1221<br />
Alonso-Perez, E 1973<br />
Aloush, V 1533<br />
Alpert, DR. 447<br />
Alpigiani, M 2178<br />
Alpízar-Rodríguez, D 1107,<br />
1921<br />
Alpoge, E 1473<br />
Alraqi, S 1502<br />
Alten, R 670, CRC37<br />
Alten, R 292, 948, 2089<br />
Althoff, C 1158<br />
Altman, R 1674<br />
Altshuler, D 811, 2121<br />
Alvarez, B 1615<br />
Alvarez-Fuentes, M 1884<br />
Alvizuri, S 1578<br />
Amamoto, T 1026<br />
Ambrose, KR 112, 114<br />
Ambrosi, A 422, 1359,<br />
1727, 2059<br />
Amengual, O 1401, 1406<br />
Amerilyo, G 1607<br />
Amezcua-Guerra, L 192<br />
Amigo, MCarmen 1395<br />
Amin, MA 707, 711, 1475,<br />
1756<br />
Amin, S 206, 216, 2143<br />
Amital, H 535, 851, 1137<br />
Amjadi, S 1001<br />
Ammendolia, C 598, 750<br />
Amos, CI 539<br />
Amos, CI 743<br />
Amos, CI 850, 2055<br />
Amoura, Z 151, 432, 875,<br />
1123, 1124, 1125, 1226,<br />
1242, 1629, 1630, 1946,<br />
1970, 2002<br />
Amox, D 1992<br />
Amtenbrink, A 753<br />
An, H 689<br />
An, L 2135<br />
Anand, B 1432<br />
Anandarajah, AP 278<br />
Ananieva, L 1212<br />
Anastassiades, T 1565<br />
Anaya, J 842, 1351, 1824<br />
and the A9001140<br />
Investigators, 1691,<br />
1706<br />
and the OAI Investigators<br />
group, 659<br />
and the STOPP Consortium,<br />
242<br />
Anders, CK. 1922<br />
Andersen, AB 1021<br />
Andersen, LS 1881<br />
Andersen, LSmedegaard<br />
1042, 2180<br />
Andersen, NT 120<br />
Anderson, A 1985<br />
Anderson, JR 421<br />
362
Anderson, J 323<br />
Anderson, ME 1374<br />
Anderson, MR. 417<br />
Anderson, ME 1198, 1222<br />
Anderson, M 1368, 2091<br />
Anderson, R 734<br />
Andersone, D 670, CRC37<br />
Andersson, ML.E. 194,<br />
1704<br />
Andersson, MLE 1461<br />
Andersson, U 2067<br />
André, C 1325<br />
Andrabi, TR. 2109<br />
Andrade, LE 520, 1722<br />
Andrade, LCoelho 1361<br />
Andrade, LC. 1204<br />
Andrade, RM 493, 1140<br />
Andrade, SE 631<br />
Andreu, JL 121<br />
Andreu, J 1646, 1887<br />
Andrews, BS. 692<br />
Andrews, J 1932<br />
Andrews, K 521<br />
Anemaet, W 1458, 1465<br />
Ang, D 126<br />
Angeles, S 884<br />
Angerer, H 1454<br />
Anis, AH. 80<br />
Anis, A 2026<br />
Anis, AH 77, 100, 833<br />
Anjos, LE 1012<br />
Anklesaria, P 2084<br />
Anolik, J 1424<br />
Anolik, JH 1907<br />
Anthony, KK 1383<br />
Antivalle, M 1015<br />
Antonio, M 334<br />
Anuntiyo, J 1955<br />
Anzai, N 1619<br />
Aoyagi, K 1840<br />
Apparailly, F 2137<br />
Appel, H 576, 577, 579,<br />
614<br />
Appenzeller, S 879<br />
Appleton, B 1684<br />
APPLING, W- 67<br />
Apte, M 493, 1138, 1140,<br />
1919<br />
Arabshahi, B 247<br />
Arai, M 49<br />
Araji, S 1172<br />
Aral, O 812<br />
Aramaki, T 353, 386,<br />
1294, 1611<br />
Aranda, R 699, 950<br />
Aranow, C 426<br />
Aranow, C 1960<br />
Aranow, C 450<br />
Aranow, C 244, 532, 882,<br />
883, 1318<br />
Aranow, Kenneth C.<br />
Kalunian, CB. 2157<br />
Arata-kawai, H 1755<br />
Aratake, K 1840<br />
Archambaud, F 1226<br />
Arciniegas, D 492<br />
Arden, N 201<br />
Arden, NK 684<br />
Arend, WP 2129<br />
Arend, WP. 1768<br />
Arendt, MD 1623<br />
Arendzen, JH. 2104<br />
Arenzana, F 1472<br />
Ares, M 1739<br />
Argyropoulou, MI 1005<br />
Arima, K 353, 386, 1840<br />
Aringer, M 434, 516, 517,<br />
518, 1917<br />
Aristide, L 2057<br />
Arkachaisri, T 229, 230<br />
Arkfeld, D 124<br />
Arkfeld, DG 2111<br />
Arkun, R 275<br />
Ärlestig, L 379<br />
Arnaud, B 790<br />
Arnaud, L 1226<br />
Arnett, F 69<br />
Arnett, FC 36, 37, 38, 59<br />
Arnett, FC. 58<br />
Arnold, S 1054, CRC18<br />
Arnold, W 2112<br />
Arnold, WJ 1459<br />
Arntz, OJ 149, 1380<br />
Aronow, BJ. 1709<br />
Arozenius, H 1778<br />
Arthur, E 180, 549<br />
Arulmani, U 1680<br />
Arvanitis, A 1771<br />
Asahara, H 772<br />
Asai, S 496<br />
Asanuma, Y 1792, 1899<br />
Asensio, C 1048<br />
Asfa, S 1080, 1081<br />
Asherson, R 1397<br />
Askanase, AD 442<br />
Askling, J 820, 821<br />
Askling, J 701, 1061, 1344<br />
Aslam, L 441<br />
Asmadidjaja, P 675<br />
Asmawidjaja, P 1297<br />
Assad-Khalil, S 1233<br />
Assassi, S 37, 38<br />
Astbury, C 954, 2085<br />
Atagunduz, P 1027, 1173<br />
Atalay, F 1031<br />
Atallah, M 1607<br />
Atashili, J 740<br />
Atisha-Fregoso, Y 1133<br />
Atkinson, E 2143<br />
Atsumi, T 533, 1055, 1334,<br />
1400, 1401, 1406<br />
Attur, M 782, 846, 1449,<br />
1590<br />
Atxotegi, J 1615<br />
Atzeni, F 1015, 1101<br />
Au, T 444<br />
Aubin, F 593, 1156<br />
Audo, R 144<br />
Audoly, L 132, 2134, 2135<br />
Audoly, LA 46<br />
Auger, I 744<br />
Aujay, M 939<br />
Austin, JS. 2038<br />
Autoimmunity Centers of<br />
Excellence, 1091<br />
Avalos, I 445, 1145, 1146<br />
Avcin, T 2179<br />
Avorn, J 1342, 1822<br />
Avouac, J 30, 61, 62,<br />
1162, 1372, 1373<br />
Axford, J 1639, 1956, 1959<br />
Axmann, R 2003<br />
Ayala-López, W 690<br />
Ayano, E 937<br />
Aydın, S 1027<br />
Aydin, SZ 1173<br />
Ayis, S 97<br />
aymard, g 1125<br />
Azem, M 862<br />
Azoulay, E 880<br />
Azpeitia, Á 332<br />
Azuma, J 296<br />
Azzari, C 1731<br />
B<br />
Bıcakcigil, M 1828, 2019<br />
Baarsen, LG. 39<br />
Baba, S 18, 1129, 1644<br />
Babonian, C 1956<br />
Baca, V 2178<br />
Bachelez, H 593<br />
Backer, MJ.G. 938<br />
Backhaus, M 133, 650,<br />
654, 730<br />
Backman, C 1262<br />
Bacon, PA. 1239<br />
Bacquet, H 961<br />
Bader, LA 159<br />
Bader-Meunier, B 233, 880<br />
Badesch, D 2166<br />
Badiani, P 203<br />
Badiani, P 199, 2049<br />
Badley, E 77, 172, 354,<br />
1262, 1495, 1888, 2026<br />
Badley, EM 809, 833, 2032<br />
Badley, EM. 1258<br />
Badot, V 1796, 1801<br />
Bae, E 775, 928, 975<br />
Bae, J 1177<br />
Bae, J 548<br />
Bae, SC. 1960<br />
Bae, S 450, 546, 548, 555,<br />
813, 1105, 1115, 1116,<br />
2157<br />
Bae, S 1606<br />
Bae, Y 1177<br />
Baechler, E 762<br />
Baechler, EC 2056<br />
Baecklund, E 333, 670,<br />
CRC37<br />
Baek, HJ 1994, 1995<br />
Baek, S 931, 1764<br />
Baer, AN 1654<br />
Baerwald, C 381, 538,<br />
1054, 2126, CRC18<br />
Baeten, D 358, 366, 561,<br />
575, 1306, 1439<br />
Baggen, JM 307<br />
Bahrt, K 942, 943<br />
Bai, M 1914<br />
Bai, S 1283<br />
Bai-Yu, Z 1886<br />
Baier, A 1058<br />
Baildam, E 908, 909<br />
Baillet, AC 550<br />
Bair, E 103<br />
Bajana-Miranda, S 399<br />
Bajema, I 382, 725<br />
Bajema, IM 390<br />
Bajnok, E 920, 1481<br />
Bajocchi, G 1231<br />
Bajocchi, G 1228<br />
Baker, A 274<br />
Baker, D 988, 1153, 1154<br />
Baker, K 197<br />
Bakker, LE. 1838<br />
Bakker, MF 340<br />
Bala, M 988<br />
Bala, M 351, 504, 1153,<br />
CRC33, CRC38, CRC44<br />
Balada, E 1973<br />
Balancini, B 251<br />
Balandraud, NS 744<br />
Balanescu, AR 182<br />
Balblanc, J 1156<br />
Balboni, I 2070<br />
Baldassare, A 695, 947<br />
Baldassare, AR 2088<br />
Baldi, M 2082<br />
Baldissera, E 1234<br />
Baleux, F 1472<br />
Ballal, S 1160<br />
Ballantyne, PJ 91<br />
Ballehr, L 653<br />
Balow, J 1599<br />
Balsa, A 613, 1887<br />
Balsa Criado, A 603<br />
Bamford, S 630<br />
Banas, B 130<br />
abstract author Index<br />
363
abstract author Author Index<br />
Banda, NK 1768<br />
Banda, NK. 2129<br />
Bandeira, M 2178<br />
Banfield, C 269<br />
Bange, F 1582<br />
Bangert, CC 2071<br />
Bank, I 1720<br />
Bankhurst, AD 177, 345, 455, 736,<br />
1672<br />
Bannink, J 309<br />
Bansback, N 80<br />
Bansback, N 100, 1504<br />
Baptiste, Y 262<br />
Bar - Shira, A 105<br />
Bar Yehuda, S 851, 1787<br />
Bar-Ziv, Y 1270<br />
Barakat, RK 1207<br />
Baraliakos, X 751<br />
Baranauskaite, A 333<br />
Baratelli, M 884<br />
Baráth, S 1993<br />
Barbadillo, C 121<br />
Barbarroja, N 2057<br />
Barber, M 160<br />
Barber-Harris, J 733<br />
Barcellona, R 857, 2178<br />
Barcellos, KS 1722<br />
Barcellos, KSpät Albino 1361<br />
Barcellos, LF 1972<br />
Barceló, P 1029<br />
Barcenilla, A 1740<br />
Barchudarowa, F 133<br />
Barclay, M 1800<br />
Bardal, A 350<br />
Bardet, M 283<br />
Bardin, T 593<br />
Bardwell, PD 1989<br />
Barendregt, PJ 76<br />
Barer, F 1787<br />
Barete, S 1630<br />
Barham, B 856, 874<br />
Barillas, L 884<br />
Barinstein, L 884<br />
Barisoni, L 442<br />
Barkauskaite, V 1965<br />
Barkham, N 1163<br />
Barlas, P 1251<br />
Barlow, J 828<br />
Barnard, J 1424<br />
Barnes, KC 747<br />
Barnes, M 1281<br />
Barnes, MG. 1709<br />
Barnes, T 651<br />
Barnes, TC 19<br />
Baron, AE 748<br />
Baron, G 1484<br />
Baron, M 5, 26, 1197, 1201, 1202,<br />
2163, 2165<br />
Barr, AE 2074<br />
Barr, WG 733<br />
Barrat, FJ 522<br />
Barrat, FJ. 2128<br />
Barrett, J 715, 1522, 1523, 1524<br />
Barrett-Connor, E 1546<br />
Barrientos, O 816<br />
Barron, M 1111<br />
Barsdorf, AI 244, 882<br />
Barsoum, W 1737<br />
Bartelds, GM 380<br />
Barthel, HRichard 1675<br />
Bartlett, SJ 747, 981, 1017, 1037,<br />
2035, 2188<br />
Bartlett, SJ. 2186<br />
Barton, A 552, 553, 556, 1799, 2120,<br />
2122<br />
Bas Minguet, J 1894<br />
Bashkin, A 1025<br />
Basilico, F 687<br />
Baslund, B 2086<br />
Bass, A 1349<br />
Bass, DL 270<br />
Bastecka, D 1035<br />
Bastian, LA. 1922<br />
Baszo, A 227<br />
Bathon, JM 957<br />
Bathon, JM. 988<br />
Bathon, J 996, 997, 998, 1007, 1341<br />
Bathon, JM 747, 981, 992, 1017,<br />
1037, 2035, 2088<br />
Bathon, JM. 2186<br />
Batley, M 601<br />
Batliwalla, F 850, 1794, 2055<br />
Batliwalla, FM 2056<br />
Batot-Michel, C 645, 694<br />
Batra, KL 2150<br />
Batra, KL. 341, 1889, 2187<br />
Batres, C 882<br />
Batsis, JA 837<br />
Batterman, A 2041<br />
batteux, f 1366<br />
Batticciotto, A 1015<br />
Batuca, J 1411<br />
Baudouin, V 880<br />
Bauer, DC 618<br />
Bauer, JW 2056<br />
Bauernfeind, B 1917<br />
Baughman, RP 861, 863<br />
Baum, W 2003<br />
Baumgartner, SW 682, 957<br />
Baumgartner, S 303<br />
Bayakly, R 505, 506<br />
Bayle, J 56<br />
Bayona, J 1824<br />
Bazzichi, L 372, 1213<br />
Beals, C 2077<br />
Beals for the OAI Investigators, C 215<br />
Bearcroft, PW 122<br />
Beary, JF 2140<br />
Beaton, D 77<br />
Beatriz, A 334<br />
Beaulieu, AD 2089<br />
Becerra, E 1898<br />
Bechanovic, K 422<br />
Bechi, P 1217<br />
Beck, T 201<br />
Becker, J 699, 950<br />
Becker, J 1489<br />
Becker, J 1497<br />
Becker, MA 757, 758, 1622<br />
Beckman, E 947, 1432<br />
Bedane, C 593<br />
Beer, Y 1270<br />
Beglin, C 1268<br />
Begovich, AB 2000<br />
Behar, SM 1028<br />
Behera, MA. 1922<br />
Behlke, M 1769<br />
Behnam, Z 1956<br />
Behrens, E 760<br />
Behrens, EM 1608<br />
Behrens, F 2164<br />
Behrens, T 762<br />
Behrens, TW 1972<br />
Behrens, TW 811, 1968, 2055, 2056<br />
Beilinson, N 1533<br />
Belarbi, L 1244<br />
Belasco, J 884<br />
Belenguer, R 1090, 1399<br />
Belfer, I 103<br />
Belilos, E 1250<br />
Belitskaya-Levy, I 846<br />
Bell, A 1932<br />
Bell, AL 1317<br />
Bell, DA 1746<br />
Bell, M 172<br />
Bell, MJ. 178<br />
Belmont, HM 442<br />
Belmonte, M 333<br />
Belmonte, R 1934<br />
Belmonte-López, Á 287<br />
Belomestnov, P 168<br />
Belot, A 880<br />
Belouski, S 1906<br />
Belouski, SS 1422<br />
Beltramelli, M 222, 2178<br />
Beltran, E 1029<br />
Beltrán, J 1090<br />
Ben-Zvi, I 1318<br />
Benajamin, E 806<br />
Bendele, A 929<br />
Bendersky, A 1720<br />
Bene, M 1576<br />
Benedict, S 1270<br />
Bengtsson, AA 814, 1132<br />
Bengtsson, A 1535<br />
Bengtsson, C 377<br />
Benhamou, CL 2140<br />
Benhamou, M 73, 75<br />
Benjamin, M 564<br />
Bennell, KL 764<br />
364
Bennett, AN 1157<br />
Bennett, M 939<br />
Bennett, R 653<br />
Bennett, R 1541<br />
Bennett, RM 125<br />
Bennink, MB 149, 1380<br />
Benseler, S 876<br />
Benson, MD 1296<br />
Benson, RA 1990<br />
Benveniste, O 1630<br />
Benza, R 16<br />
Bera, L 1976<br />
Beregi, J 1371<br />
Berek, C 406<br />
Berenbaum, F 73, 718, 1447<br />
Berger, SA 1057<br />
Berger, T 410<br />
Berghea, CE 182<br />
Berghea, F 182<br />
Berglin, E 1073<br />
Berglund, G 374, 1010<br />
Bergman, M 1821<br />
Bergman, M 164, 732, 1810<br />
Bergman, S 1506<br />
Bergström, U 286, 374<br />
Berkun, Y 2179<br />
Berkun, Y 1720, 1978<br />
Berlo, SE 938<br />
Berman, A 956<br />
Berman, B 85<br />
Berman, JR 1349, 1948<br />
Bernatsky, S 985, 986, 1193, 1657,<br />
1960<br />
Bernatsky, S 804<br />
Berner Hammer, H 662<br />
Berney, S 428<br />
Bernit, E 871<br />
Bernstein, B 2083<br />
Bernstein, JE. 1689<br />
Bershadsky, B 1737<br />
Bertani, L 1015<br />
Berthelot, JM 1295<br />
Berthelot, J 283, 1249<br />
Berthier, S 550<br />
Bertolaccini, M 1396<br />
Bertoli, AM 1141, 1930<br />
Bertolini, D 592<br />
Bertsias, G 393<br />
Besedovsky, HO 1747<br />
Bessems, M 127<br />
Bessis, N 915<br />
BETSOU, F 1227<br />
Beukelman, T 228<br />
Beyer, A 376<br />
Beyer, M 456<br />
Beylot-Barry, M 593<br />
Bhan, R 1106<br />
Bharadwaj, A 601<br />
Bhardwaj, N 1647<br />
Bhaskarabhatla, M 1286<br />
Bhat, SS 125<br />
Bhattacharyya, S 1216<br />
Bialkowski, A 677<br />
Bianchi, M 222<br />
Bica, BE.G.R. 1204<br />
BICAKCIGIL, M 1635<br />
Bichile, L 949<br />
Biedermann, S 1282<br />
Bienkowska, J 1078, 1794<br />
Biesen, R 133, 1954<br />
Biggioggero, M 222, 1404<br />
Bijl, M 1964<br />
Bijlsma, J 951<br />
Bijlsma, JWJ 340, 626, 792, 831,<br />
1379, 1462, 1676, 1683, 1991<br />
Bijzet, J 580, 866, 1964<br />
Bilaniuk, LT 247<br />
Bilek, LD 766<br />
Bilezikian, J 2138<br />
Bili, A 669, 735<br />
Bilotta, R 1284<br />
Binard, A 1295<br />
Binder, N 674<br />
Binder, NB 2063<br />
Bingham, CA 252<br />
Bingham, CO 303, 726<br />
Bingham, CO. 96<br />
Bingham III, CO 257, 1017<br />
Binkley, N 1546<br />
Binks, MH 1066<br />
Binstadt, BAnthony 1714<br />
Bird, P 2151<br />
Birlik, M 1653<br />
Birnbaum, J 452, 453<br />
Birrel, FN 662<br />
Bischoff-Ferrari, HA 628, 1550, 1698,<br />
2076<br />
Bishop, A 2037<br />
Bissell, M 181<br />
Bizzini, B 915<br />
Black, C 63, 2146<br />
Black, CM 3, 9, 14, 1200, 1225, 2167<br />
Black, CM. 57<br />
Black, D 623<br />
Black, DM 618<br />
Blackburn, MR 42<br />
Blackshear, PJ. 1307<br />
Blake, S 1448<br />
Blakey, GE 954<br />
Blanch, J 1444, 1549<br />
Blanco, F 595, 596, 1187, 1188, 1189<br />
Blanco, F 1887<br />
Blanco, FJ 391, 1446, 1451, 1452,<br />
1471<br />
Blanco, F 1795<br />
blanco, p 1366<br />
Blankier, S 1730<br />
Blasie, C 274<br />
Blelock, S 2078<br />
Block, AJ 221, 679, 680<br />
Block, E 780<br />
Block, JA 170, 171, 1112, 1113, 1490<br />
Block, JA 186, 187, 188, 191, 315,<br />
316, 1023, 2072, 2073<br />
Block, JA. 189, 190<br />
Blom, AB 1453, 2061<br />
Blom, A 1460, 1757<br />
Blom, M 299<br />
Bluemke, DA 1925<br />
Blum, A 645, 694<br />
Blumentals, WA. 620, 621, 622, 1556<br />
Blumenthal, R 997, 998, 1007, 1341<br />
Blüml, S 674<br />
Bo, S 2133<br />
Bobba, R 1924<br />
Bober, LA 1748<br />
Bocelli-Tyndall, C 28<br />
Boers, A 1164<br />
Boers, M 965, 1804<br />
Boespflug, ND 34<br />
Bohnsack, J 681, 1718<br />
Bohnsack, JF 897<br />
Bohnsack, JF. 1708<br />
Boiardi, L 788, 1228, 1231, 1805<br />
Boice, J 1690<br />
Boileau, C 61, 62<br />
Boileau, C 661<br />
Boini, S 1511<br />
Boire, G 86, 87, 88, 804<br />
boissier, m 915<br />
Boivin, J 1193, 1657<br />
Bojalil, R 104<br />
Bojinca, V 182<br />
Bokarewa, M 365, 1791, 1879<br />
Boki, KA 1159<br />
Boki, K 295<br />
Bolek, R 425<br />
Bolen, J 720, 2054<br />
Bolignese, J 653<br />
Bolognese, M 1545<br />
Bolstad, AIsine 1078<br />
Bolt, I 246<br />
Bolvig, L 120<br />
Boman, A 1778<br />
Boman, K 1002, 1003<br />
Bombardier, C 77, 86, 87, 88, 354,<br />
1812, 1888<br />
Bombardieri, S 372, 991, 1213<br />
Bomsztyk, K 1760<br />
Bonacci, B 1378<br />
Bonacci, E 1101<br />
Bonanni, E 962<br />
Boncompagni, A 222<br />
Bondeva, T 1058<br />
Bone, HG. 1544<br />
Bonelli, M 1975<br />
Bonelli, MM 519<br />
Bonfa, E 184, 1127, 1144<br />
Bonfá, E 879, 1104<br />
Bongrand, P 1474<br />
abstract author Index<br />
365
abstract author Index<br />
Bonilla, A 1451<br />
Bonner, P 761<br />
BONY, C 2060<br />
<strong>Book</strong>binder, S 309<br />
Boom, HD 1775<br />
Boonen, A 1816<br />
Boonen, A 586, 616, 1166, 1180,<br />
1493, 1815<br />
Boonen, S 618, 619, 623, 666, 2140<br />
Boonen, S 2138<br />
Boonen, S 665<br />
Booth, S 1686<br />
Boots, A 325<br />
Boots, AH 1439<br />
Bootsma, H 1196<br />
Boracchi, P 11, 12<br />
Borba, EF 184, 1012, 1104, 1127,<br />
1144, 1950<br />
Borderie, D 1373<br />
Borges, CT.L. 1204<br />
Borges, JLC 1547<br />
Borghi, M 1337<br />
Borghi, O 1404<br />
Borham, A 113<br />
Bork, D 884<br />
Borm, G 1819<br />
Borrebaeck, CAK 814<br />
Bortolotto, LA 1144<br />
Bortoluzzo, AB. 1204<br />
Bos, CL. 39<br />
Bos, E 1439<br />
Bos, WH 380<br />
Bosari, S 2145<br />
Boscardin, WJohn 1736<br />
Bosello, S 23, 373, 1223<br />
Boskey, AL 1669<br />
BOSSHARD, S 705, 1240<br />
Bossi, P 1629<br />
Boström, C 2189<br />
Botha-Scheepers, S 1697<br />
Botsios, C 592, 1640<br />
Bouck, T 1907<br />
Boudinet, H 744<br />
Boudreau, R 1839, 2075<br />
BOUFFI, C 2060<br />
Boullart, L 324<br />
Boumier, P 1892<br />
Boumpas, D 295<br />
Boumpas, DT 393, 525, 844, 848,<br />
1479, 1605<br />
Bourgain, C 1324<br />
BOURGEOIS, A 1227<br />
Bourgeois, P 73, 75, 767<br />
Boutrin, A 429<br />
Bove, A 1388, 1389, 1397, 1399,<br />
1577, 1594, 1931<br />
Bowen, M 1417<br />
Bowes, J 552, 2120, 2122<br />
Bowman, SJ 1098, 1099<br />
Bowman, SJ 1094<br />
Bowness, P 562<br />
Bowyer, SL 254<br />
Boyce, BF 1476<br />
Boyce, M 1906<br />
Boyce, V 1906<br />
Boyd, PR 263<br />
Boyer, J 541<br />
Bøyesen, P 634<br />
Boyington, JE. A. 2048<br />
Boyle, DL 131, 148, 673, 916, 917,<br />
926, 1308<br />
Boyle, E 598, 750, 1168<br />
Boyle, J 709<br />
Braakman-Jansen, AMA 71<br />
Bracaglia, C 248, CRC01<br />
Braccini, A 28<br />
Bradbury, LA 563, 1321, 1323<br />
Braddock, M 1772<br />
Bradke, A 417<br />
Bradley, L 1543<br />
Bradna, P 1035<br />
Bradshaw, SG 1426<br />
Brady, T 720, 2054<br />
Brady, TJ 719<br />
Braga, L 740<br />
BRAGGSS, 552, 553<br />
Braghetto, L 1640<br />
Brahn, E 1573<br />
Bramson, CR 1459<br />
Branco, J 1712<br />
Brandenburg, S 150<br />
Brandt, HC 614<br />
Brandt, J 1186<br />
Brandt, K 1691, 1706<br />
Brantly, ML 2014<br />
Brar, A 2183<br />
Brasington, R 272<br />
Bratt, J 260<br />
Braun, J 1153, 1154, 1494<br />
Braun, J 751<br />
Braun, J 753, 1158, 1186<br />
Bräutigam, K 526<br />
Bravo, JF 1633<br />
Brazier, M 1892<br />
Breban, M 566, 1324, 1325<br />
Breda, L 2082<br />
Breedveld, FC 262<br />
Breedveld, F 639, 1705<br />
Breedveld, FC 98, 1697, 2153<br />
Breedveld, FC. 256, 300, 697, 2087<br />
Breitbach, M 967<br />
Bremander, AB 2031, 2047<br />
Brennan, D 802<br />
Brenol, JT. 1536<br />
Brent, LH 1580<br />
Brentano, F 1591, 1597, 1598, 2123<br />
Brescia, AC 240, 241, 894, 2176<br />
Brescia, AC. 2175<br />
Bresnihan, B 670, 746, CRC37<br />
Bresnihan, B 308, 330, 331, 797,<br />
1183, 1191, 1265, 1266, 1267,<br />
1439, 1603, 1604<br />
Brett, A 1695<br />
Breuer, GS 704<br />
Breur, G 690<br />
Brewer, ED 878<br />
Brewer, JM 1990<br />
Brey, RL. 2095, 2161<br />
Brezinsek, H 1346<br />
Briançon, D 1156<br />
Bridges, SL 2184<br />
Brigham Rheumatoid Arthritis<br />
Sequential Study (BRA, S 2121<br />
Brigham-Burke, M 274<br />
Brinckerhoff, CE 2136<br />
Brintnell, W 1746<br />
Brisca, G 249<br />
Brissard, M 1818<br />
Brito, I 1712<br />
Brito-Zerón, P 1399, 1577, 1594,<br />
1595, 1931, 2006<br />
Britsemmer, K 1020<br />
Brixen, K 738<br />
Brockbank, J 1937<br />
Brockbank, JE. 2096<br />
BROCQ, O 972<br />
Brodsky, A 270<br />
Brodsky, R 440, 1935<br />
Brook, AS 1174<br />
Brookhart, M 1555<br />
Brooks, P 1740<br />
Brooks, SA 2132<br />
Brooks, WM 455<br />
Brorson, J 862<br />
Brough, GM 9<br />
Brousse, A 1156<br />
Brousse, N 875<br />
Broussole, C 1394<br />
Brouwer, E 580<br />
Brouwers, JRBJ 71<br />
Brown, A 167<br />
Brown, DH 643<br />
Brown, EE 499<br />
Brown, JP 1565<br />
Brown, J 1135<br />
Brown, KC 2033<br />
Brown, M 492<br />
Brown, MA 559, 563, 1321, 1323<br />
Brown, S 653<br />
Brown Jr., RD 1237, 1238<br />
Browning, J 425<br />
Browning, JL 1423<br />
Browning, JL. 1078<br />
Bruce, B 1516<br />
Bruce, I 507, 508, 509, 1918<br />
Bruce, I 1960<br />
Bruce, I 450<br />
Bruce, IN 556, 1000, 1932, 2120,<br />
2122<br />
Bruce, Mary Ann Dooley, I 2157<br />
366
Brulhart, L 330, 331, 1183<br />
Brune, K 858<br />
Bruner, BF 1364, 1912<br />
Bruner, BF. 510<br />
Bruner, GR 501, 839, 1111, 1136<br />
Bruner, GR. 514<br />
Brunet, C 871<br />
Brunner, H 235<br />
Brunner, HI 234, 236, 883, 885, 912<br />
Bruno, M 1269<br />
Bruns, L 922<br />
Brus, HLM 299<br />
Bruton, J 2067<br />
Bruyere, O 738<br />
Bruyn, GA.W. 580<br />
Bryan, RL 2127<br />
Bryant, S 135, 1989<br />
BSPAR group, 2122<br />
BSR Control Centre Consortium, 1343<br />
Bucciarelli, S 1388, 1397<br />
Buch, MH 21<br />
Buchanan, RR 1164<br />
Buchbinder, R 160, 768, 2044<br />
Büchler, C 147<br />
Buck, R 217, 218, 657, 1691, 1706,<br />
1890<br />
Buckley, CD 562<br />
Budd, R 1936<br />
Buendia, P 2057<br />
Bultink, IE.M. 1548<br />
Bungartz, C 342<br />
Bunn, CC 3<br />
Bunn, D 320, CRC06<br />
Bunn, DK 1000<br />
Buoncompagni, A 227, 249<br />
Buonuomo, P 248, CRC01<br />
Burch, F 1684<br />
Burckhardt, H 1158<br />
Burdorf, A 76, 1492<br />
Burell, C 1287<br />
Bures, J 1035<br />
Burge, D 309<br />
Burger, D 65<br />
Burgess, J 637<br />
Burgess, L 929<br />
Burgio, DE 2140<br />
Burgos-Vargas, R 679, 680<br />
Burgos-Vargas, R 749, 898, 1186,<br />
2178<br />
Burguet, A 350<br />
Burke, L 262<br />
Burkly, L 130, 155, 413, 1962<br />
Burlingame, R 1012, 1891<br />
Burlingame, RW. 521<br />
Burmester, G 267, 1502<br />
Burmester, GR 959<br />
Burmester, G 945<br />
Burmester, GR 142, 1482<br />
Burmester, G 1416<br />
Burmester, G 823<br />
Burmester, G 314, 405, 654, 1079,<br />
1415, 1954<br />
Burmester, G 133, 650<br />
Burnette, M 1432<br />
Burnham, JM 239, 889, 2177<br />
Burnley, L 239<br />
Burns, A 3<br />
Burns, S 1719<br />
Burr, ML 974<br />
Burrage, PS 2136<br />
Burstein, D 217, 218, 641<br />
Burtt, N 811<br />
Busch, R 323<br />
Buskila, D 1529, 1540<br />
Busquets, N 1184<br />
Busso, N 1280, 1586<br />
Butrimiene, I 1296<br />
Buttaro, C 1078<br />
Buttgereit, F 314, 654, 948, 1482,<br />
2065<br />
Buyon, J 1435<br />
Buyon, JP 231, 1923<br />
Buyon, JP. 143, 442, 2128<br />
Buyske, S 304, 1279<br />
Bykerk, V 293, 2154<br />
Bykerk, VP 354, 1812<br />
Bynum, SK 415<br />
Byrne-Dugan, CJ 112, 114<br />
Byun, H 1780<br />
C<br />
Caballero, CVinicio 1642<br />
Cabiati, M 1213<br />
Cabiedes, J 1133<br />
Cabral, DA 242<br />
Cabral, D 1385<br />
Cacoub, P 151, 1123, 1124, 1226,<br />
1242, 1629, 1630, 2002, 2008,<br />
2015, 2016, 2025<br />
Cadarette, SM 1555<br />
Cadwell, C 1724, 1725<br />
Cadwell, R 549<br />
Caetano-Lopes, J 602, 1712<br />
Cagnoli, P 798, 1152, 1913<br />
Cahue, S 210, 211, 212, 658<br />
Cai, A 274<br />
Cai, Y 1312<br />
Caines, A 1649<br />
Cairns, E 1746<br />
Cakir, N 1542<br />
Calabrese, LH 867, 868, 1643<br />
Calabri, G 1731<br />
Calamia, K 1237, 1238<br />
Calamia, KT 1233<br />
Calaza, M 1973<br />
Caldana, WC 1842, 1895<br />
Calderaro, D 1204<br />
Caldron, P 653<br />
Caleyachetty, R 1396<br />
Caligiuri, P 861<br />
Cáliz, R 1887<br />
Call, S 1811<br />
Callahan, LF 808, 2042, 2052, 2184<br />
Callahan, LF. 1252, 2048<br />
Callegari, P 989, CRC17<br />
Callejas, J 1648<br />
Callon, K 756<br />
Calvet, J 1444<br />
Calvo, E 847<br />
Calvo-Alen, J 1821<br />
Calvo-Alen, J 1090<br />
Camafeita, E 847<br />
Caminos, J 1210<br />
Camp, J 2143<br />
Campbell, D 1986<br />
Campbell, PL 707, 1475<br />
Campbell, R 1254<br />
Campbell, S 413<br />
Campbell, SR 130<br />
Campos, J 121<br />
Campos, LM 2179<br />
Campos, LL 879<br />
Camps, M 1090<br />
Camps, M 1058<br />
Can, G 1653<br />
Canadian Scleroderma Research<br />
Group, 5, 1201, 1202<br />
Canas, CA 1393<br />
Cañas, C 1642<br />
Candon, S 1089<br />
Cañellas, J 1574<br />
CAÑETE, JD 561, 1795, 1901<br />
Canhao, H 602, 1712<br />
CaNIOS Investigators, 804<br />
Canizares, M 1485<br />
Cannon, GW 923, 1567, 1745, 1766<br />
Cannon, GW. 984, 1811<br />
Cantaert, T 358, 366, 575, 1306,<br />
1434, 1439<br />
Cantagrel, A 541<br />
Cantini, F 606<br />
Cao, Y 1301<br />
Capannini, S 632<br />
Capar, S 1653<br />
Caparbo, VF 1469, 1560<br />
Capell, HA 968, 977, 979, 999<br />
Caplan, L 1194<br />
Caporali, R 1101<br />
Caputo, R 226<br />
Caramaschi, P 1212<br />
Caramés, B 391, 1446, 1452<br />
Carbone, L 635<br />
Carbone, LD. 1047<br />
Carbonell, J 1444, 1549<br />
Carcelain, G 151<br />
Carcereri, R 594, 1159<br />
Cardin, SP 879<br />
Cardon, LR 1321<br />
Caricchio, R 415<br />
abstract author Index<br />
367
abstract author Index<br />
Carlesso, G 1417<br />
Carlos, P 1850<br />
Carlson, J 1011<br />
Carlsson, A 814<br />
Carlsten, H 1791, 1885, 1947<br />
Carlton, K 2151<br />
Carlton, S 860<br />
Carmona, L 834, 1626<br />
Carneiro, SC. S. 1204<br />
Carneiro-Sampaio, MS. 886<br />
Caron, B 203<br />
Carpena, M 1898<br />
Carpintero, MF 1634<br />
Carr, P 162<br />
Carrasco, JAntonio 1170<br />
Carrasco, S 1726<br />
Carreira, P 1934, 1973<br />
Carreira, PE. 6, 7, 1221<br />
Carreira, P 10<br />
CARREIRA, P 1661<br />
Carreira, V 1471<br />
Carreño, L 1898<br />
Carreras-Margalef, E 399, 1587<br />
Carrington, KL 2038<br />
Carroll, C 1333<br />
Carson, C 180<br />
Carson, KA 437<br />
Carson, KA. 1319, 2161<br />
Carsons, SE 776, 1250, 1774<br />
Carta, S 249<br />
Carter, A 2120, 2122<br />
Carter, JD 667, 1354, 1355, 1569,<br />
1570, CRC20<br />
Carter, RH 1299<br />
Carthen, F 1905<br />
Carty, S 1782<br />
Carulli, J 743, 1794<br />
Carulli, JP 2055<br />
Carvajal, I 1797<br />
Carvalho, JF 1391<br />
Carvalho, LM 879<br />
Casali, B 788, 1231, 1805<br />
Casanova, F 346<br />
Casas, N 625, 1642<br />
Casas González, M 1898<br />
Casasola-Vargas, J 749<br />
Casciola-Rosen, L 747<br />
Caspi, D 873, 1025, 1978<br />
Cassidy, A 1610<br />
Castañeda, S 1797<br />
Castiblanco, J 842, 1351<br />
Castillo, C 646<br />
Castro, MC 287<br />
Castro, P 350<br />
Catalano-Pons, C 253<br />
Catanoso, M 1231<br />
Catanoso, M 1228<br />
Catanoso, WJ Parsons, M 610<br />
Catastrophic Antiphospholipid<br />
Syndrome (CAPS) Regi, s 1397<br />
Catchpole, T 1825<br />
Catrina, AI 359<br />
Catrina, AI 393<br />
Catrina, A 1784<br />
Cattalini, M 2175<br />
Cauley, PJ 623<br />
Cauli, A 574, 606, 610, 647<br />
Cavaleiro, J 1712<br />
Cavanaugh, PF 276<br />
Cavett, JW 1287<br />
Cawkwell, L 1163<br />
Cazalis, M 547<br />
Cazzato, M 670, CRC37<br />
Cazzato, M 991<br />
Ceccherini, I 2082<br />
Celi, F 219<br />
Celik, S 1821<br />
Celik, S 1178<br />
Celis, R 561<br />
Centola, M 180, 525, 529, 549, 1710,<br />
1711, 1724, 1725, 1733, 2183<br />
Cervera, R 2179<br />
Cervera, R 1388, 1389, 1397, 1402,<br />
1403, 1931<br />
Cetin, A 275<br />
Cha, H 775, 928, 975, 1247<br />
Chabra, S 692<br />
Chada-Boreham, H 1200<br />
Chadha-Boreham, H 14<br />
Chae, J 1601<br />
Chae, S 573, 822<br />
Chaganti, K 201<br />
Chaganti, R 2116<br />
Chai, J 928<br />
Chaib, A 1933<br />
Chaki, H 1779<br />
Chakravarty, E 1118, 1916<br />
Chakravarty, EF 4, 1034, 2114<br />
Chalom, E 884<br />
Chalumeau, N 1124<br />
Chamberland, DL 644<br />
Chambers, A 1641<br />
Chambers, SA 1911<br />
Chambost, H 869<br />
Chams-Davatchi, C 1232<br />
Chan, AT 562<br />
Chan, B 1746<br />
Chan, EK.L 1835<br />
Chan, EK.L. 1419<br />
Chan, ES 776, 1774<br />
Chan, ESL 42<br />
Chan, EYT 1941<br />
Chan, H 921<br />
Chan, W 636, 1554<br />
Chan, WW 630<br />
Chan, W 631<br />
Chanchani, E 815<br />
Chandran, V 597, 1186, 1190, 2096,<br />
2097, 2098<br />
Chang, A 211<br />
Chang, C 132<br />
Chang, D 305<br />
Chang, H 987<br />
Chang, H 1817<br />
Chang, HY 1216<br />
Chang, HJ 741, 817<br />
Chang, H 150<br />
Chang, MT. 198<br />
Chang, N 408, 567, 1312<br />
Chang, RW 741, 817, 836<br />
Chang, S 1442<br />
Chapman, P 1800<br />
Chappell, A 1543<br />
Charakida, M 1411<br />
Charef, P 14, 1200<br />
Charlanne, H 1371<br />
Charles, C 218<br />
Charles, C 446<br />
Charles-Schoeman, C 1001, 1668<br />
Charlionet, R 1428<br />
Charlotte, F 151, 875, 1629<br />
Chary-Valckenaere, I 645, 694, 1576<br />
Chase, WF 1674<br />
Chaser, B 1710, 1711<br />
Chastre, J 1946<br />
CHATELAIN, D 705, 1227, 1240<br />
Chatenoud, L 1089<br />
Chatfield, SM 1164<br />
Chatham, W 426<br />
Chatterton, RT 800, 801<br />
Chaturvedi, D 1614<br />
Chaudhry, S 2170<br />
Chauhan, AK 255, 901, 1367, 1375,<br />
1716<br />
Cheatwood, A 1820<br />
Chedeville, G 881<br />
Chee, MM 977, 979<br />
Cheetham, C 281<br />
Cheetham, CT 1820<br />
Chen, B 132, 840<br />
Chen, C 438, 439, 1390<br />
Chen, H 293, 2154<br />
Chen, J 134<br />
Chen, J 1883<br />
Chen, JJH 1528<br />
Chen, L 1068<br />
Chen, LX 1103, 1346, 1356, 1542<br />
Chen, LX. 1350<br />
Chen, N 101<br />
Chen, P 1408<br />
Chen, P 627<br />
Chen, PP 1337<br />
Chen, S 672<br />
Chen, S 1748<br />
Chen, S 1953<br />
Chen, W 743<br />
Chen, W 446, 2091<br />
Chen, Y 1710, 1711, 1733<br />
Chen, Y 1592<br />
Chen, Y 57, 2146<br />
368
Cheng, H 635, 636, 1552, 1554<br />
Cheng, KK 828, 829<br />
Cheng, L 1417<br />
Cheong, H 813<br />
Chester, K 346<br />
Cheu, M 1432<br />
Cheung, C 1500<br />
Cheung, PP 1174<br />
Cheung, Y 400, 1312<br />
Chhaya, S 653<br />
Chi, E 960<br />
Chia, F 436, 1149<br />
Chiaramonte, B 733<br />
Chiba, J 1450<br />
Chiba, K 136<br />
Chibnik, L 2150<br />
Chibnik, LB 360, 648, 664, 1369<br />
Chikura, BG 24<br />
Chin, H 2023<br />
Chindalore, V 428<br />
Chino, Y 412<br />
Chinoy, H 1666<br />
Chiocchia, G 61, 1324<br />
Chira, P 237, 238<br />
Chirinos-Rojas, CL 263<br />
Chiu, Y 153, 572<br />
Chizzolini, C 65<br />
Chmiel, J 101<br />
Chng, H 436, 1147, 1149<br />
Cho, C 369, 1043, 1944, 1977<br />
Cho, J 1177<br />
Cho, M 1443, 1764, 1977<br />
Cho, M 931, 1764<br />
Cho, M 640<br />
Cho, N 642<br />
Choe, J 1105, 1830<br />
Chohan, S 862, 863<br />
Choi, AMK 54<br />
Choi, HK 686, 1625, 2099, 2100<br />
Choi, K 859<br />
Choi, S 1908<br />
Choi, S 1045<br />
Choi, S 322, 388, 624<br />
Chon, Y 682, 957, 960, 1806<br />
Chon, Y 303<br />
Chopra, A 815, 949, 1571, CRC24<br />
Choquet, S 1629<br />
Chott, RC 787<br />
Choulaki, C 1605<br />
Chover-Gonzalez, A 1628<br />
Chowdhary, VR 1236<br />
Chowdhury, P 132<br />
Choy, E 195, 1502<br />
Choy, EHS 583<br />
Chriscinske, SJ 106, 108<br />
Christensen, AF 1440<br />
Christensen, IJ 1881<br />
Christian, V 1829<br />
Christiansen, C 1882<br />
Christianson, T 1237, 1238<br />
Christner, P 1903<br />
Christodoulou, MI 1362<br />
Christopher-Stine, L 1121, 1392,<br />
1928, 2090<br />
Chryssochoou, E 271<br />
Chu, C 838<br />
Chu, C 1760<br />
Chu, T 609<br />
Chubick, A 288, 2088<br />
Chujo, S 49<br />
Chung, A 741<br />
Chung, CP 445, 1145, 1146, 1148,<br />
1514, CRC45<br />
Chung, C 640<br />
Chung, H 573, 822<br />
Chung, J 1906<br />
Chung, J 1637<br />
Chung, KC 21<br />
Chung, L 4, 26, 2163, 2165<br />
Chung, LS 1208<br />
Chung, SA. 838<br />
Chwiesko, S 30<br />
Cibere, J 1507<br />
Cibere, J 809, 833, 1272, 1499, 1702<br />
Cibotti, R 46<br />
Cid, MC 784, 1483<br />
Cid, M 128<br />
Cid, M 1230<br />
Cieza, A 1180<br />
Cifaldi, M 99<br />
Cifaldi, M 98, 101, 830<br />
Cillero-Pastor, B 391, 1446, 1452<br />
Cimaz, R 2179<br />
Cimaz, R 222, 223, 226, 253, 632,<br />
880, 1404, 1731, CRC02<br />
Cimino, L 1231<br />
Cipher, D 1008, 1567<br />
Cipher, DJ. 984<br />
Ciphers, D 1811<br />
CIRIA, M 1444, 1549<br />
Civamide Cream Study Group, 1689<br />
Clancy, M 197, 2115<br />
Clancy, M 207<br />
Clancy, R 442, 1435<br />
Clancy, RM 143<br />
Clancy, RM. 1923, 2128<br />
Clark, B 756<br />
Clark, EA. 411<br />
Clark, M 861<br />
Clark, SL 1972<br />
Clark, T 2018<br />
Clark, TM 2020<br />
Clarke, AE 503<br />
Clarke, A 1960<br />
Clarke, AE. 986, 1193, 1657<br />
Clarke, A 450, 985<br />
Clarke, AE 2157<br />
Clarke, AE. 1115, 1116<br />
Clarke, SA 2078<br />
Claudepierre, P 1159<br />
Claudio, JO 804<br />
Clauw, DJ 107, 116, 117<br />
Clauw, DJ 103, 106, 108, 109, 110,<br />
112, 114, 126, 713, 714, 1527<br />
Clauw, DJ. 115, 716, 1525, 1526,<br />
1537<br />
Clavel, C 1829<br />
Claver, G 1389<br />
Clayburne, GM 1627<br />
Clements, P 30, 134<br />
Clements, PJ 2162<br />
Clifford, B 897, 1708, 1718<br />
Clowse, ME.B. 1922<br />
Clutter, SD 1715<br />
Coates, L 1163<br />
Coates, LC 1157<br />
Cobaugh, DJ. 1263<br />
Cobb, BL 1084<br />
Coblyn, J 1028<br />
Coblyn, J 2121<br />
Coblyn, JS 734<br />
Cobo, T 600, 604<br />
Cobo- Ibañez, T 603<br />
Cobo-Ibáñez, T 613<br />
Coccia, M 1984<br />
Cochran, E 252<br />
Cocuzza, M 1104<br />
Codd, M 1833<br />
Codd, MB 330, 1183<br />
Codding, C 288<br />
Codding, C 180<br />
Cohen, DS 608<br />
Cohen, H 1529<br />
COHEN, P 2024<br />
Cohen, P 1102<br />
Cohen, PL 1091<br />
Cohen, S 267, 1684<br />
Cohen, S 851, 1787<br />
Cohen, S 698, 953<br />
Cohen-Solal, M 1048<br />
Colaci, M 1224<br />
Colaço, B 1906<br />
Colbert, RA 1281, 1283<br />
Colbert, RA. 1709<br />
Colbourn, J 2106<br />
Colden-Stanfield, M 1336<br />
Cole, DE. 1117<br />
Cole, JC 70<br />
Colina, M 279<br />
Coll, M 1549<br />
Collado, M 1887<br />
Collantes, E 1175<br />
Colley, L 1272<br />
Collier, D 26, 1194, 2163, 2165<br />
Collins, CE 1575<br />
Collins, KR 1575<br />
Collins, R 1771<br />
Colmegna, I 362<br />
Colodro, A 1648<br />
colombat, m 2008<br />
abstract author Index<br />
369
abstract author Index<br />
Colon-Emeric, C 666<br />
Comans, EFI 693<br />
Combe, B 1821<br />
Combe, B 73, 144, 497, 498, 700,<br />
1051<br />
Combes, A 1946<br />
Combs, A 1771<br />
Comets, E 1085<br />
Comina, D 2145<br />
Comis, L 678<br />
Comte, A 253<br />
Conaghan, P 197<br />
Conaghan, PG 660, 662, 1485, 1701,<br />
1841<br />
Condemi, J 426<br />
Congedo, V 219<br />
Conigliaro, P 1990<br />
Conn, DL 2184<br />
Connelly, M 1383<br />
Conner-Spady, B 586, 587, 588<br />
Connolly, MKari 1216<br />
Connolly, MKari 40<br />
Connolly, M 2071, 2144<br />
Connolly, M 797<br />
Connolly, S 651<br />
Connor, AM 1057<br />
Conroy, MB 2075<br />
Consensi, A 372, 991<br />
Consolaro, A 227, 904<br />
Constantin, A 541<br />
Constantinescu, C 182<br />
Constantinescu, F 1863<br />
Constantino, F 1576<br />
Contel, N 1771<br />
Conway, P 318, 319<br />
Cook, K 1417<br />
Cook, R 2098<br />
Cook, RR. 1186<br />
Cooke, JP. 447<br />
Coolican, M 1740<br />
Coomer, B 888<br />
Cooper, C 684<br />
Cooper, GS 804, 1110, 2160<br />
Cooper, GS. 1254<br />
Cooper, RG 1666<br />
Cooper, S 2088<br />
Cope, A 1998<br />
Copel, J 231<br />
Coppéré, B 1645<br />
Coral Alvarado, P 1210<br />
Corbera-Bellalta, M 784<br />
Corbo, M 1798<br />
Corcoran, C 638<br />
CORDIER, J 2024<br />
Cornélis, F 543, 1065<br />
Cornelissen, F 1297<br />
Cornet, PL. N 680<br />
Cornett, M 1268<br />
Cornish, J 756, 1192<br />
Corona, F 222<br />
Corr, M 137, 916<br />
Corrigall, VM 1589<br />
Corsi, T 923, 1745, 1766<br />
Corti, L 2145<br />
Cortis, E 248, CRC01<br />
Corvol, M 718<br />
Cosan, F 812<br />
Cosgrove, AC 707<br />
Cosman, F 618<br />
Cosman, F 2138<br />
Cosman, F 1547<br />
Costa, GP. 1204<br />
Costa, IP. 1204<br />
Costa, P 1712<br />
Coste, J 1244, 1511<br />
costedoat, n 1125<br />
Costedoat-Chalumeau, N 1123, 1946<br />
Costenbader, KH 360, 2043, 2150<br />
Cöster, L 260<br />
Cöster, L 1535<br />
Costner, M 450, 2071<br />
Cotsapas, C 2121<br />
Couoh-Hernandez, L 192<br />
Courteau, J 826<br />
Courtenay, B 1740<br />
Covucci, A 679, 680, 1039<br />
Cox, DP 1092<br />
Cox, SMargaret 1259<br />
Cox, V 739<br />
Cox, VL. 161, 183<br />
Coyle, A 1315<br />
Coyle, AJ 46, 132, 429, 512, 840,<br />
1417<br />
Coyle, A 2134<br />
Coyle, A 2135<br />
Coyle, K 1655<br />
Cozzi, F 65<br />
Cozzi, L 592<br />
Craft, J 1613<br />
Craft, J 1311<br />
Craft, N 1573<br />
Craggs, JG. 1538<br />
Cramer, JA. 1556<br />
Cramp, F 2045<br />
Cranney, A 2141<br />
Cravets, M 267<br />
Cravioto, M 1107, 1921<br />
Cremer, MA 1765<br />
Crespo-Pagnussat, SM. 1376<br />
Cresswell, L 507<br />
Crisman, C 1353<br />
Criswell, LA 1092<br />
Criswell, LA 743, 838, 850, 1256,<br />
1972, 2055<br />
Crofford, LJ 115, 1069, 1584, 1763<br />
Croft, P 193, 1275, 2102<br />
Croll, SD 755<br />
Cron, RQ 247, 1979<br />
Cronstein, BN 41, 42, 156, 780<br />
Cross, A 1600<br />
Cross, M 1740<br />
Cross, M 1740<br />
Crow, MK 511, 512, 872, 1358, 1602,<br />
1713<br />
Crow, MK. 513<br />
Crowe, SR 1581<br />
Crowson, CS 663, 1732<br />
Crowson, CS. 683, 1004, 1052, 1880,<br />
2185<br />
Crusius, JB.A. 380<br />
Cruwys, S 1772<br />
Cruz-Robles, D 104, 1752<br />
Csuka, ME 1208<br />
Csuka, M 26, 2163, 2165<br />
Cuadrado, MJ 2057<br />
Cucchiara, A 2092<br />
Cucho, M 816, 1578<br />
Cuckson, C 1396<br />
Cudrici, C 1966<br />
Cugno, M 962<br />
Cui, J 341, 537, 1064, 1889<br />
Cukier, FL 1013<br />
Cullinane Carli, C 297, 1808<br />
Cullis-Hill, D 1685<br />
Cummings, S 201, 623<br />
Cunninghame Graham, DS 811<br />
Cuoghi, I 373<br />
Cupples, LAdrienne 2039<br />
Curley, LL. 510<br />
Curran, J 861, 862, 863<br />
Curry, E 798, 1152, 1913<br />
Curtis, J 200, 282<br />
Curtis, JR 213, 214, 636, 1024, 1552,<br />
1553, 1554, 1703<br />
Curtis, J 123<br />
Curtis, J 2062<br />
Curtis, JR 310, 635<br />
Curtis, SP 1690<br />
Cushing, E 1424<br />
Cutolo, M 333<br />
Cutolo, M 270, 964<br />
Cutolo, ME 1203<br />
Cutro, MS 606<br />
Cutter, G 1992<br />
Cuttica, R 2178<br />
Czarny, A 791, 795<br />
Czirjak, L 1, 30<br />
D<br />
D’Agostino, MA 564<br />
D’Alfonso, S 1973<br />
D’Angelo, S 610<br />
D’Anjou, M 661<br />
D’Cruz, D 507, 508, 509<br />
D’Cruz, DP 441, 1229, 1411, 1933<br />
D’dorsi, E 1891<br />
D’Onofrio, M 653<br />
D’Osualdo, A 2082<br />
D’Souza, A 1080, 1081, 1957<br />
370
D’Souza, DN 1543<br />
D’Agostino,, M 662<br />
D’Alleva, PR 1127<br />
D´Álmeida, V 1391<br />
Da Silva, C 348<br />
Dabbous, O 82, 174, 285, 970, 971,<br />
989, CRC13, CRC14, CRC17, CRC28,<br />
CRC29, CRC30, CRC31, CRC34,<br />
CRC35, CRC36, CRC39, CRC40,<br />
CRC42, CRC43, CRC47, CRC50<br />
Dabrowski, C 215, 2077<br />
Dackhammar, C 260<br />
Dadabhoy, D 126<br />
Dadoniene, J 1821<br />
Dagna, L 1234<br />
Dahle, C 1455<br />
Dahmen, R 2036<br />
Dai, L 1068, 1356<br />
Daikeler, T 28, 1572<br />
Daisuke, H 1016<br />
Dajee, M 939<br />
Dal Monte, P 274<br />
Dal Porto, J 1749<br />
Dalbeth, N 756, 1192, 1624, CRC23<br />
Dall’Acqua, W 1417<br />
Dallob, AL 276<br />
Dalphin, M 1906<br />
Dalsky, GP 665<br />
Daly, MJ 2121<br />
Damle, A 1794<br />
Damoiseaux, R 2101<br />
Damschroeder, M 1417<br />
Danielides, S 872<br />
Daniels, T 1092<br />
Danilevicius, CF 1469, 1560<br />
Dankbar, B 367, 392<br />
Dankó, K 1070, 1837<br />
Dankof, A 1079<br />
Daragon, A 543, 961, 1892<br />
Darah, G 630<br />
Darnell, A 1931<br />
Darnell, S 912<br />
Dasgupta, B 706<br />
Dasic, G 1546<br />
Dass, S 1094<br />
Dastmalchi, M 1656, 1671<br />
Dattani, I 1679<br />
Dauser, D 1328, 1332<br />
Davatchi, F 1232, 1233<br />
Dave, M 782<br />
Daveau, R 543, 1428, 1892<br />
Davey, MP. 1742<br />
Davì, S 233<br />
David, JR 1756<br />
Davidson, A 1409, 1473<br />
Davidson, J 908, 909<br />
Davidson, TS 1987<br />
Davies, L 743, 2121<br />
Davies, LR.L. 811<br />
Davies, L 1504<br />
Davies, R 215<br />
Davies, RJ 441<br />
Davignon, J 541<br />
Dávila, L 1133<br />
Davis, AM 2028<br />
Davis, A 1262, 1495<br />
Davis, AM 1485, 1500, 1702<br />
Davis, C 231<br />
Davis, H 1596<br />
Davis, JC 559, 1321<br />
Davis, JC. 581, 612, 1179, 1186<br />
Davis, JM. 1004, 1880<br />
Davis, L 1194<br />
Davis, SA 1561<br />
Davis for the ATLAS Study Group, J<br />
1160, 1494<br />
Dawes, P 2086<br />
Dawson-Hughes, B 203<br />
Dawson-Hughes, B 199, 2049<br />
Day, AJ 1481<br />
Day, C 641<br />
Dayer, J 65<br />
De Abreu, P 350<br />
De Agustín, J 1029<br />
De Almeida, C 2058<br />
De Andrés, MC 1451<br />
De Angelis, V 1404<br />
De Bakker, DH 765<br />
De Bandt, M 1295<br />
de Bazelaire, C 31<br />
De Benedictis F, Martino S, Breda L,<br />
Stenboeg E, P, a 891<br />
de Blas, G 1646<br />
De Boer, TN 1683<br />
de Bruyn, M 675<br />
de Carvalho, A 1042<br />
De Clerck, L 324<br />
De Cobelli, F 1234<br />
de Cortie, CJ. 933<br />
De Feo, F 372<br />
De Gendt, CMA 90, 299<br />
de Jong, Z 2104<br />
de Jonge, WJ. 771<br />
de Jonge-Bok, JM. 300<br />
De Keyser, F 324, 325, 1434, 1439,<br />
1493, 1829<br />
de Koning, HD 856<br />
de la Red, G 1402<br />
De la Torre, I 1898<br />
de Launay, D 138<br />
de Leeuw, K 1196, 1964<br />
De Leonardis, F 279<br />
De Libero, C 226<br />
de los Reyes, M 429, 430, 840<br />
de Man, YA 1838<br />
de Martino, M 226, 632<br />
De Miguel, E 600, 604, 646, 1626<br />
de Miguel- Mendieta, E 603<br />
De Miguel-Mendieta, E 613<br />
De Nijs, RNJ 626<br />
De Pablo, P 352, 759<br />
de Portu, S 606<br />
de Rooij, DRAM 90, 299<br />
de Rooij, M 1273<br />
De Rycke, L 1439<br />
De Santis, M 23, 1223<br />
de Sonnaville, PB.J. 697<br />
De Vita, S 272<br />
De Vlam, K 1493<br />
De Vlam, KL 1182<br />
de Vogel, L 675<br />
de Vries, N 380<br />
de Vries-Bouwstra, JK. 256, 697<br />
De-Brum Fernandes, AJ 826<br />
Deal, CL 617<br />
Deane, K 1289<br />
Deane, KD 748<br />
Deanfield, JE 1411<br />
Deback, C 151<br />
Debandt, M 1249<br />
Debord, J 432, 1123<br />
Debre, P 1970<br />
DECHELLOT, P 1093<br />
Dechow, FJ 26<br />
Dechow, FJ. 2163, 2165<br />
Decramer, S 880<br />
Dedrick, R 762<br />
Dees, C 43, 2147<br />
Deforce, D 1325, 1434, 1829<br />
DeFranco, AL 418<br />
Defranoux, N 1802<br />
Degar, BA 1714<br />
Degive, C 1652<br />
Degotardi, PJ. 1382<br />
DeGroot, J 1457<br />
DeGroot, P 1410<br />
DeGuire, P 721, 798, 1152, 1260,<br />
1913<br />
DeGuzman, MM 878<br />
Dehlin, MI 365<br />
Dejaco, C 1243<br />
Dekker, J 765, 1273, 1274, 2036<br />
del Amo, J 1887<br />
Del Galdo, F 51, 52, 1211, 2058<br />
Del Giudice, J 695, 1432<br />
Del Maschio, A 1234<br />
Del Nagro, C 1749<br />
Del Papa, N 2145<br />
del Pino, J 1090<br />
del Rey, A 1747<br />
del Rey, MJ 1472<br />
del Rincon, I 289, 1056<br />
Del Ry, S 1213<br />
Del Valle, L 851, 1787<br />
Delaney, TA 46<br />
Delaporte, E 593<br />
Delavallee, L 915<br />
DeLay, ML 1283<br />
Deleault, KM. 2132<br />
Deleuran, B 770<br />
abstract author Index<br />
371
abstract author Index<br />
Deleuran, BW 1769<br />
Delferriere, D 738<br />
Delfino, L 249<br />
Delgado Alves, J 1411<br />
Delgado-Vega, AM 842<br />
Deligny, C 29, 31<br />
Della Rossa, A 1213<br />
Dellaripa, PF 2014<br />
Dellarippa, PF 2000<br />
Dellinger, W 22<br />
Delluc, A 151, 1242, 1629, 2002<br />
Delmas, P 619, 623<br />
Delmas, PD 618, 2140<br />
Deloukas, P 559, 1321<br />
Delpech, M 565<br />
Delzell, E 635, 636, 1552, 1554<br />
DeMarco, PJ 1575<br />
Dember, L 1296<br />
Demir, C 133<br />
Demo, S 939<br />
Deng, G 1744<br />
Dennis, G 428, 1315<br />
Denny, MF 522<br />
Dent, PB 242<br />
Dentel, N 1487<br />
Denton, CP 1374<br />
Denton, C 30, 63, 2146<br />
Denton, CP 3, 9, 14, 45, 1199, 1200,<br />
1225, 2162, 2164, 2167<br />
Denton, CP. 57<br />
Denys, A 915<br />
Deodhar, A 288, 944, 1154<br />
Deodhar, A 1153<br />
Deodhar, AA 125<br />
DePablo, P 648, 1900<br />
Deprez, P 1156<br />
Derikx, HJ.G.M. 1548<br />
Derk, CT 15, 20, 1208<br />
Derk, C 1212<br />
DerMovsesian, A 270<br />
Dernis, E 1652<br />
Desai, S 1573<br />
DeSanctis, J 1609<br />
Descalzo, M 834<br />
Descloux, E 223, 880<br />
Desmoulins, F 1089<br />
Desmurs-Clavel, H 1645<br />
DeSouza, Y 1092<br />
Dessole, G 574<br />
DeStefano, AL 537<br />
Deswaef, A 629, 1557<br />
Detert, J 314, 650<br />
Detmar, M 2123<br />
Detrano, R 998, 1007, 1341<br />
Deuter, C 1241<br />
Devarajan, P 234, 235<br />
DeVellis, R 2048<br />
DeVellis, RF. 2042<br />
Devesa-Giner, I 1300<br />
Devine, AB 1317<br />
Devlin, J 1502<br />
Devogelaer, J 625, 738<br />
Devore, MD. 492<br />
Dewulf, L 324<br />
Dhaenens, M 1325<br />
Dhar, JPatricia 1106<br />
Dhar, JPatricia 798, 1152, 1913<br />
Dhote, R 1244<br />
Di Iorgi, N 904<br />
Di Maggio, A 592, 1640<br />
Diaconu, DA 995<br />
Dial, EJ 860<br />
Diamond, B 244, 419, 1133, 1318<br />
Diamond, S 1658<br />
Diasparra, J 790<br />
Diatchenko, L 103<br />
Diaz, M 47<br />
Diaz-Torne, C 1009, 1068, 1356,<br />
1542<br />
Diboll, J 1985<br />
Dick, J 567<br />
Dick, W 1698<br />
Dickens, C 1491, 1498, 1530<br />
Dickson, MC 1066<br />
Didelot, R 744<br />
Diehl, MP 669, 735<br />
Diekman, L 560<br />
Diemert, MClaude 151<br />
Dieppe, P 97, 835, 1499, 1702<br />
Dieudé, P 543, 1033<br />
Diez-Merchán, I 1898<br />
Dignat-George, F 1474<br />
Dijkmans, BAC 959, 1160, 1494<br />
Dijkmans, B 639, 1705<br />
Dijkmans, BA C 965, 1804<br />
Dijkmans, BA. 300, 1020, 1831<br />
Dijkmans, BA.C. 39, 256, 380, 697,<br />
1161, 1548<br />
Dijkmans, BAC 581, 693<br />
Dimic, A 670, CRC37<br />
Dinarello, CA 871, 1305<br />
Ding, B 539, 545, 1061<br />
Ding, C 637<br />
Dinnall, J 415<br />
Dinnella, JE 1627<br />
Dintinger, H 1576<br />
DiPaolo, RJ 1987<br />
DIRESKENELI, H 1027, 1173, 1635,<br />
2019<br />
Diri, E 715<br />
DiSipio, C 877<br />
Diskin, K 426<br />
Distler, J 1762, 2003<br />
Distler, JHW 44<br />
Distler, JH.W. 43, 2147<br />
Distler, JHW 2149<br />
Distler, O 43, 44, 2147, 2149, 2164<br />
Dixey, J 321<br />
Dixon, MF 263<br />
Dixon, WG 976, 1343<br />
Docampo, E 1444<br />
Dodick, T 522<br />
Doerfling, P 1507<br />
Doering, G 948<br />
Doerner, T 1079<br />
Doherty, M 2051<br />
Doherty, S 662<br />
Dolhain, RJ.E.M. 1838<br />
Dominguez, N 1287<br />
Domino, SE 707, 1475<br />
Domsic, RT 2, 1292<br />
Donald, AE 1411<br />
Donaldson, KJ 1937<br />
Dong, J 150<br />
Dong, W 819, 825<br />
Dong, W 1909<br />
Dong, Y 1092<br />
Dong-hui, Z 1886<br />
Donley, DW 665<br />
Donn, R 2120, 2122<br />
Donnelly, S 1610, 1833<br />
Donohue, J 1684<br />
Donovan Hanson, K 722<br />
Doodes, PD 1301<br />
Dooley, MA. 1960<br />
Dorai Raj, AK 1174<br />
Dore, C 19<br />
Dore, R 944<br />
Dore, RK. 953<br />
Dorgham, K 1970<br />
Doria, A 535<br />
Dormont, D 1946<br />
Dorner, T 1413, 1431<br />
Dorri, Y 1081<br />
Dorris, ML 566, 1326<br />
Dosekun, AK 1207<br />
Dostal, C 1973<br />
Dou, X 40<br />
Douda, T 1035<br />
Dougados, M 258, 267, 950, 1494<br />
Dougados, M 662, 1162, 1249, 1485<br />
Dougados, MR 2088<br />
Douglas, J 1130<br />
Doveri, M 991<br />
Dow, T 630<br />
Doward, LC 1701<br />
Dowd, JE 888<br />
Doyle, DV 263<br />
Doyle, MK. 988<br />
Dozmorov, I 1724, 1725<br />
Drachenberg, C 1966<br />
Dragovic, R 2065<br />
Dragun, D 1215<br />
Drange, S 2110<br />
Dreher, DS 1674<br />
Dreiser, RLiliane 1674<br />
Drenkard, C 505, 506<br />
Drezner, MK. 1544<br />
Drosos, A 333<br />
Drosos, A 295<br />
372
Drosos, AA 1005, 1914<br />
Drynda, S 1827<br />
Du, J 860<br />
Du, YZhu 1091<br />
Duan, R 715, 1524<br />
Duarte, AL.B. 1204<br />
Dube, S 1827<br />
Dube, T 819, 825<br />
Dubertret, L 593<br />
Dubner, SE 2177<br />
DUBOC, D 2024<br />
Dubois, RW 1120<br />
Dubourg, O 1652<br />
DUCROIX, J 705, 1227, 1240<br />
duffau, p 1366<br />
Duffy, EM 1317<br />
Dufour-van den Goorbergh, BC.M.<br />
1838<br />
Duftner, C 1243<br />
Dugan, E 2071<br />
Dugan, EM 1659<br />
Dugowson, C 26<br />
DUHAUT, P 705, 1227, 1240<br />
Dummer, W 695<br />
Dumoulin-Richez, C 203<br />
Dunbar-Jacob, J 2050<br />
Duncan, R 193<br />
Dunham, J 1904<br />
Dunker, S 1378<br />
Dunlop, D 210, 211, 212, 741<br />
Dunlop, DD 817, 836<br />
Dunstan, CR 2065<br />
Dunstan, R 1890<br />
Duong, TT. 1728<br />
Dupré, B 2189<br />
Duquesne, A 253, CRC02<br />
Duquesroix, B 1678<br />
Durán, CE 1393<br />
Durán, S 1138, 1139, 1919<br />
Durand, J 871<br />
Durand, J 869<br />
Durez, P 324, 1796, 1801<br />
Durham, R 572<br />
Durieu, I 223<br />
Duryea, J 648, 664<br />
Dussault, P 1561<br />
Dutz, JP 2100<br />
Duval, N 1463<br />
Duymaz Tozkir, J 843<br />
Dwivedi, RC 554<br />
Dwyer, D 1767<br />
Dyer, AR 2159<br />
Dziedzic, KS 2102<br />
Dzikaite, V 1727<br />
Dziurla, R 1482<br />
E<br />
Ea, H 1048<br />
Eardley, L 1311<br />
Eastell, R 618<br />
Eastell, R 623<br />
Eastwood, M 57<br />
Eastwood, M 2146<br />
Eberhardt, K 983<br />
Ebina, K 1677<br />
Echtermeyer, F 1456, 2110<br />
Eckman, M 1510<br />
Eckstein, F 210, 211, 212, 657,<br />
658, 659<br />
Ecosse, E 1511<br />
Edberg, J 2128<br />
Edberg, JC 514, 2000, 2014, 2124<br />
Edberg, JC. 499, 1131, 1138<br />
Edelman, SD 776<br />
Edgar, M 926<br />
Edge, K 1198<br />
Edmonds, JP 2151<br />
Edmundowicz, D 2159<br />
Edwards, CJ 684<br />
Edwards, MC 2042<br />
Edwards, S 1600<br />
Eekman, DA 1548<br />
Efde, M 580<br />
Egido, J 1751<br />
Eguchi, K 353, 386, 1294, 1611, 1840<br />
Egurbide, MVictoria 1395<br />
Ehresmann, G 124<br />
Eichenfield, A 1384<br />
Eichenfield, AH 877, 882<br />
Eid, H 1741<br />
Eid, P 1360<br />
Eijbouts, A 995<br />
Einhorn, E 1542<br />
EIRA Study Group, 545<br />
Eisenberg, DF. 504, CRC33, CRC44<br />
Eisenberg, D 1120<br />
Ejbjerg, B 2180<br />
Ekblad, L 1778<br />
Ekindjian, O 1373<br />
Eklund, A 359<br />
Eklund, K 273<br />
Ekman, EF 1734<br />
Ekström, G 1778<br />
El-Gabalawy, H 747, 1049, 1836<br />
El-Gabalawy, HS 554, 2183<br />
Elashoff, R 134<br />
Elbaum, D 918<br />
Elden, A 268<br />
Eldestein, D 1738<br />
Eldin, KW 878<br />
Eldredge, D 1541<br />
Elelwaut, D 1829<br />
Elewaut, D 558, 1325, 1434<br />
Elfving, Å 1359<br />
Elhalal, U 2094<br />
Elhasanein, KF 1951<br />
Elias, B 1049, 1836<br />
Eliopoulos, E 844, 848<br />
Elisa, M 1850<br />
Elisaf, M 1005<br />
Elkan, A 264<br />
Elkayam, O 873, 1025, 1533<br />
Elkon, K 1958<br />
Elkon, KB 69, 1309, 1760<br />
Elkon, KB. 411<br />
Ell, C 1680<br />
Elligsen, T 1881<br />
Ellingsen, T 1042<br />
Ellingsen, T 154, 1785, 1786, 2180<br />
Ellis, A 1740<br />
Ellison, RC 805<br />
Ellison, R 685<br />
Ellison, WT. 1689<br />
Ellman, M 861, 863<br />
Ellsworth, J 242<br />
Elmore, SW 1989<br />
Eloranta, M 515, 1359<br />
Eltringham, MS 910<br />
Elzinga, EH 693<br />
Emamian, ES 1100<br />
Emani, S 631<br />
Emdin, M 1213<br />
Emery, HM 905, 1381<br />
Emery, P 261, 262, 950<br />
Emery, P 14, 257, 266, 327, 564,<br />
660, 1094, 1157, 1163, 1200, 1701,<br />
1841, 1932, 2088, 2120, 2122<br />
Emi, M 1878, 2181<br />
Emkey, R 1545<br />
Emkey, RD. 620, 621<br />
Emmett, C 321<br />
Emmons, J 2132<br />
Emrani, PS 84, 1693<br />
Enama, J 1839<br />
Endean, AL 684<br />
Endou, H 1619<br />
Endreffy, E 1973<br />
Endres, R 1047<br />
Enghard, P 405, 406, 1954<br />
English, NJ 731<br />
Englund, M 742<br />
Englund, M 204<br />
Enokihara, MMaria Simões Silva 1361<br />
Enriquez, E 7, 1221<br />
Epidemiological Investigation of<br />
Rheumatoid Arthri, t 2121<br />
Epstein, S 1545<br />
ERCILLA, G 1901<br />
Erdozain, JG 1395<br />
Erekul, K 1482<br />
Erer, B 812<br />
Ergin, S 275<br />
Erickson, J 414<br />
Eriksen, E 623, 666<br />
Eriksen, EF 618, 619<br />
abstract author Index<br />
373
abstract author Index<br />
Eriksson, C 1002, 1003<br />
Erkan, D 1398<br />
Erlandsson Harris, H 2067<br />
Ernestam, S 260<br />
Ervin, JE. 1689<br />
Esbjörnsson, M 1656<br />
Escalante, A 289, 1056<br />
Escriou, V 2137<br />
Esdaile, J 1507<br />
Esdaile, J 2100<br />
Esdaile, JM 1272<br />
Esen, B 1178<br />
Eskiyurt, N 275<br />
Espada, G 233<br />
Espigol, G 128, 784, 1230, 1483<br />
Espinosa, A 1359<br />
Espinosa, G 1388, 1389, 1395, 1397,<br />
1402, 1403, 1931<br />
Espinosa, V 1385<br />
Espinosa-Morales, R 192<br />
Espinoza, LR 27, 1354<br />
Esposito, D 2112<br />
Essenmacher, L 1106<br />
Esserman, D 689<br />
Eto, Y 1466, 1558<br />
Ettlin, D 246<br />
Ettner, SL 1736<br />
EuDaly, J 420<br />
Eugene, E 1356<br />
Eugene, HS. 510<br />
Eugui, EM 1749<br />
Eulie, B 884<br />
EULLER-ZIEGLER, L 972<br />
Eusebio, R 2140<br />
Eva, P 334<br />
Evans, DM 1321<br />
Evans, HG 1302, 1588<br />
Evers, AW.M. 1492<br />
Exarchou, S 333<br />
Eyre, S 2120, 2122<br />
F<br />
F, F 891<br />
F, R 200<br />
Fabbri, C 1127<br />
Fabri, V 629, 1557<br />
FAIN, O 1244, 2024<br />
Fakharzadeh, SS 2071<br />
Falçao, S 600<br />
Falcini, F 222, 226, 632, 1731, 2178<br />
Falk, RJ 2023<br />
Fall, N 1281<br />
Fallon, R 761<br />
Fama, TA 162<br />
Fan, Z 1463<br />
Fangradt, M 1482<br />
Fantini, F 11, 12, 962, CRC16<br />
Fardellone, P 543, 1428, 1892<br />
Farewell, V 507, 508, 509<br />
Farewell, V 1960<br />
Farewell, VT. 2097<br />
Farge, D 28, 29, 30, 31<br />
Farge Bancel, D 1<br />
Farkas, B 920<br />
Farkas, G 306<br />
Farnarier, C 871, 1474<br />
Farnetti, E 788, 1231, 1805<br />
Farraccioli, GF 98<br />
Farragher, TM 320, 1000, CRC06<br />
Fasanmade, A 956<br />
Fasoli, E 2145<br />
Faßold, A 1628<br />
Fasth, AE. R. 1671<br />
Fatenejad, S 265, 1022<br />
Fathalla, BM 887<br />
Fatima, F 1014<br />
Faucon, B 541<br />
Faure, G 1576<br />
Fautrel, B 73, 75, 767<br />
Fava, RA 1078<br />
Favalli, E 962<br />
Fawcett, PT 240, 241, 894, 2176<br />
Fawcett, PT. 2175<br />
Faye, A 253<br />
Fazio, S 1146<br />
Fearon, U 746<br />
Fearon, U 797, 1603, 1604<br />
Febrônio, MV 879<br />
Fechtenbaum, J 738<br />
Fedele, AL 373<br />
Federici, S 2082<br />
Feghali-Bostwick, CA 53, 54, 55<br />
Fehringer, EV 982<br />
Feierl, E 434, 516, 517<br />
Feingersh, D 1984<br />
Feinstein, DE 1580<br />
Feist, E 1079<br />
Fekete, A 1070, 1993<br />
Feldman, BM 2028<br />
Feldman, DP. 1536<br />
Felici, E 2178<br />
Felson, D 200, 213, 214, 1703<br />
Felson, DT 206, 742, 1694, 2053,<br />
2173<br />
Felson, D 196<br />
Felson, DT 204, 205, 1486, 1700,<br />
2062<br />
Felson, DT. 207, 209, 807<br />
Felson, D 197, 208, 216, 685, 806,<br />
1686<br />
Felt, J 2112<br />
Feng, C 278<br />
Feo, L 1136<br />
Ferbas, J 1422, 1906<br />
Ferbert, S 111, 1531, 1532<br />
Ferenkeh-Koroma, A 1918<br />
Ferguson, PJ 890<br />
Ferlito, F 249<br />
Fernandes, RW 72<br />
Fernández, C 1187<br />
Fernández, C 595<br />
Fernandez, I 409<br />
Fernández, MC 1471<br />
Fernández, M 493, 1140<br />
Fernandez, P 42, 776<br />
Fernandez, V 1316<br />
Fernández-Castro, M 121<br />
Fernandez-Gutierrez, B 847, 1053,<br />
1076<br />
Fernández-Nebro, A 287<br />
Fernandez-Sueiro, J 1175<br />
Fernández-Sueiro, JL 595, 596, 1187,<br />
1188, 1189<br />
Fernández-Sueiro, J 610<br />
Ferraccioli, G 1821<br />
Ferraccioli, G 23, 266, 373, 1223<br />
Ferran, CJ 2133<br />
Ferrara, DE 1336<br />
Ferrari, C 904<br />
Ferreira, AF 184<br />
Ferreira, GA 1128<br />
Ferreiros-Vidal, I 1973, 1974<br />
Ferrera, F 402<br />
Ferri, C 1224<br />
Ferris, N 1610, 1833<br />
Ferrone, C 964<br />
Fert, I 566, 1325<br />
Fertig, N 2, 1666, 2068<br />
Ferucci, ED 1046<br />
Fessler, BJ. 16<br />
FETISSOV, SO 1093<br />
Feudtner, C 247, 889<br />
Feuerman, M 1250<br />
Fèvre, C 1892<br />
Fezatte, HB. 1689<br />
Fiechtner, J 947<br />
Fiechtner, J 1890<br />
Fields, T 1349, 2034, 2041<br />
Fifield, J 1328, 1332<br />
Filaci, G 402<br />
File, EA 617<br />
Filer, AD 562<br />
Filice, A 1228<br />
Filipovich, A 1714<br />
Filipow, PL 655<br />
Filipowicz-Sosnowska, A 947<br />
Filipowicz-Sosnowska, A 1296<br />
Filley, CM. 492<br />
Filocamo, G 227, 904, 913<br />
Finch, MB 1317<br />
Finckh, A 80<br />
Finckh, A 648, 2108<br />
Fine, DM 437<br />
Fine, JS 1748<br />
Finès, P 809, 833<br />
Fineschi, S 65<br />
Finkelstein, A 1533<br />
Finkelstein, JS 638<br />
Finley, E 494<br />
374
Finnegan, A 1301<br />
Fiocco, U 592, 1640<br />
Fiorentino, D 26, 2071, 2163, 2165<br />
Firestein, G 781<br />
Firestein, GS 131, 148, 364, 673,<br />
916, 917, 926<br />
First, DE 1200<br />
Fischbach, M 38<br />
Fish, N 892<br />
Fisher, B 1303<br />
Fisher, C 1674, 1678<br />
Fisher, D 684<br />
Fisher, JE 91<br />
Fishman, P 851, 1787<br />
Fishman, R 1678<br />
Fishoeder, A 1647<br />
Fitzgerald, GKelley 1271<br />
Fitzgerald, J 446<br />
FitzGerald, JD 1736<br />
Fitzgerald, M 551<br />
FitzGerald, O 746, 1181<br />
FitzGerald, O 308, 330, 331, 797,<br />
1183, 1191, 1265, 1266, 1267,<br />
1603, 1604<br />
Flake, AW 1608<br />
Flanagan, W 809, 833<br />
Flato, B 896, 911, 2081<br />
Fleischmann, RM 957<br />
Fleischmann, R 277<br />
Fleischmann, RM 173, 2088<br />
Fleishaker, EL 1763<br />
Flemming, B 1769<br />
Fleson, D 2115<br />
Fletcher, J 2049<br />
Fletcher, T 591<br />
Flics, S 1253, 1384<br />
Fligelstone, K 30<br />
Flinn, D 180, 549<br />
Flint-Wagner, H 1268<br />
FLIPO, R 1673<br />
Florea, L 31<br />
Flores, N 137<br />
Flores, R 1348<br />
Florian, H 1523, 1524<br />
FLORY, P 972<br />
Flouri, I 295<br />
Floyd, P 180<br />
Flynn, JA 610<br />
Foïs, E 28<br />
Foeldvari, I 1, 225, 895, 900, 2164<br />
Fogelman, AM. 1001<br />
Fogg, L 171<br />
Fois, E 2016<br />
Földvari, I 30<br />
Foltz, V 73, 75, 767<br />
Fonseca, AR 879<br />
Fonseca, A 1739<br />
fonseca, c 63<br />
Fonseca, JE 602, 1712<br />
Font, Ronald van Vollenhoven, J<br />
2157<br />
Fontaine, KR 981, 1037<br />
Fontenele, SM. 1204<br />
Foody, JJ 733<br />
for the A9001140 Investigators, 657<br />
for the ATLAS Study Group, 581<br />
for the Autoimmunity Centers of<br />
Excellence, 1102<br />
for the Club Rhumatismes et<br />
Inflammation (CRI), 1249<br />
for the Epidemiology Study Group,<br />
820, 821<br />
for the EUSTAR Group, 1<br />
For the Members of the German<br />
Etanercept Registry, 225<br />
for the Multicenter Osteoarthritis<br />
Study Group, 196<br />
for the other coauthors of the<br />
Omeract Gout StudyG, r 1624<br />
for the other coauthors of the<br />
Scleroderma Clinica, l 2162<br />
for the PACE investigators, 606<br />
for the WGGER Research Group,<br />
2000, 2014<br />
Fored, M 1344<br />
Forns, X 1577, 2006<br />
Førre, Ø 2081<br />
Førre, ØT 1632<br />
Forsbach, A 1596<br />
Forsblad d’Elia, H 1791<br />
Forsblad d´Elia, H 1885, 1947<br />
Forslind, K 260<br />
Forslind, K 1815, 1879<br />
Fortin, PR. 1960<br />
Fortin, P 450<br />
Fortin, PR 502, 804<br />
Fortin, PR. 1115, 1116, 1924, 2157<br />
Fossel, AH 2150<br />
Foster, HE 158, 908, 909, 910<br />
Foster, M 1772<br />
Foster, N 2051<br />
Foster, NE 1251, 2037<br />
Foucher, KC 191<br />
Foucher, KC. 2073<br />
Fougere, L 1130<br />
Fougnie, D 115<br />
Fox, PC 1098, 1099<br />
Fox, PT. 2095<br />
Fox, S 1225<br />
Fragiadaki, K 271<br />
Fragoso, J 104<br />
Fragoso-Loyo, HE 1133<br />
Fragouli, E 844<br />
Frail, DE. 787<br />
Frampton, C 1800<br />
Francès, C 1125, 1630<br />
Francesco, Z 1<br />
Francis, S 798, 1152, 1913<br />
Franck-Larsson, K 17<br />
Frank, C 1181<br />
Frank, E 1307<br />
Frank, M 1181<br />
Frank, M 1710, 1711, 1733<br />
Frank, MBarton 1724, 1725<br />
Frank, M 549<br />
Frank, S 2124<br />
Franklin, C 2095<br />
Franklin, J 820, 821<br />
Frankovich, J 237, 238<br />
Fransen, J 90, 299, 308, 995, 1819<br />
Franzos, G 364<br />
Fraser, A 1163<br />
Fraser, O 1639<br />
Fraser, SM 1650<br />
Frayssinet, H 1678<br />
Fredberg, U 120<br />
Freeston, JE 1841<br />
Freimuth, W 426, 427, 1316<br />
Freire, EA.M. 1204<br />
Freire, M 1189<br />
French, M 1645<br />
French, MR 1499, 1500, 1702<br />
French Vasculitis Study Group, 2013<br />
Frenkel, J 2082<br />
Fresko, I 853, 2019<br />
Freundlich, B 1161<br />
Freundlich, B 305, 344<br />
Frey, D 2076<br />
Frey, N 259<br />
Frey, O 922<br />
Frezza, D 373<br />
Frick, KD 85<br />
Fridman, J 1771<br />
Friedman, DM. 231<br />
Friedman, S 1771<br />
Friend, S 1992<br />
Fries, JF 1516, 2114<br />
Frisch, M 385<br />
Frisoni, L 415<br />
Friswell, M 910<br />
Fritz, J 899<br />
Fritzler, M 1049<br />
Fritzler, MJ 1419<br />
Frommer, K 147<br />
Frostegård, J 264<br />
Fry, K 762<br />
Fu, K 425<br />
Fudman, E 695<br />
Fudman, E 2084<br />
Fuerst, D 1456<br />
Fuerst, M 1456<br />
Fuhrhop, R 921<br />
Fujii, H 362<br />
Fujii, K 344<br />
Fujii, T 495<br />
Fujikawa, K 353, 386, 1840<br />
Fujimoto, M 48, 49, 50, 1209, 1218<br />
Fujio, K 1743<br />
Fujisawa, A 1707<br />
Fujita, Y 495<br />
abstract author Index<br />
375
abstract author Index<br />
Fukae, J 533<br />
Fukae, M 1788<br />
Fukasawa, C 1129<br />
Fukuya, Y 1338<br />
Fuller, R 184, 1127, 1677<br />
Funahashi, K 1878, 2181<br />
Funovits, J 298, 355, 1512, 2152,<br />
2153<br />
Furie, R 427, 1316<br />
Furst, D 261<br />
Furst, DE 987<br />
Furst, DE 1208<br />
Furst, D 30, 134<br />
Furst, DE 14, 266, 294, 643, 726,<br />
958, 1817, 2162, 2164<br />
Furst, DE. 1001<br />
Furuichi, H 540<br />
Furukawa, M 496<br />
Furuya, T 1071<br />
Furuzawa-Carballeda, J 1687, 1752<br />
Fury, W 1282<br />
G<br />
G. Sturfelt, O. Nived, R 1960<br />
Gaber, T 1482, 2065<br />
Gabriel, SE 1735, 2113<br />
Gabriel, SE. 683, 1004, 1880, 2185<br />
Gabrielli, A 1199, 2145<br />
Gadi, V 34, 368<br />
Gaelle, G 1041<br />
Gaffney, PM 1972, 1976<br />
Gaffney, PM. 811<br />
Gaffo, A 16<br />
Gafni, A 1564, 1566<br />
Gagliese, L 1500<br />
Gaines, E 1904<br />
Gal, I 920<br />
Galanopoulou, VK 1910<br />
Galant, C 1796, 1801<br />
Galbiati, V 962<br />
Galdo, F 595, 596, 1187, 1188, 1189<br />
Galdo, F 1446, 1451, 1471<br />
Gale, D 216<br />
Galindo, M 1934<br />
GALINDO, M 1661<br />
Gall, V 80<br />
Gallinaro, AL 906<br />
Gallucci, S 415, 1608<br />
Galy, A 2137<br />
Gamboa, R 816, 1578<br />
Gammill, HS 34<br />
Gandhi, M 699<br />
Ganser, G 225, 900<br />
Gao, H 130, 413<br />
Gao, P 747<br />
Gao, Z 1787<br />
Garau, P 647<br />
Garaux, S 534<br />
Garay, S 2179<br />
Garay Toth, B 30<br />
Garbuz, DS 833<br />
Garcìa, J 1934<br />
Garceau, D 1296<br />
Garces, M 1210<br />
Garcia, E 1268<br />
García, LF 1609<br />
Garcia, P 619<br />
García Castro, M 1898<br />
Garcia-Casares, E 1574<br />
Garcia-Fructuoso, F 104<br />
Garcia-Gonzalez, A 161, 183<br />
García-Hernández, FJ 1648<br />
Garcia-Martinez, A 128, 784,<br />
1230, 1483<br />
Garcia-Melchor, E 1574<br />
Garcia-Munitis, P 913<br />
Garcia-Poma, A 1514, CRC45<br />
Garcia-Vicuña, R 287, 1797<br />
Gardne, S 137<br />
Gardner, E 175<br />
Gardner, L 143<br />
Gardner-Medwin, J 908, 909<br />
Garnero, P 275, 1171, 1696, 1804<br />
Garred, P 385, 1042<br />
Garside, P 1990<br />
Garvin, KL 982<br />
Gary, HS 1235<br />
Gasser, JA 619<br />
Gastaldi, R 904<br />
Gaston, JHill 1994, 1995<br />
Gastonguay, L 1272<br />
Gatell, JM 2006<br />
Gatterova, J 789<br />
Gattorno, M 2179<br />
Gattorno, M 249, 857, 2082<br />
Gatumu, M 1078<br />
Gaudin, P 550<br />
Gaugris, S 688, 1501<br />
Gauldie, J 2134<br />
Gause, D 96<br />
Gaustad, P 896<br />
Gautier, E 1698<br />
Gaxotte, V 1371<br />
Gay, RE 375, 745, 1044, 1059, 1429,<br />
1591, 1597, 1598, 2123<br />
Gay, RE. 44<br />
Gay, S 43, 44, 147, 375, 745, 1044,<br />
1058, 1059, 1063, 1429, 1591,<br />
1597, 1598, 2123, 2147, 2149<br />
Gaydos, J 687<br />
Gayet, A 1892<br />
Gaylis, N 288<br />
Ge, B 722, 724<br />
Geborek, P 260<br />
Geborek, P 295, 727, 980,<br />
1195, 1818<br />
Géher, P 1821<br />
Geisser, ME 1527<br />
Gelber, A 998, 1007, 1341<br />
GEMA Study Group, Fundación<br />
Española de Reumatolog, i 1626<br />
Gendreau, R 716, 1525, 1526, 1537<br />
Gendrel, D 253<br />
Genevay, S 2108<br />
Genovese, M 261, 267, 695<br />
Genovese, MC 262, 699, 942,<br />
943, 957<br />
Genovese, M 327<br />
George, JN 870<br />
George, S 511<br />
Georgiadis, AN 1005<br />
Geraghty, DE 1046<br />
Gerard, HC 1355, 1569, 1570<br />
Gerards, AH. 256<br />
Gerdle, B 1535<br />
Gerl, V 526<br />
Gerlag, D 1306<br />
Gerlag, DM 955, 1775<br />
Gerlag, DM. 1290<br />
Gerling, IC 1765<br />
Gerloni, V 679, 680<br />
Gerloni, V 681, CRC16<br />
Germar, K 521<br />
Gerstein, M 1720<br />
Getsy, JA 1120<br />
Geurts, J 149<br />
Geusens, P 956<br />
Geusens, P 633, 1171, 1433<br />
Geusens, P 127<br />
Geuskens, GA 76, 1492<br />
Ghahramani, N 1988<br />
Ghayur, T 135, 1989<br />
ghillani, p 2002<br />
Ghinoi, A 1228, 1231<br />
Ghosh, AK 2144<br />
Ghosh, P 1685<br />
Giacomelli, C 372<br />
Giambra, V 373<br />
Gianelli, U 2145<br />
Giani, T 226, 632<br />
Giannessi, D 1213<br />
Giannini, C 1237, 1238<br />
Giannini, EH 679, 680, 682, 960<br />
Giannini, E 681, 2162<br />
Giannini, EH 895, 1282<br />
Gibbs, A 1191<br />
Gibson, DS 1716, 2078<br />
Gignac, M 77, 1262, 1495, 2026<br />
Gignac, MA. 304<br />
Gil, A 1090<br />
Gil, KM 1383<br />
Gilbert, A 2163, 2165<br />
Gilbert, D 543, 1428<br />
Giles, B 1715<br />
Giles, I 1408<br />
Giles, I 1333, 2093<br />
Giles, J 996, 997, 998, 1007, 1341<br />
Giles, JT 126, 992, 1017, 1037<br />
Giles-Komar, J 274<br />
376
Gilhooley, NM 731<br />
Gilkeson, GS 1364<br />
Gilkeson, G 423, 1426<br />
Gilkeson, GS 839, 1111, 2184<br />
Gilkeson, GS. 420, 1254, 1593, 1949<br />
Gill, G 645, 694<br />
Gilliam, BE 901, 903<br />
Gillis, J 78, 232, 1503, 2118<br />
Gillott, TJ 1631<br />
Gilmer, K 285, CRC13, CRC14<br />
Ginawi, A 974<br />
Ginsburg, S 1510<br />
Ginzler, E 427, 1316<br />
Ginzler, E 1960<br />
Ginzler, E 450<br />
Ginzler, EM 431<br />
Ginzler, EM. 521, 1115, 1116, 2157<br />
Gioannini, TL 2010<br />
Gioe, T 1699<br />
Girard Madoux, M 1645<br />
Girardi, G 1335<br />
Girardin, SE 2130<br />
GIRAUDEAU, B 1673<br />
Giri, B 152<br />
Girschick, H 900<br />
Girschick, HJosef 1721<br />
Giuggioli, D 1224<br />
Giuliano, T 372<br />
Gladman, D 583<br />
Gladman, D 1960<br />
Gladman, D 450, 502, 610, 1495,<br />
1924<br />
Gladman, DD 557, 597, 1322<br />
Gladman, DD. 1115, 1116, 1117,<br />
1143, 1186, 1190, 2096, 2097,<br />
2098, 2157, 2170<br />
Glant, TT 849, 920, 1742<br />
Glass, DN 1281, 2079, 2080<br />
Glass, DN. 1709<br />
Glass, JM 110, 112, 114, 115<br />
Glass, R 341, 537, 638, 1889<br />
Glass, RJ 1064<br />
Glatigny, S 566<br />
Glenn, SB 1945<br />
Glenwick, DS. 1382<br />
Glick, H 74<br />
Glick, L 1350<br />
Glickstein, LJ 1352<br />
Gliddon, A 19<br />
Gluckman, E 28<br />
Godang, K 2081<br />
Godeau, B 1124<br />
Godo, JR 121<br />
GOEB, V 543, 961, 1428<br />
Goehring, E 1909<br />
Goekoop-Ruiterman, YP.M. 256, 697<br />
Goel, N 306<br />
Goelz, E 1688<br />
Goeppinger, J 723<br />
Goess, C 414<br />
Goetzel, R 1255<br />
Goetzel, RZ 79<br />
Gogus, F 670, CRC37<br />
Gogus, F 275, 1031<br />
Going, S 1268<br />
Golan, K 2034<br />
Gold, M 1675<br />
Goldbach-Mansky, R 219, 678,<br />
874, 2027<br />
Goldblatt, F 1135<br />
Golden-Mason, L 1603<br />
Goldenberg, D 1526<br />
Goldenstein-Schainberg, C 679, 680<br />
Goldenstein-Schainberg, C 902,<br />
906, 1726<br />
Goldin, J 134<br />
Goldman, J 1118, 1916<br />
Goldsmith, DP. 887<br />
Goldstein, E 939<br />
Golightly, YM 808<br />
Gollasch, M 1215<br />
Golmia, AP 1842, 1895<br />
Golmia, R 1739<br />
GÓMARA, M 1901<br />
Gomariz, RP 1040<br />
Gomes Pedro, J 1712<br />
Gomez de la Concha, E 1053, 1076<br />
Gomez Reino, JJ 263<br />
Gomez Vaquero, C 1894<br />
Gómez-Puerta, J 561<br />
GOMEZ-REINO, F 1661<br />
Gomez-Reino, JJ 332, 334, 1445,<br />
1973, 1974<br />
Gomez-Vaquero, C 1009, 1184,<br />
1356, 1542<br />
Gommerman, JL 1423<br />
Gonçalves, C 1677<br />
Gonçalves, R 902, 1950<br />
González, A 1983<br />
Gonzalez, A 1445, 1973, 1974<br />
Gonzalez, C 1175<br />
González, JA. 332<br />
Gonzalez, J 395, 1421<br />
Gonzalez, L 1225<br />
González, LA 493, 1140<br />
González, LA. 1919<br />
González-Álvaro, I 1797<br />
González-Díaz de Rábago, E 1898<br />
Gonzalez-Escribano, F 1973<br />
González-Fernández, C 1898<br />
Gonzalez-Gay, MA 1245, 1626<br />
González-Rivera, J 1884<br />
Gonzeles, L 180<br />
Gooberman-Hill, R 97<br />
Goodacre, JA 752<br />
Goodacre, L 752<br />
Goodall, J 1937<br />
Goodfield, M 1374<br />
Goodman, RA 963<br />
Goodman, S 681, 895<br />
Goodpaster, BH 2075<br />
Goodson, NJ 1014, 1198<br />
Goodwin, SP 905, 1381<br />
Gøransson, LG 456<br />
Gordon, C 503, 507, 508, 509, 1918<br />
Gordon, C 1960<br />
Gordon, C 450, 1932<br />
Gordon, CP. 1115, 1116<br />
Gordon, CP. 2157<br />
Gordon, D 599<br />
Gordon, KB 959, 960<br />
Gordon, RD. 1689<br />
Gorelik, G 1365<br />
Gorevic, PD 1296<br />
Gorochov, G 1970<br />
Goronzy, JJ. 362<br />
Gosch, C 1992<br />
Gossec, L 670, CRC37<br />
Gosset, M 1447<br />
Gota, C 802<br />
Goto, D 371, 387, 412, 671, 793,<br />
914, 934, 1083, 1753, 1759<br />
Gottenberg, J 1051, 1087, 1089,<br />
1249, 1360<br />
Gottlieb, AB 960<br />
Gottlieb, B 1709<br />
goulevestre, c 1366<br />
Goulielmos, GN 844, 848<br />
Goupille, PM 1181<br />
Goupille, P 1033, 1051<br />
Gourh, P 36, 37, 38<br />
Gourley, M 1658<br />
Gourraud, P 541<br />
Goutman, S 862, 863<br />
Govoni, M 279<br />
Grabiec, A 145<br />
Grace, PJ 112<br />
Gracely, RH 103, 106, 108, 109, 110,<br />
112, 114, 713, 714<br />
Gracia-Criado, A 1403<br />
GRAELL, E 1887, 1901<br />
Graf, W 17<br />
Graham, RR 811, 2055<br />
Graham, T 885<br />
Graham, T 236<br />
Grainger, A 197<br />
Grainger, A 651<br />
Grainger, AJ 660<br />
Granados, P 350<br />
Granath, F 1344<br />
Granel, B 1212<br />
Granfors, K 569<br />
Grange, L 550<br />
Grange, S 259<br />
Graninger, WB 434, 1454<br />
Grant, AV 747<br />
Grau, J 128<br />
Grauel, E 137<br />
Gravallese, E 638<br />
Grayson, PC. 207<br />
abstract author Index<br />
377
abstract author Index<br />
Graziani, D 2145<br />
Greenberg, J 99, 282, 310, 987<br />
Greenberg, J 846, 958, 1817<br />
Greenberg, L 1348<br />
Greenfield, E 1359<br />
Greenspan, D 1092<br />
Greenspan, JS 1092<br />
Greenspan, S 2138<br />
Greenwald, M 267, 288<br />
Greenwald, M 257, 272<br />
Greenwell, C 1320<br />
Greenwood, CM. T. 804<br />
Gregersen, P 762<br />
Gregersen, PK 539<br />
Gregersen, PK 555, 743, 850, 1794,<br />
2055, 2056, 2121<br />
Gregoire, L 1106<br />
Gregory, J 26, 2165<br />
Gregory, K 756<br />
Greidanus, NV 833<br />
Greidinger, EL 409, 1376, 1634<br />
Gremese, E 373<br />
Grennan, D 752<br />
Grenzig, W 1487<br />
Greve, JM. D. 1563<br />
Greve, OJ 456<br />
Grevers, L 1460<br />
Grevers, LC 129<br />
Griep, EN 578<br />
Grier, A 331, 1183<br />
Griffin, F 113<br />
Griffin, T 1281<br />
Griffin, TA. 1709<br />
Griffini, S 962<br />
Griffith, JF 1155<br />
Griffiths, B 507, 508, 509, 1918<br />
Griffiths, B 1932<br />
Griffiths, MM 1745, 1766<br />
Griffiths, MM. 923<br />
Grigoryan, M 206<br />
Grimaldi, CM 419<br />
Grimes, I 168, 220, 1291<br />
Grimm, A 492<br />
Gringhuis, SI 769<br />
Grisar, JC 1975<br />
GRISOT, C 972<br />
Groeneboer, S 1685<br />
Grof-Tisza, P 1715<br />
Grollero, M 1203<br />
Grom, A 233<br />
Grom, AA 1281<br />
Grom, AA. 1709<br />
Groner, KH 112, 114<br />
Groot, D 138, 145, 1776<br />
Gross, AJ 418<br />
Gross, KDoug 807<br />
Gross, R 25<br />
Gross, R 1652<br />
Gross, TF 421<br />
Grossi, C 1337<br />
Grossman, J 446, 2091<br />
Grossmann, P 526<br />
Grotle, M 2047<br />
Grove, G 1904<br />
Groves, CJ 1417<br />
Groves, CJ. 46<br />
Groves, C 2134<br />
Gruber, B 26, 2163, 2165<br />
Gruber, H 781, 1614<br />
Gruen, J 1413<br />
Gruen, JR 133<br />
Gruetzkau, A 133, 823, 1413<br />
Grundtman, C 1632, 1784, 2067<br />
Grunewald, J 359<br />
Gu, J 1989<br />
Gu, Y 584<br />
Gualandro, SM 902<br />
Gualtierotti, R 11, 12<br />
Guan, J 835<br />
Guarienti, J 1536<br />
Guedes, LK 1127<br />
Guedes, LK.N. 1019<br />
Guerini, H 662<br />
Guermazi, A 200, 206, 208, 216, 742<br />
Guermazi, A 204, 205, 209, 210<br />
Guerne, P 2108<br />
Guevara, J 228<br />
Guh, D 100<br />
Guillemin, F 73, 1511<br />
GUILLEVIN, L 14, 1199, 1200, 1244,<br />
1373, 2013, 2023, 2024<br />
GUILPAIN, P 2013, 2024<br />
Guis, S 744<br />
Gujrathi, S 695<br />
Gul, A 812, 843<br />
Güler-Yüksel, M 639<br />
Güler-Yüksel, M 1705<br />
Güler-Yüksel, M 300<br />
Gülfe, A 727<br />
Gulko, PS 923, 1766<br />
Gullick, N 348, 611<br />
Gumucio, D 844<br />
Gundle, R 562<br />
Günendi, Z 1031<br />
Gunnarsson, I 1257, 1952, 2169<br />
Gunnarsson, M 1061<br />
Guo, J 927<br />
Guo, L 1287<br />
Guo, R 1476<br />
Guo, X 58, 59<br />
Guskiewicz, KM. 808<br />
Guthridge, JM 421, 1364, 1912<br />
Guthridge, JM 35, 501, 839, 1287,<br />
1581<br />
Guthridge, JM. 1425, 1579<br />
Guthrie, JP 1569<br />
Gutierrez, C 816, 1578<br />
Gutierrez-Cañas, I 1040<br />
Gutierrez-Roelens, I 524<br />
Gutierrez-Suarez, R 749<br />
Guzian, M 744<br />
Guzman, R 1890<br />
Gwilliam, R 559, 1321<br />
Gyetvai, Á 1070<br />
H<br />
Häntzschel, H 381<br />
Haas, CS 711<br />
Haas, M 1935<br />
Haavardsholm, EA 634<br />
Haaz, S 1037, 2035, 2186, 2188<br />
Habib, RA 1951<br />
Hachulla, A 1371<br />
Hachulla, E 1085, 1086, 1095,<br />
1371, 1373<br />
Hacquard-Bouder, C 1325<br />
Haefner, R 225<br />
Haerinck, S 1325<br />
Haeupl, T 133, 823<br />
Hafström, I 264, 1815, 1879<br />
Hagel, S 2047<br />
Hagen, K 2047<br />
Hagerty, D 267<br />
Hagerty, D 2088<br />
Haggerty, H 221<br />
Haggerty, HG 1798<br />
Haghshenas, J 707<br />
Hahn, B 2091<br />
Hahn, BH 402, 403, 407, 435, 446,<br />
1368, 1955<br />
Hahn, PC 500<br />
Hahne, M 497, 498<br />
Haibel, H 753, 1158<br />
Haig, G 715, 1522, 1523, 1524<br />
Haines, K 234, 235, 884<br />
Haines, K 924<br />
Hakala, MS 907<br />
Hakoda, M 1071<br />
Haley, P 1771<br />
Haley, SM 1486, 1700<br />
Halfon, P 2016<br />
Hall, P 1980<br />
Halperin, N 1270<br />
Halpern, MT 830<br />
Halse, J 619<br />
Hama, M 649, 656<br />
Hamaguchi, M 1060<br />
Hamaguchi, Y 1209<br />
Hamann, D 1831<br />
Hamdulay, S 708, 709<br />
Hamid, A 1126<br />
Hammaker, D 148, 673, 917<br />
Hammaker, DR 131, 364<br />
Hammond, A 157, 1329<br />
Hammond, A 601<br />
Hammond, C 1268<br />
Hampson, R 968, 977, 979, 999<br />
Hamuryudan, V 853, 1248<br />
Hamza, S 960, 1022<br />
378
HAMZE SINNO, M 1093<br />
Han, C 174, 988, CRC30, CRC36<br />
Han, C 504, 1153, CRC33, CRC44<br />
Han, J 956, 1154<br />
Han, S 2030<br />
Han, S 839<br />
Han, T 546<br />
Handa, R 949<br />
Handeland, K 896<br />
Handeland, KS 911<br />
Handwerger, B 454<br />
Hang Pham, T 874<br />
Haniffa, M 1985<br />
Hanley, E 781, 1614<br />
Hanly, JG 1960<br />
Hanly, J 450<br />
Hanly, JG 804, 1130<br />
Hanly, JG. 1115, 1116, 2157<br />
Hannan, MT 2039<br />
Hannonen, P 273, 2155<br />
Hansen, A 339<br />
Hansen, G 1881<br />
Hansen, G 1042, 2180<br />
Hansen, I 1881<br />
Hansen, I 154, 1042, 1785,<br />
1786, 2180<br />
Hansen, JA 1046<br />
Hansen, T 1821<br />
Häntzschel, H 2126, 2149<br />
Haque, S 1932<br />
Haque, UJ 981<br />
Hara, M 18, 33, 312, 313, 542, 994,<br />
1016, 1036, 1067, 1129, 1644<br />
Hara, T 1218, 1219, 1220, 1606<br />
Haraoui, B 303<br />
Harboe, E 456<br />
Harigai, M 344, 1338<br />
Haring, N 270<br />
Harlaar, J 1274<br />
Harle, J 869, 871, 1124<br />
Härle, P 1747<br />
Harlev, M 1137<br />
Harley, C 1556<br />
Harley, I 839, 1287<br />
Harley, ITW 35<br />
Harley, JB 421, 1364, 1912<br />
Harley, JB 35, 501, 839, 1111, 1136,<br />
1287, 1945, 1967, 1972, 2080,<br />
2124, 2125<br />
Harley, JB. 510, 513, 514, 1084,<br />
1425, 1579<br />
HARO, I 1901<br />
Haroche, J 432, 875, 1123, 1226,<br />
1946, 1970<br />
Harp, K 168<br />
Harrington, T 1347<br />
Harris, ML 747<br />
Harris, RC 110<br />
Harris, RE 103, 106, 109, 713<br />
Harris, RH 714<br />
Harris, ST. 621, 622<br />
Harrison, M 1504<br />
Harrison, M 884<br />
Harrison, MJ 2034<br />
Hart, D 1049, 1836<br />
Harte, SE 107<br />
Hartgring, SAY 1379, 1991<br />
Hartl, F 619<br />
Haruna, M 396<br />
Haruta, K 1788<br />
Harvey, W 216<br />
Hascelik, Z 275<br />
Hasegawa, M 48, 50, 1209, 1218<br />
Hasegawa, N 1032<br />
Haselwood, DM. 1689<br />
Haselwood, D 1675<br />
Hashemi, M 725<br />
Hashimoto, H 1968, 1971<br />
Hashimoto, J 301<br />
Hashimoto, M 495, 1670<br />
Hashimoto, N 1662<br />
Hashimoto, R 1338<br />
Hashimoto, T 533, 1055<br />
Hashiramoto, A 544, 925, 930, 1779<br />
Hashizume, Y 1478<br />
Hashkes, P 679, 680<br />
Hashkes, P 884<br />
Hashkes, PJ 254<br />
Hashkes, PJ. 1282<br />
Haskard, D 709<br />
Haskard, DO 708<br />
Haslam, J 1695<br />
Hassell, A 1504<br />
Hassett, AL 304, 1279, 1327, 1519<br />
Hasty, KA 67, 68<br />
Hatakeyama, A 1636<br />
Hatch, G 2111<br />
Hatemi, G 853, 865, 1162, 1178,<br />
1248<br />
Hatron, P 1095, 1371<br />
Hauber, AB. 351, CRC38<br />
Hauck, W 1296<br />
Hauet-Broere, F 938<br />
Haugeberg, G 169, 268, 634,<br />
1470, 1562<br />
Haugen, AJ 326, 1638<br />
Haupl, T 142, 1413, 1416, 1482<br />
Hauschildt, S 2126<br />
Hausdorf, G 526<br />
Hauselmann, HJ 2076<br />
Hauser, I 433<br />
Hawker, GA 91, 835, 1485, 1499,<br />
1500, 1702, 2117<br />
Hawker, GA. 1258<br />
Hawkey, C 1680<br />
Hawkins, PN 1296<br />
Hay, E 193<br />
Hay, EM 1251, 2037<br />
Hay, E 2051<br />
Hay, J 242<br />
Hayashi, K 564<br />
Hayashi, N 1897<br />
Hayashi, N 8<br />
Hayashi, S 328<br />
Hayashi, Y 146, 1077<br />
Hayer, S 1058<br />
Hayes, B 635<br />
Hayes, DF 126<br />
Hays, RD 1510<br />
Hazen, MM 1714<br />
Hazenberg, B 1296<br />
Hazenberg, BP 866<br />
Hazes, JM.W. 76, 1492, 1838<br />
Hazleman, BL 122<br />
Heß, E 381<br />
Head, AJ 159<br />
Heald, A 2084<br />
Healy, A 551<br />
Heath, N 2106<br />
Heath, S 1324<br />
Hector, R 1120<br />
Hed, J 1455<br />
Heegaard, N 1042<br />
Heidecke, H 1215<br />
Heidenreich, A 1092<br />
Heie, RAndre 1470<br />
Heike, T 1707<br />
Heilman, BP 2074<br />
Heilweil-Harel, M 1137<br />
Hein, G 1882<br />
Heinegård, D 66<br />
Heinhuis, B 1305<br />
Heinzel, P 433<br />
Heinzl, H 1185<br />
Heldmann, F 753<br />
Hélène, L 915<br />
Helfgott, S 1028<br />
Helgetveit, K 326, 1638<br />
Heller, JE 2187<br />
Hellerstein, M 1288<br />
Hellio, M 2077<br />
Hellio, M 217, 218<br />
Hellio Le Graverand, M 659, 1691,<br />
1692, 1706<br />
Hellio Le Graverand-Gastineau, M<br />
215<br />
Hellio-Le Graverand, M 657<br />
Helliwell, P 610, 1186, 2098<br />
Hellström, H 260<br />
Helmers, SB 1667<br />
Helmick, CG 740<br />
Helmick, C 720, 818, 1505<br />
Helmick, CG 810, 2054<br />
Helmke, N 1534<br />
Hemmatazad, H 44, 375<br />
Hempfing, A 577<br />
Henderson, J 282<br />
Hendriks, R 675, 1297<br />
Henne, WA 690<br />
Henriksson, C 1535<br />
abstract author Index<br />
379
abstract author Index<br />
Henriksson, KG 1535<br />
Henry, NLynn 126<br />
Hensch, A 650<br />
Hensor, EM A 1841<br />
Hensor, EMA 660, 662<br />
Hepburn-Scott, H 761<br />
Herborn, G 333<br />
Herbst, R 132, 1417<br />
Herings, RMC 688<br />
Herlenius, E 1727<br />
Herlin, T 250<br />
Herman, D 917<br />
Herman, S 1304<br />
Hermann, GA. 1103<br />
Hermann, J 1454<br />
Hermann, K 1154<br />
Hermann, K 650, 654, 1158<br />
Hermansson, M 359<br />
Hermine, O 283<br />
Hernandez, F 104<br />
Hernández, M 1795<br />
Hernandez, V 2057<br />
Hernandez-Molina, G 208<br />
Hernandez-Rodriguez, J 128, 784,<br />
1230, 1483, 2018, 2020, 2022<br />
Hernandez-Santana, A 1616<br />
Herranz-Varela, Á 287<br />
Herrero-Beaumont, G 270, 1044,<br />
1591, 1751<br />
Herrick, AL 1374<br />
Herrick, AL 24, 1198<br />
Hersh, A 78, 1503, 2118<br />
Hersh, AO 232<br />
Hershko, A 1137, 1758<br />
Herzer, P 342<br />
Herzog, C 1307<br />
Hess, H 425<br />
Hesselstrand, R 66, 814<br />
Hessey, E 272, 2088<br />
Hessian, PA 1072<br />
Hession, C 425<br />
Hetland, M 670, CRC37<br />
Hetland, ML 1881<br />
Hetland, M 1785, 1786<br />
Hetland, ML 154, 339<br />
Hetland, MLund 1021, 1042, 2180<br />
Hettema, ME 1196<br />
Hewagama, A 141<br />
Hewett, JE 722, 724<br />
Hewitt, G 610<br />
Hewlett, S 2045<br />
Heydrich, R 577<br />
Heywood, W 1333<br />
Hickey, S 1176<br />
Hicks, MJ 878<br />
Hidaka, T 1789<br />
Hidalgo, V 600<br />
Hider, S 2122<br />
Hiepe, F 133, 433, 526, 1413<br />
Hierse, F 730<br />
Hietpas, J 214<br />
Higaki, M 937<br />
Higami, S 1129<br />
Higgins, GC 236<br />
Higgins, GC. 885<br />
High, WA 1369<br />
Highton, J 1072<br />
Hilário, MO 879<br />
Hilario, MO E 1722<br />
Hilda, R 1850<br />
Hildenbrand, H 678<br />
Hilkens, C 1985<br />
Hill, CL 2044<br />
Hill, H 1903<br />
Hill, J 1251<br />
Hilliquin, P 1065<br />
Hillstrom, HJ 2074<br />
Hincapie, M 1824<br />
Hines, P 1810<br />
Hinkel, M 1269<br />
Hinks, A 2120, 2122<br />
Hinman, RS 764<br />
Hinyard, LJ 89<br />
Hirakata, M 1032, 1206, 1663, 1664,<br />
1665<br />
Hirao, M 301<br />
Hirata, A 8<br />
Hires, A 861, 862, 863<br />
Hirohata, S 13, 1961<br />
Hirono, S 1779<br />
Hirsch, JW 430<br />
Hirsch, J 840<br />
Hirsch, R 1715, 1839<br />
Hirsh, J 175<br />
Hitchon, C 804<br />
Hitchon, CA 2183<br />
Hizel, K 1031<br />
Ho, H 1883<br />
Ho, KWah 605<br />
Ho, L 444, 1108, 1109<br />
Ho, P 556<br />
Hoar, B 802<br />
Hochberg, M 282, 820, 821<br />
Hochberg, MC 740<br />
Hochberg, M 85<br />
Hochberg, MC 2142<br />
Hochberg, MC. 858<br />
Hock, C 153<br />
Hocking, L 2120, 2122<br />
Hodgson, R 651<br />
Hodsman, A 1564, 1566<br />
Hoefler, E 518<br />
Hoekstra, M 333<br />
Hoekstra, OS 693<br />
Hoenen-Clavert, V 645, 694<br />
Hoes, JN 626, 831<br />
Hofbauer, R 1628<br />
Hoff, M 268<br />
Hoffman, GS 702, 2000, 2004, 2014,<br />
2018, 2020, 2022<br />
Hoffman, H 168, 220, 1291, 2127<br />
Hoffman, RW 409, 1634<br />
Hoffman, RW. 1376<br />
Hoffmann, M 1761<br />
Hoffmann, O 2063<br />
Hofmann, I 1714<br />
Hogan, SL 2023<br />
Hogarth, K 861, 862<br />
Hoglund, LT 2074<br />
Hoiberg, M 1562<br />
Hojaili, B 532<br />
Hojo, T 1060<br />
Hokland, M 770<br />
Holck, P 578, 1181<br />
Holcox, JP 1411<br />
Holden, M 2051<br />
Holers, VM 2184<br />
Holers, VMichael 748<br />
Holers, V 1289, 1768, 2129<br />
Holgado, S 1574<br />
Hollan, I 1632<br />
Holland, M 763<br />
Holliday, SL. 2095, 2161<br />
Hollis, BW. 1949<br />
Holm, C 770<br />
Holm, MB 176, 1330<br />
Holman, AJ 119, 335<br />
Holmdahl, R 1436, 1437, 1761<br />
Holmes, T 237, 238<br />
Holmes-Rovner, M 159<br />
Holmqvist, A 1821<br />
Holt, E 607<br />
Holz, GG 156<br />
Holzenberger, M 1447<br />
Holzer, U 899<br />
Hom, C 679, 680<br />
Homburger, HA. 1052, 1832<br />
Hong, S 884<br />
Hong, SD 2083<br />
Hong, S 1177, 1637<br />
Hong, Y 363<br />
Hood, MA 1383<br />
Hoogwerf, B 802<br />
Hooijkaas, H 1838<br />
Hooker, R 1811<br />
Hooker, R 1008<br />
Hooker, RS 166, 984, 1567<br />
Hooper, M 305<br />
Hootman, J 720, 1505, 2054<br />
Hootman, JM 810<br />
Hopman, W 1565<br />
Horger, M 899<br />
Horita, T 533, 1055, 1334, 1400,<br />
1401, 1406<br />
Horneff, G 225, 895, 900<br />
Hørslev-Pedersen, K 1881<br />
Hørslev-Petersen, K 333<br />
Horslev-Petersen, K 154, 1042, 1440,<br />
1785, 1786, 2180<br />
Horton, R 1253, 1384, 2041<br />
380
Horvath, DV 520, 1722<br />
Horváth, IF. 1070, 1837<br />
Horwood, N 1998<br />
Hosaka, M 329<br />
Hoshino, K 1663<br />
Hosono, O 1478<br />
Hostmann, B 526<br />
Hot, A 1041, 1394, 1645<br />
Houbiers, J 325<br />
Houghton, K 1385<br />
Houghton, KM 243<br />
Houssiau, F 434<br />
Houssiau, FA 524, 1796, 1801<br />
Howard, B 1863<br />
Howard, G 2184<br />
Howard, KA 1769<br />
Howe, FA 1959<br />
Howe, H 436, 1147, 1149<br />
Howell, K 1225, 2167<br />
Howie, AJ 3<br />
Hoyer, BF. 1413<br />
Hoyles, R 45<br />
Hsia, J 1863<br />
Hsu, B 504, CRC33<br />
Hsu, E 55<br />
Hsu, H 1285, 1299<br />
Hsu, J 237, 238<br />
Hsu, MC 109, 1527<br />
Hsu, V 26, 2163, 2165<br />
Hsu, VM 1208<br />
Hsu, W 598, 750<br />
Hu, H 618, 619<br />
Hu, H 438, 439<br />
Hu, N 841<br />
Hu, S 607<br />
Hu, X 41<br />
Hua, J 512<br />
Huaman, G 20<br />
Huang, C 1528<br />
Huang, D 1643<br />
Huang, F 568<br />
Huang, J 802<br />
Huang, M 845<br />
Huang, M 1840<br />
Huang, Q 1075<br />
Huang, Q 384<br />
Huang, R 1814<br />
Huang, W 1621<br />
Huber, AM 242, 881<br />
Huber, AM 1386, 1659<br />
Huber, J 1698<br />
Huber, LC 2149<br />
Huber, LC. 44<br />
Huber, V 1454<br />
Hubert, HB 2114<br />
Hubert, P 880<br />
Huddleston, JM 837<br />
Huddleston, PM 837<br />
Huddy, N 429<br />
Hudelmaier, M 210, 211, 212, 657,<br />
658, 659<br />
Hudson, AP 1355, 1569, 1570<br />
Hudson, AP. 1354<br />
Hudson, M 5, 1201, 1202<br />
Hudson, TJ 804<br />
Hueber, W 748, 1794<br />
Hueber, WJ 1289<br />
Huggins, JL 1427<br />
Hughes, GRV 441, 1411<br />
Hughes, GC 411<br />
Hughes, L 197<br />
Hughes, LB 198, 2184<br />
Hügle, T 1572<br />
Hugos, C 125<br />
Hugot, J 1680<br />
Huisingh-Scheetz, M 741<br />
Huisman, M 670, CRC37<br />
Huisman, MA 1683<br />
Huizinga, T 382, 725<br />
Huizinga, TW.J. 2087<br />
Huizinga, TW.J. 769<br />
Huizinga, TWJ 390<br />
Hulot, JS 1123<br />
Hulot, J 432, 1125<br />
Hulsmans, HM.J. 2087<br />
Hulsmans, HMj 626<br />
Hum, D 1463<br />
Humbert, M 1095, 1126, 2164<br />
Hume, JR 2010<br />
Hummers, L 26<br />
Hummers, LK 22, 1208<br />
Humrich, J 1954<br />
Humrich, JY 405, 406<br />
Hunder, GG 1237, 1238<br />
Hung, EW 1103<br />
Hunt, BJ 758<br />
Hunt, S 685<br />
Hunt, SC 805<br />
Hunter, D 202, 2077<br />
Hunter, DJ 206, 216<br />
Hunter, DJ 204, 205, 1486, 1700<br />
Hunter, DJ. 209<br />
Hunter, D 195, 208, 215<br />
Huppertz, H 681<br />
Hur, G 1780<br />
Hur, J 573, 822<br />
Hur, N 1105<br />
Hurley, MV 807<br />
Huscher, D 2065, 2164<br />
Husni, E 867, 868<br />
Husni, M 607, 608, 1737, 2099<br />
Huston, KA 1559<br />
Huston III, J 1237, 1238<br />
Hutas, G 920, 1481<br />
Hutcheson, J 401, 774, 1770<br />
Hutcheson, J 494, 1905<br />
Hutchings, A 706<br />
Hutchings, D 35<br />
Huter, ENI 1987<br />
Hwang, J 1780<br />
Hwang, K 140<br />
Hyldgaard, L 120<br />
Hyldstrup, L 666<br />
Hylton, DM 755<br />
Hynd, R 180, 549<br />
Hyphantis, TN 1914<br />
Hyrich, K 552, 553, 1799<br />
Hyrich, KL 754, 908, 909, 976, 1343,<br />
CRC11<br />
I<br />
Iaccarino, G 2021<br />
Iacob, M 182<br />
Ibaňez, D 1116<br />
Ibañez, D 1115, 1117, 1143, 2157<br />
Ibba, V 574<br />
Ibba-Manneschi, L 1217<br />
Ichida, H 1129, 1644<br />
Ichikawa, N 1071<br />
Ichinose, K 353, 1294<br />
Ida, H 353, 386, 1294, 1611, 1840<br />
Ide, H 329, 1096, 1441, 1660, 1896,<br />
2005<br />
Ideguchi, H 785, 854<br />
Iglesias, A 1210<br />
Iglesias, C 332<br />
Iglesias Gamarra, A 1642<br />
Ihata, A 649, 656<br />
Iikuni, N 313, 1036, 1067<br />
Iizuka, N 13<br />
Ikari, K 361, 542, 1067<br />
Ikawa, Y 49<br />
Ikeda, K 1094<br />
Ikeda, K 1419<br />
Ikehara, W 1013<br />
Ikezawa, Z 64, 855<br />
Iliceto, S 647<br />
Ilivanova, EP 263<br />
Ilowite, NT 682<br />
Ilowite, N 818, 1281, 1709<br />
Imanishi, Y 544<br />
Imhof, BA 1480<br />
Imling, D 1487<br />
Immonen, K 1821<br />
Immonen, K 907<br />
Impens, AJ 14, 21, 1200<br />
Imundo, L 252<br />
Imundo, L 1384<br />
Imundo, LF 877, 882<br />
Imura, Y 495<br />
Inanc, M 2019<br />
INANC, N 1027, 1635<br />
Ince, A 303<br />
Indiveri, F 402<br />
Inge J Sørensen, Julia S Johansen, Ole<br />
R Madsen, N, i 590<br />
Ingegnoli, F 11, 12, 962<br />
Ingraham, KM 15<br />
Ingvarsson, J 814<br />
abstract author Index<br />
381
abstract author Index<br />
Inman, R 1153<br />
Inman, R 1176, 1495<br />
Inman, RD 557, 560, 567, 571, 597,<br />
598, 655, 750, 898, 1165, 1168,<br />
1169, 1284, 1322, 1355<br />
Inman, RD. 1186, 1190, 1354<br />
Innala, L 1006<br />
Inokuma, S 344, 1902<br />
Inomata, H 1826<br />
Inoue, A 914<br />
Inoue, A 671, 934, 1753<br />
Inoue, E 312, 313, 994, 1016, 1067<br />
Inoue, H 2001<br />
Inoue, K 344, 1450<br />
Inoue, T 364<br />
Intema, F 1457, 1676<br />
Ioannidis, G 1564, 1565, 1566<br />
Ioannou, M 1479, 1605<br />
Ionescu, RM 182<br />
Ioseliani, M 245<br />
Ireland, K 763<br />
Irigoyen, M 287<br />
Isaacs, J 552, 553, 1799<br />
Isaacs, JD 1985<br />
Isenberg, D 507, 508, 509, 1408,<br />
1918<br />
Isenberg, DA 503<br />
Isenberg, D 1960<br />
Isenberg, D 450, 1135, 1333, 1911,<br />
1932<br />
Isenberg, DA 2093<br />
Isenberg, DA. 1115, 1116, 2157<br />
Ishibashi, T 1792<br />
Ishido, M 2069<br />
Ishigami, H 370<br />
Ishigatsubo, Y 649, 656, 785, 854,<br />
1030<br />
Ishiguro, N 344<br />
Ishihara, G 1466, 1558<br />
Ishihara, T 1664<br />
Ishihara, T 937<br />
Ishii, M 1464, 2064<br />
Ishimaru, N 146, 1077<br />
Ishimori, ML 1120<br />
Ishino, H 1060<br />
Isozaki, T 329, 1096, 1441, 1660,<br />
1896, 2005<br />
Itami, Y 1377, 1996<br />
Itamura, J 2111<br />
Ito, M 544<br />
Ito, S 371, 387, 412, 671, 793, 914,<br />
934, 1083, 1753, 1759<br />
Ito, S 1728, 1730<br />
Ito, Y 1670<br />
Itoh, H 1878<br />
Itoh, K 1150<br />
Ittah, M 1087, 1360<br />
Iversen, L 770<br />
Iversen, MD 2040<br />
Iwai, K 1464, 2064<br />
Iwamoto, N 386, 1840<br />
Iwamoto, T 1067<br />
Iwanaga, N 353, 1840<br />
Iwanami, K 671, 914, 934, 1753<br />
Iwasaki, T 936, 1662, 1754<br />
Iwata, S 1478<br />
Iwata, S 317, 357, 1781, 1939<br />
Iwata, Y 1218, 1606<br />
Izawa, T 146<br />
Izmailova, E 537<br />
Izmailova, ES 551<br />
Izmirly, P 143, 442, 1923, 2128<br />
Izquierdo, E 1472<br />
Izumi, Y 1840<br />
Izumi, Y 8<br />
Jørgensen, A 770<br />
Jacbsson, LTH 374<br />
Jackson, AJ 856<br />
Jackson, I 1302<br />
Jacob, CO 399<br />
Jacob, GL. 1832<br />
Jacob, N 399<br />
Jacob, T 1836<br />
Jacobelli, S 1983<br />
Jacobs, JWG 340, 626, 831<br />
Jacobs, KMG 792, 1379, 1991<br />
Jacobs-Kosmin, D 1903<br />
Jacobsen, S 1881<br />
Jacobsen, S 385, 1021, 1042, 2180<br />
Jacobson, KA 1787<br />
Jacobsson, C 1818<br />
Jacobsson, L 993<br />
Jacobsson, LTH 286, 1010, 1011,<br />
1818, 2047<br />
Jacq, L 1065<br />
Jacques, C 1447<br />
Jaffee, B 551<br />
Jagger, AL 1588<br />
Jaglal, SB 2028, 2117<br />
Jagodic, M 422<br />
Jaimes, K 409, 1634<br />
Jain, MS 678<br />
Jais, X 1095, 1126<br />
Jajoo, R 653<br />
Jakstadt, M 1482<br />
Jallal, B 132, 429, 430, 761, 840,<br />
1315<br />
Jamal, A 505, 506<br />
Jamal, S 293, 354, 1888, 2154<br />
Jamard, B 541<br />
James, JA 421, 1364, 1912<br />
James, J 1435<br />
James, JA 35, 501, 514, 839, 870,<br />
1111, 1287, 1581, 1945, 2125<br />
James, JA. 510, 1425, 1579<br />
J<br />
James, NT 2033<br />
James-Newton, L 252<br />
James-Newton, L 1658<br />
Jamin, C 534<br />
Jamshidi, A 1232<br />
Jan Wu, Y 1883<br />
Jandial, S 158<br />
Jang, S 1177<br />
Jann, MM 1742<br />
Jansen, J 1501<br />
Jansen, NWD 1462<br />
Jansen, TL 90, 299<br />
Jansen, TL.Th.A. 580<br />
Janssen, L 579<br />
Janssen, S 1182<br />
Jansson, E 2189<br />
Jarosova, K 895<br />
Järvinen, P 594<br />
Jarvis, JN 1710, 1711, 1733<br />
Jarvis, JN. 1724, 1725<br />
Jarvis, LB 1994<br />
Jarvis, LB 1995<br />
Jaskowski, T 1903<br />
Jasmin, J 2058<br />
Javaid, M 200, 201<br />
Javaid, M 2062<br />
Javaid, M 2116<br />
Jawa, V 1906<br />
Jay, R 653<br />
Jayakumar, K 321, 1816<br />
Jayne, D 2012<br />
Jeanneret, D 1244<br />
Jeffries, M 394, 1620<br />
Jeka, S 947<br />
Jenks, SA 1418<br />
Jennings, K 1559<br />
Jensen, DV 1021<br />
Jeon, C 775, 975, 1247<br />
Jeon, C 928<br />
Jeremiah, F 199<br />
Jernick, S 719<br />
Jessop, DS 1628<br />
Jesus, AA 886<br />
Jette, AM 2053<br />
Jette, AM 1486, 1700<br />
Jevnikar, AM 1746<br />
Jhang, JS 1142<br />
Ji, J 322, 388, 624<br />
Jiang, CQ 828, 829<br />
Jiang, J 939<br />
Jiang, K 1710, 1711, 1733<br />
Jill P. Buyon, D 1115, 1116<br />
Jimenez, SA 20, 51, 52, 1211, 1641,<br />
2058<br />
Jimenez, S 1403<br />
Jiménez-Alonso, J 1090<br />
Jin, E 1177<br />
Jiwa, F 1564, 1566<br />
Joas, J 203<br />
Joas, J 199<br />
382
Joas, JP. 2049<br />
Job, G 1285<br />
Job-Deslandre, C 253<br />
Joelsson, JK 297, 1808<br />
Jog, NR 415<br />
Joh, T 435<br />
Johansen, JS 1881<br />
Johansen, P 1825<br />
Johansen, S 1092<br />
John, A 290<br />
John, AK 827<br />
John, RD 560<br />
John, S 1588<br />
John, T 576<br />
Johnen, C 526<br />
Johnsen, V 169, 1470, 1562<br />
Johnson, A 247<br />
Johnson, CR 177, 455, 1672<br />
Johnson, CR. 345, 736<br />
Johnson, FR. 351, CRC38<br />
Johnson, J 522<br />
Johnson, K 99<br />
Johnson, K 438, 439<br />
Johnson, RA 722<br />
Johnston, DG 1317<br />
Johnstone, D 1564, 1566<br />
Jolles, B 1698<br />
Jolley, D 768<br />
Jolly, M 171<br />
Jolly, M 170, 1112, 1113, 1490<br />
Jonas, B 2184<br />
Jonas, M 654<br />
Jones, EA 1530<br />
Jones, GT 712, 1530<br />
Jones, G 637<br />
Jones, JK 1909<br />
Jones, KL 1352<br />
Jones, KA 1498<br />
Jones, K 1541<br />
Jones, KD 125<br />
Jones, PE 1017<br />
Jones, P 321, 1192<br />
Jones, R 440, 1935<br />
Jongbloed, S 1990<br />
Jonsdottir, T 2169<br />
Jönsen, A 1132<br />
Jönsson, H 1704<br />
Joo, K 615<br />
Joo, Y 573, 822<br />
Joos, R 681<br />
Joosten, L 1762<br />
Joosten, LA 1298, 1305, 1453, 2061,<br />
2130<br />
Joosten, LA.B. 149, 1300<br />
Joosten, LAB 1380<br />
Jordan, JM 740<br />
Jordan, J 195<br />
Jordan, J 1485<br />
Jordan, JM 833, 1499, 1702<br />
Jordan, R 1092<br />
Jorge, AS. 378<br />
Jorgensen, C 2086<br />
JORGENSEN, C 2060, 2137<br />
Jørgensen, L 424<br />
Joseph, L 503<br />
Joseph, L 1193, 1657<br />
Joseph-Ridge, N 757, 758, 1622<br />
Joshi, BV 1787<br />
Joshi, C 699, 950<br />
Josse, R 1565<br />
Jou, I 672<br />
Jouen, F 961<br />
Jousse, S 534<br />
Joven, B 10<br />
Joven, BE 6, 7, 1221, 1661<br />
Jover, JA 1053, 1076<br />
Ju, J 1442, 1443, 1944<br />
Juanola, X 1175<br />
Juarranz, Y 1040<br />
Judge, A 835<br />
Judyann, O 1281<br />
Juengel, A 44, 375, 1044, 1429, 2149<br />
Julian, BA 1423<br />
Julian, L 78, 232, 1503, 2118<br />
Julian, LJ 1277<br />
Julian, LJ. 1256<br />
Julien, C 565<br />
Jun, H 1082<br />
Juneau, P 1459<br />
Jung, L 895<br />
Jung, N 1438, CRC25<br />
Jung, SM 760<br />
Jung, Y 1977<br />
Junker, P 1881<br />
Junker, P 1042, 1440, 2180<br />
Junkins-Hopkins, J 1904<br />
Jurik, A 2180<br />
K<br />
K. Kalunian, A 1960<br />
Kaci, L 638<br />
Kadoya, M 1060<br />
Kadzielski, C 251<br />
Kaell, A 288<br />
Kagan, A 1369<br />
Kahaleh, B 26, 60, 2148, 2163, 2165<br />
Kahan, A 1212<br />
Kahan, A 61, 62, 1372, 1373<br />
Kahan, BD 58<br />
Kahler, KH 630<br />
Kahler, K 631<br />
Kahler, KH. 96<br />
Kahn, P 1384<br />
Kahn, PJ 877, 882, 1409<br />
Kai, Y 1789<br />
Kaieda, S 932<br />
Kaine, J 695<br />
Kaipiainen-Seppänen, O 273, 2155<br />
Kaiser, SM 1565<br />
Kakehi, T 1026<br />
Kakiuchi, T 777<br />
Kakumanu, P 500, 1835<br />
Kalaaji, M 424<br />
Kalak, R 2065<br />
Kalden, J 610<br />
Kalden, JR 1062<br />
Kalden, JR. 1982<br />
Kale, AS 878<br />
Kalish, RA 1353<br />
Kaliyaperumal, A 1906<br />
Kallab, V 1477<br />
Kallankara, S 1631<br />
Kallarackal-Malaikal, T 1152<br />
Kallarackal-Maliakal, T 798, 1913<br />
Kallas, E 520<br />
Kallberg, H 377, 536, 1061<br />
Kalled, S 425<br />
Kallen, MA. 94, 95, 161, 183, 1738<br />
Kallenberg, CG.m 703<br />
Kallenberg, CG.M. 1964<br />
Kallenberg, CGM 1196<br />
Kallikorm, R 1821<br />
Kalliomäki, S 1778<br />
Kalunian, K 1308<br />
Kalunian, KC. 1963<br />
Kälvesten, J 268, 1056<br />
Kamachi, M 353, 1840<br />
Kamalı, S 2019<br />
Kamataki, A 1636<br />
Kamataki, A 2001<br />
Kamatani, N 18, 33, 312, 313, 542,<br />
990, 994, 1016, 1036, 1067, 1071,<br />
1129, 1151, 1619, 1644<br />
Kamath, TV 1098, 1099<br />
Kambe, N 893, 1707<br />
Kamdar, AA 878<br />
Kameda, H 370, CRC03<br />
kamel, m 1741<br />
Kamen, DL 1364<br />
Kamen, DL 1111<br />
Kamen, DL. 1949<br />
Kamp, S 494, 1905<br />
Kämpe, O 2059<br />
Kamradt, T 922<br />
Kanai, Y 1619<br />
Kanakoudi, F 295<br />
Kanangat, S 68<br />
Kanangat, S- 67<br />
Kanazawa, N 893<br />
Kane, D 662<br />
Kaneko, A 1466, 1558<br />
Kaneko, Y 1032, 1206, 1664, 1665<br />
KANG, AH 67<br />
Kang, AH. 1047<br />
Kang, C 546<br />
Kang, E 531<br />
Kang, E 1908<br />
Kang, I 140<br />
Kang, J 1908<br />
abstract author Index<br />
383
abstract author Index<br />
Kang, J 935<br />
Kang, S 1780<br />
Kang, S 2111<br />
Kang, Y 935, 1105<br />
Kanno, T 33, 1129, 1644<br />
Kao, C 1528<br />
Kapetanovic, MC 727, 983<br />
Kapitány, A 1070<br />
Kaplan, MJ 522, 1585<br />
Kaplan, MJ. 417<br />
Kaplan, R 1510<br />
Kaplan, Z 1529<br />
Kaplanski, G 869, 871, 1124, 1474<br />
Kapolka, D 333<br />
Kapoor, D 210<br />
Kapoor, M 1069, 1584, 1763<br />
Kappou-Rigatou, I 1973<br />
Kapsogeorgou, EK 1357, 1358, 1362,<br />
1602<br />
Karaarslan, Y 2019<br />
Karababa, M 1280, 1586<br />
KARAISKOS, DA 1093<br />
Karakida, T 1788<br />
Karakus, R 1031<br />
Karan, A 275<br />
Karapolat, H 275<br />
Karasawa, R 1450, 2011<br />
Karasawa, S 1467<br />
Karlson, EW 360, 537, 1064, 1916,<br />
2043<br />
Karlsson, J 727<br />
Karonitsch, T 516, 517, 1477, 1975<br />
Karouzakis, E 745, 1044<br />
Karp, DS 2125<br />
Karp, K 1002, 1003<br />
Karras, D 295<br />
Karsdal, MA 1882<br />
Karsdal, MA. 1767<br />
Kary, S 578, 594<br />
Kary, S 945<br />
Kasama, T 329, 1096, 1441, 1660,<br />
1896, 2005<br />
Kaski, J 1956<br />
Kasle, S 1268, 1276<br />
Kasperkovitz, PV 769<br />
Kasraeian, S 2111<br />
Kassner, A 66<br />
Kastberg, H 2086<br />
Kastelein, JJ. P. 1775<br />
Kastner, B 515<br />
Kastner, D 874<br />
Kastner, DL 555, 743, 850, 856,<br />
1599, 1601, 2055<br />
Katada, Y 1834<br />
Kataoka, H 533, 1055, 1334, 1400,<br />
1401, 1406<br />
Kataoka, H 136<br />
Kataria, R 1580<br />
Kato, T 1644<br />
Kato, T 1450, 1467, 2011<br />
Katsiari, CG 271<br />
Katsicas, MM 251<br />
Katsuki, Y 1664<br />
Katsumata, Y 33<br />
Katz, J 1863<br />
Katz, JN 1342<br />
Katz, JN 84, 687, 734, 832, 1555,<br />
1693, 1822<br />
Katz, J 1348<br />
Katz, P 78, 232, 1277, 1503, 2118<br />
Katz, PP. 1256, 1278<br />
Katz, R 1118, 1520, 1916<br />
Katz, RS 111, 118, 443, 1521, 1531,<br />
1532, 1534<br />
Katz, S 2160<br />
Kaufman, I 1025<br />
Kaufman, KM 421<br />
Kaufman, KM 35, 514, 839, 1287,<br />
1967, 2124, 2125<br />
Kauppi, M 273, 2155<br />
Kaura, D 224<br />
Kautiainen, H 670, 1502, CRC37<br />
Kautiainen, H 273, 336, 907, 2155<br />
Kavanagh, P 1610<br />
Kavanaugh, A 282, 988, 1806<br />
Kavanaugh, A 305, 306, 728, 941,<br />
1291, 1308, 1807, 1814<br />
Kavanaugh, AF 294<br />
Kavanaugh, AF. 1186, 2098<br />
Kavanuagh, AF 302<br />
Kavanugh, A 272<br />
Kawabata, D 419<br />
Kawaguchi, Y 18, 33, 1129, 1644<br />
Kawahito, Y 1060<br />
Kawai, S 296, 777, 794, 1826,<br />
1938, CRC12<br />
Kawai, T 1707<br />
Kawakami, A 353, 386, 1294,<br />
1611, 1840<br />
Kawakami, K 496<br />
Kawakami, M 852<br />
Kawamoto, M 33<br />
Kawano, S 1897<br />
Kawasaki, A 1968, 1971<br />
Kawasaki, H 1478<br />
Kawashima, M 1041<br />
Kawashiri, S 353<br />
Kawashiri, S 1840<br />
Kawazoe, T 930<br />
Kay, J 32, 1369<br />
Kay, LJ 910<br />
Kayan, A 1828<br />
Kayo, AH 1331<br />
Kayser, C 520, 1204, 1722<br />
Kazi, S 984, 1567, 1811<br />
Ke, X 2120, 2122<br />
Kean, M 134<br />
Keat, A 599, 1176<br />
Keating, R 862<br />
Keddache, M 2079<br />
Keegan, MT 837<br />
Keeling, SO 587, 588, 589<br />
Keen, HI 662, 1163<br />
Keenan, A 1701<br />
keiger, K 1999<br />
Keininger, DL 946<br />
Keiserman, MW 1204<br />
Kekow, J 1827<br />
Kellenberger, CJ. 246<br />
Kellermann, SA 1802<br />
Kelley, J 2000<br />
Kellner, D 1459<br />
Kellner, H 1153<br />
Kellner, H 1158<br />
Kellner, JD 224<br />
Kelly, JA 1912<br />
Kelly, JA 501, 514, 1287, 1967, 2125<br />
Kelly, S 1502<br />
Kelly, T 862<br />
Kelly-Scumpia, K 523<br />
Kelly-Scumpia, KM 1612<br />
Kelly-Scunpia, KM 398<br />
Kelman, A 288<br />
Kelsoe, G 1091<br />
Kendall, S 1535<br />
Keniry, A 559, 1321<br />
Kenkel, J 1309<br />
Kennedy, A 746<br />
Kennedy, C 1565<br />
Kennedy, M 1800<br />
Kennedy, S 454<br />
Kennel de March, A 1576<br />
Kenneth C. Kalunian, C 1115, 1116<br />
Keogh, E 1172, 1988<br />
Keogh, EA 1992<br />
Keogh, KA 2009<br />
Keren, R 889<br />
Kern, M 1794<br />
Kerr, D 452<br />
Kerr, G 93, 984, 1008, 1567, 1811<br />
Kerstens, PJ S M 1804<br />
Kerstens, PJ.S.M. 697<br />
Keser, G 2019<br />
Keshmand, H 31<br />
Keske, B 653<br />
Kessler, CL 84, 1693<br />
Kessler, RC 102<br />
Keuchel, M 1680<br />
Keysor, JJ 2053<br />
Keystone, E 261, 262, 282<br />
Keystone, E 257, 277, 293, 700, 940,<br />
951, 1807, 2154<br />
Keystone, EC 173, 294, 298, 302,<br />
303, 1057, 2088<br />
Khalili, A 1081<br />
Khalili, H 1794<br />
Khamashta, M 507, 508, 509<br />
Khamashta, MA 1395, 1396,<br />
1933, 2057<br />
Khamashta, MA. 1115, 1116, 2157<br />
384
Khan, IU 152<br />
Khan, K 45, 57, 2146<br />
Khan, MA 560<br />
Khan, M 1186<br />
Khan, S 1639<br />
Khan, Y 1250<br />
Khandelwal, S 170, 171, 1113<br />
Khanna, D 4, 167, 643, 1510, 1817,<br />
2162<br />
Khanna, S 1592<br />
Khasnis, A 2022<br />
Khatri, N 714<br />
Khoo, KB 1174<br />
Khorana, R 1863<br />
Khosla, S 2143<br />
Khoury, M 2137<br />
Khubchandani, R 233<br />
Kiani, A 438, 439, 449, 1121, 1122,<br />
1390, 1392, 1925, 1928, 1929, 2090<br />
Kicker, P 219<br />
Kickingbird, LM. 1724<br />
Kickler, TS 1390<br />
Kida, D 1466, 1558<br />
Kiel, DP 628, 2039<br />
Kiener, H 1477<br />
Kiener, P 46, 132, 429, 430, 761,<br />
840, 1417, 2134, 2135<br />
Kievit, W 90, 299, 308<br />
Kikuta, J 1464<br />
Killen, PD. 417<br />
Kilpatrick, J 35, 514, 1287, 2125<br />
Kim, A 859<br />
Kim, C 1177<br />
Kim, D 69, 1958<br />
Kim, D 1072<br />
Kim, E 1904<br />
Kim, G 931, 1764<br />
Kim, H 140<br />
Kim, H 548, 615, 813<br />
Kim, H 1442, 1443, 1764, 1944, 1977<br />
Kim, H 676<br />
Kim, H 1105<br />
Kim, H 642<br />
Kim, H 928<br />
Kim, H 369, 1043, 1944<br />
Kim, H 369, 1043<br />
Kim, I 546, 548, 570, 813<br />
Kim, I 1443, 1977<br />
Kim, I 935<br />
Kim, JS 689<br />
Kim, J 548<br />
Kim, J 1045<br />
Kim, J 1105, 1830<br />
Kim, J 1651<br />
Kim, J 775, 975<br />
Kim, J 137<br />
Kim, K 1443<br />
Kim, K 935<br />
Kim, M 83<br />
Kim, M 231<br />
Kim, S 107<br />
Kim, S 686<br />
Kim, S 109<br />
Kim, S 615<br />
Kim, S 642<br />
Kim, S 642<br />
Kim, S 931, 1764<br />
Kim, S 1830<br />
Kim, T 548, 570, 571, 573, 615, 822<br />
Kim, T 570, 571, 615<br />
Kim, W 369, 1043<br />
Kim, Y 1553<br />
Kim, Y 1749<br />
Kim, Y 1790<br />
Kim, Y 1997<br />
Kim, Y 363<br />
Kim, YTaek 1792<br />
Kim, Y 2030<br />
Kim, Y 1637<br />
Kim, Y 548, 1105<br />
Kim-Howard, X 839<br />
Kimberly, R 2128<br />
Kimberly, RP 499, 1138, 2124<br />
Kimberly, RP. 514, 1131, 1930<br />
Kimel, M 101<br />
Kimler, B 1320<br />
Kimura, T 540<br />
Kimura, Y 1282<br />
Kinderlerer, A 709<br />
King, YE 976<br />
Kingdon, EJ 3<br />
Kinjo, M 1568<br />
Kinloch, A 1303<br />
Kinne, RW 376<br />
Kinsley, D 1748<br />
Kiraz, S 2019<br />
Kirazli, Y 275<br />
Kirchner, D 1715<br />
Kirchner, HLester 702, 1235<br />
Kirino, Y 649, 785, 854, 1030<br />
Kirino, Y 656<br />
Kirk, C 939<br />
Kirkham, B 348, 611<br />
Kirkham, BW 338<br />
Kirou, K 1315<br />
Kirou, KA 511, 512<br />
Kirwan, J 1496<br />
Kirwan, JR 2045<br />
Kishi, J 783<br />
Kishimoto, T 296<br />
Kiss, E 535<br />
Kiss, MH. B. 1726<br />
Kita, Y 1943<br />
Kitagawa, K 1092<br />
Kitahama, M 990, 1151<br />
Kitahara, K 777, 794, 1826<br />
Kitamura, C 293, 2154<br />
Kitano, M 1662<br />
Kitano, S 936, 1754<br />
Kivitz, A 1160, 1494, 1684<br />
Kivitz, A 581, 1291, 1678, 2084<br />
Kjems, J 1769<br />
Klaasen, R 955<br />
Klaff, L 26<br />
Klareskog, L 265, 359<br />
Klareskog, L 297, 305, 377, 536, 539,<br />
545, 1061, 1430, 1436, 1437, 1784,<br />
1808, 1877, 2055, 2121<br />
Klarlund, M 385<br />
Klatzmann, D 2015<br />
Klein, A 880<br />
Klein, NJ 1411<br />
Klein, RQ 2071<br />
Klein-Gitelman, M 235, 885<br />
Klein-Gitelman, MS 236<br />
Klein-Gitelman, M 234<br />
Klenk, EI 1283<br />
Klok, RM 71<br />
Klokkerud, M 2047<br />
Kloppenburg, M 1705<br />
Kloppenburg, M 662, 1697<br />
Knechtle, S 438, 439<br />
Knedla, A 147, 1063<br />
Kneitz, C 1431<br />
Knight, A 701<br />
Knol, D 1274<br />
Knowlton, N 180, 525, 1710, 1711,<br />
1733, 2183<br />
Knudsen, LS 1881<br />
Knuth, A 1429<br />
Knutson, KL. 1880<br />
Ko, AT 1690<br />
Kobayashi, H 1205<br />
Kobayashi, K 1407<br />
Kobayashi, M 785, 854, 1030<br />
Kobayashi, S 361<br />
Kobayashi, Y 1205<br />
Kocakaya, O 1173<br />
Koch, AE 707, 711, 1475, 1480, 1623,<br />
1756, 1783<br />
Koch, K 929<br />
Kochen, JA. L. 1019<br />
Kochi, Y 386, 1050<br />
Kochunov, P 2095<br />
Koczan, D 376<br />
Koduri, G 321, 1816<br />
Koeck, J 150<br />
Koenders, MI 129, 1300<br />
Koenders, MI. 1298<br />
Koenig, A 1161<br />
Koening, C 2004<br />
Koening, CL 702, 2018, 2020, 2022<br />
Koetter, I 677, 1241<br />
Koffeman, EC 1992<br />
Koh, E 775, 928, 975, 1247<br />
Koh, J 1651<br />
Kohen, M 695<br />
Kohles, JD. 1544, 1546<br />
Kohno, M 1060<br />
Kohno, M 371, 387<br />
abstract author Index<br />
385
abstract author Index<br />
Kohsaka, H 1793<br />
Koike, T 344, 347, 356, 533, 1055,<br />
1334, 1400, 1401, 1406<br />
Kojima, F 1069, 1584, 1763<br />
Kokkonen, H 379, 1073<br />
Kolla, R 1592<br />
Kolli, K 1715<br />
Kollias, G 674, 1307<br />
Kolling, C 375, 745, 1044, 1059,<br />
1591, 1597, 2123<br />
Kollnberger, S 562<br />
Kolls, JK 1299<br />
Kolly, L 1280<br />
Kolsrud, B 264<br />
Kolta, S 738<br />
Komai, K 544, 824<br />
Komarow, H 856<br />
Komura, K 1218, 1219, 1220, 1606<br />
Kondo, H 13<br />
Kondo, M 852<br />
Kondos, GT 2159<br />
Kone-Paut, I 2082, CRC02<br />
Kong, J 369, 1043<br />
Kong, K 436, 1147, 1149<br />
Kono, H 1902<br />
Konthur, Z 1415, 1416<br />
Kontoyiannis, D 271<br />
Konya, M 653<br />
Kopec, J 1507<br />
Kopec, J 1272<br />
Kopec, JA 809, 833<br />
Kopec, JA. 2100<br />
Korach, K 420<br />
Korbet, SM. 443<br />
Korman, A 1984<br />
Kornfeld, M 455<br />
Korpela, M 2155<br />
Kortekaas, MC 662<br />
Koseki, Y 990, 1151<br />
Kotake, S 1071<br />
Kötter, I 1158<br />
Koutala, E 393<br />
Kovacs, A 1973<br />
Kovarik, C 1904<br />
Kovats, S 399, 1587<br />
Kowal-Bielecka, O 1, 30<br />
Kowalski, S 906<br />
Kowalski, SC. 1019<br />
Koyano, S 1878, 2181<br />
Koziol, D 678<br />
Kozora, E 492<br />
Kragstrup, TW 770<br />
Kramer, S 912<br />
Krammer, G 1680<br />
Krammer, G 1681<br />
Krasieva, T 692<br />
Krasnokutsky, S 290, 846, 966<br />
Krasowska, D 1212<br />
Krathen, MS 1904<br />
Krause, A 730<br />
Krausz, S 145<br />
Kremer, J 99, 282, 310, 699, 950,<br />
987, 989, CRC17<br />
Kremer, JM 957<br />
Kremer, J 728, 958, 1817<br />
Kremers, CJ.W. 2105<br />
Kretsos, K 1802<br />
Krieg, AM. 1310, 1596<br />
Krishnan, E 1292, 1625, 1839, 2075,<br />
2156<br />
Krishnan, N 217, 218<br />
Krishnaswami, S 978<br />
Kristensen, L 980<br />
Kristensen, L 727<br />
Kristjansdottir, H 1952<br />
Kritikos, H 525<br />
Kritikos, HD 393<br />
Kritikos, I 295<br />
Kroenke, G 2003<br />
Kroese, M 127<br />
Krog, J 154<br />
Krogstad, P 1723<br />
Krohkin, O 554<br />
Krohn, K 625, 627, 763, 1468<br />
Kron, M 578, 594, 1159, 1181<br />
Kron, M 945<br />
Kronke, G 1762<br />
Krug, HE 1293, 1688<br />
Kruseman, A 633<br />
Krystufkova, O 1667<br />
Kuan, EL 1584<br />
Kubota, T 1338, 2069<br />
Kubota, T 937<br />
Kubow, A 1386<br />
Kuchroo, VK 1359<br />
Kudo, M 1030<br />
Kudo-Tanaka, E 1834<br />
Kudra, M 517<br />
Kuemmerle-Deschner, J 899<br />
Kuemmerle-Deschner, JB 677<br />
Kuenzler, P 1044<br />
Kuester, R 900<br />
Kuhlman, R 1306<br />
Kuhne, M 576<br />
Kühnel, I 1058<br />
Kuipers, E 688<br />
Kuis, W 938<br />
Kuivenhoven, JA 933<br />
Kujawa, J 425, 1423<br />
Kumagai, S 2182<br />
Kumagai, S 1897<br />
Kumano, K 1943<br />
Kumar, A 180<br />
Kumar, D 1650<br />
Kumar, P 1475<br />
Kumar, S 876<br />
Kumazawa, C 1377, 1996<br />
Kun, EWai-lin 605<br />
Kunimatsu, J 1150<br />
Kuno, H 1662<br />
Kunz, M 658<br />
Kuo, S 1883<br />
Kuper, IH 90, 299<br />
Kupper, H 578, 594, 1159, 1160,<br />
1181, 1494<br />
Kupper, H 581, 753, 945, 1158<br />
KURASAWA, K 1943<br />
Kurien, BT 529, 1080, 1957<br />
Kurien, B 1081<br />
Kuriya, B 1812<br />
Kurnik, D 445, 1145<br />
Kuroda, S 1074, 1773<br />
Kuroiwa, T 1662<br />
Kuroki, M 1789<br />
Kurosaka, M 328<br />
Kurtz, D 2041<br />
Kuru, T 1370<br />
Kusaoi, M 1968<br />
Kushnaryov, A 1688<br />
Kusunoki, N 777, 794<br />
Kusunoki, Y 1826, 1938, CRC12<br />
Kuta, E 1417<br />
Kuuse, R 1821<br />
Kuwana, M 18, 64, 855, 1206, 1407,<br />
1663, 1664, 1665<br />
Kvern, B 1564, 1566<br />
Kvien, T 267<br />
Kvien, T 830<br />
Kvien, TK 268, 326, 634, 1512, 1638,<br />
1864<br />
Kvist, G 1947<br />
Kwak, H 676<br />
Kwan, K 1783<br />
Kwan-Morley, J 1904<br />
Kwoh, CKent 93, 1839<br />
Kwoh, C 2075<br />
Kwoh, K 1487<br />
Kwok, CL 609<br />
Kwok, P 838<br />
Kwok, S 1977<br />
Kwok, S 369, 1043, 1944<br />
Kwon, S 1105<br />
Kyburz, D 1597, 2123<br />
Kyogoku, C 1968<br />
Kyrmizi, I 848, 1479, 1605<br />
L<br />
La Cava, A 402, 403, 407, 1368, 1955<br />
La Madrid, K 816<br />
La Montagna, G 582<br />
LÃvgren, T 515<br />
Laan, RFJM 995<br />
Labò, E 913<br />
Labourier, E 1999<br />
Lacaille, D 820, 821<br />
Lacaille, D 77, 92, 1262, 2026, 2100<br />
LaCava, A 2091<br />
Lacey, R 1275<br />
Lacey, T 1695<br />
386
Lachenbruch, PA 1659<br />
Lachmann, HJ 1296<br />
LaCivita, CL 1263<br />
Lacy, E 274<br />
Lademacher, C 757, 758, 1622<br />
Ladhani, A 667, CRC20<br />
Lafeber, FPJG 792, 1379, 1457,<br />
1462, 1676, 1683, 1991<br />
Lafosse, C 258<br />
Lafyatis, R 56<br />
Lagu-Joshi, V 815, 1571<br />
Laguno, M 2006<br />
Lahfa, M 593<br />
Laifer, G 1572<br />
Laiño, M 350<br />
Lakos, G 1070, 1837, 1993<br />
Lal, P 762<br />
Lam, C 1109<br />
Lam, GK 747<br />
Lam, TH 828, 829<br />
Lama, G 1223<br />
Lama, N 1101<br />
Lambert, M 1371<br />
Lambert, N 744<br />
Lambert, NC 29<br />
Lambert, RGS 589<br />
Lambert, RGW 655, 1165<br />
Lambertenghi Deliliers, G 2145<br />
Lambrianides, A 1408<br />
Lambrianides, A 1333<br />
Lammers, L 1456<br />
Lammertsma, AA 693<br />
Lampa, J 927<br />
Lanas, A 1517<br />
Lancaster, W 1106<br />
Landau, DA 2015, 2016<br />
Landewe, R 952, 1154, 1803<br />
Landewe, R 30, 940, 1171, 1186<br />
Landewé, RB 696<br />
Landewé, RB M 965<br />
Landewe, R 127<br />
Landon, GC. 1738<br />
Landzberg, BR 1948<br />
Lane, N 200, 201<br />
Lane, N 953, 2116<br />
Lane, NE 807<br />
Lanfranchi, H 1092<br />
Lang, B 242<br />
Lang, BA 1386<br />
Lang, T 2116<br />
Lange, C 1682<br />
Langefeld, CD 2000, 2079, 2080,<br />
2124<br />
Langefeld, CD. 514<br />
Langford, CA 702, 1235, 2018, 2020<br />
Lanier, AP 1046<br />
Lanyon, P 1932<br />
Lanza, G 921<br />
Lanza, M 372<br />
Lao, L 85<br />
Lao, XQ 829<br />
Lao-Villadoniga, J 104<br />
Laoussadi, S 565<br />
Lapedis, J 106<br />
Lapidus, SK 236, 885<br />
Lapsley, H 1740<br />
Lard, LR. 2087<br />
Largeau, C 2137<br />
Larghero, J 28<br />
Largo, R 1751<br />
Larguero, J 29<br />
Lark, M 1448<br />
LaRosa, GJ. 918<br />
Larson, M 806<br />
Larson, PJ 276<br />
Lasbleiz, S 1065<br />
Lasigliè, D 249<br />
Lassere, MN 2151<br />
Laster, AJ 635<br />
Latchman, D 1408<br />
Latchman, D 1333<br />
Lathrop, M 1324<br />
LaTorre, C 1642<br />
Latorre, LC 1018<br />
Latorre, L 1013<br />
Latorre, LC 1842, 1895<br />
Lattanzi, B 227<br />
Lau, AC 1728, 1730<br />
Lau, C 1941<br />
Lau, T 436, 1149<br />
Lauder, S 1782<br />
Lauer, MS 254<br />
Launay, D 31, 1095, 1126, 1371<br />
Laupacis, A 86, 87, 88<br />
Lauridsen, UB 1881<br />
Lauridsen, UBirk 1042<br />
Laurindo, IM 1012<br />
Laurindo, IM M 1019<br />
Lauster, R 1482<br />
Lauwerys, BR 524, 1796, 1801<br />
LaValley, M 216, 2173<br />
LaValley, MP 2053<br />
LaValley, M 2119<br />
Lavalley, MP 199<br />
LaValley, MP. 2049<br />
Lavecchia, C 666<br />
Lavi, I 1617<br />
Lavie, F 662, 1087<br />
Law, W 436, 1149<br />
Lawrence, P 954<br />
Laxer, RM 1168<br />
Laxer, RM 898<br />
Laxminarayana, D 152, 1088<br />
Lazar, AM 748<br />
Lazar, MA. 2092<br />
Lazaro, D 1349<br />
Lazaro, MAlicia 270<br />
Lazovskis, J 333<br />
Lazzari, AA 1561<br />
LBSL02/99 Study Grp, 426, 427, 1316<br />
Le, B 22<br />
Le, JM 555, 2055<br />
Le Bars, M 258<br />
le Cessie, S 2105<br />
le CRI et la SFR, 73<br />
Le Dantec, C 534<br />
Le Loët, X 543, 961, 1428, 1892<br />
Le Pavec, J 1126<br />
Le Thi Huong, D 1124, 1946<br />
Leahey, WJ 1317<br />
Learch, T 612, 1179<br />
Learch, TL 1321<br />
Leask, A 57, 2146<br />
Leavitt, F 111, 118, 1531, 1532<br />
Lebeau, D 1630<br />
LeBlanc, C 242<br />
LeBoff, MS 638<br />
Lebon, P 1360<br />
Leboreiro, I 192<br />
Lebre, MC 378<br />
Lebre, MC. 918<br />
Leceta, J 1040<br />
Lechat, P 432, 1123, 1125<br />
Lecourt, S 28<br />
Lee, A 896<br />
Lee, A 850<br />
Lee, AT 743, 2055<br />
Lee, C 1790, 1997<br />
Lee, C 511<br />
Lee, D 155, 638<br />
Lee, DM 1755<br />
Lee, E 427<br />
Lee, E 531, 640, 676, 859, 1651<br />
Lee, E 531, 640, 676, 859, 1651<br />
Lee, E 1288<br />
Lee, H 363<br />
Lee, H 555, 850, 2055<br />
Lee, H 570, 571<br />
Lee, J 1177<br />
Lee, J 1192<br />
Lee, J 1105<br />
Lee, J 931, 1764<br />
Lee, J 931, 1764<br />
Lee, J 531<br />
Lee, KJ 189, 190<br />
Lee, LA 2071<br />
Lee, N 570<br />
Lee, P 929<br />
Lee, P 523, 1969<br />
Lee, PY 397, 398, 1612<br />
Lee, S 1177<br />
Lee, S 363<br />
Lee, S 1908<br />
Lee, S 448, 1105, 1926, 1927<br />
Lee, SH. 846<br />
Lee, S 1045, 1908<br />
Lee, SJ 728, 1814<br />
Lee, Y 1177<br />
Lee, Y 928, 975, 1247<br />
Lee, Y 1105<br />
abstract author Index<br />
387
abstract author Index<br />
Lee, Y 322, 388, 624<br />
Lee, Y 531, 676<br />
Lee, Y 1780<br />
Lee, Z 676<br />
Leech, M 1980<br />
Lefevre, P 869<br />
Lefèvre, S 147, 1063<br />
Lehman, T 1713<br />
Lehman, TJ A 884<br />
Lehman, TJ.A. 513<br />
Lehnigk, U 1072<br />
Lei, W 841<br />
Leib, E 162<br />
Leibling, M 643<br />
Leigh, C 1545<br />
Leirisalo-Repo, M 1161, 1181<br />
Leirisalo-Repo, M 273, 336, 2155<br />
Leisen, J 798, 1152, 1913<br />
Leite, V 1739<br />
Lek, P 1778<br />
Lema, B 391, 1446, 1452<br />
Lemaire, R 56<br />
Lemann, M 283, 1033<br />
Lemar, H 1984<br />
Lemmey, AB 346<br />
Lems, W 639, 1705<br />
Lems, W 1273, 1274<br />
Lems, WF 965, 1548, 1804<br />
Lems, WF. 1020<br />
Lenert, L 1814<br />
Leon, EP 1012<br />
Leon, JM 1100<br />
Leon, Y 1029<br />
Leonard, MB 239, 2177<br />
Leonard, S 640<br />
Leoni, P 45, 63<br />
Lepajolec, C 1360<br />
Lepore, L 222, 2178<br />
Leppert, PC. 1922<br />
Lequerré, T 961<br />
Leroux, G 1125, 1946<br />
Leslie, DM. 2123<br />
Lessard, C 811<br />
Leung, BPL 436, 1149<br />
Leung, KY 609<br />
Leung, YYing 605<br />
Levarht, EWN 390<br />
Levarht, N 382, 725<br />
Levartovsky, D 1025<br />
Levesque, MC 1091<br />
Levesque, MC. 1102<br />
Levin, R 1555<br />
Levin, R 428<br />
Levine, Y 926<br />
Levy, DM 244, 877, 882, 883, 1384<br />
Levy, EN 1559<br />
Levy, GD 281, 1820<br />
Levy, L 798, 1152, 1913<br />
Levy, RA. 1204<br />
Levy-Neto, M 2068<br />
Lewallen, D 1735, 2113<br />
Lewander, P 1455<br />
Lewiecki, EM 619<br />
Lewiecki, EM. 1556<br />
Lewiecki, E 2139<br />
Lewis, C 213, 214, 1703<br />
Lewis, CE 742, 1694, 2053<br />
Lewis, CElizabeth 807<br />
Lewis, C 2115<br />
Lewis, C 196<br />
Lewis, CE. 198<br />
Lewis, EJ. 443<br />
Lewis, E 1913<br />
Lewis, EE 798, 1152<br />
Lewis, E 939<br />
Lewis, MJ 441<br />
Lewis, S 763<br />
Lheritier, K 1681<br />
Lhote, F 1244<br />
Li, EK 1155<br />
Li, EK. 609, 1915<br />
Li, EKwok-Ming 605<br />
Li, J 960<br />
Li, J 305, 726<br />
Li, L 1314<br />
Li, L 1259<br />
Li, M 609<br />
Li, M 446, 1001, 2091<br />
Li, N 1082<br />
Li, Q 1314, 2125<br />
Li, R 628<br />
Li, S 528<br />
Li, S 1508<br />
Li, S 1282<br />
Li, T 503, 950<br />
Li, TT 102<br />
Li, TK. 609, 1915<br />
Li, T 70, 79, 81, 304, 1255, 1489,<br />
1496, 2171<br />
Li, W 850, 1794, 2055<br />
Li, X 1320<br />
Li, X 77, 100<br />
Li, X 549<br />
Li, Y 1771<br />
Li, Y 841<br />
Li, Y 397, 523, 1969<br />
Lian, T 436, 1147, 1149<br />
Liang, KP 1236<br />
Liang, KP. 683<br />
Liang, L 845<br />
Liang, M 1507<br />
Liang, MH. 80<br />
Liao, KP 1061, 2150<br />
Libby, CJ 1382<br />
Liberzon, I 116, 117<br />
Libianu, S 182<br />
Lichtenberger, LM 860<br />
Lidington, E 708, 709<br />
Lidsky, M 161, 183<br />
Lidtke, R 187, 188, 2073<br />
Lie, D 1886<br />
Lien, G 2081<br />
Lim, BW 764<br />
Lim, M 573, 822<br />
Lim, SSam 505, 506<br />
Lima, FR 1563, 1677<br />
Limb, C 2070<br />
Limburg, PC 703<br />
Limón-Camacho, L 1114, 1752<br />
Lin, HW 170<br />
Lin, J 134<br />
Lin, J 1363<br />
Lin, L 74<br />
Lin, L 672<br />
Lin, P 70<br />
Lin, P 672<br />
Lin, S 1022<br />
Lin, S 682, 957, 960, 1806<br />
Lin, S 305<br />
Lin, W 689<br />
Lin, WF 1842, 1895<br />
Lin, YH 1621<br />
Linardakis, C 393<br />
Lindegaard, H 1881<br />
Lindegaard, H 1042, 2180<br />
Lindegaard, HMerete 1440<br />
Lindgren, H 1506<br />
Lindquist, E 2047<br />
Lindqvist, E 983<br />
Lindsley, HB 1559<br />
Lineker, S 172<br />
Lingala, B 74, 2114<br />
Linnik, MD 435<br />
Linton, MF 1146<br />
Lions, C 1371<br />
Lioté, F 1048<br />
Lipford, G 1310, 1596<br />
Liphaus, BL 1726<br />
Liphaus, BL. 886<br />
Lippuner, K 623<br />
Lips, PT. 1020<br />
Lipsky, P 2125<br />
Lipsky, PE. 1982<br />
Lires-Deán, M 391, 1446, 1452<br />
MISSING: Lis S Andersen, Ole<br />
Majgaard, Anne Gitte Loft, Jon, E<br />
Lisa, C 1106<br />
Lisanti, MP 2058<br />
Lisbona, P 1549<br />
Lisse, J 427<br />
Lisse, JR. 1689<br />
Lisse, JR 1268<br />
Listing, J 751<br />
Listing, J 342, 730, 753<br />
Litinsky, I 1025<br />
Littlejohn, T 309<br />
Littlejohn, TW 1681<br />
Liu, C 1363<br />
Liu, DT 442<br />
Liu, H 41<br />
388
Liu, K 1314<br />
Liu, M 1310<br />
Liu, P 1601<br />
Liu, X 1336<br />
Liu, Y 739<br />
Liu, Z 1473<br />
Liveborn, M 1821<br />
Ljung, L 260<br />
Ljung, L 1006<br />
Llanos, C 1435<br />
Llorente, L 1133<br />
Lloyd, EJ 757, 1622<br />
Lo, G 202, 203, 2077<br />
Lo, G 1900<br />
Lo, N 1508<br />
Lobito, AA 856<br />
Lobitz, P 1293<br />
Lochting, I 2047<br />
Lockard, MA 1269, 2074<br />
Lockshin, MD 1398<br />
Loddenkemper, C 577<br />
Loeffler, B 781, 1614<br />
Loell, IM 1656<br />
Loeser, RF 1448<br />
Loeuille, D 645, 694, 1576<br />
Loh, C 400, 408, 1312<br />
Loh, Y 1229<br />
Lohmander, S 1485<br />
Lohse, A 1156<br />
LOIRE, R 705, 1240<br />
Loiseau, P 1085, 1087<br />
Lomont, ABarranjard 1013<br />
Lomonte, AB 1842, 1895<br />
Lomonte, AB 1018<br />
Londou, A 871<br />
Long, D 1448<br />
Long, KR 787<br />
Looney, C 739<br />
Looney, R 1424<br />
Lopes, JB 1469, 1560<br />
López, J 847<br />
Lopez, L 929<br />
López de Padilla, CM 2066<br />
López-Armada, MJ 391, 1446, 1452<br />
Lopez-Benitez, J 892<br />
López-Longo, F 1898<br />
Lopez-Olivo, MA. 94, 95, 161, 183,<br />
973, 1738, 2109<br />
Lopez-Pedrera, C 2057<br />
Lord, GM 1302<br />
Lord, P 754, CRC11<br />
Lorenz, H 433<br />
Lorenz, RG 1299<br />
Lories, RJ 1182<br />
Lories, RJ.U. 717<br />
Lorig, KR 723<br />
Losina, E 84, 687, 832, 1693<br />
Lottenburger, T 1881<br />
Lottenburger, T 1042, 1440, 2180<br />
Loubiere, LS 34, 368<br />
Loughlin, J 1445<br />
Louie, J 726<br />
Louie, JS 643<br />
Lovell, DJ 679, 680, 682, 959<br />
Lovell, DE 2162<br />
Lovell, DJ 681, 895<br />
Lovell, DJ. 1282<br />
Lovy, MR 963<br />
Low, JM 901, 1716<br />
Low, PS 663, 690<br />
Lowe, VJ 663<br />
Lowenstein, M 695<br />
Loy, A 249<br />
Loza, E 1159<br />
Lozano, E 128, 784, 1230, 1483<br />
Lozano, F 1399, 1577, 1594, 1595,<br />
1795<br />
Lu, Q 841<br />
Lu, R 1364<br />
Lu, Y 1476<br />
Lubatti, C 11, 12<br />
Lubberts, E 675, 1297<br />
Lubin, S 80<br />
Lubrano, E 606, 610<br />
Lucas, M 2<br />
Lucero, M 292<br />
Luchi, M 215, 2077<br />
Luckey, M 2138<br />
Luera, N 2070<br />
Luggen, M 699<br />
Luggen, M 291<br />
Lui, L 201<br />
Luis, ER 1355<br />
Lukert, BP 1559<br />
Lukitsch, I 1215<br />
Lum, C 723<br />
Lunardi, F 1640<br />
Lundberg, I 1632<br />
Lundberg, IE 1656, 1667, 1671, 2067,<br />
2189<br />
Lundberg, K 1303, 1437<br />
Lundell, D 1748<br />
Lundstedt, T 1778<br />
Lundstr�m, E 1003<br />
Lundstr�m, E 1002<br />
Lundström, E 536<br />
Luning Prak, N 1091<br />
Lunt, M 320, 754, 908, 909, 1343,<br />
CRC06, CRC11<br />
Luo, L 560<br />
Luo, MP 1494<br />
Luo, S 1883<br />
Luo, Y 818, 1505<br />
Luo, Y 841<br />
Luosujärvi, R 273, 2155<br />
Lupus Interferon Skin Activity Study<br />
(LISA) Invest, i 1315<br />
Lupus Interferon Skin Activity Study<br />
Investigators, 428<br />
Lutterodt, F 425<br />
Luukkainen, R 670, CRC37<br />
Luukkainen, R 2155<br />
Luyrink, L 1281<br />
Luyrink, LK. 1709<br />
Luyten, FP 1439<br />
Luyten, FP. 717<br />
Ly, TT 1575<br />
Ly-Pen, D 1646<br />
Lyden, AK 112, 114, 1527<br />
Lyden, ER. 766<br />
Lyles, J 721<br />
Lyles, K 666<br />
Lynch, J 200, 202<br />
M<br />
M. Petri, M. Khamashta, J 1960<br />
Ma, C 1883<br />
Macchioni, P 1228, 1231<br />
MacDermott, E 884<br />
Macdonald, L 755<br />
MacDonald, PA 757, 758, 1622<br />
MacDonald, TM 1681<br />
Macedo, A 611<br />
Macedo, AM 338<br />
Macfarlane, GJ 712, 1491, 1498,<br />
1518, 1530<br />
MacGregor, A 2017<br />
Machold, K 2103<br />
Machold, KP 1185<br />
Machuy, D 142<br />
Macías-Hernández, SI. 1687<br />
Maciaszek, JW 1583<br />
Maciejewska, H 44, 375, 1429<br />
Macip-Rodríguez, P 1752<br />
Mackay, M 532, 1318<br />
Mackey, D 201<br />
Mackman, N 1335<br />
Macksymowych, W 558<br />
Mackworth-Young, C 1411<br />
Maclean, JR 102<br />
Maclean, R 83<br />
MacLean, R 70, 79, 81, 304, 1255,<br />
1810<br />
MacPeek, D 591, 952, 1022, 1803<br />
Madaio, M 415<br />
Maddipati, R 856<br />
Maddison, P 507, 508, 509, 1918<br />
Maddison, P 19, 450<br />
Maddison, PJ 346<br />
Madej, M 791, 795<br />
Mader, R 1617<br />
Madhok, R 968, 977, 979<br />
Madsen, HOle 385, 1042<br />
Maduskuie, VL 240, 894<br />
Maduskuie, VL. 2175<br />
Maestroni, L 744<br />
Maezawa, Y 1943<br />
Magalhaes, CS 2179<br />
Magaziner, J 666<br />
abstract author Index<br />
389
abstract author Index<br />
Magder, L 438, 439, 440, 449, 1121,<br />
1122, 1392, 1928, 1929, 1935,<br />
2090, 2158<br />
Magder, LS. 448, 1926, 1927<br />
Maghnie, M 904<br />
Maglione, W 2145<br />
Magnani, A 788<br />
Magni-Manzoni, S 245, 904, 913,<br />
2178<br />
Magnusson, M 365<br />
Magnusson, S 1006<br />
Magrey, MN 867, 868, 2004<br />
Magrini, F 261<br />
Magrini, F 257<br />
Maguna, M 1214<br />
Maher, NE 537, 551, 1064<br />
Maher, NE. 341, 1889, 2187<br />
Maheu, E 662<br />
Mahoney, J 1928, 2090<br />
Mahoney, JA. 1926, 1927<br />
Mahowald, ML 1293, 1688<br />
Mahr, AD 1244, 2012, 2014<br />
Mahrban Moqadam, Q 1685<br />
Maier, A 1028<br />
Maier, SM 1080<br />
Maillard, S 2178<br />
Maillefert, J 333<br />
Main, C 2037<br />
Maisonobe, T 1630<br />
Maixner, W 103<br />
Majdan, M 333<br />
Majeski, P 1293<br />
Majgaard, O 2180<br />
Mak, TW 410<br />
Mäkinen, H 1502<br />
Makinen, S 1310<br />
Makkuni, D 706<br />
Makol, A 343<br />
Makrygiannakis, D 359<br />
Makrygiannakis, D 393, 1784<br />
Maksymowych, W 616, 1186<br />
Maksymowych, WP 557, 585, 586,<br />
587, 588, 589, 655, 1164, 1165,<br />
1166, 1167, 1322<br />
Maksymowych, WP. 560<br />
Malaise, M 324<br />
Malamet, RL. 800<br />
Malattia, C 227, 904<br />
Malaviya, AN. 343<br />
Maldonado, M 1376<br />
Malek, Z 1226<br />
Malesci, D 582<br />
Malik, A 1627<br />
Malik, S 1136<br />
Malizos, KN 1445<br />
Mallen, CD 1275<br />
Malleson, P 1385<br />
Mallon, C 1167<br />
Malmstrom, V 1436, 1437, 1667,<br />
1671<br />
Maltinti, M 1213<br />
Malysheva, O 538, CRC18<br />
Mameli, A 647<br />
Mamelli, A 574<br />
Mamura, M 371<br />
Mamyrova, G 252<br />
Man, Z 2140<br />
Manadan, AM 315, 316, 1023<br />
Manary, S 2106<br />
Mandel, D 944<br />
Mandell, B 1346<br />
Maneiro, E 1451<br />
Manetti, M 1217<br />
Manger, B 1181<br />
Mangueira, C 1739<br />
Mangueira, CL. 886<br />
Manheim, LM 836<br />
Manjarrez-Orduno, N 1427<br />
Mann, H 1667<br />
Mannalithara, A 312, 313<br />
Manning, AM 1749<br />
Manning, J 221<br />
Manning, JB 24<br />
Manning, SC 320, CRC06<br />
Manoussakis, MN 1357<br />
Mansfield, PJ 1475, 1623, 1756<br />
Mansilla-Lory, J 192<br />
Manson, JE 360<br />
Mansour, A 884<br />
Mantika, I 1159<br />
Mantilla, RDario 1642<br />
Mantovani, LG 606<br />
Manz, R 1413<br />
Manzi, S 503<br />
Manzi, S 1960<br />
Manzi, S 450, 1363<br />
Manzi, SM 2159<br />
Manzi, Rosalind Ramsey-Goldman,<br />
S 2157<br />
Mao, S 132, 2134, 2135<br />
Maradit Kremers, H 683, 1004, 2185<br />
Maratheftis, CI 1357<br />
MARCH, L 1499, 1702, 1740<br />
Marchesoni, A 610<br />
Marchetti, G 763<br />
Marchini, M 1973<br />
Marco, F 847<br />
Marcora, SM 346<br />
Marcos, M 1751<br />
Marcus, D 161, 183, 739<br />
Marcus, R 665<br />
Marder, W 798, 1152, 1913<br />
Mariano, MT 1224<br />
Marie, S 886<br />
Mariette, X 283, 1033, 1051, 1085,<br />
1086, 1087, 1089, 1249, 1360<br />
Marijnissen, ACA 1676<br />
Marin, F 665<br />
Marini, A 249<br />
Marinou, I 1066<br />
Marinov, AD 1715<br />
Marion, M 2124<br />
Marion, MC 514, 2000, 2079<br />
Marjanovic, N 782<br />
Marjanovic, Z 31<br />
Marker, H 1678<br />
Markland, J 1049, 1836<br />
Markowitz, M 892<br />
Marks, B 1311<br />
Marks, LD 630<br />
Maroli, AN 1621<br />
Maroni, S 456<br />
Marotte, H 547, 790<br />
Marques-Neto, J 1204<br />
Marquet, P 432, 1123<br />
Marra, C 80<br />
Marra, CA 1272<br />
Marra, CA. 100<br />
Marshak-Rothstein, A 1583<br />
Marshall, DR. 1765<br />
Marshall, M 210, 211, 212, 658<br />
Marshall, SW 808<br />
Martel-Pelletier, J 661, 1463<br />
Martens, AC 938<br />
Martin, B 1164<br />
Martin, C 1024<br />
Martin, C 263<br />
Martin, DA 1309<br />
Martin, DA. 411<br />
Martin, J 1245, 1973<br />
Martin, M 744<br />
Martin, P 1950<br />
Martin, R 26, 309, 2163, 2165<br />
Martin, RW 159<br />
Martin, S 715, 1524<br />
Martin, TM 559<br />
Martin, TM. 560, 1742<br />
Martín Mola, E 600, 604, 646<br />
Martin-Mola, E 1161<br />
Martín-Mola, E 603, 613<br />
Martindale, J 752<br />
Martinez, A 180<br />
Martínez, A 1887<br />
Martínez, C 1040<br />
Martinez, L 409<br />
Martinez Gamboa, L 1079<br />
Martinez- Vidal, P 1934<br />
Martínez-Berriotxoa, A 1648<br />
Martinez-Doncel, A 1053, 1076<br />
Martinez-Lavin, M 192<br />
Martinez-Lavin, M 104<br />
Martini, A 679, 680, 2179<br />
Martini, A 227, 233, 245, 681, 857,<br />
895, 904, 913, 2082, 2178<br />
Martino, S 2082<br />
Martinot, M 2016<br />
Maruyama, J 1902<br />
Mary Anne Dooley, I 1115, 1116<br />
Marzan, K 2083<br />
Marzo-Ortega, H 1157<br />
390
Maschek, S 659<br />
Masciocchi, M 1212<br />
Mashida, A 824<br />
Masi, AT 800, 801<br />
Maskala-Streff, L 189<br />
Mason, D 277, 700, 941<br />
Mason, E 1251<br />
Mason, JC 708, 709<br />
Massai, C 1731<br />
Massardo, L 1983<br />
Massarotti, E 81<br />
Massarotti, EM 1900<br />
Mastbergen, SC 1457, 1683<br />
Masuda, I 33<br />
Masuko, K 1450, 1467, 2011<br />
Mat, C 1248<br />
Matarese, G 1955<br />
Mateo, I 1934<br />
Mateo, L 1574<br />
Mathew, S 1647<br />
Mathews, R 635<br />
Mathian, A 1970<br />
Mathieson, PW. 130<br />
Mathieu, A 574, 606, 610, 647<br />
Mathieu, S 135, 1989<br />
Mathony, K 225<br />
Mathsson, L 515, 1430<br />
matignon, m 2008<br />
Matinez-Gamboa, L 142<br />
Matshushita, T 48<br />
Matshushita, Y 48<br />
Matsubara, T 1878, 2181<br />
Matsudaira, R 349<br />
Matsui, H 371<br />
Matsui, K 1662<br />
MATSUI, Y 1515<br />
Matsuishita, T 50<br />
Matsumoto, I 371, 387, 412, 671,<br />
793, 914, 934, 1071, 1083, 1753,<br />
1759<br />
Matsumoto, K 936<br />
Matsumoto, N 1938, CRC12<br />
Matsunawa, M 329, 1096, 1441,<br />
1660, 1896, 2005<br />
Matsuoka, N 1611<br />
Matsushita, M 349<br />
Matsushita, M 1834<br />
Matsushita, T 1209<br />
Matsuura, E 1407<br />
Matsuzaki, Y 1902<br />
Matteson, EL 262<br />
Matteson, E 663<br />
Matteson, EL 690, 1011, 1236<br />
Matteson, EL. 1052<br />
Matthews, E 2163, 2165<br />
Mattioli, C 373<br />
Mattison, C 1262<br />
Matucci Cerinic, M 606<br />
Matucci-Cerinic, M 1212<br />
Matucci-Cerinic, M 14, 30, 1200,<br />
1217, 2162, 2164<br />
Matucci-Cerinic, M 1<br />
Matucci-Cernic, M 951<br />
Matzelle, M 414<br />
Matzinger, M 242<br />
Matzkin, E 2140<br />
Mauerhan, D 781, 1614<br />
Maury, E 282<br />
Mautalen, C 618, 666<br />
MAVRAGANI, CP 1093<br />
Mavragani, CP 872, 1358, 1602<br />
Mavreas, V 1914<br />
Mavrikakis, M 271<br />
Mavromati, M 1973<br />
Max, M 103<br />
Maxwell, J 1799<br />
Maxwell, T 1679<br />
Mayer, CT 760<br />
Mayes, M 26, 2163, 2165<br />
Mayes, MD 36, 38, 1207, 1208, 2162<br />
Mayo-Bond, L 713<br />
MAZIERE, J 1227<br />
Mazodier, K 869, 871, 1124<br />
Mazor, K 631<br />
Mazzantini, M 991<br />
Mazzone, A 372<br />
Mazzuca, S 1691, 1706<br />
Mazzuca, SA 1692<br />
McAdams, E 203<br />
McAdams, EL 199<br />
McAdams, EL. 2049<br />
McAlindon, M 1680<br />
McAlindon, T 202, 203, 2077<br />
McAlindon, T 352, 759<br />
McAlindon, TE 199, 1693, 1900<br />
McAlindon, TE. 2049<br />
McAlister, WH 892<br />
McAllister, C 2078<br />
McBeth, J 1491, 1498, 1518, 1530<br />
McCabe, D 1734<br />
McCahan, SM 241, 2176<br />
McCain, A 427<br />
McCallum, JA 1940<br />
McCarey, DW 1650<br />
McCarthy, CJ 1610, 1833<br />
McCarthy, D 414, 1989<br />
McCarthy, G 1616<br />
McCarthy, GM 1610, 1833<br />
McCauley, J 2188<br />
McCloskey, L 1903<br />
McClung, MR 2140<br />
McCluskie, M 1596<br />
McCormick, J 797<br />
McCormick, M 1772<br />
McCoy, M 1504<br />
McCree, P 216<br />
McCrindle, BW 1730<br />
McCulloch, CE 2062<br />
McCune, J 426<br />
McCune, WJoseph 522<br />
McCune, WJoseph 798, 1152, 1913<br />
McCurdy, G 1130<br />
McElhone, K 1918, 1937<br />
McEntegart, A 999<br />
Mcfadden, ERegis 702<br />
McGarvey, ML 1580<br />
McGhee, JL. 1710, 1711<br />
McGhee, T 1733<br />
McGinnis, R 559, 1321<br />
McGonagle, D 564, 1157<br />
McGwin, G 493, 1131, 1139, 1140,<br />
1919, 1930, 2124<br />
McHenry, MT 1317<br />
McHugh, GC 1352<br />
McHugh, N 507, 508, 509, 1181, 1374<br />
McHugh, N 1906, 1932<br />
McHugh, NJ. 2098<br />
McHugh, PF 864<br />
McIlraith, M 278, 681<br />
McIlraith, MJ 895<br />
McInnes, IB 518, 1990, 2085<br />
McIntyre, D 1507<br />
McKay, J 426, 1316<br />
McKee, R 1710, 1711<br />
McKellar, G 968, 977, 979, 999<br />
McKendry, RJ 165<br />
McKennan, SP 1701<br />
McKenzie, C 217, 218, 641<br />
McKenzie, T 804<br />
McKinney, L 2135<br />
McLaren, J 1932<br />
McLean, L 1098, 1099, 1432<br />
McLean, RR 2039<br />
McLean, SA 116, 117<br />
McLean, SA 103<br />
McLennan, C 208<br />
McLennan, CE. 209<br />
McLinden, D 912<br />
McMahon, A 910<br />
McMahon, G 1616<br />
McMahon, M 1001<br />
McMahon, MA 446, 2091<br />
McMorrow, JP 796<br />
McNair, PD 1091<br />
McNallan, KT 1732<br />
McNally, B 897, 1708, 1718<br />
McNearney, T 38<br />
McNoe, L 1072<br />
McPherson, D 2159<br />
McQueen, F 756<br />
McQueen, FM 1192<br />
Mcrann, M 1794<br />
McVeigh, GE 1317<br />
Meani, L 12<br />
Mease, PJ 583, 959, 960, 1160<br />
Mease, P 716, 941, 1525, 1526, 2084<br />
Mease, PJ 173<br />
Mease, PJ. 581, 1186, 2098<br />
Mebius, RE. 358<br />
Medeiros, AC 879, 1950<br />
abstract author Index<br />
391
abstract author Index<br />
Medich, J 681<br />
Medich, JR 895<br />
Medina, M 816, 1578<br />
Medrano, F 1648<br />
Medsger, TA. 2<br />
Meduri, G 718<br />
Mehta, BM 1390<br />
Mehta, H 522<br />
Mehta, J 734<br />
Mehta, M 25<br />
Mei, H 1413<br />
Meier, E 591<br />
Meier, FMP 147<br />
Meier, S 654<br />
Meini, A 857, 2082<br />
Meini A, Nukay A, for Paediatric<br />
Rheumatology Euro, p 891<br />
Meissner, B 970, 971, CRC29, CRC39,<br />
CRC42, CRC50<br />
Mejjad, O 543, 961, 1892<br />
Melichian, DS 2144<br />
Melikoglu, M 853<br />
Mellilo, N 1933<br />
Mellis, S 168, 220, 874, 1291<br />
Melo Gomes, JA 1712<br />
Melo-Gomes, J 679<br />
Melo-Gomes, JA 680<br />
Meloni, L 647<br />
Melson, P 912<br />
Melton, LJ 2143<br />
Ménard, J 961<br />
Mendelbaum, M 1025<br />
Mendelson, C 2029<br />
Mendelson, E 1025<br />
Menegus, M 1907<br />
Menezes, PR 1560<br />
Meng, L 1886<br />
Meng, M 820, 821, 1039<br />
Meng, W 1091<br />
Mensah, K 572<br />
Mensah, KA 153<br />
Menter, A 584<br />
Merkel, PA 2000, 2012, 2014, 2162<br />
Merlini, G 1296<br />
Merlini, G 857<br />
Meroni, PL 2179<br />
Meroni, P 1337, 1398<br />
Meroni, P 65, 1404<br />
Meroni for the APS group-Italian<br />
Rheumatol Society, P 1387<br />
Merrill, JT 426, 427<br />
Merrill, J 1960<br />
Merrill, JT 428, 450, 494, 1905, 2125<br />
Merrill, JT. 514, 1115, 1116, 2157<br />
Mertens, R 629, 1557<br />
Meschia, JF 1237, 1238<br />
Mesenbrink, P 618, 619, 623, 666<br />
Messing, S 99<br />
Messman, R 690<br />
Messmann, RA 663<br />
Metyas, S 2111<br />
Metyas, SK 124<br />
Metz, C 1983<br />
Meune, C 1373<br />
Meusch, U 2126<br />
Mevorach, D 1607, 1978, 2094<br />
Meyer, B 518<br />
Meyer, KH. 608<br />
Meyer, LH 367<br />
Meyer, LH. 1058, 1307<br />
Meyer, O 1373<br />
Meyers-Eaton, J 236<br />
Mezin, F 2108<br />
Meziti, S 565<br />
Miceli-Richard, C 1324<br />
Miceli-Richard, C 1051, 1085, 1086,<br />
1087, 1360<br />
Michael, AA 177, 345, 1672<br />
Michael, AA. 736<br />
Michael, H 144<br />
Michaelson, J 130, 413, 1962<br />
Michaud, K 80<br />
Michaud, K 280, 291, 323, 729, 803,<br />
969, 982, 1034, 1118, 1340, 1509,<br />
1520<br />
Michel, B 44, 375, 1429<br />
Michel, BA 745, 1059, 1591, 1598,<br />
2076, 2123, 2149<br />
Michel, JE 1480<br />
Michel, M 1124<br />
Michels, H 900<br />
Michelutti, A 373<br />
Michet, CJ 1236<br />
Micó, M 1090, 1648<br />
Miconnet, I 1586<br />
Midha, A 1772<br />
Mielants, H 324, 1493<br />
Mielenz, T 2042, 2052<br />
Mielenz, TJ. 1252<br />
Miettunen, PM 242<br />
Miettunen, P 233<br />
Miettunen, PM 224<br />
Migita, K 1294<br />
Migliaresi, S 1973, 2021<br />
Migone, T 2083<br />
Miguel, L 1427<br />
Mikdashi, JA 454, 1345<br />
Mikecz, K 920, 1458, 1465, 1481<br />
Mikkel Østergaard, 590<br />
Mikkelsen, K 169, 1632<br />
Mikolaitis, R 1113<br />
Mikolaitis, R 189<br />
Mikolaitis, RA 186<br />
Mikulis, B 217<br />
Mikuls, T 984, 1008, 1567, 1811<br />
Mikuls, TR 982, 2184<br />
Milano, A 40, 1216, 2144<br />
Milia, A 1217<br />
Millán, I 121, 1646<br />
MILLASSEAU, E 972<br />
Miller, CW 2033<br />
Miller, C 585<br />
Miller, D 492<br />
Miller, DV 1236, 1237, 1238<br />
Miller, F 252, 1655<br />
Miller, F 1658<br />
Miller, FW 1659<br />
Miller, JL 276<br />
Miller, P 619<br />
Miller, P 2138<br />
Miller, P 627, 1468<br />
Miller, PD 2139, 2141<br />
Miller, PD. 621<br />
Mills, K 1333<br />
Miltenburg, A 325<br />
Mimori, A 1150<br />
Mimori, T 495, 1670<br />
Mimura, T 1792, 1899<br />
Minden, K 895<br />
Minea, M 182<br />
Mineau, F 1463<br />
Miner, P 549<br />
Mínguez, S 1574<br />
Miniati, I 30<br />
Minnock, P 1821<br />
Minnock, P 1265, 1266, 1267<br />
Minor, MA 724<br />
Minota, S 1958<br />
Miossec, P 1041<br />
Miossec, P 547, 790, 1041<br />
Mirar Study Group, 332<br />
Misaghi, A 2127<br />
Mishra, N 416, 710, 1313, 1999<br />
Misra, R 1717<br />
Mistry, Y 116, 117<br />
Mithal, A 668, 737, 1339<br />
Mittereder, N 1417<br />
Miura, R 8<br />
Miura, Y 328, 396<br />
Miwa, Y 329, 1096, 1441, 1660,<br />
1896, 2005<br />
Mix, KS 796, 1590<br />
Miyachi, Y 1707<br />
Miyake, B 1907<br />
Miyake, S 932<br />
Miyaki, S 772<br />
Miyakuni, Y 1902<br />
Miyara, M 1970<br />
Miyasaka, N 296, 1338, 1793, 2069<br />
Miyashita, R 1968<br />
Miyatake, K 1834<br />
Mizuki, N 855<br />
Mizushima, Y 937<br />
Mjaavatten, MD 326, 1638<br />
Moallem, E 1758<br />
Mocchi, M 904<br />
Moder, KG 663<br />
Mody, E 608<br />
Modzelewski, J 2065<br />
Moebius, D 225<br />
392
Moeller, T 1958<br />
Moffit, K 1358<br />
Mogard, E 2031<br />
Mogg, R 599, 1176<br />
Mogun, H 2142<br />
Mohammad, A <strong>2007</strong><br />
Mohan, C 401, 436, 1149, 1286, 1314<br />
Mohan, M 126<br />
Moilanen, E 273, 2155<br />
Mok, C 444, 1108, 1109<br />
Mok, M 1941<br />
Molano, I 423, 1426<br />
Moldawer, L 397<br />
Moldawer, LL 1612<br />
Moldofsky, H 1539<br />
Molitor, J 69<br />
Moll, C 561, 1795<br />
Møller, BK 154, 1785<br />
Møller, BKuno 1786<br />
Molloy, ES 1235, 1643, 2018, 2020,<br />
2022<br />
Molloy, M 331, 1183<br />
Momohara, S 361, 542, 1067<br />
Monestier, M 415, 1309<br />
Monrad, SU 417, 1585<br />
Monrad, SU. 1584<br />
Monte, K 919<br />
Monteagudo, I 1898<br />
Montecucco, C 1101<br />
Montenegro-Rodrigues, R 1331<br />
Montgomery, DS 1066<br />
Montico, M 2175<br />
Montie, P 1262<br />
Montiel, J 1884<br />
Montiel-Manzano, G 1410, 1412<br />
Montisci, R 647<br />
Moon, H 1790, 1997<br />
Moon, K 531<br />
Moore, J 1065<br />
Moore, K 666<br />
Moore, L 1265, 1266, 1267<br />
Moore, S 1723<br />
Moore, TL 255, 901, 903, 1367, 1375,<br />
1716<br />
Moore, TL 24<br />
Moorjani, GR 177, 345, 451, 1672<br />
Moorjani, GR. 736<br />
Moorthy, LN 1519<br />
Moorthy, LNandini 884, 1713<br />
Moots, R 19, 651, 1600<br />
Moots, RJ 1014, 1198, 1222<br />
Mor, A 782<br />
Mora, G 1214<br />
Morales, M 2092<br />
Morand, E 1980<br />
Morand, EE 1756<br />
Morand, EF 773<br />
moranne, o 2008<br />
Morato, EFlávio 1891<br />
Morawietz, L 1079<br />
Morbach, H 405, 1721<br />
Mordoh, J 1214<br />
Morea, JM 125<br />
moreau, j 1366<br />
Moreau, M 661<br />
Morehouse, C 2135<br />
Morehouse, C 840<br />
Morehouse, CA 430<br />
Morehouse, C 761<br />
Morel, F 550<br />
Morel, J 144, 497, 498, 1249<br />
Moreland, L 950<br />
Moreland, LW 262, 957<br />
Moreland, LW 257<br />
Morell-Dubois, S 1371<br />
Morelli, A 373<br />
Moreno-Rubio, J 1751<br />
Moreta, E 99<br />
Morgan, A 552, 553, 1799, 2120,<br />
2122<br />
Morgan, G 2070<br />
Morgan DeWitt, E 74<br />
Morgenstern, DE 663<br />
Mori, M 1902<br />
Mori, S 1788<br />
Morimoto, C 1478<br />
Morimoto, D 383<br />
Morimoto, K 1779<br />
Morinobu, A 1897, 2182<br />
Moriondo, M 1731<br />
Moritz, F 2149<br />
Moriyama, K 146<br />
Moriyama, M 852<br />
Morris, A 1278<br />
Morrisey, J 1945<br />
Morrison, E 999<br />
Morriss, R 1491, 1498<br />
Morriss, RK 1530<br />
Morrissey, R 1370<br />
Morrow, S 1167<br />
Morrow, TJ 107<br />
Mosdol, H 1470, 1562<br />
Moser, K 811<br />
Moser, KL 1100, 1972, 1976<br />
Moses, N 1246, 1513<br />
Moshfeghian, A 640<br />
Mosquera, J 596, 1187<br />
Moss, R 1534<br />
Motsko, SP 1909<br />
Möttönen, T 336, 2155<br />
mougenot, b 2008<br />
Mougin, B 547, 790<br />
Mountz, JD 1285, 1299<br />
Mourao, ASP 1712<br />
Mouthon, L 1212<br />
MOUTHON, L 1373, 2024<br />
MOUTSOPOULOS, HM 1093<br />
Moutsopoulos, HM 872, 1357, 1358,<br />
1362, 1602<br />
Moutsopoulos, NM 1362<br />
Movasat, A 10<br />
Mowinckel, P 1864<br />
Mozaffarian, N 530<br />
Muchamuel, T 939<br />
Mudano, A 1553<br />
Mueller, A 1882<br />
Mueller, I 2174<br />
Mueller, RB 1062<br />
Mueller-Ladner, U 1<br />
Muir, L 1374<br />
Mukaida, N 49<br />
Mulero, J 1887<br />
Mullan, R 797<br />
Mullazehi, M 1430, 1877<br />
Müller, B 1572<br />
Müller, D 1215<br />
Müller, L 246<br />
Muller, R 670, CRC37<br />
Müller-Ladner, U 30, 147, 433, 1063,<br />
1158, 1217<br />
Müllner, J 355<br />
Mumm, S 892<br />
Mundwiler, ML 643<br />
Muñoz, E 1175<br />
Muñoz, P 121<br />
Muñoz, S 1399, 1577, 1594, 1595<br />
Muñoz, S 600, 604<br />
Muñoz-Chable, O 1687<br />
Muñoz-Fernández, S 603, 613<br />
Munson, M 929<br />
Mura, V 574<br />
Murad, YM 1481<br />
Murakami, S 347, 356<br />
Murakami, S 785, 854, 1030<br />
Murakawa, Y 852<br />
Muramatsu, M 1878, 2181<br />
Murata, M 824<br />
Murata, M 1450<br />
Muroi, E 1218, 1219, 1220<br />
Murphy, AJ 755<br />
Murphy, E 333<br />
Murphy, EP 796, 1590<br />
Murphy, L 720, 2054<br />
Murray, BJ 1500<br />
Murray, PK 1235<br />
Murru, V 1396<br />
Murtaza, A 135, 1989<br />
Murukutla, N 1098, 1099<br />
Mus, A 675, 1297<br />
Musberg-Galili, R 851<br />
Muschler, G 1737<br />
Mushtaq, S 315<br />
Musick, M 52, 2058<br />
Musser, DR 722<br />
Mustafa, Z 1445<br />
Mutatkar, S 723<br />
Mutlu, N 1828<br />
Mutti, A 1015<br />
Muvarak, N 1608<br />
Myers, A 910<br />
abstract author Index<br />
393
abstract author Index<br />
Myones, BL 878<br />
N<br />
Nĕmcová, D 681<br />
Na, K 571<br />
Nacci, F 222<br />
Nachman, PH 2023<br />
Nacionales, D 523, 1969<br />
Nacionales, DC 397, 398<br />
Nacionales, DC. 1612<br />
Nacken, W 1460, 1757<br />
Nackos, E 2092<br />
Nadig, RS 431<br />
Nadji, A 1232<br />
Nadler, DR 1282<br />
Nadler, SG 1798<br />
Naeem, M 1658<br />
Naessens, JM 837<br />
Nagasaka, Y 540<br />
Nagatomo, Y 1789<br />
Nah, S 1637, 1790, 1997<br />
Naim, A 174, CRC30, CRC31, CRC35,<br />
CRC36, CRC40, CRC46, CRC47<br />
Naiman, B 2135<br />
Nakada, H 1060<br />
Nakagawa, H 1334, 1400<br />
Nakagawa, N 1943<br />
Nakahara, H 301<br />
Nakahata, T 1707<br />
Nakajima, A 994, 1036, 1644<br />
Nakajima, K 1792, 1899<br />
Nakamura, H 353, 386, 1611, 1840<br />
Nakamura, H 1467<br />
Nakamura, T 936<br />
Nakamura, Y 1083<br />
Nakano, K 357<br />
Nakano, Y 2010<br />
Nakasa, T 772<br />
Nakasato, M 1793<br />
Nakashima, H 1026<br />
Nakayama, H 1902<br />
Nakazawa, T 1897<br />
Nakou, M 525<br />
Nakstad, B 911<br />
Nam, E 935, 1105<br />
Namey, TC 1097<br />
Namjou, B 527<br />
Nanke, Y 1071<br />
Nanki, T 1338, 2069<br />
Nannini, C 1052<br />
Napalkov, P 819, 825<br />
Napalkov, P 1909<br />
Naparstek, Y 1137, 1758<br />
Naparstek, Y 1978<br />
Naqibuddin, M 1134, 1319, 2095,<br />
2161<br />
Narain, S 500, 1612<br />
Narang, J 551<br />
Naranjo, A 670, CRC37<br />
Narasimulu, G 949<br />
Narayana, S 2095<br />
Nardacchione, R 592, 1640<br />
Nardi, N 1594, 1595<br />
Narita, H 1779<br />
Narukawa, T 1834<br />
Narula, SK 1748<br />
Narvaez, J 652, 1009, 1038, 1184,<br />
1894<br />
Narvaez, J 652, 1038, 1894<br />
Nasello, M 1907<br />
Nash, P 2164<br />
Nasir, A 282<br />
Nasonov, EL 1296<br />
Natalia, Z 1824<br />
Natarajan, N 1539<br />
Nath, SK 501, 839, 1287<br />
Näther, M 1215<br />
Natter, M 892<br />
Naumann, L 314, 654<br />
Naureckas, E 862<br />
Navarro, TP 1128<br />
Nawata, M 1939<br />
Naz, SM 1000<br />
Nazarian, RM 1369<br />
Nazmul-Hossain, AN.M. 1100<br />
Neate, C 1547, 2139<br />
Nedelec, B 565<br />
Nedovic, J 333<br />
Neeck, G 967<br />
Neely, A 103<br />
Neff, J 1724<br />
Negishi, M 329, 1096, 1441, 1660,<br />
1896, 2005<br />
Negoro, N 496<br />
Neidhart, M 375, 745, 1044, 1429,<br />
1591<br />
Neilan, C 1771<br />
Nelissen, RG.H.H. 2104, 2105<br />
Nell Duxneuner, VP 1185<br />
Nelson, AE 740<br />
Nelson, E 1268<br />
Nelson, J 34, 368, 1046<br />
Nelson, JLee 1049<br />
Nelson, S 234, 235, 236<br />
Nemec, P 789<br />
Nemelivsky, Y 1449<br />
Neogi, T 208, 685, 806, 1686<br />
Neogi, T 205, 209, 2062<br />
Neri, R 991<br />
Nesher, G 704<br />
Nesher, R 704<br />
Nesspor, T 274<br />
Netea, MG 2130<br />
Neugebauer, K 367, 389, 1058, 1307,<br />
2110<br />
Neumann, E 147, 1063, 1217<br />
Neumann, G 648<br />
Neumann, L 1529, 1540<br />
Nevitt, M 200, 201, 202, 213, 214,<br />
742, 1703, 2115<br />
Nevitt, MC 1694, 2053<br />
Nevitt, M 198<br />
Nevitt, M 196, 659, 2075, 2116<br />
Nevitt, MC 2062<br />
Nevitt, MC. 807<br />
Newkirk, MM. 1836<br />
Newman, AB 2075<br />
Newman, E 669<br />
Newman, ED 731, 735<br />
Newmark, R 944<br />
Newmark, R 337, 698, 953<br />
Newton, C 116, 117<br />
Newton, KR 1719<br />
Newton, R 1771<br />
Ng, B 161<br />
Ng, B 183<br />
Ng, C 746<br />
Ng, C 308, 330, 331, 1183<br />
Nghiem, A 416<br />
Ngo, D 1980<br />
Nguyen, AB. 1725<br />
Nguyen, KD 156<br />
Nguyen, M 180<br />
Nguyen, T 180, 2183<br />
Nguyen, TP 1986<br />
Nguyen, T 1596<br />
Nguyen, V 1966<br />
Nguyen-Khoa, B 1909<br />
Ni, L 1684<br />
Ni, P 1486, 1700<br />
Niaudet, P 880<br />
Nicassio, P 1120<br />
Nicchitta, CV 1075<br />
nicco, c 1366<br />
Niccoli, A 248<br />
Nichol, MB 630<br />
Nicholas, AP 359<br />
Nicholl, BI 1491, 1498<br />
Nicholl, R 1906<br />
Nicholls, E 2051<br />
Nichols, M 951<br />
Nickdel, MB 1990<br />
Nicklin, JK 2045<br />
Nicklin, MJ.H. 1298<br />
Nicol, A 1772<br />
Nicola, PJ 1712<br />
Nicoli, D 788, 1231, 1805<br />
Niculescu, F 1966<br />
Nielen, MM. 1831<br />
Nielsen, HJ 1881<br />
Nielsen, RH. 1767<br />
Nienhuis, HL 1964<br />
Nieskowska, A 1946<br />
Niewold, TB 513, 872<br />
Nigh, M 724<br />
Nigon, D 541<br />
Nihtyanova, SI 9<br />
Niimi, M 1060<br />
Nijhuis, F 127<br />
394
Nikpour, M 1143<br />
Nilsson, J 374, 993, 1818<br />
Nilsson, K 286, 1818<br />
Ninan, E 1937<br />
Ninet, J 1394, 1645<br />
Nir, A 2094<br />
Nishi, K 13<br />
Nishida, K 772<br />
Nishikaku, F 540<br />
Nishikomori, R 893, 1707<br />
Nishimagi, E 18<br />
Nishimoto, N 296, 301<br />
Nishimura, K 1036<br />
Nishimura, K 1897, 2182<br />
Nishio, S 1826, 1938, CRC12<br />
Nishioka, K 1450, 2011<br />
Niu, F 281, 1820<br />
Niu, J 195, 197, 206, 208, 213, 214,<br />
215, 216, 805, 1694, 1703, 2077<br />
Niu, J 123, 196, 198, 204, 205, 209,<br />
807, 2115, 2119<br />
Nived, O 450, 1132<br />
Nocton, J 236, 885<br />
NOEL, D 2060<br />
Noel, W 324<br />
Nogami, Y 285, CRC13, CRC14<br />
Nogueira, L 1829<br />
Noguti, MA E 1391<br />
Nojima, T 495<br />
Nolla, JM. 1009, 1184<br />
Nolla, J 652, 1038, 1894<br />
Nomura, K 1074, 1773<br />
Nonogaki, S 1361<br />
Nonomura, Y 1793<br />
Noordenbos, T 575<br />
Norambuena, A 1983<br />
Norambuena, X 245<br />
Norifumi, S 357<br />
Noronha, A 862<br />
Norris, JM 748<br />
North <strong>American</strong> Rheumatoid Arthritis<br />
Consortium (NA, R 2121<br />
Norton, EC. 1252<br />
Nossent, J 424<br />
Nosyk, B 100<br />
Noth, I 861<br />
Notkins, AL. 1082<br />
Notterman, D 1713<br />
Novak, J 1423<br />
Novak, L 1423<br />
Novofestovsky, I 1617<br />
Nowak, B 791, 795<br />
Nozaki, T 1826<br />
Nuite, M 203<br />
Nuite, M 199, 2049<br />
Nunes, MJ 1018, 1842, 1895<br />
Nurmohamed, MT 380<br />
Nyberg, F 1965<br />
Nygaard, H 326, 1638<br />
Nyhäll-Wåhlin, B 993<br />
Nzeusseu Toukap, A 1796<br />
Nzeusseu-Toukap, A 1801<br />
O<br />
O’Brien, CM 2028<br />
O’Brien, E 1538<br />
O’Brien, K 494<br />
O’Brien, M 1641<br />
O’Brien, MS 15, 1211<br />
O’Connor, A 702<br />
O’Connor, P 651<br />
O’Dell, JR 982<br />
O’Dell, JR. 766<br />
O’Donnell, J 1800<br />
O’Donnell, JB 1734<br />
O’Flynn, E 331, 1183<br />
O’Gorman, J 947<br />
O’Hanlon, T 252<br />
O’Mahoney, M 143, 2128<br />
O’Neil, K 234, 235<br />
O’Neil, KM 1724, 1725<br />
O’Neil, KM. 1710, 1711<br />
O’Neill, M 1265, 1266, 1267<br />
O’Neill, SG 2093<br />
O’Prey, FM 1317<br />
O’Reilly, D 1825<br />
O’Rourke, KS 1088<br />
O’Shea, F 1186<br />
O’Shea, FD 597, 598, 750, 898, 1168,<br />
1169<br />
O’Shea, FD. 1190<br />
O’Toole, G 1833<br />
O`Neill, S 1408<br />
Oakley, S 611<br />
Oakley, SP 338<br />
Oatis, CA 1269<br />
Obici, L 857, 2082<br />
Ochaion, A 1787<br />
Ochaion, A 851<br />
Ochani, M 926<br />
Ochi, M 772<br />
Ochoa, L 619<br />
Odai, T 329, 1096, 1441, 1660, 1896,<br />
2005<br />
Oddis, CV 1666<br />
Oddis, CV. 2068<br />
Odegard, J 1311<br />
Oding, R 260, 1821<br />
Oen, K 242<br />
Oen, K 1049<br />
Oeser, A 445, 1145, 1146, 1148<br />
Oestensen, M 823<br />
Oestergaard, S 1767<br />
Ogasawara, H 1942<br />
Ogawa, F 1218, 1219, 1220, 1606<br />
Ogawa, K 8<br />
Ogawa, T 8<br />
Ogawa, Y 1981<br />
Ogdie, AR 1068<br />
Ogura, T 8<br />
Oh, H 1764<br />
Oh, J 1790<br />
Oh, J 1997<br />
Ohashi, J 1968, 1971<br />
Ohlsson, C 1947<br />
Ohno, S 785, 854, 1030<br />
Ohnuma, K 1478<br />
Ohresser, M 1086<br />
Ohshima, S 1464, 1834, 2064<br />
Ohyanagi, N 2069<br />
OKADA, M 1515<br />
Okafuji, I 893, 1707<br />
Okamoto, A 1682, 1743<br />
Okamoto, H 361, 1036<br />
Okawa, J 1904, 2071<br />
Okay, TS 1104<br />
Okayama, A 1789<br />
Okazaki, Y 64, 1407<br />
Oki, S 932<br />
Oksenberg, JR 838<br />
Oku, B 812<br />
Oku, K 1406<br />
Okun, M 584<br />
Ola Nived, G 1115<br />
Ola Nived, G 1116<br />
Olarsch, S 1486, 1700<br />
Oldenhof, J 858<br />
Olech, E 1905<br />
Olenginski, TP 1347<br />
Olivé, A 287, 1574<br />
Oliveira, NC. 1563<br />
Oliveira, S 2178<br />
Oliver, SJ 864, 1647<br />
Oliver-Miñarro, D 1898<br />
Oliver-Miñarro, D 1221<br />
Oliveri, M 964<br />
Olivieri, I 1159<br />
Olivieri, I 606, 610, 2098<br />
Olivieri, M 1203<br />
Oliviero, F 592<br />
Ollier, WE 1666<br />
Olorenshaw, I 1088<br />
Olsen, N 1315<br />
Olsen, R 424<br />
Olson, E 710<br />
Olson, J 234, 235, 885, 1709<br />
Olson, JC. 236<br />
Olson, L 135, 414<br />
Olson, LM. 787<br />
Olson, N 681<br />
Olsson, T 422<br />
Omdal, R 456<br />
Omura, K 495<br />
on behalf of EUSTAR centers, 30<br />
abstract author Index<br />
395
abstract author Index<br />
on behalf of the ARIES Study Group,<br />
2166<br />
on behalf of the BSR Biologics<br />
Register, 754, 976, 1343, CRC11<br />
On behalf of the COBRA study group,<br />
965<br />
On Behalf of the QUEST-RA Group,<br />
333, 670, 1502, 1821, CRC37<br />
Onel, K 235, 236, 884, 885<br />
Onel, KB 1282<br />
Onel, K 234<br />
Onen, F 1653<br />
Onuma, K 396<br />
Onuma, S 1942<br />
Ooka, S 2011<br />
Opava, CH 2189<br />
Ophir, J 851<br />
Opitz, CF 2164<br />
Oral, EA 252<br />
Orav, JE 628<br />
Orbach, H 535<br />
Ordi-Ros, J 1973<br />
Oreiro, N 595, 596, 1187<br />
Oreiro, N 1887<br />
Origuchi, T 353, 386, 1611, 1840<br />
Orozco-Narváez, A 1133<br />
Orr - Urtreger, A 105<br />
Ortega, L 1751<br />
Ortiz, AM 1797<br />
Ortiz, J 1974<br />
Ortiz, KR 1842, 1895<br />
Ortiz, Z 94, 95<br />
Orwoll, E 2116<br />
Ory, P 944<br />
Ory, P 698<br />
Ory, R 278<br />
Osban, J 549<br />
Osborn, B 1458<br />
Osborne, R 160<br />
Osborne, RH 2044<br />
Osgood, G 1282<br />
Oshima, H 1551<br />
Oshita, K 136<br />
Osial, T 1487<br />
Ospelt, C 745, 1059, 1591, 1597,<br />
1598<br />
OSRA Study Group, 2151<br />
Ostelo, RW 765<br />
Oster, G 81<br />
Østergaard, M 1881<br />
Østergaard, M 2086<br />
Østergaard, M 1042, 1192, 2180<br />
Ostor, AJ K 122, 974<br />
Oszust, C 1354, 1355, 1569<br />
Oteng, B 1272<br />
Otieno, F 20<br />
Otkjaer, K 770<br />
Otley, A 1386<br />
Otsuka, M 892<br />
Ott, SJ 181<br />
Ottaviani, S 718<br />
Ottery, FD 1621<br />
Ottosson, L 422, 1359, 1727, 2059<br />
Ouimet, GM. 1649<br />
Out, T 366<br />
Owczarczyk, KM 1438, CRC25<br />
Owen, T 1424<br />
Ozaki, S 1205, 2011<br />
Ozdemir, S 351, CRC38<br />
Özden, I 1828<br />
Ozdogan, H 865, 1178<br />
Ozen, S 233<br />
Ozer, H 853<br />
Özer, H 2019<br />
Ozminkowski, R 1255<br />
Ozminkowski, RJ 79<br />
Ozturk, MA 1173<br />
Ozturk, Z 987<br />
Ozyazgan, Y 1248<br />
Pablos, JL 1040, 1472<br />
Pachman, LM 1669, 2070<br />
Pachot, A 547, 790<br />
Pacifico, D 2106<br />
Padeh, S 1720<br />
Padyukov, L 377, 536, 539, 545,<br />
2055, 2121<br />
Paessler, M 1356<br />
Page, CE 1782<br />
Paget, S 1253, 1349, 1384, 2041<br />
Paget, SA 2034<br />
Pagliari, LJ 2133<br />
Pagliaro, L 680<br />
Pagnin, E 1640<br />
PAGNOUX, C 2013, 2023, 2024<br />
Paige, CJ 1057<br />
Pak, C 973, 1738<br />
Pakozdi, A 711, 1225, 1480, 1756,<br />
1783, 2167<br />
Pala, D 57<br />
Palacin, A 561<br />
Palaganas, M 1495<br />
Palermo, L 623<br />
Palermo, N 1686<br />
Palieraki, K 1914<br />
Pallarés, L 1090, 1648<br />
Pallot-Prades, B 1033<br />
Palmer, G 1449<br />
Palmer, RH. 716, 1525, 1526<br />
Palmqvist, N 1778<br />
Paltiel, ADavid 84<br />
Paludan, SR 1769<br />
Panaccione, R 959<br />
Panayi, GS 338, 1589<br />
Pandey, J 252<br />
Pang, Y 109, 110, 714<br />
P<br />
Pangan, AL 959<br />
Pangan, AL 861<br />
Panigada, S 913<br />
Panigrahi, AK 418<br />
Panopalis, P 503<br />
Panopalis, P 78, 232, 1277, 1503,<br />
2118<br />
Paolino, S 964<br />
Paolozzi, L 270<br />
Pap, T 367, 375, 389, 392, 1058,<br />
1307, 1456, 1762, 2110<br />
Papa, M 1234<br />
Papa, S 364<br />
Papadaki, E 525<br />
Papadopoulos, I 295<br />
Papadopoulos, JH 1282<br />
Papadopoulos, NG 1910<br />
Papaioannou, A 1564, 1565, 1566<br />
Papalia, MC 373<br />
Papamichael, C 271<br />
Papasteriades, C 1973<br />
Pappas, DA 992<br />
Pappone, N 606<br />
Parameswaran, V 637<br />
Paran, D 1025, 1978<br />
Parikh, P 1675<br />
Parimi, N 2116<br />
Parise, C 630<br />
Parish, MC 748<br />
Parizot, C 1970<br />
Park, AJ 1893<br />
Park, B 813<br />
Park, CC. 924<br />
Park, DC 115<br />
Park, GB 1893<br />
Park, H 856<br />
PARK, H- 67<br />
Park, JY 782<br />
Park, J 1727<br />
Park, J 640<br />
Park, KS 177, 345, 1672<br />
Park, KS. 736<br />
Park, M 1977<br />
Park, M 1045, 1908<br />
Park, S 2030<br />
Park, S 1830<br />
Park, S 1442, 1443, 1944, 1977<br />
Park, W 1105<br />
Park, Y 1592<br />
Park, Y 1908<br />
Park, Y 1105<br />
Parker, A 537, 551<br />
Parker, D 1740<br />
Parker, JC 722<br />
Parker, TM 1111, 1949<br />
Parks, J 710<br />
Parlati, F 939<br />
Parmar, H 2085<br />
Parodi, A 233<br />
396
Parodi, M 1203<br />
Parrish, LA 748<br />
Parrish, LA. 1289<br />
Parsa, D 181<br />
Parsonage, G 562<br />
Partala, P 1910<br />
Pascual, E 1626<br />
Pascual, V 2070<br />
Pascual-Salcedo, D 1887<br />
Pashine, A 1749<br />
Passiu, G 574, 647<br />
Passo, M 234, 235<br />
Passon, D 1438, CRC25<br />
Pastor, C 816, 1578<br />
Pastrana, M 121<br />
Patel, DR 141<br />
Patel, J 846<br />
Patel, P 2070<br />
Patel, R 106, 108<br />
Pathipvanich, P 180<br />
Patkar, N 1024<br />
Patoka, R 851, 1787<br />
Patole, P 69<br />
Patra, K 302, 327, 1807<br />
Pattacini, L 788, 1231, 1805<br />
Patwardhan, B 949, CRC24<br />
Pau, E 408, 1312<br />
Paul, FL 1165<br />
Paul, SM 678<br />
Pauley, KM 1419<br />
Pauling, J 1176<br />
Paulos, C 690<br />
Paulus, H 1001<br />
Pavkova - Goldbergova, M 789<br />
Pavlitou-Tsiontsi, A 1910<br />
Pavlov, VA 926<br />
Pawlikowska, L 838<br />
Payen-Champenois, C 179<br />
Payne, D 1666<br />
Paz, E 679, 680<br />
Paz, E 1221<br />
Paz, N 551<br />
Peake, NJ 1729<br />
Pease, CT 1094<br />
Peat, G 193, 1275<br />
Peavy, GM. 692<br />
Peccin, MStella 1331<br />
Peck, A 69<br />
Peddle, L 557, 1322<br />
Pedersen, JK 1881<br />
Pedersen, JKristian 1042, 2180<br />
Pedersen, M 385<br />
Pedersen, R 265, 952, 1803<br />
Pedersen, SJ 590<br />
Pediatric Rheumatology Collaborative<br />
Study Group, 682<br />
Peers, K 1918<br />
Peeters, AJ. 2105<br />
Peeters, AJ. 2087<br />
Peeters, J 717<br />
Peets, T 333<br />
Peeva, E 395, 1421<br />
Pelagatti, M 249, 857, 2082<br />
Peleg, A 1540<br />
Peleg, R 1540<br />
Pellegrin, J 1124, 1366<br />
PELLET, H 705, 1240<br />
Pelletier, J 661, 1463<br />
Pellett, FJ. 2096<br />
Peltomäki, T 246<br />
Peluso, G 23<br />
Pena, AH 1850<br />
Pena Ayala, A 192<br />
Pendergrass, SA 40<br />
Pendleton, A 662<br />
Peng, J 1567<br />
Peng, SL 1749<br />
Penn, H 3, 63<br />
Pennings, MT 1410<br />
Perard, L 1394, 1645, 2025<br />
Perdok, RJ 583<br />
Pereira, IA 1012<br />
Pereira, IAlves 1891<br />
Pereira, PL 899<br />
Pereira, RM R 184<br />
Pereira, RM. R. 1469, 1560, 1563<br />
Pereira Silva, JA. 602<br />
Peretz, A 324<br />
Perez, JL 959<br />
Perez, JL 294<br />
Perez, M 1376, 1634<br />
Perez, MD 878<br />
PÉREZ, ML 1901<br />
Perez-Edo, L 1549<br />
Perez-Edo, L 1444<br />
Perez-Liz, G 851, 1787<br />
Perez-Ruiz, F 1615, 1626<br />
Perez-Valero, I 1395<br />
Perich, R 816, 1578<br />
Perles, Z 2094<br />
Perlman, H 401, 774, 1770<br />
Perna, M 447<br />
Perrett, JH 954, 2085<br />
Perrot, S 179<br />
Perruccio, AV 1485, 2032<br />
Persson, J 1010<br />
Pértega, S 595, 596, 1187, 1188,<br />
1189<br />
Peschken, C 881<br />
Peschken, C 1049, 1836<br />
PESCHKEN, CA 1110, 2160<br />
Pessler, F 760, 1068, 1356, 1542<br />
Peter, H 1199<br />
Peter, W 1273<br />
Peter J. Maddison, A 1115<br />
Peter Maddison, A 1116<br />
Peterfy, C 944<br />
Peters, E 653<br />
Peters, MA 389, 392, 1058, 2110<br />
Petersen, J 2086<br />
Peterson, C 598, 750<br />
Peterson, M 25, 884, 1713<br />
Peterson, M 337<br />
Peterson, PL 1959<br />
Petersson, IF 260<br />
Petersson, I 980, 993<br />
Petersson, IF 194, 1461, 1704, 2047<br />
Petit-Teixeira, E 1065<br />
Petraki, E 844<br />
Petri, M 426, 503, 1316<br />
Petri, M 437, 438, 439, 440, 448,<br />
449, 450, 452, 453, 499, 762, 997,<br />
998, 1007, 1116, 1118, 1121, 1122,<br />
1131, 1134, 1315, 1319, 1341,<br />
1390, 1392, 1916, 1925, 1926,<br />
1927, 1928, 1929, 1930, 1935,<br />
1936, 2056, 2090, 2095, 2124,<br />
2158, 2161<br />
Petri, MA 514<br />
Petri, MA. 1115, 2157<br />
Petrillo, A 2021<br />
Pettersson, S 1257<br />
Petty, R 881<br />
Petty, R 1385<br />
Petukhova, M 102<br />
Pfeffer, B 1384<br />
Pfeiffer-Jensen, M 120, 250<br />
Pflugbeil, S 1185<br />
Pham, C 921<br />
PHAM, T 1673<br />
Pham, T 219<br />
Pheneger, J 929<br />
Phillips, K 14, 1200<br />
Phillips, SB 1689<br />
Piccoli, A 592<br />
Pickard, AS 171, 1113<br />
Pickard, ASimon 170<br />
Pickard, L 1565<br />
Pickard, M 551<br />
Pickles, D 1163<br />
Pieper, C 666<br />
Pierangeli, S 1333<br />
Pierangeli, SS 1336, 1337, 1410, 1412<br />
Pierce, D 1602<br />
Piercy, H 1222<br />
Pierer, M 538, 1054, CRC18<br />
Pierucetti, LB 1013<br />
Pietrapertosa, D 373<br />
Pietrobattista, A 248<br />
Pietrogrande MC, Unsal U, Ozen S,<br />
Magni Manzoni S, , 891<br />
Piette, JCharles 151, 1629, 1630<br />
Piette, J 1242, 1394, 2002, 2025<br />
PIETTE, J 432, 705, 875, 1123, 1124,<br />
1125, 1226, 1240, 1946, 1970, 2016<br />
Pietz, K 739<br />
Piga, M 574, 647<br />
Pigenet, A 1447<br />
Pignac-Kobinger, J 1376, 1634<br />
Pijpers, E 633<br />
abstract author Index<br />
397
abstract author Index<br />
Pileckyte, M 43, 44, 2147<br />
Pileckyte, M 2149<br />
Pilkington, C 2178<br />
Pillinger, MH 782, 1349<br />
Pincus, T 333, 670, 1502, 1821,<br />
CRC37<br />
Pincus, T 163, 164, 311, 732, 978,<br />
1809, 1810<br />
Pinczewski, L 1740<br />
Pineau, CA. 1193, 1657<br />
Pineda, C 192<br />
Pineda, L 426, 427<br />
Pinnelli, M 23<br />
Pino, S 229, 230<br />
Pinto, A 1563<br />
Pinto, J 595, 596, 1187, 1188, 1189<br />
Pinto, J 1795<br />
Pinto, P 602, 1712<br />
Pipitone, N 1186, 1228, 1231, 1805<br />
Pippa, MG 1018<br />
Pippa, MGuadalupe 1013<br />
Piras, M 647<br />
Pisters, MF 765<br />
Pistorio, A 227, 245, 913<br />
Pitashny, M 410, 532<br />
Piton, A 1449<br />
Pitsillides, AA. 57<br />
Pittrow, D 2164<br />
Piva, SR 1271<br />
Pizzorni, C 1203<br />
Plaas, A 1458, 1465<br />
plaisier, e 2008<br />
Planck, SR. 1742<br />
Planelles, L 497, 498<br />
Plant, M 269<br />
Plass, N 219, 2027<br />
Plat, M 1652<br />
Plaza, J 1388, 1389, 1402, 1403<br />
Plebani, S 857<br />
Plenge, R 743, 2121<br />
Plenge, RM 537, 539, 850, 2055<br />
Poage, C 38<br />
Podda, R 2178<br />
Pødenphant, J 1881<br />
Pødenphant, J 339, 1042<br />
Podrebarac, T 951<br />
Poggio, E 702<br />
Pogosian, S 289<br />
Pohl, C 670, CRC37<br />
Pohlers, D 376<br />
Poholek, A 1311<br />
Pointon, JJ 559, 563, 1323<br />
Pointon, JJ 1321<br />
Polak, AA 1683<br />
Poliyedath, A 316, 1023<br />
Pollard, S 220<br />
Polzer, K 674, 1304, 1762, 1998,<br />
2003<br />
Pomar, J 1395<br />
Pombo-Suarez, M 1445<br />
Pomeroy, E 599, 1176<br />
Ponce de Leon, D 1578<br />
Poncet, C 179<br />
Pontifex, EK 331, 1183, 1191<br />
Poole, A 571<br />
Poole, BD 510, 1425, 1579<br />
Poole, JL 2029<br />
Poon, W 1109<br />
Popa, C 995, 1305<br />
Pope, J 26, 263, 804, 1110, 2163,<br />
2165, 2160<br />
Pope, JE 1197, 1199, 1649<br />
Pope, R 139, 786<br />
Pope, RM 2133<br />
Pope, RM. 384, 924, 1075<br />
Porcedda, Mathias Gruenke, E 610<br />
Porceddu, Philip Mease, R 610<br />
Porcher-Vasseur, N 1089<br />
Porru, G 574, 610<br />
Post, W 449, 997, 998, 1007, 1341,<br />
1928, 2090<br />
Postell, MM 894<br />
Posthumus, MD. 580<br />
POSTLETHWAITE, AE 67, 68, 1047<br />
Postma, MJ 71<br />
Poston, L 1396<br />
Poston, S 1556<br />
Potter, C 552, 553, 1799<br />
Potts, JE 243<br />
Pouchot, J 1511<br />
Poulain, C 566, 1325<br />
Poulain, C 767<br />
Poullin, P 869<br />
Poulton, KV 1666<br />
Pouplin, S 543<br />
Pourel, J 645, 694, 1576<br />
Powell, A 589<br />
Power, C 712<br />
Power, JDenise 2032<br />
Power, J 1258<br />
Prabu, A 507, 508, 509<br />
Prahalad, S 897, 1708, 1718<br />
Prak, NL 418<br />
Prak, NLuning 1102<br />
Prakken, BJ 938<br />
Prasad, P 210, 211, 212<br />
Predeteanu, D 182<br />
Prendergast, FG 663<br />
Preston, B 1984<br />
Preuss, A 1715<br />
Prevost, A 122<br />
Price, DD. 1538<br />
Prieto, S 128, 1230<br />
Prieur, AM 679, 680<br />
Prieur, A 681, CRC07<br />
Pringe, A 233<br />
Prior, CM 1833<br />
Pritchard, C 942<br />
Pritchard, CH 1580<br />
Prodinger, B 2103<br />
Prokopowitsch, AS 1144<br />
Propert, K 1904<br />
Prost, E 724<br />
Protogerou, A 271<br />
Proudfoot, AE. I. 924<br />
Proudman, S 1684<br />
Proulx, ST 1476<br />
Proulx, ST 691, 1750<br />
Proust, A 1087<br />
Provan, SA 1864<br />
Puechal, X 1085, 1086, 1652<br />
Pullerits, R 1791, 1885<br />
Pulsatelli, L 1228<br />
Punaro, M 236, 885<br />
Pundt, N 367, 389, 392, 1058, 1307,<br />
1762<br />
Punzi, L 592, 606, 1640<br />
Puolakka, K 273, 336<br />
Purcell, S 2121<br />
Putova, I 1667<br />
Putterman, C 130, 410, 413,<br />
532, 1962<br />
Q<br />
Q. Qi, J 1960<br />
Qatanani, M 2092<br />
Qi, Q 1130<br />
Qian, L 362<br />
Qin, X 1286<br />
Qing, X 410, 532<br />
Qiu, X 841<br />
Quach, H 1972<br />
Quach, TD 1420<br />
Qualls, CR 451<br />
Quan, T 1613<br />
Quartier, P 253, 880, CRC02, CRC07<br />
Queyrel, V 1371<br />
Quillard, M 961<br />
Quimbo, R 82, CRC28, CRC34, CRC43<br />
Quine, CL 1581<br />
Quintana, G 1210<br />
Quintana, M 1642<br />
Quintero, MV 879<br />
Quirici, N 2145<br />
Qureshi, A 607<br />
Qureshi, AA 2099<br />
Qvist, P 1767, 1882<br />
R<br />
RÃnnblom, L 515<br />
RÃnnelid, J 515, 1430, 1877<br />
Raab, D 2112<br />
Raab, DJ 1459<br />
Raaschou, P 1344<br />
Rabenda, V 629, 1557<br />
Rabquer, BJ 707, 1475, 1480<br />
Racewicz, A 2140<br />
Radacs, M 1481<br />
398
Radbruch, A 526<br />
Radbruch, A 133, 150, 823, 1413<br />
Radda, I 1477<br />
Radin, AR 1282<br />
Radominski, SC. 1204<br />
Radovits, B 1819<br />
Radovits, BJ 308, 995<br />
Radstake, TR. 1298<br />
Radvanski, DC 1279, 1327, 1519<br />
Ragavendra, N 446, 2091<br />
Raggi, P 445, 1146, 1148<br />
Ragi-Eis, S 1545<br />
Rahbar, A 1671<br />
Rahman, A 507, 508, 509, 1408<br />
Rahman, A 1135, 1333, 1911, 1932,<br />
2093<br />
Rahman, M 82, 174, 285, 970, 971,<br />
CRC13, CRC14, CRC28, CRC29,<br />
CRC30, CRC31, CRC32, CRC34,<br />
CRC35, CRC36, CRC39, CRC40,<br />
CRC42, CRC43, CRC46, CRC47,<br />
CRC50<br />
Rahman, MU 956, 988<br />
Rahman, M 809, 833<br />
Rahman, M 2100<br />
Rahman, P 557, 1186, 1322, 2096,<br />
2098<br />
Raine, R 1911<br />
Rajappa, SM 1239<br />
Rajkumar, V 2146<br />
RAK, JM 29<br />
Rak, JMarta 744<br />
Ralph, JA 773<br />
Ramachandran, R 806<br />
Ramanoelina, J 1244<br />
Ramanujam, M 1409, 1473<br />
Ramelli, G 1586<br />
Ramírez, LA 1609<br />
Ramos, PS 1976<br />
Ramos-Casals, M 1090, 1399, 1577,<br />
1594, 1595, 1648, 1931, 2006<br />
Ramos-Kuri, M 104<br />
Ramos-Remus, C 292<br />
Ramsay, PP 1972<br />
Ramsey, SE 242<br />
Ramsey, SE 1386<br />
Ramsey-Goldman, R 450, 499, 514,<br />
1131, 1930, 2124, 2159<br />
Ran, Y 1270<br />
Rana, A 1468<br />
Randi, A 709<br />
Randisi, G 1015<br />
Randolph, GJ 1584<br />
Rangan, B 1008, 1567<br />
Rangan, BV. 166, 984<br />
Ranganath, V 987<br />
Ranganath, V 1817<br />
Ranger, AM 1423<br />
Rankin, B 1678<br />
Rankin, E 828, 829<br />
Rannou, F 718<br />
Ransohoff, RM 1643<br />
Rantapää-Dahlqvist, S 1006<br />
Rantapää Dahlqvist, S 379, 1073<br />
Rantap��-Dahlqvist, S 1002,<br />
1003<br />
Ranzolin, A 1536<br />
Rao, D 1544<br />
Rao, S 1774<br />
Rao, URK 1014<br />
Rao, V 1920<br />
Raphael, M 283<br />
Rapley, T 158<br />
Rapp, A 519, 1477<br />
Raptopoulou, A 525<br />
Raptopoulou, AP 393<br />
Raschi, E 1337, 1404<br />
Rasmussen, HErik 1422<br />
Raspe, H 1488, 1823<br />
Rat, A 73, 645, 694, 1576<br />
Rat, A 1511<br />
RATIO, 283, 1033<br />
Ratzlaff, C 1507<br />
Rau, R 333<br />
Rau, R 730<br />
Rauschkolb-Loeffler, C 1682<br />
Raut, A 949<br />
RAVAUD, P 75, 283, 1033, 1484, 1673<br />
Ravelli, A 2179<br />
Ravelli, A 227, 233, 245, 249, 904,<br />
913, 2178<br />
Ravn, P 1021<br />
Rawlings, D 1986<br />
Ray, D 1491, 1498, 1518<br />
Ray, K 280<br />
Ray, M 47<br />
Ray, MN 1263<br />
Ray, S 98<br />
Raynauld, J 661<br />
Rea, KM. 1585<br />
Rebuli, R 1680<br />
Rebuli, R 1679<br />
Recio-Mayoral, A 1956<br />
Recke, A 751<br />
Recker, RR 619<br />
Recker, RR 2139<br />
Recknor, C 666<br />
Recknor, C 625, 1547<br />
Reddy, S 1378<br />
Reddy, ST. 1001<br />
Reddy, S 1091<br />
Redecha, P 1335<br />
Redlich, K 674, 1304, 1762, 2003,<br />
2063<br />
Redmond, AC 1163<br />
Reed, AM 1732, 2066<br />
Reed, G 282, 310, 987, 989, CRC17<br />
Reed, G 728, 958, 1817<br />
Reed, MR 255<br />
Reed, S 74<br />
Reedquist, K 1306<br />
Reedquist, KA. 138, 145, 1776<br />
Reehal, V 2111<br />
Reese, V 923, 1766<br />
Reeve, J 558<br />
Reeve, JP 557, 1322<br />
Reeves, Q 1192<br />
Reeves, W 397<br />
Reeves, WH 398, 500, 523, 1419,<br />
1612, 1835, 1969<br />
Regenass, S 1572<br />
Regier, J 123<br />
Reginster, JY 1547<br />
Reginster, J 629, 738, 1517, 1681<br />
Reginster, J 1557<br />
Rego, I 1452, 1795<br />
Reichel, A 922<br />
Reichenbach, S 208<br />
Reichlin, M 1425<br />
Reichmann, WM 84, 1693<br />
Reid, DM 2120, 2122<br />
Reid, I 619<br />
Reid, I 756, 1192<br />
Reider, L 1078<br />
Reiff, AO 682<br />
Reiff, A 681, 884, 895, 1723, 2083<br />
Reiff, AO. 1282<br />
Rein, AJTT 2094<br />
Reina, D 1009, 1894<br />
Reiner, I 1607, 1978<br />
Reinhardt, J 755<br />
Reinus, WR 2074<br />
Reisine, S 1328, 1332<br />
Reiss, AB 776, 1774<br />
Reiss, W 262<br />
Reitblat, A 851<br />
Reitblat, T 851<br />
Reiter, WJ 689<br />
Reize, P 2174<br />
Rejchrt, S 1035<br />
Rekvig, O 424<br />
Remeseiro, S 1471<br />
Remmers, EF 555, 743, 923, 1745,<br />
1766, 2055<br />
Renahan, K 504, CRC33, CRC44<br />
Rendall, E 1772<br />
Rengel Colina, YY 1059<br />
Renner, JB 740<br />
Resche-Rigon, M 2025<br />
Resende, C 602<br />
Ress, RM 1120<br />
Restrepo, JFelix 1642<br />
Restrepo, J 1210<br />
Restuccia, G 1228, 1231<br />
Reveille, JD 38, 493, 499, 559, 1138,<br />
1140, 1141, 1142, 1321, 2124, 2168<br />
Reveille, JD. 161, 183, 514, 612,<br />
1131, 1139, 1179, 1186, 1919, 1930<br />
abstract author Index<br />
399
abstract author Index<br />
Reverter, J 1388, 1389, 1399, 1402,<br />
1403<br />
Revicki, D 101<br />
Reynolds, AV 318, 319<br />
Reynolds, H 1923<br />
Reynolds, PR 1715<br />
Reynolds, T 2038<br />
Rhew, EY 2159<br />
Rho, Y 322, 388, 624, 1148<br />
Rhodes, J 453<br />
Rhodes, LA 660<br />
Rhodus, NL 1100<br />
Riarh, R 1169<br />
Riarrh, R 1284<br />
Ribeiro, AR 902, 1950<br />
Ribeiro, LH 1842, 1895<br />
Ribeiro, SL. E. 1204<br />
Ricca, L 667, 1354, 1355, CRC20<br />
Ricci, L 632, 1731<br />
Ricci L, Pistorio A, Zulian F, Calabri<br />
GB, Vitale, A 891<br />
Richard, D 1681<br />
Richards, CC 122<br />
Richards, HB 1969<br />
Richards, J 1008, 1811<br />
Richards, JS 1567<br />
Richards, JS. 984<br />
Richards, LJ 1628<br />
Richardson, B 141, 1365<br />
Richardson, J 1176<br />
Richardson, M 183<br />
Richardson, MN. 161<br />
Richette, P 593, 718<br />
Richez, C 1583, 2131<br />
Richl, P 1721<br />
Richman, L 429<br />
Richy, FF 1517<br />
Rider, L 252, 1655<br />
Rider, LG 1659<br />
Rider, V 1320<br />
Ridley, D 99<br />
Riemekasten, G 14, 405, 406, 1200,<br />
1215, 1954<br />
Riera, E 287<br />
Rifkin, IR 1583, 2131<br />
Rigby, W 2086<br />
Riggs, BL 2143<br />
Rihl, M 1582<br />
Riise, OR 896, 911<br />
Rince, P 283<br />
Rincheval, N 73, 75, 1051<br />
Ringertz, B 264<br />
Ringsdal, V 339<br />
Ritchlin, CT 583<br />
Ritchlin, CT 153, 278, 572, 691, 1750<br />
Ritter, P 723<br />
Rivera, T 442, 1923<br />
Rizzatti, M 1536<br />
Rizzi, M 402<br />
Robazzi, TC 879<br />
Robb, R 2143<br />
Robbie, G 428<br />
Roberts, C 1374<br />
Roberts, R 1800<br />
Roberts, V 1581<br />
Robinson, D 116, 117<br />
Robinson, D 1049, 1836<br />
Robinson, D 1120<br />
Robinson, E 1192<br />
Robinson, ME. 1538<br />
Robinson, TM 368<br />
Robinson, W 1794<br />
Robinson, WH 568, 748, 1289<br />
Rocca Rey, LA 89<br />
Rocha, C 497, 498<br />
Rodby, R 170, 171, 1113<br />
Rodby, R 1490<br />
Rødevand, E 594, 1181<br />
Rodevand, E 169<br />
Rodgers, J 1771<br />
Rodrigues, J 951<br />
Rodrigues, PT 184<br />
Rodriguez, E 2022<br />
Rodriguez, L 1053, 1076<br />
Rodríguez, M 332<br />
Rodríguez-Mahou, M 1898<br />
Rodríguez-Moreno, J 1184<br />
Rodriguez-Pla, A 992, 1007<br />
Rodriguez-Reyna, TS. 2<br />
Rodríquez Zubieta, M 1214<br />
Roebuck-Spencer, TM 883<br />
Roehrs, T 1438, CRC25<br />
Roelofs, MF. 1298<br />
Roemer, F 208<br />
Roemer, FW 742<br />
Roemer, FW 204, 205<br />
Roemer, FW. 209<br />
Roettcher, P 254<br />
Roger, VL. 683, 1004, 2185<br />
Rogers, JC. 176, 1330<br />
Rogers, N 1904<br />
Rogers, P 92<br />
Rogers, TB 1100<br />
Rohde, GElise 1470, 1562<br />
Rohekar, S 1284<br />
Roig-Vilaseca, D 1184<br />
Rojas, M 1609<br />
Rojas Vargas, LM 1175<br />
Rojas-Villaraga, A 842<br />
Rojas-Villarraga, A 1351, 1824<br />
Rojkovich, B 333, 670, CRC37<br />
Rojkovich, B 2086<br />
Rolando, E 1850<br />
Roldan, CA 451, 455<br />
Roll, P 1431<br />
Rollín Toledo, R 847<br />
Roman, MJ. 447<br />
Roman, RM 1613<br />
Romanowski, W 1821<br />
Romay-Penabad, Z 1336, 1410, 1412<br />
Romero, J 860<br />
Romero-Díaz, J 1107, 1114, 1921<br />
Rommel, C 1058<br />
Ronald van Vollenhoven, J 1115,<br />
1116<br />
Ronchezel, MV 879<br />
ronco, p 2008<br />
Ronday, HK. 2087<br />
Ronday, KH 90<br />
Rondon, F 1210, 1642<br />
Ronfani, L 2175<br />
Rönnblom, A 17<br />
Rönnelid, J 377, 536<br />
Ronniger, J 427<br />
Rooney, M 2078<br />
Rooney, ME 1716<br />
Roorda, L 1273, 2036<br />
Roos, E 1485<br />
Roosendaal, G 1462<br />
Rosa, CM 602<br />
Rosa, N 2021<br />
Rosalind Ramsey-Goldman, S 1115<br />
Rosalind Ramsey-Goldman, S 1116<br />
Rosas, J 1090<br />
Rose, CD 240, 241, 894, 2175, 2176<br />
Rose, J 1253, 1384<br />
Rose, M 1904, 2071<br />
Rose, M 1516<br />
Roselló, R 332<br />
Rosen, A 747<br />
Rosen, P 1839<br />
Rosen, SD 1755<br />
Rosenbaum, JT 559<br />
Rosenbaum, JT. 560, 1742<br />
Rosenberg, SH 1989<br />
Rosenberger, S 405<br />
Rosendaal, FR 1697<br />
Rosenfeld, G 395, 1421<br />
Rosengren, S 673, 1308<br />
Rosenkranz, ME 1715<br />
Rosenthal, H 1582<br />
Rosenzwajg, M 2015<br />
Rosenzweig, HL 1742<br />
Rosing, D 1658<br />
Rosowski, M 526<br />
Ross, GS 882<br />
Ross, R 1541<br />
Rossi, A 372<br />
Rossi, F 245, 2178<br />
Rossi, F 1228<br />
Rossol, M 1054, 2126<br />
Roth, J 225, 1460, 1757<br />
Roth, M 134<br />
Rothenbuhler, R 690<br />
Rother, K 252, 1655<br />
Rothfield, N 26, 2163, 2165<br />
Rothlein, LR 1264<br />
Rottapel, R 365<br />
Roubenoff, R 537, 551, 2039<br />
Roubille, C 497, 498<br />
400
Roudier, C 744<br />
Roudier, J 744<br />
Rouhani, FN 2014<br />
Roundtree, AK 94<br />
Roundtree, AK. 95<br />
Roux, C 2140<br />
ROUX, C 738, 972<br />
Roux, S 14, 1200<br />
Rovensky, J 292<br />
Rovensky, J 895<br />
Rovin, BH 437<br />
Rowe, D 1417<br />
Rowe, K 257, 266<br />
ROY, C 75, 1673<br />
Roy, V 1312<br />
Royalty, JE 276<br />
Royle, L 2129<br />
Rozemuller, H 938<br />
Rozenberg, S 767<br />
Rozman, B 2179<br />
Rubaltelli, L 592<br />
Rubartelli, A 249<br />
Rubbert, A 967, 1438, CRC25<br />
Rubbert-Roth, A 2089<br />
Rubeiz, H 862<br />
Rubens, M 106<br />
Rubin, B 863<br />
Rubin, LJ 14, 1200, 2164<br />
Rubio-Perez, N 680<br />
Rubio-Perez, NE 679<br />
Rudd, PM. 2129<br />
Rudel, T 142<br />
Rudenga, BJ 1613<br />
Ruderman, E 261<br />
Ruderman, EM 726, 733<br />
Rudert, M 2174<br />
Rudge, JS 755<br />
Rudwaleit, M 578, 1159<br />
Rudwaleit, M 579, 614, 753, 945,<br />
1158, 1170<br />
Rueda, B 1245<br />
Rueda, P 1472<br />
Ruekle, T 1058<br />
Ruether, W 1456<br />
Ruhwald, M 1021<br />
Ruiz, ME 1575<br />
Ruiz, M 2006<br />
Ruiz, P 416, 1313<br />
Ruiz, X 54<br />
Ruiz-Romero, C 1471<br />
Rump, J 1777<br />
Runge, C 1488, 1823<br />
Ruperto, N 679, 680<br />
Ruperto, N 227, 233, 245, 681, 895,<br />
2178<br />
Rus, V 1966<br />
Ruscazio, M 647<br />
Rush, CM 1990<br />
Russak, S 1120<br />
Russell, A 699, 950<br />
Russell, AS 587, 588, 589<br />
Russo, R 251<br />
Rustenburg, F 39<br />
Rustenburg, F 307<br />
Ruth, JH 707, 711, 1623, 1756<br />
Ruzickova, S 1973<br />
Ryan, MH. 2080<br />
Ryde, A 1778<br />
Ryu, HJung 1651<br />
Ryu, H 531, 676<br />
Ryu, JH 663<br />
Ryu, J 344<br />
S<br />
S, S 117<br />
SÃdergren, A 1006<br />
SÃderlund, L 1006<br />
Saad Magalhaes, C 679, 680<br />
Saad Magalhães, C 233, 2178<br />
Saadoun, D 1242, 2002, 2008, 2015,<br />
2016, 2025<br />
Saag, KG 213, 635, 636, 1024, 1552,<br />
1553, 1554, 1703<br />
Saag, K 2138<br />
Saag, KG. 665, 1263<br />
Saatvedt, K 1632<br />
Sabahi, I 1008<br />
Sabahi, R 1424<br />
Sabbadini, M 1234<br />
Sabela, F 334<br />
Sabharwal, T 1933<br />
Saccol, MF 1563<br />
Sachs, G 779<br />
Sack, B 1694, 2115<br />
Sack, B 207<br />
Sack, K 1092<br />
Sacks, J 720, 2054<br />
Sacks, JJ 818<br />
Sacks, S 827<br />
Sadeghi-Abdolahi, B 1232<br />
Sadik, HY 1198<br />
Sadis, S 1890<br />
Sadkiewicz, S 1502<br />
Saeki, Y 1464, 1834, 2064<br />
Saewert, M 943<br />
Saghafi, O 1814<br />
Saha, S 927<br />
Saha, S 395, 1421<br />
SAHIN, N 1635<br />
Said-Nahal, R 1324<br />
Saint-Cyr, C 242<br />
Saint-Marcoux, F 432<br />
Saito, E 1032, 1206<br />
Saito, E 8<br />
Saito, K 317, 357, 1781, 1939<br />
Saito, K 1466, 1558<br />
Saito, M 1707<br />
Sakai, H 1707<br />
Sakai, H 370<br />
Sakai, Y 328<br />
Saketkoo, L 27<br />
Sakurai, T 990, 1151<br />
Sala, E 2178<br />
Sala, I 233<br />
Sala Soriano, E 1719<br />
Salach, L 1564, 1566<br />
Salacinski, A 763<br />
Salaffi, F 1502<br />
Salazar, J 425<br />
Saleem, M 130<br />
Salers, P 1474<br />
Salgado, E 1934<br />
Salgado, MF. 1204<br />
SALLE, V 1227<br />
Sallstig, P 1679<br />
Salmon, D 283, 1033<br />
Salmon, J 1335<br />
Salmon, JE. 447<br />
Salomon, J 1253<br />
Salomonsson, S 422, 1727<br />
Salonen, D 278<br />
Salonen, D 597, 598, 750, 1165, 1190<br />
Salonen, DC 655<br />
Saluja, M 815, 949<br />
Salvarani, C 606, 610, 788, 1228,<br />
1231, 1237, 1238, 1243, 1805, 2098<br />
Salvat, C 1447<br />
Salvo, D 1228<br />
Sambrook, PN. 620<br />
Sampaio-Barros, PD 1204<br />
Sampedro, M 1319, 2095, 2161<br />
Samuel, CE 152<br />
Samuels, J 846<br />
Sanches, CMunhoz 1331<br />
Sanchez, A 816, 1578<br />
Sanchez, C 816, 1578<br />
Sánchez, G 561<br />
Sanchez, ML 1142, 2043, 2168<br />
Sánchez, M 1483<br />
Sanchez-Guerrero, J 450, 1107,<br />
1114, 1115, 1116, 1133, 1921, 2157<br />
Sánchez-Olaso, A 1646<br />
Sanchez-Pernaute, O 1044, 1591,<br />
1751, 2123<br />
Sanchez-Ramón, S 1898<br />
Sánchez-Tapias, JM 1577, 2006<br />
Sandborg, C 237, 238<br />
Sandborg, C 895<br />
Sandborn, WJ 663<br />
Sanders, ME. 145<br />
Sandig, G 1482<br />
Sandin, S 701<br />
Sandler, C 1072<br />
Sandorfi, N 1211<br />
Sandy, J 1465<br />
Sangle, S 1229<br />
Sangle, SR 441, 1411, 1933<br />
abstract author Index<br />
401
abstract author Index<br />
SANMARTI, R 332, 561, 1795,<br />
1887, 1901<br />
Sanna, S 574, 647<br />
Sano, H 936, 1662, 1754<br />
Santer, D 69, 1958<br />
Santiago, B 1040, 1472<br />
Santiago, M 1824<br />
Santiago, MB. 1204<br />
Santo, AH 799<br />
Santos, AB 879<br />
Santos, LL 1756<br />
Santos, MJ 1712<br />
Sanz, I 1288, 1414, 1418, 1420,<br />
1424, 1427<br />
Sanz, J 121<br />
Saraux, A 534, 1295<br />
Sarawate, CA 102<br />
Sarawate, C 1556<br />
Sargent, JL 40, 1216, 2144<br />
Sari, I 1653<br />
Sarkar, S 1584<br />
Sarkis, KS. 1013<br />
Sarmukkadam, S 949<br />
Sarniak, R 1383<br />
Sarno, R 1686<br />
SARUHAN DIRESKENELI, G 843, 1635<br />
Sarzi-Puttini, P 1015, 1101<br />
Sasaki, N 1636, 2001<br />
Sasso, EH 583<br />
Sasso, E 327, 1807<br />
Sasso, EH 302<br />
Sather, B 1986<br />
Sato, EI 799, 1128, 1391<br />
Sato, E 1036<br />
Sato, J 245<br />
Sato, K 783<br />
Sato, K 1792, 1899<br />
Sato, N 136<br />
Sato, S 48, 50, 1218, 1219, 1220,<br />
1606<br />
Sato, S 1032, 1206, 1663, 1664, 1665<br />
Sato, T 1663<br />
Sato, T 495<br />
Sato, T 1206<br />
Sato, T 1466, 1558<br />
Satoh, M 397, 398, 500, 523, 1419,<br />
1612, 1835<br />
Satoh, T 18, 64, 855<br />
Satumtira, N 566, 1326<br />
Sauliere, N 694<br />
Sauma, ML.C. 1204<br />
Saurenmann, RK 246<br />
Sautet, A 1447<br />
Savage, L 585, 1321<br />
Savage, SV 304, 1279, 1327, 1519<br />
Savitskaya, A 519<br />
Savolainen, AH 907<br />
Savouret, J 718<br />
Savran, Y 1653<br />
Sawada, S 1826<br />
Sawai, T 1636, 2001<br />
Sawalha, AH 394, 1136, 1365, 1620,<br />
2125<br />
Sawamukai, N 317, 1781<br />
Sawka, AM 1565<br />
Saxne, T 66, 727, 983, 1461<br />
Sayers, B 1985<br />
Sayre, EC 809, 833<br />
Scagliori, E 592, 1640<br />
Scallon, B 274<br />
Scarpa, R 606, 610<br />
Scarpignato, C 1517<br />
Scatizzi, JC 401, 774, 1770<br />
Scavullo, C 2145<br />
scerra, s 1242<br />
Schachna, L 586, 1164, 1166<br />
Schaefer, F 1456<br />
Schaeffler, A 948<br />
Schaeren, S 1698<br />
Schaeverbeke, T 283, 1033<br />
Schäfer, J 2174<br />
Schäffler, A 147<br />
Schalkwijk, CG 1964<br />
Schanberg, LE. 1383<br />
Schechtman, J 695, 944<br />
Scheel, AK 650<br />
Scheel, K 2103<br />
Scheffler, S 1079<br />
Scheffold, A 150<br />
Scheinberg, M 679, 680<br />
Scheinberg, MAaron 1739<br />
Scheinecker, C 516, 519, 674, 1304,<br />
1477, 1762<br />
Scheja, A 1195<br />
Schellevis, FG 765<br />
Schemmann, G 1713<br />
Schentag, CT 597, 2170<br />
Schentag, CT. 1190, 2096, 2097<br />
Scherberich, A 28<br />
Scherle, P 1771<br />
Scherman, D 2137<br />
Schett, G 43, 673, 1058, 1304, 1307,<br />
1762, 1998, 2003, 2063, 2147<br />
Scheurig, C 654<br />
Schiff, M 942, 943, 1813<br />
Schiff, MH 957, 1160, 1494<br />
Schiff, M 858<br />
Schiff, MH 173, 726<br />
Schiff, MH. 581<br />
Schifferli, K 2134<br />
Schiødt, M 1092<br />
Schiopu, E 14, 21, 1200, 1208<br />
Schirmer, M 1233, 1243<br />
Schleinitz, N 869, 871<br />
Schlenk, EA 2050<br />
Schlesinger, N 113, 1618<br />
Schlincker, A 600<br />
Schmidely, N 258<br />
SCHMIDT, J 1227<br />
Schmidt, K 1215<br />
Schmidt, RE 1582, 1973<br />
Schmitt, W 433<br />
Schmitz, A 1119<br />
Schmucker, AC 2136<br />
Schnaeker, E 392<br />
Schnäker, E 367<br />
Schneeweiss, S 1342, 1822, 2142<br />
Schneider, H 1679<br />
Schneider, M 730, 1488, 1823<br />
Schneider, RI. 1425<br />
Schnitzer, TJ. 1689<br />
Schnitzer, T 1678, 1679<br />
Schnitzler, MA 89<br />
Schoels, M 284, 355<br />
Schoenborn, H 1777<br />
Schoenwetter, M 1120<br />
Schon, S 116<br />
Schopf, L 135<br />
Schoster, B 2048<br />
Schraner, T 246<br />
Schroeder, M 1049<br />
Schueller-Weidekamm, C 662<br />
Schuller, R 858<br />
Schulman, K 827<br />
Schulman, K 74<br />
Schulpen, G 127<br />
Schultz, D 1106<br />
Schultz, H 2010<br />
Schulze-Koops, H 1062, 1982, 1998<br />
Schulze-Tanzil, G 576<br />
Schumacher, HR 757<br />
Schumacher, H 560, 1350, 1569,<br />
1570<br />
Schumacher, H 760, 1068, 1346,<br />
1356, 1542, 1624, 1627<br />
Schumacher, R 168<br />
Schumann, GG 745<br />
Schur, PH 2150<br />
Schürer, S 406<br />
Schwartz, A 1106<br />
Schwartz, A 414<br />
Schwartz, JI 276<br />
Schwartz, MM. 443<br />
Schwartz, N 532<br />
Schwartz, P 22<br />
Schwarz, E 572<br />
Schwarz, EM 153, 691, 1476, 1750<br />
Schwarz, MK. 1058<br />
SCIENCE Meta-analysis Group, 2141<br />
Scofield, RH 1111<br />
Scofield, RHal 527, 528, 1136<br />
Scofield, RHal 529, 1080, 1957<br />
Scofield, R 1081<br />
Scopaz, KA 1271<br />
Scott, D 2017<br />
Scott, DGI 1932<br />
Scott, DJ 713<br />
Scott, GC 415<br />
Scott, P 2127<br />
Scott, W 996<br />
402
Scranton, R 1822<br />
Scuccimarri, R 242<br />
Scumpia, K 1969<br />
Scumpia, PO 397, 1612<br />
Scurati, S 1337, 1404<br />
Sebag, M 1829<br />
Sebastiani, G 1973<br />
Sebastiani, M 1224<br />
Sebba, A 620, 627<br />
Sebring, N 252<br />
Secchi, M 964, 1203<br />
Sedarati, F 1545, 1547, 2139<br />
See, K 625<br />
Seed, P 1396<br />
Seeman, E 2138<br />
Segal, BM 1098, 1099<br />
Segal, BM 1100<br />
Segal, M 523<br />
Segal, MS 500, 1969<br />
Segal, N 213, 1703<br />
Segal, NA 123, 196<br />
Segami, MI 1514, CRC45<br />
Segarra, M 128, 784, 1230, 1483<br />
Segawa, S 1759<br />
Segawa, S 793<br />
Segelmark, M <strong>2007</strong><br />
Segura, M 1395<br />
Segura-Esquivel, MI 192<br />
Segurado, O 99<br />
Segurado, O 1809, 2153<br />
Segurado, OG 294<br />
Seibel, MJ 2065<br />
Seibold, J 30<br />
Seibold, JR 14, 21, 1200, 1208, 2162,<br />
2164<br />
Seielstad, M 539, 545<br />
Seifert, E 1778<br />
Seignon, J 166<br />
Seki, N 136<br />
Sekiguchi, M 1662<br />
Sekiya, F 349<br />
Selby, M 1984<br />
Seldin, MF 743, 850, 1972, 2055,<br />
2121<br />
Seleznick, M 1354, 1355<br />
Sellam, J 1087, 1360, 1946, 2008<br />
Sellas, A 1029<br />
Selva-O’Callaghan, A 1648<br />
Selvaag, AMarit 2081<br />
Sembhi, H 2177<br />
Sene, D 151, 1242, 1629, 1630, 2002,<br />
2025<br />
Senecal, J 503<br />
seneschal, j 1366<br />
Sengupta, M 186, 187<br />
Sengupta, R 599, 1176<br />
Senoo, T 1060<br />
Seo, M 2030<br />
Seo, P 2009<br />
Seo, Y 642<br />
Sepanski, R 635<br />
Sepici, V 275<br />
Sequeira, W 315, 316, 1023<br />
Seriolo, B 964, 1203, 1679<br />
SEROR, R 1484, 2013<br />
Serra, J 1444<br />
Serre, G 1829<br />
Seshan, S 1602<br />
Sestak, AL 501, 839, 1945, 1967<br />
Seta, N 64<br />
Setoguchi, S 1342, 1568<br />
Setoyama, Y 1377, 1981, 1996<br />
Setty, AR 2099<br />
seve, P 1394<br />
Severens, H 127<br />
SEVESTRE, H 705, 1240<br />
Sewell, C 1639<br />
Seyahi, E 853, 1178, 1248<br />
Seyer, JM. 1047<br />
Seys, PE.H. 256<br />
Sfikakis, PP 271<br />
Sfriso, P 592, 1640<br />
Shadbolt, B 1174<br />
Shadick, N 81, 638<br />
Shadick, NA 360, 537, 551, 1064,<br />
2121<br />
Shadick, NA. 341, 1889, 2187<br />
Shah, A 2156<br />
Shah, AA. 22<br />
Shah, M 2156<br />
Shaham, B 1723, 2083<br />
Shaheen, AW 1264<br />
Shaheen, N 1264<br />
Shahnaz, S 416<br />
Shahouri, S 323<br />
Shahram, F 1232<br />
Shahrara, S 139, 384, 711, 786, 924<br />
Shakib, S 269<br />
Shakoor, N 186, 187, 189, 190, 191,<br />
2072<br />
Shaltis, D 798, 1152, 1913<br />
Shams, H 1232<br />
Shanahan, J 26, 2163, 2165<br />
Shane, E 665<br />
Shane, P 285, CRC13, CRC14<br />
Shanmugam, VK 1370<br />
Shanmugarajah, S 2096<br />
Shao, T 572<br />
Shapiro, L 26, 2163, 2165<br />
Shapiro, LS 1208<br />
Shariati, Z 1924<br />
Sharma, L 196, 210, 211, 212, 658<br />
Sharon, KL 1904<br />
Sharp, J 944<br />
Sharp, J 2153<br />
Sharp, JT 2151<br />
Sharp, JT. 698<br />
Shaver, T 323<br />
Shaw, AM 52<br />
Shaw, M 1432<br />
Shaw, T 261, 262, 267<br />
Shaw, T 266<br />
Shealy, D 274<br />
Shealy, DJ 691, 1750<br />
Sheehy, C 333<br />
Sheen, D 573, 822<br />
Sheinberg, MA. 886<br />
Shelmerdine, J 1918<br />
Shen, N 1953<br />
Shenk, K 939<br />
Shenouda, N 242<br />
Shentag, Arno WR van Kuijk, C 610<br />
Shepard, S 1771<br />
Shergy, W 944<br />
Sherry, D 1709<br />
Sherry, DD 1281<br />
Shete, S 36<br />
Shetty, SK 641<br />
Shevach, EM 1987<br />
Shi, B 139<br />
Shi, G 1771<br />
Shi, N 290<br />
Shi, S 571<br />
Shi-wen, X 57<br />
Shiau, A 672<br />
Shiboski, C 1092<br />
Shiboski, S 1092<br />
Shibuya, M 1743<br />
Shidara, K 1016<br />
Shields, J 939<br />
Shiff, N 1385<br />
Shigihara, T 1082<br />
Shih, FF 919<br />
Shilling, R 862<br />
Shim, S 573, 822<br />
Shimane, K 1050<br />
Shimano, K 136<br />
Shimizu, A 1150<br />
SHIMIZU, H 1515<br />
Shimizu, K 1218, 1220, 1606<br />
Shin, D 1028<br />
Shin, H 548, 813<br />
Shin, JM 779<br />
Shindo, Y 1792<br />
Shindo, Y 1899<br />
Shinners, E 1265, 1266, 1267<br />
Shinozaki, M 542, 1036<br />
Shiozawa, F 1096<br />
Shiozawa, K 824<br />
Shiozawa, S 328, 396, 544, 824, 925,<br />
930, 1779<br />
Shirasaki, F 49<br />
Shiwen, X 45, 2146<br />
Shoda, H 1743<br />
Shoenfeld, Y 535<br />
Shoham, N 1599<br />
Shott, P 270<br />
Shott, S 1534<br />
Shreffler, J 2048<br />
Shroff, S 874<br />
abstract author Index<br />
403
abstract author Index<br />
Shu, C 309<br />
Shults, J 239, 2177<br />
Shwonek, P 939<br />
S�dergren, A 1002, 1003<br />
S�derlund, L 1002, 1003<br />
MISSING: Siamopoulou-Mavridou A,<br />
Butbul Uziel J, Rigante D,, D<br />
Siannis, F 1960<br />
Sibbitt, WL 177, 451, 736, 1672<br />
Sibbitt, WL. 345, 455<br />
Sibilia, J 1502<br />
SIBLEY, M 1261<br />
Sica, G 1223<br />
Siddiqui, L 237, 238<br />
Sidiropoulos, P 295, 393, 525, 844,<br />
1162<br />
Siegel, RM 856<br />
Sieper, J 594, 1160, 1161, 1494<br />
Sieper, J 576, 577, 579, 581, 614,<br />
753, 1158, 1170<br />
Sierakowski, S 670, CRC37<br />
Sierakowski, S 2086<br />
Sierra-Zorita, R 627<br />
Siff, SJ. 1738<br />
Sigal, LH 221, 679, 680<br />
Sigal, LH 1279, 1327, 1519<br />
Sikara, MP 1405<br />
Silman, A 1374<br />
Silva, A 1983<br />
Silva, CA 679, 680, 2179<br />
Silva, CA 879, 906, 1104<br />
Silva, CA A 1722, 1726<br />
Silva, CA. 886<br />
Silva, L 121, 1887<br />
Silva, NP 1391<br />
Silva, RG 1013, 1018<br />
Silva-Fernández, L 431<br />
Silver, R 30<br />
Silver, RM 1208<br />
Silverman, E 881<br />
Silverman, ED 2179<br />
Silverman, E 876, 1110, 2160<br />
Silverman, GJ 1592<br />
Silverman, GJ. 521<br />
Silverman, JM 643<br />
Silverman, S 2141<br />
Silverman, SL. 622, 1546, 1556<br />
Sim Shin, ES 528<br />
Simard, N 1057<br />
Simmen, BR 1598<br />
Simms, R 26, 2163, 2165<br />
Simms, SE 2050<br />
Simon, A 856<br />
Simon, B 1680<br />
Simón, L 1887<br />
Simon, M 1394, 1645<br />
Simon, TA 820, 821, 1039, 1798<br />
Simon, T 280<br />
Simonelli, C 1546<br />
Simonelli, LE 1327<br />
Simonini, G 226, 632, 1731<br />
Simonneau, G 1095, 1126<br />
Simpson, S 1522<br />
Sims, GP 1417<br />
Sims, GP. 132<br />
Singer, N 234, 235, CRC09<br />
Singh, G 312, 313, 668, 737, 1339,<br />
1517<br />
Singh, H 1559<br />
Singh, JA 1688, 1699, 1735, 2113<br />
Singh, RP 407<br />
Singh, RR 134<br />
Singh, S 762<br />
Singh, S 438, 439, 2056<br />
Sinisi, S 221<br />
Sinnathurai, P 974<br />
Sipka, S 1837<br />
Sirvent, E 1009, 1894<br />
Sisó, A 1931<br />
Sitbon, O 1126<br />
Siu, G 1906<br />
Siu, Y 444<br />
Siva, C 722<br />
Sivakumar, S 1239<br />
Sizing, I 1423<br />
SjÃberg, O 1430<br />
Sjöberg, B 264<br />
Sjödin, A 1778<br />
Skag, A 623<br />
Skaggs, B 446<br />
Skaggs, V 1581<br />
Skakic, V 670, 1502, CRC37<br />
Skalski, L 106, 108<br />
Skapenko, A 1062, 1982, 1998<br />
Skare, TL. 1204<br />
Skarstein, K 1078<br />
Skhirtladse, C 43, 2147<br />
Skidmore, B 94, 95, 973<br />
Skinner, J 2017<br />
Skinner, M 1296<br />
Skinner, SJ. 2132<br />
Skjødt, H 1881<br />
Skjødt, H 1042, 2180<br />
Sklo, M 1007<br />
Skoczen, S 1814<br />
Skogh, T 1455<br />
Skold, M 359<br />
Skomsvoll, JFredrik 169<br />
Skoniecki, D 687<br />
Skopouli, F 295<br />
Skopouli, FN 1973<br />
Skovron, ML 1039<br />
Skriner, K 1415, 1416, 1761<br />
Skripnikova, IA 618<br />
Slack, R 1825<br />
Slattery, C 2056<br />
Sloan, J 1699<br />
Sloetjes, A 1460, 1757<br />
Sloetjes, AW 129<br />
Slusher, J 1376<br />
SMAIL, A 1227<br />
Smale, S 1782<br />
Small, A 1534<br />
Small, B 1534<br />
Smarr, KL 722<br />
Smedby, T 1002, 1006<br />
Smeets, T 138<br />
Smeets, TJ. M. 1776<br />
Smiles, S 846<br />
Smit, AJ 1196, 1964<br />
Smith, A 1616<br />
Smith, C 804<br />
Smith, DD 1559<br />
Smith, E 26, 2163, 2165<br />
Smith, EA 2184<br />
Smith, J 752<br />
Smith, JA 1283<br />
Smith, MR 678<br />
Smith, SR 584<br />
Smith, T 756, 1192<br />
Smith, WP 1046<br />
Smitten, AL 820, 821<br />
Smolen, J 988, 1813<br />
Smolen, J 272, 284, 292, 298, 674,<br />
696, 941, 1762, 1917, 2089, 2103<br />
Smolen, JS 434, 516, 517, 518, 519,<br />
951, 1185, 1477, 1512, 1975, 2063,<br />
2152, 2153<br />
Smolen, JS. 355<br />
Smolen, JS 662<br />
Sneed, K 1354, 1355<br />
Snelgrove, J 1354, 1355, 1569<br />
Snell, NJ 2085<br />
Sniekers, YH 1457<br />
Sniezek, J 2054<br />
Snir, O 1436, 1437, 1784<br />
Snowhite, I 416, 1313<br />
Snyder, C 874, 2027<br />
Snyder, MR 1052<br />
Snyder, MR. 1832<br />
So, A 1280, 1586<br />
Soares, PM 1104<br />
Sobel, E 398, 523, 1969<br />
Sobel, ES 500, 1835<br />
Sobkoviak, R 384<br />
Soborg, B 1021<br />
Sochor, MR 116, 117<br />
Soderberg, S 1003<br />
Söderberg-Naucler, C 1671<br />
Söderlin, M 980<br />
Soejima, M 18, 33, 1129, 1644<br />
Soerensen, H 967<br />
Sohn, I 1177<br />
Sokalska-Jurkiewicz, MA 791, 795<br />
Sokka, T 333, 670, 1502, 1821,<br />
CRC37<br />
Sokol, RJ 1106<br />
Solans, R 1090<br />
Solari, N 857<br />
Soldal, DMagne 169, 1470, 1562<br />
404
Soldi, A 962<br />
Solé, M 1931<br />
Soleiman, A 518, 2003<br />
Solis-Vallejo, E 2178<br />
Sollymossy, C 321<br />
Solomon, D 1553<br />
Solomon, DH 84, 638, 734, 1342,<br />
1555, 1568, 1822, 2142<br />
Solomon, DH. 341, 1889<br />
Solus, J 1148<br />
Solus, JF 445, 1146<br />
Somers, EC 522, 721, 798, 1152,<br />
1260, 1913<br />
Somers, K 1433<br />
Somers, V 1433<br />
Sommier, J 645, 694<br />
Sone, S 783<br />
Sonesson, S 422, 1727<br />
Song, G 322, 388, 624<br />
Song, I 614, 1162, 1170<br />
Song, J 210, 211, 212, 817, 836<br />
Song, J 2074<br />
Song, J 1780<br />
Song, JS 1893<br />
Song, X 1448<br />
Song, Y 531, 640, 676, 1651<br />
Sontheimer, RD 2071<br />
Soon, JA 1272<br />
Soós, L 1070, 1837, 1993<br />
Sopko, KS 451<br />
Soria, N 1399, 1594, 1595, 1931<br />
Sorkin, LS 917<br />
Sormani, M 2082<br />
Sotgia, F 2058<br />
Soto, L 728<br />
Soto-Abraham, V 1752<br />
Soucek, M 789<br />
Soukup, T 1035<br />
Soumillion, A 378<br />
Sousa, A 1712<br />
Sousa, E 602<br />
Souza, AWS 1391<br />
Souza, DCC 799<br />
Souza, LA L 906<br />
Sovran, F 592, 1640<br />
Sowders, DP 1283<br />
Soza, A 1983<br />
Spachidou, MP 1357<br />
Spadaro, A 606, 610<br />
Spaeth, M 1543<br />
Spalding, SJ 230<br />
Spalding, SJ 1839<br />
Spalding, WM 1734<br />
Spangler, J 229, 230<br />
Spaniolo, G 695<br />
Spannow, A 250<br />
Spanò, C 1223<br />
Sparks, R 1771<br />
Specks, U 2014<br />
Specks, U 2000, 2009<br />
Spector, T 738<br />
Spee, Cvon 1436, 1437<br />
Speed, CA 122<br />
Spencer, C 85<br />
Spevak, L 1669<br />
Speyer, I 300, 2087<br />
Spiegelman, D 628<br />
Spieler, W 594<br />
Spieler, W 1158<br />
Spiera, H 25<br />
Spiera, RF 25, 2000, 2014<br />
Spiller, I 614<br />
Spoorenberg, A 580<br />
Sporn, MB 2136<br />
Spray, HE 954<br />
Springall, R 104<br />
Springer, S 721<br />
Sridharan, S 591<br />
Srikrishnan, R 521<br />
Sritharan, M 181<br />
Srivastava, S 1709, 2079<br />
SSATG (South Swedish Arthritis<br />
Treatment Group), 727<br />
St. Clair, EWilliam 1102, 2000<br />
St. Clair, EWilliam 1091<br />
St. Clair, E 2014<br />
St. Clair, R 710<br />
St. Pierre, Y 503<br />
St. Pierre, Y 1193, 1657<br />
Stagi, S 632<br />
Stahl, GL. 2129<br />
Stam, WB 1501<br />
Stamatelopoulos, KS 271<br />
Stamm, T 1185, 1917, 2103<br />
Stamp, LK 1800<br />
Stancati, A 1502<br />
Stanczyk, J 1597, 2123<br />
Stanek, PA 894<br />
Stanescu, B 182<br />
Stang, PE 102<br />
Stankovic, A 1502<br />
Stanley, EL. 96<br />
Stanus, AL 1299<br />
Staples, M 160<br />
Staquet, K 274<br />
Stark, A 1106<br />
Starr, J 653<br />
Starz, TW 1487<br />
Starz, TW. 176, 1330<br />
Staud, R 1538<br />
Stearns, V 126<br />
Stedman, M 638<br />
Stedman, MR 1555<br />
Steeber, D 48<br />
Steel, J 1937<br />
Steen, V 26, 2163, 2165<br />
Steen, VD 15, 1208, 2162<br />
Steen, VD. 1370<br />
Steengaard-Pedersen, K 1881<br />
Steer, S 2120, 2122<br />
Steere, AC 1352<br />
Stefanick, M 2116<br />
Stegeman, CA 703<br />
Stein, CMichael 445, 1145, 1146<br />
Stein, C 1148<br />
Stein, D 168, 220<br />
Steinbrich-Zoellner, M 133<br />
Steiner, CW 1975<br />
Steiner, C 516<br />
Steiner, G 516, 517, 1761<br />
Steiner, G 434, 518, 1975<br />
Steiner, M 613<br />
Steinerova, M 603, 604<br />
Steininger, G 1507<br />
Steinman, R 54<br />
Steinmeyer, J 147, 1063<br />
Steinsson, K 1960<br />
Steinsson, K 1115, 1116, 1952, 2157<br />
Steinwachs, D 85<br />
Stenboeg, E 250<br />
Stengaard-Pedersen, K 120, 154,<br />
1042, 1785, 1786, 2180<br />
Stephenson, JJ 82, CRC28, CRC34,<br />
CRC43<br />
Stepkowski, SM 58<br />
Steptoe, S 1686<br />
Sterlacci, W 1243<br />
Stern, E 2105<br />
Stern, S 427<br />
Stetson, T 241, 894, 2176<br />
Steultjens, M 1273, 1274, 2036<br />
Steup, A 1682<br />
Stevens, AM 530<br />
Stevens, R 827<br />
Stevens, RL 533, 1055<br />
Stevens, SR 960<br />
Stewart, J 2138<br />
Stewart, L 1499<br />
Stienstra, Y 1196<br />
Stinissen, P 1433<br />
Stöckl-Hiesleitner, S 518<br />
Stohl, W 426, 427, 1316<br />
Stohl, W 2083<br />
Stoica, A 182<br />
Stojanov, S 1601<br />
Stolina, M 1767<br />
Stoll, T 1115, 1116, 2157<br />
Stone, JH 2000, 2014<br />
Stone, M 1186<br />
Stone, MA 599, 1176<br />
Storniolo, A 126<br />
Stott, D 22<br />
Stouracova, M 789<br />
Strachan, D 2120, 2122<br />
Stradner, MH 1454<br />
Strand, V 99, 282, 1316<br />
Strand, V 696, 940, 946, 958<br />
Strandberg, L 422, 1359, 1727, 1965,<br />
2059<br />
Strange, C 761<br />
abstract author Index<br />
405
abstract author Index<br />
Strangfeld, A 342, 730<br />
Stratton, RJ 3<br />
Straub, RH 1628, 1747,<br />
2065<br />
Strausbauch, MA. 1880<br />
Street, R 739<br />
Strek, M 861<br />
Strickland, FM 141<br />
Stroes, EG. S. 1775<br />
Strömbeck, B 2047<br />
Stropuviene, S 670, CRC37<br />
Strusberg, I 956<br />
Stucki, G 1180, 1917, 2076<br />
Study Group, A 1344<br />
Study WA18230 investigator<br />
group, 263<br />
Stuebiger, N 1241<br />
Stuhlmuller, B 142<br />
Stummvoll, GH 1987<br />
Sturfelt, G 450, 814, 1010,<br />
1011, 1132<br />
Sturfelt, Ola Nived, G<br />
2157<br />
Stürmer, T 1555<br />
Stürz, H 147, 1063<br />
Su, J 502<br />
Su, L 1962<br />
Su, S 1528<br />
Su, Y 841<br />
Suarez, B 1795<br />
Suarez-Almazor, M 94,<br />
95, 161, 183, 739, 973,<br />
1499, 1702<br />
Suarez-Almazor, ME. 1738,<br />
2109<br />
Suarez-Gestal, M 1973,<br />
1974<br />
Suda, A 649, 656<br />
Suddason, T 1302<br />
Sudman, M 2079<br />
Suechiro, RM 906<br />
Suehiro, RM 1104<br />
Sueli, C 610<br />
Suffa, N 1721<br />
Sugahara, K 136<br />
Sugai, S 1092<br />
Sugihara, M 387<br />
Sugihra, M 371<br />
Sugimoto, N 496<br />
Sugishita, H 1466, 1558<br />
Sugiura, T 18, 33, 852,<br />
1129, 1644<br />
Sugiyama, D 1897, 2182<br />
Sugiyama, T 1943<br />
Suguro, T 777, 794<br />
Suh, C 1105<br />
Suh, Y 640<br />
Suissa, S 820, 821<br />
Suissa, S 986<br />
Suissa, S 985<br />
Sukel, MP.P. 688<br />
Sule, S 2163, 2165<br />
Sule, SD 26<br />
Sulli, A 964, 1203<br />
Sumer, EU 1882<br />
Sumida, T 371, 387, 412,<br />
671, 793, 914, 934,<br />
1071, 1083, 1753, 1759<br />
Sumita, Y 33, 852<br />
Sumner, DR 188, 191<br />
Sun, H 1599<br />
Sun, S 1528<br />
Sun, X 1760<br />
Sun, Y 269<br />
Sun, Y 1748<br />
Sun, Y 781, 1614<br />
Sun, Z 1760<br />
Sundgren, PC 109, 110<br />
Sundgren, PC. 714<br />
Sundt, TM 1236<br />
Supronik, J 619<br />
Sutton, C 180<br />
Sutton-Tyrrell, K 2159<br />
Suwa, A 1032, 1206, 1663,<br />
1664, 1665<br />
Suzaki, M 1026<br />
Suzukawa, M 344<br />
Suzuki, A 1050<br />
Suzuki, A 1150<br />
Suzuki, H 1338<br />
Suzuki, K 317, 1781, 1939<br />
Suzuki, K 357<br />
Suzuki, K 1377, 1996,<br />
CRC03<br />
Suzuki, M 234, 235<br />
Suzuki, M 370<br />
Suzuki, T 371, 387<br />
Suzuki, Y 1032, 1206<br />
Svejgaard, A 1042<br />
Svendsen, A 1881<br />
Svendsen, A 1042<br />
Svendsen, AJ 2180<br />
Svendsen, KH. 1625<br />
Svenson, JL 420, 1593<br />
Svensson, B 1815, 1879<br />
Svensson, CI 364<br />
Svenungsson, E 1257<br />
Swart, JF 938<br />
Swarup, A 653<br />
Swearingen, C 163, 311, 978<br />
Sweeney, G 687<br />
Sweeney, SE 1963<br />
Sweet, P 692<br />
Sweetser, M 261, 262<br />
Sweetser, M 257<br />
Sweiss, N 695<br />
Sweiss, N 26, 2163, 2165<br />
Sweiss, NJ 861, 862, 863<br />
Swor, R 116, 117<br />
Syed, RH 903<br />
Sylvain, C 939<br />
Symmons, D 1504<br />
Symmons, DP M 754, 976,<br />
CRC11<br />
Symmons, DP.M 320,<br />
CRC06<br />
Symmons, DPM 1000, 1343<br />
Systemic Lupus<br />
Erythematosus in the<br />
Community Stud, y<br />
1916<br />
Syversen, U 1470<br />
Szabó, Z 1070, 1837, 1993<br />
Szabolcs, H 1947<br />
Szajubok, JM. 1204<br />
Szak, S 155<br />
Szechiński, J 791<br />
Szechinski, J 795, 948<br />
Szegedi, G 1070<br />
Szekanecz, Z 535, 1070,<br />
1837, 1993<br />
Szklo, M 997, 998, 1341<br />
Szodoray, P 1993<br />
Sztajnbok, F 679, 680,<br />
2179<br />
Sztrympf, B 1126<br />
T<br />
Taal, E 2046, 2107, 2172<br />
Taams, LS 1302, 1588<br />
Tabussi, D 884<br />
Tacheci, I 1035<br />
Taddio, A 2175<br />
Tagashira, S 540<br />
Taha, R 113<br />
Tahiri, K 718<br />
Tahiri-Fizgerald, E 946<br />
Tai, M 672<br />
Taillefer, SS. 5<br />
Tait, TJ 1631<br />
Tajima, M 1788<br />
Tajima, R 932<br />
Tak, PP 307, 366, 575,<br />
610, 933, 955, 1306,<br />
1439, 1775, 1776<br />
Tak, PP. 138, 145, 358,<br />
378, 771, 918, 1290<br />
Tak, P 380<br />
Tak, PP 263<br />
Takabayashi, K 1943<br />
Takada, T 1664, 1665<br />
Takagi, K 33<br />
Takagi, K 1826, 1938,<br />
CRC12<br />
Takagi, S 1902<br />
Takahashi, H 855<br />
Takahashi, K 1768, 2129<br />
Takahashi, K 64, 855<br />
Takahashi, K 1743<br />
Takahashi, M 328<br />
Takahashi, N 149<br />
TAKAHASHI, Y 1150<br />
Takajyo, I 1789<br />
Takao, S 1840<br />
Takasaki, Y 349, 1788,<br />
1942, 1968, 1971<br />
Takase, K 649<br />
Takayama, L 1469, 1560,<br />
1563<br />
Takehara, K 30, 48, 49,<br />
50, 1209<br />
Takei, M 1826<br />
Takeno, M 649, 656, 785,<br />
854, 1030<br />
Takeuchi, N 1060<br />
Takeuchi, T 296, 344, 347,<br />
356, 370, 1377, 1981,<br />
1996, CRC03<br />
Talarico, R 991<br />
Tam, LShan 605<br />
Tam, L 609, 1155, 1915<br />
Tamai, M 353, 386, 1840<br />
Tamez, J 215<br />
Tamez, J 217, 218<br />
Tammaru, M 1821<br />
Tamres, LK 2050<br />
Tamura, N 349, 1788<br />
Tan, A 564<br />
Tan, CD 2022<br />
Tan, FK 36, 37, 38<br />
Tan, fK. 58<br />
Tanaka, E 312, 313<br />
Tanaka, F 1840<br />
Tanaka, H 1478<br />
Tanaka, I 1551<br />
Tanaka, S 13<br />
Tanaka, Y 934<br />
Tanaka, Y 317, 344, 357,<br />
1781, 1939<br />
Tanaka-Watanabe, Y 914,<br />
1753<br />
Tang, B 82, 174, 285, 970,<br />
971, CRC13, CRC14,<br />
CRC28, CRC29, CRC30,<br />
CRC31, CRC32, CRC34,<br />
CRC35, CRC36, CRC39,<br />
CRC40, CRC42, CRC43,<br />
CRC46, CRC47, CRC50<br />
Tang, B 1153, CRC27,<br />
CRC41, CRC48, CRC49<br />
Tani, K 783<br />
Taniguchi, A 1619<br />
Taniguchi, Y 396<br />
Tanikawa, A 2071<br />
Tanizaki, H 1707<br />
Tankersley, C 269<br />
Tanner, B 635<br />
Tansey, MJ 435<br />
Tao, H 1409, 1473<br />
406
Tardif, G 1463<br />
Tarelli, E 1639<br />
Targoff, I 252<br />
Targoff, IN. 2068<br />
Tarkowski, A 365, 1879,<br />
1885<br />
Tarner, IH 1063, 1217<br />
Tarp, U 1881<br />
Tarp, U 339, 1042, 1785,<br />
1786, 2180<br />
Tarrant, TK 689, 1264<br />
Tasan, D 1828<br />
Tasch, MA 34<br />
Tascilar, K 865, 1248<br />
Tashkin, D 134<br />
Tassi, S 249<br />
Tassies, D 1388, 1389,<br />
1399, 1402, 1403<br />
Tassiulas, I 1479, 1605<br />
Tateishi, K 328<br />
Tatsuki, Y 285, CRC13,<br />
CRC14<br />
Tatsuki, Y 356<br />
Taubert, D 1438, CRC25<br />
Taurog, JD 566, 1326<br />
Taurog, JD. 644<br />
Tavares, R 86, 87, 88<br />
Taveras, AG 1748<br />
Taylor, K 627, 1468<br />
Taylor, KA 665<br />
Taylor, KM 689<br />
Taylor, L 2071<br />
Taylor, M 819, 825<br />
Taylor, M 318, 319<br />
Taylor, P 333<br />
Taylor, W 610, 1186, 1192<br />
Taylor, WJ 1624<br />
Taylor-Fesler, D 1932<br />
Tchérakian, C 1126<br />
Tedder, T 48, 1417<br />
Tedder, TF 1606<br />
Teff, K 2092<br />
Teh, L 507, 508, 509<br />
Teh, L 1932<br />
Teh, L 1918, 1937<br />
Tehrani-Banihashemi, A<br />
1232<br />
Teixeira, C 1449<br />
Teixeira, L 2013<br />
Teixeira, MScarpin 1361<br />
Teixeira, VH 1065<br />
Teixeira da Costa, J 1712<br />
Tejedor, D 1887<br />
Tejpal, N 58<br />
Teleman, A 260<br />
Teles, J 1712<br />
Telles, RWS 1128<br />
Temkin, V 2133<br />
ten Klooster, PM 2046,<br />
2172<br />
Tena, X 1574<br />
Tencati, M 1335<br />
Tenenhouse, A 1565<br />
Teng, GG 310, 1703<br />
Teng, J 1497<br />
Teng, Y 382, 725<br />
Tengowski, M 1691, 1706<br />
Tengowski, MW 1695<br />
Tengvar, T 2189<br />
Tennant, A 1485<br />
Tennant, A 1701<br />
Tennie, C 1063<br />
Teodorescu, M 1903<br />
Teodori, M 190<br />
Tepas, M 1473<br />
Ter Borg, M 1306<br />
Terada, T 533<br />
Terai, C 990, 1151<br />
Teramoto, K 496<br />
Terao, K 1026<br />
Terkeltaub, R 685<br />
Terkeltaub, R 2127<br />
Terrazas, HN 1514, CRC45<br />
Terrett, J 1984<br />
Terzibasioglu, A 275<br />
Terzyan, S 1957<br />
Tesar, V 433<br />
Tesfasyone, H 762<br />
Tesfasyone, H 2056<br />
Tesiram, JM 501<br />
Tesser, JR. 653<br />
Tessitore, E 2108<br />
Tezuka, M 1441<br />
Thabane, L 1564, 1566<br />
Thacker, S 522<br />
Thakore, M 1561<br />
The 1000 Canadian Faces<br />
of Lupus Investigators,<br />
1110, 2160<br />
The BIOGEAS Study Group,<br />
1648<br />
The Canadian Scleroderma<br />
Research Group, 1197<br />
The EIRA study group, 377<br />
The GEMESS Study Group,<br />
1090<br />
The INSPIRE Study Group,<br />
1186<br />
The MOST Investigators,<br />
2053<br />
the Neo-RACo Trial Group,<br />
273<br />
The Systemic Lupus<br />
Erythematosus in the<br />
Community, S 1118<br />
Theander, J 260<br />
Theate, I 1801<br />
Theiler, R 1550<br />
Theilet, R 1698<br />
Theis, K 720, 810, 2054<br />
Theobald, M 1462<br />
Therneau, TM. 683, 1004,<br />
1880, 2185<br />
Thiel, A 150<br />
Thiele, GM. 766<br />
Thiele, RG 1618<br />
Thiesen, H 39<br />
Thiesen, H 376<br />
Thiruchelvam, D 2117<br />
Thomas, E 193, 1251,<br />
1275, 2037, 2102<br />
Thomas, GNeil 828, 829<br />
Thomas, J 1825<br />
Thomas, JK 1422<br />
Thomas, K 494<br />
Thomas, L 1600<br />
Thomas, P 1904<br />
Thomas-L’Otellier, M 1428<br />
Thombs, B 1201<br />
Thombs, BD 5<br />
Thompson, AE. 1649<br />
Thompson, DM 527<br />
Thompson, H 82, 174, 285,<br />
970, 971, CRC13, CRC14,<br />
CRC28, CRC29, CRC30,<br />
CRC31, CRC34, CRC35,<br />
CRC36, CRC39, CRC40,<br />
CRC42, CRC43, CRC47,<br />
CRC50<br />
Thompson, LF 1581<br />
Thompson, SJ 1589<br />
Thompson, S 1281<br />
Thompson, SD 2079, 2080<br />
Thompson, SD. 1709<br />
Thomsen, HS 2180<br />
Thomson, K 1130<br />
Thomson, W 908, 909,<br />
2120, 2122<br />
Thon, A 225, 900<br />
Thong, BYH 436, 1147,<br />
1149<br />
Thorne, C 951<br />
Thörner, Å 260<br />
Thornton, J 908, 909<br />
Thornton, S 1281<br />
Thorp, LE 188, 191<br />
Thorre, K 629, 1557<br />
Thorsen, J 1785, 1786<br />
Thorsteinsdottir, T 1952<br />
Thorstensson, CA 97, 194,<br />
1704<br />
Throne, M 220<br />
Thumboo, J 1508<br />
Thurlings, R 366<br />
Thurlings, RM 358, 1290<br />
Tian, C 743<br />
Tian, J 512<br />
Tian, SY 1924<br />
Tian, Y 414<br />
Tiemessen, MM 1588<br />
Tierney, A 968, 977, 979,<br />
999<br />
Tieulé, N 1946<br />
Tilleman, K 1434<br />
Tillemans, SP.R. 1838<br />
Tilley, R 1335<br />
Timmer, T 366<br />
Timmer, TC 39<br />
Timmer, TC.G. 769<br />
Tincani, A 1398<br />
Tindall, E 261<br />
Ting, G 1822<br />
Tirodkar, M 817<br />
Tiwari, N 692<br />
Tizziani, VAP 902<br />
Tjensvoll, AB 456<br />
Tlustochowicz, W 1821<br />
To, C 444, 1108, 1109<br />
Tobias, A 834<br />
Tobón, GJ 1393<br />
Tochimoto, A 18, 33<br />
Toda, Y 185<br />
Toes, R 382, 725<br />
Toes, RE.M. 2087<br />
Toes, REM 390<br />
Toescu, V 1932<br />
Togo, M 285, CRC13,<br />
CRC14<br />
Togo, M 347, 356<br />
Toh, M 547, 1041, 1645<br />
Tohidast-Akrad, M 1761<br />
Tohyama, S 1788<br />
Tokunaga, D 1060<br />
Tokunaga, K 1968<br />
Tokunaga, M 1939<br />
Toledo, RA. 1204<br />
Toloza, S 333, 670, 1502,<br />
1821, CRC37<br />
Toloza, S 1117, 1143,<br />
2096, 2098<br />
Tolstykh, I 200<br />
Tolusso, B 23, 373, 1223<br />
Tom, BD.M. 2097<br />
Tomatsu, T 312, 313, 361,<br />
542, 994, 1016, 1036,<br />
1067<br />
Tomita, T 383, 1074, 1773<br />
Tomita, Y 1218, 1606<br />
Tomlinson, B 609<br />
Tomlinson, G 86, 87, 88<br />
Tommasini, A 2082<br />
Tomooka, B 568<br />
Tomooka, BH 748, 1289<br />
Toms, J 1035<br />
Toner, J 2115<br />
Tong, K 444<br />
Tong, L 505<br />
Tonner, MChristine 1256<br />
Tony, H 272, 967<br />
Tony, H 1431<br />
abstract author Index<br />
407
abstract author Index<br />
Torfing, T 2180<br />
Torgerson, TR 1979<br />
Toriyama, S 1878, 2181<br />
Torner, J 742<br />
Torner, JC 1694, 2053<br />
Torner, JC 123, 196<br />
Torner, JC. 807<br />
Torner, J 197<br />
Törnqvist, B 260<br />
Toro Gutierrez, CEnrique<br />
1642<br />
Torralba, KD 1940<br />
TORRES, C 1661<br />
Torres, R 755<br />
Torres, SCarolina 1019<br />
Totaro, M 373<br />
Toth, E 1680<br />
Totterman, S 215<br />
Totterman, S 217, 218<br />
Toubi, E 1137<br />
Touitou, I 2082<br />
Toumi, H 564<br />
Tousson, A 1299<br />
Townley-Tilson, D 2132<br />
Townsend, A 1259<br />
Townsend, P 1333<br />
Toyama, Y 361<br />
Tracey, A 1374<br />
Tracey, KJ 926<br />
Trad, S 1970<br />
Trail, L 2178<br />
Tran, TM 2133<br />
Trapp, R 695, 944, 1432<br />
Trauzeddel, R 225<br />
Tremoulet, A 1992<br />
Trevisani, VFernandes Moça<br />
1331<br />
Triadafilopoulos, G 668,<br />
737, 1339<br />
Triana, E 1376<br />
Trieu, EP. 2068<br />
Trigona, W 761, 840<br />
Trocme, C 550<br />
Trollinger, D 138<br />
Trollmo, C 1667, 1671<br />
Trombley, R 187<br />
Trombley, RM 186, 2072<br />
Tron, F 1428<br />
Tron, F 543, 961, 1892<br />
Troncy, É 661<br />
Trotta, F 279<br />
Trotter, D 2112<br />
Troum, OM 173<br />
Troxel, AB 1904<br />
Troxell, M 237, 238<br />
Truedsson, L 1011<br />
Trueman, P 318, 319<br />
Trupin, L 78, 232, 1256,<br />
1277, 1503, 2118<br />
Trysberg, E 1962<br />
Trzaska, S 42<br />
Tsai, K 1813<br />
Tsang, YWah 829<br />
Tsao, BP. 521<br />
Tschirschmann, M 1482<br />
Tschopp, J 1280<br />
Tse, SML 898, 1168<br />
Tse, W 1669<br />
Tselepis, AD 1005<br />
Tseng, C 442<br />
Tseng, L 1679<br />
Tsevat, J 1510<br />
Tsezou, A 1445<br />
Tsiaousis, G 1910<br />
Tsifetaki, N 1914<br />
Tsitsami, E 227<br />
Tsoras, MK 2080<br />
Tsuboi, H 301<br />
Tsuboi, H 1083<br />
Tsubota, K 1981<br />
Tsuchiya, N 1071, 1968,<br />
1971<br />
Tsuda, H 1942<br />
Tsui, FWL 1284<br />
Tsui, H 1284<br />
Tsuji, G 1897<br />
Tsuji, W 944<br />
Tsuji, W 337, 698, 953<br />
Tsujimura, S 1781<br />
Tsukahara, S 361, 542<br />
Tsukamoto, M 1466, 1558<br />
Tsukimura, N 185<br />
Tsumiyama, K 925, 930<br />
Tsunemi, S 936, 1754<br />
Tsuno, N 1743<br />
Tsuru, T 1026<br />
Tsutsumi, A 371, 387,<br />
412, 671, 793, 914, 934,<br />
1083, 1753, 1759<br />
Tsuyuki, RT 1272<br />
Tsuzaka, K 1377, 1981,<br />
1996, CRC03<br />
TTSH Lupus Study Group,<br />
1147<br />
Tu, X 99<br />
Tubach, F 283, 1033, 1484<br />
Tubergen, EJ 159<br />
Tubouchi, Y 1060<br />
Tucker, LB 881<br />
Tucker, L 234, 235, 1385<br />
Tucker, LB 243<br />
Tuerk, B 1477, 2063<br />
Tugwell, P 1489, 1496,<br />
2171<br />
Tumpek, J 1837<br />
Tunc, R 333<br />
Tunç, E 2019<br />
Tuncel, J 1761<br />
Tungekar, F 1933<br />
Tunick, P 1923<br />
Turesson, C 286, 374, 993,<br />
1010, 1011, 1818<br />
Türk, B 674<br />
Turner, M 180<br />
Turner, MJ 1283<br />
Turner, S 1587<br />
Turrel, F 547<br />
Tuzun, F 275<br />
Tuzun, H 853<br />
Tworoger, SS 360<br />
Tymms, KE 1174<br />
Tymofyeyev, Y 215<br />
Tyndall, A 1, 28, 30, 1572<br />
Tyring, S 584<br />
Tytherleigh-Strong, G 122<br />
Tzaribachev, N 677, 899,<br />
2174<br />
Tzioufas, AG. 1082<br />
U<br />
Uchimura, C 396<br />
Uchimura, K 1755<br />
Udayan, R 637<br />
Udell, J 266<br />
Uebelhart, D 2076<br />
Ueda, A 649, 656, 785,<br />
854<br />
Ueda, Y 540<br />
Ueland, T 2081<br />
Ueno, S 1789<br />
Uetana, M 386<br />
Uetani, M 1840<br />
Ugarte, M 816, 1578<br />
Ugazio, A 248<br />
Ujfalussy, I 1821<br />
Ujfalussy, I 610<br />
Ulfgren, AK 359<br />
Ullmann, N 245, 904<br />
Ulmansky, R 1137, 1758<br />
Ulrich, W 518<br />
Umehara, H 1092<br />
Umekita, K 1789<br />
Umeshita-Sasai, M 1834<br />
Umezawa, K 1338<br />
Umlauf, MG 2033<br />
UNCOVER Investigators,<br />
86, 87, 88<br />
Undeutsch, R 405, 406,<br />
1954<br />
Uniyal, S 1746<br />
Unkerskov, J 339<br />
Urano, W 1619<br />
Urbanus, RT 1410<br />
Urcelay, E 1053, 1076<br />
Ureña, I 287, 1626<br />
Urganus, AL 1669<br />
Uribe, A 881<br />
Urowitz, MB. 1960<br />
Urowitz, M 450, 502, 804,<br />
1116, 1924<br />
Urowitz, MB. 1115, 1117,<br />
1143, 2157<br />
Ursum, J 380, 1020, 1831,<br />
2036<br />
Usadel, S 1777<br />
Ustek, D 812<br />
Usui, T 495, 1670<br />
Uto, K 925<br />
Utset, TO 1119<br />
Utset, TO. 1920<br />
Utz, PJ 2070<br />
Uutela, T 2155<br />
Uyar, F 843<br />
Uzan, B 1048<br />
Uzan, G 61<br />
V<br />
V, MI. 1752<br />
Vaamonde, C 391, 1446,<br />
1452<br />
Vacca, A 574, 647<br />
Vacca, Rosario Peluso,<br />
A 610<br />
Vaddi, K 1771<br />
Vadhavkar, S 668, 737,<br />
1339<br />
Vaegler, M 2174<br />
Vaessen, SF.C. 933<br />
Vahldiek, J 614<br />
Vail, A 24<br />
Vail, E 917<br />
Valentini, G 30, 2021<br />
Valenzuela, G 1468<br />
Valeriano, J 667, 1354,<br />
1355, CRC20<br />
Valet, G 1438, CRC25<br />
Vallejo, AN 2066<br />
Vallerskog, T 1667<br />
Vallø, J 2180<br />
Valverde, J 652, 1038,<br />
1894<br />
van Aken, J 2087<br />
van Baarsen, LG 307<br />
van Bavel, J 1501<br />
van Berkel, M 1180<br />
van de Laar, MA.F.J. 2046<br />
van de Laar, MAFJ 71, 72,<br />
90, 299, 2107, 2172<br />
van de Loo, FA 1305<br />
van de Loo, FA.J. 149<br />
van de Loo, FAJ 1380<br />
van de Ven, A 1988<br />
van den Berg, W 1762<br />
van den Berg, WB 129,<br />
149, 1300, 1305, 1380,<br />
1453, 2061, 2130<br />
408
van den Berg, WB. 1298<br />
van den Berg, W 1460,<br />
1757<br />
Van den Bosch, F 1181<br />
Van den Bosch, F 263,<br />
324, 325<br />
van den Bosch, F 945<br />
Van den Eynde, BJ 524,<br />
1796, 1801<br />
van den Hoogen, F 30<br />
van der Esch, M 1273,<br />
1274<br />
van der Giesen, FJ. 2104,<br />
2105<br />
van der Heijde, D 265,<br />
952, 1153, 1154, 1160,<br />
1494, 1803<br />
van der Heijde, D 305,<br />
581, 696, 698, 940,<br />
1171, 1180, 1186, 2184<br />
van der Heijdel, D 1816<br />
Van der Heijden, GJMG<br />
831<br />
van der Horst, AR. 1831<br />
van der Horst-Bruinsma,<br />
IE 380<br />
van der Hulst, EJ. 1134<br />
Van Der Kooij, SM 256,<br />
697<br />
van der Kooij, SM. 300<br />
van der Kraan, PM 2061<br />
van der Laken, CJ 693<br />
van der Leeden, M 1273,<br />
2036<br />
van der Linden, M 688<br />
van der Linden, S 1161<br />
van der Linden, S 633,<br />
1171<br />
van der Pouw Kraan,<br />
TC.t.m. 39<br />
van der Pouw Kraan, TT<br />
307<br />
van der Pouw-Kraan, T<br />
366<br />
van der Stadt, RJ 380,<br />
1831<br />
van der Wielen, P 1072<br />
van der Zanden, EP. 771<br />
van Dongen, H 2087<br />
van Eden, W 1742<br />
van Gameren, II 866<br />
van Hamburg, J 675<br />
van Helden, S 633<br />
van het Hof, B 769<br />
van Kooten, PJ. 1742<br />
van Kuijk, AW.R 1776<br />
van Laar, J 382<br />
van Laar, J 725<br />
van Laar, JM 390<br />
van Lankveld, WJ. 2105<br />
Van Lent, PL 1460, 1757,<br />
2061<br />
van Lent, PL.E.M. 129<br />
van Lent, PM 1453<br />
van Leuven, SI. 1775<br />
Van Lierop, M 1439<br />
van Maanen, MA 771, 918<br />
Van Meeteren, NLU 765<br />
van Oijen, PLM 299<br />
van Ooijen, PCM 90<br />
van Oosterhout, M 390<br />
Van Praet, J 1829<br />
van Raaij, A 149<br />
van Riel, P 258<br />
van Riel, P 1497<br />
van Riel, PL.C.M. 2046<br />
Van Riel, PLCM 90, 299,<br />
995, 1819, 2172<br />
van Riel*, PLCM 308<br />
van Rijswijk, MH 866<br />
van Roermund, PM 1676<br />
van Rooijen, N 397<br />
van Roon, JAG 792, 1379,<br />
1462, 1991<br />
van Schaardenburg, D 256,<br />
380, 1020, 1831, 2036<br />
van Seventer, JM 2131<br />
van Staa, T 684<br />
Van Steendam, K 1434<br />
van Tuyl, LH D 965, 1804<br />
Van Vollenhoven, R 261<br />
Van Vollenhoven, RF 260,<br />
1181<br />
Van Vollenhoven, R 327,<br />
1430<br />
Van Vollenhoven, RF 98,<br />
257, 266, 297, 1808,<br />
1877, 2169<br />
Van Wijk, F 938<br />
Vanasse, A 826<br />
Vander Cruyssen, B 324,<br />
325, 1493<br />
Vander Cruyssen, BJ 1685,<br />
1829<br />
Vandercruyssen, B 558<br />
Vandooren, B 366, 575,<br />
1306, 1439<br />
vanhille, p 2008<br />
Vanhoof, J 1159<br />
VanHuysen, C 798, 1152,<br />
1913<br />
Vannecke, C 629, 1557<br />
Vanoverloop, J 629, 1557<br />
VanVoorhees, A 1904<br />
Varade, J 1053, 1076<br />
Varas, B 350<br />
Varela, D 1351<br />
Varga, J 1208, 1216, 2144,<br />
2162<br />
Vargas, A 104, 1594, 1595,<br />
2006<br />
Vargas, A 104<br />
Vargas-Alarcon, G 104<br />
Varghese, B 690<br />
Varnum, B 269<br />
Vas, J 415<br />
Vasanth, LC 2034<br />
Vasculitis Research Unit.<br />
Department of Internal<br />
M, e 128<br />
Vasey, FB 667, 1355,<br />
CRC20<br />
Vasey, FB. 1354<br />
Vasku, A 789<br />
Vásquez, GM 1609<br />
Vastesaeger, N 324, 1493<br />
Vasudevan, G 438, 439<br />
Vavalle, J 1264<br />
Vázquez, I 561<br />
Vazquez, L 884<br />
Vazquez-Mellado, J 749<br />
Veale, DJ 746<br />
Veale, D 797, 1186, 1265,<br />
1266, 1267<br />
Veale, DJ 308, 330, 331,<br />
1183, 1191, 1603, 1604<br />
Veehof, MM 2046, 2107,<br />
2172<br />
Veenbergen, S 1380<br />
Veenhof, C 765<br />
Veer, Evander 580<br />
Vega-Ostertag, M 1336<br />
Vehe, RK 895<br />
Veinot, P 172<br />
Veit, V 871<br />
Velasco, F 2057<br />
Velez, M 585<br />
Vellenga, E 866<br />
Velte, C 1425<br />
Venables, P 1303, 1437<br />
Vencovsky, J 951, 1667<br />
Vendiola, RM 1909<br />
Vendramini, M 1012<br />
Venetsanopoulou, AI 1914<br />
Venkatesh, J 419<br />
Ventura, D 1015<br />
Ventura, F 602<br />
Venugopalan, A 815, 1571<br />
Vera-Llonch, M 81<br />
Verani, RR 1207<br />
Verbruggen, G 1493, 1685<br />
Verbruggen, L 324<br />
Verbsky, JW 1378<br />
Verhoef, J 2047<br />
Verity, A 1668<br />
Verpooten, G 629, 1557<br />
Verrecchia, F 28, 29<br />
Versari, A 1228<br />
Verstappen, S 1821<br />
Verstappen, SMM 831<br />
Vervoordeldonk, MJ. 771,<br />
918, 933<br />
Verweij, CL 307<br />
Verweij, CL. 39, 769<br />
Vesely, SK 870<br />
Vesprini, E 1213<br />
Vestaby, H 169<br />
Vestergaard, A 2180<br />
Vey, C 1269<br />
Veys, E 1439<br />
Vezzù, M 592<br />
VIALLARD, J 1124, 1366,<br />
2024<br />
Viana, VS T 1012<br />
Viana Queiroz, M 602,<br />
1712<br />
Vicente, E 287<br />
Vicuña, L 1983<br />
Vieira, LEnriconi dos Anjos<br />
1891<br />
Vieira, QF 520, 1722<br />
VIGNAUX, O 2024<br />
Vignon, E 1691, 1692,<br />
1706<br />
Viguier, M 593<br />
Vila, LM 493, 499, 514,<br />
1139, 1141, 1142, 1930,<br />
2124, 2168<br />
Vilá, LM. 1138, 1140, 1919<br />
Vilá,, LA. 1131<br />
Villela, R 1197<br />
Villiger, P 823<br />
Vincent, M 269<br />
Vinkenoog, M 138, 1776<br />
Viola, S 249, 913<br />
Vis, M 1548<br />
Visconti, C 913<br />
Vishne, T 535<br />
Visser, K 300, 2087<br />
Vital, EM 1094<br />
Vitale, R 227<br />
Vittecoq, O 543, 961,<br />
1428, 1892<br />
Vitton, O 716<br />
Vivino, FB 1098, 1099<br />
Vivino, FB 1103<br />
Vivino, FB. 1102<br />
Vlachoyiannopoulos, PG<br />
1405<br />
Vlad, S 806<br />
Vlad, VM 182<br />
Vladutiu, GD. 1654<br />
Vliet Vlieland, TP. M. 2105<br />
Vliet Vlieland, TP.M. 2104<br />
Vliet Vlieland, T 2047<br />
Vogel-Claussen, J 1925<br />
Vogl, T 1460, 1757<br />
Vogt, M 1487<br />
Vogt, MT. 2<br />
Volin, MV. 924<br />
abstract author Index<br />
409
abstract author Index<br />
Vollmer, J 1596<br />
Volmer, T 1488, 1823<br />
von Dalwigk, K 519<br />
Von Feldt, J 1904<br />
Von Feldt, J 2092<br />
Von Gizycki, H 431<br />
von Hinueber, U 342<br />
von Restorff, C 1550<br />
von Scheven, E 232<br />
von Wilmowsky, H 967<br />
Vonkeman, HE 71, 72<br />
Vora, SS 1378<br />
Vos, K 1290<br />
Voskuyl, AE 693, 965, 1804<br />
Voskuyl, AE. 39<br />
Vosse, D 1171<br />
Voulgari, PV 1005, 1914<br />
Vulfova, I 290<br />
Vulfova, I 966<br />
Vyse, TJ 811<br />
W<br />
WÃ¥llberg-Jonsson, S 1006<br />
Wada, Y 47<br />
Wagie, AE 837<br />
Wagner, AD 1582<br />
Wagner, B 288, 819, 825<br />
Wagner, B 257<br />
Wagner, C 956<br />
Wagner, CL. 1949<br />
Wagner, JA 276<br />
Wagner, MS 1732<br />
Wagner, U 538, 1054,<br />
2126, CRC18<br />
Wagner, U 538<br />
Wagner-Weiner, L 681<br />
Wahle, M 381, 538, CRC18<br />
Wahren, M 1727<br />
Wahren-Herlenius, M 422,<br />
1359, 1965, 2059<br />
Waisberg, MG 1842, 1895<br />
Wajdula, J 265, 591, 960,<br />
1022, 1803<br />
Wajdula, R 952<br />
Waka, A 526<br />
Wakabayashi, K 329, 1096,<br />
1441, 1660, 1896, 2005<br />
Wakabayashi, T 1032,<br />
1206<br />
Wakamatsu, E 1083<br />
Wakefield, R 564<br />
Wakefield, RJ 662, 1841<br />
Wakeland, EK 2125<br />
Wakeland, WE 1314<br />
Waldburger, J 926<br />
Walensky, RP 84<br />
Walia, DS 1559<br />
Walitt, B 1863<br />
Walker, A 1708<br />
Walker, A 897<br />
Walker, NL 1650<br />
Wallace, CA 682<br />
Wallace, CA 1282<br />
Wallace, DJ 427, 1316<br />
Wallace, DJ. 1960<br />
Wallace, D 446<br />
Wallace, D 309<br />
Wallace, DJ 450, 643,<br />
1120, 1315<br />
Wallace, DJ. 1115, 1116,<br />
2095, 2157, 2161<br />
Wallace, D 1102<br />
Wallenstein, GV. 70<br />
Wallis, G 529<br />
Walsh, C 746<br />
Walsh, CAE 331, 1183,<br />
1603, 1604<br />
Walsh, M 2012<br />
Walsh, S 1328, 1332<br />
Waltbrand, E 260<br />
Walters, K 1066<br />
Waltrip, RW 1621<br />
Wandstrat, AE 2125<br />
Wang, C 352<br />
Wang, C 1883<br />
Wang, C 672<br />
Wang, D 274<br />
Wang, H 1863<br />
Wang, J 134<br />
Wang, J 1528<br />
Wang, J 1299<br />
Wang, J 199, 1900, 2049<br />
Wang, L 414<br />
Wang, MM 2085<br />
Wang, N 195<br />
Wang, N 2062<br />
Wang, S 1255<br />
Wang, S 79<br />
Wang, S 1733<br />
Wang, X 644<br />
Wang, Y 421<br />
Wang, Y 845<br />
Wang, Y 412<br />
Wang, Y 60, 2148<br />
Wang, Y 1417<br />
Wang, Y 1287<br />
Wang, Y 1301<br />
Wang, Z 83<br />
Wani, SR 1575<br />
Ward, CD 2083<br />
Ward, E 1417<br />
Ward, F 1047<br />
Ward, JM 1987<br />
Ward, J 1134<br />
Ward, LM 242<br />
Ward, MM 559, 612, 1179,<br />
1321<br />
Warden, DW 870, 1945<br />
Wark, JD 738<br />
Warner, MR 665<br />
Warren, RW 878<br />
Warrington, KJ 1236<br />
Wassenberg, S 342<br />
Watanabe, J 1001<br />
Watanabe, R 854, 1030<br />
Watanabe, T 1788<br />
Watanabe-Tanaka, Y 671<br />
Watanuki, Y 1030<br />
Wathne, K 896, 911<br />
Watier, H 1086<br />
Watson, DK 1426<br />
Watson, KD 754, 976, 1343<br />
Watt, I 1705<br />
Watt, I 662, 1697<br />
Watts, R 2017<br />
Weaver, M 947<br />
Webb, R 1620<br />
Weber, AA 1904<br />
Wechsler, B 875, 1244,<br />
1629, 1630<br />
Wedderburn, L 1719<br />
Wedderburn, LR 908, 909<br />
Wedgwood, J 1102<br />
Wedgwood, R 441<br />
Weeratna, R 1310, 1596<br />
Wei, C 1414<br />
Wei, H 917<br />
Wei, N 1308, 1459, 1890,<br />
2084<br />
Wei, Y 1282<br />
Weidensaul, D 323<br />
Weiler, TA 2080<br />
Weinans, H 1457<br />
Weinberg, K 1723<br />
Weinblatt, ME 957<br />
Weinblatt, M 1807<br />
Weinblatt, ME 173, 294,<br />
537, 551, 726, 1028,<br />
1064, 1342, 1822, 2121<br />
Weinblatt, ME. 341, 638,<br />
2187<br />
Weiner, HL 404<br />
Weinshenker, BG 663<br />
Weinstein, A 1316<br />
Weinstein, A 1348, 1575, 1863<br />
Weinstein, E 1349<br />
Weinstein, J 1969<br />
Weinstein, JS 398, 523,<br />
1612<br />
Weinstein, JS. 397<br />
Weinstein, S 220, 874,<br />
1291<br />
Weintraub, E 454<br />
Weise, M 1655<br />
Weisman, MH 426<br />
Weisman, M 446, 450<br />
Weisman, MH 559, 560,<br />
643, 1120, 1321<br />
Weisman, MH. 612, 1179,<br />
2095, 2161<br />
Weiss, B 1121, 1392<br />
Weiss, J 2034<br />
Weiss, JP 2010<br />
Weiss, PF 247, 889<br />
Weisstuch, JM 442<br />
Welin Henriksson, E 1257,<br />
2169<br />
Wellcome Trust Case-<br />
Control Consortium,<br />
563, 1321, 1323<br />
Wells, AD 1979<br />
Wells, AU 14, 1200<br />
Wells, G 258<br />
Wells, G 1489, 2141, 2171<br />
Wells, GA 1496, 1497<br />
Wendler, J 967<br />
Wendler, J 1062<br />
Wendling, D 1156<br />
Weng, HH 960, 1806<br />
Weng, S 155<br />
Wengier, L 2044<br />
Wenglén, C 1778<br />
Wenkert, D 892<br />
Wenting, MJG 1991<br />
Wenting-van Wijk, MJG<br />
792<br />
Wermuth, PJ 51<br />
Werth, V 450<br />
Werth, VP 1904, 2071<br />
West, S 492<br />
Westedt, M 2087<br />
Wester, M 429<br />
Westerblad, H 2067<br />
Westfall, AO 636, 1552,<br />
1554<br />
Westfall, AO 2184<br />
Westhoff, G 1488, 1823<br />
Westhovens, R 699, 950,<br />
956, 988<br />
Westhovens, R 81, 1489,<br />
2171<br />
Westhovens, R 324<br />
Wettstein, PJ. 1880<br />
Wetzker, R 1058<br />
Weyand, CM. 362<br />
Wheeler, C 761<br />
Wheeler, L 203<br />
Wheeler, LM 199<br />
Wheeler, LM. 2049<br />
Whelan, BR 1610<br />
Whelan, JP 890<br />
Whisler, R 181<br />
Whitcher, J 1092<br />
White, A 272<br />
White, B 428, 429, 430,<br />
1315<br />
White, D 2053<br />
410
White, M 80<br />
White, PH 1348<br />
White, W 428<br />
White, WI 430<br />
White, W 761, 840<br />
Whitesides, JF 1091<br />
Whitfield, ML 40, 1216,<br />
2132, 2144<br />
Whiting, A 1718<br />
Whittum-Hudson, JA 1569,<br />
1570<br />
Whyte, MP 892<br />
W�llberg Jonsson, S<br />
1002, 1003<br />
Wick, MC 1430, 1877<br />
Wickline, S 921<br />
Widhe, M 1436, 1437<br />
Widmer, R 1215<br />
Wiedeman, A 530<br />
Wierk, A 225<br />
Wiers, K 234, 235, 236,<br />
885<br />
Wiggs, E 678<br />
Wigler, I 1025<br />
Wigley, FM 1208<br />
Wigley, F 30<br />
Wigley, FM. 22, 26, 2163,<br />
2165<br />
Wiist, D 1364<br />
Wijbrandts, CA 307, 955,<br />
1775, 1776<br />
Wijbrandts, CA. 358, 1290<br />
Wiland, P 791, 795<br />
Wilder, RL 923, 1745,<br />
1766<br />
Wilder, T 42<br />
Wildmann, J 1747<br />
Wildt, M 1195<br />
Wiley-Exley, E 1252<br />
Wilhelm, T 376<br />
Wilke, C 170, 171, 1113<br />
Wilkins, JA 554<br />
Willems, MJ 2107<br />
Willer, K 2029<br />
Willett, GM 766<br />
Willett, WC 628<br />
Williams, AS 1782<br />
Williams, A 641<br />
Williams, CJ 1641<br />
Williams, DA 112<br />
Williams, DA 103, 106,<br />
108, 114, 1527, 1537<br />
Williams, DA. 1525<br />
Williams, G 762<br />
Williams, J 93<br />
Williams, S 97<br />
Williams-Weese, C 1136<br />
Williamson, P 1154<br />
Willian, MK 584<br />
Willis, L 180, 549<br />
Willisch, A 595, 596, 1187,<br />
1188, 1189<br />
Wilson, AG 552, 553,<br />
1066, 1799, 2120, 2122<br />
Wilson, BJ 1174<br />
Wilson, C 1423<br />
Wilson, C 919<br />
Wilson, D 1507<br />
Wilson, DC 1715<br />
Wilson, H 1225<br />
Wilson, J 2056<br />
Wilson, M 874<br />
Wilson, S 346<br />
Wilson, S 494, 1905<br />
Wiltse, C 1543<br />
Wimmer, MA 188, 191<br />
Wimmer, MA. 2073<br />
Winalski, C 638, 664<br />
Wingren, C 814<br />
Wingrove, C 492<br />
Winkler, J 929<br />
Wipff, J 1212<br />
Wipff, J 62, 253, 1372,<br />
1373<br />
Wirth, W 657, 658, 659<br />
Wise, B 195<br />
Wise, RA. 22<br />
Wither, J 567, 804<br />
Wither, JE 400, 408, 1312<br />
Witte, A 1984<br />
Witte, S 948<br />
Witte, T 1582, 1973<br />
Wittenburg, G 406<br />
Wittoek, R 325, 1493<br />
Witzmann, G 284<br />
Wixler, V 367<br />
Wofsy, Jill P. Buyon, D<br />
2157<br />
Wöhling, H 433<br />
Wolbink, G 380<br />
Wolf, J 284<br />
Wolfe, F 820, 821<br />
Wolfe, F 168, 1291, 1559<br />
Wolfe, F 81, 280, 291,<br />
323, 648, 664, 729, 803,<br />
850, 969, 982, 1034,<br />
1118, 1340, 1509, 1520,<br />
1916, 2043, 2119<br />
Wolfe, K 706<br />
Wolff, C 1633<br />
Wolff, C 1628, 1747<br />
Wolff-Vorbeck, G 1777<br />
Wollenberg, H 1827<br />
Wollheim, FA 1195<br />
Wolterbeek, R 2104<br />
Womack, C 635<br />
Won SooK, B 2030<br />
Wong, K 2183<br />
Wong, M 269<br />
Wong, M 625, 627, 1468<br />
Wong, R 1159, 1160, 1494<br />
Wong, R 753<br />
Wong, RL. 581<br />
Wong, W 1941<br />
Woo, J 322, 388, 624<br />
Woo, P 2082<br />
Woo, T 939<br />
Wood, AK. 1768, 2129<br />
Wood, GCraig 669<br />
Wood, GCraig 735<br />
Wood, GM 1599<br />
Wood, SG. 1078<br />
Woodard, J 740<br />
Woodard, T 180<br />
Woods, JM 711, 924<br />
Woods, RM 1417<br />
WOODS, S- 67<br />
Woodward, AL 1714<br />
Woodworth, T 259, 292,<br />
827, 2089<br />
Woolf, A 670, CRC37<br />
Wootton, J 1383<br />
Wordsworth, BPaul 563,<br />
1323<br />
Wordsworth, P 1159, 1494<br />
Wordsworth, P 559, 1321,<br />
2120<br />
Worley, S 254<br />
Wörnert, M 260<br />
Worthington, J 552, 553,<br />
556, 1799, 2120, 2122<br />
Wright, A 929<br />
Wright, BM 254<br />
Wright, D 1621<br />
Wright, D 233<br />
Wright, EA 84, 687, 832,<br />
1693<br />
Wright, J 1268<br />
Wright, SA 1317<br />
Wright, TB 239<br />
Wrigley, TV. 764<br />
Wu, A 1092<br />
Wu, A 1365<br />
Wu, C 672<br />
Wu, C 135<br />
Wu, HY 404<br />
Wu, H 132, 1417, 2135<br />
Wu, H 1288<br />
Wu, J 1883, 2124<br />
Wu, M 2144<br />
Wu, Q 1285, 1299<br />
Wu, T 1286<br />
Wu, Y 504, CRC33<br />
Wulffraat, NM 938<br />
Wunrau, C 367, 392, 1058<br />
Wuttge, DM 814, 1195<br />
Wyman, B 657, 659, 1691,<br />
1706<br />
Wyman, B 217, 218<br />
X<br />
Xavier, RM 1536<br />
Xiao, C 2052<br />
Xibille, DX 1884<br />
Xie, A 1024<br />
Xie, C 1286<br />
Xing, L 691, 1476, 1750<br />
Xingchang, W 224<br />
Xiong, H 59<br />
Xiong, M 59, 560<br />
Xochiquetzal, H 1850<br />
Xu, K 172<br />
Xu, L 1417<br />
Xu, W 1153, 1154<br />
Xu, Y 2134<br />
Y<br />
Yaghoobzadeh, Y 1001<br />
Yago, T 932, 1071<br />
Yaguchi, S 1788<br />
Yagüe, J 2006<br />
Yaici, A 1126<br />
Yajima, N 329, 1096,<br />
1441, 1660, 1896, 2005<br />
Yamada, H 1205<br />
Yamada, R 1050<br />
Yamada, T 994, 1016,<br />
1036<br />
Yamagata, H 1835<br />
Yamaguchi, S 852<br />
Yamaguchi, Y 64, 855,<br />
1663<br />
Yamaguchi, Y 1743<br />
Yamaji, K 1942<br />
Yamamoto, A 1060<br />
Yamamoto, K 386, 1050,<br />
1743<br />
Yamamoto, K 296<br />
Yamamoto, T 1779<br />
Yamamura, T 932<br />
Yamana, J 1980<br />
Yamanaka, H 312, 313,<br />
344, 542, 994, 1016,<br />
1036, 1067, 1619<br />
Yamanaka, M 1619<br />
Yamaoka, K 357, 1939<br />
Yamashita, EM 879<br />
Yamashita, H 1150<br />
Yamauchi, K 2001<br />
Yamori, T 1788<br />
Yan, B 1953<br />
Yan, M 1314<br />
Yan, Z 368, 1046<br />
Yanai, A 1150<br />
Yancopoulos, GD 755<br />
Yang, H 2083<br />
Yang, H 1177, 2030<br />
Yang, J 1765<br />
abstract author Index<br />
411
abstract author Index<br />
Yang, K 1508<br />
Yang, L 1069, 1763<br />
Yang, M 742, 1694<br />
Yang, M 807<br />
Yang, P 1285, 1299<br />
Yang, X 841<br />
Yang, X 845<br />
Yang, Y 1046<br />
Yang, YH 1980<br />
Yano, T 347<br />
Yao, Q 1573<br />
Yao, R 2137<br />
Yao, Y 132, 429, 430, 761,<br />
840, 1315, 2135<br />
Yaron, M 105<br />
Yassin, LM 1609<br />
Yasuda, K 1583, 2131<br />
Yasuda, S 533, 1055, 1334,<br />
1400, 1401, 1406<br />
Yasuda, T 778<br />
Yasuoka, H 53, 54<br />
Yavorsky, A 1616<br />
Yavuz, S 1027, 1828<br />
Yazdany, J 78, 232, 1256,<br />
1277, 1503, 2118<br />
Yazici, H 853, 1248, 1513<br />
Yazici, Y 670, CRC37<br />
Yazici, Y 164, 290, 732,<br />
966, 1246, 1513, 1810<br />
Ye, Q 1314<br />
ye, s 1953<br />
Ye, X 1765<br />
YEAR consortium, 2120, 2122<br />
Yee, C 507, 508, 509<br />
Yeleswaram, S 1771<br />
Yelin, E 78, 1277, 1503<br />
Yelin, E 84, 232, 1256,<br />
2118<br />
Yelin, EH. 1278<br />
Yellin, M 1984<br />
Yen, K 1528<br />
Yeo, J 935<br />
Yeo, S 1508<br />
Yeung, RS.M. 1728, 1729,<br />
1730<br />
Yi, J 1299<br />
Yilmaz, A 275<br />
Yin, M 288, 1098, 1099, 1432<br />
Ying, J 235, 885<br />
Ying-Qian, M 1886<br />
Yocum, D 261, 819, 825<br />
Yocum, S 1457<br />
Yokoe, I 1205<br />
Yokota, K 1792, 1899<br />
Yoo, B 1790, 1997<br />
Yoo, D 555<br />
Yoo, S 369, 1043<br />
Yoo, W 363<br />
Yood, R 631<br />
Yoon, C 1944<br />
Yoon, H 363<br />
Yoon, J 1443<br />
Yoon, J 1082<br />
Yoshida, A 1902<br />
Yoshida, K 824<br />
Yoshida, T 1413<br />
Yoshida, Y 1792, 1899<br />
Yoshifuji, H 495, 1670<br />
Yoshiga, Y 793, 1759<br />
Yoshikawa, H 301, 383,<br />
1074, 1773<br />
Yoshikawa, T 1060<br />
Yoshimi, R 649<br />
Yoshimoto, K 1377, 1981,<br />
1996<br />
Yoshio, N 301<br />
Yoshio, T 1958, 1961<br />
Yoshioka, T 1707<br />
Yoshizawa, T 148, 673<br />
You, K 1478<br />
Youinou, P 534<br />
Young, A 321, 1816<br />
Young, DL 1802<br />
Young, F 1906<br />
Young, JP 715, 1522,<br />
1523, 1524<br />
Young, J 1251, 2051<br />
Young, M 1822<br />
Youssef, H 1932<br />
Yousuf, S 85<br />
Yu, DT 568<br />
Yu, DTY 569, 2101<br />
Yu, K 1108, 1109<br />
Yu, S 1679<br />
Yu, T 609<br />
Yu, V 1680<br />
Yu, X 1068<br />
Yu, Y 1749<br />
Yuan, J 841<br />
Yuan, Y 83<br />
Yucel, E 2019<br />
Yudo, K 1450<br />
Yudoh, K 1467, 2011<br />
Yue, D 1746<br />
Yuen, S 1197<br />
Yun, H 813<br />
Yurdakul, S 853, 865, 1248<br />
Yuste, J 1135<br />
Z<br />
Zachariah, E 1713<br />
Zacharias, LA 1905<br />
Zacher, J 1674<br />
Zack, DJeske 1422<br />
Zaczyńska, E 791<br />
Zaczynska, E 795<br />
Zagury, D 915<br />
Zahalkova, L 11, 12<br />
Zahr, N 432, 1123<br />
Zaiss, MM 1998<br />
Zaleski, EM 116, 117<br />
Zamani, O 594<br />
Zanchetta, JR 2140<br />
Zandman-Goddard, G 535<br />
Zang, Y 409<br />
Zarazabal, L 640<br />
Zarco, P 1175<br />
Zarnitzky, C 1892<br />
Zarowny-Wierzbinska, D<br />
1502<br />
Zautra, AJ 1276<br />
Zavadil, J 143<br />
Zea, A 350<br />
Zeft, A 1718<br />
Zeft, AS 897, 1708<br />
Zeher, M 1070, 1837<br />
Zeidler, H 1158, 1488,<br />
1582, 1823<br />
Zeiher, BG. 1890<br />
Zeise, E 1158<br />
Zeiseniss, P 1992<br />
Zelenika, D 1324<br />
Zell Gillis, J 1277<br />
Zemel, BS 239, 2177<br />
Zendman, AJW 359<br />
Zeng, L 428, 1315<br />
Zeni, S 11, 12<br />
Zepp, C 1596<br />
Zer, C 779<br />
Zerbini, C 623<br />
Zerbini, CA 1013, 1018,<br />
1842, 1895<br />
Zerkak, D 1373<br />
Zernetkina, V 1966<br />
Zevallos, F 816<br />
Zhan, Z 845<br />
Zhang, B 2173<br />
Zhang, D 1196<br />
Zhang, D 2010<br />
Zhang, G 841<br />
Zhang, H 776, 1774<br />
Zhang, J 666<br />
Zhang, JS 2168<br />
Zhang, J 46, 2134<br />
Zhang, J 423<br />
Zhang, K 411, 1309<br />
Zhang, L 1994<br />
Zhang, L 492<br />
Zhang, L 1995<br />
Zhang, LF 134<br />
Zhang, M 1800<br />
Zhang, Q 1476<br />
Zhang, S 1092<br />
Zhang, WS 828, 829<br />
Zhang, W 100<br />
Zhang, XK 1426<br />
Zhang, X 1992<br />
Zhang, X 1508<br />
Zhang, Y 1694, 2077<br />
Zhang, YQ 805<br />
Zhang, Y 366<br />
Zhang, Y 195, 215, 216,<br />
685, 2115<br />
Zhang, Y 395<br />
Zhang, Y 198, 2062<br />
Zhang, YQ 204<br />
Zhao, L 568, 569, 2101<br />
Zhao, LPing 1046<br />
Zhao, M 47<br />
Zhao, N 504, CRC33<br />
Zhao, Y 1669<br />
Zhao, Z 410, 413<br />
Zheng, P 143<br />
Zheng, TS 155<br />
Zheng, TS. 1776<br />
Zhong, J 426, 1316<br />
Zhou, H 2065<br />
Zhou, J 1314<br />
Zhou, J 1286<br />
Zhou, L 944<br />
Zhou, L 698, 953<br />
Zhou, Q 2098<br />
Zhou, W 1359<br />
Zhou, X 942<br />
Zhou, X 37, 58, 59, 559,<br />
560, 1321<br />
Zhou, Y 841<br />
Zhou, Y 1287<br />
Zhu, M 421<br />
Zhu, T 609<br />
Zhuang, H 523, 1969<br />
Zibit, MJ. 2187<br />
Zickert, A 260<br />
Ziegenbein, M 437<br />
Zierhut, M 1241<br />
Zimmermann, AF. 1204<br />
Zink, A 342, 730, 1488,<br />
1823<br />
Zinovieva, E 1324<br />
Ziolkowska, A 1313<br />
Zlotnick, S 858<br />
Zmuda, J 430, 761, 840<br />
Zohar, S 31<br />
Zoltick, PW 1608<br />
Zoma, A 450<br />
Zoma, Peter Maddison, AA.<br />
2157<br />
Zouboulis, CC 1233<br />
Zrioual, S 1041<br />
Zubieta, J 713<br />
Zulian, F 30, 222, 2082,<br />
2178<br />
Zuurmond, AM 1457<br />
Zwerdling, RG 890<br />
Zwerina, J 1304, 1762,<br />
1998, 2003<br />
412
A<br />
AAdler, Ronald<br />
Imaging of Rheumatic Diseases<br />
Disclosure:<br />
Aletaha, Daniel, MD, MSc<br />
RA New Treatments Clinical Trials II<br />
Disclosure: Abbott, Sanofi-Aventis, Shering-<br />
Plough, Wyeth, 5 Consulting fees.<br />
Arden, Nigel K.<br />
Osteoarthritis: Clinical Aspects II<br />
Disclosure: Roche, 2 Research grants; MSD,<br />
2 Research grants; Novartis, 2 Research<br />
grants; Schering-Plough, 2 Research grants;<br />
Q-Med, 5 Consulting fees; Pfizer, 8 Speakers<br />
bureau; MSD, 8 Speakers bureau; Roche,<br />
8 Speakers bureau; Servier, 8 Speakers<br />
bureau; Rottapharm, 8 Speakers bureau.<br />
Aringer, Martin, MD<br />
SLE: Human Etiology and Pathogenesis<br />
Disclosure: Centocor, 2 Research grants.<br />
B<br />
Baeten, Dominique<br />
Spondylarthropathies and Psoriatic<br />
Arthritis: Pathogenesis, Etiology<br />
Disclosure: Nothing to disclose.<br />
Barilla-LaBarca, Maria-Louise, MD<br />
Education<br />
Disclosure: Nothing to disclose.<br />
Baron, Murray<br />
Systemic Sclerosis, Fibrosing Syndromes<br />
and Raynaud’s: Clinical Aspects and<br />
Therapeutics I<br />
Disclosure: Actelion, Encysive, Pfizer.<br />
Bathon, Joan<br />
Predictors of Disease Severity and RA<br />
Treatment Response<br />
Disclosure: IDEC, Amgen, Bristol Myers<br />
Squibb, Rinat Neurosciences, 2 Research<br />
grants; Abbott, Novartis, 5 Consulting fees.<br />
Bingham, Clifton O., M.D.<br />
RA New Treatments Clinical Trials I<br />
Genentech, Abbott, Amgen, Wyeth, Bristol<br />
Myers Squibb, 2 Research grants;<br />
Disclosure: Novartis, Merck, Abbott, Amgen,<br />
5 Consulting fees.<br />
Birnbaum, Neal S., MD<br />
Discovery <strong>2007</strong>: Advances in the<br />
Management of Arthritis and Osteoporosis<br />
Disclosure:<br />
Bockenstedt, Linda<br />
Infection: Related Rheumatic Disease<br />
Disclosure: I have NIH and CDC sponsored<br />
research grants on Lyme disease.<br />
Borenstein, David<br />
Physical Activity in Musculoskeletal<br />
Disorders<br />
Disclosure: Pfizer, Alpharma, Biovail,<br />
CombinatoRx, 5 Consulting fees; Pfizer,<br />
Pricara, Abbott, 8 Speakers bureau.<br />
Boulware, Dennis W.<br />
Eclectic Rheumatology<br />
Disclosure: Nothing to disclose.<br />
Brahn, Ernest<br />
Animal Models of Rheumatoid Arthritis:<br />
Pathogenesis and Novel Therapeutic Targets<br />
Disclosure: Nothing to disclose.<br />
Brasington, Richard<br />
Education<br />
Disclosure: Centocor; Biogen-Idec; Human<br />
Genome Sciences;Abbott, 2 Research grants;<br />
Genentech; Biogen-Idec; Abbott; Centocor,<br />
8 Speakers bureau.<br />
C<br />
Carmona, Loreto, MD, PhD<br />
Epidemiology and Health Services Research:<br />
Primary, Secondary and Tertiary Prevention<br />
Disclosure:None.<br />
Chakravarty, Eliza F., MD<br />
The Epidemiology of SLE<br />
Disclosure: Nothing to disclose.<br />
Chan, Andrew C., MD, PhD<br />
B-Cell Biology and Targets in Autoimmune<br />
Disease<br />
Disclosure: Employee of GNE, 1 Stocks or<br />
Stock options (in a for-profit corporation);<br />
Full time employee of GNE, 3 Employment<br />
(full or part time).<br />
Chen, Lan X., MD, PhD<br />
Uric Acid and Gout<br />
Disclosure: Nothing to disclose.<br />
Chwalek, Marcia, MS, RN, ANP<br />
Arthritis in the Community<br />
Disclosure: Nothing to disclose.<br />
Clarke, Ann E., MD<br />
The Epidemiology of SLE<br />
Disclosure: Bristol Myers Squibb, 5<br />
Consulting fees; Human Genome Sciences,<br />
9 Other.<br />
Cohen, Marc David, MD<br />
Therapeutic and Diagnostic Strategies in RA<br />
Disclosure: Wyeth, AMgen, Centocor, Abbott,<br />
Genetech, 5 Consulting fees.<br />
Corr, Mary<br />
RA Pathogenesis: Genetics and the Environment<br />
Disclosure: nih, 2 Research grants; UCSD, 3<br />
Employment (full or part time); va medical<br />
center, 3 Employment (full or part time).<br />
Costenbader, Karen H., MD MPH<br />
SLE: Markers of Disease<br />
Disclosure: Nothing to disclose.<br />
Crow, Mary K.<br />
Pathogenesis of Sjogren’s Syndrome<br />
Disclosure: Nothing to disclose.<br />
D<br />
D’Cruz, David P.<br />
SLE: Markers of Disease<br />
Disclosure: Aspreva, 2 Research grants; Bristol<br />
Myers Squibb, Aspreva, 5 Consulting fees.<br />
Davis, John C., MD, MPH<br />
Spondylarthropathies and Psoriatic<br />
Arthritis: Treatment I<br />
Disclosure: Centocor, 2 Research grants;<br />
Abbott, 2 Research grants; Amgen, 2 Research<br />
grants; Wyeth, 8 Speakers bureau.<br />
E<br />
Edwards, N Lawrence, MD<br />
Eclectic Rheumatology<br />
Disclosure: TAP Pharmaceuticals,<br />
Savient Pharmaceutical, and Genzyme<br />
Pharmaceutical, 5 Consulting fees.<br />
F<br />
Firestein, Gary S., MD<br />
Discovery <strong>2007</strong>: Insights into Autoimmunity<br />
Disclosure:<br />
Fisher, Nadine M., EdD<br />
Physical Activity in Musculoskeletal Disorders<br />
Disclosure: Nothing to disclose.<br />
Fox, David A., MD<br />
Discovery <strong>2007</strong>: Advances in the<br />
Management of Arthritis and Osteoporosis<br />
Disclosure:<br />
abstract moderator Index<br />
Biundo, Joseph<br />
Advances in Orthopedics<br />
Disclosure:<br />
Clements, Philip<br />
Systemic Sclerosis, Fibrosing Syndromes<br />
and Raynaud’s: Clinical Aspects and<br />
Therapeutics II<br />
Disclosure: Novartis, 2 Research grants;<br />
Millenium, 5 Consulting fees; Encysive,<br />
Actelion, 8 Speakers bureau.<br />
413
G<br />
H<br />
K<br />
Gabriel, Sherine, MD<br />
Biologic Therapies and RA Comorbidity<br />
Disclosure: NIH: Mayo Clinic Center for<br />
Clinical & Translational Research, 2<br />
Research grants; NIH: The Mayo Clinic<br />
Research Training <strong>Program</strong> (K30), 2<br />
Research grants; NIH: Multidisciplinary<br />
Clinical Research Career Development<br />
<strong>Program</strong> (K12), 2 Research grants; NIH:<br />
Heart Disease and Rheumatoid Arthritis,<br />
2 Research grants; NIH: Heart Disease in<br />
Psoriasis, 2 Research grants; Mayo Clnic,<br />
Department of HEalth Sciences Research,<br />
3 Employment (full or part time); Institute<br />
for Work & Health, 8 Speakers bureau;<br />
AMGEN-Wyeth, 8 Speakers bureau; UCLA-<br />
Pearson Memorial, 8 Speakers bureau;<br />
University of Toronto, 8 Speakers bureau;<br />
SPARTAN, 8 Speakers bureau; AAMC-Great<br />
Group, 8 Speakers bureau; AAMC Annual<br />
<strong>Meeting</strong>, 8 Speakers bureau.<br />
Gelber, Allan C.<br />
Epidemiology and Health Services Research:<br />
Comorbidities and Rheumatic Disease<br />
Disclosure: NIH/NIAMS; <strong>ACR</strong>/REF, 2<br />
Research grants.<br />
Harrington, J Timothy, MD<br />
Improving Quality of Care by Design,<br />
Redesign and Innovation<br />
Disclosure: Abbott Laboratories, 2 Research<br />
grants; Bionicare Inc, 5 Consulting fees;<br />
CORRONA, 6 Non-remunerative position<br />
of influence - board member; Abbott<br />
Laboratories, Alliance for Better Bone<br />
Health, 8 Speakers bureau.<br />
Haskard, Dorian O., DM FRCP<br />
Arthritis: An Angiogenesis-Dependent<br />
Disease<br />
Disclosure: Nothing to disclose.<br />
Henderson, Carol J., PhD, RD<br />
Building Resilience: Kids and Joints<br />
Disclosure: Nothing to disclose.<br />
Ho, I-Cheng<br />
T-Cell Modulation in Autoimmunity<br />
Disclosure: Nothing to disclose.<br />
Hobbs, Kathryn<br />
RA New Treatments Clinical Trials II<br />
Disclosure: Centocor, Abbott, Amgen,<br />
Wyeth, Genentech, BMS, 8 Speakers bureau.<br />
Katz, Jeffrey N., MD, MS<br />
Discovery <strong>2007</strong>: Pathogenesis and<br />
Treatment of Inflammatory<br />
Disclosure:<br />
Kavanaugh, Arthur F., MD<br />
Predictors of Disease Severity and RA<br />
Treatment Response<br />
Disclosure: Nothing to disclose.<br />
Klareskog, Lars<br />
Genetics, Genomics and Proteomics<br />
Disclosure:<br />
Klein-Gitelman, Marisa S.,<br />
Building Resilience: Kids and Joints<br />
Disclosure: NIH, FDA, ALR, Cincinnati<br />
Children’s Hospital, 2 Research grants.<br />
Koch, Alisa E.<br />
Arthritis: An Angiogenesis-Dependent Disease<br />
Disclosure: Tap Pharma and Predix Pharma,<br />
2 Research grants; AstraZeneca, PLC;<br />
Genentech; Proctor and Gamble Pharma;<br />
Predix Pharma; Clinical Advisors, LLC;<br />
Gerson Lerhrman Group; Kirkland and Ellis<br />
LLP, 5 Consulting fees.<br />
abstract moderator Index<br />
Genovese, Mark C., MD<br />
RA New Treatments Clinical Trials I<br />
Disclosure: Biogen-Idec, BMS, Abbott,<br />
Genentech, Serono, Wyeth, Roche, 2<br />
Research grants; BMS, Genentech, Roche,<br />
Wyeth, Abbott, 5 Consulting fees.<br />
Gershwin, M. Eric, MD<br />
B-Cell Biology and Targets in Autoimmune<br />
Disease<br />
Disclosure: Nothing to disclose.<br />
Geusens, Piet<br />
Osteoporosis Treatment and Epidemiologic<br />
Updates<br />
Disclosure: Nothing to disclose.<br />
Gignac, Monique A., PhD<br />
Emotional Well-being<br />
Disclosure: Nothing to disclose.<br />
Gladman, Dafna D.<br />
Spondylarthropathies and Psoriatic<br />
Arthritis: Treatment II<br />
Disclosure: Abbott Canada, Amgen/Wyeth<br />
Canada, Pfizer Canada, Schering Canada,<br />
Wyeth Global, Canadian Institutes of<br />
Health Resaerch, Krembil Foundation, 2<br />
Research grants; Abbott Canada, Amgen/<br />
Wyeth Canada, Schering Canada, 5<br />
Consulting fees.<br />
Grossman, Jennifer<br />
SLE: Novel Therapies<br />
Disclosure: NIH, LRI, ALR, Genentech,<br />
TEVA, BMS, Aspreva, Roche, 2 Research<br />
grants; Genentech, 5 Consulting fees.<br />
Hunder, Gene G., MD<br />
Vasculitis<br />
Disclosure: Abbott, 8 Speakers bureau.<br />
Huttenlocher, Anna<br />
Pediatric Rheumatology: Determinants and<br />
Markers of Disease<br />
Disclosure: Nothing to disclose.<br />
I<br />
Isaacs, John D., PhD FRCP<br />
Biologic Therapies in RA: Clinical Aspects<br />
Disclosure: Abbott, Wyeth, 2 Research<br />
grants; Roche, BMS, GSK, Almirall, 5<br />
Consulting fees; Roche, 8 Speakers bureau.<br />
J<br />
Jeffrey, Janet E., RN PhD<br />
Fibromyalgia Perspectives<br />
Disclosure: Nothing to disclose.<br />
Jordan, Joanne<br />
Osteoarthritis: Clinical Aspects II<br />
Disclosure: Novartis, 5 Consulting fees;<br />
GlaxoSmithKline, 5 Consulting fees; Cerimon<br />
Pharmaceuticals, 5 Consulting fees.<br />
Kowal-Bielecka, Otylia, MD<br />
Systemic Sclerosis, Fibrosing Syndromes<br />
and Raynaud’s: Clinical Aspects and<br />
Therapeutics II<br />
Disclosure: Nothing to disclose.<br />
Kvien, Tore K., MD PhD<br />
Epidemiology and Health Services Research:<br />
Comorbidities and Rheumatic Disease<br />
Disclosure: Wyeth, Abbott, MSD, Schering-<br />
Plough, BMS, Roche, 2 Research grants;<br />
MSD, Roche, Wyeth, Abbott, CombinatoRx,<br />
5 Consulting fees; MSD, Roche, Wyeth,<br />
Abbott, BMS, 8 Speakers bureau.<br />
L<br />
Lamprecht, Peter<br />
Vasculitis<br />
Disclosure: DFG-La1339 (German Research<br />
Society), 2 Research grants.<br />
Landewé, Robert B.<br />
Spondylarthropathies and Psoriatic<br />
Arthritis: Treatment II<br />
Disclosure: Abbott, Amgen, Astra, Centocor,<br />
Schering, UCB, Wyeth, 5 Consulting fees.<br />
Loeser, Richard F., MD<br />
Biology and Pathology of Bone and Joint<br />
Disclosure: Centocor Inc., 2 Research<br />
grants; Osteoarthritis Research Society<br />
International, 6 Non-remunerative position<br />
of influence - board member.<br />
414
M<br />
Maksymowych, Walter P.<br />
Spondylarthropathies and Psoriatic Arthritis:<br />
Treatment I<br />
Disclosure: Abbott Labs, Schering Canada,<br />
Amgen/Wyeth, 5 Consulting fees.<br />
Manzi, SusanMD, MPH<br />
Discovery <strong>2007</strong>: Insights into Autoimmunity<br />
Disclosure:<br />
Martin, Tammy M., PhD<br />
Spondylarthropathies and Psoriatic Arthritis:<br />
Pathogenesis, Etiology<br />
Disclosure: Nothing to disclose.<br />
Matteson, Eric<br />
Biologic Therapies in RA: Clinical Aspects<br />
Disclosure: Exact Sciences, 1 Stocks or<br />
Stock options (in a for-profit corporation);<br />
<strong>American</strong> College of Rheumatology,<br />
Amgen, Asta, Biogen-IDEC, Burroughs-<br />
Wellcome, Centocor, Cypress, Endocyte,<br />
Inc., Genentech, Hoffmann-LaRoche,<br />
Human Genome Sciences, Immunex,<br />
Protein Design Laborat, 2 Research grants;<br />
Nastech, Pharmacia & Upjohn, Schering,<br />
Wyeth, Xoma Corporation, 2 Research<br />
grants; Amgen, Aventis, Bristol-Myers-<br />
Squibb, Centocor/Johnson & Johnson,<br />
Genentech, Immunex, Mayo Foundation,<br />
Novartis, National Institutes of Health,<br />
2 Research grants; Mayo Clinic, 3<br />
Employment (full or part time); Amgen,<br />
BoneandJoint.org; BiogenIDEC, Burroughs-<br />
Wellcome, Centocor*, Covance, Endocyte,<br />
Inc.*, Novartis, Regeneron, SGS-US Testing<br />
Company Inc., Takeda, Upjohn, Watermark<br />
Research, 5 Consulting fees.<br />
Matucci Cerinic, Marco, Professor<br />
Pathogenesis of Systemic Sclerosis: Key<br />
Pathways and Molecular Targets for Therapy<br />
Disclosure: Nothing to disclose.<br />
Mayes, Maureen D.<br />
Systemic Sclerosis, Fibrosing Syndromes<br />
and Raynaud’s: Clinical Aspects and<br />
Therapeutics I<br />
Disclosure: Actelion, RAPIDS study of<br />
Bosentan in SSc digital ulcers., 2 Research<br />
grants; Actelion - design and analysis<br />
of clinical trials., 5 Consulting fees;<br />
Novartis - Data and Safety Monitoring<br />
Board, 5 Consulting fees; Actelion Pharma,<br />
8 Speakers bureau; Encysive Pharma, 8<br />
Speakers bureau.<br />
McBeth, John, PhD<br />
Fibromyalgia: Etiology and Treatment<br />
Disclosure: Nothing to disclose.<br />
Meroni, Pier Luigi<br />
Antiphospholipid Syndrome: Mechanisms of<br />
Vascular Pathology<br />
Disclosure: Nothing to disclose.<br />
Merrill, Joan T., MD<br />
Antiphospholipid Syndrome: Mechanisms of<br />
Vascular Pathology<br />
Disclosure: NIH, OCAST, IBM, Aspreva,<br />
Genentech, 2 Research grants; Oklahoma<br />
Medical Research Foundation, Lupus<br />
Foundation of America, 3 Employment<br />
(full or part time); Lupus Foundation of<br />
America, Bristol Myers Squibb, Genentech,<br />
Wyeth Ayerst, Aspreva, Human Genome<br />
Sciences, Amgen, Medimmune, 5 Consulting<br />
fees; Bristol Myers Squibb, Aspreva, Lupus<br />
Foundation of America, Genentech, 8<br />
Speakers bureau.<br />
Messier, Stephen P., PhD<br />
Osteoarthritis: Clinical Aspects I<br />
Disclosure: Nothing to disclose.<br />
Mikuls, Ted R.<br />
Biologic Therapies and RA Comorbidity<br />
Disclosure: Grants from NIH, Arthritis<br />
Foundation, Abbott, and Amgen; Previous<br />
consultant to Tap and BMS.<br />
Miyasaka, Nobuyuki<br />
RA Pathogenesis: Molecular Mechanisms<br />
Disclosure: Wyeth, Takeda, Tanabe,<br />
Abbott, 5 Consulting fees.<br />
Morand, Eric F.<br />
RA Pathogenesis: Genetics and the Environment<br />
Disclosure: Cortical Pty Ltd, 1 Stocks or<br />
Stock options (in a for-profit corporation);<br />
CSL Inc; CryptoPharma, 5 Consulting fees.<br />
Moutsopoulos, H. M., MD, FACP, FRCP<br />
Pathogenesis of Sjogren’s Syndrome<br />
H.M. MoutsopoulosNone.<br />
N<br />
Newman, Eric<br />
Improving Quality of Care by Design, Redesign<br />
and Innovation<br />
Disclosure: Nothing to disclose.<br />
O’Neil, Kathleen M., MD<br />
Pediatric Rheumatic Diseases: New<br />
Developments in Diagnosis, Treatment and<br />
Natural History<br />
Disclosure: <strong>ACR</strong>/REF Academic Re-Entry<br />
Award, 2 Research grants; NIAMS R03<br />
AR052453, 2 Research grants; OCAST Health<br />
Research HR06-068, 2 Research grants.<br />
O<br />
O’Shea, John<br />
IL-17 and Related Cytokines in Rheumatic<br />
Disease<br />
Disclosure: Jak3 Patent.<br />
Oddis, Chester V.<br />
Muscle Biology, Myositis and Myopathies:<br />
New Insights Regarding Mechanism and<br />
Clinical Assessment<br />
Disclosure: Genentech support of an NIHfunded<br />
research trial, 2 Research grants;<br />
Genentech; MedImmune, 5 Consulting fees.<br />
Oen, Kiem<br />
Pediatric Rheumatic Diseases: New<br />
Developments in Diagnosis, Treatment and<br />
Natural History<br />
Disclosure: Nothing to disclose.<br />
Opava, Christina H., PhD, RPT<br />
Living the Good Life with Rheumatic Disease<br />
Disclosure:<br />
Orloff, Karen A., BS, CCRC<br />
SLE and Inflammatory Arthritis: Disease<br />
Activity and Outcomes Research<br />
Disclosure:<br />
P<br />
Perl, Andras, MD, PhD<br />
T-Cell Modulation in Autoimmunity<br />
Disclosure: Nothing to disclose.<br />
Pham, Christine, MD<br />
Innate Immunity Leading to Rheumatic Disease<br />
Disclosure: NIH, Sandler <strong>Program</strong> for Asthma<br />
Research, 2 Research grants.<br />
Pope, Richard M.<br />
Novel Molecular Mediators and Treatments<br />
Disclosure: Nothing to disclose.<br />
Pope, Richard M.<br />
RA Pathogenesis: Molecular Mechanisms<br />
Disclosure: Nothing to disclose.<br />
Ramsey-Goldman, Rosalind, MD, DrPH<br />
Discovery <strong>2007</strong>: Pathogenesis and Treatment<br />
of Inflammatory<br />
Disclosure:<br />
abstract moderator Index<br />
415
abstract moderator Index<br />
R<br />
Rose, Carlos D., MD<br />
Biologics in Pediatric Rheumatology:<br />
Clinical Trial Results<br />
Disclosure: Amgen, 8 Speakers bureau.<br />
Sanz, Inaki<br />
SLE: Human Etiology and Pathogenesis<br />
Disclosure: Biogen, 2 Research grants;<br />
Genentech, 5 Consulting fees; Wyeth, 5<br />
Consulting fees.<br />
S<br />
Schumacher, H. Ralph, MD<br />
Uric Acid and Gout<br />
Disclosure: TAP, Wyeth,Cherrypharm,<br />
2 Research grants; Savient,Ipsen, TAP<br />
,Regeneron, Pfizer, Merck, 5 Consulting fees.<br />
Schwarz, Edward, PhD<br />
Biology and Pathology of Bone and Joint<br />
Disclosure: NIH, Centocor, Amgen, 2<br />
Research grants; Centocor, Amgen,<br />
Genzyme, 5 Consulting fees; Amgen, 8<br />
Speakers bureau.<br />
Sebba, Anthony I., MD<br />
Osteoporosis Treatment and<br />
Epidemiologic Updates<br />
Disclosure: Merck Amgen Roche,Lilly, 4<br />
Partnership; Merck Amgen Roche,Lilly, 5<br />
Consulting fees.<br />
Sharma, Leena<br />
Osteoarthritis: Clinical Aspects I<br />
Disclosure: Nothing to disclose.<br />
Siegel, Richard M., MD, PhD<br />
Novel Molecular Mediators and Treatments<br />
Disclosure: Nothing to disclose.<br />
Silverman, Gregg<br />
Genetics, Genomics and Proteomics<br />
Disclosure: Nothing to disclose.<br />
Singer, Nora G., M.D.<br />
Pediatric Rheumatology: Determinants and<br />
Markers of Disease<br />
Disclosure: Arthritis Foundation, NIH, ALR,<br />
Pfizer, Merck, Endo, 2 Research grants;<br />
Abbott Immunology, 5 Consulting fees;<br />
Abbott Immunology, 8 Speakers bureau;<br />
Clinical Studies-Amgen, Roche, Genetech,<br />
Serono, Pfizer BMS, 9 Other.<br />
Steere, Allen C.<br />
Infection: Related Rheumatic Disease<br />
Disclosure: Viramed.<br />
Suarez-Almazor, Maria<br />
Epidemiology and Health Services Research:<br />
Primary, Secondary and Tertiary Prevention<br />
Disclosure: M. Suarez-AlmazorNIH, AHRQ, 2<br />
Research grants.<br />
T<br />
Taal, Erik, PhD<br />
Considerations in Arthritis Self-Help <strong>Program</strong>s<br />
Disclosure: Nothing to disclose.<br />
Tak, Paul P., MD, PhD<br />
Therapeutic and Diagnostic Strategies in RA<br />
Disclosure: Millennium, 2 Research grants;<br />
Biogen, 2 Research grants; Astellas, 2<br />
Research grants; Roche, 2 Research grants;<br />
Array BioPharma, 2 Research grants;<br />
Abbott, 2 Research grants; Merck Serono,<br />
2 Research grants; Amgen, 2 Research<br />
grants; Centocor, 2 Research grants; BMS,<br />
2 Research grants; Arthrogen, 2 Research<br />
grants; Promics, 2 Research grants; Abbott,<br />
5 Consulting fees; BMS, 5 Consulting<br />
fees; Roche, 5 Consulting fees; Wyeth,<br />
5 Consulting fees; Astellas, 5 Consulting<br />
fees; Array BioPharma, 5 Consulting<br />
fees; AstraZeneca, 5 Consulting fees;<br />
Merck Serono, 5 Consulting fees; GSK, 5<br />
Consulting fees; NovoNordisk, 5 Consulting<br />
fees; Roche, 8 Speakers bureau; Chief<br />
<strong>Scientific</strong> Officer of Arthrogen bv, 9 Other.<br />
Tan, Filemon<br />
Pathogenesis of Systemic Sclerosis: Key<br />
Pathways and Molecular Targets for Therapy<br />
Disclosure: Nothing to disclose.<br />
V<br />
Van Den Berg, Wim B., PhD<br />
IL-17 and Related Cytokines in<br />
Rheumatic Disease<br />
Disclosure: Nothing to disclose.<br />
Van Vollenhoven, Ronald<br />
SLE: Novel Therapies<br />
Disclosure: Nothing to disclose.<br />
VandenBerg, Wim B.<br />
Animal Models of Rheumatoid Arthritis:<br />
Pathogenesis and Novel Therapeutic Targets<br />
Disclosure: Nothing to disclose.<br />
Via, Charles S.<br />
SLE: Animal Models<br />
Disclosure: Nothing to disclose.<br />
W<br />
Wallace, Daniel<br />
Fibromyalgia: Etiology and Treatment<br />
Disclosure: Nothing to disclose.<br />
Winalski, Carl<br />
Imaging of Rheumatic Diseases<br />
Disclosure: Pfizer, Inc., 1 Stocks or Stock<br />
options (in a for-profit corporation);<br />
Abbott Laboratories, 2 Research grants;<br />
Genzyme Biosurgery, Inc., 2 Research<br />
grants; Smith & Nephew, Inc., 2 Research<br />
grants; Johnson & Johnson Regenerative<br />
Therapeutics, 2 Research grants;<br />
ConforMIS, Inc., 5 Consulting fees.<br />
Wither, Joan, MD PhD<br />
SLE: Animal Models<br />
Disclosure: The Arthritis Society, Canadian<br />
Institutes of Health Research, 2 Research grants.<br />
Wortmann, Robert L., M.D.<br />
Muscle Biology, Myositis and Myopathies:<br />
New Insights Regarding Mechanism and<br />
Clinical Assessment<br />
Disclosure: Nothing to disclose.<br />
Wouters, Carine, MD PhD<br />
Biologics in Pediatric Rheumatology:<br />
Clinical Trial Results<br />
Disclosure: Nothing to disclose.<br />
Z<br />
Zeidler, Henning<br />
Advances in Orthopedics<br />
Disclosure: Merck Sharp Dome, 8 Speakers<br />
bureau; Merk Sharp Dome, Wyeth,Pfizer, 5<br />
Consulting fees.<br />
416
Notes<br />
www.rheumatology.org—Rheumatology’s Home on the Web 417
abstract keyword Index<br />
3D structure 658,844,848,1957<br />
3<br />
A<br />
abatacept 81,83,221,258,318,319,679,6<br />
80,699,820,821,942,943,950,1039,148<br />
9,1496,1497,1798,1810,1813<br />
access to care 73,74,86,87,160,178,721<br />
,908,910,1260,1381,1385<br />
activities of daily living (ADL) 76,227<br />
acupressure/acupuncture<br />
85,352,713,739,1251<br />
acute-phase reactants<br />
168,220,867,1228,2091<br />
adalimumab 98,100,271,278,286,294,3<br />
48,578,581,584,594,650,681,753,830,<br />
861,862,863,873,895,945,955,959,115<br />
8,1159,1160,1181,1494,1775,1796,18<br />
01,1809,CRC31<br />
adenosine 41,42,156,776,780<br />
adhesion molecules 48,573,593,920,107<br />
8,1149,1474,1477,1478,1480,1481,16<br />
32,1755,1928<br />
adiponectin 219,777,794<br />
adjuvant arthritis 924,1745,1758,1988<br />
adolescent patients 879,883<br />
adrenomedullin 1048<br />
adult-onset Still’s disease 279<br />
adverse events 306,334,350,428,431,<br />
434,831,958,964,1340,CRC14,CRC18<br />
,CRC21<br />
African-<strong>American</strong>s 15,514,817,1111,126<br />
3,1622,1949,2184<br />
aging 619,623,836,1018,1467,2114<br />
alcohol 336,374,1142<br />
<strong>American</strong> College of Rheumatology<br />
166,1913<br />
amyloidosis<br />
287,865,866,907,990,1238,1296<br />
anakinra 219,249,677,857,2027,CRC02<br />
analgesics 860,917,1293,1688,1689<br />
ANCA 890,2003,2005,2009,2010,2012<br />
anemia 988,1138,1194<br />
anergy 925,1420<br />
angiogenesis 62,369,672,711,746,921,9<br />
36,1356,1472,1475,2149<br />
angiopoietin 2149<br />
angiotensin 1139,CRC21<br />
animal models 45,48,50,107,396,400,40<br />
3,407,408,410,416,421,422,425,540,5<br />
66,567,661,672,674,675,692,711,717,<br />
755,787,860,915,920,922,933,1063,10<br />
81,1298,1311,1312,1314,1325,1453,1<br />
457,1601,1606,1669,1670,1727,1743,<br />
1757,1987,2001,2058,2061,2069<br />
ankylosing spondylitis (AS) 169,558,559,<br />
560,566,567,568,569,570,571,573,574<br />
,577,578,579,581,582,585,586,587,58<br />
8,589,591,594,595,597,599,601,602,6<br />
12,614,615,655,750,751,752,753,754,<br />
822,1027,1153,1154,1157,1158,1159,<br />
1160,1161,1162,1163,1164,1165,1166<br />
,1167,1168,1169,1170,1171,1172,117<br />
3,1174,1175,1176,1177,1179,1186,11<br />
88,1189,1321,1322,1325,1493,1494,1<br />
995,2101,CRC08,CRC11<br />
annexin 1980<br />
anti-agalactosyl IgG antibodies 1651<br />
anti-beta 2 glycoprotein 1<br />
1336,1338,1396,1405,1407,1410<br />
anti-CCP 181,325,349,377,379,380<br />
,537,538,901,903,1049,1061,107<br />
0,1073,1101,1651,1825,1826,182<br />
7,1829,1830,1832,1833,1834,183<br />
7,1840,1841,1893,1894,1897,189<br />
8,1900,1901,1905,2150,2182<br />
anti-DNA, anti-dsDNA 349,424,435,450,<br />
963,1903,1910,1936,1977<br />
anti-endothelial antibody 1636<br />
anti-IL6 296,301,534,934,1026,1805<br />
anti-TNF drugs 81,82,90,94,95,265,274<br />
,277,279,283,287,291,295,299,306,3<br />
08,314,323,330,331,335,339,342,344<br />
,347,356,371,552,553,580,584,601,6<br />
34,651,696,700,727,729,730,754,779<br />
,915,929,934,940,941,946,959,960,9<br />
61,969,970,971,972,973,976,980,102<br />
1,1022,1029,1030,1033,1156,1157,11<br />
59,1181,1183,1264,1343,1344,1604,1<br />
611,1705,1794,1799,1803,1805,1827<br />
,1878,2084,2108,2111,CRC11,CRC16,<br />
CRC17,CRC27,CRC28,CRC29,CRC34,C<br />
RC39,CRC41,CRC43,CRC46,CRC47,CR<br />
C48,CRC50<br />
antibodies 221,244,366,517,529,886,9<br />
14,1012,1081,1133,1218,1289,1303,<br />
1433,1684,1721,1831,1893,1898,20<br />
86,2093<br />
anticardiolipin 1151,1336,1392,1394,13<br />
96,1397,1408,1410,1412,1924<br />
anticoagulation 859<br />
antigen-presenting cell<br />
793,1380,1647,1953,1995<br />
antigens 402,1289<br />
antimalarial drugs 1310<br />
antinuclear antibodies (ANA)<br />
495,961,1515,1907,1913<br />
antioxidants 1218,1220<br />
antiphospholipid syndrome 223,450,13<br />
33,1334,1335,1336,1337,1338,1387,1<br />
388,1389,1390,1391,1393,1394,1395,<br />
1397,1398,1399,1400,1402,1403,140<br />
4,1406,1408,1409,1410,1411,1412,1<br />
933,2057,2179<br />
anxiety 328<br />
AP-1 1779<br />
apoptosis 144,357,389,391,401,775,842<br />
,1057,1357,1446,1451,1592,1600,160<br />
7,1608,1609,1725,1726,1770,1780,17<br />
84,1966,1978,1983,1999,2126,2133<br />
arteriosclerosis 710,1394,1403,1956<br />
arthrocentesis 345,736,910,1350,1672<br />
arthropathy 7,517,1631<br />
arthroplasty 833,835,836,837,1699,173<br />
5,1736,1738,2044,2111,2112,2113<br />
arthroscopy 122,390,835<br />
asymmetrical dimethylarginine<br />
447,1926<br />
atherosclerosis 445,446,449,1001,10<br />
12,1015,1109,1115,1116,1144,114<br />
5,1146,1147,1148,1196,1235,1408,<br />
1609,1751,1775,1899,1923,1925,1<br />
928,1929,1930,1964,2090,2091,20<br />
92,2100,2156,2157<br />
autoantibodies 18,39,65,143,398,406,5<br />
10,512,521,526,553,683,747,748,761<br />
,870,1071,1215,1219,1221,1285,1299<br />
,1308,1363,1364,1407,1416,1425,142<br />
7,1429,1430,1436,1437,1663,1664,16<br />
65,1666,1667,1727,1749,1838,1903,1<br />
912,1941,1958,1960,1961,1983,1986<br />
,2059,2068<br />
autoantigens 1361,1415,1416,1419,142<br />
5,1428,1429,1434,1435,1957,1965,20<br />
11,2068,2070<br />
autoimmune diseases 138,415,515,51<br />
9,793,804,842,851,1079,1264,1305,<br />
1364,1421,1435,1643,1651,1765,20<br />
00,2130<br />
autoimmunity 824,919,922,1297,1367,1<br />
413,1592,1602,1642,1742,1761,1987<br />
autologous transplantation 29<br />
autonomic function 104,335,927<br />
azathioprine 845<br />
B<br />
B cells 257,262,263,266,272,288,309,37<br />
3,381,382,395,402,418,419,426,427,5<br />
34,695,914,1078,1091,1102,1223,128<br />
6,1288,1308,1313,1316,1414,1417,14<br />
20,1421,1422,1424,1426,1431,1433,1<br />
438,1606,1721,1750,1777,1907,1939,<br />
1977,1993,2020,2086,2088,CRC25<br />
B lymphocyte stimulator (BLyS) 50,151,<br />
419,426,427,498,852,1051,1089,1312,<br />
1316,1423,1424,1667,1981,2083<br />
back pain 116,738,750,767,768,1734,2<br />
037,2108<br />
bacterial infections 1569,1570<br />
BAFF receptor 1422,1432<br />
Beh‡et’s syndrome 561,843,852,853,85<br />
4,855,1232,1233,1241,1244,1246,124<br />
7,1248,1635,2021<br />
biochemical markers<br />
106,806,1171,1696<br />
418<br />
Abstracts for the <strong>ACR</strong> Clinical Research Conference are designated as CRC
iologic response modifiers 74,282,296,<br />
297,315,606,967,974,1023,1808<br />
biomarkers 19,40,52,66,133,153,33<br />
7,360,430,436,496,532,540,550,5<br />
51,568,572,579,590,814,846,851,<br />
1051,1068,1148,1149,1210,1290,<br />
1439,1440,1455,1709,1789,1794,<br />
1802,1882,1890,1895,2056,2090<br />
biomechanical testing<br />
187,1269,1273,1274,2074<br />
bisphosphonates 222,224,618,620,621,6<br />
22,630,636,892,1544,1546,1552,1554,<br />
1555,1556,1558,1564,2138,2140,2142<br />
Blau syndrome 893,1641<br />
body mass 837,996,1013,1018,2049<br />
bone density 201,203,242,268,617,624,<br />
626,628,632,634,635,637,639,640,654<br />
,1019,1056,1121,1392,1568,1815,206<br />
2,2076,2143,2177<br />
bone marrow transplantation 1723<br />
bone metabolism 317,383,580,892,1192<br />
,1441,1457,1466,1558,1563,1892,199<br />
8,2064,2065,2140<br />
bosentan 1209<br />
BXD2 1285,1299<br />
C<br />
C-reactive protein (CRP) 124,259,448,5<br />
83,637,759,1141,1198,1291,1461,157<br />
5,1897,2039<br />
calcinosis 8,1669<br />
calcium phosphate 1614,1616<br />
calcium pyrophosphate dihydrate (CPPD)<br />
1456,1615,1618<br />
capillary microscopy 11,12,1203<br />
cardiovascular disease 16,372,448,522,<br />
611,647,683,685,802,826,828,962,98<br />
7,995,997,998,999,1000,1002,1003,1<br />
005,1006,1008,1010,1014,1128,1147,<br />
1177,1205,1277,1340,1341,1371,1391<br />
,1395,1533,1617,1650,1864,1909,192<br />
6,1927,1931,1932,1975,2093,2094,21<br />
58,2159,2185<br />
carpal tunnel syndrome 1646<br />
cartilage 203,205,215,217,218,577,641,<br />
659,1300,1439,1440,1447,1449,1451,<br />
1455,1456,1458,1459,1462,1683,1696<br />
,1757,1767,1782<br />
CCP 390,500,1416,1835,1877,1891<br />
celecoxib 1683<br />
cell biology 156,362<br />
central nervous system involvement 4<br />
95,926,1129,1136,1237,1238,1643,1<br />
941,1961<br />
cerebrovascular disease 684<br />
chemokines 65,130,139,154,413,676,77<br />
7,786,924,1059,1441,1472,1473,1478,<br />
1591,1623,1748,1749,1785,1786,1896<br />
,1954,1969,2005,2063<br />
cholesterol 776,1143,1774<br />
chondrocytes 576,718,782,1446,1448,1<br />
449,1450,1451,1452,1460,1465,1467,<br />
1471,1590,1765,2060<br />
Churg-Strauss syndrome<br />
1650,2001,2017,2024<br />
citrulline 359,1221,1303,1430,1434,14<br />
37,1746<br />
classification criteria<br />
443,871,891,1092,1912,2150<br />
clinical practice guidelines 30,75,88,9<br />
0,94,752,891,908,1265,1266,1267,1<br />
469,1741<br />
clinical trials 26,168,220,263,269,277,3<br />
03,311,428,435,627,682,695,700,716,<br />
753,757,941,947,949,954,957,960,119<br />
1,1291,1317,1468,1525,1526,1537,16<br />
46,1678,1684,1686,1798,1992,2049,2<br />
085,2086,2098,2162,2163,2152,2173<br />
coagulation disorder 869,1389,1390<br />
cognitive dysfunction<br />
110,115,492,882,883<br />
colchicine 1232<br />
collagen 59,60,918,923,1436,1766,21<br />
44,2147<br />
community programs 172,724<br />
comorbidity 282,803,965,987,1006,103<br />
4,1509,1699,1850,2054,2164<br />
complement 255,708,886,1135,1335,13<br />
67,1375,1768,2129<br />
compliance 161,183,631,2107<br />
complimentary and alternative therapy<br />
1164,1252,1386,1637,1783<br />
computed tomography (CT) 853,2143<br />
connective tissue disease 867,868,887,<br />
1199,1265,1266,1515,2166<br />
coping skills<br />
906,1327,1382,1492,1529,1534<br />
corticosteroids 313,624,784,889,937,10<br />
13,1250,1559,1610,1656,2022,2175<br />
cost 77,78,80,82,83,85,89,291,503,606,<br />
837,1255,CRC28,CRC34,CRC39,CRC43<br />
costimulatory molecules<br />
280,394,530,1304,1984<br />
COX inhibitors 688,776,826,1222,1501<br />
COX-2 96,281,794,1653,1734<br />
cryoglobulinemia 1242,2002,2006,2008,<br />
2015,2016,2025<br />
crystal-induced arthritis 1580,2127<br />
cyclooxygenase 276,737,782<br />
cyclophosphamide 406,440,878,1104,12<br />
11,1266,1644,1922,1935,2024<br />
cytokines 130,134,137,140,145,155,18<br />
0,381,391,412,413,497,515,529,544,<br />
562,568,569,637,671,675,748,787,79<br />
2,856,871,894,926,939,954,1041,106<br />
6,1082,1172,1209,1217,1230,1297,12<br />
99,1301,1305,1378,1379,1419,1446,1<br />
447,1448,1597,1608,1623,1717,1718<br />
,1756,1759,1760,1762,1771,1772,177<br />
6,1778,1791,1885,1890,1928,1955,1<br />
962,1991,2001,2069,2085,2127,2137<br />
,2175,2183<br />
D<br />
damage index 1119,<strong>2007</strong>,2071<br />
decision analysis 228,1510<br />
demography 1193<br />
dendritic cells 146,399,408,515,566,86<br />
4,1074,1362,1583,1584,1585,1586,15<br />
87,1589,1592,1607,1608,1613,1647,1<br />
978,1985,1990,2010,2066,2131,2132<br />
densiometric study 1009,1469<br />
depression 5,183,328,329,454,864,1036<br />
,1037,1277,1278,1279,1327,1519,153<br />
8,1541,1738,2035<br />
dermatomyositis 1660,1663,1668,2066,<br />
2068,2071,2178<br />
diabetes 998,1061,1625,2156<br />
diagnostic criteria 587,588,614,646,705<br />
,804,1162,1185,1240,1353,1615,1626,<br />
1627,1834,1901<br />
diffuse idiopathic skeletal hyperostosis<br />
(DISH) 1617<br />
disability 304,312,313,502,729,816,817<br />
,913,981,988,1169,1274,1466,1485,14<br />
95,1539,2026,2036,2053,2114,2119<br />
disease activity 22,164,173,227,235,29<br />
8,312,325,327,333,340,341,358,382,4<br />
25,507,508,509,535,551,574,585,649<br />
,663,732,752,766,884,967,984,993,9<br />
95,1008,1019,1036,1042,1045,1122,1<br />
142,1170,1186,1188,1191,1198,1234,<br />
1466,1536,1659,1724,1789,1806,1807<br />
,1810,1811,1812,1813,1814,1819,182<br />
2,1839,1842,1889,1895,1908,2089,21<br />
70,2172,CRC37<br />
disease-modifying antirheumatic drugs<br />
(DMARDs) 75,86,87,88,92,93,159,29<br />
0,293,341,355,684,697,734,827,974,9<br />
79,986,1888,2154,2173,2183<br />
DNA 35,1367,CRC22<br />
Doppler ultrasound 1005<br />
doxycycline 1728<br />
drug dosage<br />
324,351,CRC32,CRC38,CRC40,CRC49<br />
drug interaction 858,859,CRC18<br />
drug toxicity 126,667,CRC20<br />
dual energy x-ray absorptiometry (DEXA)<br />
635,731,1561,1562,1563,1567<br />
abstract keyword Index<br />
Abstracts for the <strong>ACR</strong> Clinical Research Conference are designated as CRC 419
abstract keyword Index<br />
E<br />
economics 70,77,79,80,98,100,102,175,<br />
504,578,670,1633,CRC09,CRC26,CRC3<br />
3,CRC37,CRC49<br />
education, medical 157,158,172,175,76<br />
8,905,1345,1347,1348,1349,1384,156<br />
4,1566,1888,2040<br />
education, patient 123,159,160,161,72<br />
3,1329,1348,1673,2034,2038,2041<br />
elderly patients 719,1345,1500,1560<br />
endothelial cells 61,64,1475,1923,1964<br />
endothelin 784,1199<br />
endothelium<br />
63,442,708,709,1002,1474,1975<br />
enthesopathy 207,564,594,595,600,613<br />
environmental factors<br />
76,112,361,925,1073,1119,2053<br />
eosinophils 1630<br />
epidemiology 99,200,201,213,214,254,2<br />
82,360,501,685,712,798,805,808,810,<br />
815,816,818,820,821,825,828,829,103<br />
9,1152,1193,1201,1202,1204,1244,12<br />
95,1488,1506,1507,1535,1553,1571,1<br />
638,1657,1703,1704,1708,1821,1863,<br />
1921,2017,2032,2036,2039,2052,2054<br />
,2075,2097,2116,2158<br />
etanercept 225,265,303,318,319,322,3<br />
44,591,682,726,865,873,900,952,957<br />
,1022,1045,1161,1182,1558,1640,164<br />
8,1713,1803<br />
ethnic studies 1110,1131,2160<br />
etoricoxib 1690<br />
exercise 112,114,346,724,765,766,12<br />
68,1273,1331,1370,1937,2050,2051<br />
,2189<br />
extraarticular manifestations<br />
993,1010,1011,1072,1818<br />
F<br />
familial Mediterranean fever<br />
812,1178,1601,2082<br />
family studies<br />
379,501,521,528,565,1521,2096<br />
fatigue 125,243,456,1097,1098,1100,12<br />
57,1258,1538,1656,2045<br />
Fc receptors<br />
129,1086,1605,1795,1883,2128<br />
fever 844,1294,1902<br />
fibrinogen 1044,1591<br />
fibroblasts 41,43,47,54,57,58,67,147,1<br />
55,376,378,389,392,562,707,745,769<br />
,771,780,786,975,1058,1063,1306,13<br />
07,1477,1780,2058,2110,2144,2145,<br />
2146,2147<br />
fibromyalgia 103,104,105,107,111,113,<br />
118,119,124,125,127,176,712,714,715<br />
,716,1099,1279,1327,1328,1329,1330,<br />
1331,1332,1382,1519,1520,1521,1522<br />
,1523,1524,1525,1526,1528,1529,153<br />
1,1532,1533,1534,1535,1536,1537,15<br />
39,1540,1541,1542,1543,2030<br />
fibrosis 14,23,27,41,42,43,44,49,51,53<br />
,54,55,56,65,67,68,143,1214,1217,2<br />
145,2146<br />
foot 642,1631,1824,2036<br />
fractures 242,626,633,636,666,1184,14<br />
44,1470,1552,1553,1554,1560,1561,1<br />
562,1564,1565,1566,2117,2142,2143<br />
functional status 321,596,612,678,767,<br />
1169,1486,1700,1820,2029,2033,2105<br />
G<br />
gait 188,191,1163,2072,2073<br />
galectin 531,1214,1983<br />
gastrointestinal complications 15,17,18<br />
,281,668,688,827,1035,1194,1211,155<br />
5,1680,1943,1948<br />
gender 91,141,260,420,513,528,744,83<br />
9,979,980,1054,1250,1808<br />
gene therapy 149,711,933,1743,2084<br />
genetic factors 373,379,422,536,541,5<br />
43,544,552,557,558,559,560,565,573<br />
,747,790,801,811,812,824,838,839,8<br />
42,843,849,890,923,925,1011,1050,1<br />
052,1064,1065,1067,1073,1076,1085,<br />
1086,1087,1106,1138,1245,1284,128<br />
7,1321,1322,1324,1401,1445,1712,17<br />
14,1731,1745,1766,1795,1967,1969,1<br />
971,1972,1973,1974,1976,2000,2014<br />
,2055,2122<br />
genetic research 33,103,104,105,142,1<br />
52,388,514,537,538,542,545,546,548<br />
,556,563,743,789,813,845,850,1053,<br />
1084,1088,1202,1294,1314,1323,133<br />
4,1389,1400,1402,1713,1952,1968,19<br />
71,1976,2079,2096,2120,2121,2124,2<br />
125,CRC22<br />
genomics 35,36,38,39,60,307,429,539,5<br />
45,547,549,743,760,840,1072,1281,14<br />
13,1710,1711,1799,1887,2079,2080,2<br />
121,2148,2176<br />
giant cell arteritis 128,646,704,705,706<br />
,784,1227,1230,1231,1235,1236,1240,<br />
1243,1245,1250,1483<br />
glomerulonephritis 443,1207<br />
glucocorticoids 289,311,314,625,773,80<br />
2,831,948,953,965,992,1129,1551,178<br />
4,1804,2012,2065,CRC18<br />
glucosamine sulfate 1751<br />
glycoproteins 1060,1449,1639<br />
gout 89,755,756,757,758,760,1619,162<br />
0,1621,1622,1623,1624,1625,1626,1<br />
627,CRC23<br />
growth factors 900<br />
H<br />
hand 268,641,1674,1677,1685,2028,210<br />
2,2103,2104,2105,2106<br />
Health Assessment Questionnaire 168,3<br />
02,320,605,909,949,1037,1486,1502,1<br />
516,1700,1820,2103,CRC06<br />
health behaviors 1505<br />
health care 78,79,93,97,171,505,506,7<br />
33,810,905,1272,1503,1736,1822,204<br />
0,2118,CRC27,CRC48<br />
health disparity 723,CRC45<br />
health education 160,608,905,1347<br />
health status 596,607,1180,1276,1381<br />
,1504,1516,1740,2032,2042,2044,20<br />
46,2187<br />
heart disease<br />
13,686,1004,1342,1632,1925,2024<br />
heat-shock proteins 1075,1463,1589<br />
hematopoietic stem cells 362<br />
heme oxygenase-1 709,785,854<br />
heparan sulfate proteoglycans<br />
57,1996,2110<br />
hepatitis<br />
315,1242,2002,2015,2016,CRC09<br />
hip osteoarthritis 189,201,1679,1735<br />
Hispanic patients 817<br />
histone 44,145,375,841<br />
HLA antigens 34,380,538,574,843,1047,<br />
1175,1325,1326,1666,CRC05<br />
HLA genes 34,368,377,536,539,543,560<br />
,569,570,744,1049,1056,1071,1283,13<br />
41,1665,1732,1800,1972,2101<br />
HMGB1 2067<br />
homocysteine 447,902<br />
hormones 411,420,829,1082,1104,1206,<br />
1320,1587,1593,1791,1885<br />
HRQOL 607,946,1120,1492,1511,1514,1<br />
699,1737,1918,1937,2046<br />
hyaluronan 778,1481,1677<br />
hydroxychloroquine 493,1125<br />
hypermobility 1633<br />
hypertension 1681,1946<br />
hyperuricemia 16,686,757,758,805,1622<br />
hypothalamic-pituitary-adrenal axis<br />
1518,1541<br />
hypoxia 746,975,1450,1482<br />
I<br />
ibandronate 620,621,622,1544,1545,15<br />
46,1547,1556,2139,2141<br />
imaging techniques 106,107,108,109,11<br />
0,122,230,641,644,648,655,659,663,6<br />
64,689,690,692,938,1170,1234,1239,1<br />
616,1618,1839,1850<br />
imatinib mesilate 32,370,875<br />
immune complex 1309,1375,1716,2129<br />
420<br />
Abstracts for the <strong>ACR</strong> Clinical Research Conference are designated as CRC
immune function 141,385,933,943,10<br />
41,1042,1245,1586,1723,1731,1906<br />
,1980<br />
immunoglobulin therapy 1639,1940<br />
immunoglobulins 261<br />
immunosuppression 1128,1132,1573,1<br />
596,1662,1754,1786,1973,1974,201<br />
8,CRC15<br />
infection 287,821,825,896,960,1021,1<br />
024,1105,1127,1132,1135,1354,135<br />
5,1356,1570,1571,1572,1573,1574,1<br />
576,1578,1580,1582,1909,1950,201<br />
0,CRC15<br />
inflammation 53,67,69,124,147,240,387<br />
,445,644,690,759,772,774,785,787,85<br />
6,894,951,1001,1040,1069,1145,1174,<br />
1227,1230,1280,1302,1335,1337,1404<br />
,1473,1480,1481,1483,1569,1593,159<br />
9,1600,1629,1639,1641,1710,1717,17<br />
52,1769,1864,1899,1984,2127<br />
inflammatory arthritis 178,270,326,330<br />
,562,644,689,772,792,909,929,1183,1<br />
264,1576,1637,1638,1759,1763,1782,<br />
1841,1994,2034<br />
inflammatory bowel disease (IBD)<br />
549,591,897,1986<br />
infliximab 83,226,256,284,285,307,324,<br />
329,334,347,349,353,356,434,582,65<br />
5,693,749,862,863,865,873,956,962,9<br />
63,989,1025,1153,1154,1155,1165,11<br />
74,1267,1648,1896,2126,2155,CRC13,<br />
CRC14,CRC31,CRC35,CRC40,CRC41,C<br />
RC48,CRC49<br />
insulin resistance 252,609,992,1007<br />
insulin-like growth factor 1518<br />
integrins 1478,1479<br />
interferons 69,129,133,396,397,398,39<br />
9,512,513,514,522,523,524,571,762,7<br />
69,780,811,916,1032,1085,1241,1315,<br />
1318,1359,1360,1409,1613,1634,1782<br />
,1958,1963,1968,2070<br />
interleukins (IL) 42,128,129,135,136,15<br />
0,220,249,269,292,371,405,516,518,5<br />
57,559,678,718,770,771,789,874,931,<br />
1195,1291,1300,1322,1378,1443,1454<br />
,1462,1684,1748,1758,1764,1881,199<br />
4,2061,2089,2122,2125<br />
J<br />
joint destruction 186,267,638,978,1305<br />
,1448,1460,1462,1830,2130<br />
joint procedures 177,345,736,899,1293,<br />
1672,1688,1698,2175<br />
juvenile arthritis 221,225,228,250,255,<br />
632,749,888,897,898,900,901,902,903<br />
,906,911,912,1708,1713,1714,1716,17<br />
18,1720,1721,2028,2078,2083,CRC02<br />
juvenile dermatomyositis 251,252,1655<br />
,1659,1669,1732,1733,2070<br />
juvenile rheumatoid arthritis 227,245,<br />
246,247,248,249,679,680,681,682,89<br />
5,899,904,906,907,910,913,1281,128<br />
2,1386,1710,1711,1712,1715,1719,17<br />
22,2079,2080,2081,2122,2176,2177,C<br />
RC01,CRC16<br />
juvenile sclerosis/scleroderma<br />
1,229,230,1723<br />
K<br />
Kawasaki disease<br />
891,1728,1729,1730,1731<br />
kinase 848,926,1771<br />
kinetics 1288<br />
knee 84,185,186,188,190,191,193,194,<br />
196,197,198,200,206,208,209,212,216<br />
,592,657,764,807,832,1251,1269,1270<br />
,1275,1350,1508,1675,1676,1687,169<br />
1,1692,1693,1694,1695,1704,1706,20<br />
62,2073,2074,2112,2113,2115,CRC26<br />
L<br />
La/SS-B 1089,1136<br />
laboratory tests<br />
181,310,1346,1891,1903<br />
leflunomid 275,310<br />
leukocytes 823,1755,1940<br />
lipids 264,286,446,609,710,902,1014,11<br />
44,1146,1884<br />
longitudinal studies<br />
296,297,881,952,1803,2037,2102<br />
lupus anticoagulant 1388,1396<br />
lupus nephritis 234,235,237,238,406<br />
,409,410,411,412,414,415,417,420<br />
,423,424,431,436,437,440,444,49<br />
6,504,532,878,1149,1150,1151,11<br />
52,1207,1255,1286,1313,1314,193<br />
1,1934,1935,1942,1966,CRC33<br />
Lyme disease<br />
240,241,894,1279,1352,1353,1519<br />
lymphocytes 1311,1421,1611,1902,1980<br />
lymphoid neogenesis<br />
358,366,1078,1476,1629<br />
lymphoma 283,819,989,1629,CRC17<br />
M<br />
macrophage activation syndrome<br />
233,871,1281,1645,1660,1714<br />
macrophages 49,51,58,139,378,401,689<br />
,710,756,774,786,1458,1479,1588,160<br />
5,1607,1753,1774,2133<br />
magnetic resonance imaging (MRI) 119<br />
,202,204,205,206,208,209,210,211,2<br />
12,215,217,218,224,246,275,278,386<br />
,456,643,651,652,653,654,656,657,6<br />
58,661,691,742,1038,1158,1205,136<br />
9,1371,1650,1750,1840,1894,1959,2<br />
077,2180<br />
major histocompatibility complex (MHC)<br />
824,850,1046,1632,2067,2132<br />
malignancy 819,820,985,986,994,1106,<br />
1344,1611,1920<br />
MAP kinase 57,131,138,364,673,1479,<br />
1605,2003<br />
Marfan syndrome 56<br />
matrix metalloproteinase (MMP) 68,364<br />
,375,1307,1445,1452,1454,1463,1728,<br />
1790,1882,2110,2136<br />
MCP-1 439,707,1756,1927,2063<br />
mesenchymal stem cells 28,847,938<br />
meta-analysis 95,686,973,1372,1517<br />
metabolic syndrome<br />
1007,1008,1015,1617,1625<br />
metalloproteinases 1044<br />
methotrexate 260,270,310,316,964,1<br />
016,1155,1610,1774,1800,2080,208<br />
7,CRC24<br />
microarray 37,40,149,241,525,540,547,<br />
779,781,846,1216,1414,1482,1709,17<br />
11,1724,1725,1765,2060<br />
migration inhibitory factor (MIF)<br />
773,1644,1756<br />
mitochondria 1452,1471<br />
mixed connective tissue disease<br />
409,1126,1376,1634,1636<br />
MMP 367,386,541,542,796,1460,1483,1<br />
730,1757,1981<br />
monoclonal antibodies 394,1124,1984<br />
monocytes 64,142,397,523,530,691,14<br />
06,1770<br />
morbidity and mortality 1,2,6,20,254,2<br />
89,444,799,802,877,880,959,976,978,<br />
984,990,1000,1004,1108,1254,1292,1<br />
658,1661,2185<br />
mPGES-1 1584,1763<br />
muscle biopsy 1654,1664<br />
muscle strength<br />
196,346,764,1268,2072,2075<br />
musculoskeletal disorders 126,768,815,<br />
816,1345,1506,1517,1550,1649<br />
mycophenolate mofetil<br />
27,431,432,1122,1123,1929<br />
myopathy 1644,1654,1655,1661<br />
myositis 252,1652,1654,1656,1657,16<br />
58,1664,1665,1666,1667,1668,2067<br />
,2069<br />
N<br />
naproxen 858,1680<br />
Native <strong>American</strong>s 1046,1836<br />
nephritis 130,413,415,434,442,518,53<br />
1,1423<br />
abstract keyword Index<br />
Abstracts for the <strong>ACR</strong> Clinical Research Conference are designated as CRC 421
abstract keyword Index<br />
nephrogenic fibrosing dermopathy<br />
32,51,1369<br />
neuroimaging 119,452,455,492,714<br />
neurologic involvement 452,453,455,77<br />
1,918,927,1099,1652,1946<br />
neuropeptides 1040,1093,1689<br />
neuropsychiatric disorders 455,502,852,<br />
1130,1131,1133,1915,1960,1961<br />
neutrophils 63,1600,1748<br />
NF-kB 778,848,851,1338,1412,1641,17<br />
73,1787<br />
nitric oxide 778,791<br />
NOMID 219,678,1707,2027<br />
nonsteroidal antiinflammatory drugs<br />
(NSAIDs) 71,72,96,276,281,668,688<br />
,737,859,860,968,1035,1222,1501,1<br />
517,1653,1674,1675,1678,1681,169<br />
0,CRC21<br />
nutrition 628,1009<br />
O<br />
obesity<br />
239,660,997,1235,1884,2115,2155<br />
occupational therapy 338,2106,2107<br />
ocular involvement 226,2021<br />
opioids 713,1628<br />
orthopedics 185,736,1736,1737,1739<br />
osteoarthritis 85,91,184,185,186,187,1<br />
88,190,192,193,194,195,197,198,199,<br />
200,202,203,204,205,206,207,208,209<br />
,210,211,212,213,214,215,216,217,21<br />
8,598,657,658,659,660,661,662,717,7<br />
38,739,740,741,742,763,764,765,781,<br />
806,807,808,809,832,833,834,835,846<br />
,847,982,1258,1262,1268,1269,1270,1<br />
271,1272,1273,1274,1275,1445,1447,<br />
1453,1454,1456,1457,1458,1459,1461<br />
,1463,1465,1467,1471,1485,1499,150<br />
0,1501,1511,1542,1614,1616,1628,16<br />
73,1674,1675,1676,1677,1678,1680,1<br />
681,1682,1683,1685,1686,1687,1689,<br />
1690,1691,1692,1693,1694,1695,1696<br />
,1697,1698,1701,1702,1703,1704,170<br />
5,1706,1740,2035,2048,2049,2051,20<br />
61,2062,2073,2074,2075,2076,2077,2<br />
103,2112,2115,2116,2136,CRC19<br />
osteoblasts, osteoclasts 153,363,383,57<br />
2,577,676,756,1192,1443,1464,1739,1<br />
762,1788,2063,2064<br />
osteonecrosis 2174<br />
osteopontin 372<br />
osteoporosis 162,617,618,619,620,621,<br />
622,623,625,626,627,628,629,630,63<br />
1,633,635,636,638,640,665,666,731,<br />
955,1020,1117,1171,1184,1347,1444<br />
,1468,1469,1470,1544,1545,1546,15<br />
47,1548,1549,1550,1551,1552,1553,<br />
1554,1555,1556,1557,1559,1560,156<br />
1,1562,1565,1567,1739,1947,2038,2<br />
039,2064,2116,2117,2138,2139,2140<br />
,2141,2142<br />
osteoprotegerin 438,2081<br />
outcome measures 21,98,169,172,174,1<br />
76,177,180,229,230,304,320,336,351,<br />
507,508,585,586,589,604,662,669,670<br />
,735,885,983,1130,1163,1166,1167,11<br />
68,1200,1256,1321,1330,1438,1484,1<br />
485,1496,1509,1511,1516,1621,1624,<br />
1697,1701,1702,1806,1811,1819,1821<br />
,1889,1904,2071,2104,2171,2178,CRC<br />
06,CRC25,CRC30,CRC32,CRC36,CRC38<br />
,CRC42,CRC46<br />
oxidative stress<br />
63,746,1218,1220,1231,1365<br />
P<br />
p21 774<br />
p38 MAP kinase 779,929,1406<br />
p53 1219<br />
pain 97,103,114,117,120,123,179,193,1<br />
95,196,198,199,352,714,715,716,917,<br />
1064,1293,1328,1330,1331,1332,1383<br />
,1444,1491,1498,1499,1518,1522,152<br />
3,1524,1525,1526,1530,1535,1537,15<br />
38,1542,1631,1649,1688,1702,1703,1<br />
735,2033,2076,2077,2113<br />
paraoxonase 1411<br />
parathyroid hormone<br />
625,627,1468,1559,2138<br />
PDGF 370,875<br />
pediatric rheumatology 158,222,223,2<br />
24,232,233,234,235,236,237,238,239<br />
,241,242,243,244,245,247,250,253,2<br />
54,677,818,877,878,881,882,885,888<br />
,889,892,908,909,912,913,1383,1385<br />
,1659,1709,1722,1726,2066,2082,208<br />
3,2177,2178<br />
pharmacology 156,259,269,276,1097,11<br />
23,1156,1783<br />
phospholipid-binding proteins 1401<br />
photophoresis CRC01<br />
physical activity 114,211,1465,1507,20<br />
31,2050,2052,2186,2189<br />
physical examination 121,330<br />
physical function 194,302,763,912,118<br />
7,1271,1527,1563,1698,1807,2030,2<br />
102,2105<br />
physical therapy 191,765,2051<br />
PI3K 1058,1788<br />
plasma cells 1413,1427,1442,1970<br />
platelets 494,858,1224,1366<br />
polyarteritis nodosa CRC07,CRC09<br />
polychondritis 1642<br />
polymerase chain reaction (PCR)<br />
511,1231<br />
polymyalgia rheumatica<br />
1227,1243,1295<br />
polymyositis/dermatomyositis (PM/DM)<br />
1657,1662,1668,1670,1671<br />
population studies 97,339,720,984,1487<br />
,1488,1823,2032,2054,2117,2120<br />
positron emission tomography (PET)<br />
656,693,713,1226,1228,1528,2095<br />
practice guidelines 1515<br />
prednisolone, prednisone<br />
948,951,966,1034<br />
pregnancy 4,368,730,823,879,1333,133<br />
7,1398,1490,1838,CRC16<br />
prescribing trends 290,889,1653<br />
prevention 633,666<br />
prognostic factors 13,116,117,307,326,<br />
343,355,387,904,1052,1062,1072,115<br />
0,1248,1275,1373,1638,1797,1815,18<br />
25,1833,1840,1879,1887,1892,2021,2<br />
022,2023,2037,2180<br />
prolactin 800<br />
proprioception 189,190,807,2072<br />
prostaglandins 391,782,1069,1584<br />
proteases 783,788,939,1670<br />
proteinuria 424,437,1924<br />
proteomics 234,550,554,847,1289,1415<br />
,1428,1715,1716,2011,2056,2057<br />
psoriatic arthritis 278,331,556,557,5<br />
61,572,583,584,593,595,597,605,6<br />
06,607,608,609,610,611,652,1156,<br />
1181,1182,1184,1185,1186,1188,11<br />
89,1190,1191,1192,2096,2097,209<br />
8,2099,2100,2170<br />
psychological status 195,712,1113,1278<br />
,1498,1530,1908,1914,2033<br />
psychometrics<br />
170,1093,2042,2048,2050,2104<br />
psychosocial factors 108,1262,1271,13<br />
83,1491,1492,1527,2026,2035,2041,<br />
2187,2188<br />
pulmonary complications 6,19,27,31,33<br />
,55,853,1095,1126,1199,1206,1210,13<br />
43,1370,1373,1636,1661,1662,2166<br />
pulmonary function 14,23,1195,1208<br />
pyrin 844,1599,1601<br />
Q<br />
qualitative research 719,1257,1259,149<br />
9,1917,2034,2164,CRC23<br />
quality of care 73,92,162,167,177,179,<br />
354,669,733,734,735,1823,2118<br />
quality of life 17,70,84,99,170,232,236,<br />
273,292,318,319,715,884,1098,1120,1<br />
183,1187,1254,1272,1381,1382,1484,<br />
1489,1491,1494,1495,1504,1508,1522<br />
,1524,1540,1701,1824,1915,2026,216<br />
9,2171,CRC23,CRC44,CRC45<br />
questionnaires 163,164,174,608,732,126<br />
2,1349,1502,1649,1809,1810,1814,204<br />
3,2045,2097,2170,2172,CRC30,CRC36<br />
422<br />
Abstracts for the <strong>ACR</strong> Clinical Research Conference are designated as CRC
R<br />
race/ethnicity<br />
192,623,740,798,836,1911,2159<br />
radiography 7,118,207,245,248,321,583<br />
,645,648,664,696,698,740,742,751,9<br />
04,940,944,996,1173,1189,1190,1691<br />
,1692,1693,1694,1695,1706,1816,188<br />
1,2087,2153<br />
randomized trials 176,184,300,739,119<br />
7,1251,2151,2186<br />
RANK/RANKL 146,337,363,575,698,944,<br />
953,1442,2081<br />
Raynaud’s phenomenon 9,10,11,12,20,<br />
22,24,26,1203,1213,1225,2163,2165,<br />
2167,CRC04<br />
reactive arthritis<br />
1284,1354,1355,1569,1570<br />
regulatory cells 150,403,404,405,407,5<br />
19,855,919,1302,1362,1368,1379,15<br />
88,1953,1955,1979,1982,1986,1994,<br />
1995,1997<br />
rehabilitation 763,767,1270,2031,2047<br />
Reiter’s syndrome 1354,1355<br />
relationships 1276<br />
remission 237,238,293,300,340,582,697<br />
,830,952,972,1114,1604,1804,1807,1<br />
879,2152,2153<br />
renal disease 3,32,89,438,439,441,49<br />
8,503,702,907,1152,1369,1593,193<br />
6,2008<br />
response criteria 229,353,679,1497,151<br />
2,2151,2152,2154<br />
rheumatoid arthritis (RA) 70,73,75,81,8<br />
6,87,88,90,92,93,94,95,99,100,101,1<br />
02,142,144,145,146,153,155,159,163,<br />
164,165,167,173,174,180,181,258,261<br />
,262,265,267,268,274,285,286,288,28<br />
9,293,294,298,299,301,302,304,305,3<br />
08,309,311,312,313,315,316,317,321,<br />
323,325,327,328,329,331,333,335,336<br />
,338,340,341,342,343,346,348,352,35<br />
4,355,357,360,361,362,367,368,369,3<br />
72,373,374,375,381,383,389,392,447,<br />
500,536,537,539,541,543,544,545,546<br />
,547,549,550,551,552,553,554,555,62<br />
4,634,638,639,643,645,648,649,650,6<br />
52,653,654,663,664,669,670,672,674,<br />
684,690,693,694,695,699,722,726,727<br />
,730,732,734,743,745,748,766,770,78<br />
8,789,791,792,800,801,819,823,825,8<br />
27,828,829,834,850,920,942,943,945<br />
,947,949,950,955,956,958,961,962,96<br />
7,968,969,971,973,974,975,976,977,9<br />
78,979,983,985,987,988,989,990,991,<br />
992,994,995,996,997,998,999,1000,10<br />
01,1002,1003,1004,1005,1006,1007,1<br />
009,1010,1011,1012,1013,1014,1015,<br />
1016,1017,1018,1019,1020,1023,1024<br />
,1025,1026,1027,1028,1029,1030,103<br />
1,1034,1035,1036,1037,1038,1047,10<br />
49,1050,1052,1054,1058,1060,1061,1<br />
062,1064,1065,1067,1069,1070,1071,<br />
1259,1261,1276,1278,1302,1303,1304<br />
,1307,1339,1341,1342,1343,1344,137<br />
9,1428,1429,1431,1432,1436,1437,14<br />
40,1441,1455,1475,1480,1484,1488,1<br />
489,1493,1496,1497,1502,1504,1514,<br />
1536,1567,1578,1597,1598,1603,1628<br />
,1705,1763,1769,1771,1775,1776,177<br />
7,1779,1780,1792,1794,1796,1798,18<br />
01,1806,1809,1811,1812,1813,1814,1<br />
815,1816,1817,1818,1819,1821,1822,<br />
1823,1824,1826,1827,1828,1829,1830<br />
,1831,1832,1834,1835,1837,1838,183<br />
9,1842,1850,1863,1864,1877,1878,18<br />
79,1880,1881,1882,1883,1884,1885,1<br />
886,1887,1888,1889,1891,1892,1893,<br />
1894,1895,1897,1898,1899,1900,1901<br />
,1989,1991,2031,2038,2041,2045,204<br />
6,2047,2048,2055,2109,2111,2119,21<br />
20,2121,2123,2136,2137,2150,2171,2<br />
172,2173,2182,2185,2187,CRC13,CRC<br />
14,CRC17,CRC24,CRC29,CRC30,CRC31<br />
,CRC32,CRC34,CRC35,CRC36,CRC37,C<br />
RC39,CRC40,CRC41,CRC45<br />
rheumatoid arthritis, animal models 13<br />
6,137,671,673,676,849,914,916,919,9<br />
21,923,924,927,928,930,931,932,934,<br />
935,936,937,938,1280,1285,1301,138<br />
0,1742,1745,1746,1747,1749,1751,17<br />
52,1753,1754,1755,1759,1760,1761,1<br />
764,1766,1767,1768,1770,1772,1773,<br />
1779,1990,2129,2135<br />
rheumatoid arthritis, pathogenesis 131,<br />
147,148,154,359,363,364,365,371,378<br />
,380,382,384,385,387,388,393,548,70<br />
7,744,747,932,1040,1041,1042,1045,1<br />
046,1048,1051,1053,1055,1056,1063,<br />
1066,1074,1076,1351,1430,1472,1635<br />
,1744,1762,1836,1993,2130,2181<br />
rheumatoid arthritis, synovium 358,376<br />
,390,393,775,797,935,1043,1059,1308<br />
,1442,1776,1890<br />
rheumatoid arthritis, treatment 74,80,<br />
256,257,259,260,263,264,266,270,27<br />
1,272,273,275,277,280,283,284,290,2<br />
91,292,295,297,300,303,306,314,320,<br />
322,332,337,339,344,347,351,353,35<br />
6,651,696,697,698,700,725,726,728,7<br />
29,790,803,921,936,939,940,941,944,<br />
946,948,951,953,954,957,963,964,965<br />
,969,970,972,980,981,982,986,1032,1<br />
033,1340,1439,1551,1744,1754,1772,<br />
1773,1778,1781,1783,1785,1786,1787<br />
,1788,1789,1790,1791,1793,1795,179<br />
7,1799,1800,1802,1804,1808,1818,18<br />
25,1896,1992,2084,2085,2087,2088,2<br />
089,2151,2154,2155,2180,2184,CRC03<br />
,CRC06,CRC27,CRC28,CRC38,CRC42,C<br />
RC46,CRC47,CRC50<br />
rheumatoid factor 343,683,901,1833,18<br />
36,1883,1900,1905,2182<br />
rheumatoid vasculitis 1249<br />
rheumatologic practice 165,166,173,17<br />
5,333,354,653,1259,1487,1523,1820<br />
ribonucleoprotein (RNP)<br />
1415,1612,2128<br />
risk assessment 611,1143<br />
risk factors 125,192,210,374,385,453,5<br />
27,612,800,801,911,994,1115,1116,1<br />
263,1509,1530,1658,1732,1950,2099<br />
,2100,2181<br />
rituximab 257,261,262,266,267,272,28<br />
8,332,441,725,869,876,1091,1094,11<br />
02,1124,1223,1249,1265,1290,1431,1<br />
438,1648,1939,2009,2020,2025,2088,<br />
2169,CRC25<br />
RNA 1088,1377,1419,1459,1612,2137<br />
S<br />
sarcoidosis 861,862,863,864,1647<br />
self-management 719,720,721,722,723,<br />
1914,2030,2188<br />
serologic tests<br />
542,1111,1213,1353,1797,1832<br />
SF36 605,2186<br />
shoulder disorders 121,122,1350,1741<br />
sialoadenitis 1079,1080,1083<br />
sicca syndrome 1103<br />
signal transduction 138,139,148,152,41<br />
8,533,673,822,916,917,930,1286,1365<br />
,1418,1474,1963,1966<br />
single-nucleotide polymorphisms 36,38<br />
6,546,548,555,640,813,822,1050,105<br />
4,1066,1084,1087,1324,1401,1619,18<br />
78,2124,2181<br />
Sj”gren’s syndrome 1077,1079,1080,10<br />
81,1082,1083,1084,1085,1086,1087,1<br />
088,1089,1090,1092,1093,1094,1095,<br />
1096,1097,1098,1099,1100,1101,1102<br />
,1103,1351,1357,1358,1359,1360,136<br />
1,1362,1577,1594,1595,CRC10<br />
Sj�gren’s syndrome 1091<br />
SLEDAI 497,509,532,762,1112,1114,112<br />
7,1910,1970<br />
sleep disturbances 1103,1500<br />
social support<br />
182,183,741,1253,1384,1738,2029<br />
socioeconomic factors 182,616,977,999<br />
,1179,1256,1514,1540<br />
spine involvement 8,118,598,738,1153,<br />
1160,1582,2109<br />
spondylarthropathy 225,558,563,564<br />
,565,575,576,580,590,596,597,598,<br />
600,603,604,613,614,616,749,750,<br />
770,897,898,1155,1157,1168,1178,<br />
1180,1187,1190,1283,1323,1324,13<br />
26,1495,1582,1708,2101<br />
SSA/Ro-SSB/La 231,422,1080,1359,1361,143<br />
5,1727,1965,2059,2094<br />
statin 25,449,708,709,1057,1121,1730,1792<br />
statistical methods<br />
abstract keyword Index<br />
Abstracts for the <strong>ACR</strong> Clinical Research Conference are designated as CRC 423
abstract keyword Index<br />
809,1068,1107,CRC22<br />
STATs 516,555,791,795<br />
stem cells 31,61,567,2060,2174<br />
Still’s disease 1645<br />
subchondral bone 691<br />
surgery 111,301,1646,2109<br />
surveys 165,166,178,721,815,1260,132<br />
9,1346,2042<br />
synovial cells 131,144,148,149,240,357<br />
,366,370,384,692,775,777,781,788,7<br />
94,796,1044,1048,1057,1074,1075,1<br />
614,1719,1790,1792,1793,1796,1801<br />
,1805,2176<br />
synovial fluid 204,345,384,1060,1075,1<br />
346,1580,1603,1627,1715,1718,1720<br />
synovitis 197,255,561,575,592,694,772,<br />
1068,1101,1261,1290,1306,1356,1640<br />
,1717,1750,1886,2078<br />
systemic lupus erythematosus (SLE) 38,<br />
78,79,133,170,171,223,231,232,233,2<br />
36,239,243,244,394,395,396,397,398,<br />
399,400,401,402,403,404,405,407,408<br />
,411,416,419,421,425,426,427,428,43<br />
2,433,435,436,438,439,441,442,443,4<br />
45,446,448,449,450,451,452,453,454,<br />
456,493,494,495,496,497,498,499,500<br />
,501,502,503,504,505,506,507,508,50<br />
9,510,511,512,513,516,517,520,521,5<br />
22,523,524,525,526,527,528,529,530,<br />
531,533,534,535,798,799,811,812,813<br />
,814,838,839,841,870,876,877,879,88<br />
0,881,882,883,884,885,886,1104,1105<br />
,1106,1107,1108,1109,1110,1111,111<br />
2,1113,1114,1115,1116,1117,1118,11<br />
19,1120,1121,1122,1123,1124,1125,1<br />
126,1127,1128,1129,1130,1131,1133,<br />
1134,1135,1136,1137,1138,1139,1140<br />
,1141,1142,1143,1144,1145,1146,114<br />
7,1148,1150,1151,1254,1255,1256,12<br />
57,1277,1287,1288,1292,1309,1310,1<br />
312,1313,1315,1316,1317,1318,1319,<br />
1320,1334,1363,1364,1365,1366,1368<br />
,1376,1377,1390,1400,1409,1418,142<br />
2,1424,1425,1426,1427,1432,1490,15<br />
03,1579,1581,1583,1585,1596,1609,1<br />
613,1634,1643,1724,1725,1726,1902,<br />
1904,1905,1906,1907,1908,1909,1910<br />
,1911,1912,1913,1914,1915,1916,191<br />
7,1918,1919,1920,1921,1922,1923,19<br />
25,1926,1927,1929,1930,1932,1933,1<br />
936,1937,1938,1939,1940,1941,1943,<br />
1944,1945,1947,1948,1949,1950,1951<br />
,1952,1953,1954,1955,1956,1957,195<br />
8,1959,1960,1962,1963,1964,1965,19<br />
67,1968,1969,1970,1971,1972,1973,1<br />
974,1975,1976,1977,1978,1996,1999,<br />
2055,2056,2090,2091,2092,2093,2094<br />
,2095,2118,2124,2125,2131,2134,215<br />
6,2157,2158,2159,2160,2161,2168,21<br />
69,2189,CRC03,CRC12,CRC33<br />
systemic sclerosis 1,2,3,4,5,6,7,8,9,10,<br />
11,12,13,14,16,17,18,19,20,21,22,23,<br />
24,25,28,29,30,31,33,34,35,36,37,38,<br />
39,40,43,44,46,48,49,50,52,53,54,55,<br />
56,59,60,61,62,64,66,68,69,134,647,<br />
814,1193,1194,1195,1196,1197,1198,<br />
1200,1201,1202,1203,1204,1205,1206<br />
,1207,1208,1209,1210,1211,1212,121<br />
3,1214,1215,1216,1217,1219,1220,12<br />
21,1222,1223,1224,1225,1370,1371,1<br />
372,1373,1374,2029,2058,2144,2145,<br />
2146,2147,2148,2149,2162,2164,2167<br />
T<br />
T cells 52,58,140,141,150,152,393,409,<br />
412,520,533,576,593,675,703,841,922<br />
,930,932,1062,1083,1172,1243,1297,1<br />
298,1301,1311,1326,1363,1375,1376,<br />
1377,1378,1380,1407,1482,1589,1603<br />
,1604,1620,1671,1719,1720,1722,174<br />
3,1746,1761,1784,1954,1956,1979,19<br />
81,1982,1985,1987,1988,1991,1993,1<br />
996,1998,1999,CRC01<br />
tacrolimus 317,1781,1938,CRC03,CRC12<br />
Takayasu_s arteritis 656,1226,1229,123<br />
4,1239,1635,2019,CRC05<br />
temporal arteritis 704,706<br />
temporomandibular joint 246,247,248<br />
tendonitis/bursitis 1672<br />
teriparatide 617,665<br />
thalidomide 1248<br />
thrombocytopenia<br />
494,869,870,876,1945<br />
thromboembolism 444,1109<br />
thrombosis 1247,1333,1387,1388,1391,<br />
1397,1402,1403,1404,1924,1930,2013<br />
thyroid 872<br />
tissue growth factor (TGF)<br />
47,59,134,143<br />
tissue necrosis factor (TNF) 305,332,35<br />
0,367,526,571,667,1024,1300,1339,14<br />
77,1787,CRC20<br />
tobacco 123,359,361,377,527,2184<br />
tolerance<br />
418,1414,1418,1420,1985,1988<br />
toll-like receptor 132,137,410,854,1283<br />
,1284,1298,1309,1310,1318,1357,144<br />
3,1453,1583,1590,1591,1594,1596,15<br />
97,1612,1764,2131<br />
total joint replacement 84,687,832,834<br />
,982,983,1292,1737,1740,2114<br />
tramadol 1734<br />
transcription factor 45,423,773,796,142<br />
6,1590,1760,1979<br />
transforming growth factor 45,376,1216<br />
transplantation 423,702<br />
TRAPS 856,857,1294,2082<br />
trauma 808<br />
treatment 30,161,163,184,226,228,258<br />
,323,334,342,404,416,417,433,454,55<br />
4,592,630,665,699,754,810,918,937,9<br />
42,947,950,1162,1232,1241,1247,129<br />
5,1315,1320,1368,1545,1547,1548,16<br />
45,1676,1685,1752,1938,1948,2106,2<br />
139,2141,2166,CRC04,CRC05,CRC07,C<br />
RC08,CRC12,CRC19<br />
tuberculosis 285,316,1021,1022,1023,<br />
1027,1028,1029,1030,1031,1032,10<br />
33,1351,1574,1576,1578,1610,1835<br />
,CRC13<br />
tumor necrosis factor (TNF) 322,324,38<br />
8,518,674,728,785,790,898,966,1028,<br />
1161,1306,1342,1513,1712,1753,1769<br />
,1777,1997,2126,2132,2133<br />
type II collagen 1047,1767,1768,1877<br />
U<br />
ulcers 9,71,72,1224,1374,1393<br />
ultrasound 120,250,284,564,600,604,61<br />
3,645,646,649,650,662,694,1618,174<br />
1,1841,1842<br />
uric acid 685,759,760,805,1615,1619,1<br />
620,1621<br />
utilization review 179<br />
V<br />
vaccines 915,1025,1026,1581,CRC15<br />
vascular endothelial growth factors<br />
(VEGF) 369,511<br />
vascular function 271,1215,2148<br />
vasculitis 704,890,1228,1236,1237,1238<br />
,1239,1242,1246,2002,2003,2004,200<br />
5,<strong>2007</strong>,2008,2009,2011,2012,2013,20<br />
15,2016,2022,2023,2025<br />
vasospasm 24<br />
viruses 1132,1360,1571,1579,1671<br />
viscosupplementation CRC26<br />
vitamins 199,535,888,981,1117,1550,1<br />
686,1949<br />
vocational rehabilitation 338<br />
W<br />
Wegener’s granulomatosis 701,702,703,<br />
1573,2000,2004,<strong>2007</strong>,2013,2014,2017<br />
,2018,2020,2023<br />
weight loss 1673<br />
women’s health 667,1105,1107,1263,13<br />
28,1332,1921,1922,2099,CRC20<br />
424<br />
Abstracts for the <strong>ACR</strong> Clinical Research Conference are designated as CRC
MP3<br />
Package Selections<br />
$595<br />
$395<br />
$225<br />
$195<br />
$175<br />
$135<br />
$135<br />
$125<br />
The Works! Complete Conference Audio Plus Video CD-ROM<br />
All Audio and Video Sessions Covering the <strong>2007</strong> <strong>ACR</strong>/<strong>ARHP</strong> <strong>Scientific</strong> <strong>Meeting</strong><br />
• Audio CD option available for $1,195.<br />
Complete Conference Audio<br />
All Audio Sessions Covering the <strong>2007</strong> <strong>ACR</strong>/<strong>ARHP</strong> <strong>Scientific</strong> <strong>Meeting</strong><br />
• Audio CD option available for $995.<br />
Clinical Educational Track<br />
Includes 9 Clinical Symposia, 4 Practice Issues, Year in Review, & 3 Special Lectures<br />
4628, 4630, 4631, 4632, 4640, 4642, 4643, 4646, 4647, 4652, 4656, 4662, 4663, 4664, 4666, 4669, 4673, 4674,<br />
4680, 4681, 4686, 4688, 4689, 4691, 4694<br />
Basic Research Educational Track<br />
Includes 3 Plenary Sessions, 8 Basic Science Symposia, 3 Immunology Updates, & 7 State-of-the-Art Sessions<br />
4629, 4633, 4634, 4636, 4641, 4645, 4647, 4648, 4649, 4653, 4657, 4661, 4667, 4670, 4673, 4685, 4688, 4690, 4693<br />
<strong>ARHP</strong> Sessions<br />
Includes Clinical Focus Course, 3 Rheumatic Disease Updates, 2 Clinical Symposia, & 2 General Sessions<br />
4626, 4635, 4637, 4650, 4651, 4654, 4655, 4664, 4665, 4668, 4671, 4675, 4676, 4677, 4678, 4679, 4687, 4692, 4695<br />
Top 10 Clinical Sessions<br />
Includes 5 Clinical Symposia, 3 Medical Aspects of Rheumatic Diseases, & 2 Special Sessions<br />
4632, 4642, 4646, 4652, 4658, 4662, 4669, 4684, 4686, 4691<br />
Top 10 Research Sessions<br />
Includes 7 Clinical Symposia, Year in Review, & 2 Medical Aspects of Rheumatic Diseases<br />
4629, 4630, 4633, 4641, 4645, 4653, 4661, 4670, 4685, 4690<br />
The Best of Pediatrics Sessions<br />
Includes 4 State-of-the-Art Sessions, 5 Basic Science Symposia, & 1 Special Session<br />
4632, 4634, 4642, 4662, 4664, 4666, 4670, 4687, 4690<br />
$125<br />
<strong>ACR</strong> Review Course<br />
• Audio CD option available for $155.<br />
• Video CD-ROM option available for $195.<br />
New in <strong>2007</strong>!<br />
Save on shipping charges<br />
with new online products!<br />
Order before 5:00 p m on Thursday, November 8 to<br />
receive a 10% discount on your entire order.<br />
Order Online At<br />
<strong>ACR</strong><strong>Meeting</strong>s.com<br />
View All Sessions<br />
Inside >>><br />
www.rheumatology.org—Rheumatology’s Home on the Web 425
Individual Sessions<br />
tuesday, November 6<br />
4625 <strong>ACR</strong> Basic Research Conference (2-day session)<br />
Wednesday, November 7<br />
4626 <strong>ARHP</strong> Clinical Focus Course<br />
4627 <strong>ACR</strong> Review Course<br />
4628 <strong>ACR</strong>/<strong>ARHP</strong> Opening Lecture and Awards<br />
thursday, November 8<br />
4629 <strong>ACR</strong> State-of-the Art: Th17 Cells<br />
4630 <strong>ACR</strong> REF Special Session: Osteoclasts<br />
4631 <strong>ACR</strong> Year in Review<br />
4632 <strong>ACR</strong> Medical Aspects of Rheumatic Diseases:<br />
Obesity<br />
4633 <strong>ACR</strong> State-of-the-Art- Apoptosis: Death by a<br />
Thousand Cuts<br />
4634 <strong>ACR</strong> State-of-the-Art-Management of<br />
Complications of Systemic Juvenile Idiopathic<br />
Arthritis<br />
4635 <strong>ARHP</strong> General Session 1: The Physician, The<br />
Patient, The Disease<br />
4636 <strong>ACR</strong> Plenary Session 1: Discovery <strong>2007</strong><br />
4637 <strong>ARHP</strong>: Improving Sleep: Non-Pharmalogical<br />
Strategies<br />
4638 Rheumatic Disease Update: Lyme Disease<br />
4639 Career Choices in Rheumatology: Many<br />
Choices, Great Opportunities<br />
4640 <strong>ACR</strong> Practice Issues: Physician Fee Schedule<br />
4641 <strong>ACR</strong> Basic Science Symposium: Signal<br />
Transduction Pathways in Scleroderma<br />
4642 <strong>ACR</strong> Clinical Symposium: Challenges in the<br />
Management of Lupus<br />
4643 <strong>ACR</strong> REF Special Session: Signaling<br />
Pathways Controlling Chondrocyte Maturation:<br />
Implications for the Development and Treatment<br />
of Osteoarthritis<br />
4644 Advances in the Management of Total Hip<br />
Arthroplasty Patients: <strong>Meeting</strong> the Challenges<br />
of Reduced Length of Stay<br />
4645 <strong>ACR</strong> Basic Science Symposium: Regenerating<br />
Musculosketal Tissues<br />
4646 <strong>ACR</strong> Clinical Symposium: Sjögren’s Syndrome<br />
friday, November 9<br />
4647 <strong>ACR</strong> Immunology Update: Genetics of<br />
Autoimmunity<br />
4648 <strong>ACR</strong> State-of-the-Art Clinicopathologic<br />
Conference<br />
4649 <strong>ACR</strong> State-of-the-Art Bioimaging: Visualizing<br />
the Immune Response<br />
4650 <strong>ARHP</strong>: What’s New and Noteworthy in <strong>2007</strong>: A<br />
Review for Health Professionals<br />
4651 <strong>ARHP</strong>: Rheumatic Disease Update: Adult and<br />
Juvenile Dermatomyositis/Polymositis<br />
4652 <strong>ACR</strong> Medical Aspects of Rheumatic Diseases:<br />
Pulmonary Hypertension<br />
4653 <strong>ACR</strong> State-of-the-Art MicroRNAs and Gene<br />
Regulation<br />
4654 <strong>ARHP</strong>: Improving Patient Safety - Prevention of<br />
Medication Errors in Rheumatology Practice<br />
4655 <strong>ARHP</strong> General Session II: A Critical Unmet<br />
Need of Patients<br />
4656 <strong>ACR</strong> Practice Issues: Avoiding the Legal Pain<br />
of Pain Management<br />
4657 <strong>ACR</strong> Plenary Session II: Discovery <strong>2007</strong><br />
4658 <strong>ACR</strong> Special Session: <strong>ACR</strong> Curbside Consults-<br />
Ask the Professors<br />
4659 <strong>ACR</strong> Special Lecture: <strong>ACR</strong> Workforce Issues:<br />
The Future of Our Enterprise<br />
4660 <strong>ACR</strong> Special Session: Young Investigators: The<br />
New Triple Threat<br />
4661 <strong>ACR</strong> Basic Science Symposium: Bone<br />
Remodeling: New Targets in Rheumatic<br />
Disease<br />
4662 <strong>ACR</strong> Clinical Symposia: Doing the Right<br />
Thing: Evidence and Guidelines for Rheumatic<br />
Arthritis Treatment<br />
4663 <strong>ACR</strong> CORC Forum: Building a Stronger<br />
Physician Practice<br />
426<br />
Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
4664 <strong>ACR</strong>/<strong>ARHP</strong> Combined Clinical Symposium:<br />
Practical Pediatric Rheumatic Rehab<br />
4665 <strong>ARHP</strong>: Enriching Your Practice Through the<br />
Use of Health Professionals<br />
4666 <strong>ACR</strong> Clinical Symposium: Issues in Biologic<br />
Therapy<br />
4667 <strong>ACR</strong> Basic Science Symposia: Ion Channels in<br />
Inflammation<br />
4668 <strong>ARHP</strong>: Beyond Fatigue and Pain<br />
saturday, November 10<br />
4669 <strong>ACR</strong> Medical Aspects of Rheumatic Disease:<br />
Hepatitis C<br />
4670 <strong>ACR</strong> State-of-the-Art: Inflammasomes to Fever<br />
4671 <strong>ARHP</strong>: How do you know your patient is taking<br />
medicines, exercising and following other<br />
regimens you recommended?<br />
4672 <strong>ACR</strong> Special Session: Arthritis and<br />
Rheumatism at 50<br />
4673 <strong>ACR</strong> Immunology Updates for Clinicians: T-Cell<br />
Subsets: The Family Grows<br />
4674 <strong>ACR</strong> REF Special Lecture: The Vocation of<br />
Medicine<br />
4675 <strong>ARHP</strong>: Sexuality and Disability<br />
4676 <strong>ARHP</strong>: Rheumatic Disease Update:<br />
Polymyalgia Rheumatica/Giant Cell Arthritis<br />
4677 <strong>ARHP</strong>: Facilitating Cognitive and Behavioral<br />
Change<br />
4678 <strong>ARHP</strong>: Fall Prevention in Community-Living<br />
Older Adults<br />
4679 <strong>ARHP</strong>: Rheumatic Disease Update:<br />
Scleroderma<br />
4680 <strong>ACR</strong> Practice Issues: EMR in the Physician’s<br />
Office<br />
4681 <strong>ACR</strong> Clinical Symposium: Practical<br />
Management of Challenging Pain Syndrome<br />
4682 <strong>ACR</strong> Plenary Session III: Discovery <strong>2007</strong><br />
4683 <strong>ACR</strong> Basic Science Symposium: The Aging<br />
Immune System<br />
4684 <strong>ACR</strong> Special Session: The Great Debate:<br />
Peripheral MRI Results Should Early<br />
Intervention with Biologics in RA<br />
4685 <strong>ACR</strong> Basic Science Symposium: Gender in<br />
Rheumatic Disease<br />
4686 <strong>ACR</strong> Clinical Symposium: Why is my patient<br />
with Myositis not getting better?<br />
4687 <strong>ACR</strong>/<strong>ARHP</strong> Combined Clinical Symposium:<br />
Management of Psychiatric Illness in Children<br />
and Adolescents with Rheumatic Disease<br />
sunday, November 11<br />
4688 <strong>ACR</strong> Immunology Updates for Clinicians: Innate<br />
Immunity<br />
4689 <strong>ACR</strong> Practice Issues: Coding is Your Friend<br />
4690 <strong>ACR</strong> Basic Science Symposium: RA from<br />
Bench to Bedside<br />
4691 <strong>ACR</strong> Clinical Symposia: Challenging Topics in<br />
Bone Disease<br />
4692 <strong>ARHP</strong>: Fundamental Regulatory Aspects of<br />
Clinical Research<br />
4693 <strong>ACR</strong> Basic Science Symposium: Inflammation,<br />
Atherosclerosis and the Rheumatic Disease<br />
4694 <strong>ACR</strong> Clinical Symposia: Rheumatologic Skin<br />
Disease<br />
4695 <strong>ARHP</strong>: Fibromyalgia: An innovative approach<br />
to understanding the relationship between daily<br />
activities and symptoms<br />
Also available on Video CD-ROM<br />
and as Video Webcast.<br />
Order before 5:00 p m on Thursday, November 8 to receive a<br />
10% discount on your entire order.<br />
Order Online At<br />
<strong>ACR</strong><strong>Meeting</strong>s.com<br />
1 (866) 702-3278<br />
1 (770) 805-6292<br />
www.rheumatology.org—Rheumatology’s Home on the Web<br />
427
Also Available:<br />
Additional <strong>ACR</strong> Multimedia Products<br />
Purchase these programs on-site at the <strong>2007</strong> <strong>ACR</strong>/<strong>ARHP</strong> <strong>Scientific</strong> <strong>Meeting</strong> and<br />
receive special discounts!<br />
Order<br />
<strong>2007</strong> State-of-the-Art Clinical Symposium<br />
Qty Format Price<br />
<strong>2007</strong> SOTA Complete Conference Audio MP3 CD $225<br />
Conference Recordings<br />
Ordering Instructions<br />
To order conference recordings of the <strong>2007</strong> <strong>ACR</strong>/<strong>ARHP</strong> <strong>Scientific</strong> <strong>Meeting</strong>, please complete the order form in your<br />
attendee breifcase and return to the Sales Booth located next to <strong>ACR</strong> Central by 1:00 PM Sunday, November 11, <strong>2007</strong> or<br />
order online at www.ARC<strong>Meeting</strong>s.com.<br />
Pick Up Information<br />
You may choose to have your order shipped to you at your expense. To avoid shipping charges, you may choose to pick<br />
up your order on-site or access online products. If your order can be completed on-site, you may pick it up at the Sales<br />
Booth by 1:00 PM on Sunday. Completed orders that are NOT picked up will be shipped at the customer’s expense.<br />
Product Descriptions<br />
Audio CDs allow you to hear everything you would hear when attending a session. They will play in car CD players, home<br />
stereos, or any other standard CD player. Most sessions will consist of 2 or more discs.<br />
MP3 CDs allow more files to be saved onto one disc than traditional audio CD’s. They can be played on any computer<br />
and the files may be transferred directly to an MP3 player. Some newer home and car CD players can play MP3 CD’s.<br />
Video CD-ROMs contain session video and synchronized PowerPoint slides in an easy-to-use interface. They allow you<br />
to watch and listen to the session on your computer while reading any papers or slides submitted by the speaker.<br />
NOTE: Only selected sessions will be available on video.<br />
System Requirements: CD-ROM Drive; Sound Card; Windows 98, 2000, XP, or greater; Internet Explorer 6.0 or<br />
greater; & Windows Media Player 9.0 or greater<br />
ONLINE PRODUCTS<br />
Audio Podcasts allow you to hear everything you would hear on an MP3 CD or Audio CD while avoiding<br />
shipping costs. After purchasing podcasts, you can access them by visiting www.<strong>ACR</strong><strong>Meeting</strong>s.com and<br />
logging in with your attendee or member number. Podcasts can be streamed over the internet or downloaded<br />
to your computer and placed onto an MP3 player or burned to a CD.<br />
Video Webcasts contain session video and synchronized PowerPoint slides in an easy-to-use online interface<br />
identical to the Video CD-ROM product. After purchasing video webcasts, you can access them by visiting<br />
www.<strong>ACR</strong><strong>Meeting</strong>s.com and logging in with your attendee or member number.<br />
Video Podcasts allow you to hear session audio while viewing synchronized PowerPoint slides. These files<br />
can be viewed on your computer or easily downloaded and transferred to your video iPod. This product will be<br />
available for purchase after the meeting at www.<strong>ACR</strong><strong>Meeting</strong>s.com.<br />
Speaker Materials<br />
All <strong>2007</strong> <strong>ACR</strong>/<strong>ARHP</strong> <strong>Scientific</strong> <strong>Meeting</strong> attendees will received the CD-ROM Syllabus after the meeting concludes. To<br />
access the online syllabus during the meeting, visit www.<strong>ACR</strong><strong>Meeting</strong>s.com and login with your attendee number printed<br />
on the back of your name badge.<br />
Order before 5:00 p m on Thursday, November 8 to receive a 10% discount on your entire order.<br />
www.rheumatology.org—Rheumatology’s Home on the Web 429
Order before 5:00 p m on Thursday, November 8 to<br />
>>> receive a 10% discount on your entire order.<br />
Order<br />
Qty Format Price<br />
The Works! Complete Conference □ MP3 CD $595<br />
Audio and Video CD-ROM<br />
□ Audio CD $1195<br />
Complete Conference Audio □ MP3 CD $395<br />
□ Audio CD $995<br />
<strong>ACR</strong> Review Course<br />
□ MP3 CD $125<br />
(4627)<br />
□ Audio CD $155<br />
□ CD-ROM $195<br />
<strong>ACR</strong> Basic Research Conference<br />
(4625)<br />
□ MP3 CD $125<br />
□ Audio CD $155<br />
□ CD-ROM $155<br />
<strong>ARHP</strong> Sessions □ MP3 CD $175<br />
Top 10 Clinical Sessions □ MP3 CD $135<br />
Top 10 Research Sessions □ MP3 CD $135<br />
The Best of Pediatrics Sessions □ MP3 CD $125<br />
Basic Research Educational Track □ MP3 CD $195<br />
Clinical Educational Track □ MP3 CD $225<br />
Individual Sessions<br />
Make Selections on Right ►<br />
Qty Price Format Total<br />
M @ $18 Each<br />
MP3 CD<br />
A @ $20 Each<br />
Audio CD<br />
V @ $35 Each<br />
CD-ROM<br />
<strong>2007</strong> ANNUAL MEETING SUBTOTAL<br />
ADDITIONAL <strong>ACR</strong> PRODUCT SUBTOTAL (On Reverse)<br />
Shipping<br />
□ On-Site Pickup on by 1:00 PM Sunday<br />
FREE<br />
□ Online Access Only (Podcasts and Webcasts) FREE<br />
□ Domestic $6/$20 □ Int’l $20/40 (Partial/Full*)<br />
*Add $20 dom./$40 intl. for each full conference audio CD package purchased.<br />
ORDER TOTAL<br />
Payment<br />
Card Number<br />
Exp. Date<br />
Signature:<br />
Address (Please print legibly or attach business card here.)<br />
Name:<br />
Confirmation Number (located on the back of ID badge):<br />
Address 1:<br />
Address 2:<br />
City, State:<br />
Zip:<br />
Country:<br />
Home Phone:<br />
On-site Phone:<br />
E-mail Address:<br />
Individual Sessions<br />
Order Number:<br />
V M A V M A V M A<br />
□ □ 4626 □ □ 4650 □ □ □ 4673<br />
□ □ □ 4628 □ □ 4651 □ □ 4674<br />
□ □ 4629 □ □ □ 4652 □ □ 4675<br />
□ □ □ 4630 □ □ □ 4653 □ □ 4676<br />
□ □ □ 4631 □ □ 4654 □ □ 4677<br />
□ □ □ 4632 □ □ 4655 □ □ 4678<br />
□ □ □ 4633 □ □ 4656 □ □ 4679<br />
□ □ 4634 □ □ 4657 □ □ 4680<br />
□ □ 4635 □ □ □ 4658 □ □ □ 4681<br />
□ □ 4636 □ □ 4659 □ □ 4682<br />
□ □ 4637 □ □ 4660 □ □ □ 4683<br />
□ □ 4638 □ □ □ 4661 □ □ □ 4684<br />
□ □ 4639 □ □ □ 4662 □ □ □ 4685<br />
□ □ 4640 □ □ 4663 □ □ □ 4686<br />
□ □ □ 4641 □ □ □ 4664 □ □ □ 4687<br />
□ □ □ 4642 □ □ 4665 □ □ □ 4688<br />
□ □ □ 4643 □ □ □ 4666 □ □ 4689<br />
□ □ 4644 □ □ □ 4667 □ □ □ 4690<br />
□ □ □ 4645 □ □ 4668 □ □ □ 4691<br />
□ □ □ 4646 □ □ □ 4669 □ □ 4692<br />
□ □ □ 4647 □ □ □ 4670 □ □ □ 4693<br />
□ □ 4648 □ □ 4671 □ □ □ 4694<br />
□ □ □ 4649 □ □ □ 4672 □ □ 4695<br />
V = Video CD-ROM M = MP3 Audio CD A = Traditional Audio CD<br />
>>> New in <strong>2007</strong> - save on shipping!<br />
All sessions recorded at the <strong>2007</strong> <strong>ACR</strong>/<strong>ARHP</strong> <strong>Scientific</strong><br />
<strong>Meeting</strong> will be available online!<br />
• Audio Podcasts - listen to session audio on your computer<br />
or on-the-go with a portable MP3 player.<br />
• Video Webcasts - get the on-site experience with session<br />
video and synchronized presentations just as you<br />
would with a video CD-ROM.<br />
Select “Online Access Only” in the Shipping section.<br />
We will e-mail you when products may be accessed.<br />
Impact Media Solutions, Inc.<br />
3300 Highlands Parkway, Suite 290<br />
Smyrna, GA 30082<br />
Phone: 1-866-702-3278 or 1-770-805-6292<br />
Fax: 1-404-303-7111<br />
Order online at www.<strong>ACR</strong><strong>Meeting</strong>s.com<br />
Questions? E-mail support@impactmediasolutions.net<br />
430 Visit <strong>ACR</strong> Central for <strong>ACR</strong>/<strong>ARHP</strong> programs, products and services!
Change language